Selegiline	NN	O	O
-	NN	O	O
induced	NN	O	O
postural	NN	O	B
hypotension	NN	O	I
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
:	NN	O	O
a	NN	O	O
longitudinal	NN	O	O
study	NN	O	O
on	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
drug	NN	O	O
withdrawal	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
United	NN	O	O
Kingdom	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
Disease	NN	O	I
Research	NN	O	O
Group	NN	O	O
(	NN	O	O
UKPDRG	NN	O	O
)	NN	O	O
trial	NN	O	O
found	NN	O	O
an	NN	O	O
increased	NN	O	O
mortality	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
10	NN	O	O
mg	NN	O	O
selegiline	NN	O	O
per	NN	O	O
day	NN	O	O
and	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
taking	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
alone	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
therapy	NN	O	O
with	NN	O	O
selegiline	NN	O	O
and	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
selective	NN	O	O
systolic	NN	O	B
orthostatic	NN	O	I
hypotension	NN	O	I
which	NN	O	O
was	NN	O	O
abolished	NN	O	O
by	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
selegiline	NN	O	O
.	NN	O	O

This	NN	O	O
unwanted	NN	O	O
effect	NN	O	O
on	NN	O	O
postural	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
not	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
underlying	NN	O	O
autonomic	NN	O	O
failure	NN	O	O
.	NN	O	O

The	NN	O	O
aims	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
were	NN	O	O
to	NN	O	O
confirm	NN	O	O
our	NN	O	O
previous	NN	O	O
findings	NN	O	O
in	NN	O	O
a	NN	O	O
separate	NN	O	O
cohort	NN	O	O
of	NN	O	O
patients	NN	O	O
and	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
consequences	NN	O	O
of	NN	O	O
stopping	NN	O	O
selegiline	NN	O	O
in	NN	O	O
the	NN	O	O
expectation	NN	O	O
that	NN	O	O
this	NN	O	O
might	NN	O	O
shed	NN	O	O
light	NN	O	O
on	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
the	NN	O	O
drug	NN	O	O
causes	NN	O	O
orthostatic	NN	O	B
hypotension	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
cardiovascular	NN	O	O
responses	NN	O	O
to	NN	O	O
standing	NN	O	O
and	NN	O	O
head	NN	O	O
-	NN	O	O
up	NN	O	O
tilt	NN	O	O
were	NN	O	O
studied	NN	O	O
repeatedly	NN	O	O
in	NN	O	O
PD	NN	O	B
patients	NN	O	O
receiving	NN	O	O
selegiline	NN	O	O
and	NN	O	O
as	NN	O	O
the	NN	O	O
drug	NN	O	O
was	NN	O	O
withdrawn	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Head	NN	O	O
-	NN	O	O
up	NN	O	O
tilt	NN	O	O
caused	NN	O	O
systolic	NN	O	B
orthostatic	NN	O	I
hypotension	NN	O	I
which	NN	O	O
was	NN	O	O
marked	NN	O	O
in	NN	O	O
six	NN	O	O
of	NN	O	O
20	NN	O	O
PD	NN	O	B
patients	NN	O	O
on	NN	O	O
selegiline	NN	O	O
,	NN	O	O
one	NN	O	O
of	NN	O	O
whom	NN	O	O
lost	NN	O	O
consciousness	NN	O	O
with	NN	O	O
unrecordable	NN	O	O
blood	NN	O	O
pressures	NN	O	O
.	NN	O	O

A	NN	O	O
lesser	NN	O	O
degree	NN	O	O
of	NN	O	O
orthostatic	NN	O	B
hypotension	NN	O	I
occurred	NN	O	O
with	NN	O	O
standing	NN	O	O
.	NN	O	O

Orthostatic	NN	O	B
hypotension	NN	O	I
was	NN	O	O
ameliorated	NN	O	O
4	NN	O	O
days	NN	O	O
after	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
selegiline	NN	O	O
and	NN	O	O
totally	NN	O	O
abolished	NN	O	O
7	NN	O	O
days	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Stopping	NN	O	O
selegiline	NN	O	O
also	NN	O	O
significantly	NN	O	O
reduced	NN	O	B
the	NN	O	I
supine	NN	O	I
systolic	NN	O	I
and	NN	O	I
diastolic	NN	O	I
blood	NN	O	I
pressures	NN	O	I
consistent	NN	O	O
with	NN	O	O
a	NN	O	O
previously	NN	O	O
undescribed	NN	O	O
supine	NN	O	O
pressor	NN	O	O
action	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
confirms	NN	O	O
our	NN	O	O
previous	NN	O	O
finding	NN	O	O
that	NN	O	O
selegiline	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
selective	NN	O	O
orthostatic	NN	O	B
hypotension	NN	O	I
.	NN	O	O

The	NN	O	O
possibilities	NN	O	O
that	NN	O	O
these	NN	O	O
cardiovascular	NN	O	O
findings	NN	O	O
might	NN	O	O
be	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
inhibition	NN	O	O
of	NN	O	O
monoamine	NN	O	O
oxidase	NN	O	O
or	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
and	NN	O	O
metamphetamine	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
on	NN	O	O
effects	NN	O	O
of	NN	O	O
irrigation	NN	O	O
solutions	NN	O	O
on	NN	O	O
rat	NN	O	O
bladders	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
on	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
certain	NN	O	O
irrigating	NN	O	O
fluids	NN	O	O
on	NN	O	O
the	NN	O	O
rat	NN	O	O
bladder	NN	O	O
for	NN	O	O
18	NN	O	O
hours	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
the	NN	O	O
degradation	NN	O	O
product	NN	O	O
p	NN	O	O
-	NN	O	O
choloroaniline	NN	O	O
is	NN	O	O
not	NN	O	O
a	NN	O	O
significant	NN	O	O
factor	NN	O	O
in	NN	O	O
chlorhexidine	NN	O	O
-	NN	O	O
digluconate	NN	O	O
associated	NN	O	O
erosive	NN	O	O
cystitis	NN	O	B
.	NN	O	O

A	NN	O	O
high	NN	O	O
percentage	NN	O	O
of	NN	O	O
kanamycin	NN	O	O
-	NN	O	O
colistin	NN	O	O
and	NN	O	O
povidone	NN	O	O
-	NN	O	O
iodine	NN	O	O
irrigations	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
erosive	NN	O	O
cystitis	NN	O	B
and	NN	O	O
suggested	NN	O	O
a	NN	O	O
possible	NN	O	O
complication	NN	O	O
with	NN	O	O
human	NN	O	O
usage	NN	O	O
.	NN	O	O

Picloxydine	NN	O	O
irrigations	NN	O	O
appeared	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
lower	NN	O	O
incidence	NN	O	O
of	NN	O	O
erosive	NN	O	O
cystitis	NN	O	B
but	NN	O	O
further	NN	O	O
studies	NN	O	O
would	NN	O	O
have	NN	O	O
to	NN	O	O
be	NN	O	O
performed	NN	O	O
before	NN	O	O
it	NN	O	O
could	NN	O	O
be	NN	O	O
recommended	NN	O	O
for	NN	O	O
use	NN	O	O
in	NN	O	O
urological	NN	O	O
procedures	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
tetrandrine	NN	O	O
and	NN	O	O
fangchinoline	NN	O	O
on	NN	O	O
experimental	NN	O	O
thrombosis	NN	O	B
in	NN	O	O
mice	NN	O	O
and	NN	O	O
human	NN	O	O
platelet	NN	O	B
aggregation	NN	O	I
.	NN	O	O

Tetrandrine	NN	O	O
(	NN	O	O
TET	NN	O	O
)	NN	O	O
and	NN	O	O
fangchinoline	NN	O	O
(	NN	O	O
FAN	NN	O	O
)	NN	O	O
are	NN	O	O
two	NN	O	O
naturally	NN	O	O
occurring	NN	O	O
analogues	NN	O	O
with	NN	O	O
a	NN	O	O
bisbenzylisoquinoline	NN	O	O
structure	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
TET	NN	O	O
and	NN	O	O
FAN	NN	O	O
on	NN	O	O
the	NN	O	O
experimental	NN	O	O
thrombosis	NN	O	B
induced	NN	O	O
by	NN	O	O
collagen	NN	O	O
plus	NN	O	O
epinephrine	NN	O	O
(	NN	O	O
EP	NN	O	O
)	NN	O	O
in	NN	O	O
mice	NN	O	O
,	NN	O	O
and	NN	O	O
platelet	NN	O	B
aggregation	NN	O	I
and	NN	O	O
blood	NN	O	B
coagulation	NN	O	I
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
in	NN	O	O
vivo	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
administration	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
of	NN	O	O
TET	NN	O	O
and	NN	O	O
FAN	NN	O	O
in	NN	O	O
mice	NN	O	O
showed	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
thrombosis	NN	O	B
by	NN	O	O
55	NN	O	O
%	NN	O	O
and	NN	O	O
35	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
while	NN	O	O
acetylsalicylic	NN	O	O
acid	NN	O	O
(	NN	O	O
ASA	NN	O	O
,	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
positive	NN	O	O
control	NN	O	O
,	NN	O	O
showed	NN	O	O
only	NN	O	O
30	NN	O	O
%	NN	O	O
inhibition	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
vitro	NN	O	O
human	NN	O	O
platelet	NN	O	B
aggregations	NN	O	I
induced	NN	O	O
by	NN	O	O
the	NN	O	O
agonists	NN	O	O
used	NN	O	O
in	NN	O	O
tests	NN	O	O
,	NN	O	O
TET	NN	O	O
and	NN	O	O
FAN	NN	O	O
showed	NN	O	O
the	NN	O	O
inhibitions	NN	O	O
dose	NN	O	O
dependently	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
neither	NN	O	O
TET	NN	O	O
nor	NN	O	O
FAN	NN	O	O
showed	NN	O	O
any	NN	O	O
anticoagulation	NN	O	O
activities	NN	O	O
in	NN	O	O
the	NN	O	O
measurement	NN	O	O
of	NN	O	O
the	NN	O	O
activated	NN	O	O
partial	NN	O	O
thromboplastin	NN	O	O
time	NN	O	O
(	NN	O	O
APTT	NN	O	O
)	NN	O	O
,	NN	O	O
prothrombin	NN	O	O
time	NN	O	O
(	NN	O	O
PT	NN	O	O
)	NN	O	O
and	NN	O	O
thrombin	NN	O	O
time	NN	O	O
(	NN	O	O
TT	NN	O	O
)	NN	O	O
using	NN	O	O
human	NN	O	O
-	NN	O	O
citrated	NN	O	O
plasma	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
antithrombosis	NN	O	O
of	NN	O	O
TET	NN	O	O
and	NN	O	O
FAN	NN	O	O
in	NN	O	O
mice	NN	O	O
may	NN	O	O
be	NN	O	O
mainly	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
antiplatelet	NN	O	O
aggregation	NN	O	O
activities	NN	O	O
.	NN	O	O

Angioedema	NN	O	B
due	NN	O	O
to	NN	O	O
ACE	NN	O	O
inhibitors	NN	O	O
:	NN	O	O
common	NN	O	O
and	NN	O	O
inadequately	NN	O	O
diagnosed	NN	O	O
.	NN	O	O

The	NN	O	O
estimated	NN	O	O
incidence	NN	O	O
of	NN	O	O
angioedema	NN	O	B
during	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
inhibitor	NN	O	O
treatment	NN	O	O
is	NN	O	O
between	NN	O	O
1	NN	O	O
and	NN	O	O
7	NN	O	O
per	NN	O	O
thousand	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
potentially	NN	O	O
serious	NN	O	O
adverse	NN	O	O
effect	NN	O	O
is	NN	O	O
often	NN	O	O
preceded	NN	O	O
by	NN	O	O
minor	NN	O	O
manifestations	NN	O	O
that	NN	O	O
may	NN	O	O
serve	NN	O	O
as	NN	O	O
a	NN	O	O
warning	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
mood	NN	O	B
disorder	NN	O	I
:	NN	O	O
prevalence	NN	O	O
rates	NN	O	O
and	NN	O	O
psychiatric	NN	O	B
symptoms	NN	O	O
in	NN	O	O
an	NN	O	O
outpatient	NN	O	O
cocaine	NN	O	O
-	NN	O	O
dependent	NN	O	O
sample	NN	O	O
.	NN	O	O

This	NN	O	O
paper	NN	O	O
attempts	NN	O	O
to	NN	O	O
examine	NN	O	O
and	NN	O	O
compare	NN	O	O
prevalence	NN	O	O
rates	NN	O	O
and	NN	O	O
symptom	NN	O	O
patterns	NN	O	O
of	NN	O	O
DSM	NN	O	O
substance	NN	O	O
-	NN	O	O
induced	NN	O	O
and	NN	O	O
other	NN	O	O
mood	NN	O	B
disorders	NN	O	I
.	NN	O	O

243	NN	O	O
cocaine	NN	O	O
-	NN	O	O
dependent	NN	O	O
outpatients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
mood	NN	O	B
disorder	NN	O	I
(	NN	O	O
CIMD	NN	O	B
)	NN	O	O
,	NN	O	O
other	NN	O	O
mood	NN	O	B
disorders	NN	O	I
,	NN	O	O
or	NN	O	O
no	NN	O	O
mood	NN	O	B
disorder	NN	O	I
were	NN	O	O
compared	NN	O	O
on	NN	O	O
measures	NN	O	O
of	NN	O	O
psychiatric	NN	O	B
symptoms	NN	O	O
.	NN	O	O

The	NN	O	O
prevalence	NN	O	O
rate	NN	O	O
for	NN	O	O
CIMD	NN	O	B
was	NN	O	O
12	NN	O	O
%	NN	O	O
at	NN	O	O
baseline	NN	O	O
.	NN	O	O

Introduction	NN	O	O
of	NN	O	O
the	NN	O	O
DSM	NN	O	O
-	NN	O	O
IV	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
CIMD	NN	O	B
did	NN	O	O
not	NN	O	O
substantially	NN	O	O
affect	NN	O	O
rates	NN	O	O
of	NN	O	O
the	NN	O	O
other	NN	O	O
depressive	NN	O	B
disorders	NN	O	I
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
CIMD	NN	O	B
had	NN	O	O
symptom	NN	O	O
severity	NN	O	O
levels	NN	O	O
between	NN	O	O
those	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
a	NN	O	O
mood	NN	O	B
disorder	NN	O	I
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
some	NN	O	O
validity	NN	O	O
for	NN	O	O
the	NN	O	O
new	NN	O	O
DSM	NN	O	O
-	NN	O	O
IV	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
CIMD	NN	O	B
,	NN	O	O
but	NN	O	O
also	NN	O	O
suggest	NN	O	O
that	NN	O	O
it	NN	O	O
requires	NN	O	O
further	NN	O	O
specification	NN	O	O
and	NN	O	O
replication	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
fucoidan	NN	O	O
treatment	NN	O	O
on	NN	O	O
collagenase	NN	O	O
-	NN	O	O
induced	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Inflammatory	NN	O	O
cells	NN	O	O
are	NN	O	O
postulated	NN	O	O
to	NN	O	O
mediate	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	B
damage	NN	O	I
following	NN	O	O
ischemic	NN	O	B
stroke	NN	O	I
.	NN	O	O

Intracerebral	NN	O	B
hemorrhage	NN	O	I
is	NN	O	O
associated	NN	O	O
with	NN	O	O
more	NN	O	O
inflammation	NN	O	B
than	NN	O	O
ischemic	NN	O	B
stroke	NN	O	I
.	NN	O	O

We	NN	O	O
tested	NN	O	O
the	NN	O	O
sulfated	NN	O	O
polysaccharide	NN	O	O
fucoidan	NN	O	O
,	NN	O	O
which	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
reduce	NN	O	O
inflammatory	NN	O	O
brain	NN	O	B
damage	NN	O	I
,	NN	O	O
in	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
induced	NN	O	O
by	NN	O	O
injection	NN	O	O
of	NN	O	O
bacterial	NN	O	O
collagenase	NN	O	O
into	NN	O	O
the	NN	O	O
caudate	NN	O	O
nucleus	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
seven	NN	O	O
day	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
fucoidan	NN	O	O
(	NN	O	O
30	NN	O	O
micrograms	NN	O	O
h	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
or	NN	O	O
vehicle	NN	O	O
.	NN	O	O

The	NN	O	O
hematoma	NN	O	B
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
vivo	NN	O	O
by	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
.	NN	O	O

Motor	NN	O	O
behavior	NN	O	O
,	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
,	NN	O	O
and	NN	O	O
skilled	NN	O	O
forelimb	NN	O	O
function	NN	O	O
were	NN	O	O
tested	NN	O	O
repeatedly	NN	O	O
for	NN	O	O
six	NN	O	O
weeks	NN	O	O
.	NN	O	O

Fucoidan	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
exhibited	NN	O	O
evidence	NN	O	O
of	NN	O	O
impaired	NN	O	B
blood	NN	O	I
clotting	NN	O	I
and	NN	O	O
hemodilution	NN	O	B
,	NN	O	O
had	NN	O	O
larger	NN	O	O
hematomas	NN	O	B
,	NN	O	O
and	NN	O	O
tended	NN	O	O
to	NN	O	O
have	NN	O	O
less	NN	O	O
inflammation	NN	O	B
in	NN	O	O
the	NN	O	O
vicinity	NN	O	O
of	NN	O	O
the	NN	O	O
hematoma	NN	O	B
after	NN	O	O
three	NN	O	O
days	NN	O	O
.	NN	O	O

They	NN	O	O
showed	NN	O	O
significantly	NN	O	O
more	NN	O	O
rapid	NN	O	O
improvement	NN	O	O
of	NN	O	O
motor	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
week	NN	O	O
following	NN	O	O
hemorrhage	NN	O	B
and	NN	O	O
better	NN	O	O
memory	NN	O	O
retention	NN	O	O
in	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
test	NN	O	O
.	NN	O	O

Acute	NN	O	O
white	NN	O	B
matter	NN	O	I
edema	NN	O	I
and	NN	O	O
eventual	NN	O	O
neuronal	NN	O	B
loss	NN	O	I
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
adjacent	NN	O	O
to	NN	O	O
the	NN	O	O
hematoma	NN	O	B
did	NN	O	O
not	NN	O	O
differ	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Investigation	NN	O	O
of	NN	O	O
more	NN	O	O
specific	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
agents	NN	O	O
and	NN	O	O
hemodiluting	NN	O	O
agents	NN	O	O
are	NN	O	O
warranted	NN	O	O
in	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
.	NN	O	O

Recurarization	NN	O	O
in	NN	O	O
the	NN	O	O
recovery	NN	O	O
room	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
recurarization	NN	O	O
in	NN	O	O
the	NN	O	O
recovery	NN	O	O
room	NN	O	O
is	NN	O	O
reported	NN	O	O
.	NN	O	O

Accumulation	NN	O	O
of	NN	O	O
atracurium	NN	O	O
in	NN	O	O
the	NN	O	O
intravenous	NN	O	O
line	NN	O	O
led	NN	O	O
to	NN	O	O
recurarization	NN	O	O
after	NN	O	O
flushing	NN	O	O
the	NN	O	O
line	NN	O	O
in	NN	O	O
the	NN	O	O
recovery	NN	O	O
room	NN	O	O
.	NN	O	O

A	NN	O	O
respiratory	NN	O	B
arrest	NN	O	I
with	NN	O	O
severe	NN	O	O
desaturation	NN	O	B
and	NN	O	O
bradycardia	NN	O	B
occurred	NN	O	O
.	NN	O	O

Circumstances	NN	O	O
leading	NN	O	O
to	NN	O	O
this	NN	O	O
event	NN	O	O
and	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
enabling	NN	O	O
a	NN	O	O
neuromuscular	NN	O	B
blockade	NN	O	I
to	NN	O	O
occur	NN	O	O
,	NN	O	O
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
small	NN	O	O
dose	NN	O	O
of	NN	O	O
relaxant	NN	O	O
,	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

The	NN	O	O
haemodynamic	NN	O	O
effects	NN	O	O
of	NN	O	O
propofol	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
ephedrine	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
(	NN	O	O
ASA	NN	O	O
groups	NN	O	O
3	NN	O	O
and	NN	O	O
4	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
marked	NN	O	O
vasodilator	NN	O	O
and	NN	O	O
negative	NN	O	O
inotropic	NN	O	O
effects	NN	O	O
of	NN	O	O
propofol	NN	O	O
are	NN	O	O
disadvantages	NN	O	O
in	NN	O	O
frail	NN	O	O
elderly	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
adding	NN	O	O
different	NN	O	O
doses	NN	O	O
of	NN	O	O
ephedrine	NN	O	O
to	NN	O	O
propofol	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
obtund	NN	O	O
the	NN	O	O
hypotensive	NN	O	B
response	NN	O	O
.	NN	O	O

The	NN	O	O
haemodynamic	NN	O	O
effects	NN	O	O
of	NN	O	O
adding	NN	O	O
15	NN	O	O
,	NN	O	O
20	NN	O	O
or	NN	O	O
25	NN	O	O
mg	NN	O	O
of	NN	O	O
ephedrine	NN	O	O
to	NN	O	O
200	NN	O	O
mg	NN	O	O
of	NN	O	O
propofol	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
control	NN	O	O
in	NN	O	O
40	NN	O	O
ASA	NN	O	O
3	NN	O	O
/	NN	O	O
4	NN	O	O
patients	NN	O	O
over	NN	O	O
60	NN	O	O
years	NN	O	O
presenting	NN	O	O
for	NN	O	O
genito	NN	O	O
-	NN	O	O
urinary	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
addition	NN	O	O
of	NN	O	O
ephedrine	NN	O	O
to	NN	O	O
propofol	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
effective	NN	O	O
method	NN	O	O
of	NN	O	O
obtunding	NN	O	O
the	NN	O	O
hypotensive	NN	O	B
response	NN	O	O
to	NN	O	O
propofol	NN	O	O
at	NN	O	O
all	NN	O	O
doses	NN	O	O
used	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
marked	NN	O	O
tachycardia	NN	O	B
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
ephedrine	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
propofol	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
majority	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
occasionally	NN	O	O
reaching	NN	O	O
high	NN	O	O
levels	NN	O	O
in	NN	O	O
individual	NN	O	O
patients	NN	O	O
.	NN	O	O

Due	NN	O	O
to	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
this	NN	O	O
tachycardia	NN	O	B
inducing	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
,	NN	O	O
we	NN	O	O
would	NN	O	O
not	NN	O	O
recommend	NN	O	O
the	NN	O	O
use	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
of	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
ephedrine	NN	O	O
/	NN	O	O
propofol	NN	O	O
/	NN	O	O
mixtures	NN	O	O
studied	NN	O	O
.	NN	O	O

Gemcitabine	NN	O	O
plus	NN	O	O
vinorelbine	NN	O	O
in	NN	O	O
nonsmall	NN	O	B
cell	NN	O	I
lung	NN	O	I
carcinoma	NN	O	I
patients	NN	O	O
age	NN	O	O
70	NN	O	O
years	NN	O	O
or	NN	O	O
older	NN	O	O
or	NN	O	O
patients	NN	O	O
who	NN	O	O
cannot	NN	O	O
receive	NN	O	O
cisplatin	NN	O	O
.	NN	O	O

Oncopaz	NN	O	O
Cooperative	NN	O	O
Group	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Although	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
nonsmall	NN	O	B
cell	NN	O	I
lung	NN	O	I
carcinoma	NN	O	I
(	NN	O	O
NSCLC	NN	O	B
)	NN	O	O
is	NN	O	O
high	NN	O	O
among	NN	O	O
elderly	NN	O	O
patients	NN	O	O
,	NN	O	O
few	NN	O	O
data	NN	O	O
are	NN	O	O
available	NN	O	O
regarding	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
toxicity	NN	O	B
of	NN	O	O
chemotherapy	NN	O	O
in	NN	O	O
this	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Recent	NN	O	O
reports	NN	O	O
indicate	NN	O	O
that	NN	O	O
single	NN	O	O
agent	NN	O	O
therapy	NN	O	O
with	NN	O	O
vinorelbine	NN	O	O
(	NN	O	O
VNB	NN	O	O
)	NN	O	O
or	NN	O	O
gemcitabine	NN	O	O
(	NN	O	O
GEM	NN	O	O
)	NN	O	O
may	NN	O	O
obtain	NN	O	O
a	NN	O	O
response	NN	O	O
rate	NN	O	O
of	NN	O	O
20	NN	O	O
-	NN	O	O
30	NN	O	O
%	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
,	NN	O	O
with	NN	O	O
acceptable	NN	O	O
toxicity	NN	O	B
and	NN	O	O
improvement	NN	O	O
in	NN	O	O
symptoms	NN	O	O
and	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
toxicity	NN	O	B
of	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
GEM	NN	O	O
and	NN	O	O
VNB	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
NSCLC	NN	O	B
or	NN	O	O
those	NN	O	O
with	NN	O	O
some	NN	O	O
contraindication	NN	O	O
to	NN	O	O
receiving	NN	O	O
cisplatin	NN	O	O
were	NN	O	O
assessed	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Forty	NN	O	O
-	NN	O	O
nine	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
NSCLC	NN	O	B
were	NN	O	O
included	NN	O	O
,	NN	O	O
38	NN	O	O
of	NN	O	O
whom	NN	O	O
were	NN	O	O
age	NN	O	O
>	NN	O	O
/	NN	O	O
=	NN	O	O
70	NN	O	O
years	NN	O	O
and	NN	O	O
11	NN	O	O
were	NN	O	O
age	NN	O	O
<	NN	O	O
70	NN	O	O
years	NN	O	O
but	NN	O	O
who	NN	O	O
had	NN	O	O
some	NN	O	O
contraindication	NN	O	O
to	NN	O	O
receiving	NN	O	O
cisplatin	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
and	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Treatment	NN	O	O
was	NN	O	O
comprised	NN	O	O
of	NN	O	O
VNB	NN	O	O
,	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
plus	NN	O	O
GEM	NN	O	O
,	NN	O	O
1000	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
both	NN	O	O
on	NN	O	O
Days	NN	O	O
1	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
and	NN	O	O
15	NN	O	O
every	NN	O	O
28	NN	O	O
days	NN	O	O
.	NN	O	O

Patients	NN	O	O
received	NN	O	O
a	NN	O	O
minimum	NN	O	O
of	NN	O	O
three	NN	O	O
courses	NN	O	O
unless	NN	O	O
progressive	NN	O	O
disease	NN	O	O
was	NN	O	O
detected	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
One	NN	O	O
hundred	NN	O	O
sixty	NN	O	O
-	NN	O	O
five	NN	O	O
courses	NN	O	O
were	NN	O	O
administered	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
median	NN	O	O
of	NN	O	O
3	NN	O	O
.	NN	O	O

6	NN	O	O
courses	NN	O	O
per	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
was	NN	O	O
26	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
15	NN	O	O
-	NN	O	O
41	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
attained	NN	O	O
a	NN	O	O
complete	NN	O	O
response	NN	O	O
(	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
11	NN	O	O
patients	NN	O	O
(	NN	O	O
22	NN	O	O
%	NN	O	O
)	NN	O	O
achieved	NN	O	O
a	NN	O	O
partial	NN	O	O
response	NN	O	O
.	NN	O	O

Eastern	NN	O	O
Cooperative	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
performance	NN	O	O
status	NN	O	O
improved	NN	O	O
in	NN	O	O
35	NN	O	O
%	NN	O	O
of	NN	O	O
those	NN	O	O
patients	NN	O	O
with	NN	O	O
an	NN	O	O
initial	NN	O	O
value	NN	O	O
>	NN	O	O
0	NN	O	O
,	NN	O	O
whereas	NN	O	O
relief	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
1	NN	O	O
symptom	NN	O	O
without	NN	O	O
worsening	NN	O	O
of	NN	O	O
other	NN	O	O
symptoms	NN	O	O
was	NN	O	O
noted	NN	O	O
in	NN	O	O
27	NN	O	O
patients	NN	O	O
(	NN	O	O
55	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
time	NN	O	O
to	NN	O	O
progression	NN	O	O
was	NN	O	O
16	NN	O	O
weeks	NN	O	O
and	NN	O	O
the	NN	O	O
1	NN	O	O
-	NN	O	O
year	NN	O	O
survival	NN	O	O
rate	NN	O	O
was	NN	O	O
33	NN	O	O
%	NN	O	O
.	NN	O	O

Toxicity	NN	O	B
was	NN	O	O
mild	NN	O	O
.	NN	O	O

Six	NN	O	O
patients	NN	O	O
(	NN	O	O
12	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
World	NN	O	O
Health	NN	O	O
Organization	NN	O	O
Grade	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
,	NN	O	O
2	NN	O	O
patients	NN	O	O
(	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
Grade	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
thrombocytopenia	NN	O	B
,	NN	O	O
and	NN	O	O
2	NN	O	O
patients	NN	O	O
(	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
Grade	NN	O	O
3	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
neutropenia	NN	O	B
(	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
died	NN	O	O
of	NN	O	O
sepsis	NN	O	B
.	NN	O	O

The	NN	O	O
median	NN	O	O
age	NN	O	O
of	NN	O	O
those	NN	O	O
patients	NN	O	O
developing	NN	O	O
Grade	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
remaining	NN	O	O
patients	NN	O	O
(	NN	O	O
75	NN	O	O
years	NN	O	O
vs	NN	O	O
.	NN	O	O
72	NN	O	O
years	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
047	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
combination	NN	O	O
of	NN	O	O
GEM	NN	O	O
and	NN	O	O
VNB	NN	O	O
is	NN	O	O
moderately	NN	O	O
active	NN	O	O
and	NN	O	O
well	NN	O	O
tolerated	NN	O	O
except	NN	O	O
in	NN	O	O
patients	NN	O	O
age	NN	O	O
>	NN	O	O
/	NN	O	O
=	NN	O	O
75	NN	O	O
years	NN	O	O
.	NN	O	O

This	NN	O	O
age	NN	O	O
group	NN	O	O
had	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
myelosuppression	NN	O	B
.	NN	O	O

Therefore	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
use	NN	O	O
of	NN	O	O
granulocyte	NN	O	O
-	NN	O	O
colony	NN	O	O
stimulating	NN	O	O
factor	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
with	NN	O	O
this	NN	O	O
treatment	NN	O	O
.	NN	O	O

New	NN	O	O
chemotherapy	NN	O	O
combinations	NN	O	O
with	NN	O	O
higher	NN	O	O
activity	NN	O	O
and	NN	O	O
lower	NN	O	O
toxicity	NN	O	B
are	NN	O	O
needed	NN	O	O
for	NN	O	O
elderly	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
NSCLC	NN	O	B
.	NN	O	O

A	NN	O	O
selective	NN	O	O
dopamine	NN	O	O
D4	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
NRA0160	NN	O	O
:	NN	O	O
a	NN	O	O
preclinical	NN	O	O
neuropharmacological	NN	O	O
profile	NN	O	O
.	NN	O	O

NRA0160	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
[	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
4	NN	O	O
-	NN	O	O
(	NN	O	O
3	NN	O	O
-	NN	O	O
fluorobenzylidene	NN	O	O
)	NN	O	O
piperidin	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
yl	NN	O	O
)	NN	O	O
ethyl	NN	O	O
]	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
(	NN	O	O
4	NN	O	O
-	NN	O	O
fluorophenyl	NN	O	O
)	NN	O	O
thiazole	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
carboxamide	NN	O	O
,	NN	O	O
has	NN	O	O
a	NN	O	O
high	NN	O	O
affinity	NN	O	O
for	NN	O	O
human	NN	O	O
cloned	NN	O	O
dopamine	NN	O	O
D4	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
D4	NN	O	O
.	NN	O	O
4	NN	O	O
and	NN	O	O
D4	NN	O	O
.	NN	O	O
7	NN	O	O
receptors	NN	O	O
,	NN	O	O
with	NN	O	O
Ki	NN	O	O
values	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
and	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
nM	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

NRA0160	NN	O	O
is	NN	O	O
over	NN	O	O
20	NN	O	O
,	NN	O	O
000fold	NN	O	O
more	NN	O	O
potent	NN	O	O
at	NN	O	O
the	NN	O	O
dopamine	NN	O	O
D4	NN	O	O
.	NN	O	O
2	NN	O	O
receptor	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
human	NN	O	O
cloned	NN	O	O
dopamine	NN	O	O
D2L	NN	O	O
receptor	NN	O	O
.	NN	O	O

NRA0160	NN	O	O
has	NN	O	O
negligible	NN	O	O
affinity	NN	O	O
for	NN	O	O
the	NN	O	O
human	NN	O	O
cloned	NN	O	O
dopamine	NN	O	O
D3	NN	O	O
receptor	NN	O	O
(	NN	O	O
Ki	NN	O	O
=	NN	O	O
39	NN	O	O
nM	NN	O	O
)	NN	O	O
,	NN	O	O
rat	NN	O	O
serotonin	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
)	NN	O	O
2A	NN	O	O
receptors	NN	O	O
(	NN	O	O
Ki	NN	O	O
=	NN	O	O
180	NN	O	O
nM	NN	O	O
)	NN	O	O
and	NN	O	O
rat	NN	O	O
alpha1	NN	O	O
adrenoceptor	NN	O	O
(	NN	O	O
Ki	NN	O	O
=	NN	O	O
237	NN	O	O
nM	NN	O	O
)	NN	O	O
.	NN	O	O

NRA0160	NN	O	O
and	NN	O	O
clozapine	NN	O	O
antagonized	NN	O	O
locomotor	NN	O	O
hyperactivity	NN	O	B
induced	NN	O	O
by	NN	O	O
methamphetamine	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

NRA0160	NN	O	O
and	NN	O	O
clozapine	NN	O	O
antagonized	NN	O	O
MAP	NN	O	O
-	NN	O	O
induced	NN	O	O
stereotyped	NN	O	O
behavior	NN	O	O
in	NN	O	O
mice	NN	O	O
,	NN	O	O
although	NN	O	O
their	NN	O	O
effects	NN	O	O
did	NN	O	O
not	NN	O	O
exceed	NN	O	O
50	NN	O	O
%	NN	O	O
inhibition	NN	O	O
,	NN	O	O
even	NN	O	O
at	NN	O	O
the	NN	O	O
highest	NN	O	O
dose	NN	O	O
given	NN	O	O
.	NN	O	O

NRA0160	NN	O	O
and	NN	O	O
clozapine	NN	O	O
significantly	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
in	NN	O	O
rats	NN	O	O
,	NN	O	O
although	NN	O	O
their	NN	O	O
effects	NN	O	O
did	NN	O	O
not	NN	O	O
exceed	NN	O	O
50	NN	O	O
%	NN	O	O
induction	NN	O	O
even	NN	O	O
at	NN	O	O
the	NN	O	O
highest	NN	O	O
dose	NN	O	O
given	NN	O	O
.	NN	O	O

NRA0160	NN	O	O
and	NN	O	O
clozapine	NN	O	O
significantly	NN	O	O
reversed	NN	O	O
the	NN	O	O
disruption	NN	O	O
of	NN	O	O
prepulse	NN	O	O
inhibition	NN	O	O
(	NN	O	O
PPI	NN	O	O
)	NN	O	O
in	NN	O	O
rats	NN	O	O
produced	NN	O	O
by	NN	O	O
apomorphine	NN	O	O
.	NN	O	O

NRA0160	NN	O	O
and	NN	O	O
clozapine	NN	O	O
significantly	NN	O	O
shortened	NN	O	O
the	NN	O	O
phencyclidine	NN	O	O
(	NN	O	O
PCP	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
prolonged	NN	O	O
swimming	NN	O	O
latency	NN	O	O
in	NN	O	O
rats	NN	O	O
in	NN	O	O
a	NN	O	O
water	NN	O	O
maze	NN	O	O
task	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
NRA0160	NN	O	O
may	NN	O	O
have	NN	O	O
unique	NN	O	O
antipsychotic	NN	O	O
activities	NN	O	O
without	NN	O	O
the	NN	O	O
liability	NN	O	O
of	NN	O	O
motor	NN	O	O
side	NN	O	O
effects	NN	O	O
typical	NN	O	O
of	NN	O	O
classical	NN	O	O
antipsychotics	NN	O	O
.	NN	O	O

Warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
artery	NN	O	B
calcification	NN	O	I
is	NN	O	O
accelerated	NN	O	O
by	NN	O	O
growth	NN	O	O
and	NN	O	O
vitamin	NN	O	O
D	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
studies	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
growth	NN	O	O
and	NN	O	O
vitamin	NN	O	O
D	NN	O	O
treatment	NN	O	O
enhance	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
artery	NN	O	B
calcification	NN	O	I
in	NN	O	O
rats	NN	O	O
given	NN	O	O
sufficient	NN	O	O
doses	NN	O	O
of	NN	O	O
Warfarin	NN	O	O
to	NN	O	O
inhibit	NN	O	O
gamma	NN	O	O
-	NN	O	O
carboxylation	NN	O	O
of	NN	O	O
matrix	NN	O	O
Gla	NN	O	O
protein	NN	O	O
,	NN	O	O
a	NN	O	O
calcification	NN	O	B
inhibitor	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
expressed	NN	O	O
by	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
cells	NN	O	O
and	NN	O	O
macrophages	NN	O	O
in	NN	O	O
the	NN	O	O
artery	NN	O	O
wall	NN	O	O
.	NN	O	O

The	NN	O	O
first	NN	O	O
series	NN	O	O
of	NN	O	O
experiments	NN	O	O
examined	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
age	NN	O	O
and	NN	O	O
growth	NN	O	O
status	NN	O	O
on	NN	O	O
artery	NN	O	B
calcification	NN	O	I
in	NN	O	O
Warfarin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Treatment	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
with	NN	O	O
Warfarin	NN	O	O
caused	NN	O	O
massive	NN	O	O
focal	NN	O	O
calcification	NN	O	B
of	NN	O	I
the	NN	O	I
artery	NN	O	I
media	NN	O	O
in	NN	O	O
20	NN	O	O
-	NN	O	O
day	NN	O	O
-	NN	O	O
old	NN	O	O
rats	NN	O	O
and	NN	O	O
less	NN	O	O
extensive	NN	O	O
focal	NN	O	O
calcification	NN	O	B
in	NN	O	O
42	NN	O	O
-	NN	O	O
day	NN	O	O
-	NN	O	O
old	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
no	NN	O	O
artery	NN	O	B
calcification	NN	O	I
could	NN	O	O
be	NN	O	O
detected	NN	O	O
in	NN	O	O
10	NN	O	O
-	NN	O	O
month	NN	O	O
-	NN	O	O
old	NN	O	O
adult	NN	O	O
rats	NN	O	O
even	NN	O	O
after	NN	O	O
4	NN	O	O
weeks	NN	O	O
of	NN	O	O
Warfarin	NN	O	O
treatment	NN	O	O
.	NN	O	O

To	NN	O	O
directly	NN	O	O
examine	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
growth	NN	O	O
to	NN	O	O
Warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
artery	NN	O	B
calcification	NN	O	I
in	NN	O	O
animals	NN	O	O
of	NN	O	O
the	NN	O	O
same	NN	O	O
age	NN	O	O
,	NN	O	O
20	NN	O	O
-	NN	O	O
day	NN	O	O
-	NN	O	O
old	NN	O	O
rats	NN	O	O
were	NN	O	O
fed	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
either	NN	O	O
an	NN	O	O
ad	NN	O	O
libitum	NN	O	O
diet	NN	O	O
or	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
g	NN	O	O
/	NN	O	O
d	NN	O	O
restricted	NN	O	O
diet	NN	O	O
that	NN	O	O
maintains	NN	O	O
weight	NN	O	O
but	NN	O	O
prevents	NN	O	O
growth	NN	O	O
.	NN	O	O

Concurrent	NN	O	O
treatment	NN	O	O
of	NN	O	O
both	NN	O	O
dietary	NN	O	O
groups	NN	O	O
with	NN	O	O
Warfarin	NN	O	O
produced	NN	O	O
massive	NN	O	O
focal	NN	O	O
calcification	NN	O	B
of	NN	O	I
the	NN	O	I
artery	NN	O	I
media	NN	O	O
in	NN	O	O
the	NN	O	O
ad	NN	O	O
libitum	NN	O	O
-	NN	O	O
fed	NN	O	O
rats	NN	O	O
but	NN	O	O
no	NN	O	O
detectable	NN	O	O
artery	NN	O	B
calcification	NN	O	I
in	NN	O	O
the	NN	O	O
restricted	NN	O	O
-	NN	O	O
diet	NN	O	O
,	NN	O	O
growth	NN	O	O
-	NN	O	O
inhibited	NN	O	O
group	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
explanation	NN	O	O
for	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
artery	NN	O	B
calcification	NN	O	I
and	NN	O	O
growth	NN	O	O
status	NN	O	O
cannot	NN	O	O
be	NN	O	O
determined	NN	O	O
from	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
relationship	NN	O	O
between	NN	O	O
higher	NN	O	O
serum	NN	O	O
phosphate	NN	O	O
and	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
artery	NN	O	B
calcification	NN	O	I
,	NN	O	O
with	NN	O	O
30	NN	O	O
%	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
serum	NN	O	O
phosphate	NN	O	O
in	NN	O	O
young	NN	O	O
,	NN	O	O
ad	NN	O	O
libitum	NN	O	O
-	NN	O	O
fed	NN	O	O
rats	NN	O	O
compared	NN	O	O
with	NN	O	O
either	NN	O	O
of	NN	O	O
the	NN	O	O
groups	NN	O	O
that	NN	O	O
was	NN	O	O
resistant	NN	O	O
to	NN	O	O
Warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
artery	NN	O	B
calcification	NN	O	I
,	NN	O	O
ie	NN	O	O
,	NN	O	O
the	NN	O	O
10	NN	O	O
-	NN	O	O
month	NN	O	O
-	NN	O	O
old	NN	O	O
rats	NN	O	O
and	NN	O	O
the	NN	O	O
restricted	NN	O	O
-	NN	O	O
diet	NN	O	O
,	NN	O	O
growth	NN	O	O
-	NN	O	O
inhibited	NN	O	O
young	NN	O	O
rats	NN	O	O
.	NN	O	O

This	NN	O	O
observation	NN	O	O
suggests	NN	O	O
that	NN	O	O
increased	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
Warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
artery	NN	O	B
calcification	NN	O	I
could	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
higher	NN	O	O
serum	NN	O	O
phosphate	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
second	NN	O	O
set	NN	O	O
of	NN	O	O
experiments	NN	O	O
examined	NN	O	O
the	NN	O	O
possible	NN	O	O
synergy	NN	O	O
between	NN	O	O
vitamin	NN	O	O
D	NN	O	O
and	NN	O	O
Warfarin	NN	O	O
in	NN	O	O
artery	NN	O	B
calcification	NN	O	I
.	NN	O	O

High	NN	O	O
doses	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D	NN	O	O
are	NN	O	O
known	NN	O	O
to	NN	O	O
cause	NN	O	O
calcification	NN	O	B
of	NN	O	I
the	NN	O	I
artery	NN	O	I
media	NN	O	O
in	NN	O	O
as	NN	O	O
little	NN	O	O
as	NN	O	O
3	NN	O	O
to	NN	O	O
4	NN	O	O
days	NN	O	O
.	NN	O	O

High	NN	O	O
doses	NN	O	O
of	NN	O	O
the	NN	O	O
vitamin	NN	O	O
K	NN	O	O
antagonist	NN	O	O
Warfarin	NN	O	O
are	NN	O	O
also	NN	O	O
known	NN	O	O
to	NN	O	O
cause	NN	O	O
calcification	NN	O	B
of	NN	O	I
the	NN	O	I
artery	NN	O	I
media	NN	O	O
,	NN	O	O
but	NN	O	O
at	NN	O	O
treatment	NN	O	O
times	NN	O	O
of	NN	O	O
2	NN	O	O
weeks	NN	O	O
or	NN	O	O
longer	NN	O	O
yet	NN	O	O
not	NN	O	O
at	NN	O	O
1	NN	O	O
week	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
synergy	NN	O	O
between	NN	O	O
these	NN	O	O
2	NN	O	O
treatments	NN	O	O
and	NN	O	O
found	NN	O	O
that	NN	O	O
concurrent	NN	O	O
Warfarin	NN	O	O
administration	NN	O	O
dramatically	NN	O	O
increased	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
calcification	NN	O	B
in	NN	O	O
the	NN	O	O
media	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
at	NN	O	O
3	NN	O	O
and	NN	O	O
4	NN	O	O
days	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
close	NN	O	O
parallel	NN	O	O
between	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D	NN	O	O
dose	NN	O	O
on	NN	O	O
artery	NN	O	B
calcification	NN	O	I
and	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D	NN	O	O
dose	NN	O	O
on	NN	O	O
the	NN	O	O
elevation	NN	O	O
of	NN	O	O
serum	NN	O	O
calcium	NN	O	O
,	NN	O	O
which	NN	O	O
suggests	NN	O	O
that	NN	O	O
vitamin	NN	O	O
D	NN	O	O
may	NN	O	O
induce	NN	O	O
artery	NN	O	B
calcification	NN	O	I
through	NN	O	O
its	NN	O	O
effect	NN	O	O
on	NN	O	O
serum	NN	O	O
calcium	NN	O	O
.	NN	O	O

Because	NN	O	O
Warfarin	NN	O	O
treatment	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
elevation	NN	O	O
in	NN	O	O
serum	NN	O	O
calcium	NN	O	O
produced	NN	O	O
by	NN	O	O
vitamin	NN	O	O
D	NN	O	O
,	NN	O	O
the	NN	O	O
synergy	NN	O	O
between	NN	O	O
Warfarin	NN	O	O
and	NN	O	O
vitamin	NN	O	O
D	NN	O	O
is	NN	O	O
probably	NN	O	O
best	NN	O	O
explained	NN	O	O
by	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
Warfarin	NN	O	O
inhibits	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
matrix	NN	O	O
Gla	NN	O	O
protein	NN	O	O
as	NN	O	O
a	NN	O	O
calcification	NN	O	B
inhibitor	NN	O	O
.	NN	O	O

High	NN	O	O
levels	NN	O	O
of	NN	O	O
matrix	NN	O	O
Gla	NN	O	O
protein	NN	O	O
are	NN	O	O
found	NN	O	O
at	NN	O	O
sites	NN	O	O
of	NN	O	O
artery	NN	O	B
calcification	NN	O	I
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
vitamin	NN	O	O
D	NN	O	O
plus	NN	O	O
Warfarin	NN	O	O
,	NN	O	O
and	NN	O	O
chemical	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
protein	NN	O	O
that	NN	O	O
accumulated	NN	O	O
was	NN	O	O
indeed	NN	O	O
not	NN	O	O
gamma	NN	O	O
-	NN	O	O
carboxylated	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
indicate	NN	O	O
that	NN	O	O
although	NN	O	O
the	NN	O	O
gamma	NN	O	O
-	NN	O	O
carboxyglutamate	NN	O	O
residues	NN	O	O
of	NN	O	O
matrix	NN	O	O
Gla	NN	O	O
protein	NN	O	O
are	NN	O	O
apparently	NN	O	O
required	NN	O	O
for	NN	O	O
its	NN	O	O
function	NN	O	O
as	NN	O	O
a	NN	O	O
calcification	NN	O	B
inhibitor	NN	O	O
,	NN	O	O
they	NN	O	O
are	NN	O	O
not	NN	O	O
required	NN	O	O
for	NN	O	O
its	NN	O	O
accumulation	NN	O	O
at	NN	O	O
calcification	NN	O	B
sites	NN	O	O
.	NN	O	O

Test	NN	O	O
conditions	NN	O	O
influence	NN	O	O
the	NN	O	O
response	NN	O	O
to	NN	O	O
a	NN	O	O
drug	NN	O	O
challenge	NN	O	O
in	NN	O	O
rodents	NN	O	O
.	NN	O	O

These	NN	O	O
studies	NN	O	O
were	NN	O	O
conducted	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
differential	NN	O	O
response	NN	O	O
to	NN	O	O
a	NN	O	O
drug	NN	O	O
challenge	NN	O	O
under	NN	O	O
varied	NN	O	O
experimental	NN	O	O
test	NN	O	O
conditions	NN	O	O
routinely	NN	O	O
employed	NN	O	O
to	NN	O	O
study	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
behavioral	NN	O	O
and	NN	O	O
neurophysiological	NN	O	O
responses	NN	O	O
in	NN	O	O
rodents	NN	O	O
.	NN	O	O

Apomorphine	NN	O	O
,	NN	O	O
a	NN	O	O
nonselective	NN	O	O
dopamine	NN	O	O
agonist	NN	O	O
,	NN	O	O
was	NN	O	O
selected	NN	O	O
due	NN	O	O
to	NN	O	O
its	NN	O	O
biphasic	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
,	NN	O	O
its	NN	O	O
ability	NN	O	O
to	NN	O	O
induce	NN	O	O
hypothermia	NN	O	B
,	NN	O	O
and	NN	O	O
to	NN	O	O
produce	NN	O	O
distinct	NN	O	O
changes	NN	O	O
to	NN	O	O
dopamine	NN	O	O
turnover	NN	O	O
in	NN	O	O
the	NN	O	O
rodent	NN	O	O
brain	NN	O	O
.	NN	O	O

From	NN	O	O
such	NN	O	O
experiments	NN	O	O
there	NN	O	O
is	NN	O	O
evidence	NN	O	O
that	NN	O	O
characterization	NN	O	O
and	NN	O	O
detection	NN	O	O
of	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
activity	NN	O	O
in	NN	O	O
rodents	NN	O	O
critically	NN	O	O
depends	NN	O	O
upon	NN	O	O
the	NN	O	O
test	NN	O	O
conditions	NN	O	O
employed	NN	O	O
.	NN	O	O

In	NN	O	O
rats	NN	O	O
,	NN	O	O
detection	NN	O	O
of	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
was	NN	O	O
facilitated	NN	O	O
by	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
acclimatization	NN	O	O
to	NN	O	O
the	NN	O	O
test	NN	O	O
conditions	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
test	NN	O	O
conditions	NN	O	O
can	NN	O	O
impact	NN	O	O
upon	NN	O	O
other	NN	O	O
physiological	NN	O	O
responses	NN	O	O
to	NN	O	O
apomorphine	NN	O	O
such	NN	O	O
as	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hypothermia	NN	O	B
.	NN	O	O

In	NN	O	O
mice	NN	O	O
,	NN	O	O
apomorphine	NN	O	O
produced	NN	O	O
qualitatively	NN	O	O
different	NN	O	O
responses	NN	O	O
under	NN	O	O
novel	NN	O	O
conditions	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
those	NN	O	O
behaviors	NN	O	O
elicited	NN	O	O
in	NN	O	O
the	NN	O	O
home	NN	O	O
test	NN	O	O
cage	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
induced	NN	O	O
gross	NN	O	O
activity	NN	O	O
counts	NN	O	O
were	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
novel	NN	O	O
exploratory	NN	O	O
box	NN	O	O
only	NN	O	O
,	NN	O	O
while	NN	O	O
measures	NN	O	O
of	NN	O	O
stereotypic	NN	O	O
behavior	NN	O	O
were	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
.	NN	O	O

By	NN	O	O
contrast	NN	O	O
,	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotion	NN	O	O
was	NN	O	O
more	NN	O	O
prominent	NN	O	O
in	NN	O	O
the	NN	O	O
novel	NN	O	O
exploratory	NN	O	O
box	NN	O	O
.	NN	O	O

Dopamine	NN	O	O
turnover	NN	O	O
ratios	NN	O	O
(	NN	O	O
DOPAC	NN	O	O
:	NN	O	O
DA	NN	O	O
and	NN	O	O
HVA	NN	O	O
:	NN	O	O
DA	NN	O	O
)	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
lower	NN	O	O
in	NN	O	O
those	NN	O	O
animals	NN	O	O
exposed	NN	O	O
to	NN	O	O
the	NN	O	O
exploratory	NN	O	O
box	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
their	NN	O	O
home	NN	O	O
cage	NN	O	O
counterparts	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
reductions	NN	O	O
in	NN	O	O
striatal	NN	O	O
dopamine	NN	O	O
turnover	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
both	NN	O	O
novel	NN	O	O
and	NN	O	O
home	NN	O	O
cage	NN	O	O
environments	NN	O	O
.	NN	O	O

The	NN	O	O
implications	NN	O	O
of	NN	O	O
these	NN	O	O
findings	NN	O	O
are	NN	O	O
discussed	NN	O	O
with	NN	O	O
particular	NN	O	O
emphasis	NN	O	O
upon	NN	O	O
conducting	NN	O	O
psychopharmacological	NN	O	O
challenge	NN	O	O
tests	NN	O	O
in	NN	O	O
rodents	NN	O	O
.	NN	O	O

Hemolysis	NN	O	B
of	NN	O	O
human	NN	O	O
erythrocytes	NN	O	O
induced	NN	O	O
by	NN	O	O
tamoxifen	NN	O	O
is	NN	O	O
related	NN	O	O
to	NN	O	O
disruption	NN	O	O
of	NN	O	O
membrane	NN	O	O
structure	NN	O	O
.	NN	O	O

Tamoxifen	NN	O	O
(	NN	O	O
TAM	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
antiestrogenic	NN	O	O
drug	NN	O	O
most	NN	O	O
widely	NN	O	O
prescribed	NN	O	O
in	NN	O	O
the	NN	O	O
chemotherapy	NN	O	O
of	NN	O	O
breast	NN	O	B
cancer	NN	O	I
,	NN	O	O
induces	NN	O	O
changes	NN	O	O
in	NN	O	O
normal	NN	O	O
discoid	NN	O	O
shape	NN	O	O
of	NN	O	O
erythrocytes	NN	O	O
and	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
.	NN	O	O

This	NN	O	O
work	NN	O	O
evaluates	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
TAM	NN	O	O
on	NN	O	O
isolated	NN	O	O
human	NN	O	O
erythrocytes	NN	O	O
,	NN	O	O
attempting	NN	O	O
to	NN	O	O
identify	NN	O	O
the	NN	O	O
underlying	NN	O	O
mechanisms	NN	O	O
on	NN	O	O
TAM	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
and	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
biomembranes	NN	O	O
in	NN	O	O
its	NN	O	O
cytostatic	NN	O	O
action	NN	O	O
mechanisms	NN	O	O
.	NN	O	O

TAM	NN	O	O
induces	NN	O	O
hemolysis	NN	O	B
of	NN	O	O
erythrocytes	NN	O	O
as	NN	O	O
a	NN	O	O
function	NN	O	O
of	NN	O	O
concentration	NN	O	O
.	NN	O	O

The	NN	O	O
extension	NN	O	O
of	NN	O	O
hemolysis	NN	O	B
is	NN	O	O
variable	NN	O	O
with	NN	O	O
erythrocyte	NN	O	O
samples	NN	O	O
,	NN	O	O
but	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
microM	NN	O	O
TAM	NN	O	O
induces	NN	O	O
total	NN	O	O
hemolysis	NN	O	B
of	NN	O	O
all	NN	O	O
tested	NN	O	O
suspensions	NN	O	O
.	NN	O	O

Despite	NN	O	O
inducing	NN	O	O
extensive	NN	O	O
erythrocyte	NN	O	O
lysis	NN	O	O
,	NN	O	O
TAM	NN	O	O
does	NN	O	O
not	NN	O	O
shift	NN	O	O
the	NN	O	O
osmotic	NN	O	O
fragility	NN	O	O
curves	NN	O	O
of	NN	O	O
erythrocytes	NN	O	O
.	NN	O	O

The	NN	O	O
hemolytic	NN	O	B
effect	NN	O	O
of	NN	O	O
TAM	NN	O	O
is	NN	O	O
prevented	NN	O	O
by	NN	O	O
low	NN	O	O
concentrations	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
tocopherol	NN	O	O
(	NN	O	O
alpha	NN	O	O
-	NN	O	O
T	NN	O	O
)	NN	O	O
and	NN	O	O
alpha	NN	O	O
-	NN	O	O
tocopherol	NN	O	O
acetate	NN	O	O
(	NN	O	O
alpha	NN	O	O
-	NN	O	O
TAc	NN	O	O
)	NN	O	O
(	NN	O	O
inactivated	NN	O	O
functional	NN	O	O
hydroxyl	NN	O	O
)	NN	O	O
indicating	NN	O	O
that	NN	O	O
TAM	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolysis	NN	O	B
is	NN	O	O
not	NN	O	O
related	NN	O	O
to	NN	O	O
oxidative	NN	O	O
membrane	NN	O	O
damage	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
further	NN	O	O
evidenced	NN	O	O
by	NN	O	O
absence	NN	O	O
of	NN	O	O
oxygen	NN	O	O
consumption	NN	O	O
and	NN	O	O
hemoglobin	NN	O	O
oxidation	NN	O	O
both	NN	O	O
determined	NN	O	O
in	NN	O	O
parallel	NN	O	O
with	NN	O	O
TAM	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolysis	NN	O	B
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
it	NN	O	O
was	NN	O	O
observed	NN	O	O
that	NN	O	O
TAM	NN	O	O
inhibits	NN	O	O
the	NN	O	O
peroxidation	NN	O	O
of	NN	O	O
human	NN	O	O
erythrocytes	NN	O	O
induced	NN	O	O
by	NN	O	O
AAPH	NN	O	O
,	NN	O	O
thus	NN	O	O
ruling	NN	O	O
out	NN	O	O
TAM	NN	O	O
-	NN	O	O
induced	NN	O	O
cell	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O

Hemolysis	NN	O	B
caused	NN	O	O
by	NN	O	O
TAM	NN	O	O
was	NN	O	O
not	NN	O	O
preceded	NN	O	O
by	NN	O	O
the	NN	O	O
leakage	NN	O	O
of	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
from	NN	O	O
the	NN	O	O
cells	NN	O	O
,	NN	O	O
also	NN	O	O
excluding	NN	O	O
a	NN	O	O
colloid	NN	O	O
-	NN	O	O
osmotic	NN	O	O
type	NN	O	O
mechanism	NN	O	O
of	NN	O	O
hemolysis	NN	O	B
,	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
effects	NN	O	O
on	NN	O	O
osmotic	NN	O	O
fragility	NN	O	O
curves	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
TAM	NN	O	O
induces	NN	O	O
release	NN	O	O
of	NN	O	O
peripheral	NN	O	O
proteins	NN	O	O
of	NN	O	O
membrane	NN	O	O
-	NN	O	O
cytoskeleton	NN	O	O
and	NN	O	O
cytosol	NN	O	O
proteins	NN	O	O
essentially	NN	O	O
bound	NN	O	O
to	NN	O	O
band	NN	O	O
3	NN	O	O
.	NN	O	O

Either	NN	O	O
alpha	NN	O	O
-	NN	O	O
T	NN	O	O
or	NN	O	O
alpha	NN	O	O
-	NN	O	O
TAc	NN	O	O
increases	NN	O	O
membrane	NN	O	O
packing	NN	O	O
and	NN	O	O
prevents	NN	O	O
TAM	NN	O	O
partition	NN	O	O
into	NN	O	O
model	NN	O	O
membranes	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
protection	NN	O	O
from	NN	O	O
hemolysis	NN	O	B
by	NN	O	O
tocopherols	NN	O	O
is	NN	O	O
related	NN	O	O
to	NN	O	O
a	NN	O	O
decreased	NN	O	O
TAM	NN	O	O
incorporation	NN	O	O
in	NN	O	O
condensed	NN	O	O
membranes	NN	O	O
and	NN	O	O
the	NN	O	O
structural	NN	O	O
damage	NN	O	O
of	NN	O	O
the	NN	O	O
erythrocyte	NN	O	O
membrane	NN	O	O
is	NN	O	O
consequently	NN	O	O
avoided	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
TAM	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolysis	NN	O	B
results	NN	O	O
from	NN	O	O
a	NN	O	O
structural	NN	O	O
perturbation	NN	O	O
of	NN	O	O
red	NN	O	O
cell	NN	O	O
membrane	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
framework	NN	O	O
of	NN	O	O
the	NN	O	O
erythrocyte	NN	O	O
membrane	NN	O	O
and	NN	O	O
its	NN	O	O
cytoskeleton	NN	O	O
caused	NN	O	O
by	NN	O	O
its	NN	O	O
high	NN	O	O
partition	NN	O	O
in	NN	O	O
the	NN	O	O
membrane	NN	O	O
.	NN	O	O

These	NN	O	O
defects	NN	O	O
explain	NN	O	O
the	NN	O	O
abnormal	NN	O	O
erythrocyte	NN	O	O
shape	NN	O	O
and	NN	O	O
decreased	NN	O	O
mechanical	NN	O	O
stability	NN	O	O
promoted	NN	O	O
by	NN	O	O
TAM	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
since	NN	O	O
membrane	NN	O	O
leakage	NN	O	O
is	NN	O	O
a	NN	O	O
final	NN	O	O
stage	NN	O	O
of	NN	O	O
cytotoxicity	NN	O	O
,	NN	O	O
the	NN	O	O
disruption	NN	O	O
of	NN	O	O
the	NN	O	O
structural	NN	O	O
characteristics	NN	O	O
of	NN	O	O
biomembranes	NN	O	O
by	NN	O	O
TAM	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
multiple	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
its	NN	O	O
anticancer	NN	O	O
action	NN	O	O
.	NN	O	O

Changes	NN	O	O
of	NN	O	O
sodium	NN	O	O
and	NN	O	O
ATP	NN	O	O
affinities	NN	O	O
of	NN	O	O
the	NN	O	O
cardiac	NN	O	O
(	NN	O	O
Na	NN	O	O
,	NN	O	O
K	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
during	NN	O	O
and	NN	O	O
after	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
deficient	NN	O	O
hypertension	NN	O	B
.	NN	O	O

In	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
system	NN	O	O
,	NN	O	O
NO	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
functions	NN	O	O
.	NN	O	O

Inhibition	NN	O	O
of	NN	O	O
NO	NN	O	O
synthesis	NN	O	O
induces	NN	O	O
sustained	NN	O	O
hypertension	NN	O	B
.	NN	O	O

In	NN	O	O
several	NN	O	O
models	NN	O	O
of	NN	O	O
hypertension	NN	O	B
,	NN	O	O
elevation	NN	O	O
of	NN	O	O
intracellular	NN	O	O
sodium	NN	O	O
level	NN	O	O
was	NN	O	O
documented	NN	O	O
in	NN	O	O
cardiac	NN	O	O
tissue	NN	O	O
.	NN	O	O

To	NN	O	O
assess	NN	O	O
the	NN	O	O
molecular	NN	O	O
basis	NN	O	O
of	NN	O	O
disturbances	NN	O	O
in	NN	O	O
transmembraneous	NN	O	O
transport	NN	O	O
of	NN	O	O
Na	NN	O	O
+	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
the	NN	O	O
response	NN	O	O
of	NN	O	O
cardiac	NN	O	O
(	NN	O	O
Na	NN	O	O
,	NN	O	O
K	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
to	NN	O	O
NO	NN	O	O
-	NN	O	O
deficient	NN	O	O
hypertension	NN	O	B
induced	NN	O	O
in	NN	O	O
rats	NN	O	O
by	NN	O	O
NO	NN	O	O
-	NN	O	O
synthase	NN	O	O
inhibition	NN	O	O
with	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
N	NN	O	O
(	NN	O	O
G	NN	O	O
)	NN	O	O
-	NN	O	O
nitro	NN	O	O
-	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
methyl	NN	O	O
ester	NN	O	O
(	NN	O	O
L	NN	O	O
-	NN	O	O
NAME	NN	O	O
)	NN	O	O
for	NN	O	O
4	NN	O	O
four	NN	O	O
weeks	NN	O	O
.	NN	O	O

After	NN	O	O
4	NN	O	O
-	NN	O	O
week	NN	O	O
administration	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
NAME	NN	O	O
,	NN	O	O
the	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
SBP	NN	O	O
)	NN	O	O
increased	NN	O	O
by	NN	O	O
36	NN	O	O
%	NN	O	O
.	NN	O	O

Two	NN	O	O
weeks	NN	O	O
after	NN	O	O
terminating	NN	O	O
the	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
SBP	NN	O	O
recovered	NN	O	O
to	NN	O	O
control	NN	O	O
value	NN	O	O
.	NN	O	O

When	NN	O	O
activating	NN	O	O
the	NN	O	O
(	NN	O	O
Na	NN	O	O
,	NN	O	O
K	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
with	NN	O	O
its	NN	O	O
substrate	NN	O	O
ATP	NN	O	O
,	NN	O	O
no	NN	O	O
changes	NN	O	O
in	NN	O	O
Km	NN	O	O
and	NN	O	O
Vmax	NN	O	O
values	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
NO	NN	O	O
-	NN	O	O
deficient	NN	O	O
rats	NN	O	O
.	NN	O	O

During	NN	O	O
activation	NN	O	O
with	NN	O	O
Na	NN	O	O
+	NN	O	O
,	NN	O	O
the	NN	O	O
Vmax	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
,	NN	O	O
however	NN	O	O
the	NN	O	O
K	NN	O	O
(	NN	O	O
Na	NN	O	O
)	NN	O	O
increased	NN	O	O
by	NN	O	O
50	NN	O	O
%	NN	O	O
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
profound	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
affinity	NN	O	O
of	NN	O	O
the	NN	O	O
Na	NN	O	O
+	NN	O	O
-	NN	O	O
binding	NN	O	O
site	NN	O	O
in	NN	O	O
NO	NN	O	O
-	NN	O	O
deficient	NN	O	O
rats	NN	O	O
.	NN	O	O

After	NN	O	O
recovery	NN	O	O
from	NN	O	O
hypertension	NN	O	B
,	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
(	NN	O	O
Na	NN	O	O
,	NN	O	O
K	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
increased	NN	O	O
,	NN	O	O
due	NN	O	O
to	NN	O	O
higher	NN	O	O
affinity	NN	O	O
of	NN	O	O
the	NN	O	O
ATP	NN	O	O
-	NN	O	O
binding	NN	O	O
site	NN	O	O
,	NN	O	O
as	NN	O	O
revealed	NN	O	O
from	NN	O	O
the	NN	O	O
lowered	NN	O	O
Km	NN	O	O
value	NN	O	O
for	NN	O	O
ATP	NN	O	O
.	NN	O	O

The	NN	O	O
K	NN	O	O
(	NN	O	O
Na	NN	O	O
)	NN	O	O
value	NN	O	O
for	NN	O	O
Na	NN	O	O
+	NN	O	O
returned	NN	O	O
to	NN	O	O
control	NN	O	O
value	NN	O	O
.	NN	O	O

Inhibition	NN	O	O
of	NN	O	O
NO	NN	O	O
-	NN	O	O
synthase	NN	O	O
induced	NN	O	O
a	NN	O	O
reversible	NN	O	O
hypertension	NN	O	B
accompanied	NN	O	O
by	NN	O	O
depressed	NN	O	B
Na	NN	O	O
+	NN	O	O
-	NN	O	O
extrusion	NN	O	O
from	NN	O	O
cardiac	NN	O	O
cells	NN	O	O
as	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
deteriorated	NN	O	O
Na	NN	O	O
+	NN	O	O
-	NN	O	O
binding	NN	O	O
properties	NN	O	O
of	NN	O	O
the	NN	O	O
(	NN	O	O
Na	NN	O	O
,	NN	O	O
K	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
.	NN	O	O

After	NN	O	O
recovery	NN	O	O
of	NN	O	O
blood	NN	O	O
pressure	NN	O	O
to	NN	O	O
control	NN	O	O
values	NN	O	O
,	NN	O	O
the	NN	O	O
extrusion	NN	O	O
of	NN	O	O
Na	NN	O	O
+	NN	O	O
from	NN	O	O
cardiac	NN	O	O
cells	NN	O	O
was	NN	O	O
normalized	NN	O	O
,	NN	O	O
as	NN	O	O
revealed	NN	O	O
by	NN	O	O
restoration	NN	O	O
of	NN	O	O
the	NN	O	O
(	NN	O	O
Na	NN	O	O
,	NN	O	O
K	NN	O	O
)	NN	O	O
-	NN	O	O
ATPase	NN	O	O
activity	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
isoproterenol	NN	O	O
on	NN	O	O
bromocriptine	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
in	NN	O	O
conscious	NN	O	O
rats	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
that	NN	O	O
bromocriptine	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
,	NN	O	O
which	NN	O	O
persisted	NN	O	O
after	NN	O	O
adrenalectomy	NN	O	O
,	NN	O	O
is	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
mediated	NN	O	O
by	NN	O	O
central	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
receptor	NN	O	O
activation	NN	O	O
and	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
reduced	NN	O	O
by	NN	O	O
5	NN	O	O
-	NN	O	O
day	NN	O	O
isoproterenol	NN	O	O
pretreatment	NN	O	O
,	NN	O	O
supporting	NN	O	O
therefore	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
this	NN	O	O
effect	NN	O	O
is	NN	O	O
dependent	NN	O	O
on	NN	O	O
sympathetic	NN	O	O
outflow	NN	O	O
to	NN	O	O
the	NN	O	O
heart	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
examine	NN	O	O
whether	NN	O	O
prolonged	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
isoproterenol	NN	O	O
could	NN	O	O
abolish	NN	O	O
bromocriptine	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
in	NN	O	O
conscious	NN	O	O
rats	NN	O	O
.	NN	O	O

Isoproterenol	NN	O	O
pretreatment	NN	O	O
for	NN	O	O
15	NN	O	O
days	NN	O	O
caused	NN	O	O
cardiac	NN	O	B
hypertrophy	NN	O	I
without	NN	O	O
affecting	NN	O	O
baseline	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

In	NN	O	O
control	NN	O	O
rats	NN	O	O
,	NN	O	O
intravenous	NN	O	O
bromocriptine	NN	O	O
(	NN	O	O
150	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
induced	NN	O	O
significant	NN	O	O
hypotension	NN	O	B
and	NN	O	O
tachycardia	NN	O	B
.	NN	O	O

Bromocriptine	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
was	NN	O	O
unaffected	NN	O	O
by	NN	O	O
isoproterenol	NN	O	O
pretreatment	NN	O	O
,	NN	O	O
while	NN	O	O
tachycardia	NN	O	B
was	NN	O	O
reversed	NN	O	O
to	NN	O	O
significant	NN	O	O
bradycardia	NN	O	B
,	NN	O	O
an	NN	O	O
effect	NN	O	O
that	NN	O	O
was	NN	O	O
partly	NN	O	O
reduced	NN	O	O
by	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
domperidone	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

Neither	NN	O	O
cardiac	NN	O	O
vagal	NN	O	O
nor	NN	O	O
sympathetic	NN	O	O
tone	NN	O	O
was	NN	O	O
altered	NN	O	O
by	NN	O	O
isoproterenol	NN	O	O
pretreatment	NN	O	O
.	NN	O	O

In	NN	O	O
isolated	NN	O	O
perfused	NN	O	O
heart	NN	O	O
preparations	NN	O	O
from	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
pretreated	NN	O	O
rats	NN	O	O
,	NN	O	O
the	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
maximal	NN	O	O
increase	NN	O	O
in	NN	O	O
left	NN	O	O
ventricular	NN	O	O
systolic	NN	O	O
pressure	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
saline	NN	O	O
-	NN	O	O
pretreated	NN	O	O
rats	NN	O	O
(	NN	O	O
the	NN	O	O
EC50	NN	O	O
of	NN	O	O
the	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
left	NN	O	O
ventricular	NN	O	O
systolic	NN	O	O
pressure	NN	O	O
was	NN	O	O
enhanced	NN	O	O
approximately	NN	O	O
22	NN	O	O
-	NN	O	O
fold	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
15	NN	O	O
-	NN	O	O
day	NN	O	O
isoproterenol	NN	O	O
pretreatment	NN	O	O
not	NN	O	O
only	NN	O	O
abolished	NN	O	O
but	NN	O	O
reversed	NN	O	O
bromocriptine	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
to	NN	O	O
bradycardia	NN	O	B
,	NN	O	O
an	NN	O	O
effect	NN	O	O
that	NN	O	O
is	NN	O	O
mainly	NN	O	O
related	NN	O	O
to	NN	O	O
further	NN	O	O
cardiac	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
desensitization	NN	O	O
rather	NN	O	O
than	NN	O	O
to	NN	O	O
impairment	NN	O	O
of	NN	O	O
autonomic	NN	O	O
regulation	NN	O	O
of	NN	O	O
the	NN	O	O
heart	NN	O	O
.	NN	O	O

They	NN	O	O
suggest	NN	O	O
that	NN	O	O
,	NN	O	O
in	NN	O	O
normal	NN	O	O
conscious	NN	O	O
rats	NN	O	O
,	NN	O	O
the	NN	O	O
central	NN	O	O
tachycardia	NN	O	B
of	NN	O	O
bromocriptine	NN	O	O
appears	NN	O	O
to	NN	O	O
predominate	NN	O	O
and	NN	O	O
to	NN	O	O
mask	NN	O	O
the	NN	O	O
bradycardia	NN	O	B
of	NN	O	O
this	NN	O	O
agonist	NN	O	O
at	NN	O	O
peripheral	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
receptors	NN	O	O
.	NN	O	O

A	NN	O	O
developmental	NN	O	O
analysis	NN	O	O
of	NN	O	O
clonidine	NN	O	O
'	NN	O	O
s	NN	O	O
effects	NN	O	O
on	NN	O	O
cardiac	NN	O	O
rate	NN	O	O
and	NN	O	O
ultrasound	NN	O	O
production	NN	O	O
in	NN	O	O
infant	NN	O	O
rats	NN	O	O
.	NN	O	O

Under	NN	O	O
controlled	NN	O	O
conditions	NN	O	O
,	NN	O	O
infant	NN	O	O
rats	NN	O	O
emit	NN	O	O
ultrasonic	NN	O	O
vocalizations	NN	O	O
during	NN	O	O
extreme	NN	O	O
cold	NN	O	O
exposure	NN	O	O
and	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
alpha	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
adrenoceptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
clonidine	NN	O	O
.	NN	O	O

Previous	NN	O	O
investigations	NN	O	O
have	NN	O	O
determined	NN	O	O
that	NN	O	O
,	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
clonidine	NN	O	O
,	NN	O	O
ultrasound	NN	O	O
production	NN	O	O
increases	NN	O	O
through	NN	O	O
the	NN	O	O
2nd	NN	O	O
-	NN	O	O
week	NN	O	O
postpartum	NN	O	O
and	NN	O	O
decreases	NN	O	O
thereafter	NN	O	O
.	NN	O	O

Given	NN	O	O
that	NN	O	O
sympathetic	NN	O	O
neural	NN	O	O
dominance	NN	O	O
exhibits	NN	O	O
a	NN	O	O
similar	NN	O	O
developmental	NN	O	O
pattern	NN	O	O
,	NN	O	O
and	NN	O	O
given	NN	O	O
that	NN	O	O
clonidine	NN	O	O
induces	NN	O	O
sympathetic	NN	O	O
withdrawal	NN	O	O
and	NN	O	O
bradycardia	NN	O	B
,	NN	O	O
we	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
clonidine	NN	O	O
'	NN	O	O
s	NN	O	O
developmental	NN	O	O
effects	NN	O	O
on	NN	O	O
cardiac	NN	O	O
rate	NN	O	O
and	NN	O	O
ultrasound	NN	O	O
production	NN	O	O
would	NN	O	O
mirror	NN	O	O
each	NN	O	O
other	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
experiment	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
clonidine	NN	O	O
administration	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
on	NN	O	O
cardiac	NN	O	O
rate	NN	O	O
and	NN	O	O
ultrasound	NN	O	O
production	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
2	NN	O	O
-	NN	O	O
,	NN	O	O
8	NN	O	O
-	NN	O	O
,	NN	O	O
15	NN	O	O
-	NN	O	O
,	NN	O	O
and	NN	O	O
20	NN	O	O
-	NN	O	O
day	NN	O	O
-	NN	O	O
old	NN	O	O
rats	NN	O	O
.	NN	O	O

Age	NN	O	O
-	NN	O	O
related	NN	O	O
changes	NN	O	O
in	NN	O	O
ultrasound	NN	O	O
production	NN	O	O
corresponded	NN	O	O
with	NN	O	O
changes	NN	O	O
in	NN	O	O
cardiovascular	NN	O	O
variables	NN	O	O
,	NN	O	O
including	NN	O	O
baseline	NN	O	O
cardiac	NN	O	O
rate	NN	O	O
and	NN	O	O
clonidine	NN	O	O
-	NN	O	O
induced	NN	O	O
bradycardia	NN	O	B
.	NN	O	O

This	NN	O	O
experiment	NN	O	O
is	NN	O	O
discussed	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
ultrasound	NN	O	O
production	NN	O	O
is	NN	O	O
the	NN	O	O
acoustic	NN	O	O
by	NN	O	O
-	NN	O	O
product	NN	O	O
of	NN	O	O
a	NN	O	O
physiological	NN	O	O
maneuver	NN	O	O
that	NN	O	O
compensates	NN	O	O
for	NN	O	O
clonidine	NN	O	O
'	NN	O	O
s	NN	O	O
detrimental	NN	O	O
effects	NN	O	O
on	NN	O	O
cardiovascular	NN	O	O
function	NN	O	O
.	NN	O	O

Recurrent	NN	O	O
use	NN	O	O
of	NN	O	O
newer	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
and	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
.	NN	O	O

The	NN	O	O
epidemiological	NN	O	O
studies	NN	O	O
that	NN	O	O
assessed	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
(	NN	O	O
VTE	NN	O	B
)	NN	O	O
associated	NN	O	O
with	NN	O	O
newer	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
(	NN	O	O
OC	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
distinguish	NN	O	O
between	NN	O	O
patterns	NN	O	O
of	NN	O	O
OC	NN	O	O
use	NN	O	O
,	NN	O	O
namely	NN	O	O
first	NN	O	O
-	NN	O	O
time	NN	O	O
users	NN	O	O
,	NN	O	O
repeaters	NN	O	O
and	NN	O	O
switchers	NN	O	O
.	NN	O	O

Data	NN	O	O
from	NN	O	O
a	NN	O	O
Transnational	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
VTE	NN	O	B
for	NN	O	O
the	NN	O	O
latter	NN	O	O
patterns	NN	O	O
of	NN	O	O
use	NN	O	O
,	NN	O	O
while	NN	O	O
accounting	NN	O	O
for	NN	O	O
duration	NN	O	O
of	NN	O	O
use	NN	O	O
.	NN	O	O

Over	NN	O	O
the	NN	O	O
period	NN	O	O
1993	NN	O	O
-	NN	O	O
1996	NN	O	O
,	NN	O	O
551	NN	O	O
cases	NN	O	O
of	NN	O	O
VTE	NN	O	B
were	NN	O	O
identified	NN	O	O
in	NN	O	O
Germany	NN	O	O
and	NN	O	O
the	NN	O	O
UK	NN	O	O
along	NN	O	O
with	NN	O	O
2066	NN	O	O
controls	NN	O	O
.	NN	O	O

Totals	NN	O	O
of	NN	O	O
128	NN	O	O
cases	NN	O	O
and	NN	O	O
650	NN	O	O
controls	NN	O	O
were	NN	O	O
analysed	NN	O	O
for	NN	O	O
repeat	NN	O	O
use	NN	O	O
and	NN	O	O
135	NN	O	O
cases	NN	O	O
and	NN	O	O
622	NN	O	O
controls	NN	O	O
for	NN	O	O
switching	NN	O	O
patterns	NN	O	O
.	NN	O	O

The	NN	O	O
adjusted	NN	O	O
rate	NN	O	O
ratio	NN	O	O
of	NN	O	O
VTE	NN	O	B
for	NN	O	O
repeat	NN	O	O
users	NN	O	O
of	NN	O	O
third	NN	O	O
generation	NN	O	O
OC	NN	O	O
was	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
relative	NN	O	O
to	NN	O	O
repeat	NN	O	O
users	NN	O	O
of	NN	O	O
second	NN	O	O
generation	NN	O	O
pills	NN	O	O
,	NN	O	O
whereas	NN	O	O
it	NN	O	O
was	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
for	NN	O	O
switchers	NN	O	O
from	NN	O	O
second	NN	O	O
to	NN	O	O
third	NN	O	O
generation	NN	O	O
pills	NN	O	O
relative	NN	O	O
to	NN	O	O
switchers	NN	O	O
from	NN	O	O
third	NN	O	O
to	NN	O	O
second	NN	O	O
generation	NN	O	O
pills	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
second	NN	O	O
and	NN	O	O
third	NN	O	O
generation	NN	O	O
agents	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
equivalent	NN	O	O
risks	NN	O	O
of	NN	O	O
VTE	NN	O	B
when	NN	O	O
the	NN	O	O
same	NN	O	O
agent	NN	O	O
is	NN	O	O
used	NN	O	O
repeatedly	NN	O	O
after	NN	O	O
interruption	NN	O	O
periods	NN	O	O
or	NN	O	O
when	NN	O	O
users	NN	O	O
are	NN	O	O
switched	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
generations	NN	O	O
of	NN	O	O
pills	NN	O	O
.	NN	O	O

These	NN	O	O
analyses	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
higher	NN	O	O
risk	NN	O	O
observed	NN	O	O
for	NN	O	O
the	NN	O	O
newer	NN	O	O
OC	NN	O	O
in	NN	O	O
other	NN	O	O
studies	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
inadequate	NN	O	O
comparisons	NN	O	O
of	NN	O	O
pill	NN	O	O
users	NN	O	O
with	NN	O	O
different	NN	O	O
patterns	NN	O	O
of	NN	O	O
pill	NN	O	O
use	NN	O	O
.	NN	O	O

Differential	NN	O	O
effects	NN	O	O
of	NN	O	O
systemically	NN	O	O
administered	NN	O	O
ketamine	NN	O	O
and	NN	O	O
lidocaine	NN	O	O
on	NN	O	O
dynamic	NN	O	O
and	NN	O	O
static	NN	O	O
hyperalgesia	NN	O	B
induced	NN	O	O
by	NN	O	O
intradermal	NN	O	O
capsaicin	NN	O	O
in	NN	O	O
humans	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
examined	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
systemic	NN	O	O
administration	NN	O	O
of	NN	O	O
ketamine	NN	O	O
and	NN	O	O
lidocaine	NN	O	O
on	NN	O	O
brush	NN	O	O
-	NN	O	O
evoked	NN	O	O
(	NN	O	O
dynamic	NN	O	O
)	NN	O	O
pain	NN	O	B
and	NN	O	O
punctate	NN	O	O
-	NN	O	O
evoked	NN	O	O
(	NN	O	O
static	NN	O	O
)	NN	O	O
hyperalgesia	NN	O	B
induced	NN	O	O
by	NN	O	O
capsaicin	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
crossover	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
12	NN	O	O
volunteers	NN	O	O
in	NN	O	O
three	NN	O	O
experiments	NN	O	O
.	NN	O	O

Capsaicin	NN	O	O
100	NN	O	O
micrograms	NN	O	O
was	NN	O	O
injected	NN	O	O
intradermally	NN	O	O
on	NN	O	O
the	NN	O	O
volar	NN	O	O
forearm	NN	O	O
followed	NN	O	O
by	NN	O	O
an	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
infusion	NN	O	O
of	NN	O	O
ketamine	NN	O	O
(	NN	O	O
bolus	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
over	NN	O	O
10	NN	O	O
min	NN	O	O
followed	NN	O	O
by	NN	O	O
infusion	NN	O	O
of	NN	O	O
7	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
lidocaine	NN	O	O
5	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
or	NN	O	O
saline	NN	O	O
for	NN	O	O
50	NN	O	O
min	NN	O	O
.	NN	O	O

Infusion	NN	O	O
started	NN	O	O
15	NN	O	O
min	NN	O	O
after	NN	O	O
injection	NN	O	O
of	NN	O	O
capsaicin	NN	O	O
.	NN	O	O

The	NN	O	O
following	NN	O	O
were	NN	O	O
measured	NN	O	O
:	NN	O	O
spontaneous	NN	O	O
pain	NN	O	B
,	NN	O	O
pain	NN	O	B
evoked	NN	O	O
by	NN	O	O
punctate	NN	O	O
and	NN	O	O
brush	NN	O	O
stimuli	NN	O	O
(	NN	O	O
VAS	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
areas	NN	O	O
of	NN	O	O
brush	NN	O	O
-	NN	O	O
evoked	NN	O	O
and	NN	O	O
punctate	NN	O	O
-	NN	O	O
evoked	NN	O	O
hyperalgesia	NN	O	B
.	NN	O	O

Ketamine	NN	O	O
reduced	NN	O	O
both	NN	O	O
the	NN	O	O
area	NN	O	O
of	NN	O	O
brush	NN	O	O
-	NN	O	O
evoked	NN	O	O
and	NN	O	O
punctate	NN	O	O
-	NN	O	O
evoked	NN	O	O
hyperalgesia	NN	O	B
significantly	NN	O	O
and	NN	O	O
it	NN	O	O
tended	NN	O	O
to	NN	O	O
reduce	NN	O	O
brush	NN	O	O
-	NN	O	O
evoked	NN	O	O
pain	NN	O	B
.	NN	O	O

Lidocaine	NN	O	O
reduced	NN	O	O
the	NN	O	O
area	NN	O	O
of	NN	O	O
punctate	NN	O	O
-	NN	O	O
evoked	NN	O	O
hyperalgesia	NN	O	B
significantly	NN	O	O
.	NN	O	O

It	NN	O	O
tended	NN	O	O
to	NN	O	O
reduce	NN	O	O
VAS	NN	O	O
scores	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
pain	NN	O	B
but	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
evoked	NN	O	O
pain	NN	O	B
.	NN	O	O

The	NN	O	O
differential	NN	O	O
effects	NN	O	O
of	NN	O	O
ketamine	NN	O	O
and	NN	O	O
lidocaine	NN	O	O
on	NN	O	O
static	NN	O	O
and	NN	O	O
dynamic	NN	O	O
hyperalgesia	NN	O	B
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
two	NN	O	O
types	NN	O	O
of	NN	O	O
hyperalgesia	NN	O	B
are	NN	O	O
mediated	NN	O	O
by	NN	O	O
separate	NN	O	O
mechanisms	NN	O	O
and	NN	O	O
have	NN	O	O
a	NN	O	O
distinct	NN	O	O
pharmacology	NN	O	O
.	NN	O	O

Development	NN	O	O
of	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
aggressive	NN	O	B
behavior	NN	O	I
:	NN	O	O
comparison	NN	O	O
of	NN	O	O
adult	NN	O	O
male	NN	O	O
and	NN	O	O
female	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
once	NN	O	O
daily	NN	O	O
)	NN	O	O
aggressive	NN	O	B
behavior	NN	O	I
of	NN	O	O
adult	NN	O	O
male	NN	O	O
and	NN	O	O
female	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
obtained	NN	O	O
from	NN	O	O
the	NN	O	O
same	NN	O	O
breeder	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
two	NN	O	O
consecutive	NN	O	O
sets	NN	O	O
.	NN	O	O

In	NN	O	O
male	NN	O	O
animals	NN	O	O
,	NN	O	O
repeated	NN	O	O
apomorphine	NN	O	O
treatment	NN	O	O
induced	NN	O	O
a	NN	O	O
gradual	NN	O	O
development	NN	O	O
of	NN	O	O
aggressive	NN	O	B
behavior	NN	O	I
as	NN	O	O
evidenced	NN	O	O
by	NN	O	O
the	NN	O	O
increased	NN	O	O
intensity	NN	O	O
of	NN	O	O
aggressiveness	NN	O	B
and	NN	O	O
shortened	NN	O	O
latency	NN	O	O
before	NN	O	O
the	NN	O	O
first	NN	O	O
attack	NN	O	O
toward	NN	O	O
the	NN	O	O
opponent	NN	O	O
.	NN	O	O

In	NN	O	O
female	NN	O	O
rats	NN	O	O
,	NN	O	O
only	NN	O	O
a	NN	O	O
weak	NN	O	O
tendency	NN	O	O
toward	NN	O	O
aggressiveness	NN	O	B
was	NN	O	O
found	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
demonstrates	NN	O	O
gender	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
the	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
aggressive	NN	O	B
behavior	NN	O	I
and	NN	O	O
indicates	NN	O	O
that	NN	O	O
the	NN	O	O
female	NN	O	O
rats	NN	O	O
do	NN	O	O
not	NN	O	O
fill	NN	O	O
the	NN	O	O
validation	NN	O	O
criteria	NN	O	O
for	NN	O	O
use	NN	O	O
in	NN	O	O
this	NN	O	O
method	NN	O	O
.	NN	O	O

Intracranial	NN	O	B
aneurysms	NN	O	I
and	NN	O	O
cocaine	NN	O	B
abuse	NN	O	I
:	NN	O	O
analysis	NN	O	O
of	NN	O	O
prognostic	NN	O	O
indicators	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
outcome	NN	O	O
of	NN	O	O
subarachnoid	NN	O	B
hemorrhage	NN	O	I
associated	NN	O	O
with	NN	O	O
cocaine	NN	O	B
abuse	NN	O	I
is	NN	O	O
reportedly	NN	O	O
poor	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
no	NN	O	O
study	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
has	NN	O	O
reported	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
a	NN	O	O
statistical	NN	O	O
model	NN	O	O
to	NN	O	O
analyze	NN	O	O
the	NN	O	O
variables	NN	O	O
that	NN	O	O
influence	NN	O	O
outcome	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
review	NN	O	O
of	NN	O	O
admissions	NN	O	O
during	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
revealed	NN	O	O
14	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
related	NN	O	O
aneurysms	NN	O	B
.	NN	O	O

This	NN	O	O
group	NN	O	O
was	NN	O	O
compared	NN	O	O
with	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
of	NN	O	O
135	NN	O	O
patients	NN	O	O
with	NN	O	O
ruptured	NN	O	B
aneurysms	NN	O	I
and	NN	O	O
no	NN	O	O
history	NN	O	O
of	NN	O	O
cocaine	NN	O	B
abuse	NN	O	I
.	NN	O	O

Age	NN	O	O
at	NN	O	O
presentation	NN	O	O
,	NN	O	O
time	NN	O	O
of	NN	O	O
ictus	NN	O	O
after	NN	O	O
intoxication	NN	O	O
,	NN	O	O
Hunt	NN	O	O
and	NN	O	O
Hess	NN	O	O
grade	NN	O	O
of	NN	O	O
subarachnoid	NN	O	B
hemorrhage	NN	O	I
,	NN	O	O
size	NN	O	O
of	NN	O	O
the	NN	O	O
aneurysm	NN	O	B
,	NN	O	O
location	NN	O	O
of	NN	O	O
the	NN	O	O
aneurysm	NN	O	B
,	NN	O	O
and	NN	O	O
the	NN	O	O
Glasgow	NN	O	O
Outcome	NN	O	O
Scale	NN	O	O
score	NN	O	O
were	NN	O	O
assessed	NN	O	O
and	NN	O	O
compared	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
group	NN	O	O
were	NN	O	O
significantly	NN	O	O
younger	NN	O	O
than	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
002	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
group	NN	O	O
,	NN	O	O
all	NN	O	O
aneurysms	NN	O	B
were	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
anterior	NN	O	O
circulation	NN	O	O
.	NN	O	O

The	NN	O	O
majority	NN	O	O
of	NN	O	O
these	NN	O	O
aneurysms	NN	O	B
were	NN	O	O
smaller	NN	O	O
than	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
08	NN	O	O
mm	NN	O	O
versus	NN	O	O
11	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
4	NN	O	O
mm	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
differences	NN	O	O
in	NN	O	O
mortality	NN	O	O
and	NN	O	O
morbidity	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
were	NN	O	O
not	NN	O	O
significant	NN	O	O
.	NN	O	O

Hunt	NN	O	O
and	NN	O	O
Hess	NN	O	O
grade	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
and	NN	O	O
age	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
007	NN	O	O
)	NN	O	O
were	NN	O	O
significant	NN	O	O
predictors	NN	O	O
of	NN	O	O
outcome	NN	O	O
for	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
related	NN	O	O
aneurysms	NN	O	B
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Cocaine	NN	O	O
use	NN	O	O
predisposed	NN	O	O
aneurysmal	NN	O	B
rupture	NN	O	I
at	NN	O	O
a	NN	O	O
significantly	NN	O	O
earlier	NN	O	O
age	NN	O	O
and	NN	O	O
in	NN	O	O
much	NN	O	O
smaller	NN	O	O
aneurysms	NN	O	B
.	NN	O	O

Contrary	NN	O	O
to	NN	O	O
the	NN	O	O
published	NN	O	O
literature	NN	O	O
,	NN	O	O
this	NN	O	O
group	NN	O	O
did	NN	O	O
reasonably	NN	O	O
well	NN	O	O
with	NN	O	O
aggressive	NN	O	O
management	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
intravenous	NN	O	O
nimodipine	NN	O	O
on	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
outcome	NN	O	O
after	NN	O	O
acute	NN	O	B
stroke	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
PURPOSE	NN	O	O
:	NN	O	O
The	NN	O	O
Intravenous	NN	O	O
Nimodipine	NN	O	O
West	NN	O	O
European	NN	O	O
Stroke	NN	O	B
Trial	NN	O	O
(	NN	O	O
INWEST	NN	O	O
)	NN	O	O
found	NN	O	O
a	NN	O	O
correlation	NN	O	O
between	NN	O	O
nimodipine	NN	O	O
-	NN	O	O
induced	NN	O	O
reduction	NN	O	B
in	NN	O	I
blood	NN	O	I
pressure	NN	O	I
(	NN	O	O
BP	NN	O	O
)	NN	O	O
and	NN	O	O
an	NN	O	O
unfavorable	NN	O	O
outcome	NN	O	O
in	NN	O	O
acute	NN	O	B
stroke	NN	O	I
.	NN	O	O

We	NN	O	O
sought	NN	O	O
to	NN	O	O
confirm	NN	O	O
this	NN	O	O
correlation	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
adjustment	NN	O	O
for	NN	O	O
prognostic	NN	O	O
variables	NN	O	O
and	NN	O	O
to	NN	O	O
investigate	NN	O	O
outcome	NN	O	O
in	NN	O	O
subgroups	NN	O	O
with	NN	O	O
increasing	NN	O	O
levels	NN	O	O
of	NN	O	O
BP	NN	O	B
reduction	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Patients	NN	O	O
with	NN	O	O
a	NN	O	O
clinical	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
ischemic	NN	O	B
stroke	NN	O	I
(	NN	O	O
within	NN	O	O
24	NN	O	O
hours	NN	O	O
)	NN	O	O
were	NN	O	O
consecutively	NN	O	O
allocated	NN	O	O
to	NN	O	O
receive	NN	O	O
placebo	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
100	NN	O	O
)	NN	O	O
,	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
h	NN	O	O
(	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
)	NN	O	O
nimodipine	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
101	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
h	NN	O	O
(	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
)	NN	O	O
nimodipine	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
94	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
correlation	NN	O	O
between	NN	O	O
average	NN	O	O
BP	NN	O	O
change	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
2	NN	O	O
days	NN	O	O
and	NN	O	O
the	NN	O	O
outcome	NN	O	O
at	NN	O	O
day	NN	O	O
21	NN	O	O
was	NN	O	O
analyzed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Two	NN	O	O
hundred	NN	O	O
sixty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
this	NN	O	O
analysis	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
92	NN	O	O
,	NN	O	O
93	NN	O	O
,	NN	O	O
and	NN	O	O
80	NN	O	O
for	NN	O	O
placebo	NN	O	O
,	NN	O	O
low	NN	O	O
dose	NN	O	O
,	NN	O	O
and	NN	O	O
high	NN	O	O
dose	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Nimodipine	NN	O	O
treatment	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
reduction	NN	O	B
in	NN	O	I
systolic	NN	O	I
BP	NN	O	I
(	NN	O	O
SBP	NN	O	O
)	NN	O	O
and	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
(	NN	O	O
DBP	NN	O	O
)	NN	O	O
from	NN	O	O
baseline	NN	O	O
compared	NN	O	O
with	NN	O	O
placebo	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
few	NN	O	O
days	NN	O	O
.	NN	O	O

In	NN	O	O
multivariate	NN	O	O
analysis	NN	O	O
,	NN	O	O
a	NN	O	O
significant	NN	O	O
correlation	NN	O	O
between	NN	O	O
DBP	NN	O	B
reduction	NN	O	I
and	NN	O	O
worsening	NN	O	O
of	NN	O	O
the	NN	O	O
neurological	NN	O	O
score	NN	O	O
was	NN	O	O
found	NN	O	O
for	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
group	NN	O	O
(	NN	O	O
beta	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
49	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
048	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
a	NN	O	O
DBP	NN	O	B
reduction	NN	O	I
of	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
20	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
group	NN	O	O
had	NN	O	O
a	NN	O	O
significantly	NN	O	O
increased	NN	O	O
adjusted	NN	O	O
OR	NN	O	O
for	NN	O	O
the	NN	O	O
compound	NN	O	O
outcome	NN	O	O
variable	NN	O	O
death	NN	O	B
or	NN	O	O
dependency	NN	O	O
(	NN	O	O
Barthel	NN	O	O
Index	NN	O	O
<	NN	O	O
60	NN	O	O
)	NN	O	O
(	NN	O	O
n	NN	O	O
/	NN	O	O
N	NN	O	O
=	NN	O	O
25	NN	O	O
/	NN	O	O
26	NN	O	O
,	NN	O	O
OR	NN	O	O
10	NN	O	O
.	NN	O	O
16	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1	NN	O	O
.	NN	O	O
02	NN	O	O
to	NN	O	O
101	NN	O	O
.	NN	O	O
74	NN	O	O
)	NN	O	O
and	NN	O	O
death	NN	O	B
alone	NN	O	O
(	NN	O	O
n	NN	O	O
/	NN	O	O
N	NN	O	O
=	NN	O	O
9	NN	O	O
/	NN	O	O
26	NN	O	O
,	NN	O	O
OR	NN	O	O
4	NN	O	O
.	NN	O	O
336	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1	NN	O	O
.	NN	O	O
131	NN	O	O
16	NN	O	O
.	NN	O	O
619	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
all	NN	O	O
placebo	NN	O	O
patients	NN	O	O
(	NN	O	O
n	NN	O	O
/	NN	O	O
N	NN	O	O
=	NN	O	O
62	NN	O	O
/	NN	O	O
92	NN	O	O
and	NN	O	O
14	NN	O	O
/	NN	O	O
92	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
correlation	NN	O	O
between	NN	O	O
SBP	NN	O	O
change	NN	O	O
and	NN	O	O
outcome	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
DBP	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
SBP	NN	O	O
,	NN	O	O
reduction	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
neurological	NN	O	O
worsening	NN	O	O
after	NN	O	O
the	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
nimodipine	NN	O	O
after	NN	O	O
acute	NN	O	B
stroke	NN	O	I
.	NN	O	O

For	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
nimodipine	NN	O	O
,	NN	O	O
the	NN	O	O
results	NN	O	O
were	NN	O	O
not	NN	O	O
conclusive	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
do	NN	O	O
not	NN	O	O
confirm	NN	O	O
or	NN	O	O
exclude	NN	O	O
a	NN	O	O
neuroprotective	NN	O	O
property	NN	O	O
of	NN	O	O
nimodipine	NN	O	O
.	NN	O	O

Neonatal	NN	O	O
pyridoxine	NN	O	O
responsive	NN	O	O
convulsions	NN	O	B
due	NN	O	O
to	NN	O	O
isoniazid	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
17	NN	O	O
-	NN	O	O
day	NN	O	O
-	NN	O	O
old	NN	O	O
infant	NN	O	O
on	NN	O	O
isoniazid	NN	O	O
therapy	NN	O	O
13	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
daily	NN	O	O
from	NN	O	O
birth	NN	O	O
because	NN	O	O
of	NN	O	O
maternal	NN	O	O
tuberculosis	NN	O	B
was	NN	O	O
admitted	NN	O	O
after	NN	O	O
4	NN	O	O
days	NN	O	O
of	NN	O	O
clonic	NN	O	B
fits	NN	O	I
.	NN	O	O

No	NN	O	O
underlying	NN	O	O
infective	NN	O	O
or	NN	O	O
biochemical	NN	O	O
cause	NN	O	O
could	NN	O	O
be	NN	O	O
found	NN	O	O
.	NN	O	O

The	NN	O	O
fits	NN	O	B
ceased	NN	O	O
within	NN	O	O
4	NN	O	O
hours	NN	O	O
of	NN	O	O
administering	NN	O	O
intramuscular	NN	O	O
pyridoxine	NN	O	O
,	NN	O	O
suggesting	NN	O	O
an	NN	O	O
aetiology	NN	O	O
of	NN	O	O
pyridoxine	NN	O	O
deficiency	NN	O	O
secondary	NN	O	O
to	NN	O	O
isoniazid	NN	O	O
medication	NN	O	O
.	NN	O	O

Ketamine	NN	O	O
sedation	NN	O	O
for	NN	O	O
the	NN	O	O
reduction	NN	O	O
of	NN	O	O
children	NN	O	O
'	NN	O	O
s	NN	O	O
fractures	NN	O	B
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
There	NN	O	O
recently	NN	O	O
has	NN	O	O
been	NN	O	O
a	NN	O	O
resurgence	NN	O	O
in	NN	O	O
the	NN	O	O
utilization	NN	O	O
of	NN	O	O
ketamine	NN	O	O
,	NN	O	O
a	NN	O	O
unique	NN	O	O
anesthetic	NN	O	O
,	NN	O	O
for	NN	O	O
emergency	NN	O	O
-	NN	O	O
department	NN	O	O
procedures	NN	O	O
requiring	NN	O	O
sedation	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
ketamine	NN	O	O
for	NN	O	O
sedation	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
children	NN	O	O
'	NN	O	O
s	NN	O	O
fractures	NN	O	B
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
One	NN	O	O
hundred	NN	O	O
and	NN	O	O
fourteen	NN	O	O
children	NN	O	O
(	NN	O	O
average	NN	O	O
age	NN	O	O
,	NN	O	O
5	NN	O	O
.	NN	O	O
3	NN	O	O
years	NN	O	O
;	NN	O	O
range	NN	O	O
,	NN	O	O
twelve	NN	O	O
months	NN	O	O
to	NN	O	O
ten	NN	O	O
years	NN	O	O
and	NN	O	O
ten	NN	O	O
months	NN	O	O
)	NN	O	O
who	NN	O	O
underwent	NN	O	O
closed	NN	O	O
reduction	NN	O	O
of	NN	O	O
an	NN	O	O
isolated	NN	O	O
fracture	NN	O	B
or	NN	O	O
dislocation	NN	O	B
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
at	NN	O	O
a	NN	O	O
level	NN	O	O
-	NN	O	O
I	NN	O	O
trauma	NN	O	B
center	NN	O	O
were	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Ketamine	NN	O	O
hydrochloride	NN	O	O
was	NN	O	O
administered	NN	O	O
intravenously	NN	O	O
(	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
two	NN	O	O
milligrams	NN	O	O
per	NN	O	O
kilogram	NN	O	O
of	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
in	NN	O	O
ninety	NN	O	O
-	NN	O	O
nine	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
and	NN	O	O
intramuscularly	NN	O	O
(	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
four	NN	O	O
milligrams	NN	O	O
per	NN	O	O
kilogram	NN	O	O
of	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
fifteen	NN	O	O
.	NN	O	O

A	NN	O	O
board	NN	O	O
-	NN	O	O
certified	NN	O	O
emergency	NN	O	O
physician	NN	O	O
skilled	NN	O	O
in	NN	O	O
airway	NN	O	O
management	NN	O	O
supervised	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
anesthetic	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
monitored	NN	O	O
by	NN	O	O
a	NN	O	O
registered	NN	O	O
nurse	NN	O	O
.	NN	O	O

Any	NN	O	O
pain	NN	O	B
during	NN	O	O
the	NN	O	O
reduction	NN	O	O
was	NN	O	O
rated	NN	O	O
by	NN	O	O
the	NN	O	O
orthopaedic	NN	O	O
surgeon	NN	O	O
treating	NN	O	O
the	NN	O	O
patient	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
Children	NN	O	O
'	NN	O	O
s	NN	O	O
Hospital	NN	O	O
of	NN	O	O
Eastern	NN	O	O
Ontario	NN	O	O
Pain	NN	O	B
Scale	NN	O	O
(	NN	O	O
CHEOPS	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
average	NN	O	O
time	NN	O	O
from	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
ketamine	NN	O	O
to	NN	O	O
manipulation	NN	O	O
of	NN	O	O
the	NN	O	O
fracture	NN	O	B
or	NN	O	O
dislocation	NN	O	B
was	NN	O	O
one	NN	O	O
minute	NN	O	O
and	NN	O	O
thirty	NN	O	O
-	NN	O	O
six	NN	O	O
seconds	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
twenty	NN	O	O
seconds	NN	O	O
to	NN	O	O
five	NN	O	O
minutes	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
average	NN	O	O
time	NN	O	O
from	NN	O	O
intramuscular	NN	O	O
administration	NN	O	O
to	NN	O	O
manipulation	NN	O	O
was	NN	O	O
four	NN	O	O
minutes	NN	O	O
and	NN	O	O
forty	NN	O	O
-	NN	O	O
two	NN	O	O
seconds	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
sixty	NN	O	O
seconds	NN	O	O
to	NN	O	O
fifteen	NN	O	O
minutes	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
score	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
Children	NN	O	O
'	NN	O	O
s	NN	O	O
Hospital	NN	O	O
of	NN	O	O
Eastern	NN	O	O
Ontario	NN	O	O
Pain	NN	O	B
Scale	NN	O	O
was	NN	O	O
6	NN	O	O
.	NN	O	O
4	NN	O	O
points	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
5	NN	O	O
to	NN	O	O
10	NN	O	O
points	NN	O	O
)	NN	O	O
,	NN	O	O
reflecting	NN	O	O
minimal	NN	O	O
or	NN	O	O
no	NN	O	O
pain	NN	O	B
during	NN	O	O
fracture	NN	O	B
reduction	NN	O	O
.	NN	O	O

Adequate	NN	O	O
fracture	NN	O	B
reduction	NN	O	O
was	NN	O	O
obtained	NN	O	O
in	NN	O	O
111	NN	O	O
of	NN	O	O
the	NN	O	O
children	NN	O	O
.	NN	O	O

Ninety	NN	O	O
-	NN	O	O
nine	NN	O	O
percent	NN	O	O
(	NN	O	O
sixty	NN	O	O
-	NN	O	O
eight	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
sixty	NN	O	O
-	NN	O	O
nine	NN	O	O
parents	NN	O	O
present	NN	O	O
during	NN	O	O
the	NN	O	O
reduction	NN	O	O
were	NN	O	O
pleased	NN	O	O
with	NN	O	O
the	NN	O	O
sedation	NN	O	O
and	NN	O	O
would	NN	O	O
allow	NN	O	O
it	NN	O	O
to	NN	O	O
be	NN	O	O
used	NN	O	O
again	NN	O	O
in	NN	O	O
a	NN	O	O
similar	NN	O	O
situation	NN	O	O
.	NN	O	O

Patency	NN	O	O
of	NN	O	O
the	NN	O	O
airway	NN	O	O
and	NN	O	O
independent	NN	O	O
respiration	NN	O	O
were	NN	O	O
maintained	NN	O	O
in	NN	O	O
all	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
.	NN	O	O

Blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
remained	NN	O	O
stable	NN	O	O
.	NN	O	O

Minor	NN	O	O
side	NN	O	O
effects	NN	O	O
included	NN	O	O
nausea	NN	O	B
(	NN	O	O
thirteen	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
emesis	NN	O	B
(	NN	O	O
eight	NN	O	O
of	NN	O	O
the	NN	O	O
thirteen	NN	O	O
patients	NN	O	O
with	NN	O	O
nausea	NN	O	B
)	NN	O	O
,	NN	O	O
clumsiness	NN	O	B
(	NN	O	O
evident	NN	O	O
as	NN	O	O
ataxic	NN	O	B
movements	NN	O	I
in	NN	O	O
ten	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
dysphoric	NN	O	B
reaction	NN	O	I
(	NN	O	O
one	NN	O	O
patient	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
sequelae	NN	O	O
were	NN	O	O
noted	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
patients	NN	O	O
had	NN	O	O
hallucinations	NN	O	B
or	NN	O	O
nightmares	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Ketamine	NN	O	O
reliably	NN	O	O
,	NN	O	O
safely	NN	O	O
,	NN	O	O
and	NN	O	O
quickly	NN	O	O
provided	NN	O	O
adequate	NN	O	O
sedation	NN	O	O
to	NN	O	O
effectively	NN	O	O
facilitate	NN	O	O
the	NN	O	O
reduction	NN	O	O
of	NN	O	O
children	NN	O	O
'	NN	O	O
s	NN	O	O
fractures	NN	O	B
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
at	NN	O	O
our	NN	O	O
institution	NN	O	O
.	NN	O	O

Ketamine	NN	O	O
should	NN	O	O
only	NN	O	O
be	NN	O	O
used	NN	O	O
in	NN	O	O
an	NN	O	O
environment	NN	O	O
such	NN	O	O
as	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
,	NN	O	O
where	NN	O	O
proper	NN	O	O
one	NN	O	O
-	NN	O	O
on	NN	O	O
-	NN	O	O
one	NN	O	O
monitoring	NN	O	O
is	NN	O	O
used	NN	O	O
and	NN	O	O
board	NN	O	O
-	NN	O	O
certified	NN	O	O
physicians	NN	O	O
skilled	NN	O	O
in	NN	O	O
airway	NN	O	O
management	NN	O	O
are	NN	O	O
directly	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
care	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
.	NN	O	O

Cyclosporine	NN	O	O
and	NN	O	O
tacrolimus	NN	O	O
-	NN	O	O
associated	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
(	NN	O	O
TMA	NN	O	B
)	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
has	NN	O	O
been	NN	O	O
well	NN	O	O
documented	NN	O	O
.	NN	O	O

Treatments	NN	O	O
have	NN	O	O
included	NN	O	O
discontinuation	NN	O	O
or	NN	O	O
reduction	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
dose	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
concurrent	NN	O	O
plasma	NN	O	O
exchange	NN	O	O
,	NN	O	O
plasma	NN	O	O
infusion	NN	O	O
,	NN	O	O
anticoagulation	NN	O	O
,	NN	O	O
and	NN	O	O
intravenous	NN	O	O
immunoglobulin	NN	O	O
G	NN	O	O
infusion	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
for	NN	O	O
recipients	NN	O	O
of	NN	O	O
organ	NN	O	O
transplantation	NN	O	O
,	NN	O	O
removing	NN	O	O
the	NN	O	O
inciting	NN	O	O
agent	NN	O	O
is	NN	O	O
not	NN	O	O
without	NN	O	O
the	NN	O	O
attendant	NN	O	O
risk	NN	O	O
of	NN	O	O
precipitating	NN	O	O
acute	NN	O	O
rejection	NN	O	O
and	NN	O	O
graft	NN	O	O
loss	NN	O	O
.	NN	O	O

The	NN	O	O
last	NN	O	O
decade	NN	O	O
has	NN	O	O
seen	NN	O	O
the	NN	O	O
emergence	NN	O	O
of	NN	O	O
tacrolimus	NN	O	O
as	NN	O	O
a	NN	O	O
potent	NN	O	O
immunosuppressive	NN	O	O
agent	NN	O	O
with	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
action	NN	O	O
virtually	NN	O	O
identical	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
result	NN	O	O
,	NN	O	O
switching	NN	O	O
to	NN	O	O
tacrolimus	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
viable	NN	O	O
therapeutic	NN	O	O
option	NN	O	O
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
-	NN	O	O
induced	NN	O	O
TMA	NN	O	B
.	NN	O	O

With	NN	O	O
the	NN	O	O
more	NN	O	O
widespread	NN	O	O
application	NN	O	O
of	NN	O	O
tacrolimus	NN	O	O
in	NN	O	O
organ	NN	O	O
transplantation	NN	O	O
,	NN	O	O
tacrolimus	NN	O	O
-	NN	O	O
associated	NN	O	O
TMA	NN	O	B
has	NN	O	O
also	NN	O	O
been	NN	O	O
recognized	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
literature	NN	O	O
regarding	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
the	NN	O	O
recurrence	NN	O	O
of	NN	O	O
TMA	NN	O	B
in	NN	O	O
patients	NN	O	O
exposed	NN	O	O
sequentially	NN	O	O
to	NN	O	O
cyclosporine	NN	O	O
and	NN	O	O
tacrolimus	NN	O	O
is	NN	O	O
limited	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
living	NN	O	O
donor	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipient	NN	O	O
who	NN	O	O
developed	NN	O	O
cyclosporine	NN	O	O
-	NN	O	O
induced	NN	O	O
TMA	NN	O	B
that	NN	O	O
responded	NN	O	O
to	NN	O	O
the	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
plasmapheresis	NN	O	O
and	NN	O	O
fresh	NN	O	O
frozen	NN	O	O
plasma	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
.	NN	O	O

Introduction	NN	O	O
of	NN	O	O
tacrolimus	NN	O	O
as	NN	O	O
an	NN	O	O
alternative	NN	O	O
immunosuppressive	NN	O	O
agent	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
recurrence	NN	O	O
of	NN	O	O
TMA	NN	O	B
and	NN	O	O
the	NN	O	O
subsequent	NN	O	O
loss	NN	O	O
of	NN	O	O
the	NN	O	O
renal	NN	O	O
allograft	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
are	NN	O	O
switched	NN	O	O
from	NN	O	O
cyclosporine	NN	O	O
to	NN	O	O
tacrolimus	NN	O	O
or	NN	O	O
vice	NN	O	O
versa	NN	O	O
should	NN	O	O
be	NN	O	O
closely	NN	O	O
monitored	NN	O	O
for	NN	O	O
the	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
of	NN	O	O
recurrent	NN	O	O
TMA	NN	O	B
.	NN	O	O

Analgesic	NN	O	O
effect	NN	O	O
of	NN	O	O
intravenous	NN	O	O
ketamine	NN	O	O
in	NN	O	O
cancer	NN	O	B
patients	NN	O	O
on	NN	O	O
morphine	NN	O	O
therapy	NN	O	O
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
crossover	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
dose	NN	O	O
study	NN	O	O
.	NN	O	O

Pain	NN	O	B
not	NN	O	O
responsive	NN	O	O
to	NN	O	O
morphine	NN	O	O
is	NN	O	O
often	NN	O	O
problematic	NN	O	O
.	NN	O	O

Animal	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
have	NN	O	O
suggested	NN	O	O
that	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
(	NN	O	O
NMDA	NN	O	O
)	NN	O	O
antagonists	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
ketamine	NN	O	O
,	NN	O	O
may	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
improving	NN	O	O
opioid	NN	O	O
analgesia	NN	O	O
in	NN	O	O
difficult	NN	O	O
pain	NN	O	B
syndromes	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
neuropathic	NN	O	B
pain	NN	O	I
.	NN	O	O

A	NN	O	O
slow	NN	O	O
bolus	NN	O	O
of	NN	O	O
subhypnotic	NN	O	O
doses	NN	O	O
of	NN	O	O
ketamine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
or	NN	O	O
0	NN	O	O
.	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
given	NN	O	O
to	NN	O	O
10	NN	O	O
cancer	NN	O	B
patients	NN	O	O
whose	NN	O	O
pain	NN	O	B
was	NN	O	O
unrelieved	NN	O	O
by	NN	O	O
morphine	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
crossover	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
dose	NN	O	O
study	NN	O	O
.	NN	O	O

Pain	NN	O	B
intensity	NN	O	O
on	NN	O	O
a	NN	O	O
0	NN	O	O
to	NN	O	O
10	NN	O	O
numerical	NN	O	O
scale	NN	O	O
;	NN	O	O
nausea	NN	O	B
and	NN	O	O
vomiting	NN	O	B
,	NN	O	O
drowsiness	NN	O	O
,	NN	O	O
confusion	NN	O	B
,	NN	O	O
and	NN	O	O
dry	NN	O	B
mouth	NN	O	I
,	NN	O	O
using	NN	O	O
a	NN	O	O
scale	NN	O	O
from	NN	O	O
0	NN	O	O
to	NN	O	O
3	NN	O	O
(	NN	O	O
not	NN	O	O
at	NN	O	O
all	NN	O	O
,	NN	O	O
slight	NN	O	O
,	NN	O	O
a	NN	O	O
lot	NN	O	O
,	NN	O	O
awful	NN	O	O
)	NN	O	O
;	NN	O	O
Mini	NN	O	O
-	NN	O	O
Mental	NN	O	O
State	NN	O	O
Examination	NN	O	O
(	NN	O	O
MMSE	NN	O	O
)	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
30	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
were	NN	O	O
recorded	NN	O	O
before	NN	O	O
administration	NN	O	O
of	NN	O	O
drugs	NN	O	O
(	NN	O	O
T0	NN	O	O
)	NN	O	O
and	NN	O	O
after	NN	O	O
30	NN	O	O
minutes	NN	O	O
(	NN	O	O
T30	NN	O	O
)	NN	O	O
,	NN	O	O
60	NN	O	O
minutes	NN	O	O
(	NN	O	O
T60	NN	O	O
)	NN	O	O
,	NN	O	O
120	NN	O	O
minutes	NN	O	O
(	NN	O	O
T120	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
180	NN	O	O
minutes	NN	O	O
(	NN	O	O
T180	NN	O	O
)	NN	O	O
.	NN	O	O

Ketamine	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
saline	NN	O	O
solution	NN	O	O
,	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
pain	NN	O	B
intensity	NN	O	O
in	NN	O	O
almost	NN	O	O
all	NN	O	O
the	NN	O	O
patients	NN	O	O
at	NN	O	O
both	NN	O	O
doses	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
was	NN	O	O
more	NN	O	O
relevant	NN	O	O
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
higher	NN	O	O
doses	NN	O	O
.	NN	O	O

Hallucinations	NN	O	B
occurred	NN	O	O
in	NN	O	O
4	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
an	NN	O	O
unpleasant	NN	O	O
sensation	NN	O	O
(	NN	O	O
"	NN	O	O
empty	NN	O	O
head	NN	O	O
"	NN	O	O
)	NN	O	O
was	NN	O	O
also	NN	O	O
reported	NN	O	O
by	NN	O	O
2	NN	O	O
patients	NN	O	O
.	NN	O	O

These	NN	O	O
episodes	NN	O	O
reversed	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
diazepam	NN	O	O
1	NN	O	O
mg	NN	O	O
intravenously	NN	O	O
.	NN	O	O

Significant	NN	O	O
increases	NN	O	O
in	NN	O	O
drowsiness	NN	O	O
were	NN	O	O
reported	NN	O	O
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
ketamine	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
and	NN	O	O
were	NN	O	O
more	NN	O	O
marked	NN	O	O
with	NN	O	O
ketamine	NN	O	O
0	NN	O	O
.	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
MMSE	NN	O	O
was	NN	O	O
observed	NN	O	O
at	NN	O	O
T30	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
0	NN	O	O
.	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
ketamine	NN	O	O
.	NN	O	O

Ketamine	NN	O	O
can	NN	O	O
improve	NN	O	O
morphine	NN	O	O
analgesia	NN	O	O
in	NN	O	O
difficult	NN	O	O
pain	NN	O	B
syndromes	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
neuropathic	NN	O	B
pain	NN	O	I
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
central	NN	O	O
adverse	NN	O	O
effects	NN	O	O
should	NN	O	O
be	NN	O	O
taken	NN	O	O
into	NN	O	O
account	NN	O	O
,	NN	O	O
especially	NN	O	O
when	NN	O	O
using	NN	O	O
higher	NN	O	O
doses	NN	O	O
.	NN	O	O

This	NN	O	O
observation	NN	O	O
should	NN	O	O
be	NN	O	O
tested	NN	O	O
in	NN	O	O
studies	NN	O	O
of	NN	O	O
prolonged	NN	O	O
ketamine	NN	O	O
administration	NN	O	O
.	NN	O	O

Paclitaxel	NN	O	O
,	NN	O	O
cisplatin	NN	O	O
,	NN	O	O
and	NN	O	O
gemcitabine	NN	O	O
combination	NN	O	O
chemotherapy	NN	O	O
within	NN	O	O
a	NN	O	O
multidisciplinary	NN	O	O
therapeutic	NN	O	O
approach	NN	O	O
in	NN	O	O
metastatic	NN	O	O
nonsmall	NN	O	B
cell	NN	O	I
lung	NN	O	I
carcinoma	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Cisplatin	NN	O	O
-	NN	O	O
based	NN	O	O
chemotherapy	NN	O	O
combinations	NN	O	O
improve	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
and	NN	O	O
survival	NN	O	O
in	NN	O	O
advanced	NN	O	O
nonsmall	NN	O	B
cell	NN	O	I
lung	NN	O	I
carcinoma	NN	O	I
(	NN	O	O
NSCLC	NN	O	B
)	NN	O	O
.	NN	O	O

The	NN	O	O
emergence	NN	O	O
of	NN	O	O
new	NN	O	O
active	NN	O	O
drugs	NN	O	O
might	NN	O	O
translate	NN	O	O
into	NN	O	O
more	NN	O	O
effective	NN	O	O
regimens	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
this	NN	O	O
disease	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
feasibility	NN	O	O
,	NN	O	O
response	NN	O	O
rate	NN	O	O
,	NN	O	O
and	NN	O	O
toxicity	NN	O	B
of	NN	O	O
a	NN	O	O
paclitaxel	NN	O	O
,	NN	O	O
cisplatin	NN	O	O
,	NN	O	O
and	NN	O	O
gemcitabine	NN	O	O
combination	NN	O	O
to	NN	O	O
treat	NN	O	O
metastatic	NN	O	O
NSCLC	NN	O	B
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
five	NN	O	O
consecutive	NN	O	O
chemotherapy	NN	O	O
-	NN	O	O
naive	NN	O	O
patients	NN	O	O
with	NN	O	O
Stage	NN	O	O
IV	NN	O	O
NSCLC	NN	O	B
and	NN	O	O
an	NN	O	O
Eastern	NN	O	O
Cooperative	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
performance	NN	O	O
status	NN	O	O
of	NN	O	O
0	NN	O	O
-	NN	O	O
2	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
paclitaxel	NN	O	O
(	NN	O	O
135	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
given	NN	O	O
intravenously	NN	O	O
in	NN	O	O
3	NN	O	O
hours	NN	O	O
)	NN	O	O
on	NN	O	O
Day	NN	O	O
1	NN	O	O
,	NN	O	O
cisplatin	NN	O	O
(	NN	O	O
120	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
given	NN	O	O
intravenously	NN	O	O
in	NN	O	O
6	NN	O	O
hours	NN	O	O
)	NN	O	O
on	NN	O	O
Day	NN	O	O
1	NN	O	O
,	NN	O	O
and	NN	O	O
gemcitabine	NN	O	O
(	NN	O	O
800	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
given	NN	O	O
intravenously	NN	O	O
in	NN	O	O
30	NN	O	O
minutes	NN	O	O
)	NN	O	O
on	NN	O	O
Days	NN	O	O
1	NN	O	O
and	NN	O	O
8	NN	O	O
,	NN	O	O
every	NN	O	O
4	NN	O	O
weeks	NN	O	O
.	NN	O	O

Although	NN	O	O
responding	NN	O	O
patients	NN	O	O
were	NN	O	O
scheduled	NN	O	O
to	NN	O	O
receive	NN	O	O
consolidation	NN	O	O
radiotherapy	NN	O	O
and	NN	O	O
24	NN	O	O
patients	NN	O	O
received	NN	O	O
preplanned	NN	O	O
second	NN	O	O
-	NN	O	O
line	NN	O	O
chemotherapy	NN	O	O
after	NN	O	O
disease	NN	O	O
progression	NN	O	O
,	NN	O	O
the	NN	O	O
response	NN	O	O
and	NN	O	O
toxicity	NN	O	B
rates	NN	O	O
reported	NN	O	O
refer	NN	O	O
only	NN	O	O
to	NN	O	O
the	NN	O	O
chemotherapy	NN	O	O
regimen	NN	O	O
given	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
examined	NN	O	O
for	NN	O	O
toxicity	NN	O	B
;	NN	O	O
34	NN	O	O
were	NN	O	O
examinable	NN	O	O
for	NN	O	O
response	NN	O	O
.	NN	O	O

An	NN	O	O
objective	NN	O	O
response	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
73	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
,	NN	O	O
55	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
87	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
including	NN	O	O
4	NN	O	O
complete	NN	O	O
responses	NN	O	O
(	NN	O	O
11	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

According	NN	O	O
to	NN	O	O
intention	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
treat	NN	O	O
,	NN	O	O
the	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
was	NN	O	O
71	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
53	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
85	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
154	NN	O	O
courses	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
the	NN	O	O
median	NN	O	O
dose	NN	O	O
intensity	NN	O	O
was	NN	O	O
131	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
for	NN	O	O
paclitaxel	NN	O	O
(	NN	O	O
97	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
117	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
for	NN	O	O
cisplatin	NN	O	O
(	NN	O	O
97	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
1378	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
for	NN	O	O
gemcitabine	NN	O	O
(	NN	O	O
86	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

World	NN	O	O
Health	NN	O	O
Organization	NN	O	O
Grade	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
neutropenia	NN	O	B
and	NN	O	O
thrombocytopenia	NN	O	B
occurred	NN	O	O
in	NN	O	O
39	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
and	NN	O	O
11	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
one	NN	O	O
treatment	NN	O	O
-	NN	O	O
related	NN	O	O
death	NN	O	B
.	NN	O	O

Nonhematologic	NN	O	O
toxicities	NN	O	B
were	NN	O	O
mild	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
22	NN	O	O
months	NN	O	O
,	NN	O	O
the	NN	O	O
median	NN	O	O
progression	NN	O	O
free	NN	O	O
survival	NN	O	O
rate	NN	O	O
was	NN	O	O
7	NN	O	O
months	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
median	NN	O	O
survival	NN	O	O
time	NN	O	O
was	NN	O	O
16	NN	O	O
months	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
combination	NN	O	O
of	NN	O	O
paclitaxel	NN	O	O
,	NN	O	O
cisplatin	NN	O	O
,	NN	O	O
and	NN	O	O
gemcitabine	NN	O	O
is	NN	O	O
well	NN	O	O
tolerated	NN	O	O
and	NN	O	O
shows	NN	O	O
high	NN	O	O
activity	NN	O	O
in	NN	O	O
metastatic	NN	O	O
NSCLC	NN	O	B
.	NN	O	O

This	NN	O	O
treatment	NN	O	O
merits	NN	O	O
further	NN	O	O
comparison	NN	O	O
with	NN	O	O
other	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
based	NN	O	O
regimens	NN	O	O
.	NN	O	O

Serotonergic	NN	O	O
antidepressants	NN	O	O
and	NN	O	O
urinary	NN	O	B
incontinence	NN	O	I
.	NN	O	O

Many	NN	O	O
new	NN	O	O
serotonergic	NN	O	O
antidepressants	NN	O	O
have	NN	O	O
been	NN	O	O
introduced	NN	O	O
over	NN	O	O
the	NN	O	O
past	NN	O	O
decade	NN	O	O
.	NN	O	O

Although	NN	O	O
urinary	NN	O	B
incontinence	NN	O	I
is	NN	O	O
listed	NN	O	O
as	NN	O	O
one	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
in	NN	O	O
their	NN	O	O
package	NN	O	O
inserts	NN	O	O
there	NN	O	O
is	NN	O	O
only	NN	O	O
one	NN	O	O
report	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

This	NN	O	O
concerns	NN	O	O
2	NN	O	O
male	NN	O	O
patients	NN	O	O
who	NN	O	O
experienced	NN	O	O
incontinence	NN	O	B
while	NN	O	O
taking	NN	O	O
venlafaxine	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
paper	NN	O	O
the	NN	O	O
authors	NN	O	O
describe	NN	O	O
2	NN	O	O
female	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
incontinence	NN	O	B
secondary	NN	O	O
to	NN	O	O
the	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NN	O	O
paroxetine	NN	O	O
and	NN	O	O
sertraline	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
a	NN	O	O
third	NN	O	O
who	NN	O	O
developed	NN	O	O
this	NN	O	O
side	NN	O	O
effect	NN	O	O
on	NN	O	O
venlafaxine	NN	O	O
.	NN	O	O

In	NN	O	O
2	NN	O	O
of	NN	O	O
the	NN	O	O
3	NN	O	O
cases	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
also	NN	O	O
taking	NN	O	O
lithium	NN	O	O
carbonate	NN	O	O
and	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
,	NN	O	O
both	NN	O	O
of	NN	O	O
which	NN	O	O
could	NN	O	O
have	NN	O	O
contributed	NN	O	O
to	NN	O	O
the	NN	O	O
incontinence	NN	O	B
.	NN	O	O

Animal	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
incontinence	NN	O	B
secondary	NN	O	O
to	NN	O	O
serotonergic	NN	O	O
antidepressants	NN	O	O
could	NN	O	O
be	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
5HT4	NN	O	O
receptors	NN	O	O
found	NN	O	O
on	NN	O	O
the	NN	O	O
bladder	NN	O	O
.	NN	O	O

Further	NN	O	O
research	NN	O	O
is	NN	O	O
needed	NN	O	O
to	NN	O	O
delineate	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
this	NN	O	O
troubling	NN	O	O
side	NN	O	O
effect	NN	O	O
and	NN	O	O
how	NN	O	O
best	NN	O	O
to	NN	O	O
treat	NN	O	O
it	NN	O	O
.	NN	O	O

Acute	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
:	NN	O	O
differential	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
six	NN	O	O
inbred	NN	O	O
mouse	NN	O	O
strains	NN	O	O
.	NN	O	O

Mature	NN	O	O
male	NN	O	O
and	NN	O	O
female	NN	O	O
mice	NN	O	O
from	NN	O	O
six	NN	O	O
inbred	NN	O	O
stains	NN	O	O
were	NN	O	O
tested	NN	O	O
for	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
behavioral	NN	O	O
seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
cocaine	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
was	NN	O	O
injected	NN	O	O
ip	NN	O	O
over	NN	O	O
a	NN	O	O
range	NN	O	O
of	NN	O	O
doses	NN	O	O
(	NN	O	O
50	NN	O	O
-	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
behavior	NN	O	O
was	NN	O	O
monitored	NN	O	O
for	NN	O	O
20	NN	O	O
minutes	NN	O	O
.	NN	O	O

Seizure	NN	O	B
end	NN	O	O
points	NN	O	O
included	NN	O	O
latency	NN	O	O
to	NN	O	O
forelimb	NN	O	O
or	NN	O	O
hindlimb	NN	O	O
clonus	NN	O	O
,	NN	O	O
latency	NN	O	O
to	NN	O	O
clonic	NN	O	O
running	NN	O	O
seizure	NN	O	B
and	NN	O	O
latency	NN	O	O
to	NN	O	O
jumping	NN	O	O
bouncing	NN	O	O
seizure	NN	O	B
.	NN	O	O

A	NN	O	O
range	NN	O	O
of	NN	O	O
strain	NN	O	O
specific	NN	O	O
sensitivities	NN	O	O
was	NN	O	O
documented	NN	O	O
with	NN	O	O
A	NN	O	O
/	NN	O	O
J	NN	O	O
and	NN	O	O
SJL	NN	O	O
mice	NN	O	O
being	NN	O	O
most	NN	O	O
sensitive	NN	O	O
and	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6J	NN	O	O
most	NN	O	O
resistant	NN	O	O
.	NN	O	O

DBA	NN	O	O
/	NN	O	O
2J	NN	O	O
,	NN	O	O
BALB	NN	O	O
/	NN	O	O
cByJ	NN	O	O
and	NN	O	O
NZW	NN	O	O
/	NN	O	O
LacJ	NN	O	O
strains	NN	O	O
exhibited	NN	O	O
intermediate	NN	O	O
sensitivity	NN	O	O
.	NN	O	O

EEG	NN	O	O
recordings	NN	O	O
were	NN	O	O
made	NN	O	O
in	NN	O	O
SJL	NN	O	O
,	NN	O	O
A	NN	O	O
/	NN	O	O
J	NN	O	O
and	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6J	NN	O	O
mice	NN	O	O
revealing	NN	O	O
a	NN	O	O
close	NN	O	O
correspondence	NN	O	O
between	NN	O	O
electrical	NN	O	O
activity	NN	O	O
and	NN	O	O
behavior	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
levels	NN	O	O
of	NN	O	O
cocaine	NN	O	O
determined	NN	O	O
in	NN	O	O
hippocampus	NN	O	O
and	NN	O	O
cortex	NN	O	O
were	NN	O	O
not	NN	O	O
different	NN	O	O
between	NN	O	O
sensitive	NN	O	O
and	NN	O	O
resistant	NN	O	O
strains	NN	O	O
.	NN	O	O

Additional	NN	O	O
studies	NN	O	O
of	NN	O	O
these	NN	O	O
murine	NN	O	O
strains	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
for	NN	O	O
investigating	NN	O	O
genetic	NN	O	O
influences	NN	O	O
on	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
.	NN	O	O

Hypotension	NN	O	B
following	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
tizanidine	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
an	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
for	NN	O	O
chronic	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Centrally	NN	O	O
acting	NN	O	O
alpha	NN	O	O
-	NN	O	O
2	NN	O	O
adrenergic	NN	O	O
agonists	NN	O	O
are	NN	O	O
one	NN	O	O
of	NN	O	O
several	NN	O	O
pharmacologic	NN	O	O
agents	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
spasticity	NN	O	B
related	NN	O	O
to	NN	O	O
disorders	NN	O	B
of	NN	O	I
the	NN	O	I
central	NN	O	I
nervous	NN	O	I
system	NN	O	I
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
their	NN	O	O
effects	NN	O	O
on	NN	O	O
spasticity	NN	O	B
,	NN	O	O
certain	NN	O	O
adverse	NN	O	O
cardiorespiratory	NN	O	O
effects	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

Adults	NN	O	O
chronically	NN	O	O
treated	NN	O	O
with	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitors	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
limited	NN	O	O
ability	NN	O	O
to	NN	O	O
respond	NN	O	O
to	NN	O	O
hypotension	NN	O	B
when	NN	O	O
the	NN	O	O
sympathetic	NN	O	O
response	NN	O	O
is	NN	O	O
simultaneously	NN	O	O
blocked	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
present	NN	O	O
a	NN	O	O
10	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
chronically	NN	O	O
treated	NN	O	O
with	NN	O	O
lisinopril	NN	O	O
,	NN	O	O
an	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
to	NN	O	O
control	NN	O	O
hypertension	NN	O	B
who	NN	O	O
developed	NN	O	O
hypotension	NN	O	B
following	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
tizanidine	NN	O	O
,	NN	O	O
an	NN	O	O
alpha	NN	O	O
-	NN	O	O
2	NN	O	O
agonist	NN	O	O
,	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
spasticity	NN	O	B
.	NN	O	O

The	NN	O	O
possible	NN	O	O
interaction	NN	O	O
of	NN	O	O
tizanidine	NN	O	O
and	NN	O	O
other	NN	O	O
antihypertensive	NN	O	O
agents	NN	O	O
should	NN	O	O
be	NN	O	O
kept	NN	O	O
in	NN	O	O
mind	NN	O	O
when	NN	O	O
prescribing	NN	O	O
therapy	NN	O	O
to	NN	O	O
treat	NN	O	O
either	NN	O	O
hypertension	NN	O	B
or	NN	O	O
spasticity	NN	O	B
in	NN	O	O
such	NN	O	O
patients	NN	O	O
.	NN	O	O

Two	NN	O	O
mouse	NN	O	O
lines	NN	O	O
selected	NN	O	O
for	NN	O	O
differential	NN	O	O
sensitivities	NN	O	O
to	NN	O	O
beta	NN	O	O
-	NN	O	O
carboline	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
are	NN	O	O
also	NN	O	O
differentially	NN	O	O
sensitive	NN	O	O
to	NN	O	O
various	NN	O	O
pharmacological	NN	O	O
effects	NN	O	O
of	NN	O	O
other	NN	O	O
GABA	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
receptor	NN	O	O
ligands	NN	O	O
.	NN	O	O

Two	NN	O	O
mouse	NN	O	O
lines	NN	O	O
were	NN	O	O
selectively	NN	O	O
bred	NN	O	O
according	NN	O	O
to	NN	O	O
their	NN	O	O
sensitivity	NN	O	O
(	NN	O	O
BS	NN	O	O
line	NN	O	O
)	NN	O	O
or	NN	O	O
resistance	NN	O	O
(	NN	O	O
BR	NN	O	O
line	NN	O	O
)	NN	O	O
to	NN	O	O
seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
injection	NN	O	O
of	NN	O	O
methyl	NN	O	O
beta	NN	O	O
-	NN	O	O
carboline	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
carboxylate	NN	O	O
(	NN	O	O
beta	NN	O	O
-	NN	O	O
CCM	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
inverse	NN	O	O
agonist	NN	O	O
of	NN	O	O
the	NN	O	O
GABA	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
receptor	NN	O	O
benzodiazepine	NN	O	O
site	NN	O	O
.	NN	O	O

Our	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
characterize	NN	O	O
both	NN	O	O
lines	NN	O	O
'	NN	O	O
sensitivities	NN	O	O
to	NN	O	O
various	NN	O	O
physiological	NN	O	O
effects	NN	O	O
of	NN	O	O
other	NN	O	O
ligands	NN	O	O
of	NN	O	O
the	NN	O	O
GABA	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
receptor	NN	O	O
.	NN	O	O

We	NN	O	O
measured	NN	O	O
diazepam	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiolysis	NN	O	O
with	NN	O	O
the	NN	O	O
elevated	NN	O	O
plus	NN	O	O
-	NN	O	O
maze	NN	O	O
test	NN	O	O
,	NN	O	O
diazepam	NN	O	O
-	NN	O	O
induced	NN	O	O
sedation	NN	O	O
by	NN	O	O
recording	NN	O	O
the	NN	O	O
vigilance	NN	O	O
states	NN	O	O
,	NN	O	O
and	NN	O	O
picrotoxin	NN	O	O
-	NN	O	O
and	NN	O	O
pentylenetetrazol	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
after	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
injections	NN	O	O
.	NN	O	O

Results	NN	O	O
presented	NN	O	O
here	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
differential	NN	O	O
sensitivities	NN	O	O
of	NN	O	O
BS	NN	O	O
and	NN	O	O
BR	NN	O	O
lines	NN	O	O
to	NN	O	O
beta	NN	O	O
-	NN	O	O
CCM	NN	O	O
can	NN	O	O
be	NN	O	O
extended	NN	O	O
to	NN	O	O
diazepam	NN	O	O
,	NN	O	O
picrotoxin	NN	O	O
,	NN	O	O
and	NN	O	O
pentylenetetrazol	NN	O	O
,	NN	O	O
suggesting	NN	O	O
a	NN	O	O
genetic	NN	O	O
selection	NN	O	O
of	NN	O	O
a	NN	O	O
general	NN	O	O
sensitivity	NN	O	O
and	NN	O	O
resistance	NN	O	O
to	NN	O	O
several	NN	O	O
ligands	NN	O	O
of	NN	O	O
the	NN	O	O
GABA	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
receptor	NN	O	O
.	NN	O	O

Propylthiouracil	NN	O	O
-	NN	O	O
induced	NN	O	O
perinuclear	NN	O	O
-	NN	O	O
staining	NN	O	O
antineutrophil	NN	O	O
cytoplasmic	NN	O	O
autoantibody	NN	O	O
-	NN	O	O
positive	NN	O	O
vasculitis	NN	O	B
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
pericarditis	NN	O	B
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
propylthiouracil	NN	O	O
-	NN	O	O
induced	NN	O	O
vasculitis	NN	O	B
manifesting	NN	O	O
with	NN	O	O
pericarditis	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
present	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
report	NN	O	O
of	NN	O	O
a	NN	O	O
woman	NN	O	O
with	NN	O	O
hyperthyroidism	NN	O	B
treated	NN	O	O
with	NN	O	O
propylthiouracil	NN	O	O
in	NN	O	O
whom	NN	O	O
a	NN	O	O
syndrome	NN	O	O
of	NN	O	O
pericarditis	NN	O	B
,	NN	O	O
fever	NN	O	B
,	NN	O	O
and	NN	O	O
glomerulonephritis	NN	O	B
developed	NN	O	O
.	NN	O	O

Serologic	NN	O	O
testing	NN	O	O
and	NN	O	O
immunologic	NN	O	O
studies	NN	O	O
were	NN	O	O
done	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
pericardial	NN	O	O
biopsy	NN	O	O
was	NN	O	O
performed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
25	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
Graves	NN	O	B
'	NN	O	I
disease	NN	O	I
had	NN	O	O
a	NN	O	O
febrile	NN	O	B
illness	NN	O	I
and	NN	O	O
evidence	NN	O	O
of	NN	O	O
pericarditis	NN	O	B
,	NN	O	O
which	NN	O	O
was	NN	O	O
confirmed	NN	O	O
by	NN	O	O
biopsy	NN	O	O
.	NN	O	O

Serologic	NN	O	O
evaluation	NN	O	O
revealed	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
perinuclear	NN	O	O
-	NN	O	O
staining	NN	O	O
antineutrophil	NN	O	O
cytoplasmic	NN	O	O
autoantibodies	NN	O	O
(	NN	O	O
pANCA	NN	O	O
)	NN	O	O
against	NN	O	O
myeloperoxidase	NN	O	O
(	NN	O	O
MPO	NN	O	O
)	NN	O	O
.	NN	O	O

Propylthiouracil	NN	O	O
therapy	NN	O	O
was	NN	O	O
withdrawn	NN	O	O
,	NN	O	O
and	NN	O	O
she	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
1	NN	O	O
-	NN	O	O
month	NN	O	O
course	NN	O	O
of	NN	O	O
prednisone	NN	O	O
,	NN	O	O
which	NN	O	O
alleviated	NN	O	O
her	NN	O	O
symptoms	NN	O	O
.	NN	O	O

A	NN	O	O
literature	NN	O	O
review	NN	O	O
revealed	NN	O	O
no	NN	O	O
prior	NN	O	O
reports	NN	O	O
of	NN	O	O
pericarditis	NN	O	B
in	NN	O	O
anti	NN	O	O
-	NN	O	O
MPO	NN	O	O
pANCA	NN	O	O
-	NN	O	O
positive	NN	O	O
vasculitis	NN	O	B
associated	NN	O	O
with	NN	O	O
propylthio	NN	O	O
-	NN	O	O
uracil	NN	O	O
therapy	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Pericarditis	NN	O	B
may	NN	O	O
be	NN	O	O
the	NN	O	O
initial	NN	O	O
manifestation	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
vasculitis	NN	O	B
attributable	NN	O	O
to	NN	O	O
propylthio	NN	O	O
-	NN	O	O
uracil	NN	O	O
therapy	NN	O	O
.	NN	O	O

Repeated	NN	O	O
transient	NN	O	O
anuria	NN	O	B
following	NN	O	O
losartan	NN	O	O
administration	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
a	NN	O	O
solitary	NN	O	O
kidney	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
70	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
hypertensive	NN	O	B
man	NN	O	O
with	NN	O	O
a	NN	O	O
solitary	NN	O	O
kidney	NN	O	O
and	NN	O	O
chronic	NN	O	B
renal	NN	O	I
insufficiency	NN	O	I
who	NN	O	O
developed	NN	O	O
two	NN	O	O
episodes	NN	O	O
of	NN	O	O
transient	NN	O	O
anuria	NN	O	B
after	NN	O	O
losartan	NN	O	O
administration	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
hospitalized	NN	O	O
for	NN	O	O
a	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
with	NN	O	O
pulmonary	NN	O	B
edema	NN	O	I
,	NN	O	O
treated	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
diuretics	NN	O	O
.	NN	O	O

Due	NN	O	O
to	NN	O	O
severe	NN	O	O
systolic	NN	O	B
dysfunction	NN	O	I
losartan	NN	O	O
was	NN	O	O
prescribed	NN	O	O
.	NN	O	O

Surprisingly	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
dose	NN	O	O
of	NN	O	O
50	NN	O	O
mg	NN	O	O
of	NN	O	O
losartan	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
sudden	NN	O	O
anuria	NN	O	B
,	NN	O	O
which	NN	O	O
lasted	NN	O	O
eight	NN	O	O
hours	NN	O	O
despite	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
furosemide	NN	O	O
and	NN	O	O
amine	NN	O	O
infusion	NN	O	O
.	NN	O	O

One	NN	O	O
week	NN	O	O
later	NN	O	O
,	NN	O	O
by	NN	O	O
mistake	NN	O	O
,	NN	O	O
losartan	NN	O	O
was	NN	O	O
prescribed	NN	O	O
again	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
second	NN	O	O
dose	NN	O	O
of	NN	O	O
50	NN	O	O
mg	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
developed	NN	O	O
a	NN	O	O
second	NN	O	O
episode	NN	O	O
of	NN	O	O
transient	NN	O	O
anuria	NN	O	B
lasting	NN	O	O
10	NN	O	O
hours	NN	O	O
.	NN	O	O

During	NN	O	O
these	NN	O	O
two	NN	O	O
episodes	NN	O	O
,	NN	O	O
his	NN	O	O
blood	NN	O	O
pressure	NN	O	O
diminished	NN	O	O
but	NN	O	O
no	NN	O	O
severe	NN	O	O
hypotension	NN	O	B
was	NN	O	O
noted	NN	O	O
.	NN	O	O

Ultimately	NN	O	O
,	NN	O	O
an	NN	O	O
arteriography	NN	O	O
showed	NN	O	O
a	NN	O	O
70	NN	O	O
-	NN	O	O
80	NN	O	O
%	NN	O	O
renal	NN	O	B
artery	NN	O	I
stenosis	NN	O	I
.	NN	O	O

In	NN	O	O
this	NN	O	O
patient	NN	O	O
,	NN	O	O
renal	NN	O	B
artery	NN	O	I
stenosis	NN	O	I
combined	NN	O	O
with	NN	O	O
heart	NN	O	B
failure	NN	O	I
and	NN	O	O
diuretic	NN	O	O
therapy	NN	O	O
certainly	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
strong	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
(	NN	O	O
RAS	NN	O	O
)	NN	O	O
.	NN	O	O

Under	NN	O	O
such	NN	O	O
conditions	NN	O	O
,	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
receptor	NN	O	O
blockade	NN	O	O
by	NN	O	O
losartan	NN	O	O
probably	NN	O	O
induced	NN	O	O
a	NN	O	O
critical	NN	O	O
fall	NN	O	O
in	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
pressure	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
report	NN	O	O
highlights	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
the	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
losartan	NN	O	O
can	NN	O	O
cause	NN	O	O
serious	NN	O	O
unexpected	NN	O	O
complications	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
renovascular	NN	O	B
disease	NN	O	I
and	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
with	NN	O	O
extreme	NN	O	O
caution	NN	O	O
in	NN	O	O
this	NN	O	O
setting	NN	O	O
.	NN	O	O

Calcineurin	NN	O	O
-	NN	O	O
inhibitor	NN	O	O
induced	NN	O	O
pain	NN	O	B
syndrome	NN	O	O
(	NN	O	O
CIPS	NN	O	B
)	NN	O	O
:	NN	O	O
a	NN	O	O
severe	NN	O	O
disabling	NN	O	O
complication	NN	O	O
after	NN	O	O
organ	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Bone	NN	O	O
pain	NN	O	B
after	NN	O	O
transplantation	NN	O	O
is	NN	O	O
a	NN	O	O
frequent	NN	O	O
complication	NN	O	O
that	NN	O	O
can	NN	O	O
be	NN	O	O
caused	NN	O	O
by	NN	O	O
several	NN	O	O
diseases	NN	O	O
.	NN	O	O

Treatment	NN	O	O
strategies	NN	O	O
depend	NN	O	O
on	NN	O	O
the	NN	O	O
correct	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
the	NN	O	O
pain	NN	O	B
.	NN	O	O

Nine	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
pain	NN	O	B
in	NN	O	O
their	NN	O	O
feet	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
registered	NN	O	O
after	NN	O	O
transplantation	NN	O	O
,	NN	O	O
were	NN	O	O
investigated	NN	O	O
.	NN	O	O

Bone	NN	O	O
scans	NN	O	O
showed	NN	O	O
an	NN	O	O
increased	NN	O	O
tracer	NN	O	O
uptake	NN	O	O
of	NN	O	O
the	NN	O	O
foot	NN	O	O
bones	NN	O	O
.	NN	O	O

Magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
demonstrated	NN	O	O
bone	NN	O	B
marrow	NN	O	I
oedema	NN	O	I
in	NN	O	O
the	NN	O	O
painful	NN	O	O
bones	NN	O	O
.	NN	O	O

Pain	NN	O	B
was	NN	O	O
not	NN	O	O
explained	NN	O	O
by	NN	O	O
other	NN	O	O
diseases	NN	O	O
causing	NN	O	O
foot	NN	O	O
pain	NN	O	B
,	NN	O	O
like	NN	O	O
reflex	NN	O	B
sympathetic	NN	O	I
dystrophy	NN	O	I
,	NN	O	O
polyneuropathy	NN	O	B
,	NN	O	O
Morton	NN	O	B
'	NN	O	I
s	NN	O	I
neuralgia	NN	O	I
,	NN	O	O
gout	NN	O	B
,	NN	O	O
osteoporosis	NN	O	B
,	NN	O	O
avascular	NN	O	B
necrosis	NN	O	I
,	NN	O	O
intermittent	NN	O	B
claudication	NN	O	I
,	NN	O	O
orthopaedic	NN	O	O
foot	NN	O	B
deformities	NN	O	I
,	NN	O	O
stress	NN	O	B
fractures	NN	O	I
,	NN	O	O
and	NN	O	O
hyperparathyroidism	NN	O	B
.	NN	O	O

The	NN	O	O
reduction	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
-	NN	O	O
or	NN	O	O
tacrolimus	NN	O	O
trough	NN	O	O
levels	NN	O	O
and	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
led	NN	O	O
to	NN	O	O
relief	NN	O	O
of	NN	O	O
pain	NN	O	B
.	NN	O	O

The	NN	O	O
Calcineurin	NN	O	O
-	NN	O	O
inhibitor	NN	O	O
Induced	NN	O	O
Pain	NN	O	B
Syndrome	NN	O	O
(	NN	O	O
CIPS	NN	O	B
)	NN	O	O
is	NN	O	O
a	NN	O	O
rare	NN	O	O
but	NN	O	O
severe	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
cyclosporine	NN	O	O
or	NN	O	O
tacrolimus	NN	O	O
and	NN	O	O
is	NN	O	O
accurately	NN	O	O
diagnosed	NN	O	O
by	NN	O	O
its	NN	O	O
typical	NN	O	O
presentation	NN	O	O
,	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
and	NN	O	O
bone	NN	O	O
scans	NN	O	O
.	NN	O	O

Incorrect	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
the	NN	O	O
syndrome	NN	O	O
will	NN	O	O
lead	NN	O	O
to	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
of	NN	O	O
life	NN	O	O
quality	NN	O	O
in	NN	O	O
patients	NN	O	O
suffering	NN	O	O
from	NN	O	O
CIPS	NN	O	B
.	NN	O	O

Brain	NN	O	O
natriuretic	NN	O	O
peptide	NN	O	O
is	NN	O	O
a	NN	O	O
predictor	NN	O	O
of	NN	O	O
anthracycline	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Anthracyclines	NN	O	O
are	NN	O	O
effective	NN	O	O
antineoplastic	NN	O	O
drugs	NN	O	O
,	NN	O	O
but	NN	O	O
they	NN	O	O
frequently	NN	O	O
cause	NN	O	O
dose	NN	O	O
-	NN	O	O
related	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

The	NN	O	O
cardiotoxicity	NN	O	B
of	NN	O	O
conventional	NN	O	O
anthracycline	NN	O	O
therapy	NN	O	O
highlights	NN	O	O
a	NN	O	O
need	NN	O	O
to	NN	O	O
search	NN	O	O
for	NN	O	O
methods	NN	O	O
that	NN	O	O
are	NN	O	O
highly	NN	O	O
sensitive	NN	O	O
and	NN	O	O
capable	NN	O	O
of	NN	O	O
predicting	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

We	NN	O	O
measured	NN	O	O
the	NN	O	O
plasma	NN	O	O
level	NN	O	O
of	NN	O	O
brain	NN	O	O
natriuretic	NN	O	O
peptide	NN	O	O
(	NN	O	O
BNP	NN	O	O
)	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
BNP	NN	O	O
might	NN	O	O
serve	NN	O	O
as	NN	O	O
a	NN	O	O
simple	NN	O	O
diagnostic	NN	O	O
indicator	NN	O	O
of	NN	O	O
anthracycline	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
leukemia	NN	O	I
treated	NN	O	O
with	NN	O	O
a	NN	O	O
daunorubicin	NN	O	O
(	NN	O	O
DNR	NN	O	O
)	NN	O	O
-	NN	O	O
containing	NN	O	O
regimen	NN	O	O
.	NN	O	O

Thirteen	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
leukemia	NN	O	I
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
DNR	NN	O	O
-	NN	O	O
containing	NN	O	O
regimen	NN	O	O
.	NN	O	O

Cardiac	NN	O	O
functions	NN	O	O
were	NN	O	O
evaluated	NN	O	O
with	NN	O	O
radionuclide	NN	O	O
angiography	NN	O	O
before	NN	O	O
chemotherapies	NN	O	O
.	NN	O	O

The	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
atrial	NN	O	O
natriuretic	NN	O	O
peptide	NN	O	O
(	NN	O	O
ANP	NN	O	O
)	NN	O	O
and	NN	O	O
BNP	NN	O	O
were	NN	O	O
measured	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
radionuclide	NN	O	O
angiography	NN	O	O
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
developed	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
after	NN	O	O
the	NN	O	O
completion	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
were	NN	O	O
diagnosed	NN	O	O
as	NN	O	O
having	NN	O	O
subclinical	NN	O	O
heart	NN	O	B
failure	NN	O	I
after	NN	O	O
the	NN	O	O
completion	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

The	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
BNP	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
clinical	NN	O	O
and	NN	O	O
subclinical	NN	O	O
heart	NN	O	B
failure	NN	O	I
increased	NN	O	O
above	NN	O	O
the	NN	O	O
normal	NN	O	O
limit	NN	O	O
(	NN	O	O
40	NN	O	O
pg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
before	NN	O	O
the	NN	O	O
detection	NN	O	O
of	NN	O	O
clinical	NN	O	O
or	NN	O	O
subclinical	NN	O	O
heart	NN	O	B
failure	NN	O	I
by	NN	O	O
radionuclide	NN	O	O
angiography	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
BNP	NN	O	O
did	NN	O	O
not	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
patients	NN	O	O
without	NN	O	O
heart	NN	O	B
failure	NN	O	I
given	NN	O	O
DNR	NN	O	O
,	NN	O	O
even	NN	O	O
at	NN	O	O
more	NN	O	O
than	NN	O	O
700	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
plasma	NN	O	O
level	NN	O	O
of	NN	O	O
ANP	NN	O	O
did	NN	O	O
not	NN	O	O
always	NN	O	O
increase	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
clinical	NN	O	O
and	NN	O	O
subclinical	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

These	NN	O	O
preliminary	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
BNP	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
as	NN	O	O
an	NN	O	O
early	NN	O	O
and	NN	O	O
sensitive	NN	O	O
indicator	NN	O	O
of	NN	O	O
anthracycline	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Nephrotoxicity	NN	O	B
of	NN	O	O
combined	NN	O	O
cephalothin	NN	O	O
-	NN	O	O
gentamicin	NN	O	O
regimen	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
developed	NN	O	O
acute	NN	O	B
tubular	NN	O	I
necrosis	NN	O	I
,	NN	O	O
characterized	NN	O	O
clinically	NN	O	O
by	NN	O	O
acute	NN	O	O
oliguric	NN	O	B
renal	NN	O	I
failure	NN	O	I
,	NN	O	O
while	NN	O	O
they	NN	O	O
were	NN	O	O
receiving	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
cephalothin	NN	O	O
sodium	NN	O	O
and	NN	O	O
gentamicin	NN	O	O
sulfate	NN	O	O
therapy	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
are	NN	O	O
given	NN	O	O
this	NN	O	O
drug	NN	O	O
regimen	NN	O	O
should	NN	O	O
be	NN	O	O
observed	NN	O	O
very	NN	O	O
carefully	NN	O	O
for	NN	O	O
early	NN	O	O
signs	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

High	NN	O	O
doses	NN	O	O
of	NN	O	O
this	NN	O	O
antibiotic	NN	O	O
combination	NN	O	O
should	NN	O	O
be	NN	O	O
avoided	NN	O	O
especially	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
should	NN	O	O
not	NN	O	O
be	NN	O	O
given	NN	O	O
this	NN	O	O
regimen	NN	O	O
.	NN	O	O

In	NN	O	O
vivo	NN	O	O
protection	NN	O	O
of	NN	O	O
dna	NN	O	O
damage	NN	O	O
associated	NN	O	O
apoptotic	NN	O	O
and	NN	O	O
necrotic	NN	O	B
cell	NN	O	O
deaths	NN	O	O
during	NN	O	O
acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
,	NN	O	O
amiodarone	NN	O	O
-	NN	O	O
induced	NN	O	O
lung	NN	O	B
toxicity	NN	O	I
and	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
by	NN	O	O
a	NN	O	O
novel	NN	O	O
IH636	NN	O	O
grape	NN	O	O
seed	NN	O	O
proanthocyanidin	NN	O	O
extract	NN	O	O
.	NN	O	O

Grape	NN	O	O
seed	NN	O	O
extract	NN	O	O
,	NN	O	O
primarily	NN	O	O
a	NN	O	O
mixture	NN	O	O
of	NN	O	O
proanthocyanidins	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
modulate	NN	O	O
a	NN	O	O
wide	NN	O	O
-	NN	O	O
range	NN	O	O
of	NN	O	O
biological	NN	O	O
,	NN	O	O
pharmacological	NN	O	O
and	NN	O	O
toxicological	NN	O	O
effects	NN	O	O
which	NN	O	O
are	NN	O	O
mainly	NN	O	O
cytoprotective	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
assessed	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
IH636	NN	O	O
grape	NN	O	O
seed	NN	O	O
proanthocyanidin	NN	O	O
extract	NN	O	O
(	NN	O	O
GSPE	NN	O	O
)	NN	O	O
to	NN	O	O
prevent	NN	O	O
acetaminophen	NN	O	O
(	NN	O	O
AAP	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
,	NN	O	O
amiodarone	NN	O	O
(	NN	O	O
AMI	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
lung	NN	O	B
toxicity	NN	O	I
,	NN	O	O
and	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
DOX	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Experimental	NN	O	O
design	NN	O	O
consisted	NN	O	O
of	NN	O	O
four	NN	O	O
groups	NN	O	O
:	NN	O	O
control	NN	O	O
(	NN	O	O
vehicle	NN	O	O
alone	NN	O	O
)	NN	O	O
,	NN	O	O
GSPE	NN	O	O
alone	NN	O	O
,	NN	O	O
drug	NN	O	O
alone	NN	O	O
and	NN	O	O
GSPE	NN	O	O
+	NN	O	O
drug	NN	O	O
.	NN	O	O

For	NN	O	O
the	NN	O	O
cytoprotection	NN	O	O
study	NN	O	O
,	NN	O	O
animals	NN	O	O
were	NN	O	O
orally	NN	O	O
gavaged	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
Kg	NN	O	O
GSPE	NN	O	O
for	NN	O	O
7	NN	O	O
-	NN	O	O
10	NN	O	O
days	NN	O	O
followed	NN	O	O
by	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
injections	NN	O	O
of	NN	O	O
organ	NN	O	O
specific	NN	O	O
three	NN	O	O
drugs	NN	O	O
(	NN	O	O
AAP	NN	O	O
:	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
Kg	NN	O	O
for	NN	O	O
24	NN	O	O
h	NN	O	O
;	NN	O	O
AMI	NN	O	O
:	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
Kg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
four	NN	O	O
days	NN	O	O
;	NN	O	O
DOX	NN	O	O
:	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
Kg	NN	O	O
for	NN	O	O
48	NN	O	O
h	NN	O	O
)	NN	O	O
.	NN	O	O

Parameters	NN	O	O
of	NN	O	O
study	NN	O	O
included	NN	O	O
analysis	NN	O	O
of	NN	O	O
serum	NN	O	O
chemistry	NN	O	O
(	NN	O	O
ALT	NN	O	O
,	NN	O	O
BUN	NN	O	O
and	NN	O	O
CPK	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
orderly	NN	O	O
fragmentation	NN	O	O
of	NN	O	O
genomic	NN	O	O
DNA	NN	O	O
(	NN	O	O
both	NN	O	O
endonuclease	NN	O	O
-	NN	O	O
dependent	NN	O	O
and	NN	O	O
independent	NN	O	O
)	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
microscopic	NN	O	O
evaluation	NN	O	O
of	NN	O	O
damage	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
protection	NN	O	O
in	NN	O	O
corresponding	NN	O	O
PAS	NN	O	O
stained	NN	O	O
tissues	NN	O	O
.	NN	O	O

Results	NN	O	O
indicate	NN	O	O
that	NN	O	O
GSPE	NN	O	O
preexposure	NN	O	O
prior	NN	O	O
to	NN	O	O
AAP	NN	O	O
,	NN	O	O
AMI	NN	O	O
and	NN	O	O
DOX	NN	O	O
,	NN	O	O
provided	NN	O	O
near	NN	O	O
complete	NN	O	O
protection	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
serum	NN	O	O
chemistry	NN	O	O
changes	NN	O	O
(	NN	O	O
ALT	NN	O	O
,	NN	O	O
BUN	NN	O	O
and	NN	O	O
CPK	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
DNA	NN	O	O
fragmentation	NN	O	O
.	NN	O	O

Histopathological	NN	O	O
examination	NN	O	O
of	NN	O	O
kidney	NN	O	O
,	NN	O	O
heart	NN	O	O
and	NN	O	O
lung	NN	O	O
sections	NN	O	O
revealed	NN	O	O
moderate	NN	O	O
to	NN	O	O
massive	NN	O	O
tissue	NN	O	B
damage	NN	O	I
with	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
morphological	NN	O	O
aberrations	NN	O	O
by	NN	O	O
all	NN	O	O
the	NN	O	O
three	NN	O	O
drugs	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
GSPE	NN	O	O
preexposure	NN	O	O
than	NN	O	O
in	NN	O	O
its	NN	O	O
presence	NN	O	O
.	NN	O	O

GSPE	NN	O	O
+	NN	O	O
drug	NN	O	O
exposed	NN	O	O
tissues	NN	O	O
exhibited	NN	O	O
minor	NN	O	O
residual	NN	O	O
damage	NN	O	O
or	NN	O	O
near	NN	O	O
total	NN	O	O
recovery	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
histopathological	NN	O	O
alterations	NN	O	O
mirrored	NN	O	O
both	NN	O	O
serum	NN	O	O
chemistry	NN	O	O
changes	NN	O	O
and	NN	O	O
the	NN	O	O
pattern	NN	O	O
of	NN	O	O
DNA	NN	O	O
fragmentation	NN	O	O
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
all	NN	O	O
the	NN	O	O
drugs	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
,	NN	O	O
AAP	NN	O	O
,	NN	O	O
AMI	NN	O	O
and	NN	O	O
DOX	NN	O	O
induced	NN	O	O
apoptotic	NN	O	O
death	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
necrosis	NN	O	B
in	NN	O	O
the	NN	O	O
respective	NN	O	O
organs	NN	O	O
which	NN	O	O
was	NN	O	O
very	NN	O	O
effectively	NN	O	O
blocked	NN	O	O
by	NN	O	O
GSPE	NN	O	O
.	NN	O	O

Since	NN	O	O
AAP	NN	O	O
,	NN	O	O
AMI	NN	O	O
and	NN	O	O
DOX	NN	O	O
undergo	NN	O	O
biotransformation	NN	O	O
and	NN	O	O
are	NN	O	O
known	NN	O	O
to	NN	O	O
produce	NN	O	O
damaging	NN	O	O
radicals	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
the	NN	O	O
protection	NN	O	O
by	NN	O	O
GSPE	NN	O	O
may	NN	O	O
be	NN	O	O
linked	NN	O	O
to	NN	O	O
both	NN	O	O
inhibition	NN	O	O
of	NN	O	O
metabolism	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
detoxification	NN	O	O
of	NN	O	O
cytotoxic	NN	O	O
radicals	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
its	NN	O	O
'	NN	O	O
presumed	NN	O	O
contribution	NN	O	O
to	NN	O	O
DNA	NN	O	O
repair	NN	O	O
may	NN	O	O
be	NN	O	O
another	NN	O	O
important	NN	O	O
attribute	NN	O	O
,	NN	O	O
which	NN	O	O
played	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
chemoprevention	NN	O	O
process	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
this	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
the	NN	O	O
first	NN	O	O
report	NN	O	O
on	NN	O	O
AMI	NN	O	O
-	NN	O	O
induced	NN	O	O
apoptotic	NN	O	O
death	NN	O	O
in	NN	O	O
the	NN	O	O
lung	NN	O	O
tissue	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
these	NN	O	O
events	NN	O	O
undoubtedly	NN	O	O
establish	NN	O	O
GSPE	NN	O	O
'	NN	O	O
s	NN	O	O
abundant	NN	O	O
bioavailability	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
power	NN	O	O
to	NN	O	O
defend	NN	O	O
multiple	NN	O	O
target	NN	O	O
organs	NN	O	O
from	NN	O	O
toxic	NN	O	O
assaults	NN	O	O
induced	NN	O	O
by	NN	O	O
structurally	NN	O	O
diverse	NN	O	O
and	NN	O	O
functionally	NN	O	O
different	NN	O	O
entities	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Antidepressant	NN	O	O
-	NN	O	O
induced	NN	O	O
mania	NN	O	B
in	NN	O	O
bipolar	NN	O	B
patients	NN	O	O
:	NN	O	O
identification	NN	O	O
of	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Concerns	NN	O	O
about	NN	O	O
possible	NN	O	O
risks	NN	O	O
of	NN	O	O
switching	NN	O	O
to	NN	O	O
mania	NN	O	B
associated	NN	O	O
with	NN	O	O
antidepressants	NN	O	O
continue	NN	O	O
to	NN	O	O
interfere	NN	O	O
with	NN	O	O
the	NN	O	O
establishment	NN	O	O
of	NN	O	O
an	NN	O	O
optimal	NN	O	O
treatment	NN	O	O
paradigm	NN	O	O
for	NN	O	O
bipolar	NN	O	B
depression	NN	O	I
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
The	NN	O	O
response	NN	O	O
of	NN	O	O
44	NN	O	O
patients	NN	O	O
meeting	NN	O	O
DSM	NN	O	O
-	NN	O	O
IV	NN	O	O
criteria	NN	O	O
for	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
to	NN	O	O
naturalistic	NN	O	O
treatment	NN	O	O
was	NN	O	O
assessed	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
6	NN	O	O
weeks	NN	O	O
using	NN	O	O
the	NN	O	O
Montgomery	NN	O	O
-	NN	O	O
Asberg	NN	O	O
Depression	NN	O	O
Rating	NN	O	O
Scale	NN	O	O
and	NN	O	O
the	NN	O	O
Bech	NN	O	O
-	NN	O	O
Rafaelson	NN	O	O
Mania	NN	O	O
Rating	NN	O	O
Scale	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
experienced	NN	O	O
a	NN	O	O
manic	NN	O	B
or	NN	O	O
hypomanic	NN	O	B
switch	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
on	NN	O	O
several	NN	O	O
variables	NN	O	O
including	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
diagnosis	NN	O	O
(	NN	O	O
DSM	NN	O	B
-	NN	O	I
IV	NN	O	I
bipolar	NN	O	I
I	NN	O	I
vs	NN	O	O
.	NN	O	O
bipolar	NN	O	B
II	NN	O	I
)	NN	O	O
,	NN	O	O
number	NN	O	O
of	NN	O	O
previous	NN	O	O
manic	NN	O	B
episodes	NN	O	O
,	NN	O	O
type	NN	O	O
of	NN	O	O
antidepressant	NN	O	O
therapy	NN	O	O
used	NN	O	O
(	NN	O	O
electroconvulsive	NN	O	O
therapy	NN	O	O
vs	NN	O	O
.	NN	O	O
antidepressant	NN	O	O
drugs	NN	O	O
and	NN	O	O
,	NN	O	O
more	NN	O	O
particularly	NN	O	O
,	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NN	O	O
[	NN	O	O
SSRIs	NN	O	O
]	NN	O	O
)	NN	O	O
,	NN	O	O
use	NN	O	O
and	NN	O	O
type	NN	O	O
of	NN	O	O
mood	NN	O	O
stabilizers	NN	O	O
(	NN	O	O
lithium	NN	O	O
vs	NN	O	O
.	NN	O	O
anticonvulsants	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
temperament	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
,	NN	O	O
assessed	NN	O	O
during	NN	O	O
a	NN	O	O
normothymic	NN	O	O
period	NN	O	O
using	NN	O	O
the	NN	O	O
hyperthymia	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
Semi	NN	O	O
-	NN	O	O
structured	NN	O	O
Affective	NN	O	O
Temperament	NN	O	O
Interview	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Switches	NN	O	O
to	NN	O	O
hypomania	NN	O	B
or	NN	O	O
mania	NN	O	B
occurred	NN	O	O
in	NN	O	O
27	NN	O	O
%	NN	O	O
of	NN	O	O
all	NN	O	O
patients	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
(	NN	O	O
and	NN	O	O
in	NN	O	O
24	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
subgroup	NN	O	O
of	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
SSRIs	NN	O	O
[	NN	O	O
8	NN	O	O
/	NN	O	O
33	NN	O	O
]	NN	O	O
)	NN	O	O
;	NN	O	O
16	NN	O	O
%	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
experienced	NN	O	O
manic	NN	O	B
episodes	NN	O	O
,	NN	O	O
and	NN	O	O
11	NN	O	O
%	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
5	NN	O	O
)	NN	O	O
experienced	NN	O	O
hypomanic	NN	O	B
episodes	NN	O	O
.	NN	O	O

Sex	NN	O	O
,	NN	O	O
age	NN	O	O
,	NN	O	O
diagnosis	NN	O	O
(	NN	O	O
bipolar	NN	O	B
I	NN	O	I
vs	NN	O	O
.	NN	O	O
bipolar	NN	O	B
II	NN	O	I
)	NN	O	O
,	NN	O	O
and	NN	O	O
additional	NN	O	O
treatment	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
switching	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
mood	NN	O	O
switches	NN	O	O
seemed	NN	O	O
not	NN	O	O
to	NN	O	O
differ	NN	O	O
between	NN	O	O
patients	NN	O	O
receiving	NN	O	O
an	NN	O	O
anticonvulsant	NN	O	O
and	NN	O	O
those	NN	O	O
receiving	NN	O	O
no	NN	O	O
mood	NN	O	O
stabilizer	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
mood	NN	O	O
switches	NN	O	O
were	NN	O	O
less	NN	O	O
frequent	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
lithium	NN	O	O
(	NN	O	O
15	NN	O	O
%	NN	O	O
,	NN	O	O
4	NN	O	O
/	NN	O	O
26	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
patients	NN	O	O
not	NN	O	O
treated	NN	O	O
with	NN	O	O
lithium	NN	O	O
(	NN	O	O
44	NN	O	O
%	NN	O	O
,	NN	O	O
8	NN	O	O
/	NN	O	O
18	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
.	NN	O	O
04	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
previous	NN	O	O
manic	NN	O	B
episodes	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
probability	NN	O	O
of	NN	O	O
switching	NN	O	O
,	NN	O	O
whereas	NN	O	O
a	NN	O	O
high	NN	O	O
score	NN	O	O
on	NN	O	O
the	NN	O	O
hyperthymia	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
Semistructured	NN	O	O
Affective	NN	O	O
Temperament	NN	O	O
Interview	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
greater	NN	O	O
risk	NN	O	O
of	NN	O	O
switching	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
.	NN	O	O
008	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
frequency	NN	O	O
of	NN	O	O
mood	NN	O	O
switching	NN	O	O
associated	NN	O	O
with	NN	O	O
acute	NN	O	O
antidepressant	NN	O	O
therapy	NN	O	O
may	NN	O	O
be	NN	O	O
reduced	NN	O	O
by	NN	O	O
lithium	NN	O	O
treatment	NN	O	O
.	NN	O	O

Particular	NN	O	O
attention	NN	O	O
should	NN	O	O
be	NN	O	O
paid	NN	O	O
to	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
hyperthymic	NN	O	O
temperament	NN	O	O
,	NN	O	O
who	NN	O	O
have	NN	O	O
a	NN	O	O
greater	NN	O	O
risk	NN	O	O
of	NN	O	O
mood	NN	O	O
switches	NN	O	O
.	NN	O	O

Peritubular	NN	O	O
capillary	NN	O	O
basement	NN	O	O
membrane	NN	O	O
reduplication	NN	O	O
in	NN	O	O
allografts	NN	O	O
and	NN	O	O
native	NN	O	O
kidney	NN	O	B
disease	NN	O	I
:	NN	O	O
a	NN	O	O
clinicopathologic	NN	O	O
study	NN	O	O
of	NN	O	O
278	NN	O	O
consecutive	NN	O	O
renal	NN	O	O
specimens	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
An	NN	O	O
association	NN	O	O
has	NN	O	O
been	NN	O	O
found	NN	O	O
between	NN	O	O
transplant	NN	O	B
glomerulopathy	NN	O	I
(	NN	O	O
TG	NN	O	B
)	NN	O	O
and	NN	O	O
reduplication	NN	O	O
of	NN	O	O
peritubular	NN	O	O
capillary	NN	O	O
basement	NN	O	O
membranes	NN	O	O
(	NN	O	O
PTCR	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
such	NN	O	O
an	NN	O	O
association	NN	O	O
is	NN	O	O
of	NN	O	O
practical	NN	O	O
and	NN	O	O
theoretical	NN	O	O
importance	NN	O	O
,	NN	O	O
only	NN	O	O
one	NN	O	O
prospective	NN	O	O
study	NN	O	O
has	NN	O	O
tried	NN	O	O
to	NN	O	O
confirm	NN	O	O
it	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
examined	NN	O	O
278	NN	O	O
consecutive	NN	O	O
renal	NN	O	O
specimens	NN	O	O
(	NN	O	O
from	NN	O	O
135	NN	O	O
transplants	NN	O	O
and	NN	O	O
143	NN	O	O
native	NN	O	O
kidneys	NN	O	O
)	NN	O	O
for	NN	O	O
ultrastructural	NN	O	O
evidence	NN	O	O
of	NN	O	O
PTCR	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
renal	NN	O	O
allografts	NN	O	O
with	NN	O	O
TG	NN	O	B
,	NN	O	O
we	NN	O	O
also	NN	O	O
examined	NN	O	O
grafts	NN	O	O
with	NN	O	O
acute	NN	O	O
rejection	NN	O	O
,	NN	O	O
recurrent	NN	O	O
glomerulonephritis	NN	O	B
,	NN	O	O
chronic	NN	O	B
allograft	NN	O	I
nephropathy	NN	O	I
and	NN	O	O
stable	NN	O	O
grafts	NN	O	O
(	NN	O	O
"	NN	O	O
protocol	NN	O	O
biopsies	NN	O	O
"	NN	O	O
)	NN	O	O
.	NN	O	O

Native	NN	O	O
kidney	NN	O	O
specimens	NN	O	O
included	NN	O	O
a	NN	O	O
wide	NN	O	O
range	NN	O	O
of	NN	O	O
glomerulopathies	NN	O	B
as	NN	O	O
well	NN	O	O
as	NN	O	O
cases	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
,	NN	O	O
malignant	NN	O	B
hypertension	NN	O	I
,	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
,	NN	O	O
and	NN	O	O
acute	NN	O	B
tubular	NN	O	I
necrosis	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
found	NN	O	O
PTCR	NN	O	O
in	NN	O	O
14	NN	O	O
of	NN	O	O
15	NN	O	O
cases	NN	O	O
of	NN	O	O
TG	NN	O	B
,	NN	O	O
in	NN	O	O
7	NN	O	O
transplant	NN	O	O
biopsy	NN	O	O
specimens	NN	O	O
without	NN	O	O
TG	NN	O	B
,	NN	O	O
and	NN	O	O
in	NN	O	O
13	NN	O	O
of	NN	O	O
143	NN	O	O
native	NN	O	O
kidney	NN	O	O
biopsy	NN	O	O
specimens	NN	O	O
.	NN	O	O

These	NN	O	O
13	NN	O	O
included	NN	O	O
cases	NN	O	O
of	NN	O	O
malignant	NN	O	B
hypertension	NN	O	I
,	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
,	NN	O	O
lupus	NN	O	B
nephritis	NN	O	I
,	NN	O	O
Henoch	NN	O	B
-	NN	O	I
Schonlein	NN	O	I
nephritis	NN	O	I
,	NN	O	O
crescentic	NN	O	O
glomerulonephritis	NN	O	B
,	NN	O	O
and	NN	O	O
cocaine	NN	O	O
-	NN	O	O
related	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
.	NN	O	O

Mild	NN	O	O
PTCR	NN	O	O
in	NN	O	O
allografts	NN	O	O
without	NN	O	O
TG	NN	O	B
did	NN	O	O
not	NN	O	O
predict	NN	O	O
renal	NN	O	B
failure	NN	O	I
or	NN	O	O
significant	NN	O	O
proteinuria	NN	O	B
after	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
periods	NN	O	O
of	NN	O	O
between	NN	O	O
3	NN	O	O
months	NN	O	O
and	NN	O	O
1	NN	O	O
year	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
We	NN	O	O
conclude	NN	O	O
that	NN	O	O
in	NN	O	O
transplants	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
strong	NN	O	O
association	NN	O	O
between	NN	O	O
well	NN	O	O
-	NN	O	O
developed	NN	O	O
PTCR	NN	O	O
and	NN	O	O
TG	NN	O	B
,	NN	O	O
while	NN	O	O
the	NN	O	O
significance	NN	O	O
of	NN	O	O
mild	NN	O	O
PTCR	NN	O	O
and	NN	O	O
its	NN	O	O
predictive	NN	O	O
value	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
TG	NN	O	B
is	NN	O	O
unclear	NN	O	O
.	NN	O	O

PTCR	NN	O	O
also	NN	O	O
occurs	NN	O	O
in	NN	O	O
certain	NN	O	O
native	NN	O	O
kidney	NN	O	B
diseases	NN	O	I
,	NN	O	O
though	NN	O	O
the	NN	O	O
association	NN	O	O
is	NN	O	O
not	NN	O	O
as	NN	O	O
strong	NN	O	O
as	NN	O	O
that	NN	O	O
for	NN	O	O
TG	NN	O	B
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
repeated	NN	O	O
endothelial	NN	O	B
injury	NN	O	I
,	NN	O	O
including	NN	O	O
immunologic	NN	O	B
injury	NN	O	I
,	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
this	NN	O	O
lesion	NN	O	O
both	NN	O	O
in	NN	O	O
allografts	NN	O	O
and	NN	O	O
native	NN	O	O
kidneys	NN	O	O
.	NN	O	O

Caffeine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
arrhythmia	NN	O	I
:	NN	O	O
an	NN	O	O
unrecognised	NN	O	O
danger	NN	O	O
of	NN	O	O
healthfood	NN	O	O
products	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
25	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
mitral	NN	O	B
valve	NN	O	I
prolapse	NN	O	I
who	NN	O	O
developed	NN	O	O
intractable	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
after	NN	O	O
consuming	NN	O	O
a	NN	O	O
"	NN	O	O
natural	NN	O	O
energy	NN	O	O
"	NN	O	O
guarana	NN	O	O
health	NN	O	O
drink	NN	O	O
containing	NN	O	O
a	NN	O	O
high	NN	O	O
concentration	NN	O	O
of	NN	O	O
caffeine	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
highlights	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
adequate	NN	O	O
labelling	NN	O	O
and	NN	O	O
regulation	NN	O	O
of	NN	O	O
such	NN	O	O
products	NN	O	O
.	NN	O	O

Conformationally	NN	O	O
restricted	NN	O	O
analogs	NN	O	O
of	NN	O	O
BD1008	NN	O	O
and	NN	O	O
an	NN	O	O
antisense	NN	O	O
oligodeoxynucleotide	NN	O	O
targeting	NN	O	O
sigma1	NN	O	O
receptors	NN	O	O
produce	NN	O	O
anti	NN	O	O
-	NN	O	O
cocaine	NN	O	O
effects	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
'	NN	O	O
s	NN	O	O
ability	NN	O	O
to	NN	O	O
interact	NN	O	O
with	NN	O	O
sigma	NN	O	O
receptors	NN	O	O
suggests	NN	O	O
that	NN	O	O
these	NN	O	O
proteins	NN	O	O
mediate	NN	O	O
some	NN	O	O
of	NN	O	O
its	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
three	NN	O	O
novel	NN	O	O
sigma	NN	O	O
receptor	NN	O	O
ligands	NN	O	O
with	NN	O	O
antagonist	NN	O	O
activity	NN	O	O
were	NN	O	O
evaluated	NN	O	O
in	NN	O	O
Swiss	NN	O	O
Webster	NN	O	O
mice	NN	O	O
:	NN	O	O
BD1018	NN	O	O
(	NN	O	O
3S	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
[	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dichlorophenyl	NN	O	O
)	NN	O	O
ethyl	NN	O	O
]	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
diazabicyclo	NN	O	O
[	NN	O	O
4	NN	O	O
.	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
]	NN	O	O
nonane	NN	O	O
)	NN	O	O
,	NN	O	O
BD1063	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
[	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dichlorophenyl	NN	O	O
)	NN	O	O
ethyl	NN	O	O
]	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
methylpiperazine	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
LR132	NN	O	O
(	NN	O	O
1R	NN	O	O
,	NN	O	O
2S	NN	O	O
-	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
cis	NN	O	O
-	NN	O	O
N	NN	O	O
-	NN	O	O
[	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dichlorophenyl	NN	O	O
)	NN	O	O
ethyl	NN	O	O
]	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
pyrrolidinyl	NN	O	O
)	NN	O	O
cyclohexylamine	NN	O	O
)	NN	O	O
.	NN	O	O

Competition	NN	O	O
binding	NN	O	O
assays	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
all	NN	O	O
three	NN	O	O
compounds	NN	O	O
have	NN	O	O
high	NN	O	O
affinities	NN	O	O
for	NN	O	O
sigma1	NN	O	O
receptors	NN	O	O
.	NN	O	O

The	NN	O	O
three	NN	O	O
compounds	NN	O	O
vary	NN	O	O
in	NN	O	O
their	NN	O	O
affinities	NN	O	O
for	NN	O	O
sigma2	NN	O	O
receptors	NN	O	O
and	NN	O	O
exhibit	NN	O	O
negligible	NN	O	O
affinities	NN	O	O
for	NN	O	O
dopamine	NN	O	O
,	NN	O	O
opioid	NN	O	O
,	NN	O	O
GABA	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
and	NN	O	O
NMDA	NN	O	O
receptors	NN	O	O
.	NN	O	O

In	NN	O	O
behavioral	NN	O	O
studies	NN	O	O
,	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
of	NN	O	O
mice	NN	O	O
with	NN	O	O
BD1018	NN	O	O
,	NN	O	O
BD1063	NN	O	O
,	NN	O	O
or	NN	O	O
LR132	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
and	NN	O	O
lethality	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
post	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
LR132	NN	O	O
prevented	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
lethality	NN	O	O
in	NN	O	O
a	NN	O	O
significant	NN	O	O
proportion	NN	O	O
of	NN	O	O
animals	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
the	NN	O	O
protection	NN	O	O
provided	NN	O	O
by	NN	O	O
the	NN	O	O
putative	NN	O	O
antagonists	NN	O	O
,	NN	O	O
the	NN	O	O
well	NN	O	O
-	NN	O	O
characterized	NN	O	O
sigma	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
di	NN	O	O
-	NN	O	O
o	NN	O	O
-	NN	O	O
tolylguanidine	NN	O	O
(	NN	O	O
DTG	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
novel	NN	O	O
sigma	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
BD1031	NN	O	O
(	NN	O	O
3R	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
[	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dichlorophenyl	NN	O	O
)	NN	O	O
ethyl	NN	O	O
]	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
diazabicyclo	NN	O	O
[	NN	O	O
4	NN	O	O
.	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
]	NN	O	O
nonane	NN	O	O
)	NN	O	O
each	NN	O	O
worsened	NN	O	O
the	NN	O	O
behavioral	NN	O	O
toxicity	NN	O	B
of	NN	O	O
cocaine	NN	O	O
.	NN	O	O

At	NN	O	O
doses	NN	O	O
where	NN	O	O
alone	NN	O	O
,	NN	O	O
they	NN	O	O
produced	NN	O	O
no	NN	O	O
significant	NN	O	O
effects	NN	O	O
on	NN	O	O
locomotion	NN	O	O
,	NN	O	O
BD1018	NN	O	O
,	NN	O	O
BD1063	NN	O	O
and	NN	O	O
LR132	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
the	NN	O	O
locomotor	NN	O	O
stimulatory	NN	O	O
effects	NN	O	O
of	NN	O	O
cocaine	NN	O	O
.	NN	O	O

To	NN	O	O
further	NN	O	O
validate	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
the	NN	O	O
anti	NN	O	O
-	NN	O	O
cocaine	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
novel	NN	O	O
ligands	NN	O	O
involved	NN	O	O
antagonism	NN	O	O
of	NN	O	O
sigma	NN	O	O
receptors	NN	O	O
,	NN	O	O
an	NN	O	O
antisense	NN	O	O
oligodeoxynucleotide	NN	O	O
against	NN	O	O
sigma1	NN	O	O
receptors	NN	O	O
was	NN	O	O
also	NN	O	O
shown	NN	O	O
to	NN	O	O
significantly	NN	O	O
attenuate	NN	O	O
the	NN	O	O
convulsive	NN	O	B
and	NN	O	O
locomotor	NN	O	O
stimulatory	NN	O	O
effects	NN	O	O
of	NN	O	O
cocaine	NN	O	O
.	NN	O	O

Together	NN	O	O
,	NN	O	O
the	NN	O	O
data	NN	O	O
suggests	NN	O	O
that	NN	O	O
functional	NN	O	O
antagonism	NN	O	O
of	NN	O	O
sigma	NN	O	O
receptors	NN	O	O
is	NN	O	O
capable	NN	O	O
of	NN	O	O
attenuating	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
behaviors	NN	O	O
.	NN	O	O

Ranitidine	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
in	NN	O	O
a	NN	O	O
cadaveric	NN	O	O
renal	NN	O	O
allograft	NN	O	O
.	NN	O	O

Ranitidine	NN	O	O
frequently	NN	O	O
is	NN	O	O
used	NN	O	O
for	NN	O	O
preventing	NN	O	O
peptic	NN	O	O
ulceration	NN	O	O
after	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
.	NN	O	O

This	NN	O	O
drug	NN	O	O
occasionally	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
in	NN	O	O
native	NN	O	O
kidneys	NN	O	O
.	NN	O	O

There	NN	O	O
are	NN	O	O
no	NN	O	O
similar	NN	O	O
reports	NN	O	O
with	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
ranitidine	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
in	NN	O	O
a	NN	O	O
recipient	NN	O	O
of	NN	O	O
a	NN	O	O
cadaveric	NN	O	O
renal	NN	O	O
allograft	NN	O	O
presenting	NN	O	O
with	NN	O	O
acute	NN	O	O
allograft	NN	O	O
dysfunction	NN	O	O
within	NN	O	O
48	NN	O	O
hours	NN	O	O
of	NN	O	O
exposure	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

The	NN	O	O
biopsy	NN	O	O
specimen	NN	O	O
showed	NN	O	O
pathognomonic	NN	O	O
features	NN	O	O
,	NN	O	O
including	NN	O	O
eosinophilic	NN	O	O
infiltration	NN	O	O
of	NN	O	O
the	NN	O	O
interstitial	NN	O	O
compartment	NN	O	O
.	NN	O	O

Allograft	NN	O	O
function	NN	O	O
improved	NN	O	O
rapidly	NN	O	O
and	NN	O	O
returned	NN	O	O
to	NN	O	O
baseline	NN	O	O
after	NN	O	O
stopping	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Liver	NN	O	B
disease	NN	O	I
caused	NN	O	O
by	NN	O	O
propylthiouracil	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
presents	NN	O	O
the	NN	O	O
clinical	NN	O	O
,	NN	O	O
laboratory	NN	O	O
,	NN	O	O
and	NN	O	O
light	NN	O	O
and	NN	O	O
electron	NN	O	O
microscopic	NN	O	O
observations	NN	O	O
on	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
chronic	NN	O	B
active	NN	O	I
(	NN	O	I
aggressive	NN	O	I
)	NN	O	I
hepatitis	NN	O	I
caused	NN	O	O
by	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
propylthiouracil	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
an	NN	O	O
addition	NN	O	O
to	NN	O	O
the	NN	O	O
list	NN	O	O
of	NN	O	O
drugs	NN	O	O
that	NN	O	O
must	NN	O	O
be	NN	O	O
considered	NN	O	O
in	NN	O	O
the	NN	O	O
evaluation	NN	O	O
of	NN	O	O
chronic	NN	O	O
liver	NN	O	B
disease	NN	O	I
.	NN	O	O

Withdrawal	NN	O	B
-	NN	O	I
emergent	NN	O	I
rabbit	NN	O	I
syndrome	NN	O	I
during	NN	O	O
dose	NN	O	O
reduction	NN	O	O
of	NN	O	O
risperidone	NN	O	O
.	NN	O	O

Rabbit	NN	O	B
syndrome	NN	O	I
(	NN	O	O
RS	NN	O	B
)	NN	O	O
is	NN	O	O
a	NN	O	O
rare	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effect	NN	O	O
caused	NN	O	O
by	NN	O	O
prolonged	NN	O	O
neuroleptic	NN	O	O
medication	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
withdrawal	NN	O	B
-	NN	O	I
emergent	NN	O	I
RS	NN	O	I
,	NN	O	O
which	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
of	NN	O	O
its	NN	O	O
kind	NN	O	O
to	NN	O	O
be	NN	O	O
reported	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
developed	NN	O	O
RS	NN	O	B
during	NN	O	O
dose	NN	O	O
reduction	NN	O	O
of	NN	O	O
risperidone	NN	O	O
.	NN	O	O

The	NN	O	O
symptom	NN	O	O
was	NN	O	O
treated	NN	O	O
successfully	NN	O	O
with	NN	O	O
trihexyphenidyl	NN	O	O
anticholinergic	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
underlying	NN	O	O
mechanism	NN	O	O
of	NN	O	O
withdrawal	NN	O	B
-	NN	O	I
emergent	NN	O	I
RS	NN	O	I
in	NN	O	O
the	NN	O	O
present	NN	O	O
case	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
pharmacological	NN	O	O
profile	NN	O	O
of	NN	O	O
risperidone	NN	O	O
,	NN	O	O
a	NN	O	O
serotonin	NN	O	O
-	NN	O	O
dopamine	NN	O	O
antagonist	NN	O	O
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
pathophysiologic	NN	O	O
influence	NN	O	O
of	NN	O	O
the	NN	O	O
serotonin	NN	O	O
system	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
RS	NN	O	B
.	NN	O	O

Pharmacokinetic	NN	O	O
/	NN	O	O
pharmacodynamic	NN	O	O
assessment	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
E4031	NN	O	O
,	NN	O	O
cisapride	NN	O	O
,	NN	O	O
terfenadine	NN	O	O
and	NN	O	O
terodiline	NN	O	O
on	NN	O	O
monophasic	NN	O	O
action	NN	O	O
potential	NN	O	O
duration	NN	O	O
in	NN	O	O
dog	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

Torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
(	NN	O	O
TDP	NN	O	B
)	NN	O	O
is	NN	O	O
a	NN	O	O
potentially	NN	O	O
fatal	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
associated	NN	O	O
with	NN	O	O
increases	NN	O	O
in	NN	O	O
QT	NN	O	O
interval	NN	O	O
and	NN	O	O
monophasic	NN	O	O
action	NN	O	O
potential	NN	O	O
duration	NN	O	O
(	NN	O	O
MAPD	NN	O	O
)	NN	O	O
.	NN	O	O

TDP	NN	O	B
is	NN	O	O
a	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
that	NN	O	O
has	NN	O	O
led	NN	O	O
to	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
several	NN	O	O
drugs	NN	O	O
from	NN	O	O
the	NN	O	O
market	NN	O	O
(	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
terfenadine	NN	O	O
and	NN	O	O
terodiline	NN	O	O
)	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

The	NN	O	O
potential	NN	O	O
of	NN	O	O
compounds	NN	O	O
to	NN	O	O
cause	NN	O	O
TDP	NN	O	B
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
monitoring	NN	O	O
their	NN	O	O
effects	NN	O	O
on	NN	O	O
MAPD	NN	O	O
in	NN	O	O
dog	NN	O	O
.	NN	O	O

Four	NN	O	O
compounds	NN	O	O
known	NN	O	O
to	NN	O	O
increase	NN	O	O
QT	NN	O	O
interval	NN	O	O
and	NN	O	O
cause	NN	O	O
TDP	NN	O	B
were	NN	O	O
investigated	NN	O	O
:	NN	O	O
terfenadine	NN	O	O
,	NN	O	O
terodiline	NN	O	O
,	NN	O	O
cisapride	NN	O	O
and	NN	O	O
E4031	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
basis	NN	O	O
that	NN	O	O
only	NN	O	O
free	NN	O	O
drug	NN	O	O
in	NN	O	O
the	NN	O	O
systemic	NN	O	O
circulation	NN	O	O
will	NN	O	O
elicit	NN	O	O
a	NN	O	O
pharmacological	NN	O	O
response	NN	O	O
target	NN	O	O
,	NN	O	O
free	NN	O	O
concentrations	NN	O	O
in	NN	O	O
plasma	NN	O	O
were	NN	O	O
selected	NN	O	O
to	NN	O	O
mimic	NN	O	O
the	NN	O	O
free	NN	O	O
drug	NN	O	O
exposures	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

Infusion	NN	O	O
regimens	NN	O	O
were	NN	O	O
designed	NN	O	O
that	NN	O	O
rapidly	NN	O	O
achieved	NN	O	O
and	NN	O	O
maintained	NN	O	O
target	NN	O	O
-	NN	O	O
free	NN	O	O
concentrations	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
data	NN	O	O
on	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
free	NN	O	O
concentration	NN	O	O
and	NN	O	O
changes	NN	O	O
in	NN	O	O
MAPD	NN	O	O
were	NN	O	O
obtained	NN	O	O
for	NN	O	O
these	NN	O	O
compounds	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
free	NN	O	O
ED50	NN	O	O
in	NN	O	O
plasma	NN	O	O
for	NN	O	O
terfenadine	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
nM	NN	O	O
)	NN	O	O
,	NN	O	O
terodiline	NN	O	O
(	NN	O	O
76	NN	O	O
nM	NN	O	O
)	NN	O	O
,	NN	O	O
cisapride	NN	O	O
(	NN	O	O
11	NN	O	O
nM	NN	O	O
)	NN	O	O
and	NN	O	O
E4031	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
nM	NN	O	O
)	NN	O	O
closely	NN	O	O
correlate	NN	O	O
with	NN	O	O
the	NN	O	O
free	NN	O	O
concentration	NN	O	O
in	NN	O	O
man	NN	O	O
causing	NN	O	O
QT	NN	O	O
effects	NN	O	O
.	NN	O	O

For	NN	O	O
compounds	NN	O	O
that	NN	O	O
have	NN	O	O
shown	NN	O	O
TDP	NN	O	B
in	NN	O	O
the	NN	O	O
clinic	NN	O	O
(	NN	O	O
terfenadine	NN	O	O
,	NN	O	O
terodiline	NN	O	O
,	NN	O	O
cisapride	NN	O	O
)	NN	O	O
there	NN	O	O
is	NN	O	O
little	NN	O	O
differentiation	NN	O	O
between	NN	O	O
the	NN	O	O
dog	NN	O	O
ED50	NN	O	O
and	NN	O	O
the	NN	O	O
efficacious	NN	O	O
free	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
in	NN	O	O
man	NN	O	O
(	NN	O	O
<	NN	O	O
10	NN	O	O
-	NN	O	O
fold	NN	O	O
)	NN	O	O
reflecting	NN	O	O
their	NN	O	O
limited	NN	O	O
safety	NN	O	O
margins	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
underline	NN	O	O
the	NN	O	O
need	NN	O	O
to	NN	O	O
maximize	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
ratio	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
TDP	NN	O	B
in	NN	O	O
potential	NN	O	O
development	NN	O	O
candidates	NN	O	O
and	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
using	NN	O	O
free	NN	O	O
drug	NN	O	O
concentrations	NN	O	O
in	NN	O	O
pharmacokinetic	NN	O	O
/	NN	O	O
pharmacodynamic	NN	O	O
studies	NN	O	O
.	NN	O	O

Bladder	NN	O	O
retention	NN	O	B
of	NN	O	I
urine	NN	O	I
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
continuous	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
:	NN	O	O
2	NN	O	O
case	NN	O	O
reports	NN	O	O
.	NN	O	O

Sedation	NN	O	O
has	NN	O	O
been	NN	O	O
commonly	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
neonate	NN	O	O
to	NN	O	O
decrease	NN	O	O
the	NN	O	O
stress	NN	O	O
and	NN	O	O
pain	NN	O	B
from	NN	O	O
the	NN	O	O
noxious	NN	O	O
stimuli	NN	O	O
and	NN	O	O
invasive	NN	O	O
procedures	NN	O	O
in	NN	O	O
the	NN	O	O
neonatal	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
to	NN	O	O
facilitate	NN	O	O
synchrony	NN	O	O
between	NN	O	O
ventilator	NN	O	O
and	NN	O	O
spontaneous	NN	O	O
breaths	NN	O	O
.	NN	O	O

Fentanyl	NN	O	O
,	NN	O	O
an	NN	O	O
opioid	NN	O	O
analgesic	NN	O	O
,	NN	O	O
is	NN	O	O
frequently	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
neonatal	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
setting	NN	O	O
for	NN	O	O
these	NN	O	O
very	NN	O	O
purposes	NN	O	O
.	NN	O	O

Various	NN	O	O
reported	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
administration	NN	O	O
include	NN	O	O
chest	NN	O	B
wall	NN	O	I
rigidity	NN	O	I
,	NN	O	O
hypotension	NN	O	B
,	NN	O	O
respiratory	NN	O	B
depression	NN	O	I
,	NN	O	O
and	NN	O	O
bradycardia	NN	O	B
.	NN	O	O

Here	NN	O	O
,	NN	O	O
2	NN	O	O
cases	NN	O	O
of	NN	O	O
urinary	NN	O	B
bladder	NN	O	I
retention	NN	O	I
leading	NN	O	O
to	NN	O	O
renal	NN	O	O
pelvocalyceal	NN	O	O
dilatation	NN	O	O
mimicking	NN	O	O
hydronephrosis	NN	O	B
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

Fatal	NN	O	O
myeloencephalopathy	NN	O	B
due	NN	O	O
to	NN	O	O
accidental	NN	O	O
intrathecal	NN	O	O
vincristin	NN	O	O
administration	NN	O	O
:	NN	O	O
a	NN	O	O
report	NN	O	O
of	NN	O	O
two	NN	O	O
cases	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
two	NN	O	O
fatal	NN	O	O
cases	NN	O	O
of	NN	O	O
accidental	NN	O	O
intrathecal	NN	O	O
vincristine	NN	O	O
instillation	NN	O	O
in	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
year	NN	O	O
old	NN	O	O
girl	NN	O	O
with	NN	O	O
recurrent	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leucemia	NN	O	I
and	NN	O	O
a	NN	O	O
57	NN	O	O
-	NN	O	O
year	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
lymphoblastic	NN	O	B
lymphoma	NN	O	I
.	NN	O	O

The	NN	O	O
girl	NN	O	O
died	NN	O	O
seven	NN	O	O
days	NN	O	O
,	NN	O	O
the	NN	O	O
man	NN	O	O
four	NN	O	O
weeks	NN	O	O
after	NN	O	O
intrathecal	NN	O	O
injection	NN	O	O
of	NN	O	O
vincristine	NN	O	O
.	NN	O	O

Clinically	NN	O	O
,	NN	O	O
the	NN	O	O
onset	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
the	NN	O	O
signs	NN	O	O
of	NN	O	O
opistothonus	NN	O	B
,	NN	O	I
sensory	NN	O	I
and	NN	O	I
motor	NN	O	I
dysfunction	NN	O	I
and	NN	O	O
ascending	NN	O	O
paralysis	NN	O	B
.	NN	O	O

Histological	NN	O	O
and	NN	O	O
immunohistochemical	NN	O	O
investigations	NN	O	O
(	NN	O	O
HE	NN	O	O
-	NN	O	O
LFB	NN	O	O
,	NN	O	O
CD	NN	O	O
-	NN	O	O
68	NN	O	O
,	NN	O	O
Neurofilament	NN	O	O
)	NN	O	O
revealed	NN	O	O
degeneration	NN	O	B
of	NN	O	I
myelin	NN	O	I
and	NN	O	I
axons	NN	O	I
as	NN	O	O
well	NN	O	O
as	NN	O	O
pseudocystic	NN	O	B
transformation	NN	O	I
in	NN	O	O
areas	NN	O	O
exposed	NN	O	O
to	NN	O	O
vincristine	NN	O	O
,	NN	O	O
accompanied	NN	O	O
by	NN	O	O
secondary	NN	O	O
changes	NN	O	O
with	NN	O	O
numerous	NN	O	O
prominent	NN	O	O
macrophages	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
course	NN	O	O
and	NN	O	O
histopathological	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
cases	NN	O	O
are	NN	O	O
presented	NN	O	O
.	NN	O	O

A	NN	O	O
review	NN	O	O
of	NN	O	O
all	NN	O	O
reported	NN	O	O
cases	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
is	NN	O	O
given	NN	O	O
.	NN	O	O

A	NN	O	O
better	NN	O	O
controlled	NN	O	O
regimen	NN	O	O
for	NN	O	O
administering	NN	O	O
vincristine	NN	O	O
and	NN	O	O
intrathecal	NN	O	O
chemotherapy	NN	O	O
is	NN	O	O
recommended	NN	O	O
.	NN	O	O

Palpebral	NN	O	B
twitching	NN	O	I
in	NN	O	O
a	NN	O	O
depressed	NN	O	B
adolescent	NN	O	O
on	NN	O	O
citalopram	NN	O	O
.	NN	O	O

Current	NN	O	O
estimates	NN	O	O
suggest	NN	O	O
that	NN	O	O
between	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
and	NN	O	O
8	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
of	NN	O	O
children	NN	O	O
and	NN	O	O
adolescents	NN	O	O
are	NN	O	O
affected	NN	O	O
by	NN	O	O
major	NN	O	B
depression	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
favorable	NN	O	O
response	NN	O	O
to	NN	O	O
treatment	NN	O	O
with	NN	O	O
citalopram	NN	O	O
by	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
with	NN	O	O
major	NN	O	B
depression	NN	O	I
who	NN	O	O
exhibited	NN	O	O
palpebral	NN	O	B
twitching	NN	O	I
during	NN	O	O
his	NN	O	O
first	NN	O	O
2	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

This	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
a	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
citalopram	NN	O	O
as	NN	O	O
it	NN	O	O
remitted	NN	O	O
with	NN	O	O
redistribution	NN	O	O
of	NN	O	O
doses	NN	O	O
.	NN	O	O

The	NN	O	O
3	NN	O	O
-	NN	O	O
week	NN	O	O
sulphasalazine	NN	O	O
syndrome	NN	O	O
strikes	NN	O	O
again	NN	O	O
.	NN	O	O

A	NN	O	O
34	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
lady	NN	O	O
developed	NN	O	O
a	NN	O	O
constellation	NN	O	O
of	NN	O	O
dermatitis	NN	O	B
,	NN	O	O
fever	NN	O	B
,	NN	O	O
lymphadenopathy	NN	O	B
and	NN	O	O
hepatitis	NN	O	B
,	NN	O	O
beginning	NN	O	O
on	NN	O	O
the	NN	O	O
17th	NN	O	O
day	NN	O	O
of	NN	O	O
a	NN	O	O
course	NN	O	O
of	NN	O	O
oral	NN	O	O
sulphasalazine	NN	O	O
for	NN	O	O
sero	NN	O	O
-	NN	O	O
negative	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
.	NN	O	O

Cervical	NN	O	O
and	NN	O	O
inguinal	NN	O	O
lymph	NN	O	O
node	NN	O	O
biopsies	NN	O	O
showed	NN	O	O
the	NN	O	O
features	NN	O	O
of	NN	O	O
severe	NN	O	O
necrotising	NN	O	O
lymphadenitis	NN	O	B
,	NN	O	O
associated	NN	O	O
with	NN	O	O
erythrophagocytosis	NN	O	O
and	NN	O	O
prominent	NN	O	O
eosinophilic	NN	O	O
infiltrates	NN	O	O
,	NN	O	O
without	NN	O	O
viral	NN	O	O
inclusion	NN	O	O
bodies	NN	O	O
,	NN	O	O
suggestive	NN	O	O
of	NN	O	O
an	NN	O	O
adverse	NN	O	B
drug	NN	O	I
reaction	NN	O	I
.	NN	O	O
A	NN	O	O
week	NN	O	O
later	NN	O	O
,	NN	O	O
fulminant	NN	O	O
drug	NN	O	B
-	NN	O	I
induced	NN	O	I
hepatitis	NN	O	I
,	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
anti	NN	O	O
-	NN	O	O
nuclear	NN	O	O
autoantibodies	NN	O	O
(	NN	O	O
but	NN	O	O
not	NN	O	O
with	NN	O	O
other	NN	O	O
markers	NN	O	O
of	NN	O	O
autoimmunity	NN	O	B
)	NN	O	O
,	NN	O	O
and	NN	O	O
accompanied	NN	O	O
by	NN	O	O
multi	NN	O	B
-	NN	O	I
organ	NN	O	I
failure	NN	O	I
and	NN	O	O
sepsis	NN	O	B
,	NN	O	O
supervened	NN	O	O
.	NN	O	O

She	NN	O	O
subsequently	NN	O	O
died	NN	O	O
some	NN	O	O
5	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
commencement	NN	O	O
of	NN	O	O
her	NN	O	O
drug	NN	O	O
therapy	NN	O	O
.	NN	O	O
Post	NN	O	O
-	NN	O	O
mortem	NN	O	O
examination	NN	O	O
showed	NN	O	O
evidence	NN	O	O
of	NN	O	O
massive	NN	O	B
hepatocellular	NN	O	I
necrosis	NN	O	I
,	NN	O	O
acute	NN	O	O
hypersensitivity	NN	O	O
myocarditis	NN	O	B
,	NN	O	O
focal	NN	O	O
acute	NN	O	O
tubulo	NN	O	O
-	NN	O	O
interstitial	NN	O	O
nephritis	NN	O	B
and	NN	O	O
extensive	NN	O	O
bone	NN	O	B
marrow	NN	O	I
necrosis	NN	O	I
,	NN	O	O
with	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
malignancy	NN	O	B
.	NN	O	O

It	NN	O	O
is	NN	O	O
thought	NN	O	O
that	NN	O	O
the	NN	O	O
clinico	NN	O	O
-	NN	O	O
pathological	NN	O	O
features	NN	O	O
and	NN	O	O
chronology	NN	O	O
of	NN	O	O
this	NN	O	O
case	NN	O	O
bore	NN	O	O
the	NN	O	O
hallmarks	NN	O	O
of	NN	O	O
the	NN	O	O
so	NN	O	O
-	NN	O	O
called	NN	O	O
"	NN	O	O
3	NN	O	O
-	NN	O	O
week	NN	O	O
sulphasalazine	NN	O	O
syndrome	NN	O	O
"	NN	O	O
,	NN	O	O
a	NN	O	O
rare	NN	O	O
,	NN	O	O
but	NN	O	O
often	NN	O	O
fatal	NN	O	O
,	NN	O	O
immunoallergic	NN	O	O
reaction	NN	O	O
to	NN	O	O
sulphasalazine	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
prochlorperazine	NN	O	O
by	NN	O	O
15	NN	O	O
-	NN	O	O
minute	NN	O	O
infusion	NN	O	O
versus	NN	O	O
2	NN	O	O
-	NN	O	O
minute	NN	O	O
bolus	NN	O	O
does	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
akathisia	NN	O	B
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

STUDY	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
We	NN	O	O
sought	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
akathisia	NN	O	B
after	NN	O	O
administration	NN	O	O
of	NN	O	O
intravenous	NN	O	O
prochlorperazine	NN	O	O
as	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
minute	NN	O	O
bolus	NN	O	O
or	NN	O	O
15	NN	O	O
-	NN	O	O
minute	NN	O	O
infusion	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
conducted	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
of	NN	O	O
a	NN	O	O
central	NN	O	O
-	NN	O	O
city	NN	O	O
teaching	NN	O	O
hospital	NN	O	O
.	NN	O	O

Patients	NN	O	O
aged	NN	O	O
18	NN	O	O
years	NN	O	O
or	NN	O	O
older	NN	O	O
treated	NN	O	O
with	NN	O	O
prochlorperazine	NN	O	O
for	NN	O	O
headache	NN	O	B
,	NN	O	O
nausea	NN	O	B
,	NN	O	O
or	NN	O	O
vomiting	NN	O	B
were	NN	O	O
eligible	NN	O	O
for	NN	O	O
inclusion	NN	O	O
.	NN	O	O

Study	NN	O	O
participants	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
10	NN	O	O
mg	NN	O	O
of	NN	O	O
prochlorperazine	NN	O	O
administered	NN	O	O
intravenously	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
2	NN	O	O
-	NN	O	O
minute	NN	O	O
push	NN	O	O
(	NN	O	O
bolus	NN	O	O
group	NN	O	O
)	NN	O	O
or	NN	O	O
10	NN	O	O
mg	NN	O	O
diluted	NN	O	O
in	NN	O	O
50	NN	O	O
mL	NN	O	O
of	NN	O	O
normal	NN	O	O
saline	NN	O	O
solution	NN	O	O
administered	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
during	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
minute	NN	O	O
period	NN	O	O
(	NN	O	O
infusion	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
main	NN	O	O
outcome	NN	O	O
was	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
study	NN	O	O
participants	NN	O	O
experiencing	NN	O	O
akathisia	NN	O	B
within	NN	O	O
60	NN	O	O
minutes	NN	O	O
of	NN	O	O
administration	NN	O	O
.	NN	O	O

Akathisia	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
either	NN	O	O
a	NN	O	O
spontaneous	NN	O	O
report	NN	O	O
of	NN	O	O
restlessness	NN	O	O
or	NN	O	O
agitation	NN	O	B
or	NN	O	O
a	NN	O	O
change	NN	O	O
of	NN	O	O
2	NN	O	O
or	NN	O	O
more	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
-	NN	O	O
reported	NN	O	O
akathisia	NN	O	B
rating	NN	O	O
scale	NN	O	O
and	NN	O	O
a	NN	O	O
change	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
1	NN	O	O
in	NN	O	O
the	NN	O	O
investigator	NN	O	O
-	NN	O	O
observed	NN	O	O
akathisia	NN	O	B
rating	NN	O	O
scale	NN	O	O
.	NN	O	O

The	NN	O	O
intensity	NN	O	O
of	NN	O	O
headache	NN	O	B
and	NN	O	O
nausea	NN	O	B
was	NN	O	O
measured	NN	O	O
with	NN	O	O
a	NN	O	O
100	NN	O	O
-	NN	O	O
mm	NN	O	O
visual	NN	O	O
analog	NN	O	O
scale	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
One	NN	O	O
hundred	NN	O	O
patients	NN	O	O
were	NN	O	O
enrolled	NN	O	O
.	NN	O	O

One	NN	O	O
study	NN	O	O
participant	NN	O	O
was	NN	O	O
excluded	NN	O	O
after	NN	O	O
protocol	NN	O	O
violation	NN	O	O
.	NN	O	O

Seventy	NN	O	O
-	NN	O	O
three	NN	O	O
percent	NN	O	O
(	NN	O	O
73	NN	O	O
/	NN	O	O
99	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
participants	NN	O	O
were	NN	O	O
treated	NN	O	O
for	NN	O	O
headache	NN	O	B
and	NN	O	O
70	NN	O	O
%	NN	O	O
(	NN	O	O
70	NN	O	O
/	NN	O	O
99	NN	O	O
)	NN	O	O
for	NN	O	O
nausea	NN	O	B
.	NN	O	O

In	NN	O	O
the	NN	O	O
bolus	NN	O	O
group	NN	O	O
,	NN	O	O
26	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
(	NN	O	O
13	NN	O	O
/	NN	O	O
50	NN	O	O
)	NN	O	O
had	NN	O	O
akathisia	NN	O	B
compared	NN	O	O
with	NN	O	O
32	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
(	NN	O	O
16	NN	O	O
/	NN	O	O
49	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
infusion	NN	O	O
group	NN	O	O
(	NN	O	O
Delta	NN	O	O
=	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
-	NN	O	O
24	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
to	NN	O	O
11	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
bolus	NN	O	O
and	NN	O	O
infusion	NN	O	O
groups	NN	O	O
in	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
participants	NN	O	O
who	NN	O	O
saw	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
reduction	NN	O	O
in	NN	O	O
their	NN	O	O
headache	NN	O	B
intensity	NN	O	O
within	NN	O	O
30	NN	O	O
minutes	NN	O	O
was	NN	O	O
11	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
to	NN	O	O
33	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
reduction	NN	O	O
in	NN	O	O
their	NN	O	O
nausea	NN	O	B
was	NN	O	O
12	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
to	NN	O	O
29	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
A	NN	O	O
50	NN	O	O
%	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
akathisia	NN	O	B
when	NN	O	O
prochlorperazine	NN	O	O
was	NN	O	O
administered	NN	O	O
by	NN	O	O
means	NN	O	O
of	NN	O	O
15	NN	O	O
-	NN	O	O
minute	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
versus	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
minute	NN	O	O
intravenous	NN	O	O
push	NN	O	O
was	NN	O	O
not	NN	O	O
detected	NN	O	O
.	NN	O	O

The	NN	O	O
efficacy	NN	O	O
of	NN	O	O
prochlorperazine	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
headache	NN	O	B
and	NN	O	O
nausea	NN	O	B
likewise	NN	O	O
did	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
affected	NN	O	O
by	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
administration	NN	O	O
,	NN	O	O
although	NN	O	O
no	NN	O	O
formal	NN	O	O
statistical	NN	O	O
comparisons	NN	O	O
were	NN	O	O
made	NN	O	O
.	NN	O	O

Combined	NN	O	O
antiretroviral	NN	O	O
therapy	NN	O	O
causes	NN	O	O
cardiomyopathy	NN	O	B
and	NN	O	O
elevates	NN	O	O
plasma	NN	O	O
lactate	NN	O	O
in	NN	O	O
transgenic	NN	O	O
AIDS	NN	O	B
mice	NN	O	O
.	NN	O	O

Highly	NN	O	O
active	NN	O	O
antiretroviral	NN	O	O
therapy	NN	O	O
(	NN	O	O
HAART	NN	O	O
)	NN	O	O
is	NN	O	O
implicated	NN	O	O
in	NN	O	O
cardiomyopathy	NN	O	B
(	NN	O	O
CM	NN	O	B
)	NN	O	O
and	NN	O	O
in	NN	O	O
elevated	NN	O	O
plasma	NN	O	O
lactate	NN	O	O
(	NN	O	O
LA	NN	O	O
)	NN	O	O
in	NN	O	O
AIDS	NN	O	B
through	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
mitochondrial	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

To	NN	O	O
determine	NN	O	O
mitochondrial	NN	O	O
events	NN	O	O
from	NN	O	O
HAART	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
8	NN	O	O
-	NN	O	O
week	NN	O	O
-	NN	O	O
old	NN	O	O
hemizygous	NN	O	O
transgenic	NN	O	O
AIDS	NN	O	B
mice	NN	O	O
(	NN	O	O
NL4	NN	O	O
-	NN	O	O
3Delta	NN	O	O
gag	NN	O	O
/	NN	O	O
pol	NN	O	O
;	NN	O	O
TG	NN	O	O
)	NN	O	O
and	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
FVB	NN	O	O
/	NN	O	O
n	NN	O	O
littermates	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
HAART	NN	O	O
combination	NN	O	O
of	NN	O	O
zidovudine	NN	O	O
,	NN	O	O
lamivudine	NN	O	O
,	NN	O	O
and	NN	O	O
indinavir	NN	O	O
or	NN	O	O
vehicle	NN	O	O
control	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
or	NN	O	O
35	NN	O	O
days	NN	O	O
.	NN	O	O

At	NN	O	O
termination	NN	O	O
of	NN	O	O
the	NN	O	O
experiments	NN	O	O
,	NN	O	O
mice	NN	O	O
underwent	NN	O	O
echocardiography	NN	O	O
,	NN	O	O
quantitation	NN	O	O
of	NN	O	O
abundance	NN	O	O
of	NN	O	O
molecular	NN	O	O
markers	NN	O	O
of	NN	O	O
CM	NN	O	B
(	NN	O	O
ventricular	NN	O	O
mRNA	NN	O	O
encoding	NN	O	O
atrial	NN	O	O
natriuretic	NN	O	O
factor	NN	O	O
[	NN	O	O
ANF	NN	O	O
]	NN	O	O
and	NN	O	O
sarcoplasmic	NN	O	O
calcium	NN	O	O
ATPase	NN	O	O
[	NN	O	O
SERCA2	NN	O	O
]	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
determination	NN	O	O
of	NN	O	O
plasma	NN	O	O
LA	NN	O	O
.	NN	O	O

Myocardial	NN	O	O
histologic	NN	O	O
features	NN	O	O
were	NN	O	O
analyzed	NN	O	O
semiquantitatively	NN	O	O
and	NN	O	O
results	NN	O	O
were	NN	O	O
confirmed	NN	O	O
by	NN	O	O
transmission	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
.	NN	O	O

After	NN	O	O
35	NN	O	O
days	NN	O	O
in	NN	O	O
the	NN	O	O
TG	NN	O	O
+	NN	O	O
HAART	NN	O	O
cohort	NN	O	O
,	NN	O	O
left	NN	O	O
ventricular	NN	O	O
mass	NN	O	O
increased	NN	O	O
160	NN	O	O
%	NN	O	O
by	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Molecularly	NN	O	O
,	NN	O	O
ANF	NN	O	O
mRNA	NN	O	O
increased	NN	O	O
250	NN	O	O
%	NN	O	O
and	NN	O	O
SERCA2	NN	O	O
mRNA	NN	O	O
decreased	NN	O	O
57	NN	O	O
%	NN	O	O
.	NN	O	O

Biochemically	NN	O	O
,	NN	O	O
LA	NN	O	O
was	NN	O	O
elevated	NN	O	O
(	NN	O	O
8	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mM	NN	O	O
)	NN	O	O
.	NN	O	O

Pathologically	NN	O	O
,	NN	O	O
granular	NN	O	O
cytoplasmic	NN	O	O
changes	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
cardiac	NN	O	O
myocytes	NN	O	O
,	NN	O	O
indicating	NN	O	O
enlarged	NN	O	O
,	NN	O	O
damaged	NN	O	O
mitochondria	NN	O	O
.	NN	O	O

Findings	NN	O	O
were	NN	O	O
confirmed	NN	O	O
ultrastructurally	NN	O	O
.	NN	O	O

No	NN	O	O
changes	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
other	NN	O	O
cohorts	NN	O	O
.	NN	O	O

After	NN	O	O
10	NN	O	O
days	NN	O	O
,	NN	O	O
only	NN	O	O
ANF	NN	O	O
was	NN	O	O
elevated	NN	O	O
,	NN	O	O
and	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
TG	NN	O	O
+	NN	O	O
HAART	NN	O	O
cohort	NN	O	O
.	NN	O	O

Results	NN	O	O
show	NN	O	O
that	NN	O	O
cumulative	NN	O	O
HAART	NN	O	O
caused	NN	O	O
mitochondrial	NN	O	O
CM	NN	O	B
with	NN	O	O
elevated	NN	O	O
LA	NN	O	O
in	NN	O	O
AIDS	NN	O	B
transgenic	NN	O	O
mice	NN	O	O
.	NN	O	O

A	NN	O	O
Phase	NN	O	O
II	NN	O	O
trial	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
plus	NN	O	O
WR	NN	O	O
-	NN	O	O
2721	NN	O	O
(	NN	O	O
amifostine	NN	O	O
)	NN	O	O
for	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
carcinoma	NN	O	I
:	NN	O	O
an	NN	O	O
Eastern	NN	O	O
Cooperative	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
Study	NN	O	O
(	NN	O	O
E8188	NN	O	O
)	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Cisplatin	NN	O	O
has	NN	O	O
minimal	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
when	NN	O	O
used	NN	O	O
as	NN	O	O
second	NN	O	O
-	NN	O	O
or	NN	O	O
third	NN	O	O
-	NN	O	O
line	NN	O	O
treatment	NN	O	O
of	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
carcinoma	NN	O	I
.	NN	O	O

Older	NN	O	O
reports	NN	O	O
suggest	NN	O	O
an	NN	O	O
objective	NN	O	O
response	NN	O	O
rate	NN	O	O
of	NN	O	O
8	NN	O	O
%	NN	O	O
when	NN	O	O
60	NN	O	O
-	NN	O	O
120	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
is	NN	O	O
administered	NN	O	O
every	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
weeks	NN	O	O
.	NN	O	O

Although	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
effect	NN	O	O
has	NN	O	O
been	NN	O	O
observed	NN	O	O
with	NN	O	O
cisplatin	NN	O	O
,	NN	O	O
the	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
toxicities	NN	O	B
associated	NN	O	O
with	NN	O	O
cisplatin	NN	O	O
(	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
,	NN	O	O
nephrotoxicity	NN	O	B
,	NN	O	O
ototoxicity	NN	O	B
,	NN	O	O
and	NN	O	O
neurotoxicity	NN	O	B
)	NN	O	O
have	NN	O	O
limited	NN	O	O
its	NN	O	O
use	NN	O	O
as	NN	O	O
a	NN	O	O
treatment	NN	O	O
for	NN	O	O
breast	NN	O	B
carcinoma	NN	O	I
.	NN	O	O

WR	NN	O	O
-	NN	O	O
2721	NN	O	O
or	NN	O	O
amifostine	NN	O	O
initially	NN	O	O
was	NN	O	O
developed	NN	O	O
to	NN	O	O
protect	NN	O	O
military	NN	O	O
personnel	NN	O	O
in	NN	O	O
the	NN	O	O
event	NN	O	O
of	NN	O	O
nuclear	NN	O	O
war	NN	O	O
.	NN	O	O

Amifostine	NN	O	O
subsequently	NN	O	O
was	NN	O	O
shown	NN	O	O
to	NN	O	O
protect	NN	O	O
normal	NN	O	O
tissues	NN	O	O
from	NN	O	O
the	NN	O	O
toxic	NN	O	O
effects	NN	O	O
of	NN	O	O
alkylating	NN	O	O
agents	NN	O	O
and	NN	O	O
cisplatin	NN	O	O
without	NN	O	O
decreasing	NN	O	O
the	NN	O	O
antitumor	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Early	NN	O	O
trials	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
and	NN	O	O
amifostine	NN	O	O
also	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B
,	NN	O	O
ototoxicity	NN	O	B
,	NN	O	O
and	NN	O	O
neuropathy	NN	O	B
were	NN	O	O
reduced	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
Phase	NN	O	O
II	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
plus	NN	O	O
amifostine	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
progressive	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
carcinoma	NN	O	I
who	NN	O	O
had	NN	O	O
received	NN	O	O
one	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
,	NN	O	O
chemotherapy	NN	O	O
regimen	NN	O	O
for	NN	O	O
metastatic	NN	O	O
disease	NN	O	O
.	NN	O	O

Patients	NN	O	O
received	NN	O	O
amifostine	NN	O	O
,	NN	O	O
910	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
intravenously	NN	O	O
over	NN	O	O
15	NN	O	O
minutes	NN	O	O
.	NN	O	O

After	NN	O	O
completion	NN	O	O
of	NN	O	O
the	NN	O	O
amifostine	NN	O	O
infusion	NN	O	O
,	NN	O	O
cisplatin	NN	O	O
120	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
was	NN	O	O
administered	NN	O	O
over	NN	O	O
30	NN	O	O
minutes	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
hydration	NN	O	O
and	NN	O	O
mannitol	NN	O	O
was	NN	O	O
administered	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
cisplatin	NN	O	O
.	NN	O	O

Treatment	NN	O	O
was	NN	O	O
administered	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
until	NN	O	O
disease	NN	O	O
progression	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Forty	NN	O	O
-	NN	O	O
four	NN	O	O
patients	NN	O	O
were	NN	O	O
enrolled	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
of	NN	O	O
which	NN	O	O
7	NN	O	O
(	NN	O	O
16	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
ineligible	NN	O	O
.	NN	O	O

A	NN	O	O
median	NN	O	O
of	NN	O	O
2	NN	O	O
cycles	NN	O	O
of	NN	O	O
therapy	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
the	NN	O	O
37	NN	O	O
eligible	NN	O	O
patients	NN	O	O
.	NN	O	O

Six	NN	O	O
partial	NN	O	O
responses	NN	O	O
were	NN	O	O
observed	NN	O	O
for	NN	O	O
an	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
of	NN	O	O
16	NN	O	O
%	NN	O	O
.	NN	O	O

Most	NN	O	O
patients	NN	O	O
(	NN	O	O
57	NN	O	O
%	NN	O	O
)	NN	O	O
stopped	NN	O	O
treatment	NN	O	O
because	NN	O	O
of	NN	O	O
disease	NN	O	O
progression	NN	O	O
.	NN	O	O

Neurologic	NN	O	B
toxicity	NN	O	I
was	NN	O	O
reported	NN	O	O
in	NN	O	O
52	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Seven	NN	O	O
different	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
toxicities	NN	O	B
were	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
while	NN	O	O
receiving	NN	O	O
treatment	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
combination	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
and	NN	O	O
amifostine	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
of	NN	O	O
16	NN	O	O
%	NN	O	O
.	NN	O	O

Neither	NN	O	O
a	NN	O	O
tumor	NN	O	B
-	NN	O	O
protective	NN	O	O
effect	NN	O	O
nor	NN	O	O
reduced	NN	O	O
toxicity	NN	O	B
to	NN	O	O
normal	NN	O	O
tissues	NN	O	O
was	NN	O	O
observed	NN	O	O
with	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
amifostine	NN	O	O
to	NN	O	O
cisplatin	NN	O	O
in	NN	O	O
this	NN	O	O
trial	NN	O	O
.	NN	O	O

Oral	NN	O	O
contraceptives	NN	O	O
and	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
An	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
and	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
has	NN	O	O
been	NN	O	O
found	NN	O	O
in	NN	O	O
some	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
all	NN	O	O
,	NN	O	O
studies	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
this	NN	O	O
association	NN	O	O
,	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
progestagen	NN	O	O
included	NN	O	O
in	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
,	NN	O	O
desogestrel	NN	O	O
or	NN	O	O
gestodene	NN	O	O
)	NN	O	O
and	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
,	NN	O	O
levonorgestrel	NN	O	O
)	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
,	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
estrogen	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
prothrombotic	NN	O	O
mutations	NN	O	O
METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
a	NN	O	O
nationwide	NN	O	O
,	NN	O	O
population	NN	O	O
-	NN	O	O
based	NN	O	O
,	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
identified	NN	O	O
and	NN	O	O
enrolled	NN	O	O
248	NN	O	O
women	NN	O	O
18	NN	O	O
through	NN	O	O
49	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
who	NN	O	O
had	NN	O	O
had	NN	O	O
a	NN	O	O
first	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
between	NN	O	O
1990	NN	O	O
and	NN	O	O
1995	NN	O	O
and	NN	O	O
925	NN	O	O
control	NN	O	O
women	NN	O	O
who	NN	O	O
had	NN	O	O
not	NN	O	O
had	NN	O	O
a	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
and	NN	O	O
who	NN	O	O
were	NN	O	O
matched	NN	O	O
for	NN	O	O
age	NN	O	O
,	NN	O	O
calendar	NN	O	O
year	NN	O	O
of	NN	O	O
the	NN	O	O
index	NN	O	O
event	NN	O	O
,	NN	O	O
and	NN	O	O
area	NN	O	O
of	NN	O	O
residence	NN	O	O
.	NN	O	O

Subjects	NN	O	O
supplied	NN	O	O
information	NN	O	O
on	NN	O	O
oral	NN	O	O
-	NN	O	O
contraceptive	NN	O	O
use	NN	O	O
and	NN	O	O
major	NN	O	O
cardiovascular	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

An	NN	O	O
analysis	NN	O	O
for	NN	O	O
factor	NN	O	O
V	NN	O	O
Leiden	NN	O	O
and	NN	O	O
the	NN	O	O
G20210A	NN	O	O
mutation	NN	O	O
in	NN	O	O
the	NN	O	O
prothrombin	NN	O	O
gene	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
217	NN	O	O
patients	NN	O	O
and	NN	O	O
763	NN	O	O
controls	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
odds	NN	O	O
ratio	NN	O	O
for	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
among	NN	O	O
women	NN	O	O
who	NN	O	O
used	NN	O	O
any	NN	O	O
type	NN	O	O
of	NN	O	O
combined	NN	O	O
oral	NN	O	O
contraceptive	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
nonusers	NN	O	O
,	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
adjusted	NN	O	O
odds	NN	O	O
ratio	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
among	NN	O	O
women	NN	O	O
who	NN	O	O
used	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
among	NN	O	O
those	NN	O	O
who	NN	O	O
used	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
.	NN	O	O

Among	NN	O	O
women	NN	O	O
who	NN	O	O
used	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
,	NN	O	O
the	NN	O	O
odds	NN	O	O
ratio	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
for	NN	O	O
those	NN	O	O
without	NN	O	O
a	NN	O	O
prothrombotic	NN	O	O
mutation	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
to	NN	O	O
5	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
for	NN	O	O
those	NN	O	O
with	NN	O	O
a	NN	O	O
mutation	NN	O	O
CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
risk	NN	O	O
of	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
was	NN	O	O
increased	NN	O	O
among	NN	O	O
women	NN	O	O
who	NN	O	O
used	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
were	NN	O	O
inconclusive	NN	O	O
but	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
risk	NN	O	O
was	NN	O	O
lower	NN	O	O
than	NN	O	O
the	NN	O	O
risk	NN	O	O
associated	NN	O	O
with	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
was	NN	O	O
similar	NN	O	O
among	NN	O	O
women	NN	O	O
who	NN	O	O
used	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
whether	NN	O	O
or	NN	O	O
not	NN	O	O
they	NN	O	O
had	NN	O	O
a	NN	O	O
prothrombotic	NN	O	O
mutation	NN	O	O
.	NN	O	O

End	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
(	NN	O	O
ESRD	NN	O	B
)	NN	O	O
after	NN	O	O
orthotopic	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
(	NN	O	O
OLTX	NN	O	O
)	NN	O	O
using	NN	O	O
calcineurin	NN	O	O
-	NN	O	O
based	NN	O	O
immunotherapy	NN	O	O
:	NN	O	O
risk	NN	O	O
of	NN	O	O
development	NN	O	O
and	NN	O	O
treatment	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
calcineurin	NN	O	O
inhibitors	NN	O	O
cyclosporine	NN	O	O
and	NN	O	O
tacrolimus	NN	O	O
are	NN	O	O
both	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
nephrotoxic	NN	O	B
.	NN	O	O

Their	NN	O	O
use	NN	O	O
in	NN	O	O
orthotopic	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
(	NN	O	O
OLTX	NN	O	O
)	NN	O	O
has	NN	O	O
dramatically	NN	O	O
improved	NN	O	O
success	NN	O	O
rates	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
had	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
are	NN	O	O
presenting	NN	O	O
after	NN	O	O
OLTX	NN	O	O
with	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
(	NN	O	O
ESRD	NN	O	B
)	NN	O	O
.	NN	O	O

This	NN	O	O
retrospective	NN	O	O
study	NN	O	O
examines	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
treatment	NN	O	O
of	NN	O	O
ESRD	NN	O	B
and	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
(	NN	O	O
CRF	NN	O	B
)	NN	O	O
in	NN	O	O
OLTX	NN	O	O
patients	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Patients	NN	O	O
receiving	NN	O	O
an	NN	O	O
OLTX	NN	O	O
only	NN	O	O
from	NN	O	O
June	NN	O	O
1985	NN	O	O
through	NN	O	O
December	NN	O	O
of	NN	O	O
1994	NN	O	O
who	NN	O	O
survived	NN	O	O
6	NN	O	O
months	NN	O	O
postoperatively	NN	O	O
were	NN	O	O
studied	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
834	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
prospectively	NN	O	O
collected	NN	O	O
database	NN	O	O
was	NN	O	O
the	NN	O	O
source	NN	O	O
of	NN	O	O
information	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
three	NN	O	O
groups	NN	O	O
:	NN	O	O
Controls	NN	O	O
,	NN	O	O
no	NN	O	O
CRF	NN	O	B
or	NN	O	O
ESRD	NN	O	B
,	NN	O	O
n	NN	O	O
=	NN	O	O
748	NN	O	O
;	NN	O	O
CRF	NN	O	B
,	NN	O	O
sustained	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
>	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
41	NN	O	O
;	NN	O	O
and	NN	O	O
ESRD	NN	O	B
,	NN	O	O
n	NN	O	O
=	NN	O	O
45	NN	O	O
.	NN	O	O

Groups	NN	O	O
were	NN	O	O
compared	NN	O	O
for	NN	O	O
preoperative	NN	O	O
laboratory	NN	O	O
variables	NN	O	O
,	NN	O	O
diagnosis	NN	O	O
,	NN	O	O
postoperative	NN	O	O
variables	NN	O	O
,	NN	O	O
survival	NN	O	O
,	NN	O	O
type	NN	O	O
of	NN	O	O
ESRD	NN	O	B
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
survival	NN	O	O
from	NN	O	O
onset	NN	O	O
of	NN	O	O
ESRD	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
At	NN	O	O
13	NN	O	O
years	NN	O	O
after	NN	O	O
OLTX	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
severe	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
was	NN	O	O
18	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
(	NN	O	O
CRF	NN	O	B
8	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
and	NN	O	O
ESRD	NN	O	B
9	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
control	NN	O	O
patients	NN	O	O
,	NN	O	O
CRF	NN	O	B
and	NN	O	O
ESRD	NN	O	B
patients	NN	O	O
had	NN	O	O
higher	NN	O	O
preoperative	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
,	NN	O	O
a	NN	O	O
greater	NN	O	O
percentage	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
hepatorenal	NN	O	B
syndrome	NN	O	I
,	NN	O	O
higher	NN	O	O
percentage	NN	O	O
requirement	NN	O	O
for	NN	O	O
dialysis	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
3	NN	O	O
months	NN	O	O
postoperatively	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
higher	NN	O	O
1	NN	O	O
-	NN	O	O
year	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
.	NN	O	O

Multivariate	NN	O	O
stepwise	NN	O	O
logistic	NN	O	O
regression	NN	O	O
analysis	NN	O	O
using	NN	O	O
preoperative	NN	O	O
and	NN	O	O
postoperative	NN	O	O
variables	NN	O	O
identified	NN	O	O
that	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
compared	NN	O	O
with	NN	O	O
average	NN	O	O
at	NN	O	O
1	NN	O	O
year	NN	O	O
,	NN	O	O
3	NN	O	O
months	NN	O	O
,	NN	O	O
and	NN	O	O
4	NN	O	O
weeks	NN	O	O
postoperatively	NN	O	O
were	NN	O	O
independent	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
CRF	NN	O	B
or	NN	O	O
ESRD	NN	O	B
with	NN	O	O
odds	NN	O	O
ratios	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
,	NN	O	O
2	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Overall	NN	O	O
survival	NN	O	O
from	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
OLTX	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
among	NN	O	O
groups	NN	O	O
,	NN	O	O
but	NN	O	O
by	NN	O	O
year	NN	O	O
13	NN	O	O
,	NN	O	O
the	NN	O	O
survival	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
ESRD	NN	O	B
was	NN	O	O
only	NN	O	O
28	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
compared	NN	O	O
with	NN	O	O
54	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

Patients	NN	O	O
developing	NN	O	O
ESRD	NN	O	B
had	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
year	NN	O	O
survival	NN	O	O
after	NN	O	O
onset	NN	O	O
of	NN	O	O
ESRD	NN	O	B
of	NN	O	O
27	NN	O	O
%	NN	O	O
for	NN	O	O
the	NN	O	O
patients	NN	O	O
receiving	NN	O	O
hemodialysis	NN	O	O
versus	NN	O	O
71	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
for	NN	O	O
the	NN	O	O
patients	NN	O	O
developing	NN	O	O
ESRD	NN	O	B
who	NN	O	O
subsequently	NN	O	O
received	NN	O	O
kidney	NN	O	O
transplants	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Patients	NN	O	O
who	NN	O	O
are	NN	O	O
more	NN	O	O
than	NN	O	O
10	NN	O	O
years	NN	O	O
post	NN	O	O
-	NN	O	O
OLTX	NN	O	O
have	NN	O	O
CRF	NN	O	B
and	NN	O	O
ESRD	NN	O	B
at	NN	O	O
a	NN	O	O
high	NN	O	O
rate	NN	O	O
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
ESRD	NN	O	B
decreases	NN	O	O
survival	NN	O	O
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
those	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
dialysis	NN	O	O
only	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
develop	NN	O	O
ESRD	NN	O	B
have	NN	O	O
a	NN	O	O
higher	NN	O	O
preoperative	NN	O	O
and	NN	O	O
1	NN	O	O
-	NN	O	O
year	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
and	NN	O	O
are	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
hepatorenal	NN	O	B
syndrome	NN	O	I
.	NN	O	O

However	NN	O	O
,	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
at	NN	O	O
various	NN	O	O
times	NN	O	O
postoperatively	NN	O	O
is	NN	O	O
more	NN	O	O
predictive	NN	O	O
of	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
CRF	NN	O	B
or	NN	O	O
ESRD	NN	O	B
.	NN	O	O

New	NN	O	O
strategies	NN	O	O
for	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
immunosuppression	NN	O	O
may	NN	O	O
be	NN	O	O
needed	NN	O	O
to	NN	O	O
decrease	NN	O	O
this	NN	O	O
complication	NN	O	O
.	NN	O	O

Epileptic	NN	O	B
seizures	NN	O	I
following	NN	O	O
cortical	NN	O	O
application	NN	O	O
of	NN	O	O
fibrin	NN	O	O
sealants	NN	O	O
containing	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Fibrin	NN	O	O
sealants	NN	O	O
(	NN	O	O
FS	NN	O	O
)	NN	O	O
derived	NN	O	O
from	NN	O	O
human	NN	O	O
plasma	NN	O	O
are	NN	O	O
frequently	NN	O	O
used	NN	O	O
in	NN	O	O
neurosurgery	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
increase	NN	O	O
clot	NN	O	O
stability	NN	O	O
,	NN	O	O
FS	NN	O	O
typically	NN	O	O
contain	NN	O	O
aprotinin	NN	O	O
,	NN	O	O
a	NN	O	O
natural	NN	O	O
fibrinolysis	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
synthetic	NN	O	O
fibrinolysis	NN	O	O
inhibitors	NN	O	O
such	NN	O	O
as	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
(	NN	O	O
tAMCA	NN	O	O
)	NN	O	O
have	NN	O	O
been	NN	O	O
considered	NN	O	O
as	NN	O	O
substitutes	NN	O	O
for	NN	O	O
aprotinin	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
tAMCA	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
cause	NN	O	O
epileptic	NN	O	B
seizures	NN	O	I
.	NN	O	O

We	NN	O	O
wanted	NN	O	O
to	NN	O	O
study	NN	O	O
whether	NN	O	O
tAMCA	NN	O	O
retains	NN	O	O
its	NN	O	O
convulsive	NN	O	B
action	NN	O	O
if	NN	O	O
incorporated	NN	O	O
into	NN	O	O
a	NN	O	O
FS	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
FS	NN	O	O
containing	NN	O	O
aprotinin	NN	O	O
or	NN	O	O
different	NN	O	O
concentrations	NN	O	O
of	NN	O	O
tAMCA	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
47	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
were	NN	O	O
applied	NN	O	O
to	NN	O	O
the	NN	O	O
pial	NN	O	O
surface	NN	O	O
of	NN	O	O
the	NN	O	O
cortex	NN	O	O
of	NN	O	O
anaesthetized	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
response	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
was	NN	O	O
evaluated	NN	O	O
using	NN	O	O
electroencephalography	NN	O	O
and	NN	O	O
by	NN	O	O
monitoring	NN	O	O
the	NN	O	O
clinical	NN	O	O
behaviour	NN	O	O
during	NN	O	O
and	NN	O	O
after	NN	O	O
recovery	NN	O	O
from	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
:	NN	O	O
FS	NN	O	O
containing	NN	O	O
tAMCA	NN	O	O
caused	NN	O	O
paroxysmal	NN	O	O
brain	NN	O	O
activity	NN	O	O
which	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
distinct	NN	O	O
convulsive	NN	O	B
behaviours	NN	O	O
.	NN	O	O

The	NN	O	O
degree	NN	O	O
of	NN	O	O
these	NN	O	O
seizures	NN	O	B
increased	NN	O	O
with	NN	O	O
increasing	NN	O	O
concentration	NN	O	O
of	NN	O	O
tAMCA	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
FS	NN	O	O
containing	NN	O	O
47	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
tAMCA	NN	O	O
evoked	NN	O	O
generalized	NN	O	B
seizures	NN	O	I
in	NN	O	O
all	NN	O	O
tested	NN	O	O
rats	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
while	NN	O	O
the	NN	O	O
lowest	NN	O	O
concentration	NN	O	O
of	NN	O	O
tAMCA	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
only	NN	O	O
evoked	NN	O	O
brief	NN	O	O
episodes	NN	O	O
of	NN	O	O
jerk	NN	O	O
-	NN	O	O
correlated	NN	O	O
convulsive	NN	O	B
potentials	NN	O	O
in	NN	O	O
1	NN	O	O
of	NN	O	O
6	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
FS	NN	O	O
containing	NN	O	O
aprotinin	NN	O	O
did	NN	O	O
not	NN	O	O
evoke	NN	O	O
any	NN	O	O
paroxysmal	NN	O	O
activity	NN	O	O
.	NN	O	O

INTERPRETATION	NN	O	O
:	NN	O	O
Tranexamic	NN	O	O
acid	NN	O	O
retains	NN	O	O
its	NN	O	O
convulsive	NN	O	B
action	NN	O	O
within	NN	O	O
FS	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
use	NN	O	O
of	NN	O	O
FS	NN	O	O
containing	NN	O	O
tAMCA	NN	O	O
for	NN	O	O
surgery	NN	O	O
within	NN	O	O
or	NN	O	O
close	NN	O	O
to	NN	O	O
the	NN	O	O
CNS	NN	O	O
may	NN	O	O
pose	NN	O	O
a	NN	O	O
substantial	NN	O	O
risk	NN	O	O
to	NN	O	O
the	NN	O	O
patient	NN	O	O
.	NN	O	O

Sequential	NN	O	O
observations	NN	O	O
of	NN	O	O
exencephaly	NN	O	B
and	NN	O	O
subsequent	NN	O	O
morphological	NN	O	O
changes	NN	O	O
by	NN	O	O
mouse	NN	O	O
exo	NN	O	O
utero	NN	O	O
development	NN	O	O
system	NN	O	O
:	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
transformation	NN	O	O
from	NN	O	O
exencephaly	NN	O	B
to	NN	O	O
anencephaly	NN	O	B
.	NN	O	O

Anencephaly	NN	O	B
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
to	NN	O	O
develop	NN	O	O
from	NN	O	O
exencephaly	NN	O	B
;	NN	O	O
however	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
little	NN	O	O
direct	NN	O	O
experimental	NN	O	O
evidence	NN	O	O
to	NN	O	O
support	NN	O	O
this	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
transformation	NN	O	O
remains	NN	O	O
unclear	NN	O	O
.	NN	O	O

We	NN	O	O
examined	NN	O	O
this	NN	O	O
theory	NN	O	O
using	NN	O	O
the	NN	O	O
exo	NN	O	O
utero	NN	O	O
development	NN	O	O
system	NN	O	O
that	NN	O	O
allows	NN	O	O
direct	NN	O	O
and	NN	O	O
sequential	NN	O	O
observations	NN	O	O
of	NN	O	O
mid	NN	O	O
-	NN	O	O
to	NN	O	O
late	NN	O	O
-	NN	O	O
gestation	NN	O	O
mouse	NN	O	O
embryos	NN	O	O
.	NN	O	O

We	NN	O	O
observed	NN	O	O
the	NN	O	O
exencephaly	NN	O	B
induced	NN	O	O
by	NN	O	O
5	NN	O	O
-	NN	O	O
azacytidine	NN	O	O
at	NN	O	O
embryonic	NN	O	O
day	NN	O	O
13	NN	O	O
.	NN	O	O
5	NN	O	O
(	NN	O	O
E13	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
,	NN	O	O
let	NN	O	O
the	NN	O	O
embryos	NN	O	O
develop	NN	O	O
exo	NN	O	O
utero	NN	O	O
until	NN	O	O
E18	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
and	NN	O	O
re	NN	O	O
-	NN	O	O
observed	NN	O	O
the	NN	O	O
same	NN	O	O
embryos	NN	O	O
at	NN	O	O
E18	NN	O	O
.	NN	O	O
5	NN	O	O
.	NN	O	O

We	NN	O	O
confirmed	NN	O	O
several	NN	O	O
cases	NN	O	O
of	NN	O	O
transformation	NN	O	O
from	NN	O	O
exencephaly	NN	O	B
to	NN	O	O
anencephaly	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
in	NN	O	O
many	NN	O	O
cases	NN	O	O
,	NN	O	O
the	NN	O	O
exencephalic	NN	O	B
brain	NN	O	O
tissue	NN	O	O
was	NN	O	O
preserved	NN	O	O
with	NN	O	O
more	NN	O	O
or	NN	O	O
less	NN	O	O
reduction	NN	O	O
during	NN	O	O
this	NN	O	O
period	NN	O	O
.	NN	O	O

To	NN	O	O
analyze	NN	O	O
the	NN	O	O
transformation	NN	O	O
patterns	NN	O	O
,	NN	O	O
we	NN	O	O
classified	NN	O	O
the	NN	O	O
exencephaly	NN	O	B
by	NN	O	O
size	NN	O	O
and	NN	O	O
shape	NN	O	O
of	NN	O	O
the	NN	O	O
exencephalic	NN	O	B
tissue	NN	O	O
into	NN	O	O
several	NN	O	O
types	NN	O	O
at	NN	O	O
E13	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
E18	NN	O	O
.	NN	O	O
5	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
found	NN	O	O
that	NN	O	O
the	NN	O	O
transformation	NN	O	O
of	NN	O	O
exencephalic	NN	O	B
tissue	NN	O	O
was	NN	O	O
not	NN	O	O
simply	NN	O	O
size	NN	O	O
-	NN	O	O
dependent	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
cases	NN	O	O
of	NN	O	O
anencephaly	NN	O	B
at	NN	O	O
E18	NN	O	O
.	NN	O	O
5	NN	O	O
resulted	NN	O	O
from	NN	O	O
embryos	NN	O	O
with	NN	O	O
a	NN	O	O
large	NN	O	O
amount	NN	O	O
of	NN	O	O
exencephalic	NN	O	B
tissue	NN	O	O
at	NN	O	O
E13	NN	O	O
.	NN	O	O
5	NN	O	O
.	NN	O	O

Microscopic	NN	O	O
observation	NN	O	O
showed	NN	O	O
the	NN	O	O
configuration	NN	O	O
of	NN	O	O
exencephaly	NN	O	B
at	NN	O	O
E13	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
frequent	NN	O	O
hemorrhaging	NN	O	B
and	NN	O	O
detachment	NN	O	O
of	NN	O	O
the	NN	O	O
neural	NN	O	O
plate	NN	O	O
from	NN	O	O
surface	NN	O	O
ectoderm	NN	O	O
in	NN	O	O
the	NN	O	O
exencephalic	NN	O	B
head	NN	O	O
at	NN	O	O
E15	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
and	NN	O	O
multiple	NN	O	O
modes	NN	O	O
of	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
exencephalic	NN	O	B
tissue	NN	O	O
at	NN	O	O
E18	NN	O	O
.	NN	O	O
5	NN	O	O
.	NN	O	O

From	NN	O	O
observations	NN	O	O
of	NN	O	O
the	NN	O	O
vasculature	NN	O	O
,	NN	O	O
altered	NN	O	O
distribution	NN	O	O
patterns	NN	O	O
of	NN	O	O
vessels	NN	O	O
were	NN	O	O
identified	NN	O	O
in	NN	O	O
the	NN	O	O
exencephalic	NN	O	B
head	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
overgrowth	NN	O	O
of	NN	O	O
the	NN	O	O
exencephalic	NN	O	B
neural	NN	O	O
tissue	NN	O	O
causes	NN	O	O
the	NN	O	O
altered	NN	O	O
distribution	NN	O	O
patterns	NN	O	O
of	NN	O	O
vessels	NN	O	O
,	NN	O	O
subsequent	NN	O	O
peripheral	NN	O	O
circulatory	NN	O	B
failure	NN	O	I
and	NN	O	O
/	NN	O	O
or	NN	O	O
hemorrhaging	NN	O	B
in	NN	O	O
various	NN	O	O
parts	NN	O	O
of	NN	O	O
the	NN	O	O
exencephalic	NN	O	B
head	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
the	NN	O	O
multiple	NN	O	O
modes	NN	O	O
of	NN	O	O
tissue	NN	O	O
reduction	NN	O	O
during	NN	O	O
transformation	NN	O	O
from	NN	O	O
exencephaly	NN	O	B
to	NN	O	O
anencephaly	NN	O	B
.	NN	O	O

99mTc	NN	O	O
-	NN	O	O
glucarate	NN	O	O
for	NN	O	O
detection	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Infarct	NN	O	B
-	NN	O	O
avid	NN	O	O
radiopharmaceuticals	NN	O	O
are	NN	O	O
necessary	NN	O	O
for	NN	O	O
rapid	NN	O	O
and	NN	O	O
timely	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

The	NN	O	O
animal	NN	O	O
model	NN	O	O
used	NN	O	O
to	NN	O	O
produce	NN	O	O
infarction	NN	O	B
implies	NN	O	O
artery	NN	O	O
ligation	NN	O	O
but	NN	O	O
chemical	NN	O	O
induction	NN	O	O
can	NN	O	O
be	NN	O	O
easily	NN	O	O
obtained	NN	O	O
with	NN	O	O
isoproterenol	NN	O	O
.	NN	O	O

A	NN	O	O
new	NN	O	O
infarct	NN	O	B
-	NN	O	O
avid	NN	O	O
radiopharmaceutical	NN	O	O
based	NN	O	O
on	NN	O	O
glucaric	NN	O	O
acid	NN	O	O
was	NN	O	O
prepared	NN	O	O
in	NN	O	O
the	NN	O	O
hospital	NN	O	O
radiopharmacy	NN	O	O
of	NN	O	O
the	NN	O	O
INCMNSZ	NN	O	O
.	NN	O	O

99mTc	NN	O	O
-	NN	O	O
glucarate	NN	O	O
was	NN	O	O
easy	NN	O	O
to	NN	O	O
prepare	NN	O	O
,	NN	O	O
stable	NN	O	O
for	NN	O	O
96	NN	O	O
h	NN	O	O
and	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
study	NN	O	O
its	NN	O	O
biodistribution	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

Histological	NN	O	O
studies	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
rats	NN	O	O
developed	NN	O	O
an	NN	O	O
infarct	NN	O	B
18	NN	O	O
h	NN	O	O
after	NN	O	O
isoproterenol	NN	O	O
administration	NN	O	O
.	NN	O	O

The	NN	O	O
rat	NN	O	O
biodistribution	NN	O	O
studies	NN	O	O
showed	NN	O	O
a	NN	O	O
rapid	NN	O	O
blood	NN	O	O
clearance	NN	O	O
via	NN	O	O
the	NN	O	O
kidneys	NN	O	O
.	NN	O	O

Thirty	NN	O	O
minutes	NN	O	O
after	NN	O	O
99mTc	NN	O	O
-	NN	O	O
glucarate	NN	O	O
administration	NN	O	O
the	NN	O	O
standardised	NN	O	O
heart	NN	O	O
uptake	NN	O	O
value	NN	O	O
S	NN	O	O
(	NN	O	O
h	NN	O	O
)	NN	O	O
UV	NN	O	O
was	NN	O	O
4	NN	O	O
.	NN	O	O
7	NN	O	O
in	NN	O	O
infarcted	NN	O	O
rat	NN	O	O
heart	NN	O	O
which	NN	O	O
is	NN	O	O
six	NN	O	O
times	NN	O	O
more	NN	O	O
than	NN	O	O
in	NN	O	O
normal	NN	O	O
rats	NN	O	O
.	NN	O	O

ROIs	NN	O	O
drawn	NN	O	O
over	NN	O	O
the	NN	O	O
gamma	NN	O	O
camera	NN	O	O
images	NN	O	O
showed	NN	O	O
a	NN	O	O
ratio	NN	O	O
of	NN	O	O
4	NN	O	O
.	NN	O	O
4	NN	O	O
.	NN	O	O

The	NN	O	O
high	NN	O	O
image	NN	O	O
quality	NN	O	O
suggests	NN	O	O
that	NN	O	O
high	NN	O	O
contrast	NN	O	O
images	NN	O	O
can	NN	O	O
be	NN	O	O
obtained	NN	O	O
in	NN	O	O
humans	NN	O	O
and	NN	O	O
the	NN	O	O
96	NN	O	O
h	NN	O	O
stability	NN	O	O
makes	NN	O	O
it	NN	O	O
an	NN	O	O
ideal	NN	O	O
agent	NN	O	O
to	NN	O	O
detect	NN	O	O
,	NN	O	O
in	NN	O	O
patients	NN	O	O
,	NN	O	O
early	NN	O	O
cardiac	NN	O	B
infarction	NN	O	I
.	NN	O	O

Bupropion	NN	O	O
(	NN	O	O
Zyban	NN	O	O
)	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Bupropion	NN	O	O
is	NN	O	O
a	NN	O	O
monocyclic	NN	O	O
antidepressant	NN	O	O
structurally	NN	O	O
related	NN	O	O
to	NN	O	O
amphetamine	NN	O	O
.	NN	O	O

Zyban	NN	O	O
,	NN	O	O
a	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
formulation	NN	O	O
of	NN	O	O
bupropion	NN	O	O
hydrochloride	NN	O	O
,	NN	O	O
was	NN	O	O
recently	NN	O	O
released	NN	O	O
in	NN	O	O
Ireland	NN	O	O
,	NN	O	O
as	NN	O	O
a	NN	O	O
smoking	NN	O	O
cessation	NN	O	O
aid	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
initial	NN	O	O
6	NN	O	O
months	NN	O	O
since	NN	O	O
it	NN	O	O
'	NN	O	O
s	NN	O	O
introduction	NN	O	O
,	NN	O	O
12	NN	O	O
overdose	NN	O	B
cases	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
The	NN	O	O
National	NN	O	O
Poisons	NN	O	O
Information	NN	O	O
Centre	NN	O	O
.	NN	O	O

8	NN	O	O
patients	NN	O	O
developed	NN	O	O
symptoms	NN	O	O
of	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Common	NN	O	O
features	NN	O	O
included	NN	O	O
tachycardia	NN	O	B
,	NN	O	O
drowsiness	NN	O	O
,	NN	O	O
hallucinations	NN	O	B
and	NN	O	O
convulsions	NN	O	B
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
developed	NN	O	O
severe	NN	O	O
cardiac	NN	O	B
arrhythmias	NN	O	I
,	NN	O	O
including	NN	O	O
one	NN	O	O
patient	NN	O	O
who	NN	O	O
was	NN	O	O
resuscitated	NN	O	O
following	NN	O	O
a	NN	O	O
cardiac	NN	O	B
arrest	NN	O	I
.	NN	O	O

All	NN	O	O
patients	NN	O	O
recovered	NN	O	O
without	NN	O	O
sequelae	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
31	NN	O	O
year	NN	O	O
old	NN	O	O
female	NN	O	O
who	NN	O	O
required	NN	O	O
admission	NN	O	O
to	NN	O	O
the	NN	O	O
Intensive	NN	O	O
Care	NN	O	O
Unit	NN	O	O
for	NN	O	O
ventilation	NN	O	O
and	NN	O	O
full	NN	O	O
supportive	NN	O	O
therapy	NN	O	O
,	NN	O	O
following	NN	O	O
ingestion	NN	O	O
of	NN	O	O
13	NN	O	O
.	NN	O	O
5g	NN	O	O
bupropion	NN	O	O
.	NN	O	O

Recurrent	NN	O	O
seizures	NN	O	B
were	NN	O	O
treated	NN	O	O
with	NN	O	O
diazepam	NN	O	O
and	NN	O	O
broad	NN	O	O
complex	NN	O	O
tachycardia	NN	O	B
was	NN	O	O
successfully	NN	O	O
treated	NN	O	O
with	NN	O	O
adenosine	NN	O	O
.	NN	O	O

Zyban	NN	O	O
caused	NN	O	O
significant	NN	O	O
neurological	NN	O	B
and	NN	O	I
cardiovascular	NN	O	I
toxicity	NN	O	I
in	NN	O	O
overdose	NN	O	B
.	NN	O	O

The	NN	O	O
potential	NN	O	O
toxic	NN	O	O
effects	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
when	NN	O	O
prescribing	NN	O	O
it	NN	O	O
as	NN	O	O
a	NN	O	O
smoking	NN	O	O
cessation	NN	O	O
aid	NN	O	O
.	NN	O	O

GLEPP1	NN	O	O
receptor	NN	O	O
tyrosine	NN	O	O
phosphatase	NN	O	O
(	NN	O	O
Ptpro	NN	O	O
)	NN	O	O
in	NN	O	O
rat	NN	O	O
PAN	NN	O	O
nephrosis	NN	O	B
.	NN	O	O

A	NN	O	O
marker	NN	O	O
of	NN	O	O
acute	NN	O	O
podocyte	NN	O	O
injury	NN	O	O
.	NN	O	O

Glomerular	NN	O	O
epithelial	NN	O	O
protein	NN	O	O
1	NN	O	O
(	NN	O	O
GLEPP1	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
podocyte	NN	O	O
receptor	NN	O	O
membrane	NN	O	O
protein	NN	O	O
tyrosine	NN	O	O
phosphatase	NN	O	O
located	NN	O	O
on	NN	O	O
the	NN	O	O
apical	NN	O	O
cell	NN	O	O
membrane	NN	O	O
of	NN	O	O
visceral	NN	O	O
glomerular	NN	O	O
epithelial	NN	O	O
cell	NN	O	O
and	NN	O	O
foot	NN	O	O
processes	NN	O	O
.	NN	O	O

This	NN	O	O
receptor	NN	O	O
plays	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
regulating	NN	O	O
the	NN	O	O
structure	NN	O	O
and	NN	O	O
function	NN	O	O
of	NN	O	O
podocyte	NN	O	O
foot	NN	O	O
process	NN	O	O
.	NN	O	O

To	NN	O	O
better	NN	O	O
understand	NN	O	O
the	NN	O	O
utility	NN	O	O
of	NN	O	O
GLEPP1	NN	O	O
as	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
glomerular	NN	O	B
injury	NN	O	I
,	NN	O	O
the	NN	O	O
amount	NN	O	O
and	NN	O	O
distribution	NN	O	O
of	NN	O	O
GLEPP1	NN	O	O
protein	NN	O	O
and	NN	O	O
mRNA	NN	O	O
were	NN	O	O
examined	NN	O	O
by	NN	O	O
immunohistochemistry	NN	O	O
,	NN	O	O
Western	NN	O	O
blot	NN	O	O
and	NN	O	O
RNase	NN	O	O
protection	NN	O	O
assay	NN	O	O
in	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
podocyte	NN	O	O
injury	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Puromycin	NN	O	O
aminonucleoside	NN	O	O
nephrosis	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
single	NN	O	O
intraperitoneal	NN	O	O
injection	NN	O	O
of	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
(	NN	O	O
PAN	NN	O	O
,	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
100g	NN	O	O
BW	NN	O	O
)	NN	O	O
.	NN	O	O

Tissues	NN	O	O
were	NN	O	O
analyzed	NN	O	O
at	NN	O	O
0	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
7	NN	O	O
,	NN	O	O
11	NN	O	O
,	NN	O	O
21	NN	O	O
,	NN	O	O
45	NN	O	O
,	NN	O	O
80	NN	O	O
and	NN	O	O
126	NN	O	O
days	NN	O	O
after	NN	O	O
PAN	NN	O	O
injection	NN	O	O
so	NN	O	O
as	NN	O	O
to	NN	O	O
include	NN	O	O
both	NN	O	O
the	NN	O	O
acute	NN	O	O
phase	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
associated	NN	O	O
with	NN	O	O
foot	NN	O	O
process	NN	O	O
effacement	NN	O	O
(	NN	O	O
days	NN	O	O
5	NN	O	O
-	NN	O	O
11	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
chronic	NN	O	O
phase	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
associated	NN	O	O
with	NN	O	O
glomerulosclerosis	NN	O	B
(	NN	O	O
days	NN	O	O
45	NN	O	O
-	NN	O	O
126	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
day	NN	O	O
5	NN	O	O
,	NN	O	O
GLEPP1	NN	O	O
protein	NN	O	O
and	NN	O	O
mRNA	NN	O	O
were	NN	O	O
reduced	NN	O	O
from	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
(	NN	O	O
265	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
79	NN	O	O
.	NN	O	O
6	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
moles	NN	O	O
/	NN	O	O
glomerulus	NN	O	O
and	NN	O	O
100	NN	O	O
%	NN	O	O
)	NN	O	O
to	NN	O	O
15	NN	O	O
%	NN	O	O
of	NN	O	O
normal	NN	O	O
(	NN	O	O
41	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
8	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
moles	NN	O	O
/	NN	O	O
glomerulus	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
005	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
occurred	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
urinary	NN	O	O
protein	NN	O	O
content	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
to	NN	O	O
99	NN	O	O
.	NN	O	O
0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
61	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
podocalyxin	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
significantly	NN	O	O
at	NN	O	O
this	NN	O	O
time	NN	O	O
.	NN	O	O

By	NN	O	O
day	NN	O	O
11	NN	O	O
,	NN	O	O
GLEPP1	NN	O	O
protein	NN	O	O
and	NN	O	O
mRNA	NN	O	O
had	NN	O	O
begun	NN	O	O
to	NN	O	O
return	NN	O	O
towards	NN	O	O
baseline	NN	O	O
.	NN	O	O

By	NN	O	O
day	NN	O	O
45	NN	O	O
-	NN	O	O
126	NN	O	O
,	NN	O	O
at	NN	O	O
a	NN	O	O
time	NN	O	O
when	NN	O	O
glomerular	NN	O	O
scarring	NN	O	O
was	NN	O	O
present	NN	O	O
,	NN	O	O
GLEPP1	NN	O	O
was	NN	O	O
absent	NN	O	O
from	NN	O	O
glomerulosclerotic	NN	O	O
areas	NN	O	O
although	NN	O	O
the	NN	O	O
total	NN	O	O
glomerular	NN	O	O
content	NN	O	O
of	NN	O	O
GLEPP1	NN	O	O
was	NN	O	O
not	NN	O	O
different	NN	O	O
from	NN	O	O
normal	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
GLEPP1	NN	O	O
expression	NN	O	O
,	NN	O	O
unlike	NN	O	O
podocalyxin	NN	O	O
,	NN	O	O
reflects	NN	O	O
podocyte	NN	O	O
injury	NN	O	O
induced	NN	O	O
by	NN	O	O
PAN	NN	O	O
.	NN	O	O

GLEPP1	NN	O	O
expression	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
marker	NN	O	O
of	NN	O	O
podocyte	NN	O	O
injury	NN	O	O
.	NN	O	O

Antithymocyte	NN	O	O
globulin	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
penicillamine	NN	O	O
-	NN	O	O
induced	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
.	NN	O	O

A	NN	O	O
patient	NN	O	O
who	NN	O	O
received	NN	O	O
antithymocyte	NN	O	O
globulin	NN	O	O
therapy	NN	O	O
for	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
due	NN	O	O
to	NN	O	O
D	NN	O	O
-	NN	O	O
penicillamine	NN	O	O
therapy	NN	O	O
is	NN	O	O
described	NN	O	O
.	NN	O	O

Bone	NN	O	O
marrow	NN	O	O
recovery	NN	O	O
and	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
recovery	NN	O	O
were	NN	O	O
complete	NN	O	O
1	NN	O	O
month	NN	O	O
and	NN	O	O
3	NN	O	O
months	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
after	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
blood	NN	O	O
transfusion	NN	O	O
or	NN	O	O
other	NN	O	O
therapies	NN	O	O
were	NN	O	O
not	NN	O	O
necessary	NN	O	O
in	NN	O	O
a	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
of	NN	O	O
more	NN	O	O
than	NN	O	O
2	NN	O	O
years	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
antithymocyte	NN	O	O
globulin	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
optimal	NN	O	O
treatment	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
penicillamine	NN	O	O
-	NN	O	O
induced	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
.	NN	O	O

Metamizol	NN	O	O
potentiates	NN	O	O
morphine	NN	O	O
antinociception	NN	O	O
but	NN	O	O
not	NN	O	O
constipation	NN	O	B
after	NN	O	O
chronic	NN	O	O
treatment	NN	O	O
.	NN	O	O

This	NN	O	O
work	NN	O	O
evaluates	NN	O	O
the	NN	O	O
antinociceptive	NN	O	O
and	NN	O	O
constipating	NN	O	B
effects	NN	O	O
of	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
morphine	NN	O	O
with	NN	O	O
177	NN	O	O
.	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
metamizol	NN	O	O
in	NN	O	O
acutely	NN	O	O
and	NN	O	O
chronically	NN	O	O
treated	NN	O	O
(	NN	O	O
once	NN	O	O
a	NN	O	O
day	NN	O	O
for	NN	O	O
12	NN	O	O
days	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
13th	NN	O	O
day	NN	O	O
,	NN	O	O
antinociceptive	NN	O	O
effects	NN	O	O
were	NN	O	O
assessed	NN	O	O
using	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
nociception	NN	O	O
,	NN	O	O
pain	NN	O	B
-	NN	O	O
induced	NN	O	O
functional	NN	O	O
impairment	NN	O	O
model	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
charcoal	NN	O	O
meal	NN	O	O
test	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
intestinal	NN	O	O
transit	NN	O	O
.	NN	O	O

Simultaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
morphine	NN	O	O
with	NN	O	O
metamizol	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
markedly	NN	O	O
antinociceptive	NN	O	O
potentiation	NN	O	O
and	NN	O	O
an	NN	O	O
increasing	NN	O	O
of	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
after	NN	O	O
a	NN	O	O
single	NN	O	O
(	NN	O	O
298	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
vs	NN	O	O
.	NN	O	O
139	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
36	NN	O	O
units	NN	O	O
area	NN	O	O
(	NN	O	O
ua	NN	O	O
)	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
and	NN	O	O
repeated	NN	O	O
administration	NN	O	O
(	NN	O	O
280	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
17	NN	O	O
vs	NN	O	O
.	NN	O	O
131	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
22	NN	O	O
ua	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Antinociceptive	NN	O	O
effect	NN	O	O
of	NN	O	O
morphine	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
chronically	NN	O	O
treated	NN	O	O
rats	NN	O	O
(	NN	O	O
39	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
vs	NN	O	O
.	NN	O	O
18	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
au	NN	O	O
)	NN	O	O
while	NN	O	O
the	NN	O	O
combination	NN	O	O
-	NN	O	O
induced	NN	O	O
antinociception	NN	O	O
was	NN	O	O
remained	NN	O	O
similar	NN	O	O
as	NN	O	O
an	NN	O	O
acute	NN	O	O
treatment	NN	O	O
(	NN	O	O
298	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
vs	NN	O	O
.	NN	O	O
280	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
17	NN	O	O
au	NN	O	O
)	NN	O	O
.	NN	O	O

Acute	NN	O	O
antinociceptive	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
combination	NN	O	O
were	NN	O	O
partially	NN	O	O
prevented	NN	O	O
by	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
naloxone	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O

(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
partial	NN	O	O
involvement	NN	O	O
of	NN	O	O
the	NN	O	O
opioidergic	NN	O	O
system	NN	O	O
in	NN	O	O
the	NN	O	O
synergism	NN	O	O
observed	NN	O	O
.	NN	O	O

In	NN	O	O
independent	NN	O	O
groups	NN	O	O
,	NN	O	O
morphine	NN	O	O
inhibited	NN	O	O
the	NN	O	O
intestinal	NN	O	O
transit	NN	O	O
in	NN	O	O
48	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
%	NN	O	O
and	NN	O	O
38	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
%	NN	O	O
after	NN	O	O
acute	NN	O	O
and	NN	O	O
chronic	NN	O	O
treatment	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
tolerance	NN	O	O
did	NN	O	O
not	NN	O	O
develop	NN	O	O
to	NN	O	O
the	NN	O	O
constipating	NN	O	B
effects	NN	O	O
.	NN	O	O

The	NN	O	O
combination	NN	O	O
inhibited	NN	O	O
intestinal	NN	O	O
transit	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
produced	NN	O	O
by	NN	O	O
morphine	NN	O	O
regardless	NN	O	O
of	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
metamizol	NN	O	O
did	NN	O	O
not	NN	O	O
potentiate	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
constipation	NN	O	B
.	NN	O	O

These	NN	O	O
findings	NN	O	O
show	NN	O	O
a	NN	O	O
significant	NN	O	O
interaction	NN	O	O
between	NN	O	O
morphine	NN	O	O
and	NN	O	O
metamizol	NN	O	O
in	NN	O	O
chronically	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
this	NN	O	O
combination	NN	O	O
could	NN	O	O
be	NN	O	O
useful	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
chronic	NN	O	B
pain	NN	O	I
.	NN	O	O

Ifosfamide	NN	O	O
encephalopathy	NN	O	B
presenting	NN	O	O
with	NN	O	O
asterixis	NN	O	B
.	NN	O	O

CNS	NN	O	O
toxic	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
antineoplastic	NN	O	O
agent	NN	O	O
ifosfamide	NN	O	O
(	NN	O	O
IFX	NN	O	O
)	NN	O	O
are	NN	O	O
frequent	NN	O	O
and	NN	O	O
include	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
neurological	NN	O	O
symptoms	NN	O	O
that	NN	O	O
can	NN	O	O
limit	NN	O	O
drug	NN	O	O
use	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
51	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
developed	NN	O	O
severe	NN	O	O
,	NN	O	O
disabling	NN	O	O
negative	NN	O	O
myoclonus	NN	O	B
of	NN	O	O
the	NN	O	O
upper	NN	O	O
and	NN	O	O
lower	NN	O	O
extremities	NN	O	O
after	NN	O	O
the	NN	O	O
infusion	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
for	NN	O	O
plasmacytoma	NN	O	B
.	NN	O	O

He	NN	O	O
was	NN	O	O
awake	NN	O	O
,	NN	O	O
revealed	NN	O	O
no	NN	O	O
changes	NN	O	O
of	NN	O	O
mental	NN	O	O
status	NN	O	O
and	NN	O	O
at	NN	O	O
rest	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
further	NN	O	O
motor	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Cranial	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
and	NN	O	O
extensive	NN	O	O
laboratory	NN	O	O
studies	NN	O	O
failed	NN	O	O
to	NN	O	O
reveal	NN	O	O
structural	NN	O	B
lesions	NN	O	I
of	NN	O	I
the	NN	O	I
brain	NN	O	I
and	NN	O	O
metabolic	NN	O	B
abnormalities	NN	O	I
.	NN	O	O

An	NN	O	O
electroencephalogram	NN	O	O
showed	NN	O	O
continuous	NN	O	O
,	NN	O	O
generalized	NN	O	O
irregular	NN	O	O
slowing	NN	O	O
with	NN	O	O
admixed	NN	O	O
periodic	NN	O	O
triphasic	NN	O	O
waves	NN	O	O
indicating	NN	O	O
symptomatic	NN	O	O
encephalopathy	NN	O	B
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
was	NN	O	O
discontinued	NN	O	O
and	NN	O	O
within	NN	O	O
12	NN	O	O
h	NN	O	O
the	NN	O	O
asterixis	NN	O	B
resolved	NN	O	O
completely	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
patient	NN	O	O
described	NN	O	O
,	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
asterixis	NN	O	B
during	NN	O	O
infusion	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
,	NN	O	O
normal	NN	O	O
laboratory	NN	O	O
findings	NN	O	O
and	NN	O	O
imaging	NN	O	O
studies	NN	O	O
and	NN	O	O
the	NN	O	O
resolution	NN	O	O
of	NN	O	O
symptoms	NN	O	O
following	NN	O	O
the	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
suggest	NN	O	O
that	NN	O	O
negative	NN	O	O
myoclonus	NN	O	B
is	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
IFX	NN	O	O
.	NN	O	O

Antagonism	NN	O	O
between	NN	O	O
interleukin	NN	O	O
3	NN	O	O
and	NN	O	O
erythropoietin	NN	O	O
in	NN	O	O
mice	NN	O	O
with	NN	O	O
azidothymidine	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
and	NN	O	O
in	NN	O	O
bone	NN	O	O
marrow	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
.	NN	O	O

Azidothymidine	NN	O	O
(	NN	O	O
AZT	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
in	NN	O	O
mice	NN	O	O
can	NN	O	O
be	NN	O	O
reversed	NN	O	O
by	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
IGF	NN	O	O
-	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
(	NN	O	O
fusion	NN	O	O
protein	NN	O	O
of	NN	O	O
insulin	NN	O	O
-	NN	O	O
like	NN	O	O
growth	NN	O	O
factor	NN	O	O
II	NN	O	O
(	NN	O	O
IGF	NN	O	O
II	NN	O	O
)	NN	O	O
and	NN	O	O
interleukin	NN	O	O
3	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
interleukin	NN	O	O
3	NN	O	O
(	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
and	NN	O	O
erythropoietin	NN	O	O
(	NN	O	O
EPO	NN	O	O
)	NN	O	O
are	NN	O	O
known	NN	O	O
to	NN	O	O
act	NN	O	O
synergistically	NN	O	O
on	NN	O	O
hematopoietic	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
injection	NN	O	O
of	NN	O	O
IGF	NN	O	O
-	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
and	NN	O	O
EPO	NN	O	O
in	NN	O	O
AZT	NN	O	O
-	NN	O	O
treated	NN	O	O
mice	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
red	NN	O	O
cells	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
plasma	NN	O	O
EPO	NN	O	O
levels	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
IGF	NN	O	O
-	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
or	NN	O	O
EPO	NN	O	O
alone	NN	O	O
.	NN	O	O

We	NN	O	O
tested	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
the	NN	O	O
antagonistic	NN	O	O
effect	NN	O	O
of	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
and	NN	O	O
EPO	NN	O	O
on	NN	O	O
erythroid	NN	O	O
cells	NN	O	O
may	NN	O	O
be	NN	O	O
mediated	NN	O	O
by	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
.	NN	O	O

Bovine	NN	O	O
liver	NN	O	O
erythroid	NN	O	O
cells	NN	O	O
were	NN	O	O
cultured	NN	O	O
on	NN	O	O
monolayers	NN	O	O
of	NN	O	O
human	NN	O	O
bone	NN	O	O
marrow	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
previously	NN	O	O
treated	NN	O	O
with	NN	O	O
EPO	NN	O	O
and	NN	O	O
IGF	NN	O	O
-	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
of	NN	O	O
thymidine	NN	O	O
incorporation	NN	O	O
into	NN	O	O
both	NN	O	O
erythroid	NN	O	O
and	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
in	NN	O	O
cultures	NN	O	O
pre	NN	O	O
-	NN	O	O
treated	NN	O	O
with	NN	O	O
IGF	NN	O	O
-	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
and	NN	O	O
EPO	NN	O	O
.	NN	O	O

Endothelial	NN	O	O
cell	NN	O	O
culture	NN	O	O
supernatants	NN	O	O
separated	NN	O	O
by	NN	O	O
ultrafiltration	NN	O	O
and	NN	O	O
ultracentrifugation	NN	O	O
from	NN	O	O
cells	NN	O	O
treated	NN	O	O
with	NN	O	O
EPO	NN	O	O
and	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
thymidine	NN	O	O
incorporation	NN	O	O
into	NN	O	O
erythroid	NN	O	O
cells	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
identical	NN	O	O
fractions	NN	O	O
obtained	NN	O	O
from	NN	O	O
the	NN	O	O
media	NN	O	O
of	NN	O	O
cells	NN	O	O
cultured	NN	O	O
with	NN	O	O
EPO	NN	O	O
alone	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
treated	NN	O	O
simultaneously	NN	O	O
with	NN	O	O
EPO	NN	O	O
and	NN	O	O
IL	NN	O	O
-	NN	O	O
3	NN	O	O
have	NN	O	O
a	NN	O	O
negative	NN	O	O
effect	NN	O	O
on	NN	O	O
erythroid	NN	O	O
cell	NN	O	O
production	NN	O	O
.	NN	O	O

The	NN	O	O
relationship	NN	O	O
between	NN	O	O
hippocampal	NN	O	O
acetylcholine	NN	O	O
release	NN	O	O
and	NN	O	O
cholinergic	NN	O	O
convulsant	NN	O	O
sensitivity	NN	O	O
in	NN	O	O
withdrawal	NN	O	O
seizure	NN	O	B
-	NN	O	O
prone	NN	O	O
and	NN	O	O
withdrawal	NN	O	O
seizure	NN	O	B
-	NN	O	O
resistant	NN	O	O
selected	NN	O	O
mouse	NN	O	O
lines	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
septo	NN	O	O
-	NN	O	O
hippocampal	NN	O	O
cholinergic	NN	O	O
pathway	NN	O	O
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
epileptogenesis	NN	O	O
,	NN	O	O
and	NN	O	O
genetic	NN	O	O
factors	NN	O	O
influence	NN	O	O
the	NN	O	O
response	NN	O	O
to	NN	O	O
cholinergic	NN	O	O
agents	NN	O	O
,	NN	O	O
but	NN	O	O
limited	NN	O	O
data	NN	O	O
are	NN	O	O
available	NN	O	O
on	NN	O	O
cholinergic	NN	O	O
involvement	NN	O	O
in	NN	O	O
alcohol	NN	O	O
withdrawal	NN	O	O
severity	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
cholinergic	NN	O	O
activity	NN	O	O
and	NN	O	O
responsiveness	NN	O	O
and	NN	O	O
alcohol	NN	O	O
withdrawal	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
a	NN	O	O
genetic	NN	O	O
animal	NN	O	O
model	NN	O	O
of	NN	O	O
ethanol	NN	O	O
withdrawal	NN	O	O
severity	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Cholinergic	NN	O	O
convulsant	NN	O	O
sensitivity	NN	O	O
was	NN	O	O
examined	NN	O	O
in	NN	O	O
alcohol	NN	O	O
-	NN	O	O
na	NN	O	O
ve	NN	O	O
Withdrawal	NN	O	O
Seizure	NN	O	B
-	NN	O	O
Prone	NN	O	O
(	NN	O	O
WSP	NN	O	O
)	NN	O	O
and	NN	O	O
-	NN	O	O
Resistant	NN	O	O
(	NN	O	O
WSR	NN	O	O
)	NN	O	O
mice	NN	O	O
.	NN	O	O

Animals	NN	O	O
were	NN	O	O
administered	NN	O	O
nicotine	NN	O	O
,	NN	O	O
carbachol	NN	O	O
,	NN	O	O
or	NN	O	O
neostigmine	NN	O	O
via	NN	O	O
timed	NN	O	O
tail	NN	O	O
vein	NN	O	O
infusion	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
latencies	NN	O	O
to	NN	O	O
onset	NN	O	O
of	NN	O	O
tremor	NN	O	B
and	NN	O	O
clonus	NN	O	O
were	NN	O	O
recorded	NN	O	O
and	NN	O	O
converted	NN	O	O
to	NN	O	O
threshold	NN	O	O
dose	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
used	NN	O	O
microdialysis	NN	O	O
to	NN	O	O
measure	NN	O	O
basal	NN	O	O
and	NN	O	O
potassium	NN	O	O
-	NN	O	O
stimulated	NN	O	O
acetylcholine	NN	O	O
(	NN	O	O
ACh	NN	O	O
)	NN	O	O
release	NN	O	O
in	NN	O	O
the	NN	O	O
CA1	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
.	NN	O	O

Potassium	NN	O	O
was	NN	O	O
applied	NN	O	O
by	NN	O	O
reverse	NN	O	O
dialysis	NN	O	O
twice	NN	O	O
,	NN	O	O
separated	NN	O	O
by	NN	O	O
75	NN	O	O
min	NN	O	O
.	NN	O	O

Hippocampal	NN	O	O
ACh	NN	O	O
also	NN	O	O
was	NN	O	O
measured	NN	O	O
during	NN	O	O
testing	NN	O	O
for	NN	O	O
handling	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Sensitivity	NN	O	O
to	NN	O	O
several	NN	O	O
convulsion	NN	O	B
endpoints	NN	O	O
induced	NN	O	O
by	NN	O	O
nicotine	NN	O	O
,	NN	O	O
carbachol	NN	O	O
,	NN	O	O
and	NN	O	O
neostigmine	NN	O	O
were	NN	O	O
significantly	NN	O	O
greater	NN	O	O
in	NN	O	O
WSR	NN	O	O
versus	NN	O	O
WSP	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
microdialysis	NN	O	O
experiments	NN	O	O
,	NN	O	O
the	NN	O	O
lines	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
in	NN	O	O
basal	NN	O	O
release	NN	O	O
of	NN	O	O
ACh	NN	O	O
,	NN	O	O
and	NN	O	O
50	NN	O	O
mM	NN	O	O
KCl	NN	O	O
increased	NN	O	O
ACh	NN	O	O
output	NN	O	O
in	NN	O	O
both	NN	O	O
lines	NN	O	O
of	NN	O	O
mice	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
release	NN	O	O
of	NN	O	O
ACh	NN	O	O
produced	NN	O	O
by	NN	O	O
the	NN	O	O
first	NN	O	O
application	NN	O	O
of	NN	O	O
KCl	NN	O	O
was	NN	O	O
2	NN	O	O
-	NN	O	O
fold	NN	O	O
higher	NN	O	O
in	NN	O	O
WSP	NN	O	O
versus	NN	O	O
WSR	NN	O	O
mice	NN	O	O
.	NN	O	O

When	NN	O	O
hippocampal	NN	O	O
ACh	NN	O	O
was	NN	O	O
measured	NN	O	O
during	NN	O	O
testing	NN	O	O
for	NN	O	O
handling	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
,	NN	O	O
extracellular	NN	O	O
ACh	NN	O	O
was	NN	O	O
significantly	NN	O	O
elevated	NN	O	O
(	NN	O	O
192	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
WSP	NN	O	O
mice	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
nonsignificantly	NN	O	O
elevated	NN	O	O
(	NN	O	O
59	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
WSR	NN	O	O
mice	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
differences	NN	O	O
in	NN	O	O
cholinergic	NN	O	O
activity	NN	O	O
and	NN	O	O
postsynaptic	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
cholinergic	NN	O	O
convulsants	NN	O	B
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
ethanol	NN	O	O
withdrawal	NN	O	O
severity	NN	O	O
and	NN	O	O
implicate	NN	O	O
cholinergic	NN	O	O
mechanisms	NN	O	O
in	NN	O	O
alcohol	NN	O	O
withdrawal	NN	O	O
.	NN	O	O

Specifically	NN	O	O
,	NN	O	O
WSP	NN	O	O
mice	NN	O	O
may	NN	O	O
have	NN	O	O
lower	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
cholinergic	NN	O	O
convulsants	NN	O	B
compared	NN	O	O
with	NN	O	O
WSR	NN	O	O
because	NN	O	O
of	NN	O	O
postsynaptic	NN	O	O
receptor	NN	O	O
desensitization	NN	O	O
brought	NN	O	O
on	NN	O	O
by	NN	O	O
higher	NN	O	O
activity	NN	O	O
of	NN	O	O
cholinergic	NN	O	O
neurons	NN	O	O
.	NN	O	O

Capsaicin	NN	O	O
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B
pain	NN	O	I
alters	NN	O	O
the	NN	O	O
excitability	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	O
jaw	NN	O	O
-	NN	O	O
stretch	NN	O	O
reflex	NN	O	O
.	NN	O	O

The	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
painful	NN	O	O
temporomandibular	NN	O	B
disorders	NN	O	I
is	NN	O	O
not	NN	O	O
fully	NN	O	O
understood	NN	O	O
,	NN	O	O
but	NN	O	O
evidence	NN	O	O
suggests	NN	O	O
that	NN	O	O
muscle	NN	O	B
pain	NN	O	I
modulates	NN	O	O
motor	NN	O	O
function	NN	O	O
in	NN	O	O
characteristic	NN	O	O
ways	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
tested	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
activation	NN	O	O
of	NN	O	O
nociceptive	NN	O	B
muscle	NN	O	I
afferent	NN	O	O
fibers	NN	O	O
would	NN	O	O
be	NN	O	O
linked	NN	O	O
to	NN	O	O
an	NN	O	O
increased	NN	O	O
excitability	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	O
jaw	NN	O	O
-	NN	O	O
stretch	NN	O	O
reflex	NN	O	O
and	NN	O	O
whether	NN	O	O
this	NN	O	O
process	NN	O	O
would	NN	O	O
be	NN	O	O
sensitive	NN	O	O
to	NN	O	O
length	NN	O	O
and	NN	O	O
velocity	NN	O	O
of	NN	O	O
the	NN	O	O
stretch	NN	O	O
.	NN	O	O

Capsaicin	NN	O	O
(	NN	O	O
10	NN	O	O
micro	NN	O	O
g	NN	O	O
)	NN	O	O
was	NN	O	O
injected	NN	O	O
into	NN	O	O
the	NN	O	O
masseter	NN	O	O
muscle	NN	O	O
to	NN	O	O
induce	NN	O	O
pain	NN	O	B
in	NN	O	O
11	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
.	NN	O	O

Short	NN	O	O
-	NN	O	O
latency	NN	O	O
reflex	NN	O	O
responses	NN	O	O
were	NN	O	O
evoked	NN	O	O
in	NN	O	O
the	NN	O	O
masseter	NN	O	O
and	NN	O	O
temporalis	NN	O	O
muscles	NN	O	O
by	NN	O	O
a	NN	O	O
stretch	NN	O	O
device	NN	O	O
with	NN	O	O
different	NN	O	O
velocities	NN	O	O
and	NN	O	O
displacements	NN	O	O
before	NN	O	O
,	NN	O	O
during	NN	O	O
,	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
pain	NN	O	B
.	NN	O	O

The	NN	O	O
normalized	NN	O	O
reflex	NN	O	O
amplitude	NN	O	O
increased	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
velocity	NN	O	O
at	NN	O	O
a	NN	O	O
given	NN	O	O
displacement	NN	O	O
,	NN	O	O
but	NN	O	O
remained	NN	O	O
constant	NN	O	O
with	NN	O	O
different	NN	O	O
displacements	NN	O	O
at	NN	O	O
a	NN	O	O
given	NN	O	O
velocity	NN	O	O
.	NN	O	O

The	NN	O	O
normalized	NN	O	O
reflex	NN	O	O
amplitude	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
during	NN	O	O
pain	NN	O	B
,	NN	O	O
but	NN	O	O
only	NN	O	O
at	NN	O	O
faster	NN	O	O
stretches	NN	O	O
in	NN	O	O
the	NN	O	O
painful	NN	O	B
muscle	NN	O	I
.	NN	O	O

Increased	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
the	NN	O	O
fusimotor	NN	O	O
system	NN	O	O
during	NN	O	O
acute	NN	O	O
muscle	NN	O	B
pain	NN	O	I
could	NN	O	O
be	NN	O	O
one	NN	O	O
likely	NN	O	O
mechanism	NN	O	O
to	NN	O	O
explain	NN	O	O
the	NN	O	O
findings	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
HT1B	NN	O	O
receptor	NN	O	O
ligands	NN	O	O
microinjected	NN	O	O
into	NN	O	O
the	NN	O	O
accumbal	NN	O	O
shell	NN	O	O
or	NN	O	O
core	NN	O	O
on	NN	O	O
the	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	B
hyperactivity	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
HT1B	NN	O	O
receptor	NN	O	O
ligands	NN	O	O
microinjected	NN	O	O
into	NN	O	O
the	NN	O	O
subregions	NN	O	O
of	NN	O	O
the	NN	O	O
nucleus	NN	O	O
accumbens	NN	O	O
(	NN	O	O
the	NN	O	O
shell	NN	O	O
and	NN	O	O
the	NN	O	O
core	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
locomotor	NN	O	B
hyperactivity	NN	O	I
induced	NN	O	O
by	NN	O	O
cocaine	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
implanted	NN	O	O
bilaterally	NN	O	O
with	NN	O	O
cannulae	NN	O	O
into	NN	O	O
the	NN	O	O
accumbens	NN	O	O
shell	NN	O	O
or	NN	O	O
core	NN	O	O
,	NN	O	O
and	NN	O	O
then	NN	O	O
were	NN	O	O
locally	NN	O	O
injected	NN	O	O
with	NN	O	O
GR	NN	O	O
55562	NN	O	O
(	NN	O	O
an	NN	O	O
antagonist	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
HT1B	NN	O	O
receptors	NN	O	O
)	NN	O	O
or	NN	O	O
CP	NN	O	O
93129	NN	O	O
(	NN	O	O
an	NN	O	O
agonist	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
HT1B	NN	O	O
receptors	NN	O	O
)	NN	O	O
.	NN	O	O

Given	NN	O	O
alone	NN	O	O
to	NN	O	O
any	NN	O	O
accumbal	NN	O	O
subregion	NN	O	O
,	NN	O	O
GR	NN	O	O
55562	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
microg	NN	O	O
/	NN	O	O
side	NN	O	O
)	NN	O	O
or	NN	O	O
CP	NN	O	O
93129	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
microg	NN	O	O
/	NN	O	O
side	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
basal	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
.	NN	O	O

Systemic	NN	O	O
cocaine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
of	NN	O	O
rats	NN	O	O
.	NN	O	O

GR	NN	O	O
55562	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
microg	NN	O	O
/	NN	O	O
side	NN	O	O
)	NN	O	O
,	NN	O	O
administered	NN	O	O
intra	NN	O	O
-	NN	O	O
accumbens	NN	O	O
shell	NN	O	O
prior	NN	O	O
to	NN	O	O
cocaine	NN	O	O
,	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
attenuated	NN	O	O
the	NN	O	O
psychostimulant	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	B
hyperactivity	NN	O	I
.	NN	O	O

Such	NN	O	O
attenuation	NN	O	O
was	NN	O	O
not	NN	O	O
found	NN	O	O
in	NN	O	O
animals	NN	O	O
which	NN	O	O
had	NN	O	O
been	NN	O	O
injected	NN	O	O
with	NN	O	O
GR	NN	O	O
55562	NN	O	O
into	NN	O	O
the	NN	O	O
accumbens	NN	O	O
core	NN	O	O
.	NN	O	O

When	NN	O	O
injected	NN	O	O
into	NN	O	O
the	NN	O	O
accumbens	NN	O	O
shell	NN	O	O
(	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
core	NN	O	O
)	NN	O	O
before	NN	O	O
cocaine	NN	O	O
,	NN	O	O
CP	NN	O	O
93129	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
microg	NN	O	O
/	NN	O	O
side	NN	O	O
)	NN	O	O
enhanced	NN	O	O
the	NN	O	O
locomotor	NN	O	O
response	NN	O	O
to	NN	O	O
cocaine	NN	O	O
;	NN	O	O
the	NN	O	O
maximum	NN	O	O
effect	NN	O	O
being	NN	O	O
observed	NN	O	O
after	NN	O	O
10	NN	O	O
microg	NN	O	O
/	NN	O	O
side	NN	O	O
of	NN	O	O
the	NN	O	O
agonist	NN	O	O
.	NN	O	O

The	NN	O	O
later	NN	O	O
enhancement	NN	O	O
was	NN	O	O
attenuated	NN	O	O
after	NN	O	O
intra	NN	O	O
-	NN	O	O
accumbens	NN	O	O
shell	NN	O	O
treatment	NN	O	O
with	NN	O	O
GR	NN	O	O
55562	NN	O	O
(	NN	O	O
1	NN	O	O
microg	NN	O	O
/	NN	O	O
side	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
cocaine	NN	O	O
induced	NN	O	O
hyperlocomotion	NN	O	B
is	NN	O	O
modified	NN	O	O
by	NN	O	O
5	NN	O	O
-	NN	O	O
HT1B	NN	O	O
receptor	NN	O	O
ligands	NN	O	O
microinjected	NN	O	O
into	NN	O	O
the	NN	O	O
accumbens	NN	O	O
shell	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
core	NN	O	O
,	NN	O	O
this	NN	O	O
modification	NN	O	O
consisting	NN	O	O
in	NN	O	O
inhibitory	NN	O	O
and	NN	O	O
facilitatory	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
HT1B	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
(	NN	O	O
GR	NN	O	O
55562	NN	O	O
)	NN	O	O
and	NN	O	O
agonist	NN	O	O
(	NN	O	O
CP	NN	O	O
93129	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

In	NN	O	O
other	NN	O	O
words	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
accumbal	NN	O	O
shell	NN	O	O
5	NN	O	O
-	NN	O	O
HT1B	NN	O	O
receptors	NN	O	O
play	NN	O	O
a	NN	O	O
permissive	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
behavioural	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
psychostimulant	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
related	NN	O	O
chest	NN	O	B
pain	NN	O	I
:	NN	O	O
are	NN	O	O
we	NN	O	O
seeing	NN	O	O
the	NN	O	O
tip	NN	O	O
of	NN	O	O
an	NN	O	O
iceberg	NN	O	O
?	NN	O	O

The	NN	O	O
recreational	NN	O	O
use	NN	O	O
of	NN	O	O
cocaine	NN	O	O
is	NN	O	O
on	NN	O	O
the	NN	O	O
increase	NN	O	O
.	NN	O	O

The	NN	O	O
emergency	NN	O	O
nurse	NN	O	O
ought	NN	O	O
to	NN	O	O
be	NN	O	O
familiar	NN	O	O
with	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
consequences	NN	O	O
of	NN	O	O
cocaine	NN	O	O
use	NN	O	O
.	NN	O	O

In	NN	O	O
particular	NN	O	O
,	NN	O	O
the	NN	O	O
tendency	NN	O	O
of	NN	O	O
cocaine	NN	O	O
to	NN	O	O
produce	NN	O	O
chest	NN	O	B
pain	NN	O	I
ought	NN	O	O
to	NN	O	O
be	NN	O	O
in	NN	O	O
the	NN	O	O
mind	NN	O	O
of	NN	O	O
the	NN	O	O
emergency	NN	O	O
nurse	NN	O	O
when	NN	O	O
faced	NN	O	O
with	NN	O	O
a	NN	O	O
young	NN	O	O
victim	NN	O	O
of	NN	O	O
chest	NN	O	B
pain	NN	O	I
who	NN	O	O
is	NN	O	O
otherwise	NN	O	O
at	NN	O	O
low	NN	O	O
risk	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
chest	NN	O	B
pain	NN	O	I
related	NN	O	O
to	NN	O	O
cocaine	NN	O	O
use	NN	O	O
is	NN	O	O
discussed	NN	O	O
and	NN	O	O
treatment	NN	O	O
dilemmas	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
moral	NN	O	O
issues	NN	O	O
relating	NN	O	O
to	NN	O	O
the	NN	O	O
testing	NN	O	O
of	NN	O	O
potential	NN	O	O
cocaine	NN	O	O
users	NN	O	O
will	NN	O	O
be	NN	O	O
addressed	NN	O	O
.	NN	O	O

Crossover	NN	O	O
comparison	NN	O	O
of	NN	O	O
efficacy	NN	O	O
and	NN	O	O
preference	NN	O	O
for	NN	O	O
rizatriptan	NN	O	O
10	NN	O	O
mg	NN	O	O
versus	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
in	NN	O	O
migraine	NN	O	B
.	NN	O	O

Rizatriptan	NN	O	O
is	NN	O	O
a	NN	O	O
selective	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
(	NN	O	O
1B	NN	O	O
/	NN	O	O
1D	NN	O	O
)	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
with	NN	O	O
rapid	NN	O	O
oral	NN	O	O
absorption	NN	O	O
and	NN	O	O
early	NN	O	O
onset	NN	O	O
of	NN	O	O
action	NN	O	O
in	NN	O	O
the	NN	O	O
acute	NN	O	O
treatment	NN	O	O
of	NN	O	O
migraine	NN	O	B
.	NN	O	O

This	NN	O	O
randomized	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
crossover	NN	O	O
outpatient	NN	O	O
study	NN	O	O
assessed	NN	O	O
the	NN	O	O
preference	NN	O	O
for	NN	O	O
1	NN	O	O
rizatriptan	NN	O	O
10	NN	O	O
mg	NN	O	O
tablet	NN	O	O
to	NN	O	O
2	NN	O	O
ergotamine	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
caffeine	NN	O	O
100	NN	O	O
mg	NN	O	O
tablets	NN	O	O
in	NN	O	O
439	NN	O	O
patients	NN	O	O
treating	NN	O	O
a	NN	O	O
single	NN	O	O
migraine	NN	O	B
attack	NN	O	O
with	NN	O	O
each	NN	O	O
therapy	NN	O	O
.	NN	O	O

Of	NN	O	O
patients	NN	O	O
expressing	NN	O	O
a	NN	O	O
preference	NN	O	O
(	NN	O	O
89	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
more	NN	O	O
than	NN	O	O
twice	NN	O	O
as	NN	O	O
many	NN	O	O
preferred	NN	O	O
rizatriptan	NN	O	O
to	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
(	NN	O	O
69	NN	O	O
.	NN	O	O
9	NN	O	O
vs	NN	O	O
.	NN	O	O
30	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Faster	NN	O	O
relief	NN	O	O
of	NN	O	O
headache	NN	O	B
was	NN	O	O
the	NN	O	O
most	NN	O	O
important	NN	O	O
reason	NN	O	O
for	NN	O	O
preference	NN	O	O
,	NN	O	O
cited	NN	O	O
by	NN	O	O
67	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
preferring	NN	O	O
rizatriptan	NN	O	O
and	NN	O	O
54	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
preferred	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
.	NN	O	O

The	NN	O	O
co	NN	O	O
-	NN	O	O
primary	NN	O	O
endpoint	NN	O	O
of	NN	O	O
being	NN	O	O
pain	NN	O	B
free	NN	O	O
at	NN	O	O
2	NN	O	O
h	NN	O	O
was	NN	O	O
also	NN	O	O
in	NN	O	O
favor	NN	O	O
of	NN	O	O
rizatriptan	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
nine	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
were	NN	O	O
pain	NN	O	B
free	NN	O	O
2	NN	O	O
h	NN	O	O
after	NN	O	O
rizatriptan	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
24	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
treated	NN	O	O
with	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
rizatriptan	NN	O	O
being	NN	O	O
superior	NN	O	O
within	NN	O	O
1	NN	O	O
h	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Headache	NN	O	B
relief	NN	O	O
at	NN	O	O
2	NN	O	O
h	NN	O	O
was	NN	O	O
75	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
for	NN	O	O
rizatriptan	NN	O	O
and	NN	O	O
47	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
for	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
rizatriptan	NN	O	O
being	NN	O	O
superior	NN	O	O
to	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
within	NN	O	O
30	NN	O	O
min	NN	O	O
of	NN	O	O
dosing	NN	O	O
.	NN	O	O

Almost	NN	O	O
36	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
taking	NN	O	O
rizatriptan	NN	O	O
were	NN	O	O
pain	NN	O	B
free	NN	O	O
at	NN	O	O
2	NN	O	O
h	NN	O	O
and	NN	O	O
had	NN	O	O
no	NN	O	O
recurrence	NN	O	O
or	NN	O	O
need	NN	O	O
for	NN	O	O
additional	NN	O	O
medication	NN	O	O
within	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
20	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
on	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Rizatriptan	NN	O	O
was	NN	O	O
also	NN	O	O
superior	NN	O	O
to	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
in	NN	O	O
the	NN	O	O
proportions	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
no	NN	O	O
nausea	NN	O	B
,	NN	O	O
vomiting	NN	O	B
,	NN	O	O
phonophobia	NN	O	B
or	NN	O	O
photophobia	NN	O	B
and	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
normal	NN	O	O
function	NN	O	O
2	NN	O	O
h	NN	O	O
after	NN	O	O
drug	NN	O	O
intake	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

More	NN	O	O
patients	NN	O	O
were	NN	O	O
(	NN	O	O
completely	NN	O	O
,	NN	O	O
very	NN	O	O
or	NN	O	O
somewhat	NN	O	O
)	NN	O	O
satisfied	NN	O	O
2	NN	O	O
h	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
rizatriptan	NN	O	O
(	NN	O	O
69	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
than	NN	O	O
at	NN	O	O
2	NN	O	O
h	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
(	NN	O	O
38	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Recurrence	NN	O	O
rates	NN	O	O
were	NN	O	O
31	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
with	NN	O	O
rizatriptan	NN	O	O
and	NN	O	O
15	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
with	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
.	NN	O	O

Both	NN	O	O
active	NN	O	O
treatments	NN	O	O
were	NN	O	O
well	NN	O	O
tolerated	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
adverse	NN	O	O
events	NN	O	O
(	NN	O	O
incidence	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
5	NN	O	O
%	NN	O	O
in	NN	O	O
one	NN	O	O
group	NN	O	O
)	NN	O	O
after	NN	O	O
rizatriptan	NN	O	O
and	NN	O	O
ergotamine	NN	O	O
/	NN	O	O
caffeine	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
were	NN	O	O
dizziness	NN	O	B
(	NN	O	O
6	NN	O	O
.	NN	O	O
7	NN	O	O
and	NN	O	O
5	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
nausea	NN	O	B
(	NN	O	O
4	NN	O	O
.	NN	O	O
2	NN	O	O
and	NN	O	O
8	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
somnolence	NN	O	B
(	NN	O	O
5	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Severe	NN	O	O
ocular	NN	O	B
and	NN	O	I
orbital	NN	O	I
toxicity	NN	O	I
after	NN	O	O
intracarotid	NN	O	O
injection	NN	O	O
of	NN	O	O
carboplatin	NN	O	O
for	NN	O	O
recurrent	NN	O	O
glioblastomas	NN	O	B
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Glioblastoma	NN	O	B
is	NN	O	O
a	NN	O	O
malignant	NN	O	B
tumor	NN	O	I
that	NN	O	O
occurs	NN	O	O
in	NN	O	O
the	NN	O	O
cerebrum	NN	O	O
during	NN	O	O
adulthood	NN	O	O
.	NN	O	O

With	NN	O	O
current	NN	O	O
treatment	NN	O	O
regimens	NN	O	O
including	NN	O	O
combined	NN	O	O
surgery	NN	O	O
,	NN	O	O
radiation	NN	O	O
and	NN	O	O
chemotherapy	NN	O	O
,	NN	O	O
the	NN	O	O
average	NN	O	O
life	NN	O	O
expectancy	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
is	NN	O	O
limited	NN	O	O
to	NN	O	O
approximately	NN	O	O
1	NN	O	O
year	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
glioblastoma	NN	O	B
sometimes	NN	O	O
have	NN	O	O
intracarotid	NN	O	O
injection	NN	O	O
of	NN	O	O
carcinostatics	NN	O	O
added	NN	O	O
to	NN	O	O
the	NN	O	O
treatment	NN	O	O
regimen	NN	O	O
.	NN	O	O

Generally	NN	O	O
,	NN	O	O
carboplatin	NN	O	O
is	NN	O	O
said	NN	O	O
to	NN	O	O
have	NN	O	O
milder	NN	O	O
side	NN	O	O
effects	NN	O	O
than	NN	O	O
cisplatin	NN	O	O
,	NN	O	O
whose	NN	O	O
ocular	NN	O	B
and	NN	O	I
orbital	NN	O	I
toxicity	NN	O	I
are	NN	O	O
well	NN	O	O
known	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
we	NN	O	O
experienced	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
severe	NN	O	O
ocular	NN	O	B
and	NN	O	I
orbital	NN	O	I
toxicity	NN	O	I
after	NN	O	O
intracarotid	NN	O	O
injection	NN	O	O
of	NN	O	O
carboplatin	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
infrequently	NN	O	O
reported	NN	O	O
.	NN	O	O

CASE	NN	O	O
:	NN	O	O
A	NN	O	O
58	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
received	NN	O	O
an	NN	O	O
intracarotid	NN	O	O
injection	NN	O	O
of	NN	O	O
carboplatin	NN	O	O
for	NN	O	O
recurrent	NN	O	O
glioblastomas	NN	O	B
in	NN	O	O
his	NN	O	O
left	NN	O	O
temporal	NN	O	O
lobe	NN	O	O
.	NN	O	O

He	NN	O	O
complained	NN	O	O
of	NN	O	O
pain	NN	O	B
and	NN	O	I
visual	NN	O	I
disturbance	NN	O	I
in	NN	O	I
the	NN	O	I
ipsilateral	NN	O	I
eye	NN	O	I
30	NN	O	O
h	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
.	NN	O	O

Various	NN	O	O
ocular	NN	O	O
symptoms	NN	O	O
and	NN	O	O
findings	NN	O	O
caused	NN	O	O
by	NN	O	O
carboplatin	NN	O	O
toxicity	NN	O	B
were	NN	O	O
seen	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
He	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
corticosteroids	NN	O	O
and	NN	O	O
glycerin	NN	O	O
for	NN	O	O
6	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
intraocular	NN	O	O
pressure	NN	O	O
elevation	NN	O	O
caused	NN	O	O
by	NN	O	O
secondary	NN	O	O
acute	NN	O	O
angle	NN	O	O
-	NN	O	O
closure	NN	O	O
glaucoma	NN	O	B
decreased	NN	O	O
and	NN	O	O
ocular	NN	O	B
pain	NN	O	I
diminished	NN	O	O
,	NN	O	O
inexorable	NN	O	O
papilledema	NN	O	B
and	NN	O	O
exudative	NN	O	O
retinal	NN	O	B
detachment	NN	O	I
continued	NN	O	O
for	NN	O	O
3	NN	O	O
weeks	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
6	NN	O	O
weeks	NN	O	O
later	NN	O	O
,	NN	O	O
diffuse	NN	O	O
chorioretinal	NN	O	B
atrophy	NN	O	I
with	NN	O	O
optic	NN	O	B
atrophy	NN	O	I
occurred	NN	O	O
and	NN	O	O
the	NN	O	O
vision	NN	O	O
in	NN	O	O
his	NN	O	O
left	NN	O	O
eye	NN	O	O
was	NN	O	O
lost	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
When	NN	O	O
performing	NN	O	O
intracarotid	NN	O	O
injection	NN	O	O
of	NN	O	O
carboplatin	NN	O	O
,	NN	O	O
we	NN	O	O
must	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
its	NN	O	O
potentially	NN	O	O
blinding	NN	O	O
ocular	NN	O	B
toxicity	NN	O	I
.	NN	O	O

It	NN	O	O
is	NN	O	O
recommended	NN	O	O
that	NN	O	O
further	NN	O	O
studies	NN	O	O
and	NN	O	O
investigations	NN	O	O
are	NN	O	O
undertaken	NN	O	O
in	NN	O	O
the	NN	O	O
effort	NN	O	O
to	NN	O	O
minimize	NN	O	O
such	NN	O	O
severe	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Visual	NN	O	B
hallucinations	NN	O	I
associated	NN	O	O
with	NN	O	O
zonisamide	NN	O	O
.	NN	O	O

Zonisamide	NN	O	O
is	NN	O	O
a	NN	O	O
broad	NN	O	O
-	NN	O	O
spectrum	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
various	NN	O	O
types	NN	O	O
of	NN	O	O
seizures	NN	O	B
.	NN	O	O

Although	NN	O	O
visual	NN	O	B
hallucinations	NN	O	I
have	NN	O	O
not	NN	O	O
been	NN	O	O
reported	NN	O	O
as	NN	O	O
an	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
this	NN	O	O
agent	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
three	NN	O	O
patients	NN	O	O
who	NN	O	O
experienced	NN	O	O
complex	NN	O	O
visual	NN	O	B
hallucinations	NN	O	I
and	NN	O	O
altered	NN	O	O
mental	NN	O	O
status	NN	O	O
after	NN	O	O
zonisamide	NN	O	O
treatment	NN	O	O
was	NN	O	O
begun	NN	O	O
or	NN	O	O
its	NN	O	O
dosage	NN	O	O
increased	NN	O	O
.	NN	O	O

All	NN	O	O
three	NN	O	O
had	NN	O	O
been	NN	O	O
diagnosed	NN	O	O
earlier	NN	O	O
with	NN	O	O
epilepsy	NN	O	B
,	NN	O	O
and	NN	O	O
their	NN	O	O
electroencephalogram	NN	O	O
(	NN	O	O
EEG	NN	O	O
)	NN	O	O
findings	NN	O	O
were	NN	O	O
abnormal	NN	O	O
.	NN	O	O

During	NN	O	O
monitoring	NN	O	O
,	NN	O	O
visual	NN	O	B
hallucinations	NN	O	I
did	NN	O	O
not	NN	O	O
correlate	NN	O	O
with	NN	O	O
EEG	NN	O	O
readings	NN	O	O
,	NN	O	O
nor	NN	O	O
did	NN	O	O
video	NN	O	O
recording	NN	O	O
capture	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
described	NN	O	O
events	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
had	NN	O	O
experienced	NN	O	O
visual	NN	O	B
hallucinations	NN	O	I
before	NN	O	O
this	NN	O	O
event	NN	O	O
.	NN	O	O

The	NN	O	O
only	NN	O	O
recent	NN	O	O
change	NN	O	O
in	NN	O	O
their	NN	O	O
treatment	NN	O	O
was	NN	O	O
the	NN	O	O
introduction	NN	O	O
or	NN	O	O
increased	NN	O	O
dosage	NN	O	O
of	NN	O	O
zonisamide	NN	O	O
.	NN	O	O

With	NN	O	O
either	NN	O	O
discontinuation	NN	O	O
or	NN	O	O
decreased	NN	O	O
dosage	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
the	NN	O	O
symptoms	NN	O	O
disappeared	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
recur	NN	O	O
.	NN	O	O

Further	NN	O	O
observations	NN	O	O
and	NN	O	O
reports	NN	O	O
will	NN	O	O
help	NN	O	O
clarify	NN	O	O
this	NN	O	O
adverse	NN	O	O
effect	NN	O	O
.	NN	O	O

Until	NN	O	O
then	NN	O	O
,	NN	O	O
clinicians	NN	O	O
need	NN	O	O
to	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
possible	NN	O	O
complication	NN	O	O
associated	NN	O	O
with	NN	O	O
zonisamide	NN	O	O
.	NN	O	O

Anti	NN	O	O
-	NN	O	O
epileptic	NN	O	B
drugs	NN	O	O
-	NN	O	O
induced	NN	O	O
de	NN	O	O
novo	NN	O	O
absence	NN	O	B
seizures	NN	O	I
.	NN	O	O

The	NN	O	O
authors	NN	O	O
present	NN	O	O
three	NN	O	O
patients	NN	O	O
with	NN	O	O
de	NN	O	O
novo	NN	O	O
absence	NN	O	B
epilepsy	NN	O	I
after	NN	O	O
administration	NN	O	O
of	NN	O	O
carbamazepine	NN	O	O
and	NN	O	O
vigabatrin	NN	O	O
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
underlying	NN	O	O
diseases	NN	O	O
,	NN	O	O
the	NN	O	O
prognosis	NN	O	O
for	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
de	NN	O	O
novo	NN	O	O
absence	NN	O	B
seizure	NN	O	I
is	NN	O	O
good	NN	O	O
because	NN	O	O
it	NN	O	O
subsides	NN	O	O
rapidly	NN	O	O
after	NN	O	O
discontinuing	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
offending	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
-	NN	O	O
transmitted	NN	O	O
thalamocortical	NN	O	O
circuitry	NN	O	O
accounts	NN	O	O
for	NN	O	O
a	NN	O	O
major	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
underlying	NN	O	O
neurophysiology	NN	O	O
of	NN	O	O
the	NN	O	O
absence	NN	O	B
epilepsy	NN	O	I
.	NN	O	O

Because	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
de	NN	O	O
novo	NN	O	O
absence	NN	O	B
seizure	NN	O	I
is	NN	O	O
rare	NN	O	O
,	NN	O	O
pro	NN	O	O
-	NN	O	O
absence	NN	O	O
drugs	NN	O	O
can	NN	O	O
only	NN	O	O
be	NN	O	O
considered	NN	O	O
a	NN	O	O
promoting	NN	O	O
factor	NN	O	O
.	NN	O	O

The	NN	O	O
underlying	NN	O	O
epileptogenecity	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
or	NN	O	O
the	NN	O	O
synergistic	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
accompanying	NN	O	O
drugs	NN	O	O
is	NN	O	O
required	NN	O	O
to	NN	O	O
trigger	NN	O	O
the	NN	O	O
de	NN	O	O
novo	NN	O	O
absence	NN	O	B
seizure	NN	O	I
.	NN	O	O

The	NN	O	O
possibility	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
aggravation	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
whenever	NN	O	O
an	NN	O	O
unexpected	NN	O	O
increase	NN	O	O
in	NN	O	O
seizure	NN	O	B
frequency	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
new	NN	O	O
seizure	NN	O	B
types	NN	O	O
appear	NN	O	O
following	NN	O	O
a	NN	O	O
change	NN	O	O
in	NN	O	O
drug	NN	O	O
treatment	NN	O	O
.	NN	O	O

By	NN	O	O
understanding	NN	O	O
the	NN	O	O
underlying	NN	O	O
mechanism	NN	O	O
of	NN	O	O
absence	NN	O	B
epilepsy	NN	O	I
,	NN	O	O
we	NN	O	O
can	NN	O	O
avoid	NN	O	O
the	NN	O	O
inappropriate	NN	O	O
use	NN	O	O
of	NN	O	O
anticonvulsants	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
epilepsy	NN	O	B
and	NN	O	O
prevent	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
absence	NN	O	B
seizures	NN	O	I
.	NN	O	O

Prenatal	NN	O	O
dexamethasone	NN	O	O
programs	NN	O	O
hypertension	NN	O	B
and	NN	O	O
renal	NN	O	B
injury	NN	O	I
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Dexamethasone	NN	O	O
is	NN	O	O
frequently	NN	O	O
administered	NN	O	O
to	NN	O	O
the	NN	O	O
developing	NN	O	O
fetus	NN	O	O
to	NN	O	O
accelerate	NN	O	O
pulmonary	NN	O	O
development	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
prenatal	NN	O	O
dexamethasone	NN	O	O
programmed	NN	O	O
a	NN	O	O
progressive	NN	O	O
increase	NN	O	B
in	NN	O	I
blood	NN	O	I
pressure	NN	O	I
and	NN	O	O
renal	NN	O	B
injury	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Pregnant	NN	O	O
rats	NN	O	O
were	NN	O	O
given	NN	O	O
either	NN	O	O
vehicle	NN	O	O
or	NN	O	O
2	NN	O	O
daily	NN	O	O
intraperitoneal	NN	O	O
injections	NN	O	O
of	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
on	NN	O	O
gestational	NN	O	O
days	NN	O	O
11	NN	O	O
and	NN	O	O
12	NN	O	O
,	NN	O	O
13	NN	O	O
and	NN	O	O
14	NN	O	O
,	NN	O	O
15	NN	O	O
and	NN	O	O
16	NN	O	O
,	NN	O	O
17	NN	O	O
and	NN	O	O
18	NN	O	O
,	NN	O	O
or	NN	O	O
19	NN	O	O
and	NN	O	O
20	NN	O	O
.	NN	O	O

Offspring	NN	O	O
of	NN	O	O
rats	NN	O	O
administered	NN	O	O
dexamethasone	NN	O	O
on	NN	O	O
days	NN	O	O
15	NN	O	O
and	NN	O	O
16	NN	O	O
gestation	NN	O	O
had	NN	O	O
a	NN	O	O
20	NN	O	O
%	NN	O	O
reduction	NN	O	B
in	NN	O	I
glomerular	NN	O	I
number	NN	O	I
compared	NN	O	O
with	NN	O	O
control	NN	O	O
at	NN	O	O
6	NN	O	O
to	NN	O	O
9	NN	O	O
months	NN	O	O
of	NN	O	O
age	NN	O	O
(	NN	O	O
22	NN	O	O
527	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
509	NN	O	O
versus	NN	O	O
28	NN	O	O
050	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
561	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
comparable	NN	O	O
to	NN	O	O
the	NN	O	O
percent	NN	O	O
reduction	NN	O	O
in	NN	O	O
glomeruli	NN	O	O
measured	NN	O	O
at	NN	O	O
3	NN	O	O
weeks	NN	O	O
of	NN	O	O
age	NN	O	O
.	NN	O	O

Six	NN	O	O
-	NN	O	O
to	NN	O	O
9	NN	O	O
-	NN	O	O
month	NN	O	O
old	NN	O	O
rats	NN	O	O
receiving	NN	O	O
prenatal	NN	O	O
dexamethasone	NN	O	O
on	NN	O	O
days	NN	O	O
17	NN	O	O
and	NN	O	O
18	NN	O	O
of	NN	O	O
gestation	NN	O	O
had	NN	O	O
a	NN	O	O
17	NN	O	O
%	NN	O	O
reduction	NN	O	O
in	NN	O	O
glomeruli	NN	O	O
(	NN	O	O
23	NN	O	O
380	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
587	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
rats	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Male	NN	O	O
rats	NN	O	O
that	NN	O	O
received	NN	O	O
prenatal	NN	O	O
dexamethasone	NN	O	O
on	NN	O	O
days	NN	O	O
15	NN	O	O
and	NN	O	O
16	NN	O	O
,	NN	O	O
17	NN	O	O
and	NN	O	O
18	NN	O	O
,	NN	O	O
and	NN	O	O
13	NN	O	O
and	NN	O	O
14	NN	O	O
of	NN	O	O
gestation	NN	O	O
had	NN	O	O
elevated	NN	O	B
blood	NN	O	I
pressures	NN	O	I
at	NN	O	O
6	NN	O	O
months	NN	O	O
of	NN	O	O
age	NN	O	O
;	NN	O	O
the	NN	O	O
latter	NN	O	O
group	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
a	NN	O	O
reduction	NN	O	B
in	NN	O	I
glomerular	NN	O	I
number	NN	O	I
.	NN	O	O

Adult	NN	O	O
rats	NN	O	O
given	NN	O	O
dexamethasone	NN	O	O
on	NN	O	O
days	NN	O	O
15	NN	O	O
and	NN	O	O
16	NN	O	O
of	NN	O	O
gestation	NN	O	O
had	NN	O	O
more	NN	O	O
glomeruli	NN	O	O
with	NN	O	O
glomerulosclerosis	NN	O	B
than	NN	O	O
control	NN	O	O
rats	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
shows	NN	O	O
that	NN	O	O
prenatal	NN	O	O
dexamethasone	NN	O	O
in	NN	O	O
rats	NN	O	O
results	NN	O	O
in	NN	O	O
a	NN	O	O
reduction	NN	O	B
in	NN	O	I
glomerular	NN	O	I
number	NN	O	I
,	NN	O	O
glomerulosclerosis	NN	O	B
,	NN	O	O
and	NN	O	O
hypertension	NN	O	B
when	NN	O	O
administered	NN	O	O
at	NN	O	O
specific	NN	O	O
points	NN	O	O
during	NN	O	O
gestation	NN	O	O
.	NN	O	O

Hypertension	NN	O	B
was	NN	O	O
observed	NN	O	O
in	NN	O	O
animals	NN	O	O
that	NN	O	O
had	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
glomeruli	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
a	NN	O	O
group	NN	O	O
that	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
a	NN	O	O
reduction	NN	O	B
in	NN	O	I
glomerular	NN	O	I
number	NN	O	I
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
a	NN	O	O
reduction	NN	O	B
in	NN	O	I
glomerular	NN	O	I
number	NN	O	I
is	NN	O	O
not	NN	O	O
the	NN	O	O
sole	NN	O	O
cause	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Kidney	NN	O	O
function	NN	O	O
and	NN	O	O
morphology	NN	O	O
after	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
combination	NN	O	O
therapy	NN	O	O
with	NN	O	O
cyclosporine	NN	O	O
A	NN	O	O
,	NN	O	O
tacrolimus	NN	O	O
and	NN	O	O
sirolimus	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Sirolimus	NN	O	O
(	NN	O	O
SRL	NN	O	O
)	NN	O	O
may	NN	O	O
supplement	NN	O	O
calcineurin	NN	O	O
inhibitors	NN	O	O
in	NN	O	O
clinical	NN	O	O
organ	NN	O	O
transplantation	NN	O	O
.	NN	O	O

These	NN	O	O
are	NN	O	O
nephrotoxic	NN	O	B
,	NN	O	O
but	NN	O	O
SRL	NN	O	O
seems	NN	O	O
to	NN	O	O
act	NN	O	O
differently	NN	O	O
displaying	NN	O	O
only	NN	O	O
minor	NN	O	O
nephrotoxic	NN	O	B
effects	NN	O	O
,	NN	O	O
although	NN	O	O
this	NN	O	O
question	NN	O	O
is	NN	O	O
still	NN	O	O
open	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
treatment	NN	O	O
protocols	NN	O	O
where	NN	O	O
SRL	NN	O	O
was	NN	O	O
combined	NN	O	O
with	NN	O	O
a	NN	O	O
calcineurin	NN	O	O
inhibitor	NN	O	O
indications	NN	O	O
of	NN	O	O
a	NN	O	O
synergistic	NN	O	O
nephrotoxic	NN	O	B
effect	NN	O	O
were	NN	O	O
described	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
examine	NN	O	O
further	NN	O	O
the	NN	O	O
renal	NN	O	O
function	NN	O	O
,	NN	O	O
including	NN	O	O
morphological	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
kidneys	NN	O	O
of	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
either	NN	O	O
cyclosporine	NN	O	O
A	NN	O	O
(	NN	O	O
CsA	NN	O	O
)	NN	O	O
,	NN	O	O
tacrolimus	NN	O	O
(	NN	O	O
FK506	NN	O	O
)	NN	O	O
or	NN	O	O
SRL	NN	O	O
as	NN	O	O
monotherapies	NN	O	O
or	NN	O	O
in	NN	O	O
different	NN	O	O
combinations	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
For	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
2	NN	O	O
weeks	NN	O	O
,	NN	O	O
CsA	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
given	NN	O	O
orally	NN	O	O
)	NN	O	O
,	NN	O	O
FK506	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
given	NN	O	O
orally	NN	O	O
)	NN	O	O
or	NN	O	O
SRL	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
given	NN	O	O
intraperitoneally	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
once	NN	O	O
a	NN	O	O
day	NN	O	O
as	NN	O	O
these	NN	O	O
doses	NN	O	O
have	NN	O	O
earlier	NN	O	O
been	NN	O	O
found	NN	O	O
to	NN	O	O
achieve	NN	O	O
a	NN	O	O
significant	NN	O	O
immunosuppressive	NN	O	O
effect	NN	O	O
in	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
'	NN	O	O
conscious	NN	O	O
catheterized	NN	O	O
rat	NN	O	O
'	NN	O	O
model	NN	O	O
,	NN	O	O
the	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
(	NN	O	O
GFR	NN	O	O
)	NN	O	O
was	NN	O	O
measured	NN	O	O
as	NN	O	O
the	NN	O	O
clearance	NN	O	O
of	NN	O	O
Cr	NN	O	O
(	NN	O	O
EDTA	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
morphological	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
kidneys	NN	O	O
included	NN	O	O
a	NN	O	O
semi	NN	O	O
-	NN	O	O
quantitative	NN	O	O
scoring	NN	O	O
system	NN	O	O
analysing	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
striped	NN	O	O
fibrosis	NN	O	B
,	NN	O	O
subcapsular	NN	O	O
fibrosis	NN	O	B
and	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
basophilic	NN	O	O
tubules	NN	O	O
,	NN	O	O
plus	NN	O	O
an	NN	O	O
additional	NN	O	O
stereological	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
total	NN	O	O
grade	NN	O	O
of	NN	O	O
fibrosis	NN	O	B
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
stained	NN	O	O
with	NN	O	O
Sirius	NN	O	O
Red	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
CsA	NN	O	O
,	NN	O	O
FK506	NN	O	O
and	NN	O	O
SRL	NN	O	O
all	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
the	NN	O	O
GFR	NN	O	O
.	NN	O	O

A	NN	O	O
further	NN	O	O
deterioration	NN	O	O
was	NN	O	O
seen	NN	O	O
when	NN	O	O
CsA	NN	O	O
was	NN	O	O
combined	NN	O	O
with	NN	O	O
either	NN	O	O
FK506	NN	O	O
or	NN	O	O
SRL	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
GFR	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
treated	NN	O	O
with	NN	O	O
FK506	NN	O	O
plus	NN	O	O
SRL	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
treatment	NN	O	O
with	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
single	NN	O	O
substances	NN	O	O
.	NN	O	O

The	NN	O	O
morphological	NN	O	O
changes	NN	O	O
presented	NN	O	O
a	NN	O	O
similar	NN	O	O
pattern	NN	O	O
.	NN	O	O

The	NN	O	O
semi	NN	O	O
-	NN	O	O
quantitative	NN	O	O
scoring	NN	O	O
was	NN	O	O
significantly	NN	O	O
worst	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
treated	NN	O	O
with	NN	O	O
CsA	NN	O	O
plus	NN	O	O
SRL	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
total	NN	O	O
grade	NN	O	O
of	NN	O	O
fibrosis	NN	O	B
also	NN	O	O
showed	NN	O	O
the	NN	O	O
highest	NN	O	O
proportion	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
group	NN	O	O
and	NN	O	O
was	NN	O	O
significantly	NN	O	O
different	NN	O	O
from	NN	O	O
controls	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
FK506	NN	O	O
plus	NN	O	O
SRL	NN	O	O
combination	NN	O	O
showed	NN	O	O
only	NN	O	O
a	NN	O	O
marginally	NN	O	O
higher	NN	O	O
degree	NN	O	O
of	NN	O	O
fibrosis	NN	O	B
as	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
rat	NN	O	O
study	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
synergistic	NN	O	O
nephrotoxic	NN	O	B
effect	NN	O	O
of	NN	O	O
CsA	NN	O	O
plus	NN	O	O
SRL	NN	O	O
,	NN	O	O
whereas	NN	O	O
FK506	NN	O	O
plus	NN	O	O
SRL	NN	O	O
was	NN	O	O
better	NN	O	O
tolerated	NN	O	O
.	NN	O	O

Evaluation	NN	O	O
of	NN	O	O
cardiac	NN	O	O
troponin	NN	O	O
I	NN	O	O
and	NN	O	O
T	NN	O	O
levels	NN	O	O
as	NN	O	O
markers	NN	O	O
of	NN	O	O
myocardial	NN	O	B
damage	NN	O	I
in	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B
rats	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
relationship	NN	O	O
with	NN	O	O
echocardiographic	NN	O	O
and	NN	O	O
histological	NN	O	O
findings	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Cardiac	NN	O	O
troponins	NN	O	O
I	NN	O	O
(	NN	O	O
cTnI	NN	O	O
)	NN	O	O
and	NN	O	O
T	NN	O	O
(	NN	O	O
cTnT	NN	O	O
)	NN	O	O
have	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
highly	NN	O	O
sensitive	NN	O	O
and	NN	O	O
specific	NN	O	O
markers	NN	O	O
of	NN	O	O
myocardial	NN	O	B
cell	NN	O	I
injury	NN	O	I
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
value	NN	O	O
of	NN	O	O
cTnI	NN	O	O
and	NN	O	O
cTnT	NN	O	O
for	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
myocardial	NN	O	B
damage	NN	O	I
in	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
DOX	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B
,	NN	O	O
and	NN	O	O
we	NN	O	O
examined	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
serial	NN	O	O
cTnI	NN	O	O
and	NN	O	O
cTnT	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
cardiac	NN	O	B
disorders	NN	O	I
monitored	NN	O	O
by	NN	O	O
echocardiography	NN	O	O
and	NN	O	O
histological	NN	O	O
examinations	NN	O	O
in	NN	O	O
this	NN	O	O
model	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Thirty	NN	O	O
-	NN	O	O
five	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
given	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
DOX	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
,	NN	O	O
weekly	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
8	NN	O	O
weeks	NN	O	O
for	NN	O	O
a	NN	O	O
total	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
of	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BW	NN	O	O
.	NN	O	O

Ten	NN	O	O
rats	NN	O	O
received	NN	O	O
saline	NN	O	O
as	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

cTnI	NN	O	O
was	NN	O	O
measured	NN	O	O
with	NN	O	O
Access	NN	O	O
(	NN	O	O
R	NN	O	O
)	NN	O	O
(	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
research	NN	O	O
immunoassay	NN	O	O
(	NN	O	O
pg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
compared	NN	O	O
with	NN	O	O
cTnT	NN	O	O
,	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
mass	NN	O	O
and	NN	O	O
CK	NN	O	O
.	NN	O	O

By	NN	O	O
using	NN	O	O
transthoracic	NN	O	O
echocardiography	NN	O	O
,	NN	O	O
anterior	NN	O	O
and	NN	O	O
posterior	NN	O	O
wall	NN	O	O
thickness	NN	O	O
,	NN	O	O
LV	NN	O	O
diameters	NN	O	O
and	NN	O	O
LV	NN	O	O
fractional	NN	O	O
shortening	NN	O	O
(	NN	O	O
FS	NN	O	O
)	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
all	NN	O	O
rats	NN	O	O
before	NN	O	O
DOX	NN	O	O
or	NN	O	O
saline	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
weeks	NN	O	O
6	NN	O	O
and	NN	O	O
9	NN	O	O
after	NN	O	O
treatment	NN	O	O
in	NN	O	O
all	NN	O	O
surviving	NN	O	O
rats	NN	O	O
.	NN	O	O

Histology	NN	O	O
was	NN	O	O
performed	NN	O	O
in	NN	O	O
DOX	NN	O	O
-	NN	O	O
rats	NN	O	O
at	NN	O	O
6	NN	O	O
and	NN	O	O
9	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
last	NN	O	O
DOX	NN	O	O
dose	NN	O	O
and	NN	O	O
in	NN	O	O
all	NN	O	O
controls	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Eighteen	NN	O	O
of	NN	O	O
the	NN	O	O
DOX	NN	O	O
rats	NN	O	O
died	NN	O	O
prematurely	NN	O	O
of	NN	O	O
general	NN	O	O
toxicity	NN	O	B
during	NN	O	O
the	NN	O	O
9	NN	O	O
-	NN	O	O
week	NN	O	O
period	NN	O	O
.	NN	O	O

End	NN	O	O
-	NN	O	O
diastolic	NN	O	O
(	NN	O	O
ED	NN	O	O
)	NN	O	O
and	NN	O	O
end	NN	O	O
-	NN	O	O
systolic	NN	O	O
(	NN	O	O
ES	NN	O	O
)	NN	O	O
LV	NN	O	O
diameters	NN	O	O
/	NN	O	O
BW	NN	O	O
significantly	NN	O	O
increased	NN	O	O
,	NN	O	O
whereas	NN	O	O
LV	NN	O	O
FS	NN	O	O
was	NN	O	O
decreased	NN	O	O
after	NN	O	O
9	NN	O	O
weeks	NN	O	O
in	NN	O	O
the	NN	O	O
DOX	NN	O	O
group	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
parameters	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
in	NN	O	O
controls	NN	O	O
.	NN	O	O

Histological	NN	O	O
evaluation	NN	O	O
of	NN	O	O
hearts	NN	O	O
from	NN	O	O
all	NN	O	O
rats	NN	O	O
given	NN	O	O
DOX	NN	O	O
revealed	NN	O	O
significant	NN	O	O
slight	NN	O	O
degrees	NN	O	O
of	NN	O	O
perivascular	NN	O	O
and	NN	O	O
interstitial	NN	O	O
fibrosis	NN	O	B
.	NN	O	O

In	NN	O	O
7	NN	O	O
of	NN	O	O
the	NN	O	O
18	NN	O	O
rats	NN	O	O
,	NN	O	O
degeneration	NN	O	O
and	NN	O	O
myocyte	NN	O	O
vacuolisation	NN	O	O
were	NN	O	O
found	NN	O	O
.	NN	O	O

Only	NN	O	O
five	NN	O	O
of	NN	O	O
the	NN	O	O
controls	NN	O	O
exhibited	NN	O	O
evidence	NN	O	O
of	NN	O	O
very	NN	O	O
slight	NN	O	O
perivascular	NN	O	O
fibrosis	NN	O	B
.	NN	O	O

A	NN	O	O
significant	NN	O	O
rise	NN	O	O
in	NN	O	O
cTnT	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
DOX	NN	O	O
rats	NN	O	O
after	NN	O	O
cumulative	NN	O	O
doses	NN	O	O
of	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
baseline	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

cTnT	NN	O	O
found	NN	O	O
in	NN	O	O
rats	NN	O	O
after	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
were	NN	O	O
significantly	NN	O	O
greater	NN	O	O
than	NN	O	O
that	NN	O	O
found	NN	O	O
after	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
DOX	NN	O	O
.	NN	O	O

Maximal	NN	O	O
cTnI	NN	O	O
(	NN	O	O
pg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
and	NN	O	O
cTnT	NN	O	O
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
DOX	NN	O	O
rats	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
006	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
007	NN	O	O
)	NN	O	O
.	NN	O	O

cTnI	NN	O	O
(	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
,	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
mass	NN	O	O
and	NN	O	O
CK	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
in	NN	O	O
DOX	NN	O	O
rats	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
.	NN	O	O

All	NN	O	O
markers	NN	O	O
remained	NN	O	O
stable	NN	O	O
in	NN	O	O
controls	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
data	NN	O	O
revealed	NN	O	O
a	NN	O	O
significant	NN	O	O
correlation	NN	O	O
between	NN	O	O
maximal	NN	O	O
cTnT	NN	O	O
and	NN	O	O
ED	NN	O	O
and	NN	O	O
ES	NN	O	O
LV	NN	O	O
diameters	NN	O	O
/	NN	O	O
BW	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
81	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
65	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
relationship	NN	O	O
was	NN	O	O
observed	NN	O	O
between	NN	O	O
maximal	NN	O	O
cTnT	NN	O	O
and	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
myocardial	NN	O	O
morphological	NN	O	O
changes	NN	O	O
,	NN	O	O
and	NN	O	O
between	NN	O	O
LV	NN	O	O
diameters	NN	O	O
/	NN	O	O
BW	NN	O	O
and	NN	O	O
histological	NN	O	O
findings	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Among	NN	O	O
markers	NN	O	O
of	NN	O	O
ischemic	NN	O	B
injury	NN	O	I
after	NN	O	O
DOX	NN	O	O
in	NN	O	O
rats	NN	O	O
,	NN	O	O
cTnT	NN	O	O
showed	NN	O	O
the	NN	O	O
greatest	NN	O	O
ability	NN	O	O
to	NN	O	O
detect	NN	O	O
myocardial	NN	O	B
damage	NN	O	I
assessed	NN	O	O
by	NN	O	O
echocardiographic	NN	O	O
detection	NN	O	O
and	NN	O	O
histological	NN	O	O
changes	NN	O	O
.	NN	O	O

Although	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
discrepancy	NN	O	O
between	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
cTnI	NN	O	O
and	NN	O	O
cTnT	NN	O	O
after	NN	O	O
DOX	NN	O	O
,	NN	O	O
probably	NN	O	O
due	NN	O	O
to	NN	O	O
heterogeneity	NN	O	O
in	NN	O	O
cross	NN	O	O
-	NN	O	O
reactivities	NN	O	O
of	NN	O	O
mAbs	NN	O	O
to	NN	O	O
various	NN	O	O
cTnI	NN	O	O
and	NN	O	O
cTnT	NN	O	O
forms	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
likely	NN	O	O
that	NN	O	O
cTnT	NN	O	O
in	NN	O	O
rats	NN	O	O
after	NN	O	O
DOX	NN	O	O
indicates	NN	O	O
cell	NN	O	O
damage	NN	O	O
determined	NN	O	O
by	NN	O	O
the	NN	O	O
magnitude	NN	O	O
of	NN	O	O
injury	NN	O	O
induced	NN	O	O
and	NN	O	O
that	NN	O	O
cTnT	NN	O	O
should	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
marker	NN	O	O
for	NN	O	O
the	NN	O	O
prediction	NN	O	O
of	NN	O	O
experimentally	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B
and	NN	O	O
possibly	NN	O	O
for	NN	O	O
cardioprotective	NN	O	O
experiments	NN	O	O
.	NN	O	O

Octreotide	NN	O	O
-	NN	O	O
induced	NN	O	O
hypoxemia	NN	O	B
and	NN	O	O
pulmonary	NN	O	B
hypertension	NN	O	I
in	NN	O	O
premature	NN	O	O
neonates	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
report	NN	O	O
2	NN	O	O
cases	NN	O	O
of	NN	O	O
premature	NN	O	O
neonates	NN	O	O
who	NN	O	O
had	NN	O	O
enterocutaneous	NN	O	O
fistula	NN	O	B
complicating	NN	O	O
necrotizing	NN	O	B
enterocolitis	NN	O	I
.	NN	O	O

Pulmonary	NN	O	B
hypertension	NN	O	I
developed	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
somatostatin	NN	O	O
analogue	NN	O	O
,	NN	O	O
octreotide	NN	O	O
,	NN	O	O
to	NN	O	O
enhance	NN	O	O
resolution	NN	O	O
of	NN	O	O
the	NN	O	O
fistula	NN	O	B
.	NN	O	O

The	NN	O	O
authors	NN	O	O
discuss	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
this	NN	O	O
complication	NN	O	O
and	NN	O	O
recommend	NN	O	O
caution	NN	O	O
of	NN	O	O
its	NN	O	O
use	NN	O	O
in	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
premature	NN	O	O
neonates	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
in	NN	O	O
women	NN	O	O
prescribed	NN	O	O
cyproterone	NN	O	O
acetate	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
ethinyl	NN	O	O
estradiol	NN	O	O
:	NN	O	O
a	NN	O	O
nested	NN	O	O
cohort	NN	O	O
analysis	NN	O	O
and	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Cyproterone	NN	O	O
acetate	NN	O	O
combined	NN	O	O
with	NN	O	O
ethinyl	NN	O	O
estradiol	NN	O	O
(	NN	O	O
CPA	NN	O	O
/	NN	O	O
EE	NN	O	O
)	NN	O	O
is	NN	O	O
licensed	NN	O	O
in	NN	O	O
the	NN	O	O
UK	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
women	NN	O	O
with	NN	O	O
acne	NN	O	B
and	NN	O	O
hirsutism	NN	O	B
and	NN	O	O
is	NN	O	O
also	NN	O	O
a	NN	O	O
treatment	NN	O	O
option	NN	O	O
for	NN	O	O
polycystic	NN	O	B
ovary	NN	O	I
syndrome	NN	O	I
(	NN	O	O
PCOS	NN	O	B
)	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
(	NN	O	O
VTE	NN	O	B
)	NN	O	O
associated	NN	O	O
with	NN	O	O
CPA	NN	O	O
/	NN	O	O
EE	NN	O	O
compared	NN	O	O
with	NN	O	O
conventional	NN	O	O
combined	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
(	NN	O	O
COCs	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
believe	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
those	NN	O	O
studies	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
affected	NN	O	O
by	NN	O	O
residual	NN	O	O
confounding	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Using	NN	O	O
the	NN	O	O
General	NN	O	O
Practice	NN	O	O
Research	NN	O	O
Database	NN	O	O
we	NN	O	O
conducted	NN	O	O
a	NN	O	O
cohort	NN	O	O
analysis	NN	O	O
and	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
nested	NN	O	O
within	NN	O	O
a	NN	O	O
population	NN	O	O
of	NN	O	O
women	NN	O	O
aged	NN	O	O
between	NN	O	O
15	NN	O	O
and	NN	O	O
39	NN	O	O
years	NN	O	O
with	NN	O	O
acne	NN	O	B
,	NN	O	O
hirsutism	NN	O	B
or	NN	O	O
PCOS	NN	O	B
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
VTE	NN	O	B
associated	NN	O	O
with	NN	O	O
CPA	NN	O	O
/	NN	O	O
EE	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
age	NN	O	O
-	NN	O	O
adjusted	NN	O	O
incidence	NN	O	O
rate	NN	O	O
ratio	NN	O	O
for	NN	O	O
CPA	NN	O	O
/	NN	O	O
EE	NN	O	O
versus	NN	O	O
conventional	NN	O	O
COCs	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O
20	NN	O	O
[	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	NN	O	O
CI	NN	O	O
)	NN	O	O
1	NN	O	O
.	NN	O	O
35	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
58	NN	O	O
]	NN	O	O
.	NN	O	O

Using	NN	O	O
as	NN	O	O
the	NN	O	O
reference	NN	O	O
group	NN	O	O
women	NN	O	O
who	NN	O	O
were	NN	O	O
not	NN	O	O
using	NN	O	O
oral	NN	O	O
contraception	NN	O	O
,	NN	O	O
had	NN	O	O
no	NN	O	O
recent	NN	O	O
pregnancy	NN	O	O
or	NN	O	O
menopausal	NN	O	O
symptoms	NN	O	O
,	NN	O	O
the	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
analysis	NN	O	O
gave	NN	O	O
an	NN	O	O
adjusted	NN	O	O
odds	NN	O	O
ratio	NN	O	O
(	NN	O	O
OR	NN	O	O
(	NN	O	O
adj	NN	O	O
)	NN	O	O
)	NN	O	O
of	NN	O	O
7	NN	O	O
.	NN	O	O
44	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
3	NN	O	O
.	NN	O	O
67	NN	O	O
-	NN	O	O
15	NN	O	O
.	NN	O	O
08	NN	O	O
)	NN	O	O
for	NN	O	O
CPA	NN	O	O
/	NN	O	O
EE	NN	O	O
use	NN	O	O
compared	NN	O	O
with	NN	O	O
an	NN	O	O
OR	NN	O	O
(	NN	O	O
adj	NN	O	O
)	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
58	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
1	NN	O	O
.	NN	O	O
60	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
18	NN	O	O
)	NN	O	O
for	NN	O	O
use	NN	O	O
of	NN	O	O
conventional	NN	O	O
COCs	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
We	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
VTE	NN	O	B
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
CPA	NN	O	O
/	NN	O	O
EE	NN	O	O
in	NN	O	O
women	NN	O	O
with	NN	O	O
acne	NN	O	B
,	NN	O	O
hirsutism	NN	O	B
or	NN	O	O
PCOS	NN	O	B
although	NN	O	O
residual	NN	O	O
confounding	NN	O	O
by	NN	O	O
indication	NN	O	O
cannot	NN	O	O
be	NN	O	O
excluded	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
gum	NN	O	O
Arabic	NN	O	O
on	NN	O	O
gentamicin	NN	O	O
nephrotoxicity	NN	O	B
in	NN	O	O
rats	NN	O	O
:	NN	O	O
a	NN	O	O
preliminary	NN	O	O
study	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
work	NN	O	O
we	NN	O	O
assessed	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
treatment	NN	O	O
of	NN	O	O
rats	NN	O	O
with	NN	O	O
gum	NN	O	O
Arabic	NN	O	O
on	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
induced	NN	O	O
by	NN	O	O
gentamicin	NN	O	O
(	NN	O	O
GM	NN	O	O
)	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
vehicle	NN	O	O
(	NN	O	O
2	NN	O	O
mL	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
distilled	NN	O	O
water	NN	O	O
and	NN	O	O
5	NN	O	O
%	NN	O	O
w	NN	O	O
/	NN	O	O
v	NN	O	O
cellulose	NN	O	O
,	NN	O	O
10	NN	O	O
days	NN	O	O
)	NN	O	O
,	NN	O	O
gum	NN	O	O
Arabic	NN	O	O
(	NN	O	O
2	NN	O	O
mL	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
a	NN	O	O
10	NN	O	O
%	NN	O	O
w	NN	O	O
/	NN	O	O
v	NN	O	O
aqueous	NN	O	O
suspension	NN	O	O
of	NN	O	O
gum	NN	O	O
Arabic	NN	O	O
powder	NN	O	O
,	NN	O	O
orally	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
gum	NN	O	O
Arabic	NN	O	O
concomitantly	NN	O	O
with	NN	O	O
GM	NN	O	O
(	NN	O	O
80mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
intramuscularly	NN	O	O
,	NN	O	O
during	NN	O	O
the	NN	O	O
last	NN	O	O
six	NN	O	O
days	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
period	NN	O	O
)	NN	O	O
.	NN	O	O

Nephrotoxicity	NN	O	B
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
measuring	NN	O	O
the	NN	O	O
concentrations	NN	O	O
of	NN	O	O
creatinine	NN	O	O
and	NN	O	O
urea	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
and	NN	O	O
reduced	NN	O	O
glutathione	NN	O	O
(	NN	O	O
GSH	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
kidney	NN	O	O
cortex	NN	O	O
,	NN	O	O
and	NN	O	O
by	NN	O	O
light	NN	O	O
microscopic	NN	O	O
examination	NN	O	O
of	NN	O	O
kidney	NN	O	O
sections	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicated	NN	O	O
that	NN	O	O
concomitant	NN	O	O
treatment	NN	O	O
with	NN	O	O
gum	NN	O	O
Arabic	NN	O	O
and	NN	O	O
GM	NN	O	O
significantly	NN	O	O
increased	NN	O	O
creatinine	NN	O	O
and	NN	O	O
urea	NN	O	O
by	NN	O	O
about	NN	O	O
183	NN	O	O
and	NN	O	O
239	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
compared	NN	O	O
to	NN	O	O
432	NN	O	O
and	NN	O	O
346	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
cellulose	NN	O	O
and	NN	O	O
GM	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
decreased	NN	O	O
that	NN	O	O
of	NN	O	O
cortical	NN	O	O
GSH	NN	O	O
by	NN	O	O
21	NN	O	O
%	NN	O	O
(	NN	O	O
compared	NN	O	O
to	NN	O	O
27	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
cellulose	NN	O	O
plus	NN	O	O
GM	NN	O	O
group	NN	O	O
)	NN	O	O
The	NN	O	O
GM	NN	O	O
-	NN	O	O
induced	NN	O	O
proximal	NN	O	O
tubular	NN	O	B
necrosis	NN	O	I
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
slightly	NN	O	O
less	NN	O	O
severe	NN	O	O
in	NN	O	O
rats	NN	O	O
given	NN	O	O
GM	NN	O	O
together	NN	O	O
with	NN	O	O
gum	NN	O	O
Arabic	NN	O	O
than	NN	O	O
in	NN	O	O
those	NN	O	O
given	NN	O	O
GM	NN	O	O
and	NN	O	O
cellulose	NN	O	O
.	NN	O	O

It	NN	O	O
could	NN	O	O
be	NN	O	O
inferred	NN	O	O
that	NN	O	O
gum	NN	O	O
Arabic	NN	O	O
treatment	NN	O	O
has	NN	O	O
induced	NN	O	O
a	NN	O	O
modest	NN	O	O
amelioration	NN	O	O
of	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
histological	NN	O	O
and	NN	O	O
biochemical	NN	O	O
indices	NN	O	O
of	NN	O	O
GM	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

Further	NN	O	O
work	NN	O	O
is	NN	O	O
warranted	NN	O	O
on	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
treatments	NN	O	O
on	NN	O	O
renal	NN	O	O
functional	NN	O	O
aspects	NN	O	O
in	NN	O	O
models	NN	O	O
of	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
,	NN	O	O
and	NN	O	O
on	NN	O	O
the	NN	O	O
mechanism	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
involved	NN	O	O
.	NN	O	O

Increased	NN	O	O
frequency	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
with	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
docetaxel	NN	O	O
and	NN	O	O
thalidomide	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
metastatic	NN	O	O
androgen	NN	O	O
-	NN	O	O
independent	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
.	NN	O	O

STUDY	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
(	NN	O	O
VTE	NN	O	B
)	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
androgen	NN	O	O
-	NN	O	O
independent	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
who	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
docetaxel	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
thalidomide	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Retrospective	NN	O	O
analysis	NN	O	O
of	NN	O	O
a	NN	O	O
randomized	NN	O	O
phase	NN	O	O
II	NN	O	O
trial	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
National	NN	O	O
Institutes	NN	O	O
of	NN	O	O
Health	NN	O	O
clinical	NN	O	O
research	NN	O	O
center	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
Seventy	NN	O	O
men	NN	O	O
,	NN	O	O
aged	NN	O	O
50	NN	O	O
-	NN	O	O
80	NN	O	O
years	NN	O	O
,	NN	O	O
with	NN	O	O
advanced	NN	O	O
androgen	NN	O	O
-	NN	O	O
independent	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
.	NN	O	O

INTERVENTION	NN	O	O
:	NN	O	O
Each	NN	O	O
patient	NN	O	O
received	NN	O	O
either	NN	O	O
intravenous	NN	O	O
docetaxel	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
week	NN	O	O
for	NN	O	O
3	NN	O	O
consecutive	NN	O	O
weeks	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
1	NN	O	O
week	NN	O	O
off	NN	O	O
,	NN	O	O
or	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
continuous	NN	O	O
oral	NN	O	O
thalidomide	NN	O	O
200	NN	O	O
mg	NN	O	O
every	NN	O	O
evening	NN	O	O
plus	NN	O	O
the	NN	O	O
same	NN	O	O
docetaxel	NN	O	O
regimen	NN	O	O
.	NN	O	O

This	NN	O	O
4	NN	O	O
-	NN	O	O
week	NN	O	O
cycle	NN	O	O
was	NN	O	O
repeated	NN	O	O
until	NN	O	O
there	NN	O	O
was	NN	O	O
evidence	NN	O	O
of	NN	O	O
excessive	NN	O	O
toxicity	NN	O	B
or	NN	O	O
disease	NN	O	O
progression	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
AND	NN	O	O
MAIN	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
None	NN	O	O
of	NN	O	O
23	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
docetaxel	NN	O	O
alone	NN	O	O
developed	NN	O	O
VTE	NN	O	B
,	NN	O	O
whereas	NN	O	O
9	NN	O	O
of	NN	O	O
47	NN	O	O
patients	NN	O	O
(	NN	O	O
19	NN	O	O
%	NN	O	O
)	NN	O	O
who	NN	O	O
received	NN	O	O
docetaxel	NN	O	O
plus	NN	O	O
thalidomide	NN	O	O
developed	NN	O	O
VTE	NN	O	B
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
025	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
addition	NN	O	O
of	NN	O	O
thalidomide	NN	O	O
to	NN	O	O
docetaxel	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
significantly	NN	O	O
increases	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
VTE	NN	O	B
.	NN	O	O

Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
potential	NN	O	O
complication	NN	O	O
when	NN	O	O
adding	NN	O	O
thalidomide	NN	O	O
to	NN	O	O
chemotherapeutic	NN	O	O
regimens	NN	O	O
.	NN	O	O

Ticlopidine	NN	O	O
-	NN	O	O
induced	NN	O	O
cholestatic	NN	O	B
hepatitis	NN	O	I
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
2	NN	O	O
cases	NN	O	O
of	NN	O	O
ticlopidine	NN	O	O
-	NN	O	O
induced	NN	O	O
cholestatic	NN	O	B
hepatitis	NN	O	I
,	NN	O	O
investigate	NN	O	O
its	NN	O	O
mechanism	NN	O	O
,	NN	O	O
and	NN	O	O
compare	NN	O	O
the	NN	O	O
observed	NN	O	O
main	NN	O	O
characteristics	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
published	NN	O	O
cases	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARIES	NN	O	O
:	NN	O	O
Two	NN	O	O
patients	NN	O	O
developed	NN	O	O
prolonged	NN	O	O
cholestatic	NN	O	B
hepatitis	NN	O	I
after	NN	O	O
receiving	NN	O	O
ticlopidine	NN	O	O
following	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
angioplasty	NN	O	O
,	NN	O	O
with	NN	O	O
complete	NN	O	O
remission	NN	O	O
during	NN	O	O
the	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
.	NN	O	O

T	NN	O	O
-	NN	O	O
cell	NN	O	O
stimulation	NN	O	O
by	NN	O	O
therapeutic	NN	O	O
concentration	NN	O	O
of	NN	O	O
ticlopidine	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
vitro	NN	O	O
in	NN	O	O
the	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
healthy	NN	O	O
controls	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Cholestatic	NN	O	B
hepatitis	NN	O	I
is	NN	O	O
a	NN	O	O
rare	NN	O	O
complication	NN	O	O
of	NN	O	O
the	NN	O	O
antiplatelet	NN	O	O
agent	NN	O	O
ticlopidine	NN	O	O
;	NN	O	O
several	NN	O	O
cases	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
but	NN	O	O
few	NN	O	O
in	NN	O	O
the	NN	O	O
English	NN	O	O
literature	NN	O	O
.	NN	O	O

Our	NN	O	O
patients	NN	O	O
developed	NN	O	O
jaundice	NN	O	B
following	NN	O	O
treatment	NN	O	O
with	NN	O	O
ticlopidine	NN	O	O
and	NN	O	O
showed	NN	O	O
the	NN	O	O
clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
characteristics	NN	O	O
of	NN	O	O
cholestatic	NN	O	B
hepatitis	NN	O	I
,	NN	O	O
which	NN	O	O
resolved	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Hepatitis	NN	O	B
may	NN	O	O
develop	NN	O	O
weeks	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
and	NN	O	O
may	NN	O	O
run	NN	O	O
a	NN	O	O
prolonged	NN	O	O
course	NN	O	O
,	NN	O	O
but	NN	O	O
complete	NN	O	O
remission	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
all	NN	O	O
reported	NN	O	O
cases	NN	O	O
.	NN	O	O

An	NN	O	O
objective	NN	O	O
causality	NN	O	O
assessment	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
adverse	NN	O	O
drug	NN	O	O
event	NN	O	O
was	NN	O	O
probably	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
ticlopidine	NN	O	O
.	NN	O	O

The	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
this	NN	O	O
ticlopidine	NN	O	O
-	NN	O	O
induced	NN	O	O
cholestasis	NN	O	B
are	NN	O	O
unclear	NN	O	O
.	NN	O	O

Immune	NN	O	O
mechanisms	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
drug	NN	O	O
'	NN	O	O
s	NN	O	O
hepatotoxicity	NN	O	B
,	NN	O	O
as	NN	O	O
suggested	NN	O	O
by	NN	O	O
the	NN	O	O
T	NN	O	O
-	NN	O	O
cell	NN	O	O
stimulation	NN	O	O
study	NN	O	O
reported	NN	O	O
here	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Cholestatic	NN	O	B
hepatitis	NN	O	I
is	NN	O	O
a	NN	O	O
rare	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
ticlopidine	NN	O	O
that	NN	O	O
may	NN	O	O
be	NN	O	O
immune	NN	O	O
mediated	NN	O	O
.	NN	O	O

Patients	NN	O	O
receiving	NN	O	O
the	NN	O	O
drug	NN	O	O
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
with	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
along	NN	O	O
with	NN	O	O
complete	NN	O	O
blood	NN	O	O
cell	NN	O	O
counts	NN	O	O
.	NN	O	O

This	NN	O	O
complication	NN	O	O
will	NN	O	O
be	NN	O	O
observed	NN	O	O
even	NN	O	O
less	NN	O	O
often	NN	O	O
in	NN	O	O
the	NN	O	O
future	NN	O	O
as	NN	O	O
ticlopidine	NN	O	O
is	NN	O	O
being	NN	O	O
replaced	NN	O	O
by	NN	O	O
the	NN	O	O
newer	NN	O	O
antiplatelet	NN	O	O
agent	NN	O	O
clopidogrel	NN	O	O
.	NN	O	O

Epithelial	NN	O	O
sodium	NN	O	O
channel	NN	O	O
(	NN	O	O
ENaC	NN	O	O
)	NN	O	O
subunit	NN	O	O
mRNA	NN	O	O
and	NN	O	O
protein	NN	O	O
expression	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
.	NN	O	O

In	NN	O	O
experimental	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
,	NN	O	O
urinary	NN	O	O
sodium	NN	O	O
excretion	NN	O	O
is	NN	O	O
decreased	NN	O	O
during	NN	O	O
the	NN	O	O
early	NN	O	O
phase	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
.	NN	O	O

The	NN	O	O
molecular	NN	O	O
mechanism	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
leading	NN	O	O
to	NN	O	O
salt	NN	O	O
retention	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
completely	NN	O	O
elucidated	NN	O	O
.	NN	O	O

The	NN	O	O
rate	NN	O	O
-	NN	O	O
limiting	NN	O	O
constituent	NN	O	O
of	NN	O	O
collecting	NN	O	O
duct	NN	O	O
sodium	NN	O	O
transport	NN	O	O
is	NN	O	O
the	NN	O	O
epithelial	NN	O	O
sodium	NN	O	O
channel	NN	O	O
(	NN	O	O
ENaC	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
examined	NN	O	O
the	NN	O	O
abundance	NN	O	O
of	NN	O	O
ENaC	NN	O	O
subunit	NN	O	O
mRNAs	NN	O	O
and	NN	O	O
proteins	NN	O	O
in	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
(	NN	O	O
PAN	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
.	NN	O	O

The	NN	O	O
time	NN	O	O
courses	NN	O	O
of	NN	O	O
urinary	NN	O	O
sodium	NN	O	O
excretion	NN	O	O
,	NN	O	O
plasma	NN	O	O
aldosterone	NN	O	O
concentration	NN	O	O
and	NN	O	O
proteinuria	NN	O	B
were	NN	O	O
studied	NN	O	O
in	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
either	NN	O	O
PAN	NN	O	O
or	NN	O	O
vehicle	NN	O	O
.	NN	O	O

The	NN	O	O
relative	NN	O	O
amounts	NN	O	O
of	NN	O	O
alphaENaC	NN	O	O
,	NN	O	O
betaENaC	NN	O	O
and	NN	O	O
gammaENaC	NN	O	O
mRNAs	NN	O	O
were	NN	O	O
determined	NN	O	O
in	NN	O	O
kidneys	NN	O	O
from	NN	O	O
these	NN	O	O
rats	NN	O	O
by	NN	O	O
real	NN	O	O
-	NN	O	O
time	NN	O	O
quantitative	NN	O	O
TaqMan	NN	O	O
PCR	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
amounts	NN	O	O
of	NN	O	O
proteins	NN	O	O
by	NN	O	O
Western	NN	O	O
blot	NN	O	O
.	NN	O	O

The	NN	O	O
kinetics	NN	O	O
of	NN	O	O
urinary	NN	O	O
sodium	NN	O	O
excretion	NN	O	O
and	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
were	NN	O	O
comparable	NN	O	O
with	NN	O	O
those	NN	O	O
reported	NN	O	O
previously	NN	O	O
.	NN	O	O

Sodium	NN	O	O
retention	NN	O	O
occurred	NN	O	O
on	NN	O	O
days	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
and	NN	O	O
6	NN	O	O
after	NN	O	O
PAN	NN	O	O
injection	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
alphaENaC	NN	O	O
and	NN	O	O
betaENaC	NN	O	O
mRNA	NN	O	O
abundance	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
preceded	NN	O	O
sodium	NN	O	O
retention	NN	O	O
on	NN	O	O
days	NN	O	O
2	NN	O	O
and	NN	O	O
3	NN	O	O
.	NN	O	O

Conversely	NN	O	O
,	NN	O	O
down	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
alphaENaC	NN	O	O
,	NN	O	O
betaENaC	NN	O	O
and	NN	O	O
gammaENaC	NN	O	O
mRNA	NN	O	O
expression	NN	O	O
on	NN	O	O
day	NN	O	O
3	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
high	NN	O	O
aldosterone	NN	O	O
concentrations	NN	O	O
,	NN	O	O
and	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
return	NN	O	O
of	NN	O	O
sodium	NN	O	O
excretion	NN	O	O
to	NN	O	O
control	NN	O	O
values	NN	O	O
.	NN	O	O

The	NN	O	O
amounts	NN	O	O
of	NN	O	O
alphaENaC	NN	O	O
,	NN	O	O
betaENaC	NN	O	O
and	NN	O	O
gammaENaC	NN	O	O
proteins	NN	O	O
were	NN	O	O
not	NN	O	O
increased	NN	O	O
during	NN	O	O
PAN	NN	O	O
-	NN	O	O
induced	NN	O	O
sodium	NN	O	O
retention	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
ENaC	NN	O	O
mRNA	NN	O	O
expression	NN	O	O
,	NN	O	O
especially	NN	O	O
alphaENaC	NN	O	O
,	NN	O	O
is	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
very	NN	O	O
early	NN	O	O
phase	NN	O	O
of	NN	O	O
the	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
PAN	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
in	NN	O	O
rats	NN	O	O
,	NN	O	O
but	NN	O	O
appears	NN	O	O
to	NN	O	O
escape	NN	O	O
from	NN	O	O
the	NN	O	O
regulation	NN	O	O
by	NN	O	O
aldosterone	NN	O	O
after	NN	O	O
day	NN	O	O
3	NN	O	O
.	NN	O	O

Sub	NN	O	O
-	NN	O	O
chronic	NN	O	O
low	NN	O	O
dose	NN	O	O
gamma	NN	O	O
-	NN	O	O
vinyl	NN	O	O
GABA	NN	O	O
(	NN	O	O
vigabatrin	NN	O	O
)	NN	O	O
inhibits	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
increases	NN	O	O
in	NN	O	O
nucleus	NN	O	O
accumbens	NN	O	O
dopamine	NN	O	O
.	NN	O	O

RATIONALE	NN	O	O
:	NN	O	O
gamma	NN	O	O
-	NN	O	O
Vinyl	NN	O	O
GABA	NN	O	O
(	NN	O	O
GVG	NN	O	O
)	NN	O	O
irreversibly	NN	O	O
inhibits	NN	O	O
GABA	NN	O	O
-	NN	O	O
transaminase	NN	O	O
.	NN	O	O

This	NN	O	O
non	NN	O	O
-	NN	O	O
receptor	NN	O	O
mediated	NN	O	O
inhibition	NN	O	O
requires	NN	O	O
de	NN	O	O
novo	NN	O	O
synthesis	NN	O	O
for	NN	O	O
restoration	NN	O	O
of	NN	O	O
functional	NN	O	O
GABA	NN	O	O
catabolism	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
Given	NN	O	O
its	NN	O	O
preclinical	NN	O	O
success	NN	O	O
for	NN	O	O
treating	NN	O	O
substance	NN	O	B
abuse	NN	O	I
and	NN	O	O
the	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
visual	NN	O	B
field	NN	O	I
defects	NN	O	I
(	NN	O	O
VFD	NN	O	B
)	NN	O	O
associated	NN	O	O
with	NN	O	O
cumulative	NN	O	O
lifetime	NN	O	O
exposure	NN	O	O
,	NN	O	O
we	NN	O	O
explored	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
sub	NN	O	O
-	NN	O	O
chronic	NN	O	O
low	NN	O	O
dose	NN	O	O
GVG	NN	O	O
on	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
increases	NN	O	O
in	NN	O	O
nucleus	NN	O	O
accumbens	NN	O	O
(	NN	O	O
NAcc	NN	O	O
)	NN	O	O
dopamine	NN	O	O
(	NN	O	O
DA	NN	O	O
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Using	NN	O	O
in	NN	O	O
vivo	NN	O	O
microdialysis	NN	O	O
,	NN	O	O
we	NN	O	O
compared	NN	O	O
acute	NN	O	O
exposure	NN	O	O
(	NN	O	O
450	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
to	NN	O	O
an	NN	O	O
identical	NN	O	O
sub	NN	O	O
-	NN	O	O
chronic	NN	O	O
exposure	NN	O	O
(	NN	O	O
150	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
)	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
1	NN	O	O
-	NN	O	O
or	NN	O	O
3	NN	O	O
-	NN	O	O
day	NN	O	O
washout	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
we	NN	O	O
examined	NN	O	O
the	NN	O	O
low	NN	O	O
dose	NN	O	O
of	NN	O	O
150	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
)	NN	O	O
using	NN	O	O
a	NN	O	O
similar	NN	O	O
washout	NN	O	O
period	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Sub	NN	O	O
-	NN	O	O
chronic	NN	O	O
GVG	NN	O	O
exposure	NN	O	O
inhibited	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
cocaine	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
,	NN	O	O
which	NN	O	O
exceeded	NN	O	O
in	NN	O	O
magnitude	NN	O	O
and	NN	O	O
duration	NN	O	O
the	NN	O	O
identical	NN	O	O
acute	NN	O	O
dose	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Sub	NN	O	O
-	NN	O	O
chronic	NN	O	O
low	NN	O	O
dose	NN	O	O
GVG	NN	O	O
potentiates	NN	O	O
and	NN	O	O
extends	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
increases	NN	O	O
in	NN	O	O
dopamine	NN	O	O
,	NN	O	O
effectively	NN	O	O
reducing	NN	O	O
cumulative	NN	O	O
exposures	NN	O	O
and	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
VFDS	NN	O	O
.	NN	O	O

MR	NN	O	O
imaging	NN	O	O
with	NN	O	O
quantitative	NN	O	O
diffusion	NN	O	O
mapping	NN	O	O
of	NN	O	O
tacrolimus	NN	O	O
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B
in	NN	O	O
organ	NN	O	O
transplant	NN	O	O
patients	NN	O	O
.	NN	O	O

Our	NN	O	O
objective	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
brain	NN	O	O
MR	NN	O	O
imaging	NN	O	O
findings	NN	O	O
and	NN	O	O
the	NN	O	O
utility	NN	O	O
of	NN	O	O
diffusion	NN	O	O
-	NN	O	O
weighted	NN	O	O
(	NN	O	O
DW	NN	O	O
)	NN	O	O
imaging	NN	O	O
in	NN	O	O
organ	NN	O	O
transplant	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
neurologic	NN	O	O
symptoms	NN	O	O
during	NN	O	O
tacrolimus	NN	O	O
therapy	NN	O	O
.	NN	O	O

Brain	NN	O	O
MR	NN	O	O
studies	NN	O	O
,	NN	O	O
including	NN	O	O
DW	NN	O	O
imaging	NN	O	O
,	NN	O	O
were	NN	O	O
prospectively	NN	O	O
performed	NN	O	O
in	NN	O	O
14	NN	O	O
organ	NN	O	O
transplant	NN	O	O
patients	NN	O	O
receiving	NN	O	O
tacrolimus	NN	O	O
who	NN	O	O
developed	NN	O	O
neurologic	NN	O	B
complications	NN	O	I
.	NN	O	O

In	NN	O	O
each	NN	O	O
patient	NN	O	O
who	NN	O	O
had	NN	O	O
abnormalities	NN	O	O
on	NN	O	O
the	NN	O	O
initial	NN	O	O
MR	NN	O	O
study	NN	O	O
,	NN	O	O
a	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
MR	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
1	NN	O	O
month	NN	O	O
later	NN	O	O
.	NN	O	O

Apparent	NN	O	O
diffusion	NN	O	O
coefficient	NN	O	O
(	NN	O	O
ADC	NN	O	O
)	NN	O	O
values	NN	O	O
on	NN	O	O
the	NN	O	O
initial	NN	O	O
MR	NN	O	O
study	NN	O	O
were	NN	O	O
correlated	NN	O	O
with	NN	O	O
reversibility	NN	O	O
of	NN	O	O
the	NN	O	O
lesions	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
14	NN	O	O
patients	NN	O	O
,	NN	O	O
5	NN	O	O
(	NN	O	O
35	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
white	NN	O	B
matter	NN	O	I
abnormalities	NN	O	I
,	NN	O	O
1	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
putaminal	NN	O	B
hemorrhage	NN	O	I
,	NN	O	O
and	NN	O	O
8	NN	O	O
(	NN	O	O
57	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
normal	NN	O	O
findings	NN	O	O
on	NN	O	O
initial	NN	O	O
MR	NN	O	O
images	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
5	NN	O	O
patients	NN	O	O
with	NN	O	O
white	NN	O	B
matter	NN	O	I
abnormalities	NN	O	I
,	NN	O	O
4	NN	O	O
patients	NN	O	O
(	NN	O	O
80	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
)	NN	O	O
showed	NN	O	O
higher	NN	O	O
than	NN	O	O
normal	NN	O	O
ADC	NN	O	O
values	NN	O	O
on	NN	O	O
initial	NN	O	O
MR	NN	O	O
images	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
showed	NN	O	O
complete	NN	O	O
resolution	NN	O	O
on	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
images	NN	O	O
.	NN	O	O

The	NN	O	O
remaining	NN	O	O
1	NN	O	O
patient	NN	O	O
(	NN	O	O
20	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
)	NN	O	O
showed	NN	O	O
lower	NN	O	O
than	NN	O	O
normal	NN	O	O
ADC	NN	O	O
value	NN	O	O
and	NN	O	O
showed	NN	O	O
incomplete	NN	O	O
resolution	NN	O	O
with	NN	O	O
cortical	NN	O	B
laminar	NN	O	I
necrosis	NN	O	I
.	NN	O	O

Diffusion	NN	O	O
-	NN	O	O
weighted	NN	O	O
imaging	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
in	NN	O	O
predicting	NN	O	O
the	NN	O	O
outcomes	NN	O	O
of	NN	O	O
the	NN	O	O
lesions	NN	O	O
of	NN	O	O
tacrolimus	NN	O	O
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

L	NN	O	O
-	NN	O	O
arginine	NN	O	O
transport	NN	O	O
in	NN	O	O
humans	NN	O	O
with	NN	O	O
cortisol	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
.	NN	O	O

A	NN	O	O
deficient	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
-	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
system	NN	O	O
is	NN	O	O
implicated	NN	O	O
in	NN	O	O
cortisol	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
.	NN	O	O

We	NN	O	O
investigate	NN	O	O
whether	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
uptake	NN	O	O
contribute	NN	O	O
to	NN	O	O
this	NN	O	O
deficiency	NN	O	O
.	NN	O	O

Eight	NN	O	O
healthy	NN	O	O
men	NN	O	O
were	NN	O	O
recruited	NN	O	O
.	NN	O	O

Hydrocortisone	NN	O	O
acetate	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
)	NN	O	O
was	NN	O	O
given	NN	O	O
orally	NN	O	O
every	NN	O	O
6	NN	O	O
hours	NN	O	O
for	NN	O	O
24	NN	O	O
hours	NN	O	O
after	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
day	NN	O	O
fixed	NN	O	O
-	NN	O	O
salt	NN	O	O
diet	NN	O	O
(	NN	O	O
150	NN	O	O
mmol	NN	O	O
/	NN	O	O
d	NN	O	O
)	NN	O	O
.	NN	O	O

Crossover	NN	O	O
studies	NN	O	O
were	NN	O	O
performed	NN	O	O
2	NN	O	O
weeks	NN	O	O
apart	NN	O	O
.	NN	O	O

Thirty	NN	O	O
milliliters	NN	O	O
of	NN	O	O
blood	NN	O	O
was	NN	O	O
obtained	NN	O	O
for	NN	O	O
isolation	NN	O	O
of	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
mononuclear	NN	O	O
cells	NN	O	O
after	NN	O	O
each	NN	O	O
treatment	NN	O	O
period	NN	O	O
.	NN	O	O

L	NN	O	O
-	NN	O	O
arginine	NN	O	O
uptake	NN	O	O
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
mononuclear	NN	O	O
cells	NN	O	O
incubated	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
(	NN	O	O
1	NN	O	O
to	NN	O	O
300	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
,	NN	O	O
incorporating	NN	O	O
100	NN	O	O
nmol	NN	O	O
/	NN	O	O
L	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
-	NN	O	O
l	NN	O	O
-	NN	O	O
arginine	NN	O	O
for	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
5	NN	O	O
minutes	NN	O	O
at	NN	O	O
37	NN	O	O
degrees	NN	O	O
C	NN	O	O
.	NN	O	O

Forearm	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
-	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
extraction	NN	O	O
was	NN	O	O
calculated	NN	O	O
after	NN	O	O
infusion	NN	O	O
of	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
-	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
into	NN	O	O
the	NN	O	O
brachial	NN	O	O
artery	NN	O	O
at	NN	O	O
a	NN	O	O
rate	NN	O	O
of	NN	O	O
100	NN	O	O
nCi	NN	O	O
/	NN	O	O
min	NN	O	O
for	NN	O	O
80	NN	O	O
minutes	NN	O	O
.	NN	O	O

Deep	NN	O	O
forearm	NN	O	O
venous	NN	O	O
samples	NN	O	O
were	NN	O	O
collected	NN	O	O
for	NN	O	O
determination	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
extraction	NN	O	O
.	NN	O	O

Plasma	NN	O	O
cortisol	NN	O	O
concentrations	NN	O	O
were	NN	O	O
significantly	NN	O	O
raised	NN	O	O
during	NN	O	O
the	NN	O	O
active	NN	O	O
phase	NN	O	O
(	NN	O	O
323	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
43	NN	O	O
to	NN	O	O
1082	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
245	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
elevated	NN	O	O
by	NN	O	O
an	NN	O	O
average	NN	O	O
of	NN	O	O
7	NN	O	O
mm	NN	O	O
Hg	NN	O	O
.	NN	O	O

Neither	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
transport	NN	O	O
into	NN	O	O
mononuclear	NN	O	O
cells	NN	O	O
(	NN	O	O
placebo	NN	O	O
vs	NN	O	O
active	NN	O	O
,	NN	O	O
26	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
vs	NN	O	O
29	NN	O	O
.	NN	O	O
0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
pmol	NN	O	O
/	NN	O	O
10	NN	O	O
000	NN	O	O
cells	NN	O	O
per	NN	O	O
5	NN	O	O
minutes	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
at	NN	O	O
an	NN	O	O
l	NN	O	O
-	NN	O	O
arginine	NN	O	O
concentration	NN	O	O
of	NN	O	O
300	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
nor	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
extraction	NN	O	O
in	NN	O	O
the	NN	O	O
forearm	NN	O	O
(	NN	O	O
at	NN	O	O
80	NN	O	O
minutes	NN	O	O
,	NN	O	O
placebo	NN	O	O
vs	NN	O	O
active	NN	O	O
,	NN	O	O
1	NN	O	O
868	NN	O	O
904	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
434	NN	O	O
962	NN	O	O
vs	NN	O	O
2	NN	O	O
013	NN	O	O
910	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
770	NN	O	O
619	NN	O	O
disintegrations	NN	O	O
per	NN	O	O
minute	NN	O	O
)	NN	O	O
was	NN	O	O
affected	NN	O	O
by	NN	O	O
cortisol	NN	O	O
treatment	NN	O	O
;	NN	O	O
ie	NN	O	O
,	NN	O	O
that	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
uptake	NN	O	O
is	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
cortisol	NN	O	O
treatment	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
cortisol	NN	O	O
-	NN	O	O
induced	NN	O	O
increases	NN	O	B
in	NN	O	I
blood	NN	O	I
pressure	NN	O	I
are	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
the	NN	O	O
l	NN	O	O
-	NN	O	O
arginine	NN	O	O
transport	NN	O	O
system	NN	O	O
.	NN	O	O

Amount	NN	O	O
of	NN	O	O
bleeding	NN	O	B
and	NN	O	O
hematoma	NN	O	B
size	NN	O	O
in	NN	O	O
the	NN	O	O
collagenase	NN	O	O
-	NN	O	O
induced	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
rat	NN	O	O
model	NN	O	O
.	NN	O	O

The	NN	O	O
aggravated	NN	O	O
risk	NN	O	O
on	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
(	NN	O	O
ICH	NN	O	B
)	NN	O	O
with	NN	O	O
drugs	NN	O	O
used	NN	O	O
for	NN	O	O
stroke	NN	O	B
patients	NN	O	O
should	NN	O	O
be	NN	O	O
estimated	NN	O	O
carefully	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
established	NN	O	O
sensitive	NN	O	O
quantification	NN	O	O
methods	NN	O	O
and	NN	O	O
provided	NN	O	O
a	NN	O	O
rat	NN	O	O
ICH	NN	O	B
model	NN	O	O
for	NN	O	O
detection	NN	O	O
of	NN	O	O
ICH	NN	O	B
deterioration	NN	O	O
.	NN	O	O

In	NN	O	O
ICH	NN	O	B
intrastriatally	NN	O	O
induced	NN	O	O
by	NN	O	O
0	NN	O	O
.	NN	O	O
014	NN	O	O
-	NN	O	O
unit	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
070	NN	O	O
-	NN	O	O
unit	NN	O	O
,	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
350	NN	O	O
-	NN	O	O
unit	NN	O	O
collagenase	NN	O	O
,	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
bleeding	NN	O	B
was	NN	O	O
measured	NN	O	O
using	NN	O	O
a	NN	O	O
hemoglobin	NN	O	O
assay	NN	O	O
developed	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
and	NN	O	O
was	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
morphologically	NN	O	O
determined	NN	O	O
hematoma	NN	O	B
volume	NN	O	O
.	NN	O	O

The	NN	O	O
blood	NN	O	O
amounts	NN	O	O
and	NN	O	O
hematoma	NN	O	B
volumes	NN	O	O
were	NN	O	O
significantly	NN	O	O
correlated	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
hematoma	NN	O	B
induced	NN	O	O
by	NN	O	O
0	NN	O	O
.	NN	O	O
014	NN	O	O
-	NN	O	O
unit	NN	O	O
collagenase	NN	O	O
was	NN	O	O
adequate	NN	O	O
to	NN	O	O
detect	NN	O	O
ICH	NN	O	B
deterioration	NN	O	O
.	NN	O	O

In	NN	O	O
ICH	NN	O	B
induction	NN	O	O
using	NN	O	O
0	NN	O	O
.	NN	O	O
014	NN	O	O
-	NN	O	O
unit	NN	O	O
collagenase	NN	O	O
,	NN	O	O
heparin	NN	O	O
enhanced	NN	O	O
the	NN	O	O
hematoma	NN	O	B
volume	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
fold	NN	O	O
over	NN	O	O
that	NN	O	O
seen	NN	O	O
in	NN	O	O
control	NN	O	O
ICH	NN	O	B
animals	NN	O	O
and	NN	O	O
the	NN	O	O
bleeding	NN	O	B
7	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
fold	NN	O	O
.	NN	O	O

Data	NN	O	O
suggest	NN	O	O
that	NN	O	O
this	NN	O	O
sensitive	NN	O	O
hemoglobin	NN	O	O
assay	NN	O	O
is	NN	O	O
useful	NN	O	O
for	NN	O	O
ICH	NN	O	B
detection	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
a	NN	O	O
model	NN	O	O
with	NN	O	O
a	NN	O	O
small	NN	O	O
ICH	NN	O	B
induced	NN	O	O
with	NN	O	O
a	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
collagenase	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
for	NN	O	O
evaluation	NN	O	O
of	NN	O	O
drugs	NN	O	O
that	NN	O	O
may	NN	O	O
affect	NN	O	O
ICH	NN	O	B
.	NN	O	O

Estradiol	NN	O	O
reduces	NN	O	O
seizure	NN	O	B
-	NN	O	O
induced	NN	O	O
hippocampal	NN	O	B
injury	NN	O	I
in	NN	O	O
ovariectomized	NN	O	O
female	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

Estrogens	NN	O	O
protect	NN	O	O
ovariectomized	NN	O	O
rats	NN	O	O
from	NN	O	O
hippocampal	NN	O	B
injury	NN	O	I
induced	NN	O	O
by	NN	O	O
kainic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
(	NN	O	O
SE	NN	O	B
)	NN	O	O
.	NN	O	O

We	NN	O	O
compared	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
17beta	NN	O	O
-	NN	O	O
estradiol	NN	O	O
in	NN	O	O
adult	NN	O	O
male	NN	O	O
and	NN	O	O
ovariectomized	NN	O	O
female	NN	O	O
rats	NN	O	O
subjected	NN	O	O
to	NN	O	O
lithium	NN	O	O
-	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
SE	NN	O	B
.	NN	O	O

Rats	NN	O	O
received	NN	O	O
subcutaneous	NN	O	O
injections	NN	O	O
of	NN	O	O
17beta	NN	O	O
-	NN	O	O
estradiol	NN	O	O
(	NN	O	O
2	NN	O	O
microg	NN	O	O
/	NN	O	O
rat	NN	O	O
)	NN	O	O
or	NN	O	O
oil	NN	O	O
once	NN	O	O
daily	NN	O	O
for	NN	O	O
four	NN	O	O
consecutive	NN	O	O
days	NN	O	O
.	NN	O	O

SE	NN	O	B
was	NN	O	O
induced	NN	O	O
20	NN	O	O
h	NN	O	O
following	NN	O	O
the	NN	O	O
second	NN	O	O
injection	NN	O	O
and	NN	O	O
terminated	NN	O	O
3	NN	O	O
h	NN	O	O
later	NN	O	O
.	NN	O	O

The	NN	O	O
extent	NN	O	O
of	NN	O	O
silver	NN	O	O
-	NN	O	O
stained	NN	O	O
CA3	NN	O	O
and	NN	O	O
CA1	NN	O	O
hippocampal	NN	O	O
neurons	NN	O	O
was	NN	O	O
evaluated	NN	O	O
2	NN	O	O
days	NN	O	O
after	NN	O	O
SE	NN	O	B
.	NN	O	O

17beta	NN	O	O
-	NN	O	O
Estradiol	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
first	NN	O	O
clonus	NN	O	O
in	NN	O	O
ovariectomized	NN	O	O
rats	NN	O	O
but	NN	O	O
accelerated	NN	O	O
it	NN	O	O
in	NN	O	O
males	NN	O	O
.	NN	O	O

17beta	NN	O	O
-	NN	O	O
Estradiol	NN	O	O
reduced	NN	O	O
the	NN	O	O
argyrophilic	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
CA1	NN	O	O
and	NN	O	O
CA3	NN	O	O
-	NN	O	O
C	NN	O	O
sectors	NN	O	O
of	NN	O	O
ovariectomized	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
males	NN	O	O
,	NN	O	O
estradiol	NN	O	O
increased	NN	O	O
the	NN	O	O
total	NN	O	O
damage	NN	O	O
score	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
estradiol	NN	O	O
on	NN	O	O
seizure	NN	O	B
threshold	NN	O	O
and	NN	O	O
damage	NN	O	O
may	NN	O	O
be	NN	O	O
altered	NN	O	O
by	NN	O	O
sex	NN	O	O
-	NN	O	O
related	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
hormonal	NN	O	O
environment	NN	O	O
.	NN	O	O

Pseudoacromegaly	NN	O	B
induced	NN	O	O
by	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
minoxidil	NN	O	O
.	NN	O	O

Acromegaly	NN	O	B
is	NN	O	O
an	NN	O	O
endocrine	NN	O	B
disorder	NN	O	I
caused	NN	O	O
by	NN	O	O
chronic	NN	O	O
excessive	NN	O	O
growth	NN	O	O
hormone	NN	O	O
secretion	NN	O	O
from	NN	O	O
the	NN	O	O
anterior	NN	O	O
pituitary	NN	O	O
gland	NN	O	O
.	NN	O	O

Significant	NN	O	O
disfiguring	NN	O	O
changes	NN	O	O
occur	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
bone	NN	O	O
,	NN	O	O
cartilage	NN	O	O
,	NN	O	O
and	NN	O	O
soft	NN	O	O
tissue	NN	O	O
hypertrophy	NN	O	B
,	NN	O	O
including	NN	O	O
the	NN	O	O
thickening	NN	O	O
of	NN	O	O
the	NN	O	O
skin	NN	O	O
,	NN	O	O
coarsening	NN	O	O
of	NN	O	O
facial	NN	O	O
features	NN	O	O
,	NN	O	O
and	NN	O	O
cutis	NN	O	B
verticis	NN	O	I
gyrata	NN	O	I
.	NN	O	O

Pseudoacromegaly	NN	O	B
,	NN	O	O
on	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
is	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
similar	NN	O	O
acromegaloid	NN	O	O
features	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
elevated	NN	O	O
growth	NN	O	O
hormone	NN	O	O
or	NN	O	O
insulin	NN	O	O
-	NN	O	O
like	NN	O	O
growth	NN	O	O
factor	NN	O	O
levels	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
pseudoacromegaly	NN	O	B
that	NN	O	O
resulted	NN	O	O
from	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
minoxidil	NN	O	O
at	NN	O	O
an	NN	O	O
unusually	NN	O	O
high	NN	O	O
dose	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
report	NN	O	O
of	NN	O	O
pseudoacromegaly	NN	O	B
as	NN	O	O
a	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
minoxidil	NN	O	O
use	NN	O	O
.	NN	O	O

Combined	NN	O	O
androgen	NN	O	O
blockade	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
in	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
patients	NN	O	O
without	NN	O	O
bone	NN	O	O
involvement	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
onset	NN	O	O
and	NN	O	O
extent	NN	O	O
of	NN	O	O
combined	NN	O	O
androgen	NN	O	O
blockade	NN	O	O
(	NN	O	O
CAB	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
in	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
patients	NN	O	O
without	NN	O	O
bone	NN	O	O
involvement	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Forty	NN	O	O
-	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
biopsy	NN	O	O
-	NN	O	O
proven	NN	O	O
prostatic	NN	O	B
adenocarcinoma	NN	O	I
[	NN	O	O
26	NN	O	O
with	NN	O	O
stage	NN	O	O
C	NN	O	O
(	NN	O	O
T3N0M0	NN	O	O
)	NN	O	O
and	NN	O	O
16	NN	O	O
with	NN	O	O
stage	NN	O	O
D1	NN	O	O
(	NN	O	O
T3N1M0	NN	O	O
)	NN	O	O
]	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
received	NN	O	O
CAB	NN	O	O
[	NN	O	O
leuprolide	NN	O	O
acetate	NN	O	O
(	NN	O	O
LHRH	NN	O	O
-	NN	O	O
A	NN	O	O
)	NN	O	O
3	NN	O	O
.	NN	O	O
75	NN	O	O
mg	NN	O	O
,	NN	O	O
intramuscularly	NN	O	O
,	NN	O	O
every	NN	O	O
28	NN	O	O
days	NN	O	O
plus	NN	O	O
250	NN	O	O
mg	NN	O	O
flutamide	NN	O	O
,	NN	O	O
tid	NN	O	O
,	NN	O	O
per	NN	O	O
Os	NN	O	O
]	NN	O	O
and	NN	O	O
were	NN	O	O
evaluated	NN	O	O
for	NN	O	O
anemia	NN	O	B
by	NN	O	O
physical	NN	O	O
examination	NN	O	O
and	NN	O	O
laboratory	NN	O	O
tests	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
4	NN	O	O
subsequent	NN	O	O
intervals	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
and	NN	O	O
6	NN	O	O
months	NN	O	O
post	NN	O	O
-	NN	O	O
CAB	NN	O	O
)	NN	O	O
.	NN	O	O

Hb	NN	O	O
,	NN	O	O
PSA	NN	O	O
and	NN	O	O
Testosterone	NN	O	O
measurements	NN	O	O
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
stage	NN	O	O
D2	NN	O	O
-	NN	O	O
3	NN	O	O
disease	NN	O	O
,	NN	O	O
abnormal	NN	O	O
hemoglobin	NN	O	O
level	NN	O	O
or	NN	O	O
renal	NN	O	O
and	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
that	NN	O	O
were	NN	O	O
higher	NN	O	O
than	NN	O	O
the	NN	O	O
upper	NN	O	O
limits	NN	O	O
were	NN	O	O
excluded	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
six	NN	O	O
months	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
mean	NN	O	O
hemoglobin	NN	O	O
(	NN	O	O
Hb	NN	O	O
)	NN	O	O
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
declined	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
from	NN	O	O
baseline	NN	O	O
of	NN	O	O
14	NN	O	O
.	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
to	NN	O	O
14	NN	O	O
.	NN	O	O
0	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
13	NN	O	O
.	NN	O	O
5	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
13	NN	O	O
.	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
and	NN	O	O
12	NN	O	O
.	NN	O	O
7	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
at	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
and	NN	O	O
6	NN	O	O
months	NN	O	O
post	NN	O	O
-	NN	O	O
CAB	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Severe	NN	O	O
and	NN	O	O
clinically	NN	O	O
evident	NN	O	O
anemia	NN	O	B
of	NN	O	O
Hb	NN	O	O
<	NN	O	O
11	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
with	NN	O	O
clinical	NN	O	O
symptoms	NN	O	O
was	NN	O	O
detected	NN	O	O
in	NN	O	O
6	NN	O	O
patients	NN	O	O
(	NN	O	O
14	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
CAB	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
was	NN	O	O
normochromic	NN	O	O
and	NN	O	O
normocytic	NN	O	O
.	NN	O	O

At	NN	O	O
six	NN	O	O
months	NN	O	O
post	NN	O	O
-	NN	O	O
CAB	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
anemia	NN	O	B
had	NN	O	O
a	NN	O	O
Hb	NN	O	O
mean	NN	O	O
value	NN	O	O
of	NN	O	O
10	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
(	NN	O	O
X	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SE	NN	O	O
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
other	NN	O	O
patients	NN	O	O
had	NN	O	O
mild	NN	O	O
anemia	NN	O	B
with	NN	O	O
Hb	NN	O	O
mean	NN	O	O
value	NN	O	O
of	NN	O	O
13	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
17	NN	O	O
(	NN	O	O
X	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SE	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
severe	NN	O	O
anemia	NN	O	B
at	NN	O	O
6	NN	O	O
months	NN	O	O
post	NN	O	O
-	NN	O	O
CAB	NN	O	O
was	NN	O	O
predictable	NN	O	O
by	NN	O	O
the	NN	O	O
reduction	NN	O	O
of	NN	O	O
Hb	NN	O	O
baseline	NN	O	O
value	NN	O	O
of	NN	O	O
more	NN	O	O
than	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
after	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
CAB	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
severe	NN	O	O
CAB	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
in	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
patients	NN	O	O
did	NN	O	O
not	NN	O	O
correlate	NN	O	O
with	NN	O	O
T	NN	O	O
baseline	NN	O	O
values	NN	O	O
(	NN	O	O
T	NN	O	O
<	NN	O	O
3	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
versus	NN	O	O
T	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
3	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
age	NN	O	O
(	NN	O	O
<	NN	O	O
76	NN	O	O
yrs	NN	O	O
versus	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
76	NN	O	O
yrs	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
clinical	NN	O	O
stage	NN	O	O
(	NN	O	O
stage	NN	O	O
C	NN	O	O
versus	NN	O	O
stage	NN	O	O
D1	NN	O	O
)	NN	O	O
.	NN	O	O

Severe	NN	O	O
and	NN	O	O
clinically	NN	O	O
evident	NN	O	O
anemia	NN	O	B
was	NN	O	O
easily	NN	O	O
corrected	NN	O	O
by	NN	O	O
subcutaneous	NN	O	O
injections	NN	O	O
(	NN	O	O
3	NN	O	O
times	NN	O	O
/	NN	O	O
week	NN	O	O
for	NN	O	O
1	NN	O	O
month	NN	O	O
)	NN	O	O
of	NN	O	O
recombinant	NN	O	O
erythropoietin	NN	O	O
(	NN	O	O
rHuEPO	NN	O	O
-	NN	O	O
beta	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Our	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
rHuEPO	NN	O	O
-	NN	O	O
beta	NN	O	O
correctable	NN	O	O
CAB	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B
occurs	NN	O	O
in	NN	O	O
14	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
of	NN	O	O
prostate	NN	O	B
cancer	NN	O	I
patients	NN	O	O
after	NN	O	O
6	NN	O	O
months	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

Delirium	NN	O	B
during	NN	O	O
clozapine	NN	O	O
treatment	NN	O	O
:	NN	O	O
incidence	NN	O	O
and	NN	O	O
associated	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Incidence	NN	O	O
and	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
delirium	NN	O	B
during	NN	O	O
clozapine	NN	O	O
treatment	NN	O	O
require	NN	O	O
further	NN	O	O
clarification	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
used	NN	O	O
computerized	NN	O	O
pharmacy	NN	O	O
records	NN	O	O
to	NN	O	O
identify	NN	O	O
all	NN	O	O
adult	NN	O	O
psychiatric	NN	O	B
inpatients	NN	O	O
treated	NN	O	O
with	NN	O	O
clozapine	NN	O	O
(	NN	O	O
1995	NN	O	O
-	NN	O	O
96	NN	O	O
)	NN	O	O
,	NN	O	O
reviewed	NN	O	O
their	NN	O	O
medical	NN	O	O
records	NN	O	O
to	NN	O	O
score	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
delirium	NN	O	B
,	NN	O	O
and	NN	O	O
tested	NN	O	O
associations	NN	O	O
with	NN	O	O
potential	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Subjects	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
139	NN	O	O
)	NN	O	O
were	NN	O	O
72	NN	O	O
women	NN	O	O
and	NN	O	O
67	NN	O	O
men	NN	O	O
,	NN	O	O
aged	NN	O	O
40	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
.	NN	O	O
1	NN	O	O
years	NN	O	O
,	NN	O	O
hospitalized	NN	O	O
for	NN	O	O
24	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
23	NN	O	O
.	NN	O	O
3	NN	O	O
days	NN	O	O
,	NN	O	O
and	NN	O	O
given	NN	O	O
clozapine	NN	O	O
,	NN	O	O
gradually	NN	O	O
increased	NN	O	O
to	NN	O	O
an	NN	O	O
average	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
282	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
203	NN	O	O
mg	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
45	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
45	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
for	NN	O	O
18	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
16	NN	O	O
.	NN	O	O
4	NN	O	O
days	NN	O	O
.	NN	O	O

Delirium	NN	O	B
was	NN	O	O
diagnosed	NN	O	O
in	NN	O	O
14	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
incidence	NN	O	O
,	NN	O	O
or	NN	O	O
1	NN	O	O
.	NN	O	O
48	NN	O	O
cases	NN	O	O
/	NN	O	O
person	NN	O	O
-	NN	O	O
years	NN	O	O
of	NN	O	O
exposure	NN	O	O
)	NN	O	O
;	NN	O	O
71	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
of	NN	O	O
cases	NN	O	O
were	NN	O	O
moderate	NN	O	O
or	NN	O	O
severe	NN	O	O
.	NN	O	O

Associated	NN	O	O
factors	NN	O	O
were	NN	O	O
co	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
other	NN	O	O
centrally	NN	O	O
antimuscarinic	NN	O	O
agents	NN	O	O
,	NN	O	O
poor	NN	O	O
clinical	NN	O	O
outcome	NN	O	O
,	NN	O	O
older	NN	O	O
age	NN	O	O
,	NN	O	O
and	NN	O	O
longer	NN	O	O
hospitalization	NN	O	O
(	NN	O	O
by	NN	O	O
17	NN	O	O
.	NN	O	O
5	NN	O	O
days	NN	O	O
,	NN	O	O
increasing	NN	O	O
cost	NN	O	O
)	NN	O	O
;	NN	O	O
sex	NN	O	O
,	NN	O	O
diagnosis	NN	O	O
or	NN	O	O
medical	NN	O	O
co	NN	O	O
-	NN	O	O
morbidity	NN	O	O
,	NN	O	O
and	NN	O	O
daily	NN	O	O
clozapine	NN	O	O
dose	NN	O	O
,	NN	O	O
which	NN	O	O
fell	NN	O	O
with	NN	O	O
age	NN	O	O
,	NN	O	O
were	NN	O	O
unrelated	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Delirium	NN	O	B
was	NN	O	O
found	NN	O	O
in	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
clozapine	NN	O	O
-	NN	O	O
treated	NN	O	O
inpatients	NN	O	O
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
older	NN	O	O
patients	NN	O	O
exposed	NN	O	O
to	NN	O	O
other	NN	O	O
central	NN	O	O
anticholinergics	NN	O	O
.	NN	O	O

Delirium	NN	O	B
was	NN	O	O
inconsistently	NN	O	O
recognized	NN	O	O
clinically	NN	O	O
in	NN	O	O
milder	NN	O	O
cases	NN	O	O
and	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
length	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
stay	NN	O	O
and	NN	O	O
higher	NN	O	O
costs	NN	O	O
,	NN	O	O
and	NN	O	O
inferior	NN	O	O
clinical	NN	O	O
outcome	NN	O	O
.	NN	O	O

Neuroprotective	NN	O	O
action	NN	O	O
of	NN	O	O
MPEP	NN	O	O
,	NN	O	O
a	NN	O	O
selective	NN	O	O
mGluR5	NN	O	O
antagonist	NN	O	O
,	NN	O	O
in	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
dopaminergic	NN	O	O
neurotoxicity	NN	O	B
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
dopamine	NN	O	O
outflow	NN	O	O
and	NN	O	O
inhibition	NN	O	O
of	NN	O	O
hyperthermia	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
metabotropic	NN	O	O
glutamate	NN	O	O
receptor	NN	O	O
5	NN	O	O
(	NN	O	O
mGluR5	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
toxic	NN	O	O
action	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
on	NN	O	O
dopaminergic	NN	O	O
neurones	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Methamphetamine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
sc	NN	O	O
)	NN	O	O
,	NN	O	O
administered	NN	O	O
five	NN	O	O
times	NN	O	O
,	NN	O	O
reduced	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
dopamine	NN	O	O
and	NN	O	O
its	NN	O	O
metabolites	NN	O	O
in	NN	O	O
striatal	NN	O	O
tissue	NN	O	O
when	NN	O	O
measured	NN	O	O
72	NN	O	O
h	NN	O	O
after	NN	O	O
the	NN	O	O
last	NN	O	O
injection	NN	O	O
.	NN	O	O

A	NN	O	O
selective	NN	O	O
antagonist	NN	O	O
of	NN	O	O
mGluR5	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
(	NN	O	O
phenylethynyl	NN	O	O
)	NN	O	O
pyridine	NN	O	O
(	NN	O	O
MPEP	NN	O	O
;	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
,	NN	O	O
when	NN	O	O
administered	NN	O	O
five	NN	O	O
times	NN	O	O
immediately	NN	O	O
before	NN	O	O
each	NN	O	O
methamphetamine	NN	O	O
injection	NN	O	O
reversed	NN	O	O
the	NN	O	O
above	NN	O	O
-	NN	O	O
mentioned	NN	O	O
methamphetamine	NN	O	O
effects	NN	O	O
.	NN	O	O

A	NN	O	O
single	NN	O	O
MPEP	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
injection	NN	O	O
reduced	NN	O	O
the	NN	O	O
basal	NN	O	O
extracellular	NN	O	O
dopamine	NN	O	O
level	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
dopamine	NN	O	O
release	NN	O	O
stimulated	NN	O	O
either	NN	O	O
by	NN	O	O
methamphetamine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
sc	NN	O	O
)	NN	O	O
or	NN	O	O
by	NN	O	O
intrastriatally	NN	O	O
administered	NN	O	O
veratridine	NN	O	O
(	NN	O	O
100	NN	O	O
microM	NN	O	O
)	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
it	NN	O	O
transiently	NN	O	O
diminished	NN	O	O
the	NN	O	O
methamphetamine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
sc	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperthermia	NN	O	B
and	NN	O	O
reduced	NN	O	O
basal	NN	O	O
body	NN	O	O
temperature	NN	O	O
.	NN	O	O

MPEP	NN	O	O
administered	NN	O	O
into	NN	O	O
the	NN	O	O
striatum	NN	O	O
at	NN	O	O
high	NN	O	O
concentrations	NN	O	O
(	NN	O	O
500	NN	O	O
microM	NN	O	O
)	NN	O	O
increased	NN	O	O
extracellular	NN	O	O
dopamine	NN	O	O
levels	NN	O	O
,	NN	O	O
while	NN	O	O
lower	NN	O	O
concentrations	NN	O	O
(	NN	O	O
50	NN	O	O
-	NN	O	O
100	NN	O	O
microM	NN	O	O
)	NN	O	O
were	NN	O	O
devoid	NN	O	O
of	NN	O	O
any	NN	O	O
effect	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
blockade	NN	O	O
of	NN	O	O
mGluR5	NN	O	O
by	NN	O	O
MPEP	NN	O	O
may	NN	O	O
protect	NN	O	O
dopaminergic	NN	O	O
neurones	NN	O	O
against	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Neuroprotection	NN	O	O
rendered	NN	O	O
by	NN	O	O
MPEP	NN	O	O
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
dopamine	NN	O	O
efflux	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
blockade	NN	O	O
of	NN	O	O
extrastriatal	NN	O	O
mGluR5	NN	O	O
,	NN	O	O
and	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
hyperthermia	NN	O	B
.	NN	O	O

Protective	NN	O	O
efficacy	NN	O	O
of	NN	O	O
neuroactive	NN	O	O
steroids	NN	O	O
against	NN	O	O
cocaine	NN	O	O
kindled	NN	O	O
-	NN	O	O
seizures	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Neuroactive	NN	O	O
steroids	NN	O	O
demonstrate	NN	O	O
pharmacological	NN	O	O
actions	NN	O	O
that	NN	O	O
have	NN	O	O
relevance	NN	O	O
for	NN	O	O
a	NN	O	O
host	NN	O	O
of	NN	O	O
neurological	NN	O	B
and	NN	O	I
psychiatric	NN	O	I
disorders	NN	O	I
.	NN	O	O

They	NN	O	O
offer	NN	O	O
protection	NN	O	O
against	NN	O	O
seizures	NN	O	B
in	NN	O	O
a	NN	O	O
range	NN	O	O
of	NN	O	O
models	NN	O	O
and	NN	O	O
seem	NN	O	O
to	NN	O	O
inhibit	NN	O	O
certain	NN	O	O
stages	NN	O	O
of	NN	O	O
drug	NN	O	B
dependence	NN	O	I
in	NN	O	O
preclinical	NN	O	O
assessments	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
two	NN	O	O
endogenous	NN	O	O
and	NN	O	O
one	NN	O	O
synthetic	NN	O	O
neuroactive	NN	O	O
steroid	NN	O	O
that	NN	O	O
positively	NN	O	O
modulate	NN	O	O
the	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acid	NN	O	O
(	NN	O	O
GABA	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
)	NN	O	O
receptor	NN	O	O
against	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
the	NN	O	O
convulsant	NN	O	O
effects	NN	O	O
of	NN	O	O
cocaine	NN	O	O
engendered	NN	O	O
by	NN	O	O
repeated	NN	O	O
cocaine	NN	O	O
administration	NN	O	O
(	NN	O	O
seizure	NN	O	B
kindling	NN	O	O
)	NN	O	O
.	NN	O	O

Allopregnanolone	NN	O	O
(	NN	O	O
3alpha	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
5alpha	NN	O	O
-	NN	O	O
pregnan	NN	O	O
-	NN	O	O
20	NN	O	O
-	NN	O	O
one	NN	O	O
)	NN	O	O
,	NN	O	O
pregnanolone	NN	O	O
(	NN	O	O
3alpha	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
5beta	NN	O	O
-	NN	O	O
pregnan	NN	O	O
-	NN	O	O
20	NN	O	O
-	NN	O	O
one	NN	O	O
)	NN	O	O
and	NN	O	O
ganaxolone	NN	O	O
(	NN	O	O
a	NN	O	O
synthetic	NN	O	O
derivative	NN	O	O
of	NN	O	O
allopregnanolone	NN	O	O
3alpha	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
3beta	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
5alpha	NN	O	O
-	NN	O	O
pregnan	NN	O	O
-	NN	O	O
20	NN	O	O
-	NN	O	O
one	NN	O	O
)	NN	O	O
were	NN	O	O
tested	NN	O	O
for	NN	O	O
their	NN	O	O
ability	NN	O	O
to	NN	O	O
suppress	NN	O	O
the	NN	O	O
expression	NN	O	O
(	NN	O	O
anticonvulsant	NN	O	O
effect	NN	O	O
)	NN	O	O
and	NN	O	O
development	NN	O	O
(	NN	O	O
antiepileptogenic	NN	O	O
effect	NN	O	O
)	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
kindled	NN	O	O
seizures	NN	O	B
in	NN	O	O
male	NN	O	O
,	NN	O	O
Swiss	NN	O	O
-	NN	O	O
Webster	NN	O	O
mice	NN	O	O
.	NN	O	O

Kindled	NN	O	O
seizures	NN	O	B
were	NN	O	O
induced	NN	O	O
by	NN	O	O
daily	NN	O	O
administration	NN	O	O
of	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
cocaine	NN	O	O
for	NN	O	O
5	NN	O	O
days	NN	O	O
.	NN	O	O

All	NN	O	O
of	NN	O	O
these	NN	O	O
positive	NN	O	O
GABA	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
modulators	NN	O	O
suppressed	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
kindled	NN	O	O
seizures	NN	O	B
,	NN	O	O
whereas	NN	O	O
only	NN	O	O
allopregnanolone	NN	O	O
and	NN	O	O
ganaxolone	NN	O	O
inhibited	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
kindling	NN	O	O
.	NN	O	O

Allopregnanolone	NN	O	O
and	NN	O	O
pregnanolone	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
ganaxolone	NN	O	O
,	NN	O	O
also	NN	O	O
reduced	NN	O	O
cumulative	NN	O	O
lethality	NN	O	O
associated	NN	O	O
with	NN	O	O
kindling	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
some	NN	O	O
neuroactive	NN	O	O
steroids	NN	O	O
attenuate	NN	O	O
convulsant	NN	O	O
and	NN	O	O
sensitizing	NN	O	O
properties	NN	O	O
of	NN	O	O
cocaine	NN	O	O
and	NN	O	O
add	NN	O	O
to	NN	O	O
a	NN	O	O
growing	NN	O	O
literature	NN	O	O
on	NN	O	O
their	NN	O	O
potential	NN	O	O
use	NN	O	O
in	NN	O	O
the	NN	O	O
modulation	NN	O	O
of	NN	O	O
effects	NN	O	O
of	NN	O	O
drugs	NN	O	O
of	NN	O	O
abuse	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
humoral	NN	O	O
modulators	NN	O	O
of	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	B
in	NN	O	I
locomotor	NN	O	I
activity	NN	O	I
of	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
humoral	NN	O	O
modulators	NN	O	O
on	NN	O	O
the	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	B
in	NN	O	I
locomotor	NN	O	I
activity	NN	O	I
of	NN	O	O
mice	NN	O	O
was	NN	O	O
studied	NN	O	O
.	NN	O	O

The	NN	O	O
subcutaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
morphine	NN	O	O
-	NN	O	O
HC1	NN	O	O
produced	NN	O	O
a	NN	O	O
marked	NN	O	O
increase	NN	O	B
in	NN	O	I
locomotor	NN	O	I
activity	NN	O	I
in	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
morphine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
was	NN	O	O
potentiated	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
and	NN	O	O
attenuated	NN	O	O
by	NN	O	O
physostigmine	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
both	NN	O	O
methscopolamine	NN	O	O
and	NN	O	O
neostigmine	NN	O	O
,	NN	O	O
which	NN	O	O
do	NN	O	O
not	NN	O	O
penetrate	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
,	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
hyperactivity	NN	O	B
produced	NN	O	O
by	NN	O	O
morphine	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
of	NN	O	O
mice	NN	O	O
with	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyltyrosine	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
,	NN	O	O
one	NN	O	O
hour	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
tyrosine	NN	O	O
hydroxylase	NN	O	O
,	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
the	NN	O	O
activity	NN	O	O
-	NN	O	O
increasing	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
p	NN	O	O
-	NN	O	O
chlorophenylalamine	NN	O	O
(	NN	O	O
3	NN	O	O
X	NN	O	O
320	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
,	NN	O	O
24	NN	O	O
hr	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
serotonin	NN	O	O
depletor	NN	O	O
,	NN	O	O
caused	NN	O	O
no	NN	O	O
significant	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
hyperactivity	NN	O	B
.	NN	O	O

The	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
activity	NN	O	O
-	NN	O	O
increasing	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	O
are	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
release	NN	O	O
of	NN	O	O
catecholamines	NN	O	O
from	NN	O	O
adrenergic	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

And	NN	O	O
the	NN	O	O
results	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
morphine	NN	O	O
acts	NN	O	O
by	NN	O	O
retarding	NN	O	O
the	NN	O	O
release	NN	O	O
of	NN	O	O
acetylcholine	NN	O	O
at	NN	O	O
some	NN	O	O
central	NN	O	O
cholinergic	NN	O	O
synapses	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
also	NN	O	O
suggested	NN	O	O
from	NN	O	O
collected	NN	O	O
evidence	NN	O	O
that	NN	O	O
the	NN	O	O
activity	NN	O	O
-	NN	O	O
increasing	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	O
in	NN	O	O
mice	NN	O	O
are	NN	O	O
mediated	NN	O	O
by	NN	O	O
mechanisms	NN	O	O
different	NN	O	O
from	NN	O	O
those	NN	O	O
which	NN	O	O
mediate	NN	O	O
the	NN	O	O
activity	NN	O	O
-	NN	O	O
increasing	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
uninephrectomy	NN	O	O
and	NN	O	O
high	NN	O	O
protein	NN	O	O
feeding	NN	O	O
on	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Rats	NN	O	O
with	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
high	NN	O	O
protein	NN	O	O
(	NN	O	O
HP	NN	O	O
)	NN	O	O
feeding	NN	O	O
,	NN	O	O
uninephrectomy	NN	O	O
(	NN	O	O
NX	NN	O	O
)	NN	O	O
or	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
these	NN	O	O
,	NN	O	O
in	NN	O	O
an	NN	O	O
attempt	NN	O	O
to	NN	O	O
induce	NN	O	O
glomerular	NN	O	O
hyperfiltration	NN	O	O
and	NN	O	O
further	NN	O	O
progression	NN	O	O
of	NN	O	O
renal	NN	O	B
failure	NN	O	I
.	NN	O	O

Newborn	NN	O	O
female	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
fed	NN	O	O
a	NN	O	O
lithium	NN	O	O
-	NN	O	O
containing	NN	O	O
diet	NN	O	O
(	NN	O	O
50	NN	O	O
mmol	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
for	NN	O	O
8	NN	O	O
weeks	NN	O	O
and	NN	O	O
then	NN	O	O
randomized	NN	O	O
to	NN	O	O
normal	NN	O	O
diet	NN	O	O
,	NN	O	O
HP	NN	O	O
diet	NN	O	O
(	NN	O	O
40	NN	O	O
vs	NN	O	O
.	NN	O	O
19	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
NX	NN	O	O
or	NN	O	O
HP	NN	O	O
+	NN	O	O
NX	NN	O	O
for	NN	O	O
another	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

Corresponding	NN	O	O
non	NN	O	O
-	NN	O	O
lithium	NN	O	O
pretreated	NN	O	O
groups	NN	O	O
were	NN	O	O
generated	NN	O	O
.	NN	O	O

When	NN	O	O
comparing	NN	O	O
all	NN	O	O
lithium	NN	O	O
treated	NN	O	O
versus	NN	O	O
non	NN	O	O
-	NN	O	O
lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
groups	NN	O	O
,	NN	O	O
lithium	NN	O	O
caused	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
(	NN	O	O
GFR	NN	O	O
)	NN	O	O
without	NN	O	O
significant	NN	O	O
changes	NN	O	O
in	NN	O	O
effective	NN	O	O
renal	NN	O	O
plasma	NN	O	O
flow	NN	O	O
(	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
a	NN	O	O
marker	NN	O	O
secreted	NN	O	O
into	NN	O	O
the	NN	O	O
proximal	NN	O	O
tubules	NN	O	O
)	NN	O	O
or	NN	O	O
lithium	NN	O	O
clearance	NN	O	O
.	NN	O	O

Consequently	NN	O	O
,	NN	O	O
lithium	NN	O	O
pretreatment	NN	O	O
caused	NN	O	O
a	NN	O	O
fall	NN	O	O
in	NN	O	O
filtration	NN	O	O
fraction	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
fractional	NN	O	O
Li	NN	O	O
excretion	NN	O	O
.	NN	O	O

Lithium	NN	O	O
also	NN	O	O
caused	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
systolic	NN	O	O
hypertension	NN	O	B
in	NN	O	O
absence	NN	O	O
of	NN	O	O
glomerulosclerosis	NN	O	B
.	NN	O	O

HP	NN	O	O
failed	NN	O	O
to	NN	O	O
accentuante	NN	O	O
progression	NN	O	O
of	NN	O	O
renal	NN	O	B
failure	NN	O	I
and	NN	O	O
in	NN	O	O
fact	NN	O	O
tended	NN	O	O
to	NN	O	O
increase	NN	O	O
GFR	NN	O	O
and	NN	O	O
decrease	NN	O	O
plasma	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
in	NN	O	O
lithium	NN	O	O
pretreated	NN	O	O
rats	NN	O	O
.	NN	O	O

NX	NN	O	O
caused	NN	O	O
an	NN	O	O
additive	NN	O	O
deterioration	NN	O	O
in	NN	O	O
GFR	NN	O	O
which	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
was	NN	O	O
ameliorated	NN	O	O
by	NN	O	O
HP	NN	O	O
.	NN	O	O

NX	NN	O	O
+	NN	O	O
HP	NN	O	O
caused	NN	O	O
a	NN	O	O
further	NN	O	O
rise	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
in	NN	O	O
Li	NN	O	O
-	NN	O	O
pretreated	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
Li	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
even	NN	O	O
when	NN	O	O
the	NN	O	O
GFR	NN	O	O
is	NN	O	O
only	NN	O	O
modestly	NN	O	O
reduced	NN	O	O
,	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
arterial	NN	O	O
systolic	NN	O	O
hypertension	NN	O	B
.	NN	O	O

In	NN	O	O
this	NN	O	O
model	NN	O	O
of	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
the	NN	O	O
decline	NN	O	O
in	NN	O	O
GFR	NN	O	O
is	NN	O	O
not	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
corresponding	NN	O	O
fall	NN	O	O
in	NN	O	O
effective	NN	O	O
renal	NN	O	O
plasma	NN	O	O
flow	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
functional	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
nonfiltrating	NN	O	O
atubular	NN	O	O
glomeruli	NN	O	O
.	NN	O	O

The	NN	O	O
fractional	NN	O	O
reabsorption	NN	O	O
of	NN	O	O
tubular	NN	O	O
fluid	NN	O	O
by	NN	O	O
the	NN	O	O
proximal	NN	O	O
tubules	NN	O	O
is	NN	O	O
reduced	NN	O	O
,	NN	O	O
leaving	NN	O	O
the	NN	O	O
distal	NN	O	O
delivery	NN	O	O
unchanged	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Treatment	NN	O	O
of	NN	O	O
Crohn	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
with	NN	O	O
fusidic	NN	O	O
acid	NN	O	O
:	NN	O	O
an	NN	O	O
antibiotic	NN	O	O
with	NN	O	O
immunosuppressive	NN	O	O
properties	NN	O	O
similar	NN	O	O
to	NN	O	O
cyclosporin	NN	O	O
.	NN	O	O

Fusidic	NN	O	O
acid	NN	O	O
is	NN	O	O
an	NN	O	O
antibiotic	NN	O	O
with	NN	O	O
T	NN	O	O
-	NN	O	O
cell	NN	O	O
specific	NN	O	O
immunosuppressive	NN	O	O
effects	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
cyclosporin	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
new	NN	O	O
treatments	NN	O	O
for	NN	O	O
Crohn	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
,	NN	O	O
a	NN	O	O
pilot	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
pharmacodynamics	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
fusidic	NN	O	O
acid	NN	O	O
treatment	NN	O	O
in	NN	O	O
chronic	NN	O	O
active	NN	O	O
,	NN	O	O
therapy	NN	O	O
-	NN	O	O
resistant	NN	O	O
patients	NN	O	O
.	NN	O	O

Eight	NN	O	O
Crohn	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
patients	NN	O	O
were	NN	O	O
included	NN	O	O
.	NN	O	O

Fusidic	NN	O	O
acid	NN	O	O
was	NN	O	O
administered	NN	O	O
orally	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
500	NN	O	O
mg	NN	O	O
t	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
s	NN	O	O
.	NN	O	O
and	NN	O	O
the	NN	O	O
treatment	NN	O	O
was	NN	O	O
planned	NN	O	O
to	NN	O	O
last	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
disease	NN	O	O
activity	NN	O	O
was	NN	O	O
primarily	NN	O	O
measured	NN	O	O
by	NN	O	O
a	NN	O	O
modified	NN	O	O
individual	NN	O	O
grading	NN	O	O
score	NN	O	O
.	NN	O	O

Five	NN	O	O
of	NN	O	O
8	NN	O	O
patients	NN	O	O
(	NN	O	O
63	NN	O	O
%	NN	O	O
)	NN	O	O
improved	NN	O	O
during	NN	O	O
fusidic	NN	O	O
acid	NN	O	O
treatment	NN	O	O
:	NN	O	O
3	NN	O	O
at	NN	O	O
two	NN	O	O
weeks	NN	O	O
and	NN	O	O
2	NN	O	O
after	NN	O	O
four	NN	O	O
weeks	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
serious	NN	O	O
clinical	NN	O	O
side	NN	O	O
effects	NN	O	O
,	NN	O	O
but	NN	O	O
dose	NN	O	O
reduction	NN	O	O
was	NN	O	O
required	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
because	NN	O	O
of	NN	O	O
nausea	NN	O	B
.	NN	O	O

Biochemically	NN	O	O
,	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
alkaline	NN	O	O
phosphatases	NN	O	O
was	NN	O	O
noted	NN	O	O
in	NN	O	O
5	NN	O	O
of	NN	O	O
8	NN	O	O
cases	NN	O	O
(	NN	O	O
63	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
greatest	NN	O	O
increases	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
those	NN	O	O
who	NN	O	O
had	NN	O	O
elevated	NN	O	O
levels	NN	O	O
prior	NN	O	O
to	NN	O	O
treatment	NN	O	O
.	NN	O	O

All	NN	O	O
reversed	NN	O	O
to	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
levels	NN	O	O
after	NN	O	O
cessation	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
pilot	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
fusidic	NN	O	O
acid	NN	O	O
may	NN	O	O
be	NN	O	O
of	NN	O	O
benefit	NN	O	O
in	NN	O	O
selected	NN	O	O
chronic	NN	O	O
active	NN	O	O
Crohn	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
conventional	NN	O	O
treatment	NN	O	O
is	NN	O	O
ineffective	NN	O	O
.	NN	O	O

Because	NN	O	O
there	NN	O	O
seems	NN	O	O
to	NN	O	O
exist	NN	O	O
a	NN	O	O
scientific	NN	O	O
rationale	NN	O	O
for	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
fusidic	NN	O	O
acid	NN	O	O
at	NN	O	O
the	NN	O	O
cytokine	NN	O	O
level	NN	O	O
in	NN	O	O
inflammatory	NN	O	B
bowel	NN	O	I
disease	NN	O	I
,	NN	O	O
we	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
this	NN	O	O
treatment	NN	O	O
should	NN	O	O
be	NN	O	O
further	NN	O	O
investigated	NN	O	O
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
depressive	NN	O	B
status	NN	O	O
associated	NN	O	O
with	NN	O	O
topical	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
.	NN	O	O

Depression	NN	O	B
and	NN	O	O
sexual	NN	O	B
dysfunction	NN	O	I
have	NN	O	O
been	NN	O	O
related	NN	O	O
to	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
topical	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
a	NN	O	O
preliminary	NN	O	O
study	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
determine	NN	O	O
any	NN	O	O
difference	NN	O	O
between	NN	O	O
a	NN	O	O
non	NN	O	O
selective	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
(	NN	O	O
timolol	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
selective	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
(	NN	O	O
betaxolol	NN	O	O
)	NN	O	O
regarding	NN	O	O
CNS	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Eight	NN	O	O
glaucomatous	NN	O	B
patients	NN	O	O
chronically	NN	O	O
treated	NN	O	O
with	NN	O	O
timolol	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
/	NN	O	O
12h	NN	O	O
,	NN	O	O
suffering	NN	O	O
from	NN	O	O
depression	NN	O	B
diagnosed	NN	O	O
through	NN	O	O
DMS	NN	O	O
-	NN	O	O
III	NN	O	O
-	NN	O	O
R	NN	O	O
criteria	NN	O	O
,	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
six	NN	O	O
-	NN	O	O
month	NN	O	O
follow	NN	O	O
up	NN	O	O
,	NN	O	O
depression	NN	O	B
was	NN	O	O
quantified	NN	O	O
through	NN	O	O
the	NN	O	O
Beck	NN	O	O
and	NN	O	O
Zung	NN	O	O
-	NN	O	O
Conde	NN	O	O
scales	NN	O	O
every	NN	O	O
two	NN	O	O
months	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
double	NN	O	O
blind	NN	O	O
cross	NN	O	O
-	NN	O	O
over	NN	O	O
study	NN	O	O
with	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
patients	NN	O	O
under	NN	O	O
timolol	NN	O	O
treatment	NN	O	O
presented	NN	O	O
higher	NN	O	O
depression	NN	O	B
values	NN	O	O
measured	NN	O	O
through	NN	O	O
the	NN	O	O
Beck	NN	O	O
and	NN	O	O
the	NN	O	O
Zung	NN	O	O
-	NN	O	O
Conde	NN	O	O
scales	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
vs	NN	O	O
control	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
betaxolol	NN	O	O
could	NN	O	O
be	NN	O	O
less	NN	O	O
of	NN	O	O
a	NN	O	O
depression	NN	O	B
-	NN	O	O
inducer	NN	O	O
than	NN	O	O
timolol	NN	O	O
in	NN	O	O
predisposed	NN	O	O
patients	NN	O	O
.	NN	O	O

Protection	NN	O	O
against	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B
toward	NN	O	O
striatal	NN	O	O
dopamine	NN	O	O
neurons	NN	O	O
in	NN	O	O
rodents	NN	O	O
by	NN	O	O
LY274614	NN	O	O
,	NN	O	O
an	NN	O	O
excitatory	NN	O	O
amino	NN	O	O
acid	NN	O	O
antagonist	NN	O	O
.	NN	O	O

LY274614	NN	O	O
,	NN	O	O
3SR	NN	O	O
,	NN	O	O
4aRS	NN	O	O
,	NN	O	O
6SR	NN	O	O
,	NN	O	O
8aRS	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
[	NN	O	O
phosphonomethyl	NN	O	O
]	NN	O	O
decahydr	NN	O	O
oisoquinoline	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
carboxylic	NN	O	O
acid	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
described	NN	O	O
as	NN	O	O
a	NN	O	O
potent	NN	O	O
antagonist	NN	O	O
of	NN	O	O
the	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
(	NN	O	O
NMDA	NN	O	O
)	NN	O	O
subtype	NN	O	O
of	NN	O	O
glutamate	NN	O	O
receptor	NN	O	O
.	NN	O	O

Here	NN	O	O
its	NN	O	O
ability	NN	O	O
to	NN	O	O
antagonize	NN	O	O
the	NN	O	O
prolonged	NN	O	O
depletion	NN	O	O
of	NN	O	O
dopamine	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
by	NN	O	O
amphetamine	NN	O	O
in	NN	O	O
iprindole	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
is	NN	O	O
reported	NN	O	O
.	NN	O	O

A	NN	O	O
single	NN	O	O
18	NN	O	O
.	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
dose	NN	O	O
of	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
amphetamine	NN	O	O
hemisulfate	NN	O	O
,	NN	O	O
given	NN	O	O
to	NN	O	O
rats	NN	O	O
pretreated	NN	O	O
with	NN	O	O
iprindole	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
persistent	NN	O	O
depletion	NN	O	O
of	NN	O	O
dopamine	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
1	NN	O	O
week	NN	O	O
later	NN	O	O
.	NN	O	O

This	NN	O	O
prolonged	NN	O	O
depletion	NN	O	O
of	NN	O	O
dopamine	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
was	NN	O	O
antagonized	NN	O	O
by	NN	O	O
dizocilpine	NN	O	O
(	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
,	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
competitive	NN	O	O
antagonist	NN	O	O
of	NN	O	O
NMDA	NN	O	O
receptors	NN	O	O
)	NN	O	O
or	NN	O	O
by	NN	O	O
LY274614	NN	O	O
(	NN	O	O
a	NN	O	O
competitive	NN	O	O
antagonist	NN	O	O
of	NN	O	O
NMDA	NN	O	O
receptors	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
LY274614	NN	O	O
was	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
,	NN	O	O
being	NN	O	O
maximum	NN	O	O
at	NN	O	O
10	NN	O	O
-	NN	O	O
40	NN	O	O
mgkg	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
dose	NN	O	O
of	NN	O	O
LY274614	NN	O	O
was	NN	O	O
effective	NN	O	O
in	NN	O	O
antagonizing	NN	O	O
the	NN	O	O
depletion	NN	O	O
of	NN	O	O
dopamine	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
,	NN	O	O
when	NN	O	O
given	NN	O	O
as	NN	O	O
long	NN	O	O
as	NN	O	O
8	NN	O	O
hr	NN	O	O
prior	NN	O	O
to	NN	O	O
amphetamine	NN	O	O
but	NN	O	O
not	NN	O	O
when	NN	O	O
given	NN	O	O
24	NN	O	O
hr	NN	O	O
prior	NN	O	O
to	NN	O	O
amphetamine	NN	O	O
.	NN	O	O

Depletion	NN	O	O
of	NN	O	O
dopamine	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
was	NN	O	O
also	NN	O	O
antagonized	NN	O	O
when	NN	O	O
LY274614	NN	O	O
was	NN	O	O
given	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
;	NN	O	O
LY274614	NN	O	O
protected	NN	O	O
when	NN	O	O
given	NN	O	O
up	NN	O	O
to	NN	O	O
4	NN	O	O
hr	NN	O	O
after	NN	O	O
but	NN	O	O
not	NN	O	O
when	NN	O	O
given	NN	O	O
8	NN	O	O
or	NN	O	O
24	NN	O	O
hr	NN	O	O
after	NN	O	O
amphetamine	NN	O	O
.	NN	O	O

The	NN	O	O
prolonged	NN	O	O
depletion	NN	O	O
of	NN	O	O
dopamine	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
in	NN	O	O
mice	NN	O	O
,	NN	O	O
given	NN	O	O
multiple	NN	O	O
injections	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
,	NN	O	O
was	NN	O	O
also	NN	O	O
antagonized	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
and	NN	O	O
completely	NN	O	O
by	NN	O	O
LY274614	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
strengthen	NN	O	O
the	NN	O	O
evidence	NN	O	O
that	NN	O	O
the	NN	O	O
neurotoxic	NN	O	B
effect	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
and	NN	O	O
related	NN	O	O
compounds	NN	O	O
toward	NN	O	O
nigrostriatal	NN	O	O
dopamine	NN	O	O
neurons	NN	O	O
involves	NN	O	O
NMDA	NN	O	O
receptors	NN	O	O
and	NN	O	O
that	NN	O	O
LY274614	NN	O	O
is	NN	O	O
an	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
lasting	NN	O	O
in	NN	O	O
vivo	NN	O	O
effects	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Ketoconazole	NN	O	O
-	NN	O	O
induced	NN	O	O
neurologic	NN	O	B
sequelae	NN	O	I
.	NN	O	O

A	NN	O	O
77	NN	O	O
-	NN	O	O
y	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
developed	NN	O	O
weakness	NN	O	B
of	NN	O	I
extremities	NN	O	I
,	NN	O	O
legs	NN	O	B
paralysis	NN	O	I
,	NN	O	O
dysarthria	NN	O	B
and	NN	O	O
tremor	NN	O	B
1	NN	O	O
h	NN	O	O
after	NN	O	O
ingestion	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
ketoconazole	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
in	NN	O	O
his	NN	O	O
life	NN	O	O
.	NN	O	O

All	NN	O	O
complaints	NN	O	O
faded	NN	O	O
away	NN	O	O
within	NN	O	O
24	NN	O	O
h	NN	O	O
.	NN	O	O

Few	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
used	NN	O	O
another	NN	O	O
200	NN	O	O
mg	NN	O	O
ketoconazole	NN	O	O
tablet	NN	O	O
,	NN	O	O
and	NN	O	O
within	NN	O	O
an	NN	O	O
hour	NN	O	O
experienced	NN	O	O
a	NN	O	O
similar	NN	O	O
clinical	NN	O	O
picture	NN	O	O
,	NN	O	O
which	NN	O	O
resolved	NN	O	O
again	NN	O	O
spontaneously	NN	O	O
within	NN	O	O
hours	NN	O	O
.	NN	O	O

Laboratory	NN	O	O
evaluations	NN	O	O
,	NN	O	O
including	NN	O	O
head	NN	O	O
CT	NN	O	O
scan	NN	O	O
,	NN	O	O
were	NN	O	O
normal	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
illustrates	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
close	NN	O	O
vigilance	NN	O	O
in	NN	O	O
adverse	NN	O	B
drug	NN	O	I
reactions	NN	O	I
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
the	NN	O	O
elderly	NN	O	O
.	NN	O	O

Development	NN	O	O
of	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
in	NN	O	O
parkinsonian	NN	O	B
monkeys	NN	O	O
may	NN	O	O
depend	NN	O	O
upon	NN	O	O
rate	NN	O	O
of	NN	O	O
symptom	NN	O	O
onset	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
duration	NN	O	O
of	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
(	NN	O	O
LIDs	NN	O	B
)	NN	O	O
present	NN	O	O
a	NN	O	O
major	NN	O	O
problem	NN	O	O
for	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
management	NN	O	O
of	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
patients	NN	O	O
.	NN	O	O

Due	NN	O	O
to	NN	O	O
the	NN	O	O
interdependence	NN	O	O
of	NN	O	O
risk	NN	O	O
factors	NN	O	O
in	NN	O	O
clinical	NN	O	O
populations	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
difficult	NN	O	O
to	NN	O	O
independently	NN	O	O
examine	NN	O	O
factors	NN	O	O
that	NN	O	O
may	NN	O	O
influence	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
LIDs	NN	O	B
.	NN	O	O

Using	NN	O	O
macaque	NN	O	O
monkeys	NN	O	O
with	NN	O	O
different	NN	O	O
types	NN	O	O
of	NN	O	O
MPTP	NN	O	O
-	NN	O	O
induced	NN	O	O
parkinsonism	NN	O	B
,	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
evaluated	NN	O	O
the	NN	O	O
degree	NN	O	O
to	NN	O	O
which	NN	O	O
rate	NN	O	O
of	NN	O	O
symptom	NN	O	O
progression	NN	O	O
,	NN	O	O
symptom	NN	O	O
severity	NN	O	O
,	NN	O	O
and	NN	O	O
response	NN	O	O
to	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
LIDs	NN	O	B
.	NN	O	O

Monkeys	NN	O	O
with	NN	O	O
acute	NN	O	O
(	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
)	NN	O	O
MPTP	NN	O	O
exposure	NN	O	O
,	NN	O	O
rapid	NN	O	O
symptom	NN	O	O
onset	NN	O	O
and	NN	O	O
short	NN	O	O
symptom	NN	O	O
duration	NN	O	O
prior	NN	O	O
to	NN	O	O
initiation	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
developed	NN	O	O
dyskinesia	NN	O	B
between	NN	O	O
11	NN	O	O
and	NN	O	O
24	NN	O	O
days	NN	O	O
of	NN	O	O
daily	NN	O	O
levodopa	NN	O	O
administration	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
monkeys	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
MPTP	NN	O	O
exposure	NN	O	O
,	NN	O	O
slow	NN	O	O
symptom	NN	O	O
progression	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
long	NN	O	O
symptom	NN	O	O
duration	NN	O	O
prior	NN	O	O
to	NN	O	O
initiation	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
were	NN	O	O
more	NN	O	O
resistant	NN	O	O
to	NN	O	O
developing	NN	O	O
LIDs	NN	O	B
(	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
,	NN	O	O
dyskinesia	NN	O	B
developed	NN	O	O
no	NN	O	O
sooner	NN	O	O
than	NN	O	O
146	NN	O	O
days	NN	O	O
of	NN	O	O
chronic	NN	O	O
levodopa	NN	O	O
administration	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
animals	NN	O	O
were	NN	O	O
similarly	NN	O	O
symptomatic	NN	O	O
at	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
levodopa	NN	O	O
treatment	NN	O	O
and	NN	O	O
had	NN	O	O
similar	NN	O	O
therapeutic	NN	O	O
responses	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
distinct	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
propensity	NN	O	O
to	NN	O	O
develop	NN	O	O
LIDs	NN	O	B
in	NN	O	O
monkeys	NN	O	O
with	NN	O	O
different	NN	O	O
rates	NN	O	O
of	NN	O	O
symptom	NN	O	O
progression	NN	O	O
or	NN	O	O
symptom	NN	O	O
durations	NN	O	O
prior	NN	O	O
to	NN	O	O
levodopa	NN	O	O
and	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
value	NN	O	O
of	NN	O	O
these	NN	O	O
models	NN	O	O
for	NN	O	O
further	NN	O	O
studying	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
LIDs	NN	O	B
.	NN	O	O

A	NN	O	O
diet	NN	O	O
promoting	NN	O	O
sugar	NN	O	B
dependency	NN	O	I
causes	NN	O	O
behavioral	NN	O	B
cross	NN	O	I
-	NN	O	I
sensitization	NN	O	I
to	NN	O	O
a	NN	O	O
low	NN	O	O
dose	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
.	NN	O	O

Previous	NN	O	O
research	NN	O	O
in	NN	O	O
this	NN	O	O
laboratory	NN	O	O
has	NN	O	O
shown	NN	O	O
that	NN	O	O
a	NN	O	O
diet	NN	O	O
of	NN	O	O
intermittent	NN	O	O
excessive	NN	O	O
sugar	NN	O	O
consumption	NN	O	O
produces	NN	O	O
a	NN	O	O
state	NN	O	O
with	NN	O	O
neurochemical	NN	O	O
and	NN	O	O
behavioral	NN	O	O
similarities	NN	O	O
to	NN	O	O
drug	NN	O	B
dependency	NN	O	I
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
examined	NN	O	O
whether	NN	O	O
female	NN	O	O
rats	NN	O	O
on	NN	O	O
various	NN	O	O
regimens	NN	O	O
of	NN	O	O
sugar	NN	O	O
access	NN	O	O
would	NN	O	O
show	NN	O	O
behavioral	NN	O	B
cross	NN	O	I
-	NN	O	I
sensitization	NN	O	I
to	NN	O	O
a	NN	O	O
low	NN	O	O
dose	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
30	NN	O	O
-	NN	O	O
min	NN	O	O
baseline	NN	O	O
measure	NN	O	O
of	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
(	NN	O	O
day	NN	O	O
0	NN	O	O
)	NN	O	O
,	NN	O	O
animals	NN	O	O
were	NN	O	O
maintained	NN	O	O
on	NN	O	O
a	NN	O	O
cyclic	NN	O	O
diet	NN	O	O
of	NN	O	O
12	NN	O	O
-	NN	O	O
h	NN	O	O
deprivation	NN	O	O
followed	NN	O	O
by	NN	O	O
12	NN	O	O
-	NN	O	O
h	NN	O	O
access	NN	O	O
to	NN	O	O
10	NN	O	O
%	NN	O	O
sucrose	NN	O	O
solution	NN	O	O
and	NN	O	O
chow	NN	O	O
pellets	NN	O	O
(	NN	O	O
12	NN	O	O
h	NN	O	O
access	NN	O	O
starting	NN	O	O
4	NN	O	O
h	NN	O	O
after	NN	O	O
onset	NN	O	O
of	NN	O	O
the	NN	O	O
dark	NN	O	O
period	NN	O	O
)	NN	O	O
for	NN	O	O
21	NN	O	O
days	NN	O	O
.	NN	O	O

Locomotor	NN	O	O
activity	NN	O	O
was	NN	O	O
measured	NN	O	O
again	NN	O	O
for	NN	O	O
30	NN	O	O
min	NN	O	O
at	NN	O	O
the	NN	O	O
beginning	NN	O	O
of	NN	O	O
days	NN	O	O
1	NN	O	O
and	NN	O	O
21	NN	O	O
of	NN	O	O
sugar	NN	O	O
access	NN	O	O
.	NN	O	O

Beginning	NN	O	O
on	NN	O	O
day	NN	O	O
22	NN	O	O
,	NN	O	O
all	NN	O	O
rats	NN	O	O
were	NN	O	O
maintained	NN	O	O
on	NN	O	O
ad	NN	O	O
libitum	NN	O	O
chow	NN	O	O
.	NN	O	O

Nine	NN	O	O
days	NN	O	O
later	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
was	NN	O	O
measured	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
a	NN	O	O
single	NN	O	O
low	NN	O	O
dose	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
animals	NN	O	O
that	NN	O	O
had	NN	O	O
experienced	NN	O	O
cyclic	NN	O	O
sucrose	NN	O	O
and	NN	O	O
chow	NN	O	O
were	NN	O	O
hyperactive	NN	O	B
in	NN	O	O
response	NN	O	O
to	NN	O	O
amphetamine	NN	O	O
compared	NN	O	O
with	NN	O	O
four	NN	O	O
control	NN	O	O
groups	NN	O	O
(	NN	O	O
ad	NN	O	O
libitum	NN	O	O
10	NN	O	O
%	NN	O	O
sucrose	NN	O	O
and	NN	O	O
chow	NN	O	O
followed	NN	O	O
by	NN	O	O
amphetamine	NN	O	O
injection	NN	O	O
,	NN	O	O
cyclic	NN	O	O
chow	NN	O	O
followed	NN	O	O
by	NN	O	O
amphetamine	NN	O	O
injection	NN	O	O
,	NN	O	O
ad	NN	O	O
libitum	NN	O	O
chow	NN	O	O
with	NN	O	O
amphetamine	NN	O	O
,	NN	O	O
or	NN	O	O
cyclic	NN	O	O
10	NN	O	O
%	NN	O	O
sucrose	NN	O	O
and	NN	O	O
chow	NN	O	O
with	NN	O	O
a	NN	O	O
saline	NN	O	O
injection	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
a	NN	O	O
diet	NN	O	O
comprised	NN	O	O
of	NN	O	O
alternating	NN	O	O
deprivation	NN	O	O
and	NN	O	O
access	NN	O	O
to	NN	O	O
a	NN	O	O
sugar	NN	O	O
solution	NN	O	O
and	NN	O	O
chow	NN	O	O
produces	NN	O	O
bingeing	NN	O	O
on	NN	O	O
sugar	NN	O	O
that	NN	O	O
leads	NN	O	O
to	NN	O	O
a	NN	O	O
long	NN	O	O
lasting	NN	O	O
state	NN	O	O
of	NN	O	O
increased	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
amphetamine	NN	O	O
,	NN	O	O
possibly	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
lasting	NN	O	O
alteration	NN	O	O
in	NN	O	O
the	NN	O	O
dopamine	NN	O	O
system	NN	O	O
.	NN	O	O

Reversible	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
related	NN	O	O
to	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
and	NN	O	O
clinical	NN	O	O
congestive	NN	O	O
heart	NN	O	B
failure	NN	O	I
after	NN	O	O
2	NN	O	O
months	NN	O	O
of	NN	O	O
therapy	NN	O	O
with	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
(	NN	O	O
AmB	NN	O	O
)	NN	O	O
for	NN	O	O
disseminated	NN	O	O
coccidioidomycosis	NN	O	B
.	NN	O	O

His	NN	O	O
echocardiographic	NN	O	O
abnormalities	NN	O	O
and	NN	O	O
heart	NN	O	B
failure	NN	O	I
resolved	NN	O	O
after	NN	O	O
posaconazole	NN	O	O
was	NN	O	O
substituted	NN	O	O
for	NN	O	O
AmB	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
important	NN	O	O
to	NN	O	O
recognize	NN	O	O
the	NN	O	O
rare	NN	O	O
and	NN	O	O
potentially	NN	O	O
reversible	NN	O	O
toxicity	NN	O	B
of	NN	O	O
AmB	NN	O	O
.	NN	O	O

NO	NN	O	O
-	NN	O	O
induced	NN	O	O
migraine	NN	O	B
attack	NN	O	O
:	NN	O	O
strong	NN	O	O
increase	NN	O	O
in	NN	O	O
plasma	NN	O	O
calcitonin	NN	O	O
gene	NN	O	O
-	NN	O	O
related	NN	O	O
peptide	NN	O	O
(	NN	O	O
CGRP	NN	O	O
)	NN	O	O
concentration	NN	O	O
and	NN	O	O
negative	NN	O	O
correlation	NN	O	O
with	NN	O	O
platelet	NN	O	O
serotonin	NN	O	O
release	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
calcitonin	NN	O	O
gene	NN	O	O
-	NN	O	O
related	NN	O	O
peptide	NN	O	O
(	NN	O	O
CGRP	NN	O	O
)	NN	O	O
concentration	NN	O	O
and	NN	O	O
platelet	NN	O	O
serotonin	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxytriptamine	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
)	NN	O	O
content	NN	O	O
during	NN	O	O
the	NN	O	O
immediate	NN	O	O
headache	NN	O	B
and	NN	O	O
the	NN	O	O
delayed	NN	O	O
genuine	NN	O	O
migraine	NN	O	B
attack	NN	O	O
provoked	NN	O	O
by	NN	O	O
nitroglycerin	NN	O	O
.	NN	O	O

Fifteen	NN	O	O
female	NN	O	O
migraineurs	NN	O	B
(	NN	O	I
without	NN	O	I
aura	NN	O	I
)	NN	O	I
and	NN	O	O
eight	NN	O	O
controls	NN	O	O
participated	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Sublingual	NN	O	O
nitroglycerin	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
.	NN	O	O

Blood	NN	O	O
was	NN	O	O
collected	NN	O	O
from	NN	O	O
the	NN	O	O
antecubital	NN	O	O
vein	NN	O	O
four	NN	O	O
times	NN	O	O
:	NN	O	O
60	NN	O	O
min	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
the	NN	O	O
nitroglycerin	NN	O	O
application	NN	O	O
,	NN	O	O
and	NN	O	O
60	NN	O	O
and	NN	O	O
120	NN	O	O
min	NN	O	O
after	NN	O	O
the	NN	O	O
beginning	NN	O	O
of	NN	O	O
the	NN	O	O
migraine	NN	O	B
attack	NN	O	O
(	NN	O	O
mean	NN	O	O
344	NN	O	O
and	NN	O	O
404	NN	O	O
min	NN	O	O
;	NN	O	O
12	NN	O	O
subjects	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
those	NN	O	O
subjects	NN	O	O
who	NN	O	O
had	NN	O	O
no	NN	O	O
migraine	NN	O	B
attack	NN	O	O
(	NN	O	O
11	NN	O	O
subjects	NN	O	O
)	NN	O	O
a	NN	O	O
similar	NN	O	O
time	NN	O	O
schedule	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

Plasma	NN	O	O
CGRP	NN	O	O
concentration	NN	O	O
increased	NN	O	O
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
during	NN	O	O
the	NN	O	O
migraine	NN	O	B
attack	NN	O	O
and	NN	O	O
returned	NN	O	O
to	NN	O	O
baseline	NN	O	O
after	NN	O	O
the	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
migraine	NN	O	B
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
both	NN	O	O
change	NN	O	O
and	NN	O	O
peak	NN	O	O
,	NN	O	O
showed	NN	O	O
significant	NN	O	O
positive	NN	O	O
correlations	NN	O	O
with	NN	O	O
migraine	NN	O	B
headache	NN	O	B
intensity	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
plasma	NN	O	O
CGRP	NN	O	O
concentrations	NN	O	O
failed	NN	O	O
to	NN	O	O
change	NN	O	O
during	NN	O	O
immediate	NN	O	O
headache	NN	O	B
and	NN	O	O
in	NN	O	O
the	NN	O	O
subjects	NN	O	O
with	NN	O	O
no	NN	O	O
migraine	NN	O	B
attack	NN	O	O
.	NN	O	O

Basal	NN	O	O
CGRP	NN	O	O
concentration	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
and	NN	O	O
platelet	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
content	NN	O	O
tended	NN	O	O
to	NN	O	O
be	NN	O	O
lower	NN	O	O
in	NN	O	O
subjects	NN	O	O
who	NN	O	O
experienced	NN	O	O
a	NN	O	O
migraine	NN	O	B
attack	NN	O	O
.	NN	O	O

Platelet	NN	O	O
serotonin	NN	O	O
content	NN	O	O
decreased	NN	O	O
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
after	NN	O	O
nitroglycerin	NN	O	O
in	NN	O	O
subjects	NN	O	O
with	NN	O	O
no	NN	O	O
migraine	NN	O	B
attack	NN	O	O
but	NN	O	O
no	NN	O	O
consistent	NN	O	O
change	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
migraine	NN	O	B
attack	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
plasma	NN	O	O
CGRP	NN	O	O
concentration	NN	O	O
correlates	NN	O	O
with	NN	O	O
the	NN	O	O
timing	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
a	NN	O	O
migraine	NN	O	B
headache	NN	O	B
suggests	NN	O	O
a	NN	O	O
direct	NN	O	O
relationship	NN	O	O
between	NN	O	O
CGRP	NN	O	O
and	NN	O	O
migraine	NN	O	B
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
serotonin	NN	O	O
release	NN	O	O
from	NN	O	O
platelets	NN	O	O
does	NN	O	O
not	NN	O	O
provoke	NN	O	O
migraine	NN	O	B
,	NN	O	O
it	NN	O	O
may	NN	O	O
even	NN	O	O
counteract	NN	O	O
the	NN	O	O
headache	NN	O	B
and	NN	O	O
the	NN	O	O
concomitant	NN	O	O
CGRP	NN	O	O
release	NN	O	O
in	NN	O	O
this	NN	O	O
model	NN	O	O
.	NN	O	O

Hyperbaric	NN	O	O
oxygen	NN	O	O
therapy	NN	O	O
for	NN	O	O
control	NN	O	O
of	NN	O	O
intractable	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
intractable	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
due	NN	O	O
to	NN	O	O
cyclophosphamide	NN	O	O
therapy	NN	O	O
for	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
.	NN	O	O

Conservative	NN	O	O
treatment	NN	O	O
,	NN	O	O
including	NN	O	O
bladder	NN	O	O
irrigation	NN	O	O
with	NN	O	O
physiological	NN	O	O
saline	NN	O	O
and	NN	O	O
instillation	NN	O	O
of	NN	O	O
prostaglandin	NN	O	O
F2	NN	O	O
alpha	NN	O	O
,	NN	O	O
failed	NN	O	O
to	NN	O	O
totally	NN	O	O
control	NN	O	O
hemorrhage	NN	O	B
.	NN	O	O

We	NN	O	O
then	NN	O	O
used	NN	O	O
hyperbaric	NN	O	O
oxygen	NN	O	O
at	NN	O	O
an	NN	O	O
absolute	NN	O	O
pressure	NN	O	O
of	NN	O	O
2	NN	O	O
atm	NN	O	O
,	NN	O	O
5	NN	O	O
days	NN	O	O
a	NN	O	O
week	NN	O	O
for	NN	O	O
8	NN	O	O
consecutive	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
bleeding	NN	O	B
ceased	NN	O	O
completely	NN	O	O
by	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
treatment	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
remained	NN	O	O
free	NN	O	O
of	NN	O	O
hematuria	NN	O	B
thereafter	NN	O	O
.	NN	O	O

No	NN	O	O
side	NN	O	O
effect	NN	O	O
was	NN	O	O
noted	NN	O	O
during	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
future	NN	O	O
,	NN	O	O
this	NN	O	O
form	NN	O	O
of	NN	O	O
therapy	NN	O	O
can	NN	O	O
offer	NN	O	O
a	NN	O	O
safe	NN	O	O
alternative	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
.	NN	O	O

Acute	NN	O	B
psychosis	NN	O	I
due	NN	O	O
to	NN	O	O
treatment	NN	O	O
with	NN	O	O
phenytoin	NN	O	O
in	NN	O	O
a	NN	O	O
nonepileptic	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
psychosis	NN	O	B
related	NN	O	O
to	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
treatment	NN	O	O
is	NN	O	O
usually	NN	O	O
attributed	NN	O	O
to	NN	O	O
the	NN	O	O
interaction	NN	O	O
between	NN	O	O
the	NN	O	O
epileptic	NN	O	B
brain	NN	O	O
substratum	NN	O	O
and	NN	O	O
the	NN	O	O
antiepileptic	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
nonepileptic	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
psychosis	NN	O	B
following	NN	O	O
phenytoin	NN	O	O
treatment	NN	O	O
for	NN	O	O
trigeminal	NN	O	B
neuralgia	NN	O	I
is	NN	O	O
described	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
psychotic	NN	O	B
symptoms	NN	O	I
that	NN	O	O
occur	NN	O	O
following	NN	O	O
phenytoin	NN	O	O
treatment	NN	O	O
in	NN	O	O
some	NN	O	O
epileptic	NN	O	B
patients	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
direct	NN	O	O
result	NN	O	O
of	NN	O	O
medication	NN	O	O
,	NN	O	O
unrelated	NN	O	O
to	NN	O	O
seizures	NN	O	B
.	NN	O	O

Risks	NN	O	O
of	NN	O	O
the	NN	O	O
consumption	NN	O	O
of	NN	O	O
beverages	NN	O	O
containing	NN	O	O
quinine	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
Food	NN	O	O
and	NN	O	O
Drug	NN	O	O
Administration	NN	O	O
banned	NN	O	O
its	NN	O	O
use	NN	O	O
for	NN	O	O
nocturnal	NN	O	B
leg	NN	O	I
cramps	NN	O	I
due	NN	O	O
to	NN	O	O
lack	NN	O	O
of	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
,	NN	O	O
quinine	NN	O	O
is	NN	O	O
widely	NN	O	O
available	NN	O	O
in	NN	O	O
beverages	NN	O	O
including	NN	O	O
tonic	NN	O	O
water	NN	O	O
and	NN	O	O
bitter	NN	O	O
lemon	NN	O	O
.	NN	O	O

Numerous	NN	O	O
anecdotal	NN	O	O
reports	NN	O	O
suggest	NN	O	O
that	NN	O	O
products	NN	O	O
containing	NN	O	O
quinine	NN	O	O
may	NN	O	O
produce	NN	O	O
neurological	NN	O	B
complications	NN	O	I
,	NN	O	O
including	NN	O	O
confusion	NN	O	B
,	NN	O	O
altered	NN	O	O
mental	NN	O	O
status	NN	O	O
,	NN	O	O
seizures	NN	O	B
,	NN	O	O
and	NN	O	O
coma	NN	O	B
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
older	NN	O	O
women	NN	O	O
.	NN	O	O

Psychologists	NN	O	O
need	NN	O	O
to	NN	O	O
inquire	NN	O	O
about	NN	O	O
consumption	NN	O	O
of	NN	O	O
quinine	NN	O	O
-	NN	O	O
containing	NN	O	O
beverages	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
an	NN	O	O
evaluation	NN	O	O
process	NN	O	O
.	NN	O	O

Transient	NN	O	O
platypnea	NN	O	B
-	NN	O	I
orthodeoxia	NN	O	I
-	NN	O	I
like	NN	O	I
syndrome	NN	O	I
induced	NN	O	O
by	NN	O	O
propafenone	NN	O	O
overdose	NN	O	B
in	NN	O	O
a	NN	O	O
young	NN	O	O
woman	NN	O	O
with	NN	O	O
Ebstein	NN	O	B
'	NN	O	I
s	NN	O	I
anomaly	NN	O	I
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
we	NN	O	O
describe	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
37	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
white	NN	O	O
woman	NN	O	O
with	NN	O	O
Ebstein	NN	O	B
'	NN	O	I
s	NN	O	I
anomaly	NN	O	I
,	NN	O	O
who	NN	O	O
developed	NN	O	O
a	NN	O	O
rare	NN	O	O
syndrome	NN	O	O
called	NN	O	O
platypnea	NN	O	B
-	NN	O	I
orthodeoxia	NN	O	I
,	NN	O	O
characterized	NN	O	O
by	NN	O	O
massive	NN	O	O
right	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
left	NN	O	O
interatrial	NN	O	O
shunting	NN	O	O
with	NN	O	O
transient	NN	O	O
profound	NN	O	O
hypoxia	NN	O	B
and	NN	O	O
cyanosis	NN	O	B
.	NN	O	O

This	NN	O	O
shunt	NN	O	O
of	NN	O	O
blood	NN	O	O
via	NN	O	O
a	NN	O	O
patent	NN	O	B
foramen	NN	O	I
ovale	NN	O	I
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
normal	NN	O	O
pulmonary	NN	O	O
artery	NN	O	O
pressure	NN	O	O
,	NN	O	O
and	NN	O	O
was	NN	O	O
probably	NN	O	O
precipitated	NN	O	O
by	NN	O	O
a	NN	O	O
propafenone	NN	O	O
overdose	NN	O	B
.	NN	O	O

This	NN	O	O
drug	NN	O	O
caused	NN	O	O
biventricular	NN	O	B
dysfunction	NN	O	I
,	NN	O	O
due	NN	O	O
to	NN	O	O
its	NN	O	O
negative	NN	O	O
inotropic	NN	O	O
effect	NN	O	O
,	NN	O	O
and	NN	O	O
hypotension	NN	O	B
,	NN	O	O
due	NN	O	O
to	NN	O	O
its	NN	O	O
peripheral	NN	O	O
vasodilatory	NN	O	O
effect	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
gave	NN	O	O
rise	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
atrial	NN	O	O
pressure	NN	O	O
and	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
left	NN	O	O
one	NN	O	O
with	NN	O	O
a	NN	O	O
consequent	NN	O	O
stretching	NN	O	O
of	NN	O	O
the	NN	O	O
foramen	NN	O	O
ovale	NN	O	O
and	NN	O	O
the	NN	O	O
creation	NN	O	O
of	NN	O	O
massive	NN	O	O
right	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
left	NN	O	O
shunting	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
case	NN	O	O
this	NN	O	O
interatrial	NN	O	O
shunt	NN	O	O
was	NN	O	O
very	NN	O	O
accurately	NN	O	O
detected	NN	O	O
at	NN	O	O
bubble	NN	O	O
contrast	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Noxious	NN	O	O
chemical	NN	O	O
stimulation	NN	O	O
of	NN	O	O
rat	NN	O	O
facial	NN	O	O
mucosa	NN	O	O
increases	NN	O	O
intracranial	NN	O	O
blood	NN	O	O
flow	NN	O	O
through	NN	O	O
a	NN	O	O
trigemino	NN	O	O
-	NN	O	O
parasympathetic	NN	O	O
reflex	NN	O	O
-	NN	O	O
-	NN	O	O
an	NN	O	O
experimental	NN	O	O
model	NN	O	O
for	NN	O	O
vascular	NN	O	B
dysfunctions	NN	O	I
in	NN	O	O
cluster	NN	O	B
headache	NN	O	I
.	NN	O	O

Cluster	NN	O	B
headache	NN	O	I
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
typical	NN	O	O
autonomic	NN	O	O
dysfunctions	NN	O	O
including	NN	O	O
facial	NN	O	O
and	NN	O	O
intracranial	NN	O	B
vascular	NN	O	I
disturbances	NN	O	I
.	NN	O	O

Both	NN	O	O
the	NN	O	O
trigeminal	NN	O	O
and	NN	O	O
the	NN	O	O
cranial	NN	O	O
parasympathetic	NN	O	O
systems	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
mediating	NN	O	O
these	NN	O	O
dysfunctions	NN	O	O
.	NN	O	O

An	NN	O	O
experimental	NN	O	O
model	NN	O	O
was	NN	O	O
developed	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
to	NN	O	O
measure	NN	O	O
changes	NN	O	O
in	NN	O	O
lacrimation	NN	O	O
and	NN	O	O
intracranial	NN	O	O
blood	NN	O	O
flow	NN	O	O
following	NN	O	O
noxious	NN	O	O
chemical	NN	O	O
stimulation	NN	O	O
of	NN	O	O
facial	NN	O	O
mucosa	NN	O	O
.	NN	O	O

Blood	NN	O	O
flow	NN	O	O
was	NN	O	O
monitored	NN	O	O
in	NN	O	O
arteries	NN	O	O
of	NN	O	O
the	NN	O	O
exposed	NN	O	O
cranial	NN	O	O
dura	NN	O	O
mater	NN	O	O
and	NN	O	O
the	NN	O	O
parietal	NN	O	O
cortex	NN	O	O
using	NN	O	O
laser	NN	O	O
Doppler	NN	O	O
flowmetry	NN	O	O
.	NN	O	O

Capsaicin	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
-	NN	O	O
1	NN	O	O
mm	NN	O	O
)	NN	O	O
applied	NN	O	O
to	NN	O	O
oral	NN	O	O
or	NN	O	O
nasal	NN	O	O
mucosa	NN	O	O
induced	NN	O	O
increases	NN	O	B
in	NN	O	I
dural	NN	O	I
and	NN	O	I
cortical	NN	O	I
blood	NN	O	I
flow	NN	O	I
and	NN	O	O
provoked	NN	O	O
lacrimation	NN	O	O
.	NN	O	O

These	NN	O	O
responses	NN	O	O
were	NN	O	O
blocked	NN	O	O
by	NN	O	O
systemic	NN	O	O
pre	NN	O	O
-	NN	O	O
administration	NN	O	O
of	NN	O	O
hexamethonium	NN	O	O
chloride	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
evoked	NN	O	O
increases	NN	O	B
in	NN	O	I
dural	NN	O	I
blood	NN	O	I
flow	NN	O	I
were	NN	O	O
also	NN	O	O
abolished	NN	O	O
by	NN	O	O
topical	NN	O	O
pre	NN	O	O
-	NN	O	O
administration	NN	O	O
of	NN	O	O
atropine	NN	O	O
(	NN	O	O
1	NN	O	O
mm	NN	O	O
)	NN	O	O
and	NN	O	O
[	NN	O	O
Lys1	NN	O	O
,	NN	O	O
Pro2	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
Arg3	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
Tyr6	NN	O	O
]	NN	O	O
-	NN	O	O
VIP	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
mm	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
vasoactive	NN	O	O
intestinal	NN	O	O
polypeptide	NN	O	O
(	NN	O	O
VIP	NN	O	O
)	NN	O	O
antagonist	NN	O	O
,	NN	O	O
onto	NN	O	O
the	NN	O	O
exposed	NN	O	O
dura	NN	O	O
mater	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
noxious	NN	O	O
stimulation	NN	O	O
of	NN	O	O
facial	NN	O	O
mucosa	NN	O	O
increases	NN	O	O
intracranial	NN	O	O
blood	NN	O	O
flow	NN	O	O
and	NN	O	O
lacrimation	NN	O	O
via	NN	O	O
a	NN	O	O
trigemino	NN	O	O
-	NN	O	O
parasympathetic	NN	O	O
reflex	NN	O	O
.	NN	O	O

The	NN	O	O
blood	NN	O	O
flow	NN	O	O
responses	NN	O	O
seem	NN	O	O
to	NN	O	O
be	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
release	NN	O	O
of	NN	O	O
acetylcholine	NN	O	O
and	NN	O	O
VIP	NN	O	O
within	NN	O	O
the	NN	O	O
meninges	NN	O	O
.	NN	O	O

Similar	NN	O	O
mechanisms	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
cluster	NN	O	B
headache	NN	O	I
.	NN	O	O

Organophosphate	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
and	NN	O	O
prevention	NN	O	O
of	NN	O	O
neuropathological	NN	O	B
damages	NN	O	I
.	NN	O	O

Such	NN	O	O
organophosphorus	NN	O	O
(	NN	O	O
OP	NN	O	O
)	NN	O	O
compounds	NN	O	O
as	NN	O	O
diisopropylfluorophosphate	NN	O	O
(	NN	O	O
DFP	NN	O	O
)	NN	O	O
,	NN	O	O
sarin	NN	O	O
and	NN	O	O
soman	NN	O	O
are	NN	O	O
potent	NN	O	O
inhibitors	NN	O	O
of	NN	O	O
acetylcholinesterases	NN	O	O
(	NN	O	O
AChEs	NN	O	O
)	NN	O	O
and	NN	O	O
butyrylcholinesterases	NN	O	O
(	NN	O	O
BChEs	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
acute	NN	O	O
toxicity	NN	O	B
of	NN	O	O
OPs	NN	O	O
is	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
their	NN	O	O
irreversible	NN	O	O
binding	NN	O	O
with	NN	O	O
AChEs	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
elevates	NN	O	O
acetylcholine	NN	O	O
(	NN	O	O
ACh	NN	O	O
)	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
protective	NN	O	O
action	NN	O	O
of	NN	O	O
subcutaneously	NN	O	O
(	NN	O	O
SC	NN	O	O
)	NN	O	O
administered	NN	O	O
antidotes	NN	O	O
or	NN	O	O
their	NN	O	O
combinations	NN	O	O
in	NN	O	O
DFP	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BW	NN	O	O
)	NN	O	O
intoxication	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
9	NN	O	O
-	NN	O	O
10	NN	O	O
-	NN	O	O
weeks	NN	O	O
-	NN	O	O
old	NN	O	O
Han	NN	O	O
-	NN	O	O
Wistar	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
rats	NN	O	O
received	NN	O	O
AChE	NN	O	O
reactivator	NN	O	O
pralidoxime	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
chloride	NN	O	O
(	NN	O	O
2PAM	NN	O	O
)	NN	O	O
(	NN	O	O
30	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BW	NN	O	O
)	NN	O	O
,	NN	O	O
anticonvulsant	NN	O	O
diazepam	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BW	NN	O	O
)	NN	O	O
,	NN	O	O
A	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
-	NN	O	O
adenosine	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
N	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
-	NN	O	O
cyclopentyl	NN	O	O
adenosine	NN	O	O
(	NN	O	O
CPA	NN	O	O
)	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BW	NN	O	O
)	NN	O	O
,	NN	O	O
NMDA	NN	O	O
-	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
dizocilpine	NN	O	O
maleate	NN	O	O
(	NN	O	O
+	NN	O	O
-	NN	O	O
MK801	NN	O	O
hydrogen	NN	O	O
maleate	NN	O	O
)	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BW	NN	O	O
)	NN	O	O
or	NN	O	O
their	NN	O	O
combinations	NN	O	O
with	NN	O	O
cholinolytic	NN	O	O
drug	NN	O	O
atropine	NN	O	O
sulfate	NN	O	O
(	NN	O	O
50	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BW	NN	O	O
)	NN	O	O
immediately	NN	O	O
or	NN	O	O
30	NN	O	O
min	NN	O	O
after	NN	O	O
the	NN	O	O
single	NN	O	O
SC	NN	O	O
injection	NN	O	O
of	NN	O	O
DFP	NN	O	O
.	NN	O	O

The	NN	O	O
control	NN	O	O
rats	NN	O	O
received	NN	O	O
atropine	NN	O	O
sulfate	NN	O	O
,	NN	O	O
but	NN	O	O
also	NN	O	O
saline	NN	O	O
and	NN	O	O
olive	NN	O	O
oil	NN	O	O
instead	NN	O	O
of	NN	O	O
other	NN	O	O
antidotes	NN	O	O
and	NN	O	O
DFP	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

All	NN	O	O
rats	NN	O	O
were	NN	O	O
terminated	NN	O	O
either	NN	O	O
24	NN	O	O
h	NN	O	O
or	NN	O	O
3	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
DFP	NN	O	O
injection	NN	O	O
.	NN	O	O

The	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
DFP	NN	O	O
-	NN	O	O
atropine	NN	O	O
showed	NN	O	O
severe	NN	O	O
typical	NN	O	O
OP	NN	O	O
-	NN	O	O
induced	NN	O	O
toxicity	NN	O	B
signs	NN	O	O
.	NN	O	O

When	NN	O	O
CPA	NN	O	O
,	NN	O	O
diazepam	NN	O	O
or	NN	O	O
2PAM	NN	O	O
was	NN	O	O
given	NN	O	O
immediately	NN	O	O
after	NN	O	O
DFP	NN	O	O
-	NN	O	O
atropine	NN	O	O
,	NN	O	O
these	NN	O	O
treatments	NN	O	O
prevented	NN	O	O
,	NN	O	O
delayed	NN	O	O
or	NN	O	O
shortened	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
serious	NN	O	O
signs	NN	O	O
of	NN	O	O
poisoning	NN	O	B
.	NN	O	O

Atropine	NN	O	O
-	NN	O	O
MK801	NN	O	O
did	NN	O	O
not	NN	O	O
offer	NN	O	O
any	NN	O	O
additional	NN	O	O
protection	NN	O	O
against	NN	O	O
DFP	NN	O	O
toxicity	NN	O	B
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
CPA	NN	O	O
,	NN	O	O
diazepam	NN	O	O
and	NN	O	O
2PAM	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
atropine	NN	O	O
prevented	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
serious	NN	O	O
signs	NN	O	O
of	NN	O	O
poisoning	NN	O	B
and	NN	O	O
thus	NN	O	O
reduced	NN	O	O
the	NN	O	O
toxicity	NN	O	B
of	NN	O	O
DFP	NN	O	O
in	NN	O	O
rat	NN	O	O
.	NN	O	O

A	NN	O	O
pyridoxine	NN	O	O
-	NN	O	O
dependent	NN	O	O
behavioral	NN	O	B
disorder	NN	O	I
unmasked	NN	O	O
by	NN	O	O
isoniazid	NN	O	O
.	NN	O	O

A	NN	O	O
3	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
had	NN	O	O
behavioral	NN	O	B
deterioration	NN	O	I
,	NN	O	O
with	NN	O	O
hyperkinesis	NN	O	B
,	NN	O	O
irritability	NN	O	B
,	NN	O	O
and	NN	O	O
sleeping	NN	O	B
difficulties	NN	O	I
after	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
administration	NN	O	O
of	NN	O	O
isoniazid	NN	O	O
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
pharmacologic	NN	O	O
doses	NN	O	O
of	NN	O	O
pyridoxine	NN	O	O
hydrochloride	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
disappearance	NN	O	O
of	NN	O	O
symptoms	NN	O	O
.	NN	O	O

After	NN	O	O
discontinuing	NN	O	O
isoniazid	NN	O	O
therapy	NN	O	O
a	NN	O	O
similar	NN	O	O
pattern	NN	O	O
of	NN	O	O
behavior	NN	O	O
was	NN	O	O
noted	NN	O	O
that	NN	O	O
was	NN	O	O
controlled	NN	O	O
by	NN	O	O
pyridoxine	NN	O	O
.	NN	O	O

A	NN	O	O
placebo	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
,	NN	O	O
but	NN	O	O
niacinamide	NN	O	O
was	NN	O	O
as	NN	O	O
effective	NN	O	O
as	NN	O	O
pyridoxine	NN	O	O
.	NN	O	O

Periodic	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
pyridoxine	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
return	NN	O	O
of	NN	O	O
the	NN	O	O
hyperkinesis	NN	O	B
.	NN	O	O

The	NN	O	O
level	NN	O	O
of	NN	O	O
pyridoxal	NN	O	O
in	NN	O	O
the	NN	O	O
blood	NN	O	O
was	NN	O	O
normal	NN	O	O
during	NN	O	O
the	NN	O	O
periods	NN	O	O
of	NN	O	O
relapse	NN	O	O
.	NN	O	O

Metabolic	NN	O	O
studies	NN	O	O
suggested	NN	O	O
a	NN	O	O
block	NN	O	O
in	NN	O	O
the	NN	O	O
kynurenine	NN	O	O
pathway	NN	O	O
of	NN	O	O
tryptophan	NN	O	O
metabolism	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
has	NN	O	O
been	NN	O	O
followed	NN	O	O
for	NN	O	O
six	NN	O	O
years	NN	O	O
and	NN	O	O
has	NN	O	O
required	NN	O	O
pharmacologic	NN	O	O
doses	NN	O	O
of	NN	O	O
pyridoxine	NN	O	O
to	NN	O	O
control	NN	O	O
her	NN	O	O
behavior	NN	O	O
.	NN	O	O

Recurrent	NN	O	O
excitation	NN	O	O
in	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
of	NN	O	O
a	NN	O	O
murine	NN	O	O
model	NN	O	O
of	NN	O	O
temporal	NN	O	B
lobe	NN	O	I
epilepsy	NN	O	I
.	NN	O	O

Similar	NN	O	O
to	NN	O	O
rats	NN	O	O
,	NN	O	O
systemic	NN	O	O
pilocarpine	NN	O	O
injection	NN	O	O
causes	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
(	NN	O	O
SE	NN	O	B
)	NN	O	O
and	NN	O	O
the	NN	O	O
eventual	NN	O	O
development	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
seizures	NN	O	B
and	NN	O	O
mossy	NN	O	O
fiber	NN	O	O
sprouting	NN	O	O
in	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
and	NN	O	O
CD1	NN	O	O
mice	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
physiological	NN	O	O
correlates	NN	O	O
of	NN	O	O
these	NN	O	O
events	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
identified	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Population	NN	O	O
responses	NN	O	O
in	NN	O	O
granule	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
transverse	NN	O	O
slices	NN	O	O
of	NN	O	O
the	NN	O	O
ventral	NN	O	O
hippocampus	NN	O	O
from	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
treated	NN	O	O
and	NN	O	O
untreated	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
Mg	NN	O	O
(	NN	O	O
2	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
free	NN	O	O
bathing	NN	O	O
medium	NN	O	O
containing	NN	O	O
bicuculline	NN	O	O
,	NN	O	O
conditions	NN	O	O
designed	NN	O	O
to	NN	O	O
increase	NN	O	O
excitability	NN	O	O
in	NN	O	O
the	NN	O	O
slices	NN	O	O
,	NN	O	O
electrical	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
hilus	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
population	NN	O	O
spike	NN	O	O
in	NN	O	O
granule	NN	O	O
cells	NN	O	O
from	NN	O	O
control	NN	O	O
mice	NN	O	O
and	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
treated	NN	O	O
mice	NN	O	O
that	NN	O	O
did	NN	O	O
not	NN	O	O
experience	NN	O	O
SE	NN	O	B
.	NN	O	O

In	NN	O	O
SE	NN	O	B
survivors	NN	O	O
,	NN	O	O
similar	NN	O	O
stimulation	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
population	NN	O	O
spike	NN	O	O
followed	NN	O	O
,	NN	O	O
at	NN	O	O
a	NN	O	O
variable	NN	O	O
latency	NN	O	O
,	NN	O	O
by	NN	O	O
negative	NN	O	O
DC	NN	O	O
shifts	NN	O	O
and	NN	O	O
repetitive	NN	O	O
afterdischarges	NN	O	O
of	NN	O	O
3	NN	O	O
-	NN	O	O
60	NN	O	O
s	NN	O	O
duration	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
blocked	NN	O	O
by	NN	O	O
ionotropic	NN	O	O
glutamate	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
.	NN	O	O

Focal	NN	O	O
glutamate	NN	O	O
photostimulation	NN	O	O
of	NN	O	O
the	NN	O	O
granule	NN	O	O
cell	NN	O	O
layer	NN	O	O
at	NN	O	O
sites	NN	O	O
distant	NN	O	O
from	NN	O	O
the	NN	O	O
recording	NN	O	O
pipette	NN	O	O
resulted	NN	O	O
in	NN	O	O
population	NN	O	O
responses	NN	O	O
of	NN	O	O
1	NN	O	O
-	NN	O	O
30	NN	O	O
s	NN	O	O
duration	NN	O	O
in	NN	O	O
slices	NN	O	O
from	NN	O	O
SE	NN	O	B
survivors	NN	O	O
but	NN	O	O
not	NN	O	O
other	NN	O	O
groups	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
support	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
SE	NN	O	B
-	NN	O	O
induced	NN	O	O
mossy	NN	O	O
fiber	NN	O	O
sprouting	NN	O	O
and	NN	O	O
synaptic	NN	O	O
reorganization	NN	O	O
are	NN	O	O
relevant	NN	O	O
characteristics	NN	O	O
of	NN	O	O
seizure	NN	O	B
development	NN	O	O
in	NN	O	O
these	NN	O	O
murine	NN	O	O
strains	NN	O	O
,	NN	O	O
resembling	NN	O	O
rat	NN	O	O
models	NN	O	O
of	NN	O	O
human	NN	O	O
temporal	NN	O	B
lobe	NN	O	I
epilepsy	NN	O	I
.	NN	O	O

Urinary	NN	O	B
bladder	NN	O	I
cancer	NN	O	I
in	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
:	NN	O	O
risks	NN	O	O
and	NN	O	O
relation	NN	O	O
to	NN	O	O
cyclophosphamide	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
and	NN	O	O
characterise	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
,	NN	O	O
and	NN	O	O
its	NN	O	O
relation	NN	O	O
to	NN	O	O
cyclophosphamide	NN	O	O
,	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
the	NN	O	O
population	NN	O	O
based	NN	O	O
,	NN	O	O
nationwide	NN	O	O
Swedish	NN	O	O
Inpatient	NN	O	O
Register	NN	O	O
a	NN	O	O
cohort	NN	O	O
of	NN	O	O
1065	NN	O	O
patients	NN	O	O
with	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
,	NN	O	O
1969	NN	O	O
-	NN	O	O
95	NN	O	O
,	NN	O	O
was	NN	O	O
identified	NN	O	O
.	NN	O	O

Through	NN	O	O
linkage	NN	O	O
with	NN	O	O
the	NN	O	O
Swedish	NN	O	O
Cancer	NN	O	B
Register	NN	O	O
,	NN	O	O
all	NN	O	O
subjects	NN	O	O
in	NN	O	O
this	NN	O	O
cohort	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
were	NN	O	O
identified	NN	O	O
.	NN	O	O

Nested	NN	O	O
within	NN	O	O
the	NN	O	O
cohort	NN	O	O
,	NN	O	O
a	NN	O	O
matched	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
cyclophosphamide	NN	O	O
and	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
using	NN	O	O
odds	NN	O	O
ratios	NN	O	O
(	NN	O	O
ORs	NN	O	O
)	NN	O	O
as	NN	O	O
relative	NN	O	O
risk	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
cohort	NN	O	O
the	NN	O	O
cumulative	NN	O	O
risk	NN	O	O
of	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
after	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
,	NN	O	O
and	NN	O	O
the	NN	O	O
relative	NN	O	O
prevalence	NN	O	O
of	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
,	NN	O	O
were	NN	O	O
also	NN	O	O
estimated	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
median	NN	O	O
cumulative	NN	O	O
doses	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	O
among	NN	O	O
cases	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
11	NN	O	O
)	NN	O	O
and	NN	O	O
controls	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
25	NN	O	O
)	NN	O	O
were	NN	O	O
113	NN	O	O
g	NN	O	O
and	NN	O	O
25	NN	O	O
g	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
doubled	NN	O	O
for	NN	O	O
every	NN	O	O
10	NN	O	O
g	NN	O	O
increment	NN	O	O
in	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
OR	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
(	NN	O	O
CI	NN	O	O
)	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
to	NN	O	O
4	NN	O	O
.	NN	O	O
9	NN	O	O
)	NN	O	O
.	NN	O	O

Treatment	NN	O	O
duration	NN	O	O
longer	NN	O	O
than	NN	O	O
1	NN	O	O
year	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
eightfold	NN	O	O
increased	NN	O	O
risk	NN	O	O
(	NN	O	O
OR	NN	O	O
=	NN	O	O
7	NN	O	O
.	NN	O	O
7	NN	O	O
,	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
to	NN	O	O
69	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
absolute	NN	O	O
risk	NN	O	O
for	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
in	NN	O	O
the	NN	O	O
cohort	NN	O	O
reached	NN	O	O
10	NN	O	O
%	NN	O	O
16	NN	O	O
years	NN	O	O
after	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
,	NN	O	O
and	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
was	NN	O	O
(	NN	O	O
non	NN	O	O
-	NN	O	O
significantly	NN	O	O
)	NN	O	O
twice	NN	O	O
as	NN	O	O
common	NN	O	O
as	NN	O	O
expected	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
indicate	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
relationship	NN	O	O
between	NN	O	O
cyclophosphamide	NN	O	O
and	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
bladder	NN	O	B
cancer	NN	O	I
,	NN	O	O
high	NN	O	O
cumulative	NN	O	O
risks	NN	O	O
in	NN	O	O
the	NN	O	O
entire	NN	O	O
cohort	NN	O	O
,	NN	O	O
and	NN	O	O
also	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
risk	NN	O	O
factors	NN	O	O
operating	NN	O	O
even	NN	O	O
before	NN	O	O
Wegener	NN	O	B
'	NN	O	I
s	NN	O	I
granulomatosis	NN	O	I
.	NN	O	O

Differential	NN	O	O
modulation	NN	O	O
by	NN	O	O
estrogen	NN	O	O
of	NN	O	O
alpha2	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
and	NN	O	O
I1	NN	O	O
-	NN	O	O
imidazoline	NN	O	O
receptor	NN	O	O
-	NN	O	O
mediated	NN	O	O
hypotension	NN	O	B
in	NN	O	O
female	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
recently	NN	O	O
shown	NN	O	O
that	NN	O	O
estrogen	NN	O	O
negatively	NN	O	O
modulates	NN	O	O
the	NN	O	O
hypotensive	NN	O	B
effect	NN	O	O
of	NN	O	O
clonidine	NN	O	O
(	NN	O	O
mixed	NN	O	O
alpha2	NN	O	O
-	NN	O	O
/	NN	O	O
I1	NN	O	O
-	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
)	NN	O	O
in	NN	O	O
female	NN	O	O
rats	NN	O	O
and	NN	O	O
implicates	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
autonomic	NN	O	O
control	NN	O	O
in	NN	O	O
this	NN	O	O
interaction	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
investigated	NN	O	O
whether	NN	O	O
this	NN	O	O
effect	NN	O	O
of	NN	O	O
estrogen	NN	O	O
involves	NN	O	O
interaction	NN	O	O
with	NN	O	O
alpha2	NN	O	O
-	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
I1	NN	O	O
-	NN	O	O
receptors	NN	O	O
.	NN	O	O

Changes	NN	O	O
evoked	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
intraperitoneal	NN	O	O
injection	NN	O	O
of	NN	O	O
rilmenidine	NN	O	O
(	NN	O	O
600	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
selective	NN	O	O
I1	NN	O	O
-	NN	O	O
and	NN	O	O
alpha2	NN	O	O
-	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
hemodynamic	NN	O	O
variability	NN	O	O
,	NN	O	O
and	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
were	NN	O	O
assessed	NN	O	O
in	NN	O	O
radiotelemetered	NN	O	O
sham	NN	O	O
-	NN	O	O
operated	NN	O	O
and	NN	O	O
ovariectomized	NN	O	O
(	NN	O	O
Ovx	NN	O	O
)	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
female	NN	O	O
rats	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
12	NN	O	O
-	NN	O	O
wk	NN	O	O
estrogen	NN	O	O
replacement	NN	O	O
.	NN	O	O

Three	NN	O	O
time	NN	O	O
domain	NN	O	O
indexes	NN	O	O
of	NN	O	O
hemodynamic	NN	O	O
variability	NN	O	O
were	NN	O	O
employed	NN	O	O
:	NN	O	O
the	NN	O	O
standard	NN	O	O
deviation	NN	O	O
of	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
as	NN	O	O
a	NN	O	O
measure	NN	O	O
of	NN	O	O
blood	NN	O	O
pressure	NN	O	O
variability	NN	O	O
and	NN	O	O
the	NN	O	O
standard	NN	O	O
deviation	NN	O	O
of	NN	O	O
beat	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
beat	NN	O	O
intervals	NN	O	O
(	NN	O	O
SDRR	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
root	NN	O	O
mean	NN	O	O
square	NN	O	O
of	NN	O	O
successive	NN	O	O
differences	NN	O	O
in	NN	O	O
R	NN	O	O
-	NN	O	O
wave	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
R	NN	O	O
-	NN	O	O
wave	NN	O	O
intervals	NN	O	O
as	NN	O	O
measures	NN	O	O
of	NN	O	O
heart	NN	O	O
rate	NN	O	O
variability	NN	O	O
.	NN	O	O

In	NN	O	O
sham	NN	O	O
-	NN	O	O
operated	NN	O	O
rats	NN	O	O
,	NN	O	O
rilmenidine	NN	O	O
or	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
elicited	NN	O	O
similar	NN	O	O
hypotension	NN	O	B
that	NN	O	O
lasted	NN	O	O
at	NN	O	O
least	NN	O	O
5	NN	O	O
h	NN	O	O
and	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
reductions	NN	O	O
in	NN	O	O
standard	NN	O	O
deviation	NN	O	O
of	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
.	NN	O	O

SDRR	NN	O	O
was	NN	O	O
reduced	NN	O	O
only	NN	O	O
by	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
.	NN	O	O

Ovx	NN	O	O
significantly	NN	O	O
enhanced	NN	O	O
the	NN	O	O
hypotensive	NN	O	B
response	NN	O	O
to	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
,	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
rilmenidine	NN	O	O
hypotension	NN	O	B
.	NN	O	O

The	NN	O	O
enhanced	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
hypotension	NN	O	B
in	NN	O	O
Ovx	NN	O	O
rats	NN	O	O
was	NN	O	O
paralleled	NN	O	O
with	NN	O	O
further	NN	O	O
reduction	NN	O	O
in	NN	O	O
SDRR	NN	O	O
and	NN	O	O
a	NN	O	B
reduced	NN	O	I
locomotor	NN	O	I
activity	NN	O	I
.	NN	O	O

Estrogen	NN	O	O
replacement	NN	O	O
(	NN	O	O
17beta	NN	O	O
-	NN	O	O
estradiol	NN	O	O
subcutaneous	NN	O	O
pellet	NN	O	O
,	NN	O	O
14	NN	O	O
.	NN	O	O
2	NN	O	O
microg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
12	NN	O	O
wk	NN	O	O
)	NN	O	O
of	NN	O	O
Ovx	NN	O	O
rats	NN	O	O
restored	NN	O	O
the	NN	O	O
hemodynamic	NN	O	O
and	NN	O	O
locomotor	NN	O	O
effects	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
to	NN	O	O
sham	NN	O	O
-	NN	O	O
operated	NN	O	O
levels	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
estrogen	NN	O	O
downregulates	NN	O	O
alpha2	NN	O	O
-	NN	O	O
but	NN	O	O
not	NN	O	O
I1	NN	O	O
-	NN	O	O
receptor	NN	O	O
-	NN	O	O
mediated	NN	O	O
hypotension	NN	O	B
and	NN	O	O
highlight	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
the	NN	O	O
cardiac	NN	O	O
autonomic	NN	O	O
control	NN	O	O
in	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
-	NN	O	O
estrogen	NN	O	O
interaction	NN	O	O
.	NN	O	O

Severe	NN	O	O
reversible	NN	O	O
left	NN	O	B
ventricular	NN	O	I
systolic	NN	O	I
and	NN	O	I
diastolic	NN	O	I
dysfunction	NN	O	I
due	NN	O	O
to	NN	O	O
accidental	NN	O	O
iatrogenic	NN	O	O
epinephrine	NN	O	O
overdose	NN	O	B
.	NN	O	O

Catecholamine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B
due	NN	O	O
to	NN	O	O
chronic	NN	O	O
excess	NN	O	O
of	NN	O	O
endogenous	NN	O	O
catecholamines	NN	O	O
has	NN	O	O
been	NN	O	O
recognized	NN	O	O
for	NN	O	O
decades	NN	O	O
as	NN	O	O
a	NN	O	O
clinical	NN	O	O
phenomenon	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
reports	NN	O	O
of	NN	O	O
myocardial	NN	O	B
dysfunction	NN	O	I
due	NN	O	O
to	NN	O	O
acute	NN	O	O
iatrogenic	NN	O	O
overdose	NN	O	B
are	NN	O	O
rare	NN	O	O
.	NN	O	O

A	NN	O	O
35	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
whose	NN	O	O
cervix	NN	O	O
uteri	NN	O	O
was	NN	O	O
inadvertently	NN	O	O
injected	NN	O	O
with	NN	O	O
8	NN	O	O
mg	NN	O	O
of	NN	O	O
epinephrine	NN	O	O
developed	NN	O	O
myocardial	NN	O	B
stunning	NN	O	I
that	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
severe	NN	O	O
hemodynamic	NN	O	O
compromise	NN	O	O
,	NN	O	O
profound	NN	O	O
,	NN	O	O
albeit	NN	O	O
transient	NN	O	O
,	NN	O	O
left	NN	O	B
ventricular	NN	O	I
systolic	NN	O	I
and	NN	O	I
diastolic	NN	O	I
dysfunction	NN	O	I
,	NN	O	O
and	NN	O	O
only	NN	O	O
modestly	NN	O	O
elevated	NN	O	O
biochemical	NN	O	O
markers	NN	O	O
of	NN	O	O
myocardial	NN	O	B
necrosis	NN	O	I
.	NN	O	O

Our	NN	O	O
case	NN	O	O
illustrates	NN	O	O
the	NN	O	O
serious	NN	O	O
consequences	NN	O	O
of	NN	O	O
medical	NN	O	O
errors	NN	O	O
that	NN	O	O
can	NN	O	O
be	NN	O	O
avoided	NN	O	O
through	NN	O	O
improved	NN	O	O
medication	NN	O	O
labeling	NN	O	O
and	NN	O	O
staff	NN	O	O
supervision	NN	O	O
.	NN	O	O

Cardioprotective	NN	O	O
effect	NN	O	O
of	NN	O	O
tincture	NN	O	O
of	NN	O	O
Crataegus	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Tincture	NN	O	O
of	NN	O	O
Crataegus	NN	O	O
(	NN	O	O
TCR	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
alcoholic	NN	O	O
extract	NN	O	O
of	NN	O	O
the	NN	O	O
berries	NN	O	O
of	NN	O	O
hawthorn	NN	O	O
(	NN	O	O
Crataegus	NN	O	O
oxycantha	NN	O	O
)	NN	O	O
,	NN	O	O
is	NN	O	O
used	NN	O	O
in	NN	O	O
herbal	NN	O	O
and	NN	O	O
homeopathic	NN	O	O
medicine	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
done	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
TCR	NN	O	O
on	NN	O	O
experimentally	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
of	NN	O	O
TCR	NN	O	O
,	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mL	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
bodyweight	NN	O	O
per	NN	O	O
day	NN	O	O
,	NN	O	O
orally	NN	O	O
for	NN	O	O
30	NN	O	O
days	NN	O	O
,	NN	O	O
prevented	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
and	NN	O	O
activity	NN	O	O
of	NN	O	O
marker	NN	O	O
enzymes	NN	O	O
observed	NN	O	O
in	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
rats	NN	O	O
(	NN	O	O
85	NN	O	O
mg	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
for	NN	O	O
2	NN	O	O
days	NN	O	O
at	NN	O	O
an	NN	O	O
interval	NN	O	O
of	NN	O	O
24	NN	O	O
h	NN	O	O
)	NN	O	O
.	NN	O	O

TCR	NN	O	O
prevented	NN	O	O
the	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
decrease	NN	O	O
in	NN	O	O
antioxidant	NN	O	O
enzymes	NN	O	O
in	NN	O	O
the	NN	O	O
heart	NN	O	O
and	NN	O	O
increased	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
ADP	NN	O	O
-	NN	O	O
stimulated	NN	O	O
oxygen	NN	O	O
uptake	NN	O	O
and	NN	O	O
respiratory	NN	O	O
coupling	NN	O	O
ratio	NN	O	O
.	NN	O	O

TCR	NN	O	O
protected	NN	O	O
against	NN	O	O
pathological	NN	O	O
changes	NN	O	O
induced	NN	O	O
by	NN	O	O
isoproterenol	NN	O	O
in	NN	O	O
rat	NN	O	O
heart	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
TCR	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
in	NN	O	O
preventing	NN	O	O
the	NN	O	O
damage	NN	O	O
induced	NN	O	O
by	NN	O	O
isoproterenol	NN	O	O
in	NN	O	O
rat	NN	O	O
heart	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
tinnitus	NN	O	B
by	NN	O	O
intratympanic	NN	O	O
instillation	NN	O	O
of	NN	O	O
lignocaine	NN	O	O
(	NN	O	O
lidocaine	NN	O	O
)	NN	O	O
2	NN	O	O
per	NN	O	O
cent	NN	O	O
through	NN	O	O
ventilation	NN	O	O
tubes	NN	O	O
.	NN	O	O

Idiopathic	NN	O	B
subjective	NN	O	I
tinnitus	NN	O	I
(	NN	O	O
IST	NN	O	B
)	NN	O	O
is	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
obscure	NN	O	O
otological	NN	O	O
pathologies	NN	O	O
.	NN	O	O

This	NN	O	O
paper	NN	O	O
presents	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
treating	NN	O	O
IST	NN	O	B
by	NN	O	O
intratympanic	NN	O	O
instillation	NN	O	O
of	NN	O	O
lignocaine	NN	O	O
(	NN	O	O
lidocaine	NN	O	O
)	NN	O	O
2	NN	O	O
per	NN	O	O
cent	NN	O	O
through	NN	O	O
a	NN	O	O
grommet	NN	O	O
,	NN	O	O
for	NN	O	O
five	NN	O	O
weekly	NN	O	O
courses	NN	O	O
.	NN	O	O

Fifty	NN	O	O
-	NN	O	O
two	NN	O	O
patients	NN	O	O
suffering	NN	O	O
from	NN	O	O
intractable	NN	O	O
tinnitus	NN	O	B
entered	NN	O	O
this	NN	O	O
therapeutic	NN	O	O
trial	NN	O	O
,	NN	O	O
but	NN	O	O
only	NN	O	O
nine	NN	O	O
finished	NN	O	O
all	NN	O	O
five	NN	O	O
courses	NN	O	O
.	NN	O	O

In	NN	O	O
one	NN	O	O
patient	NN	O	O
,	NN	O	O
the	NN	O	O
tinnitus	NN	O	B
was	NN	O	O
almost	NN	O	O
completely	NN	O	O
abolished	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
nine	NN	O	O
patients	NN	O	O
the	NN	O	O
decompensated	NN	O	O
tinnitus	NN	O	B
changed	NN	O	O
to	NN	O	O
a	NN	O	O
compensated	NN	O	O
one	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
this	NN	O	O
mode	NN	O	O
of	NN	O	O
treatment	NN	O	O
for	NN	O	O
patients	NN	O	O
that	NN	O	O
were	NN	O	O
previously	NN	O	O
treated	NN	O	O
by	NN	O	O
drugs	NN	O	O
,	NN	O	O
acupuncture	NN	O	O
and	NN	O	O
biofeedback	NN	O	O
,	NN	O	O
with	NN	O	O
disappointing	NN	O	O
results	NN	O	O
.	NN	O	O

Patients	NN	O	O
should	NN	O	O
be	NN	O	O
warned	NN	O	O
about	NN	O	O
the	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
vertigo	NN	O	B
and	NN	O	O
vomiting	NN	O	B
,	NN	O	O
which	NN	O	O
subsides	NN	O	O
gradually	NN	O	O
with	NN	O	O
every	NN	O	O
new	NN	O	O
instillation	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
tinnitus	NN	O	B
may	NN	O	O
not	NN	O	O
disappear	NN	O	O
but	NN	O	O
will	NN	O	O
be	NN	O	O
alleviated	NN	O	O
,	NN	O	O
enabling	NN	O	O
them	NN	O	O
to	NN	O	O
cope	NN	O	O
more	NN	O	O
easily	NN	O	O
with	NN	O	O
the	NN	O	O
disease	NN	O	O
and	NN	O	O
lead	NN	O	O
a	NN	O	O
more	NN	O	O
normal	NN	O	O
life	NN	O	O
.	NN	O	O

The	NN	O	O
alpha3	NN	O	O
and	NN	O	O
beta4	NN	O	O
nicotinic	NN	O	O
acetylcholine	NN	O	O
receptor	NN	O	O
subunits	NN	O	O
are	NN	O	O
necessary	NN	O	O
for	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
hypolocomotion	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Binding	NN	O	O
of	NN	O	O
nicotine	NN	O	O
to	NN	O	O
nicotinic	NN	O	O
acetylcholine	NN	O	O
receptors	NN	O	O
(	NN	O	O
nAChRs	NN	O	O
)	NN	O	O
elicits	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
behaviors	NN	O	O
that	NN	O	O
go	NN	O	O
from	NN	O	O
altered	NN	O	O
exploration	NN	O	O
,	NN	O	O
sedation	NN	O	O
,	NN	O	O
and	NN	O	O
tremors	NN	O	B
,	NN	O	O
to	NN	O	O
seizures	NN	O	B
and	NN	O	O
death	NN	O	B
.	NN	O	O

nAChRs	NN	O	O
are	NN	O	O
pentameric	NN	O	O
ion	NN	O	O
channels	NN	O	O
usually	NN	O	O
composed	NN	O	O
of	NN	O	O
alpha	NN	O	O
and	NN	O	O
beta	NN	O	O
subunits	NN	O	O
.	NN	O	O

A	NN	O	O
gene	NN	O	O
cluster	NN	O	O
comprises	NN	O	O
the	NN	O	O
alpha3	NN	O	O
,	NN	O	O
alpha5	NN	O	O
and	NN	O	O
beta4	NN	O	O
subunits	NN	O	O
,	NN	O	O
which	NN	O	O
coassemble	NN	O	O
to	NN	O	O
form	NN	O	O
functional	NN	O	O
receptors	NN	O	O
.	NN	O	O

We	NN	O	O
examined	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
beta4	NN	O	O
subunits	NN	O	O
in	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
hypolocomotion	NN	O	B
in	NN	O	O
beta4	NN	O	O
homozygous	NN	O	O
null	NN	O	O
(	NN	O	O
beta4	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
and	NN	O	O
alpha3	NN	O	O
heterozygous	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
.	NN	O	O

beta4	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
were	NN	O	O
less	NN	O	O
sensitive	NN	O	O
to	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
nicotine	NN	O	O
both	NN	O	O
at	NN	O	O
low	NN	O	O
doses	NN	O	O
,	NN	O	O
measured	NN	O	O
as	NN	O	O
decreased	NN	O	O
exploration	NN	O	O
in	NN	O	O
an	NN	O	O
open	NN	O	O
field	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
high	NN	O	O
doses	NN	O	O
,	NN	O	O
measured	NN	O	O
as	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
.	NN	O	O

Using	NN	O	O
in	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
probes	NN	O	O
for	NN	O	O
the	NN	O	O
alpha3	NN	O	O
and	NN	O	O
alpha5	NN	O	O
subunits	NN	O	O
,	NN	O	O
we	NN	O	O
showed	NN	O	O
that	NN	O	O
alpha5	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
are	NN	O	O
unchanged	NN	O	O
,	NN	O	O
whereas	NN	O	O
alpha3	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
are	NN	O	O
selectively	NN	O	O
decreased	NN	O	O
in	NN	O	O
the	NN	O	O
mitral	NN	O	O
cell	NN	O	O
layer	NN	O	O
of	NN	O	O
the	NN	O	O
olfactory	NN	O	O
bulb	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
inferior	NN	O	O
and	NN	O	O
the	NN	O	O
superior	NN	O	O
colliculus	NN	O	O
of	NN	O	O
beta4	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
brains	NN	O	O
.	NN	O	O

alpha3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
were	NN	O	O
partially	NN	O	O
resistant	NN	O	O
to	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
when	NN	O	O
compared	NN	O	O
to	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
littermates	NN	O	O
.	NN	O	O

mRNA	NN	O	O
levels	NN	O	O
for	NN	O	O
the	NN	O	O
alpha5	NN	O	O
and	NN	O	O
the	NN	O	O
beta4	NN	O	O
subunits	NN	O	O
were	NN	O	O
unchanged	NN	O	O
in	NN	O	O
alpha3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
brains	NN	O	O
.	NN	O	O

Together	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
beta4	NN	O	O
and	NN	O	O
the	NN	O	O
alpha3	NN	O	O
subunits	NN	O	O
are	NN	O	O
mediators	NN	O	O
of	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
hypolocomotion	NN	O	B
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
sevoflurane	NN	O	O
on	NN	O	O
lidocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
.	NN	O	O

The	NN	O	O
influence	NN	O	O
of	NN	O	O
sevoflurane	NN	O	O
on	NN	O	O
lidocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
was	NN	O	O
studied	NN	O	O
in	NN	O	O
cats	NN	O	O
.	NN	O	O

The	NN	O	O
convulsive	NN	O	B
threshold	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
was	NN	O	O
41	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
.	NN	O	O

l	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
with	NN	O	O
lidocaine	NN	O	O
infusion	NN	O	O
(	NN	O	O
6	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O
min	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
)	NN	O	O
,	NN	O	O
increasing	NN	O	O
significantly	NN	O	O
to	NN	O	O
66	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
.	NN	O	O

l	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
when	NN	O	O
the	NN	O	O
end	NN	O	O
-	NN	O	O
tidal	NN	O	O
concentration	NN	O	O
of	NN	O	O
sevoflurane	NN	O	O
was	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
threshold	NN	O	O
(	NN	O	O
61	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
7	NN	O	O
mg	NN	O	O
.	NN	O	O
l	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
)	NN	O	O
during	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
sevoflurane	NN	O	O
was	NN	O	O
not	NN	O	O
significant	NN	O	O
from	NN	O	O
that	NN	O	O
during	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
sevoflurane	NN	O	O
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
celling	NN	O	O
effect	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
convulsive	NN	O	B
threshold	NN	O	O
between	NN	O	O
sevoflurane	NN	O	O
and	NN	O	O
enflurane	NN	O	O
.	NN	O	O

The	NN	O	O
rise	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
became	NN	O	O
less	NN	O	O
marked	NN	O	O
when	NN	O	O
higher	NN	O	O
concentrations	NN	O	O
of	NN	O	O
sevoflurane	NN	O	O
or	NN	O	O
enflurane	NN	O	O
were	NN	O	O
administered	NN	O	O
and	NN	O	O
the	NN	O	O
blood	NN	O	O
pressure	NN	O	O
at	NN	O	O
convulsions	NN	O	B
decreased	NN	O	O
significantly	NN	O	O
in	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
sevoflurane	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
enflurane	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
lidocaine	NN	O	O
concentrations	NN	O	O
measured	NN	O	O
when	NN	O	O
the	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
became	NN	O	O
70	NN	O	O
mmHg	NN	O	O
.	NN	O	O

Apamin	NN	O	O
,	NN	O	O
a	NN	O	O
selective	NN	O	O
blocker	NN	O	O
of	NN	O	O
calcium	NN	O	O
-	NN	O	O
dependent	NN	O	O
potassium	NN	O	O
channels	NN	O	O
,	NN	O	O
was	NN	O	O
administered	NN	O	O
intracerebroventricularly	NN	O	O
in	NN	O	O
rats	NN	O	O
anesthetized	NN	O	O
with	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
sevoflurane	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
the	NN	O	O
anticonvulsive	NN	O	O
effects	NN	O	O
.	NN	O	O

Apamin	NN	O	O
(	NN	O	O
10	NN	O	O
ng	NN	O	O
)	NN	O	O
had	NN	O	O
a	NN	O	O
tendency	NN	O	O
to	NN	O	O
decrease	NN	O	O
the	NN	O	O
convulsive	NN	O	B
threshold	NN	O	O
(	NN	O	O
21	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
2	NN	O	O
to	NN	O	O
19	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
.	NN	O	O
l	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
)	NN	O	O
but	NN	O	O
this	NN	O	O
was	NN	O	O
not	NN	O	O
statistically	NN	O	O
significant	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
sevoflurane	NN	O	O
reduces	NN	O	O
the	NN	O	O
convulsive	NN	O	B
effect	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
toxicity	NN	O	B
but	NN	O	O
carries	NN	O	O
some	NN	O	O
risk	NN	O	O
due	NN	O	O
to	NN	O	O
circulatory	NN	O	O
depression	NN	O	B
.	NN	O	O

Cardiac	NN	O	B
toxicity	NN	O	I
observed	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
based	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Cyclophosphamide	NN	O	O
is	NN	O	O
an	NN	O	O
alkylating	NN	O	O
agent	NN	O	O
given	NN	O	O
frequently	NN	O	O
as	NN	O	O
a	NN	O	O
component	NN	O	O
of	NN	O	O
many	NN	O	O
conditioning	NN	O	O
regimens	NN	O	O
.	NN	O	O

In	NN	O	O
high	NN	O	O
doses	NN	O	O
,	NN	O	O
its	NN	O	O
nonhematological	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
toxicity	NN	O	B
is	NN	O	O
cardiomyopathy	NN	O	B
.	NN	O	O

STUDY	NN	O	O
DESIGN	NN	O	O
:	NN	O	O
We	NN	O	O
combined	NN	O	O
paclitaxel	NN	O	O
,	NN	O	O
melphalan	NN	O	O
and	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cyclophosphamide	NN	O	O
,	NN	O	O
thiotepa	NN	O	O
,	NN	O	O
and	NN	O	O
carboplatin	NN	O	O
in	NN	O	O
a	NN	O	O
triple	NN	O	O
sequential	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
regimen	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
.	NN	O	O

Analysis	NN	O	O
was	NN	O	O
performed	NN	O	O
on	NN	O	O
61	NN	O	O
women	NN	O	O
with	NN	O	O
chemotherapy	NN	O	O
-	NN	O	O
responsive	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
receiving	NN	O	O
96	NN	O	O
-	NN	O	O
h	NN	O	O
infusional	NN	O	O
cyclophosphamide	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
a	NN	O	O
triple	NN	O	O
sequential	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
regimen	NN	O	O
to	NN	O	O
assess	NN	O	O
association	NN	O	O
between	NN	O	O
presence	NN	O	O
of	NN	O	O
peritransplant	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
(	NN	O	O
CHF	NN	O	B
)	NN	O	O
and	NN	O	O
the	NN	O	O
following	NN	O	O
pretreatment	NN	O	O
characteristics	NN	O	O
:	NN	O	O
presence	NN	O	O
of	NN	O	O
electrocardiogram	NN	O	O
(	NN	O	O
EKG	NN	O	O
)	NN	O	O
abnormalities	NN	O	O
,	NN	O	O
age	NN	O	O
,	NN	O	O
hypertension	NN	O	B
,	NN	O	O
prior	NN	O	O
cardiac	NN	O	O
history	NN	O	O
,	NN	O	O
smoking	NN	O	O
,	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
,	NN	O	O
prior	NN	O	O
use	NN	O	O
of	NN	O	O
anthracyclines	NN	O	O
,	NN	O	O
and	NN	O	O
left	NN	O	O
-	NN	O	O
sided	NN	O	O
chest	NN	O	O
irradiation	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Six	NN	O	O
of	NN	O	O
61	NN	O	O
women	NN	O	O
(	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
clinically	NN	O	O
reversible	NN	O	O
grade	NN	O	O
3	NN	O	O
CHF	NN	O	B
following	NN	O	O
infusional	NN	O	O
cyclophosphamide	NN	O	O
with	NN	O	O
a	NN	O	O
median	NN	O	O
percent	NN	O	O
decline	NN	O	O
in	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
of	NN	O	O
31	NN	O	O
%	NN	O	O
.	NN	O	O

Incidence	NN	O	O
of	NN	O	O
transient	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
related	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
(	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
is	NN	O	O
comparable	NN	O	O
to	NN	O	O
previous	NN	O	O
recorded	NN	O	O
literature	NN	O	O
.	NN	O	O

Older	NN	O	O
age	NN	O	O
was	NN	O	O
significantly	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
CHF	NN	O	B
development	NN	O	O
;	NN	O	O
with	NN	O	O
median	NN	O	O
ages	NN	O	O
for	NN	O	O
the	NN	O	O
entire	NN	O	O
group	NN	O	O
and	NN	O	O
for	NN	O	O
patients	NN	O	O
developing	NN	O	O
CHF	NN	O	B
of	NN	O	O
45	NN	O	O
and	NN	O	O
59	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

No	NN	O	O
association	NN	O	O
was	NN	O	O
found	NN	O	O
with	NN	O	O
other	NN	O	O
pretreatment	NN	O	O
characteristics	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
As	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
these	NN	O	O
findings	NN	O	O
,	NN	O	O
oncologists	NN	O	O
should	NN	O	O
carefully	NN	O	O
monitor	NN	O	O
fluid	NN	O	O
balance	NN	O	O
in	NN	O	O
older	NN	O	O
patients	NN	O	O
.	NN	O	O

Routine	NN	O	O
EKG	NN	O	O
monitoring	NN	O	O
during	NN	O	O
infusional	NN	O	O
cyclophosphamide	NN	O	O
did	NN	O	O
not	NN	O	O
predict	NN	O	O
CHF	NN	O	B
development	NN	O	O
.	NN	O	O

Tremor	NN	O	B
side	NN	O	O
effects	NN	O	O
of	NN	O	O
salbutamol	NN	O	O
,	NN	O	O
quantified	NN	O	O
by	NN	O	O
a	NN	O	O
laser	NN	O	O
pointer	NN	O	O
technique	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
study	NN	O	O
tremor	NN	O	B
side	NN	O	O
effects	NN	O	O
of	NN	O	O
salbutamol	NN	O	O
an	NN	O	O
easily	NN	O	O
applicable	NN	O	O
,	NN	O	O
quick	NN	O	O
and	NN	O	O
low	NN	O	O
-	NN	O	O
priced	NN	O	O
method	NN	O	O
is	NN	O	O
needed	NN	O	O
.	NN	O	O

A	NN	O	O
new	NN	O	O
method	NN	O	O
using	NN	O	O
a	NN	O	O
commercially	NN	O	O
available	NN	O	O
,	NN	O	O
pen	NN	O	O
-	NN	O	O
shaped	NN	O	O
laser	NN	O	O
pointer	NN	O	O
was	NN	O	O
developed	NN	O	O
.	NN	O	O

Aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
sensitivity	NN	O	O
,	NN	O	O
reproducibility	NN	O	O
,	NN	O	O
reference	NN	O	O
values	NN	O	O
and	NN	O	O
the	NN	O	O
agreement	NN	O	O
with	NN	O	O
a	NN	O	O
questionnaire	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Tremor	NN	O	B
was	NN	O	O
measured	NN	O	O
using	NN	O	O
a	NN	O	O
laser	NN	O	O
pointer	NN	O	O
technique	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
sensitivity	NN	O	O
we	NN	O	O
assessed	NN	O	O
tremor	NN	O	B
in	NN	O	O
44	NN	O	O
patients	NN	O	O
with	NN	O	O
obstructive	NN	O	B
lung	NN	O	I
disease	NN	O	I
after	NN	O	O
administration	NN	O	O
of	NN	O	O
cumulative	NN	O	O
doses	NN	O	O
of	NN	O	O
salbutamol	NN	O	O
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
asked	NN	O	O
to	NN	O	O
aim	NN	O	O
at	NN	O	O
the	NN	O	O
centre	NN	O	O
of	NN	O	O
a	NN	O	O
target	NN	O	O
,	NN	O	O
subdivided	NN	O	O
in	NN	O	O
concentric	NN	O	O
circles	NN	O	O
,	NN	O	O
from	NN	O	O
5	NN	O	O
m	NN	O	O
distance	NN	O	O
.	NN	O	O

The	NN	O	O
circle	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
participant	NN	O	O
succeeded	NN	O	O
to	NN	O	O
aim	NN	O	O
was	NN	O	O
recorded	NN	O	O
in	NN	O	O
millimetres	NN	O	O
radius	NN	O	O
.	NN	O	O

In	NN	O	O
another	NN	O	O
series	NN	O	O
of	NN	O	O
measurements	NN	O	O
,	NN	O	O
reproducibility	NN	O	O
and	NN	O	O
reference	NN	O	O
values	NN	O	O
of	NN	O	O
the	NN	O	O
tremor	NN	O	B
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
65	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
in	NN	O	O
three	NN	O	O
sessions	NN	O	O
,	NN	O	O
at	NN	O	O
9	NN	O	O
a	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
,	NN	O	O
4	NN	O	O
p	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
and	NN	O	O
9	NN	O	O
a	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
1	NN	O	O
week	NN	O	O
later	NN	O	O
.	NN	O	O

Postural	NN	O	O
tremor	NN	O	B
was	NN	O	O
measured	NN	O	O
with	NN	O	O
the	NN	O	O
arm	NN	O	O
horizontally	NN	O	O
outstretched	NN	O	O
rest	NN	O	O
tremor	NN	O	B
with	NN	O	O
the	NN	O	O
arm	NN	O	O
supported	NN	O	O
by	NN	O	O
an	NN	O	O
armrest	NN	O	O
and	NN	O	O
finally	NN	O	O
tremor	NN	O	B
was	NN	O	O
measured	NN	O	O
after	NN	O	O
holding	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
kg	NN	O	O
weight	NN	O	O
until	NN	O	O
exhaustion	NN	O	O
.	NN	O	O

Inter	NN	O	O
-	NN	O	O
observer	NN	O	O
variability	NN	O	O
was	NN	O	O
measured	NN	O	O
in	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
10	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
.	NN	O	O

Tremor	NN	O	B
was	NN	O	O
measured	NN	O	O
simultaneously	NN	O	O
by	NN	O	O
two	NN	O	O
independent	NN	O	O
observers	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Salbutamol	NN	O	O
significantly	NN	O	O
increased	NN	O	O
tremor	NN	O	B
severity	NN	O	O
in	NN	O	O
patients	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
way	NN	O	O
.	NN	O	O

Within	NN	O	O
healthy	NN	O	O
adults	NN	O	O
no	NN	O	O
age	NN	O	O
-	NN	O	O
dependency	NN	O	O
could	NN	O	O
be	NN	O	O
found	NN	O	O
(	NN	O	O
b	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
262	NN	O	O
mm	NN	O	O
/	NN	O	O
year	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
72	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
agreement	NN	O	O
between	NN	O	O
the	NN	O	O
questionnaire	NN	O	O
and	NN	O	O
tremor	NN	O	B
severity	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
093	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
53	NN	O	O
)	NN	O	O
.	NN	O	O

Postural	NN	O	O
tremor	NN	O	B
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
first	NN	O	O
and	NN	O	O
third	NN	O	O
session	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
07	NN	O	O
)	NN	O	O
.	NN	O	O

Support	NN	O	O
of	NN	O	O
the	NN	O	O
arm	NN	O	O
decreased	NN	O	O
tremor	NN	O	B
severity	NN	O	O
,	NN	O	O
exhaustion	NN	O	O
increased	NN	O	O
tremor	NN	O	B
severity	NN	O	O
significantly	NN	O	O
.	NN	O	O

A	NN	O	O
good	NN	O	O
agreement	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
two	NN	O	O
independent	NN	O	O
observers	NN	O	O
(	NN	O	O
interclass	NN	O	O
correlation	NN	O	O
coefficient	NN	O	O
0	NN	O	O
.	NN	O	O
72	NN	O	O
)	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Quantifying	NN	O	O
tremor	NN	O	B
by	NN	O	O
using	NN	O	O
an	NN	O	O
inexpensive	NN	O	O
laser	NN	O	O
pointer	NN	O	O
is	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
exception	NN	O	O
of	NN	O	O
children	NN	O	O
(	NN	O	O
<	NN	O	O
12	NN	O	O
years	NN	O	O
)	NN	O	O
a	NN	O	O
sensitive	NN	O	O
and	NN	O	O
reproducible	NN	O	O
method	NN	O	O
.	NN	O	O

Safety	NN	O	O
and	NN	O	O
adverse	NN	O	O
effects	NN	O	O
associated	NN	O	O
with	NN	O	O
raloxifene	NN	O	O
:	NN	O	O
multiple	NN	O	O
outcomes	NN	O	O
of	NN	O	O
raloxifene	NN	O	O
evaluation	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
examine	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
raloxifene	NN	O	O
on	NN	O	O
major	NN	O	O
adverse	NN	O	O
events	NN	O	O
that	NN	O	O
occur	NN	O	O
with	NN	O	O
postmenopausal	NN	O	O
estrogen	NN	O	O
therapy	NN	O	O
or	NN	O	O
tamoxifen	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
Multiple	NN	O	O
Outcomes	NN	O	O
of	NN	O	O
Raloxifene	NN	O	O
Evaluation	NN	O	O
,	NN	O	O
a	NN	O	O
multicenter	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trial	NN	O	O
,	NN	O	O
enrolled	NN	O	O
7	NN	O	O
,	NN	O	O
705	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
with	NN	O	O
osteoporosis	NN	O	B
.	NN	O	O

Women	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
raloxifene	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
or	NN	O	O
120	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
or	NN	O	O
placebo	NN	O	O
.	NN	O	O

Outcomes	NN	O	O
included	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
,	NN	O	O
cataracts	NN	O	B
,	NN	O	O
gallbladder	NN	O	B
disease	NN	O	I
,	NN	O	O
and	NN	O	O
endometrial	NN	O	B
hyperplasia	NN	O	I
or	NN	O	I
cancer	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
During	NN	O	O
a	NN	O	O
mean	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
3	NN	O	O
.	NN	O	O
3	NN	O	O
years	NN	O	O
,	NN	O	O
raloxifene	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
(	NN	O	O
relative	NN	O	O
risk	NN	O	O
[	NN	O	O
RR	NN	O	O
]	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
excess	NN	O	O
event	NN	O	O
rate	NN	O	O
was	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
per	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
woman	NN	O	O
-	NN	O	O
years	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
number	NN	O	O
needed	NN	O	O
to	NN	O	O
treat	NN	O	O
to	NN	O	O
cause	NN	O	O
1	NN	O	O
event	NN	O	O
was	NN	O	O
170	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
100	NN	O	O
-	NN	O	O
582	NN	O	O
)	NN	O	O
over	NN	O	O
3	NN	O	O
.	NN	O	O
3	NN	O	O
years	NN	O	O
.	NN	O	O

Risk	NN	O	O
in	NN	O	O
the	NN	O	O
raloxifene	NN	O	O
group	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
2	NN	O	O
years	NN	O	O
,	NN	O	O
but	NN	O	O
decreased	NN	O	O
to	NN	O	O
about	NN	O	O
the	NN	O	O
same	NN	O	O
rate	NN	O	O
as	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
thereafter	NN	O	O
.	NN	O	O

Raloxifene	NN	O	O
did	NN	O	O
not	NN	O	O
increase	NN	O	O
risk	NN	O	O
for	NN	O	O
cataracts	NN	O	B
(	NN	O	O
RR	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
gallbladder	NN	O	B
disease	NN	O	I
(	NN	O	O
RR	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
)	NN	O	O
,	NN	O	O
endometrial	NN	O	B
hyperplasia	NN	O	I
(	NN	O	O
RR	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
endometrial	NN	O	B
cancer	NN	O	I
(	NN	O	O
RR	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Raloxifene	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
,	NN	O	O
but	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
cataracts	NN	O	B
,	NN	O	O
gallbladder	NN	O	B
disease	NN	O	I
,	NN	O	O
endometrial	NN	O	B
hyperplasia	NN	O	I
,	NN	O	O
or	NN	O	O
endometrial	NN	O	B
cancer	NN	O	I
.	NN	O	O

LEVEL	NN	O	O
OF	NN	O	O
EVIDENCE	NN	O	O
:	NN	O	O
I	NN	O	O

Optimization	NN	O	O
of	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
.	NN	O	O

While	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
single	NN	O	O
correct	NN	O	O
starting	NN	O	O
dose	NN	O	O
for	NN	O	O
levodopa	NN	O	O
therapy	NN	O	O
,	NN	O	O
many	NN	O	O
individuals	NN	O	O
can	NN	O	O
be	NN	O	O
started	NN	O	O
on	NN	O	O
either	NN	O	O
the	NN	O	O
25	NN	O	O
/	NN	O	O
100	NN	O	O
or	NN	O	O
controlled	NN	O	O
-	NN	O	O
release	NN	O	O
formula	NN	O	O
,	NN	O	O
following	NN	O	O
the	NN	O	O
general	NN	O	O
rule	NN	O	O
not	NN	O	O
to	NN	O	O
attempt	NN	O	O
to	NN	O	O
titrate	NN	O	O
carbidopa	NN	O	O
-	NN	O	O
levodopa	NN	O	O
to	NN	O	O
the	NN	O	O
point	NN	O	O
of	NN	O	O
"	NN	O	O
normality	NN	O	O
,	NN	O	O
"	NN	O	O
which	NN	O	O
can	NN	O	O
lead	NN	O	O
to	NN	O	O
toxicity	NN	O	B
.	NN	O	O

The	NN	O	O
physician	NN	O	O
should	NN	O	O
also	NN	O	O
determine	NN	O	O
the	NN	O	O
proper	NN	O	O
use	NN	O	O
of	NN	O	O
any	NN	O	O
adjunctive	NN	O	O
medications	NN	O	O
;	NN	O	O
such	NN	O	O
combined	NN	O	O
therapy	NN	O	O
has	NN	O	O
become	NN	O	O
the	NN	O	O
standard	NN	O	O
approach	NN	O	O
to	NN	O	O
treatment	NN	O	O
.	NN	O	O

Following	NN	O	O
the	NN	O	O
initial	NN	O	O
period	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
emerging	NN	O	O
difficulties	NN	O	O
require	NN	O	O
a	NN	O	O
reassessment	NN	O	O
of	NN	O	O
therapeutic	NN	O	O
approaches	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
dosage	NN	O	O
adjustment	NN	O	O
or	NN	O	O
introduction	NN	O	O
of	NN	O	O
a	NN	O	O
dopamine	NN	O	O
agonist	NN	O	O
.	NN	O	O

Other	NN	O	O
possible	NN	O	O
adverse	NN	O	O
effects	NN	O	O
-	NN	O	O
-	NN	O	O
such	NN	O	O
as	NN	O	O
gastrointestinal	NN	O	B
disorders	NN	O	I
,	NN	O	O
orthostatic	NN	O	B
hypotension	NN	O	I
,	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B
,	NN	O	O
sleep	NN	O	B
disturbances	NN	O	I
or	NN	O	O
parasomnias	NN	O	B
,	NN	O	O
or	NN	O	O
drug	NN	O	O
interactions	NN	O	O
-	NN	O	O
-	NN	O	O
also	NN	O	O
require	NN	O	O
carefully	NN	O	O
monitored	NN	O	O
individual	NN	O	O
treatment	NN	O	O
.	NN	O	O

Nonpharmacologic	NN	O	O
concerns	NN	O	O
can	NN	O	O
help	NN	O	O
the	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
patient	NN	O	O
achieve	NN	O	O
and	NN	O	O
maintain	NN	O	O
optimal	NN	O	O
functioning	NN	O	O
,	NN	O	O
including	NN	O	O
daily	NN	O	O
exercise	NN	O	O
,	NN	O	O
physical	NN	O	O
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
involvement	NN	O	O
with	NN	O	O
support	NN	O	O
groups	NN	O	O
.	NN	O	O

Long	NN	O	O
term	NN	O	O
audiological	NN	O	O
evaluation	NN	O	O
of	NN	O	O
beta	NN	O	B
-	NN	O	I
thalassemic	NN	O	I
patients	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
identify	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
to	NN	O	O
monitor	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
hearing	NN	O	B
loss	NN	O	I
in	NN	O	O
children	NN	O	O
and	NN	O	O
young	NN	O	O
adults	NN	O	O
with	NN	O	O
beta	NN	O	B
-	NN	O	I
thalassemia	NN	O	I
major	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
One	NN	O	O
hundred	NN	O	O
and	NN	O	O
four	NN	O	O
(	NN	O	O
104	NN	O	O
)	NN	O	O
patients	NN	O	O
aged	NN	O	O
6	NN	O	O
-	NN	O	O
35	NN	O	O
years	NN	O	O
(	NN	O	O
mean	NN	O	O
17	NN	O	O
,	NN	O	O
2	NN	O	O
years	NN	O	O
)	NN	O	O
participated	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
on	NN	O	O
a	NN	O	O
regular	NN	O	O
transfusion	NN	O	O
-	NN	O	O
chelation	NN	O	O
program	NN	O	O
maintaining	NN	O	O
a	NN	O	O
mean	NN	O	O
hemoglobin	NN	O	O
level	NN	O	O
of	NN	O	O
9	NN	O	O
.	NN	O	O
5	NN	O	O
gr	NN	O	O
/	NN	O	O
dl	NN	O	O
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
receiving	NN	O	O
desferrioxamine	NN	O	O
(	NN	O	O
DFO	NN	O	O
)	NN	O	O
chelation	NN	O	O
treatment	NN	O	O
with	NN	O	O
a	NN	O	O
mean	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
50	NN	O	O
-	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
6	NN	O	O
days	NN	O	O
a	NN	O	O
week	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
six	NN	O	O
years	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
then	NN	O	O
reduced	NN	O	O
to	NN	O	O
40	NN	O	O
-	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
the	NN	O	O
following	NN	O	O
eight	NN	O	O
years	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
followed	NN	O	O
for	NN	O	O
8	NN	O	O
-	NN	O	O
14	NN	O	O
years	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Overall	NN	O	O
,	NN	O	O
21	NN	O	O
out	NN	O	O
of	NN	O	O
104	NN	O	O
patients	NN	O	O
(	NN	O	O
20	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
presented	NN	O	O
with	NN	O	O
high	NN	O	O
frequency	NN	O	O
sensorineural	NN	O	B
hearing	NN	O	I
loss	NN	O	I
(	NN	O	O
SNHL	NN	O	B
)	NN	O	O
,	NN	O	O
either	NN	O	O
unilateral	NN	O	O
or	NN	O	O
bilateral	NN	O	O
.	NN	O	O

No	NN	O	O
ototoxic	NN	O	B
factor	NN	O	O
,	NN	O	O
other	NN	O	O
than	NN	O	O
DFO	NN	O	O
,	NN	O	O
was	NN	O	O
present	NN	O	O
in	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
SNHL	NN	O	B
presented	NN	O	O
with	NN	O	O
relatively	NN	O	O
lower	NN	O	O
serum	NN	O	O
ferritin	NN	O	O
levels	NN	O	O
than	NN	O	O
those	NN	O	O
with	NN	O	O
normal	NN	O	O
hearing	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
no	NN	O	O
statistically	NN	O	O
significant	NN	O	O
difference	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Subjects	NN	O	O
with	NN	O	O
SNHL	NN	O	B
were	NN	O	O
submitted	NN	O	O
to	NN	O	O
DFO	NN	O	O
reduction	NN	O	O
or	NN	O	O
temporary	NN	O	O
withdrawal	NN	O	O
.	NN	O	O

Following	NN	O	O
intervention	NN	O	O
,	NN	O	O
7	NN	O	O
out	NN	O	O
of	NN	O	O
21	NN	O	O
affected	NN	O	O
patients	NN	O	O
recovered	NN	O	O
,	NN	O	O
10	NN	O	O
remained	NN	O	O
stable	NN	O	O
and	NN	O	O
4	NN	O	O
demonstrated	NN	O	O
aggravation	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
findings	NN	O	O
are	NN	O	O
indicative	NN	O	O
of	NN	O	O
DFO	NN	O	O
'	NN	O	O
s	NN	O	O
contributing	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hearing	NN	O	B
impairment	NN	O	I
.	NN	O	O

Regular	NN	O	O
audiologic	NN	O	O
evaluation	NN	O	O
is	NN	O	O
imperative	NN	O	O
in	NN	O	O
all	NN	O	O
thalassemic	NN	O	B
patients	NN	O	O
so	NN	O	O
that	NN	O	O
early	NN	O	O
changes	NN	O	O
may	NN	O	O
be	NN	O	O
recognized	NN	O	O
and	NN	O	O
treatment	NN	O	O
may	NN	O	O
be	NN	O	O
judiciously	NN	O	O
adjusted	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
prevent	NN	O	O
or	NN	O	O
reverse	NN	O	O
hearing	NN	O	B
impairment	NN	O	I
.	NN	O	O

Individual	NN	O	O
differences	NN	O	O
in	NN	O	O
renal	NN	O	O
ACE	NN	O	O
activity	NN	O	O
in	NN	O	O
healthy	NN	O	O
rats	NN	O	O
predict	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
damage	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
In	NN	O	O
man	NN	O	O
,	NN	O	O
differences	NN	O	O
in	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
levels	NN	O	O
,	NN	O	O
related	NN	O	O
to	NN	O	O
ACE	NN	O	O
(	NN	O	O
I	NN	O	O
/	NN	O	O
D	NN	O	O
)	NN	O	O
genotype	NN	O	O
,	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
renal	NN	O	O
prognosis	NN	O	O
.	NN	O	O

This	NN	O	O
raises	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
individual	NN	O	O
differences	NN	O	O
in	NN	O	O
renal	NN	O	O
ACE	NN	O	O
activity	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
renal	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
inflicted	NN	O	O
damage	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
the	NN	O	O
predictive	NN	O	O
effect	NN	O	O
of	NN	O	O
renal	NN	O	O
ACE	NN	O	O
activity	NN	O	O
for	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
renal	NN	O	B
damage	NN	O	I
induced	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
adriamycin	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Renal	NN	O	O
ACE	NN	O	O
activity	NN	O	O
(	NN	O	O
Hip	NN	O	O
-	NN	O	O
His	NN	O	O
-	NN	O	O
Leu	NN	O	O
cleavage	NN	O	O
by	NN	O	O
cortical	NN	O	O
homogenates	NN	O	O
)	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
renal	NN	O	O
biopsy	NN	O	O
in	NN	O	O
27	NN	O	O
adult	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

After	NN	O	O
1	NN	O	O
week	NN	O	O
of	NN	O	O
recovery	NN	O	O
,	NN	O	O
proteinuria	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
adriamycin	NN	O	O
[	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
intravenously	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
n	NN	O	O
=	NN	O	O
18	NN	O	O
;	NN	O	O
controls	NN	O	O
,	NN	O	O
saline	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
]	NN	O	O
.	NN	O	O

Proteinuria	NN	O	B
was	NN	O	O
measured	NN	O	O
every	NN	O	O
2	NN	O	O
weeks	NN	O	O
.	NN	O	O

After	NN	O	O
12	NN	O	O
weeks	NN	O	O
,	NN	O	O
rats	NN	O	O
were	NN	O	O
sacrificed	NN	O	O
and	NN	O	O
their	NN	O	O
kidneys	NN	O	O
harvested	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
As	NN	O	O
anticipated	NN	O	O
,	NN	O	O
adriamycin	NN	O	O
elicited	NN	O	O
nephrotic	NN	O	B
range	NN	O	O
proteinuria	NN	O	B
,	NN	O	O
renal	NN	O	B
interstitial	NN	O	I
damage	NN	O	I
and	NN	O	O
mild	NN	O	O
focal	NN	O	B
glomerulosclerosis	NN	O	I
.	NN	O	O

Baseline	NN	O	O
renal	NN	O	O
ACE	NN	O	O
positively	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
relative	NN	O	O
rise	NN	O	O
in	NN	O	O
proteinuria	NN	O	B
after	NN	O	O
adriamycin	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
62	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
renal	NN	O	O
interstitial	NN	O	O
alpha	NN	O	O
-	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
actin	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
49	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
interstitial	NN	O	O
macrophage	NN	O	O
influx	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
56	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
interstitial	NN	O	O
collagen	NN	O	O
III	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
53	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
glomerular	NN	O	O
alpha	NN	O	O
-	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
actin	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
74	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
and	NN	O	O
glomerular	NN	O	O
desmin	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
48	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Baseline	NN	O	O
renal	NN	O	O
ACE	NN	O	O
did	NN	O	O
not	NN	O	O
correlate	NN	O	O
with	NN	O	O
focal	NN	O	B
glomerulosclerosis	NN	O	I
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
22	NN	O	O
,	NN	O	O
NS	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
controls	NN	O	O
,	NN	O	O
no	NN	O	O
predictive	NN	O	O
values	NN	O	O
for	NN	O	O
renal	NN	O	O
parameters	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Individual	NN	O	O
differences	NN	O	O
in	NN	O	O
renal	NN	O	O
ACE	NN	O	O
activity	NN	O	O
predict	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
damage	NN	O	I
in	NN	O	O
this	NN	O	O
outbred	NN	O	O
rat	NN	O	O
strain	NN	O	O
.	NN	O	O

This	NN	O	O
supports	NN	O	O
the	NN	O	O
assumption	NN	O	O
that	NN	O	O
differences	NN	O	O
in	NN	O	O
renal	NN	O	O
ACE	NN	O	O
activity	NN	O	O
predispose	NN	O	O
to	NN	O	O
a	NN	O	O
less	NN	O	O
favourable	NN	O	O
course	NN	O	O
of	NN	O	O
renal	NN	O	B
damage	NN	O	I
.	NN	O	O

Recurrent	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
induced	NN	O	O
by	NN	O	O
azithromycin	NN	O	O
.	NN	O	O

A	NN	O	O
14	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
is	NN	O	O
reported	NN	O	O
with	NN	O	O
recurrent	NN	O	O
,	NN	O	O
azithromycin	NN	O	O
-	NN	O	O
induced	NN	O	O
,	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
.	NN	O	O

The	NN	O	O
second	NN	O	O
episode	NN	O	O
was	NN	O	O
more	NN	O	O
severe	NN	O	O
than	NN	O	O
the	NN	O	O
first	NN	O	O
;	NN	O	O
and	NN	O	O
although	NN	O	O
both	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
intensive	NN	O	O
corticosteroid	NN	O	O
therapy	NN	O	O
,	NN	O	O
renal	NN	O	O
function	NN	O	O
remained	NN	O	O
impaired	NN	O	O
.	NN	O	O

Although	NN	O	O
most	NN	O	O
cases	NN	O	O
of	NN	O	O
antibiotic	NN	O	O
induced	NN	O	O
acute	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
are	NN	O	O
benign	NN	O	O
and	NN	O	O
self	NN	O	O
-	NN	O	O
limited	NN	O	O
,	NN	O	O
some	NN	O	O
patients	NN	O	O
are	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
permanent	NN	O	O
renal	NN	O	B
injury	NN	O	I
.	NN	O	O

Spironolactone	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
and	NN	O	O
hyperkalemia	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
A	NN	O	O
previous	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
evaluating	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
spironolactone	NN	O	O
in	NN	O	O
heart	NN	O	B
failure	NN	O	I
patients	NN	O	O
reported	NN	O	O
a	NN	O	O
low	NN	O	O
risk	NN	O	O
of	NN	O	O
hyperkalemia	NN	O	B
(	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
(	NN	O	O
0	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Because	NN	O	O
treatments	NN	O	O
for	NN	O	O
heart	NN	O	B
failure	NN	O	I
have	NN	O	O
changed	NN	O	O
since	NN	O	O
the	NN	O	O
benefits	NN	O	O
of	NN	O	O
spironolactone	NN	O	O
were	NN	O	O
reported	NN	O	O
,	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
these	NN	O	O
complications	NN	O	O
may	NN	O	O
differ	NN	O	O
in	NN	O	O
current	NN	O	O
clinical	NN	O	O
practice	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
sought	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
prevalence	NN	O	O
and	NN	O	O
clinical	NN	O	O
associations	NN	O	O
of	NN	O	O
hyperkalemia	NN	O	B
and	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
in	NN	O	O
heart	NN	O	B
failure	NN	O	I
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
spironolactone	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
performed	NN	O	O
a	NN	O	O
case	NN	O	O
control	NN	O	O
study	NN	O	O
of	NN	O	O
heart	NN	O	B
failure	NN	O	I
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
spironolactone	NN	O	O
in	NN	O	O
our	NN	O	O
clinical	NN	O	O
practice	NN	O	O
.	NN	O	O

Cases	NN	O	O
were	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
hyperkalemia	NN	O	B
(	NN	O	O
K	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
>	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
mEq	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
or	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
(	NN	O	O
Cr	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
they	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
2	NN	O	O
randomly	NN	O	O
selected	NN	O	O
controls	NN	O	O
per	NN	O	O
case	NN	O	O
.	NN	O	O

Clinical	NN	O	O
characteristics	NN	O	O
,	NN	O	O
medications	NN	O	O
,	NN	O	O
and	NN	O	O
serum	NN	O	O
chemistries	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
time	NN	O	O
periods	NN	O	O
were	NN	O	O
compared	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Sixty	NN	O	O
-	NN	O	O
seven	NN	O	O
of	NN	O	O
926	NN	O	O
patients	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
required	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
spironolactone	NN	O	O
due	NN	O	O
to	NN	O	O
hyperkalemia	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
33	NN	O	O
)	NN	O	O
or	NN	O	O
renal	NN	O	B
failure	NN	O	I
(	NN	O	O
n	NN	O	O
=	NN	O	O
34	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
developed	NN	O	O
hyperkalemia	NN	O	B
were	NN	O	O
older	NN	O	O
and	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
diabetes	NN	O	B
,	NN	O	O
had	NN	O	O
higher	NN	O	O
baseline	NN	O	O
serum	NN	O	O
potassium	NN	O	O
levels	NN	O	O
and	NN	O	O
lower	NN	O	O
baseline	NN	O	O
potassium	NN	O	O
supplement	NN	O	O
doses	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
treated	NN	O	O
with	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
than	NN	O	O
controls	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
134	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
developed	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
had	NN	O	O
lower	NN	O	O
baseline	NN	O	O
body	NN	O	O
weight	NN	O	O
and	NN	O	O
higher	NN	O	O
baseline	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
,	NN	O	O
required	NN	O	O
higher	NN	O	O
doses	NN	O	O
of	NN	O	O
loop	NN	O	O
diuretics	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
treated	NN	O	O
with	NN	O	O
thiazide	NN	O	O
diuretics	NN	O	O
than	NN	O	O
controls	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Spironolactone	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperkalemia	NN	O	B
and	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
are	NN	O	O
more	NN	O	O
common	NN	O	O
in	NN	O	O
our	NN	O	O
clinical	NN	O	O
experience	NN	O	O
than	NN	O	O
reported	NN	O	O
previously	NN	O	O
.	NN	O	O

This	NN	O	O
difference	NN	O	O
is	NN	O	O
explained	NN	O	O
by	NN	O	O
patient	NN	O	O
comorbidities	NN	O	O
and	NN	O	O
more	NN	O	O
frequent	NN	O	O
use	NN	O	O
of	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
.	NN	O	O

Acute	NN	O	O
reserpine	NN	O	O
and	NN	O	O
subchronic	NN	O	O
haloperidol	NN	O	O
treatments	NN	O	O
change	NN	O	O
synaptosomal	NN	O	O
brain	NN	O	O
glutamate	NN	O	O
uptake	NN	O	O
and	NN	O	O
elicit	NN	O	O
orofacial	NN	O	B
dyskinesia	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Reserpine	NN	O	O
-	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
orofacial	NN	O	B
dyskinesia	NN	O	I
are	NN	O	O
putative	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
tardive	NN	O	B
dyskinesia	NN	O	I
(	NN	O	O
TD	NN	O	B
)	NN	O	O
whose	NN	O	O
pathophysiology	NN	O	O
has	NN	O	O
been	NN	O	O
related	NN	O	O
to	NN	O	O
free	NN	O	O
radical	NN	O	O
generation	NN	O	O
and	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
authors	NN	O	O
induced	NN	O	O
orofacial	NN	O	B
dyskinesia	NN	O	I
by	NN	O	O
acute	NN	O	O
reserpine	NN	O	O
and	NN	O	O
subchronic	NN	O	O
haloperidol	NN	O	O
administration	NN	O	O
to	NN	O	O
rats	NN	O	O
.	NN	O	O

Reserpine	NN	O	O
injection	NN	O	O
(	NN	O	O
one	NN	O	O
dose	NN	O	O
of	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
every	NN	O	O
other	NN	O	O
day	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
caused	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
,	NN	O	O
tongue	NN	O	O
protrusion	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
facial	NN	O	O
twitching	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
.	NN	O	O

Haloperidol	NN	O	O
administration	NN	O	O
(	NN	O	O
one	NN	O	O
dose	NN	O	O
of	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
once	NN	O	O
a	NN	O	O
week	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
for	NN	O	O
4	NN	O	O
weeks	NN	O	O
caused	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
,	NN	O	O
tongue	NN	O	O
protrusion	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
facial	NN	O	O
twitching	NN	O	O
observed	NN	O	O
in	NN	O	O
four	NN	O	O
weekly	NN	O	O
evaluations	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
treatments	NN	O	O
and	NN	O	O
behavioral	NN	O	O
observation	NN	O	O
,	NN	O	O
glutamate	NN	O	O
uptake	NN	O	O
by	NN	O	O
segments	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	O
was	NN	O	O
analyzed	NN	O	O
.	NN	O	O

A	NN	O	O
decreased	NN	O	O
glutamate	NN	O	O
uptake	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
subcortical	NN	O	O
parts	NN	O	O
of	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
reserpine	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
.	NN	O	O

Importantly	NN	O	O
,	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
glutamate	NN	O	O
uptake	NN	O	O
correlates	NN	O	O
negatively	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
orofacial	NN	O	B
diskinesia	NN	O	I
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
early	NN	O	O
changes	NN	O	O
in	NN	O	O
glutamate	NN	O	O
transport	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
movements	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Ceftriaxone	NN	O	O
-	NN	O	O
associated	NN	O	O
biliary	NN	O	B
pseudolithiasis	NN	O	I
in	NN	O	O
paediatric	NN	O	O
surgical	NN	O	O
patients	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
well	NN	O	O
known	NN	O	O
that	NN	O	O
ceftriaxone	NN	O	O
leads	NN	O	O
to	NN	O	O
pseudolithiasis	NN	O	B
in	NN	O	O
some	NN	O	O
patients	NN	O	O
.	NN	O	O

Clinical	NN	O	O
and	NN	O	O
experimental	NN	O	O
studies	NN	O	O
also	NN	O	O
suggest	NN	O	O
that	NN	O	O
situations	NN	O	O
causing	NN	O	O
gallbladder	NN	O	B
dysfunction	NN	O	I
,	NN	O	O
such	NN	O	O
as	NN	O	O
fasting	NN	O	O
,	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
pseudolithiasis	NN	O	B
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
clinical	NN	O	O
importance	NN	O	O
of	NN	O	O
pseudolithiasis	NN	O	B
in	NN	O	O
paediatric	NN	O	O
surgical	NN	O	O
patients	NN	O	O
receiving	NN	O	O
ceftriaxone	NN	O	O
treatment	NN	O	O
,	NN	O	O
who	NN	O	O
often	NN	O	O
had	NN	O	O
to	NN	O	O
fast	NN	O	O
in	NN	O	O
the	NN	O	O
post	NN	O	O
-	NN	O	O
operative	NN	O	O
period	NN	O	O
.	NN	O	O

Fifty	NN	O	O
children	NN	O	O
who	NN	O	O
were	NN	O	O
given	NN	O	O
ceftriaxone	NN	O	O
were	NN	O	O
evaluated	NN	O	O
by	NN	O	O
serial	NN	O	O
abdominal	NN	O	O
sonograms	NN	O	O
.	NN	O	O

Of	NN	O	O
those	NN	O	O
,	NN	O	O
13	NN	O	O
(	NN	O	O
26	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
biliary	NN	O	O
pathology	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
pseudolithiasis	NN	O	B
revealed	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
and	NN	O	O
starvation	NN	O	O
variables	NN	O	O
.	NN	O	O

After	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
,	NN	O	O
pseudolithiasis	NN	O	B
resolved	NN	O	O
spontaneously	NN	O	O
within	NN	O	O
a	NN	O	O
short	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
pseudolithiasis	NN	O	B
is	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
fasting	NN	O	O
.	NN	O	O

Coronary	NN	O	B
aneurysm	NN	O	I
after	NN	O	O
implantation	NN	O	O
of	NN	O	O
a	NN	O	O
paclitaxel	NN	O	O
-	NN	O	O
eluting	NN	O	O
stent	NN	O	O
.	NN	O	O

Formation	NN	O	O
of	NN	O	O
coronary	NN	O	B
aneurysm	NN	O	I
is	NN	O	O
a	NN	O	O
rare	NN	O	O
complication	NN	O	O
of	NN	O	O
stenting	NN	O	O
with	NN	O	O
bare	NN	O	O
metal	NN	O	O
stents	NN	O	O
,	NN	O	O
but	NN	O	O
based	NN	O	O
on	NN	O	O
experimental	NN	O	O
studies	NN	O	O
drug	NN	O	O
-	NN	O	O
eluting	NN	O	O
stents	NN	O	O
may	NN	O	O
induce	NN	O	O
toxic	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
vessel	NN	O	O
wall	NN	O	O
with	NN	O	O
incomplete	NN	O	O
stent	NN	O	O
apposition	NN	O	O
,	NN	O	O
aneurysm	NN	O	B
formation	NN	O	O
and	NN	O	O
with	NN	O	O
the	NN	O	O
potential	NN	O	O
of	NN	O	O
stent	NN	O	O
thrombosis	NN	O	B
or	NN	O	O
vessel	NN	O	B
rupture	NN	O	I
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
43	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
developed	NN	O	O
a	NN	O	O
coronary	NN	O	B
aneurysm	NN	O	I
in	NN	O	O
the	NN	O	O
right	NN	O	O
coronary	NN	O	O
artery	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
receiving	NN	O	O
a	NN	O	O
paclitaxel	NN	O	O
-	NN	O	O
eluting	NN	O	O
stent	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
asymptomatic	NN	O	O
and	NN	O	O
the	NN	O	O
aneurysm	NN	O	B
was	NN	O	O
detected	NN	O	O
in	NN	O	O
a	NN	O	O
routine	NN	O	O
control	NN	O	O
.	NN	O	O

Angiography	NN	O	O
and	NN	O	O
intracoronary	NN	O	O
ultrasound	NN	O	O
demonstrated	NN	O	O
lack	NN	O	O
of	NN	O	O
contact	NN	O	O
between	NN	O	O
stent	NN	O	O
and	NN	O	O
vessel	NN	O	O
wall	NN	O	O
in	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
mm	NN	O	O
long	NN	O	O
segment	NN	O	O
with	NN	O	O
maximal	NN	O	O
aneurysm	NN	O	B
diameter	NN	O	O
of	NN	O	O
6	NN	O	O
.	NN	O	O
0	NN	O	O
mm	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
successfully	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
graft	NN	O	O
stent	NN	O	O
.	NN	O	O

Causes	NN	O	O
of	NN	O	O
acute	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
kidney	NN	O	O
transplantation	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
Thrombotic	NN	O	B
microangiopathy	NN	O	I
is	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
known	NN	O	O
problem	NN	O	O
in	NN	O	O
patients	NN	O	O
following	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
.	NN	O	O

In	NN	O	O
postrenal	NN	O	O
transplantation	NN	O	O
,	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
is	NN	O	O
often	NN	O	O
a	NN	O	O
reflection	NN	O	O
of	NN	O	O
hemolytic	NN	O	B
uremic	NN	O	I
syndrome	NN	O	I
.	NN	O	O

We	NN	O	O
aimed	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
causes	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
in	NN	O	O
a	NN	O	O
population	NN	O	O
of	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
recipients	NN	O	O
and	NN	O	O
discuss	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
investigated	NN	O	O
the	NN	O	O
causes	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
during	NN	O	O
a	NN	O	O
1	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
,	NN	O	O
from	NN	O	O
June	NN	O	O
2003	NN	O	O
to	NN	O	O
June	NN	O	O
2004	NN	O	O
,	NN	O	O
at	NN	O	O
the	NN	O	O
King	NN	O	O
Fahad	NN	O	O
National	NN	O	O
Guard	NN	O	O
Hospital	NN	O	O
in	NN	O	O
Riyadh	NN	O	O
,	NN	O	O
Saudi	NN	O	O
Arabia	NN	O	O
,	NN	O	O
by	NN	O	O
reviewing	NN	O	O
the	NN	O	O
slides	NN	O	O
of	NN	O	O
all	NN	O	O
transplant	NN	O	O
biopsies	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
25	NN	O	O
)	NN	O	O
performed	NN	O	O
during	NN	O	O
this	NN	O	O
interval	NN	O	O
.	NN	O	O

Pre	NN	O	O
-	NN	O	O
and	NN	O	O
posttransplant	NN	O	O
crossmatching	NN	O	O
was	NN	O	O
done	NN	O	O
when	NN	O	O
possible	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Five	NN	O	O
cases	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
were	NN	O	O
found	NN	O	O
.	NN	O	O

Three	NN	O	O
of	NN	O	O
these	NN	O	O
cases	NN	O	O
were	NN	O	O
from	NN	O	O
the	NN	O	O
25	NN	O	O
transplantations	NN	O	O
performed	NN	O	O
at	NN	O	O
King	NN	O	O
Fahad	NN	O	O
National	NN	O	O
Guard	NN	O	O
Hospital	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
other	NN	O	O
2	NN	O	O
transplantations	NN	O	O
had	NN	O	O
been	NN	O	O
performed	NN	O	O
abroad	NN	O	O
and	NN	O	O
were	NN	O	O
referred	NN	O	O
to	NN	O	O
us	NN	O	O
for	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

Three	NN	O	O
cases	NN	O	O
were	NN	O	O
related	NN	O	O
to	NN	O	O
cyclosporine	NN	O	O
,	NN	O	O
and	NN	O	O
1	NN	O	O
case	NN	O	O
was	NN	O	O
secondary	NN	O	O
to	NN	O	O
both	NN	O	O
cyclosporine	NN	O	O
and	NN	O	O
tacrolimus	NN	O	O
.	NN	O	O

The	NN	O	O
fifth	NN	O	O
case	NN	O	O
had	NN	O	O
features	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
related	NN	O	O
to	NN	O	O
an	NN	O	O
antiphospholipid	NN	O	B
syndrome	NN	O	I
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
systemic	NN	O	B
lupus	NN	O	I
erythematosus	NN	O	I
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
-	NN	O	O
frequent	NN	O	O
cause	NN	O	O
of	NN	O	O
hemolytic	NN	O	B
uremic	NN	O	I
syndrome	NN	O	I
in	NN	O	O
patients	NN	O	O
following	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
is	NN	O	O
recurrence	NN	O	O
of	NN	O	O
the	NN	O	O
hemolytic	NN	O	B
uremic	NN	O	I
syndrome	NN	O	I
.	NN	O	O

Other	NN	O	O
causes	NN	O	O
include	NN	O	O
drug	NN	O	O
-	NN	O	O
related	NN	O	O
(	NN	O	O
cyclosporine	NN	O	O
,	NN	O	O
tacrolimus	NN	O	O
)	NN	O	O
toxicity	NN	O	B
,	NN	O	O
procoagulant	NN	O	O
status	NN	O	O
,	NN	O	O
and	NN	O	O
antibody	NN	O	O
-	NN	O	O
mediated	NN	O	O
rejection	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
the	NN	O	O
most	NN	O	O
-	NN	O	O
frequent	NN	O	O
cause	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
was	NN	O	O
drug	NN	O	O
related	NN	O	O
,	NN	O	O
secondary	NN	O	O
mainly	NN	O	O
to	NN	O	O
cyclosporine	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
was	NN	O	O
similar	NN	O	O
to	NN	O	O
the	NN	O	O
percentage	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
(	NN	O	O
20	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
developmental	NN	O	O
toxicity	NN	O	B
of	NN	O	O
selective	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
cyclooxygenase	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitors	NN	O	O
in	NN	O	O
CRL	NN	O	O
:	NN	O	O
(	NN	O	O
WI	NN	O	O
)	NN	O	O
WUBR	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
-	NN	O	O
-	NN	O	O
DFU	NN	O	O
and	NN	O	O
piroxicam	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Cyclooxygenase	NN	O	O
(	NN	O	O
COX	NN	O	O
)	NN	O	O
inhibitors	NN	O	O
are	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
often	NN	O	O
ingested	NN	O	O
drugs	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

Unlike	NN	O	O
general	NN	O	O
toxicity	NN	O	B
data	NN	O	O
,	NN	O	O
their	NN	O	O
prenatal	NN	O	O
toxic	NN	O	O
effects	NN	O	O
were	NN	O	O
not	NN	O	O
extensively	NN	O	O
studied	NN	O	O
before	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
experiment	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
developmental	NN	O	O
toxicity	NN	O	B
of	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
(	NN	O	O
piroxicam	NN	O	O
)	NN	O	O
and	NN	O	O
selective	NN	O	O
(	NN	O	O
DFU	NN	O	O
;	NN	O	O
5	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
dimethyl	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
(	NN	O	O
3	NN	O	O
-	NN	O	O
fluorophenyl	NN	O	O
)	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
(	NN	O	O
4	NN	O	O
-	NN	O	O
methylsulphonyl	NN	O	O
)	NN	O	O
phenyl	NN	O	O
-	NN	O	O
2	NN	O	O
(	NN	O	O
5H	NN	O	O
)	NN	O	O
-	NN	O	O
furanon	NN	O	O
)	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Drugs	NN	O	O
were	NN	O	O
separately	NN	O	O
,	NN	O	O
orally	NN	O	O
once	NN	O	O
daily	NN	O	O
dosed	NN	O	O
to	NN	O	O
pregnant	NN	O	O
rats	NN	O	O
from	NN	O	O
day	NN	O	O
8	NN	O	O
to	NN	O	O
21	NN	O	O
(	NN	O	O
GD1	NN	O	O
=	NN	O	O
plug	NN	O	O
day	NN	O	O
)	NN	O	O
.	NN	O	O

Doses	NN	O	O
were	NN	O	O
set	NN	O	O
at	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
and	NN	O	O
30	NN	O	O
.	NN	O	O
0mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
piroxicam	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
and	NN	O	O
20	NN	O	O
.	NN	O	O
0mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
DFU	NN	O	O
.	NN	O	O

Fetuses	NN	O	O
were	NN	O	O
delivered	NN	O	O
on	NN	O	O
GD	NN	O	O
21	NN	O	O
and	NN	O	O
routinely	NN	O	O
examined	NN	O	O
.	NN	O	O

Comprehensive	NN	O	O
clinical	NN	O	O
and	NN	O	O
developmental	NN	O	O
measurements	NN	O	O
were	NN	O	O
done	NN	O	O
.	NN	O	O

The	NN	O	O
pooled	NN	O	O
statistical	NN	O	O
analysis	NN	O	O
for	NN	O	O
ventricular	NN	O	B
septal	NN	O	I
(	NN	O	I
VSD	NN	O	I
)	NN	O	I
and	NN	O	I
midline	NN	O	I
(	NN	O	I
MD	NN	O	I
)	NN	O	I
defects	NN	O	I
was	NN	O	O
performed	NN	O	O
for	NN	O	O
rat	NN	O	O
fetuses	NN	O	O
exposed	NN	O	O
to	NN	O	O
piroxicam	NN	O	O
,	NN	O	O
selective	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitor	NN	O	O
based	NN	O	O
on	NN	O	O
present	NN	O	O
and	NN	O	O
historic	NN	O	O
data	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Maternal	NN	O	O
toxicity	NN	O	B
,	NN	O	O
intrauterine	NN	O	B
growth	NN	O	I
retardation	NN	O	I
,	NN	O	O
and	NN	O	O
increase	NN	O	B
of	NN	O	I
external	NN	O	I
and	NN	O	I
skeletal	NN	O	I
variations	NN	O	I
were	NN	O	O
found	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
highest	NN	O	O
dose	NN	O	O
of	NN	O	O
piroxicam	NN	O	O
.	NN	O	O

Decrease	NN	O	O
of	NN	O	O
fetal	NN	O	O
length	NN	O	O
was	NN	O	O
the	NN	O	O
only	NN	O	O
signs	NN	O	O
of	NN	O	O
the	NN	O	O
DFU	NN	O	O
developmental	NN	O	O
toxicity	NN	O	B
observed	NN	O	O
in	NN	O	O
pups	NN	O	O
exposed	NN	O	O
to	NN	O	O
the	NN	O	O
highest	NN	O	O
compound	NN	O	O
dose	NN	O	O
.	NN	O	O

Lack	NN	O	O
of	NN	O	O
teratogenicity	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
piroxicam	NN	O	O
and	NN	O	O
DFU	NN	O	O
-	NN	O	O
exposed	NN	O	O
groups	NN	O	O
.	NN	O	O

Prenatal	NN	O	O
exposure	NN	O	O
to	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
COX	NN	O	O
inhibitors	NN	O	O
increases	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
VSD	NN	O	O
and	NN	O	O
MD	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
historic	NN	O	O
control	NN	O	O
but	NN	O	O
not	NN	O	O
with	NN	O	O
selective	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Both	NN	O	O
selective	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitors	NN	O	O
were	NN	O	O
toxic	NN	O	O
for	NN	O	O
rats	NN	O	O
fetuses	NN	O	O
when	NN	O	O
administered	NN	O	O
in	NN	O	O
the	NN	O	O
highest	NN	O	O
dose	NN	O	O
.	NN	O	O

Unlike	NN	O	O
DFU	NN	O	O
,	NN	O	O
piroxicam	NN	O	O
was	NN	O	O
also	NN	O	O
highly	NN	O	O
toxic	NN	O	O
to	NN	O	O
the	NN	O	O
dams	NN	O	O
.	NN	O	O

Prenatal	NN	O	O
exposure	NN	O	O
to	NN	O	O
selective	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
inhibitors	NN	O	O
does	NN	O	O
not	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
ventricular	NN	O	B
septal	NN	O	I
and	NN	O	I
midline	NN	O	I
defects	NN	O	I
in	NN	O	O
rat	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
drugs	NN	O	O
and	NN	O	O
historic	NN	O	O
control	NN	O	O
.	NN	O	O

Lone	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
associated	NN	O	O
with	NN	O	O
creatine	NN	O	O
monohydrate	NN	O	O
supplementation	NN	O	O
.	NN	O	O

Atrial	NN	O	B
fibrillation	NN	O	I
in	NN	O	O
young	NN	O	O
patients	NN	O	O
without	NN	O	O
structural	NN	O	O
heart	NN	O	B
disease	NN	O	I
is	NN	O	O
rare	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
when	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B
is	NN	O	O
present	NN	O	O
in	NN	O	O
this	NN	O	O
population	NN	O	O
,	NN	O	O
reversible	NN	O	O
causes	NN	O	O
must	NN	O	O
be	NN	O	O
identified	NN	O	O
and	NN	O	O
resolved	NN	O	O
.	NN	O	O

Thyroid	NN	O	B
disorders	NN	O	I
,	NN	O	O
illicit	NN	O	O
drug	NN	O	O
or	NN	O	O
stimulant	NN	O	O
use	NN	O	O
,	NN	O	O
and	NN	O	O
acute	NN	O	B
alcohol	NN	O	I
intoxication	NN	O	I
are	NN	O	O
among	NN	O	O
these	NN	O	O
causes	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
30	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Caucasian	NN	O	O
man	NN	O	O
who	NN	O	O
came	NN	O	O
to	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
in	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
with	NN	O	O
rapid	NN	O	O
ventricular	NN	O	O
response	NN	O	O
.	NN	O	O

His	NN	O	O
medical	NN	O	O
history	NN	O	O
was	NN	O	O
unremarkable	NN	O	O
,	NN	O	O
except	NN	O	O
for	NN	O	O
minor	NN	O	O
fractures	NN	O	B
of	NN	O	O
the	NN	O	O
fingers	NN	O	O
and	NN	O	O
foot	NN	O	O
.	NN	O	O

Thyroid	NN	O	O
-	NN	O	O
stimulating	NN	O	O
hormone	NN	O	O
,	NN	O	O
magnesium	NN	O	O
,	NN	O	O
and	NN	O	O
potassium	NN	O	O
levels	NN	O	O
were	NN	O	O
within	NN	O	O
normal	NN	O	O
limits	NN	O	O
,	NN	O	O
urine	NN	O	O
drug	NN	O	O
screen	NN	O	O
was	NN	O	O
negative	NN	O	O
,	NN	O	O
and	NN	O	O
alcohol	NN	O	O
use	NN	O	O
was	NN	O	O
denied	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
when	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
questioned	NN	O	O
about	NN	O	O
use	NN	O	O
of	NN	O	O
herbal	NN	O	O
products	NN	O	O
and	NN	O	O
supplements	NN	O	O
,	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
creatine	NN	O	O
monohydrate	NN	O	O
was	NN	O	O
revealed	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
,	NN	O	O
anticoagulated	NN	O	O
with	NN	O	O
unfractionated	NN	O	O
heparin	NN	O	O
,	NN	O	O
and	NN	O	O
given	NN	O	O
intravenous	NN	O	O
diltiazem	NN	O	O
for	NN	O	O
rate	NN	O	O
control	NN	O	O
and	NN	O	O
intravenous	NN	O	O
amiodarone	NN	O	O
for	NN	O	O
rate	NN	O	O
and	NN	O	O
rhythm	NN	O	O
control	NN	O	O
.	NN	O	O

When	NN	O	O
discharged	NN	O	O
less	NN	O	O
than	NN	O	O
24	NN	O	O
hours	NN	O	O
later	NN	O	O
,	NN	O	O
he	NN	O	O
was	NN	O	O
receiving	NN	O	O
metoprolol	NN	O	O
and	NN	O	O
aspirin	NN	O	O
,	NN	O	O
with	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
plans	NN	O	O
for	NN	O	O
echocardiography	NN	O	O
and	NN	O	O
nuclear	NN	O	O
imaging	NN	O	O
to	NN	O	O
assess	NN	O	O
perfusion	NN	O	O
.	NN	O	O

Exogenous	NN	O	O
creatine	NN	O	O
is	NN	O	O
used	NN	O	O
by	NN	O	O
athletes	NN	O	O
to	NN	O	O
theoretically	NN	O	O
improve	NN	O	O
exercise	NN	O	O
performance	NN	O	O
.	NN	O	O

Vegetarians	NN	O	O
may	NN	O	O
also	NN	O	O
take	NN	O	O
creatine	NN	O	O
to	NN	O	O
replace	NN	O	O
what	NN	O	O
they	NN	O	O
are	NN	O	O
not	NN	O	O
consuming	NN	O	O
from	NN	O	O
meat	NN	O	O
,	NN	O	O
fish	NN	O	O
,	NN	O	O
and	NN	O	O
other	NN	O	O
animal	NN	O	O
products	NN	O	O
.	NN	O	O

Previous	NN	O	O
anecdotal	NN	O	O
reports	NN	O	O
have	NN	O	O
linked	NN	O	O
creatine	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
arrhythmia	NN	O	B
.	NN	O	O

Clinicians	NN	O	O
must	NN	O	O
be	NN	O	O
diligent	NN	O	O
when	NN	O	O
interviewing	NN	O	O
patients	NN	O	O
about	NN	O	O
their	NN	O	O
drug	NN	O	O
therapy	NN	O	O
histories	NN	O	O
and	NN	O	O
include	NN	O	O
questions	NN	O	O
about	NN	O	O
their	NN	O	O
use	NN	O	O
of	NN	O	O
herbal	NN	O	O
products	NN	O	O
and	NN	O	O
dietary	NN	O	O
supplements	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
important	NN	O	O
to	NN	O	O
report	NN	O	O
adverse	NN	O	O
effects	NN	O	O
associated	NN	O	O
with	NN	O	O
frequently	NN	O	O
consumed	NN	O	O
supplements	NN	O	O
and	NN	O	O
herbal	NN	O	O
products	NN	O	O
to	NN	O	O
the	NN	O	O
Food	NN	O	O
and	NN	O	O
Drug	NN	O	O
Administration	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

Seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
the	NN	O	O
cocaine	NN	O	O
metabolite	NN	O	O
benzoylecgonine	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
half	NN	O	O
-	NN	O	O
life	NN	O	O
(	NN	O	O
t1	NN	O	O
/	NN	O	O
2	NN	O	O
)	NN	O	O
of	NN	O	O
cocaine	NN	O	O
is	NN	O	O
relatively	NN	O	O
short	NN	O	O
,	NN	O	O
but	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
consequences	NN	O	O
of	NN	O	O
its	NN	O	O
use	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
seizures	NN	O	B
and	NN	O	O
strokes	NN	O	B
,	NN	O	O
can	NN	O	O
occur	NN	O	O
hours	NN	O	O
after	NN	O	O
exposure	NN	O	O
.	NN	O	O

This	NN	O	O
led	NN	O	O
us	NN	O	O
to	NN	O	O
hypothesize	NN	O	O
that	NN	O	O
a	NN	O	O
metabolite	NN	O	O
of	NN	O	O
cocaine	NN	O	O
may	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
some	NN	O	O
of	NN	O	O
those	NN	O	O
delayed	NN	O	O
sequelae	NN	O	O
.	NN	O	O

We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
potential	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	O
metabolite	NN	O	O
of	NN	O	O
cocaine	NN	O	O
,	NN	O	O
benzoylecgonine	NN	O	O
(	NN	O	O
BE	NN	O	O
)	NN	O	O
,	NN	O	O
to	NN	O	O
cause	NN	O	O
seizures	NN	O	B
.	NN	O	O

Two	NN	O	O
separate	NN	O	O
equimolar	NN	O	O
doses	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
mumol	NN	O	O
)	NN	O	O
of	NN	O	O
either	NN	O	O
cocaine	NN	O	O
or	NN	O	O
BE	NN	O	O
were	NN	O	O
injected	NN	O	O
ventricularly	NN	O	O
in	NN	O	O
unanesthetized	NN	O	O
juvenile	NN	O	O
rats	NN	O	O
.	NN	O	O

Treated	NN	O	O
rats	NN	O	O
were	NN	O	O
then	NN	O	O
evaluated	NN	O	O
for	NN	O	O
incidence	NN	O	O
,	NN	O	O
latency	NN	O	O
,	NN	O	O
and	NN	O	O
seizure	NN	O	B
pattern	NN	O	O
or	NN	O	O
for	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
in	NN	O	O
animals	NN	O	O
without	NN	O	O
seizures	NN	O	B
.	NN	O	O

BE	NN	O	O
-	NN	O	O
Induced	NN	O	O
seizures	NN	O	B
occurred	NN	O	O
more	NN	O	O
frequently	NN	O	O
and	NN	O	O
had	NN	O	O
significantly	NN	O	O
longer	NN	O	O
latencies	NN	O	O
than	NN	O	O
those	NN	O	O
induced	NN	O	O
by	NN	O	O
equimolar	NN	O	O
amounts	NN	O	O
of	NN	O	O
cocaine	NN	O	O
.	NN	O	O

Whereas	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
were	NN	O	O
best	NN	O	O
characterized	NN	O	O
as	NN	O	O
brief	NN	O	O
,	NN	O	O
generalized	NN	O	O
,	NN	O	O
and	NN	O	O
tonic	NN	O	O
and	NN	O	O
resulted	NN	O	O
in	NN	O	O
death	NN	O	B
,	NN	O	O
those	NN	O	O
induced	NN	O	O
by	NN	O	O
BE	NN	O	O
were	NN	O	O
prolonged	NN	O	O
,	NN	O	O
often	NN	O	O
multiple	NN	O	O
and	NN	O	O
mixed	NN	O	O
in	NN	O	O
type	NN	O	O
,	NN	O	O
and	NN	O	O
rarely	NN	O	O
resulted	NN	O	O
in	NN	O	O
death	NN	O	B
.	NN	O	O

Electrical	NN	O	O
recordings	NN	O	O
from	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
showed	NN	O	O
a	NN	O	O
rhythmic	NN	O	O
progression	NN	O	O
in	NN	O	O
EEG	NN	O	O
frequency	NN	O	O
and	NN	O	O
voltage	NN	O	O
with	NN	O	O
clinical	NN	O	O
seizure	NN	O	B
expression	NN	O	O
.	NN	O	O

BE	NN	O	O
-	NN	O	O
Injected	NN	O	O
rats	NN	O	O
that	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
seizures	NN	O	B
had	NN	O	O
significantly	NN	O	O
more	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
than	NN	O	O
cocaine	NN	O	O
-	NN	O	O
injected	NN	O	O
animals	NN	O	O
without	NN	O	O
seizures	NN	O	B
.	NN	O	O

The	NN	O	O
finding	NN	O	O
that	NN	O	O
cocaine	NN	O	O
-	NN	O	O
and	NN	O	O
BE	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
differ	NN	O	O
in	NN	O	O
several	NN	O	O
respects	NN	O	O
suggests	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
mechanism	NN	O	O
for	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
emphasizes	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
a	NN	O	O
cocaine	NN	O	O
metabolite	NN	O	O
,	NN	O	O
BE	NN	O	O
.	NN	O	O

The	NN	O	O
selective	NN	O	O
5	NN	O	O
-	NN	O	O
HT6	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
Ro4368554	NN	O	O
restores	NN	O	O
memory	NN	O	O
performance	NN	O	O
in	NN	O	O
cholinergic	NN	O	O
and	NN	O	O
serotonergic	NN	O	O
models	NN	O	O
of	NN	O	O
memory	NN	O	B
deficiency	NN	O	I
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Antagonists	NN	O	O
at	NN	O	O
serotonin	NN	O	O
type	NN	O	O
6	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
)	NN	O	O
receptors	NN	O	O
show	NN	O	O
activity	NN	O	O
in	NN	O	O
models	NN	O	O
of	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
underlying	NN	O	O
mechanism	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
are	NN	O	O
not	NN	O	O
well	NN	O	O
understood	NN	O	O
,	NN	O	O
these	NN	O	O
effects	NN	O	O
may	NN	O	O
involve	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
acetylcholine	NN	O	O
(	NN	O	O
ACh	NN	O	O
)	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
sought	NN	O	O
to	NN	O	O
characterize	NN	O	O
the	NN	O	O
cognitive	NN	O	O
-	NN	O	O
enhancing	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
antagonist	NN	O	O
Ro4368554	NN	O	O
(	NN	O	O
3	NN	O	O
-	NN	O	O
benzenesulfonyl	NN	O	O
-	NN	O	O
7	NN	O	O
-	NN	O	O
(	NN	O	O
4	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
piperazin	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
yl	NN	O	O
)	NN	O	O
1H	NN	O	O
-	NN	O	O
indole	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
rat	NN	O	O
object	NN	O	O
recognition	NN	O	O
task	NN	O	O
employing	NN	O	O
a	NN	O	O
cholinergic	NN	O	O
(	NN	O	O
scopolamine	NN	O	O
pretreatment	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
serotonergic	NN	O	O
-	NN	O	O
(	NN	O	O
tryptophan	NN	O	O
(	NN	O	O
TRP	NN	O	O
)	NN	O	O
depletion	NN	O	O
)	NN	O	O
deficient	NN	O	O
model	NN	O	O
,	NN	O	O
and	NN	O	O
compared	NN	O	O
its	NN	O	O
pattern	NN	O	O
of	NN	O	O
action	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
acetylcholinesterase	NN	O	O
inhibitor	NN	O	O
metrifonate	NN	O	O
.	NN	O	O

Initial	NN	O	O
testing	NN	O	O
in	NN	O	O
a	NN	O	O
time	NN	O	O
-	NN	O	O
dependent	NN	O	O
forgetting	NN	O	O
task	NN	O	O
employing	NN	O	O
a	NN	O	O
24	NN	O	O
-	NN	O	O
h	NN	O	O
delay	NN	O	O
between	NN	O	O
training	NN	O	O
and	NN	O	O
testing	NN	O	O
showed	NN	O	O
that	NN	O	O
metrifonate	NN	O	O
improved	NN	O	O
object	NN	O	O
recognition	NN	O	O
(	NN	O	O
at	NN	O	O
10	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
Ro4368554	NN	O	O
was	NN	O	O
inactive	NN	O	O
.	NN	O	O

Both	NN	O	O
,	NN	O	O
Ro4368554	NN	O	O
(	NN	O	O
3	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
intraperitoneally	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
)	NN	O	O
and	NN	O	O
metrifonate	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
reversed	NN	O	O
memory	NN	O	B
deficits	NN	O	I
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
and	NN	O	O
TRP	NN	O	O
depletion	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
although	NN	O	O
Ro4368554	NN	O	O
did	NN	O	O
not	NN	O	O
improve	NN	O	O
a	NN	O	O
time	NN	O	O
-	NN	O	O
related	NN	O	O
retention	NN	O	O
deficit	NN	O	O
,	NN	O	O
it	NN	O	O
reversed	NN	O	O
a	NN	O	O
cholinergic	NN	O	O
and	NN	O	O
a	NN	O	O
serotonergic	NN	O	O
memory	NN	O	B
deficit	NN	O	I
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
both	NN	O	O
mechanisms	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
facilitation	NN	O	O
of	NN	O	O
object	NN	O	O
memory	NN	O	O
by	NN	O	O
Ro4368554	NN	O	O
and	NN	O	O
,	NN	O	O
possibly	NN	O	O
,	NN	O	O
other	NN	O	O
5	NN	O	O
-	NN	O	O
HT	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
.	NN	O	O

Evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
anticocaine	NN	O	O
monoclonal	NN	O	O
antibody	NN	O	O
GNC92H2	NN	O	O
as	NN	O	O
an	NN	O	O
immunotherapy	NN	O	O
for	NN	O	O
cocaine	NN	O	B
overdose	NN	O	I
.	NN	O	O

The	NN	O	O
illicit	NN	O	O
use	NN	O	O
of	NN	O	O
cocaine	NN	O	O
continues	NN	O	O
in	NN	O	O
epidemic	NN	O	O
proportions	NN	O	O
and	NN	O	O
treatment	NN	O	O
for	NN	O	O
cocaine	NN	O	B
overdose	NN	O	I
remains	NN	O	O
elusive	NN	O	O
.	NN	O	O

Current	NN	O	O
protein	NN	O	O
-	NN	O	O
based	NN	O	O
technology	NN	O	O
offers	NN	O	O
a	NN	O	O
new	NN	O	O
therapeutic	NN	O	O
venue	NN	O	O
by	NN	O	O
which	NN	O	O
antibodies	NN	O	O
bind	NN	O	O
the	NN	O	O
drug	NN	O	O
in	NN	O	O
the	NN	O	O
blood	NN	O	O
stream	NN	O	O
,	NN	O	O
inactivating	NN	O	O
its	NN	O	O
toxic	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
therapeutic	NN	O	O
potential	NN	O	O
of	NN	O	O
the	NN	O	O
anticocaine	NN	O	O
antibody	NN	O	O
GNC92H2	NN	O	O
was	NN	O	O
examined	NN	O	O
using	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
cocaine	NN	O	B
overdose	NN	O	I
.	NN	O	O

Swiss	NN	O	O
albino	NN	O	O
mice	NN	O	O
prepared	NN	O	O
with	NN	O	O
intrajugular	NN	O	O
catheters	NN	O	O
were	NN	O	O
tested	NN	O	O
in	NN	O	O
photocell	NN	O	O
cages	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
93	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
LD50	NN	O	O
)	NN	O	O
of	NN	O	O
cocaine	NN	O	O
and	NN	O	O
GNC92H2	NN	O	O
infusions	NN	O	O
ranging	NN	O	O
from	NN	O	O
30	NN	O	O
to	NN	O	O
190	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

GNC92H2	NN	O	O
was	NN	O	O
delivered	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
,	NN	O	O
concomitantly	NN	O	O
or	NN	O	O
3	NN	O	O
min	NN	O	O
after	NN	O	O
cocaine	NN	O	O
treatment	NN	O	O
.	NN	O	O

Significant	NN	O	O
blockade	NN	O	O
of	NN	O	O
cocaine	NN	O	O
toxicity	NN	O	B
was	NN	O	O
observed	NN	O	O
with	NN	O	O
the	NN	O	O
higher	NN	O	O
dose	NN	O	O
of	NN	O	O
GNC92H2	NN	O	O
(	NN	O	O
190	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
where	NN	O	O
premorbid	NN	O	O
behaviors	NN	O	O
were	NN	O	O
reduced	NN	O	O
up	NN	O	O
to	NN	O	O
40	NN	O	O
%	NN	O	O
,	NN	O	O
seizures	NN	O	B
up	NN	O	O
to	NN	O	O
77	NN	O	O
%	NN	O	O
and	NN	O	O
death	NN	O	B
by	NN	O	O
72	NN	O	O
%	NN	O	O
.	NN	O	O

Importantly	NN	O	O
,	NN	O	O
GNC92H2	NN	O	O
prevented	NN	O	O
death	NN	O	B
even	NN	O	O
post	NN	O	O
-	NN	O	O
cocaine	NN	O	O
injection	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
support	NN	O	O
the	NN	O	O
important	NN	O	O
potential	NN	O	O
of	NN	O	O
GNC92H2	NN	O	O
as	NN	O	O
a	NN	O	O
therapeutic	NN	O	O
tool	NN	O	O
against	NN	O	O
cocaine	NN	O	B
overdose	NN	O	I
.	NN	O	O

Electrocardiographic	NN	O	O
evidence	NN	O	O
of	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
in	NN	O	O
psychiatrically	NN	O	O
hospitalized	NN	O	O
cocaine	NN	O	O
abusers	NN	O	O
.	NN	O	O

The	NN	O	O
electrocardiograms	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
of	NN	O	O
99	NN	O	O
cocaine	NN	O	O
-	NN	O	O
abusing	NN	O	O
patients	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
ECGs	NN	O	O
of	NN	O	O
50	NN	O	O
schizophrenic	NN	O	B
controls	NN	O	O
.	NN	O	O

Eleven	NN	O	O
of	NN	O	O
the	NN	O	O
cocaine	NN	O	O
abusers	NN	O	O
and	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
controls	NN	O	O
had	NN	O	O
ECG	NN	O	O
evidence	NN	O	O
of	NN	O	O
significant	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
defined	NN	O	O
as	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
,	NN	O	O
ischemia	NN	O	B
,	NN	O	O
and	NN	O	O
bundle	NN	O	B
branch	NN	O	I
block	NN	O	I
.	NN	O	O

Behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
urotensin	NN	O	O
-	NN	O	O
II	NN	O	O
centrally	NN	O	O
administered	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Urotensin	NN	O	O
-	NN	O	O
II	NN	O	O
(	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
)	NN	O	O
receptors	NN	O	O
are	NN	O	O
widely	NN	O	O
distributed	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O

Intracerebroventricular	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
injection	NN	O	O
of	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
causes	NN	O	O
hypertension	NN	O	B
and	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
stimulates	NN	O	O
prolactin	NN	O	O
and	NN	O	O
thyrotropin	NN	O	O
secretion	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
centrally	NN	O	O
administered	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
have	NN	O	O
received	NN	O	O
little	NN	O	O
attention	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
tested	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
injections	NN	O	O
of	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
on	NN	O	O
behavioral	NN	O	O
,	NN	O	O
metabolic	NN	O	O
,	NN	O	O
and	NN	O	O
endocrine	NN	O	O
responses	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
graded	NN	O	O
doses	NN	O	O
of	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
,	NN	O	O
000	NN	O	O
ng	NN	O	O
/	NN	O	O
mouse	NN	O	O
)	NN	O	O
provoked	NN	O	O
:	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
head	NN	O	O
dips	NN	O	O
in	NN	O	O
the	NN	O	O
hole	NN	O	O
-	NN	O	O
board	NN	O	O
test	NN	O	O
;	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
entries	NN	O	O
in	NN	O	O
the	NN	O	O
white	NN	O	O
chamber	NN	O	O
in	NN	O	O
the	NN	O	O
black	NN	O	O
-	NN	O	O
and	NN	O	O
-	NN	O	O
white	NN	O	O
compartment	NN	O	O
test	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
entries	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
platform	NN	O	O
and	NN	O	O
open	NN	O	O
arms	NN	O	O
in	NN	O	O
the	NN	O	O
plus	NN	O	O
-	NN	O	O
maze	NN	O	O
test	NN	O	O
;	NN	O	O
and	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
immobility	NN	O	O
in	NN	O	O
the	NN	O	O
forced	NN	O	O
-	NN	O	O
swimming	NN	O	O
test	NN	O	O
and	NN	O	O
tail	NN	O	O
suspension	NN	O	O
test	NN	O	O
.	NN	O	O

Intracerebroventricular	NN	O	O
injection	NN	O	O
of	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
also	NN	O	O
caused	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
:	NN	O	O
food	NN	O	O
intake	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
100	NN	O	O
and	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
ng	NN	O	O
/	NN	O	O
mouse	NN	O	O
,	NN	O	O
water	NN	O	O
intake	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
100	NN	O	O
-	NN	O	O
10	NN	O	O
,	NN	O	O
000	NN	O	O
ng	NN	O	O
/	NN	O	O
mouse	NN	O	O
,	NN	O	O
and	NN	O	O
horizontal	NN	O	O
locomotion	NN	O	O
activity	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
10	NN	O	O
,	NN	O	O
000	NN	O	O
ng	NN	O	O
/	NN	O	O
mouse	NN	O	O
.	NN	O	O

Whatever	NN	O	O
was	NN	O	O
the	NN	O	O
dose	NN	O	O
,	NN	O	O
the	NN	O	O
central	NN	O	O
administration	NN	O	O
of	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
body	NN	O	O
temperature	NN	O	O
,	NN	O	O
nociception	NN	O	O
,	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
penile	NN	O	B
erection	NN	O	I
and	NN	O	O
climbing	NN	O	O
behavior	NN	O	O
,	NN	O	O
and	NN	O	O
stress	NN	O	O
-	NN	O	O
induced	NN	O	O
plasma	NN	O	O
corticosterone	NN	O	O
level	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
the	NN	O	O
central	NN	O	O
injection	NN	O	O
of	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
1	NN	O	O
-	NN	O	O
10	NN	O	O
,	NN	O	O
000	NN	O	O
ng	NN	O	O
/	NN	O	O
mouse	NN	O	O
induces	NN	O	O
anxiogenic	NN	O	O
-	NN	O	O
and	NN	O	O
depressant	NN	O	O
-	NN	O	O
like	NN	O	O
effects	NN	O	O
in	NN	O	O
mouse	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
U	NN	O	O
-	NN	O	O
II	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
some	NN	O	O
aspects	NN	O	O
of	NN	O	O
psychiatric	NN	O	B
disorders	NN	O	I
.	NN	O	O

Learning	NN	O	O
of	NN	O	O
rats	NN	O	O
under	NN	O	O
amnesia	NN	O	B
caused	NN	O	O
by	NN	O	O
pentobarbital	NN	O	O
.	NN	O	O

Dissociated	NN	O	O
learning	NN	O	O
of	NN	O	O
rats	NN	O	O
in	NN	O	O
the	NN	O	O
normal	NN	O	O
state	NN	O	O
and	NN	O	O
the	NN	O	O
state	NN	O	O
of	NN	O	O
amnesia	NN	O	B
produced	NN	O	O
by	NN	O	O
pentobarbital	NN	O	O
(	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
ip	NN	O	O
)	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
trained	NN	O	O
to	NN	O	O
approach	NN	O	O
a	NN	O	O
shelf	NN	O	O
where	NN	O	O
they	NN	O	O
received	NN	O	O
food	NN	O	O
reinforcement	NN	O	O
.	NN	O	O

In	NN	O	O
Group	NN	O	O
1	NN	O	O
the	NN	O	O
rats	NN	O	O
were	NN	O	O
trained	NN	O	O
under	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
pentobarbital	NN	O	O
to	NN	O	O
run	NN	O	O
to	NN	O	O
the	NN	O	O
same	NN	O	O
shelf	NN	O	O
as	NN	O	O
in	NN	O	O
the	NN	O	O
normal	NN	O	O
state	NN	O	O
.	NN	O	O

In	NN	O	O
Group	NN	O	O
2	NN	O	O
the	NN	O	O
rats	NN	O	O
were	NN	O	O
trained	NN	O	O
to	NN	O	O
approach	NN	O	O
different	NN	O	O
shelves	NN	O	O
in	NN	O	O
different	NN	O	O
drug	NN	O	O
states	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
shown	NN	O	O
that	NN	O	O
memory	NN	O	B
dissociation	NN	O	I
occurred	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Differences	NN	O	O
in	NN	O	O
the	NN	O	O
parameters	NN	O	O
of	NN	O	O
training	NN	O	O
under	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
pentobarbital	NN	O	O
between	NN	O	O
Groups	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
were	NN	O	O
revealed	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
brain	NN	O	O
-	NN	O	O
dissociated	NN	O	O
state	NN	O	O
induced	NN	O	O
by	NN	O	O
pentobarbital	NN	O	O
is	NN	O	O
formed	NN	O	O
with	NN	O	O
the	NN	O	O
participation	NN	O	O
of	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
information	NN	O	O
perception	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
raloxifene	NN	O	O
therapy	NN	O	O
on	NN	O	O
fibrinolysis	NN	O	O
markers	NN	O	O
:	NN	O	O
TAFI	NN	O	O
,	NN	O	O
tPA	NN	O	O
,	NN	O	O
and	NN	O	O
PAI	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Markers	NN	O	O
of	NN	O	O
fibrinolysis	NN	O	O
,	NN	O	O
thrombin	NN	O	O
-	NN	O	O
activatable	NN	O	O
fibrinolysis	NN	O	O
inhibitor	NN	O	O
(	NN	O	O
TAFI	NN	O	O
)	NN	O	O
,	NN	O	O
tissue	NN	O	O
-	NN	O	O
type	NN	O	O
plasminogen	NN	O	O
activator	NN	O	O
(	NN	O	O
tPA	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
plasminogen	NN	O	O
activator	NN	O	O
inhibitor	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
PAI	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
levels	NN	O	O
were	NN	O	O
studied	NN	O	O
for	NN	O	O
the	NN	O	O
evaluation	NN	O	O
of	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
effects	NN	O	O
of	NN	O	O
raloxifene	NN	O	O
administration	NN	O	O
in	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Thirty	NN	O	O
-	NN	O	O
nine	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
with	NN	O	O
osteopenia	NN	O	B
or	NN	O	O
osteoporosis	NN	O	B
were	NN	O	O
included	NN	O	O
in	NN	O	O
this	NN	O	O
prospective	NN	O	O
,	NN	O	O
controlled	NN	O	O
clinical	NN	O	O
study	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
five	NN	O	O
women	NN	O	O
were	NN	O	O
given	NN	O	O
raloxifene	NN	O	O
hydrochloride	NN	O	O
(	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
plus	NN	O	O
calcium	NN	O	O
(	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
.	NN	O	O

Age	NN	O	O
-	NN	O	O
matched	NN	O	O
controls	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
14	NN	O	O
)	NN	O	O
were	NN	O	O
given	NN	O	O
only	NN	O	O
calcium	NN	O	O
.	NN	O	O

Plasma	NN	O	O
TAFI	NN	O	O
,	NN	O	O
tPA	NN	O	O
,	NN	O	O
and	NN	O	O
PAI	NN	O	O
-	NN	O	O
1	NN	O	O
antigen	NN	O	O
levels	NN	O	O
were	NN	O	O
measured	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
after	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
treatment	NN	O	O
by	NN	O	O
commercially	NN	O	O
available	NN	O	O
ELISA	NN	O	O
kits	NN	O	O
.	NN	O	O

Variations	NN	O	O
of	NN	O	O
individuals	NN	O	O
were	NN	O	O
assessed	NN	O	O
by	NN	O	O
Wilcoxon	NN	O	O
'	NN	O	O
s	NN	O	O
test	NN	O	O
.	NN	O	O

Relationship	NN	O	O
between	NN	O	O
those	NN	O	O
markers	NN	O	O
and	NN	O	O
demographic	NN	O	O
characteristics	NN	O	O
were	NN	O	O
investigated	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Three	NN	O	O
months	NN	O	O
of	NN	O	O
raloxifene	NN	O	O
treatment	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
TAFI	NN	O	O
antigen	NN	O	O
concentrations	NN	O	O
(	NN	O	O
16	NN	O	O
%	NN	O	O
change	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
tPA	NN	O	O
antigen	NN	O	O
concentrations	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
change	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
correlation	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
baseline	NN	O	O
TAFI	NN	O	O
antigen	NN	O	O
concentrations	NN	O	O
and	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
amenorrhea	NN	O	B
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
;	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
33	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
We	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B
thromboembolism	NN	O	I
due	NN	O	O
to	NN	O	O
raloxifene	NN	O	O
treatment	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
increased	NN	O	O
tPA	NN	O	O
levels	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
TAFI	NN	O	O
levels	NN	O	O
.	NN	O	O

Valproate	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
.	NN	O	O

Valproate	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
is	NN	O	O
a	NN	O	O
rare	NN	O	O
syndrome	NN	O	O
that	NN	O	O
may	NN	O	O
manifest	NN	O	O
in	NN	O	O
otherwise	NN	O	O
normal	NN	O	O
epileptic	NN	O	B
individuals	NN	O	O
.	NN	O	O

It	NN	O	O
may	NN	O	O
even	NN	O	O
present	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
tolerated	NN	O	O
this	NN	O	O
medicine	NN	O	O
well	NN	O	O
in	NN	O	O
the	NN	O	O
past	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
usually	NN	O	O
but	NN	O	O
not	NN	O	O
necessarily	NN	O	O
associated	NN	O	O
with	NN	O	O
hyperammonemia	NN	O	B
.	NN	O	O

The	NN	O	O
EEG	NN	O	O
shows	NN	O	O
characteristic	NN	O	O
triphasic	NN	O	O
waves	NN	O	O
in	NN	O	O
most	NN	O	O
patients	NN	O	O
with	NN	O	O
this	NN	O	O
complication	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
valproate	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
is	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
problems	NN	O	O
in	NN	O	O
diagnosing	NN	O	O
this	NN	O	O
condition	NN	O	O
are	NN	O	O
subsequently	NN	O	O
discussed	NN	O	O
.	NN	O	O

Recurrent	NN	O	O
dysphonia	NN	O	B
and	NN	O	O
acitretin	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
woman	NN	O	O
complaining	NN	O	O
of	NN	O	O
dysphonia	NN	O	B
while	NN	O	O
she	NN	O	O
was	NN	O	O
treated	NN	O	O
by	NN	O	O
acitretin	NN	O	O
.	NN	O	O

Her	NN	O	O
symptoms	NN	O	O
totally	NN	O	O
regressed	NN	O	O
after	NN	O	O
drug	NN	O	O
withdrawal	NN	O	O
and	NN	O	O
reappeared	NN	O	O
when	NN	O	O
acitretin	NN	O	O
was	NN	O	O
reintroduced	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
of	NN	O	O
acitretin	NN	O	O
-	NN	O	O
induced	NN	O	O
dysphonia	NN	O	B
.	NN	O	O

This	NN	O	O
effect	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
pharmacological	NN	O	O
effect	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
on	NN	O	O
mucous	NN	O	O
membranes	NN	O	O
.	NN	O	O

Nitro	NN	O	O
-	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
methyl	NN	O	O
ester	NN	O	O
:	NN	O	O
a	NN	O	O
potential	NN	O	O
protector	NN	O	O
against	NN	O	O
gentamicin	NN	O	O
ototoxicity	NN	O	B
.	NN	O	O

The	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
(	NN	O	O
NO	NN	O	O
)	NN	O	O
inhibitor	NN	O	O
nitro	NN	O	O
-	NN	O	O
L	NN	O	O
-	NN	O	O
arginine	NN	O	O
methyl	NN	O	O
ester	NN	O	O
(	NN	O	O
L	NN	O	O
-	NN	O	O
NAME	NN	O	O
)	NN	O	O
may	NN	O	O
act	NN	O	O
as	NN	O	O
an	NN	O	O
otoprotectant	NN	O	O
against	NN	O	O
high	NN	O	B
-	NN	O	I
frequency	NN	O	I
hearing	NN	O	I
loss	NN	O	I
caused	NN	O	O
by	NN	O	O
gentamicin	NN	O	O
,	NN	O	O
but	NN	O	O
further	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
confirm	NN	O	O
this	NN	O	O
.	NN	O	O
Aminoglycoside	NN	O	O
antibiotics	NN	O	O
are	NN	O	O
still	NN	O	O
widely	NN	O	O
used	NN	O	O
by	NN	O	O
virtue	NN	O	O
of	NN	O	O
their	NN	O	O
efficacy	NN	O	O
and	NN	O	O
low	NN	O	O
cost	NN	O	O
.	NN	O	O

Their	NN	O	O
ototoxicity	NN	O	B
is	NN	O	O
a	NN	O	O
serious	NN	O	O
health	NN	O	O
problem	NN	O	O
and	NN	O	O
,	NN	O	O
as	NN	O	O
their	NN	O	O
ototoxic	NN	O	B
mechanism	NN	O	O
involves	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
NO	NN	O	O
,	NN	O	O
we	NN	O	O
need	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
NO	NN	O	O
inhibitors	NN	O	O
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
aminoglycoside	NN	O	O
-	NN	O	O
induced	NN	O	O
sensorineural	NN	O	B
hearing	NN	O	I
loss	NN	O	I
.	NN	O	O

In	NN	O	O
this	NN	O	O
experimental	NN	O	O
study	NN	O	O
we	NN	O	O
used	NN	O	O
30	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
,	NN	O	O
27	NN	O	O
of	NN	O	O
which	NN	O	O
had	NN	O	O
gentamicin	NN	O	O
instilled	NN	O	O
into	NN	O	O
the	NN	O	O
middle	NN	O	O
ear	NN	O	O
.	NN	O	O

The	NN	O	O
otoprotectant	NN	O	O
L	NN	O	O
-	NN	O	O
NAME	NN	O	O
was	NN	O	O
administered	NN	O	O
topically	NN	O	O
to	NN	O	O
12	NN	O	O
/	NN	O	O
27	NN	O	O
animals	NN	O	O
.	NN	O	O

Its	NN	O	O
effect	NN	O	O
was	NN	O	O
determined	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
attenuation	NN	O	O
of	NN	O	O
hearing	NN	O	B
loss	NN	O	I
,	NN	O	O
measured	NN	O	O
by	NN	O	O
shifts	NN	O	O
in	NN	O	O
the	NN	O	O
auditory	NN	O	O
brainstem	NN	O	O
response	NN	O	O
threshold	NN	O	O
.	NN	O	O

L	NN	O	O
-	NN	O	O
NAME	NN	O	O
reduced	NN	O	O
gentamicin	NN	O	O
-	NN	O	O
induced	NN	O	O
hearing	NN	O	B
loss	NN	O	I
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
frequency	NN	O	O
range	NN	O	O
,	NN	O	O
but	NN	O	O
gave	NN	O	O
no	NN	O	O
protection	NN	O	O
in	NN	O	O
the	NN	O	O
middle	NN	O	O
or	NN	O	O
low	NN	O	O
frequencies	NN	O	O
.	NN	O	O

Safety	NN	O	O
profile	NN	O	O
of	NN	O	O
a	NN	O	O
nicotine	NN	O	O
lozenge	NN	O	O
compared	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
nicotine	NN	O	O
gum	NN	O	O
in	NN	O	O
adult	NN	O	O
smokers	NN	O	O
with	NN	O	O
underlying	NN	O	O
medical	NN	O	O
conditions	NN	O	O
:	NN	O	O
a	NN	O	O
12	NN	O	O
-	NN	O	O
week	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Nicotine	NN	O	O
polacrilex	NN	O	O
lozenges	NN	O	O
deliver	NN	O	O
25	NN	O	O
%	NN	O	O
to	NN	O	O
27	NN	O	O
%	NN	O	O
more	NN	O	O
nicotine	NN	O	O
compared	NN	O	O
with	NN	O	O
equivalent	NN	O	O
doses	NN	O	O
of	NN	O	O
nicotine	NN	O	O
polacrilex	NN	O	O
gum	NN	O	O
.	NN	O	O

The	NN	O	O
increased	NN	O	O
nicotine	NN	O	O
exposure	NN	O	O
from	NN	O	O
the	NN	O	O
lozenge	NN	O	O
has	NN	O	O
raised	NN	O	O
questions	NN	O	O
about	NN	O	O
the	NN	O	O
relative	NN	O	O
safety	NN	O	O
of	NN	O	O
the	NN	O	O
lozenge	NN	O	O
and	NN	O	O
gum	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
safety	NN	O	O
profiles	NN	O	O
of	NN	O	O
the	NN	O	O
4	NN	O	O
-	NN	O	O
mg	NN	O	O
nicotine	NN	O	O
lozenge	NN	O	O
and	NN	O	O
4	NN	O	O
-	NN	O	O
mg	NN	O	O
nicotine	NN	O	O
gum	NN	O	O
in	NN	O	O
smokers	NN	O	O
with	NN	O	O
selected	NN	O	O
label	NN	O	O
-	NN	O	O
restricted	NN	O	O
diseases	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
was	NN	O	O
a	NN	O	O
multicenter	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
study	NN	O	O
in	NN	O	O
adult	NN	O	O
smokers	NN	O	O
with	NN	O	O
heart	NN	O	B
disease	NN	O	I
,	NN	O	O
hypertension	NN	O	B
not	NN	O	O
controlled	NN	O	O
by	NN	O	O
medication	NN	O	O
,	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
in	NN	O	O
a	NN	O	O
1	NN	O	O
:	NN	O	O
1	NN	O	O
ratio	NN	O	O
to	NN	O	O
receive	NN	O	O
the	NN	O	O
4	NN	O	O
-	NN	O	O
mg	NN	O	O
nicotine	NN	O	O
lozenge	NN	O	O
or	NN	O	O
4	NN	O	O
-	NN	O	O
mg	NN	O	O
nicotine	NN	O	O
gum	NN	O	O
.	NN	O	O

Safety	NN	O	O
assessments	NN	O	O
were	NN	O	O
made	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
at	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
6	NN	O	O
,	NN	O	O
and	NN	O	O
12	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
product	NN	O	O
use	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Nine	NN	O	O
hundred	NN	O	O
one	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
treatment	NN	O	O
,	NN	O	O
447	NN	O	O
who	NN	O	O
received	NN	O	O
the	NN	O	O
lozenge	NN	O	O
and	NN	O	O
454	NN	O	O
who	NN	O	O
received	NN	O	O
the	NN	O	O
gum	NN	O	O
(	NN	O	O
safety	NN	O	O
population	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
majority	NN	O	O
were	NN	O	O
women	NN	O	O
(	NN	O	O
52	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
'	NN	O	O
mean	NN	O	O
age	NN	O	O
was	NN	O	O
53	NN	O	O
.	NN	O	O
9	NN	O	O
years	NN	O	O
,	NN	O	O
their	NN	O	O
mean	NN	O	O
weight	NN	O	O
was	NN	O	O
193	NN	O	O
.	NN	O	O
9	NN	O	O
pounds	NN	O	O
,	NN	O	O
and	NN	O	O
they	NN	O	O
smoked	NN	O	O
a	NN	O	O
mean	NN	O	O
of	NN	O	O
25	NN	O	O
.	NN	O	O
2	NN	O	O
cigarettes	NN	O	O
per	NN	O	O
day	NN	O	O
at	NN	O	O
baseline	NN	O	O
.	NN	O	O

Five	NN	O	O
hundred	NN	O	O
fifty	NN	O	O
-	NN	O	O
three	NN	O	O
patients	NN	O	O
,	NN	O	O
264	NN	O	O
taking	NN	O	O
the	NN	O	O
lozenge	NN	O	O
and	NN	O	O
289	NN	O	O
taking	NN	O	O
the	NN	O	O
gum	NN	O	O
,	NN	O	O
used	NN	O	O
the	NN	O	O
study	NN	O	O
product	NN	O	O
for	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
4	NN	O	O
days	NN	O	O
per	NN	O	O
week	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
2	NN	O	O
weeks	NN	O	O
(	NN	O	O
evaluable	NN	O	O
population	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
nicotine	NN	O	O
lozenge	NN	O	O
and	NN	O	O
nicotine	NN	O	O
gum	NN	O	O
were	NN	O	O
equally	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
despite	NN	O	O
increased	NN	O	O
nicotine	NN	O	O
exposure	NN	O	O
from	NN	O	O
the	NN	O	O
lozenge	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
in	NN	O	O
the	NN	O	O
2	NN	O	O
groups	NN	O	O
was	NN	O	O
similar	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
2	NN	O	O
weeks	NN	O	O
of	NN	O	O
product	NN	O	O
use	NN	O	O
(	NN	O	O
evaluation	NN	O	O
population	NN	O	O
:	NN	O	O
55	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
lozenge	NN	O	O
,	NN	O	O
54	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
gum	NN	O	O
)	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
during	NN	O	O
the	NN	O	O
entire	NN	O	O
study	NN	O	O
(	NN	O	O
safety	NN	O	O
population	NN	O	O
:	NN	O	O
63	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
and	NN	O	O
58	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Stratification	NN	O	O
of	NN	O	O
patients	NN	O	O
by	NN	O	O
sex	NN	O	O
,	NN	O	O
age	NN	O	O
,	NN	O	O
extent	NN	O	O
of	NN	O	O
concurrent	NN	O	O
smoking	NN	O	O
,	NN	O	O
extent	NN	O	O
of	NN	O	O
product	NN	O	O
use	NN	O	O
,	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
revealed	NN	O	O
no	NN	O	O
clinically	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
lozenge	NN	O	O
and	NN	O	O
gum	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
nausea	NN	O	B
(	NN	O	O
17	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
and	NN	O	O
16	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
7	NN	O	O
to	NN	O	O
6	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
,	NN	O	O
hiccups	NN	O	B
(	NN	O	O
10	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
and	NN	O	O
6	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
7	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
headache	NN	O	B
(	NN	O	O
8	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
and	NN	O	O
9	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
Cl	NN	O	O
,	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

Serious	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
reported	NN	O	O
in	NN	O	O
11	NN	O	O
and	NN	O	O
13	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
respective	NN	O	O
groups	NN	O	O
.	NN	O	O

Fewer	NN	O	O
than	NN	O	O
6	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
were	NN	O	O
considered	NN	O	O
by	NN	O	O
the	NN	O	O
investigator	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
worsening	NN	O	O
of	NN	O	O
their	NN	O	O
overall	NN	O	O
disease	NN	O	O
condition	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
majority	NN	O	O
of	NN	O	O
patients	NN	O	O
(	NN	O	O
>	NN	O	O
60	NN	O	O
%	NN	O	O
)	NN	O	O
experienced	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
their	NN	O	O
disease	NN	O	O
status	NN	O	O
from	NN	O	O
baseline	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
4	NN	O	O
-	NN	O	O
mg	NN	O	O
nicotine	NN	O	O
lozenge	NN	O	O
and	NN	O	O
4	NN	O	O
-	NN	O	O
mg	NN	O	O
nicotine	NN	O	O
gum	NN	O	O
had	NN	O	O
comparable	NN	O	O
safety	NN	O	O
profiles	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
with	NN	O	O
label	NN	O	O
-	NN	O	O
restricted	NN	O	O
medical	NN	O	O
conditions	NN	O	O
.	NN	O	O

Pharmacological	NN	O	O
modulation	NN	O	O
of	NN	O	O
pain	NN	O	B
-	NN	O	O
related	NN	O	O
brain	NN	O	O
activity	NN	O	O
during	NN	O	O
normal	NN	O	O
and	NN	O	O
central	NN	O	O
sensitization	NN	O	O
states	NN	O	O
in	NN	O	O
humans	NN	O	O
.	NN	O	O

Abnormal	NN	O	O
processing	NN	O	O
of	NN	O	O
somatosensory	NN	O	O
inputs	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
central	NN	O	O
sensitization	NN	O	O
)	NN	O	O
is	NN	O	O
the	NN	O	O
mechanism	NN	O	O
accounting	NN	O	O
for	NN	O	O
the	NN	O	O
enhanced	NN	O	O
pain	NN	O	B
sensitivity	NN	O	O
in	NN	O	O
the	NN	O	O
skin	NN	O	O
surrounding	NN	O	O
tissue	NN	O	B
injury	NN	O	I
(	NN	O	O
secondary	NN	O	B
hyperalgesia	NN	O	I
)	NN	O	O
.	NN	O	O

Secondary	NN	O	B
hyperalgesia	NN	O	I
shares	NN	O	O
clinical	NN	O	O
characteristics	NN	O	O
with	NN	O	O
neurogenic	NN	O	B
hyperalgesia	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
neuropathic	NN	O	B
pain	NN	O	I
.	NN	O	O

Abnormal	NN	O	O
brain	NN	O	O
responses	NN	O	O
to	NN	O	O
somatosensory	NN	O	O
stimuli	NN	O	O
have	NN	O	O
been	NN	O	O
found	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hyperalgesia	NN	O	B
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
normal	NN	O	O
subjects	NN	O	O
during	NN	O	O
experimental	NN	O	O
central	NN	O	O
sensitization	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
gabapentin	NN	O	O
,	NN	O	O
a	NN	O	O
drug	NN	O	O
effective	NN	O	O
in	NN	O	O
neuropathic	NN	O	B
pain	NN	O	I
patients	NN	O	O
,	NN	O	O
on	NN	O	O
brain	NN	O	O
processing	NN	O	O
of	NN	O	O
nociceptive	NN	O	O
information	NN	O	O
in	NN	O	O
normal	NN	O	O
and	NN	O	O
central	NN	O	O
sensitization	NN	O	O
states	NN	O	O
.	NN	O	O

Using	NN	O	O
functional	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
fMRI	NN	O	O
)	NN	O	O
in	NN	O	O
normal	NN	O	O
volunteers	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
the	NN	O	O
gabapentin	NN	O	O
-	NN	O	O
induced	NN	O	O
modulation	NN	O	O
of	NN	O	O
brain	NN	O	O
activity	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
nociceptive	NN	O	O
mechanical	NN	O	O
stimulation	NN	O	O
of	NN	O	O
normal	NN	O	O
skin	NN	O	O
and	NN	O	O
capsaicin	NN	O	O
-	NN	O	O
induced	NN	O	O
secondary	NN	O	B
hyperalgesia	NN	O	I
.	NN	O	O

The	NN	O	O
dose	NN	O	O
of	NN	O	O
gabapentin	NN	O	O
was	NN	O	O
1	NN	O	O
,	NN	O	O
800	NN	O	O
mg	NN	O	O
per	NN	O	O
os	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
administration	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
gabapentin	NN	O	O
reduced	NN	O	O
the	NN	O	O
activations	NN	O	O
in	NN	O	O
the	NN	O	O
bilateral	NN	O	O
operculoinsular	NN	O	O
cortex	NN	O	O
,	NN	O	O
independently	NN	O	O
of	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
central	NN	O	O
sensitization	NN	O	O
;	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
gabapentin	NN	O	O
reduced	NN	O	O
the	NN	O	O
activation	NN	O	O
in	NN	O	O
the	NN	O	O
brainstem	NN	O	O
,	NN	O	O
only	NN	O	O
during	NN	O	O
central	NN	O	O
sensitization	NN	O	O
;	NN	O	O
(	NN	O	O
iii	NN	O	O
)	NN	O	O
gabapentin	NN	O	O
suppressed	NN	O	O
stimulus	NN	O	O
-	NN	O	O
induced	NN	O	O
deactivations	NN	O	O
,	NN	O	O
only	NN	O	O
during	NN	O	O
central	NN	O	O
sensitization	NN	O	O
;	NN	O	O
this	NN	O	O
effect	NN	O	O
was	NN	O	O
more	NN	O	O
robust	NN	O	O
than	NN	O	O
the	NN	O	O
effect	NN	O	O
on	NN	O	O
brain	NN	O	O
activation	NN	O	O
.	NN	O	O

The	NN	O	O
observed	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
effects	NN	O	O
were	NN	O	O
not	NN	O	O
due	NN	O	O
to	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
baseline	NN	O	O
fMRI	NN	O	O
signal	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
gabapentin	NN	O	O
has	NN	O	O
a	NN	O	O
measurable	NN	O	O
antinociceptive	NN	O	O
effect	NN	O	O
and	NN	O	O
a	NN	O	O
stronger	NN	O	O
antihyperalgesic	NN	O	O
effect	NN	O	O
most	NN	O	O
evident	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
areas	NN	O	O
undergoing	NN	O	O
deactivation	NN	O	O
,	NN	O	O
thus	NN	O	O
supporting	NN	O	O
the	NN	O	O
concept	NN	O	O
that	NN	O	O
gabapentin	NN	O	O
is	NN	O	O
more	NN	O	O
effective	NN	O	O
in	NN	O	O
modulating	NN	O	O
nociceptive	NN	O	O
transmission	NN	O	O
when	NN	O	O
central	NN	O	O
sensitization	NN	O	O
is	NN	O	O
present	NN	O	O
.	NN	O	O

Investigation	NN	O	O
of	NN	O	O
mitochondrial	NN	O	O
involvement	NN	O	O
in	NN	O	O
the	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
epilepsy	NN	O	B
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
.	NN	O	O

Mitochondrial	NN	O	B
abnormalities	NN	O	I
have	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
several	NN	O	O
aspects	NN	O	O
of	NN	O	O
epileptogenesis	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
energy	NN	O	O
generation	NN	O	O
,	NN	O	O
control	NN	O	O
of	NN	O	O
cell	NN	O	O
death	NN	O	B
,	NN	O	O
neurotransmitter	NN	O	O
synthesis	NN	O	O
,	NN	O	O
and	NN	O	O
free	NN	O	O
radical	NN	O	O
(	NN	O	O
FR	NN	O	O
)	NN	O	O
production	NN	O	O
.	NN	O	O

Increased	NN	O	O
production	NN	O	O
of	NN	O	O
FRs	NN	O	O
may	NN	O	O
cause	NN	O	O
mtDNA	NN	O	O
damage	NN	O	O
leading	NN	O	O
to	NN	O	O
decreased	NN	O	O
activities	NN	O	O
of	NN	O	O
oxidative	NN	O	O
phosphorylation	NN	O	O
complexes	NN	O	O
containing	NN	O	O
mtDNA	NN	O	O
-	NN	O	O
encoded	NN	O	O
subunits	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
whether	NN	O	O
increased	NN	O	O
generation	NN	O	O
of	NN	O	O
FR	NN	O	O
during	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
would	NN	O	O
be	NN	O	O
sufficient	NN	O	O
to	NN	O	O
provoke	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
mtDNA	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
expression	NN	O	O
and	NN	O	O
activity	NN	O	O
of	NN	O	O
cytochrome	NN	O	O
c	NN	O	O
oxidase	NN	O	O
(	NN	O	O
CCO	NN	O	O
)	NN	O	O
,	NN	O	O
complex	NN	O	O
IV	NN	O	O
of	NN	O	O
the	NN	O	O
respiratory	NN	O	O
chain	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
chronic	NN	O	O
phase	NN	O	O
of	NN	O	O
the	NN	O	O
pilocarpine	NN	O	O
model	NN	O	O
of	NN	O	O
temporal	NN	O	B
lobe	NN	O	I
epilepsy	NN	O	I
.	NN	O	O

DNA	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
low	NN	O	O
amounts	NN	O	O
of	NN	O	O
a	NN	O	O
4	NN	O	O
.	NN	O	O
8	NN	O	O
kb	NN	O	O
mtDNA	NN	O	O
deletion	NN	O	O
but	NN	O	O
with	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
frequency	NN	O	O
or	NN	O	O
quantity	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
and	NN	O	O
experimental	NN	O	O
groups	NN	O	O
.	NN	O	O

We	NN	O	O
did	NN	O	O
not	NN	O	O
find	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
the	NN	O	O
expression	NN	O	O
and	NN	O	O
distribution	NN	O	O
of	NN	O	O
an	NN	O	O
mtDNA	NN	O	O
-	NN	O	O
encoded	NN	O	O
subunit	NN	O	O
of	NN	O	O
CCO	NN	O	O
(	NN	O	O
CCO	NN	O	O
-	NN	O	O
I	NN	O	O
)	NN	O	O
or	NN	O	O
a	NN	O	O
relative	NN	O	O
decrease	NN	O	O
in	NN	O	O
CCO	NN	O	O
-	NN	O	O
I	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
nuclear	NN	O	O
-	NN	O	O
encoded	NN	O	O
subunits	NN	O	O
(	NN	O	O
CCO	NN	O	O
-	NN	O	O
IV	NN	O	O
and	NN	O	O
SDH	NN	O	O
-	NN	O	O
fp	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
abnormality	NN	O	O
in	NN	O	O
CCO	NN	O	O
activity	NN	O	O
was	NN	O	O
observed	NN	O	O
through	NN	O	O
histochemistry	NN	O	O
.	NN	O	O

Although	NN	O	O
evidences	NN	O	O
of	NN	O	O
mitochondrial	NN	O	B
abnormalities	NN	O	I
were	NN	O	O
found	NN	O	O
in	NN	O	O
previously	NN	O	O
published	NN	O	O
studies	NN	O	O
,	NN	O	O
our	NN	O	O
results	NN	O	O
do	NN	O	O
not	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
FRs	NN	O	O
,	NN	O	O
generated	NN	O	O
during	NN	O	O
the	NN	O	O
acute	NN	O	O
phase	NN	O	O
,	NN	O	O
determined	NN	O	O
important	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
mtDNA	NN	O	O
,	NN	O	O
in	NN	O	O
expression	NN	O	O
of	NN	O	O
CCO	NN	O	O
-	NN	O	O
I	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
CCO	NN	O	O
activity	NN	O	O
.	NN	O	O

Adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blocker	NN	O	O
nitrendipine	NN	O	O
on	NN	O	O
nephrosclerosis	NN	O	B
in	NN	O	O
rats	NN	O	O
with	NN	O	O
renovascular	NN	O	B
hypertension	NN	O	I
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
week	NN	O	O
treatment	NN	O	O
with	NN	O	O
the	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blocker	NN	O	O
nitrendipine	NN	O	O
or	NN	O	O
the	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
enalapril	NN	O	O
on	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
albuminuria	NN	O	B
,	NN	O	O
renal	NN	O	O
hemodynamics	NN	O	O
,	NN	O	O
and	NN	O	O
morphology	NN	O	O
of	NN	O	O
the	NN	O	O
nonclipped	NN	O	O
kidney	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
two	NN	O	O
-	NN	O	O
kidney	NN	O	O
,	NN	O	O
one	NN	O	O
clip	NN	O	O
renovascular	NN	O	B
hypertension	NN	O	I
.	NN	O	O

Six	NN	O	O
weeks	NN	O	O
after	NN	O	O
clipping	NN	O	O
of	NN	O	O
one	NN	O	O
renal	NN	O	O
artery	NN	O	O
,	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
(	NN	O	O
178	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
three	NN	O	O
groups	NN	O	O
:	NN	O	O
untreated	NN	O	O
hypertensive	NN	O	B
controls	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
enalapril	NN	O	O
-	NN	O	O
treated	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
nitrendipine	NN	O	O
-	NN	O	O
treated	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
.	NN	O	O

Sham	NN	O	O
-	NN	O	O
operated	NN	O	O
rats	NN	O	O
served	NN	O	O
as	NN	O	O
normotensive	NN	O	O
controls	NN	O	O
(	NN	O	O
128	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
6	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
renal	NN	O	O
hemodynamics	NN	O	O
(	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
and	NN	O	O
renal	NN	O	O
plasma	NN	O	O
flow	NN	O	O
)	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
the	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
.	NN	O	O

Renal	NN	O	O
tissue	NN	O	O
was	NN	O	O
obtained	NN	O	O
for	NN	O	O
determination	NN	O	O
of	NN	O	O
glomerular	NN	O	O
size	NN	O	O
and	NN	O	O
sclerosis	NN	O	O
.	NN	O	O

Enalapril	NN	O	O
but	NN	O	O
not	NN	O	O
nitrendipine	NN	O	O
reduced	NN	O	O
blood	NN	O	O
pressure	NN	O	O
significantly	NN	O	O
.	NN	O	O

After	NN	O	O
6	NN	O	O
weeks	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
was	NN	O	O
not	NN	O	O
different	NN	O	O
among	NN	O	O
the	NN	O	O
studied	NN	O	O
groups	NN	O	O
.	NN	O	O

Renal	NN	O	O
plasma	NN	O	O
flow	NN	O	O
increased	NN	O	O
,	NN	O	O
but	NN	O	O
albumin	NN	O	O
excretion	NN	O	O
and	NN	O	O
glomerulosclerosis	NN	O	B
did	NN	O	O
not	NN	O	O
change	NN	O	O
after	NN	O	O
enalapril	NN	O	O
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
nitrendipine	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
albuminuria	NN	O	B
increased	NN	O	O
from	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
progressively	NN	O	O
to	NN	O	O
163	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
55	NN	O	O
compared	NN	O	O
with	NN	O	O
19	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9	NN	O	O
mg	NN	O	O
/	NN	O	O
24	NN	O	O
hr	NN	O	O
in	NN	O	O
the	NN	O	O
hypertensive	NN	O	B
controls	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
glomerulosclerosis	NN	O	B
index	NN	O	O
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
nitrendipine	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
hypertensive	NN	O	B
controls	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
38	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
versus	NN	O	O
0	NN	O	O
.	NN	O	O
13	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
04	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
glomerular	NN	O	O
size	NN	O	O
was	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
nitrendipine	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
(	NN	O	O
14	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
17	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
mm2	NN	O	O
)	NN	O	O
but	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
enalapril	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
(	NN	O	O
11	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
15	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
mm2	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
hypertensive	NN	O	B
controls	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
17	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
mm2	NN	O	O
)	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Ketoconazole	NN	O	O
induced	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
without	NN	O	O
concomitant	NN	O	O
use	NN	O	O
of	NN	O	O
QT	NN	O	O
interval	NN	O	O
-	NN	O	O
prolonging	NN	O	O
drug	NN	O	O
.	NN	O	O

Ketoconazole	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
proarrhythmic	NN	O	O
without	NN	O	O
concomitant	NN	O	O
use	NN	O	O
of	NN	O	O
QT	NN	O	O
interval	NN	O	O
-	NN	O	O
prolonging	NN	O	O
drugs	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
woman	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
who	NN	O	O
developed	NN	O	O
a	NN	O	O
markedly	NN	O	O
prolonged	NN	O	B
QT	NN	O	I
interval	NN	O	I
and	NN	O	O
torsades	NN	O	B
de	NN	O	I
pointes	NN	O	I
(	NN	O	O
TdP	NN	O	B
)	NN	O	O
after	NN	O	O
taking	NN	O	O
ketoconazole	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
fungal	NN	O	B
infection	NN	O	I
.	NN	O	O

Her	NN	O	O
QT	NN	O	O
interval	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
upon	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
ketoconazole	NN	O	O
.	NN	O	O

Genetic	NN	O	O
study	NN	O	O
did	NN	O	O
not	NN	O	O
find	NN	O	O
any	NN	O	O
mutation	NN	O	O
in	NN	O	O
her	NN	O	O
genes	NN	O	O
that	NN	O	O
encode	NN	O	O
cardiac	NN	O	O
IKr	NN	O	O
channel	NN	O	O
proteins	NN	O	O
.	NN	O	O

We	NN	O	O
postulate	NN	O	O
that	NN	O	O
by	NN	O	O
virtue	NN	O	O
of	NN	O	O
its	NN	O	O
direct	NN	O	O
blocking	NN	O	O
action	NN	O	O
on	NN	O	O
IKr	NN	O	O
,	NN	O	O
ketoconazole	NN	O	O
alone	NN	O	O
may	NN	O	O
prolong	NN	O	O
QT	NN	O	O
interval	NN	O	O
and	NN	O	O
induce	NN	O	O
TdP	NN	O	B
.	NN	O	O

This	NN	O	O
calls	NN	O	O
for	NN	O	O
attention	NN	O	O
when	NN	O	O
ketoconazole	NN	O	O
is	NN	O	O
administered	NN	O	O
to	NN	O	O
patients	NN	O	O
with	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
acquired	NN	O	O
long	NN	O	B
QT	NN	O	I
syndrome	NN	O	I
.	NN	O	O

Cerebral	NN	O	B
vasculitis	NN	O	I
following	NN	O	O
oral	NN	O	O
methylphenidate	NN	O	O
intake	NN	O	O
in	NN	O	O
an	NN	O	O
adult	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

Methylphenidate	NN	O	O
is	NN	O	O
structurally	NN	O	O
and	NN	O	O
functionally	NN	O	O
similar	NN	O	O
to	NN	O	O
amphetamine	NN	O	O
.	NN	O	O

Cerebral	NN	O	B
vasculitis	NN	O	I
associated	NN	O	O
with	NN	O	O
amphetamine	NN	O	B
abuse	NN	O	I
is	NN	O	O
well	NN	O	O
documented	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
rare	NN	O	O
cases	NN	O	O
ischaemic	NN	O	B
stroke	NN	O	I
has	NN	O	O
been	NN	O	O
reported	NN	O	O
after	NN	O	O
methylphenidate	NN	O	O
intake	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
63	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
who	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
methylphenidate	NN	O	O
due	NN	O	O
to	NN	O	O
hyperactivity	NN	O	B
and	NN	O	O
suffered	NN	O	O
from	NN	O	O
multiple	NN	O	O
ischaemic	NN	O	B
strokes	NN	O	I
.	NN	O	O

We	NN	O	O
consider	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
cerebral	NN	O	B
vasculitis	NN	O	I
as	NN	O	O
the	NN	O	O
most	NN	O	O
likely	NN	O	O
cause	NN	O	O
of	NN	O	O
recurrent	NN	O	O
ischaemic	NN	O	B
strokes	NN	O	I
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
any	NN	O	O
pathological	NN	O	O
findings	NN	O	O
during	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
work	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
methylphenidate	NN	O	O
mediated	NN	O	O
vasculitis	NN	O	B
should	NN	O	O
be	NN	O	O
considered	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
neurological	NN	O	O
symptoms	NN	O	O
and	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
methylphenidate	NN	O	O
therapy	NN	O	O
.	NN	O	O

This	NN	O	O
potential	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
,	NN	O	O
though	NN	O	O
very	NN	O	O
rare	NN	O	O
,	NN	O	O
represents	NN	O	O
one	NN	O	O
more	NN	O	O
reason	NN	O	O
to	NN	O	O
be	NN	O	O
very	NN	O	O
restrictive	NN	O	O
in	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
methylphenidate	NN	O	O
.	NN	O	O

MDMA	NN	O	O
polydrug	NN	O	O
users	NN	O	O
show	NN	O	O
process	NN	O	O
-	NN	O	O
specific	NN	O	O
central	NN	O	O
executive	NN	O	O
impairments	NN	O	O
coupled	NN	O	O
with	NN	O	O
impaired	NN	O	B
social	NN	O	I
and	NN	O	I
emotional	NN	O	I
judgement	NN	O	I
processes	NN	O	I
.	NN	O	O

In	NN	O	O
recent	NN	O	O
years	NN	O	O
working	NN	O	O
memory	NN	O	B
deficits	NN	O	I
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
users	NN	O	O
of	NN	O	O
MDMA	NN	O	O
(	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
methylenedioxymethamphetamine	NN	O	O
,	NN	O	O
ecstasy	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
current	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
impact	NN	O	O
of	NN	O	O
MDMA	NN	O	O
use	NN	O	O
on	NN	O	O
three	NN	O	O
separate	NN	O	O
central	NN	O	O
executive	NN	O	O
processes	NN	O	O
(	NN	O	O
set	NN	O	O
shifting	NN	O	O
,	NN	O	O
inhibition	NN	O	O
and	NN	O	O
memory	NN	O	O
updating	NN	O	O
)	NN	O	O
and	NN	O	O
also	NN	O	O
on	NN	O	O
"	NN	O	O
prefrontal	NN	O	O
"	NN	O	O
mediated	NN	O	O
social	NN	O	O
and	NN	O	O
emotional	NN	O	O
judgement	NN	O	O
processes	NN	O	O
.	NN	O	O

Fifteen	NN	O	O
polydrug	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
and	NN	O	O
15	NN	O	O
polydrug	NN	O	O
non	NN	O	O
-	NN	O	O
ecstasy	NN	O	O
user	NN	O	O
controls	NN	O	O
completed	NN	O	O
a	NN	O	O
general	NN	O	O
drug	NN	O	O
use	NN	O	O
questionnaire	NN	O	O
,	NN	O	O
the	NN	O	O
Brixton	NN	O	O
Spatial	NN	O	O
Anticipation	NN	O	O
task	NN	O	O
(	NN	O	O
set	NN	O	O
shifting	NN	O	O
)	NN	O	O
,	NN	O	O
Backward	NN	O	O
Digit	NN	O	O
Span	NN	O	O
procedure	NN	O	O
(	NN	O	O
memory	NN	O	O
updating	NN	O	O
)	NN	O	O
,	NN	O	O
Inhibition	NN	O	O
of	NN	O	O
Return	NN	O	O
(	NN	O	O
inhibition	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
emotional	NN	O	O
intelligence	NN	O	O
scale	NN	O	O
,	NN	O	O
the	NN	O	O
Tromso	NN	O	O
Social	NN	O	O
Intelligence	NN	O	O
Scale	NN	O	O
and	NN	O	O
the	NN	O	O
Dysexecutive	NN	O	O
Questionnaire	NN	O	O
(	NN	O	O
DEX	NN	O	O
)	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
MDMA	NN	O	O
-	NN	O	O
free	NN	O	O
polydrug	NN	O	O
controls	NN	O	O
,	NN	O	O
MDMA	NN	O	O
polydrug	NN	O	O
users	NN	O	O
showed	NN	O	O
impairments	NN	O	O
in	NN	O	O
set	NN	O	O
shifting	NN	O	O
and	NN	O	O
memory	NN	O	O
updating	NN	O	O
,	NN	O	O
and	NN	O	O
also	NN	O	O
in	NN	O	O
social	NN	O	O
and	NN	O	O
emotional	NN	O	O
judgement	NN	O	O
processes	NN	O	O
.	NN	O	O

The	NN	O	O
latter	NN	O	O
two	NN	O	O
deficits	NN	O	O
remained	NN	O	O
significant	NN	O	O
after	NN	O	O
controlling	NN	O	O
for	NN	O	O
other	NN	O	O
drug	NN	O	O
use	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
lend	NN	O	O
further	NN	O	O
support	NN	O	O
to	NN	O	O
the	NN	O	O
proposal	NN	O	O
that	NN	O	O
cognitive	NN	O	O
processes	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
prefrontal	NN	O	O
cortex	NN	O	O
may	NN	O	O
be	NN	O	O
impaired	NN	O	O
by	NN	O	O
recreational	NN	O	O
ecstasy	NN	O	O
use	NN	O	O
.	NN	O	O

Phase	NN	O	O
II	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
amsacrine	NN	O	O
analogue	NN	O	O
CI	NN	O	O
-	NN	O	O
921	NN	O	O
(	NN	O	O
NSC	NN	O	O
343499	NN	O	O
)	NN	O	O
in	NN	O	O
non	NN	O	B
-	NN	O	I
small	NN	O	I
cell	NN	O	I
lung	NN	O	I
cancer	NN	O	I
.	NN	O	O

CI	NN	O	O
-	NN	O	O
921	NN	O	O
(	NN	O	O
NSC	NN	O	O
343499	NN	O	O
;	NN	O	O
9	NN	O	O
-	NN	O	O
[	NN	O	O
[	NN	O	O
2	NN	O	O
-	NN	O	O
methoxy	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
[	NN	O	O
(	NN	O	O
methylsulphonyl	NN	O	O
)	NN	O	O
amino	NN	O	O
]	NN	O	O
phenyl	NN	O	O
]	NN	O	O
amino	NN	O	O
]	NN	O	O
-	NN	O	O
N	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
dimethyl	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
acridinecarboxamide	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
topoisomerase	NN	O	O
II	NN	O	O
poison	NN	O	O
with	NN	O	O
high	NN	O	O
experimental	NN	O	O
antitumour	NN	O	O
activity	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
administered	NN	O	O
by	NN	O	O
15	NN	O	O
min	NN	O	O
infusion	NN	O	O
to	NN	O	O
16	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
with	NN	O	O
non	NN	O	B
-	NN	O	I
small	NN	O	I
cell	NN	O	I
lung	NN	O	I
cancer	NN	O	I
(	NN	O	O
NSCLC	NN	O	B
)	NN	O	O
(	NN	O	O
7	NN	O	O
with	NN	O	O
no	NN	O	O
prior	NN	O	O
treatment	NN	O	O
,	NN	O	O
9	NN	O	O
patients	NN	O	O
in	NN	O	O
relapse	NN	O	O
following	NN	O	O
surgery	NN	O	O
/	NN	O	O
radiotherapy	NN	O	O
)	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
(	NN	O	O
648	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
divided	NN	O	O
over	NN	O	O
3	NN	O	O
days	NN	O	O
,	NN	O	O
repeated	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
)	NN	O	O
determined	NN	O	O
by	NN	O	O
phase	NN	O	O
I	NN	O	O
trial	NN	O	O
.	NN	O	O

Patients	NN	O	O
had	NN	O	O
a	NN	O	O
median	NN	O	O
performance	NN	O	O
status	NN	O	O
of	NN	O	O
1	NN	O	O
(	NN	O	O
WHO	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
median	NN	O	O
age	NN	O	O
of	NN	O	O
61	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
histology	NN	O	O
comprised	NN	O	O
squamous	NN	O	B
carcinoma	NN	O	I
(	NN	O	O
11	NN	O	O
)	NN	O	O
,	NN	O	O
adenocarcinoma	NN	O	B
(	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
mixed	NN	O	O
histology	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
bronchio	NN	O	B
-	NN	O	I
alveolar	NN	O	I
carcinoma	NN	O	I
(	NN	O	O
1	NN	O	O
)	NN	O	O
and	NN	O	O
large	NN	O	O
cell	NN	O	O
undifferentiated	NN	O	B
carcinoma	NN	O	I
(	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

Neutropenia	NN	O	B
grade	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
3	NN	O	O
was	NN	O	O
seen	NN	O	O
in	NN	O	O
15	NN	O	O
patients	NN	O	O
,	NN	O	O
infections	NN	O	B
with	NN	O	O
recovery	NN	O	O
in	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
grand	NN	O	O
mal	NN	O	O
seizures	NN	O	B
in	NN	O	O
1	NN	O	O
patient	NN	O	O
.	NN	O	O

Grade	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
2	NN	O	O
nausea	NN	O	B
and	NN	O	O
vomiting	NN	O	B
occurred	NN	O	O
in	NN	O	O
66	NN	O	O
%	NN	O	O
courses	NN	O	O
and	NN	O	O
phlebitis	NN	O	B
in	NN	O	O
the	NN	O	O
infusion	NN	O	O
arm	NN	O	O
in	NN	O	O
37	NN	O	O
%	NN	O	O
.	NN	O	O

1	NN	O	O
patient	NN	O	O
with	NN	O	O
squamous	NN	O	B
cell	NN	O	I
carcinoma	NN	O	I
achieved	NN	O	O
a	NN	O	O
partial	NN	O	O
response	NN	O	O
lasting	NN	O	O
5	NN	O	O
months	NN	O	O
.	NN	O	O

Further	NN	O	O
testing	NN	O	O
in	NN	O	O
this	NN	O	O
and	NN	O	O
other	NN	O	O
tumour	NN	O	B
types	NN	O	O
using	NN	O	O
multiple	NN	O	O
daily	NN	O	O
schedules	NN	O	O
is	NN	O	O
warranted	NN	O	O
.	NN	O	O

Pharmacokinetics	NN	O	O
of	NN	O	O
desipramine	NN	O	O
HCl	NN	O	O
when	NN	O	O
administered	NN	O	O
with	NN	O	O
cinacalcet	NN	O	O
HCl	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
In	NN	O	O
vitro	NN	O	O
work	NN	O	O
has	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
cinacalcet	NN	O	O
is	NN	O	O
a	NN	O	O
strong	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
cytochrome	NN	O	O
P450	NN	O	O
isoenzyme	NN	O	O
(	NN	O	O
CYP	NN	O	O
)	NN	O	O
2D6	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
cinacalcet	NN	O	O
on	NN	O	O
CYP2D6	NN	O	O
activity	NN	O	O
,	NN	O	O
using	NN	O	O
desipramine	NN	O	O
as	NN	O	O
a	NN	O	O
probe	NN	O	O
substrate	NN	O	O
,	NN	O	O
in	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Seventeen	NN	O	O
subjects	NN	O	O
who	NN	O	O
were	NN	O	O
genotyped	NN	O	O
as	NN	O	O
CYP2D6	NN	O	O
extensive	NN	O	O
metabolizers	NN	O	O
were	NN	O	O
enrolled	NN	O	O
in	NN	O	O
this	NN	O	O
randomized	NN	O	O
,	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
,	NN	O	O
crossover	NN	O	O
study	NN	O	O
to	NN	O	O
receive	NN	O	O
a	NN	O	O
single	NN	O	O
oral	NN	O	O
dose	NN	O	O
of	NN	O	O
desipramine	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
)	NN	O	O
on	NN	O	O
two	NN	O	O
separate	NN	O	O
occasions	NN	O	O
,	NN	O	O
once	NN	O	O
alone	NN	O	O
and	NN	O	O
once	NN	O	O
after	NN	O	O
multiple	NN	O	O
doses	NN	O	O
of	NN	O	O
cinacalcet	NN	O	O
(	NN	O	O
90	NN	O	O
mg	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
)	NN	O	O
.	NN	O	O

Blood	NN	O	O
samples	NN	O	O
were	NN	O	O
obtained	NN	O	O
predose	NN	O	O
and	NN	O	O
up	NN	O	O
to	NN	O	O
72	NN	O	O
h	NN	O	O
postdose	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Fourteen	NN	O	O
subjects	NN	O	O
completed	NN	O	O
both	NN	O	O
treatment	NN	O	O
arms	NN	O	O
.	NN	O	O

Relative	NN	O	O
to	NN	O	O
desipramine	NN	O	O
alone	NN	O	O
,	NN	O	O
mean	NN	O	O
AUC	NN	O	O
and	NN	O	O
C	NN	O	O
(	NN	O	O
max	NN	O	O
)	NN	O	O
of	NN	O	O
desipramine	NN	O	O
increased	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
8	NN	O	O
-	NN	O	O
fold	NN	O	O
when	NN	O	O
coadministered	NN	O	O
with	NN	O	O
cinacalcet	NN	O	O
.	NN	O	O

The	NN	O	O
t	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
,	NN	O	O
z	NN	O	O
)	NN	O	O
of	NN	O	O
desipramine	NN	O	O
was	NN	O	O
longer	NN	O	O
when	NN	O	O
desipramine	NN	O	O
was	NN	O	O
coadministered	NN	O	O
with	NN	O	O
cinacalcet	NN	O	O
(	NN	O	O
21	NN	O	O
.	NN	O	O
0	NN	O	O
versus	NN	O	O
43	NN	O	O
.	NN	O	O
3	NN	O	O
hs	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
t	NN	O	O
(	NN	O	O
max	NN	O	O
)	NN	O	O
was	NN	O	O
similar	NN	O	O
between	NN	O	O
the	NN	O	O
regimens	NN	O	O
.	NN	O	O

Fewer	NN	O	O
subjects	NN	O	O
reported	NN	O	O
adverse	NN	O	O
events	NN	O	O
following	NN	O	O
treatment	NN	O	O
with	NN	O	O
desipramine	NN	O	O
alone	NN	O	O
than	NN	O	O
when	NN	O	O
receiving	NN	O	O
desipramine	NN	O	O
with	NN	O	O
cinacalcet	NN	O	O
(	NN	O	O
33	NN	O	O
versus	NN	O	O
86	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
frequent	NN	O	O
of	NN	O	O
which	NN	O	O
(	NN	O	O
nausea	NN	O	B
and	NN	O	O
headache	NN	O	B
)	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
for	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
either	NN	O	O
desipramine	NN	O	O
or	NN	O	O
cinacalcet	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
cinacalcet	NN	O	O
is	NN	O	O
a	NN	O	O
strong	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
CYP2D6	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
during	NN	O	O
concomitant	NN	O	O
treatment	NN	O	O
with	NN	O	O
cinacalcet	NN	O	O
,	NN	O	O
dose	NN	O	O
adjustment	NN	O	O
may	NN	O	O
be	NN	O	O
necessary	NN	O	O
for	NN	O	O
drugs	NN	O	O
that	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
narrow	NN	O	O
therapeutic	NN	O	O
index	NN	O	O
and	NN	O	O
are	NN	O	O
metabolized	NN	O	O
by	NN	O	O
CYP2D6	NN	O	O
.	NN	O	O

Case	NN	O	O
report	NN	O	O
:	NN	O	O
acute	NN	O	O
unintentional	NN	O	O
carbachol	NN	O	O
intoxication	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Intoxications	NN	O	O
with	NN	O	O
carbachol	NN	O	O
,	NN	O	O
a	NN	O	O
muscarinic	NN	O	O
cholinergic	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
are	NN	O	O
rare	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
an	NN	O	O
interesting	NN	O	O
case	NN	O	O
investigating	NN	O	O
a	NN	O	O
(	NN	O	O
near	NN	O	O
)	NN	O	O
fatal	NN	O	O
poisoning	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
son	NN	O	O
of	NN	O	O
an	NN	O	O
84	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
discovered	NN	O	O
a	NN	O	O
newspaper	NN	O	O
report	NN	O	O
stating	NN	O	O
clinical	NN	O	O
success	NN	O	O
with	NN	O	O
plant	NN	O	O
extracts	NN	O	O
in	NN	O	O
Alzheimer	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

The	NN	O	O
mode	NN	O	O
of	NN	O	O
action	NN	O	O
was	NN	O	O
said	NN	O	O
to	NN	O	O
be	NN	O	O
comparable	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
synthetic	NN	O	O
compound	NN	O	O
'	NN	O	O
carbamylcholin	NN	O	O
'	NN	O	O
;	NN	O	O
that	NN	O	O
is	NN	O	O
,	NN	O	O
carbachol	NN	O	O
.	NN	O	O

He	NN	O	O
bought	NN	O	O
25	NN	O	O
g	NN	O	O
of	NN	O	O
carbachol	NN	O	O
as	NN	O	O
pure	NN	O	O
substance	NN	O	O
in	NN	O	O
a	NN	O	O
pharmacy	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
father	NN	O	O
was	NN	O	O
administered	NN	O	O
400	NN	O	O
to	NN	O	O
500	NN	O	O
mg	NN	O	O
.	NN	O	O

Carbachol	NN	O	O
concentrations	NN	O	O
in	NN	O	O
serum	NN	O	O
and	NN	O	O
urine	NN	O	O
on	NN	O	O
day	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
of	NN	O	O
hospital	NN	O	O
admission	NN	O	O
were	NN	O	O
analysed	NN	O	O
by	NN	O	O
HPLC	NN	O	O
-	NN	O	O
mass	NN	O	O
spectrometry	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Minutes	NN	O	O
after	NN	O	O
oral	NN	O	O
administration	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
developed	NN	O	O
nausea	NN	O	B
,	NN	O	O
sweating	NN	O	O
and	NN	O	O
hypotension	NN	O	B
,	NN	O	O
and	NN	O	O
finally	NN	O	O
collapsed	NN	O	O
.	NN	O	O

Bradycardia	NN	O	B
,	NN	O	O
cholinergic	NN	O	O
symptoms	NN	O	O
and	NN	O	O
asystole	NN	O	B
occurred	NN	O	O
.	NN	O	O

Initial	NN	O	O
cardiopulmonary	NN	O	O
resuscitation	NN	O	O
and	NN	O	O
immediate	NN	O	O
treatment	NN	O	O
with	NN	O	O
adrenaline	NN	O	O
(	NN	O	O
epinephrine	NN	O	O
)	NN	O	O
,	NN	O	O
atropine	NN	O	O
and	NN	O	O
furosemide	NN	O	O
was	NN	O	O
successful	NN	O	O
.	NN	O	O

On	NN	O	O
hospital	NN	O	O
admission	NN	O	O
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
of	NN	O	O
the	NN	O	O
intubated	NN	O	O
,	NN	O	O
bradyarrhythmic	NN	O	O
patient	NN	O	O
was	NN	O	O
100	NN	O	O
/	NN	O	O
65	NN	O	O
mmHg	NN	O	O
.	NN	O	O

Further	NN	O	O
signs	NN	O	O
were	NN	O	O
hyperhidrosis	NN	O	B
,	NN	O	O
hypersalivation	NN	O	B
,	NN	O	O
bronchorrhoea	NN	O	B
,	NN	O	O
and	NN	O	O
severe	NN	O	O
miosis	NN	O	B
;	NN	O	O
the	NN	O	O
electrocardiographic	NN	O	O
finding	NN	O	O
was	NN	O	O
atrio	NN	O	B
-	NN	O	I
ventricular	NN	O	I
dissociation	NN	O	I
.	NN	O	O

High	NN	O	O
doses	NN	O	O
of	NN	O	O
atropine	NN	O	O
(	NN	O	O
up	NN	O	O
to	NN	O	O
50	NN	O	O
mg	NN	O	O
per	NN	O	O
24	NN	O	O
hours	NN	O	O
)	NN	O	O
,	NN	O	O
adrenaline	NN	O	O
and	NN	O	O
dopamine	NN	O	O
were	NN	O	O
necessary	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
extubated	NN	O	O
1	NN	O	O
week	NN	O	O
later	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
increased	NN	O	O
dyspnoea	NN	O	B
and	NN	O	O
bronchospasm	NN	O	B
necessitated	NN	O	O
reintubation	NN	O	O
.	NN	O	O

Respiratory	NN	O	B
insufficiency	NN	O	I
was	NN	O	O
further	NN	O	O
worsened	NN	O	O
by	NN	O	O
Proteus	NN	O	B
mirabilis	NN	O	I
infection	NN	O	I
and	NN	O	O
severe	NN	O	O
bronchoconstriction	NN	O	O
.	NN	O	O

One	NN	O	O
week	NN	O	O
later	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
again	NN	O	O
extubated	NN	O	O
and	NN	O	O
3	NN	O	O
days	NN	O	O
later	NN	O	O
was	NN	O	O
transferred	NN	O	O
to	NN	O	O
a	NN	O	O
peripheral	NN	O	O
ward	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
next	NN	O	O
day	NN	O	O
he	NN	O	O
died	NN	O	O
,	NN	O	O
probably	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

Serum	NN	O	O
samples	NN	O	O
from	NN	O	O
the	NN	O	O
first	NN	O	O
and	NN	O	O
second	NN	O	O
days	NN	O	O
contained	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
/	NN	O	O
l	NN	O	O
carbachol	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
corresponding	NN	O	O
urine	NN	O	O
concentrations	NN	O	O
amounted	NN	O	O
to	NN	O	O
374	NN	O	O
and	NN	O	O
554	NN	O	O
mg	NN	O	O
/	NN	O	O
l	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
case	NN	O	O
started	NN	O	O
with	NN	O	O
a	NN	O	O
media	NN	O	O
report	NN	O	O
in	NN	O	O
a	NN	O	O
popular	NN	O	O
newspaper	NN	O	O
,	NN	O	O
initiated	NN	O	O
by	NN	O	O
published	NN	O	O
,	NN	O	O
peer	NN	O	O
-	NN	O	O
reviewed	NN	O	O
research	NN	O	O
on	NN	O	O
herbals	NN	O	O
,	NN	O	O
and	NN	O	O
involved	NN	O	O
human	NN	O	O
failure	NN	O	O
in	NN	O	O
a	NN	O	O
case	NN	O	O
history	NN	O	O
,	NN	O	O
medical	NN	O	O
examination	NN	O	O
and	NN	O	O
clinical	NN	O	O
treatment	NN	O	O
.	NN	O	O

For	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
,	NN	O	O
an	NN	O	O
analytical	NN	O	O
method	NN	O	O
for	NN	O	O
the	NN	O	O
determination	NN	O	O
of	NN	O	O
carbachol	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
urine	NN	O	O
has	NN	O	O
been	NN	O	O
developed	NN	O	O
.	NN	O	O

The	NN	O	O
analysed	NN	O	O
carbachol	NN	O	O
concentration	NN	O	O
exceeded	NN	O	O
the	NN	O	O
supposed	NN	O	O
serum	NN	O	O
level	NN	O	O
resulting	NN	O	O
from	NN	O	O
a	NN	O	O
therapeutic	NN	O	O
dose	NN	O	O
by	NN	O	O
a	NN	O	O
factor	NN	O	O
of	NN	O	O
130	NN	O	O
to	NN	O	O
260	NN	O	O
.	NN	O	O

Especially	NN	O	O
in	NN	O	O
old	NN	O	O
patients	NN	O	O
,	NN	O	O
intensivists	NN	O	O
should	NN	O	O
consider	NN	O	O
intoxications	NN	O	O
(	NN	O	O
with	NN	O	O
cholinergics	NN	O	O
)	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
acute	NN	O	B
cardiovascular	NN	O	I
failure	NN	O	I
.	NN	O	O

Pharmacological	NN	O	O
evidence	NN	O	O
for	NN	O	O
the	NN	O	O
potential	NN	O	O
of	NN	O	O
Daucus	NN	O	O
carota	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
cognitive	NN	O	B
dysfunctions	NN	O	I
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
aimed	NN	O	O
at	NN	O	O
investigating	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
Daucus	NN	O	O
carota	NN	O	O
seeds	NN	O	O
on	NN	O	O
cognitive	NN	O	O
functions	NN	O	O
,	NN	O	O
total	NN	O	O
serum	NN	O	O
cholesterol	NN	O	O
levels	NN	O	O
and	NN	O	O
brain	NN	O	O
cholinesterase	NN	O	O
activity	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
ethanolic	NN	O	O
extract	NN	O	O
of	NN	O	O
Daucus	NN	O	O
carota	NN	O	O
seeds	NN	O	O
(	NN	O	O
DCE	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
orally	NN	O	O
in	NN	O	O
three	NN	O	O
doses	NN	O	O
(	NN	O	O
100	NN	O	O
,	NN	O	O
200	NN	O	O
,	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
for	NN	O	O
seven	NN	O	O
successive	NN	O	O
days	NN	O	O
to	NN	O	O
different	NN	O	O
groups	NN	O	O
of	NN	O	O
young	NN	O	O
and	NN	O	O
aged	NN	O	O
mice	NN	O	O
.	NN	O	O

Elevated	NN	O	O
plus	NN	O	O
maze	NN	O	O
and	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
apparatus	NN	O	O
served	NN	O	O
as	NN	O	O
the	NN	O	O
exteroceptive	NN	O	O
behavioral	NN	O	O
models	NN	O	O
for	NN	O	O
testing	NN	O	O
memory	NN	O	O
.	NN	O	O

Diazepam	NN	O	O
-	NN	O	O
,	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
and	NN	O	O
ageing	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B
served	NN	O	O
as	NN	O	O
the	NN	O	O
interoceptive	NN	O	O
behavioral	NN	O	O
models	NN	O	O
.	NN	O	O

DCE	NN	O	O
(	NN	O	O
200	NN	O	O
,	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
showed	NN	O	O
significant	NN	O	O
improvement	NN	O	O
in	NN	O	O
memory	NN	O	O
scores	NN	O	O
of	NN	O	O
young	NN	O	O
and	NN	O	O
aged	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
extent	NN	O	O
of	NN	O	O
memory	NN	O	O
improvement	NN	O	O
evoked	NN	O	O
by	NN	O	O
DCE	NN	O	O
was	NN	O	O
23	NN	O	O
%	NN	O	O
at	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
and	NN	O	O
35	NN	O	O
%	NN	O	O
at	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
in	NN	O	O
young	NN	O	O
mice	NN	O	O
using	NN	O	O
elevated	NN	O	O
plus	NN	O	O
maze	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
significant	NN	O	O
improvements	NN	O	O
in	NN	O	O
memory	NN	O	O
scores	NN	O	O
were	NN	O	O
observed	NN	O	O
using	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
apparatus	NN	O	O
and	NN	O	O
aged	NN	O	O
mice	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
DCE	NN	O	O
reversed	NN	O	O
the	NN	O	O
amnesia	NN	O	B
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
and	NN	O	O
diazepam	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

Daucus	NN	O	O
carota	NN	O	O
extract	NN	O	O
(	NN	O	O
200	NN	O	O
,	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
reduced	NN	O	O
significantly	NN	O	O
the	NN	O	O
brain	NN	O	O
acetylcholinesterase	NN	O	O
activity	NN	O	O
and	NN	O	O
cholesterol	NN	O	O
levels	NN	O	O
in	NN	O	O
young	NN	O	O
and	NN	O	O
aged	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
extent	NN	O	O
of	NN	O	O
inhibition	NN	O	O
of	NN	O	O
brain	NN	O	O
cholinesterase	NN	O	O
activity	NN	O	O
evoked	NN	O	O
by	NN	O	O
DCE	NN	O	O
at	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
was	NN	O	O
22	NN	O	O
%	NN	O	O
in	NN	O	O
young	NN	O	O
and	NN	O	O
19	NN	O	O
%	NN	O	O
in	NN	O	O
aged	NN	O	O
mice	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
remarkable	NN	O	O
reduction	NN	O	O
in	NN	O	O
total	NN	O	O
cholesterol	NN	O	O
level	NN	O	O
as	NN	O	O
well	NN	O	O
,	NN	O	O
to	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
23	NN	O	O
%	NN	O	O
in	NN	O	O
young	NN	O	O
and	NN	O	O
21	NN	O	O
%	NN	O	O
in	NN	O	O
aged	NN	O	O
animals	NN	O	O
with	NN	O	O
this	NN	O	O
dose	NN	O	O
of	NN	O	O
DCE	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
DCE	NN	O	O
may	NN	O	O
prove	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
remedy	NN	O	O
for	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
cognitive	NN	O	B
dysfunctions	NN	O	I
on	NN	O	O
account	NN	O	O
of	NN	O	O
its	NN	O	O
multifarious	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
,	NN	O	O
memory	NN	O	O
improving	NN	O	O
property	NN	O	O
,	NN	O	O
cholesterol	NN	O	O
lowering	NN	O	O
property	NN	O	O
and	NN	O	O
anticholinesterase	NN	O	O
activity	NN	O	O
.	NN	O	O

Valproic	NN	O	O
acid	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
-	NN	O	O
-	NN	O	O
19	NN	O	O
new	NN	O	O
cases	NN	O	O
in	NN	O	O
Germany	NN	O	O
from	NN	O	O
1994	NN	O	O
to	NN	O	O
2003	NN	O	O
-	NN	O	O
-	NN	O	O
a	NN	O	O
side	NN	O	O
effect	NN	O	O
associated	NN	O	O
to	NN	O	O
VPA	NN	O	O
-	NN	O	O
therapy	NN	O	O
not	NN	O	O
only	NN	O	O
in	NN	O	O
young	NN	O	O
children	NN	O	O
.	NN	O	O

Valproic	NN	O	O
acid	NN	O	O
(	NN	O	O
VPA	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
broad	NN	O	O
-	NN	O	O
spectrum	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
and	NN	O	O
is	NN	O	O
usually	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
.	NN	O	O

Rare	NN	O	O
serious	NN	O	O
complications	NN	O	O
may	NN	O	O
occur	NN	O	O
in	NN	O	O
some	NN	O	O
patients	NN	O	O
,	NN	O	O
including	NN	O	O
haemorrhagic	NN	O	O
pancreatitis	NN	O	B
,	NN	O	O
bone	NN	O	B
marrow	NN	O	I
suppression	NN	O	I
,	NN	O	O
VPA	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatotoxicity	NN	O	B
and	NN	O	O
VPA	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
.	NN	O	O

The	NN	O	O
typical	NN	O	O
signs	NN	O	O
of	NN	O	O
VPA	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
are	NN	O	O
impaired	NN	O	B
consciousness	NN	O	I
,	NN	O	O
sometimes	NN	O	O
marked	NN	O	O
EEG	NN	O	O
background	NN	O	O
slowing	NN	O	O
,	NN	O	O
increased	NN	O	O
seizure	NN	O	B
frequency	NN	O	O
,	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
hyperammonemia	NN	O	B
.	NN	O	O

There	NN	O	O
is	NN	O	O
still	NN	O	O
no	NN	O	O
proof	NN	O	O
of	NN	O	O
causative	NN	O	O
effect	NN	O	O
of	NN	O	O
VPA	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
encephalopathy	NN	O	B
,	NN	O	O
but	NN	O	O
only	NN	O	O
of	NN	O	O
an	NN	O	O
association	NN	O	O
with	NN	O	O
an	NN	O	O
assumed	NN	O	O
causal	NN	O	O
relation	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
19	NN	O	O
patients	NN	O	O
with	NN	O	O
VPA	NN	O	O
-	NN	O	O
associated	NN	O	O
encephalopathy	NN	O	B
in	NN	O	O
Germany	NN	O	O
from	NN	O	O
the	NN	O	O
years	NN	O	O
1994	NN	O	O
to	NN	O	O
2003	NN	O	O
,	NN	O	O
none	NN	O	O
of	NN	O	O
whom	NN	O	O
had	NN	O	O
been	NN	O	O
published	NN	O	O
previously	NN	O	O
.	NN	O	O

Cerebral	NN	O	B
haemorrhage	NN	O	I
induced	NN	O	O
by	NN	O	O
warfarin	NN	O	O
-	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interactions	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
frequency	NN	O	O
,	NN	O	O
severity	NN	O	O
and	NN	O	O
preventability	NN	O	O
of	NN	O	O
warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
cerebral	NN	O	B
haemorrhages	NN	O	I
due	NN	O	O
to	NN	O	O
warfarin	NN	O	O
and	NN	O	O
warfarin	NN	O	O
-	NN	O	O
drug	NN	O	O
interactions	NN	O	O
in	NN	O	O
patients	NN	O	O
living	NN	O	O
in	NN	O	O
the	NN	O	O
county	NN	O	O
of	NN	O	O
Osterg	NN	O	O
tland	NN	O	O
,	NN	O	O
Sweden	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
All	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
diagnosed	NN	O	O
cerebral	NN	O	B
haemorrhage	NN	O	I
at	NN	O	O
three	NN	O	O
hospitals	NN	O	O
during	NN	O	O
the	NN	O	O
period	NN	O	O
2000	NN	O	O
-	NN	O	O
2002	NN	O	O
were	NN	O	O
identified	NN	O	O
.	NN	O	O

Medical	NN	O	O
records	NN	O	O
were	NN	O	O
studied	NN	O	O
retrospectively	NN	O	O
to	NN	O	O
evaluate	NN	O	O
whether	NN	O	O
warfarin	NN	O	O
and	NN	O	O
warfarin	NN	O	O
-	NN	O	O
drug	NN	O	O
interactions	NN	O	O
could	NN	O	O
have	NN	O	O
caused	NN	O	O
the	NN	O	O
cerebral	NN	O	B
haemorrhage	NN	O	I
.	NN	O	O

The	NN	O	O
proportion	NN	O	O
of	NN	O	O
possibly	NN	O	O
avoidable	NN	O	O
cases	NN	O	O
due	NN	O	O
to	NN	O	O
drug	NN	O	O
interactions	NN	O	O
was	NN	O	O
estimated	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Among	NN	O	O
593	NN	O	O
patients	NN	O	O
with	NN	O	O
cerebral	NN	O	B
haemorrhage	NN	O	I
,	NN	O	O
59	NN	O	O
(	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
assessed	NN	O	O
as	NN	O	O
related	NN	O	O
to	NN	O	O
warfarin	NN	O	O
treatment	NN	O	O
.	NN	O	O

This	NN	O	O
imply	NN	O	O
an	NN	O	O
incidence	NN	O	O
of	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
/	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
treatment	NN	O	O
years	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
59	NN	O	O
cases	NN	O	O
,	NN	O	O
26	NN	O	O
(	NN	O	O
44	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
a	NN	O	O
fatal	NN	O	O
outcome	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
136	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
)	NN	O	O
among	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
warfarin	NN	O	O
patients	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
warfarin	NN	O	O
-	NN	O	O
drug	NN	O	O
interaction	NN	O	O
could	NN	O	O
have	NN	O	O
contributed	NN	O	O
to	NN	O	O
the	NN	O	O
haemorrhage	NN	O	B
in	NN	O	O
24	NN	O	O
(	NN	O	O
41	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
warfarin	NN	O	O
patients	NN	O	O
and	NN	O	O
in	NN	O	O
7	NN	O	O
of	NN	O	O
these	NN	O	O
(	NN	O	O
12	NN	O	O
%	NN	O	O
)	NN	O	O
the	NN	O	O
bleeding	NN	O	B
complication	NN	O	O
was	NN	O	O
considered	NN	O	O
being	NN	O	O
possible	NN	O	O
to	NN	O	O
avoid	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
cerebral	NN	O	B
haemorrhages	NN	O	I
are	NN	O	O
a	NN	O	O
major	NN	O	O
clinical	NN	O	O
problem	NN	O	O
with	NN	O	O
a	NN	O	O
high	NN	O	O
fatality	NN	O	O
rate	NN	O	O
.	NN	O	O

Almost	NN	O	O
half	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
was	NN	O	O
related	NN	O	O
to	NN	O	O
a	NN	O	O
warfarin	NN	O	O
-	NN	O	O
drug	NN	O	O
interaction	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
proportion	NN	O	O
of	NN	O	O
warfarin	NN	O	O
-	NN	O	O
related	NN	O	O
cerebral	NN	O	B
haemorrhages	NN	O	I
might	NN	O	O
have	NN	O	O
been	NN	O	O
prevented	NN	O	O
if	NN	O	O
greater	NN	O	O
caution	NN	O	O
had	NN	O	O
been	NN	O	O
taken	NN	O	O
when	NN	O	O
prescribing	NN	O	O
drugs	NN	O	O
known	NN	O	O
to	NN	O	O
interact	NN	O	O
with	NN	O	O
warfarin	NN	O	O
.	NN	O	O

Antipsychotic	NN	O	O
-	NN	O	O
like	NN	O	O
profile	NN	O	O
of	NN	O	O
thioperamide	NN	O	O
,	NN	O	O
a	NN	O	O
selective	NN	O	O
H3	NN	O	O
-	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Experimental	NN	O	O
and	NN	O	O
clinical	NN	O	O
evidence	NN	O	O
points	NN	O	O
to	NN	O	O
a	NN	O	O
role	NN	O	O
of	NN	O	O
central	NN	O	O
histaminergic	NN	O	O
system	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
histamine	NN	O	O
H	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
-	NN	O	O
receptor	NN	O	O
ligands	NN	O	O
on	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
,	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
climbing	NN	O	O
behavior	NN	O	O
and	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
activities	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Catalepsy	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	O
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
apomorphine	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
and	NN	O	O
amphetamine	NN	O	O
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
were	NN	O	O
used	NN	O	O
for	NN	O	O
studying	NN	O	O
climbing	NN	O	O
behavior	NN	O	O
and	NN	O	O
locomotor	NN	O	O
activities	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

(	NN	O	O
R	NN	O	O
)	NN	O	O
-	NN	O	O
alpha	NN	O	O
-	NN	O	O
methylhistamine	NN	O	O
(	NN	O	O
RAMH	NN	O	O
)	NN	O	O
(	NN	O	O
5	NN	O	O
microg	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
and	NN	O	O
thioperamide	NN	O	O
(	NN	O	O
THP	NN	O	O
)	NN	O	O
(	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
per	NN	O	O
se	NN	O	O
did	NN	O	O
not	NN	O	O
cause	NN	O	O
catalepsy	NN	O	B
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
THP	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
75	NN	O	O
,	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
1	NN	O	O
h	NN	O	O
prior	NN	O	O
to	NN	O	O
haloperidol	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
catalepsy	NN	O	B
times	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
RAMH	NN	O	O
significantly	NN	O	O
reversed	NN	O	O
such	NN	O	O
an	NN	O	O
effect	NN	O	O
of	NN	O	O
THP	NN	O	O
(	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

RAMH	NN	O	O
per	NN	O	O
se	NN	O	O
showed	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
locomotor	NN	O	O
time	NN	O	O
,	NN	O	O
distance	NN	O	O
traveled	NN	O	O
and	NN	O	O
average	NN	O	O
speed	NN	O	O
but	NN	O	O
THP	NN	O	O
(	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
per	NN	O	O
se	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
these	NN	O	O
parameters	NN	O	O
.	NN	O	O

On	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
,	NN	O	O
THP	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
75	NN	O	O
and	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
reduced	NN	O	O
locomotor	NN	O	O
time	NN	O	O
,	NN	O	O
distance	NN	O	O
traveled	NN	O	O
and	NN	O	O
average	NN	O	O
speed	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
RAMH	NN	O	O
(	NN	O	O
5	NN	O	O
microg	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
could	NN	O	O
partially	NN	O	O
reverse	NN	O	O
such	NN	O	O
effects	NN	O	O
of	NN	O	O
THP	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

Climbing	NN	O	O
behavior	NN	O	O
induced	NN	O	O
by	NN	O	O
apomorphine	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
THP	NN	O	O
.	NN	O	O

Such	NN	O	O
an	NN	O	O
effect	NN	O	O
was	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
reversed	NN	O	O
in	NN	O	O
presence	NN	O	O
of	NN	O	O
RAMH	NN	O	O
.	NN	O	O

THP	NN	O	O
exhibited	NN	O	O
an	NN	O	O
antipsychotic	NN	O	O
-	NN	O	O
like	NN	O	O
profile	NN	O	O
by	NN	O	O
potentiating	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
,	NN	O	O
reducing	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
and	NN	O	O
reducing	NN	O	O
apomorphine	NN	O	O
-	NN	O	O
induced	NN	O	O
climbing	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Such	NN	O	O
effects	NN	O	O
of	NN	O	O
THP	NN	O	O
were	NN	O	O
reversed	NN	O	O
by	NN	O	O
RAMH	NN	O	O
indicating	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
histamine	NN	O	O
H	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
-	NN	O	O
receptors	NN	O	O
.	NN	O	O

Findings	NN	O	O
suggest	NN	O	O
a	NN	O	O
potential	NN	O	O
for	NN	O	O
H	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
-	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
in	NN	O	O
improving	NN	O	O
the	NN	O	O
refractory	NN	O	O
cases	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

Cauda	NN	O	B
equina	NN	O	I
syndrome	NN	O	I
after	NN	O	O
epidural	NN	O	O
steroid	NN	O	O
injection	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
Conventional	NN	O	O
treatment	NN	O	O
methods	NN	O	O
of	NN	O	O
lumbusacral	NN	O	O
radiculopathy	NN	O	B
are	NN	O	O
physical	NN	O	O
therapy	NN	O	O
,	NN	O	O
epidural	NN	O	O
steroid	NN	O	O
injections	NN	O	O
,	NN	O	O
oral	NN	O	O
medications	NN	O	O
,	NN	O	O
and	NN	O	O
spinal	NN	O	O
manipulative	NN	O	O
therapy	NN	O	O
.	NN	O	O

Cauda	NN	O	B
equina	NN	O	I
syndrome	NN	O	I
is	NN	O	O
a	NN	O	O
rare	NN	O	O
complication	NN	O	O
of	NN	O	O
epidural	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

The	NN	O	O
following	NN	O	O
case	NN	O	O
is	NN	O	O
a	NN	O	O
report	NN	O	O
of	NN	O	O
cauda	NN	O	B
equina	NN	O	I
syndrome	NN	O	I
possibly	NN	O	O
caused	NN	O	O
by	NN	O	O
epidural	NN	O	O
injection	NN	O	O
of	NN	O	O
triamcinolone	NN	O	O
and	NN	O	O
bupivacaine	NN	O	O
.	NN	O	O

CLINICAL	NN	O	O
FEATURES	NN	O	O
:	NN	O	O
A	NN	O	O
50	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
low	NN	O	B
back	NN	O	I
and	NN	O	I
right	NN	O	I
leg	NN	O	I
pain	NN	O	I
was	NN	O	O
scheduled	NN	O	O
for	NN	O	O
epidural	NN	O	O
steroid	NN	O	O
injection	NN	O	O
.	NN	O	O

INTERVENTION	NN	O	O
AND	NN	O	O
OUTCOME	NN	O	O
:	NN	O	O
An	NN	O	O
18	NN	O	O
-	NN	O	O
gauge	NN	O	O
Touhy	NN	O	O
needle	NN	O	O
was	NN	O	O
inserted	NN	O	O
until	NN	O	O
loss	NN	O	O
of	NN	O	O
resistance	NN	O	O
occurred	NN	O	O
at	NN	O	O
the	NN	O	O
L4	NN	O	O
-	NN	O	O
5	NN	O	O
level	NN	O	O
.	NN	O	O

Spread	NN	O	O
of	NN	O	O
the	NN	O	O
contrast	NN	O	O
medium	NN	O	O
within	NN	O	O
the	NN	O	O
epidural	NN	O	O
space	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
radiographic	NN	O	O
imaging	NN	O	O
.	NN	O	O

After	NN	O	O
verifying	NN	O	O
the	NN	O	O
epidural	NN	O	O
space	NN	O	O
,	NN	O	O
bupivacaine	NN	O	O
and	NN	O	O
triamcinolone	NN	O	O
diacetate	NN	O	O
were	NN	O	O
injected	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
injection	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
radicular	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Three	NN	O	O
hours	NN	O	O
later	NN	O	O
,	NN	O	O
she	NN	O	O
complained	NN	O	O
of	NN	O	O
perineal	NN	O	O
numbness	NN	O	B
and	NN	O	O
lower	NN	O	B
extremity	NN	O	I
weakness	NN	O	I
.	NN	O	O

The	NN	O	O
neurologic	NN	O	O
evaluation	NN	O	O
revealed	NN	O	O
loss	NN	O	B
of	NN	O	I
sensation	NN	O	I
in	NN	O	O
the	NN	O	O
saddle	NN	O	O
area	NN	O	O
and	NN	O	O
medial	NN	O	O
aspect	NN	O	O
of	NN	O	O
her	NN	O	O
right	NN	O	O
leg	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
perception	NN	O	O
of	NN	O	O
pinprick	NN	O	O
test	NN	O	O
.	NN	O	O

Deep	NN	O	O
-	NN	O	O
tendon	NN	O	O
reflexes	NN	O	O
were	NN	O	O
decreased	NN	O	O
especially	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
leg	NN	O	O
.	NN	O	O

She	NN	O	O
was	NN	O	O
unable	NN	O	O
to	NN	O	O
urinate	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
symptoms	NN	O	O
improved	NN	O	O
slightly	NN	O	O
over	NN	O	O
the	NN	O	O
next	NN	O	O
few	NN	O	O
hours	NN	O	O
.	NN	O	O

She	NN	O	O
had	NN	O	O
a	NN	O	O
gradual	NN	O	O
return	NN	O	O
of	NN	O	O
motor	NN	O	O
function	NN	O	O
and	NN	O	O
ability	NN	O	O
of	NN	O	O
feeling	NN	O	O
Foley	NN	O	O
catheter	NN	O	O
.	NN	O	O

All	NN	O	O
of	NN	O	O
the	NN	O	O
symptoms	NN	O	O
were	NN	O	O
completely	NN	O	O
resolved	NN	O	O
over	NN	O	O
the	NN	O	O
next	NN	O	O
8	NN	O	O
hours	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Complications	NN	O	O
associated	NN	O	O
with	NN	O	O
epidural	NN	O	O
steroid	NN	O	O
injections	NN	O	O
are	NN	O	O
rare	NN	O	O
.	NN	O	O

Clinical	NN	O	O
examination	NN	O	O
and	NN	O	O
continued	NN	O	O
vigilance	NN	O	O
for	NN	O	O
neurologic	NN	O	B
deterioration	NN	O	I
after	NN	O	O
epidural	NN	O	O
steroid	NN	O	O
injections	NN	O	O
is	NN	O	O
important	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
dose	NN	O	O
testosterone	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
atherosclerosis	NN	O	B
in	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
study	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
effects	NN	O	O
of	NN	O	O
androgen	NN	O	O
treatment	NN	O	O
on	NN	O	O
atherosclerosis	NN	O	B
in	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
a	NN	O	O
population	NN	O	O
-	NN	O	O
based	NN	O	O
study	NN	O	O
in	NN	O	O
513	NN	O	O
naturally	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
aged	NN	O	O
54	NN	O	O
-	NN	O	O
67	NN	O	O
years	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
self	NN	O	O
-	NN	O	O
reported	NN	O	O
intramuscularly	NN	O	O
administered	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
estrogen	NN	O	O
-	NN	O	O
testosterone	NN	O	O
therapy	NN	O	O
(	NN	O	O
estradiol	NN	O	O
-	NN	O	O
and	NN	O	O
testosterone	NN	O	O
esters	NN	O	O
)	NN	O	O
and	NN	O	O
aortic	NN	O	O
atherosclerosis	NN	O	B
.	NN	O	O

Aortic	NN	O	O
atherosclerosis	NN	O	B
was	NN	O	O
diagnosed	NN	O	O
by	NN	O	O
radiographic	NN	O	O
detection	NN	O	O
of	NN	O	O
calcified	NN	O	O
deposits	NN	O	O
in	NN	O	O
the	NN	O	O
abdominal	NN	O	O
aorta	NN	O	O
,	NN	O	O
which	NN	O	O
have	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
reflect	NN	O	O
intima	NN	O	O
atherosclerosis	NN	O	B
.	NN	O	O

Hormone	NN	O	O
therapy	NN	O	O
users	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
never	NN	O	O
users	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Intramuscular	NN	O	O
hormone	NN	O	O
therapy	NN	O	O
use	NN	O	O
for	NN	O	O
1	NN	O	O
year	NN	O	O
or	NN	O	O
longer	NN	O	O
was	NN	O	O
reported	NN	O	O
by	NN	O	O
25	NN	O	O
women	NN	O	O
.	NN	O	O

In	NN	O	O
almost	NN	O	O
half	NN	O	O
of	NN	O	O
these	NN	O	O
women	NN	O	O
severe	NN	O	O
atherosclerosis	NN	O	B
of	NN	O	O
the	NN	O	O
aorta	NN	O	O
was	NN	O	O
present	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
11	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
in	NN	O	O
women	NN	O	O
without	NN	O	O
hormone	NN	O	O
use	NN	O	O
severe	NN	O	O
atherosclerosis	NN	O	B
of	NN	O	O
the	NN	O	O
aorta	NN	O	O
was	NN	O	O
present	NN	O	O
in	NN	O	O
less	NN	O	O
than	NN	O	O
20	NN	O	O
%	NN	O	O
(	NN	O	O
OR	NN	O	O
3	NN	O	O
.	NN	O	O
1	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
adjusted	NN	O	O
for	NN	O	O
age	NN	O	O
,	NN	O	O
years	NN	O	O
since	NN	O	O
menopause	NN	O	O
,	NN	O	O
smoking	NN	O	O
,	NN	O	O
and	NN	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
association	NN	O	O
remained	NN	O	O
after	NN	O	O
additional	NN	O	O
adjustment	NN	O	O
for	NN	O	O
diabetes	NN	O	B
,	NN	O	O
cholesterol	NN	O	O
level	NN	O	O
,	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
or	NN	O	O
alcohol	NN	O	O
use	NN	O	O
.	NN	O	O

No	NN	O	O
association	NN	O	O
was	NN	O	O
found	NN	O	O
for	NN	O	O
hormone	NN	O	O
use	NN	O	O
less	NN	O	O
than	NN	O	O
1	NN	O	O
year	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
testosterone	NN	O	O
therapy	NN	O	O
may	NN	O	O
adversely	NN	O	O
affect	NN	O	O
atherosclerosis	NN	O	B
in	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
and	NN	O	O
indicate	NN	O	O
that	NN	O	O
androgen	NN	O	O
replacement	NN	O	O
in	NN	O	O
these	NN	O	O
women	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
harmless	NN	O	O
.	NN	O	O

Optimising	NN	O	O
stroke	NN	O	B
prevention	NN	O	O
in	NN	O	O
non	NN	O	O
-	NN	O	O
valvular	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
.	NN	O	O

Atrial	NN	O	B
fibrillation	NN	O	I
is	NN	O	O
associated	NN	O	O
with	NN	O	O
substantial	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
.	NN	O	O

Pooled	NN	O	O
data	NN	O	O
from	NN	O	O
trials	NN	O	O
comparing	NN	O	O
antithrombotic	NN	O	O
treatment	NN	O	O
with	NN	O	O
placebo	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
warfarin	NN	O	O
reduces	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
stroke	NN	O	B
by	NN	O	O
62	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
aspirin	NN	O	O
alone	NN	O	O
reduces	NN	O	O
the	NN	O	O
risk	NN	O	O
by	NN	O	O
22	NN	O	O
%	NN	O	O
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
in	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
,	NN	O	O
warfarin	NN	O	O
is	NN	O	O
superior	NN	O	O
to	NN	O	O
aspirin	NN	O	O
in	NN	O	O
preventing	NN	O	O
strokes	NN	O	B
,	NN	O	O
with	NN	O	O
a	NN	O	O
relative	NN	O	O
risk	NN	O	O
reduction	NN	O	O
of	NN	O	O
36	NN	O	O
%	NN	O	O
.	NN	O	O

Ximelagatran	NN	O	O
,	NN	O	O
an	NN	O	O
oral	NN	O	O
direct	NN	O	O
thrombin	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
as	NN	O	O
efficient	NN	O	O
as	NN	O	O
vitamin	NN	O	O
K	NN	O	O
antagonist	NN	O	O
drugs	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
embolic	NN	O	B
events	NN	O	I
,	NN	O	O
but	NN	O	O
has	NN	O	O
been	NN	O	O
recently	NN	O	O
withdrawn	NN	O	O
because	NN	O	O
of	NN	O	O
abnormal	NN	O	B
liver	NN	O	I
function	NN	O	I
tests	NN	O	O
.	NN	O	O

The	NN	O	O
ACTIVE	NN	O	O
-	NN	O	O
W	NN	O	O
(	NN	O	O
Atrial	NN	O	B
Fibrillation	NN	O	I
Clopidogrel	NN	O	O
Trial	NN	O	O
with	NN	O	O
Irbesartan	NN	O	O
for	NN	O	O
Prevention	NN	O	O
of	NN	O	O
Vascular	NN	O	O
Events	NN	O	O
)	NN	O	O
study	NN	O	O
has	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
warfarin	NN	O	O
is	NN	O	O
superior	NN	O	O
to	NN	O	O
platelet	NN	O	O
therapy	NN	O	O
(	NN	O	O
clopidogrel	NN	O	O
plus	NN	O	O
aspirin	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
af	NN	O	O
embolic	NN	O	B
events	NN	O	I
.	NN	O	O

Idraparinux	NN	O	O
,	NN	O	O
a	NN	O	O
Factor	NN	O	O
Xa	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
is	NN	O	O
being	NN	O	O
evaluated	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
.	NN	O	O

Angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitors	NN	O	O
and	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
receptor	NN	O	O
-	NN	O	O
blocking	NN	O	O
drugs	NN	O	O
hold	NN	O	O
promise	NN	O	O
in	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
through	NN	O	O
cardiac	NN	O	B
remodelling	NN	O	I
.	NN	O	O

Preliminary	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
statins	NN	O	O
could	NN	O	O
interfere	NN	O	O
with	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
recurrence	NN	O	O
after	NN	O	O
electrical	NN	O	O
cardioversion	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
percutaneous	NN	O	O
methods	NN	O	O
for	NN	O	O
the	NN	O	O
exclusion	NN	O	O
of	NN	O	O
left	NN	O	O
atrial	NN	O	O
appendage	NN	O	O
are	NN	O	O
under	NN	O	O
investigation	NN	O	O
in	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
.	NN	O	O

Anti	NN	O	O
-	NN	O	O
oxidant	NN	O	O
effects	NN	O	O
of	NN	O	O
atorvastatin	NN	O	O
in	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

Dexamethasone	NN	O	O
(	NN	O	O
Dex	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
endothelial	NN	O	O
dysfunction	NN	O	O
associated	NN	O	O
with	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
(	NN	O	O
NO	NN	O	O
)	NN	O	O
deficiency	NN	O	O
and	NN	O	O
increased	NN	O	O
superoxide	NN	O	O
(	NN	O	O
O2	NN	O	O
-	NN	O	O
)	NN	O	O
production	NN	O	O
.	NN	O	O

Atorvastatin	NN	O	O
(	NN	O	O
Ato	NN	O	O
)	NN	O	O
possesses	NN	O	O
pleiotropic	NN	O	O
properties	NN	O	O
that	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
improve	NN	O	O
endothelial	NN	O	O
function	NN	O	O
through	NN	O	O
increased	NN	O	O
availability	NN	O	O
of	NN	O	O
NO	NN	O	O
and	NN	O	O
reduced	NN	O	O
O2	NN	O	O
-	NN	O	O
production	NN	O	O
in	NN	O	O
various	NN	O	O
forms	NN	O	O
of	NN	O	O
hypertension	NN	O	B
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
whether	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
,	NN	O	O
Ato	NN	O	O
could	NN	O	O
prevent	NN	O	O
endothelial	NN	O	O
NO	NN	O	O
synthase	NN	O	O
(	NN	O	O
eNOS	NN	O	O
)	NN	O	O
downregulation	NN	O	O
and	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
O2	NN	O	O
-	NN	O	O
in	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
(	NN	O	O
SD	NN	O	O
)	NN	O	O
rats	NN	O	O
,	NN	O	O
thereby	NN	O	O
reducing	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

Male	NN	O	O
SD	NN	O	O
rats	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
30	NN	O	O
)	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
Ato	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
in	NN	O	O
drinking	NN	O	O
water	NN	O	O
)	NN	O	O
or	NN	O	O
tap	NN	O	O
water	NN	O	O
for	NN	O	O
15	NN	O	O
days	NN	O	O
.	NN	O	O

Dexamethasone	NN	O	O
(	NN	O	O
10	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
,	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
or	NN	O	O
saline	NN	O	O
was	NN	O	O
started	NN	O	O
after	NN	O	O
4	NN	O	O
days	NN	O	O
in	NN	O	O
Ato	NN	O	O
-	NN	O	O
treated	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
and	NN	O	O
continued	NN	O	O
for	NN	O	O
11	NN	O	O
-	NN	O	O
13	NN	O	O
days	NN	O	O
.	NN	O	O

Systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
SBP	NN	O	O
)	NN	O	O
was	NN	O	O
measured	NN	O	O
on	NN	O	O
alternate	NN	O	O
days	NN	O	O
using	NN	O	O
the	NN	O	O
tail	NN	O	O
-	NN	O	O
cuff	NN	O	O
method	NN	O	O
.	NN	O	O

Endothelial	NN	O	O
function	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
acetylcholine	NN	O	O
-	NN	O	O
induced	NN	O	O
vasorelaxation	NN	O	O
and	NN	O	O
phenylephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
vasoconstriction	NN	O	O
in	NN	O	O
aortic	NN	O	O
segments	NN	O	O
.	NN	O	O

Vascular	NN	O	O
eNOS	NN	O	O
mRNA	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
semi	NN	O	O
-	NN	O	O
quantitative	NN	O	O
reverse	NN	O	O
transcription	NN	O	O
-	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

In	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
Dex	NN	O	O
alone	NN	O	O
,	NN	O	O
SBP	NN	O	O
was	NN	O	O
increased	NN	O	O
from	NN	O	O
109	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
to	NN	O	O
133	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
mmHg	NN	O	O
on	NN	O	O
Days	NN	O	O
4	NN	O	O
and	NN	O	O
Day	NN	O	O
14	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
Ato	NN	O	O
+	NN	O	O
Dex	NN	O	O
group	NN	O	O
,	NN	O	O
SBP	NN	O	O
was	NN	O	O
increased	NN	O	O
from	NN	O	O
113	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
to	NN	O	O
119	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
mmHg	NN	O	O
on	NN	O	O
Days	NN	O	O
4	NN	O	O
to	NN	O	O
14	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
SBP	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
treated	NN	O	O
with	NN	O	O
Dex	NN	O	O
alone	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Endothelial	NN	O	O
-	NN	O	O
dependent	NN	O	O
relaxation	NN	O	O
and	NN	O	O
eNOS	NN	O	O
mRNA	NN	O	O
expression	NN	O	O
were	NN	O	O
greater	NN	O	O
in	NN	O	O
the	NN	O	O
Dex	NN	O	O
+	NN	O	O
Ato	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
Dex	NN	O	O
only	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
and	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Aortic	NN	O	O
superoxide	NN	O	O
production	NN	O	O
was	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
Dex	NN	O	O
+	NN	O	O
Ato	NN	O	O
group	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
group	NN	O	O
treated	NN	O	O
with	NN	O	O
Dex	NN	O	O
alone	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

4	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
Ato	NN	O	O
improved	NN	O	O
endothelial	NN	O	O
function	NN	O	O
,	NN	O	O
reduced	NN	O	O
superoxide	NN	O	O
production	NN	O	O
and	NN	O	O
reduced	NN	O	O
SBP	NN	O	O
in	NN	O	O
Dex	NN	O	O
-	NN	O	O
treated	NN	O	O
SD	NN	O	O
rats	NN	O	O
.	NN	O	O

Severe	NN	O	O
citrate	NN	O	O
toxicity	NN	O	B
complicating	NN	O	O
volunteer	NN	O	O
apheresis	NN	O	O
platelet	NN	O	O
donation	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
severe	NN	O	O
citrate	NN	O	O
toxicity	NN	O	B
during	NN	O	O
volunteer	NN	O	O
donor	NN	O	O
apheresis	NN	O	O
platelet	NN	O	O
collection	NN	O	O
.	NN	O	O

The	NN	O	O
donor	NN	O	O
was	NN	O	O
a	NN	O	O
40	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
,	NN	O	O
first	NN	O	O
-	NN	O	O
time	NN	O	O
apheresis	NN	O	O
platelet	NN	O	O
donor	NN	O	O
.	NN	O	O

Past	NN	O	O
medical	NN	O	O
history	NN	O	O
was	NN	O	O
remarkable	NN	O	O
for	NN	O	O
hypertension	NN	O	B
,	NN	O	O
hyperlipidemia	NN	O	B
,	NN	O	O
and	NN	O	O
depression	NN	O	B
.	NN	O	O

Reported	NN	O	O
medications	NN	O	O
included	NN	O	O
bumetanide	NN	O	O
,	NN	O	O
pravastatin	NN	O	O
,	NN	O	O
and	NN	O	O
paroxetine	NN	O	O
.	NN	O	O

Thirty	NN	O	O
minutes	NN	O	O
from	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
the	NN	O	O
procedure	NN	O	O
,	NN	O	O
the	NN	O	O
donor	NN	O	O
noted	NN	O	O
tingling	NN	O	O
around	NN	O	O
the	NN	O	O
mouth	NN	O	O
,	NN	O	O
hands	NN	O	O
,	NN	O	O
and	NN	O	O
feet	NN	O	O
.	NN	O	O

She	NN	O	O
then	NN	O	O
very	NN	O	O
rapidly	NN	O	O
developed	NN	O	O
acute	NN	O	O
onset	NN	O	O
of	NN	O	O
severe	NN	O	O
facial	NN	O	O
and	NN	O	O
extremity	NN	O	O
tetany	NN	O	B
.	NN	O	O

Empirical	NN	O	O
treatment	NN	O	O
with	NN	O	O
intravenous	NN	O	O
calcium	NN	O	O
gluconate	NN	O	O
was	NN	O	O
initiated	NN	O	O
,	NN	O	O
and	NN	O	O
muscle	NN	O	B
contractions	NN	O	I
slowly	NN	O	O
subsided	NN	O	O
over	NN	O	O
approximately	NN	O	O
10	NN	O	O
to	NN	O	O
15	NN	O	O
minutes	NN	O	O
.	NN	O	O

The	NN	O	O
events	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
a	NN	O	O
severe	NN	O	O
reaction	NN	O	O
to	NN	O	O
calcium	NN	O	O
chelation	NN	O	O
by	NN	O	O
sodium	NN	O	O
citrate	NN	O	O
anticoagulant	NN	O	O
resulting	NN	O	O
in	NN	O	O
symptomatic	NN	O	O
systemic	NN	O	O
hypocalcemia	NN	O	B
.	NN	O	O

Upon	NN	O	O
additional	NN	O	O
retrospective	NN	O	O
analysis	NN	O	O
,	NN	O	O
it	NN	O	O
was	NN	O	O
noted	NN	O	O
that	NN	O	O
bumetanide	NN	O	O
is	NN	O	O
a	NN	O	O
loop	NN	O	O
diuretic	NN	O	O
that	NN	O	O
may	NN	O	O
cause	NN	O	O
significant	NN	O	O
hypocalcemia	NN	O	B
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
careful	NN	O	O
screening	NN	O	O
for	NN	O	O
medications	NN	O	O
and	NN	O	O
underlying	NN	O	O
conditions	NN	O	O
predisposing	NN	O	O
to	NN	O	O
hypocalcemia	NN	O	B
is	NN	O	O
recommended	NN	O	O
to	NN	O	O
help	NN	O	O
prevent	NN	O	O
severe	NN	O	O
reactions	NN	O	O
due	NN	O	O
to	NN	O	O
citrate	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Laboratory	NN	O	O
measurement	NN	O	O
of	NN	O	O
pre	NN	O	O
-	NN	O	O
procedure	NN	O	O
serum	NN	O	O
calcium	NN	O	O
levels	NN	O	O
in	NN	O	O
selected	NN	O	O
donors	NN	O	O
may	NN	O	O
identify	NN	O	O
cases	NN	O	O
requiring	NN	O	O
heightened	NN	O	O
vigilance	NN	O	O
.	NN	O	O

The	NN	O	O
case	NN	O	O
also	NN	O	O
illustrates	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
maintaining	NN	O	O
preparedness	NN	O	O
for	NN	O	O
managing	NN	O	O
rare	NN	O	O
but	NN	O	O
serious	NN	O	O
reactions	NN	O	O
in	NN	O	O
volunteer	NN	O	O
apheresis	NN	O	O
blood	NN	O	O
donors	NN	O	O
.	NN	O	O

Sirolimus	NN	O	O
-	NN	O	O
associated	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Sirolimus	NN	O	O
is	NN	O	O
a	NN	O	O
novel	NN	O	O
immunosuppressant	NN	O	O
with	NN	O	O
potent	NN	O	O
antiproliferative	NN	O	O
actions	NN	O	O
through	NN	O	O
its	NN	O	O
ability	NN	O	O
to	NN	O	O
inhibit	NN	O	O
the	NN	O	O
raptor	NN	O	O
-	NN	O	O
containing	NN	O	O
mammalian	NN	O	O
target	NN	O	O
of	NN	O	O
rapamycin	NN	O	O
protein	NN	O	O
kinase	NN	O	O
.	NN	O	O

Sirolimus	NN	O	O
represents	NN	O	O
a	NN	O	O
major	NN	O	O
therapeutic	NN	O	O
advance	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
acute	NN	O	O
renal	NN	O	O
allograft	NN	O	O
rejection	NN	O	O
and	NN	O	O
chronic	NN	O	O
allograft	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

Its	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
therapy	NN	O	O
of	NN	O	O
glomerulonephritis	NN	O	B
,	NN	O	O
autoimmunity	NN	O	B
,	NN	O	O
cystic	NN	O	B
renal	NN	O	I
diseases	NN	O	I
and	NN	O	O
renal	NN	O	B
cancer	NN	O	I
is	NN	O	O
under	NN	O	O
investigation	NN	O	O
.	NN	O	O

Because	NN	O	O
sirolimus	NN	O	O
does	NN	O	O
not	NN	O	O
share	NN	O	O
the	NN	O	O
vasomotor	NN	O	O
renal	NN	O	O
adverse	NN	O	O
effects	NN	O	O
exhibited	NN	O	O
by	NN	O	O
calcineurin	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
it	NN	O	O
has	NN	O	O
been	NN	O	O
designated	NN	O	O
a	NN	O	O
'	NN	O	O
non	NN	O	O
-	NN	O	O
nephrotoxic	NN	O	B
drug	NN	O	O
'	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
clinical	NN	O	O
reports	NN	O	O
suggest	NN	O	O
that	NN	O	O
,	NN	O	O
under	NN	O	O
some	NN	O	O
circumstances	NN	O	O
,	NN	O	O
sirolimus	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
dysfunction	NN	O	I
.	NN	O	O

A	NN	O	O
common	NN	O	O
risk	NN	O	O
factor	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
presence	NN	O	O
of	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
chronic	NN	O	B
renal	NN	O	I
damage	NN	O	I
.	NN	O	O

The	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
-	NN	O	O
associated	NN	O	O
proteinuria	NN	O	B
are	NN	O	O
multifactorial	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
glomerular	NN	O	O
capillary	NN	O	O
pressure	NN	O	O
following	NN	O	O
calcineurin	NN	O	O
inhibitor	NN	O	O
withdrawal	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
also	NN	O	O
been	NN	O	O
suggested	NN	O	O
that	NN	O	O
sirolimus	NN	O	O
directly	NN	O	O
causes	NN	O	O
increased	NN	O	O
glomerular	NN	O	O
permeability	NN	O	O
/	NN	O	O
injury	NN	O	O
,	NN	O	O
but	NN	O	O
evidence	NN	O	O
for	NN	O	O
this	NN	O	O
mechanism	NN	O	O
is	NN	O	O
currently	NN	O	O
inconclusive	NN	O	O
.	NN	O	O

The	NN	O	O
acute	NN	O	B
renal	NN	O	I
dysfunction	NN	O	I
associated	NN	O	O
with	NN	O	O
sirolimus	NN	O	O
(	NN	O	O
such	NN	O	O
as	NN	O	O
in	NN	O	O
delayed	NN	O	O
graft	NN	O	O
function	NN	O	O
)	NN	O	O
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
suppression	NN	O	O
of	NN	O	O
compensatory	NN	O	O
renal	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
and	NN	O	O
survival	NN	O	O
/	NN	O	O
repair	NN	O	O
processes	NN	O	O
.	NN	O	O

Although	NN	O	O
these	NN	O	O
adverse	NN	O	O
effects	NN	O	O
occur	NN	O	O
in	NN	O	O
some	NN	O	O
patients	NN	O	O
,	NN	O	O
their	NN	O	O
occurrence	NN	O	O
could	NN	O	O
be	NN	O	O
minimised	NN	O	O
by	NN	O	O
knowledge	NN	O	O
of	NN	O	O
the	NN	O	O
molecular	NN	O	O
effects	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
on	NN	O	O
the	NN	O	O
kidney	NN	O	O
,	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
in	NN	O	O
appropriate	NN	O	O
patient	NN	O	O
populations	NN	O	O
,	NN	O	O
close	NN	O	O
monitoring	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
renal	NN	O	O
function	NN	O	O
,	NN	O	O
use	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitors	NN	O	O
or	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
receptor	NN	O	O
blockers	NN	O	O
if	NN	O	O
proteinuria	NN	O	B
occurs	NN	O	O
and	NN	O	O
withdrawal	NN	O	O
if	NN	O	O
needed	NN	O	O
.	NN	O	O

Further	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
analysis	NN	O	O
of	NN	O	O
renal	NN	O	O
allograft	NN	O	O
studies	NN	O	O
using	NN	O	O
sirolimus	NN	O	O
as	NN	O	O
de	NN	O	O
novo	NN	O	O
immunosuppression	NN	O	O
along	NN	O	O
with	NN	O	O
clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
studies	NN	O	O
will	NN	O	O
refine	NN	O	O
these	NN	O	O
issues	NN	O	O
in	NN	O	O
the	NN	O	O
future	NN	O	O
.	NN	O	O

Proteinuria	NN	O	B
after	NN	O	O
conversion	NN	O	O
to	NN	O	O
sirolimus	NN	O	O
in	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
.	NN	O	O

Sirolimus	NN	O	O
(	NN	O	O
SRL	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
new	NN	O	O
,	NN	O	O
potent	NN	O	O
immunosuppressive	NN	O	O
agent	NN	O	O
.	NN	O	O

More	NN	O	O
recently	NN	O	O
,	NN	O	O
proteinuria	NN	O	B
has	NN	O	O
been	NN	O	O
reported	NN	O	O
as	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
therapy	NN	O	O
,	NN	O	O
although	NN	O	O
the	NN	O	O
mechanism	NN	O	O
has	NN	O	O
remained	NN	O	O
unclear	NN	O	O
.	NN	O	O

We	NN	O	O
retrospectively	NN	O	O
examined	NN	O	O
the	NN	O	O
records	NN	O	O
of	NN	O	O
25	NN	O	O
renal	NN	O	O
transplant	NN	O	O
patients	NN	O	O
,	NN	O	O
who	NN	O	O
developed	NN	O	O
or	NN	O	O
displayed	NN	O	O
increased	NN	O	O
proteinuria	NN	O	B
after	NN	O	O
SRL	NN	O	O
conversion	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
cohort	NN	O	O
(	NN	O	O
14	NN	O	O
men	NN	O	O
,	NN	O	O
11	NN	O	O
women	NN	O	O
)	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
SRL	NN	O	O
as	NN	O	O
conversion	NN	O	O
therapy	NN	O	O
,	NN	O	O
due	NN	O	O
to	NN	O	O
chronic	NN	O	B
allograft	NN	O	I
nephropathy	NN	O	I
(	NN	O	O
CAN	NN	O	B
)	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
15	NN	O	O
)	NN	O	O
neoplasia	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
;	NN	O	O
Kaposi	NN	O	B
'	NN	O	I
s	NN	O	I
sarcoma	NN	O	I
,	NN	O	O
Four	NN	O	O
skin	NN	O	B
cancers	NN	O	I
,	NN	O	O
One	NN	O	O
intestinal	NN	O	B
tumors	NN	O	I
,	NN	O	O
One	NN	O	O
renal	NN	O	B
cell	NN	O	I
carsinom	NN	O	I
)	NN	O	O
or	NN	O	O
BK	NN	O	O
virus	NN	O	O
nephropathy	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

SRL	NN	O	O
was	NN	O	O
started	NN	O	O
at	NN	O	O
a	NN	O	O
mean	NN	O	O
of	NN	O	O
78	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
42	NN	O	O
(	NN	O	O
15	NN	O	O
to	NN	O	O
163	NN	O	O
)	NN	O	O
months	NN	O	O
after	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Mean	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
on	NN	O	O
SRL	NN	O	O
therapy	NN	O	O
was	NN	O	O
20	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
(	NN	O	O
6	NN	O	O
to	NN	O	O
43	NN	O	O
)	NN	O	O
months	NN	O	O
.	NN	O	O

Proteinuria	NN	O	B
increased	NN	O	O
from	NN	O	O
0	NN	O	O
.	NN	O	O
445	NN	O	O
(	NN	O	O
0	NN	O	O
to	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
g	NN	O	O
/	NN	O	O
d	NN	O	O
before	NN	O	O
conversion	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
to	NN	O	O
12	NN	O	O
)	NN	O	O
after	NN	O	O
conversion	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

Before	NN	O	O
conversion	NN	O	O
8	NN	O	O
(	NN	O	O
32	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
had	NN	O	O
no	NN	O	O
proteinuria	NN	O	B
,	NN	O	O
whereas	NN	O	O
afterwards	NN	O	O
all	NN	O	O
patients	NN	O	O
had	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

In	NN	O	O
28	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
proteinuria	NN	O	B
remained	NN	O	O
unchanged	NN	O	O
,	NN	O	O
whereas	NN	O	O
it	NN	O	O
increased	NN	O	O
in	NN	O	O
68	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

In	NN	O	O
40	NN	O	O
%	NN	O	O
it	NN	O	O
increased	NN	O	O
by	NN	O	O
more	NN	O	O
than	NN	O	O
100	NN	O	O
%	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
eight	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
showed	NN	O	O
increased	NN	O	O
proteinuria	NN	O	B
to	NN	O	O
the	NN	O	O
nephrotic	NN	O	B
range	NN	O	O
.	NN	O	O

Biopsies	NN	O	O
performed	NN	O	O
in	NN	O	O
five	NN	O	O
patients	NN	O	O
revealed	NN	O	O
new	NN	O	O
pathological	NN	O	O
changes	NN	O	O
:	NN	O	O
One	NN	O	O
membranoproliferative	NN	O	B
glomerulopathy	NN	O	I
and	NN	O	O
interstitial	NN	O	B
nephritis	NN	O	I
.	NN	O	O

These	NN	O	O
patients	NN	O	O
showed	NN	O	O
persistently	NN	O	O
good	NN	O	O
graft	NN	O	O
function	NN	O	O
.	NN	O	O

Serum	NN	O	O
creatinine	NN	O	O
values	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
significantly	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
98	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
before	NN	O	O
SRL	NN	O	O
therapy	NN	O	O
and	NN	O	O
2	NN	O	O
.	NN	O	O
53	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
at	NN	O	O
last	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
14	NN	O	O
)	NN	O	O
.	NN	O	O

Five	NN	O	O
grafts	NN	O	O
were	NN	O	O
lost	NN	O	O
and	NN	O	O
the	NN	O	O
patients	NN	O	O
returned	NN	O	O
to	NN	O	O
dialysis	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
displayed	NN	O	O
CAN	NN	O	B
and	NN	O	O
Kaposi	NN	O	B
'	NN	O	I
s	NN	O	I
sarcoma	NN	O	I
.	NN	O	O

Mean	NN	O	O
urinary	NN	O	O
protein	NN	O	O
of	NN	O	O
patients	NN	O	O
who	NN	O	O
returned	NN	O	O
to	NN	O	O
dialysis	NN	O	O
was	NN	O	O
1	NN	O	O
.	NN	O	O
26	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
g	NN	O	O
/	NN	O	O
d	NN	O	O
before	NN	O	O
and	NN	O	O
4	NN	O	O
.	NN	O	O
7	NN	O	O
(	NN	O	O
3	NN	O	O
to	NN	O	O
12	NN	O	O
)	NN	O	O
g	NN	O	O
/	NN	O	O
d	NN	O	O
after	NN	O	O
conversion	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Mean	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
level	NN	O	O
before	NN	O	O
conversion	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O
21	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
and	NN	O	O
thereafter	NN	O	O
,	NN	O	O
4	NN	O	O
.	NN	O	O
93	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

Heavy	NN	O	O
proteinuria	NN	O	B
was	NN	O	O
common	NN	O	O
after	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
SRL	NN	O	O
as	NN	O	O
rescue	NN	O	O
therapy	NN	O	O
for	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
conversion	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
for	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
not	NN	O	O
developed	NN	O	O
advanced	NN	O	O
CAN	NN	O	B
and	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

The	NN	O	O
possibility	NN	O	O
of	NN	O	O
de	NN	O	O
novo	NN	O	O
glomerular	NN	O	O
pathology	NN	O	O
under	NN	O	O
SRL	NN	O	O
treatment	NN	O	O
requires	NN	O	O
further	NN	O	O
investigation	NN	O	O
by	NN	O	O
renal	NN	O	O
biopsy	NN	O	O
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
renal	NN	O	B
toxicity	NN	O	I
in	NN	O	O
children	NN	O	O
treated	NN	O	O
for	NN	O	O
malignant	NN	O	B
mesenchymal	NN	O	I
tumors	NN	O	I
:	NN	O	O
an	NN	O	O
International	NN	O	O
Society	NN	O	O
of	NN	O	O
Pediatric	NN	O	O
Oncology	NN	O	O
report	NN	O	O
.	NN	O	O

The	NN	O	O
renal	NN	O	O
function	NN	O	O
of	NN	O	O
74	NN	O	O
children	NN	O	O
with	NN	O	O
malignant	NN	O	B
mesenchymal	NN	O	I
tumors	NN	O	I
in	NN	O	O
complete	NN	O	O
remission	NN	O	O
and	NN	O	O
who	NN	O	O
have	NN	O	O
received	NN	O	O
the	NN	O	O
same	NN	O	O
ifosfamide	NN	O	O
chemotherapy	NN	O	O
protocol	NN	O	O
(	NN	O	O
International	NN	O	O
Society	NN	O	O
of	NN	O	O
Pediatric	NN	O	O
Oncology	NN	O	O
Malignant	NN	O	B
Mesenchymal	NN	O	I
Tumor	NN	O	I
Study	NN	O	O
84	NN	O	O
[	NN	O	O
SIOP	NN	O	O
MMT	NN	O	O
84	NN	O	O
]	NN	O	O
)	NN	O	O
were	NN	O	O
studied	NN	O	O
1	NN	O	O
year	NN	O	O
after	NN	O	O
the	NN	O	O
completion	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Total	NN	O	O
cumulative	NN	O	O
doses	NN	O	O
were	NN	O	O
36	NN	O	O
or	NN	O	O
60	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
(	NN	O	O
six	NN	O	O
or	NN	O	O
10	NN	O	O
cycles	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
,	NN	O	O
vincristine	NN	O	O
,	NN	O	O
and	NN	O	O
dactinomycin	NN	O	O
[	NN	O	O
IVA	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
them	NN	O	O
had	NN	O	O
received	NN	O	O
cisplatin	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Ages	NN	O	O
ranged	NN	O	O
from	NN	O	O
4	NN	O	O
months	NN	O	O
to	NN	O	O
17	NN	O	O
years	NN	O	O
;	NN	O	O
58	NN	O	O
patients	NN	O	O
were	NN	O	O
males	NN	O	O
and	NN	O	O
42	NN	O	O
females	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
primary	NN	O	O
tumor	NN	O	B
site	NN	O	O
was	NN	O	O
the	NN	O	O
head	NN	O	O
and	NN	O	O
neck	NN	O	O
.	NN	O	O

Renal	NN	O	O
function	NN	O	O
was	NN	O	O
investigated	NN	O	O
by	NN	O	O
measuring	NN	O	O
plasma	NN	O	O
and	NN	O	O
urinary	NN	O	O
electrolytes	NN	O	O
,	NN	O	O
glucosuria	NN	O	B
,	NN	O	O
proteinuria	NN	O	B
,	NN	O	O
aminoaciduria	NN	O	B
,	NN	O	O
urinary	NN	O	O
pH	NN	O	O
,	NN	O	O
osmolarity	NN	O	O
,	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
,	NN	O	O
phosphate	NN	O	O
tubular	NN	O	O
reabsorption	NN	O	O
,	NN	O	O
beta	NN	O	O
2	NN	O	O
microglobulinuria	NN	O	O
,	NN	O	O
and	NN	O	O
lysozymuria	NN	O	O
.	NN	O	O

Fifty	NN	O	O
-	NN	O	O
eight	NN	O	O
patients	NN	O	O
(	NN	O	O
78	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
normal	NN	O	O
renal	NN	O	O
tests	NN	O	O
,	NN	O	O
whereas	NN	O	O
16	NN	O	O
patients	NN	O	O
(	NN	O	O
22	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
renal	NN	O	B
abnormalities	NN	O	I
.	NN	O	O

Two	NN	O	O
subsets	NN	O	O
of	NN	O	O
patients	NN	O	O
were	NN	O	O
identified	NN	O	O
from	NN	O	O
this	NN	O	O
latter	NN	O	O
group	NN	O	O
:	NN	O	O
the	NN	O	O
first	NN	O	O
included	NN	O	O
four	NN	O	O
patients	NN	O	O
(	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
total	NN	O	O
population	NN	O	O
)	NN	O	O
who	NN	O	O
developed	NN	O	O
major	NN	O	O
toxicity	NN	O	B
resulting	NN	O	O
in	NN	O	O
Fanconi	NN	O	B
'	NN	O	I
s	NN	O	I
syndrome	NN	O	I
(	NN	O	O
TDFS	NN	O	B
)	NN	O	O
;	NN	O	O
and	NN	O	O
the	NN	O	O
second	NN	O	O
group	NN	O	O
included	NN	O	O
five	NN	O	O
patients	NN	O	O
with	NN	O	O
elevated	NN	O	O
beta	NN	O	O
2	NN	O	O
microglobulinuria	NN	O	O
and	NN	O	O
low	NN	O	O
phosphate	NN	O	O
reabsorption	NN	O	O
.	NN	O	O

The	NN	O	O
remaining	NN	O	O
seven	NN	O	O
patients	NN	O	O
had	NN	O	O
isolated	NN	O	O
beta	NN	O	O
2	NN	O	O
microglobulinuria	NN	O	O
.	NN	O	O

Severe	NN	O	O
toxicity	NN	O	B
was	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
higher	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
of	NN	O	O
60	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
,	NN	O	O
a	NN	O	O
younger	NN	O	O
age	NN	O	O
(	NN	O	O
less	NN	O	O
than	NN	O	O
2	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
years	NN	O	O
old	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
predominance	NN	O	O
of	NN	O	O
vesicoprostatic	NN	O	O
tumor	NN	O	B
involvement	NN	O	O
.	NN	O	O

This	NN	O	O
low	NN	O	O
percentage	NN	O	O
(	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
TDFS	NN	O	O
must	NN	O	O
be	NN	O	O
evaluated	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
ifosfamide	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
mesenchymal	NN	O	B
tumors	NN	O	I
in	NN	O	O
children	NN	O	O
.	NN	O	O

Progressive	NN	O	O
myopathy	NN	O	B
with	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
MHC	NN	O	O
-	NN	O	O
I	NN	O	O
associated	NN	O	O
with	NN	O	O
statin	NN	O	O
therapy	NN	O	O
.	NN	O	O

Statins	NN	O	O
can	NN	O	O
cause	NN	O	O
a	NN	O	O
necrotizing	NN	O	O
myopathy	NN	O	B
and	NN	O	O
hyperCKaemia	NN	O	B
which	NN	O	O
is	NN	O	O
reversible	NN	O	O
on	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

What	NN	O	O
is	NN	O	O
less	NN	O	O
well	NN	O	O
known	NN	O	O
is	NN	O	O
a	NN	O	O
phenomenon	NN	O	O
whereby	NN	O	O
statins	NN	O	O
may	NN	O	O
induce	NN	O	O
a	NN	O	O
myopathy	NN	O	B
,	NN	O	O
which	NN	O	O
persists	NN	O	O
or	NN	O	O
may	NN	O	O
progress	NN	O	O
after	NN	O	O
stopping	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
muscle	NN	O	O
pathology	NN	O	O
in	NN	O	O
8	NN	O	O
such	NN	O	O
cases	NN	O	O
.	NN	O	O

All	NN	O	O
had	NN	O	O
myofibre	NN	O	O
necrosis	NN	O	B
but	NN	O	O
only	NN	O	O
3	NN	O	O
had	NN	O	O
an	NN	O	O
inflammatory	NN	O	O
infiltrate	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
cases	NN	O	O
there	NN	O	O
was	NN	O	O
diffuse	NN	O	O
or	NN	O	O
multifocal	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
MHC	NN	O	O
-	NN	O	O
I	NN	O	O
expression	NN	O	O
even	NN	O	O
in	NN	O	O
non	NN	O	O
-	NN	O	O
necrotic	NN	O	B
fibres	NN	O	O
.	NN	O	O

Progressive	NN	O	O
improvement	NN	O	O
occurred	NN	O	O
in	NN	O	O
7	NN	O	O
cases	NN	O	O
after	NN	O	O
commencement	NN	O	O
of	NN	O	O
prednisolone	NN	O	O
and	NN	O	O
methotrexate	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
one	NN	O	O
case	NN	O	O
spontaneously	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
suggest	NN	O	O
that	NN	O	O
statins	NN	O	O
may	NN	O	O
initiate	NN	O	O
an	NN	O	O
immune	NN	O	O
-	NN	O	O
mediated	NN	O	O
myopathy	NN	O	B
that	NN	O	O
persists	NN	O	O
after	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
and	NN	O	O
responds	NN	O	O
to	NN	O	O
immunosuppressive	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
this	NN	O	O
myopathy	NN	O	B
is	NN	O	O
uncertain	NN	O	O
but	NN	O	O
may	NN	O	O
involve	NN	O	O
the	NN	O	O
induction	NN	O	O
by	NN	O	O
statins	NN	O	O
of	NN	O	O
an	NN	O	O
endoplasmic	NN	O	O
reticulum	NN	O	O
stress	NN	O	O
response	NN	O	O
with	NN	O	O
associated	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
MHC	NN	O	O
-	NN	O	O
I	NN	O	O
expression	NN	O	O
and	NN	O	O
antigen	NN	O	O
presentation	NN	O	O
by	NN	O	O
muscle	NN	O	O
fibres	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
chromosome	NN	O	O
substitution	NN	O	O
strains	NN	O	O
to	NN	O	O
identify	NN	O	O
seizure	NN	O	B
susceptibility	NN	O	O
loci	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Seizure	NN	O	B
susceptibility	NN	O	O
varies	NN	O	O
among	NN	O	O
inbred	NN	O	O
mouse	NN	O	O
strains	NN	O	O
.	NN	O	O

Chromosome	NN	O	O
substitution	NN	O	O
strains	NN	O	O
(	NN	O	O
CSS	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
which	NN	O	O
a	NN	O	O
single	NN	O	O
chromosome	NN	O	O
from	NN	O	O
one	NN	O	O
inbred	NN	O	O
strain	NN	O	O
(	NN	O	O
donor	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
transferred	NN	O	O
onto	NN	O	O
a	NN	O	O
second	NN	O	O
strain	NN	O	O
(	NN	O	O
host	NN	O	O
)	NN	O	O
by	NN	O	O
repeated	NN	O	O
backcrossing	NN	O	O
,	NN	O	O
may	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
identify	NN	O	O
quantitative	NN	O	O
trait	NN	O	O
loci	NN	O	O
(	NN	O	O
QTLs	NN	O	O
)	NN	O	O
that	NN	O	O
contribute	NN	O	O
to	NN	O	O
seizure	NN	O	B
susceptibility	NN	O	O
.	NN	O	O

QTLs	NN	O	O
for	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
,	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
temporal	NN	O	B
lobe	NN	O	I
epilepsy	NN	O	I
,	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
reported	NN	O	O
,	NN	O	O
and	NN	O	O
CSS	NN	O	O
have	NN	O	O
not	NN	O	O
previously	NN	O	O
been	NN	O	O
used	NN	O	O
to	NN	O	O
localize	NN	O	O
seizure	NN	O	B
susceptibility	NN	O	O
genes	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
QTLs	NN	O	O
identified	NN	O	O
using	NN	O	O
a	NN	O	O
B6	NN	O	O
(	NN	O	O
host	NN	O	O
)	NN	O	O
x	NN	O	O
A	NN	O	O
/	NN	O	O
J	NN	O	O
(	NN	O	O
donor	NN	O	O
)	NN	O	O
CSS	NN	O	O
panel	NN	O	O
to	NN	O	O
localize	NN	O	O
genes	NN	O	O
involved	NN	O	O
in	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
.	NN	O	O

Three	NN	O	O
hundred	NN	O	O
fifty	NN	O	O
-	NN	O	O
five	NN	O	O
adult	NN	O	O
male	NN	O	O
CSS	NN	O	O
mice	NN	O	O
,	NN	O	O
58	NN	O	O
B6	NN	O	O
,	NN	O	O
and	NN	O	O
39	NN	O	O
A	NN	O	O
/	NN	O	O
J	NN	O	O
were	NN	O	O
tested	NN	O	O
for	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
.	NN	O	O

Highest	NN	O	O
stage	NN	O	O
reached	NN	O	O
and	NN	O	O
latency	NN	O	O
to	NN	O	O
each	NN	O	O
stage	NN	O	O
were	NN	O	O
recorded	NN	O	O
for	NN	O	O
all	NN	O	O
mice	NN	O	O
.	NN	O	O

B6	NN	O	O
mice	NN	O	O
were	NN	O	O
resistant	NN	O	O
to	NN	O	O
seizures	NN	O	B
and	NN	O	O
slower	NN	O	O
to	NN	O	O
reach	NN	O	O
stages	NN	O	O
compared	NN	O	O
to	NN	O	O
A	NN	O	O
/	NN	O	O
J	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
CSS	NN	O	O
for	NN	O	O
Chromosomes	NN	O	O
10	NN	O	O
and	NN	O	O
18	NN	O	O
progressed	NN	O	O
to	NN	O	O
the	NN	O	O
most	NN	O	O
severe	NN	O	O
stages	NN	O	O
,	NN	O	O
diverging	NN	O	O
dramatically	NN	O	O
from	NN	O	O
the	NN	O	O
B6	NN	O	O
phenotype	NN	O	O
.	NN	O	O

Latencies	NN	O	O
to	NN	O	O
stages	NN	O	O
were	NN	O	O
also	NN	O	O
significantly	NN	O	O
shorter	NN	O	O
for	NN	O	O
CSS10	NN	O	O
and	NN	O	O
CSS18	NN	O	O
mice	NN	O	O
.	NN	O	O

CSS	NN	O	O
mapping	NN	O	O
suggests	NN	O	O
seizure	NN	O	B
susceptibility	NN	O	O
loci	NN	O	O
on	NN	O	O
mouse	NN	O	O
Chromosomes	NN	O	O
10	NN	O	O
and	NN	O	O
18	NN	O	O
.	NN	O	O

This	NN	O	O
approach	NN	O	O
provides	NN	O	O
a	NN	O	O
framework	NN	O	O
for	NN	O	O
identifying	NN	O	O
potentially	NN	O	O
novel	NN	O	O
homologous	NN	O	O
candidate	NN	O	O
genes	NN	O	O
for	NN	O	O
human	NN	O	O
temporal	NN	O	B
lobe	NN	O	I
epilepsy	NN	O	I
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
characterization	NN	O	O
of	NN	O	O
parasympathetic	NN	O	O
and	NN	O	O
sympathetic	NN	O	O
responses	NN	O	O
in	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

In	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
in	NN	O	O
the	NN	O	O
rat	NN	O	O
,	NN	O	O
detrusor	NN	O	O
function	NN	O	O
is	NN	O	O
impaired	NN	O	O
and	NN	O	O
the	NN	O	O
expression	NN	O	O
and	NN	O	O
effects	NN	O	O
of	NN	O	O
muscarinic	NN	O	O
receptors	NN	O	O
altered	NN	O	O
.	NN	O	O

Whether	NN	O	O
or	NN	O	O
not	NN	O	O
the	NN	O	O
neuronal	NN	O	O
transmission	NN	O	O
may	NN	O	O
be	NN	O	O
affected	NN	O	O
by	NN	O	O
cystitis	NN	O	B
was	NN	O	O
presently	NN	O	O
investigated	NN	O	O
.	NN	O	O

Responses	NN	O	O
of	NN	O	O
urinary	NN	O	O
strip	NN	O	O
preparations	NN	O	O
from	NN	O	O
control	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
pretreated	NN	O	O
rats	NN	O	O
to	NN	O	O
electrical	NN	O	O
field	NN	O	O
stimulation	NN	O	O
and	NN	O	O
to	NN	O	O
agonists	NN	O	O
were	NN	O	O
assessed	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
and	NN	O	O
presence	NN	O	O
of	NN	O	O
muscarinic	NN	O	O
,	NN	O	O
adrenergic	NN	O	O
and	NN	O	O
purinergic	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
.	NN	O	O

Generally	NN	O	O
,	NN	O	O
atropine	NN	O	O
reduced	NN	O	O
contractions	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
controls	NN	O	O
,	NN	O	O
it	NN	O	O
also	NN	O	O
reduced	NN	O	O
responses	NN	O	O
to	NN	O	O
low	NN	O	O
electrical	NN	O	O
field	NN	O	O
stimulation	NN	O	O
intensity	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
5	NN	O	O
Hz	NN	O	O
)	NN	O	O
in	NN	O	O
inflamed	NN	O	O
preparations	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
types	NN	O	O
,	NN	O	O
purinoceptor	NN	O	O
desensitization	NN	O	O
with	NN	O	O
alpha	NN	O	O
,	NN	O	O
beta	NN	O	O
-	NN	O	O
methylene	NN	O	O
adenosine	NN	O	O
-	NN	O	O
5	NN	O	O
'	NN	O	O
-	NN	O	O
triphosphate	NN	O	O
(	NN	O	O
alpha	NN	O	O
,	NN	O	O
beta	NN	O	O
-	NN	O	O
meATP	NN	O	O
)	NN	O	O
caused	NN	O	O
further	NN	O	O
reductions	NN	O	O
at	NN	O	O
low	NN	O	O
frequencies	NN	O	O
(	NN	O	O
<	NN	O	O
10	NN	O	O
Hz	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
muscarinic	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
atropine	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
diphenylacetoxy	NN	O	O
-	NN	O	O
N	NN	O	O
-	NN	O	O
methylpiperidine	NN	O	O
(	NN	O	O
4	NN	O	O
-	NN	O	O
DAMP	NN	O	O
)	NN	O	O
(	NN	O	O
'	NN	O	O
M	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
/	NN	O	O
M	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
/	NN	O	O
M	NN	O	O
(	NN	O	O
5	NN	O	O
)	NN	O	O
-	NN	O	O
selective	NN	O	O
'	NN	O	O
)	NN	O	O
,	NN	O	O
methoctramine	NN	O	O
(	NN	O	O
'	NN	O	O
M	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
selective	NN	O	O
'	NN	O	O
)	NN	O	O
and	NN	O	O
pirenzepine	NN	O	O
(	NN	O	O
'	NN	O	O
M	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
-	NN	O	O
selective	NN	O	O
'	NN	O	O
)	NN	O	O
antagonized	NN	O	O
the	NN	O	O
tonic	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
electrical	NN	O	O
field	NN	O	O
stimulation	NN	O	O
-	NN	O	O
evoked	NN	O	O
contractile	NN	O	O
response	NN	O	O
more	NN	O	O
potently	NN	O	O
than	NN	O	O
the	NN	O	O
phasic	NN	O	O
component	NN	O	O
.	NN	O	O

4	NN	O	O
-	NN	O	O
DAMP	NN	O	O
inhibited	NN	O	O
the	NN	O	O
tonic	NN	O	O
contractions	NN	O	O
in	NN	O	O
controls	NN	O	O
more	NN	O	O
potently	NN	O	O
than	NN	O	O
methoctramine	NN	O	O
and	NN	O	O
pirenzepine	NN	O	O
.	NN	O	O

In	NN	O	O
inflamed	NN	O	O
preparations	NN	O	O
,	NN	O	O
the	NN	O	O
muscarinic	NN	O	O
receptor	NN	O	O
antagonism	NN	O	O
on	NN	O	O
the	NN	O	O
phasic	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
electrical	NN	O	O
field	NN	O	O
stimulation	NN	O	O
-	NN	O	O
evoked	NN	O	O
contraction	NN	O	O
was	NN	O	O
decreased	NN	O	O
and	NN	O	O
the	NN	O	O
pirenzepine	NN	O	O
and	NN	O	O
4	NN	O	O
-	NN	O	O
DAMP	NN	O	O
antagonism	NN	O	O
on	NN	O	O
the	NN	O	O
tonic	NN	O	O
component	NN	O	O
was	NN	O	O
much	NN	O	O
less	NN	O	O
efficient	NN	O	O
than	NN	O	O
in	NN	O	O
controls	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
controls	NN	O	O
,	NN	O	O
methoctramine	NN	O	O
increased	NN	O	O
-	NN	O	O
-	NN	O	O
instead	NN	O	O
of	NN	O	O
decreased	NN	O	O
-	NN	O	O
-	NN	O	O
the	NN	O	O
tonic	NN	O	O
responses	NN	O	O
at	NN	O	O
high	NN	O	O
frequencies	NN	O	O
.	NN	O	O

While	NN	O	O
contractions	NN	O	O
to	NN	O	O
carbachol	NN	O	O
and	NN	O	O
ATP	NN	O	O
were	NN	O	O
the	NN	O	O
same	NN	O	O
in	NN	O	O
inflamed	NN	O	O
and	NN	O	O
in	NN	O	O
control	NN	O	O
strips	NN	O	O
when	NN	O	O
related	NN	O	O
to	NN	O	O
a	NN	O	O
reference	NN	O	O
potassium	NN	O	O
response	NN	O	O
,	NN	O	O
isoprenaline	NN	O	O
-	NN	O	O
induced	NN	O	O
relaxations	NN	O	O
were	NN	O	O
smaller	NN	O	O
in	NN	O	O
inflamed	NN	O	O
strips	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
in	NN	O	O
cystitis	NN	O	B
substantial	NN	O	O
changes	NN	O	O
of	NN	O	O
the	NN	O	O
efferent	NN	O	O
functional	NN	O	O
responses	NN	O	O
occur	NN	O	O
.	NN	O	O

While	NN	O	O
postjunctional	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
-	NN	O	O
mediated	NN	O	O
relaxations	NN	O	O
are	NN	O	O
reduced	NN	O	O
,	NN	O	O
effects	NN	O	O
by	NN	O	O
prejunctional	NN	O	O
inhibitory	NN	O	O
muscarinic	NN	O	O
receptors	NN	O	O
may	NN	O	O
be	NN	O	O
increased	NN	O	O
.	NN	O	O

Direct	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cardiac	NN	O	O
hyperpolarization	NN	O	O
-	NN	O	O
activated	NN	O	O
cyclic	NN	O	O
nucleotide	NN	O	O
-	NN	O	O
gated	NN	O	O
pacemaker	NN	O	O
channels	NN	O	O
by	NN	O	O
clonidine	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Inhibition	NN	O	O
of	NN	O	O
cardiac	NN	O	O
sympathetic	NN	O	O
tone	NN	O	O
represents	NN	O	O
an	NN	O	O
important	NN	O	O
strategy	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
,	NN	O	O
including	NN	O	O
arrhythmia	NN	O	B
,	NN	O	O
coronary	NN	O	B
heart	NN	O	I
disease	NN	O	I
,	NN	O	O
and	NN	O	O
chronic	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
presynaptic	NN	O	O
alpha2	NN	O	O
-	NN	O	O
adrenoceptors	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
widely	NN	O	O
accepted	NN	O	O
mechanism	NN	O	O
of	NN	O	O
action	NN	O	O
of	NN	O	O
the	NN	O	O
antisympathetic	NN	O	O
drug	NN	O	O
clonidine	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
other	NN	O	O
target	NN	O	O
proteins	NN	O	O
have	NN	O	O
been	NN	O	O
postulated	NN	O	O
to	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
in	NN	O	O
vivo	NN	O	O
actions	NN	O	O
of	NN	O	O
clonidine	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
To	NN	O	O
test	NN	O	O
whether	NN	O	O
clonidine	NN	O	O
elicits	NN	O	O
pharmacological	NN	O	O
effects	NN	O	O
independent	NN	O	O
of	NN	O	O
alpha2	NN	O	O
-	NN	O	O
adrenoceptors	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
generated	NN	O	O
mice	NN	O	O
with	NN	O	O
a	NN	O	O
targeted	NN	O	O
deletion	NN	O	O
of	NN	O	O
all	NN	O	O
3	NN	O	O
alpha2	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
subtypes	NN	O	O
(	NN	O	O
alpha2ABC	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
.	NN	O	O

Alpha2ABC	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
were	NN	O	O
completely	NN	O	O
unresponsive	NN	O	O
to	NN	O	O
the	NN	O	O
analgesic	NN	O	O
and	NN	O	O
hypnotic	NN	O	O
effects	NN	O	O
of	NN	O	O
clonidine	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
clonidine	NN	O	O
significantly	NN	O	O
lowered	NN	O	O
heart	NN	O	O
rate	NN	O	O
in	NN	O	O
alpha2ABC	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
by	NN	O	O
up	NN	O	O
to	NN	O	O
150	NN	O	O
bpm	NN	O	O
.	NN	O	O

Clonidine	NN	O	O
-	NN	O	O
induced	NN	O	O
bradycardia	NN	O	B
in	NN	O	O
conscious	NN	O	O
alpha2ABC	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
was	NN	O	O
32	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
(	NN	O	O
10	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
26	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
(	NN	O	O
100	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
effect	NN	O	O
in	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
mice	NN	O	O
.	NN	O	O

A	NN	O	O
similar	NN	O	O
bradycardic	NN	O	O
effect	NN	O	O
of	NN	O	O
clonidine	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
isolated	NN	O	O
spontaneously	NN	O	O
beating	NN	O	O
right	NN	O	O
atria	NN	O	O
from	NN	O	O
alpha2ABC	NN	O	O
-	NN	O	O
knockout	NN	O	O
and	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
mice	NN	O	O
.	NN	O	O

Clonidine	NN	O	O
inhibited	NN	O	O
the	NN	O	O
native	NN	O	O
pacemaker	NN	O	O
current	NN	O	O
(	NN	O	O
I	NN	O	O
(	NN	O	O
f	NN	O	O
)	NN	O	O
)	NN	O	O
in	NN	O	O
isolated	NN	O	O
sinoatrial	NN	O	O
node	NN	O	O
pacemaker	NN	O	O
cells	NN	O	O
and	NN	O	O
the	NN	O	O
I	NN	O	O
(	NN	O	O
f	NN	O	O
)	NN	O	O
-	NN	O	O
generating	NN	O	O
hyperpolarization	NN	O	O
-	NN	O	O
activated	NN	O	O
cyclic	NN	O	O
nucleotide	NN	O	O
-	NN	O	O
gated	NN	O	O
(	NN	O	O
HCN	NN	O	O
)	NN	O	O
2	NN	O	O
and	NN	O	O
HCN4	NN	O	O
channels	NN	O	O
in	NN	O	O
transfected	NN	O	O
HEK293	NN	O	O
cells	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
blocking	NN	O	O
I	NN	O	O
(	NN	O	O
f	NN	O	O
)	NN	O	O
,	NN	O	O
clonidine	NN	O	O
reduced	NN	O	O
the	NN	O	O
slope	NN	O	O
of	NN	O	O
the	NN	O	O
diastolic	NN	O	O
depolarization	NN	O	O
and	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
pacemaker	NN	O	O
potentials	NN	O	O
in	NN	O	O
sinoatrial	NN	O	O
node	NN	O	O
cells	NN	O	O
from	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
and	NN	O	O
alpha2ABC	NN	O	O
-	NN	O	O
knockout	NN	O	O
mice	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Direct	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cardiac	NN	O	O
HCN	NN	O	O
pacemaker	NN	O	O
channels	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
bradycardic	NN	O	O
effects	NN	O	O
of	NN	O	O
clonidine	NN	O	O
gene	NN	O	O
-	NN	O	O
targeted	NN	O	O
mice	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
and	NN	O	O
thus	NN	O	O
,	NN	O	O
clonidine	NN	O	O
-	NN	O	O
like	NN	O	O
drugs	NN	O	O
represent	NN	O	O
novel	NN	O	O
structures	NN	O	O
for	NN	O	O
future	NN	O	O
HCN	NN	O	O
channel	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

Granulomatous	NN	O	B
hepatitis	NN	O	I
due	NN	O	O
to	NN	O	O
combination	NN	O	O
of	NN	O	O
amoxicillin	NN	O	O
and	NN	O	O
clavulanic	NN	O	O
acid	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
amoxicillin	NN	O	O
-	NN	O	O
clavulanic	NN	O	O
acid	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatitis	NN	O	B
with	NN	O	O
histologic	NN	O	O
multiple	NN	O	O
granulomas	NN	O	B
.	NN	O	O

This	NN	O	O
type	NN	O	O
of	NN	O	O
lesion	NN	O	O
broadens	NN	O	O
the	NN	O	O
spectrum	NN	O	O
of	NN	O	O
liver	NN	O	B
injury	NN	O	I
due	NN	O	O
to	NN	O	O
this	NN	O	O
drug	NN	O	O
combination	NN	O	O
,	NN	O	O
mainly	NN	O	O
represented	NN	O	O
by	NN	O	O
a	NN	O	O
benign	NN	O	O
cholestatic	NN	O	B
syndrome	NN	O	I
.	NN	O	O

The	NN	O	O
association	NN	O	O
of	NN	O	O
granulomas	NN	O	B
and	NN	O	O
eosinophilia	NN	O	B
favor	NN	O	O
an	NN	O	O
immunoallergic	NN	O	O
mechanism	NN	O	O
.	NN	O	O

As	NN	O	O
penicillin	NN	O	O
derivatives	NN	O	O
and	NN	O	O
amoxicillin	NN	O	O
alone	NN	O	O
are	NN	O	O
known	NN	O	O
to	NN	O	O
induce	NN	O	O
such	NN	O	O
types	NN	O	O
of	NN	O	O
lesions	NN	O	O
,	NN	O	O
the	NN	O	O
amoxicillin	NN	O	O
component	NN	O	O
,	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
a	NN	O	O
potentiating	NN	O	O
effect	NN	O	O
of	NN	O	O
clavulanic	NN	O	O
acid	NN	O	O
,	NN	O	O
might	NN	O	O
have	NN	O	O
a	NN	O	O
major	NN	O	O
role	NN	O	O
.	NN	O	O

Dobutamine	NN	O	O
stress	NN	O	O
echocardiography	NN	O	O
:	NN	O	O
a	NN	O	O
sensitive	NN	O	O
indicator	NN	O	O
of	NN	O	O
diminished	NN	O	O
myocardial	NN	O	O
function	NN	O	O
in	NN	O	O
asymptomatic	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
treated	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
survivors	NN	O	O
of	NN	O	O
childhood	NN	O	O
cancer	NN	O	B
.	NN	O	O

Doxorubicin	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
anticancer	NN	O	O
chemotherapeutic	NN	O	O
agent	NN	O	O
known	NN	O	O
to	NN	O	O
cause	NN	O	O
acute	NN	O	O
and	NN	O	O
chronic	NN	O	O
cardiomyopathy	NN	O	B
.	NN	O	O

To	NN	O	O
develop	NN	O	O
a	NN	O	O
more	NN	O	O
sensitive	NN	O	O
echocardiographic	NN	O	O
screening	NN	O	O
test	NN	O	O
for	NN	O	O
cardiac	NN	O	B
damage	NN	O	I
due	NN	O	O
to	NN	O	O
doxorubicin	NN	O	O
,	NN	O	O
a	NN	O	O
cohort	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
using	NN	O	O
dobutamine	NN	O	O
infusion	NN	O	O
to	NN	O	O
differentiate	NN	O	O
asymptomatic	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
survivors	NN	O	O
of	NN	O	O
childhood	NN	O	O
cancer	NN	O	B
treated	NN	O	O
with	NN	O	O
doxorubicin	NN	O	O
from	NN	O	O
healthy	NN	O	O
control	NN	O	O
subjects	NN	O	O
.	NN	O	O

Echocardiographic	NN	O	O
data	NN	O	O
from	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
of	NN	O	O
21	NN	O	O
patients	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
16	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
years	NN	O	O
)	NN	O	O
treated	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
to	NN	O	O
14	NN	O	O
.	NN	O	O
3	NN	O	O
years	NN	O	O
(	NN	O	O
median	NN	O	O
5	NN	O	O
.	NN	O	O
3	NN	O	O
)	NN	O	O
before	NN	O	O
this	NN	O	O
study	NN	O	O
with	NN	O	O
27	NN	O	O
to	NN	O	O
532	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
mean	NN	O	O
196	NN	O	O
)	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
echocardiographic	NN	O	O
data	NN	O	O
from	NN	O	O
12	NN	O	O
normal	NN	O	O
age	NN	O	O
-	NN	O	O
matched	NN	O	O
control	NN	O	O
subjects	NN	O	O
.	NN	O	O

Graded	NN	O	O
dobutamine	NN	O	O
infusions	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
5	NN	O	O
and	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
min	NN	O	O
were	NN	O	O
administered	NN	O	O
.	NN	O	O

Echocardiographic	NN	O	O
Doppler	NN	O	O
studies	NN	O	O
were	NN	O	O
performed	NN	O	O
before	NN	O	O
infusion	NN	O	O
and	NN	O	O
after	NN	O	O
15	NN	O	O
min	NN	O	O
of	NN	O	O
infusion	NN	O	O
at	NN	O	O
each	NN	O	O
rate	NN	O	O
.	NN	O	O

Dobutamine	NN	O	O
infusion	NN	O	O
at	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
min	NN	O	O
was	NN	O	O
discontinued	NN	O	O
after	NN	O	O
six	NN	O	O
studies	NN	O	O
secondary	NN	O	O
to	NN	O	O
a	NN	O	O
50	NN	O	O
%	NN	O	O
incidence	NN	O	O
rate	NN	O	O
of	NN	O	O
adverse	NN	O	O
symptoms	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
important	NN	O	O
findings	NN	O	O
were	NN	O	O
that	NN	O	O
compared	NN	O	O
with	NN	O	O
values	NN	O	O
in	NN	O	O
control	NN	O	O
subjects	NN	O	O
,	NN	O	O
end	NN	O	O
-	NN	O	O
systolic	NN	O	O
left	NN	O	O
ventricular	NN	O	O
posterior	NN	O	O
wall	NN	O	O
dimension	NN	O	O
and	NN	O	O
percent	NN	O	O
of	NN	O	O
left	NN	O	O
ventricular	NN	O	O
posterior	NN	O	O
wall	NN	O	O
thickening	NN	O	O
in	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
were	NN	O	O
decreased	NN	O	O
at	NN	O	O
baseline	NN	O	O
study	NN	O	O
and	NN	O	O
these	NN	O	O
findings	NN	O	O
were	NN	O	O
more	NN	O	O
clearly	NN	O	O
delineated	NN	O	O
with	NN	O	O
dobutamine	NN	O	O
stimulation	NN	O	O
.	NN	O	O

End	NN	O	O
-	NN	O	O
systolic	NN	O	O
left	NN	O	O
ventricular	NN	O	O
posterior	NN	O	O
wall	NN	O	O
dimension	NN	O	O
at	NN	O	O
baseline	NN	O	O
for	NN	O	O
the	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
was	NN	O	O
11	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
mm	NN	O	O
versus	NN	O	O
13	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
mm	NN	O	O
for	NN	O	O
control	NN	O	O
subjects	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

End	NN	O	O
-	NN	O	O
systolic	NN	O	O
left	NN	O	O
ventricular	NN	O	O
posterior	NN	O	O
wall	NN	O	O
dimension	NN	O	O
at	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
min	NN	O	O
dobutamine	NN	O	O
infusion	NN	O	O
for	NN	O	O
the	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
was	NN	O	O
14	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
mm	NN	O	O
versus	NN	O	O
19	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
mm	NN	O	O
for	NN	O	O
control	NN	O	O
subjects	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Influence	NN	O	O
of	NN	O	O
smoking	NN	O	O
on	NN	O	O
developing	NN	O	O
cochlea	NN	O	O
.	NN	O	O

Does	NN	O	O
smoking	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
affect	NN	O	O
the	NN	O	O
amplitudes	NN	O	O
of	NN	O	O
transient	NN	O	O
evoked	NN	O	O
otoacoustic	NN	O	O
emissions	NN	O	O
in	NN	O	O
newborns	NN	O	O
?	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
Maternal	NN	O	O
tobacco	NN	O	O
smoking	NN	O	O
has	NN	O	O
negative	NN	O	O
effects	NN	O	O
on	NN	O	O
fetal	NN	O	O
growth	NN	O	O
.	NN	O	O

The	NN	O	O
influence	NN	O	O
of	NN	O	O
smoking	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
on	NN	O	O
the	NN	O	O
developing	NN	O	O
cochlea	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
estimated	NN	O	O
,	NN	O	O
although	NN	O	O
smoking	NN	O	O
has	NN	O	O
been	NN	O	O
positively	NN	O	O
associated	NN	O	O
with	NN	O	O
hearing	NN	O	B
loss	NN	O	I
in	NN	O	O
adults	NN	O	O
.	NN	O	O

The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
maternal	NN	O	O
smoking	NN	O	O
on	NN	O	O
transient	NN	O	O
evoked	NN	O	O
otoacoustic	NN	O	O
emissions	NN	O	O
(	NN	O	O
TEOAEs	NN	O	O
)	NN	O	O
of	NN	O	O
healthy	NN	O	O
neonates	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
neonatal	NN	O	O
screening	NN	O	O
for	NN	O	O
hearing	NN	O	B
impairment	NN	O	I
and	NN	O	O
involved	NN	O	O
both	NN	O	O
ears	NN	O	O
of	NN	O	O
200	NN	O	O
newborns	NN	O	O
.	NN	O	O

Newborns	NN	O	O
whose	NN	O	O
mothers	NN	O	O
reported	NN	O	O
smoking	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
200	NN	O	O
ears	NN	O	O
)	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
of	NN	O	O
newborns	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
200	NN	O	O
ears	NN	O	O
)	NN	O	O
,	NN	O	O
whose	NN	O	O
mothers	NN	O	O
were	NN	O	O
non	NN	O	O
-	NN	O	O
smokers	NN	O	O
.	NN	O	O

Exposure	NN	O	O
to	NN	O	O
tobacco	NN	O	O
was	NN	O	O
characterized	NN	O	O
as	NN	O	O
low	NN	O	O
(	NN	O	O
<	NN	O	O
5	NN	O	O
cigarettes	NN	O	O
per	NN	O	O
day	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
88	NN	O	O
ears	NN	O	O
)	NN	O	O
,	NN	O	O
moderate	NN	O	O
(	NN	O	O
5	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
cigarettes	NN	O	O
per	NN	O	O
day	NN	O	O
<	NN	O	O
10	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
76	NN	O	O
)	NN	O	O
or	NN	O	O
high	NN	O	O
(	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
10	NN	O	O
cigarettes	NN	O	O
per	NN	O	O
day	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
36	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
exposed	NN	O	O
neonates	NN	O	O
,	NN	O	O
TEOAEs	NN	O	O
mean	NN	O	O
response	NN	O	O
(	NN	O	O
across	NN	O	O
frequency	NN	O	O
)	NN	O	O
and	NN	O	O
mean	NN	O	O
amplitude	NN	O	O
at	NN	O	O
4000Hz	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
in	NN	O	O
non	NN	O	O
-	NN	O	O
exposed	NN	O	O
neonates	NN	O	O
.	NN	O	O

Comparisons	NN	O	O
between	NN	O	O
exposed	NN	O	O
newborns	NN	O	O
'	NN	O	O
subgroups	NN	O	O
revealed	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
by	NN	O	O
comparing	NN	O	O
each	NN	O	O
subgroup	NN	O	O
to	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
statistically	NN	O	O
significant	NN	O	O
decreases	NN	O	B
of	NN	O	I
TEOAEs	NN	O	I
amplitudes	NN	O	I
at	NN	O	O
4000Hz	NN	O	O
for	NN	O	O
all	NN	O	O
three	NN	O	O
groups	NN	O	O
.	NN	O	O

Mean	NN	O	O
TEOAEs	NN	O	O
responses	NN	O	O
of	NN	O	O
highly	NN	O	O
exposed	NN	O	O
newborns	NN	O	O
were	NN	O	O
also	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
our	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
utero	NN	O	O
,	NN	O	O
exposure	NN	O	O
to	NN	O	O
tobacco	NN	O	O
smoking	NN	O	O
seems	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
small	NN	O	O
impact	NN	O	O
on	NN	O	O
outer	NN	O	O
hair	NN	O	O
cells	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
seem	NN	O	O
to	NN	O	O
be	NN	O	O
equally	NN	O	O
true	NN	O	O
for	NN	O	O
all	NN	O	O
exposed	NN	O	O
newborns	NN	O	O
,	NN	O	O
regardless	NN	O	O
of	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
exposure	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
establish	NN	O	O
a	NN	O	O
potential	NN	O	O
negative	NN	O	O
effect	NN	O	O
of	NN	O	O
maternal	NN	O	O
smoking	NN	O	O
on	NN	O	O
the	NN	O	O
neonate	NN	O	O
'	NN	O	O
s	NN	O	O
hearing	NN	O	O
acuity	NN	O	O
.	NN	O	O

Simvastatin	NN	O	O
-	NN	O	O
induced	NN	O	O
bilateral	NN	O	O
leg	NN	O	O
compartment	NN	O	B
syndrome	NN	O	I
and	NN	O	O
myonecrosis	NN	O	B
associated	NN	O	O
with	NN	O	O
hypothyroidism	NN	O	B
.	NN	O	O

A	NN	O	O
54	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
hypothyroid	NN	O	B
male	NN	O	O
taking	NN	O	O
thyroxine	NN	O	O
and	NN	O	O
simvastatin	NN	O	O
presented	NN	O	O
with	NN	O	O
bilateral	NN	O	O
leg	NN	O	O
compartment	NN	O	B
syndrome	NN	O	I
and	NN	O	O
myonecrosis	NN	O	B
.	NN	O	O

Urgent	NN	O	O
fasciotomies	NN	O	O
were	NN	O	O
performed	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
made	NN	O	O
an	NN	O	O
uneventful	NN	O	O
recovery	NN	O	O
with	NN	O	O
the	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
simvastatin	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
likely	NN	O	O
that	NN	O	O
this	NN	O	O
complication	NN	O	O
will	NN	O	O
be	NN	O	O
seen	NN	O	O
more	NN	O	O
often	NN	O	O
with	NN	O	O
the	NN	O	O
increased	NN	O	O
worldwide	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
and	NN	O	O
its	NN	O	O
approval	NN	O	O
for	NN	O	O
all	NN	O	O
arteriopathic	NN	O	B
patients	NN	O	O
.	NN	O	O

Neuroinflammation	NN	O	B
and	NN	O	O
behavioral	NN	O	B
abnormalities	NN	O	I
after	NN	O	O
neonatal	NN	O	O
terbutaline	NN	O	O
treatment	NN	O	O
in	NN	O	O
rats	NN	O	O
:	NN	O	O
implications	NN	O	O
for	NN	O	O
autism	NN	O	B
.	NN	O	O

Autism	NN	O	B
is	NN	O	O
a	NN	O	O
neurodevelopmental	NN	O	B
disorder	NN	O	I
presenting	NN	O	O
before	NN	O	O
3	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
with	NN	O	O
deficits	NN	O	B
in	NN	O	I
communication	NN	O	I
and	NN	O	I
social	NN	O	I
skills	NN	O	I
and	NN	O	O
repetitive	NN	O	B
behaviors	NN	O	I
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
genetic	NN	O	O
influences	NN	O	O
,	NN	O	O
recent	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
prenatal	NN	O	O
drug	NN	O	O
or	NN	O	O
chemical	NN	O	O
exposures	NN	O	O
are	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
autism	NN	O	B
.	NN	O	O

Terbutaline	NN	O	O
,	NN	O	O
a	NN	O	O
beta2	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
agonist	NN	O	O
used	NN	O	O
to	NN	O	O
arrest	NN	O	O
preterm	NN	O	B
labor	NN	O	I
,	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
concordance	NN	O	O
for	NN	O	O
autism	NN	O	B
in	NN	O	O
dizygotic	NN	O	O
twins	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
terbutaline	NN	O	O
on	NN	O	O
microglial	NN	O	O
activation	NN	O	O
in	NN	O	O
different	NN	O	O
brain	NN	O	O
regions	NN	O	O
and	NN	O	O
behavioral	NN	O	O
outcomes	NN	O	O
in	NN	O	O
developing	NN	O	O
rats	NN	O	O
.	NN	O	O

Newborn	NN	O	O
rats	NN	O	O
were	NN	O	O
given	NN	O	O
terbutaline	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
daily	NN	O	O
on	NN	O	O
postnatal	NN	O	O
days	NN	O	O
(	NN	O	O
PN	NN	O	O
)	NN	O	O
2	NN	O	O
to	NN	O	O
5	NN	O	O
or	NN	O	O
PN	NN	O	O
11	NN	O	O
to	NN	O	O
14	NN	O	O
and	NN	O	O
examined	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
the	NN	O	O
last	NN	O	O
dose	NN	O	O
and	NN	O	O
at	NN	O	O
PN	NN	O	O
30	NN	O	O
.	NN	O	O

Immunohistochemical	NN	O	O
studies	NN	O	O
showed	NN	O	O
that	NN	O	O
administration	NN	O	O
of	NN	O	O
terbutaline	NN	O	O
on	NN	O	O
PN	NN	O	O
2	NN	O	O
to	NN	O	O
5	NN	O	O
produced	NN	O	O
a	NN	O	O
robust	NN	O	O
increase	NN	O	O
in	NN	O	O
microglial	NN	O	O
activation	NN	O	O
on	NN	O	O
PN	NN	O	O
30	NN	O	O
in	NN	O	O
the	NN	O	O
cerebral	NN	O	O
cortex	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
cerebellar	NN	O	O
and	NN	O	O
cerebrocortical	NN	O	O
white	NN	O	O
matter	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
these	NN	O	O
effects	NN	O	O
occurred	NN	O	O
in	NN	O	O
animals	NN	O	O
given	NN	O	O
terbutaline	NN	O	O
on	NN	O	O
PN	NN	O	O
11	NN	O	O
to	NN	O	O
14	NN	O	O
.	NN	O	O

In	NN	O	O
behavioral	NN	O	O
tests	NN	O	O
,	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
terbutaline	NN	O	O
on	NN	O	O
PN	NN	O	O
2	NN	O	O
to	NN	O	O
5	NN	O	O
showed	NN	O	O
consistent	NN	O	O
patterns	NN	O	O
of	NN	O	O
hyper	NN	O	O
-	NN	O	O
reactivity	NN	O	O
to	NN	O	O
novelty	NN	O	O
and	NN	O	O
aversive	NN	O	O
stimuli	NN	O	O
when	NN	O	O
assessed	NN	O	O
in	NN	O	O
a	NN	O	O
novel	NN	O	O
open	NN	O	O
field	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
the	NN	O	O
acoustic	NN	O	O
startle	NN	O	O
response	NN	O	O
test	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
beta2	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
overstimulation	NN	O	O
during	NN	O	O
an	NN	O	O
early	NN	O	O
critical	NN	O	O
period	NN	O	O
results	NN	O	O
in	NN	O	O
microglial	NN	O	O
activation	NN	O	O
associated	NN	O	O
with	NN	O	O
innate	NN	O	O
neuroinflammatory	NN	O	O
pathways	NN	O	O
and	NN	O	O
behavioral	NN	O	B
abnormalities	NN	O	I
,	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
described	NN	O	O
in	NN	O	O
autism	NN	O	B
.	NN	O	O

This	NN	O	O
study	NN	O	O
provides	NN	O	O
a	NN	O	O
useful	NN	O	O
animal	NN	O	O
model	NN	O	O
for	NN	O	O
understanding	NN	O	O
the	NN	O	O
neuropathological	NN	O	O
processes	NN	O	O
underlying	NN	O	O
autism	NN	O	B
spectrum	NN	O	I
disorders	NN	O	I
.	NN	O	O

Upregulation	NN	O	O
of	NN	O	O
brain	NN	O	O
expression	NN	O	O
of	NN	O	O
P	NN	O	O
-	NN	O	O
glycoprotein	NN	O	O
in	NN	O	O
MRP2	NN	O	O
-	NN	O	O
deficient	NN	O	O
TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
rats	NN	O	O
resembles	NN	O	O
seizure	NN	O	B
-	NN	O	O
induced	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
efflux	NN	O	O
transporter	NN	O	O
in	NN	O	O
normal	NN	O	O
rats	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
The	NN	O	O
multidrug	NN	O	O
resistance	NN	O	O
protein	NN	O	O
2	NN	O	O
(	NN	O	O
MRP2	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
drug	NN	O	O
efflux	NN	O	O
transporter	NN	O	O
that	NN	O	O
is	NN	O	O
expressed	NN	O	O
predominantly	NN	O	O
at	NN	O	O
the	NN	O	O
apical	NN	O	O
domain	NN	O	O
of	NN	O	O
hepatocytes	NN	O	O
but	NN	O	O
seems	NN	O	O
also	NN	O	O
to	NN	O	O
be	NN	O	O
expressed	NN	O	O
at	NN	O	O
the	NN	O	O
apical	NN	O	O
membrane	NN	O	O
of	NN	O	O
brain	NN	O	O
capillary	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
that	NN	O	O
form	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
(	NN	O	O
BBB	NN	O	O
)	NN	O	O
.	NN	O	O

MRP2	NN	O	O
is	NN	O	O
absent	NN	O	O
in	NN	O	O
the	NN	O	O
transport	NN	O	O
-	NN	O	O
deficient	NN	O	O
(	NN	O	O
TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
)	NN	O	O
Wistar	NN	O	O
rat	NN	O	O
mutant	NN	O	O
,	NN	O	O
so	NN	O	O
that	NN	O	O
this	NN	O	O
rat	NN	O	O
strain	NN	O	O
was	NN	O	O
very	NN	O	O
helpful	NN	O	O
in	NN	O	O
defining	NN	O	O
substrates	NN	O	O
of	NN	O	O
MRP2	NN	O	O
by	NN	O	O
comparing	NN	O	O
tissue	NN	O	O
concentrations	NN	O	O
or	NN	O	O
functional	NN	O	O
activities	NN	O	O
of	NN	O	O
compounds	NN	O	O
in	NN	O	O
MRP2	NN	O	O
-	NN	O	O
deficient	NN	O	O
rats	NN	O	O
with	NN	O	O
those	NN	O	O
in	NN	O	O
transport	NN	O	O
-	NN	O	O
competent	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

By	NN	O	O
using	NN	O	O
this	NN	O	O
strategy	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
MRP2	NN	O	O
in	NN	O	O
brain	NN	O	O
access	NN	O	O
of	NN	O	O
antiepileptic	NN	O	O
drugs	NN	O	O
(	NN	O	O
AEDs	NN	O	O
)	NN	O	O
,	NN	O	O
we	NN	O	O
recently	NN	O	O
reported	NN	O	O
that	NN	O	O
phenytoin	NN	O	O
is	NN	O	O
a	NN	O	O
substrate	NN	O	O
for	NN	O	O
MRP2	NN	O	O
in	NN	O	O
the	NN	O	O
BBB	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
one	NN	O	O
drawback	NN	O	O
of	NN	O	O
such	NN	O	O
studies	NN	O	O
in	NN	O	O
genetically	NN	O	O
deficient	NN	O	O
rats	NN	O	O
is	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
compensatory	NN	O	O
changes	NN	O	O
with	NN	O	O
upregulation	NN	O	O
of	NN	O	O
other	NN	O	O
transporters	NN	O	O
can	NN	O	O
occur	NN	O	O
.	NN	O	O

This	NN	O	O
prompted	NN	O	O
us	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
brain	NN	O	O
expression	NN	O	O
of	NN	O	O
P	NN	O	O
-	NN	O	O
glycoprotein	NN	O	O
(	NN	O	O
Pgp	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
major	NN	O	O
drug	NN	O	O
efflux	NN	O	O
transporter	NN	O	O
in	NN	O	O
many	NN	O	O
tissues	NN	O	O
,	NN	O	O
including	NN	O	O
the	NN	O	O
BBB	NN	O	O
,	NN	O	O
in	NN	O	O
TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
rats	NN	O	O
compared	NN	O	O
with	NN	O	O
nonmutant	NN	O	O
(	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
)	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
expression	NN	O	O
of	NN	O	O
MRP2	NN	O	O
and	NN	O	O
Pgp	NN	O	O
in	NN	O	O
brain	NN	O	O
and	NN	O	O
liver	NN	O	O
sections	NN	O	O
of	NN	O	O
TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
rats	NN	O	O
and	NN	O	O
normal	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
was	NN	O	O
determined	NN	O	O
with	NN	O	O
immunohistochemistry	NN	O	O
,	NN	O	O
by	NN	O	O
using	NN	O	O
a	NN	O	O
novel	NN	O	O
,	NN	O	O
highly	NN	O	O
selective	NN	O	O
monoclonal	NN	O	O
MRP2	NN	O	O
antibody	NN	O	O
and	NN	O	O
the	NN	O	O
monoclonal	NN	O	O
Pgp	NN	O	O
antibody	NN	O	O
C219	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Immunofluorescence	NN	O	O
staining	NN	O	O
with	NN	O	O
the	NN	O	O
MRP2	NN	O	O
antibody	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
label	NN	O	O
a	NN	O	O
high	NN	O	O
number	NN	O	O
of	NN	O	O
microvessels	NN	O	O
throughout	NN	O	O
the	NN	O	O
brain	NN	O	O
in	NN	O	O
normal	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
,	NN	O	O
whereas	NN	O	O
such	NN	O	O
labeling	NN	O	O
was	NN	O	O
absent	NN	O	O
in	NN	O	O
TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
rats	NN	O	O
exhibited	NN	O	O
a	NN	O	O
significant	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
Pgp	NN	O	O
in	NN	O	O
brain	NN	O	O
capillary	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
compared	NN	O	O
with	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
controls	NN	O	O
.	NN	O	O

No	NN	O	O
such	NN	O	O
obvious	NN	O	O
upregulation	NN	O	O
of	NN	O	O
Pgp	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
liver	NN	O	O
sections	NN	O	O
.	NN	O	O

A	NN	O	O
comparable	NN	O	O
overexpression	NN	O	O
of	NN	O	O
Pgp	NN	O	O
in	NN	O	O
the	NN	O	O
BBB	NN	O	O
was	NN	O	O
obtained	NN	O	O
after	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
in	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

Experiments	NN	O	O
with	NN	O	O
systemic	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
Pgp	NN	O	O
substrate	NN	O	O
phenobarbital	NN	O	O
and	NN	O	O
the	NN	O	O
selective	NN	O	O
Pgp	NN	O	O
inhibitor	NN	O	O
tariquidar	NN	O	O
in	NN	O	O
TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
rats	NN	O	O
substantiated	NN	O	O
that	NN	O	O
Pgp	NN	O	O
is	NN	O	O
functional	NN	O	O
and	NN	O	O
compensates	NN	O	O
for	NN	O	O
the	NN	O	O
lack	NN	O	O
of	NN	O	O
MRP2	NN	O	O
in	NN	O	O
the	NN	O	O
BBB	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
data	NN	O	O
on	NN	O	O
TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
rats	NN	O	O
indicate	NN	O	O
that	NN	O	O
Pgp	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
compensation	NN	O	O
of	NN	O	O
MRP2	NN	O	O
deficiency	NN	O	O
in	NN	O	O
the	NN	O	O
BBB	NN	O	O
.	NN	O	O

Because	NN	O	O
such	NN	O	O
a	NN	O	O
compensatory	NN	O	O
mechanism	NN	O	O
most	NN	O	O
likely	NN	O	O
occurs	NN	O	O
to	NN	O	O
reduce	NN	O	O
injury	NN	O	B
to	NN	O	I
the	NN	O	I
brain	NN	O	I
from	NN	O	O
cytotoxic	NN	O	O
compounds	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
data	NN	O	O
substantiate	NN	O	O
the	NN	O	O
concept	NN	O	O
that	NN	O	O
MRP2	NN	O	O
performs	NN	O	O
a	NN	O	O
protective	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
BBB	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
our	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
TR	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
rats	NN	O	O
are	NN	O	O
an	NN	O	O
interesting	NN	O	O
tool	NN	O	O
to	NN	O	O
study	NN	O	O
consequences	NN	O	O
of	NN	O	O
overexpression	NN	O	O
of	NN	O	O
Pgp	NN	O	O
in	NN	O	O
the	NN	O	O
BBB	NN	O	O
on	NN	O	O
access	NN	O	O
of	NN	O	O
drugs	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
,	NN	O	O
without	NN	O	O
the	NN	O	O
need	NN	O	O
of	NN	O	O
inducing	NN	O	O
seizures	NN	O	B
or	NN	O	O
other	NN	O	O
Pgp	NN	O	O
-	NN	O	O
enhancing	NN	O	O
events	NN	O	O
for	NN	O	O
this	NN	O	O
purpose	NN	O	O
.	NN	O	O

Role	NN	O	O
of	NN	O	O
xanthine	NN	O	O
oxidase	NN	O	O
in	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

Glucocorticoid	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
(	NN	O	O
GC	NN	O	O
-	NN	O	O
HT	NN	O	B
)	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
-	NN	O	O
redox	NN	O	O
imbalance	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
xanthine	NN	O	O
oxidase	NN	O	O
(	NN	O	O
XO	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
,	NN	O	O
in	NN	O	O
dexamethasone	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
(	NN	O	O
dex	NN	O	O
-	NN	O	O
HT	NN	O	B
)	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

Thirty	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
divided	NN	O	O
randomly	NN	O	O
into	NN	O	O
four	NN	O	O
treatment	NN	O	O
groups	NN	O	O
:	NN	O	O
saline	NN	O	O
,	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
dex	NN	O	O
)	NN	O	O
,	NN	O	O
allopurinol	NN	O	O
plus	NN	O	O
saline	NN	O	O
,	NN	O	O
and	NN	O	O
allopurinol	NN	O	O
plus	NN	O	O
dex	NN	O	O
.	NN	O	O

4	NN	O	O
.	NN	O	O

Systolic	NN	O	O
blood	NN	O	O
pressures	NN	O	O
(	NN	O	O
SBP	NN	O	O
)	NN	O	O
and	NN	O	O
bodyweights	NN	O	O
were	NN	O	O
recorded	NN	O	O
each	NN	O	O
alternate	NN	O	O
day	NN	O	O
.	NN	O	O

Thymus	NN	O	O
weight	NN	O	O
was	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
serum	NN	O	O
urate	NN	O	O
to	NN	O	O
assess	NN	O	O
XO	NN	O	O
inhibition	NN	O	O
.	NN	O	O

5	NN	O	O
.	NN	O	O

Dex	NN	O	O
increased	NN	O	B
SBP	NN	O	I
(	NN	O	O
110	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
126	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
mmHg	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
and	NN	O	O
decreased	NN	O	B
thymus	NN	O	I
(	NN	O	I
P	NN	O	I
<	NN	O	I
0	NN	O	I
.	NN	O	I
001	NN	O	I
)	NN	O	I
and	NN	O	I
bodyweights	NN	O	I
(	NN	O	O
P	NN	O	O
"	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Allopurinol	NN	O	O
decreased	NN	O	O
serum	NN	O	O
urate	NN	O	O
from	NN	O	O
76	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
to	NN	O	O
30	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
in	NN	O	O
saline	NN	O	O
and	NN	O	O
from	NN	O	O
84	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
to	NN	O	O
28	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
in	NN	O	O
dex	NN	O	O
-	NN	O	O
treated	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
groups	NN	O	O
.	NN	O	O

6	NN	O	O
.	NN	O	O

Allopurinol	NN	O	O
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
dex	NN	O	O
-	NN	O	O
HT	NN	O	B
.	NN	O	O

This	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
our	NN	O	O
previous	NN	O	O
findings	NN	O	O
that	NN	O	O
allopurinol	NN	O	O
failed	NN	O	O
to	NN	O	O
prevent	NN	O	O
adrenocorticotrophic	NN	O	O
hormone	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
,	NN	O	O
suggests	NN	O	O
that	NN	O	O
XO	NN	O	O
activity	NN	O	O
is	NN	O	O
not	NN	O	O
a	NN	O	O
major	NN	O	O
determinant	NN	O	O
of	NN	O	O
GC	NN	O	O
-	NN	O	O
HT	NN	O	B
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Side	NN	O	O
effects	NN	O	O
of	NN	O	O
postoperative	NN	O	O
administration	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	O
and	NN	O	O
gentamicin	NN	O	O
into	NN	O	O
the	NN	O	O
posterior	NN	O	O
sub	NN	O	O
-	NN	O	O
Tenon	NN	O	O
'	NN	O	O
s	NN	O	O
space	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
postoperative	NN	O	O
emetic	NN	O	O
side	NN	O	O
effects	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	O
and	NN	O	O
gentamicin	NN	O	O
into	NN	O	O
the	NN	O	O
posterior	NN	O	O
sub	NN	O	O
-	NN	O	O
Tenon	NN	O	O
'	NN	O	O
s	NN	O	O
space	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
routine	NN	O	O
cataract	NN	O	B
surgery	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
St	NN	O	O
.	NN	O	O

Luke	NN	O	O
'	NN	O	O
s	NN	O	O
Hospital	NN	O	O
,	NN	O	O
Gwardamangia	NN	O	O
,	NN	O	O
Malta	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
double	NN	O	O
-	NN	O	O
armed	NN	O	O
prospective	NN	O	O
study	NN	O	O
comprised	NN	O	O
40	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
uneventful	NN	O	O
sutureless	NN	O	O
phacoemulsification	NN	O	O
under	NN	O	O
sub	NN	O	O
-	NN	O	O
Tenon	NN	O	O
'	NN	O	O
s	NN	O	O
local	NN	O	O
infiltration	NN	O	O
of	NN	O	O
3	NN	O	O
mL	NN	O	O
of	NN	O	O
plain	NN	O	O
lignocaine	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
procedure	NN	O	O
,	NN	O	O
Group	NN	O	O
A	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
had	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mL	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mL	NN	O	O
of	NN	O	O
gentamicin	NN	O	O
injected	NN	O	O
into	NN	O	O
the	NN	O	O
posterior	NN	O	O
sub	NN	O	O
-	NN	O	O
Tenon	NN	O	O
'	NN	O	O
s	NN	O	O
space	NN	O	O
and	NN	O	O
Group	NN	O	O
B	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
had	NN	O	O
the	NN	O	O
same	NN	O	O
combination	NN	O	O
injected	NN	O	O
into	NN	O	O
the	NN	O	O
anterior	NN	O	O
sub	NN	O	O
-	NN	O	O
Tenon	NN	O	O
'	NN	O	O
s	NN	O	O
space	NN	O	O
.	NN	O	O

Postoperatively	NN	O	O
,	NN	O	O
all	NN	O	O
patients	NN	O	O
were	NN	O	O
assessed	NN	O	O
for	NN	O	O
symptoms	NN	O	O
of	NN	O	O
nausea	NN	O	B
,	NN	O	I
vomiting	NN	O	I
,	NN	O	O
and	NN	O	O
headache	NN	O	B
.	NN	O	O

A	NN	O	O
chi	NN	O	O
-	NN	O	O
square	NN	O	O
test	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
statistical	NN	O	O
significance	NN	O	O
of	NN	O	O
results	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Sixty	NN	O	O
percent	NN	O	O
in	NN	O	O
Group	NN	O	O
A	NN	O	O
developed	NN	O	O
postoperative	NN	O	B
emetic	NN	O	I
symptoms	NN	O	I
,	NN	O	O
headache	NN	O	B
,	NN	O	O
or	NN	O	O
both	NN	O	O
;	NN	O	O
1	NN	O	O
patient	NN	O	O
in	NN	O	O
Group	NN	O	O
B	NN	O	O
developed	NN	O	O
symptoms	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
administration	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	O
and	NN	O	O
gentamicin	NN	O	O
in	NN	O	O
the	NN	O	O
posterior	NN	O	O
sub	NN	O	O
-	NN	O	O
Tenon	NN	O	O
'	NN	O	O
s	NN	O	O
space	NN	O	O
was	NN	O	O
related	NN	O	O
to	NN	O	O
a	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
side	NN	O	O
effects	NN	O	O
including	NN	O	O
nausea	NN	O	B
,	NN	O	I
vomiting	NN	O	I
,	NN	O	O
and	NN	O	O
headache	NN	O	B
.	NN	O	O

All	NN	O	O
adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
self	NN	O	O
-	NN	O	O
limiting	NN	O	O
.	NN	O	O

Assessment	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
non	NN	O	O
-	NN	O	O
invasive	NN	O	O
index	NN	O	O
of	NN	O	O
cardiac	NN	O	O
performance	NN	O	O
for	NN	O	O
detection	NN	O	O
of	NN	O	O
dobutamine	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Electrocardiography	NN	O	O
has	NN	O	O
a	NN	O	O
very	NN	O	O
low	NN	O	O
sensitivity	NN	O	O
in	NN	O	O
detecting	NN	O	O
dobutamine	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
the	NN	O	O
added	NN	O	O
diagnostic	NN	O	O
value	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
cardiac	NN	O	O
performance	NN	O	O
index	NN	O	O
(	NN	O	O
dP	NN	O	O
/	NN	O	O
dtejc	NN	O	O
)	NN	O	O
measurement	NN	O	O
,	NN	O	O
based	NN	O	O
on	NN	O	O
brachial	NN	O	O
artery	NN	O	O
flow	NN	O	O
changes	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
standard	NN	O	O
12	NN	O	O
-	NN	O	O
lead	NN	O	O
ECG	NN	O	O
,	NN	O	O
for	NN	O	O
detecting	NN	O	O
dobutamine	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
,	NN	O	O
using	NN	O	O
Tc99m	NN	O	O
-	NN	O	O
Sestamibi	NN	O	O
single	NN	O	O
-	NN	O	O
photon	NN	O	O
emission	NN	O	O
computed	NN	O	O
tomography	NN	O	O
as	NN	O	O
the	NN	O	O
gold	NN	O	O
standard	NN	O	O
of	NN	O	O
comparison	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
ischemia	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
study	NN	O	O
group	NN	O	O
comprised	NN	O	O
40	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
Sestamibi	NN	O	O
-	NN	O	O
SPECT	NN	O	O
/	NN	O	O
dobutamine	NN	O	O
stress	NN	O	O
test	NN	O	O
.	NN	O	O

Simultaneous	NN	O	O
measurements	NN	O	O
of	NN	O	O
ECG	NN	O	O
and	NN	O	O
brachial	NN	O	O
artery	NN	O	O
dP	NN	O	O
/	NN	O	O
dtejc	NN	O	O
were	NN	O	O
performed	NN	O	O
at	NN	O	O
each	NN	O	O
dobutamine	NN	O	O
level	NN	O	O
.	NN	O	O

In	NN	O	O
19	NN	O	O
of	NN	O	O
the	NN	O	O
40	NN	O	O
patients	NN	O	O
perfusion	NN	O	O
defects	NN	O	O
compatible	NN	O	O
with	NN	O	O
ischemia	NN	O	B
were	NN	O	O
detected	NN	O	O
on	NN	O	O
SPECT	NN	O	O
.	NN	O	O

The	NN	O	O
increase	NN	O	O
in	NN	O	O
dP	NN	O	O
/	NN	O	O
dtejc	NN	O	O
during	NN	O	O
infusion	NN	O	O
of	NN	O	O
dobutamine	NN	O	O
in	NN	O	O
this	NN	O	O
group	NN	O	O
was	NN	O	O
severely	NN	O	O
impaired	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
ischemic	NN	O	O
group	NN	O	O
.	NN	O	O

dP	NN	O	O
/	NN	O	O
dtejc	NN	O	O
outcome	NN	O	O
was	NN	O	O
combined	NN	O	O
with	NN	O	O
the	NN	O	O
ECG	NN	O	O
results	NN	O	O
,	NN	O	O
giving	NN	O	O
an	NN	O	O
ECG	NN	O	O
-	NN	O	O
enhanced	NN	O	O
value	NN	O	O
,	NN	O	O
and	NN	O	O
compared	NN	O	O
to	NN	O	O
ECG	NN	O	O
alone	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
sensitivity	NN	O	O
improved	NN	O	O
dramatically	NN	O	O
from	NN	O	O
16	NN	O	O
%	NN	O	O
to	NN	O	O
79	NN	O	O
%	NN	O	O
,	NN	O	O
positive	NN	O	O
predictive	NN	O	O
value	NN	O	O
increased	NN	O	O
from	NN	O	O
60	NN	O	O
%	NN	O	O
to	NN	O	O
68	NN	O	O
%	NN	O	O
and	NN	O	O
negative	NN	O	O
predictive	NN	O	O
value	NN	O	O
from	NN	O	O
54	NN	O	O
%	NN	O	O
to	NN	O	O
78	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
specificity	NN	O	O
decreased	NN	O	O
from	NN	O	O
90	NN	O	O
%	NN	O	O
to	NN	O	O
67	NN	O	O
%	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
If	NN	O	O
ECG	NN	O	O
alone	NN	O	O
is	NN	O	O
used	NN	O	O
for	NN	O	O
specificity	NN	O	O
,	NN	O	O
the	NN	O	O
combination	NN	O	O
with	NN	O	O
dP	NN	O	O
/	NN	O	O
dtejc	NN	O	O
improved	NN	O	O
the	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
the	NN	O	O
test	NN	O	O
and	NN	O	O
could	NN	O	O
be	NN	O	O
a	NN	O	O
cost	NN	O	O
-	NN	O	O
savings	NN	O	O
alternative	NN	O	O
to	NN	O	O
cardiac	NN	O	O
imaging	NN	O	O
or	NN	O	O
perfusion	NN	O	O
studies	NN	O	O
to	NN	O	O
detect	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
,	NN	O	O
especially	NN	O	O
in	NN	O	O
patients	NN	O	O
unable	NN	O	O
to	NN	O	O
exercise	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
:	NN	O	O
clinical	NN	O	O
observations	NN	O	O
and	NN	O	O
pathogenetic	NN	O	O
considerations	NN	O	O
.	NN	O	O

Clinical	NN	O	O
and	NN	O	O
experimental	NN	O	O
data	NN	O	O
published	NN	O	O
to	NN	O	O
date	NN	O	O
suggest	NN	O	O
several	NN	O	O
possible	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
cocaine	NN	O	O
may	NN	O	O
result	NN	O	O
in	NN	O	O
acute	NN	O	B
myocardial	NN	O	I
infarction	NN	O	I
.	NN	O	O

In	NN	O	O
individuals	NN	O	O
with	NN	O	O
preexisting	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
grade	NN	O	O
coronary	NN	O	O
arterial	NN	O	O
narrowing	NN	O	O
,	NN	O	O
acute	NN	O	B
myocardial	NN	O	I
infarction	NN	O	I
may	NN	O	O
result	NN	O	O
from	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
myocardial	NN	O	O
oxygen	NN	O	O
demand	NN	O	O
associated	NN	O	O
with	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
rate	NN	O	O
-	NN	O	O
pressure	NN	O	O
product	NN	O	O
.	NN	O	O

In	NN	O	O
other	NN	O	O
individuals	NN	O	O
with	NN	O	O
no	NN	O	O
underlying	NN	O	O
atherosclerotic	NN	O	B
obstruction	NN	O	I
,	NN	O	O
coronary	NN	O	B
occlusion	NN	O	I
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
spasm	NN	O	B
,	NN	O	O
thrombus	NN	O	B
,	NN	O	O
or	NN	O	O
both	NN	O	O
.	NN	O	O

With	NN	O	O
regard	NN	O	O
to	NN	O	O
spasm	NN	O	B
,	NN	O	O
the	NN	O	O
clinical	NN	O	O
findings	NN	O	O
are	NN	O	O
largely	NN	O	O
circumstantial	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
locus	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
vasoconstriction	NN	O	O
remains	NN	O	O
speculative	NN	O	O
.	NN	O	O

Although	NN	O	O
certain	NN	O	O
clinical	NN	O	O
and	NN	O	O
experimental	NN	O	O
findings	NN	O	O
support	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
spasm	NN	O	B
involves	NN	O	O
the	NN	O	O
epicardial	NN	O	O
,	NN	O	O
medium	NN	O	O
-	NN	O	O
size	NN	O	O
vessels	NN	O	O
,	NN	O	O
other	NN	O	O
data	NN	O	O
suggest	NN	O	O
intramural	NN	O	O
vasoconstriction	NN	O	O
.	NN	O	O

Diffuse	NN	O	O
intramural	NN	O	O
vasoconstriction	NN	O	O
is	NN	O	O
not	NN	O	O
consistent	NN	O	O
with	NN	O	O
reports	NN	O	O
of	NN	O	O
segmental	NN	O	O
,	NN	O	O
discrete	NN	O	O
infarction	NN	O	B
.	NN	O	O

Whereas	NN	O	O
certain	NN	O	O
in	NN	O	O
vivo	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
these	NN	O	O
effects	NN	O	O
are	NN	O	O
alpha	NN	O	O
-	NN	O	O
mediated	NN	O	O
,	NN	O	O
other	NN	O	O
in	NN	O	O
vitro	NN	O	O
data	NN	O	O
suggest	NN	O	O
the	NN	O	O
opposite	NN	O	O
.	NN	O	O

The	NN	O	O
finding	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
vasoconstriction	NN	O	O
in	NN	O	O
segments	NN	O	O
of	NN	O	O
(	NN	O	O
noninnervated	NN	O	O
)	NN	O	O
human	NN	O	O
umbilical	NN	O	O
artery	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
intact	NN	O	O
innervation	NN	O	O
is	NN	O	O
not	NN	O	O
sufficient	NN	O	O
to	NN	O	O
explain	NN	O	O
the	NN	O	O
discrepant	NN	O	O
data	NN	O	O
involving	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
mediated	NN	O	O
effects	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
the	NN	O	O
contribution	NN	O	O
of	NN	O	O
a	NN	O	O
primary	NN	O	O
,	NN	O	O
thrombotic	NN	O	B
effect	NN	O	O
of	NN	O	O
cocaine	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
excluded	NN	O	O
.	NN	O	O

Proteomic	NN	O	O
analysis	NN	O	O
of	NN	O	O
striatal	NN	O	O
proteins	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B
.	NN	O	O

L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B
(	NN	O	O
LID	NN	O	B
)	NN	O	O
is	NN	O	O
among	NN	O	O
the	NN	O	O
motor	NN	O	O
complications	NN	O	O
that	NN	O	O
arise	NN	O	O
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
patients	NN	O	O
after	NN	O	O
a	NN	O	O
prolonged	NN	O	O
treatment	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
.	NN	O	O

To	NN	O	O
this	NN	O	O
day	NN	O	O
,	NN	O	O
transcriptome	NN	O	O
analysis	NN	O	O
has	NN	O	O
been	NN	O	O
performed	NN	O	O
in	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
LID	NN	O	B
[	NN	O	O
Neurobiol	NN	O	O
.	NN	O	O
Dis	NN	O	O
.	NN	O	O
,	NN	O	O
17	NN	O	O
(	NN	O	O
2004	NN	O	O
)	NN	O	O
,	NN	O	O
219	NN	O	O
]	NN	O	O
but	NN	O	O
information	NN	O	O
regarding	NN	O	O
the	NN	O	O
proteome	NN	O	O
is	NN	O	O
still	NN	O	O
lacking	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
changes	NN	O	O
occurring	NN	O	O
at	NN	O	O
the	NN	O	O
protein	NN	O	O
level	NN	O	O
in	NN	O	O
striatal	NN	O	O
samples	NN	O	O
obtained	NN	O	O
from	NN	O	O
the	NN	O	O
unilaterally	NN	O	O
6	NN	O	O
-	NN	O	O
hydroxydopamine	NN	O	O
-	NN	O	O
lesion	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
PD	NN	O	B
treated	NN	O	O
with	NN	O	O
saline	NN	O	O
,	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
or	NN	O	O
bromocriptine	NN	O	O
using	NN	O	O
two	NN	O	O
-	NN	O	O
dimensional	NN	O	O
difference	NN	O	O
gel	NN	O	O
electrophoresis	NN	O	O
and	NN	O	O
mass	NN	O	O
spectrometry	NN	O	O
(	NN	O	O
MS	NN	O	O
)	NN	O	O
.	NN	O	O

Rats	NN	O	O
treated	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
DOPA	NN	O	O
were	NN	O	O
allocated	NN	O	O
to	NN	O	O
two	NN	O	O
groups	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
LID	NN	O	B
.	NN	O	O

Among	NN	O	O
the	NN	O	O
2000	NN	O	O
spots	NN	O	O
compared	NN	O	O
for	NN	O	O
statistical	NN	O	O
difference	NN	O	O
,	NN	O	O
67	NN	O	O
spots	NN	O	O
were	NN	O	O
significantly	NN	O	O
changed	NN	O	O
in	NN	O	O
abundance	NN	O	O
and	NN	O	O
identified	NN	O	O
using	NN	O	O
matrix	NN	O	O
-	NN	O	O
assisted	NN	O	O
laser	NN	O	O
desorption	NN	O	O
/	NN	O	O
ionization	NN	O	O
time	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
flight	NN	O	O
MS	NN	O	O
,	NN	O	O
atmospheric	NN	O	O
pressure	NN	O	O
matrix	NN	O	O
-	NN	O	O
assisted	NN	O	O
laser	NN	O	O
desorption	NN	O	O
/	NN	O	O
ionization	NN	O	O
and	NN	O	O
HPLC	NN	O	O
coupled	NN	O	O
tandem	NN	O	O
MS	NN	O	O
(	NN	O	O
LC	NN	O	O
/	NN	O	O
MS	NN	O	O
/	NN	O	O
MS	NN	O	O
)	NN	O	O
.	NN	O	O

Out	NN	O	O
of	NN	O	O
these	NN	O	O
67	NN	O	O
proteins	NN	O	O
,	NN	O	O
LID	NN	O	B
significantly	NN	O	O
changed	NN	O	O
the	NN	O	O
expression	NN	O	O
level	NN	O	O
of	NN	O	O
five	NN	O	O
proteins	NN	O	O
:	NN	O	O
alphabeta	NN	O	O
-	NN	O	O
crystalin	NN	O	O
,	NN	O	O
gamma	NN	O	O
-	NN	O	O
enolase	NN	O	O
,	NN	O	O
guanidoacetate	NN	O	O
methyltransferase	NN	O	O
,	NN	O	O
vinculin	NN	O	O
,	NN	O	O
and	NN	O	O
proteasome	NN	O	O
alpha	NN	O	O
-	NN	O	O
2	NN	O	O
subunit	NN	O	O
.	NN	O	O

Complementary	NN	O	O
techniques	NN	O	O
such	NN	O	O
as	NN	O	O
western	NN	O	O
immunoblotting	NN	O	O
and	NN	O	O
immunohistochemistry	NN	O	O
were	NN	O	O
performed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
validity	NN	O	O
of	NN	O	O
the	NN	O	O
data	NN	O	O
obtained	NN	O	O
using	NN	O	O
the	NN	O	O
proteomic	NN	O	O
approach	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
this	NN	O	O
study	NN	O	O
provides	NN	O	O
new	NN	O	O
insights	NN	O	O
into	NN	O	O
the	NN	O	O
protein	NN	O	O
changes	NN	O	O
occurring	NN	O	O
in	NN	O	O
LID	NN	O	B
.	NN	O	O

Cardiac	NN	O	O
Angiography	NN	O	O
in	NN	O	O
Renally	NN	O	O
Impaired	NN	O	O
Patients	NN	O	O
(	NN	O	O
CARE	NN	O	O
)	NN	O	O
study	NN	O	O
:	NN	O	O
a	NN	O	O
randomized	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trial	NN	O	O
of	NN	O	O
contrast	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	B
kidney	NN	O	I
disease	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
No	NN	O	O
direct	NN	O	O
comparisons	NN	O	O
exist	NN	O	O
of	NN	O	O
the	NN	O	O
renal	NN	O	O
tolerability	NN	O	O
of	NN	O	O
the	NN	O	O
low	NN	O	O
-	NN	O	O
osmolality	NN	O	O
contrast	NN	O	O
medium	NN	O	O
iopamidol	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
iso	NN	O	O
-	NN	O	O
osmolality	NN	O	O
contrast	NN	O	O
medium	NN	O	O
iodixanol	NN	O	O
in	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
present	NN	O	O
study	NN	O	O
is	NN	O	O
a	NN	O	O
multicenter	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
comparison	NN	O	O
of	NN	O	O
iopamidol	NN	O	O
and	NN	O	O
iodixanol	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	B
kidney	NN	O	I
disease	NN	O	I
(	NN	O	O
estimated	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
,	NN	O	O
20	NN	O	O
to	NN	O	O
59	NN	O	O
mL	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
who	NN	O	O
underwent	NN	O	O
cardiac	NN	O	O
angiography	NN	O	O
or	NN	O	O
percutaneous	NN	O	O
coronary	NN	O	O
interventions	NN	O	O
.	NN	O	O

Serum	NN	O	O
creatinine	NN	O	O
(	NN	O	O
SCr	NN	O	O
)	NN	O	O
levels	NN	O	O
and	NN	O	O
estimated	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
were	NN	O	O
assessed	NN	O	O
at	NN	O	O
baseline	NN	O	O
and	NN	O	O
2	NN	O	O
to	NN	O	O
5	NN	O	O
days	NN	O	O
after	NN	O	O
receiving	NN	O	O
medications	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
was	NN	O	O
a	NN	O	O
postdose	NN	O	O
SCr	NN	O	O
increase	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
44	NN	O	O
.	NN	O	O
2	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
over	NN	O	O
baseline	NN	O	O
.	NN	O	O

Secondary	NN	O	O
outcomes	NN	O	O
were	NN	O	O
a	NN	O	O
postdose	NN	O	O
SCr	NN	O	O
increase	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
25	NN	O	O
%	NN	O	O
,	NN	O	O
a	NN	O	O
postdose	NN	O	O
estimated	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
decrease	NN	O	O
of	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
25	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
mean	NN	O	O
peak	NN	O	O
change	NN	O	O
in	NN	O	O
SCr	NN	O	O
.	NN	O	O

In	NN	O	O
414	NN	O	O
patients	NN	O	O
,	NN	O	O
contrast	NN	O	O
volume	NN	O	O
,	NN	O	O
presence	NN	O	O
of	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
,	NN	O	O
use	NN	O	O
of	NN	O	O
N	NN	O	O
-	NN	O	O
acetylcysteine	NN	O	O
,	NN	O	O
mean	NN	O	O
baseline	NN	O	O
SCr	NN	O	O
,	NN	O	O
and	NN	O	O
estimated	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
were	NN	O	O
comparable	NN	O	O
in	NN	O	O
the	NN	O	O
2	NN	O	O
groups	NN	O	O
.	NN	O	O

SCr	NN	O	O
increases	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
occurred	NN	O	O
in	NN	O	O
4	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
(	NN	O	O
9	NN	O	O
of	NN	O	O
204	NN	O	O
patients	NN	O	O
)	NN	O	O
after	NN	O	O
iopamidol	NN	O	O
and	NN	O	O
6	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
(	NN	O	O
14	NN	O	O
of	NN	O	O
210	NN	O	O
patients	NN	O	O
)	NN	O	O
after	NN	O	O
iodixanol	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
39	NN	O	O
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
rates	NN	O	O
of	NN	O	O
SCr	NN	O	O
increases	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
25	NN	O	O
%	NN	O	O
were	NN	O	O
9	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
and	NN	O	O
12	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
44	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
diabetes	NN	O	B
,	NN	O	O
SCr	NN	O	O
increases	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
were	NN	O	O
5	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
(	NN	O	O
4	NN	O	O
of	NN	O	O
78	NN	O	O
patients	NN	O	O
)	NN	O	O
with	NN	O	O
iopamidol	NN	O	O
and	NN	O	O
13	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
(	NN	O	O
12	NN	O	O
of	NN	O	O
92	NN	O	O
patients	NN	O	O
)	NN	O	O
with	NN	O	O
iodixanol	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
11	NN	O	O
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
SCr	NN	O	O
increases	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
25	NN	O	O
%	NN	O	O
were	NN	O	O
10	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
and	NN	O	O
15	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
37	NN	O	O
)	NN	O	O
.	NN	O	O

Mean	NN	O	O
post	NN	O	O
-	NN	O	O
SCr	NN	O	O
increases	NN	O	O
were	NN	O	O
significantly	NN	O	O
less	NN	O	O
with	NN	O	O
iopamidol	NN	O	O
(	NN	O	O
all	NN	O	O
patients	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
07	NN	O	O
versus	NN	O	O
0	NN	O	O
.	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
,	NN	O	O
6	NN	O	O
.	NN	O	O
2	NN	O	O
versus	NN	O	O
10	NN	O	O
.	NN	O	O
6	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
;	NN	O	O
patients	NN	O	O
with	NN	O	O
diabetes	NN	O	B
:	NN	O	O
0	NN	O	O
.	NN	O	O
07	NN	O	O
versus	NN	O	O
0	NN	O	O
.	NN	O	O
16	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
,	NN	O	O
6	NN	O	O
.	NN	O	O
2	NN	O	O
versus	NN	O	O
14	NN	O	O
.	NN	O	O
1	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
rate	NN	O	O
of	NN	O	O
contrast	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
defined	NN	O	O
by	NN	O	O
multiple	NN	O	O
end	NN	O	O
points	NN	O	O
,	NN	O	O
is	NN	O	O
not	NN	O	O
statistically	NN	O	O
different	NN	O	O
after	NN	O	O
the	NN	O	O
intraarterial	NN	O	O
administration	NN	O	O
of	NN	O	O
iopamidol	NN	O	O
or	NN	O	O
iodixanol	NN	O	O
to	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
,	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
.	NN	O	O

Any	NN	O	O
true	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
agents	NN	O	O
is	NN	O	O
small	NN	O	O
and	NN	O	O
not	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
clinically	NN	O	O
significant	NN	O	O
.	NN	O	O

A	NN	O	O
novel	NN	O	O
compound	NN	O	O
,	NN	O	O
maltolyl	NN	O	O
p	NN	O	O
-	NN	O	O
coumarate	NN	O	O
,	NN	O	O
attenuates	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
and	NN	O	O
shows	NN	O	O
neuroprotective	NN	O	O
effects	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
dementia	NN	O	B
models	NN	O	O
.	NN	O	O

To	NN	O	O
develop	NN	O	O
a	NN	O	O
novel	NN	O	O
and	NN	O	O
effective	NN	O	O
drug	NN	O	O
that	NN	O	O
could	NN	O	O
enhance	NN	O	O
cognitive	NN	O	O
function	NN	O	O
and	NN	O	O
neuroprotection	NN	O	O
,	NN	O	O
we	NN	O	O
newly	NN	O	O
synthesized	NN	O	O
maltolyl	NN	O	O
p	NN	O	O
-	NN	O	O
coumarate	NN	O	O
by	NN	O	O
the	NN	O	O
esterification	NN	O	O
of	NN	O	O
maltol	NN	O	O
and	NN	O	O
p	NN	O	O
-	NN	O	O
coumaric	NN	O	O
acid	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
whether	NN	O	O
maltolyl	NN	O	O
p	NN	O	O
-	NN	O	O
coumarate	NN	O	O
could	NN	O	O
improve	NN	O	O
cognitive	NN	O	B
decline	NN	O	I
in	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
injected	NN	O	O
rats	NN	O	O
and	NN	O	O
in	NN	O	O
amyloid	NN	O	O
beta	NN	O	O
peptide	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
42	NN	O	O
)	NN	O	O
-	NN	O	O
infused	NN	O	O
rats	NN	O	O
.	NN	O	O

Maltolyl	NN	O	O
p	NN	O	O
-	NN	O	O
coumarate	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
attenuate	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
in	NN	O	O
both	NN	O	O
rat	NN	O	O
models	NN	O	O
using	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
test	NN	O	O
and	NN	O	O
to	NN	O	O
reduce	NN	O	O
apoptotic	NN	O	O
cell	NN	O	O
death	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
of	NN	O	O
the	NN	O	O
amyloid	NN	O	O
beta	NN	O	O
peptide	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
42	NN	O	O
)	NN	O	O
-	NN	O	O
infused	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
examined	NN	O	O
the	NN	O	O
neuroprotective	NN	O	O
effects	NN	O	O
of	NN	O	O
maltolyl	NN	O	O
p	NN	O	O
-	NN	O	O
coumarate	NN	O	O
in	NN	O	O
vitro	NN	O	O
using	NN	O	O
SH	NN	O	O
-	NN	O	O
SY5Y	NN	O	O
cells	NN	O	O
.	NN	O	O

Cells	NN	O	O
were	NN	O	O
pretreated	NN	O	O
with	NN	O	O
maltolyl	NN	O	O
p	NN	O	O
-	NN	O	O
coumarate	NN	O	O
,	NN	O	O
before	NN	O	O
exposed	NN	O	O
to	NN	O	O
amyloid	NN	O	O
beta	NN	O	O
peptide	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
42	NN	O	O
)	NN	O	O
,	NN	O	O
glutamate	NN	O	O
or	NN	O	O
H2O2	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
maltolyl	NN	O	O
p	NN	O	O
-	NN	O	O
coumarate	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
apoptotic	NN	O	O
cell	NN	O	O
death	NN	O	O
and	NN	O	O
reduced	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
,	NN	O	O
cytochrome	NN	O	O
c	NN	O	O
release	NN	O	O
,	NN	O	O
and	NN	O	O
caspase	NN	O	O
3	NN	O	O
activation	NN	O	O
.	NN	O	O

Taking	NN	O	O
these	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
results	NN	O	O
together	NN	O	O
,	NN	O	O
our	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
maltolyl	NN	O	O
p	NN	O	O
-	NN	O	O
coumarate	NN	O	O
is	NN	O	O
a	NN	O	O
potentially	NN	O	O
effective	NN	O	O
candidate	NN	O	O
against	NN	O	O
Alzheimer	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
that	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
wide	NN	O	O
spread	NN	O	O
neuronal	NN	O	B
death	NN	O	I
and	NN	O	O
progressive	NN	O	O
decline	NN	O	B
of	NN	O	I
cognitive	NN	O	I
function	NN	O	I
.	NN	O	O

Attenuation	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
nigrostriatal	NN	O	O
dopaminergic	NN	O	O
neurotoxicity	NN	O	B
in	NN	O	O
mice	NN	O	O
by	NN	O	O
lipopolysaccharide	NN	O	O
pretreatment	NN	O	O
.	NN	O	O

Immunological	NN	O	O
activation	NN	O	O
has	NN	O	O
been	NN	O	O
proposed	NN	O	O
to	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
dopaminergic	NN	O	B
terminal	NN	O	I
damage	NN	O	I
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
examined	NN	O	O
the	NN	O	O
roles	NN	O	O
of	NN	O	O
lipopolysaccharide	NN	O	O
,	NN	O	O
a	NN	O	O
pro	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
and	NN	O	O
inflammatory	NN	O	O
factor	NN	O	O
,	NN	O	O
treatment	NN	O	O
in	NN	O	O
modulating	NN	O	O
the	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
nigrostriatal	NN	O	O
dopamine	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

Lipopolysaccharide	NN	O	O
pretreatment	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
basal	NN	O	O
body	NN	O	O
temperature	NN	O	O
or	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
elicited	NN	O	O
hyperthermia	NN	O	B
three	NN	O	O
days	NN	O	O
later	NN	O	O
.	NN	O	O

Such	NN	O	O
systemic	NN	O	O
lipopolysaccharide	NN	O	O
treatment	NN	O	O
mitigated	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
striatal	NN	O	O
dopamine	NN	O	O
and	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dihydroxyphenylacetic	NN	O	O
acid	NN	O	O
depletions	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

As	NN	O	O
the	NN	O	O
most	NN	O	O
potent	NN	O	O
dose	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
of	NN	O	O
lipopolysaccharide	NN	O	O
was	NN	O	O
administered	NN	O	O
two	NN	O	O
weeks	NN	O	O
,	NN	O	O
one	NN	O	O
day	NN	O	O
before	NN	O	O
or	NN	O	O
after	NN	O	O
the	NN	O	O
methamphetamine	NN	O	O
dosing	NN	O	O
regimen	NN	O	O
,	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
striatal	NN	O	O
dopamine	NN	O	O
and	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dihydroxyphenylacetic	NN	O	O
acid	NN	O	O
depletions	NN	O	O
remained	NN	O	O
unaltered	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
systemic	NN	O	O
lipopolysaccharide	NN	O	O
pretreatment	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
attenuated	NN	O	O
local	NN	O	O
methamphetamine	NN	O	O
infusion	NN	O	O
-	NN	O	O
produced	NN	O	O
dopamine	NN	O	O
and	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dihydroxyphenylacetic	NN	O	O
acid	NN	O	O
depletions	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
lipopolysaccharide	NN	O	O
is	NN	O	O
less	NN	O	O
likely	NN	O	O
due	NN	O	O
to	NN	O	O
interrupted	NN	O	O
peripheral	NN	O	O
distribution	NN	O	O
or	NN	O	O
metabolism	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
.	NN	O	O

We	NN	O	O
concluded	NN	O	O
a	NN	O	O
critical	NN	O	O
time	NN	O	O
window	NN	O	O
for	NN	O	O
systemic	NN	O	O
lipopolysaccharide	NN	O	O
pretreatment	NN	O	O
in	NN	O	O
exerting	NN	O	O
effective	NN	O	O
protection	NN	O	O
against	NN	O	O
methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
nigrostriatal	NN	O	O
dopamine	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

Acute	NN	O	O
myocarditis	NN	O	B
associated	NN	O	O
with	NN	O	O
clozapine	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
A	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
myocarditis	NN	O	B
associated	NN	O	O
with	NN	O	O
the	NN	O	O
commencement	NN	O	O
of	NN	O	O
clozapine	NN	O	O
is	NN	O	O
described	NN	O	O
,	NN	O	O
highlighting	NN	O	O
the	NN	O	O
onset	NN	O	O
,	NN	O	O
course	NN	O	O
and	NN	O	O
possible	NN	O	O
contributing	NN	O	O
factors	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
an	NN	O	O
urgent	NN	O	O
need	NN	O	O
to	NN	O	O
raise	NN	O	O
awareness	NN	O	O
about	NN	O	O
this	NN	O	O
potentially	NN	O	O
fatal	NN	O	O
complication	NN	O	O
of	NN	O	O
clozapine	NN	O	O
use	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
20	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
with	NN	O	O
schizophrenia	NN	O	B
developed	NN	O	O
a	NN	O	O
sudden	NN	O	O
onset	NN	O	O
of	NN	O	O
myocarditis	NN	O	B
after	NN	O	O
commencement	NN	O	O
of	NN	O	O
clozapine	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
recovered	NN	O	O
with	NN	O	O
intensive	NN	O	O
medical	NN	O	O
support	NN	O	O
.	NN	O	O

The	NN	O	O
symptoms	NN	O	O
occurred	NN	O	O
around	NN	O	O
2	NN	O	O
weeks	NN	O	O
after	NN	O	O
starting	NN	O	O
clozapine	NN	O	O
in	NN	O	O
an	NN	O	O
inpatient	NN	O	O
setting	NN	O	O
.	NN	O	O

Possible	NN	O	O
contributing	NN	O	O
factors	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
concomitant	NN	O	O
antidepressant	NN	O	O
use	NN	O	O
and	NN	O	O
unaccustomed	NN	O	O
physical	NN	O	O
activity	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Myocarditis	NN	O	B
is	NN	O	O
an	NN	O	O
increasingly	NN	O	O
recognized	NN	O	O
complication	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
clozapine	NN	O	O
.	NN	O	O

It	NN	O	O
can	NN	O	O
be	NN	O	O
fatal	NN	O	O
if	NN	O	O
not	NN	O	O
recognized	NN	O	O
and	NN	O	O
treated	NN	O	O
early	NN	O	O
.	NN	O	O

Considering	NN	O	O
that	NN	O	O
clozapine	NN	O	O
remains	NN	O	O
the	NN	O	O
gold	NN	O	O
standard	NN	O	O
in	NN	O	O
treatment	NN	O	O
of	NN	O	O
resistant	NN	O	O
psychosis	NN	O	B
,	NN	O	O
there	NN	O	O
is	NN	O	O
an	NN	O	O
urgent	NN	O	O
need	NN	O	O
to	NN	O	O
raise	NN	O	O
awareness	NN	O	O
among	NN	O	O
medical	NN	O	O
and	NN	O	O
paramedical	NN	O	O
staff	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
care	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

There	NN	O	O
are	NN	O	O
also	NN	O	O
implications	NN	O	O
for	NN	O	O
recommendations	NN	O	O
and	NN	O	O
regulations	NN	O	O
regarding	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
clozapine	NN	O	O
.	NN	O	O

Severe	NN	O	O
rhabdomyolysis	NN	O	B
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
secondary	NN	O	O
to	NN	O	O
concomitant	NN	O	O
use	NN	O	O
of	NN	O	O
simvastatin	NN	O	O
,	NN	O	O
amiodarone	NN	O	O
,	NN	O	O
and	NN	O	O
atazanavir	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
severe	NN	O	O
interaction	NN	O	O
between	NN	O	O
simvastatin	NN	O	O
,	NN	O	O
amiodarone	NN	O	O
,	NN	O	O
and	NN	O	O
atazanavir	NN	O	O
resulting	NN	O	O
in	NN	O	O
rhabdomyolysis	NN	O	B
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
A	NN	O	O
72	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
white	NN	O	O
man	NN	O	O
with	NN	O	O
underlying	NN	O	O
human	NN	O	B
immunodeficiency	NN	O	I
virus	NN	O	I
,	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
,	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
,	NN	O	O
and	NN	O	O
hyperlipidemia	NN	O	B
presented	NN	O	O
with	NN	O	O
generalized	NN	O	O
pain	NN	O	B
,	NN	O	O
fatigue	NN	O	B
,	NN	O	O
and	NN	O	O
dark	NN	O	O
orange	NN	O	O
urine	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
taking	NN	O	O
80	NN	O	O
mg	NN	O	O
simvastatin	NN	O	O
at	NN	O	O
bedtime	NN	O	O
(	NN	O	O
initiated	NN	O	O
27	NN	O	O
days	NN	O	O
earlier	NN	O	O
)	NN	O	O
;	NN	O	O
amiodarone	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
400	NN	O	O
mg	NN	O	O
daily	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
,	NN	O	O
then	NN	O	O
200	NN	O	O
mg	NN	O	O
daily	NN	O	O
(	NN	O	O
initiated	NN	O	O
19	NN	O	O
days	NN	O	O
earlier	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
400	NN	O	O
mg	NN	O	O
atazanavir	NN	O	O
daily	NN	O	O
(	NN	O	O
initiated	NN	O	O
at	NN	O	O
least	NN	O	O
2	NN	O	O
years	NN	O	O
previously	NN	O	O
)	NN	O	O
.	NN	O	O

Laboratory	NN	O	O
evaluation	NN	O	O
revealed	NN	O	O
66	NN	O	O
,	NN	O	O
680	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
creatine	NN	O	O
kinase	NN	O	O
,	NN	O	O
93	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
blood	NN	O	O
urea	NN	O	O
nitrogen	NN	O	O
,	NN	O	O
4	NN	O	O
.	NN	O	O
6	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
creatinine	NN	O	O
,	NN	O	O
1579	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
aspartate	NN	O	O
aminotransferase	NN	O	O
,	NN	O	O
and	NN	O	O
738	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
alanine	NN	O	O
aminotransferase	NN	O	O
.	NN	O	O

Simvastatin	NN	O	O
,	NN	O	O
amiodarone	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
human	NN	O	B
immunodeficiency	NN	O	I
virus	NN	O	I
medications	NN	O	O
were	NN	O	O
all	NN	O	O
temporarily	NN	O	O
discontinued	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
given	NN	O	O
forced	NN	O	O
alkaline	NN	O	O
diuresis	NN	O	O
and	NN	O	O
started	NN	O	O
on	NN	O	O
dialysis	NN	O	O
.	NN	O	O

Nine	NN	O	O
days	NN	O	O
later	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
creatine	NN	O	O
kinase	NN	O	O
had	NN	O	O
dropped	NN	O	O
to	NN	O	O
1695	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
and	NN	O	O
creatinine	NN	O	O
was	NN	O	O
3	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
discharged	NN	O	O
and	NN	O	O
continued	NN	O	O
outpatient	NN	O	O
dialysis	NN	O	O
for	NN	O	O
1	NN	O	O
month	NN	O	O
until	NN	O	O
his	NN	O	O
renal	NN	O	O
function	NN	O	O
recovered	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
The	NN	O	O
risk	NN	O	O
of	NN	O	O
rhabdomyolysis	NN	O	B
is	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
concomitant	NN	O	O
drugs	NN	O	O
that	NN	O	O
inhibit	NN	O	O
simvastatin	NN	O	O
metabolism	NN	O	O
.	NN	O	O

Simvastatin	NN	O	O
is	NN	O	O
metabolized	NN	O	O
by	NN	O	O
CYP3A4	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
and	NN	O	O
atazanavir	NN	O	O
are	NN	O	O
recognized	NN	O	O
CYP3A4	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Pharmacokinetic	NN	O	O
differences	NN	O	O
in	NN	O	O
statins	NN	O	O
are	NN	O	O
an	NN	O	O
important	NN	O	O
consideration	NN	O	O
for	NN	O	O
assessing	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
potential	NN	O	O
drug	NN	O	O
interactions	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
requiring	NN	O	O
the	NN	O	O
concurrent	NN	O	O
use	NN	O	O
of	NN	O	O
statins	NN	O	O
and	NN	O	O
CYP3A4	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
pravastatin	NN	O	O
,	NN	O	O
fluvastatin	NN	O	O
,	NN	O	O
and	NN	O	O
rosuvastatin	NN	O	O
carry	NN	O	O
the	NN	O	O
lowest	NN	O	O
risk	NN	O	O
of	NN	O	O
drug	NN	O	O
interactions	NN	O	O
;	NN	O	O
atorvastatin	NN	O	O
carries	NN	O	O
moderate	NN	O	O
risk	NN	O	O
,	NN	O	O
whereas	NN	O	O
simvastatin	NN	O	O
and	NN	O	O
lovastatin	NN	O	O
have	NN	O	O
the	NN	O	O
highest	NN	O	O
risk	NN	O	O
and	NN	O	O
should	NN	O	O
be	NN	O	O
avoided	NN	O	O
in	NN	O	O
patients	NN	O	O
taking	NN	O	O
concomitant	NN	O	O
CYP3A4	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

Interaction	NN	O	O
between	NN	O	O
warfarin	NN	O	O
and	NN	O	O
levofloxacin	NN	O	O
:	NN	O	O
case	NN	O	O
series	NN	O	O
.	NN	O	O

Warfarin	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
widely	NN	O	O
used	NN	O	O
oral	NN	O	O
anticoagulant	NN	O	O
and	NN	O	O
is	NN	O	O
indicated	NN	O	O
for	NN	O	O
many	NN	O	O
clinical	NN	O	O
conditions	NN	O	O
.	NN	O	O

Levofloxacin	NN	O	O
,	NN	O	O
a	NN	O	O
fluoroquinolone	NN	O	O
,	NN	O	O
is	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
commonly	NN	O	O
prescribed	NN	O	O
antibiotics	NN	O	O
in	NN	O	O
clinical	NN	O	O
practice	NN	O	O
and	NN	O	O
is	NN	O	O
effective	NN	O	O
against	NN	O	O
Gram	NN	O	O
-	NN	O	O
positive	NN	O	O
,	NN	O	O
Gram	NN	O	O
-	NN	O	O
negative	NN	O	O
,	NN	O	O
and	NN	O	O
atypical	NN	O	O
bacteria	NN	O	O
.	NN	O	O

While	NN	O	O
small	NN	O	O
prospective	NN	O	O
studies	NN	O	O
have	NN	O	O
not	NN	O	O
revealed	NN	O	O
any	NN	O	O
significant	NN	O	O
drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interaction	NN	O	O
between	NN	O	O
warfarin	NN	O	O
and	NN	O	O
levofloxacin	NN	O	O
,	NN	O	O
several	NN	O	O
case	NN	O	O
reports	NN	O	O
have	NN	O	O
indicated	NN	O	O
that	NN	O	O
levofloxacin	NN	O	O
may	NN	O	O
significantly	NN	O	O
potentiate	NN	O	O
the	NN	O	O
anticoagulation	NN	O	O
effect	NN	O	O
of	NN	O	O
warfarin	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
3	NN	O	O
cases	NN	O	O
of	NN	O	O
serious	NN	O	O
bleeding	NN	O	B
complications	NN	O	O
that	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
the	NN	O	O
interaction	NN	O	O
between	NN	O	O
warfarin	NN	O	O
and	NN	O	O
levofloxacin	NN	O	O
.	NN	O	O

Physicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
potential	NN	O	O
interaction	NN	O	O
and	NN	O	O
use	NN	O	O
caution	NN	O	O
when	NN	O	O
prescribing	NN	O	O
levofloxacin	NN	O	O
to	NN	O	O
patients	NN	O	O
taking	NN	O	O
warfarin	NN	O	O
.	NN	O	O

Mutations	NN	O	O
associated	NN	O	O
with	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
resistance	NN	O	O
in	NN	O	O
therapy	NN	O	O
-	NN	O	O
na	NN	O	O
ve	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	I
(	NN	O	I
HBV	NN	O	I
)	NN	O	I
infected	NN	O	I
patients	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
HIV	NN	O	B
co	NN	O	I
-	NN	O	I
infection	NN	O	I
:	NN	O	O
implications	NN	O	O
for	NN	O	O
antiretroviral	NN	O	O
therapy	NN	O	O
in	NN	O	O
HBV	NN	O	B
and	NN	O	I
HIV	NN	O	I
co	NN	O	I
-	NN	O	I
infected	NN	O	I
South	NN	O	O
African	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
an	NN	O	O
exploratory	NN	O	O
study	NN	O	O
to	NN	O	O
investigate	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
resistant	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
(	NN	O	O
HBV	NN	O	O
)	NN	O	O
strains	NN	O	O
in	NN	O	O
selected	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
na	NN	O	O
ve	NN	O	O
HBV	NN	O	O
carriers	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
human	NN	O	B
immunodeficiency	NN	O	I
virus	NN	O	I
(	NN	O	I
HIV	NN	O	I
)	NN	O	I
co	NN	O	I
-	NN	O	I
infection	NN	O	I
in	NN	O	O
South	NN	O	O
African	NN	O	O
patients	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
five	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
na	NN	O	O
ve	NN	O	O
HBV	NN	O	B
infected	NN	O	I
patients	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
HIV	NN	O	B
co	NN	O	I
-	NN	O	I
infection	NN	O	I
were	NN	O	O
studied	NN	O	O
:	NN	O	O
15	NN	O	O
chronic	NN	O	O
HBV	NN	O	B
mono	NN	O	I
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
and	NN	O	O
20	NN	O	O
HBV	NN	O	B
-	NN	O	I
HIV	NN	O	I
co	NN	O	I
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
.	NN	O	O

The	NN	O	O
latter	NN	O	O
group	NN	O	O
was	NN	O	O
further	NN	O	O
sub	NN	O	O
-	NN	O	O
divided	NN	O	O
into	NN	O	O
13	NN	O	O
occult	NN	O	O
HBV	NN	O	O
(	NN	O	O
HBsAg	NN	O	O
-	NN	O	O
negative	NN	O	O
)	NN	O	O
and	NN	O	O
7	NN	O	O
overt	NN	O	O
HBV	NN	O	O
(	NN	O	O
HBsAg	NN	O	O
-	NN	O	O
positive	NN	O	O
)	NN	O	O
patients	NN	O	O
.	NN	O	O

HBsAg	NN	O	O
,	NN	O	O
anti	NN	O	O
-	NN	O	O
HBs	NN	O	O
,	NN	O	O
anti	NN	O	O
-	NN	O	O
HBc	NN	O	O
,	NN	O	O
and	NN	O	O
anti	NN	O	O
-	NN	O	O
HIV	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
were	NN	O	O
determined	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
routine	NN	O	O
diagnosis	NN	O	O
using	NN	O	O
Axsym	NN	O	O
assays	NN	O	O
(	NN	O	O
Abbott	NN	O	O
Laboratories	NN	O	O
,	NN	O	O
North	NN	O	O
Chicago	NN	O	O
,	NN	O	O
IL	NN	O	O
)	NN	O	O
.	NN	O	O

Serum	NN	O	O
samples	NN	O	O
were	NN	O	O
PCR	NN	O	O
amplified	NN	O	O
with	NN	O	O
HBV	NN	O	O
reverse	NN	O	O
transcriptase	NN	O	O
(	NN	O	O
RT	NN	O	O
)	NN	O	O
primers	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
direct	NN	O	O
sequencing	NN	O	O
across	NN	O	O
the	NN	O	O
tyrosine	NN	O	O
-	NN	O	O
methionine	NN	O	O
-	NN	O	O
aspartate	NN	O	O
-	NN	O	O
aspartate	NN	O	O
(	NN	O	O
YMDD	NN	O	O
)	NN	O	O
motif	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	O
catalytic	NN	O	O
region	NN	O	O
in	NN	O	O
the	NN	O	O
C	NN	O	O
domain	NN	O	O
of	NN	O	O
the	NN	O	O
HBV	NN	O	O
RT	NN	O	O
enzyme	NN	O	O
.	NN	O	O

HBV	NN	O	O
viral	NN	O	O
load	NN	O	O
was	NN	O	O
performed	NN	O	O
with	NN	O	O
Amplicor	NN	O	O
HBV	NN	O	O
Monitor	NN	O	O
test	NN	O	O
v2	NN	O	O
.	NN	O	O
0	NN	O	O
(	NN	O	O
Roche	NN	O	O
Diagnostics	NN	O	O
,	NN	O	O
Penzberg	NN	O	O
,	NN	O	O
Germany	NN	O	O
)	NN	O	O
.	NN	O	O

HBV	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
resistant	NN	O	O
strains	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
3	NN	O	O
of	NN	O	O
15	NN	O	O
mono	NN	O	O
-	NN	O	O
infected	NN	O	O
chronic	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
patients	NN	O	O
and	NN	O	O
10	NN	O	O
of	NN	O	O
20	NN	O	O
HBV	NN	O	B
-	NN	O	I
HIV	NN	O	I
co	NN	O	I
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
.	NN	O	O

To	NN	O	O
the	NN	O	O
best	NN	O	O
of	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
constitutes	NN	O	O
the	NN	O	O
first	NN	O	O
report	NN	O	O
of	NN	O	O
HBV	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
resistant	NN	O	O
strains	NN	O	O
in	NN	O	O
therapy	NN	O	O
-	NN	O	O
na	NN	O	O
ve	NN	O	O
HBV	NN	O	B
-	NN	O	I
HIV	NN	O	I
co	NN	O	I
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
.	NN	O	O

The	NN	O	O
HBV	NN	O	O
viral	NN	O	O
loads	NN	O	O
for	NN	O	O
mono	NN	O	O
-	NN	O	O
infected	NN	O	O
and	NN	O	O
co	NN	O	O
-	NN	O	O
infected	NN	O	O
patients	NN	O	O
ranged	NN	O	O
from	NN	O	O
3	NN	O	O
.	NN	O	O
32	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
82	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
7	NN	O	O
)	NN	O	O
and	NN	O	O
<	NN	O	O
200	NN	O	O
to	NN	O	O
4	NN	O	O
.	NN	O	O
40	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
copies	NN	O	O
/	NN	O	O
ml	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

It	NN	O	O
remains	NN	O	O
to	NN	O	O
be	NN	O	O
seen	NN	O	O
whether	NN	O	O
such	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
antiviral	NN	O	O
mutations	NN	O	O
could	NN	O	O
result	NN	O	O
in	NN	O	O
widespread	NN	O	O
emergence	NN	O	O
of	NN	O	O
HBV	NN	O	O
resistant	NN	O	O
strains	NN	O	O
when	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
containing	NN	O	O
highly	NN	O	O
active	NN	O	O
antiretroviral	NN	O	O
(	NN	O	O
ARV	NN	O	O
)	NN	O	O
treatment	NN	O	O
(	NN	O	O
HAART	NN	O	O
)	NN	O	O
regimens	NN	O	O
become	NN	O	O
widely	NN	O	O
applied	NN	O	O
in	NN	O	O
South	NN	O	O
Africa	NN	O	O
,	NN	O	O
as	NN	O	O
this	NN	O	O
is	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
potential	NN	O	O
implications	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
HBV	NN	O	B
-	NN	O	I
HIV	NN	O	I
co	NN	O	I
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
.	NN	O	O

Rabbit	NN	O	B
syndrome	NN	O	I
,	NN	O	O
antidepressant	NN	O	O
use	NN	O	O
,	NN	O	O
and	NN	O	O
cerebral	NN	O	O
perfusion	NN	O	O
SPECT	NN	O	O
scan	NN	O	O
findings	NN	O	O
.	NN	O	O

The	NN	O	O
rabbit	NN	O	B
syndrome	NN	O	I
is	NN	O	O
an	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effect	NN	O	O
associated	NN	O	O
with	NN	O	O
chronic	NN	O	O
neuroleptic	NN	O	O
therapy	NN	O	O
.	NN	O	O

Its	NN	O	O
occurrence	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
imipramine	NN	O	O
is	NN	O	O
described	NN	O	O
,	NN	O	O
representing	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
antidepressants	NN	O	O
.	NN	O	O

Repeated	NN	O	O
cerebral	NN	O	O
perfusion	NN	O	O
SPECT	NN	O	O
scans	NN	O	O
revealed	NN	O	O
decreased	NN	O	B
basal	NN	O	I
ganglia	NN	O	I
perfusion	NN	O	I
while	NN	O	O
the	NN	O	O
movement	NN	O	B
disorder	NN	O	I
was	NN	O	O
present	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
return	NN	O	O
to	NN	O	O
normal	NN	O	O
perfusion	NN	O	O
when	NN	O	O
the	NN	O	O
rabbit	NN	O	B
syndrome	NN	O	I
resolved	NN	O	O
.	NN	O	O

Estrogen	NN	O	O
prevents	NN	O	O
cholesteryl	NN	O	O
ester	NN	O	O
accumulation	NN	O	O
in	NN	O	O
macrophages	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
HIV	NN	O	O
protease	NN	O	O
inhibitor	NN	O	O
ritonavir	NN	O	O
.	NN	O	O

Individuals	NN	O	O
with	NN	O	O
HIV	NN	O	O
can	NN	O	O
now	NN	O	O
live	NN	O	O
long	NN	O	O
lives	NN	O	O
with	NN	O	O
drug	NN	O	O
therapy	NN	O	O
that	NN	O	O
often	NN	O	O
includes	NN	O	O
protease	NN	O	O
inhibitors	NN	O	O
such	NN	O	O
as	NN	O	O
ritonavir	NN	O	O
.	NN	O	O

Many	NN	O	O
patients	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
develop	NN	O	O
negative	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
side	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
premature	NN	O	B
atherosclerosis	NN	O	I
.	NN	O	O

We	NN	O	O
have	NN	O	O
previously	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
ritonavir	NN	O	O
treatment	NN	O	O
increases	NN	O	O
atherosclerotic	NN	O	B
lesion	NN	O	I
formation	NN	O	O
in	NN	O	O
male	NN	O	O
mice	NN	O	O
to	NN	O	O
a	NN	O	O
greater	NN	O	O
extent	NN	O	O
than	NN	O	O
in	NN	O	O
female	NN	O	O
mice	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
monocytes	NN	O	O
isolated	NN	O	O
from	NN	O	O
ritonavir	NN	O	O
-	NN	O	O
treated	NN	O	O
females	NN	O	O
had	NN	O	O
less	NN	O	O
cholesteryl	NN	O	O
ester	NN	O	O
accumulation	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
investigated	NN	O	O
the	NN	O	O
molecular	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
female	NN	O	O
hormones	NN	O	O
influence	NN	O	O
cholesterol	NN	O	O
metabolism	NN	O	O
in	NN	O	O
macrophages	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
HIV	NN	O	O
protease	NN	O	O
inhibitor	NN	O	O
ritonavir	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
utilized	NN	O	O
the	NN	O	O
human	NN	O	O
monocyte	NN	O	O
cell	NN	O	O
line	NN	O	O
,	NN	O	O
THP	NN	O	O
-	NN	O	O
1	NN	O	O
as	NN	O	O
a	NN	O	O
model	NN	O	O
to	NN	O	O
address	NN	O	O
this	NN	O	O
question	NN	O	O
.	NN	O	O

Briefly	NN	O	O
,	NN	O	O
cells	NN	O	O
were	NN	O	O
differentiated	NN	O	O
for	NN	O	O
72	NN	O	O
h	NN	O	O
with	NN	O	O
100	NN	O	O
nM	NN	O	O
PMA	NN	O	O
to	NN	O	O
obtain	NN	O	O
a	NN	O	O
macrophage	NN	O	O
-	NN	O	O
like	NN	O	O
phenotype	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
1	NN	O	O
nM	NN	O	O
17beta	NN	O	O
-	NN	O	O
estradiol	NN	O	O
(	NN	O	O
E2	NN	O	O
)	NN	O	O
,	NN	O	O
100	NN	O	O
nM	NN	O	O
progesterone	NN	O	O
or	NN	O	O
vehicle	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
%	NN	O	O
ethanol	NN	O	O
)	NN	O	O
.	NN	O	O

Cells	NN	O	O
were	NN	O	O
then	NN	O	O
treated	NN	O	O
with	NN	O	O
30	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
ritonavir	NN	O	O
or	NN	O	O
vehicle	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
aggregated	NN	O	O
LDL	NN	O	O
for	NN	O	O
24	NN	O	O
h	NN	O	O
.	NN	O	O

Cell	NN	O	O
extracts	NN	O	O
were	NN	O	O
harvested	NN	O	O
,	NN	O	O
and	NN	O	O
lipid	NN	O	O
or	NN	O	O
total	NN	O	O
RNA	NN	O	O
was	NN	O	O
isolated	NN	O	O
.	NN	O	O

E2	NN	O	O
decreased	NN	O	O
the	NN	O	O
accumulation	NN	O	O
of	NN	O	O
cholesteryl	NN	O	O
esters	NN	O	O
in	NN	O	O
macrophages	NN	O	O
following	NN	O	O
ritonavir	NN	O	O
treatment	NN	O	O
.	NN	O	O

Ritonavir	NN	O	O
increased	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
scavenger	NN	O	O
receptor	NN	O	O
,	NN	O	O
CD36	NN	O	O
mRNA	NN	O	O
,	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
uptake	NN	O	O
of	NN	O	O
LDL	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
ritonavir	NN	O	O
treatment	NN	O	O
selectively	NN	O	O
increased	NN	O	O
the	NN	O	O
relative	NN	O	O
levels	NN	O	O
of	NN	O	O
PPARgamma	NN	O	O
mRNA	NN	O	O
,	NN	O	O
a	NN	O	O
transcription	NN	O	O
factor	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
CD36	NN	O	O
mRNA	NN	O	O
expression	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
E2	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
failed	NN	O	O
to	NN	O	O
prevent	NN	O	O
these	NN	O	O
increases	NN	O	O
at	NN	O	O
the	NN	O	O
mRNA	NN	O	O
level	NN	O	O
.	NN	O	O

E2	NN	O	O
did	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
significantly	NN	O	O
suppress	NN	O	O
CD36	NN	O	O
protein	NN	O	O
levels	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
fluorescent	NN	O	O
immunocytochemistry	NN	O	O
.	NN	O	O

This	NN	O	O
data	NN	O	O
suggests	NN	O	O
that	NN	O	O
E2	NN	O	O
modifies	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
CD36	NN	O	O
at	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
protein	NN	O	O
expression	NN	O	O
in	NN	O	O
monocyte	NN	O	O
-	NN	O	O
derived	NN	O	O
macrophages	NN	O	O
resulting	NN	O	O
in	NN	O	O
reduced	NN	O	O
cholesteryl	NN	O	O
ester	NN	O	O
accumulation	NN	O	O
following	NN	O	O
ritonavir	NN	O	O
treatment	NN	O	O
.	NN	O	O

Acute	NN	O	O
hepatitis	NN	O	B
attack	NN	O	O
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
telithromycin	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Antibiotic	NN	O	O
-	NN	O	O
associated	NN	O	O
hepatotoxicity	NN	O	B
is	NN	O	O
rare	NN	O	O
.	NN	O	O

With	NN	O	O
widespread	NN	O	O
use	NN	O	O
of	NN	O	O
antimicrobial	NN	O	O
agents	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
occurs	NN	O	O
frequently	NN	O	O
,	NN	O	O
and	NN	O	O
among	NN	O	O
adverse	NN	O	B
drug	NN	O	I
reactions	NN	O	I
,	NN	O	O
idiosyncratic	NN	O	O
reactions	NN	O	O
are	NN	O	O
the	NN	O	O
most	NN	O	O
serious	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
25	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
patient	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
height	NN	O	O
of	NN	O	O
175	NN	O	O
cm	NN	O	O
and	NN	O	O
weight	NN	O	O
of	NN	O	O
72	NN	O	O
kg	NN	O	O
presented	NN	O	O
to	NN	O	O
Marmara	NN	O	O
University	NN	O	O
Hospital	NN	O	O
Emergency	NN	O	O
Department	NN	O	O
,	NN	O	O
Istanbul	NN	O	O
,	NN	O	O
Turkey	NN	O	O
,	NN	O	O
with	NN	O	O
5	NN	O	O
days	NN	O	O
'	NN	O	O
history	NN	O	O
of	NN	O	O
jaundice	NN	O	B
,	NN	O	O
malaise	NN	O	O
,	NN	O	O
nausea	NN	O	B
,	NN	O	O
and	NN	O	O
vomiting	NN	O	B
.	NN	O	O

He	NN	O	O
had	NN	O	O
been	NN	O	O
prescribed	NN	O	O
telithromycin	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
PO	NN	O	O
to	NN	O	O
treat	NN	O	O
an	NN	O	O
upper	NN	O	B
respiratory	NN	O	I
tract	NN	O	I
infection	NN	O	I
7	NN	O	O
days	NN	O	O
prior	NN	O	O
.	NN	O	O

Admission	NN	O	O
laboratory	NN	O	O
tests	NN	O	O
were	NN	O	O
as	NN	O	O
follows	NN	O	O
:	NN	O	O
alanine	NN	O	O
aminotransferase	NN	O	O
,	NN	O	O
67	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
reference	NN	O	O
range	NN	O	O
,	NN	O	O
10	NN	O	O
-	NN	O	O
37	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
;	NN	O	O
aspartate	NN	O	O
aminotransferase	NN	O	O
,	NN	O	O
98	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
40	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
;	NN	O	O
alkaline	NN	O	O
phosphatase	NN	O	O
,	NN	O	O
513	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
270	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
;	NN	O	O
gamma	NN	O	O
-	NN	O	O
glutamyltransferase	NN	O	O
,	NN	O	O
32	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
7	NN	O	O
-	NN	O	O
49	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
;	NN	O	O
amylase	NN	O	O
,	NN	O	O
46	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
220	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
;	NN	O	O
total	NN	O	O
bilirubin	NN	O	O
,	NN	O	O
20	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
;	NN	O	O
direct	NN	O	O
bilirubin	NN	O	O
,	NN	O	O
14	NN	O	O
.	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
albumin	NN	O	O
,	NN	O	O
4	NN	O	O
.	NN	O	O
7	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
toxin	NN	O	O
,	NN	O	O
alcohol	NN	O	O
,	NN	O	O
or	NN	O	O
other	NN	O	O
drugs	NN	O	O
were	NN	O	O
reported	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
suffered	NN	O	O
a	NN	O	O
previous	NN	O	O
episode	NN	O	O
of	NN	O	O
"	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
of	NN	O	O
unknown	NN	O	O
origin	NN	O	O
,	NN	O	O
"	NN	O	O
that	NN	O	O
occurred	NN	O	O
after	NN	O	O
telithromycin	NN	O	O
usage	NN	O	O
.	NN	O	O

Both	NN	O	O
incidents	NN	O	O
occurred	NN	O	O
within	NN	O	O
a	NN	O	O
year	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Telithromycin	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
of	NN	O	O
the	NN	O	O
ketolide	NN	O	O
antibacterials	NN	O	O
to	NN	O	O
receive	NN	O	O
US	NN	O	O
Food	NN	O	O
and	NN	O	O
Drug	NN	O	O
Administration	NN	O	O
approval	NN	O	O
for	NN	O	O
clinical	NN	O	O
use	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
infrequent	NN	O	O
and	NN	O	O
usually	NN	O	O
reversible	NN	O	O
severe	NN	O	O
hepatic	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Based	NN	O	O
on	NN	O	O
a	NN	O	O
score	NN	O	O
of	NN	O	O
8	NN	O	O
on	NN	O	O
the	NN	O	O
Naranjo	NN	O	O
adverse	NN	O	B
drug	NN	O	I
reaction	NN	O	I
probability	NN	O	O
scale	NN	O	O
,	NN	O	O
telithromycin	NN	O	O
was	NN	O	O
the	NN	O	O
probable	NN	O	O
cause	NN	O	O
of	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
in	NN	O	O
this	NN	O	O
patient	NN	O	O
,	NN	O	O
and	NN	O	O
pathological	NN	O	O
findings	NN	O	O
suggested	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
toxic	NN	O	B
hepatitis	NN	O	I
.	NN	O	O

Recurrence	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
attack	NN	O	O
might	NN	O	O
have	NN	O	O
been	NN	O	O
avoided	NN	O	O
if	NN	O	O
the	NN	O	O
initial	NN	O	O
incident	NN	O	O
had	NN	O	O
been	NN	O	O
communicated	NN	O	O
to	NN	O	O
the	NN	O	O
attending	NN	O	O
physician	NN	O	O
who	NN	O	O
prescribed	NN	O	O
telithromycin	NN	O	O
the	NN	O	O
second	NN	O	O
time	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Here	NN	O	O
we	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
probably	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
telithromycin	NN	O	O
.	NN	O	O

A	NN	O	O
study	NN	O	O
on	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
subcutaneous	NN	O	O
heparin	NN	O	O
injection	NN	O	O
on	NN	O	O
bruising	NN	O	B
and	NN	O	O
pain	NN	O	B
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
injection	NN	O	O
duration	NN	O	O
on	NN	O	O
bruising	NN	O	B
and	NN	O	O
pain	NN	O	B
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
subcutaneous	NN	O	O
injection	NN	O	O
of	NN	O	O
heparin	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Although	NN	O	O
different	NN	O	O
methods	NN	O	O
to	NN	O	O
prevent	NN	O	O
bruising	NN	O	B
and	NN	O	O
pain	NN	O	B
following	NN	O	O
the	NN	O	O
subcutaneous	NN	O	O
injection	NN	O	O
of	NN	O	O
heparin	NN	O	O
have	NN	O	O
been	NN	O	O
widely	NN	O	O
studied	NN	O	O
and	NN	O	O
described	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
injection	NN	O	O
duration	NN	O	O
on	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
bruising	NN	O	B
and	NN	O	O
pain	NN	O	B
is	NN	O	O
little	NN	O	O
documented	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
as	NN	O	O
within	NN	O	O
-	NN	O	O
subject	NN	O	O
,	NN	O	O
quasi	NN	O	O
-	NN	O	O
experimental	NN	O	O
research	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
The	NN	O	O
sample	NN	O	O
for	NN	O	O
the	NN	O	O
study	NN	O	O
consisted	NN	O	O
of	NN	O	O
50	NN	O	O
patients	NN	O	O
to	NN	O	O
whom	NN	O	O
subcutaneous	NN	O	O
heparin	NN	O	O
was	NN	O	O
administered	NN	O	O
.	NN	O	O

Heparin	NN	O	O
was	NN	O	O
injected	NN	O	O
over	NN	O	O
10	NN	O	O
seconds	NN	O	O
on	NN	O	O
the	NN	O	O
right	NN	O	O
abdominal	NN	O	O
site	NN	O	O
and	NN	O	O
30	NN	O	O
seconds	NN	O	O
on	NN	O	O
the	NN	O	O
left	NN	O	O
abdominal	NN	O	O
site	NN	O	O
.	NN	O	O

Injections	NN	O	O
areas	NN	O	O
were	NN	O	O
assessed	NN	O	O
for	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
bruising	NN	O	B
at	NN	O	O
48	NN	O	O
and	NN	O	O
72	NN	O	O
hours	NN	O	O
after	NN	O	O
each	NN	O	O
injection	NN	O	O
.	NN	O	O

Dimensions	NN	O	O
of	NN	O	O
the	NN	O	O
bruising	NN	O	B
on	NN	O	O
the	NN	O	O
heparin	NN	O	O
applied	NN	O	O
areas	NN	O	O
were	NN	O	O
measured	NN	O	O
using	NN	O	O
transparent	NN	O	O
millimetric	NN	O	O
measuring	NN	O	O
paper	NN	O	O
.	NN	O	O

The	NN	O	O
visual	NN	O	O
analog	NN	O	O
scale	NN	O	O
(	NN	O	O
VAS	NN	O	O
)	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
pain	NN	O	B
intensity	NN	O	O
and	NN	O	O
a	NN	O	O
stop	NN	O	O
-	NN	O	O
watch	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
time	NN	O	O
the	NN	O	O
pain	NN	O	B
period	NN	O	O
.	NN	O	O

Data	NN	O	O
were	NN	O	O
analysed	NN	O	O
using	NN	O	O
chi	NN	O	O
-	NN	O	O
square	NN	O	O
test	NN	O	O
,	NN	O	O
Mann	NN	O	O
-	NN	O	O
Whitney	NN	O	O
U	NN	O	O
,	NN	O	O
Wilcoxon	NN	O	O
signed	NN	O	O
ranks	NN	O	O
tests	NN	O	O
and	NN	O	O
correlation	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
percentage	NN	O	O
of	NN	O	O
bruising	NN	O	B
occurrence	NN	O	O
was	NN	O	O
64	NN	O	O
%	NN	O	O
with	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
10	NN	O	O
seconds	NN	O	O
duration	NN	O	O
and	NN	O	O
42	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
30	NN	O	O
-	NN	O	O
second	NN	O	O
injection	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
determined	NN	O	O
that	NN	O	O
the	NN	O	O
size	NN	O	O
of	NN	O	O
the	NN	O	O
bruising	NN	O	B
was	NN	O	O
smaller	NN	O	O
in	NN	O	O
the	NN	O	O
30	NN	O	O
-	NN	O	O
second	NN	O	O
injection	NN	O	O
.	NN	O	O

Pain	NN	O	B
intensity	NN	O	O
and	NN	O	O
pain	NN	O	B
period	NN	O	O
were	NN	O	O
statistically	NN	O	O
significantly	NN	O	O
lower	NN	O	O
for	NN	O	O
the	NN	O	O
30	NN	O	O
-	NN	O	O
second	NN	O	O
injection	NN	O	O
than	NN	O	O
for	NN	O	O
the	NN	O	O
10	NN	O	O
-	NN	O	O
second	NN	O	O
injection	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
It	NN	O	O
was	NN	O	O
determined	NN	O	O
that	NN	O	O
injection	NN	O	O
duration	NN	O	O
had	NN	O	O
an	NN	O	O
effect	NN	O	O
on	NN	O	O
bruising	NN	O	B
and	NN	O	O
pain	NN	O	B
following	NN	O	O
the	NN	O	O
subcutaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
heparin	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
should	NN	O	O
be	NN	O	O
repeated	NN	O	O
on	NN	O	O
a	NN	O	O
larger	NN	O	O
sample	NN	O	O
.	NN	O	O

RELEVANCE	NN	O	O
TO	NN	O	O
CLINICAL	NN	O	O
PRACTICE	NN	O	O
:	NN	O	O
When	NN	O	O
administering	NN	O	O
subcutaneous	NN	O	O
heparin	NN	O	O
injections	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
important	NN	O	O
to	NN	O	O
extend	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
injection	NN	O	O
.	NN	O	O

Acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
in	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
regular	NN	O	O
alcohol	NN	O	O
consumption	NN	O	O
ingesting	NN	O	O
paracetamol	NN	O	O
at	NN	O	O
therapeutic	NN	O	O
dosage	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
possible	NN	O	O
role	NN	O	O
of	NN	O	O
alcohol	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B
associated	NN	O	O
with	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
of	NN	O	O
paracetamol	NN	O	O
(	NN	O	O
acetaminophen	NN	O	O
)	NN	O	O
is	NN	O	O
currently	NN	O	O
debated	NN	O	O
.	NN	O	O

CASE	NN	O	O
REPORT	NN	O	O
:	NN	O	O
We	NN	O	O
describe	NN	O	O
2	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
regular	NN	O	O
consumers	NN	O	O
of	NN	O	O
alcohol	NN	O	O
and	NN	O	O
who	NN	O	O
developed	NN	O	O
liver	NN	O	B
failure	NN	O	I
within	NN	O	O
3	NN	O	O
-	NN	O	O
5	NN	O	O
days	NN	O	O
after	NN	O	O
hospitalization	NN	O	O
and	NN	O	O
stopping	NN	O	O
alcohol	NN	O	O
consumption	NN	O	O
while	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
4	NN	O	O
g	NN	O	O
paracetamol	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

A	NN	O	O
paracetamol	NN	O	O
serum	NN	O	O
level	NN	O	O
obtained	NN	O	O
in	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
was	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
toxic	NN	O	O
range	NN	O	O
.	NN	O	O

Possible	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
of	NN	O	O
paracetamol	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
patients	NN	O	O
with	NN	O	O
risk	NN	O	O
factors	NN	O	O
,	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
regular	NN	O	O
consumption	NN	O	O
of	NN	O	O
alcohol	NN	O	O
,	NN	O	O
liver	NN	O	B
failure	NN	O	I
is	NN	O	O
possible	NN	O	O
when	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
are	NN	O	O
ingested	NN	O	O
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
the	NN	O	O
paracetamol	NN	O	O
dose	NN	O	O
should	NN	O	O
not	NN	O	O
exceed	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
day	NN	O	O
in	NN	O	O
such	NN	O	O
patients	NN	O	O
and	NN	O	O
that	NN	O	O
their	NN	O	O
liver	NN	O	O
function	NN	O	O
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
closely	NN	O	O
while	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
paracetamol	NN	O	O
.	NN	O	O

Associations	NN	O	O
between	NN	O	O
use	NN	O	O
of	NN	O	O
benzodiazepines	NN	O	O
or	NN	O	O
related	NN	O	O
drugs	NN	O	O
and	NN	O	O
health	NN	O	O
,	NN	O	O
physical	NN	O	O
abilities	NN	O	O
and	NN	O	O
cognitive	NN	O	O
function	NN	O	O
:	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
randomised	NN	O	O
clinical	NN	O	O
study	NN	O	O
in	NN	O	O
the	NN	O	O
elderly	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
describe	NN	O	O
associations	NN	O	O
between	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
benzodiazepines	NN	O	O
or	NN	O	O
related	NN	O	O
drugs	NN	O	O
(	NN	O	O
BZDs	NN	O	O
/	NN	O	O
RDs	NN	O	O
)	NN	O	O
and	NN	O	O
health	NN	O	O
,	NN	O	O
functional	NN	O	O
abilities	NN	O	O
and	NN	O	O
cognitive	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
elderly	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
non	NN	O	O
-	NN	O	O
randomised	NN	O	O
clinical	NN	O	O
study	NN	O	O
of	NN	O	O
patients	NN	O	O
aged	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
65	NN	O	O
years	NN	O	O
admitted	NN	O	O
to	NN	O	O
acute	NN	O	O
hospital	NN	O	O
wards	NN	O	O
during	NN	O	O
1	NN	O	O
month	NN	O	O
.	NN	O	O

164	NN	O	O
patients	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
standard	NN	O	O
deviation	NN	O	O
[	NN	O	O
SD	NN	O	O
]	NN	O	O
81	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
8	NN	O	O
years	NN	O	O
)	NN	O	O
were	NN	O	O
admitted	NN	O	O
.	NN	O	O

Of	NN	O	O
these	NN	O	O
,	NN	O	O
nearly	NN	O	O
half	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
78	NN	O	O
)	NN	O	O
had	NN	O	O
used	NN	O	O
BZDs	NN	O	O
/	NN	O	O
RDs	NN	O	O
before	NN	O	O
admission	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
remainder	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
86	NN	O	O
)	NN	O	O
were	NN	O	O
non	NN	O	O
-	NN	O	O
users	NN	O	O
.	NN	O	O

Cognitive	NN	O	O
ability	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
the	NN	O	O
Mini	NN	O	O
-	NN	O	O
Mental	NN	O	O
State	NN	O	O
Examination	NN	O	O
(	NN	O	O
MMSE	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
scoring	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
20	NN	O	O
MMSE	NN	O	O
sum	NN	O	O
points	NN	O	O
were	NN	O	O
interviewed	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
79	NN	O	O
)	NN	O	O
and	NN	O	O
questioned	NN	O	O
regarding	NN	O	O
symptoms	NN	O	O
and	NN	O	O
functional	NN	O	O
abilities	NN	O	O
during	NN	O	O
the	NN	O	O
week	NN	O	O
prior	NN	O	O
to	NN	O	O
admission	NN	O	O
.	NN	O	O

Data	NN	O	O
on	NN	O	O
use	NN	O	O
of	NN	O	O
BZDs	NN	O	O
/	NN	O	O
RDs	NN	O	O
before	NN	O	O
admission	NN	O	O
,	NN	O	O
current	NN	O	O
medications	NN	O	O
and	NN	O	O
discharge	NN	O	O
diagnoses	NN	O	O
were	NN	O	O
collected	NN	O	O
from	NN	O	O
medical	NN	O	O
records	NN	O	O
.	NN	O	O

Health	NN	O	O
,	NN	O	O
physical	NN	O	O
abilities	NN	O	O
and	NN	O	O
cognitive	NN	O	O
function	NN	O	O
were	NN	O	O
compared	NN	O	O
between	NN	O	O
BZD	NN	O	O
/	NN	O	O
RD	NN	O	O
users	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
users	NN	O	O
,	NN	O	O
and	NN	O	O
adjustments	NN	O	O
were	NN	O	O
made	NN	O	O
for	NN	O	O
confounding	NN	O	O
variables	NN	O	O
.	NN	O	O

The	NN	O	O
residual	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
of	NN	O	O
oxazepam	NN	O	O
,	NN	O	O
temazepam	NN	O	O
and	NN	O	O
zopiclone	NN	O	O
were	NN	O	O
analysed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
duration	NN	O	O
of	NN	O	O
BZD	NN	O	O
/	NN	O	O
RD	NN	O	O
use	NN	O	O
was	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
years	NN	O	O
(	NN	O	O
range	NN	O	O
1	NN	O	O
-	NN	O	O
31	NN	O	O
)	NN	O	O
.	NN	O	O

Two	NN	O	O
or	NN	O	O
three	NN	O	O
BZDs	NN	O	O
/	NN	O	O
RDs	NN	O	O
were	NN	O	O
concomitantly	NN	O	O
taken	NN	O	O
by	NN	O	O
26	NN	O	O
%	NN	O	O
of	NN	O	O
users	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
female	NN	O	O
sex	NN	O	O
and	NN	O	O
use	NN	O	O
of	NN	O	O
a	NN	O	O
higher	NN	O	O
number	NN	O	O
of	NN	O	O
drugs	NN	O	O
with	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
CNS	NN	O	O
,	NN	O	O
which	NN	O	O
tended	NN	O	O
to	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
diagnosed	NN	O	O
dementia	NN	O	B
.	NN	O	O

After	NN	O	O
adjustment	NN	O	O
for	NN	O	O
these	NN	O	O
variables	NN	O	O
as	NN	O	O
confounders	NN	O	O
,	NN	O	O
use	NN	O	O
of	NN	O	O
BZDs	NN	O	O
/	NN	O	O
RDs	NN	O	O
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
cognitive	NN	O	O
function	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
the	NN	O	O
MMSE	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
use	NN	O	O
of	NN	O	O
BZDs	NN	O	O
/	NN	O	O
RDs	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
dizziness	NN	O	B
,	NN	O	O
inability	NN	O	B
to	NN	O	I
sleep	NN	O	I
after	NN	O	O
awaking	NN	O	O
at	NN	O	O
night	NN	O	O
and	NN	O	O
tiredness	NN	O	B
in	NN	O	O
the	NN	O	O
mornings	NN	O	O
during	NN	O	O
the	NN	O	O
week	NN	O	O
prior	NN	O	O
to	NN	O	O
admission	NN	O	O
and	NN	O	O
with	NN	O	O
stronger	NN	O	O
depressive	NN	O	B
symptoms	NN	O	I
measured	NN	O	O
at	NN	O	O
the	NN	O	O
beginning	NN	O	O
of	NN	O	O
the	NN	O	O
hospital	NN	O	O
stay	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
BZDs	NN	O	O
/	NN	O	O
RDs	NN	O	O
tended	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
reduced	NN	O	O
ability	NN	O	O
to	NN	O	O
walk	NN	O	O
and	NN	O	O
shorter	NN	O	O
night	NN	O	O
-	NN	O	O
time	NN	O	O
sleep	NN	O	O
during	NN	O	O
the	NN	O	O
week	NN	O	O
prior	NN	O	O
to	NN	O	O
admission	NN	O	O
.	NN	O	O

A	NN	O	O
higher	NN	O	O
residual	NN	O	O
serum	NN	O	O
concentration	NN	O	O
of	NN	O	O
temazepam	NN	O	O
correlated	NN	O	O
with	NN	O	O
a	NN	O	O
lower	NN	O	O
MMSE	NN	O	O
sum	NN	O	O
score	NN	O	O
after	NN	O	O
adjustment	NN	O	O
for	NN	O	O
confounding	NN	O	O
variables	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
and	NN	O	O
concomitant	NN	O	O
use	NN	O	O
of	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
BZD	NN	O	O
/	NN	O	O
RD	NN	O	O
were	NN	O	O
common	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
hospitalised	NN	O	O
because	NN	O	O
of	NN	O	O
acute	NN	O	O
illnesses	NN	O	O
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
daytime	NN	O	O
and	NN	O	O
night	NN	O	O
-	NN	O	O
time	NN	O	O
symptoms	NN	O	O
indicative	NN	O	O
of	NN	O	O
poorer	NN	O	O
health	NN	O	O
and	NN	O	O
potentially	NN	O	O
caused	NN	O	O
by	NN	O	O
the	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
.	NN	O	O

Acute	NN	O	O
vocal	NN	O	B
fold	NN	O	I
palsy	NN	O	I
after	NN	O	O
acute	NN	O	O
disulfiram	NN	O	O
intoxication	NN	O	O
.	NN	O	O

Acute	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
caused	NN	O	O
by	NN	O	O
a	NN	O	O
disulfiram	NN	O	O
overdose	NN	O	B
is	NN	O	O
very	NN	O	O
rare	NN	O	O
and	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
report	NN	O	O
of	NN	O	O
it	NN	O	O
leading	NN	O	O
to	NN	O	O
vocal	NN	O	B
fold	NN	O	I
palsy	NN	O	I
.	NN	O	O

A	NN	O	O
49	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
was	NN	O	O
transferred	NN	O	O
to	NN	O	O
our	NN	O	O
department	NN	O	O
because	NN	O	O
of	NN	O	O
quadriparesis	NN	O	B
,	NN	O	O
lancinating	NN	O	O
pain	NN	O	B
,	NN	O	O
sensory	NN	O	B
loss	NN	O	I
,	NN	O	O
and	NN	O	O
paresthesia	NN	O	B
of	NN	O	O
the	NN	O	O
distal	NN	O	O
limbs	NN	O	O
.	NN	O	O

One	NN	O	O
month	NN	O	O
previously	NN	O	O
,	NN	O	O
she	NN	O	O
had	NN	O	O
taken	NN	O	O
a	NN	O	O
single	NN	O	O
high	NN	O	O
dose	NN	O	O
of	NN	O	O
disulfiram	NN	O	O
(	NN	O	O
130	NN	O	O
tablets	NN	O	O
of	NN	O	O
ALCOHOL	NN	O	O
STOP	NN	O	O
TAB	NN	O	O
,	NN	O	O
Shin	NN	O	O
-	NN	O	O
Poong	NN	O	O
Pharm	NN	O	O
.	NN	O	O
Co	NN	O	O
.	NN	O	O
,	NN	O	O
Ansan	NN	O	O
,	NN	O	O
Korea	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
suicide	NN	O	O
attempt	NN	O	O
.	NN	O	O

She	NN	O	O
was	NN	O	O
not	NN	O	O
an	NN	O	O
alcoholic	NN	O	O
.	NN	O	O

For	NN	O	O
the	NN	O	O
first	NN	O	O
few	NN	O	O
days	NN	O	O
after	NN	O	O
ingestion	NN	O	O
,	NN	O	O
she	NN	O	O
was	NN	O	O
in	NN	O	O
a	NN	O	O
confused	NN	O	O
state	NN	O	O
and	NN	O	O
had	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
ataxia	NN	O	B
and	NN	O	O
giddiness	NN	O	B
.	NN	O	O

She	NN	O	O
noticed	NN	O	O
hoarseness	NN	O	B
and	NN	O	O
distally	NN	O	O
accentuated	NN	O	O
motor	NN	O	O
and	NN	O	O
sensory	NN	O	O
dysfunction	NN	O	O
after	NN	O	O
she	NN	O	O
had	NN	O	O
recovered	NN	O	O
from	NN	O	O
this	NN	O	O
state	NN	O	O
.	NN	O	O

A	NN	O	O
nerve	NN	O	O
conduction	NN	O	O
study	NN	O	O
was	NN	O	O
consistent	NN	O	O
with	NN	O	O
severe	NN	O	O
sensorimotor	NN	O	O
axonal	NN	O	O
polyneuropathy	NN	O	B
.	NN	O	O

Laryngeal	NN	O	O
electromyography	NN	O	O
(	NN	O	O
thyroarytenoid	NN	O	O
muscle	NN	O	O
)	NN	O	O
showed	NN	O	O
ample	NN	O	O
denervation	NN	O	O
potentials	NN	O	O
.	NN	O	O

Laryngoscopy	NN	O	O
revealed	NN	O	O
asymmetric	NN	O	O
vocal	NN	O	O
fold	NN	O	O
movements	NN	O	O
during	NN	O	O
phonation	NN	O	O
.	NN	O	O

Her	NN	O	O
vocal	NN	O	O
change	NN	O	O
and	NN	O	O
weakness	NN	O	O
began	NN	O	O
to	NN	O	O
improve	NN	O	O
spontaneously	NN	O	O
about	NN	O	O
3	NN	O	O
weeks	NN	O	O
after	NN	O	O
transfer	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
palsy	NN	O	B
of	NN	O	O
the	NN	O	O
recurrent	NN	O	O
laryngeal	NN	O	O
nerve	NN	O	O
and	NN	O	O
superimposed	NN	O	O
severe	NN	O	O
acute	NN	O	O
sensorimotor	NN	O	O
axonal	NN	O	O
polyneuropathy	NN	O	B
caused	NN	O	O
by	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
disulfiram	NN	O	O
intoxication	NN	O	O
.	NN	O	O

Encephalopathy	NN	O	B
induced	NN	O	O
by	NN	O	O
levetiracetam	NN	O	O
added	NN	O	O
to	NN	O	O
valproate	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
We	NN	O	O
report	NN	O	O
on	NN	O	O
the	NN	O	O
manifestation	NN	O	O
of	NN	O	O
a	NN	O	O
levetiracetam	NN	O	O
(	NN	O	O
LEV	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
.	NN	O	O

FINDINGS	NN	O	O
:	NN	O	O
A	NN	O	O
28	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
suffering	NN	O	O
from	NN	O	O
idiopathic	NN	O	B
epilepsy	NN	O	I
with	NN	O	O
generalized	NN	O	O
seizures	NN	O	B
was	NN	O	O
treated	NN	O	O
with	NN	O	O
LEV	NN	O	O
(	NN	O	O
3000	NN	O	O
mg	NN	O	O
)	NN	O	O
added	NN	O	O
to	NN	O	O
valproate	NN	O	O
(	NN	O	O
VPA	NN	O	O
)	NN	O	O
(	NN	O	O
2000	NN	O	O
mg	NN	O	O
)	NN	O	O
.	NN	O	O

Frequency	NN	O	O
of	NN	O	O
generalized	NN	O	O
tonic	NN	O	B
-	NN	O	I
clonic	NN	O	I
seizures	NN	O	I
increased	NN	O	O
from	NN	O	O
one	NN	O	O
per	NN	O	O
6	NN	O	O
months	NN	O	O
to	NN	O	O
two	NN	O	O
per	NN	O	O
month	NN	O	O
.	NN	O	O

Neuropsychological	NN	O	O
testing	NN	O	O
showed	NN	O	O
impaired	NN	O	B
word	NN	O	I
fluency	NN	O	I
,	NN	O	I
psychomotor	NN	O	I
speed	NN	O	I
and	NN	O	I
working	NN	O	I
memory	NN	O	I
.	NN	O	O

The	NN	O	O
interictal	NN	O	O
electroencephalogram	NN	O	O
(	NN	O	O
EEG	NN	O	O
)	NN	O	O
showed	NN	O	O
a	NN	O	O
generalized	NN	O	O
slowing	NN	O	O
to	NN	O	O
5	NN	O	O
per	NN	O	O
second	NN	O	O
theta	NN	O	O
rhythms	NN	O	O
with	NN	O	O
bilateral	NN	O	O
generalized	NN	O	O
high	NN	O	O
-	NN	O	O
amplitude	NN	O	O
discharges	NN	O	O
.	NN	O	O

OUTCOME	NN	O	O
:	NN	O	O
Following	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
LEV	NN	O	O
,	NN	O	O
EEG	NN	O	O
and	NN	O	O
neuropsychological	NN	O	O
findings	NN	O	O
improved	NN	O	O
and	NN	O	O
seizure	NN	O	B
frequency	NN	O	O
decreased	NN	O	O
.	NN	O	O

Norepinephrine	NN	O	O
signaling	NN	O	O
through	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
receptors	NN	O	O
is	NN	O	O
critical	NN	O	O
for	NN	O	O
expression	NN	O	O
of	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Cocaine	NN	O	O
is	NN	O	O
a	NN	O	O
widely	NN	O	O
abused	NN	O	O
psychostimulant	NN	O	O
that	NN	O	O
has	NN	O	O
both	NN	O	O
rewarding	NN	O	O
and	NN	O	O
aversive	NN	O	O
properties	NN	O	O
.	NN	O	O

While	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
underlying	NN	O	O
cocaine	NN	O	O
'	NN	O	O
s	NN	O	O
rewarding	NN	O	O
effects	NN	O	O
have	NN	O	O
been	NN	O	O
studied	NN	O	O
extensively	NN	O	O
,	NN	O	O
less	NN	O	O
attention	NN	O	O
has	NN	O	O
been	NN	O	O
paid	NN	O	O
to	NN	O	O
the	NN	O	O
unpleasant	NN	O	O
behavioral	NN	O	O
states	NN	O	O
induced	NN	O	O
by	NN	O	O
cocaine	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
anxiety	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
evaluated	NN	O	O
the	NN	O	O
performance	NN	O	O
of	NN	O	O
dopamine	NN	O	O
beta	NN	O	O
-	NN	O	O
hydroxylase	NN	O	O
knockout	NN	O	O
(	NN	O	O
Dbh	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
,	NN	O	O
which	NN	O	O
lack	NN	O	O
norepinephrine	NN	O	O
(	NN	O	O
NE	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
elevated	NN	O	O
plus	NN	O	O
maze	NN	O	O
(	NN	O	O
EPM	NN	O	O
)	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
contribution	NN	O	O
of	NN	O	O
noradrenergic	NN	O	O
signaling	NN	O	O
to	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
found	NN	O	O
that	NN	O	O
cocaine	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
increased	NN	O	O
anxiety	NN	O	B
-	NN	O	O
like	NN	O	O
behavior	NN	O	O
in	NN	O	O
control	NN	O	O
(	NN	O	O
Dbh	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
,	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
open	NN	O	O
arm	NN	O	O
exploration	NN	O	O
.	NN	O	O

The	NN	O	O
Dbh	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
had	NN	O	O
normal	NN	O	O
baseline	NN	O	O
performance	NN	O	O
in	NN	O	O
the	NN	O	O
EPM	NN	O	O
but	NN	O	O
were	NN	O	O
completely	NN	O	O
resistant	NN	O	O
to	NN	O	O
the	NN	O	O
anxiogenic	NN	O	O
effects	NN	O	O
of	NN	O	O
cocaine	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
was	NN	O	O
also	NN	O	O
attenuated	NN	O	O
in	NN	O	O
Dbh	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
following	NN	O	O
administration	NN	O	O
of	NN	O	O
disulfiram	NN	O	O
,	NN	O	O
a	NN	O	O
dopamine	NN	O	O
beta	NN	O	O
-	NN	O	O
hydroxylase	NN	O	O
(	NN	O	O
DBH	NN	O	O
)	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

In	NN	O	O
experiments	NN	O	O
using	NN	O	O
specific	NN	O	O
adrenergic	NN	O	O
antagonists	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
propranolol	NN	O	O
blocked	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
-	NN	O	O
like	NN	O	O
behavior	NN	O	O
in	NN	O	O
Dbh	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
and	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
C57BL6	NN	O	O
/	NN	O	O
J	NN	O	O
mice	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
alpha	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
antagonist	NN	O	O
prazosin	NN	O	O
and	NN	O	O
the	NN	O	O
alpha	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
antagonist	NN	O	O
yohimbine	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
noradrenergic	NN	O	O
signaling	NN	O	O
via	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
receptors	NN	O	O
is	NN	O	O
required	NN	O	O
for	NN	O	O
cocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
anxiety	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Hypothalamic	NN	O	O
prolactin	NN	O	O
receptor	NN	O	O
messenger	NN	O	O
ribonucleic	NN	O	O
acid	NN	O	O
levels	NN	O	O
,	NN	O	O
prolactin	NN	O	O
signaling	NN	O	O
,	NN	O	O
and	NN	O	O
hyperprolactinemic	NN	O	B
inhibition	NN	O	O
of	NN	O	O
pulsatile	NN	O	O
luteinizing	NN	O	O
hormone	NN	O	O
secretion	NN	O	O
are	NN	O	O
dependent	NN	O	O
on	NN	O	O
estradiol	NN	O	O
.	NN	O	O

Hyperprolactinemia	NN	O	B
can	NN	O	O
reduce	NN	O	O
fertility	NN	O	O
and	NN	O	O
libido	NN	O	O
.	NN	O	O

Although	NN	O	O
central	NN	O	O
prolactin	NN	O	O
actions	NN	O	O
are	NN	O	O
thought	NN	O	O
to	NN	O	O
contribute	NN	O	O
to	NN	O	O
this	NN	O	O
,	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
poorly	NN	O	O
understood	NN	O	O
.	NN	O	O

We	NN	O	O
first	NN	O	O
tested	NN	O	O
whether	NN	O	O
chronic	NN	O	O
hyperprolactinemia	NN	O	B
inhibited	NN	O	O
two	NN	O	O
neuroendocrine	NN	O	O
parameters	NN	O	O
necessary	NN	O	O
for	NN	O	O
female	NN	O	O
fertility	NN	O	O
:	NN	O	O
pulsatile	NN	O	O
LH	NN	O	O
secretion	NN	O	O
and	NN	O	O
the	NN	O	O
estrogen	NN	O	O
-	NN	O	O
induced	NN	O	O
LH	NN	O	O
surge	NN	O	O
.	NN	O	O

Chronic	NN	O	O
hyperprolactinemia	NN	O	B
induced	NN	O	O
by	NN	O	O
the	NN	O	O
dopamine	NN	O	O
antagonist	NN	O	O
sulpiride	NN	O	O
caused	NN	O	O
a	NN	O	O
40	NN	O	O
%	NN	O	O
reduction	NN	O	O
LH	NN	O	O
pulse	NN	O	O
frequency	NN	O	O
in	NN	O	O
ovariectomized	NN	O	O
rats	NN	O	O
,	NN	O	O
but	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
chronic	NN	O	O
low	NN	O	O
levels	NN	O	O
of	NN	O	O
estradiol	NN	O	O
.	NN	O	O

Sulpiride	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
magnitude	NN	O	O
of	NN	O	O
a	NN	O	O
steroid	NN	O	O
-	NN	O	O
induced	NN	O	O
LH	NN	O	O
surge	NN	O	O
or	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
GnRH	NN	O	O
neurons	NN	O	O
activated	NN	O	O
during	NN	O	O
the	NN	O	O
surge	NN	O	O
.	NN	O	O

Estradiol	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
influence	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
long	NN	O	O
form	NN	O	O
of	NN	O	O
prolactin	NN	O	O
receptors	NN	O	O
(	NN	O	O
PRL	NN	O	O
-	NN	O	O
R	NN	O	O
)	NN	O	O
and	NN	O	O
components	NN	O	O
of	NN	O	O
prolactin	NN	O	O
'	NN	O	O
s	NN	O	O
signaling	NN	O	O
pathway	NN	O	O
.	NN	O	O

To	NN	O	O
test	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
estrogen	NN	O	O
increases	NN	O	O
PRL	NN	O	O
-	NN	O	O
R	NN	O	O
expression	NN	O	O
and	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
prolactin	NN	O	O
,	NN	O	O
we	NN	O	O
next	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
estradiol	NN	O	O
greatly	NN	O	O
augments	NN	O	O
prolactin	NN	O	O
-	NN	O	O
induced	NN	O	O
STAT5	NN	O	O
activation	NN	O	O
.	NN	O	O

Lastly	NN	O	O
,	NN	O	O
we	NN	O	O
measured	NN	O	O
PRL	NN	O	O
-	NN	O	O
R	NN	O	O
and	NN	O	O
suppressor	NN	O	O
of	NN	O	O
cytokine	NN	O	O
signaling	NN	O	O
(	NN	O	O
SOCS	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
-	NN	O	O
3	NN	O	O
and	NN	O	O
CIS	NN	O	O
,	NN	O	O
which	NN	O	O
reflect	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
prolactin	NN	O	O
signaling	NN	O	O
)	NN	O	O
mRNAs	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
sulpiride	NN	O	O
and	NN	O	O
estradiol	NN	O	O
.	NN	O	O

Sulpiride	NN	O	O
induced	NN	O	O
only	NN	O	O
SOCS	NN	O	O
-	NN	O	O
1	NN	O	O
in	NN	O	O
the	NN	O	O
medial	NN	O	O
preoptic	NN	O	O
area	NN	O	O
,	NN	O	O
where	NN	O	O
GnRH	NN	O	O
neurons	NN	O	O
are	NN	O	O
regulated	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
the	NN	O	O
arcuate	NN	O	O
nucleus	NN	O	O
and	NN	O	O
choroid	NN	O	O
plexus	NN	O	O
,	NN	O	O
PRL	NN	O	O
-	NN	O	O
R	NN	O	O
,	NN	O	O
SOCS	NN	O	O
-	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
CIS	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
were	NN	O	O
also	NN	O	O
induced	NN	O	O
.	NN	O	O

Estradiol	NN	O	O
enhanced	NN	O	O
these	NN	O	O
effects	NN	O	O
on	NN	O	O
SOCS	NN	O	O
-	NN	O	O
3	NN	O	O
and	NN	O	O
CIS	NN	O	O
.	NN	O	O

Interestingly	NN	O	O
,	NN	O	O
estradiol	NN	O	O
also	NN	O	O
induced	NN	O	O
PRL	NN	O	O
-	NN	O	O
R	NN	O	O
,	NN	O	O
SOCS	NN	O	O
-	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
CIS	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
independently	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
GnRH	NN	O	O
pulse	NN	O	O
frequency	NN	O	O
is	NN	O	O
inhibited	NN	O	O
by	NN	O	O
chronic	NN	O	O
hyperprolactinemia	NN	O	B
in	NN	O	O
a	NN	O	O
steroid	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

They	NN	O	O
also	NN	O	O
provide	NN	O	O
evidence	NN	O	O
for	NN	O	O
estradiol	NN	O	O
-	NN	O	O
dependent	NN	O	O
and	NN	O	O
brain	NN	O	O
region	NN	O	O
-	NN	O	O
specific	NN	O	O
regulation	NN	O	O
of	NN	O	O
PRL	NN	O	O
-	NN	O	O
R	NN	O	O
expression	NN	O	O
and	NN	O	O
signaling	NN	O	O
responses	NN	O	O
by	NN	O	O
prolactin	NN	O	O
.	NN	O	O

Clonidine	NN	O	O
for	NN	O	O
attention	NN	O	B
-	NN	O	I
deficit	NN	O	I
/	NN	O	I
hyperactivity	NN	O	I
disorder	NN	O	I
:	NN	O	O
II	NN	O	O
.	NN	O	O

ECG	NN	O	O
changes	NN	O	O
and	NN	O	O
adverse	NN	O	O
events	NN	O	O
analysis	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
examine	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
clonidine	NN	O	O
used	NN	O	O
alone	NN	O	O
or	NN	O	O
with	NN	O	O
methylphenidate	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
attention	NN	O	B
-	NN	O	I
deficit	NN	O	I
/	NN	O	I
hyperactivity	NN	O	I
disorder	NN	O	I
(	NN	O	O
ADHD	NN	O	B
)	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
In	NN	O	O
a	NN	O	O
16	NN	O	O
-	NN	O	O
week	NN	O	O
multicenter	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trial	NN	O	O
,	NN	O	O
122	NN	O	O
children	NN	O	O
with	NN	O	O
ADHD	NN	O	B
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
clonidine	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
31	NN	O	O
)	NN	O	O
,	NN	O	O
methylphenidate	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
29	NN	O	O
)	NN	O	O
,	NN	O	O
clonidine	NN	O	O
and	NN	O	O
methylphenidate	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
32	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
30	NN	O	O
)	NN	O	O
.	NN	O	O

Doses	NN	O	O
were	NN	O	O
flexibly	NN	O	O
titrated	NN	O	O
up	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
clonidine	NN	O	O
and	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
methylphenidate	NN	O	O
(	NN	O	O
both	NN	O	O
with	NN	O	O
divided	NN	O	O
dosing	NN	O	O
)	NN	O	O
.	NN	O	O

Groups	NN	O	O
were	NN	O	O
compared	NN	O	O
regarding	NN	O	O
adverse	NN	O	O
events	NN	O	O
and	NN	O	O
changes	NN	O	O
from	NN	O	O
baseline	NN	O	O
to	NN	O	O
week	NN	O	O
16	NN	O	O
in	NN	O	O
electrocardiograms	NN	O	O
and	NN	O	O
vital	NN	O	O
signs	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
There	NN	O	O
were	NN	O	O
more	NN	O	O
incidents	NN	O	O
of	NN	O	O
bradycardia	NN	O	B
in	NN	O	O
subjects	NN	O	O
treated	NN	O	O
with	NN	O	O
clonidine	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
not	NN	O	O
treated	NN	O	O
with	NN	O	O
clonidine	NN	O	O
(	NN	O	O
17	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
versus	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
other	NN	O	O
significant	NN	O	O
group	NN	O	O
differences	NN	O	O
regarding	NN	O	O
electrocardiogram	NN	O	O
and	NN	O	O
other	NN	O	O
cardiovascular	NN	O	O
outcomes	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
suggestions	NN	O	O
of	NN	O	O
interactions	NN	O	O
between	NN	O	O
clonidine	NN	O	O
and	NN	O	O
methylphenidate	NN	O	O
regarding	NN	O	O
cardiovascular	NN	O	O
outcomes	NN	O	O
.	NN	O	O

Moderate	NN	O	O
or	NN	O	O
severe	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
more	NN	O	O
common	NN	O	O
in	NN	O	O
subjects	NN	O	O
on	NN	O	O
clonidine	NN	O	O
(	NN	O	O
79	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
versus	NN	O	O
49	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
.	NN	O	O
0006	NN	O	O
)	NN	O	O
but	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
higher	NN	O	O
rates	NN	O	O
of	NN	O	O
early	NN	O	O
study	NN	O	O
withdrawal	NN	O	O
.	NN	O	O

Drowsiness	NN	O	B
was	NN	O	O
common	NN	O	O
on	NN	O	O
clonidine	NN	O	O
,	NN	O	O
but	NN	O	O
generally	NN	O	O
resolved	NN	O	O
by	NN	O	O
6	NN	O	O
to	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Clonidine	NN	O	O
,	NN	O	O
used	NN	O	O
alone	NN	O	O
or	NN	O	O
with	NN	O	O
methylphenidate	NN	O	O
,	NN	O	O
appears	NN	O	O
safe	NN	O	O
and	NN	O	O
well	NN	O	O
tolerated	NN	O	O
in	NN	O	O
childhood	NN	O	O
ADHD	NN	O	B
.	NN	O	O

Physicians	NN	O	O
prescribing	NN	O	O
clonidine	NN	O	O
should	NN	O	O
monitor	NN	O	O
for	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
advise	NN	O	O
patients	NN	O	O
about	NN	O	O
the	NN	O	O
high	NN	O	O
likelihood	NN	O	O
of	NN	O	O
initial	NN	O	O
drowsiness	NN	O	B
.	NN	O	O

Renal	NN	O	B
Fanconi	NN	O	I
syndrome	NN	O	I
and	NN	O	O
myopathy	NN	O	B
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
:	NN	O	O
drug	NN	O	O
-	NN	O	O
related	NN	O	O
mitochondrial	NN	O	B
cytopathy	NN	O	I
?	NN	O	O

Advances	NN	O	O
in	NN	O	O
the	NN	O	O
field	NN	O	O
of	NN	O	O
transplantation	NN	O	O
provide	NN	O	O
a	NN	O	O
better	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
and	NN	O	O
allow	NN	O	O
more	NN	O	O
favorable	NN	O	O
conditions	NN	O	O
for	NN	O	O
growth	NN	O	O
and	NN	O	O
development	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
combinations	NN	O	O
of	NN	O	O
different	NN	O	O
therapeutic	NN	O	O
regimens	NN	O	O
require	NN	O	O
consideration	NN	O	O
of	NN	O	O
potential	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
yr	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
who	NN	O	O
had	NN	O	O
orthotopic	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
because	NN	O	O
of	NN	O	O
Wilson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

Tacrolimus	NN	O	O
,	NN	O	O
MMF	NN	O	O
,	NN	O	O
and	NN	O	O
steroids	NN	O	O
were	NN	O	O
given	NN	O	O
as	NN	O	O
immunosuppressant	NN	O	O
.	NN	O	O

Lamivudine	NN	O	O
was	NN	O	O
added	NN	O	O
because	NN	O	O
of	NN	O	O
de	NN	O	O
nova	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
infection	NN	O	I
during	NN	O	O
her	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

Three	NN	O	O
yr	NN	O	O
after	NN	O	O
transplantation	NN	O	O
she	NN	O	O
developed	NN	O	O
renal	NN	O	B
Fanconi	NN	O	I
syndrome	NN	O	I
with	NN	O	O
severe	NN	O	O
metabolic	NN	O	B
acidosis	NN	O	I
,	NN	O	O
hypophosphatemia	NN	O	B
,	NN	O	O
glycosuria	NN	O	B
,	NN	O	O
and	NN	O	O
aminoaciduria	NN	O	B
.	NN	O	O

Although	NN	O	O
tacrolimus	NN	O	O
was	NN	O	O
suspected	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
late	NN	O	O
post	NN	O	O
-	NN	O	O
transplant	NN	O	O
renal	NN	O	O
acidosis	NN	O	B
and	NN	O	O
was	NN	O	O
replaced	NN	O	O
by	NN	O	O
sirolimus	NN	O	O
,	NN	O	O
acidosis	NN	O	B
,	NN	O	O
and	NN	O	O
electrolyte	NN	O	O
imbalance	NN	O	O
got	NN	O	O
worse	NN	O	O
.	NN	O	O

Proximal	NN	O	O
muscle	NN	O	B
weakness	NN	O	I
has	NN	O	O
developed	NN	O	O
during	NN	O	O
her	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

Fanconi	NN	O	B
syndrome	NN	O	I
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
myopathy	NN	O	B
,	NN	O	O
is	NN	O	O
well	NN	O	O
recognized	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
mitochondrial	NN	O	B
disorders	NN	O	I
and	NN	O	O
caused	NN	O	O
by	NN	O	O
depletion	NN	O	O
of	NN	O	O
mtDNA	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
our	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
tubular	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
myopathy	NN	O	B
may	NN	O	O
have	NN	O	O
resulted	NN	O	O
from	NN	O	O
mitochondrial	NN	O	B
dysfunction	NN	O	I
which	NN	O	O
is	NN	O	O
triggered	NN	O	O
by	NN	O	O
tacrolimus	NN	O	O
and	NN	O	O
augmented	NN	O	O
by	NN	O	O
lamivudine	NN	O	O
.	NN	O	O

Higher	NN	O	O
optical	NN	O	O
density	NN	O	O
of	NN	O	O
an	NN	O	O
antigen	NN	O	O
assay	NN	O	O
predicts	NN	O	O
thrombosis	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
correlate	NN	O	O
optical	NN	O	O
density	NN	O	O
and	NN	O	O
percent	NN	O	O
inhibition	NN	O	O
of	NN	O	O
a	NN	O	O
two	NN	O	O
-	NN	O	O
step	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
(	NN	O	O
HIT	NN	O	B
)	NN	O	O
antigen	NN	O	O
assay	NN	O	O
with	NN	O	O
thrombosis	NN	O	B
;	NN	O	O
the	NN	O	O
assay	NN	O	O
utilizes	NN	O	O
reaction	NN	O	O
inhibition	NN	O	O
characteristics	NN	O	O
of	NN	O	O
a	NN	O	O
high	NN	O	O
heparin	NN	O	O
concentration	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Patients	NN	O	O
with	NN	O	O
more	NN	O	O
than	NN	O	O
50	NN	O	O
%	NN	O	O
decrease	NN	O	O
in	NN	O	O
platelet	NN	O	O
count	NN	O	O
or	NN	O	O
thrombocytopenia	NN	O	B
(	NN	O	O
<	NN	O	O
150	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
heparin	NN	O	O
,	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
positive	NN	O	O
two	NN	O	O
-	NN	O	O
step	NN	O	O
antigen	NN	O	O
assay	NN	O	O
[	NN	O	O
optical	NN	O	O
density	NN	O	O
(	NN	O	O
OD	NN	O	O
)	NN	O	O
>	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
and	NN	O	O
>	NN	O	O
50	NN	O	O
inhibition	NN	O	O
with	NN	O	O
high	NN	O	O
concentration	NN	O	O
of	NN	O	O
heparin	NN	O	O
]	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Forty	NN	O	O
of	NN	O	O
94	NN	O	O
HIT	NN	O	B
patients	NN	O	O
had	NN	O	O
thrombosis	NN	O	B
at	NN	O	O
diagnosis	NN	O	O
;	NN	O	O
54	NN	O	O
/	NN	O	O
94	NN	O	O
had	NN	O	O
isolated	NN	O	O
-	NN	O	O
HIT	NN	O	B
without	NN	O	O
thrombosis	NN	O	B
.	NN	O	O

Eight	NN	O	O
of	NN	O	O
the	NN	O	O
isolated	NN	O	O
-	NN	O	O
HIT	NN	O	B
patients	NN	O	O
developed	NN	O	O
thrombosis	NN	O	B
within	NN	O	O
the	NN	O	O
next	NN	O	O
30	NN	O	O
d	NN	O	O
;	NN	O	O
thus	NN	O	O
,	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
48	NN	O	O
patients	NN	O	O
had	NN	O	O
thrombosis	NN	O	B
at	NN	O	O
day	NN	O	O
30	NN	O	O
.	NN	O	O

At	NN	O	O
diagnosis	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
OD	NN	O	O
between	NN	O	O
HIT	NN	O	B
patients	NN	O	O
with	NN	O	O
thrombosis	NN	O	B
and	NN	O	O
those	NN	O	O
with	NN	O	O
isolated	NN	O	O
-	NN	O	O
HIT	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
OD	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
with	NN	O	O
thrombosis	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
48	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
34	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
89	NN	O	O
)	NN	O	O
,	NN	O	O
including	NN	O	O
isolated	NN	O	O
-	NN	O	O
HIT	NN	O	B
patients	NN	O	O
who	NN	O	O
later	NN	O	O
developed	NN	O	O
thrombosis	NN	O	B
within	NN	O	O
30	NN	O	O
d	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
84	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
64	NN	O	O
)	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
isolated	NN	O	O
-	NN	O	O
HIT	NN	O	B
patients	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
develop	NN	O	O
thrombosis	NN	O	B
(	NN	O	O
0	NN	O	O
.	NN	O	O
96	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
75	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
011	NN	O	O
and	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
008	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
Receiver	NN	O	O
Operative	NN	O	O
Characteristic	NN	O	O
Curve	NN	O	O
showed	NN	O	O
that	NN	O	O
OD	NN	O	O
>	NN	O	O
1	NN	O	O
.	NN	O	O
27	NN	O	O
in	NN	O	O
the	NN	O	O
isolated	NN	O	O
-	NN	O	O
HIT	NN	O	B
group	NN	O	O
had	NN	O	O
a	NN	O	O
significantly	NN	O	O
higher	NN	O	O
chance	NN	O	O
of	NN	O	O
developing	NN	O	O
thrombosis	NN	O	B
by	NN	O	O
day	NN	O	O
30	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
these	NN	O	O
groups	NN	O	O
showed	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
percent	NN	O	O
inhibition	NN	O	O
.	NN	O	O

Multivariate	NN	O	O
analysis	NN	O	O
showed	NN	O	O
a	NN	O	O
2	NN	O	O
.	NN	O	O
8	NN	O	O
-	NN	O	O
fold	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
thrombosis	NN	O	B
in	NN	O	O
females	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
thrombotic	NN	O	B
risk	NN	O	O
increased	NN	O	O
with	NN	O	O
age	NN	O	O
and	NN	O	O
OD	NN	O	O
values	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Higher	NN	O	O
OD	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
significant	NN	O	O
risk	NN	O	O
of	NN	O	O
subsequent	NN	O	O
thrombosis	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
isolated	NN	O	O
-	NN	O	O
HIT	NN	O	B
;	NN	O	O
percent	NN	O	O
inhibition	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
was	NN	O	O
not	NN	O	O
predictive	NN	O	O
.	NN	O	O

Thalidomide	NN	O	O
has	NN	O	O
limited	NN	O	O
single	NN	O	O
-	NN	O	O
agent	NN	O	O
activity	NN	O	O
in	NN	O	O
relapsed	NN	O	O
or	NN	O	O
refractory	NN	O	O
indolent	NN	O	O
non	NN	O	B
-	NN	O	I
Hodgkin	NN	O	I
lymphomas	NN	O	I
:	NN	O	O
a	NN	O	O
phase	NN	O	O
II	NN	O	O
trial	NN	O	O
of	NN	O	O
the	NN	O	O
Cancer	NN	O	B
and	NN	O	O
Leukemia	NN	O	B
Group	NN	O	O
B	NN	O	O
.	NN	O	O

Thalidomide	NN	O	O
is	NN	O	O
an	NN	O	O
immunomodulatory	NN	O	O
agent	NN	O	O
with	NN	O	O
demonstrated	NN	O	O
activity	NN	O	O
in	NN	O	O
multiple	NN	O	B
myeloma	NN	O	I
,	NN	O	O
mantle	NN	O	B
cell	NN	O	I
lymphoma	NN	O	I
and	NN	O	O
lymphoplasmacytic	NN	O	B
lymphoma	NN	O	I
.	NN	O	O

Its	NN	O	O
activity	NN	O	O
is	NN	O	O
believed	NN	O	O
to	NN	O	O
be	NN	O	O
due	NN	O	O
modulation	NN	O	O
of	NN	O	O
the	NN	O	O
tumour	NN	O	B
milieu	NN	O	O
,	NN	O	O
including	NN	O	O
downregulation	NN	O	O
of	NN	O	O
angiogenesis	NN	O	O
and	NN	O	O
inflammatory	NN	O	O
cytokines	NN	O	O
.	NN	O	O

Between	NN	O	O
July	NN	O	O
2001	NN	O	O
and	NN	O	O
April	NN	O	O
2004	NN	O	O
,	NN	O	O
24	NN	O	O
patients	NN	O	O
with	NN	O	O
relapsed	NN	O	O
/	NN	O	O
refractory	NN	O	O
indolent	NN	O	O
lymphomas	NN	O	B
received	NN	O	O
thalidomide	NN	O	O
200	NN	O	O
mg	NN	O	O
daily	NN	O	O
with	NN	O	O
escalation	NN	O	O
by	NN	O	O
100	NN	O	O
mg	NN	O	O
daily	NN	O	O
every	NN	O	O
1	NN	O	O
-	NN	O	O
2	NN	O	O
weeks	NN	O	O
as	NN	O	O
tolerated	NN	O	O
,	NN	O	O
up	NN	O	O
to	NN	O	O
a	NN	O	O
maximum	NN	O	O
of	NN	O	O
800	NN	O	O
mg	NN	O	O
daily	NN	O	O
.	NN	O	O

Patients	NN	O	O
had	NN	O	O
received	NN	O	O
a	NN	O	O
median	NN	O	O
of	NN	O	O
2	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
1	NN	O	O
-	NN	O	O
4	NN	O	O
)	NN	O	O
prior	NN	O	O
regimens	NN	O	O
.	NN	O	O

Of	NN	O	O
24	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
,	NN	O	O
two	NN	O	O
achieved	NN	O	O
a	NN	O	O
complete	NN	O	O
remission	NN	O	O
and	NN	O	O
one	NN	O	O
achieved	NN	O	O
a	NN	O	O
partial	NN	O	O
remission	NN	O	O
for	NN	O	O
an	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
of	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
:	NN	O	O
2	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
32	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Eleven	NN	O	O
patients	NN	O	O
progressed	NN	O	O
during	NN	O	O
therapy	NN	O	O
.	NN	O	O

Grade	NN	O	O
3	NN	O	O
-	NN	O	O
4	NN	O	O
adverse	NN	O	O
effects	NN	O	O
included	NN	O	O
myelosuppression	NN	O	B
,	NN	O	O
fatigue	NN	O	B
,	NN	O	O
somnolence	NN	O	B
/	NN	O	O
depressed	NN	O	B
mood	NN	O	I
,	NN	O	O
neuropathy	NN	O	B
and	NN	O	O
dyspnea	NN	O	B
.	NN	O	O

Of	NN	O	O
concern	NN	O	O
was	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
four	NN	O	O
thromboembolic	NN	O	B
events	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
failed	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
an	NN	O	O
important	NN	O	O
response	NN	O	O
rate	NN	O	O
to	NN	O	O
single	NN	O	O
agent	NN	O	O
thalidomide	NN	O	O
in	NN	O	O
indolent	NN	O	O
lymphomas	NN	O	B
and	NN	O	O
contrast	NN	O	O
with	NN	O	O
the	NN	O	O
higher	NN	O	O
activity	NN	O	O
level	NN	O	O
reported	NN	O	O
with	NN	O	O
the	NN	O	O
second	NN	O	O
generation	NN	O	O
immunomodulatory	NN	O	O
agent	NN	O	O
,	NN	O	O
lenalidomide	NN	O	O
.	NN	O	O

Sex	NN	O	O
differences	NN	O	O
in	NN	O	O
NMDA	NN	O	O
antagonist	NN	O	O
enhancement	NN	O	O
of	NN	O	O
morphine	NN	O	O
antihyperalgesia	NN	O	O
in	NN	O	O
a	NN	O	O
capsaicin	NN	O	O
model	NN	O	O
of	NN	O	O
persistent	NN	O	O
pain	NN	O	B
:	NN	O	O
comparisons	NN	O	O
to	NN	O	O
two	NN	O	O
models	NN	O	O
of	NN	O	O
acute	NN	O	B
pain	NN	O	I
.	NN	O	O

In	NN	O	O
acute	NN	O	B
pain	NN	O	I
models	NN	O	O
,	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
(	NN	O	O
NMDA	NN	O	O
)	NN	O	O
antagonists	NN	O	O
enhance	NN	O	O
the	NN	O	O
antinociceptive	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	O
to	NN	O	O
a	NN	O	O
greater	NN	O	O
extent	NN	O	O
in	NN	O	O
males	NN	O	O
than	NN	O	O
females	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
investigation	NN	O	O
was	NN	O	O
to	NN	O	O
extend	NN	O	O
these	NN	O	O
findings	NN	O	O
to	NN	O	O
a	NN	O	O
persistent	NN	O	O
pain	NN	O	B
model	NN	O	O
which	NN	O	O
could	NN	O	O
be	NN	O	O
distinguished	NN	O	O
from	NN	O	O
acute	NN	O	B
pain	NN	O	I
models	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
the	NN	O	O
nociceptive	NN	O	O
fibers	NN	O	O
activated	NN	O	O
,	NN	O	O
neurochemical	NN	O	O
substrates	NN	O	O
,	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
nociceptive	NN	O	O
stimulus	NN	O	O
.	NN	O	O

To	NN	O	O
this	NN	O	O
end	NN	O	O
,	NN	O	O
persistent	NN	O	O
hyperalgesia	NN	O	B
was	NN	O	O
induced	NN	O	O
by	NN	O	O
administration	NN	O	O
of	NN	O	O
capsaicin	NN	O	O
in	NN	O	O
the	NN	O	O
tail	NN	O	O
of	NN	O	O
gonadally	NN	O	O
intact	NN	O	O
F344	NN	O	O
rats	NN	O	O
,	NN	O	O
following	NN	O	O
which	NN	O	O
the	NN	O	O
tail	NN	O	O
was	NN	O	O
immersed	NN	O	O
in	NN	O	O
a	NN	O	O
mildly	NN	O	O
noxious	NN	O	O
thermal	NN	O	O
stimulus	NN	O	O
,	NN	O	O
and	NN	O	O
tail	NN	O	O
-	NN	O	O
withdrawal	NN	O	O
latencies	NN	O	O
measured	NN	O	O
.	NN	O	O

For	NN	O	O
comparison	NN	O	O
,	NN	O	O
tests	NN	O	O
were	NN	O	O
conducted	NN	O	O
in	NN	O	O
two	NN	O	O
acute	NN	O	B
pain	NN	O	I
models	NN	O	O
,	NN	O	O
the	NN	O	O
hotplate	NN	O	O
and	NN	O	O
warm	NN	O	O
water	NN	O	O
tail	NN	O	O
-	NN	O	O
withdrawal	NN	O	O
procedures	NN	O	O
.	NN	O	O

In	NN	O	O
males	NN	O	O
,	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
competitive	NN	O	O
NMDA	NN	O	O
antagonist	NN	O	O
dextromethorphan	NN	O	O
enhanced	NN	O	O
the	NN	O	O
antihyperalgesic	NN	O	O
effect	NN	O	O
of	NN	O	O
low	NN	O	O
to	NN	O	O
moderate	NN	O	O
doses	NN	O	O
of	NN	O	O
morphine	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
and	NN	O	O
time	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

Across	NN	O	O
the	NN	O	O
doses	NN	O	O
and	NN	O	O
pretreatment	NN	O	O
times	NN	O	O
examined	NN	O	O
,	NN	O	O
enhancement	NN	O	O
was	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
females	NN	O	O
.	NN	O	O

Enhancement	NN	O	O
of	NN	O	O
morphine	NN	O	O
antinociception	NN	O	O
by	NN	O	O
dextromethorphan	NN	O	O
was	NN	O	O
seen	NN	O	O
in	NN	O	O
both	NN	O	O
males	NN	O	O
and	NN	O	O
females	NN	O	O
in	NN	O	O
the	NN	O	O
acute	NN	O	B
pain	NN	O	I
models	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
magnitude	NN	O	O
of	NN	O	O
this	NN	O	O
effect	NN	O	O
being	NN	O	O
greater	NN	O	O
in	NN	O	O
males	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
sexually	NN	O	O
-	NN	O	O
dimorphic	NN	O	O
interaction	NN	O	O
between	NN	O	O
NMDA	NN	O	O
antagonists	NN	O	O
and	NN	O	O
morphine	NN	O	O
in	NN	O	O
a	NN	O	O
persistent	NN	O	O
pain	NN	O	B
model	NN	O	O
that	NN	O	O
can	NN	O	O
be	NN	O	O
distinguished	NN	O	O
from	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
acute	NN	O	B
pain	NN	O	I
models	NN	O	O
.	NN	O	O

Development	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
after	NN	O	O
switch	NN	O	O
to	NN	O	O
sirolimus	NN	O	O
-	NN	O	O
based	NN	O	O
immunosuppression	NN	O	O
in	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
cardiac	NN	O	O
transplant	NN	O	O
patients	NN	O	O
.	NN	O	O

Calcineurin	NN	O	O
-	NN	O	O
inhibitor	NN	O	O
therapy	NN	O	O
can	NN	O	O
lead	NN	O	O
to	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
in	NN	O	O
heart	NN	O	O
transplantation	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
novel	NN	O	O
immunosuppressive	NN	O	O
(	NN	O	O
IS	NN	O	O
)	NN	O	O
drug	NN	O	O
sirolmus	NN	O	O
(	NN	O	O
Srl	NN	O	O
)	NN	O	O
lacks	NN	O	O
nephrotoxic	NN	O	B
effects	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
proteinuria	NN	O	B
associated	NN	O	O
with	NN	O	O
Srl	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
following	NN	O	O
renal	NN	O	O
transplantation	NN	O	O
.	NN	O	O

In	NN	O	O
cardiac	NN	O	O
transplantation	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
associated	NN	O	O
with	NN	O	O
Srl	NN	O	O
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
cardiac	NN	O	O
transplant	NN	O	O
patients	NN	O	O
were	NN	O	O
switched	NN	O	O
from	NN	O	O
cyclosporine	NN	O	O
to	NN	O	O
Srl	NN	O	O
-	NN	O	O
based	NN	O	O
IS	NN	O	O
.	NN	O	O

Concomitant	NN	O	O
IS	NN	O	O
consisted	NN	O	O
of	NN	O	O
mycophenolate	NN	O	O
mofetil	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
steroids	NN	O	O
.	NN	O	O

Proteinuria	NN	O	O
increased	NN	O	O
significantly	NN	O	O
from	NN	O	O
a	NN	O	O
median	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
13	NN	O	O
g	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
range	NN	O	O
0	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
preswitch	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
23	NN	O	O
g	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O
88	NN	O	O
)	NN	O	O
at	NN	O	O
24	NN	O	O
months	NN	O	O
postswitch	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0024	NN	O	O
)	NN	O	O
.	NN	O	O

Before	NN	O	O
the	NN	O	O
switch	NN	O	O
,	NN	O	O
11	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
had	NN	O	O
high	NN	O	O
-	NN	O	O
grade	NN	O	O
proteinuria	NN	O	B
(	NN	O	O
>	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
g	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
;	NN	O	O
this	NN	O	O
increased	NN	O	O
to	NN	O	O
22	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
postswitch	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
006	NN	O	O
)	NN	O	O
.	NN	O	O

ACE	NN	O	O
inhibitor	NN	O	O
and	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
releasing	NN	O	O
blocker	NN	O	O
(	NN	O	O
ARB	NN	O	O
)	NN	O	O
therapy	NN	O	O
reduced	NN	O	O
proteinuria	NN	O	B
development	NN	O	O
.	NN	O	O

Patients	NN	O	O
without	NN	O	O
proteinuria	NN	O	B
had	NN	O	O
increased	NN	O	O
renal	NN	O	O
function	NN	O	O
(	NN	O	O
median	NN	O	O
42	NN	O	O
.	NN	O	O
5	NN	O	O
vs	NN	O	O
.	NN	O	O
64	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
high	NN	O	O
-	NN	O	O
grade	NN	O	O
proteinuria	NN	O	B
showed	NN	O	O
decreased	NN	O	O
renal	NN	O	O
function	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
(	NN	O	O
median	NN	O	O
39	NN	O	O
.	NN	O	O
6	NN	O	O
vs	NN	O	O
.	NN	O	O
29	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
125	NN	O	O
)	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
proteinuria	NN	O	B
may	NN	O	O
develop	NN	O	O
in	NN	O	O
cardiac	NN	O	O
transplant	NN	O	O
patients	NN	O	O
after	NN	O	O
switch	NN	O	O
to	NN	O	O
Srl	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
have	NN	O	O
an	NN	O	O
adverse	NN	O	O
effect	NN	O	O
on	NN	O	O
renal	NN	O	O
function	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

Srl	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
with	NN	O	O
ACEi	NN	O	O
/	NN	O	O
ARB	NN	O	O
therapy	NN	O	O
and	NN	O	O
patients	NN	O	O
monitored	NN	O	O
for	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
increased	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Ginsenoside	NN	O	O
Rg1	NN	O	O
restores	NN	O	O
the	NN	O	O
impairment	NN	O	B
of	NN	O	I
learning	NN	O	I
induced	NN	O	O
by	NN	O	O
chronic	NN	O	O
morphine	NN	O	O
administration	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Rg1	NN	O	O
,	NN	O	O
as	NN	O	O
a	NN	O	O
ginsenoside	NN	O	O
extracted	NN	O	O
from	NN	O	O
Panax	NN	O	O
ginseng	NN	O	O
,	NN	O	O
could	NN	O	O
ameliorate	NN	O	O
spatial	NN	O	O
learning	NN	O	B
impairment	NN	O	I
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
Rg1	NN	O	O
might	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
agent	NN	O	O
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
and	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
Rg1	NN	O	O
on	NN	O	O
learning	NN	O	B
impairment	NN	O	I
by	NN	O	O
chronic	NN	O	O
morphine	NN	O	O
administration	NN	O	O
and	NN	O	O
the	NN	O	O
mechanism	NN	O	O
responsible	NN	O	O
for	NN	O	O
this	NN	O	O
effect	NN	O	O
.	NN	O	O

Male	NN	O	O
rats	NN	O	O
were	NN	O	O
subcutaneously	NN	O	O
injected	NN	O	O
with	NN	O	O
morphine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
twice	NN	O	O
a	NN	O	O
day	NN	O	O
at	NN	O	O
12	NN	O	O
hour	NN	O	O
intervals	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
,	NN	O	O
and	NN	O	O
Rg1	NN	O	O
(	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
intraperitoneally	NN	O	O
injected	NN	O	O
2	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
second	NN	O	O
injection	NN	O	O
of	NN	O	O
morphine	NN	O	O
once	NN	O	O
a	NN	O	O
day	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
.	NN	O	O

Spatial	NN	O	O
learning	NN	O	O
capacity	NN	O	O
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
the	NN	O	O
Morris	NN	O	O
water	NN	O	O
maze	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
Morphine	NN	O	O
/	NN	O	O
Rg1	NN	O	O
decreased	NN	O	O
escape	NN	O	O
latency	NN	O	O
and	NN	O	O
increased	NN	O	O
the	NN	O	O
time	NN	O	O
spent	NN	O	O
in	NN	O	O
platform	NN	O	O
quadrant	NN	O	O
and	NN	O	O
entering	NN	O	O
frequency	NN	O	O
.	NN	O	O

By	NN	O	O
implantation	NN	O	O
of	NN	O	O
electrodes	NN	O	O
and	NN	O	O
electrophysiological	NN	O	O
recording	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
the	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
Rg1	NN	O	O
restored	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
potentiation	NN	O	O
(	NN	O	O
LTP	NN	O	O
)	NN	O	O
impaired	NN	O	O
by	NN	O	O
morphine	NN	O	O
in	NN	O	O
both	NN	O	O
freely	NN	O	O
moving	NN	O	O
and	NN	O	O
anaesthetised	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
electrophysiological	NN	O	O
recording	NN	O	O
in	NN	O	O
vitro	NN	O	O
showed	NN	O	O
that	NN	O	O
Rg1	NN	O	O
restored	NN	O	O
the	NN	O	O
LTP	NN	O	O
in	NN	O	O
slices	NN	O	O
from	NN	O	O
the	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
morphine	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
changed	NN	O	O
LTP	NN	O	O
in	NN	O	O
the	NN	O	O
slices	NN	O	O
from	NN	O	O
normal	NN	O	O
saline	NN	O	O
-	NN	O	O
or	NN	O	O
morphine	NN	O	O
/	NN	O	O
Rg1	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
;	NN	O	O
this	NN	O	O
restoration	NN	O	O
could	NN	O	O
be	NN	O	O
inhibited	NN	O	O
by	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
(	NN	O	O
NMDA	NN	O	O
)	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
MK801	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
Rg1	NN	O	O
may	NN	O	O
significantly	NN	O	O
improve	NN	O	O
the	NN	O	O
spatial	NN	O	O
learning	NN	O	O
capacity	NN	O	O
impaired	NN	O	O
by	NN	O	O
chonic	NN	O	O
morphine	NN	O	O
administration	NN	O	O
and	NN	O	O
restore	NN	O	O
the	NN	O	O
morphine	NN	O	O
-	NN	O	O
inhibited	NN	O	O
LTP	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
is	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
dependent	NN	O	O
.	NN	O	O

Synthesis	NN	O	O
of	NN	O	O
N	NN	O	O
-	NN	O	O
pyrimidinyl	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
phenoxyacetamides	NN	O	O
as	NN	O	O
adenosine	NN	O	O
A2A	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
.	NN	O	O

A	NN	O	O
series	NN	O	O
of	NN	O	O
N	NN	O	O
-	NN	O	O
pyrimidinyl	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
phenoxyacetamide	NN	O	O
adenosine	NN	O	O
A	NN	O	O
(	NN	O	O
2A	NN	O	O
)	NN	O	O
antagonists	NN	O	O
is	NN	O	O
described	NN	O	O
.	NN	O	O

SAR	NN	O	O
studies	NN	O	O
led	NN	O	O
to	NN	O	O
compound	NN	O	O
14	NN	O	O
with	NN	O	O
excellent	NN	O	O
potency	NN	O	O
(	NN	O	O
K	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
4	NN	O	O
nM	NN	O	O
)	NN	O	O
,	NN	O	O
selectivity	NN	O	O
(	NN	O	O
A	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
/	NN	O	O
A	NN	O	O
(	NN	O	O
2A	NN	O	O
)	NN	O	O
>	NN	O	O
100	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
efficacy	NN	O	O
(	NN	O	O
MED	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
model	NN	O	O
for	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

Evidence	NN	O	O
for	NN	O	O
an	NN	O	O
involvement	NN	O	O
of	NN	O	O
D1	NN	O	O
and	NN	O	O
D2	NN	O	O
dopamine	NN	O	O
receptors	NN	O	O
in	NN	O	O
mediating	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
suggested	NN	O	O
that	NN	O	O
repeated	NN	O	O
exposure	NN	O	O
of	NN	O	O
rats	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
or	NN	O	O
to	NN	O	O
the	NN	O	O
experimental	NN	O	O
environment	NN	O	O
is	NN	O	O
necessary	NN	O	O
to	NN	O	O
observe	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
stimulation	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
habituation	NN	O	O
to	NN	O	O
the	NN	O	O
experimental	NN	O	O
environment	NN	O	O
on	NN	O	O
the	NN	O	O
stimulant	NN	O	O
effect	NN	O	O
of	NN	O	O
nicotine	NN	O	O
in	NN	O	O
rats	NN	O	O
was	NN	O	O
examined	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
dopamine	NN	O	O
receptors	NN	O	O
in	NN	O	O
mediating	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
stimulation	NN	O	O
was	NN	O	O
investigated	NN	O	O
by	NN	O	O
examining	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
selective	NN	O	O
D1	NN	O	O
and	NN	O	O
D2	NN	O	O
dopamine	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
on	NN	O	O
activity	NN	O	O
induced	NN	O	O
by	NN	O	O
nicotine	NN	O	O
.	NN	O	O

Locomotor	NN	O	O
activity	NN	O	O
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
tested	NN	O	O
in	NN	O	O
photocell	NN	O	O
cages	NN	O	O
.	NN	O	O

Nicotine	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
caused	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	B
in	NN	O	I
locomotor	NN	O	I
activity	NN	O	I
in	NN	O	O
rats	NN	O	O
that	NN	O	O
were	NN	O	O
habituated	NN	O	O
to	NN	O	O
the	NN	O	O
test	NN	O	O
environment	NN	O	O
,	NN	O	O
but	NN	O	O
had	NN	O	O
only	NN	O	O
a	NN	O	O
weak	NN	O	O
and	NN	O	O
delayed	NN	O	O
stimulant	NN	O	O
action	NN	O	O
in	NN	O	O
rats	NN	O	O
that	NN	O	O
were	NN	O	O
unfamiliar	NN	O	O
with	NN	O	O
the	NN	O	O
test	NN	O	O
environment	NN	O	O
.	NN	O	O

The	NN	O	O
stimulant	NN	O	O
action	NN	O	O
of	NN	O	O
nicotine	NN	O	O
was	NN	O	O
blocked	NN	O	O
by	NN	O	O
the	NN	O	O
central	NN	O	O
nicotinic	NN	O	O
antagonist	NN	O	O
mecamylamine	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
the	NN	O	O
peripheral	NN	O	O
nicotinic	NN	O	O
blocker	NN	O	O
hexamethonium	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
response	NN	O	O
is	NN	O	O
probably	NN	O	O
mediated	NN	O	O
by	NN	O	O
central	NN	O	O
nicotinic	NN	O	O
receptors	NN	O	O
.	NN	O	O

Nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
was	NN	O	O
blocked	NN	O	O
by	NN	O	O
the	NN	O	O
selective	NN	O	O
D1	NN	O	O
antagonist	NN	O	O
SCH	NN	O	O
23390	NN	O	O
,	NN	O	O
the	NN	O	O
selective	NN	O	O
D2	NN	O	O
antagonist	NN	O	O
raclopride	NN	O	O
and	NN	O	O
the	NN	O	O
D1	NN	O	O
/	NN	O	O
D2	NN	O	O
antagonist	NN	O	O
fluphenazine	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
the	NN	O	O
D2	NN	O	O
agonist	NN	O	O
PHNO	NN	O	O
enhanced	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
D1	NN	O	O
agonist	NN	O	O
SKF	NN	O	O
38393	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
acute	NN	O	O
nicotine	NN	O	O
injection	NN	O	O
induces	NN	O	O
a	NN	O	O
pronounced	NN	O	O
hyperactivity	NN	O	B
in	NN	O	O
rats	NN	O	O
habituated	NN	O	O
to	NN	O	O
the	NN	O	O
test	NN	O	O
environment	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
mediated	NN	O	O
by	NN	O	O
central	NN	O	O
nicotine	NN	O	O
receptors	NN	O	O
,	NN	O	O
possibly	NN	O	O
located	NN	O	O
on	NN	O	O
dopaminergic	NN	O	O
neurons	NN	O	O
,	NN	O	O
and	NN	O	O
also	NN	O	O
requires	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
both	NN	O	O
D1	NN	O	O
and	NN	O	O
D2	NN	O	O
dopamine	NN	O	O
receptors	NN	O	O
.	NN	O	O

Central	NN	O	O
retinal	NN	O	B
vein	NN	O	I
occlusion	NN	O	I
associated	NN	O	O
with	NN	O	O
clomiphene	NN	O	O
-	NN	O	O
induced	NN	O	O
ovulation	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
central	NN	O	O
retinal	NN	O	B
vein	NN	O	I
occlusion	NN	O	I
associated	NN	O	O
with	NN	O	O
clomiphene	NN	O	O
citrate	NN	O	O
(	NN	O	O
CC	NN	O	O
)	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Case	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Ophthalmology	NN	O	O
clinic	NN	O	O
of	NN	O	O
an	NN	O	O
academic	NN	O	O
hospital	NN	O	O
.	NN	O	O

PATIENT	NN	O	O
(	NN	O	O
S	NN	O	O
)	NN	O	O
:	NN	O	O
A	NN	O	O
36	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
referred	NN	O	O
from	NN	O	O
the	NN	O	O
infertility	NN	O	B
clinic	NN	O	O
for	NN	O	O
blurred	NN	O	B
vision	NN	O	I
.	NN	O	O

INTERVENTION	NN	O	O
(	NN	O	O
S	NN	O	O
)	NN	O	O
:	NN	O	O
Ophthalmic	NN	O	O
examination	NN	O	O
after	NN	O	O
CC	NN	O	O
therapy	NN	O	O
.	NN	O	O

MAIN	NN	O	O
OUTCOME	NN	O	O
MEASURE	NN	O	O
(	NN	O	O
S	NN	O	O
)	NN	O	O
:	NN	O	O
Central	NN	O	O
retinal	NN	O	B
vein	NN	O	I
occlusion	NN	O	I
after	NN	O	O
ovulation	NN	O	O
induction	NN	O	O
with	NN	O	O
CC	NN	O	O
.	NN	O	O

RESULT	NN	O	O
(	NN	O	O
S	NN	O	O
)	NN	O	O
:	NN	O	O
A	NN	O	O
36	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Chinese	NN	O	O
woman	NN	O	O
developed	NN	O	O
central	NN	O	O
retinal	NN	O	B
vein	NN	O	I
occlusion	NN	O	I
after	NN	O	O
eight	NN	O	O
courses	NN	O	O
of	NN	O	O
CC	NN	O	O
.	NN	O	O

A	NN	O	O
search	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
on	NN	O	O
the	NN	O	O
thromboembolic	NN	O	B
complications	NN	O	O
of	NN	O	O
CC	NN	O	O
does	NN	O	O
not	NN	O	O
include	NN	O	O
this	NN	O	O
severe	NN	O	O
ophthalmic	NN	O	O
complication	NN	O	O
,	NN	O	O
although	NN	O	O
mild	NN	O	O
visual	NN	O	B
disturbance	NN	O	I
after	NN	O	O
CC	NN	O	O
intake	NN	O	O
is	NN	O	O
not	NN	O	O
uncommon	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
(	NN	O	O
S	NN	O	O
)	NN	O	O
:	NN	O	O
This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
of	NN	O	O
central	NN	O	O
retinal	NN	O	B
vein	NN	O	I
occlusion	NN	O	I
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
CC	NN	O	O
.	NN	O	O

Extra	NN	O	O
caution	NN	O	O
is	NN	O	O
warranted	NN	O	O
in	NN	O	O
treating	NN	O	O
infertility	NN	O	B
patients	NN	O	O
with	NN	O	O
CC	NN	O	O
,	NN	O	O
and	NN	O	O
patients	NN	O	O
should	NN	O	O
be	NN	O	O
well	NN	O	O
informed	NN	O	O
of	NN	O	O
this	NN	O	O
side	NN	O	O
effect	NN	O	O
before	NN	O	O
commencement	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

Acute	NN	O	O
bronchodilating	NN	O	O
effects	NN	O	O
of	NN	O	O
ipratropium	NN	O	O
bromide	NN	O	O
and	NN	O	O
theophylline	NN	O	O
in	NN	O	O
chronic	NN	O	B
obstructive	NN	O	I
pulmonary	NN	O	I
disease	NN	O	I
.	NN	O	O

The	NN	O	O
bronchodilator	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
ipratropium	NN	O	O
bromide	NN	O	O
aerosol	NN	O	O
(	NN	O	O
36	NN	O	O
micrograms	NN	O	O
)	NN	O	O
and	NN	O	O
short	NN	O	O
-	NN	O	O
acting	NN	O	O
theophylline	NN	O	O
tablets	NN	O	O
(	NN	O	O
dose	NN	O	O
titrated	NN	O	O
to	NN	O	O
produce	NN	O	O
serum	NN	O	O
levels	NN	O	O
of	NN	O	O
10	NN	O	O
-	NN	O	O
20	NN	O	O
micrograms	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
were	NN	O	O
compared	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
crossover	NN	O	O
study	NN	O	O
in	NN	O	O
21	NN	O	O
patients	NN	O	O
with	NN	O	O
stable	NN	O	O
,	NN	O	O
chronic	NN	O	B
obstructive	NN	O	I
pulmonary	NN	O	I
disease	NN	O	I
.	NN	O	O

Mean	NN	O	O
peak	NN	O	O
forced	NN	O	O
expiratory	NN	O	O
volume	NN	O	O
in	NN	O	O
1	NN	O	O
second	NN	O	O
(	NN	O	O
FEV1	NN	O	O
)	NN	O	O
increases	NN	O	O
over	NN	O	O
baseline	NN	O	O
and	NN	O	O
the	NN	O	O
proportion	NN	O	O
of	NN	O	O
patients	NN	O	O
attaining	NN	O	O
at	NN	O	O
least	NN	O	O
a	NN	O	O
15	NN	O	O
%	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
FEV1	NN	O	O
(	NN	O	O
responders	NN	O	O
)	NN	O	O
were	NN	O	O
31	NN	O	O
%	NN	O	O
and	NN	O	O
90	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
for	NN	O	O
ipratropium	NN	O	O
and	NN	O	O
17	NN	O	O
%	NN	O	O
and	NN	O	O
50	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
for	NN	O	O
theophylline	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
FEV1	NN	O	O
increases	NN	O	O
during	NN	O	O
the	NN	O	O
6	NN	O	O
-	NN	O	O
hour	NN	O	O
observation	NN	O	O
period	NN	O	O
were	NN	O	O
18	NN	O	O
%	NN	O	O
for	NN	O	O
ipratropium	NN	O	O
and	NN	O	O
8	NN	O	O
%	NN	O	O
for	NN	O	O
theophylline	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
was	NN	O	O
3	NN	O	O
.	NN	O	O
8	NN	O	O
hours	NN	O	O
with	NN	O	O
ipratropium	NN	O	O
and	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
hours	NN	O	O
with	NN	O	O
theophylline	NN	O	O
.	NN	O	O

While	NN	O	O
side	NN	O	O
effects	NN	O	O
were	NN	O	O
rare	NN	O	O
,	NN	O	O
those	NN	O	O
experienced	NN	O	O
after	NN	O	O
theophylline	NN	O	O
use	NN	O	O
did	NN	O	O
involve	NN	O	O
the	NN	O	O
cardiovascular	NN	O	B
and	NN	O	I
gastrointestinal	NN	O	I
systems	NN	O	I
.	NN	O	O

These	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
ipratropium	NN	O	O
is	NN	O	O
a	NN	O	O
more	NN	O	O
potent	NN	O	O
bronchodilator	NN	O	O
than	NN	O	O
oral	NN	O	O
theophylline	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	B
airflow	NN	O	I
obstruction	NN	O	I
.	NN	O	O

Methamphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B
and	NN	O	O
microglial	NN	O	O
activation	NN	O	O
are	NN	O	O
not	NN	O	O
mediated	NN	O	O
by	NN	O	O
fractalkine	NN	O	O
receptor	NN	O	O
signaling	NN	O	O
.	NN	O	O

Methamphetamine	NN	O	O
(	NN	O	O
METH	NN	O	O
)	NN	O	O
damages	NN	O	O
dopamine	NN	O	O
(	NN	O	O
DA	NN	O	O
)	NN	O	O
nerve	NN	O	O
endings	NN	O	O
by	NN	O	O
a	NN	O	O
process	NN	O	O
that	NN	O	O
has	NN	O	O
been	NN	O	O
linked	NN	O	O
to	NN	O	O
microglial	NN	O	O
activation	NN	O	O
but	NN	O	O
the	NN	O	O
signaling	NN	O	O
pathways	NN	O	O
that	NN	O	O
mediate	NN	O	O
this	NN	O	O
response	NN	O	O
have	NN	O	O
not	NN	O	O
yet	NN	O	O
been	NN	O	O
delineated	NN	O	O
.	NN	O	O

Cardona	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O

[	NN	O	O
Nat	NN	O	O
.	NN	O	O
Neurosci	NN	O	O
.	NN	O	O
9	NN	O	O
(	NN	O	O
2006	NN	O	O
)	NN	O	O
,	NN	O	O
917	NN	O	O
]	NN	O	O
recently	NN	O	O
identified	NN	O	O
the	NN	O	O
microglial	NN	O	O
-	NN	O	O
specific	NN	O	O
fractalkine	NN	O	O
receptor	NN	O	O
(	NN	O	O
CX3CR1	NN	O	O
)	NN	O	O
as	NN	O	O
an	NN	O	O
important	NN	O	O
mediator	NN	O	O
of	NN	O	O
MPTP	NN	O	O
-	NN	O	O
induced	NN	O	O
neurodegeneration	NN	O	B
of	NN	O	O
DA	NN	O	O
neurons	NN	O	O
.	NN	O	O

Because	NN	O	O
the	NN	O	O
CNS	NN	O	B
damage	NN	O	I
caused	NN	O	O
by	NN	O	O
METH	NN	O	O
and	NN	O	O
MPTP	NN	O	O
is	NN	O	O
highly	NN	O	O
selective	NN	O	O
for	NN	O	O
the	NN	O	O
DA	NN	O	O
neuronal	NN	O	O
system	NN	O	O
in	NN	O	O
mouse	NN	O	O
models	NN	O	O
of	NN	O	O
neurotoxicity	NN	O	B
,	NN	O	O
we	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
the	NN	O	O
CX3CR1	NN	O	O
plays	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
METH	NN	O	O
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B
and	NN	O	O
microglial	NN	O	O
activation	NN	O	O
.	NN	O	O

Mice	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
CX3CR1	NN	O	O
gene	NN	O	O
has	NN	O	O
been	NN	O	O
deleted	NN	O	O
and	NN	O	O
replaced	NN	O	O
with	NN	O	O
a	NN	O	O
cDNA	NN	O	O
encoding	NN	O	O
enhanced	NN	O	O
green	NN	O	O
fluorescent	NN	O	O
protein	NN	O	O
(	NN	O	O
eGFP	NN	O	O
)	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
METH	NN	O	O
and	NN	O	O
examined	NN	O	O
for	NN	O	O
striatal	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

METH	NN	O	O
depleted	NN	O	O
DA	NN	O	O
,	NN	O	O
caused	NN	O	O
microglial	NN	O	O
activation	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
body	NN	O	O
temperature	NN	O	O
in	NN	O	O
CX3CR1	NN	O	O
knockout	NN	O	O
mice	NN	O	O
to	NN	O	O
the	NN	O	O
same	NN	O	O
extent	NN	O	O
and	NN	O	O
over	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
course	NN	O	O
seen	NN	O	O
in	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
METH	NN	O	O
in	NN	O	O
CX3CR1	NN	O	O
knockout	NN	O	O
mice	NN	O	O
were	NN	O	O
not	NN	O	O
gender	NN	O	O
-	NN	O	O
dependent	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
extend	NN	O	O
beyond	NN	O	O
the	NN	O	O
striatum	NN	O	O
.	NN	O	O

Striatal	NN	O	O
microglia	NN	O	O
expressing	NN	O	O
eGFP	NN	O	O
constitutively	NN	O	O
show	NN	O	O
morphological	NN	O	O
changes	NN	O	O
after	NN	O	O
METH	NN	O	O
that	NN	O	O
are	NN	O	O
characteristic	NN	O	O
of	NN	O	O
activation	NN	O	O
.	NN	O	O

This	NN	O	O
response	NN	O	O
was	NN	O	O
restricted	NN	O	O
to	NN	O	O
the	NN	O	O
striatum	NN	O	O
and	NN	O	O
contrasted	NN	O	O
sharply	NN	O	O
with	NN	O	O
unresponsive	NN	O	O
eGFP	NN	O	O
-	NN	O	O
microglia	NN	O	O
in	NN	O	O
surrounding	NN	O	O
brain	NN	O	O
areas	NN	O	O
that	NN	O	O
are	NN	O	O
not	NN	O	O
damaged	NN	O	O
by	NN	O	O
METH	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
from	NN	O	O
these	NN	O	O
studies	NN	O	O
that	NN	O	O
CX3CR1	NN	O	O
signaling	NN	O	O
does	NN	O	O
not	NN	O	O
modulate	NN	O	O
METH	NN	O	O
neurotoxicity	NN	O	B
or	NN	O	O
microglial	NN	O	O
activation	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
it	NN	O	O
appears	NN	O	O
that	NN	O	O
striatal	NN	O	O
-	NN	O	O
resident	NN	O	O
microglia	NN	O	O
respond	NN	O	O
to	NN	O	O
METH	NN	O	O
with	NN	O	O
an	NN	O	O
activation	NN	O	O
cascade	NN	O	O
and	NN	O	O
then	NN	O	O
return	NN	O	O
to	NN	O	O
a	NN	O	O
surveying	NN	O	O
state	NN	O	O
without	NN	O	O
undergoing	NN	O	O
apoptosis	NN	O	O
or	NN	O	O
migration	NN	O	O
.	NN	O	O

Nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
nystagmus	NN	O	B
correlates	NN	O	O
with	NN	O	O
midpontine	NN	O	O
activation	NN	O	O
.	NN	O	O

The	NN	O	O
pathomechanism	NN	O	O
of	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
nystagmus	NN	O	B
(	NN	O	O
NIN	NN	O	B
)	NN	O	O
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
delineate	NN	O	O
brain	NN	O	O
structures	NN	O	O
that	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
NIN	NN	O	B
generation	NN	O	O
.	NN	O	O

Eight	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
inhaled	NN	O	O
nicotine	NN	O	O
in	NN	O	O
darkness	NN	O	O
during	NN	O	O
a	NN	O	O
functional	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
fMRI	NN	O	O
)	NN	O	O
experiment	NN	O	O
;	NN	O	O
eye	NN	O	O
movements	NN	O	O
were	NN	O	O
registered	NN	O	O
using	NN	O	O
video	NN	O	O
-	NN	O	O
oculography	NN	O	O
.	NN	O	O

NIN	NN	O	B
correlated	NN	O	O
with	NN	O	O
blood	NN	O	O
oxygen	NN	O	O
level	NN	O	O
-	NN	O	O
dependent	NN	O	O
(	NN	O	O
BOLD	NN	O	O
)	NN	O	O
activity	NN	O	O
levels	NN	O	O
in	NN	O	O
a	NN	O	O
midpontine	NN	O	O
site	NN	O	O
in	NN	O	O
the	NN	O	O
posterior	NN	O	O
basis	NN	O	O
pontis	NN	O	O
.	NN	O	O

NIN	NN	O	B
-	NN	O	O
induced	NN	O	O
midpontine	NN	O	O
activation	NN	O	O
may	NN	O	O
correspond	NN	O	O
to	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
dorsomedial	NN	O	O
pontine	NN	O	O
nuclei	NN	O	O
and	NN	O	O
the	NN	O	O
nucleus	NN	O	O
reticularis	NN	O	O
tegmenti	NN	O	O
pontis	NN	O	O
,	NN	O	O
structures	NN	O	O
known	NN	O	O
to	NN	O	O
participate	NN	O	O
in	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
multidirectional	NN	O	O
saccades	NN	O	O
and	NN	O	O
smooth	NN	O	O
pursuit	NN	O	O
eye	NN	O	O
movements	NN	O	O
.	NN	O	O

Acute	NN	O	O
effects	NN	O	O
of	NN	O	O
N	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
propylpentanoyl	NN	O	O
)	NN	O	O
urea	NN	O	O
on	NN	O	O
hippocampal	NN	O	O
amino	NN	O	O
acid	NN	O	O
neurotransmitters	NN	O	O
in	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizure	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
anticonvulsant	NN	O	O
activity	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
hippocampal	NN	O	O
amino	NN	O	O
acid	NN	O	O
neurotransmitters	NN	O	O
(	NN	O	O
glutamate	NN	O	O
,	NN	O	O
aspartate	NN	O	O
,	NN	O	O
glycine	NN	O	O
and	NN	O	O
GABA	NN	O	O
)	NN	O	O
of	NN	O	O
N	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
propylpentanoyl	NN	O	O
)	NN	O	O
urea	NN	O	O
(	NN	O	O
VPU	NN	O	O
)	NN	O	O
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
its	NN	O	O
parent	NN	O	O
compound	NN	O	O
,	NN	O	O
valproic	NN	O	O
acid	NN	O	O
(	NN	O	O
VPA	NN	O	O
)	NN	O	O
.	NN	O	O

VPU	NN	O	O
was	NN	O	O
more	NN	O	O
potent	NN	O	O
than	NN	O	O
VPA	NN	O	O
,	NN	O	O
exhibiting	NN	O	O
the	NN	O	O
median	NN	O	O
effective	NN	O	O
dose	NN	O	O
(	NN	O	O
ED	NN	O	O
(	NN	O	O
50	NN	O	O
)	NN	O	O
)	NN	O	O
of	NN	O	O
49	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
in	NN	O	O
protecting	NN	O	O
rats	NN	O	O
against	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizure	NN	O	B
whereas	NN	O	O
the	NN	O	O
corresponding	NN	O	O
value	NN	O	O
for	NN	O	O
VPA	NN	O	O
was	NN	O	O
322	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

In	NN	O	O
vivo	NN	O	O
microdialysis	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
an	NN	O	O
intraperitoneal	NN	O	O
administration	NN	O	O
of	NN	O	O
pilocarpine	NN	O	O
induced	NN	O	O
a	NN	O	O
pronounced	NN	O	O
increment	NN	O	O
of	NN	O	O
hippocampal	NN	O	O
glutamate	NN	O	O
and	NN	O	O
aspartate	NN	O	O
whereas	NN	O	O
no	NN	O	O
significant	NN	O	O
change	NN	O	O
was	NN	O	O
observed	NN	O	O
on	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
glycine	NN	O	O
and	NN	O	O
GABA	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
either	NN	O	O
VPU	NN	O	O
(	NN	O	O
50	NN	O	O
and	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
VPA	NN	O	O
(	NN	O	O
300	NN	O	O
and	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
completely	NN	O	O
abolished	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
evoked	NN	O	O
increases	NN	O	O
in	NN	O	O
extracellular	NN	O	O
glutamate	NN	O	O
and	NN	O	O
aspartate	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
reduction	NN	O	O
was	NN	O	O
also	NN	O	O
observed	NN	O	O
on	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
GABA	NN	O	O
and	NN	O	O
glycine	NN	O	O
but	NN	O	O
less	NN	O	O
than	NN	O	O
a	NN	O	O
drastic	NN	O	O
reduction	NN	O	O
of	NN	O	O
glutamate	NN	O	O
and	NN	O	O
aspartate	NN	O	O
level	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
the	NN	O	O
finding	NN	O	O
that	NN	O	O
VPU	NN	O	O
and	NN	O	O
VPA	NN	O	O
could	NN	O	O
protect	NN	O	O
the	NN	O	O
animals	NN	O	O
against	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizure	NN	O	B
it	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
reduction	NN	O	O
of	NN	O	O
inhibitory	NN	O	O
amino	NN	O	O
acid	NN	O	O
neurotransmitters	NN	O	O
was	NN	O	O
comparatively	NN	O	O
minor	NN	O	O
and	NN	O	O
offset	NN	O	O
by	NN	O	O
a	NN	O	O
pronounced	NN	O	O
reduction	NN	O	O
of	NN	O	O
glutamate	NN	O	O
and	NN	O	O
aspartate	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
like	NN	O	O
VPA	NN	O	O
,	NN	O	O
the	NN	O	O
finding	NN	O	O
that	NN	O	O
VPU	NN	O	O
could	NN	O	O
drastically	NN	O	O
reduce	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
increases	NN	O	O
in	NN	O	O
glutamate	NN	O	O
and	NN	O	O
aspartate	NN	O	O
should	NN	O	O
account	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
partly	NN	O	O
,	NN	O	O
for	NN	O	O
its	NN	O	O
anticonvulsant	NN	O	O
activity	NN	O	O
observed	NN	O	O
in	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
seizure	NN	O	B
in	NN	O	O
experimental	NN	O	O
animals	NN	O	O
.	NN	O	O

Some	NN	O	O
other	NN	O	O
mechanism	NN	O	O
than	NN	O	O
those	NN	O	O
being	NN	O	O
reported	NN	O	O
herein	NN	O	O
should	NN	O	O
be	NN	O	O
further	NN	O	O
investigated	NN	O	O
.	NN	O	O

Protective	NN	O	O
effect	NN	O	O
of	NN	O	O
verapamil	NN	O	O
on	NN	O	O
gastric	NN	O	B
hemorrhagic	NN	O	I
ulcers	NN	O	B
in	NN	O	O
severe	NN	O	O
atherosclerotic	NN	O	B
rats	NN	O	O
.	NN	O	O

Studies	NN	O	O
concerning	NN	O	O
with	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
gastric	NN	O	B
hemorrhage	NN	O	I
and	NN	O	O
mucosal	NN	O	O
ulceration	NN	O	O
produced	NN	O	O
in	NN	O	O
atherosclerotic	NN	O	B
rats	NN	O	O
are	NN	O	O
lacking	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
gastric	NN	O	O
acid	NN	O	O
back	NN	O	O
-	NN	O	O
diffusion	NN	O	O
,	NN	O	O
mast	NN	O	O
cell	NN	O	O
histamine	NN	O	O
release	NN	O	O
,	NN	O	O
lipid	NN	O	O
peroxide	NN	O	O
(	NN	O	O
LPO	NN	O	O
)	NN	O	O
generation	NN	O	O
and	NN	O	O
mucosal	NN	O	O
microvascular	NN	O	O
permeability	NN	O	O
in	NN	O	O
modulating	NN	O	O
gastric	NN	O	B
hemorrhage	NN	O	I
and	NN	O	O
ulcer	NN	O	B
in	NN	O	O
rats	NN	O	O
with	NN	O	O
atherosclerosis	NN	O	B
induced	NN	O	O
by	NN	O	O
coadministration	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D2	NN	O	O
and	NN	O	O
cholesterol	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
the	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
verapamil	NN	O	O
on	NN	O	O
this	NN	O	O
ulcer	NN	O	B
model	NN	O	O
was	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
challenged	NN	O	O
intragastrically	NN	O	O
once	NN	O	O
daily	NN	O	O
for	NN	O	O
9	NN	O	O
days	NN	O	O
with	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
ml	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
corn	NN	O	O
oil	NN	O	O
containing	NN	O	O
vitamin	NN	O	O
D2	NN	O	O
and	NN	O	O
cholesterol	NN	O	O
to	NN	O	O
induce	NN	O	O
atherosclerosis	NN	O	B
.	NN	O	O

Control	NN	O	O
rats	NN	O	O
received	NN	O	O
corn	NN	O	O
oil	NN	O	O
only	NN	O	O
.	NN	O	O

After	NN	O	O
gastric	NN	O	O
surgery	NN	O	O
,	NN	O	O
rat	NN	O	O
stomachs	NN	O	O
were	NN	O	O
irrigated	NN	O	O
for	NN	O	O
3	NN	O	O
h	NN	O	O
with	NN	O	O
either	NN	O	O
simulated	NN	O	O
gastric	NN	O	O
juice	NN	O	O
or	NN	O	O
normal	NN	O	O
saline	NN	O	O
.	NN	O	O

Gastric	NN	O	O
acid	NN	O	O
back	NN	O	O
-	NN	O	O
diffusion	NN	O	O
,	NN	O	O
mucosal	NN	O	O
LPO	NN	O	O
generation	NN	O	O
,	NN	O	O
histamine	NN	O	O
concentration	NN	O	O
,	NN	O	O
microvascular	NN	O	O
permeability	NN	O	O
,	NN	O	O
luminal	NN	O	O
hemoglobin	NN	O	O
content	NN	O	O
and	NN	O	O
ulcer	NN	O	B
areas	NN	O	O
were	NN	O	O
determined	NN	O	O
.	NN	O	O

Elevated	NN	O	O
atherosclerotic	NN	O	B
parameters	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
serum	NN	O	O
calcium	NN	O	O
,	NN	O	O
total	NN	O	O
cholesterol	NN	O	O
and	NN	O	O
low	NN	O	O
-	NN	O	O
density	NN	O	O
lipoprotein	NN	O	O
concentration	NN	O	O
were	NN	O	O
obtained	NN	O	O
in	NN	O	O
atherosclerotic	NN	O	B
rats	NN	O	O
.	NN	O	O

Severe	NN	O	O
gastric	NN	O	O
ulcers	NN	O	B
accompanied	NN	O	O
with	NN	O	O
increased	NN	O	O
ulcerogenic	NN	O	O
factors	NN	O	O
,	NN	O	O
including	NN	O	O
gastric	NN	O	O
acid	NN	O	O
back	NN	O	O
-	NN	O	O
diffusion	NN	O	O
,	NN	O	O
histamine	NN	O	O
release	NN	O	O
,	NN	O	O
LPO	NN	O	O
generation	NN	O	O
and	NN	O	O
luminal	NN	O	O
hemoglobin	NN	O	O
content	NN	O	O
were	NN	O	O
also	NN	O	O
observed	NN	O	O
in	NN	O	O
these	NN	O	O
rats	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
a	NN	O	O
positive	NN	O	O
correlation	NN	O	O
of	NN	O	O
histamine	NN	O	O
to	NN	O	O
gastric	NN	O	B
hemorrhage	NN	O	I
and	NN	O	O
to	NN	O	O
ulcer	NN	O	B
was	NN	O	O
found	NN	O	O
in	NN	O	O
those	NN	O	O
atherosclerotic	NN	O	B
rats	NN	O	O
.	NN	O	O

This	NN	O	O
hemorrhagic	NN	O	B
ulcer	NN	O	B
and	NN	O	O
various	NN	O	O
ulcerogenic	NN	O	O
parameters	NN	O	O
were	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
ameliorated	NN	O	O
by	NN	O	O
daily	NN	O	O
intragastric	NN	O	O
verapamil	NN	O	O
.	NN	O	O

Atherosclerosis	NN	O	B
could	NN	O	O
produce	NN	O	O
gastric	NN	O	B
hemorrhagic	NN	O	I
ulcer	NN	O	B
via	NN	O	O
aggravation	NN	O	O
of	NN	O	O
gastric	NN	O	O
acid	NN	O	O
back	NN	O	O
-	NN	O	O
diffusion	NN	O	O
,	NN	O	O
LPO	NN	O	O
generation	NN	O	O
,	NN	O	O
histamine	NN	O	O
release	NN	O	O
and	NN	O	O
microvascular	NN	O	O
permeability	NN	O	O
that	NN	O	O
could	NN	O	O
be	NN	O	O
ameliorated	NN	O	O
by	NN	O	O
verapamil	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Lamivudine	NN	O	O
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
reactivation	NN	O	O
in	NN	O	O
hepatitis	NN	O	O
-	NN	O	O
B	NN	O	O
surface	NN	O	O
antigen	NN	O	O
(	NN	O	O
HBSAG	NN	O	O
)	NN	O	O
seropositive	NN	O	O
cancer	NN	O	B
patients	NN	O	O
undergoing	NN	O	O
cytotoxic	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
(	NN	O	O
HBV	NN	O	O
)	NN	O	O
is	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	O
causes	NN	O	O
of	NN	O	O
chronic	NN	O	O
liver	NN	O	B
disease	NN	O	I
worldwide	NN	O	O
.	NN	O	O

Cancer	NN	O	B
patients	NN	O	O
who	NN	O	O
are	NN	O	O
chronic	NN	O	O
carriers	NN	O	O
of	NN	O	O
HBV	NN	O	O
have	NN	O	O
a	NN	O	O
higher	NN	O	O
hepatic	NN	O	B
complication	NN	O	I
rate	NN	O	O
while	NN	O	O
receiving	NN	O	O
cytotoxic	NN	O	O
chemotherapy	NN	O	O
(	NN	O	O
CT	NN	O	O
)	NN	O	O
and	NN	O	O
this	NN	O	O
has	NN	O	O
mainly	NN	O	O
been	NN	O	O
attributed	NN	O	O
to	NN	O	O
HBV	NN	O	O
reactivation	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
cancer	NN	O	B
patients	NN	O	O
who	NN	O	O
have	NN	O	O
solid	NN	O	O
and	NN	O	O
hematological	NN	O	B
malignancies	NN	O	I
with	NN	O	O
chronic	NN	O	O
HBV	NN	O	B
infection	NN	O	I
received	NN	O	O
the	NN	O	O
antiviral	NN	O	O
agent	NN	O	O
lamivudine	NN	O	O
prior	NN	O	O
and	NN	O	O
during	NN	O	O
CT	NN	O	O
compared	NN	O	O
with	NN	O	O
historical	NN	O	O
control	NN	O	O
group	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
receive	NN	O	O
lamivudine	NN	O	O
.	NN	O	O

The	NN	O	O
objectives	NN	O	O
were	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
lamivudine	NN	O	O
in	NN	O	O
reducing	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
HBV	NN	O	O
reactivation	NN	O	O
,	NN	O	O
and	NN	O	O
diminishing	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
during	NN	O	O
CT	NN	O	O
.	NN	O	O

Two	NN	O	O
groups	NN	O	O
were	NN	O	O
compared	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
prophylactic	NN	O	O
lamivudin	NN	O	O
group	NN	O	O
consisted	NN	O	O
of	NN	O	O
37	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
prophylactic	NN	O	O
lamivudine	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
historical	NN	O	O
controls	NN	O	O
consisted	NN	O	O
of	NN	O	O
50	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
CT	NN	O	O
without	NN	O	O
prophylactic	NN	O	O
lamivudine	NN	O	O
.	NN	O	O

They	NN	O	O
were	NN	O	O
followed	NN	O	O
up	NN	O	O
during	NN	O	O
and	NN	O	O
for	NN	O	O
8	NN	O	O
weeks	NN	O	O
after	NN	O	O
CT	NN	O	O
.	NN	O	O

The	NN	O	O
outcomes	NN	O	O
were	NN	O	O
compared	NN	O	O
for	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Of	NN	O	O
our	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
50	NN	O	O
)	NN	O	O
,	NN	O	O
21	NN	O	O
patients	NN	O	O
(	NN	O	O
42	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
established	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

Twelve	NN	O	O
(	NN	O	O
24	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
them	NN	O	O
were	NN	O	O
evaluated	NN	O	O
as	NN	O	O
severe	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

In	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
lamivudine	NN	O	O
group	NN	O	O
severe	NN	O	O
hepatitis	NN	O	B
were	NN	O	O
observed	NN	O	O
only	NN	O	O
in	NN	O	O
1	NN	O	O
patient	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
37	NN	O	O
patients	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
006	NN	O	O
)	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
the	NN	O	O
mean	NN	O	O
ALT	NN	O	O
values	NN	O	O
revealed	NN	O	O
significantly	NN	O	O
higher	NN	O	O
mean	NN	O	O
alanine	NN	O	O
aminotransferase	NN	O	O
(	NN	O	O
ALT	NN	O	O
)	NN	O	O
values	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
than	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
lamivudine	NN	O	O
group	NN	O	O
;	NN	O	O
154	NN	O	O
:	NN	O	O
64	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
32	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
prophylactic	NN	O	O
lamivudine	NN	O	O
significantly	NN	O	O
decreases	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
HBV	NN	O	O
reactivation	NN	O	O
and	NN	O	O
overall	NN	O	O
morbidity	NN	O	O
in	NN	O	O
cancer	NN	O	B
patients	NN	O	O
during	NN	O	O
and	NN	O	O
after	NN	O	O
immunosuppressive	NN	O	O
therapy	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
most	NN	O	O
appropriate	NN	O	O
nucleoside	NN	O	O
or	NN	O	O
nucleotide	NN	O	O
analogue	NN	O	O
for	NN	O	O
antiviral	NN	O	O
prophylaxis	NN	O	O
during	NN	O	O
CT	NN	O	O
and	NN	O	O
the	NN	O	O
optimal	NN	O	O
duration	NN	O	O
of	NN	O	O
administration	NN	O	O
after	NN	O	O
completion	NN	O	O
of	NN	O	O
CT	NN	O	O
.	NN	O	O

Recovery	NN	O	O
of	NN	O	O
tacrolimus	NN	O	O
-	NN	O	O
associated	NN	O	O
brachial	NN	O	B
neuritis	NN	O	I
after	NN	O	O
conversion	NN	O	O
to	NN	O	O
everolimus	NN	O	O
in	NN	O	O
a	NN	O	O
pediatric	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipient	NN	O	O
-	NN	O	O
-	NN	O	O
case	NN	O	O
report	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

TAC	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
potent	NN	O	O
immunosuppressive	NN	O	O
agent	NN	O	O
for	NN	O	O
solid	NN	O	O
organ	NN	O	O
transplantation	NN	O	O
in	NN	O	O
pediatrics	NN	O	O
.	NN	O	O

Neurotoxicity	NN	O	B
is	NN	O	O
a	NN	O	O
potentially	NN	O	O
serious	NN	O	O
toxic	NN	O	O
effect	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
encephalopathy	NN	O	B
,	NN	O	O
headaches	NN	O	B
,	NN	O	O
seizures	NN	O	B
,	NN	O	O
or	NN	O	O
neurological	NN	O	B
deficits	NN	O	I
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
an	NN	O	O
eight	NN	O	O
-	NN	O	O
and	NN	O	O
-	NN	O	O
a	NN	O	O
-	NN	O	O
half	NN	O	O
-	NN	O	O
yr	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipient	NN	O	O
with	NN	O	O
right	NN	O	O
BN	NN	O	O
.	NN	O	O

MRI	NN	O	O
demonstrated	NN	O	O
hyperintense	NN	O	O
T2	NN	O	O
signals	NN	O	O
in	NN	O	O
the	NN	O	O
cervical	NN	O	O
cord	NN	O	O
and	NN	O	O
right	NN	O	O
brachial	NN	O	O
plexus	NN	O	O
roots	NN	O	O
indicative	NN	O	O
of	NN	O	O
both	NN	O	O
myelitis	NN	O	B
and	NN	O	O
right	NN	O	O
brachial	NN	O	B
plexitis	NN	O	I
.	NN	O	O

Symptoms	NN	O	O
persisted	NN	O	O
for	NN	O	O
three	NN	O	O
months	NN	O	O
despite	NN	O	O
TAC	NN	O	O
dose	NN	O	O
reduction	NN	O	O
,	NN	O	O
administration	NN	O	O
of	NN	O	O
IVIG	NN	O	O
and	NN	O	O
four	NN	O	O
doses	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	O
pulse	NN	O	O
therapy	NN	O	O
.	NN	O	O

Improvement	NN	O	O
and	NN	O	O
eventually	NN	O	O
full	NN	O	O
recovery	NN	O	O
only	NN	O	O
occurred	NN	O	O
after	NN	O	O
TAC	NN	O	O
was	NN	O	O
completely	NN	O	O
discontinued	NN	O	O
and	NN	O	O
successfully	NN	O	O
replaced	NN	O	O
by	NN	O	O
everolimus	NN	O	O
.	NN	O	O

Omitting	NN	O	O
fentanyl	NN	O	O
reduces	NN	O	O
nausea	NN	O	B
and	NN	O	O
vomiting	NN	O	B
,	NN	O	O
without	NN	O	O
increasing	NN	O	O
pain	NN	O	B
,	NN	O	O
after	NN	O	O
sevoflurane	NN	O	O
for	NN	O	O
day	NN	O	O
surgery	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
AND	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
Despite	NN	O	O
advantages	NN	O	O
of	NN	O	O
induction	NN	O	O
and	NN	O	O
maintenance	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
sevoflurane	NN	O	O
,	NN	O	O
postoperative	NN	O	B
nausea	NN	O	I
and	NN	O	I
vomiting	NN	O	I
occurs	NN	O	O
frequently	NN	O	O
.	NN	O	O

Fentanyl	NN	O	O
is	NN	O	O
a	NN	O	O
commonly	NN	O	O
used	NN	O	O
supplement	NN	O	O
that	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
this	NN	O	O
,	NN	O	O
although	NN	O	O
it	NN	O	O
may	NN	O	O
also	NN	O	O
improve	NN	O	O
analgesia	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
postoperative	NN	O	B
nausea	NN	O	I
and	NN	O	I
vomiting	NN	O	I
and	NN	O	O
pain	NN	O	B
in	NN	O	O
the	NN	O	O
first	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
sevoflurane	NN	O	O
anaesthesia	NN	O	O
in	NN	O	O
216	NN	O	O
adult	NN	O	O
day	NN	O	O
surgery	NN	O	O
patients	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
either	NN	O	O
receive	NN	O	O
or	NN	O	O
not	NN	O	O
receive	NN	O	O
1	NN	O	O
1	NN	O	O
fentanyl	NN	O	O
,	NN	O	O
while	NN	O	O
a	NN	O	O
third	NN	O	O
group	NN	O	O
received	NN	O	O
dexamethasone	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
fentanyl	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Omission	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
did	NN	O	O
not	NN	O	O
reduce	NN	O	O
the	NN	O	O
overall	NN	O	O
incidence	NN	O	O
of	NN	O	O
postoperative	NN	O	B
nausea	NN	O	I
and	NN	O	I
vomiting	NN	O	I
,	NN	O	O
but	NN	O	O
did	NN	O	O
reduce	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
vomiting	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
nausea	NN	O	B
prior	NN	O	O
to	NN	O	O
discharge	NN	O	O
from	NN	O	O
20	NN	O	O
%	NN	O	O
and	NN	O	O
17	NN	O	O
%	NN	O	O
with	NN	O	O
fentanyl	NN	O	O
and	NN	O	O
fentanyl	NN	O	O
-	NN	O	O
dexamethasone	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
to	NN	O	O
5	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
013	NN	O	O
)	NN	O	O
.	NN	O	O

Antiemetic	NN	O	O
requirements	NN	O	O
were	NN	O	O
reduced	NN	O	O
from	NN	O	O
24	NN	O	O
%	NN	O	O
and	NN	O	O
31	NN	O	O
%	NN	O	O
to	NN	O	O
7	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0012	NN	O	O
)	NN	O	O
.	NN	O	O

Dexamethasone	NN	O	O
had	NN	O	O
no	NN	O	O
significant	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
incidence	NN	O	O
or	NN	O	O
severity	NN	O	O
of	NN	O	O
postoperative	NN	O	B
nausea	NN	O	I
and	NN	O	I
vomiting	NN	O	I
.	NN	O	O

Combining	NN	O	O
the	NN	O	O
two	NN	O	O
fentanyl	NN	O	O
groups	NN	O	O
revealed	NN	O	O
further	NN	O	O
significant	NN	O	O
benefits	NN	O	O
from	NN	O	O
the	NN	O	O
avoidance	NN	O	O
of	NN	O	O
opioids	NN	O	O
,	NN	O	O
reducing	NN	O	O
postoperative	NN	O	B
nausea	NN	O	I
and	NN	O	I
vomiting	NN	O	I
and	NN	O	O
nausea	NN	O	B
prior	NN	O	O
to	NN	O	O
discharge	NN	O	O
from	NN	O	O
35	NN	O	O
%	NN	O	O
and	NN	O	O
33	NN	O	O
%	NN	O	O
to	NN	O	O
22	NN	O	O
%	NN	O	O
and	NN	O	O
19	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
049	NN	O	O
and	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
035	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
while	NN	O	O
nausea	NN	O	B
in	NN	O	O
the	NN	O	O
first	NN	O	O
24	NN	O	O
h	NN	O	O
was	NN	O	O
decreased	NN	O	O
from	NN	O	O
42	NN	O	O
%	NN	O	O
to	NN	O	O
27	NN	O	O
%	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
034	NN	O	O
)	NN	O	O
.	NN	O	O

Pain	NN	O	B
severity	NN	O	O
and	NN	O	O
analgesic	NN	O	O
requirements	NN	O	O
were	NN	O	O
unaffected	NN	O	O
by	NN	O	O
the	NN	O	O
omission	NN	O	O
of	NN	O	O
fentanyl	NN	O	O
.	NN	O	O

Fentanyl	NN	O	O
did	NN	O	O
reduce	NN	O	O
minor	NN	O	O
intraoperative	NN	O	O
movement	NN	O	O
but	NN	O	O
had	NN	O	O
no	NN	O	O
sevoflurane	NN	O	O
-	NN	O	O
sparing	NN	O	O
effect	NN	O	O
and	NN	O	O
increased	NN	O	O
respiratory	NN	O	B
depression	NN	O	I
,	NN	O	O
hypotension	NN	O	B
and	NN	O	O
bradycardia	NN	O	B
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
As	NN	O	O
fentanyl	NN	O	O
exacerbated	NN	O	O
postoperative	NN	O	B
nausea	NN	O	I
and	NN	O	I
vomiting	NN	O	I
without	NN	O	O
an	NN	O	O
improvement	NN	O	O
in	NN	O	O
postoperative	NN	O	B
pain	NN	O	I
and	NN	O	O
also	NN	O	O
had	NN	O	O
adverse	NN	O	O
cardiorespiratory	NN	O	O
effects	NN	O	O
,	NN	O	O
it	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
unnecessary	NN	O	O
and	NN	O	O
possibly	NN	O	O
detrimental	NN	O	O
supplement	NN	O	O
to	NN	O	O
sevoflurane	NN	O	O
in	NN	O	O
day	NN	O	O
surgery	NN	O	O
.	NN	O	O

Valvular	NN	O	B
heart	NN	O	I
disease	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
treated	NN	O	O
with	NN	O	O
pergolide	NN	O	O
.	NN	O	O

Course	NN	O	O
following	NN	O	O
treatment	NN	O	O
modifications	NN	O	O
.	NN	O	O

Valvular	NN	O	B
heart	NN	O	I
abnormalities	NN	O	I
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
treated	NN	O	O
with	NN	O	O
pergolide	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
these	NN	O	O
abnormalities	NN	O	O
vary	NN	O	O
from	NN	O	O
study	NN	O	O
to	NN	O	O
study	NN	O	O
and	NN	O	O
their	NN	O	O
course	NN	O	O
after	NN	O	O
drug	NN	O	O
withdrawal	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
systematically	NN	O	O
assessed	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
estimate	NN	O	O
the	NN	O	O
frequency	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
valvular	NN	O	B
heart	NN	O	I
abnormality	NN	O	I
and	NN	O	O
its	NN	O	O
possible	NN	O	O
reversibility	NN	O	O
after	NN	O	O
drug	NN	O	O
withdrawal	NN	O	O
in	NN	O	O
a	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
All	NN	O	O
PD	NN	O	B
patients	NN	O	O
in	NN	O	O
the	NN	O	O
Amiens	NN	O	O
area	NN	O	O
treated	NN	O	O
with	NN	O	O
pergolide	NN	O	O
were	NN	O	O
invited	NN	O	O
to	NN	O	O
attend	NN	O	O
a	NN	O	O
cardiologic	NN	O	O
assessment	NN	O	O
including	NN	O	O
transthoracic	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Thirty	NN	O	O
PD	NN	O	B
patients	NN	O	O
participated	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
second	NN	O	O
echocardiography	NN	O	O
was	NN	O	O
performed	NN	O	O
(	NN	O	O
median	NN	O	O
interval	NN	O	O
:	NN	O	O
13	NN	O	O
months	NN	O	O
)	NN	O	O
after	NN	O	O
pergolide	NN	O	O
withdrawal	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
patients	NN	O	O
)	NN	O	O
.	NN	O	O

Controls	NN	O	O
were	NN	O	O
age	NN	O	O
-	NN	O	O
and	NN	O	O
sex	NN	O	O
-	NN	O	O
matched	NN	O	O
non	NN	O	O
-	NN	O	O
PD	NN	O	B
patients	NN	O	O
referred	NN	O	O
to	NN	O	O
the	NN	O	O
cardiology	NN	O	O
department	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Compared	NN	O	O
to	NN	O	O
controls	NN	O	O
,	NN	O	O
aortic	NN	O	B
regurgitation	NN	O	I
(	NN	O	O
OR	NN	O	O
:	NN	O	O
3	NN	O	O
.	NN	O	O
1	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
IC	NN	O	O
:	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
and	NN	O	O
mitral	NN	O	B
regurgitation	NN	O	I
(	NN	O	O
OR	NN	O	O
:	NN	O	O
10	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
IC	NN	O	O
:	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
53	NN	O	O
)	NN	O	O
were	NN	O	O
more	NN	O	O
frequent	NN	O	O
in	NN	O	O
PD	NN	O	B
patients	NN	O	O
(	NN	O	O
tricuspid	NN	O	O
:	NN	O	O
NS	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
affected	NN	O	O
valves	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
sum	NN	O	O
of	NN	O	O
regurgitation	NN	O	O
grades	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
09	NN	O	O
)	NN	O	O
were	NN	O	O
higher	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
008	NN	O	O
and	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
006	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
pergolide	NN	O	O
group	NN	O	O
.	NN	O	O

Severity	NN	O	O
of	NN	O	O
regurgitation	NN	O	O
was	NN	O	O
not	NN	O	O
correlated	NN	O	O
with	NN	O	O
pergolide	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
.	NN	O	O

A	NN	O	O
restrictive	NN	O	O
pattern	NN	O	O
of	NN	O	O
valvular	NN	O	B
regurgitation	NN	O	I
,	NN	O	O
suggestive	NN	O	O
of	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
pergolide	NN	O	O
,	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
12	NN	O	O
/	NN	O	O
30	NN	O	O
(	NN	O	O
40	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
including	NN	O	O
two	NN	O	O
with	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

Pergolide	NN	O	O
was	NN	O	O
discontinued	NN	O	O
in	NN	O	O
10	NN	O	O
patients	NN	O	O
with	NN	O	O
valvular	NN	O	B
heart	NN	O	I
disease	NN	O	I
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
lower	NN	O	O
regurgitation	NN	O	O
grade	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
second	NN	O	O
transthoracic	NN	O	O
echocardiography	NN	O	O
and	NN	O	O
the	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
heart	NN	O	B
failure	NN	O	I
returned	NN	O	O
to	NN	O	O
nearly	NN	O	O
normal	NN	O	O
clinical	NN	O	O
examination	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
supports	NN	O	O
the	NN	O	O
high	NN	O	O
frequency	NN	O	O
of	NN	O	O
restrictive	NN	O	O
valve	NN	O	B
regurgitation	NN	O	I
in	NN	O	O
PD	NN	O	B
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
pergolide	NN	O	O
and	NN	O	O
reveals	NN	O	O
that	NN	O	O
a	NN	O	O
significant	NN	O	O
improvement	NN	O	O
is	NN	O	O
usual	NN	O	O
when	NN	O	O
the	NN	O	O
treatment	NN	O	O
is	NN	O	O
converted	NN	O	O
to	NN	O	O
non	NN	O	O
-	NN	O	O
ergot	NN	O	O
dopamine	NN	O	O
agonists	NN	O	O
.	NN	O	O

Adriamycin	NN	O	O
-	NN	O	O
induced	NN	O	O
autophagic	NN	O	O
cardiomyocyte	NN	O	O
death	NN	O	B
plays	NN	O	O
a	NN	O	O
pathogenic	NN	O	O
role	NN	O	O
in	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
mechanisms	NN	O	O
underlying	NN	O	O
heart	NN	O	B
failure	NN	O	I
induced	NN	O	O
by	NN	O	O
adriamycin	NN	O	O
are	NN	O	O
very	NN	O	O
complicated	NN	O	O
and	NN	O	O
still	NN	O	O
unclear	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
autophagy	NN	O	O
was	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
heart	NN	O	B
failure	NN	O	I
induced	NN	O	O
by	NN	O	O
adriamycin	NN	O	O
,	NN	O	O
so	NN	O	O
that	NN	O	O
we	NN	O	O
can	NN	O	O
develop	NN	O	O
a	NN	O	O
novel	NN	O	O
treatment	NN	O	O
strategy	NN	O	O
for	NN	O	O
heart	NN	O	B
failure	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
3	NN	O	O
-	NN	O	O
methyladenine	NN	O	O
(	NN	O	O
3MA	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
specific	NN	O	O
inhibitor	NN	O	O
on	NN	O	O
autophagy	NN	O	O
was	NN	O	O
used	NN	O	O
in	NN	O	O
a	NN	O	O
heart	NN	O	B
failure	NN	O	I
model	NN	O	O
of	NN	O	O
rats	NN	O	O
induced	NN	O	O
by	NN	O	O
adriamycin	NN	O	O
.	NN	O	O

Neonatal	NN	O	O
cardiomyocytes	NN	O	O
were	NN	O	O
isolated	NN	O	O
from	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rat	NN	O	O
hearts	NN	O	O
and	NN	O	O
randomly	NN	O	O
divided	NN	O	O
into	NN	O	O
controls	NN	O	O
,	NN	O	O
an	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
3MA	NN	O	O
plus	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
.	NN	O	O

We	NN	O	O
then	NN	O	O
examined	NN	O	O
the	NN	O	O
morphology	NN	O	O
,	NN	O	O
expression	NN	O	O
of	NN	O	O
beclin	NN	O	O
1	NN	O	O
gene	NN	O	O
,	NN	O	O
mitochondrial	NN	O	O
permeability	NN	O	O
transition	NN	O	O
(	NN	O	O
MPT	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
Na	NN	O	O
+	NN	O	O
-	NN	O	O
K	NN	O	O
+	NN	O	O
ATPase	NN	O	O
activity	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
assessed	NN	O	O
cell	NN	O	O
viability	NN	O	O
,	NN	O	O
mitochondrial	NN	O	O
membrane	NN	O	O
potential	NN	O	O
changes	NN	O	O
and	NN	O	O
counted	NN	O	O
autophagic	NN	O	O
vacuoles	NN	O	O
in	NN	O	O
cultured	NN	O	O
cardiomyocytes	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
we	NN	O	O
analyzed	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
autophagy	NN	O	O
associated	NN	O	O
gene	NN	O	O
,	NN	O	O
beclin	NN	O	O
1	NN	O	O
using	NN	O	O
RT	NN	O	O
-	NN	O	O
PCR	NN	O	O
and	NN	O	O
Western	NN	O	O
blotting	NN	O	O
in	NN	O	O
an	NN	O	O
animal	NN	O	O
model	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
3MA	NN	O	O
significantly	NN	O	O
improved	NN	O	O
cardiac	NN	O	O
function	NN	O	O
and	NN	O	O
reduced	NN	O	O
mitochondrial	NN	O	O
injury	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
adriamycin	NN	O	O
induced	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
autophagic	NN	O	O
vacuoles	NN	O	O
,	NN	O	O
and	NN	O	O
3MA	NN	O	O
strongly	NN	O	O
downregulated	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
beclin	NN	O	O
1	NN	O	O
in	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
induced	NN	O	O
failing	NN	O	O
heart	NN	O	O
and	NN	O	O
inhibited	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
autophagic	NN	O	O
vacuoles	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Autophagic	NN	O	O
cardiomyocyte	NN	O	O
death	NN	O	B
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
heart	NN	O	B
failure	NN	O	I
in	NN	O	O
rats	NN	O	O
induced	NN	O	O
by	NN	O	O
adriamycin	NN	O	O
.	NN	O	O

Mitochondrial	NN	O	O
injury	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
heart	NN	O	B
failure	NN	O	I
caused	NN	O	O
by	NN	O	O
adriamycin	NN	O	O
via	NN	O	O
the	NN	O	O
autophagy	NN	O	O
pathway	NN	O	O
.	NN	O	O

mToR	NN	O	O
inhibitors	NN	O	O
-	NN	O	O
induced	NN	O	O
proteinuria	NN	O	B
:	NN	O	O
mechanisms	NN	O	O
,	NN	O	O
significance	NN	O	O
,	NN	O	O
and	NN	O	O
management	NN	O	O
.	NN	O	O

Massive	NN	O	O
urinary	NN	O	O
protein	NN	O	O
excretion	NN	O	O
has	NN	O	O
been	NN	O	O
observed	NN	O	O
after	NN	O	O
conversion	NN	O	O
from	NN	O	O
calcineurin	NN	O	O
inhibitors	NN	O	O
to	NN	O	O
mammalian	NN	O	O
target	NN	O	O
of	NN	O	O
rapamycin	NN	O	O
(	NN	O	O
mToR	NN	O	O
)	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
especially	NN	O	O
sirolimus	NN	O	O
,	NN	O	O
in	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
with	NN	O	O
chronic	NN	O	B
allograft	NN	O	I
nephropathy	NN	O	I
.	NN	O	O

Because	NN	O	O
proteinuria	NN	O	B
is	NN	O	O
a	NN	O	O
major	NN	O	O
predictive	NN	O	O
factor	NN	O	O
of	NN	O	O
poor	NN	O	O
transplantation	NN	O	O
outcome	NN	O	O
,	NN	O	O
many	NN	O	O
studies	NN	O	O
focused	NN	O	O
on	NN	O	O
this	NN	O	O
adverse	NN	O	O
event	NN	O	O
during	NN	O	O
the	NN	O	O
past	NN	O	O
years	NN	O	O
.	NN	O	O

Whether	NN	O	O
proteinuria	NN	O	B
was	NN	O	O
due	NN	O	O
to	NN	O	O
sirolimus	NN	O	O
or	NN	O	O
only	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
calcineurin	NN	O	O
inhibitors	NN	O	O
withdrawal	NN	O	O
remained	NN	O	O
unsolved	NN	O	O
until	NN	O	O
high	NN	O	O
range	NN	O	O
proteinuria	NN	O	B
has	NN	O	O
been	NN	O	O
observed	NN	O	O
during	NN	O	O
sirolimus	NN	O	O
therapy	NN	O	O
in	NN	O	O
islet	NN	O	O
transplantation	NN	O	O
and	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
sirolimus	NN	O	O
de	NN	O	O
novo	NN	O	O
.	NN	O	O

Podocyte	NN	O	O
injury	NN	O	O
and	NN	O	O
focal	NN	O	O
segmental	NN	O	O
glomerulosclerosis	NN	O	B
have	NN	O	O
been	NN	O	O
related	NN	O	O
to	NN	O	O
mToR	NN	O	O
inhibition	NN	O	O
in	NN	O	O
some	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
pathways	NN	O	O
underlying	NN	O	O
these	NN	O	O
lesions	NN	O	O
remain	NN	O	O
hypothetic	NN	O	O
.	NN	O	O

We	NN	O	O
discuss	NN	O	O
herein	NN	O	O
the	NN	O	O
possible	NN	O	O
mechanisms	NN	O	O
and	NN	O	O
the	NN	O	O
significance	NN	O	O
of	NN	O	O
mToR	NN	O	O
blockade	NN	O	O
-	NN	O	O
induced	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

Neuropsychiatric	NN	O	O
side	NN	O	O
effects	NN	O	O
after	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
mefloquine	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
describes	NN	O	O
neuropsychiatric	NN	O	O
side	NN	O	O
effects	NN	O	O
in	NN	O	O
patients	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
mefloquine	NN	O	O
.	NN	O	O

Reactions	NN	O	O
consisted	NN	O	O
mainly	NN	O	O
of	NN	O	O
seizures	NN	O	B
,	NN	O	O
acute	NN	O	O
psychoses	NN	O	B
,	NN	O	O
anxiety	NN	O	B
neurosis	NN	O	I
,	NN	O	O
and	NN	O	O
major	NN	O	O
disturbances	NN	O	B
of	NN	O	I
sleep	NN	O	I
-	NN	O	I
wake	NN	O	I
rhythm	NN	O	I
.	NN	O	O

Side	NN	O	O
effects	NN	O	O
occurred	NN	O	O
after	NN	O	O
both	NN	O	O
therapeutic	NN	O	O
and	NN	O	O
prophylactic	NN	O	O
intake	NN	O	O
and	NN	O	O
were	NN	O	O
graded	NN	O	O
from	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
risk	NN	O	O
analysis	NN	O	O
of	NN	O	O
neuropsychiatric	NN	O	O
side	NN	O	O
effects	NN	O	O
in	NN	O	O
Germany	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
estimated	NN	O	O
that	NN	O	O
one	NN	O	O
of	NN	O	O
8	NN	O	O
,	NN	O	O
000	NN	O	O
mefloquine	NN	O	O
users	NN	O	O
suffers	NN	O	O
from	NN	O	O
such	NN	O	O
reactions	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
calculation	NN	O	O
revealed	NN	O	O
that	NN	O	O
one	NN	O	O
of	NN	O	O
215	NN	O	O
therapeutic	NN	O	O
users	NN	O	O
had	NN	O	O
reactions	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
one	NN	O	O
of	NN	O	O
13	NN	O	O
,	NN	O	O
000	NN	O	O
in	NN	O	O
the	NN	O	O
prophylaxis	NN	O	O
group	NN	O	O
,	NN	O	O
making	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
neuropsychiatric	NN	O	O
reactions	NN	O	O
after	NN	O	O
mefloquine	NN	O	O
treatment	NN	O	O
60	NN	O	O
times	NN	O	O
higher	NN	O	O
than	NN	O	O
after	NN	O	O
prophylaxis	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
certain	NN	O	O
limitations	NN	O	O
for	NN	O	O
malaria	NN	O	B
prophylaxis	NN	O	O
and	NN	O	O
treatment	NN	O	O
with	NN	O	O
mefloquine	NN	O	O
are	NN	O	O
recommended	NN	O	O
.	NN	O	O

Prenatal	NN	O	O
protein	NN	O	O
deprivation	NN	O	O
alters	NN	O	O
dopamine	NN	O	O
-	NN	O	O
mediated	NN	O	O
behaviors	NN	O	O
and	NN	O	O
dopaminergic	NN	O	O
and	NN	O	O
glutamatergic	NN	O	O
receptor	NN	O	O
binding	NN	O	O
.	NN	O	O

Epidemiological	NN	O	O
evidence	NN	O	O
indicates	NN	O	O
that	NN	O	O
prenatal	NN	O	O
nutritional	NN	O	O
deprivation	NN	O	O
may	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

The	NN	O	O
goal	NN	O	O
of	NN	O	O
these	NN	O	O
studies	NN	O	O
was	NN	O	O
to	NN	O	O
use	NN	O	O
an	NN	O	O
animal	NN	O	O
model	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
prenatal	NN	O	O
protein	NN	O	O
deprivation	NN	O	O
on	NN	O	O
behaviors	NN	O	O
and	NN	O	O
receptor	NN	O	O
binding	NN	O	O
with	NN	O	O
relevance	NN	O	O
to	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

We	NN	O	O
report	NN	O	O
that	NN	O	O
prenatally	NN	O	O
protein	NN	O	O
deprived	NN	O	O
(	NN	O	O
PD	NN	O	O
)	NN	O	O
female	NN	O	O
rats	NN	O	O
showed	NN	O	O
an	NN	O	O
increased	NN	O	O
stereotypic	NN	O	O
response	NN	O	O
to	NN	O	O
apomorphine	NN	O	O
and	NN	O	O
an	NN	O	O
increased	NN	O	O
locomotor	NN	O	O
response	NN	O	O
to	NN	O	O
amphetamine	NN	O	O
in	NN	O	O
adulthood	NN	O	O
.	NN	O	O

These	NN	O	O
differences	NN	O	O
were	NN	O	O
not	NN	O	O
observed	NN	O	O
during	NN	O	O
puberty	NN	O	O
.	NN	O	O

No	NN	O	O
changes	NN	O	O
in	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B
or	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotion	NN	O	O
were	NN	O	O
seen	NN	O	O
following	NN	O	O
PD	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
PD	NN	O	O
female	NN	O	O
rats	NN	O	O
showed	NN	O	O
increased	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
H	NN	O	O
-	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
binding	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
and	NN	O	O
hippocampus	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
.	NN	O	O

PD	NN	O	O
female	NN	O	O
rats	NN	O	O
also	NN	O	O
showed	NN	O	O
increased	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
H	NN	O	O
-	NN	O	O
haloperidol	NN	O	O
binding	NN	O	O
and	NN	O	O
decreased	NN	O	O
dopamine	NN	O	O
transporter	NN	O	O
binding	NN	O	O
in	NN	O	O
striatum	NN	O	O
.	NN	O	O

No	NN	O	O
statistically	NN	O	O
significant	NN	O	O
changes	NN	O	O
in	NN	O	O
behavior	NN	O	O
or	NN	O	O
receptor	NN	O	O
binding	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
PD	NN	O	O
males	NN	O	O
with	NN	O	O
the	NN	O	O
exception	NN	O	O
of	NN	O	O
increased	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
H	NN	O	O
-	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
binding	NN	O	O
in	NN	O	O
cortex	NN	O	O
.	NN	O	O

This	NN	O	O
animal	NN	O	O
model	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
prenatal	NN	O	O
nutritional	NN	O	B
deficiency	NN	O	I
enhances	NN	O	O
risk	NN	O	O
for	NN	O	O
schizophrenia	NN	O	B
in	NN	O	O
humans	NN	O	O
and	NN	O	O
may	NN	O	O
also	NN	O	O
have	NN	O	O
implications	NN	O	O
for	NN	O	O
developmental	NN	O	O
processes	NN	O	O
leading	NN	O	O
to	NN	O	O
differential	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
drugs	NN	O	O
of	NN	O	O
abuse	NN	O	O
.	NN	O	O

Adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
topical	NN	O	O
papaverine	NN	O	O
on	NN	O	O
auditory	NN	O	O
nerve	NN	O	O
function	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Papaverine	NN	O	O
hydrochloride	NN	O	O
is	NN	O	O
a	NN	O	O
direct	NN	O	O
-	NN	O	O
acting	NN	O	O
vasodilator	NN	O	O
used	NN	O	O
to	NN	O	O
manage	NN	O	O
vasospasm	NN	O	B
during	NN	O	O
various	NN	O	O
neurosurgical	NN	O	O
operations	NN	O	O
.	NN	O	O

Transient	NN	O	O
cranial	NN	O	B
nerve	NN	O	I
dysfunction	NN	O	I
has	NN	O	O
been	NN	O	O
described	NN	O	O
in	NN	O	O
a	NN	O	O
few	NN	O	O
cases	NN	O	O
with	NN	O	O
topical	NN	O	O
papaverine	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
supports	NN	O	O
previous	NN	O	O
reports	NN	O	O
and	NN	O	O
provides	NN	O	O
neurophysiological	NN	O	O
evidence	NN	O	O
of	NN	O	O
an	NN	O	O
adverse	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
auditory	NN	O	O
nerve	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
conducted	NN	O	O
a	NN	O	O
retrospective	NN	O	O
review	NN	O	O
of	NN	O	O
70	NN	O	O
consecutive	NN	O	O
microvascular	NN	O	O
decompression	NN	O	O
operations	NN	O	O
and	NN	O	O
studied	NN	O	O
those	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
topical	NN	O	O
papaverine	NN	O	O
for	NN	O	O
vasospasm	NN	O	B
.	NN	O	O

Topical	NN	O	O
papaverine	NN	O	O
was	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
direct	NN	O	O
therapeutic	NN	O	O
action	NN	O	O
to	NN	O	O
manage	NN	O	O
vasospasm	NN	O	B
in	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
11	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
timing	NN	O	O
of	NN	O	O
papaverine	NN	O	O
application	NN	O	O
and	NN	O	O
ongoing	NN	O	O
operative	NN	O	O
events	NN	O	O
was	NN	O	O
reviewed	NN	O	O
relative	NN	O	O
to	NN	O	O
changes	NN	O	O
in	NN	O	O
neurophysiological	NN	O	O
recordings	NN	O	O
.	NN	O	O

Brainstem	NN	O	O
auditory	NN	O	O
evoked	NN	O	O
potentials	NN	O	O
(	NN	O	O
BAEPs	NN	O	O
)	NN	O	O
were	NN	O	O
routinely	NN	O	O
used	NN	O	O
to	NN	O	O
monitor	NN	O	O
cochlear	NN	O	O
nerve	NN	O	O
function	NN	O	O
during	NN	O	O
these	NN	O	O
operations	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
:	NN	O	O
A	NN	O	O
temporal	NN	O	O
relationship	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
topical	NN	O	O
papaverine	NN	O	O
and	NN	O	O
BAEP	NN	O	O
changes	NN	O	O
leading	NN	O	O
to	NN	O	O
complete	NN	O	O
waveform	NN	O	O
loss	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
temporal	NN	O	O
delay	NN	O	O
between	NN	O	O
papaverine	NN	O	O
and	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
an	NN	O	O
adverse	NN	O	O
BAEP	NN	O	O
change	NN	O	O
was	NN	O	O
5	NN	O	O
min	NN	O	O
.	NN	O	O

In	NN	O	O
10	NN	O	O
of	NN	O	O
11	NN	O	O
patients	NN	O	O
,	NN	O	O
BAEP	NN	O	O
waves	NN	O	O
II	NN	O	O
/	NN	O	O
III	NN	O	O
-	NN	O	O
V	NN	O	O
completely	NN	O	O
disappeared	NN	O	O
within	NN	O	O
2	NN	O	O
to	NN	O	O
25	NN	O	O
min	NN	O	O
after	NN	O	O
papaverine	NN	O	O
.	NN	O	O

Eight	NN	O	O
of	NN	O	O
these	NN	O	O
10	NN	O	O
patients	NN	O	O
had	NN	O	O
complete	NN	O	O
loss	NN	O	O
of	NN	O	O
BAEP	NN	O	O
waveforms	NN	O	O
within	NN	O	O
10	NN	O	O
min	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
showed	NN	O	O
no	NN	O	O
recovery	NN	O	O
of	NN	O	O
later	NN	O	O
waves	NN	O	O
and	NN	O	O
a	NN	O	O
delayed	NN	O	O
profound	NN	O	O
sensorineural	NN	O	B
hearing	NN	O	I
loss	NN	O	I
.	NN	O	O

The	NN	O	O
average	NN	O	O
recovery	NN	O	O
time	NN	O	O
of	NN	O	O
BAEP	NN	O	O
waveforms	NN	O	O
to	NN	O	O
pre	NN	O	O
-	NN	O	O
papaverine	NN	O	O
baseline	NN	O	O
values	NN	O	O
was	NN	O	O
39	NN	O	O
min	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Topical	NN	O	O
papaverine	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
vasospasm	NN	O	B
was	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
a	NN	O	O
transient	NN	O	O
disturbance	NN	O	O
in	NN	O	O
neurophysiological	NN	O	O
function	NN	O	O
of	NN	O	O
the	NN	O	O
ascending	NN	O	O
auditory	NN	O	O
brainstem	NN	O	O
pathway	NN	O	O
.	NN	O	O

The	NN	O	O
complete	NN	O	O
disappearance	NN	O	O
of	NN	O	O
BAEP	NN	O	O
waveforms	NN	O	O
with	NN	O	O
a	NN	O	O
consistent	NN	O	O
temporal	NN	O	O
delay	NN	O	O
suggests	NN	O	O
a	NN	O	O
possible	NN	O	O
adverse	NN	O	B
effect	NN	O	I
on	NN	O	I
the	NN	O	I
proximal	NN	O	I
eighth	NN	O	I
nerve	NN	O	I
.	NN	O	O

Recommendations	NN	O	O
to	NN	O	O
avoid	NN	O	O
potential	NN	O	O
cranial	NN	O	B
nerve	NN	O	I
deficits	NN	O	I
from	NN	O	O
papaverine	NN	O	O
are	NN	O	O
provided	NN	O	O
.	NN	O	O

Simvastatin	NN	O	O
-	NN	O	O
ezetimibe	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatic	NN	O	B
failure	NN	O	I
necessitating	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Abstract	NN	O	O
Serum	NN	O	O
aminotransferase	NN	O	O
elevations	NN	O	O
are	NN	O	O
a	NN	O	O
commonly	NN	O	O
known	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
3	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
methylglutaryl	NN	O	O
coenzyme	NN	O	O
A	NN	O	O
reductase	NN	O	O
inhibitor	NN	O	O
(	NN	O	O
statin	NN	O	O
)	NN	O	O
therapy	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
hepatotoxic	NN	O	B
events	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
widely	NN	O	O
published	NN	O	O
with	NN	O	O
ezetimibe	NN	O	O
or	NN	O	O
the	NN	O	O
combination	NN	O	O
agent	NN	O	O
simvastatin	NN	O	O
-	NN	O	O
ezetimibe	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
70	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Hispanic	NN	O	O
woman	NN	O	O
who	NN	O	O
developed	NN	O	O
fulminant	NN	O	B
hepatic	NN	O	I
failure	NN	O	I
necessitating	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
10	NN	O	O
weeks	NN	O	O
after	NN	O	O
conversion	NN	O	O
from	NN	O	O
simvastatin	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
to	NN	O	O
simvastatin	NN	O	O
10	NN	O	O
mg	NN	O	O
-	NN	O	O
ezetimibe	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
lipid	NN	O	O
panel	NN	O	O
had	NN	O	O
been	NN	O	O
maintained	NN	O	O
with	NN	O	O
simvastatin	NN	O	O
for	NN	O	O
18	NN	O	O
months	NN	O	O
before	NN	O	O
the	NN	O	O
conversion	NN	O	O
without	NN	O	O
evidence	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B
.	NN	O	O

A	NN	O	O
routine	NN	O	O
laboratory	NN	O	O
work	NN	O	O
-	NN	O	O
up	NN	O	O
10	NN	O	O
weeks	NN	O	O
after	NN	O	O
conversion	NN	O	O
revealed	NN	O	O
elevated	NN	O	O
serum	NN	O	O
aminotransferase	NN	O	O
levels	NN	O	O
.	NN	O	O

Simvastatinezetimibe	NN	O	O
and	NN	O	O
escitalopram	NN	O	O
(	NN	O	O
which	NN	O	O
she	NN	O	O
was	NN	O	O
taking	NN	O	O
for	NN	O	O
depression	NN	O	B
)	NN	O	O
were	NN	O	O
discontinued	NN	O	O
,	NN	O	O
and	NN	O	O
other	NN	O	O
potential	NN	O	O
causes	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B
were	NN	O	O
excluded	NN	O	O
.	NN	O	O

A	NN	O	O
repeat	NN	O	O
work	NN	O	O
-	NN	O	O
up	NN	O	O
revealed	NN	O	O
further	NN	O	O
elevations	NN	O	O
in	NN	O	O
aminotransferase	NN	O	O
levels	NN	O	O
,	NN	O	O
and	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
revealed	NN	O	O
evidence	NN	O	O
of	NN	O	O
moderate	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
severe	NN	O	O
drug	NN	O	B
toxicity	NN	O	I
.	NN	O	O

She	NN	O	O
underwent	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
with	NN	O	O
an	NN	O	O
uneventful	NN	O	O
postoperative	NN	O	O
course	NN	O	O
.	NN	O	O

Her	NN	O	O
aminotransferase	NN	O	O
levels	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
by	NN	O	O
postoperative	NN	O	O
day	NN	O	O
23	NN	O	O
,	NN	O	O
and	NN	O	O
her	NN	O	O
2	NN	O	O
-	NN	O	O
year	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
showed	NN	O	O
no	NN	O	O
adverse	NN	O	O
events	NN	O	O
.	NN	O	O

Ezetimibe	NN	O	O
undergoes	NN	O	O
extensive	NN	O	O
glucuronidation	NN	O	O
by	NN	O	O
uridine	NN	O	O
diphosphate	NN	O	O
glucoronosyltransferases	NN	O	O
(	NN	O	O
UGT	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
intestine	NN	O	O
and	NN	O	O
liver	NN	O	O
and	NN	O	O
may	NN	O	O
have	NN	O	O
inhibited	NN	O	O
the	NN	O	O
glucuronidation	NN	O	O
of	NN	O	O
simvastatin	NN	O	O
hydroxy	NN	O	O
acid	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
increased	NN	O	O
simvastatin	NN	O	O
exposure	NN	O	O
and	NN	O	O
subsequent	NN	O	O
hepatotoxicity	NN	O	B
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
report	NN	O	O
of	NN	O	O
simvastatin	NN	O	O
-	NN	O	O
ezetimibe	NN	O	O
-	NN	O	O
induced	NN	O	O
liver	NN	O	B
failure	NN	O	I
that	NN	O	O
resulted	NN	O	O
in	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

We	NN	O	O
postulate	NN	O	O
that	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
the	NN	O	O
simvastatinezetimibe	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatotoxicity	NN	O	B
is	NN	O	O
the	NN	O	O
increased	NN	O	O
simvastatin	NN	O	O
exposure	NN	O	O
by	NN	O	O
ezetimibe	NN	O	O
inhibition	NN	O	O
of	NN	O	O
UGT	NN	O	O
enzymes	NN	O	O
.	NN	O	O

Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
potential	NN	O	O
hepatotoxicity	NN	O	B
with	NN	O	O
simvastatin	NN	O	O
-	NN	O	O
ezetimibe	NN	O	O
especially	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
and	NN	O	O
should	NN	O	O
carefully	NN	O	O
monitor	NN	O	O
serum	NN	O	O
aminotransferase	NN	O	O
levels	NN	O	O
when	NN	O	O
starting	NN	O	O
therapy	NN	O	O
and	NN	O	O
titrating	NN	O	O
the	NN	O	O
dosage	NN	O	O
.	NN	O	O

Massive	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
after	NN	O	O
oral	NN	O	O
bisphosphonate	NN	O	O
(	NN	O	O
alendronate	NN	O	O
)	NN	O	O
administration	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
focal	NN	O	B
segmental	NN	O	I
glomerulosclerosis	NN	O	I
.	NN	O	O

A	NN	O	O
61	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Japanese	NN	O	O
man	NN	O	O
with	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
due	NN	O	O
to	NN	O	O
focal	NN	O	B
segmental	NN	O	I
glomerulosclerosis	NN	O	I
was	NN	O	O
initially	NN	O	O
responding	NN	O	O
well	NN	O	O
to	NN	O	O
steroid	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
amount	NN	O	O
of	NN	O	O
daily	NN	O	O
urinary	NN	O	O
protein	NN	O	O
decreased	NN	O	O
from	NN	O	O
15	NN	O	O
.	NN	O	O
6	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O
8	NN	O	O
g	NN	O	O
.	NN	O	O

Within	NN	O	O
14	NN	O	O
days	NN	O	O
of	NN	O	O
the	NN	O	O
oral	NN	O	O
bisphosphonate	NN	O	O
(	NN	O	O
alendronate	NN	O	O
sodium	NN	O	O
)	NN	O	O
administration	NN	O	O
,	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
daily	NN	O	O
urinary	NN	O	O
protein	NN	O	O
increased	NN	O	O
rapidly	NN	O	O
up	NN	O	O
to	NN	O	O
12	NN	O	O
.	NN	O	O
8	NN	O	O
g	NN	O	O
with	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
.	NN	O	O

After	NN	O	O
discontinuing	NN	O	O
the	NN	O	O
oral	NN	O	O
alendronate	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
underwent	NN	O	O
six	NN	O	O
cycles	NN	O	O
of	NN	O	O
hemodialysis	NN	O	O
and	NN	O	O
four	NN	O	O
cycles	NN	O	O
of	NN	O	O
LDL	NN	O	O
apheresis	NN	O	O
.	NN	O	O

Urinary	NN	O	O
volume	NN	O	O
and	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
recovered	NN	O	O
to	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
,	NN	O	O
with	NN	O	O
urinary	NN	O	O
protein	NN	O	O
disappearing	NN	O	O
completely	NN	O	O
within	NN	O	O
40	NN	O	O
days	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
not	NN	O	O
only	NN	O	O
intravenous	NN	O	O
,	NN	O	O
but	NN	O	O
also	NN	O	O
oral	NN	O	O
bisphosphonates	NN	O	O
can	NN	O	O
aggravate	NN	O	O
proteinuria	NN	O	B
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
.	NN	O	O

Serum	NN	O	O
-	NN	O	O
and	NN	O	O
glucocorticoid	NN	O	O
-	NN	O	O
inducible	NN	O	O
kinase	NN	O	O
1	NN	O	O
in	NN	O	O
doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
.	NN	O	O

Doxorubicin	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
leads	NN	O	O
to	NN	O	O
epithelial	NN	O	O
sodium	NN	O	O
channel	NN	O	O
(	NN	O	O
ENaC	NN	O	O
)	NN	O	O
-	NN	O	O
dependent	NN	O	O
volume	NN	O	B
retention	NN	O	I
and	NN	O	O
renal	NN	O	O
fibrosis	NN	O	B
.	NN	O	O

The	NN	O	O
aldosterone	NN	O	O
-	NN	O	O
sensitive	NN	O	O
serum	NN	O	O
-	NN	O	O
and	NN	O	O
glucocorticoid	NN	O	O
-	NN	O	O
inducible	NN	O	O
kinase	NN	O	O
SGK1	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
participate	NN	O	O
in	NN	O	O
the	NN	O	O
stimulation	NN	O	O
of	NN	O	O
ENaC	NN	O	O
and	NN	O	O
to	NN	O	O
mediate	NN	O	O
renal	NN	O	O
fibrosis	NN	O	B
following	NN	O	O
mineralocorticoid	NN	O	O
and	NN	O	O
salt	NN	O	O
excess	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
to	NN	O	O
elucidate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
SGK1	NN	O	O
in	NN	O	O
the	NN	O	O
volume	NN	O	B
retention	NN	O	I
and	NN	O	O
fibrosis	NN	O	B
during	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
.	NN	O	O

To	NN	O	O
this	NN	O	O
end	NN	O	O
,	NN	O	O
doxorubicin	NN	O	O
(	NN	O	O
15	NN	O	O
mug	NN	O	O
/	NN	O	O
g	NN	O	O
body	NN	O	O
wt	NN	O	O
)	NN	O	O
was	NN	O	O
injected	NN	O	O
intravenously	NN	O	O
into	NN	O	O
gene	NN	O	O
-	NN	O	O
targeted	NN	O	O
mice	NN	O	O
lacking	NN	O	O
SGK1	NN	O	O
(	NN	O	O
sgk1	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
)	NN	O	O
and	NN	O	O
their	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
littermates	NN	O	O
(	NN	O	O
sgk1	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
)	NN	O	O
)	NN	O	O
.	NN	O	O

Doxorubicin	NN	O	O
treatment	NN	O	O
resulted	NN	O	O
in	NN	O	O
heavy	NN	O	O
proteinuria	NN	O	B
(	NN	O	O
>	NN	O	O
100	NN	O	O
mg	NN	O	O
protein	NN	O	O
/	NN	O	O
mg	NN	O	O
crea	NN	O	O
)	NN	O	O
in	NN	O	O
15	NN	O	O
/	NN	O	O
44	NN	O	O
of	NN	O	O
sgk1	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
)	NN	O	O
and	NN	O	O
15	NN	O	O
/	NN	O	O
44	NN	O	O
of	NN	O	O
sgk1	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
leading	NN	O	O
to	NN	O	O
severe	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
with	NN	O	O
ascites	NN	O	B
,	NN	O	O
lipidemia	NN	O	B
,	NN	O	O
and	NN	O	O
hypoalbuminemia	NN	O	B
in	NN	O	O
both	NN	O	O
genotypes	NN	O	O
.	NN	O	O

Plasma	NN	O	O
aldosterone	NN	O	O
levels	NN	O	O
increased	NN	O	O
in	NN	O	O
nephrotic	NN	O	B
mice	NN	O	O
of	NN	O	O
both	NN	O	O
genotypes	NN	O	O
and	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
increased	NN	O	O
SGK1	NN	O	O
protein	NN	O	O
expression	NN	O	O
in	NN	O	O
sgk1	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
)	NN	O	O
mice	NN	O	O
.	NN	O	O

Urinary	NN	O	O
sodium	NN	O	O
excretion	NN	O	O
reached	NN	O	O
signficantly	NN	O	O
lower	NN	O	O
values	NN	O	O
in	NN	O	O
sgk1	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
)	NN	O	O
mice	NN	O	O
(	NN	O	O
15	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
mumol	NN	O	O
/	NN	O	O
mg	NN	O	O
crea	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
sgk1	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
(	NN	O	O
35	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
mumol	NN	O	O
/	NN	O	O
mg	NN	O	O
crea	NN	O	O
)	NN	O	O
and	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
significantly	NN	O	O
higher	NN	O	O
body	NN	O	O
weight	NN	O	B
gain	NN	O	I
in	NN	O	O
sgk1	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
sgk1	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
(	NN	O	O
+	NN	O	O
6	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
vs	NN	O	O
.	NN	O	O
+	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
g	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
,	NN	O	O
serum	NN	O	O
urea	NN	O	O
concentrations	NN	O	O
increased	NN	O	O
significantly	NN	O	O
faster	NN	O	O
in	NN	O	O
sgk1	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
than	NN	O	O
in	NN	O	O
sgk1	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
)	NN	O	O
mice	NN	O	O
leading	NN	O	O
to	NN	O	O
uremia	NN	O	B
and	NN	O	O
a	NN	O	O
reduced	NN	O	O
median	NN	O	O
survival	NN	O	O
in	NN	O	O
sgk1	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
(	NN	O	O
29	NN	O	O
vs	NN	O	O
.	NN	O	O
40	NN	O	O
days	NN	O	O
in	NN	O	O
sgk1	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
)	NN	O	O
mice	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
gene	NN	O	O
-	NN	O	O
targeted	NN	O	O
mice	NN	O	O
lacking	NN	O	O
SGK1	NN	O	O
showed	NN	O	O
blunted	NN	O	O
volume	NN	O	B
retention	NN	O	I
,	NN	O	O
yet	NN	O	O
were	NN	O	O
not	NN	O	O
protected	NN	O	O
against	NN	O	O
renal	NN	O	O
fibrosis	NN	O	B
during	NN	O	O
experimental	NN	O	O
nephrotic	NN	O	B
syndrome	NN	O	I
.	NN	O	O

Severe	NN	O	O
thrombocytopenia	NN	O	B
and	NN	O	O
haemolytic	NN	O	B
anaemia	NN	O	I
associated	NN	O	O
with	NN	O	O
ciprofloxacin	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
with	NN	O	O
fatal	NN	O	O
outcome	NN	O	O
.	NN	O	O

Haematological	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
associated	NN	O	O
with	NN	O	O
fatal	NN	O	O
outcome	NN	O	O
are	NN	O	O
rare	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
ciprofloxacin	NN	O	O
.	NN	O	O

A	NN	O	O
30	NN	O	O
-	NN	O	O
year	NN	O	O
old	NN	O	O
Caucasian	NN	O	O
man	NN	O	O
reported	NN	O	O
with	NN	O	O
abdominal	NN	O	B
pain	NN	O	I
and	NN	O	O
jaundice	NN	O	B
after	NN	O	O
3	NN	O	O
-	NN	O	O
day	NN	O	O
administration	NN	O	O
of	NN	O	O
oral	NN	O	O
ciprofloxacin	NN	O	O
for	NN	O	O
a	NN	O	O
suspect	NN	O	O
of	NN	O	O
urinary	NN	O	B
tract	NN	O	I
infection	NN	O	I
.	NN	O	O

Clinical	NN	O	O
evaluations	NN	O	O
suggested	NN	O	O
an	NN	O	O
initial	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
severe	NN	O	O
thrombocytopenia	NN	O	B
and	NN	O	O
haemolysis	NN	O	B
.	NN	O	O

The	NN	O	O
patient	NN	O	O
progressively	NN	O	O
developed	NN	O	O
petechiae	NN	O	B
and	NN	O	O
purpura	NN	O	B
on	NN	O	O
thorax	NN	O	O
and	NN	O	O
lower	NN	O	O
limbs	NN	O	O
.	NN	O	O

Despite	NN	O	O
pharmacological	NN	O	O
and	NN	O	O
supportive	NN	O	O
interventions	NN	O	O
,	NN	O	O
laboratory	NN	O	O
parameters	NN	O	O
worsened	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
died	NN	O	O
17	NN	O	O
hours	NN	O	O
after	NN	O	O
admission	NN	O	O
.	NN	O	O

An	NN	O	O
accurate	NN	O	O
autopsy	NN	O	O
revealed	NN	O	O
most	NN	O	O
organs	NN	O	O
with	NN	O	O
diffuse	NN	O	O
petechial	NN	O	O
haemorrhages	NN	O	B
.	NN	O	O

No	NN	O	O
signs	NN	O	O
of	NN	O	O
bone	NN	O	B
marrow	NN	O	I
depression	NN	O	I
were	NN	O	O
found	NN	O	O
.	NN	O	O

No	NN	O	O
thrombi	NN	O	B
or	NN	O	O
signs	NN	O	O
of	NN	O	O
microangiopathies	NN	O	B
were	NN	O	O
observed	NN	O	O
in	NN	O	O
arterial	NN	O	O
vessels	NN	O	O
.	NN	O	O

Blood	NN	O	O
and	NN	O	O
urine	NN	O	O
cultures	NN	O	O
did	NN	O	O
not	NN	O	O
show	NN	O	O
any	NN	O	O
bacterial	NN	O	O
growth	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
report	NN	O	O
shows	NN	O	O
that	NN	O	O
ciprofloxacin	NN	O	O
may	NN	O	O
precipitate	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
thrombocytopenia	NN	O	B
and	NN	O	O
haemolytic	NN	O	B
anaemia	NN	O	I
,	NN	O	O
even	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
phases	NN	O	O
of	NN	O	O
treatment	NN	O	O
and	NN	O	O
without	NN	O	O
apparent	NN	O	O
previous	NN	O	O
exposures	NN	O	O
.	NN	O	O

Alpha	NN	O	O
-	NN	O	O
lipoic	NN	O	O
acid	NN	O	O
prevents	NN	O	O
mitochondrial	NN	O	B
damage	NN	O	I
and	NN	O	O
neurotoxicity	NN	O	B
in	NN	O	O
experimental	NN	O	O
chemotherapy	NN	O	O
neuropathy	NN	O	B
.	NN	O	O

The	NN	O	O
study	NN	O	O
investigates	NN	O	O
if	NN	O	O
alpha	NN	O	O
-	NN	O	O
lipoic	NN	O	O
acid	NN	O	O
is	NN	O	O
neuroprotective	NN	O	O
against	NN	O	O
chemotherapy	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B
,	NN	O	O
if	NN	O	O
mitochondrial	NN	O	B
damage	NN	O	I
plays	NN	O	O
a	NN	O	O
critical	NN	O	O
role	NN	O	O
in	NN	O	O
toxic	NN	O	B
neurodegenerative	NN	O	I
cascade	NN	O	I
,	NN	O	O
and	NN	O	O
if	NN	O	O
neuroprotective	NN	O	O
effects	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
lipoic	NN	O	O
acid	NN	O	O
depend	NN	O	O
on	NN	O	O
mitochondria	NN	O	O
protection	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
an	NN	O	O
in	NN	O	O
vitro	NN	O	O
model	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
induced	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
that	NN	O	O
closely	NN	O	O
mimic	NN	O	O
the	NN	O	O
in	NN	O	O
vivo	NN	O	O
condition	NN	O	O
by	NN	O	O
exposing	NN	O	O
primary	NN	O	O
cultures	NN	O	O
of	NN	O	O
dorsal	NN	O	O
root	NN	O	O
ganglion	NN	O	O
(	NN	O	O
DRG	NN	O	O
)	NN	O	O
sensory	NN	O	O
neurons	NN	O	O
to	NN	O	O
paclitaxel	NN	O	O
and	NN	O	O
cisplatin	NN	O	O
,	NN	O	O
two	NN	O	O
widely	NN	O	O
used	NN	O	O
and	NN	O	O
highly	NN	O	O
effective	NN	O	O
chemotherapeutic	NN	O	O
drugs	NN	O	O
.	NN	O	O

This	NN	O	O
approach	NN	O	O
allowed	NN	O	O
investigating	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
lipoic	NN	O	O
acid	NN	O	O
in	NN	O	O
preventing	NN	O	O
axonal	NN	O	B
damage	NN	O	I
and	NN	O	O
apoptosis	NN	O	O
and	NN	O	O
the	NN	O	O
function	NN	O	O
and	NN	O	O
ultrastructural	NN	O	O
morphology	NN	O	O
of	NN	O	O
mitochondria	NN	O	O
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
toxic	NN	O	O
agents	NN	O	O
and	NN	O	O
alpha	NN	O	O
-	NN	O	O
lipoic	NN	O	O
acid	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
both	NN	O	O
cisplatin	NN	O	O
and	NN	O	O
paclitaxel	NN	O	O
cause	NN	O	O
early	NN	O	O
mitochondrial	NN	O	B
impairment	NN	O	I
with	NN	O	O
loss	NN	O	O
of	NN	O	O
membrane	NN	O	O
potential	NN	O	O
and	NN	O	O
induction	NN	O	O
of	NN	O	O
autophagic	NN	O	O
vacuoles	NN	O	O
in	NN	O	O
neurons	NN	O	O
.	NN	O	O

Alpha	NN	O	O
-	NN	O	O
lipoic	NN	O	O
acid	NN	O	O
exerts	NN	O	O
neuroprotective	NN	O	O
effects	NN	O	O
against	NN	O	O
chemotherapy	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B
in	NN	O	O
sensory	NN	O	O
neurons	NN	O	O
:	NN	O	O
it	NN	O	O
rescues	NN	O	O
the	NN	O	O
mitochondrial	NN	O	B
toxicity	NN	O	I
and	NN	O	O
induces	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
frataxin	NN	O	O
,	NN	O	O
an	NN	O	O
essential	NN	O	O
mitochondrial	NN	O	O
protein	NN	O	O
with	NN	O	O
anti	NN	O	O
-	NN	O	O
oxidant	NN	O	O
and	NN	O	O
chaperone	NN	O	O
properties	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
mitochondrial	NN	O	B
toxicity	NN	O	I
is	NN	O	O
an	NN	O	O
early	NN	O	O
common	NN	O	O
event	NN	O	O
both	NN	O	O
in	NN	O	O
paclitaxel	NN	O	O
and	NN	O	O
cisplatin	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

Alpha	NN	O	O
-	NN	O	O
lipoic	NN	O	O
acid	NN	O	O
protects	NN	O	O
sensory	NN	O	O
neurons	NN	O	O
through	NN	O	O
its	NN	O	O
anti	NN	O	O
-	NN	O	O
oxidant	NN	O	O
and	NN	O	O
mitochondrial	NN	O	O
regulatory	NN	O	O
functions	NN	O	O
,	NN	O	O
possibly	NN	O	O
inducing	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
frataxin	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
alpha	NN	O	O
-	NN	O	O
lipoic	NN	O	O
acid	NN	O	O
might	NN	O	O
reduce	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
developing	NN	O	O
peripheral	NN	O	B
nerve	NN	O	I
toxicity	NN	O	I
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
encourage	NN	O	O
further	NN	O	O
confirmatory	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

Toxicity	NN	O	B
in	NN	O	O
rhesus	NN	O	O
monkeys	NN	O	O
following	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
8	NN	O	O
-	NN	O	O
aminoquinoline	NN	O	O
8	NN	O	O
-	NN	O	O
[	NN	O	O
(	NN	O	O
4	NN	O	O
-	NN	O	O
amino	NN	O	O
-	NN	O	O
l	NN	O	O
-	NN	O	O
methylbutyl	NN	O	O
)	NN	O	O
amino	NN	O	O
]	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
(	NN	O	O
l	NN	O	O
-	NN	O	O
hexyloxy	NN	O	O
)	NN	O	O
-	NN	O	O
6	NN	O	O
-	NN	O	O
methoxy	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
methylquinoline	NN	O	O
(	NN	O	O
WR242511	NN	O	O
)	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Many	NN	O	O
substances	NN	O	O
that	NN	O	O
form	NN	O	O
methemoglobin	NN	O	O
(	NN	O	O
MHb	NN	O	O
)	NN	O	O
effectively	NN	O	O
counter	NN	O	O
cyanide	NN	O	O
(	NN	O	O
CN	NN	O	O
)	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Although	NN	O	O
MHb	NN	O	O
formers	NN	O	O
are	NN	O	O
generally	NN	O	O
applied	NN	O	O
as	NN	O	O
treatments	NN	O	O
for	NN	O	O
CN	NN	O	O
poisoning	NN	O	B
,	NN	O	O
it	NN	O	O
has	NN	O	O
been	NN	O	O
proposed	NN	O	O
that	NN	O	O
a	NN	O	O
stable	NN	O	O
,	NN	O	O
long	NN	O	O
-	NN	O	O
acting	NN	O	O
MHb	NN	O	O
former	NN	O	O
could	NN	O	O
serve	NN	O	O
as	NN	O	O
a	NN	O	O
CN	NN	O	O
pretreatment	NN	O	O
.	NN	O	O

Using	NN	O	O
this	NN	O	O
rationale	NN	O	O
,	NN	O	O
the	NN	O	O
8	NN	O	O
-	NN	O	O
aminoquinoline	NN	O	O
WR242511	NN	O	O
,	NN	O	O
a	NN	O	O
potent	NN	O	O
long	NN	O	O
-	NN	O	O
lasting	NN	O	O
MHb	NN	O	O
former	NN	O	O
in	NN	O	O
rodents	NN	O	O
and	NN	O	O
beagle	NN	O	O
dogs	NN	O	O
,	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
the	NN	O	O
rhesus	NN	O	O
monkey	NN	O	O
for	NN	O	O
advanced	NN	O	O
development	NN	O	O
as	NN	O	O
a	NN	O	O
potential	NN	O	O
CN	NN	O	O
pretreatment	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
WR242511	NN	O	O
was	NN	O	O
administered	NN	O	O
intravenously	NN	O	O
(	NN	O	O
IV	NN	O	O
)	NN	O	O
in	NN	O	O
2	NN	O	O
female	NN	O	O
and	NN	O	O
4	NN	O	O
male	NN	O	O
rhesus	NN	O	O
monkeys	NN	O	O
in	NN	O	O
doses	NN	O	O
of	NN	O	O
3	NN	O	O
.	NN	O	O
5	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
7	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
a	NN	O	O
single	NN	O	O
male	NN	O	O
also	NN	O	O
received	NN	O	O
WR242511	NN	O	O
orally	NN	O	O
(	NN	O	O
PO	NN	O	O
)	NN	O	O
at	NN	O	O
7	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Health	NN	O	O
status	NN	O	O
and	NN	O	O
MHb	NN	O	O
levels	NN	O	O
were	NN	O	O
monitored	NN	O	O
following	NN	O	O
exposure	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
selected	NN	O	O
doses	NN	O	O
of	NN	O	O
WR242511	NN	O	O
,	NN	O	O
which	NN	O	O
produced	NN	O	O
significant	NN	O	O
methemoglobinemia	NN	O	B
in	NN	O	O
beagle	NN	O	O
dogs	NN	O	O
in	NN	O	O
earlier	NN	O	O
studies	NN	O	O
conducted	NN	O	O
elsewhere	NN	O	O
,	NN	O	O
produced	NN	O	O
very	NN	O	O
little	NN	O	O
MHb	NN	O	O
(	NN	O	O
mean	NN	O	O
<	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
rhesus	NN	O	O
monkey	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
transient	NN	O	O
hemoglobinuria	NN	O	B
was	NN	O	O
noted	NN	O	O
approximately	NN	O	O
60	NN	O	O
minutes	NN	O	O
postinjection	NN	O	O
of	NN	O	O
WR242511	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
5	NN	O	O
or	NN	O	O
7	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
2	NN	O	O
lethalities	NN	O	O
occurred	NN	O	O
(	NN	O	O
one	NN	O	O
IV	NN	O	O
and	NN	O	O
one	NN	O	O
PO	NN	O	O
)	NN	O	O
following	NN	O	O
the	NN	O	O
7	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
dose	NN	O	O
.	NN	O	O

Myoglobinuria	NN	O	B
was	NN	O	O
also	NN	O	O
observed	NN	O	O
following	NN	O	O
the	NN	O	O
7	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
dose	NN	O	O
.	NN	O	O

Histopathology	NN	O	O
analyses	NN	O	O
in	NN	O	O
the	NN	O	O
2	NN	O	O
animals	NN	O	O
that	NN	O	O
died	NN	O	O
revealed	NN	O	O
liver	NN	O	B
and	NN	O	I
kidney	NN	O	I
toxicity	NN	O	I
,	NN	O	O
with	NN	O	O
greater	NN	O	O
severity	NN	O	O
in	NN	O	O
the	NN	O	O
orally	NN	O	O
-	NN	O	O
treated	NN	O	O
animal	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
data	NN	O	O
demonstrate	NN	O	O
direct	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
indirect	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
toxicity	NN	O	B
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
WR242511	NN	O	O
should	NN	O	O
not	NN	O	O
be	NN	O	O
pursued	NN	O	O
as	NN	O	O
a	NN	O	O
pretreatment	NN	O	O
for	NN	O	O
CN	NN	O	O
poisoning	NN	O	B
unless	NN	O	O
the	NN	O	O
anti	NN	O	O
-	NN	O	O
CN	NN	O	O
characteristics	NN	O	O
of	NN	O	O
this	NN	O	O
compound	NN	O	O
can	NN	O	O
be	NN	O	O
successfully	NN	O	O
dissociated	NN	O	O
from	NN	O	O
those	NN	O	O
producing	NN	O	O
undesirable	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Repetitive	NN	O	O
transcranial	NN	O	O
magnetic	NN	O	O
stimulation	NN	O	O
for	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

In	NN	O	O
a	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
single	NN	O	O
-	NN	O	O
blinded	NN	O	O
,	NN	O	O
crossover	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
assessed	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
"	NN	O	O
real	NN	O	O
"	NN	O	O
repetitive	NN	O	O
transcranial	NN	O	O
magnetic	NN	O	O
stimulation	NN	O	O
(	NN	O	O
rTMS	NN	O	O
)	NN	O	O
versus	NN	O	O
"	NN	O	O
sham	NN	O	O
"	NN	O	O
rTMS	NN	O	O
(	NN	O	O
placebo	NN	O	O
)	NN	O	O
on	NN	O	O
peak	NN	O	O
dose	NN	O	O
dyskinesias	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
.	NN	O	O

Ten	NN	O	O
patients	NN	O	O
with	NN	O	O
PD	NN	O	B
and	NN	O	O
prominent	NN	O	O
dyskinesias	NN	O	B
had	NN	O	O
rTMS	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
800	NN	O	O
pulses	NN	O	O
;	NN	O	O
1	NN	O	O
Hz	NN	O	O
rate	NN	O	O
)	NN	O	O
delivered	NN	O	O
over	NN	O	O
the	NN	O	O
motor	NN	O	O
cortex	NN	O	O
for	NN	O	O
4	NN	O	O
consecutive	NN	O	O
days	NN	O	O
twice	NN	O	O
,	NN	O	O
once	NN	O	O
real	NN	O	O
stimuli	NN	O	O
and	NN	O	O
once	NN	O	O
sham	NN	O	O
stimulation	NN	O	O
were	NN	O	O
used	NN	O	O
;	NN	O	O
evaluations	NN	O	O
were	NN	O	O
done	NN	O	O
at	NN	O	O
the	NN	O	O
baseline	NN	O	O
and	NN	O	O
1	NN	O	O
day	NN	O	O
after	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
each	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
series	NN	O	O
.	NN	O	O

Direct	NN	O	O
comparison	NN	O	O
between	NN	O	O
sham	NN	O	O
and	NN	O	O
real	NN	O	O
rTMS	NN	O	O
effects	NN	O	O
showed	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
clinician	NN	O	O
-	NN	O	O
assessed	NN	O	O
dyskinesia	NN	O	B
severity	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
comparison	NN	O	O
with	NN	O	O
the	NN	O	O
baseline	NN	O	O
showed	NN	O	O
small	NN	O	O
but	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
dyskinesia	NN	O	B
severity	NN	O	O
following	NN	O	O
real	NN	O	O
rTMS	NN	O	O
but	NN	O	O
not	NN	O	O
placebo	NN	O	O
.	NN	O	O

The	NN	O	O
major	NN	O	O
effect	NN	O	O
was	NN	O	O
on	NN	O	O
dystonia	NN	O	B
subscore	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
in	NN	O	O
patient	NN	O	O
diaries	NN	O	O
,	NN	O	O
although	NN	O	O
both	NN	O	O
treatments	NN	O	O
caused	NN	O	O
reduction	NN	O	O
in	NN	O	O
subjective	NN	O	O
dyskinesia	NN	O	B
scores	NN	O	O
during	NN	O	O
the	NN	O	O
days	NN	O	O
of	NN	O	O
intervention	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
was	NN	O	O
sustained	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
intervention	NN	O	O
for	NN	O	O
the	NN	O	O
real	NN	O	O
rTMS	NN	O	O
only	NN	O	O
.	NN	O	O

Following	NN	O	O
rTMS	NN	O	O
,	NN	O	O
no	NN	O	O
side	NN	O	O
effects	NN	O	O
and	NN	O	O
no	NN	O	O
adverse	NN	O	O
effects	NN	O	O
on	NN	O	O
motor	NN	O	O
function	NN	O	O
and	NN	O	O
PD	NN	O	B
symptoms	NN	O	O
were	NN	O	O
noted	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
the	NN	O	O
existence	NN	O	O
of	NN	O	O
residual	NN	O	O
beneficial	NN	O	O
clinical	NN	O	O
aftereffects	NN	O	O
of	NN	O	O
consecutive	NN	O	O
daily	NN	O	O
applications	NN	O	O
of	NN	O	O
low	NN	O	O
-	NN	O	O
frequency	NN	O	O
rTMS	NN	O	O
on	NN	O	O
dyskinesias	NN	O	B
in	NN	O	O
PD	NN	O	B
.	NN	O	O

The	NN	O	O
effects	NN	O	O
may	NN	O	O
be	NN	O	O
further	NN	O	O
exploited	NN	O	O
for	NN	O	O
potential	NN	O	O
therapeutic	NN	O	O
uses	NN	O	O
.	NN	O	O

Intracavernous	NN	O	O
epinephrine	NN	O	O
:	NN	O	O
a	NN	O	O
minimally	NN	O	O
invasive	NN	O	O
treatment	NN	O	O
for	NN	O	O
priapism	NN	O	B
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
.	NN	O	O

Priapism	NN	O	B
is	NN	O	O
the	NN	O	O
prolonged	NN	O	O
erection	NN	O	O
of	NN	O	O
the	NN	O	O
penis	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
sexual	NN	O	O
arousal	NN	O	O
.	NN	O	O

A	NN	O	O
45	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
,	NN	O	O
an	NN	O	O
admitted	NN	O	O
frequent	NN	O	O
cocaine	NN	O	O
user	NN	O	O
,	NN	O	O
presented	NN	O	O
to	NN	O	O
the	NN	O	O
Emergency	NN	O	O
Department	NN	O	O
(	NN	O	O
ED	NN	O	O
)	NN	O	O
on	NN	O	O
two	NN	O	O
separate	NN	O	O
occasions	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
priapism	NN	O	B
after	NN	O	O
cocaine	NN	O	O
use	NN	O	O
.	NN	O	O

The	NN	O	O
management	NN	O	O
options	NN	O	O
in	NN	O	O
the	NN	O	O
ED	NN	O	O
,	NN	O	O
as	NN	O	O
exemplified	NN	O	O
by	NN	O	O
four	NN	O	O
individual	NN	O	O
case	NN	O	O
reports	NN	O	O
,	NN	O	O
in	NN	O	O
particular	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
a	NN	O	O
minimally	NN	O	O
invasive	NN	O	O
method	NN	O	O
of	NN	O	O
intracorporal	NN	O	O
epinephrine	NN	O	O
instillation	NN	O	O
,	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Prophylactic	NN	O	O
use	NN	O	O
of	NN	O	O
lamivudine	NN	O	O
with	NN	O	O
chronic	NN	O	O
immunosuppressive	NN	O	O
therapy	NN	O	O
for	NN	O	O
rheumatologic	NN	O	B
disorders	NN	O	I
.	NN	O	O

The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
report	NN	O	O
our	NN	O	O
experience	NN	O	O
concerning	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
administration	NN	O	O
of	NN	O	O
lamivudine	NN	O	O
in	NN	O	O
hepatitis	NN	O	O
B	NN	O	O
virus	NN	O	O
surface	NN	O	O
antigen	NN	O	O
(	NN	O	O
HBs	NN	O	O
Ag	NN	O	O
)	NN	O	O
positive	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatologic	NN	O	B
disease	NN	O	I
.	NN	O	O

From	NN	O	O
June	NN	O	O
2004	NN	O	O
to	NN	O	O
October	NN	O	O
2006	NN	O	O
,	NN	O	O
11	NN	O	O
HBs	NN	O	O
Ag	NN	O	O
positive	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatologic	NN	O	B
diseases	NN	O	I
,	NN	O	O
who	NN	O	O
were	NN	O	O
on	NN	O	O
both	NN	O	O
immunosuppressive	NN	O	O
and	NN	O	O
prophylactic	NN	O	O
lamivudine	NN	O	O
therapies	NN	O	O
,	NN	O	O
were	NN	O	O
retrospectively	NN	O	O
assessed	NN	O	O
.	NN	O	O

Liver	NN	O	O
function	NN	O	O
tests	NN	O	O
,	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
(	NN	O	O
HBV	NN	O	O
)	NN	O	O
serologic	NN	O	O
markers	NN	O	O
,	NN	O	O
and	NN	O	O
HBV	NN	O	O
DNA	NN	O	O
levels	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
during	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
were	NN	O	O
obtained	NN	O	O
from	NN	O	O
hospital	NN	O	O
file	NN	O	O
records	NN	O	O
.	NN	O	O

Eleven	NN	O	O
patients	NN	O	O
(	NN	O	O
six	NN	O	O
male	NN	O	O
)	NN	O	O
with	NN	O	O
median	NN	O	O
age	NN	O	O
47	NN	O	O
years	NN	O	O
(	NN	O	O
range	NN	O	O
27	NN	O	O
-	NN	O	O
73	NN	O	O
)	NN	O	O
,	NN	O	O
median	NN	O	O
disease	NN	O	O
duration	NN	O	O
50	NN	O	O
months	NN	O	O
(	NN	O	O
range	NN	O	O
9	NN	O	O
-	NN	O	O
178	NN	O	O
)	NN	O	O
and	NN	O	O
median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
of	NN	O	O
patients	NN	O	O
13	NN	O	O
.	NN	O	O
8	NN	O	O
months	NN	O	O
(	NN	O	O
range	NN	O	O
5	NN	O	O
-	NN	O	O
27	NN	O	O
)	NN	O	O
were	NN	O	O
enrolled	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
.	NN	O	O

Lamivudine	NN	O	O
therapy	NN	O	O
was	NN	O	O
started	NN	O	O
3	NN	O	O
-	NN	O	O
7	NN	O	O
days	NN	O	O
prior	NN	O	O
to	NN	O	O
immunosuppressive	NN	O	O
therapy	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

Baseline	NN	O	O
,	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
were	NN	O	O
elevated	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
(	NN	O	O
fourth	NN	O	O
patient	NN	O	O
:	NN	O	O
ALT	NN	O	O
:	NN	O	O
122	NN	O	O
IU	NN	O	O
/	NN	O	O
l	NN	O	O
,	NN	O	O
AST	NN	O	O
:	NN	O	O
111	NN	O	O
IU	NN	O	O
/	NN	O	O
l	NN	O	O
,	NN	O	O
tenth	NN	O	O
patient	NN	O	O
:	NN	O	O
ALT	NN	O	O
:	NN	O	O
294	NN	O	O
IU	NN	O	O
/	NN	O	O
l	NN	O	O
,	NN	O	O
AST	NN	O	O
:	NN	O	O
274	NN	O	O
IU	NN	O	O
/	NN	O	O
l	NN	O	O
,	NN	O	O
with	NN	O	O
minimal	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
in	NN	O	O
both	NN	O	O
)	NN	O	O
.	NN	O	O

Shortly	NN	O	O
after	NN	O	O
treatment	NN	O	O
their	NN	O	O
tests	NN	O	O
normalized	NN	O	O
and	NN	O	O
during	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
had	NN	O	O
abnormal	NN	O	B
liver	NN	O	I
function	NN	O	I
tests	NN	O	O
.	NN	O	O

In	NN	O	O
four	NN	O	O
patients	NN	O	O
HBV	NN	O	O
DNA	NN	O	O
levels	NN	O	O
were	NN	O	O
higher	NN	O	O
than	NN	O	O
normal	NN	O	O
at	NN	O	O
baseline	NN	O	O
.	NN	O	O

Two	NN	O	O
of	NN	O	O
these	NN	O	O
normalized	NN	O	O
and	NN	O	O
the	NN	O	O
others	NN	O	O
increased	NN	O	O
later	NN	O	O
.	NN	O	O

In	NN	O	O
three	NN	O	O
additional	NN	O	O
patients	NN	O	O
,	NN	O	O
HBV	NN	O	O
DNA	NN	O	O
levels	NN	O	O
were	NN	O	O
increased	NN	O	O
during	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
had	NN	O	O
significant	NN	O	O
clinical	NN	O	O
sings	NN	O	O
of	NN	O	O
HBV	NN	O	O
activation	NN	O	O
.	NN	O	O

Lamivudine	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
and	NN	O	O
was	NN	O	O
continued	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

Prophylactic	NN	O	O
administration	NN	O	O
of	NN	O	O
lamivudine	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
required	NN	O	O
immunosuppressive	NN	O	O
therapy	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
safe	NN	O	O
,	NN	O	O
well	NN	O	O
tolerated	NN	O	O
and	NN	O	O
effective	NN	O	O
in	NN	O	O
preventing	NN	O	O
HBV	NN	O	O
reactivation	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
green	NN	O	O
tea	NN	O	O
and	NN	O	O
vitamin	NN	O	O
E	NN	O	O
combination	NN	O	O
in	NN	O	O
isoproterenol	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
aimed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
combined	NN	O	O
effects	NN	O	O
of	NN	O	O
green	NN	O	O
tea	NN	O	O
and	NN	O	O
vitamin	NN	O	O
E	NN	O	O
on	NN	O	O
heart	NN	O	O
weight	NN	O	O
,	NN	O	O
body	NN	O	O
weight	NN	O	O
,	NN	O	O
serum	NN	O	O
marker	NN	O	O
enzymes	NN	O	O
,	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
,	NN	O	O
endogenous	NN	O	O
antioxidants	NN	O	O
and	NN	O	O
membrane	NN	O	O
bound	NN	O	O
ATPases	NN	O	O
in	NN	O	O
isoproterenol	NN	O	O
(	NN	O	O
ISO	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Adult	NN	O	O
male	NN	O	O
albino	NN	O	O
rats	NN	O	O
,	NN	O	O
treated	NN	O	O
with	NN	O	O
ISO	NN	O	O
(	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
for	NN	O	O
2	NN	O	O
days	NN	O	O
at	NN	O	O
an	NN	O	O
interval	NN	O	O
of	NN	O	O
24	NN	O	O
h	NN	O	O
caused	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
elevation	NN	O	O
of	NN	O	O
heart	NN	O	O
weight	NN	O	O
,	NN	O	O
serum	NN	O	O
marker	NN	O	O
enzymes	NN	O	O
,	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
and	NN	O	O
Ca	NN	O	O
+	NN	O	O
2	NN	O	O
ATPase	NN	O	O
level	NN	O	O
whereas	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
decrease	NN	O	O
in	NN	O	O
body	NN	O	O
weight	NN	O	O
,	NN	O	O
endogenous	NN	O	O
antioxidants	NN	O	O
,	NN	O	O
Na	NN	O	O
+	NN	O	O
/	NN	O	O
K	NN	O	O
+	NN	O	O
ATPase	NN	O	O
and	NN	O	O
Mg	NN	O	O
+	NN	O	O
2	NN	O	O
ATPase	NN	O	O
levels	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
green	NN	O	O
tea	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
and	NN	O	O
vitamin	NN	O	O
E	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
together	NN	O	O
for	NN	O	O
30	NN	O	O
consecutive	NN	O	O
days	NN	O	O
and	NN	O	O
challenged	NN	O	O
with	NN	O	O
ISO	NN	O	O
on	NN	O	O
the	NN	O	O
day	NN	O	O
29th	NN	O	O
and	NN	O	O
30th	NN	O	O
,	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
decrease	NN	O	O
in	NN	O	O
heart	NN	O	O
weight	NN	O	O
,	NN	O	O
serum	NN	O	O
marker	NN	O	O
enzymes	NN	O	O
,	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
,	NN	O	O
Ca	NN	O	O
+	NN	O	O
2	NN	O	O
ATPase	NN	O	O
and	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
body	NN	O	O
weight	NN	O	O
,	NN	O	O
endogenous	NN	O	O
antioxidants	NN	O	O
,	NN	O	O
Na	NN	O	O
+	NN	O	O
/	NN	O	O
K	NN	O	O
+	NN	O	O
ATPase	NN	O	O
and	NN	O	O
Mg	NN	O	O
+	NN	O	O
2	NN	O	O
ATPase	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
ISO	NN	O	O
treated	NN	O	O
group	NN	O	O
and	NN	O	O
green	NN	O	O
tea	NN	O	O
or	NN	O	O
vitamin	NN	O	O
E	NN	O	O
alone	NN	O	O
treated	NN	O	O
groups	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
the	NN	O	O
synergistic	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
green	NN	O	O
tea	NN	O	O
and	NN	O	O
vitamin	NN	O	O
E	NN	O	O
during	NN	O	O
ISO	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Irreversible	NN	O	O
damage	NN	O	O
to	NN	O	O
the	NN	O	O
medullary	NN	O	O
interstitium	NN	O	O
in	NN	O	O
experimental	NN	O	O
analgesic	NN	O	O
nephropathy	NN	O	B
in	NN	O	O
F344	NN	O	O
rats	NN	O	O
.	NN	O	O

Renal	NN	O	B
papillary	NN	O	I
necrosis	NN	O	I
(	NN	O	O
RPN	NN	O	B
)	NN	O	O
and	NN	O	O
a	NN	O	O
decreased	NN	O	O
urinary	NN	O	O
concentrating	NN	O	O
ability	NN	O	O
developed	NN	O	O
during	NN	O	O
continuous	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
aspirin	NN	O	O
and	NN	O	O
paracetamol	NN	O	O
in	NN	O	O
female	NN	O	O
Fischer	NN	O	O
344	NN	O	O
rats	NN	O	O
.	NN	O	O

Renal	NN	O	O
structure	NN	O	O
and	NN	O	O
concentrating	NN	O	O
ability	NN	O	O
were	NN	O	O
examined	NN	O	O
after	NN	O	O
a	NN	O	O
recovery	NN	O	O
period	NN	O	O
of	NN	O	O
up	NN	O	O
to	NN	O	O
18	NN	O	O
weeks	NN	O	O
,	NN	O	O
when	NN	O	O
no	NN	O	O
analgesics	NN	O	O
were	NN	O	O
given	NN	O	O
,	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
the	NN	O	O
analgesic	NN	O	O
-	NN	O	O
induced	NN	O	O
changes	NN	O	O
were	NN	O	O
reversible	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
repair	NN	O	O
to	NN	O	O
the	NN	O	O
damaged	NN	O	O
medullary	NN	O	O
interstitial	NN	O	O
matrix	NN	O	O
,	NN	O	O
or	NN	O	O
proliferation	NN	O	O
of	NN	O	O
remaining	NN	O	O
undamaged	NN	O	O
type	NN	O	O
1	NN	O	O
medullary	NN	O	O
interstitial	NN	O	O
cells	NN	O	O
after	NN	O	O
the	NN	O	O
recovery	NN	O	O
period	NN	O	O
following	NN	O	O
analgesic	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
recovery	NN	O	O
of	NN	O	O
urinary	NN	O	O
concentrating	NN	O	O
ability	NN	O	O
was	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
length	NN	O	O
of	NN	O	O
analgesic	NN	O	O
treatment	NN	O	O
and	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
the	NN	O	O
resulting	NN	O	O
inner	NN	O	O
medullary	NN	O	O
structural	NN	O	O
damage	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
early	NN	O	O
stages	NN	O	O
of	NN	O	O
analgesic	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
urinary	NN	O	O
concentrating	NN	O	O
ability	NN	O	O
were	NN	O	O
reversible	NN	O	O
,	NN	O	O
but	NN	O	O
after	NN	O	O
prolonged	NN	O	O
analgesic	NN	O	O
treatment	NN	O	O
,	NN	O	O
maximum	NN	O	O
urinary	NN	O	O
concentrating	NN	O	O
ability	NN	O	O
failed	NN	O	O
to	NN	O	O
recover	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
shows	NN	O	O
that	NN	O	O
prolonged	NN	O	O
analgesic	NN	O	O
treatment	NN	O	O
in	NN	O	O
Fischer	NN	O	O
344	NN	O	O
rats	NN	O	O
causes	NN	O	O
progressive	NN	O	O
and	NN	O	O
irreversible	NN	O	O
damage	NN	O	O
to	NN	O	O
the	NN	O	O
interstitial	NN	O	O
matrix	NN	O	O
and	NN	O	O
type	NN	O	O
1	NN	O	O
interstitial	NN	O	O
cells	NN	O	O
leading	NN	O	O
to	NN	O	O
RPN	NN	O	B
.	NN	O	O

The	NN	O	O
associated	NN	O	O
urinary	NN	O	O
concentrating	NN	O	O
defect	NN	O	O
is	NN	O	O
reversible	NN	O	O
only	NN	O	O
during	NN	O	O
the	NN	O	O
early	NN	O	O
stages	NN	O	O
of	NN	O	O
structural	NN	O	O
damage	NN	O	O
to	NN	O	O
the	NN	O	O
inner	NN	O	O
medulla	NN	O	O
.	NN	O	O

Testosterone	NN	O	O
-	NN	O	O
dependent	NN	O	O
hypertension	NN	O	B
and	NN	O	O
upregulation	NN	O	O
of	NN	O	O
intrarenal	NN	O	O
angiotensinogen	NN	O	O
in	NN	O	O
Dahl	NN	O	O
salt	NN	O	O
-	NN	O	O
sensitive	NN	O	O
rats	NN	O	O
.	NN	O	O

Blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
BP	NN	O	O
)	NN	O	O
is	NN	O	O
more	NN	O	O
salt	NN	O	O
sensitive	NN	O	O
in	NN	O	O
men	NN	O	O
than	NN	O	O
in	NN	O	O
premenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

In	NN	O	O
Dahl	NN	O	O
salt	NN	O	O
-	NN	O	O
sensitive	NN	O	O
rats	NN	O	O
(	NN	O	O
DS	NN	O	O
)	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
salt	NN	O	O
(	NN	O	O
HS	NN	O	O
)	NN	O	O
diet	NN	O	O
increases	NN	O	O
BP	NN	O	O
more	NN	O	O
in	NN	O	O
males	NN	O	O
than	NN	O	O
females	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
to	NN	O	O
the	NN	O	O
systemic	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
suppressed	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
HS	NN	O	O
in	NN	O	O
male	NN	O	O
DS	NN	O	O
,	NN	O	O
intrarenal	NN	O	O
angiotensinogen	NN	O	O
expression	NN	O	O
is	NN	O	O
increased	NN	O	O
,	NN	O	O
and	NN	O	O
intrarenal	NN	O	O
levels	NN	O	O
of	NN	O	O
ANG	NN	O	O
II	NN	O	O
are	NN	O	O
not	NN	O	O
suppressed	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
was	NN	O	O
tested	NN	O	O
that	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
sexual	NN	O	O
dimorphism	NN	O	O
in	NN	O	O
HS	NN	O	O
-	NN	O	O
induced	NN	O	O
upregulation	NN	O	O
of	NN	O	O
intrarenal	NN	O	O
angiotensinogen	NN	O	O
mediated	NN	O	O
by	NN	O	O
testosterone	NN	O	O
that	NN	O	O
also	NN	O	O
causes	NN	O	O
increases	NN	O	O
in	NN	O	O
BP	NN	O	O
and	NN	O	O
renal	NN	O	B
injury	NN	O	I
.	NN	O	O

On	NN	O	O
a	NN	O	O
low	NN	O	O
-	NN	O	O
salt	NN	O	O
(	NN	O	O
LS	NN	O	O
)	NN	O	O
diet	NN	O	O
,	NN	O	O
male	NN	O	O
DS	NN	O	O
had	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
intrarenal	NN	O	O
angiotensinogen	NN	O	O
mRNA	NN	O	O
than	NN	O	O
females	NN	O	O
.	NN	O	O

HS	NN	O	O
diet	NN	O	O
for	NN	O	O
4	NN	O	O
wk	NN	O	O
increased	NN	O	O
renal	NN	O	O
cortical	NN	O	O
angiotensinogen	NN	O	O
mRNA	NN	O	O
and	NN	O	O
protein	NN	O	O
only	NN	O	O
in	NN	O	O
male	NN	O	O
DS	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
prevented	NN	O	O
by	NN	O	O
castration	NN	O	O
.	NN	O	O

Ovariectomy	NN	O	O
of	NN	O	O
female	NN	O	O
DS	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
intrarenal	NN	O	O
angiotensinogen	NN	O	O
expression	NN	O	O
on	NN	O	O
either	NN	O	O
diet	NN	O	O
.	NN	O	O

Radiotelemetric	NN	O	O
BP	NN	O	O
was	NN	O	O
similar	NN	O	O
between	NN	O	O
males	NN	O	O
and	NN	O	O
castrated	NN	O	O
rats	NN	O	O
on	NN	O	O
LS	NN	O	O
diet	NN	O	O
.	NN	O	O

HS	NN	O	O
diet	NN	O	O
for	NN	O	O
4	NN	O	O
wk	NN	O	O
caused	NN	O	O
a	NN	O	O
progressive	NN	O	O
increase	NN	O	O
in	NN	O	O
BP	NN	O	O
,	NN	O	O
protein	NN	O	O
and	NN	O	O
albumin	NN	O	O
excretion	NN	O	O
,	NN	O	O
and	NN	O	O
glomerular	NN	O	B
sclerosis	NN	O	I
in	NN	O	O
male	NN	O	O
DS	NN	O	O
rats	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
attenuated	NN	O	O
by	NN	O	O
castration	NN	O	O
.	NN	O	O

Testosterone	NN	O	O
replacement	NN	O	O
in	NN	O	O
castrated	NN	O	O
DS	NN	O	O
rats	NN	O	O
increased	NN	O	O
BP	NN	O	O
,	NN	O	O
renal	NN	O	B
injury	NN	O	I
,	NN	O	O
and	NN	O	O
upregulation	NN	O	O
of	NN	O	O
renal	NN	O	O
angiotensinogen	NN	O	O
associated	NN	O	O
with	NN	O	O
HS	NN	O	O
diet	NN	O	O
.	NN	O	O

Testosterone	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hypertension	NN	O	B
and	NN	O	O
renal	NN	O	B
injury	NN	O	I
in	NN	O	O
male	NN	O	O
DS	NN	O	O
rats	NN	O	O
on	NN	O	O
HS	NN	O	O
diet	NN	O	O
possibly	NN	O	O
through	NN	O	O
upregulation	NN	O	O
of	NN	O	O
the	NN	O	O
intrarenal	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
.	NN	O	O

Explicit	NN	O	O
episodic	NN	O	O
memory	NN	O	O
for	NN	O	O
sensory	NN	O	O
-	NN	O	O
discriminative	NN	O	O
components	NN	O	O
of	NN	O	O
capsaicin	NN	O	O
-	NN	O	O
induced	NN	O	O
pain	NN	O	B
:	NN	O	O
immediate	NN	O	O
and	NN	O	O
delayed	NN	O	O
ratings	NN	O	O
.	NN	O	O

Pain	NN	O	B
memory	NN	O	O
is	NN	O	O
thought	NN	O	O
to	NN	O	O
affect	NN	O	O
future	NN	O	O
pain	NN	O	B
sensitivity	NN	O	O
and	NN	O	O
thus	NN	O	O
contribute	NN	O	O
to	NN	O	O
clinical	NN	O	O
pain	NN	O	B
conditions	NN	O	O
.	NN	O	O

Systematic	NN	O	O
investigations	NN	O	O
of	NN	O	O
the	NN	O	O
human	NN	O	O
capacity	NN	O	O
to	NN	O	O
remember	NN	O	O
sensory	NN	O	O
features	NN	O	O
of	NN	O	O
experimental	NN	O	O
pain	NN	O	B
are	NN	O	O
sparse	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
address	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
pain	NN	O	B
memory	NN	O	O
,	NN	O	O
nine	NN	O	O
healthy	NN	O	O
male	NN	O	O
volunteers	NN	O	O
received	NN	O	O
intradermal	NN	O	O
injections	NN	O	O
of	NN	O	O
three	NN	O	O
doses	NN	O	O
of	NN	O	O
capsaicin	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
,	NN	O	O
1	NN	O	O
and	NN	O	O
20	NN	O	O
microg	NN	O	O
,	NN	O	O
separated	NN	O	O
by	NN	O	O
15	NN	O	O
min	NN	O	O
breaks	NN	O	O
)	NN	O	O
,	NN	O	O
each	NN	O	O
given	NN	O	O
three	NN	O	O
times	NN	O	O
in	NN	O	O
a	NN	O	O
balanced	NN	O	O
design	NN	O	O
across	NN	O	O
three	NN	O	O
sessions	NN	O	O
at	NN	O	O
one	NN	O	O
week	NN	O	O
intervals	NN	O	O
.	NN	O	O

Pain	NN	O	B
rating	NN	O	O
was	NN	O	O
performed	NN	O	O
using	NN	O	O
a	NN	O	O
computerized	NN	O	O
visual	NN	O	O
analogue	NN	O	O
scale	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
100	NN	O	O
)	NN	O	O
digitized	NN	O	O
at	NN	O	O
1	NN	O	O
/	NN	O	O
s	NN	O	O
,	NN	O	O
either	NN	O	O
immediately	NN	O	O
online	NN	O	O
or	NN	O	O
one	NN	O	O
hour	NN	O	O
or	NN	O	O
one	NN	O	O
day	NN	O	O
after	NN	O	O
injection	NN	O	O
.	NN	O	O

Subjects	NN	O	O
also	NN	O	O
recalled	NN	O	O
their	NN	O	O
pains	NN	O	B
one	NN	O	O
week	NN	O	O
later	NN	O	O
.	NN	O	O

Capsaicin	NN	O	O
injection	NN	O	O
reliably	NN	O	O
induced	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
flare	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
without	NN	O	O
any	NN	O	O
difference	NN	O	O
within	NN	O	O
or	NN	O	O
across	NN	O	O
sessions	NN	O	O
.	NN	O	O

The	NN	O	O
strong	NN	O	O
burning	NN	O	O
pain	NN	O	B
decayed	NN	O	O
exponentially	NN	O	O
within	NN	O	O
a	NN	O	O
few	NN	O	O
minutes	NN	O	O
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
able	NN	O	O
to	NN	O	O
reliably	NN	O	O
discriminate	NN	O	O
pain	NN	O	B
magnitude	NN	O	O
and	NN	O	O
duration	NN	O	O
across	NN	O	O
capsaicin	NN	O	O
doses	NN	O	O
(	NN	O	O
both	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
regardless	NN	O	O
of	NN	O	O
whether	NN	O	O
first	NN	O	O
-	NN	O	O
time	NN	O	O
ratings	NN	O	O
were	NN	O	O
requested	NN	O	O
immediately	NN	O	O
,	NN	O	O
after	NN	O	O
one	NN	O	O
hour	NN	O	O
or	NN	O	O
after	NN	O	O
one	NN	O	O
day	NN	O	O
.	NN	O	O

Pain	NN	O	B
recall	NN	O	O
after	NN	O	O
one	NN	O	O
week	NN	O	O
was	NN	O	O
similarly	NN	O	O
precise	NN	O	O
(	NN	O	O
magnitude	NN	O	O
:	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
,	NN	O	O
duration	NN	O	O
:	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Correlation	NN	O	O
with	NN	O	O
rating	NN	O	O
recall	NN	O	O
after	NN	O	O
one	NN	O	O
week	NN	O	O
was	NN	O	O
best	NN	O	O
when	NN	O	O
first	NN	O	O
-	NN	O	O
time	NN	O	O
ratings	NN	O	O
were	NN	O	O
requested	NN	O	O
as	NN	O	O
late	NN	O	O
as	NN	O	O
one	NN	O	O
day	NN	O	O
after	NN	O	O
injection	NN	O	O
(	NN	O	O
R	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
79	NN	O	O
)	NN	O	O
indicating	NN	O	O
that	NN	O	O
both	NN	O	O
rating	NN	O	O
retrievals	NN	O	O
utilized	NN	O	O
similar	NN	O	O
memory	NN	O	O
traces	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
a	NN	O	O
reliable	NN	O	O
memory	NN	O	O
for	NN	O	O
magnitude	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
experimentally	NN	O	O
induced	NN	O	O
pain	NN	O	B
.	NN	O	O

The	NN	O	O
data	NN	O	O
further	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
consolidation	NN	O	O
of	NN	O	O
this	NN	O	O
memory	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
interim	NN	O	O
stage	NN	O	O
,	NN	O	O
and	NN	O	O
may	NN	O	O
take	NN	O	O
up	NN	O	O
to	NN	O	O
one	NN	O	O
day	NN	O	O
.	NN	O	O

Severe	NN	O	O
and	NN	O	O
long	NN	O	O
lasting	NN	O	O
cholestasis	NN	O	B
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
co	NN	O	O
-	NN	O	O
trimoxazole	NN	O	O
treatment	NN	O	O
for	NN	O	O
Pneumocystis	NN	O	B
pneumonia	NN	O	I
in	NN	O	O
HIV	NN	O	B
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
-	NN	O	O
-	NN	O	O
a	NN	O	O
report	NN	O	O
of	NN	O	O
two	NN	O	O
cases	NN	O	O
.	NN	O	O

Pneumocystis	NN	O	B
pneumonia	NN	O	I
(	NN	O	O
PCP	NN	O	B
)	NN	O	O
,	NN	O	O
a	NN	O	O
common	NN	O	O
opportunistic	NN	O	B
infection	NN	O	I
in	NN	O	O
HIV	NN	O	B
-	NN	O	I
infected	NN	O	I
individuals	NN	O	O
,	NN	O	O
is	NN	O	O
generally	NN	O	O
treated	NN	O	O
with	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
co	NN	O	O
-	NN	O	O
trimoxazole	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
treatment	NN	O	O
is	NN	O	O
often	NN	O	O
limited	NN	O	O
by	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
severely	NN	O	O
immunocompromised	NN	O	O
HIV	NN	O	B
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
severe	NN	O	O
intrahepatic	NN	O	B
cholestasis	NN	O	I
,	NN	O	O
and	NN	O	O
in	NN	O	O
one	NN	O	O
patient	NN	O	O
lesions	NN	O	O
mimicking	NN	O	O
liver	NN	O	B
abscess	NN	O	I
formation	NN	O	O
on	NN	O	O
radiologic	NN	O	O
exams	NN	O	O
,	NN	O	O
during	NN	O	O
co	NN	O	O
-	NN	O	O
trimoxazole	NN	O	O
treatment	NN	O	O
for	NN	O	O
PCP	NN	O	B
.	NN	O	O

Whereas	NN	O	O
patient	NN	O	O
1	NN	O	O
showed	NN	O	O
lesions	NN	O	O
of	NN	O	O
up	NN	O	O
to	NN	O	O
1	NN	O	O
cm	NN	O	O
readily	NN	O	O
detectable	NN	O	O
on	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
under	NN	O	O
prolonged	NN	O	O
co	NN	O	O
-	NN	O	O
trimoxazole	NN	O	O
treatment	NN	O	O
,	NN	O	O
therapy	NN	O	O
of	NN	O	O
patient	NN	O	O
2	NN	O	O
was	NN	O	O
switched	NN	O	O
early	NN	O	O
.	NN	O	O

Bradykinin	NN	O	O
receptors	NN	O	O
antagonists	NN	O	O
and	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
synthase	NN	O	O
inhibitors	NN	O	O
in	NN	O	O
vincristine	NN	O	O
and	NN	O	O
streptozotocin	NN	O	O
induced	NN	O	O
hyperalgesia	NN	O	B
in	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
diabetic	NN	O	B
neuropathy	NN	O	I
rat	NN	O	O
model	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
The	NN	O	O
influence	NN	O	O
of	NN	O	O
an	NN	O	O
irreversible	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
constitutive	NN	O	O
NO	NN	O	O
synthase	NN	O	O
(	NN	O	O
L	NN	O	O
-	NN	O	O
NOArg	NN	O	O
;	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
relatively	NN	O	O
selective	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
inducible	NN	O	O
NO	NN	O	O
synthase	NN	O	O
(	NN	O	O
L	NN	O	O
-	NN	O	O
NIL	NN	O	O
;	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
relatively	NN	O	O
specific	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
neuronal	NN	O	O
NO	NN	O	O
synthase	NN	O	O
(	NN	O	O
7	NN	O	O
-	NN	O	O
NI	NN	O	O
;	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
,	NN	O	O
on	NN	O	O
antihyperalgesic	NN	O	O
action	NN	O	O
of	NN	O	O
selective	NN	O	O
antagonists	NN	O	O
of	NN	O	O
B2	NN	O	O
and	NN	O	O
B1	NN	O	O
receptors	NN	O	O
:	NN	O	O
D	NN	O	O
-	NN	O	O
Arg	NN	O	O
-	NN	O	O
[	NN	O	O
Hyp3	NN	O	O
,	NN	O	O
Thi5	NN	O	O
,	NN	O	O
D	NN	O	O
-	NN	O	O
Tic7	NN	O	O
,	NN	O	O
Oic8	NN	O	O
]	NN	O	O
bradykinin	NN	O	O
(	NN	O	O
HOE	NN	O	O
140	NN	O	O
;	NN	O	O
70	NN	O	O
nmol	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
or	NN	O	O
des	NN	O	O
Arg10	NN	O	O
HOE	NN	O	O
140	NN	O	O
(	NN	O	O
70	NN	O	O
nmol	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
model	NN	O	O
of	NN	O	O
diabetic	NN	O	B
(	NN	O	I
streptozotocin	NN	O	I
-	NN	O	I
induced	NN	O	I
)	NN	O	I
and	NN	O	I
toxic	NN	O	I
(	NN	O	I
vincristine	NN	O	I
-	NN	O	I
induced	NN	O	I
)	NN	O	I
neuropathy	NN	O	I
was	NN	O	O
investigated	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
changes	NN	O	O
in	NN	O	O
pain	NN	O	B
thresholds	NN	O	O
were	NN	O	O
determined	NN	O	O
using	NN	O	O
mechanical	NN	O	O
stimuli	NN	O	O
-	NN	O	O
-	NN	O	O
the	NN	O	O
modification	NN	O	O
of	NN	O	O
the	NN	O	O
classic	NN	O	O
paw	NN	O	O
withdrawal	NN	O	O
test	NN	O	O
described	NN	O	O
by	NN	O	O
Randall	NN	O	O
-	NN	O	O
Selitto	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
paper	NN	O	O
confirm	NN	O	O
that	NN	O	O
inhibition	NN	O	O
of	NN	O	O
bradykinin	NN	O	O
receptors	NN	O	O
and	NN	O	O
inducible	NN	O	O
NO	NN	O	O
synthase	NN	O	O
but	NN	O	O
not	NN	O	O
neuronal	NN	O	O
NO	NN	O	O
synthase	NN	O	O
activity	NN	O	O
reduces	NN	O	O
diabetic	NN	O	B
hyperalgesia	NN	O	I
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
L	NN	O	O
-	NN	O	O
NOArg	NN	O	O
and	NN	O	O
L	NN	O	O
-	NN	O	O
NIL	NN	O	O
but	NN	O	O
not	NN	O	O
7	NN	O	O
-	NN	O	O
NI	NN	O	O
,	NN	O	O
significantly	NN	O	O
increases	NN	O	O
antihyperalgesic	NN	O	O
activity	NN	O	O
both	NN	O	O
HOE	NN	O	O
140	NN	O	O
and	NN	O	O
des	NN	O	O
Arg10	NN	O	O
HOE	NN	O	O
140	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
also	NN	O	O
shown	NN	O	O
that	NN	O	O
both	NN	O	O
products	NN	O	O
of	NN	O	O
inducible	NN	O	O
NO	NN	O	O
synthase	NN	O	O
and	NN	O	O
neuronal	NN	O	O
NO	NN	O	O
synthase	NN	O	O
activation	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
bradykinin	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
hyperalgesia	NN	O	B
produced	NN	O	O
by	NN	O	O
vincristine	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
L	NN	O	O
-	NN	O	O
NOArg	NN	O	O
and	NN	O	O
7	NN	O	O
-	NN	O	O
NI	NN	O	O
but	NN	O	O
not	NN	O	O
L	NN	O	O
-	NN	O	O
NIL	NN	O	O
intensify	NN	O	O
antihyperalgesic	NN	O	O
activity	NN	O	O
of	NN	O	O
HOE	NN	O	O
140	NN	O	O
or	NN	O	O
des	NN	O	O
-	NN	O	O
Arg10HOE	NN	O	O
140	NN	O	O
in	NN	O	O
toxic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Results	NN	O	O
of	NN	O	O
these	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
B1	NN	O	O
and	NN	O	O
B2	NN	O	O
receptors	NN	O	O
are	NN	O	O
engaged	NN	O	O
in	NN	O	O
transmission	NN	O	O
of	NN	O	O
nociceptive	NN	O	O
stimuli	NN	O	O
in	NN	O	O
both	NN	O	O
diabetic	NN	O	B
and	NN	O	I
toxic	NN	O	I
neuropathy	NN	O	I
.	NN	O	O

In	NN	O	O
streptozotocin	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperalgesia	NN	O	B
,	NN	O	O
inducible	NN	O	O
NO	NN	O	O
synthase	NN	O	O
participates	NN	O	O
in	NN	O	O
pronociceptive	NN	O	O
activity	NN	O	O
of	NN	O	O
bradykinin	NN	O	O
,	NN	O	O
whereas	NN	O	O
in	NN	O	O
vincristine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperalgesia	NN	O	B
bradykinin	NN	O	O
seemed	NN	O	O
to	NN	O	O
activate	NN	O	O
neuronal	NN	O	O
NO	NN	O	O
synthase	NN	O	O
pathway	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
concomitant	NN	O	O
administration	NN	O	O
of	NN	O	O
small	NN	O	O
doses	NN	O	O
of	NN	O	O
bradykinin	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
and	NN	O	O
NO	NN	O	O
synthase	NN	O	O
inhibitors	NN	O	O
can	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
alleviation	NN	O	O
of	NN	O	O
neuropathic	NN	O	B
pain	NN	O	I
,	NN	O	O
even	NN	O	O
in	NN	O	O
hospital	NN	O	O
care	NN	O	O
.	NN	O	O

Confusion	NN	O	B
,	NN	O	O
a	NN	O	O
rather	NN	O	O
serious	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
with	NN	O	O
valproic	NN	O	O
acid	NN	O	O
:	NN	O	O
a	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
French	NN	O	O
Pharmacovigilance	NN	O	O
database	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Confusion	NN	O	B
is	NN	O	O
an	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
frequently	NN	O	O
observed	NN	O	O
with	NN	O	O
valproic	NN	O	O
acid	NN	O	O
.	NN	O	O

Some	NN	O	O
case	NN	O	O
reports	NN	O	O
are	NN	O	O
published	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
but	NN	O	O
no	NN	O	O
systematic	NN	O	O
study	NN	O	O
from	NN	O	O
a	NN	O	O
sample	NN	O	O
of	NN	O	O
patients	NN	O	O
has	NN	O	O
been	NN	O	O
published	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
this	NN	O	O
study	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
describe	NN	O	O
the	NN	O	O
main	NN	O	O
characteristics	NN	O	O
of	NN	O	O
this	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Using	NN	O	O
the	NN	O	O
French	NN	O	O
Pharmacovigilance	NN	O	O
database	NN	O	O
,	NN	O	O
we	NN	O	O
selected	NN	O	O
the	NN	O	O
cases	NN	O	O
of	NN	O	O
confusion	NN	O	B
reported	NN	O	O
since	NN	O	O
1985	NN	O	O
with	NN	O	O
valproic	NN	O	O
acid	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
272	NN	O	O
cases	NN	O	O
of	NN	O	O
confusion	NN	O	B
were	NN	O	O
reported	NN	O	O
with	NN	O	O
valproic	NN	O	O
acid	NN	O	O
:	NN	O	O
153	NN	O	O
women	NN	O	O
and	NN	O	O
119	NN	O	O
men	NN	O	O
.	NN	O	O

Confusion	NN	O	B
mostly	NN	O	O
occurred	NN	O	O
during	NN	O	O
the	NN	O	O
two	NN	O	O
first	NN	O	O
weeks	NN	O	O
following	NN	O	O
valproic	NN	O	O
acid	NN	O	O
exposure	NN	O	O
(	NN	O	O
39	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
"	NN	O	O
serious	NN	O	O
"	NN	O	O
for	NN	O	O
almost	NN	O	O
2	NN	O	O
/	NN	O	O
3	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
(	NN	O	O
62	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
its	NN	O	O
outcome	NN	O	O
favourable	NN	O	O
in	NN	O	O
most	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
(	NN	O	O
82	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
occurrence	NN	O	O
of	NN	O	O
this	NN	O	O
ADR	NN	O	O
was	NN	O	O
more	NN	O	O
frequent	NN	O	O
in	NN	O	O
patients	NN	O	O
aged	NN	O	O
between	NN	O	O
61	NN	O	O
and	NN	O	O
80	NN	O	O
years	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
work	NN	O	O
shows	NN	O	O
that	NN	O	O
confusion	NN	O	B
with	NN	O	O
valproic	NN	O	O
acid	NN	O	O
is	NN	O	O
a	NN	O	O
serious	NN	O	O
,	NN	O	O
rather	NN	O	O
frequent	NN	O	O
but	NN	O	O
reversible	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
.	NN	O	O

It	NN	O	O
occurs	NN	O	O
especially	NN	O	O
in	NN	O	O
older	NN	O	O
patients	NN	O	O
and	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
two	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Reversible	NN	O	O
inferior	NN	O	B
colliculus	NN	O	I
lesion	NN	O	I
in	NN	O	O
metronidazole	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
:	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
findings	NN	O	O
on	NN	O	O
diffusion	NN	O	O
-	NN	O	O
weighted	NN	O	O
and	NN	O	O
fluid	NN	O	O
attenuated	NN	O	O
inversion	NN	O	O
recovery	NN	O	O
imaging	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
This	NN	O	O
is	NN	O	O
to	NN	O	O
present	NN	O	O
reversible	NN	O	O
inferior	NN	O	B
colliculus	NN	O	I
lesions	NN	O	I
in	NN	O	O
metronidazole	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
,	NN	O	O
to	NN	O	O
focus	NN	O	O
on	NN	O	O
the	NN	O	O
diffusion	NN	O	O
-	NN	O	O
weighted	NN	O	O
imaging	NN	O	O
(	NN	O	O
DWI	NN	O	O
)	NN	O	O
and	NN	O	O
fluid	NN	O	O
attenuated	NN	O	O
inversion	NN	O	O
recovery	NN	O	O
(	NN	O	O
FLAIR	NN	O	O
)	NN	O	O
imaging	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
From	NN	O	O
November	NN	O	O
2005	NN	O	O
to	NN	O	O
September	NN	O	O
2007	NN	O	O
,	NN	O	O
8	NN	O	O
patients	NN	O	O
(	NN	O	O
5	NN	O	O
men	NN	O	O
and	NN	O	O
3	NN	O	O
women	NN	O	O
)	NN	O	O
were	NN	O	O
diagnosed	NN	O	O
as	NN	O	O
having	NN	O	O
metronidazole	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
(	NN	O	O
age	NN	O	O
range	NN	O	O
;	NN	O	O
43	NN	O	O
-	NN	O	O
78	NN	O	O
years	NN	O	O
)	NN	O	O
.	NN	O	O

They	NN	O	O
had	NN	O	O
been	NN	O	O
taking	NN	O	O
metronidazole	NN	O	O
(	NN	O	O
total	NN	O	O
dosage	NN	O	O
,	NN	O	O
45	NN	O	O
-	NN	O	O
120	NN	O	O
g	NN	O	O
;	NN	O	O
duration	NN	O	O
,	NN	O	O
30	NN	O	O
days	NN	O	O
to	NN	O	O
2	NN	O	O
months	NN	O	O
)	NN	O	O
to	NN	O	O
treat	NN	O	O
the	NN	O	O
infection	NN	O	B
in	NN	O	O
various	NN	O	O
organs	NN	O	O
.	NN	O	O

Initial	NN	O	O
brain	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
MRI	NN	O	O
)	NN	O	O
were	NN	O	O
obtained	NN	O	O
after	NN	O	O
the	NN	O	O
hospitalization	NN	O	O
,	NN	O	O
including	NN	O	O
DWI	NN	O	O
(	NN	O	O
8	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
apparent	NN	O	O
diffusion	NN	O	O
coefficient	NN	O	O
(	NN	O	O
ADC	NN	O	O
)	NN	O	O
map	NN	O	O
(	NN	O	O
4	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
FLAIR	NN	O	O
(	NN	O	O
7	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
T2	NN	O	O
-	NN	O	O
weighted	NN	O	O
image	NN	O	O
(	NN	O	O
8	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

Follow	NN	O	O
-	NN	O	O
up	NN	O	O
MRIs	NN	O	O
were	NN	O	O
performed	NN	O	O
on	NN	O	O
5	NN	O	O
patients	NN	O	O
from	NN	O	O
third	NN	O	O
to	NN	O	O
14th	NN	O	O
days	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
metronidazole	NN	O	O
administration	NN	O	O
.	NN	O	O

Findings	NN	O	O
of	NN	O	O
initial	NN	O	O
and	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
MRIs	NN	O	O
were	NN	O	O
retrospectively	NN	O	O
evaluated	NN	O	O
by	NN	O	O
2	NN	O	O
neuroradiologists	NN	O	O
by	NN	O	O
consensus	NN	O	O
,	NN	O	O
to	NN	O	O
analyze	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
abnormal	NN	O	O
signal	NN	O	O
intensities	NN	O	O
,	NN	O	O
their	NN	O	O
locations	NN	O	O
,	NN	O	O
and	NN	O	O
signal	NN	O	O
changes	NN	O	O
on	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
images	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Initial	NN	O	O
MRIs	NN	O	O
showed	NN	O	O
abnormal	NN	O	O
high	NN	O	O
signal	NN	O	O
intensities	NN	O	O
on	NN	O	O
DWI	NN	O	O
and	NN	O	O
FLAIR	NN	O	O
(	NN	O	O
or	NN	O	O
T2	NN	O	O
-	NN	O	O
weighted	NN	O	O
image	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
dentate	NN	O	O
nucleus	NN	O	O
(	NN	O	O
8	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
inferior	NN	O	O
colliculus	NN	O	O
(	NN	O	O
6	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
corpus	NN	O	O
callosum	NN	O	O
(	NN	O	O
2	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
pons	NN	O	O
(	NN	O	O
2	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
medulla	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
bilateral	NN	O	O
cerebral	NN	O	O
white	NN	O	O
matter	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
signal	NN	O	O
intensity	NN	O	O
lesions	NN	O	O
on	NN	O	O
DWI	NN	O	O
tended	NN	O	O
to	NN	O	O
show	NN	O	O
low	NN	O	O
signal	NN	O	O
intensity	NN	O	O
on	NN	O	O
ADC	NN	O	O
map	NN	O	O
(	NN	O	O
3	NN	O	O
/	NN	O	O
4	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
one	NN	O	O
patient	NN	O	O
,	NN	O	O
high	NN	O	O
signal	NN	O	O
intensity	NN	O	O
was	NN	O	O
shown	NN	O	O
at	NN	O	O
bilateral	NN	O	O
dentate	NN	O	O
nuclei	NN	O	O
on	NN	O	O
not	NN	O	O
only	NN	O	O
DWI	NN	O	O
but	NN	O	O
also	NN	O	O
ADC	NN	O	O
map	NN	O	O
.	NN	O	O

All	NN	O	O
the	NN	O	O
lesions	NN	O	O
in	NN	O	O
dentate	NN	O	O
,	NN	O	O
inferior	NN	O	O
colliculus	NN	O	O
,	NN	O	O
pons	NN	O	O
,	NN	O	O
and	NN	O	O
medullas	NN	O	O
had	NN	O	O
been	NN	O	O
resolved	NN	O	O
completely	NN	O	O
on	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
MRIs	NN	O	O
in	NN	O	O
5	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
1	NN	O	O
patient	NN	O	O
of	NN	O	O
them	NN	O	O
,	NN	O	O
corpus	NN	O	O
callosal	NN	O	B
lesion	NN	O	I
persisted	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Reversible	NN	O	O
inferior	NN	O	B
colliculus	NN	O	I
lesions	NN	O	I
could	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
the	NN	O	O
characteristic	NN	O	O
for	NN	O	O
metronidazole	NN	O	O
-	NN	O	O
induced	NN	O	O
encephalopathy	NN	O	B
,	NN	O	O
next	NN	O	O
to	NN	O	O
the	NN	O	O
dentate	NN	O	O
nucleus	NN	O	O
involvement	NN	O	O
.	NN	O	O

Clinically	NN	O	O
significant	NN	O	O
proteinuria	NN	O	B
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
to	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Sirolimus	NN	O	O
is	NN	O	O
the	NN	O	O
latest	NN	O	O
immunosuppressive	NN	O	O
agent	NN	O	O
used	NN	O	O
to	NN	O	O
prevent	NN	O	O
rejection	NN	O	O
,	NN	O	O
and	NN	O	O
may	NN	O	O
have	NN	O	O
less	NN	O	O
nephrotoxicity	NN	O	B
than	NN	O	O
calcineurin	NN	O	O
inhibitor	NN	O	O
(	NN	O	O
CNI	NN	O	O
)	NN	O	O
-	NN	O	O
based	NN	O	O
regimens	NN	O	O
.	NN	O	O

To	NN	O	O
date	NN	O	O
there	NN	O	O
has	NN	O	O
been	NN	O	O
little	NN	O	O
documentation	NN	O	O
of	NN	O	O
clinically	NN	O	O
significant	NN	O	O
proteinuria	NN	O	B
linked	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
encountered	NN	O	O
several	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
substantial	NN	O	O
proteinuria	NN	O	B
associated	NN	O	O
with	NN	O	O
sirolimus	NN	O	O
use	NN	O	O
.	NN	O	O

In	NN	O	O
each	NN	O	O
patient	NN	O	O
,	NN	O	O
the	NN	O	O
close	NN	O	O
temporal	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
commencement	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
therapy	NN	O	O
and	NN	O	O
proteinuria	NN	O	B
implicated	NN	O	O
sirolimus	NN	O	O
as	NN	O	O
the	NN	O	O
most	NN	O	O
likely	NN	O	O
etiology	NN	O	O
of	NN	O	O
the	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
analyzed	NN	O	O
the	NN	O	O
clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
information	NN	O	O
available	NN	O	O
for	NN	O	O
all	NN	O	O
119	NN	O	O
patients	NN	O	O
transplanted	NN	O	O
at	NN	O	O
the	NN	O	O
Washington	NN	O	O
Hospital	NN	O	O
Center	NN	O	O
between	NN	O	O
1999	NN	O	O
-	NN	O	O
2003	NN	O	O
for	NN	O	O
whom	NN	O	O
sirolimus	NN	O	O
was	NN	O	O
a	NN	O	O
component	NN	O	O
of	NN	O	O
their	NN	O	O
immunosuppressant	NN	O	O
regimen	NN	O	O
.	NN	O	O

In	NN	O	O
these	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
magnitude	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
was	NN	O	O
assessed	NN	O	O
on	NN	O	O
morning	NN	O	O
urine	NN	O	O
samples	NN	O	O
by	NN	O	O
turbidometric	NN	O	O
measurement	NN	O	O
or	NN	O	O
random	NN	O	O
urine	NN	O	O
protein	NN	O	O
:	NN	O	O
creatinine	NN	O	O
ratios	NN	O	O
,	NN	O	O
an	NN	O	O
estimate	NN	O	O
of	NN	O	O
grams	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
/	NN	O	O
day	NN	O	O
.	NN	O	O

Laboratory	NN	O	O
results	NN	O	O
were	NN	O	O
compared	NN	O	O
between	NN	O	O
prior	NN	O	O
,	NN	O	O
during	NN	O	O
and	NN	O	O
following	NN	O	O
sirolimus	NN	O	O
use	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
eight	NN	O	O
patients	NN	O	O
(	NN	O	O
24	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
increased	NN	O	O
proteinuria	NN	O	B
from	NN	O	O
baseline	NN	O	O
during	NN	O	O
their	NN	O	O
post	NN	O	O
-	NN	O	O
transplantation	NN	O	O
course	NN	O	O
.	NN	O	O

In	NN	O	O
21	NN	O	O
patients	NN	O	O
an	NN	O	O
alternative	NN	O	O
cause	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
was	NN	O	O
either	NN	O	O
obvious	NN	O	O
or	NN	O	O
insufficient	NN	O	O
data	NN	O	O
was	NN	O	O
available	NN	O	O
to	NN	O	O
be	NN	O	O
conclusive	NN	O	O
.	NN	O	O

In	NN	O	O
7	NN	O	O
of	NN	O	O
the	NN	O	O
28	NN	O	O
patients	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
striking	NN	O	O
temporal	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
and	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
nephrotic	NN	O	B
-	NN	O	O
range	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

Proteinuria	NN	O	B
correlated	NN	O	O
most	NN	O	O
strongly	NN	O	O
with	NN	O	O
sirolimus	NN	O	O
therapy	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
other	NN	O	O
demographic	NN	O	O
and	NN	O	O
clinical	NN	O	O
variables	NN	O	O
.	NN	O	O

In	NN	O	O
most	NN	O	O
patients	NN	O	O
,	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
sirolimus	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
decrease	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
resolution	NN	O	O
,	NN	O	O
of	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Sirolimus	NN	O	O
induces	NN	O	O
or	NN	O	O
aggravates	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
proteinuria	NN	O	B
in	NN	O	O
an	NN	O	O
unpredictable	NN	O	O
subset	NN	O	O
of	NN	O	O
renal	NN	O	O
allograft	NN	O	O
recipients	NN	O	O
.	NN	O	O

Proteinuria	NN	O	B
may	NN	O	O
improve	NN	O	O
,	NN	O	O
but	NN	O	O
does	NN	O	O
not	NN	O	O
resolve	NN	O	O
,	NN	O	O
when	NN	O	O
sirolimus	NN	O	O
is	NN	O	O
withdrawn	NN	O	O
.	NN	O	O

Components	NN	O	O
of	NN	O	O
lemon	NN	O	O
essential	NN	O	O
oil	NN	O	O
attenuate	NN	O	O
dementia	NN	O	B
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
.	NN	O	O

The	NN	O	O
anti	NN	O	O
-	NN	O	O
dementia	NN	O	B
effects	NN	O	O
of	NN	O	O
s	NN	O	O
-	NN	O	O
limonene	NN	O	O
and	NN	O	O
s	NN	O	O
-	NN	O	O
perillyl	NN	O	O
alcohol	NN	O	O
were	NN	O	O
observed	NN	O	O
using	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
test	NN	O	O
(	NN	O	O
PA	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
open	NN	O	O
field	NN	O	O
habituation	NN	O	O
test	NN	O	O
(	NN	O	O
OFH	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
lemon	NN	O	O
essential	NN	O	O
oils	NN	O	O
showed	NN	O	O
strong	NN	O	O
ability	NN	O	O
to	NN	O	O
improve	NN	O	O
memory	NN	O	B
impaired	NN	O	I
by	NN	O	O
scopolamine	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
s	NN	O	O
-	NN	O	O
perillyl	NN	O	O
alcohol	NN	O	O
relieved	NN	O	O
the	NN	O	O
deficit	NN	O	B
of	NN	O	I
associative	NN	O	I
memory	NN	O	I
in	NN	O	O
PA	NN	O	O
only	NN	O	O
,	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
improve	NN	O	O
non	NN	O	O
-	NN	O	O
associative	NN	O	O
memory	NN	O	O
significantly	NN	O	O
in	NN	O	O
OFH	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
neurotransmitter	NN	O	O
concentration	NN	O	O
in	NN	O	O
some	NN	O	O
brain	NN	O	O
regions	NN	O	O
on	NN	O	O
the	NN	O	O
test	NN	O	O
day	NN	O	O
showed	NN	O	O
that	NN	O	O
dopamine	NN	O	O
concentration	NN	O	O
of	NN	O	O
the	NN	O	O
vehicle	NN	O	O
/	NN	O	O
scopolamine	NN	O	O
group	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
vehicle	NN	O	O
/	NN	O	O
vehicle	NN	O	O
group	NN	O	O
,	NN	O	O
but	NN	O	O
this	NN	O	O
phenomenon	NN	O	O
was	NN	O	O
reversed	NN	O	O
when	NN	O	O
s	NN	O	O
-	NN	O	O
limonene	NN	O	O
or	NN	O	O
s	NN	O	O
-	NN	O	O
perillyl	NN	O	O
alcohol	NN	O	O
were	NN	O	O
administered	NN	O	O
before	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
scopolamine	NN	O	O
.	NN	O	O

Simultaneously	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
these	NN	O	O
two	NN	O	O
lemon	NN	O	O
essential	NN	O	O
oil	NN	O	O
components	NN	O	O
could	NN	O	O
inhibit	NN	O	O
acetylcholinesterase	NN	O	O
activity	NN	O	O
in	NN	O	O
vitro	NN	O	O
using	NN	O	O
the	NN	O	O
Ellman	NN	O	O
method	NN	O	O
.	NN	O	O

Attentional	NN	O	O
modulation	NN	O	O
of	NN	O	O
perceived	NN	O	O
pain	NN	O	B
intensity	NN	O	O
in	NN	O	O
capsaicin	NN	O	O
-	NN	O	O
induced	NN	O	O
secondary	NN	O	O
hyperalgesia	NN	O	B
.	NN	O	O

Perceived	NN	O	O
pain	NN	O	B
intensity	NN	O	O
is	NN	O	O
modulated	NN	O	O
by	NN	O	O
attention	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
that	NN	O	O
how	NN	O	O
pain	NN	O	B
intensity	NN	O	O
ratings	NN	O	O
are	NN	O	O
affected	NN	O	O
by	NN	O	O
attention	NN	O	O
in	NN	O	O
capsaicin	NN	O	O
-	NN	O	O
induced	NN	O	O
secondary	NN	O	O
hyperalgesia	NN	O	B
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
perceived	NN	O	O
pain	NN	O	B
intensity	NN	O	O
in	NN	O	O
secondary	NN	O	O
hyperalgesia	NN	O	B
is	NN	O	O
decreased	NN	O	O
when	NN	O	O
attention	NN	O	O
is	NN	O	O
distracted	NN	O	O
away	NN	O	O
from	NN	O	O
the	NN	O	O
painful	NN	O	O
pinprick	NN	O	O
stimulus	NN	O	O
with	NN	O	O
a	NN	O	O
visual	NN	O	O
task	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
it	NN	O	O
was	NN	O	O
found	NN	O	O
that	NN	O	O
the	NN	O	O
magnitude	NN	O	O
of	NN	O	O
attentional	NN	O	O
modulation	NN	O	O
in	NN	O	O
secondary	NN	O	O
hyperalgesia	NN	O	B
is	NN	O	O
very	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
capsaicin	NN	O	O
-	NN	O	O
untreated	NN	O	O
,	NN	O	O
control	NN	O	O
condition	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
,	NN	O	O
showing	NN	O	O
no	NN	O	O
interaction	NN	O	O
between	NN	O	O
capsaicin	NN	O	O
treatment	NN	O	O
and	NN	O	O
attentional	NN	O	O
modulation	NN	O	O
suggest	NN	O	O
that	NN	O	O
capsaicin	NN	O	O
-	NN	O	O
induced	NN	O	O
secondary	NN	O	O
hyperalgesia	NN	O	B
and	NN	O	O
attention	NN	O	O
might	NN	O	O
affect	NN	O	O
mechanical	NN	O	O
pain	NN	O	B
through	NN	O	O
independent	NN	O	O
mechanisms	NN	O	O
.	NN	O	O

Cardioprotective	NN	O	O
effect	NN	O	O
of	NN	O	O
salvianolic	NN	O	O
acid	NN	O	O
A	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
cardioprotective	NN	O	O
potential	NN	O	O
of	NN	O	O
salvianolic	NN	O	O
acid	NN	O	O
A	NN	O	O
on	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Hemodynamic	NN	O	O
parameters	NN	O	O
and	NN	O	O
lead	NN	O	O
II	NN	O	O
electrocardiograph	NN	O	O
were	NN	O	O
monitored	NN	O	O
and	NN	O	O
recorded	NN	O	O
continuously	NN	O	O
.	NN	O	O

Cardiac	NN	O	O
marker	NN	O	O
enzymes	NN	O	O
and	NN	O	O
antioxidative	NN	O	O
parameters	NN	O	O
in	NN	O	O
serum	NN	O	O
and	NN	O	O
heart	NN	O	O
tissues	NN	O	O
were	NN	O	O
measured	NN	O	O
.	NN	O	O

Assay	NN	O	O
for	NN	O	O
mitochondrial	NN	O	O
respiratory	NN	O	O
function	NN	O	O
and	NN	O	O
histopathological	NN	O	O
examination	NN	O	O
of	NN	O	O
heart	NN	O	O
tissues	NN	O	O
were	NN	O	O
performed	NN	O	O
.	NN	O	O

Isoproterenol	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
showed	NN	O	O
significant	NN	O	O
increases	NN	O	O
in	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
lactate	NN	O	O
dehydrogenase	NN	O	O
,	NN	O	O
aspartate	NN	O	O
transaminase	NN	O	O
,	NN	O	O
creatine	NN	O	O
kinase	NN	O	O
and	NN	O	O
malondialdehyde	NN	O	O
and	NN	O	O
significant	NN	O	O
decreases	NN	O	O
in	NN	O	O
the	NN	O	O
activities	NN	O	O
of	NN	O	O
superoxide	NN	O	O
dismutase	NN	O	O
,	NN	O	O
catalase	NN	O	O
and	NN	O	O
glutathione	NN	O	O
peroxidase	NN	O	O
in	NN	O	O
serum	NN	O	O
and	NN	O	O
heart	NN	O	O
.	NN	O	O

These	NN	O	O
rats	NN	O	O
also	NN	O	O
showed	NN	O	O
declines	NN	O	O
in	NN	O	O
left	NN	O	O
ventricular	NN	O	O
systolic	NN	O	O
pressure	NN	O	O
,	NN	O	O
maximum	NN	O	O
and	NN	O	O
minimum	NN	O	O
rate	NN	O	O
of	NN	O	O
developed	NN	O	O
left	NN	O	O
ventricular	NN	O	O
pressure	NN	O	O
,	NN	O	O
and	NN	O	O
elevation	NN	O	O
of	NN	O	O
left	NN	O	O
ventricular	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
and	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
mitochondrial	NN	O	O
respiratory	NN	O	B
dysfunction	NN	O	I
characterized	NN	O	O
by	NN	O	O
decreased	NN	O	O
respiratory	NN	O	O
control	NN	O	O
ratio	NN	O	O
and	NN	O	O
ADP	NN	O	O
/	NN	O	O
O	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
salvianolic	NN	O	O
acid	NN	O	O
A	NN	O	O
for	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
8	NN	O	O
days	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
and	NN	O	O
improved	NN	O	O
mitochondrial	NN	O	O
respiratory	NN	O	O
function	NN	O	O
.	NN	O	O

The	NN	O	O
protective	NN	O	O
role	NN	O	O
of	NN	O	O
salvianolic	NN	O	O
acid	NN	O	O
A	NN	O	O
against	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
damage	NN	O	I
was	NN	O	O
further	NN	O	O
confirmed	NN	O	O
by	NN	O	O
histopathological	NN	O	O
examination	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
our	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
salvianolic	NN	O	O
acid	NN	O	O
A	NN	O	O
possessing	NN	O	O
antioxidant	NN	O	O
activity	NN	O	O
has	NN	O	O
a	NN	O	O
significant	NN	O	O
protective	NN	O	O
effect	NN	O	O
against	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
glutamate	NN	O	O
supplementation	NN	O	O
failed	NN	O	O
to	NN	O	O
protect	NN	O	O
against	NN	O	O
peripheral	NN	O	B
neurotoxicity	NN	O	I
of	NN	O	O
paclitaxel	NN	O	O
.	NN	O	O

Toxic	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
is	NN	O	O
still	NN	O	O
a	NN	O	O
significant	NN	O	O
limiting	NN	O	O
factor	NN	O	O
for	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
paclitaxel	NN	O	O
(	NN	O	O
PAC	NN	O	O
)	NN	O	O
,	NN	O	O
although	NN	O	O
glutamate	NN	O	O
and	NN	O	O
its	NN	O	O
closely	NN	O	O
related	NN	O	O
amino	NN	O	O
acid	NN	O	O
glutamine	NN	O	O
were	NN	O	O
claimed	NN	O	O
to	NN	O	O
ameliorate	NN	O	O
PAC	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

This	NN	O	O
pilot	NN	O	O
trial	NN	O	O
aimed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
glutamate	NN	O	O
supplementation	NN	O	O
for	NN	O	O
preventing	NN	O	O
PAC	NN	O	O
-	NN	O	O
induced	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blinded	NN	O	O
clinical	NN	O	O
and	NN	O	O
electro	NN	O	O
-	NN	O	O
diagnostic	NN	O	O
study	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
three	NN	O	O
ovarian	NN	O	B
cancer	NN	O	I
patients	NN	O	O
were	NN	O	O
available	NN	O	O
for	NN	O	O
analysis	NN	O	O
following	NN	O	O
six	NN	O	O
cycles	NN	O	O
of	NN	O	O
the	NN	O	O
same	NN	O	O
PAC	NN	O	O
-	NN	O	O
containing	NN	O	O
regimen	NN	O	O
:	NN	O	O
23	NN	O	O
had	NN	O	O
been	NN	O	O
supplemented	NN	O	O
by	NN	O	O
glutamate	NN	O	O
all	NN	O	O
along	NN	O	O
the	NN	O	O
treatment	NN	O	O
period	NN	O	O
,	NN	O	O
at	NN	O	O
a	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
three	NN	O	O
times	NN	O	O
500	NN	O	O
mg	NN	O	O
(	NN	O	O
group	NN	O	O
G	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
20	NN	O	O
had	NN	O	O
received	NN	O	O
a	NN	O	O
placebo	NN	O	O
(	NN	O	O
group	NN	O	O
P	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
evaluated	NN	O	O
by	NN	O	O
neurological	NN	O	O
examinations	NN	O	O
,	NN	O	O
questionnaires	NN	O	O
and	NN	O	O
sensory	NN	O	O
-	NN	O	O
motor	NN	O	O
nerve	NN	O	O
conduction	NN	O	O
studies	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
signs	NN	O	O
or	NN	O	O
symptoms	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
although	NN	O	O
neurotoxicity	NN	O	B
symptoms	NN	O	O
presented	NN	O	O
mostly	NN	O	O
with	NN	O	O
lower	NN	O	O
scores	NN	O	O
of	NN	O	O
severity	NN	O	O
in	NN	O	O
group	NN	O	O
G	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
this	NN	O	O
difference	NN	O	O
reached	NN	O	O
statistical	NN	O	O
significance	NN	O	O
only	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
reported	NN	O	O
pain	NN	O	B
sensation	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
011	NN	O	O
)	NN	O	O
.	NN	O	O

Also	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
abnormal	NN	O	O
electro	NN	O	O
-	NN	O	O
diagnostic	NN	O	O
findings	NN	O	O
showed	NN	O	O
similarity	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
(	NN	O	O
G	NN	O	O
:	NN	O	O
7	NN	O	O
/	NN	O	O
23	NN	O	O
=	NN	O	O
30	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
;	NN	O	O
P	NN	O	O
:	NN	O	O
6	NN	O	O
/	NN	O	O
20	NN	O	O
=	NN	O	O
30	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
pilot	NN	O	O
study	NN	O	O
leads	NN	O	O
to	NN	O	O
the	NN	O	O
conclusion	NN	O	O
that	NN	O	O
glutamate	NN	O	O
supplementation	NN	O	O
at	NN	O	O
the	NN	O	O
chosen	NN	O	O
regimen	NN	O	O
fails	NN	O	O
to	NN	O	O
protect	NN	O	O
against	NN	O	O
peripheral	NN	O	B
neurotoxicity	NN	O	I
of	NN	O	O
PAC	NN	O	O
.	NN	O	O

Development	NN	O	O
of	NN	O	O
ocular	NN	O	B
myasthenia	NN	O	I
during	NN	O	O
pegylated	NN	O	O
interferon	NN	O	O
and	NN	O	O
ribavirin	NN	O	O
treatment	NN	O	O
for	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
C	NN	O	I
.	NN	O	O

A	NN	O	O
63	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
experienced	NN	O	O
sudden	NN	O	O
diplopia	NN	O	B
after	NN	O	O
9	NN	O	O
weeks	NN	O	O
of	NN	O	O
administration	NN	O	O
of	NN	O	O
pegylated	NN	O	O
interferon	NN	O	O
(	NN	O	O
IFN	NN	O	O
)	NN	O	O
alpha	NN	O	O
-	NN	O	O
2b	NN	O	O
and	NN	O	O
ribavirin	NN	O	O
for	NN	O	O
chronic	NN	O	B
hepatitis	NN	O	I
C	NN	O	I
(	NN	O	O
CHC	NN	O	B
)	NN	O	O
.	NN	O	O

Ophthalmologic	NN	O	O
examinations	NN	O	O
showed	NN	O	O
ptosis	NN	O	B
on	NN	O	I
the	NN	O	I
right	NN	O	I
upper	NN	O	I
lid	NN	O	I
and	NN	O	O
restricted	NN	O	B
right	NN	O	I
eye	NN	O	I
movement	NN	O	I
without	NN	O	O
any	NN	O	O
other	NN	O	O
neurological	NN	O	O
signs	NN	O	O
.	NN	O	O

A	NN	O	O
brain	NN	O	O
imaging	NN	O	O
study	NN	O	O
and	NN	O	O
repetitive	NN	O	O
nerve	NN	O	O
stimulation	NN	O	O
test	NN	O	O
indicated	NN	O	O
no	NN	O	O
abnormality	NN	O	O
.	NN	O	O

The	NN	O	O
acetylcholine	NN	O	O
receptor	NN	O	O
antibody	NN	O	O
titer	NN	O	O
and	NN	O	O
response	NN	O	O
to	NN	O	O
acetylcholinesterase	NN	O	O
inhibitors	NN	O	O
were	NN	O	O
negative	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
thyroid	NN	O	O
function	NN	O	O
tests	NN	O	O
were	NN	O	O
normal	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
ophthalmological	NN	O	O
symptoms	NN	O	O
improved	NN	O	O
rapidly	NN	O	O
3	NN	O	O
weeks	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
pegylated	NN	O	O
IFN	NN	O	O
alpha	NN	O	O
-	NN	O	O
2b	NN	O	O
and	NN	O	O
ribavirin	NN	O	O
.	NN	O	O

The	NN	O	O
ocular	NN	O	B
myasthenia	NN	O	I
associated	NN	O	O
with	NN	O	O
combination	NN	O	O
therapy	NN	O	O
of	NN	O	O
pegylated	NN	O	O
IFN	NN	O	O
alpha	NN	O	O
-	NN	O	O
2b	NN	O	O
and	NN	O	O
ribavirin	NN	O	O
for	NN	O	O
CHC	NN	O	B
is	NN	O	O
very	NN	O	O
rarely	NN	O	O
reported	NN	O	O
;	NN	O	O
therefore	NN	O	O
,	NN	O	O
we	NN	O	O
present	NN	O	O
this	NN	O	O
case	NN	O	O
with	NN	O	O
a	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
various	NN	O	O
eye	NN	O	O
complications	NN	O	O
of	NN	O	O
IFN	NN	O	O
therapy	NN	O	O
.	NN	O	O

Learning	NN	O	B
and	NN	O	I
memory	NN	O	I
deficits	NN	O	I
in	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
and	NN	O	O
their	NN	O	O
neural	NN	O	O
correlates	NN	O	O
during	NN	O	O
a	NN	O	O
face	NN	O	O
-	NN	O	O
learning	NN	O	O
task	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
consistently	NN	O	O
shown	NN	O	O
that	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
display	NN	O	O
impairments	NN	O	B
in	NN	O	I
learning	NN	O	I
and	NN	O	I
memory	NN	O	I
performance	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
working	NN	O	O
memory	NN	O	O
processing	NN	O	O
in	NN	O	O
ecstasy	NN	O	O
users	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
neural	NN	O	O
alterations	NN	O	O
in	NN	O	O
hippocampal	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
cortical	NN	O	O
regions	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
functional	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
fMRI	NN	O	O
)	NN	O	O
.	NN	O	O

Using	NN	O	O
functional	NN	O	O
imaging	NN	O	O
and	NN	O	O
a	NN	O	O
face	NN	O	O
-	NN	O	O
learning	NN	O	O
task	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
neural	NN	O	O
correlates	NN	O	O
of	NN	O	O
encoding	NN	O	O
and	NN	O	O
recalling	NN	O	O
face	NN	O	O
-	NN	O	O
name	NN	O	O
associations	NN	O	O
in	NN	O	O
20	NN	O	O
recreational	NN	O	O
drug	NN	O	O
users	NN	O	O
whose	NN	O	O
predominant	NN	O	O
drug	NN	O	O
use	NN	O	O
was	NN	O	O
ecstasy	NN	O	O
and	NN	O	O
20	NN	O	O
controls	NN	O	O
.	NN	O	O

To	NN	O	O
address	NN	O	O
the	NN	O	O
potential	NN	O	O
confounding	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
cannabis	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
ecstasy	NN	O	O
using	NN	O	O
group	NN	O	O
,	NN	O	O
a	NN	O	O
second	NN	O	O
analysis	NN	O	O
included	NN	O	O
14	NN	O	O
previously	NN	O	O
tested	NN	O	O
cannabis	NN	O	O
users	NN	O	O
(	NN	O	O
Nestor	NN	O	O
,	NN	O	O
L	NN	O	O
.	NN	O	O
,	NN	O	O
Roberts	NN	O	O
,	NN	O	O
G	NN	O	O
.	NN	O	O
,	NN	O	O
Garavan	NN	O	O
,	NN	O	O
H	NN	O	O
.	NN	O	O
,	NN	O	O
Hester	NN	O	O
,	NN	O	O
R	NN	O	O
.	NN	O	O
,	NN	O	O
2008	NN	O	O
.	NN	O	O
Deficits	NN	O	B
in	NN	O	I
learning	NN	O	I
and	NN	O	I
memory	NN	O	I
:	NN	O	O
parahippocampal	NN	O	O
hyperactivity	NN	O	B
and	NN	O	O
frontocortical	NN	O	O
hypoactivity	NN	O	O
in	NN	O	O
cannabis	NN	O	O
users	NN	O	O
.	NN	O	O
Neuroimage	NN	O	O
40	NN	O	O
,	NN	O	O
1328	NN	O	O
-	NN	O	O
1339	NN	O	O
)	NN	O	O
.	NN	O	O

Ecstasy	NN	O	O
users	NN	O	O
performed	NN	O	O
significantly	NN	O	O
worse	NN	O	O
in	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
and	NN	O	O
cannabis	NN	O	O
users	NN	O	O
.	NN	O	O

A	NN	O	O
conjunction	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
encode	NN	O	O
and	NN	O	O
recall	NN	O	O
phases	NN	O	O
of	NN	O	O
the	NN	O	O
task	NN	O	O
revealed	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
specific	NN	O	O
hyperactivity	NN	O	B
in	NN	O	O
bilateral	NN	O	O
frontal	NN	O	O
regions	NN	O	O
,	NN	O	O
left	NN	O	O
temporal	NN	O	O
,	NN	O	O
right	NN	O	O
parietal	NN	O	O
,	NN	O	O
bilateral	NN	O	O
temporal	NN	O	O
,	NN	O	O
and	NN	O	O
bilateral	NN	O	O
occipital	NN	O	O
brain	NN	O	O
regions	NN	O	O
.	NN	O	O

Ecstasy	NN	O	O
-	NN	O	O
specific	NN	O	O
hypoactivity	NN	O	O
was	NN	O	O
evident	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
dorsal	NN	O	O
anterior	NN	O	O
cingulated	NN	O	O
cortex	NN	O	O
(	NN	O	O
ACC	NN	O	O
)	NN	O	O
and	NN	O	O
left	NN	O	O
posterior	NN	O	O
cingulated	NN	O	O
cortex	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
ecstasy	NN	O	O
and	NN	O	O
cannabis	NN	O	O
groups	NN	O	O
brain	NN	O	O
activation	NN	O	O
was	NN	O	O
decreased	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
medial	NN	O	O
frontal	NN	O	O
gyrus	NN	O	O
,	NN	O	O
left	NN	O	O
parahippocampal	NN	O	O
gyrus	NN	O	O
,	NN	O	O
left	NN	O	O
dorsal	NN	O	O
cingulate	NN	O	O
gyrus	NN	O	O
,	NN	O	O
and	NN	O	O
left	NN	O	O
caudate	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
elucidated	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
related	NN	O	O
deficits	NN	O	O
,	NN	O	O
only	NN	O	O
some	NN	O	O
of	NN	O	O
which	NN	O	O
might	NN	O	O
be	NN	O	O
attributed	NN	O	O
to	NN	O	O
cannabis	NN	O	O
use	NN	O	O
.	NN	O	O

These	NN	O	O
ecstasy	NN	O	O
-	NN	O	O
specific	NN	O	O
effects	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
vulnerability	NN	O	O
of	NN	O	O
isocortical	NN	O	O
and	NN	O	O
allocortical	NN	O	O
regions	NN	O	O
to	NN	O	O
the	NN	O	O
neurotoxic	NN	O	B
effects	NN	O	O
of	NN	O	O
ecstasy	NN	O	O
.	NN	O	O

Disulfiram	NN	O	O
-	NN	O	O
like	NN	O	O
syndrome	NN	O	O
after	NN	O	O
hydrogen	NN	O	O
cyanamide	NN	O	O
professional	NN	O	O
skin	NN	O	O
exposure	NN	O	O
:	NN	O	O
two	NN	O	O
case	NN	O	O
reports	NN	O	O
in	NN	O	O
France	NN	O	O
.	NN	O	O

Hydrogen	NN	O	O
cyanamide	NN	O	O
is	NN	O	O
a	NN	O	O
plant	NN	O	O
growth	NN	O	O
regulator	NN	O	O
used	NN	O	O
in	NN	O	O
agriculture	NN	O	O
to	NN	O	O
induce	NN	O	O
bud	NN	O	O
break	NN	O	O
in	NN	O	O
fruit	NN	O	O
trees	NN	O	O
.	NN	O	O

Contact	NN	O	O
with	NN	O	O
the	NN	O	O
skin	NN	O	O
can	NN	O	O
result	NN	O	O
in	NN	O	O
percutaneous	NN	O	O
absorption	NN	O	O
of	NN	O	O
the	NN	O	O
substance	NN	O	O
that	NN	O	O
inhibits	NN	O	O
aldehyde	NN	O	O
dehydrogenase	NN	O	O
and	NN	O	O
can	NN	O	O
induce	NN	O	O
acetaldehyde	NN	O	O
syndrome	NN	O	O
in	NN	O	O
case	NN	O	O
of	NN	O	O
alcohol	NN	O	O
use	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
report	NN	O	O
is	NN	O	O
to	NN	O	O
describe	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
a	NN	O	O
disulfiram	NN	O	O
-	NN	O	O
like	NN	O	O
syndrome	NN	O	O
following	NN	O	O
occupational	NN	O	O
exposure	NN	O	O
to	NN	O	O
hydrogen	NN	O	O
cyanamide	NN	O	O
.	NN	O	O

The	NN	O	O
first	NN	O	O
case	NN	O	O
involved	NN	O	O
a	NN	O	O
59	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
used	NN	O	O
Dormex	NN	O	O
,	NN	O	O
which	NN	O	O
contains	NN	O	O
hydrogen	NN	O	O
cyanamide	NN	O	O
,	NN	O	O
without	NN	O	O
protection	NN	O	O
after	NN	O	O
consuming	NN	O	O
a	NN	O	O
large	NN	O	O
amount	NN	O	O
of	NN	O	O
alcohol	NN	O	O
during	NN	O	O
a	NN	O	O
meal	NN	O	O
.	NN	O	O

In	NN	O	O
less	NN	O	O
than	NN	O	O
1	NN	O	O
hour	NN	O	O
after	NN	O	O
the	NN	O	O
ingestion	NN	O	O
of	NN	O	O
alcohol	NN	O	O
,	NN	O	O
he	NN	O	O
developed	NN	O	O
malaise	NN	O	O
with	NN	O	O
flushing	NN	O	B
of	NN	O	I
the	NN	O	I
face	NN	O	I
,	NN	O	O
tachycardia	NN	O	B
,	NN	O	O
and	NN	O	O
dyspnea	NN	O	B
.	NN	O	O

Manifestations	NN	O	O
regressed	NN	O	O
spontaneously	NN	O	O
under	NN	O	O
surveillance	NN	O	O
in	NN	O	O
the	NN	O	O
hospital	NN	O	O
.	NN	O	O

The	NN	O	O
second	NN	O	O
case	NN	O	O
occurred	NN	O	O
in	NN	O	O
a	NN	O	O
55	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
farmer	NN	O	O
following	NN	O	O
cutaneous	NN	O	O
contact	NN	O	O
with	NN	O	O
Dormex	NN	O	O
.	NN	O	O

Five	NN	O	O
hours	NN	O	O
after	NN	O	O
exposure	NN	O	O
,	NN	O	O
he	NN	O	O
developed	NN	O	O
disulfiram	NN	O	O
-	NN	O	O
like	NN	O	O
syndrome	NN	O	O
with	NN	O	O
flushing	NN	O	B
,	NN	O	O
tachycardia	NN	O	B
,	NN	O	O
and	NN	O	O
arterial	NN	O	B
hypotension	NN	O	I
after	NN	O	O
consuming	NN	O	O
three	NN	O	O
glasses	NN	O	O
of	NN	O	O
wine	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
recovered	NN	O	O
spontaneously	NN	O	O
in	NN	O	O
3	NN	O	O
hours	NN	O	O
under	NN	O	O
surveillance	NN	O	O
in	NN	O	O
the	NN	O	O
hospital	NN	O	O
.	NN	O	O

These	NN	O	O
cases	NN	O	O
confirm	NN	O	O
the	NN	O	O
necessity	NN	O	O
of	NN	O	O
avoiding	NN	O	O
alcohol	NN	O	O
consumption	NN	O	O
as	NN	O	O
recommended	NN	O	O
in	NN	O	O
the	NN	O	O
instructions	NN	O	O
for	NN	O	O
use	NN	O	O
of	NN	O	O
Dormex	NN	O	O
and	NN	O	O
of	NN	O	O
preventing	NN	O	O
cutaneous	NN	O	O
contact	NN	O	O
during	NN	O	O
use	NN	O	O
.	NN	O	O

Sulpiride	NN	O	O
-	NN	O	O
induced	NN	O	O
tardive	NN	O	B
dystonia	NN	O	I
.	NN	O	O

Sulpiride	NN	O	O
is	NN	O	O
a	NN	O	O
selective	NN	O	O
D2	NN	O	O
-	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
with	NN	O	O
antipsychotic	NN	O	O
and	NN	O	O
antidepressant	NN	O	O
properties	NN	O	O
.	NN	O	O

Although	NN	O	O
initially	NN	O	O
thought	NN	O	O
to	NN	O	O
be	NN	O	O
free	NN	O	O
of	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
,	NN	O	O
sulpiride	NN	O	O
-	NN	O	O
induced	NN	O	O
tardive	NN	O	B
dyskinesia	NN	O	I
and	NN	O	O
parkinsonism	NN	O	B
have	NN	O	O
been	NN	O	O
reported	NN	O	O
occasionally	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
a	NN	O	O
37	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
developed	NN	O	O
persistent	NN	O	O
segmental	NN	O	O
dystonia	NN	O	B
within	NN	O	O
2	NN	O	O
months	NN	O	O
after	NN	O	O
starting	NN	O	O
sulpiride	NN	O	O
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
could	NN	O	O
not	NN	O	O
find	NN	O	O
any	NN	O	O
previous	NN	O	O
reports	NN	O	O
of	NN	O	O
sulpiride	NN	O	O
-	NN	O	O
induced	NN	O	O
tardive	NN	O	B
dystonia	NN	O	I
.	NN	O	O

Comparative	NN	O	O
cognitive	NN	O	O
and	NN	O	O
subjective	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
immediate	NN	O	O
-	NN	O	O
release	NN	O	O
oxycodone	NN	O	O
in	NN	O	O
healthy	NN	O	O
middle	NN	O	O
-	NN	O	O
aged	NN	O	O
and	NN	O	O
older	NN	O	O
adults	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
measured	NN	O	O
the	NN	O	O
objective	NN	O	O
and	NN	O	O
subjective	NN	O	O
neurocognitive	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
10	NN	O	O
-	NN	O	O
mg	NN	O	O
dose	NN	O	O
of	NN	O	O
immediate	NN	O	O
-	NN	O	O
release	NN	O	O
oxycodone	NN	O	O
in	NN	O	O
healthy	NN	O	O
,	NN	O	O
older	NN	O	O
(	NN	O	O
>	NN	O	O
65	NN	O	O
years	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
middle	NN	O	O
-	NN	O	O
aged	NN	O	O
(	NN	O	O
35	NN	O	O
to	NN	O	O
55	NN	O	O
years	NN	O	O
)	NN	O	O
adults	NN	O	O
who	NN	O	O
were	NN	O	O
not	NN	O	O
suffering	NN	O	O
from	NN	O	O
chronic	NN	O	O
or	NN	O	O
significant	NN	O	O
daily	NN	O	O
pain	NN	O	B
.	NN	O	O

Seventy	NN	O	O
-	NN	O	O
one	NN	O	O
participants	NN	O	O
completed	NN	O	O
2	NN	O	O
separate	NN	O	O
study	NN	O	O
days	NN	O	O
and	NN	O	O
were	NN	O	O
blind	NN	O	O
to	NN	O	O
medication	NN	O	O
condition	NN	O	O
(	NN	O	O
placebo	NN	O	O
,	NN	O	O
10	NN	O	O
-	NN	O	O
mg	NN	O	O
oxycodone	NN	O	O
)	NN	O	O
.	NN	O	O

Plasma	NN	O	O
oxycodone	NN	O	O
concentration	NN	O	O
peaked	NN	O	O
between	NN	O	O
60	NN	O	O
and	NN	O	O
90	NN	O	O
minutes	NN	O	O
postdose	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
and	NN	O	O
pupil	NN	O	O
size	NN	O	O
,	NN	O	O
an	NN	O	O
indication	NN	O	O
of	NN	O	O
physiological	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
medication	NN	O	O
,	NN	O	O
peaked	NN	O	O
at	NN	O	O
approximately	NN	O	O
90	NN	O	O
to	NN	O	O
120	NN	O	O
minutes	NN	O	O
postdose	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Significant	NN	O	O
declines	NN	O	B
in	NN	O	I
simple	NN	O	I
and	NN	O	I
sustained	NN	O	I
attention	NN	O	I
,	NN	O	I
working	NN	O	I
memory	NN	O	I
,	NN	O	I
and	NN	O	I
verbal	NN	O	I
memory	NN	O	I
were	NN	O	O
observed	NN	O	O
at	NN	O	O
1	NN	O	O
hour	NN	O	O
postdose	NN	O	O
compared	NN	O	O
to	NN	O	O
baseline	NN	O	O
for	NN	O	O
both	NN	O	O
age	NN	O	O
groups	NN	O	O
with	NN	O	O
a	NN	O	O
trend	NN	O	O
toward	NN	O	O
return	NN	O	O
to	NN	O	O
baseline	NN	O	O
by	NN	O	O
5	NN	O	O
hours	NN	O	O
postdose	NN	O	O
.	NN	O	O

For	NN	O	O
almost	NN	O	O
all	NN	O	O
cognitive	NN	O	O
measures	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
medication	NN	O	O
by	NN	O	O
age	NN	O	O
-	NN	O	O
interaction	NN	O	O
effects	NN	O	O
,	NN	O	O
which	NN	O	O
indicates	NN	O	O
that	NN	O	O
the	NN	O	O
2	NN	O	O
age	NN	O	O
groups	NN	O	O
exhibited	NN	O	O
similar	NN	O	O
responses	NN	O	O
to	NN	O	O
the	NN	O	O
medication	NN	O	O
challenge	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
for	NN	O	O
healthy	NN	O	O
older	NN	O	O
adults	NN	O	O
who	NN	O	O
are	NN	O	O
not	NN	O	O
suffering	NN	O	O
from	NN	O	O
chronic	NN	O	B
pain	NN	O	I
,	NN	O	O
neurocognitive	NN	O	O
and	NN	O	O
pharmacodynamic	NN	O	O
changes	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
a	NN	O	O
10	NN	O	O
-	NN	O	O
mg	NN	O	O
dose	NN	O	O
of	NN	O	O
immediate	NN	O	O
-	NN	O	O
release	NN	O	O
oxycodone	NN	O	O
are	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
observed	NN	O	O
for	NN	O	O
middle	NN	O	O
-	NN	O	O
aged	NN	O	O
adults	NN	O	O
.	NN	O	O

PERSPECTIVE	NN	O	O
:	NN	O	O
Study	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
metabolism	NN	O	O
,	NN	O	O
neurocognitive	NN	O	O
effects	NN	O	O
,	NN	O	O
and	NN	O	O
physical	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
oral	NN	O	O
oxycodone	NN	O	O
are	NN	O	O
similar	NN	O	O
for	NN	O	O
healthy	NN	O	O
middle	NN	O	O
-	NN	O	O
aged	NN	O	O
and	NN	O	O
older	NN	O	O
adults	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
clinicians	NN	O	O
should	NN	O	O
not	NN	O	O
avoid	NN	O	O
prescribing	NN	O	O
oral	NN	O	O
opioids	NN	O	O
to	NN	O	O
older	NN	O	O
adults	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
belief	NN	O	O
that	NN	O	O
older	NN	O	O
adults	NN	O	O
are	NN	O	O
at	NN	O	O
higher	NN	O	O
risk	NN	O	O
for	NN	O	O
side	NN	O	O
effects	NN	O	O
than	NN	O	O
younger	NN	O	O
adults	NN	O	O
.	NN	O	O

The	NN	O	O
glycine	NN	O	O
transporter	NN	O	O
-	NN	O	O
1	NN	O	O
inhibitor	NN	O	O
SSR103800	NN	O	O
displays	NN	O	O
a	NN	O	O
selective	NN	O	O
and	NN	O	O
specific	NN	O	O
antipsychotic	NN	O	O
-	NN	O	O
like	NN	O	O
profile	NN	O	O
in	NN	O	O
normal	NN	O	O
and	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
.	NN	O	O

Schizophrenia	NN	O	B
has	NN	O	O
been	NN	O	O
initially	NN	O	O
associated	NN	O	O
with	NN	O	O
dysfunction	NN	O	O
in	NN	O	O
dopamine	NN	O	O
neurotransmission	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
observation	NN	O	O
that	NN	O	O
antagonists	NN	O	O
of	NN	O	O
the	NN	O	O
glutamate	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
aspartate	NN	O	O
(	NN	O	O
NMDA	NN	O	O
)	NN	O	O
receptor	NN	O	O
produce	NN	O	O
schizophrenic	NN	O	B
-	NN	O	O
like	NN	O	O
symptoms	NN	O	O
in	NN	O	O
humans	NN	O	O
has	NN	O	O
led	NN	O	O
to	NN	O	O
the	NN	O	O
idea	NN	O	O
of	NN	O	O
a	NN	O	O
dysfunctioning	NN	O	O
of	NN	O	O
the	NN	O	O
glutamatergic	NN	O	O
system	NN	O	O
via	NN	O	O
its	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
result	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
growing	NN	O	O
interest	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
pharmacological	NN	O	O
agents	NN	O	O
with	NN	O	O
potential	NN	O	O
antipsychotic	NN	O	O
properties	NN	O	O
that	NN	O	O
enhance	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
glutamatergic	NN	O	O
system	NN	O	O
via	NN	O	O
a	NN	O	O
modulation	NN	O	O
of	NN	O	O
the	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
.	NN	O	O

Among	NN	O	O
them	NN	O	O
are	NN	O	O
glycine	NN	O	O
transporter	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
GlyT1	NN	O	O
)	NN	O	O
inhibitors	NN	O	O
such	NN	O	O
as	NN	O	O
SSR103800	NN	O	O
,	NN	O	O
which	NN	O	O
indirectly	NN	O	O
enhance	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
function	NN	O	O
by	NN	O	O
increasing	NN	O	O
the	NN	O	O
glycine	NN	O	O
(	NN	O	O
a	NN	O	O
co	NN	O	O
-	NN	O	O
agonist	NN	O	O
for	NN	O	O
the	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
)	NN	O	O
levels	NN	O	O
in	NN	O	O
the	NN	O	O
synapse	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
aimed	NN	O	O
at	NN	O	O
investigating	NN	O	O
the	NN	O	O
potential	NN	O	O
antipsychotic	NN	O	O
-	NN	O	O
like	NN	O	O
properties	NN	O	O
of	NN	O	O
SSR103800	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
particular	NN	O	O
focus	NN	O	O
on	NN	O	O
models	NN	O	O
of	NN	O	O
hyperactivity	NN	O	B
,	NN	O	O
involving	NN	O	O
either	NN	O	O
drug	NN	O	O
challenge	NN	O	O
(	NN	O	O
ie	NN	O	O
,	NN	O	O
amphetamine	NN	O	O
and	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
)	NN	O	O
or	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
(	NN	O	O
ie	NN	O	O
,	NN	O	O
NMDA	NN	O	O
Nr1	NN	O	O
(	NN	O	O
neo	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
and	NN	O	O
DAT	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
)	NN	O	O
.	NN	O	O

Results	NN	O	O
showed	NN	O	O
that	NN	O	O
SSR103800	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
blocked	NN	O	O
hyperactivity	NN	O	B
induced	NN	O	O
by	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
competitive	NN	O	O
NMDA	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
MK	NN	O	O
-	NN	O	O
801	NN	O	O
and	NN	O	O
partially	NN	O	O
reversed	NN	O	O
spontaneous	NN	O	O
hyperactivity	NN	O	B
of	NN	O	O
NMDA	NN	O	O
Nr1	NN	O	O
(	NN	O	O
neo	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
SSR103800	NN	O	O
failed	NN	O	O
to	NN	O	O
affect	NN	O	O
hyperactivity	NN	O	B
induced	NN	O	O
by	NN	O	O
amphetamine	NN	O	O
or	NN	O	O
naturally	NN	O	O
observed	NN	O	O
in	NN	O	O
dopamine	NN	O	O
transporter	NN	O	O
(	NN	O	O
DAT	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
)	NN	O	O
knockout	NN	O	O
mice	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

Importantly	NN	O	O
,	NN	O	O
both	NN	O	O
classical	NN	O	O
(	NN	O	O
haloperidol	NN	O	O
)	NN	O	O
and	NN	O	O
atypical	NN	O	O
(	NN	O	O
olanzapine	NN	O	O
,	NN	O	O
clozapine	NN	O	O
and	NN	O	O
aripiprazole	NN	O	O
)	NN	O	O
antipsychotics	NN	O	O
were	NN	O	O
effective	NN	O	O
in	NN	O	O
all	NN	O	O
these	NN	O	O
models	NN	O	O
of	NN	O	O
hyperactivity	NN	O	B
.	NN	O	O

However	NN	O	O
,	NN	O	O
unlike	NN	O	O
these	NN	O	O
latter	NN	O	O
,	NN	O	O
SSR103800	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
catalepsy	NN	O	B
(	NN	O	O
retention	NN	O	O
on	NN	O	O
the	NN	O	O
bar	NN	O	O
test	NN	O	O
)	NN	O	O
up	NN	O	O
to	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O

Together	NN	O	O
these	NN	O	O
findings	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
GlyT1	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
SSR103800	NN	O	O
,	NN	O	O
produces	NN	O	O
antipsychotic	NN	O	O
-	NN	O	O
like	NN	O	O
effects	NN	O	O
,	NN	O	O
which	NN	O	O
differ	NN	O	O
from	NN	O	O
those	NN	O	O
observed	NN	O	O
with	NN	O	O
compounds	NN	O	O
primarily	NN	O	O
targeting	NN	O	O
the	NN	O	O
dopaminergic	NN	O	O
system	NN	O	O
,	NN	O	O
and	NN	O	O
has	NN	O	O
a	NN	O	O
reduced	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
potential	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
these	NN	O	O
latter	NN	O	O
drugs	NN	O	O
.	NN	O	O

Pyrrolidine	NN	O	O
dithiocarbamate	NN	O	O
protects	NN	O	O
the	NN	O	O
piriform	NN	O	O
cortex	NN	O	O
in	NN	O	O
the	NN	O	O
pilocarpine	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
model	NN	O	O
.	NN	O	O

Pyrrolidine	NN	O	O
dithiocarbamate	NN	O	O
(	NN	O	O
PDTC	NN	O	O
)	NN	O	O
has	NN	O	O
a	NN	O	O
dual	NN	O	O
mechanism	NN	O	O
of	NN	O	O
action	NN	O	O
as	NN	O	O
an	NN	O	O
antioxidant	NN	O	O
and	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
the	NN	O	O
transcription	NN	O	O
factor	NN	O	O
kappa	NN	O	O
-	NN	O	O
beta	NN	O	O
.	NN	O	O

Both	NN	O	O
,	NN	O	O
production	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
activation	NN	O	O
of	NN	O	O
NF	NN	O	O
-	NN	O	O
kappaB	NN	O	O
have	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
severe	NN	O	O
neuronal	NN	O	B
damage	NN	O	I
in	NN	O	O
different	NN	O	O
sub	NN	O	O
-	NN	O	O
regions	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
the	NN	O	O
surrounding	NN	O	O
cortices	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
PDTC	NN	O	O
on	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
-	NN	O	O
associated	NN	O	O
cell	NN	O	O
loss	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
and	NN	O	O
piriform	NN	O	O
cortex	NN	O	O
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
fractionated	NN	O	O
pilocarpine	NN	O	O
model	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
150	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
PDTC	NN	O	O
before	NN	O	O
and	NN	O	O
following	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
mortality	NN	O	O
rate	NN	O	O
to	NN	O	O
100	NN	O	O
%	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
PDTC	NN	O	O
(	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
exert	NN	O	O
major	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
a	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
or	NN	O	O
the	NN	O	O
mortality	NN	O	O
rate	NN	O	O
.	NN	O	O

In	NN	O	O
vehicle	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
caused	NN	O	O
pronounced	NN	O	O
neuronal	NN	O	B
damage	NN	O	I
in	NN	O	O
the	NN	O	O
piriform	NN	O	O
cortex	NN	O	O
comprising	NN	O	O
both	NN	O	O
pyramidal	NN	O	O
cells	NN	O	O
and	NN	O	O
interneurons	NN	O	O
.	NN	O	O

Low	NN	O	O
-	NN	O	O
dose	NN	O	O
PDTC	NN	O	O
treatment	NN	O	O
almost	NN	O	O
completely	NN	O	O
protected	NN	O	O
from	NN	O	O
lesions	NN	O	O
in	NN	O	O
the	NN	O	O
piriform	NN	O	O
cortex	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
neuronal	NN	O	O
density	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampal	NN	O	O
hilar	NN	O	O
formation	NN	O	O
was	NN	O	O
identified	NN	O	O
in	NN	O	O
vehicle	NN	O	O
-	NN	O	O
and	NN	O	O
PDTC	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
following	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
the	NN	O	O
NF	NN	O	O
-	NN	O	O
kappaB	NN	O	O
inhibitor	NN	O	O
and	NN	O	O
antioxidant	NN	O	O
PDTC	NN	O	O
protected	NN	O	O
the	NN	O	O
piriform	NN	O	O
cortex	NN	O	O
,	NN	O	O
whereas	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
hilar	NN	O	O
neuronal	NN	O	B
loss	NN	O	I
.	NN	O	O

These	NN	O	O
data	NN	O	O
might	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
and	NN	O	O
activation	NN	O	O
of	NN	O	O
NF	NN	O	O
-	NN	O	O
kappaB	NN	O	O
plays	NN	O	O
a	NN	O	O
more	NN	O	O
central	NN	O	O
role	NN	O	O
in	NN	O	O
seizure	NN	O	B
-	NN	O	O
associated	NN	O	O
neuronal	NN	O	B
damage	NN	O	I
in	NN	O	O
the	NN	O	O
temporal	NN	O	O
cortex	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
hippocampal	NN	O	O
hilus	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
future	NN	O	O
investigations	NN	O	O
are	NN	O	O
necessary	NN	O	O
to	NN	O	O
exactly	NN	O	O
analyze	NN	O	O
the	NN	O	O
biochemical	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
PDTC	NN	O	O
exerted	NN	O	O
its	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
in	NN	O	O
the	NN	O	O
piriform	NN	O	O
cortex	NN	O	O
.	NN	O	O

Anaesthetists	NN	O	O
'	NN	O	O
nightmare	NN	O	O
:	NN	O	O
masseter	NN	O	B
spasm	NN	O	I
after	NN	O	O
induction	NN	O	O
in	NN	O	O
an	NN	O	O
undiagnosed	NN	O	O
case	NN	O	O
of	NN	O	O
myotonia	NN	O	B
congenita	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
an	NN	O	O
undiagnosed	NN	O	O
case	NN	O	O
of	NN	O	O
myotonia	NN	O	B
congenita	NN	O	I
in	NN	O	O
a	NN	O	O
24	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
previously	NN	O	O
healthy	NN	O	O
primigravida	NN	O	O
,	NN	O	O
who	NN	O	O
developed	NN	O	O
life	NN	O	O
threatening	NN	O	O
masseter	NN	O	B
spasm	NN	O	I
following	NN	O	O
a	NN	O	O
standard	NN	O	O
dose	NN	O	O
of	NN	O	O
intravenous	NN	O	O
suxamethonium	NN	O	O
for	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

Neither	NN	O	O
the	NN	O	O
patient	NN	O	O
nor	NN	O	O
the	NN	O	O
anaesthetist	NN	O	O
was	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
before	NN	O	O
this	NN	O	O
potentially	NN	O	O
lethal	NN	O	O
complication	NN	O	O
occurred	NN	O	O
.	NN	O	O

Twin	NN	O	O
preterm	NN	O	O
neonates	NN	O	O
with	NN	O	O
cardiac	NN	O	B
toxicity	NN	O	I
related	NN	O	O
to	NN	O	O
lopinavir	NN	O	O
/	NN	O	O
ritonavir	NN	O	O
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
twin	NN	O	O
neonates	NN	O	O
who	NN	O	O
were	NN	O	O
born	NN	O	O
prematurely	NN	O	O
at	NN	O	O
32	NN	O	O
weeks	NN	O	O
of	NN	O	O
gestation	NN	O	O
to	NN	O	O
a	NN	O	O
mother	NN	O	O
with	NN	O	O
human	NN	O	B
immunodeficiency	NN	O	I
virus	NN	O	I
infection	NN	O	I
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
twins	NN	O	O
developed	NN	O	O
complete	NN	O	O
heart	NN	O	B
block	NN	O	I
and	NN	O	O
dilated	NN	O	B
cardiomyopathy	NN	O	I
related	NN	O	O
to	NN	O	O
lopinavir	NN	O	O
/	NN	O	O
ritonavir	NN	O	O
therapy	NN	O	O
,	NN	O	O
a	NN	O	O
boosted	NN	O	O
protease	NN	O	O
-	NN	O	O
inhibitor	NN	O	O
agent	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
other	NN	O	O
twin	NN	O	O
developed	NN	O	O
mild	NN	O	O
bradycardia	NN	O	B
.	NN	O	O

We	NN	O	O
recommend	NN	O	O
caution	NN	O	O
in	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
lopinavir	NN	O	O
/	NN	O	O
ritonavir	NN	O	O
in	NN	O	O
the	NN	O	O
immediate	NN	O	O
neonatal	NN	O	O
period	NN	O	O
.	NN	O	O

When	NN	O	O
drugs	NN	O	O
disappear	NN	O	O
from	NN	O	O
the	NN	O	O
patient	NN	O	O
:	NN	O	O
elimination	NN	O	O
of	NN	O	O
intravenous	NN	O	O
medication	NN	O	O
by	NN	O	O
hemodiafiltration	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
three	NN	O	O
hours	NN	O	O
after	NN	O	O
heart	NN	O	O
transplantation	NN	O	O
,	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
acute	NN	O	O
right	NN	O	B
heart	NN	O	I
failure	NN	O	I
was	NN	O	O
diagnosed	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
requiring	NN	O	O
continuous	NN	O	O
venovenous	NN	O	O
hemodiafiltration	NN	O	O
(	NN	O	O
CVVHDF	NN	O	O
)	NN	O	O
.	NN	O	O

Increasing	NN	O	O
doses	NN	O	O
of	NN	O	O
catecholamines	NN	O	O
,	NN	O	O
sedatives	NN	O	O
,	NN	O	O
and	NN	O	O
muscle	NN	O	O
relaxants	NN	O	O
administered	NN	O	O
through	NN	O	O
a	NN	O	O
central	NN	O	O
venous	NN	O	O
catheter	NN	O	O
were	NN	O	O
ineffective	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
a	NN	O	O
bolus	NN	O	O
of	NN	O	O
epinephrine	NN	O	O
injected	NN	O	O
through	NN	O	O
an	NN	O	O
alternative	NN	O	O
catheter	NN	O	O
provoked	NN	O	O
a	NN	O	O
hypertensive	NN	O	B
crisis	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
interference	NN	O	O
with	NN	O	O
the	NN	O	O
central	NN	O	O
venous	NN	O	O
infusion	NN	O	O
by	NN	O	O
the	NN	O	O
dialysis	NN	O	O
catheter	NN	O	O
was	NN	O	O
suspected	NN	O	O
.	NN	O	O

The	NN	O	O
catheters	NN	O	O
were	NN	O	O
changed	NN	O	O
,	NN	O	O
and	NN	O	O
hemodynamics	NN	O	O
stabilized	NN	O	O
at	NN	O	O
lower	NN	O	O
catecholamine	NN	O	O
doses	NN	O	O
.	NN	O	O

When	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
IV	NN	O	O
drugs	NN	O	O
are	NN	O	O
inadequate	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
CVVHDF	NN	O	O
,	NN	O	O
interference	NN	O	O
with	NN	O	O
adjacent	NN	O	O
catheters	NN	O	O
resulting	NN	O	O
in	NN	O	O
elimination	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
by	NN	O	O
CVVHDF	NN	O	O
should	NN	O	O
be	NN	O	O
suspected	NN	O	O
.	NN	O	O

Less	NN	O	O
frequent	NN	O	O
lithium	NN	O	O
administration	NN	O	O
and	NN	O	O
lower	NN	O	O
urine	NN	O	O
volume	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
patients	NN	O	O
maintained	NN	O	O
on	NN	O	O
a	NN	O	O
regimen	NN	O	O
of	NN	O	O
lithium	NN	O	O
on	NN	O	O
a	NN	O	O
once	NN	O	O
-	NN	O	O
per	NN	O	O
-	NN	O	O
day	NN	O	O
schedule	NN	O	O
have	NN	O	O
lower	NN	O	O
urine	NN	O	O
volumes	NN	O	O
than	NN	O	O
do	NN	O	O
patients	NN	O	O
receiving	NN	O	O
multiple	NN	O	O
doses	NN	O	O
per	NN	O	O
day	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
This	NN	O	O
was	NN	O	O
a	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
study	NN	O	O
of	NN	O	O
85	NN	O	O
patients	NN	O	O
from	NN	O	O
a	NN	O	O
lithium	NN	O	O
clinic	NN	O	O
who	NN	O	O
received	NN	O	O
different	NN	O	O
dose	NN	O	O
schedules	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
for	NN	O	O
measurement	NN	O	O
of	NN	O	O
lithium	NN	O	O
level	NN	O	O
,	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
,	NN	O	O
urine	NN	O	O
volume	NN	O	O
,	NN	O	O
and	NN	O	O
maximum	NN	O	O
osmolality	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Multiple	NN	O	O
daily	NN	O	O
doses	NN	O	O
of	NN	O	O
lithium	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
higher	NN	O	O
urine	NN	O	O
volumes	NN	O	O
.	NN	O	O

The	NN	O	O
dosing	NN	O	O
schedule	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
lithium	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
lithium	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
maximum	NN	O	O
osmolality	NN	O	O
or	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Urine	NN	O	O
volume	NN	O	O
can	NN	O	O
be	NN	O	O
reduced	NN	O	O
by	NN	O	O
giving	NN	O	O
lithium	NN	O	O
once	NN	O	O
daily	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
by	NN	O	O
lowering	NN	O	O
the	NN	O	O
total	NN	O	O
daily	NN	O	O
dose	NN	O	O
.	NN	O	O

Lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
polyuria	NN	O	B
seems	NN	O	O
to	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
extrarenal	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
to	NN	O	O
renal	NN	O	O
effects	NN	O	O
.	NN	O	O

Antibacterial	NN	O	O
medication	NN	O	O
use	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
and	NN	O	O
risk	NN	O	O
of	NN	O	O
birth	NN	O	B
defects	NN	O	I
:	NN	O	O
National	NN	O	O
Birth	NN	O	B
Defects	NN	O	I
Prevention	NN	O	O
Study	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
estimate	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
antibacterial	NN	O	O
medications	NN	O	O
and	NN	O	O
selected	NN	O	O
birth	NN	O	B
defects	NN	O	I
.	NN	O	O

DESIGN	NN	O	O
,	NN	O	O
SETTING	NN	O	O
,	NN	O	O
AND	NN	O	O
PARTICIPANTS	NN	O	O
:	NN	O	O
Population	NN	O	O
-	NN	O	O
based	NN	O	O
,	NN	O	O
multisite	NN	O	O
,	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
of	NN	O	O
women	NN	O	O
who	NN	O	O
had	NN	O	O
pregnancies	NN	O	O
affected	NN	O	O
by	NN	O	O
1	NN	O	O
of	NN	O	O
more	NN	O	O
than	NN	O	O
30	NN	O	O
eligible	NN	O	O
major	NN	O	O
birth	NN	O	B
defects	NN	O	I
identified	NN	O	O
via	NN	O	O
birth	NN	O	B
defect	NN	O	I
surveillance	NN	O	O
programs	NN	O	O
in	NN	O	O
10	NN	O	O
states	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
13	NN	O	O
155	NN	O	O
)	NN	O	O
and	NN	O	O
control	NN	O	O
women	NN	O	O
randomly	NN	O	O
selected	NN	O	O
from	NN	O	O
the	NN	O	O
same	NN	O	O
geographical	NN	O	O
regions	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4941	NN	O	O
)	NN	O	O
.	NN	O	O

MAIN	NN	O	O
EXPOSURE	NN	O	O
:	NN	O	O
Reported	NN	O	O
maternal	NN	O	O
use	NN	O	O
of	NN	O	O
antibacterials	NN	O	O
(	NN	O	O
1	NN	O	O
month	NN	O	O
before	NN	O	O
pregnancy	NN	O	O
through	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
first	NN	O	O
trimester	NN	O	O
)	NN	O	O
.	NN	O	O

MAIN	NN	O	O
OUTCOME	NN	O	O
MEASURE	NN	O	O
:	NN	O	O
Odds	NN	O	O
ratios	NN	O	O
(	NN	O	O
ORs	NN	O	O
)	NN	O	O
measuring	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
antibacterial	NN	O	O
use	NN	O	O
and	NN	O	O
selected	NN	O	O
birth	NN	O	B
defects	NN	O	I
adjusted	NN	O	O
for	NN	O	O
potential	NN	O	O
confounders	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
reported	NN	O	O
use	NN	O	O
of	NN	O	O
antibacterials	NN	O	O
increased	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
,	NN	O	O
peaking	NN	O	O
during	NN	O	O
the	NN	O	O
third	NN	O	O
month	NN	O	O
.	NN	O	O

Sulfonamides	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
anencephaly	NN	O	B
(	NN	O	O
adjusted	NN	O	O
OR	NN	O	O
[	NN	O	O
AOR	NN	O	O
]	NN	O	O
=	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
hypoplastic	NN	O	B
left	NN	O	I
heart	NN	O	I
syndrome	NN	O	I
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
7	NN	O	O
.	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
coarctation	NN	O	B
of	NN	O	I
the	NN	O	I
aorta	NN	O	I
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
choanal	NN	O	B
atresia	NN	O	I
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
8	NN	O	O
.	NN	O	O
0	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
-	NN	O	O
23	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
,	NN	O	O
transverse	NN	O	B
limb	NN	O	I
deficiency	NN	O	I
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
9	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
diaphragmatic	NN	O	B
hernia	NN	O	I
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
.	NN	O	O

Nitrofurantoins	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
anophthalmia	NN	O	B
or	NN	O	O
microphthalmos	NN	O	B
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
3	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
12	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
hypoplastic	NN	O	B
left	NN	O	I
heart	NN	O	I
syndrome	NN	O	I
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
4	NN	O	O
.	NN	O	O
2	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
atrial	NN	O	B
septal	NN	O	I
defects	NN	O	I
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
cleft	NN	O	B
lip	NN	O	I
with	NN	O	O
cleft	NN	O	B
palate	NN	O	I
(	NN	O	O
AOR	NN	O	O
=	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
9	NN	O	O
)	NN	O	O
.	NN	O	O

Other	NN	O	O
antibacterial	NN	O	O
agents	NN	O	O
that	NN	O	O
showed	NN	O	O
associations	NN	O	O
included	NN	O	O
erythromycins	NN	O	O
(	NN	O	O
2	NN	O	O
defects	NN	O	O
)	NN	O	O
,	NN	O	O
penicillins	NN	O	O
(	NN	O	O
1	NN	O	O
defect	NN	O	O
)	NN	O	O
,	NN	O	O
cephalosporins	NN	O	O
(	NN	O	O
1	NN	O	O
defect	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
quinolones	NN	O	O
(	NN	O	O
1	NN	O	O
defect	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Reassuringly	NN	O	O
,	NN	O	O
penicillins	NN	O	O
,	NN	O	O
erythromycins	NN	O	O
,	NN	O	O
and	NN	O	O
cephalosporins	NN	O	O
,	NN	O	O
although	NN	O	O
used	NN	O	O
commonly	NN	O	O
by	NN	O	O
pregnant	NN	O	O
women	NN	O	O
,	NN	O	O
were	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
many	NN	O	O
birth	NN	O	B
defects	NN	O	I
.	NN	O	O

Sulfonamides	NN	O	O
and	NN	O	O
nitrofurantoins	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
several	NN	O	O
birth	NN	O	B
defects	NN	O	I
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
need	NN	O	O
for	NN	O	O
additional	NN	O	O
scrutiny	NN	O	O
.	NN	O	O

Differential	NN	O	O
impact	NN	O	O
of	NN	O	O
immune	NN	O	O
escape	NN	O	O
mutations	NN	O	O
G145R	NN	O	O
and	NN	O	O
P120T	NN	O	O
on	NN	O	O
the	NN	O	O
replication	NN	O	O
of	NN	O	O
lamivudine	NN	O	O
-	NN	O	O
resistant	NN	O	O
hepatitis	NN	O	O
B	NN	O	O
virus	NN	O	O
e	NN	O	O
antigen	NN	O	O
-	NN	O	O
positive	NN	O	O
and	NN	O	O
-	NN	O	O
negative	NN	O	O
strains	NN	O	O
.	NN	O	O

Immune	NN	O	O
escape	NN	O	O
variants	NN	O	O
of	NN	O	O
the	NN	O	O
hepatitis	NN	O	B
B	NN	O	I
virus	NN	O	O
(	NN	O	O
HBV	NN	O	O
)	NN	O	O
represent	NN	O	O
an	NN	O	O
emerging	NN	O	O
clinical	NN	O	O
challenge	NN	O	O
,	NN	O	O
because	NN	O	O
they	NN	O	O
can	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
vaccine	NN	O	O
escape	NN	O	O
,	NN	O	O
HBV	NN	O	O
reactivation	NN	O	O
,	NN	O	O
and	NN	O	O
failure	NN	O	O
of	NN	O	O
diagnostic	NN	O	O
tests	NN	O	O
.	NN	O	O

Recent	NN	O	O
data	NN	O	O
suggest	NN	O	O
a	NN	O	O
preferential	NN	O	O
selection	NN	O	O
of	NN	O	O
immune	NN	O	O
escape	NN	O	O
mutants	NN	O	O
in	NN	O	O
distinct	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
leukocyte	NN	O	O
compartments	NN	O	O
of	NN	O	O
infected	NN	O	O
individuals	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
systematically	NN	O	O
analyzed	NN	O	O
the	NN	O	O
functional	NN	O	O
impact	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
prevalent	NN	O	O
immune	NN	O	O
escape	NN	O	O
variants	NN	O	O
,	NN	O	O
the	NN	O	O
sG145R	NN	O	O
and	NN	O	O
sP120T	NN	O	O
mutants	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
viral	NN	O	O
replication	NN	O	O
efficacy	NN	O	O
and	NN	O	O
antiviral	NN	O	O
drug	NN	O	O
susceptibility	NN	O	O
of	NN	O	O
common	NN	O	O
treatment	NN	O	O
-	NN	O	O
associated	NN	O	O
mutants	NN	O	O
with	NN	O	O
resistance	NN	O	O
to	NN	O	O
lamivudine	NN	O	O
(	NN	O	O
LAM	NN	O	O
)	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
HBeAg	NN	O	O
negativity	NN	O	O
.	NN	O	O

Replication	NN	O	O
-	NN	O	O
competent	NN	O	O
HBV	NN	O	O
strains	NN	O	O
with	NN	O	O
sG145R	NN	O	O
or	NN	O	O
sP120T	NN	O	O
and	NN	O	O
LAM	NN	O	O
resistance	NN	O	O
(	NN	O	O
rtM204I	NN	O	O
or	NN	O	O
rtL180M	NN	O	O
/	NN	O	O
rtM204V	NN	O	O
)	NN	O	O
were	NN	O	O
generated	NN	O	O
on	NN	O	O
an	NN	O	O
HBeAg	NN	O	O
-	NN	O	O
positive	NN	O	O
and	NN	O	O
an	NN	O	O
HBeAg	NN	O	O
-	NN	O	O
negative	NN	O	O
background	NN	O	O
with	NN	O	O
precore	NN	O	O
(	NN	O	O
PC	NN	O	O
)	NN	O	O
and	NN	O	O
basal	NN	O	O
core	NN	O	O
promoter	NN	O	O
(	NN	O	O
BCP	NN	O	O
)	NN	O	O
mutants	NN	O	O
.	NN	O	O

The	NN	O	O
sG145R	NN	O	O
mutation	NN	O	O
strongly	NN	O	O
reduced	NN	O	O
HBsAg	NN	O	O
levels	NN	O	O
and	NN	O	O
was	NN	O	O
able	NN	O	O
to	NN	O	O
fully	NN	O	O
restore	NN	O	O
the	NN	O	O
impaired	NN	O	O
replication	NN	O	O
of	NN	O	O
LAM	NN	O	O
-	NN	O	O
resistant	NN	O	O
HBV	NN	O	O
mutants	NN	O	O
to	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
HBV	NN	O	O
,	NN	O	O
and	NN	O	O
PC	NN	O	O
or	NN	O	O
BCP	NN	O	O
mutations	NN	O	O
further	NN	O	O
enhanced	NN	O	O
viral	NN	O	O
replication	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
sP120T	NN	O	O
substitution	NN	O	O
also	NN	O	O
impaired	NN	O	O
HBsAg	NN	O	O
secretion	NN	O	O
,	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
enhance	NN	O	O
the	NN	O	O
replication	NN	O	O
of	NN	O	O
LAM	NN	O	O
-	NN	O	O
resistant	NN	O	O
clones	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
concomitant	NN	O	O
occurrence	NN	O	O
of	NN	O	O
HBeAg	NN	O	O
negativity	NN	O	O
(	NN	O	O
PC	NN	O	O
/	NN	O	O
BCP	NN	O	O
)	NN	O	O
,	NN	O	O
sP120T	NN	O	O
,	NN	O	O
and	NN	O	O
LAM	NN	O	O
resistance	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
restoration	NN	O	O
of	NN	O	O
replication	NN	O	O
to	NN	O	O
levels	NN	O	O
of	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
HBV	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
clones	NN	O	O
with	NN	O	O
combined	NN	O	O
immune	NN	O	O
escape	NN	O	O
and	NN	O	O
LAM	NN	O	O
resistance	NN	O	O
mutations	NN	O	O
,	NN	O	O
the	NN	O	O
nucleotide	NN	O	O
analogues	NN	O	O
adefovir	NN	O	O
and	NN	O	O
tenofovir	NN	O	O
remained	NN	O	O
effective	NN	O	O
in	NN	O	O
suppressing	NN	O	O
viral	NN	O	O
replication	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
reveal	NN	O	O
the	NN	O	O
differential	NN	O	O
impact	NN	O	O
of	NN	O	O
immune	NN	O	O
escape	NN	O	O
variants	NN	O	O
on	NN	O	O
the	NN	O	O
replication	NN	O	O
and	NN	O	O
drug	NN	O	O
susceptibility	NN	O	O
of	NN	O	O
complex	NN	O	O
HBV	NN	O	O
mutants	NN	O	O
,	NN	O	O
supporting	NN	O	O
the	NN	O	O
need	NN	O	O
of	NN	O	O
close	NN	O	O
surveillance	NN	O	O
and	NN	O	O
treatment	NN	O	O
adjustment	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
selection	NN	O	O
of	NN	O	O
distinct	NN	O	O
mutational	NN	O	O
patterns	NN	O	O
.	NN	O	O

Hemolytic	NN	O	B
anemia	NN	O	I
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
omeprazole	NN	O	O
.	NN	O	O

Omeprazole	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
drug	NN	O	O
designed	NN	O	O
to	NN	O	O
block	NN	O	O
the	NN	O	O
final	NN	O	O
step	NN	O	O
in	NN	O	O
the	NN	O	O
acid	NN	O	O
secretory	NN	O	O
process	NN	O	O
within	NN	O	O
the	NN	O	O
parietal	NN	O	O
cell	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
extremely	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
peptic	NN	O	B
ulcer	NN	O	I
disease	NN	O	I
,	NN	O	O
reflux	NN	O	B
esophagitis	NN	O	I
,	NN	O	O
and	NN	O	O
the	NN	O	O
Zollinger	NN	O	B
-	NN	O	I
Ellison	NN	O	I
syndrome	NN	O	I
.	NN	O	O

Although	NN	O	O
clinical	NN	O	O
experience	NN	O	O
with	NN	O	O
omeprazole	NN	O	O
is	NN	O	O
still	NN	O	O
limited	NN	O	O
,	NN	O	O
many	NN	O	O
controlled	NN	O	O
studies	NN	O	O
have	NN	O	O
established	NN	O	O
the	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
safety	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
serious	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
adverse	NN	O	O
reaction	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
omeprazole	NN	O	O
:	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
.	NN	O	O

The	NN	O	O
patient	NN	O	O
developed	NN	O	O
weakness	NN	O	O
,	NN	O	O
lethargy	NN	O	B
,	NN	O	O
and	NN	O	O
shortness	NN	O	B
of	NN	O	I
breath	NN	O	I
2	NN	O	O
days	NN	O	O
after	NN	O	O
starting	NN	O	O
therapy	NN	O	O
with	NN	O	O
omeprazole	NN	O	O
.	NN	O	O

Two	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
her	NN	O	O
hematocrit	NN	O	O
had	NN	O	O
decreased	NN	O	O
from	NN	O	O
44	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
to	NN	O	O
20	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
she	NN	O	O
had	NN	O	O
a	NN	O	O
positive	NN	O	O
direct	NN	O	O
Coombs	NN	O	O
antiglobulin	NN	O	O
test	NN	O	O
and	NN	O	O
an	NN	O	O
elevated	NN	O	O
indirect	NN	O	O
bilirubin	NN	O	O
.	NN	O	O

After	NN	O	O
she	NN	O	O
discontinued	NN	O	O
the	NN	O	O
omeprazole	NN	O	O
,	NN	O	O
her	NN	O	O
hemoglobin	NN	O	O
and	NN	O	O
hematocrit	NN	O	O
gradually	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
omeprazole	NN	O	O
caused	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
is	NN	O	O
uncertain	NN	O	O
,	NN	O	O
but	NN	O	O
physicians	NN	O	O
should	NN	O	O
be	NN	O	O
alerted	NN	O	O
to	NN	O	O
this	NN	O	O
possible	NN	O	O
adverse	NN	O	O
effect	NN	O	O
.	NN	O	O

Phenylephrine	NN	O	O
but	NN	O	O
not	NN	O	O
ephedrine	NN	O	O
reduces	NN	O	B
frontal	NN	O	I
lobe	NN	O	I
oxygenation	NN	O	I
following	NN	O	O
anesthesia	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Vasopressor	NN	O	O
agents	NN	O	O
are	NN	O	O
used	NN	O	O
to	NN	O	O
correct	NN	O	O
anesthesia	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

We	NN	O	O
describe	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
phenylephrine	NN	O	O
and	NN	O	O
ephedrine	NN	O	O
on	NN	O	O
frontal	NN	O	O
lobe	NN	O	O
oxygenation	NN	O	O
(	NN	O	O
S	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
O	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
following	NN	O	O
anesthesia	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Following	NN	O	O
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
by	NN	O	O
fentanyl	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
15	NN	O	O
mg	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
)	NN	O	O
and	NN	O	O
propofol	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
)	NN	O	O
,	NN	O	O
13	NN	O	O
patients	NN	O	O
received	NN	O	O
phenylephrine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
mg	NN	O	O
iv	NN	O	O
)	NN	O	O
and	NN	O	O
12	NN	O	O
patients	NN	O	O
received	NN	O	O
ephedrine	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
iv	NN	O	O
)	NN	O	O
to	NN	O	O
restore	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
.	NN	O	O

Heart	NN	O	O
rate	NN	O	O
(	NN	O	O
HR	NN	O	O
)	NN	O	O
,	NN	O	O
MAP	NN	O	O
,	NN	O	O
stroke	NN	O	B
volume	NN	O	O
(	NN	O	O
SV	NN	O	O
)	NN	O	O
,	NN	O	O
cardiac	NN	O	O
output	NN	O	O
(	NN	O	O
CO	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
frontal	NN	O	O
lobe	NN	O	O
oxygenation	NN	O	O
(	NN	O	O
S	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
O	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
were	NN	O	O
registered	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	B
decrease	NN	O	I
in	NN	O	I
MAP	NN	O	I
,	NN	O	I
HR	NN	O	I
,	NN	O	I
SV	NN	O	I
,	NN	O	I
and	NN	O	I
CO	NN	O	I
concomitant	NN	O	O
with	NN	O	O
an	NN	O	O
elevation	NN	O	O
in	NN	O	O
S	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
O	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
administration	NN	O	O
of	NN	O	O
phenylephrine	NN	O	O
,	NN	O	O
MAP	NN	O	O
increased	NN	O	O
(	NN	O	O
51	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
to	NN	O	O
81	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
mmHg	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
;	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
a	NN	O	O
14	NN	O	O
%	NN	O	O
(	NN	O	O
from	NN	O	O
70	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
%	NN	O	O
to	NN	O	O
60	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
reduction	NN	O	O
in	NN	O	O
S	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
O	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
followed	NN	O	O
with	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
CO	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
l	NN	O	O
min	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
ephedrine	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
similar	NN	O	O
increase	NN	O	O
in	NN	O	O
MAP	NN	O	O
(	NN	O	O
53	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9	NN	O	O
to	NN	O	O
79	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
mmHg	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
restored	NN	O	O
CO	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
to	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
l	NN	O	O
min	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
preserved	NN	O	O
S	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
O	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
utilization	NN	O	O
of	NN	O	O
phenylephrine	NN	O	O
to	NN	O	O
correct	NN	O	O
hypotension	NN	O	B
induced	NN	O	O
by	NN	O	O
anesthesia	NN	O	O
has	NN	O	O
a	NN	O	O
negative	NN	O	O
impact	NN	O	O
on	NN	O	O
S	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
O	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
while	NN	O	O
ephedrine	NN	O	O
maintains	NN	O	O
frontal	NN	O	O
lobe	NN	O	O
oxygenation	NN	O	O
potentially	NN	O	O
related	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
CO	NN	O	O
.	NN	O	O

Prolonged	NN	O	O
elevation	NN	O	O
of	NN	O	O
plasma	NN	O	O
argatroban	NN	O	O
in	NN	O	O
a	NN	O	O
cardiac	NN	O	O
transplant	NN	O	O
patient	NN	O	O
with	NN	O	O
a	NN	O	O
suspected	NN	O	O
history	NN	O	O
of	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
with	NN	O	O
thrombosis	NN	O	B
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Direct	NN	O	O
thrombin	NN	O	O
inhibitors	NN	O	O
(	NN	O	O
DTIs	NN	O	O
)	NN	O	O
provide	NN	O	O
an	NN	O	O
alternative	NN	O	O
method	NN	O	O
of	NN	O	O
anticoagulation	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
heparin	NN	O	O
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B
(	NN	O	O
HIT	NN	O	B
)	NN	O	O
or	NN	O	O
HIT	NN	O	B
with	NN	O	O
thrombosis	NN	O	B
(	NN	O	O
HITT	NN	O	B
)	NN	O	O
undergoing	NN	O	O
cardiopulmonary	NN	O	O
bypass	NN	O	O
(	NN	O	O
CPB	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
following	NN	O	O
report	NN	O	O
,	NN	O	O
a	NN	O	O
65	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
critically	NN	O	B
ill	NN	O	I
patient	NN	O	O
with	NN	O	O
a	NN	O	O
suspected	NN	O	O
history	NN	O	O
of	NN	O	O
HITT	NN	O	B
was	NN	O	O
administered	NN	O	O
argatroban	NN	O	O
for	NN	O	O
anticoagulation	NN	O	O
on	NN	O	O
bypass	NN	O	O
during	NN	O	O
heart	NN	O	O
transplantation	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
required	NN	O	O
massive	NN	O	O
transfusion	NN	O	O
support	NN	O	O
(	NN	O	O
55	NN	O	O
units	NN	O	O
of	NN	O	O
red	NN	O	O
blood	NN	O	O
cells	NN	O	O
,	NN	O	O
42	NN	O	O
units	NN	O	O
of	NN	O	O
fresh	NN	O	O
-	NN	O	O
frozen	NN	O	O
plasma	NN	O	O
,	NN	O	O
40	NN	O	O
units	NN	O	O
of	NN	O	O
cryoprecipitate	NN	O	O
,	NN	O	O
40	NN	O	O
units	NN	O	O
of	NN	O	O
platelets	NN	O	O
,	NN	O	O
and	NN	O	O
three	NN	O	O
doses	NN	O	O
of	NN	O	O
recombinant	NN	O	O
Factor	NN	O	O
VIIa	NN	O	O
)	NN	O	O
for	NN	O	O
severe	NN	O	O
intraoperative	NN	O	B
and	NN	O	I
postoperative	NN	O	I
bleeding	NN	O	I
.	NN	O	O

STUDY	NN	O	O
DESIGN	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Plasma	NN	O	O
samples	NN	O	O
from	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
CPB	NN	O	O
were	NN	O	O
analyzed	NN	O	O
postoperatively	NN	O	O
for	NN	O	O
argatroban	NN	O	O
concentration	NN	O	O
using	NN	O	O
a	NN	O	O
modified	NN	O	O
ecarin	NN	O	O
clotting	NN	O	O
time	NN	O	O
(	NN	O	O
ECT	NN	O	O
)	NN	O	O
assay	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Unexpectedly	NN	O	O
high	NN	O	O
concentrations	NN	O	O
of	NN	O	O
argatroban	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
these	NN	O	O
samples	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
0	NN	O	O
-	NN	O	O
32	NN	O	O
microg	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
prolonged	NN	O	O
plasma	NN	O	O
argatroban	NN	O	O
half	NN	O	O
life	NN	O	O
(	NN	O	O
t	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
of	NN	O	O
514	NN	O	O
minutes	NN	O	O
was	NN	O	O
observed	NN	O	O
(	NN	O	O
published	NN	O	O
elimination	NN	O	O
t	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
)	NN	O	O
is	NN	O	O
39	NN	O	O
-	NN	O	O
51	NN	O	O
minutes	NN	O	O
[	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
181	NN	O	O
minutes	NN	O	O
with	NN	O	O
hepatic	NN	O	B
impairment	NN	O	I
]	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Correlation	NN	O	O
of	NN	O	O
plasma	NN	O	O
argatroban	NN	O	O
concentration	NN	O	O
versus	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
coagulation	NN	O	O
variables	NN	O	O
and	NN	O	O
clinical	NN	O	O
course	NN	O	O
suggest	NN	O	O
that	NN	O	O
prolonged	NN	O	O
elevated	NN	O	O
levels	NN	O	O
of	NN	O	O
plasma	NN	O	O
argatroban	NN	O	O
may	NN	O	O
have	NN	O	O
contributed	NN	O	O
to	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
extended	NN	O	O
coagulopathy	NN	O	B
.	NN	O	O

Because	NN	O	O
DTIs	NN	O	O
do	NN	O	O
not	NN	O	O
have	NN	O	O
reversal	NN	O	O
agents	NN	O	O
,	NN	O	O
surgical	NN	O	O
teams	NN	O	O
and	NN	O	O
transfusion	NN	O	O
services	NN	O	O
should	NN	O	O
remain	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
massive	NN	O	O
transfusion	NN	O	O
events	NN	O	O
during	NN	O	O
anticoagulation	NN	O	O
with	NN	O	O
these	NN	O	O
agents	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
report	NN	O	O
to	NN	O	O
measure	NN	O	O
plasma	NN	O	O
argatroban	NN	O	O
concentration	NN	O	O
in	NN	O	O
the	NN	O	O
context	NN	O	O
of	NN	O	O
CPB	NN	O	O
and	NN	O	O
extended	NN	O	O
coagulopathy	NN	O	B
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
adjunctive	NN	O	O
bupropion	NN	O	O
on	NN	O	O
male	NN	O	O
sexual	NN	O	B
dysfunction	NN	O	I
induced	NN	O	O
by	NN	O	O
a	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitor	NN	O	O
:	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
and	NN	O	O
randomized	NN	O	O
study	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
adjunctive	NN	O	O
bupropion	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
(	NN	O	O
SR	NN	O	O
)	NN	O	O
on	NN	O	O
male	NN	O	O
sexual	NN	O	B
dysfunction	NN	O	I
(	NN	O	O
SD	NN	O	B
)	NN	O	O
induced	NN	O	O
by	NN	O	O
a	NN	O	O
selective	NN	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitor	NN	O	O
(	NN	O	O
SSRI	NN	O	O
)	NN	O	O
,	NN	O	O
as	NN	O	O
SD	NN	O	B
is	NN	O	O
a	NN	O	O
common	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
of	NN	O	O
SSRIs	NN	O	O
and	NN	O	O
the	NN	O	O
most	NN	O	O
effective	NN	O	O
treatments	NN	O	O
have	NN	O	O
yet	NN	O	O
to	NN	O	O
be	NN	O	O
determined	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
randomized	NN	O	O
sample	NN	O	O
consisted	NN	O	O
of	NN	O	O
234	NN	O	O
euthymic	NN	O	O
men	NN	O	O
who	NN	O	O
were	NN	O	O
receiving	NN	O	O
some	NN	O	O
type	NN	O	O
of	NN	O	O
SSRI	NN	O	O
.	NN	O	O

The	NN	O	O
men	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
bupropion	NN	O	O
SR	NN	O	O
(	NN	O	O
150	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
,	NN	O	O
117	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
twice	NN	O	O
daily	NN	O	O
,	NN	O	O
117	NN	O	O
)	NN	O	O
for	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

Efficacy	NN	O	O
was	NN	O	O
evaluated	NN	O	O
using	NN	O	O
the	NN	O	O
Clinical	NN	O	O
Global	NN	O	O
Impression	NN	O	O
-	NN	O	O
Sexual	NN	O	O
Function	NN	O	O
(	NN	O	O
CGI	NN	O	O
-	NN	O	O
SF	NN	O	O
;	NN	O	O
the	NN	O	O
primary	NN	O	O
outcome	NN	O	O
measure	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
International	NN	O	O
Index	NN	O	O
of	NN	O	O
Erectile	NN	O	O
Function	NN	O	O
(	NN	O	O
IIEF	NN	O	O
)	NN	O	O
,	NN	O	O
Arizona	NN	O	O
Sexual	NN	O	O
Experience	NN	O	O
Scale	NN	O	O
(	NN	O	O
ASEX	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
Erectile	NN	O	B
Dysfunction	NN	O	I
Inventory	NN	O	O
of	NN	O	O
Treatment	NN	O	O
Satisfaction	NN	O	O
(	NN	O	O
EDITS	NN	O	O
)	NN	O	O
(	NN	O	O
secondary	NN	O	O
outcome	NN	O	O
measures	NN	O	O
)	NN	O	O
.	NN	O	O

Participants	NN	O	O
were	NN	O	O
followed	NN	O	O
biweekly	NN	O	O
during	NN	O	O
study	NN	O	O
period	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
After	NN	O	O
12	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
(	NN	O	O
sd	NN	O	O
)	NN	O	O
scores	NN	O	O
for	NN	O	O
CGI	NN	O	O
-	NN	O	O
SF	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
better	NN	O	O
,	NN	O	O
in	NN	O	O
patients	NN	O	O
on	NN	O	O
bupropion	NN	O	O
SR	NN	O	O
,	NN	O	O
at	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
,	NN	O	O
at	NN	O	O
3	NN	O	O
.	NN	O	O
9	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

Men	NN	O	O
who	NN	O	O
received	NN	O	O
bupropion	NN	O	O
had	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
total	NN	O	O
IIEF	NN	O	O
score	NN	O	O
(	NN	O	O
54	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
vs	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
003	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
five	NN	O	O
different	NN	O	O
domains	NN	O	O
of	NN	O	O
the	NN	O	O
IIEF	NN	O	O
.	NN	O	O

Total	NN	O	O
ASEX	NN	O	O
scores	NN	O	O
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
better	NN	O	O
,	NN	O	O
among	NN	O	O
men	NN	O	O
who	NN	O	O
received	NN	O	O
bupropion	NN	O	O
than	NN	O	O
placebo	NN	O	O
,	NN	O	O
at	NN	O	O
15	NN	O	O
.	NN	O	O
5	NN	O	O
(	NN	O	O
4	NN	O	O
.	NN	O	O
3	NN	O	O
)	NN	O	O
vs	NN	O	O
21	NN	O	O
.	NN	O	O
5	NN	O	O
(	NN	O	O
4	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
002	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
EDITS	NN	O	O
scores	NN	O	O
were	NN	O	O
67	NN	O	O
.	NN	O	O
4	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
for	NN	O	O
the	NN	O	O
bupropion	NN	O	O
and	NN	O	O
36	NN	O	O
.	NN	O	O
3	NN	O	O
(	NN	O	O
11	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
for	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
ASEX	NN	O	O
score	NN	O	O
and	NN	O	O
CGI	NN	O	O
-	NN	O	O
SF	NN	O	O
score	NN	O	O
were	NN	O	O
correlated	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
003	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
linear	NN	O	O
regression	NN	O	O
analyses	NN	O	O
the	NN	O	O
CGI	NN	O	O
-	NN	O	O
SF	NN	O	O
score	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
significantly	NN	O	O
by	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
SD	NN	O	B
,	NN	O	O
type	NN	O	O
of	NN	O	O
SSRI	NN	O	O
used	NN	O	O
and	NN	O	O
age	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Bupropion	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
treatment	NN	O	O
for	NN	O	O
male	NN	O	O
SD	NN	O	B
induced	NN	O	O
by	NN	O	O
SSRIs	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
provide	NN	O	O
empirical	NN	O	O
support	NN	O	O
for	NN	O	O
conducting	NN	O	O
a	NN	O	O
further	NN	O	O
study	NN	O	O
of	NN	O	O
bupropion	NN	O	O
.	NN	O	O

Prevention	NN	O	O
of	NN	O	O
seizures	NN	O	B
and	NN	O	O
reorganization	NN	O	O
of	NN	O	O
hippocampal	NN	O	O
functions	NN	O	O
by	NN	O	O
transplantation	NN	O	O
of	NN	O	O
bone	NN	O	O
marrow	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
acute	NN	O	O
phase	NN	O	O
of	NN	O	O
experimental	NN	O	O
epilepsy	NN	O	B
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
potential	NN	O	O
of	NN	O	O
bone	NN	O	O
marrow	NN	O	O
mononuclear	NN	O	O
cells	NN	O	O
(	NN	O	O
BMCs	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
epilepsy	NN	O	B
induced	NN	O	O
by	NN	O	O
pilocarpine	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

BMCs	NN	O	O
obtained	NN	O	O
from	NN	O	O
green	NN	O	O
fluorescent	NN	O	O
protein	NN	O	O
(	NN	O	O
GFP	NN	O	O
)	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
or	NN	O	O
rats	NN	O	O
were	NN	O	O
transplanted	NN	O	O
intravenously	NN	O	O
after	NN	O	O
induction	NN	O	O
of	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
(	NN	O	O
SE	NN	O	B
)	NN	O	O
.	NN	O	O

Spontaneous	NN	O	B
recurrent	NN	O	I
seizures	NN	O	I
(	NN	O	O
SRS	NN	O	B
)	NN	O	O
were	NN	O	O
monitored	NN	O	O
using	NN	O	O
Racine	NN	O	O
'	NN	O	O
s	NN	O	O
seizure	NN	O	B
severity	NN	O	O
scale	NN	O	O
.	NN	O	O

All	NN	O	O
of	NN	O	O
the	NN	O	O
rats	NN	O	O
in	NN	O	O
the	NN	O	O
saline	NN	O	O
-	NN	O	O
treated	NN	O	O
epileptic	NN	O	B
control	NN	O	O
group	NN	O	O
developed	NN	O	O
SRS	NN	O	B
,	NN	O	O
whereas	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
BMC	NN	O	O
-	NN	O	O
treated	NN	O	O
epileptic	NN	O	B
animals	NN	O	O
had	NN	O	O
seizures	NN	O	B
in	NN	O	O
the	NN	O	O
short	NN	O	O
term	NN	O	O
(	NN	O	O
15	NN	O	O
days	NN	O	O
after	NN	O	O
transplantation	NN	O	O
)	NN	O	O
,	NN	O	O
regardless	NN	O	O
of	NN	O	O
the	NN	O	O
BMC	NN	O	O
source	NN	O	O
.	NN	O	O

Over	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
chronic	NN	O	O
phase	NN	O	O
(	NN	O	O
120	NN	O	O
days	NN	O	O
after	NN	O	O
transplantation	NN	O	O
)	NN	O	O
,	NN	O	O
only	NN	O	O
25	NN	O	O
%	NN	O	O
of	NN	O	O
BMC	NN	O	O
-	NN	O	O
treated	NN	O	O
epileptic	NN	O	B
animals	NN	O	O
had	NN	O	O
seizures	NN	O	B
,	NN	O	O
but	NN	O	O
with	NN	O	O
a	NN	O	O
lower	NN	O	O
frequency	NN	O	O
and	NN	O	O
duration	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
epileptic	NN	O	B
control	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
density	NN	O	O
of	NN	O	O
hippocampal	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
brains	NN	O	O
of	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
BMCs	NN	O	O
was	NN	O	O
markedly	NN	O	O
preserved	NN	O	O
.	NN	O	O

At	NN	O	O
hippocampal	NN	O	O
Schaeffer	NN	O	O
collateral	NN	O	O
-	NN	O	O
CA1	NN	O	O
synapses	NN	O	O
,	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
potentiation	NN	O	O
was	NN	O	O
preserved	NN	O	O
in	NN	O	O
BMC	NN	O	O
-	NN	O	O
transplanted	NN	O	O
rats	NN	O	O
compared	NN	O	O
to	NN	O	O
epileptic	NN	O	B
controls	NN	O	O
.	NN	O	O

The	NN	O	O
donor	NN	O	O
-	NN	O	O
derived	NN	O	O
GFP	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
cells	NN	O	O
were	NN	O	O
rarely	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
brains	NN	O	O
of	NN	O	O
transplanted	NN	O	O
epileptic	NN	O	B
rats	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
treatment	NN	O	O
with	NN	O	O
BMCs	NN	O	O
can	NN	O	O
prevent	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
chronic	NN	O	O
seizures	NN	O	B
,	NN	O	O
reduce	NN	O	O
neuronal	NN	O	B
loss	NN	O	I
,	NN	O	O
and	NN	O	O
influence	NN	O	O
the	NN	O	O
reorganization	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampal	NN	O	O
neuronal	NN	O	O
network	NN	O	O
.	NN	O	O

Normalizing	NN	O	O
effects	NN	O	O
of	NN	O	O
modafinil	NN	O	O
on	NN	O	O
sleep	NN	O	O
in	NN	O	O
chronic	NN	O	O
cocaine	NN	O	O
users	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
morning	NN	O	O
-	NN	O	O
dosed	NN	O	O
modafinil	NN	O	O
on	NN	O	O
sleep	NN	O	O
and	NN	O	O
daytime	NN	O	B
sleepiness	NN	O	I
in	NN	O	O
chronic	NN	O	O
cocaine	NN	O	O
users	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Twenty	NN	O	O
cocaine	NN	O	O
-	NN	O	O
dependent	NN	O	O
participants	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
receive	NN	O	O
modafinil	NN	O	O
,	NN	O	O
400	NN	O	O
mg	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
every	NN	O	O
morning	NN	O	O
at	NN	O	O
7	NN	O	O
:	NN	O	O
30	NN	O	O
a	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
for	NN	O	O
16	NN	O	O
days	NN	O	O
in	NN	O	O
an	NN	O	O
inpatient	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
randomized	NN	O	O
trial	NN	O	O
.	NN	O	O

Participants	NN	O	O
underwent	NN	O	O
polysomnographic	NN	O	O
sleep	NN	O	O
recordings	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
to	NN	O	O
3	NN	O	O
,	NN	O	O
7	NN	O	O
to	NN	O	O
9	NN	O	O
,	NN	O	O
and	NN	O	O
14	NN	O	O
to	NN	O	O
16	NN	O	O
(	NN	O	O
first	NN	O	O
,	NN	O	O
second	NN	O	O
,	NN	O	O
and	NN	O	O
third	NN	O	O
weeks	NN	O	O
of	NN	O	O
abstinence	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
Multiple	NN	O	O
Sleep	NN	O	O
Latency	NN	O	O
Test	NN	O	O
was	NN	O	O
performed	NN	O	O
at	NN	O	O
11	NN	O	O
:	NN	O	O
30	NN	O	O
a	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
,	NN	O	O
2	NN	O	O
:	NN	O	O
00	NN	O	O
p	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
,	NN	O	O
and	NN	O	O
4	NN	O	O
:	NN	O	O
30	NN	O	O
p	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
on	NN	O	O
days	NN	O	O
2	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
and	NN	O	O
15	NN	O	O
.	NN	O	O

For	NN	O	O
comparison	NN	O	O
of	NN	O	O
sleep	NN	O	O
architecture	NN	O	O
variables	NN	O	O
,	NN	O	O
12	NN	O	O
healthy	NN	O	O
comparison	NN	O	O
participants	NN	O	O
underwent	NN	O	O
a	NN	O	O
single	NN	O	O
night	NN	O	O
of	NN	O	O
experimental	NN	O	O
polysomnography	NN	O	O
that	NN	O	O
followed	NN	O	O
1	NN	O	O
night	NN	O	O
of	NN	O	O
accommodation	NN	O	O
polysomnography	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Progressive	NN	O	O
abstinence	NN	O	O
from	NN	O	O
cocaine	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
worsening	NN	O	O
of	NN	O	O
all	NN	O	O
measured	NN	O	O
polysomnographic	NN	O	O
sleep	NN	O	O
outcomes	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
placebo	NN	O	O
,	NN	O	O
modafinil	NN	O	O
decreased	NN	O	O
nighttime	NN	O	O
sleep	NN	O	O
latency	NN	O	O
and	NN	O	O
increased	NN	O	O
slow	NN	O	O
-	NN	O	O
wave	NN	O	O
sleep	NN	O	O
time	NN	O	O
in	NN	O	O
cocaine	NN	O	O
-	NN	O	O
dependent	NN	O	O
participants	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
modafinil	NN	O	O
interacted	NN	O	O
with	NN	O	O
the	NN	O	O
abstinence	NN	O	O
week	NN	O	O
and	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
longer	NN	O	O
total	NN	O	O
sleep	NN	O	O
time	NN	O	O
and	NN	O	O
shorter	NN	O	O
REM	NN	O	O
sleep	NN	O	O
latency	NN	O	O
in	NN	O	O
the	NN	O	O
third	NN	O	O
week	NN	O	O
of	NN	O	O
abstinence	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
slow	NN	O	O
-	NN	O	O
wave	NN	O	O
sleep	NN	O	O
time	NN	O	O
,	NN	O	O
total	NN	O	O
sleep	NN	O	O
time	NN	O	O
,	NN	O	O
and	NN	O	O
sleep	NN	O	O
latency	NN	O	O
in	NN	O	O
cocaine	NN	O	O
-	NN	O	O
dependent	NN	O	O
and	NN	O	O
healthy	NN	O	O
participants	NN	O	O
revealed	NN	O	O
a	NN	O	O
normalizing	NN	O	O
effect	NN	O	O
of	NN	O	O
modafinil	NN	O	O
in	NN	O	O
cocaine	NN	O	O
-	NN	O	O
dependent	NN	O	O
participants	NN	O	O
.	NN	O	O

Modafinil	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
daytime	NN	O	O
sleep	NN	O	O
latency	NN	O	O
,	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
the	NN	O	O
Multiple	NN	O	O
Sleep	NN	O	O
Latency	NN	O	O
Test	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
nearly	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
subjective	NN	O	O
daytime	NN	O	B
sleepiness	NN	O	I
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Morning	NN	O	O
-	NN	O	O
dosed	NN	O	O
modafinil	NN	O	O
promotes	NN	O	O
nocturnal	NN	O	O
sleep	NN	O	O
,	NN	O	O
normalizes	NN	O	O
sleep	NN	O	O
architecture	NN	O	O
,	NN	O	O
and	NN	O	O
decreases	NN	O	O
daytime	NN	O	B
sleepiness	NN	O	I
in	NN	O	O
abstinent	NN	O	O
cocaine	NN	O	O
users	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
may	NN	O	O
be	NN	O	O
relevant	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
cocaine	NN	O	O
dependence	NN	O	O
.	NN	O	O

Safety	NN	O	O
of	NN	O	O
transesophageal	NN	O	O
echocardiography	NN	O	O
in	NN	O	O
adults	NN	O	O
:	NN	O	O
study	NN	O	O
in	NN	O	O
a	NN	O	O
multidisciplinary	NN	O	O
hospital	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
TEE	NN	O	O
is	NN	O	O
a	NN	O	O
semi	NN	O	O
-	NN	O	O
invasive	NN	O	O
tool	NN	O	O
broadly	NN	O	O
used	NN	O	O
and	NN	O	O
its	NN	O	O
utilization	NN	O	O
associated	NN	O	O
to	NN	O	O
sedatives	NN	O	O
drugs	NN	O	O
might	NN	O	O
to	NN	O	O
affect	NN	O	O
the	NN	O	O
procedure	NN	O	O
safety	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
to	NN	O	O
analyze	NN	O	O
aspects	NN	O	O
of	NN	O	O
TEE	NN	O	O
safety	NN	O	O
associated	NN	O	O
to	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
Midazolan	NN	O	O
(	NN	O	O
MZ	NN	O	O
)	NN	O	O
and	NN	O	O
Flumazenil	NN	O	O
(	NN	O	O
FL	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
the	NN	O	O
clinical	NN	O	O
variables	NN	O	O
on	NN	O	O
the	NN	O	O
event	NN	O	O
rate	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
prospective	NN	O	O
study	NN	O	O
with	NN	O	O
137	NN	O	O
patients	NN	O	O
that	NN	O	O
underwent	NN	O	O
TEE	NN	O	O
with	NN	O	O
MZ	NN	O	O
associated	NN	O	O
to	NN	O	O
moderate	NN	O	O
sedation	NN	O	O
.	NN	O	O

We	NN	O	O
analyzed	NN	O	O
the	NN	O	O
following	NN	O	O
events	NN	O	O
:	NN	O	O
complications	NN	O	O
related	NN	O	O
with	NN	O	O
the	NN	O	O
topical	NN	O	O
anesthesia	NN	O	O
,	NN	O	O
with	NN	O	O
MZ	NN	O	O
use	NN	O	O
and	NN	O	O
with	NN	O	O
the	NN	O	O
procedure	NN	O	O
.	NN	O	O

Uni	NN	O	O
-	NN	O	O
and	NN	O	O
multivariate	NN	O	O
analyses	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
test	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
the	NN	O	O
clinical	NN	O	O
variables	NN	O	O
:	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
stroke	NN	O	B
,	NN	O	O
myocardiopathy	NN	O	B
(	NN	O	O
MP	NN	O	B
)	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
test	NN	O	O
,	NN	O	O
mitral	NN	O	B
regurgitation	NN	O	I
(	NN	O	O
MR	NN	O	B
)	NN	O	O
and	NN	O	O
the	NN	O	O
MZ	NN	O	O
dose	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
patients	NN	O	O
(	NN	O	O
65	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
16	NN	O	O
yrs	NN	O	O
;	NN	O	O
58	NN	O	O
%	NN	O	O
males	NN	O	O
)	NN	O	O
finished	NN	O	O
the	NN	O	O
examination	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
doses	NN	O	O
of	NN	O	O
MZ	NN	O	O
and	NN	O	O
FL	NN	O	O
were	NN	O	O
4	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
28	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
examination	NN	O	O
and	NN	O	O
the	NN	O	O
mean	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
(	NN	O	O
EF	NN	O	O
)	NN	O	O
were	NN	O	O
16	NN	O	O
.	NN	O	O
4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
minutes	NN	O	O
and	NN	O	O
60	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Mild	NN	O	O
hypoxia	NN	O	B
(	NN	O	O
SO2	NN	O	O
<	NN	O	O
90	NN	O	O
%	NN	O	O
)	NN	O	O
was	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
event	NN	O	O
(	NN	O	O
11	NN	O	O
patients	NN	O	O
)	NN	O	O
;	NN	O	O
3	NN	O	O
patients	NN	O	O
(	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
presented	NN	O	O
transient	NN	O	O
hypoxia	NN	O	B
due	NN	O	O
to	NN	O	O
upper	NN	O	O
airway	NN	O	B
obstruction	NN	O	I
by	NN	O	O
probe	NN	O	O
introduction	NN	O	O
and	NN	O	O
8	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
due	NN	O	O
to	NN	O	O
hypoxia	NN	O	B
caused	NN	O	O
by	NN	O	O
MZ	NN	O	O
use	NN	O	O
.	NN	O	O

Transient	NN	O	O
hypotension	NN	O	B
(	NN	O	O
SAP	NN	O	O
<	NN	O	O
90mmHg	NN	O	O
)	NN	O	O
occurred	NN	O	O
in	NN	O	O
1	NN	O	O
patient	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
multivariate	NN	O	O
analysis	NN	O	O
showed	NN	O	O
that	NN	O	O
severe	NN	O	O
MR	NN	O	B
,	NN	O	O
MP	NN	O	B
(	NN	O	O
EF	NN	O	O
<	NN	O	O
45	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
MZ	NN	O	O
(	NN	O	O
>	NN	O	O
5mg	NN	O	O
)	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
events	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
EF	NN	O	O
was	NN	O	O
40	NN	O	O
%	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
with	NN	O	O
MP	NN	O	B
and	NN	O	O
44	NN	O	O
%	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
with	NN	O	O
severe	NN	O	O
MR	NN	O	B
and	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
a	NN	O	O
factor	NN	O	O
associated	NN	O	O
with	NN	O	O
clinical	NN	O	O
events	NN	O	O
in	NN	O	O
the	NN	O	O
last	NN	O	O
group	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
TEE	NN	O	O
with	NN	O	O
sedation	NN	O	O
presents	NN	O	O
a	NN	O	O
low	NN	O	O
rate	NN	O	O
of	NN	O	O
events	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
severe	NN	O	O
events	NN	O	O
and	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
need	NN	O	O
to	NN	O	O
interrupt	NN	O	O
the	NN	O	O
examinations	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
direct	NN	O	O
intracoronary	NN	O	O
administration	NN	O	O
of	NN	O	O
methylergonovine	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
variant	NN	O	B
angina	NN	O	I
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
intracoronary	NN	O	O
administration	NN	O	O
of	NN	O	O
methylergonovine	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
21	NN	O	O
patients	NN	O	O
with	NN	O	O
variant	NN	O	B
angina	NN	O	I
and	NN	O	O
22	NN	O	O
patients	NN	O	O
with	NN	O	O
atypical	NN	O	O
chest	NN	O	B
pain	NN	O	I
and	NN	O	O
in	NN	O	O
others	NN	O	O
without	NN	O	O
angina	NN	O	B
pectoris	NN	O	I
(	NN	O	O
control	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

Methylergonovine	NN	O	O
was	NN	O	O
administered	NN	O	O
continuously	NN	O	O
at	NN	O	O
a	NN	O	O
rate	NN	O	O
of	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
min	NN	O	O
up	NN	O	O
to	NN	O	O
50	NN	O	O
micrograms	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
patients	NN	O	O
with	NN	O	O
variant	NN	O	B
angina	NN	O	I
,	NN	O	O
coronary	NN	O	B
spasm	NN	O	I
was	NN	O	O
provoked	NN	O	O
at	NN	O	O
a	NN	O	O
mean	NN	O	O
dose	NN	O	O
of	NN	O	O
28	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
micrograms	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
neither	NN	O	O
ischemic	NN	O	O
ST	NN	O	O
change	NN	O	O
nor	NN	O	O
localized	NN	O	O
spasm	NN	O	B
occurred	NN	O	O
.	NN	O	O

The	NN	O	O
basal	NN	O	O
tone	NN	O	O
of	NN	O	O
the	NN	O	O
right	NN	O	O
coronary	NN	O	O
artery	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
left	NN	O	O
coronary	NN	O	O
artery	NN	O	O
.	NN	O	O

The	NN	O	O
percentage	NN	O	O
of	NN	O	O
vasoconstriction	NN	O	O
of	NN	O	O
the	NN	O	O
right	NN	O	O
coronary	NN	O	O
artery	NN	O	O
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
left	NN	O	O
coronary	NN	O	O
artery	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
spasm	NN	O	B
provocation	NN	O	O
tests	NN	O	O
,	NN	O	O
which	NN	O	O
use	NN	O	O
an	NN	O	O
intracoronary	NN	O	O
injection	NN	O	O
of	NN	O	O
a	NN	O	O
relatively	NN	O	O
low	NN	O	O
dose	NN	O	O
of	NN	O	O
methylergonovine	NN	O	O
,	NN	O	O
have	NN	O	O
a	NN	O	O
high	NN	O	O
sensitivity	NN	O	O
in	NN	O	O
variant	NN	O	B
angina	NN	O	I
and	NN	O	O
the	NN	O	O
vasoreactivity	NN	O	O
of	NN	O	O
the	NN	O	O
right	NN	O	O
coronary	NN	O	O
artery	NN	O	O
may	NN	O	O
be	NN	O	O
greater	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
other	NN	O	O
coronary	NN	O	O
arteries	NN	O	O
.	NN	O	O

Oral	NN	O	O
manifestations	NN	O	O
of	NN	O	O
"	NN	O	O
meth	NN	O	B
mouth	NN	O	I
"	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
documentation	NN	O	O
of	NN	O	O
this	NN	O	O
clinical	NN	O	O
case	NN	O	O
is	NN	O	O
to	NN	O	O
make	NN	O	O
clinicians	NN	O	O
aware	NN	O	O
of	NN	O	O
"	NN	O	O
meth	NN	O	B
mouth	NN	O	I
"	NN	O	O
and	NN	O	O
the	NN	O	O
medical	NN	O	O
risks	NN	O	O
associated	NN	O	O
with	NN	O	O
this	NN	O	O
serious	NN	O	O
condition	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Methamphetamine	NN	O	O
is	NN	O	O
a	NN	O	O
very	NN	O	O
addictive	NN	O	O
,	NN	O	O
powerful	NN	O	O
stimulant	NN	O	O
that	NN	O	O
increases	NN	O	O
wakefulness	NN	O	O
and	NN	O	O
physical	NN	O	O
activity	NN	O	O
and	NN	O	O
can	NN	O	O
produce	NN	O	O
other	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
cardiac	NN	O	B
dysrhythmias	NN	O	I
,	NN	O	O
hypertension	NN	O	B
,	NN	O	O
hallucinations	NN	O	B
,	NN	O	O
and	NN	O	O
violent	NN	O	B
behavior	NN	O	I
.	NN	O	O

Dental	NN	O	O
patients	NN	O	O
abusing	NN	O	O
methamphetamine	NN	O	O
can	NN	O	O
present	NN	O	O
with	NN	O	O
poor	NN	O	O
oral	NN	O	O
hygiene	NN	O	O
,	NN	O	O
xerostomia	NN	O	B
,	NN	O	O
rampant	NN	O	O
caries	NN	O	B
(	NN	O	O
"	NN	O	O
meth	NN	O	B
mouth	NN	O	I
"	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
excessive	NN	O	O
tooth	NN	O	B
wear	NN	O	I
.	NN	O	O

Oral	NN	O	O
rehabilitation	NN	O	O
of	NN	O	O
patients	NN	O	O
using	NN	O	O
methamphetamine	NN	O	O
can	NN	O	O
be	NN	O	O
challenging	NN	O	O
.	NN	O	O

CASE	NN	O	O
DESCRIPTION	NN	O	O
:	NN	O	O
A	NN	O	O
30	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Caucasian	NN	O	O
woman	NN	O	O
presented	NN	O	O
with	NN	O	O
dental	NN	O	O
pain	NN	O	B
,	NN	O	O
bad	NN	O	B
breath	NN	O	I
,	NN	O	O
and	NN	O	O
self	NN	O	O
-	NN	O	O
reported	NN	O	O
poor	NN	O	O
esthetics	NN	O	O
.	NN	O	O

A	NN	O	O
comprehensive	NN	O	O
examination	NN	O	O
including	NN	O	O
her	NN	O	O
medical	NN	O	O
history	NN	O	O
,	NN	O	O
panoramic	NN	O	O
radiograph	NN	O	O
,	NN	O	O
and	NN	O	O
intraoral	NN	O	O
examination	NN	O	O
revealed	NN	O	O
19	NN	O	O
carious	NN	O	B
lesions	NN	O	I
,	NN	O	O
which	NN	O	O
is	NN	O	O
not	NN	O	O
very	NN	O	O
common	NN	O	O
for	NN	O	O
a	NN	O	O
healthy	NN	O	O
adult	NN	O	O
.	NN	O	O

She	NN	O	O
reported	NN	O	O
her	NN	O	O
use	NN	O	O
of	NN	O	O
methamphetamine	NN	O	O
for	NN	O	O
five	NN	O	O
years	NN	O	O
and	NN	O	O
had	NN	O	O
not	NN	O	O
experienced	NN	O	O
any	NN	O	O
major	NN	O	O
carious	NN	O	B
episodes	NN	O	I
before	NN	O	O
she	NN	O	O
started	NN	O	O
using	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

SUMMARY	NN	O	O
:	NN	O	O
The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
medical	NN	O	O
and	NN	O	O
dental	NN	O	O
histories	NN	O	O
along	NN	O	O
with	NN	O	O
radiographic	NN	O	O
and	NN	O	O
clinical	NN	O	O
findings	NN	O	O
lead	NN	O	O
to	NN	O	O
a	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
"	NN	O	O
meth	NN	O	B
mouth	NN	O	I
.	NN	O	O
"	NN	O	O
Although	NN	O	O
three	NN	O	O
different	NN	O	O
dental	NN	O	O
treatment	NN	O	O
modalities	NN	O	O
(	NN	O	O
either	NN	O	O
conventional	NN	O	O
or	NN	O	O
implant	NN	O	O
-	NN	O	O
supported	NN	O	O
)	NN	O	O
have	NN	O	O
been	NN	O	O
offered	NN	O	O
to	NN	O	O
the	NN	O	O
patient	NN	O	O
since	NN	O	O
August	NN	O	O
2007	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
has	NN	O	O
yet	NN	O	O
to	NN	O	O
initiate	NN	O	O
any	NN	O	O
treatment	NN	O	O
.	NN	O	O

CLINICAL	NN	O	O
SIGNIFICANCE	NN	O	O
:	NN	O	O
This	NN	O	O
clinical	NN	O	O
case	NN	O	O
showing	NN	O	O
oral	NN	O	O
manifestations	NN	O	O
of	NN	O	O
meth	NN	O	B
mouth	NN	O	I
was	NN	O	O
presented	NN	O	O
to	NN	O	O
help	NN	O	O
dental	NN	O	O
practitioners	NN	O	O
recognize	NN	O	O
and	NN	O	O
manage	NN	O	O
patients	NN	O	O
who	NN	O	O
may	NN	O	O
be	NN	O	O
abusing	NN	O	O
methamphetamines	NN	O	O
.	NN	O	O

Dental	NN	O	O
practitioners	NN	O	O
also	NN	O	O
may	NN	O	O
be	NN	O	O
skeptical	NN	O	O
about	NN	O	O
the	NN	O	O
reliability	NN	O	O
of	NN	O	O
appointment	NN	O	O
keeping	NN	O	O
by	NN	O	O
these	NN	O	O
patients	NN	O	O
,	NN	O	O
as	NN	O	O
they	NN	O	O
frequently	NN	O	O
miss	NN	O	O
their	NN	O	O
appointments	NN	O	O
without	NN	O	O
reasonable	NN	O	O
justification	NN	O	O
.	NN	O	O

Antituberculosis	NN	O	O
therapy	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
:	NN	O	O
magnitude	NN	O	O
,	NN	O	O
profile	NN	O	O
,	NN	O	O
prognosis	NN	O	O
,	NN	O	O
and	NN	O	O
predictors	NN	O	O
of	NN	O	O
outcome	NN	O	O
.	NN	O	O

Antituberculosis	NN	O	O
therapy	NN	O	O
(	NN	O	O
ATT	NN	O	O
)	NN	O	O
-	NN	O	O
associated	NN	O	O
acute	NN	O	B
liver	NN	O	I
failure	NN	O	I
(	NN	O	O
ATT	NN	O	O
-	NN	O	O
ALF	NN	O	B
)	NN	O	O
is	NN	O	O
the	NN	O	O
commonest	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
in	NN	O	O
South	NN	O	O
Asia	NN	O	O
.	NN	O	O

Prospective	NN	O	O
studies	NN	O	O
on	NN	O	O
ATT	NN	O	O
-	NN	O	O
ALF	NN	O	B
are	NN	O	O
lacking	NN	O	O
.	NN	O	O

The	NN	O	O
current	NN	O	O
study	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
the	NN	O	O
magnitude	NN	O	O
,	NN	O	O
clinical	NN	O	O
course	NN	O	O
,	NN	O	O
outcome	NN	O	O
,	NN	O	O
and	NN	O	O
prognostic	NN	O	O
factors	NN	O	O
in	NN	O	O
ATT	NN	O	O
-	NN	O	O
ALF	NN	O	B
.	NN	O	O

From	NN	O	O
January	NN	O	O
1986	NN	O	O
to	NN	O	O
January	NN	O	O
2009	NN	O	O
,	NN	O	O
1223	NN	O	O
consecutive	NN	O	O
ALF	NN	O	B
patients	NN	O	O
were	NN	O	O
evaluated	NN	O	O
:	NN	O	O
ATT	NN	O	O
alone	NN	O	O
was	NN	O	O
the	NN	O	O
cause	NN	O	O
in	NN	O	O
70	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
.	NN	O	O

Another	NN	O	O
15	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
had	NN	O	O
ATT	NN	O	O
and	NN	O	O
simultaneous	NN	O	O
hepatitis	NN	O	B
virus	NN	O	I
infection	NN	O	I
.	NN	O	O

In	NN	O	O
44	NN	O	O
(	NN	O	O
62	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
,	NN	O	O
ATT	NN	O	O
was	NN	O	O
prescribed	NN	O	O
empirically	NN	O	O
without	NN	O	O
definitive	NN	O	O
evidence	NN	O	O
of	NN	O	O
tuberculosis	NN	O	B
.	NN	O	O

ATT	NN	O	O
-	NN	O	O
ALF	NN	O	B
patients	NN	O	O
were	NN	O	O
younger	NN	O	O
(	NN	O	O
32	NN	O	O
.	NN	O	O
87	NN	O	O
[	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
15	NN	O	O
.	NN	O	O
8	NN	O	O
]	NN	O	O
years	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
49	NN	O	O
(	NN	O	O
70	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
them	NN	O	O
were	NN	O	O
women	NN	O	O
.	NN	O	O

Most	NN	O	O
had	NN	O	O
hyperacute	NN	O	O
presentation	NN	O	O
;	NN	O	O
the	NN	O	O
median	NN	O	O
icterus	NN	O	B
encephalopathy	NN	O	B
interval	NN	O	O
was	NN	O	O
4	NN	O	O
.	NN	O	O
5	NN	O	O
(	NN	O	O
0	NN	O	O
-	NN	O	O
30	NN	O	O
)	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
duration	NN	O	O
of	NN	O	O
ATT	NN	O	O
before	NN	O	O
ALF	NN	O	B
was	NN	O	O
30	NN	O	O
(	NN	O	O
7	NN	O	O
-	NN	O	O
350	NN	O	O
)	NN	O	O
days	NN	O	O
.	NN	O	O

At	NN	O	O
presentation	NN	O	O
,	NN	O	O
advanced	NN	O	O
encephalopathy	NN	O	B
and	NN	O	O
cerebral	NN	O	B
edema	NN	O	I
were	NN	O	O
present	NN	O	O
in	NN	O	O
51	NN	O	O
(	NN	O	O
76	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
29	NN	O	O
(	NN	O	O
41	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Gastrointestinal	NN	O	B
bleed	NN	O	I
,	NN	O	O
seizures	NN	O	B
,	NN	O	O
infection	NN	O	B
,	NN	O	O
and	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
were	NN	O	O
documented	NN	O	O
in	NN	O	O
seven	NN	O	O
(	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
five	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
26	NN	O	O
(	NN	O	O
37	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
seven	NN	O	O
(	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
hepatitis	NN	O	B
E	NN	O	I
virus	NN	O	O
(	NN	O	O
HEV	NN	O	O
)	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
A	NN	O	O
non	NN	O	O
-	NN	O	O
E	NN	O	O
-	NN	O	O
induced	NN	O	O
ALF	NN	O	B
,	NN	O	O
ATT	NN	O	O
-	NN	O	O
ALF	NN	O	B
patients	NN	O	O
had	NN	O	O
nearly	NN	O	O
similar	NN	O	O
presentations	NN	O	O
except	NN	O	O
for	NN	O	O
older	NN	O	O
age	NN	O	O
and	NN	O	O
less	NN	O	O
elevation	NN	O	O
of	NN	O	O
liver	NN	O	O
enzymes	NN	O	O
.	NN	O	O

The	NN	O	O
mortality	NN	O	O
rate	NN	O	O
among	NN	O	O
patients	NN	O	O
with	NN	O	O
ATT	NN	O	O
-	NN	O	O
ALF	NN	O	B
was	NN	O	O
high	NN	O	O
(	NN	O	O
67	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
47	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
only	NN	O	O
23	NN	O	O
(	NN	O	O
32	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
recovered	NN	O	O
with	NN	O	O
medical	NN	O	O
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
multivariate	NN	O	O
analysis	NN	O	O
,	NN	O	O
three	NN	O	O
factors	NN	O	O
independently	NN	O	O
predicted	NN	O	O
mortality	NN	O	O
:	NN	O	O
serum	NN	O	O
bilirubin	NN	O	O
(	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
10	NN	O	O
.	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
,	NN	O	O
prothrombin	NN	O	O
time	NN	O	O
(	NN	O	O
PT	NN	O	O
)	NN	O	O
prolongation	NN	O	O
(	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
26	NN	O	O
seconds	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
grade	NN	O	O
III	NN	O	O
/	NN	O	O
IV	NN	O	O
encephalopathy	NN	O	B
at	NN	O	O
presentation	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
ATT	NN	O	O
-	NN	O	O
ALF	NN	O	B
constituted	NN	O	O
5	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
of	NN	O	O
ALF	NN	O	B
at	NN	O	O
our	NN	O	O
center	NN	O	O
and	NN	O	O
had	NN	O	O
a	NN	O	O
high	NN	O	O
mortality	NN	O	O
rate	NN	O	O
.	NN	O	O

Because	NN	O	O
the	NN	O	O
mortality	NN	O	O
rate	NN	O	O
is	NN	O	O
so	NN	O	O
high	NN	O	O
,	NN	O	O
determining	NN	O	O
which	NN	O	O
factors	NN	O	O
are	NN	O	O
predictors	NN	O	O
is	NN	O	O
less	NN	O	O
important	NN	O	O
.	NN	O	O

A	NN	O	O
high	NN	O	O
proportion	NN	O	O
of	NN	O	O
patients	NN	O	O
had	NN	O	O
consumed	NN	O	O
ATT	NN	O	O
empirically	NN	O	O
,	NN	O	O
which	NN	O	O
could	NN	O	O
have	NN	O	O
been	NN	O	O
prevented	NN	O	O
.	NN	O	O

Design	NN	O	O
and	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
HYPREN	NN	O	O
-	NN	O	O
trial	NN	O	O
:	NN	O	O
safety	NN	O	O
of	NN	O	O
enalapril	NN	O	O
and	NN	O	O
prazosin	NN	O	O
in	NN	O	O
the	NN	O	O
initial	NN	O	O
treatment	NN	O	O
phase	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
.	NN	O	O

Since	NN	O	O
the	NN	O	O
introduction	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
inhibitors	NN	O	O
into	NN	O	O
the	NN	O	O
adjunctive	NN	O	O
treatment	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
,	NN	O	O
cases	NN	O	O
of	NN	O	O
severe	NN	O	O
hypotension	NN	O	B
,	NN	O	O
especially	NN	O	O
on	NN	O	O
the	NN	O	O
first	NN	O	O
day	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
have	NN	O	O
occasionally	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

To	NN	O	O
assess	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
the	NN	O	O
ACE	NN	O	O
inhibitor	NN	O	O
enalapril	NN	O	O
a	NN	O	O
multicenter	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
prazosin	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
was	NN	O	O
designed	NN	O	O
that	NN	O	O
compared	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
symptomatic	NN	O	O
hypotension	NN	O	B
on	NN	O	O
the	NN	O	O
first	NN	O	O
day	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Trial	NN	O	O
medication	NN	O	O
was	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
enalapril	NN	O	O
or	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
prazosin	NN	O	O
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
1210	NN	O	O
inpatients	NN	O	O
with	NN	O	O
New	NN	O	O
York	NN	O	O
Heart	NN	O	O
Association	NN	O	O
(	NN	O	O
NYHA	NN	O	O
)	NN	O	O
functional	NN	O	O
class	NN	O	O
II	NN	O	O
and	NN	O	O
III	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
received	NN	O	O
enalapril	NN	O	O
experienced	NN	O	O
clinically	NN	O	O
and	NN	O	O
statistically	NN	O	O
significantly	NN	O	O
less	NN	O	O
symptomatic	NN	O	O
hypotension	NN	O	B
(	NN	O	O
5	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
than	NN	O	O
the	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
prazosin	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
recovered	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
concluded	NN	O	O
that	NN	O	O
treatment	NN	O	O
with	NN	O	O
enalapril	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
and	NN	O	O
it	NN	O	O
is	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
unreasonable	NN	O	O
to	NN	O	O
restrict	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
enalapril	NN	O	O
to	NN	O	O
inpatients	NN	O	O
.	NN	O	O

Central	NN	O	B
nervous	NN	O	I
system	NN	O	I
complications	NN	O	I
during	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
in	NN	O	O
a	NN	O	O
single	NN	O	O
pediatric	NN	O	O
institution	NN	O	O
.	NN	O	O

Central	NN	O	B
nervous	NN	O	I
system	NN	O	I
(	NN	O	I
CNS	NN	O	I
)	NN	O	I
complications	NN	O	I
during	NN	O	O
treatment	NN	O	O
of	NN	O	O
childhood	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
(	NN	O	O
ALL	NN	O	B
)	NN	O	O
remain	NN	O	O
a	NN	O	O
challenging	NN	O	O
clinical	NN	O	O
problem	NN	O	O
.	NN	O	O

Outcome	NN	O	O
improvement	NN	O	O
with	NN	O	O
more	NN	O	O
intensive	NN	O	O
chemotherapy	NN	O	O
has	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
analyzed	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
neurological	NN	O	B
complications	NN	O	I
during	NN	O	O
ALL	NN	O	B
treatment	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
pediatric	NN	O	O
institution	NN	O	O
,	NN	O	O
focusing	NN	O	O
on	NN	O	O
clinical	NN	O	O
,	NN	O	O
radiological	NN	O	O
,	NN	O	O
and	NN	O	O
electrophysiological	NN	O	O
findings	NN	O	O
.	NN	O	O

Exclusion	NN	O	O
criteria	NN	O	O
included	NN	O	O
CNS	NN	O	O
leukemic	NN	O	B
infiltration	NN	O	I
at	NN	O	O
diagnosis	NN	O	O
,	NN	O	O
therapy	NN	O	O
-	NN	O	O
related	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
,	NN	O	O
late	NN	O	O
-	NN	O	O
onset	NN	O	O
encephalopathy	NN	O	B
,	NN	O	O
or	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
neurocognitive	NN	O	B
defects	NN	O	I
.	NN	O	O

During	NN	O	O
a	NN	O	O
9	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
,	NN	O	O
we	NN	O	O
retrospectively	NN	O	O
collected	NN	O	O
27	NN	O	O
neurological	NN	O	O
events	NN	O	O
(	NN	O	O
11	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
as	NN	O	O
many	NN	O	O
patients	NN	O	O
,	NN	O	O
from	NN	O	O
253	NN	O	O
children	NN	O	O
enrolled	NN	O	O
in	NN	O	O
the	NN	O	O
ALL	NN	O	B
front	NN	O	O
-	NN	O	O
line	NN	O	O
protocol	NN	O	O
.	NN	O	O

CNS	NN	O	O
complications	NN	O	O
included	NN	O	O
posterior	NN	O	O
reversible	NN	O	O
leukoencephalopathy	NN	O	B
syndrome	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
,	NN	O	O
stroke	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
5	NN	O	O
)	NN	O	O
,	NN	O	O
temporal	NN	O	B
lobe	NN	O	I
epilepsy	NN	O	I
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
methotrexate	NN	O	O
toxicity	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
syndrome	NN	O	O
of	NN	O	O
inappropriate	NN	O	B
antidiuretic	NN	O	I
hormone	NN	O	I
secretion	NN	O	I
(	NN	O	O
n	NN	O	O
=	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
other	NN	O	O
unclassified	NN	O	O
events	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
CNS	NN	O	O
complications	NN	O	O
are	NN	O	O
frequent	NN	O	O
events	NN	O	O
during	NN	O	O
ALL	NN	O	B
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
require	NN	O	O
rapid	NN	O	O
detection	NN	O	O
and	NN	O	O
prompt	NN	O	O
treatment	NN	O	O
to	NN	O	O
limit	NN	O	O
permanent	NN	O	O
damage	NN	O	O
.	NN	O	O

Cocaine	NN	O	O
causes	NN	O	O
memory	NN	O	B
and	NN	O	I
learning	NN	O	I
impairments	NN	O	I
in	NN	O	O
rats	NN	O	O
:	NN	O	O
involvement	NN	O	O
of	NN	O	O
nuclear	NN	O	O
factor	NN	O	O
kappa	NN	O	O
B	NN	O	O
and	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
,	NN	O	O
and	NN	O	O
prevention	NN	O	O
by	NN	O	O
topiramate	NN	O	O
.	NN	O	O

Different	NN	O	O
mechanisms	NN	O	O
have	NN	O	O
been	NN	O	O
suggested	NN	O	O
for	NN	O	O
cocaine	NN	O	O
toxicity	NN	O	B
including	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
but	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
oxidative	NN	O	O
status	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
and	NN	O	O
cocaine	NN	O	O
induced	NN	O	O
-	NN	O	O
behaviour	NN	O	O
is	NN	O	O
poorly	NN	O	O
understood	NN	O	O
.	NN	O	O

Nuclear	NN	O	O
factor	NN	O	O
kappa	NN	O	O
B	NN	O	O
(	NN	O	O
NFkappaB	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
sensor	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
participates	NN	O	O
in	NN	O	O
memory	NN	O	O
formation	NN	O	O
that	NN	O	O
could	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
drug	NN	O	O
toxicity	NN	O	B
and	NN	O	O
addiction	NN	O	O
mechanisms	NN	O	O
.	NN	O	O

Therefore	NN	O	O
NFkappaB	NN	O	O
activity	NN	O	O
,	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
,	NN	O	O
neuronal	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
synthase	NN	O	O
(	NN	O	O
nNOS	NN	O	O
)	NN	O	O
activity	NN	O	O
,	NN	O	O
spatial	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
topiramate	NN	O	O
,	NN	O	O
a	NN	O	O
previously	NN	O	O
proposed	NN	O	O
therapy	NN	O	O
for	NN	O	O
cocaine	NN	O	B
addiction	NN	O	I
,	NN	O	O
were	NN	O	O
evaluated	NN	O	O
in	NN	O	O
an	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
cocaine	NN	O	O
administration	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

NFkappaB	NN	O	O
activity	NN	O	O
was	NN	O	O
decreased	NN	O	O
in	NN	O	O
the	NN	O	O
frontal	NN	O	O
cortex	NN	O	O
of	NN	O	O
cocaine	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
GSH	NN	O	O
concentration	NN	O	O
and	NN	O	O
glutathione	NN	O	O
peroxidase	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
,	NN	O	O
whereas	NN	O	O
nNOS	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
was	NN	O	O
increased	NN	O	O
.	NN	O	O

Memory	NN	O	O
retrieval	NN	O	O
of	NN	O	O
experiences	NN	O	O
acquired	NN	O	O
prior	NN	O	O
to	NN	O	O
cocaine	NN	O	O
administration	NN	O	O
was	NN	O	O
impaired	NN	O	O
and	NN	O	O
negatively	NN	O	O
correlated	NN	O	O
with	NN	O	O
NFkappaB	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
frontal	NN	O	O
cortex	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
learning	NN	O	O
of	NN	O	O
new	NN	O	O
tasks	NN	O	O
was	NN	O	O
enhanced	NN	O	O
and	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
increase	NN	O	O
of	NN	O	O
nNOS	NN	O	O
activity	NN	O	O
and	NN	O	O
the	NN	O	O
decrease	NN	O	O
of	NN	O	O
glutathione	NN	O	O
peroxidase	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
provide	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
possible	NN	O	O
mechanistic	NN	O	O
role	NN	O	O
of	NN	O	O
oxidative	NN	O	O
and	NN	O	O
nitrosative	NN	O	O
stress	NN	O	O
and	NN	O	O
NFkappaB	NN	O	O
in	NN	O	O
the	NN	O	O
alterations	NN	O	O
induced	NN	O	O
by	NN	O	O
cocaine	NN	O	O
.	NN	O	O

Topiramate	NN	O	O
prevented	NN	O	O
all	NN	O	O
the	NN	O	O
alterations	NN	O	O
observed	NN	O	O
,	NN	O	O
showing	NN	O	O
novel	NN	O	O
neuroprotective	NN	O	O
properties	NN	O	O
.	NN	O	O

Efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
asenapine	NN	O	O
in	NN	O	O
a	NN	O	O
placebo	NN	O	O
-	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	O
exacerbation	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B
.	NN	O	O

Asenapine	NN	O	O
is	NN	O	O
approved	NN	O	O
by	NN	O	O
the	NN	O	O
Food	NN	O	O
and	NN	O	O
Drugs	NN	O	O
Administration	NN	O	O
in	NN	O	O
adults	NN	O	O
for	NN	O	O
acute	NN	O	O
treatment	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B
or	NN	O	O
of	NN	O	O
manic	NN	O	B
or	NN	O	O
mixed	NN	O	O
episodes	NN	O	O
associated	NN	O	O
with	NN	O	O
bipolar	NN	O	B
I	NN	O	I
disorder	NN	O	I
with	NN	O	O
or	NN	O	O
without	NN	O	O
psychotic	NN	O	B
features	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
6	NN	O	O
-	NN	O	O
week	NN	O	O
trial	NN	O	O
,	NN	O	O
458	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	O
schizophrenia	NN	O	B
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
fixed	NN	O	O
-	NN	O	O
dose	NN	O	O
treatment	NN	O	O
with	NN	O	O
asenapine	NN	O	O
at	NN	O	O
5	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
(	NN	O	O
BID	NN	O	O
)	NN	O	O
,	NN	O	O
asenapine	NN	O	O
at	NN	O	O
10	NN	O	O
mg	NN	O	O
BID	NN	O	O
,	NN	O	O
placebo	NN	O	O
,	NN	O	O
or	NN	O	O
haloperidol	NN	O	O
at	NN	O	O
4	NN	O	O
mg	NN	O	O
BID	NN	O	O
(	NN	O	O
to	NN	O	O
verify	NN	O	O
assay	NN	O	O
sensitivity	NN	O	O
)	NN	O	O
.	NN	O	O

With	NN	O	O
last	NN	O	O
observations	NN	O	O
carried	NN	O	O
forward	NN	O	O
(	NN	O	O
LOCF	NN	O	O
)	NN	O	O
,	NN	O	O
mean	NN	O	O
Positive	NN	O	O
and	NN	O	O
Negative	NN	O	O
Syndrome	NN	O	O
Scale	NN	O	O
total	NN	O	O
score	NN	O	O
reductions	NN	O	O
from	NN	O	O
baseline	NN	O	O
to	NN	O	O
endpoint	NN	O	O
were	NN	O	O
significantly	NN	O	O
greater	NN	O	O
with	NN	O	O
asenapine	NN	O	O
at	NN	O	O
5	NN	O	O
mg	NN	O	O
BID	NN	O	O
(	NN	O	O
-	NN	O	O
16	NN	O	O
.	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
(	NN	O	O
-	NN	O	O
15	NN	O	O
.	NN	O	O
4	NN	O	O
)	NN	O	O
than	NN	O	O
placebo	NN	O	O
(	NN	O	O
-	NN	O	O
10	NN	O	O
.	NN	O	O
7	NN	O	O
;	NN	O	O
both	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
;	NN	O	O
using	NN	O	O
mixed	NN	O	O
model	NN	O	O
for	NN	O	O
repeated	NN	O	O
measures	NN	O	O
(	NN	O	O
MMRM	NN	O	O
)	NN	O	O
,	NN	O	O
changes	NN	O	O
at	NN	O	O
day	NN	O	O
42	NN	O	O
were	NN	O	O
significantly	NN	O	O
greater	NN	O	O
with	NN	O	O
asenapine	NN	O	O
at	NN	O	O
5	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
BID	NN	O	O
(	NN	O	O
-	NN	O	O
21	NN	O	O
.	NN	O	O
3	NN	O	O
and	NN	O	O
-	NN	O	O
19	NN	O	O
.	NN	O	O
4	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
(	NN	O	O
-	NN	O	O
20	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
than	NN	O	O
placebo	NN	O	O
(	NN	O	O
-	NN	O	O
14	NN	O	O
.	NN	O	O
6	NN	O	O
;	NN	O	O
all	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
Positive	NN	O	O
and	NN	O	O
Negative	NN	O	O
Syndrome	NN	O	O
Scale	NN	O	O
positive	NN	O	O
subscale	NN	O	O
,	NN	O	O
all	NN	O	O
treatments	NN	O	O
were	NN	O	O
superior	NN	O	O
to	NN	O	O
placebo	NN	O	O
with	NN	O	O
LOCF	NN	O	O
and	NN	O	O
MMRM	NN	O	O
;	NN	O	O
asenapine	NN	O	O
at	NN	O	O
5	NN	O	O
mg	NN	O	O
BID	NN	O	O
was	NN	O	O
superior	NN	O	O
to	NN	O	O
placebo	NN	O	O
on	NN	O	O
the	NN	O	O
negative	NN	O	O
subscale	NN	O	O
with	NN	O	O
MMRM	NN	O	O
and	NN	O	O
on	NN	O	O
the	NN	O	O
general	NN	O	O
psychopathology	NN	O	O
subscale	NN	O	O
with	NN	O	O
LOCF	NN	O	O
and	NN	O	O
MMRM	NN	O	O
.	NN	O	O

Treatment	NN	O	O
-	NN	O	O
related	NN	O	O
adverse	NN	O	O
events	NN	O	O
(	NN	O	O
AEs	NN	O	O
)	NN	O	O
occurred	NN	O	O
in	NN	O	O
44	NN	O	O
%	NN	O	O
and	NN	O	O
52	NN	O	O
%	NN	O	O
,	NN	O	O
57	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
41	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
asenapine	NN	O	O
at	NN	O	O
5	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
BID	NN	O	O
,	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
and	NN	O	O
placebo	NN	O	O
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Extrapyramidal	NN	O	B
symptoms	NN	O	I
reported	NN	O	O
as	NN	O	O
AEs	NN	O	O
occurred	NN	O	O
in	NN	O	O
15	NN	O	O
%	NN	O	O
and	NN	O	O
18	NN	O	O
%	NN	O	O
,	NN	O	O
34	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
asenapine	NN	O	O
at	NN	O	O
5	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
BID	NN	O	O
,	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
and	NN	O	O
placebo	NN	O	O
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Across	NN	O	O
all	NN	O	O
groups	NN	O	O
,	NN	O	O
no	NN	O	O
more	NN	O	O
than	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
had	NN	O	O
clinically	NN	O	O
significant	NN	O	O
weight	NN	O	O
change	NN	O	O
.	NN	O	O

Post	NN	O	O
hoc	NN	O	O
analyses	NN	O	O
indicated	NN	O	O
that	NN	O	O
efficacy	NN	O	O
was	NN	O	O
similar	NN	O	O
with	NN	O	O
asenapine	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
;	NN	O	O
greater	NN	O	O
contrasts	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
AEs	NN	O	O
,	NN	O	O
especially	NN	O	O
extrapyramidal	NN	O	B
symptoms	NN	O	I
.	NN	O	O

Salvage	NN	O	O
therapy	NN	O	O
with	NN	O	O
nelarabine	NN	O	O
,	NN	O	O
etoposide	NN	O	O
,	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
in	NN	O	O
relapsed	NN	O	O
/	NN	O	O
refractory	NN	O	O
paediatric	NN	O	O
T	NN	O	B
-	NN	O	I
cell	NN	O	I
lymphoblastic	NN	O	I
leukaemia	NN	O	I
and	NN	O	I
lymphoma	NN	O	I
.	NN	O	O

A	NN	O	O
combination	NN	O	O
of	NN	O	O
5	NN	O	O
d	NN	O	O
of	NN	O	O
nelarabine	NN	O	O
(	NN	O	O
AraG	NN	O	O
)	NN	O	O
with	NN	O	O
5	NN	O	O
d	NN	O	O
of	NN	O	O
etoposide	NN	O	O
(	NN	O	O
VP	NN	O	O
)	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
CPM	NN	O	O
)	NN	O	O
and	NN	O	O
prophylactic	NN	O	O
intrathecal	NN	O	O
chemotherapy	NN	O	O
was	NN	O	O
used	NN	O	O
as	NN	O	O
salvage	NN	O	O
therapy	NN	O	O
in	NN	O	O
seven	NN	O	O
children	NN	O	O
with	NN	O	O
refractory	NN	O	O
or	NN	O	O
relapsed	NN	O	O
T	NN	O	B
-	NN	O	I
cell	NN	O	I
leukaemia	NN	O	I
or	NN	O	I
lymphoma	NN	O	I
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
side	NN	O	O
effects	NN	O	O
attributable	NN	O	O
to	NN	O	O
the	NN	O	O
AraG	NN	O	O
included	NN	O	O
Grade	NN	O	O
2	NN	O	O
and	NN	O	O
3	NN	O	O
sensory	NN	O	O
and	NN	O	O
motor	NN	O	O
neuropathy	NN	O	B
and	NN	O	O
musculoskeletal	NN	O	B
pain	NN	O	I
.	NN	O	O

Haematological	NN	O	B
toxicity	NN	O	I
was	NN	O	O
greater	NN	O	O
for	NN	O	O
the	NN	O	O
combination	NN	O	O
than	NN	O	O
AraG	NN	O	O
alone	NN	O	O
,	NN	O	O
although	NN	O	O
median	NN	O	O
time	NN	O	O
to	NN	O	O
neutrophil	NN	O	O
and	NN	O	O
platelet	NN	O	O
recovery	NN	O	O
was	NN	O	O
consistent	NN	O	O
with	NN	O	O
other	NN	O	O
salvage	NN	O	O
therapies	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
had	NN	O	O
some	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
combined	NN	O	O
therapy	NN	O	O
and	NN	O	O
five	NN	O	O
of	NN	O	O
the	NN	O	O
seven	NN	O	O
went	NN	O	O
into	NN	O	O
complete	NN	O	O
remission	NN	O	O
after	NN	O	O
one	NN	O	O
or	NN	O	O
two	NN	O	O
courses	NN	O	O
of	NN	O	O
AraG	NN	O	O
/	NN	O	O
VP	NN	O	O
/	NN	O	O
CPM	NN	O	O
.	NN	O	O

Our	NN	O	O
experience	NN	O	O
supports	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
giving	NN	O	O
AraG	NN	O	O
as	NN	O	O
salvage	NN	O	O
therapy	NN	O	O
in	NN	O	O
synchrony	NN	O	O
with	NN	O	O
etoposide	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
,	NN	O	O
although	NN	O	O
neurological	NN	O	B
toxicity	NN	O	I
must	NN	O	O
be	NN	O	O
closely	NN	O	O
monitored	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
adriamycin	NN	O	O
combined	NN	O	O
with	NN	O	O
whole	NN	O	O
body	NN	O	O
hyperthermia	NN	O	B
on	NN	O	O
tumor	NN	O	B
and	NN	O	O
normal	NN	O	O
tissues	NN	O	O
.	NN	O	O

Thermal	NN	O	O
enhancement	NN	O	O
of	NN	O	O
Adriamycin	NN	O	O
-	NN	O	O
mediated	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
and	NN	O	O
normal	NN	O	O
tissue	NN	O	O
toxicities	NN	O	B
by	NN	O	O
whole	NN	O	O
body	NN	O	O
hyperthermia	NN	O	B
were	NN	O	O
compared	NN	O	O
using	NN	O	O
a	NN	O	O
F344	NN	O	O
rat	NN	O	O
model	NN	O	O
.	NN	O	O

Antitumor	NN	O	O
activity	NN	O	O
was	NN	O	O
studied	NN	O	O
using	NN	O	O
a	NN	O	O
tumor	NN	O	B
growth	NN	O	O
delay	NN	O	O
assay	NN	O	O
.	NN	O	O

Acute	NN	O	O
normal	NN	O	O
tissue	NN	O	O
toxicities	NN	O	B
(	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
,	NN	O	O
leukopenia	NN	O	B
and	NN	O	O
thrombocytopenia	NN	O	B
)	NN	O	O
and	NN	O	O
late	NN	O	O
normal	NN	O	O
tissue	NN	O	O
toxicities	NN	O	B
(	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
,	NN	O	O
myocardial	NN	O	B
and	NN	O	I
kidney	NN	O	I
injury	NN	O	I
)	NN	O	O
were	NN	O	O
evaluated	NN	O	O
by	NN	O	O
functional	NN	O	O
/	NN	O	O
physiological	NN	O	O
assays	NN	O	O
and	NN	O	O
by	NN	O	O
morphological	NN	O	O
techniques	NN	O	O
.	NN	O	O

Whole	NN	O	O
body	NN	O	O
hyperthermia	NN	O	B
(	NN	O	O
120	NN	O	O
min	NN	O	O
at	NN	O	O
41	NN	O	O
.	NN	O	O
5	NN	O	O
degrees	NN	O	O
C	NN	O	O
)	NN	O	O
enhanced	NN	O	O
both	NN	O	O
Adriamycin	NN	O	O
-	NN	O	O
mediated	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
and	NN	O	O
toxic	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
thermal	NN	O	O
enhancement	NN	O	O
ratio	NN	O	O
calculated	NN	O	O
for	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
was	NN	O	O
1	NN	O	O
.	NN	O	O
6	NN	O	O
.	NN	O	O

Thermal	NN	O	O
enhancement	NN	O	O
ratios	NN	O	O
estimated	NN	O	O
for	NN	O	O
"	NN	O	O
acute	NN	O	O
"	NN	O	O
hematological	NN	O	O
changes	NN	O	O
were	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
whereas	NN	O	O
those	NN	O	O
estimated	NN	O	O
for	NN	O	O
"	NN	O	O
late	NN	O	O
"	NN	O	O
damage	NN	O	O
(	NN	O	O
based	NN	O	O
on	NN	O	O
morphological	NN	O	O
cardiac	NN	O	B
and	NN	O	I
renal	NN	O	I
lesions	NN	O	I
)	NN	O	O
varied	NN	O	O
between	NN	O	O
2	NN	O	O
.	NN	O	O
4	NN	O	O
and	NN	O	O
4	NN	O	O
.	NN	O	O
3	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
while	NN	O	O
whole	NN	O	O
body	NN	O	O
hyperthermia	NN	O	B
enhances	NN	O	O
Adriamycin	NN	O	O
-	NN	O	O
mediated	NN	O	O
antitumor	NN	O	O
effect	NN	O	O
,	NN	O	O
normal	NN	O	O
tissue	NN	O	O
toxicity	NN	O	B
is	NN	O	O
also	NN	O	O
increased	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
potential	NN	O	O
therapeutic	NN	O	O
gain	NN	O	O
of	NN	O	O
the	NN	O	O
combined	NN	O	O
modality	NN	O	O
treatment	NN	O	O
is	NN	O	O
eroded	NN	O	O
.	NN	O	O

Permeability	NN	O	O
,	NN	O	O
ultrastructural	NN	O	O
changes	NN	O	O
,	NN	O	O
and	NN	O	O
distribution	NN	O	O
of	NN	O	O
novel	NN	O	O
proteins	NN	O	O
in	NN	O	O
the	NN	O	O
glomerular	NN	O	O
barrier	NN	O	O
in	NN	O	O
early	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
nephrosis	NN	O	B
.	NN	O	O

BACKGROUND	NN	O	O
/	NN	O	O
AIMS	NN	O	O
:	NN	O	O
It	NN	O	O
is	NN	O	O
still	NN	O	O
unclear	NN	O	O
what	NN	O	O
happens	NN	O	O
in	NN	O	O
the	NN	O	O
glomerulus	NN	O	O
when	NN	O	O
proteinuria	NN	O	B
starts	NN	O	O
.	NN	O	O

Using	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
nephrosis	NN	O	B
(	NN	O	O
PAN	NN	O	O
)	NN	O	O
rats	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
early	NN	O	O
ultrastructural	NN	O	O
and	NN	O	O
permeability	NN	O	O
changes	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
podocyte	NN	O	O
-	NN	O	O
associated	NN	O	O
molecules	NN	O	O
nephrin	NN	O	O
,	NN	O	O
a	NN	O	O
-	NN	O	O
actinin	NN	O	O
,	NN	O	O
dendrin	NN	O	O
,	NN	O	O
and	NN	O	O
plekhh2	NN	O	O
,	NN	O	O
the	NN	O	O
last	NN	O	O
two	NN	O	O
of	NN	O	O
which	NN	O	O
were	NN	O	O
only	NN	O	O
recently	NN	O	O
discovered	NN	O	O
in	NN	O	O
podocytes	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Using	NN	O	O
immune	NN	O	O
stainings	NN	O	O
,	NN	O	O
semiquantitative	NN	O	O
measurement	NN	O	O
was	NN	O	O
performed	NN	O	O
under	NN	O	O
the	NN	O	O
electron	NN	O	O
microscope	NN	O	O
.	NN	O	O

Permeability	NN	O	O
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
isolated	NN	O	O
kidney	NN	O	O
perfusion	NN	O	O
with	NN	O	O
tracers	NN	O	O
.	NN	O	O

Possible	NN	O	O
effects	NN	O	O
of	NN	O	O
ACE	NN	O	O
inhibition	NN	O	O
were	NN	O	O
tested	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
By	NN	O	O
day	NN	O	O
2	NN	O	O
,	NN	O	O
some	NN	O	O
patchy	NN	O	O
foot	NN	O	O
process	NN	O	O
effacement	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
proteinuria	NN	O	B
,	NN	O	O
appeared	NN	O	O
.	NN	O	O

The	NN	O	O
amount	NN	O	O
of	NN	O	O
nephrin	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
both	NN	O	O
diseased	NN	O	O
and	NN	O	O
normal	NN	O	O
areas	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
proteins	NN	O	O
showed	NN	O	O
few	NN	O	O
changes	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
limited	NN	O	O
to	NN	O	O
diseased	NN	O	O
areas	NN	O	O
.	NN	O	O

By	NN	O	O
day	NN	O	O
4	NN	O	O
,	NN	O	O
foot	NN	O	O
process	NN	O	O
effacement	NN	O	O
was	NN	O	O
complete	NN	O	O
and	NN	O	O
proteinuria	NN	O	B
appeared	NN	O	O
in	NN	O	O
parallel	NN	O	O
with	NN	O	O
signs	NN	O	O
of	NN	O	O
size	NN	O	O
barrier	NN	O	O
damage	NN	O	O
.	NN	O	O

Nephrin	NN	O	O
decreased	NN	O	O
further	NN	O	O
,	NN	O	O
while	NN	O	O
dendrin	NN	O	O
and	NN	O	O
plekhh2	NN	O	O
also	NN	O	O
decreased	NN	O	O
but	NN	O	O
a	NN	O	O
-	NN	O	O
actinin	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
.	NN	O	O

ACE	NN	O	O
inhibition	NN	O	O
had	NN	O	O
no	NN	O	O
significant	NN	O	O
protective	NN	O	O
effect	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
PAN	NN	O	O
glomeruli	NN	O	O
already	NN	O	O
showed	NN	O	O
significant	NN	O	O
pathology	NN	O	O
by	NN	O	O
day	NN	O	O
4	NN	O	O
,	NN	O	O
despite	NN	O	O
relatively	NN	O	O
mild	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

This	NN	O	O
was	NN	O	O
preceded	NN	O	O
by	NN	O	O
altered	NN	O	O
nephrin	NN	O	O
expression	NN	O	O
,	NN	O	O
supporting	NN	O	O
its	NN	O	O
pivotal	NN	O	O
role	NN	O	O
in	NN	O	O
podocyte	NN	O	O
morphology	NN	O	O
.	NN	O	O

The	NN	O	O
novel	NN	O	O
proteins	NN	O	O
dendrin	NN	O	O
and	NN	O	O
plekhh2	NN	O	O
were	NN	O	O
both	NN	O	O
reduced	NN	O	O
,	NN	O	O
suggesting	NN	O	O
roles	NN	O	O
in	NN	O	O
PAN	NN	O	O
,	NN	O	O
whereas	NN	O	O
a	NN	O	O
-	NN	O	O
actinin	NN	O	O
was	NN	O	O
unchanged	NN	O	O
.	NN	O	O

A	NN	O	O
novel	NN	O	O
,	NN	O	O
multiple	NN	O	O
symptom	NN	O	O
model	NN	O	O
of	NN	O	O
obsessive	NN	O	B
-	NN	O	I
compulsive	NN	O	I
-	NN	O	I
like	NN	O	I
behaviors	NN	O	I
in	NN	O	O
animals	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Current	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
obsessive	NN	O	B
-	NN	O	I
compulsive	NN	O	I
disorder	NN	O	I
(	NN	O	O
OCD	NN	O	B
)	NN	O	O
typically	NN	O	O
involve	NN	O	O
acute	NN	O	O
,	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
symptom	NN	O	O
provocation	NN	O	O
or	NN	O	O
a	NN	O	O
genetic	NN	O	O
association	NN	O	O
with	NN	O	O
stereotypies	NN	O	O
or	NN	O	O
anxiety	NN	O	B
.	NN	O	O

None	NN	O	O
of	NN	O	O
these	NN	O	O
current	NN	O	O
models	NN	O	O
demonstrate	NN	O	O
multiple	NN	O	O
OCD	NN	O	B
-	NN	O	O
like	NN	O	O
behaviors	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Neonatal	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
clomipramine	NN	O	O
or	NN	O	O
vehicle	NN	O	O
between	NN	O	O
days	NN	O	O
9	NN	O	O
and	NN	O	O
16	NN	O	O
twice	NN	O	O
daily	NN	O	O
and	NN	O	O
behaviorally	NN	O	O
tested	NN	O	O
in	NN	O	O
adulthood	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Clomipramine	NN	O	O
exposure	NN	O	O
in	NN	O	O
immature	NN	O	O
rats	NN	O	O
produced	NN	O	O
significant	NN	O	O
behavioral	NN	O	O
and	NN	O	O
biochemical	NN	O	O
changes	NN	O	O
that	NN	O	O
include	NN	O	O
enhanced	NN	O	O
anxiety	NN	O	B
(	NN	O	O
elevated	NN	O	O
plus	NN	O	O
maze	NN	O	O
and	NN	O	O
marble	NN	O	O
burying	NN	O	O
)	NN	O	O
,	NN	O	O
behavioral	NN	O	B
inflexibility	NN	O	I
(	NN	O	O
perseveration	NN	O	O
in	NN	O	O
the	NN	O	O
spontaneous	NN	O	O
alternation	NN	O	O
task	NN	O	O
and	NN	O	O
impaired	NN	O	O
reversal	NN	O	O
learning	NN	O	O
)	NN	O	O
,	NN	O	O
working	NN	O	O
memory	NN	O	B
impairment	NN	O	I
(	NN	O	O
e	NN	O	O
.	NN	O	O
g	NN	O	O
.	NN	O	O
,	NN	O	O
win	NN	O	O
-	NN	O	O
shift	NN	O	O
paradigm	NN	O	O
)	NN	O	O
,	NN	O	O
hoarding	NN	O	B
,	NN	O	O
and	NN	O	O
corticostriatal	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Dopamine	NN	O	O
D2	NN	O	O
receptors	NN	O	O
were	NN	O	O
elevated	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
,	NN	O	O
whereas	NN	O	O
serotonin	NN	O	O
2C	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
serotonin	NN	O	O
1A	NN	O	O
,	NN	O	O
receptors	NN	O	O
were	NN	O	O
elevated	NN	O	O
in	NN	O	O
the	NN	O	O
orbital	NN	O	O
frontal	NN	O	O
cortex	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
demonstration	NN	O	O
of	NN	O	O
multiple	NN	O	O
symptoms	NN	O	O
consistent	NN	O	O
with	NN	O	O
an	NN	O	O
OCD	NN	O	B
-	NN	O	O
like	NN	O	O
profile	NN	O	O
in	NN	O	O
animals	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
these	NN	O	O
behaviors	NN	O	O
are	NN	O	O
accompanied	NN	O	O
by	NN	O	O
biochemical	NN	O	O
changes	NN	O	O
in	NN	O	O
brain	NN	O	O
regions	NN	O	O
previously	NN	O	O
identified	NN	O	O
as	NN	O	O
relevant	NN	O	O
to	NN	O	O
OCD	NN	O	B
.	NN	O	O

This	NN	O	O
novel	NN	O	O
model	NN	O	O
of	NN	O	O
OCD	NN	O	B
demonstrates	NN	O	O
that	NN	O	O
drug	NN	O	O
exposure	NN	O	O
during	NN	O	O
a	NN	O	O
sensitive	NN	O	O
period	NN	O	O
can	NN	O	O
program	NN	O	O
disease	NN	O	O
-	NN	O	O
like	NN	O	O
systems	NN	O	O
permanently	NN	O	O
,	NN	O	O
which	NN	O	O
could	NN	O	O
have	NN	O	O
implications	NN	O	O
for	NN	O	O
current	NN	O	O
and	NN	O	O
future	NN	O	O
therapeutic	NN	O	O
strategies	NN	O	O
for	NN	O	O
this	NN	O	O
and	NN	O	O
other	NN	O	O
psychiatric	NN	O	B
disorders	NN	O	I
.	NN	O	O

Elevation	NN	O	O
of	NN	O	O
ADAM10	NN	O	O
,	NN	O	O
ADAM17	NN	O	O
,	NN	O	O
MMP	NN	O	O
-	NN	O	O
2	NN	O	O
and	NN	O	O
MMP	NN	O	O
-	NN	O	O
9	NN	O	O
expression	NN	O	O
with	NN	O	O
media	NN	O	O
degeneration	NN	O	O
features	NN	O	O
CaCl2	NN	O	O
-	NN	O	O
induced	NN	O	O
thoracic	NN	O	B
aortic	NN	O	I
aneurysm	NN	O	I
in	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
establish	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
thoracic	NN	O	B
aortic	NN	O	I
aneurysm	NN	O	I
(	NN	O	O
TAA	NN	O	B
)	NN	O	O
by	NN	O	O
calcium	NN	O	O
chloride	NN	O	O
(	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
arterial	NN	O	B
injury	NN	O	I
and	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
potential	NN	O	O
role	NN	O	O
of	NN	O	O
a	NN	O	O
disintegrin	NN	O	O
and	NN	O	O
metalloproteinase	NN	O	O
(	NN	O	O
ADAM	NN	O	O
)	NN	O	O
,	NN	O	O
matrix	NN	O	O
metalloproteinases	NN	O	O
(	NN	O	O
MMPs	NN	O	O
)	NN	O	O
and	NN	O	O
their	NN	O	O
endogenous	NN	O	O
inhibitors	NN	O	O
(	NN	O	O
TIMPs	NN	O	O
)	NN	O	O
in	NN	O	O
TAA	NN	O	B
formation	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Thoracic	NN	O	O
aorta	NN	O	O
of	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
was	NN	O	O
exposed	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
5M	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
or	NN	O	O
normal	NN	O	O
saline	NN	O	O
(	NN	O	O
NaCl	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
12weeks	NN	O	O
,	NN	O	O
animals	NN	O	O
were	NN	O	O
euthanized	NN	O	O
,	NN	O	O
and	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
,	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
untreated	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
and	NN	O	O
NaCl	NN	O	O
-	NN	O	O
treated	NN	O	O
aortic	NN	O	O
segments	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
were	NN	O	O
collected	NN	O	O
for	NN	O	O
histological	NN	O	O
and	NN	O	O
molecular	NN	O	O
assessments	NN	O	O
.	NN	O	O

MMP	NN	O	O
-	NN	O	O
TIMP	NN	O	O
and	NN	O	O
ADAM	NN	O	O
mRNAs	NN	O	O
were	NN	O	O
semi	NN	O	O
-	NN	O	O
quantitatively	NN	O	O
analyzed	NN	O	O
and	NN	O	O
protein	NN	O	O
expressions	NN	O	O
were	NN	O	O
determined	NN	O	O
by	NN	O	O
immunohistochemistry	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Despite	NN	O	O
similar	NN	O	O
external	NN	O	O
diameters	NN	O	O
among	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
and	NN	O	O
NaCl	NN	O	O
-	NN	O	O
treated	NN	O	O
segments	NN	O	O
,	NN	O	O
aneurymal	NN	O	O
alteration	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
,	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
media	NN	O	O
degeneration	NN	O	O
with	NN	O	O
regional	NN	O	O
disruption	NN	O	O
,	NN	O	O
fragmentation	NN	O	O
of	NN	O	O
elastic	NN	O	O
fiber	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
collagen	NN	O	O
deposition	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
,	NN	O	O
100	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
segments	NN	O	O
.	NN	O	O

MMP	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
MMP	NN	O	O
-	NN	O	O
9	NN	O	O
,	NN	O	O
ADAM	NN	O	O
-	NN	O	O
10	NN	O	O
and	NN	O	O
ADAM	NN	O	O
-	NN	O	O
17	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
were	NN	O	O
increased	NN	O	O
in	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
segments	NN	O	O
(	NN	O	O
all	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
trends	NN	O	O
of	NN	O	O
elevation	NN	O	O
in	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
untreated	NN	O	O
segments	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
NaCl	NN	O	O
-	NN	O	O
treated	NN	O	O
segments	NN	O	O
.	NN	O	O

Immunohistochemistry	NN	O	O
displayed	NN	O	O
significantly	NN	O	O
increased	NN	O	O
expressions	NN	O	O
of	NN	O	O
MMP	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
MMP	NN	O	O
-	NN	O	O
9	NN	O	O
,	NN	O	O
ADAM	NN	O	O
-	NN	O	O
10	NN	O	O
and	NN	O	O
ADAM	NN	O	O
-	NN	O	O
17	NN	O	O
(	NN	O	O
all	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
in	NN	O	O
intima	NN	O	O
and	NN	O	O
media	NN	O	O
for	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
segments	NN	O	O
.	NN	O	O

TIMP	NN	O	O
mRNA	NN	O	O
and	NN	O	O
tissue	NN	O	O
levels	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
obviously	NN	O	O
among	NN	O	O
the	NN	O	O
three	NN	O	O
aortic	NN	O	O
segments	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
establishes	NN	O	O
a	NN	O	O
TAA	NN	O	B
model	NN	O	O
by	NN	O	O
periarterial	NN	O	O
CaCl	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
exposure	NN	O	O
in	NN	O	O
rats	NN	O	O
,	NN	O	O
and	NN	O	O
demonstrates	NN	O	O
a	NN	O	O
significant	NN	O	O
elevation	NN	O	O
of	NN	O	O
expression	NN	O	O
of	NN	O	O
MMP	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
MMP	NN	O	O
-	NN	O	O
9	NN	O	O
,	NN	O	O
ADAM10	NN	O	O
and	NN	O	O
ADAM17	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
vascular	NN	O	O
remodeling	NN	O	O
.	NN	O	O

Suxamethonium	NN	O	O
induced	NN	O	O
prolonged	NN	O	O
apnea	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
receiving	NN	O	O
electroconvulsive	NN	O	O
therapy	NN	O	O
.	NN	O	O

Suxamethonium	NN	O	O
causes	NN	O	O
prolonged	NN	O	O
apnea	NN	O	B
in	NN	O	O
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
pseudocholinesterase	NN	O	O
enzyme	NN	O	O
gets	NN	O	O
deactivated	NN	O	O
by	NN	O	O
organophosphorus	NN	O	O
(	NN	O	O
OP	NN	O	O
)	NN	O	O
poisons	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
present	NN	O	O
a	NN	O	O
similar	NN	O	O
incident	NN	O	O
in	NN	O	O
a	NN	O	O
severely	NN	O	O
depressed	NN	O	B
patient	NN	O	O
who	NN	O	O
received	NN	O	O
electroconvulsive	NN	O	O
therapy	NN	O	O
(	NN	O	O
ECT	NN	O	O
)	NN	O	O
.	NN	O	O

Prolonged	NN	O	O
apnea	NN	O	B
in	NN	O	O
our	NN	O	O
case	NN	O	O
ensued	NN	O	O
because	NN	O	O
the	NN	O	O
information	NN	O	O
about	NN	O	O
suicidal	NN	O	O
attempt	NN	O	O
by	NN	O	O
OP	NN	O	O
compound	NN	O	O
was	NN	O	O
concealed	NN	O	O
from	NN	O	O
the	NN	O	O
treating	NN	O	O
team	NN	O	O
.	NN	O	O

Curcumin	NN	O	O
ameliorates	NN	O	O
cognitive	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
oxidative	NN	O	O
damage	NN	O	O
in	NN	O	O
phenobarbitone	NN	O	O
and	NN	O	O
carbamazepine	NN	O	O
administered	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
antiepileptic	NN	O	O
drugs	NN	O	O
,	NN	O	O
phenobarbitone	NN	O	O
and	NN	O	O
carbamazepine	NN	O	O
are	NN	O	O
well	NN	O	O
known	NN	O	O
to	NN	O	O
cause	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
on	NN	O	O
chronic	NN	O	O
use	NN	O	O
.	NN	O	O

The	NN	O	O
increase	NN	O	O
in	NN	O	O
free	NN	O	O
radical	NN	O	O
generation	NN	O	O
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
as	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
important	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
by	NN	O	O
antiepileptic	NN	O	O
drugs	NN	O	O
.	NN	O	O

Curcumin	NN	O	O
has	NN	O	O
shown	NN	O	O
antioxidant	NN	O	O
,	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
and	NN	O	O
neuro	NN	O	O
-	NN	O	O
protective	NN	O	O
properties	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
chronic	NN	O	O
curcumin	NN	O	O
administration	NN	O	O
on	NN	O	O
phenobarbitone	NN	O	O
-	NN	O	O
and	NN	O	O
carbamazepine	NN	O	O
-	NN	O	O
induced	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
and	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Pharmacokinetic	NN	O	O
interactions	NN	O	O
of	NN	O	O
curcumin	NN	O	O
with	NN	O	O
phenobarbitone	NN	O	O
and	NN	O	O
carbamazepine	NN	O	O
were	NN	O	O
also	NN	O	O
studied	NN	O	O
.	NN	O	O

Vehicle	NN	O	O
/	NN	O	O
drugs	NN	O	O
were	NN	O	O
administered	NN	O	O
daily	NN	O	O
for	NN	O	O
21days	NN	O	O
to	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

Passive	NN	O	O
avoidance	NN	O	O
paradigm	NN	O	O
and	NN	O	O
elevated	NN	O	O
plus	NN	O	O
maze	NN	O	O
test	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
assess	NN	O	O
cognitive	NN	O	O
function	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
study	NN	O	O
period	NN	O	O
,	NN	O	O
serum	NN	O	O
phenobarbitone	NN	O	O
and	NN	O	O
carbamazepine	NN	O	O
,	NN	O	O
whole	NN	O	O
brain	NN	O	O
malondialdehyde	NN	O	O
and	NN	O	O
reduced	NN	O	O
glutathione	NN	O	O
levels	NN	O	O
were	NN	O	O
estimated	NN	O	O
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
phenobarbitone	NN	O	O
and	NN	O	O
carbamazepine	NN	O	O
for	NN	O	O
21days	NN	O	O
caused	NN	O	O
a	NN	O	O
significant	NN	O	O
impairment	NN	O	B
of	NN	O	I
learning	NN	O	I
and	NN	O	I
memory	NN	O	I
as	NN	O	O
well	NN	O	O
as	NN	O	O
an	NN	O	O
increased	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O

Concomitant	NN	O	O
curcumin	NN	O	O
administration	NN	O	O
prevented	NN	O	O
the	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
and	NN	O	O
decreased	NN	O	O
the	NN	O	O
increased	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
induced	NN	O	O
by	NN	O	O
these	NN	O	O
antiepileptic	NN	O	O
drugs	NN	O	O
.	NN	O	O

Curcumin	NN	O	O
co	NN	O	O
-	NN	O	O
administration	NN	O	O
did	NN	O	O
not	NN	O	O
cause	NN	O	O
any	NN	O	O
significant	NN	O	O
alteration	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
of	NN	O	O
both	NN	O	O
phenobarbitone	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
carbamazepine	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
curcumin	NN	O	O
has	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
in	NN	O	O
mitigating	NN	O	O
the	NN	O	O
deterioration	NN	O	B
of	NN	O	I
cognitive	NN	O	I
functions	NN	O	I
and	NN	O	O
oxidative	NN	O	O
damage	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
phenobarbitone	NN	O	O
and	NN	O	O
carbamazepine	NN	O	O
without	NN	O	O
significantly	NN	O	O
altering	NN	O	O
their	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
curcumin	NN	O	O
can	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
a	NN	O	O
potential	NN	O	O
safe	NN	O	O
and	NN	O	O
effective	NN	O	O
adjuvant	NN	O	O
to	NN	O	O
phenobarbitone	NN	O	O
and	NN	O	O
carbamazepine	NN	O	O
therapy	NN	O	O
in	NN	O	O
preventing	NN	O	O
cognitive	NN	O	B
impairment	NN	O	I
associated	NN	O	O
with	NN	O	O
these	NN	O	O
drugs	NN	O	O
.	NN	O	O

Can	NN	O	O
angiogenesis	NN	O	O
be	NN	O	O
a	NN	O	O
target	NN	O	O
of	NN	O	O
treatment	NN	O	O
for	NN	O	O
ribavirin	NN	O	O
associated	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
?	NN	O	O

BACKGROUND	NN	O	O
/	NN	O	O
AIMS	NN	O	O
:	NN	O	O
Recently	NN	O	O
ribavirin	NN	O	O
has	NN	O	O
been	NN	O	O
found	NN	O	O
to	NN	O	O
inhibit	NN	O	O
angiogenesis	NN	O	O
and	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
angiogenesis	NN	O	O
inhibitors	NN	O	O
such	NN	O	O
as	NN	O	O
sunitinib	NN	O	O
and	NN	O	O
sorafenib	NN	O	O
have	NN	O	O
been	NN	O	O
found	NN	O	O
to	NN	O	O
cause	NN	O	O
acute	NN	O	O
hemolysis	NN	O	B
.	NN	O	O

We	NN	O	O
aimed	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
relation	NN	O	O
between	NN	O	O
hemoglobin	NN	O	O
,	NN	O	O
haptoglobin	NN	O	O
and	NN	O	O
angiogenesis	NN	O	O
soluble	NN	O	O
markers	NN	O	O
which	NN	O	O
are	NN	O	O
modifiable	NN	O	O
and	NN	O	O
can	NN	O	O
help	NN	O	O
in	NN	O	O
developing	NN	O	O
strategies	NN	O	O
against	NN	O	O
anemia	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Fourteen	NN	O	O
patients	NN	O	O
chronically	NN	O	B
infected	NN	O	I
with	NN	O	I
hepatitis	NN	O	I
C	NN	O	I
virus	NN	O	I
were	NN	O	O
treated	NN	O	O
by	NN	O	O
pegylated	NN	O	O
interferon	NN	O	O
alpha	NN	O	O
2a	NN	O	O
and	NN	O	O
ribavirin	NN	O	O
.	NN	O	O

Serum	NN	O	O
hemoglobin	NN	O	O
,	NN	O	O
haptoglobin	NN	O	O
and	NN	O	O
angiogenesis	NN	O	O
markers	NN	O	O
of	NN	O	O
vascular	NN	O	O
endothelial	NN	O	O
growth	NN	O	O
factor	NN	O	O
and	NN	O	O
angiopoetin	NN	O	O
-	NN	O	O
2	NN	O	O
were	NN	O	O
investigated	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
therapy	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
observed	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
haptoglobin	NN	O	O
levels	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
period	NN	O	O
.	NN	O	O

Hemoglobin	NN	O	O
levels	NN	O	O
also	NN	O	O
decreased	NN	O	O
but	NN	O	O
insignificantly	NN	O	O
by	NN	O	O
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
with	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
serum	NN	O	O
levels	NN	O	O
of	NN	O	O
angiogenesis	NN	O	O
factors	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
significantly	NN	O	O
by	NN	O	O
pegylated	NN	O	O
interferon	NN	O	O
and	NN	O	O
ribavirin	NN	O	O
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
no	NN	O	O
correlation	NN	O	O
of	NN	O	O
angiogenesis	NN	O	O
soluble	NN	O	O
markers	NN	O	O
with	NN	O	O
either	NN	O	O
hemoglobin	NN	O	O
or	NN	O	O
haptoglobin	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
study	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
investigating	NN	O	O
a	NN	O	O
link	NN	O	O
between	NN	O	O
angiogenesis	NN	O	O
soluble	NN	O	O
markers	NN	O	O
and	NN	O	O
ribavirin	NN	O	O
induced	NN	O	O
anemia	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hepatitis	NN	O	B
C	NN	O	I
and	NN	O	O
we	NN	O	O
could	NN	O	O
not	NN	O	O
find	NN	O	O
any	NN	O	O
relation	NN	O	O
.	NN	O	O

Future	NN	O	O
research	NN	O	O
with	NN	O	O
larger	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
is	NN	O	O
needed	NN	O	O
to	NN	O	O
find	NN	O	O
out	NN	O	O
modifiable	NN	O	O
factors	NN	O	O
that	NN	O	O
will	NN	O	O
improve	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
ribavirin	NN	O	O
therapy	NN	O	O
.	NN	O	O

Reduction	NN	O	O
in	NN	O	O
injection	NN	O	O
pain	NN	O	B
using	NN	O	O
buffered	NN	O	O
lidocaine	NN	O	O
as	NN	O	O
a	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
before	NN	O	O
cardiac	NN	O	O
catheterization	NN	O	O
.	NN	O	O

Previous	NN	O	O
reports	NN	O	O
have	NN	O	O
suggested	NN	O	O
that	NN	O	O
pain	NN	O	B
associated	NN	O	O
with	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
is	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
acidic	NN	O	O
pH	NN	O	O
of	NN	O	O
the	NN	O	O
solution	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
if	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
a	NN	O	O
buffering	NN	O	O
solution	NN	O	O
to	NN	O	O
adjust	NN	O	O
the	NN	O	O
pH	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
into	NN	O	O
the	NN	O	O
physiologic	NN	O	O
range	NN	O	O
would	NN	O	O
reduce	NN	O	O
pain	NN	O	B
during	NN	O	O
injection	NN	O	O
,	NN	O	O
we	NN	O	O
performed	NN	O	O
a	NN	O	O
blinded	NN	O	O
randomized	NN	O	O
study	NN	O	O
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
cardiac	NN	O	O
catheterization	NN	O	O
.	NN	O	O

Twenty	NN	O	O
patients	NN	O	O
were	NN	O	O
asked	NN	O	O
to	NN	O	O
quantify	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
pain	NN	O	B
after	NN	O	O
receiving	NN	O	O
standard	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
one	NN	O	O
femoral	NN	O	O
area	NN	O	O
and	NN	O	O
buffered	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
the	NN	O	O
opposite	NN	O	O
femoral	NN	O	O
area	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
pain	NN	O	B
score	NN	O	O
for	NN	O	O
buffered	NN	O	O
lidocaine	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
the	NN	O	O
mean	NN	O	O
score	NN	O	O
for	NN	O	O
standard	NN	O	O
lidocaine	NN	O	O
(	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
vs	NN	O	O
.	NN	O	O
3	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
pH	NN	O	O
adjustment	NN	O	O
of	NN	O	O
standard	NN	O	O
lidocaine	NN	O	O
can	NN	O	O
be	NN	O	O
accomplished	NN	O	O
easily	NN	O	O
in	NN	O	O
the	NN	O	O
catheterization	NN	O	O
laboratory	NN	O	O
before	NN	O	O
injection	NN	O	O
and	NN	O	O
results	NN	O	O
in	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
pain	NN	O	B
occurring	NN	O	O
during	NN	O	O
the	NN	O	O
infiltration	NN	O	O
of	NN	O	O
tissues	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
alpha	NN	O	O
-	NN	O	O
glyceryl	NN	O	O
-	NN	O	O
phosphorylcholine	NN	O	O
on	NN	O	O
amnesia	NN	O	B
caused	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
to	NN	O	O
test	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
alpha	NN	O	O
-	NN	O	O
glycerylphosphorylcholine	NN	O	O
(	NN	O	O
L	NN	O	O
-	NN	O	O
alpha	NN	O	O
-	NN	O	O
GFC	NN	O	O
)	NN	O	O
on	NN	O	O
memory	NN	O	B
impairment	NN	O	I
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
two	NN	O	O
healthy	NN	O	O
young	NN	O	O
volunteers	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
four	NN	O	O
different	NN	O	O
groups	NN	O	O
.	NN	O	O

They	NN	O	O
were	NN	O	O
given	NN	O	O
a	NN	O	O
ten	NN	O	O
day	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
either	NN	O	O
L	NN	O	O
-	NN	O	O
alpha	NN	O	O
-	NN	O	O
GFC	NN	O	O
or	NN	O	O
placebo	NN	O	O
,	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
,	NN	O	O
and	NN	O	O
on	NN	O	O
the	NN	O	O
eleventh	NN	O	O
day	NN	O	O
either	NN	O	O
scopolamine	NN	O	O
or	NN	O	O
placebo	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O

Before	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
6	NN	O	O
h	NN	O	O
after	NN	O	O
injection	NN	O	O
the	NN	O	O
subjects	NN	O	O
were	NN	O	O
given	NN	O	O
attention	NN	O	O
and	NN	O	O
mnemonic	NN	O	O
tests	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
drug	NN	O	O
is	NN	O	O
able	NN	O	O
to	NN	O	O
antagonize	NN	O	O
impairment	NN	O	B
of	NN	O	I
attention	NN	O	I
and	NN	O	I
memory	NN	O	I
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
.	NN	O	O

Safety	NN	O	O
of	NN	O	O
capecitabine	NN	O	O
:	NN	O	O
a	NN	O	O
review	NN	O	O
.	NN	O	O

IMPORTANCE	NN	O	O
OF	NN	O	O
THE	NN	O	O
FIELD	NN	O	O
:	NN	O	O
Fluoropyrimidines	NN	O	O
,	NN	O	O
in	NN	O	O
particular	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
,	NN	O	O
have	NN	O	O
been	NN	O	O
the	NN	O	O
mainstay	NN	O	O
of	NN	O	O
treatment	NN	O	O
for	NN	O	O
several	NN	O	O
solid	NN	O	O
tumors	NN	O	B
,	NN	O	O
including	NN	O	O
colorectal	NN	O	B
,	NN	O	I
breast	NN	O	I
and	NN	O	I
head	NN	O	I
and	NN	O	I
neck	NN	O	I
cancers	NN	O	I
,	NN	O	O
for	NN	O	O
>	NN	O	O
40	NN	O	O
years	NN	O	O
.	NN	O	O

AREAS	NN	O	O
COVERED	NN	O	O
IN	NN	O	O
THIS	NN	O	O
REVIEW	NN	O	O
:	NN	O	O
This	NN	O	O
article	NN	O	O
reviews	NN	O	O
the	NN	O	O
pharmacology	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
capecitabine	NN	O	O
with	NN	O	O
a	NN	O	O
special	NN	O	O
emphasis	NN	O	O
on	NN	O	O
its	NN	O	O
safety	NN	O	O
.	NN	O	O

WHAT	NN	O	O
THE	NN	O	O
READER	NN	O	O
WILL	NN	O	O
GAIN	NN	O	O
:	NN	O	O
The	NN	O	O
reader	NN	O	O
will	NN	O	O
gain	NN	O	O
better	NN	O	O
insight	NN	O	O
into	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
capecitabine	NN	O	O
in	NN	O	O
special	NN	O	O
populations	NN	O	O
such	NN	O	O
as	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
age	NN	O	O
,	NN	O	O
renal	NN	O	B
and	NN	O	I
kidney	NN	O	I
disease	NN	O	I
.	NN	O	O

We	NN	O	O
also	NN	O	O
explore	NN	O	O
different	NN	O	O
dosing	NN	O	O
and	NN	O	O
schedules	NN	O	O
of	NN	O	O
capecitabine	NN	O	O
administration	NN	O	O
.	NN	O	O

TAKE	NN	O	O
HOME	NN	O	O
MESSAGE	NN	O	O
:	NN	O	O
Capecitabine	NN	O	O
is	NN	O	O
an	NN	O	O
oral	NN	O	O
prodrug	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
and	NN	O	O
was	NN	O	O
developed	NN	O	O
to	NN	O	O
fulfill	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
a	NN	O	O
more	NN	O	O
convenient	NN	O	O
therapy	NN	O	O
and	NN	O	O
provide	NN	O	O
an	NN	O	O
improved	NN	O	O
safety	NN	O	O
/	NN	O	O
efficacy	NN	O	O
profile	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
shown	NN	O	O
promising	NN	O	O
results	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
chemotherapeutic	NN	O	O
agents	NN	O	O
in	NN	O	O
colorectal	NN	O	B
,	NN	O	I
breast	NN	O	I
,	NN	O	I
pancreaticobiliary	NN	O	I
,	NN	O	I
gastric	NN	O	I
,	NN	O	I
renal	NN	O	I
cell	NN	O	I
and	NN	O	I
head	NN	O	I
and	NN	O	I
neck	NN	O	I
cancers	NN	O	I
.	NN	O	O

The	NN	O	O
most	NN	O	O
commonly	NN	O	O
reported	NN	O	O
toxic	NN	O	O
effects	NN	O	O
of	NN	O	O
capecitabine	NN	O	O
are	NN	O	O
diarrhea	NN	O	B
,	NN	O	O
nausea	NN	O	B
,	NN	O	O
vomiting	NN	O	B
,	NN	O	O
stomatitis	NN	O	B
and	NN	O	O
hand	NN	O	B
-	NN	O	I
foot	NN	O	I
syndrome	NN	O	I
.	NN	O	O

Capecitabine	NN	O	O
has	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
established	NN	O	O
safety	NN	O	O
profile	NN	O	O
and	NN	O	O
can	NN	O	O
be	NN	O	O
given	NN	O	O
safely	NN	O	O
to	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
age	NN	O	O
,	NN	O	O
hepatic	NN	O	B
and	NN	O	I
renal	NN	O	I
dysfunctions	NN	O	I
.	NN	O	O

Levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
:	NN	O	O
filling	NN	O	O
the	NN	O	O
bench	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
bedside	NN	O	O
gap	NN	O	O
.	NN	O	O

Levodopa	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
effective	NN	O	O
drug	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
dopamine	NN	O	O
precursor	NN	O	O
is	NN	O	O
complicated	NN	O	O
by	NN	O	O
highly	NN	O	O
disabling	NN	O	O
fluctuations	NN	O	O
and	NN	O	O
dyskinesias	NN	O	B
.	NN	O	O

Although	NN	O	O
preclinical	NN	O	O
and	NN	O	O
clinical	NN	O	O
findings	NN	O	O
suggest	NN	O	O
pulsatile	NN	O	O
stimulation	NN	O	O
of	NN	O	O
striatal	NN	O	O
postsynaptic	NN	O	O
receptors	NN	O	O
as	NN	O	O
a	NN	O	O
key	NN	O	O
mechanism	NN	O	O
underlying	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
,	NN	O	O
their	NN	O	O
pathogenesis	NN	O	O
is	NN	O	O
still	NN	O	O
unclear	NN	O	O
.	NN	O	O

In	NN	O	O
recent	NN	O	O
years	NN	O	O
,	NN	O	O
evidence	NN	O	O
from	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
has	NN	O	O
provided	NN	O	O
important	NN	O	O
information	NN	O	O
to	NN	O	O
understand	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
specific	NN	O	O
receptor	NN	O	O
and	NN	O	O
post	NN	O	O
-	NN	O	O
receptor	NN	O	O
molecular	NN	O	O
mechanisms	NN	O	O
underlying	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
dyskinetic	NN	O	B
movements	NN	O	I
.	NN	O	O

Recent	NN	O	O
preclinical	NN	O	O
and	NN	O	O
clinical	NN	O	O
data	NN	O	O
from	NN	O	O
promising	NN	O	O
lines	NN	O	O
of	NN	O	O
research	NN	O	O
focus	NN	O	O
on	NN	O	O
the	NN	O	O
differential	NN	O	O
role	NN	O	O
of	NN	O	O
presynaptic	NN	O	O
versus	NN	O	O
postsynaptic	NN	O	O
mechanisms	NN	O	O
,	NN	O	O
dopamine	NN	O	O
receptor	NN	O	O
subtypes	NN	O	O
,	NN	O	O
ionotropic	NN	O	O
and	NN	O	O
metabotropic	NN	O	O
glutamate	NN	O	O
receptors	NN	O	O
,	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
dopaminergic	NN	O	O
neurotransmitter	NN	O	O
systems	NN	O	O
in	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
pallidal	NN	O	O
neurotensin	NN	O	O
on	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
parkinsonian	NN	O	B
catalepsy	NN	O	I
:	NN	O	O
behavioral	NN	O	O
and	NN	O	O
electrophysiological	NN	O	O
studies	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
globus	NN	O	O
pallidus	NN	O	O
plays	NN	O	O
a	NN	O	O
critical	NN	O	O
role	NN	O	O
in	NN	O	O
movement	NN	O	O
regulation	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
have	NN	O	O
indicated	NN	O	O
that	NN	O	O
the	NN	O	O
globus	NN	O	O
pallidus	NN	O	O
receives	NN	O	O
neurotensinergic	NN	O	O
innervation	NN	O	O
from	NN	O	O
the	NN	O	O
striatum	NN	O	O
,	NN	O	O
and	NN	O	O
systemic	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
neurotensin	NN	O	O
analog	NN	O	O
could	NN	O	O
produce	NN	O	O
antiparkinsonian	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
aimed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
pallidal	NN	O	O
neurotensin	NN	O	O
on	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
parkinsonian	NN	O	B
symptoms	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Behavioral	NN	O	O
experiments	NN	O	O
and	NN	O	O
electrophysiological	NN	O	O
recordings	NN	O	O
were	NN	O	O
performed	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Bilateral	NN	O	O
infusions	NN	O	O
of	NN	O	O
neurotensin	NN	O	O
into	NN	O	O
the	NN	O	O
globus	NN	O	O
pallidus	NN	O	O
reversed	NN	O	O
haloperidol	NN	O	O
-	NN	O	O
induced	NN	O	O
parkinsonian	NN	O	B
catalepsy	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Electrophysiological	NN	O	O
recordings	NN	O	O
showed	NN	O	O
that	NN	O	O
microinjection	NN	O	O
of	NN	O	O
neurotensin	NN	O	O
induced	NN	O	O
excitation	NN	O	O
of	NN	O	O
pallidal	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
systemic	NN	O	O
haloperidol	NN	O	O
administration	NN	O	O
.	NN	O	O

The	NN	O	O
neurotensin	NN	O	O
type	NN	O	O
-	NN	O	O
1	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
SR48692	NN	O	O
blocked	NN	O	O
both	NN	O	O
the	NN	O	O
behavioral	NN	O	O
and	NN	O	O
the	NN	O	O
electrophysiological	NN	O	O
effects	NN	O	O
induced	NN	O	O
by	NN	O	O
neurotensin	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Activation	NN	O	O
of	NN	O	O
pallidal	NN	O	O
neurotensin	NN	O	O
receptors	NN	O	O
may	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
neurotensin	NN	O	O
-	NN	O	O
induced	NN	O	O
antiparkinsonian	NN	O	O
effects	NN	O	O
.	NN	O	O

Carmofur	NN	O	O
-	NN	O	O
induced	NN	O	O
organic	NN	O	B
mental	NN	O	I
disorders	NN	O	I
.	NN	O	O

Organic	NN	O	B
mental	NN	O	I
disorder	NN	O	I
was	NN	O	O
observed	NN	O	O
in	NN	O	O
a	NN	O	O
29	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
in	NN	O	O
the	NN	O	O
prognostic	NN	O	O
period	NN	O	O
after	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
carmofur	NN	O	O
-	NN	O	O
induced	NN	O	O
leukoencephalopathy	NN	O	B
.	NN	O	O

Symptoms	NN	O	O
such	NN	O	O
as	NN	O	O
euphoria	NN	O	O
,	NN	O	O
emotional	NN	O	O
lability	NN	O	O
and	NN	O	O
puerile	NN	O	O
attitude	NN	O	O
noted	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
were	NN	O	O
diagnosed	NN	O	O
as	NN	O	O
organic	NN	O	B
personality	NN	O	I
syndrome	NN	O	I
according	NN	O	O
to	NN	O	O
the	NN	O	O
criteria	NN	O	O
defined	NN	O	O
in	NN	O	O
the	NN	O	O
DSM	NN	O	O
-	NN	O	O
III	NN	O	O
-	NN	O	O
R	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
referred	NN	O	O
to	NN	O	O
as	NN	O	O
a	NN	O	O
frontal	NN	O	B
lobe	NN	O	I
syndrome	NN	O	I
.	NN	O	O

Brain	NN	O	O
CT	NN	O	O
revealed	NN	O	O
a	NN	O	O
periventricular	NN	O	O
low	NN	O	O
density	NN	O	O
area	NN	O	O
in	NN	O	O
the	NN	O	O
frontal	NN	O	O
white	NN	O	O
matter	NN	O	O
and	NN	O	O
moderate	NN	O	O
dilatation	NN	O	O
of	NN	O	O
the	NN	O	O
lateral	NN	O	O
ventricles	NN	O	O
especially	NN	O	O
at	NN	O	O
the	NN	O	O
bilateral	NN	O	O
anterior	NN	O	O
horns	NN	O	O
.	NN	O	O

Consequently	NN	O	O
,	NN	O	O
carmofur	NN	O	O
-	NN	O	O
induced	NN	O	O
leukoencephalopathy	NN	O	B
may	NN	O	O
uncommonly	NN	O	O
result	NN	O	O
in	NN	O	O
organic	NN	O	B
personality	NN	O	I
syndrome	NN	O	I
in	NN	O	O
the	NN	O	O
residual	NN	O	O
state	NN	O	O
.	NN	O	O

It	NN	O	O
may	NN	O	O
be	NN	O	O
attributed	NN	O	O
to	NN	O	O
the	NN	O	O
structural	NN	O	B
damage	NN	O	I
to	NN	O	I
the	NN	O	I
frontal	NN	O	I
lobe	NN	O	I
.	NN	O	O

Butyrylcholinesterase	NN	O	O
gene	NN	O	O
mutations	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
prolonged	NN	O	O
apnea	NN	O	B
after	NN	O	O
succinylcholine	NN	O	O
for	NN	O	O
electroconvulsive	NN	O	O
therapy	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
electroconvulsive	NN	O	O
therapy	NN	O	O
(	NN	O	O
ECT	NN	O	O
)	NN	O	O
often	NN	O	O
receive	NN	O	O
succinylcholine	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
anesthetic	NN	O	O
procedure	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
may	NN	O	O
be	NN	O	O
prolonged	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
genetic	NN	O	O
variants	NN	O	O
of	NN	O	O
the	NN	O	O
butyrylcholinesterase	NN	O	O
enzyme	NN	O	O
(	NN	O	O
BChE	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
being	NN	O	O
the	NN	O	O
K	NN	O	O
-	NN	O	O
and	NN	O	O
the	NN	O	O
A	NN	O	O
-	NN	O	O
variants	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
clinical	NN	O	O
significance	NN	O	O
of	NN	O	O
genetic	NN	O	O
variants	NN	O	O
in	NN	O	O
butyrylcholinesterase	NN	O	O
gene	NN	O	O
(	NN	O	O
BCHE	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
suspected	NN	O	O
prolonged	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
of	NN	O	O
succinylcholine	NN	O	O
after	NN	O	O
ECT	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
13	NN	O	O
patients	NN	O	O
were	NN	O	O
referred	NN	O	O
to	NN	O	O
the	NN	O	O
Danish	NN	O	O
Cholinesterase	NN	O	O
Research	NN	O	O
Unit	NN	O	O
after	NN	O	O
ECT	NN	O	O
during	NN	O	O
38	NN	O	O
months	NN	O	O
.	NN	O	O

We	NN	O	O
determined	NN	O	O
the	NN	O	O
BChE	NN	O	O
activity	NN	O	O
and	NN	O	O
the	NN	O	O
BCHE	NN	O	O
genotype	NN	O	O
using	NN	O	O
molecular	NN	O	O
genetic	NN	O	O
methods	NN	O	O
,	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
apnea	NN	O	B
,	NN	O	O
time	NN	O	O
to	NN	O	O
sufficient	NN	O	O
spontaneous	NN	O	O
ventilation	NN	O	O
and	NN	O	O
whether	NN	O	O
neuromuscular	NN	O	O
monitoring	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	O
of	NN	O	O
apnea	NN	O	B
was	NN	O	O
compared	NN	O	O
with	NN	O	O
published	NN	O	O
data	NN	O	O
on	NN	O	O
normal	NN	O	O
subjects	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
in	NN	O	O
11	NN	O	O
patients	NN	O	O
,	NN	O	O
mutations	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
BCHE	NN	O	O
gene	NN	O	O
,	NN	O	O
the	NN	O	O
K	NN	O	O
-	NN	O	O
variant	NN	O	O
being	NN	O	O
the	NN	O	O
most	NN	O	O
frequent	NN	O	O
.	NN	O	O

The	NN	O	O
duration	NN	O	O
of	NN	O	O
apnea	NN	O	B
was	NN	O	O
5	NN	O	O
-	NN	O	O
15	NN	O	O
min	NN	O	O
compared	NN	O	O
with	NN	O	O
3	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O
3	NN	O	O
min	NN	O	O
from	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

Severe	NN	O	O
distress	NN	O	O
was	NN	O	O
noted	NN	O	O
in	NN	O	O
the	NN	O	O
recovery	NN	O	O
phase	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
.	NN	O	O

Neuromuscular	NN	O	O
monitoring	NN	O	O
was	NN	O	O
used	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
eleven	NN	O	O
of	NN	O	O
13	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
prolonged	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
of	NN	O	O
succinylcholine	NN	O	O
had	NN	O	O
mutations	NN	O	O
in	NN	O	O
BCHE	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
possible	NN	O	O
reason	NN	O	O
for	NN	O	O
a	NN	O	O
prolonged	NN	O	O
period	NN	O	O
of	NN	O	O
apnea	NN	O	B
.	NN	O	O

We	NN	O	O
recommend	NN	O	O
objective	NN	O	O
neuromuscular	NN	O	O
monitoring	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
ECT	NN	O	O
.	NN	O	O

Perhexiline	NN	O	O
maleate	NN	O	O
and	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

Peripheral	NN	O	B
neuropathy	NN	O	I
has	NN	O	O
been	NN	O	O
noted	NN	O	O
as	NN	O	O
a	NN	O	O
complication	NN	O	O
of	NN	O	O
therapy	NN	O	O
with	NN	O	O
perhexiline	NN	O	O
maleate	NN	O	O
,	NN	O	O
a	NN	O	O
drug	NN	O	O
widely	NN	O	O
used	NN	O	O
in	NN	O	O
France	NN	O	O
(	NN	O	O
and	NN	O	O
in	NN	O	O
clinical	NN	O	O
trials	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
)	NN	O	O
for	NN	O	O
the	NN	O	O
prophylactic	NN	O	O
treatment	NN	O	O
of	NN	O	O
angina	NN	O	B
pectoris	NN	O	I
.	NN	O	O

In	NN	O	O
24	NN	O	O
patients	NN	O	O
with	NN	O	O
this	NN	O	O
complication	NN	O	O
,	NN	O	O
the	NN	O	O
marked	NN	O	O
slowing	NN	O	O
of	NN	O	O
motor	NN	O	O
nerve	NN	O	O
conduction	NN	O	O
velocity	NN	O	O
and	NN	O	O
the	NN	O	O
electromyographic	NN	O	O
changes	NN	O	O
imply	NN	O	O
mainly	NN	O	O
a	NN	O	O
demyelinating	NN	O	B
disorder	NN	O	I
.	NN	O	O

Improvement	NN	O	O
was	NN	O	O
noted	NN	O	O
with	NN	O	O
cessation	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
few	NN	O	O
cases	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
active	NN	O	O
denervation	NN	O	O
signified	NN	O	O
a	NN	O	O
poor	NN	O	O
prognosis	NN	O	O
,	NN	O	O
with	NN	O	O
only	NN	O	O
slight	NN	O	O
improvement	NN	O	O
.	NN	O	O

The	NN	O	O
underlying	NN	O	O
mechanism	NN	O	O
causing	NN	O	O
the	NN	O	O
neuropathy	NN	O	B
is	NN	O	O
not	NN	O	O
yet	NN	O	O
fully	NN	O	O
known	NN	O	O
,	NN	O	O
although	NN	O	O
some	NN	O	O
evidence	NN	O	O
indicates	NN	O	O
that	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
lipid	NN	O	O
storage	NN	O	O
process	NN	O	O
.	NN	O	O

A	NN	O	O
phase	NN	O	O
I	NN	O	O
study	NN	O	O
of	NN	O	O
4	NN	O	O
'	NN	O	O
-	NN	O	O
0	NN	O	O
-	NN	O	O
tetrahydropyranyladriamycin	NN	O	O
.	NN	O	O

Clinical	NN	O	O
pharmacology	NN	O	O
and	NN	O	O
pharmacokinetics	NN	O	O
.	NN	O	O

A	NN	O	O
Phase	NN	O	O
I	NN	O	O
study	NN	O	O
of	NN	O	O
intravenous	NN	O	O
(	NN	O	O
IV	NN	O	O
)	NN	O	O
bolus	NN	O	O
4	NN	O	O
'	NN	O	O
-	NN	O	O
0	NN	O	O
-	NN	O	O
tetrahydropyranyladriamycin	NN	O	O
(	NN	O	O
Pirarubicin	NN	O	O
)	NN	O	O
was	NN	O	O
done	NN	O	O
in	NN	O	O
55	NN	O	O
patients	NN	O	O
in	NN	O	O
good	NN	O	O
performance	NN	O	O
status	NN	O	O
with	NN	O	O
refractory	NN	O	O
tumors	NN	O	B
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
six	NN	O	O
had	NN	O	O
minimal	NN	O	O
prior	NN	O	O
therapy	NN	O	O
(	NN	O	O
good	NN	O	O
risk	NN	O	O
)	NN	O	O
,	NN	O	O
23	NN	O	O
had	NN	O	O
extensive	NN	O	O
prior	NN	O	O
therapy	NN	O	O
(	NN	O	O
poor	NN	O	O
risk	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
six	NN	O	O
had	NN	O	O
renal	NN	O	B
and	NN	O	I
/	NN	O	I
or	NN	O	I
hepatic	NN	O	I
dysfunction	NN	O	I
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
167	NN	O	O
courses	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
15	NN	O	O
to	NN	O	O
70	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
were	NN	O	O
evaluable	NN	O	O
.	NN	O	O

Maximum	NN	O	O
tolerated	NN	O	O
dose	NN	O	O
in	NN	O	O
good	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
was	NN	O	O
70	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
poor	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
,	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
toxic	NN	O	O
effect	NN	O	O
was	NN	O	O
transient	NN	O	O
noncumulative	NN	O	O
granulocytopenia	NN	O	B
.	NN	O	O

Granulocyte	NN	O	O
nadir	NN	O	O
was	NN	O	O
on	NN	O	O
day	NN	O	O
14	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
22	NN	O	O
)	NN	O	O
.	NN	O	O

Less	NN	O	O
frequent	NN	O	O
toxic	NN	O	O
effects	NN	O	O
included	NN	O	O
thrombocytopenia	NN	O	B
,	NN	O	O
anemia	NN	O	B
,	NN	O	O
nausea	NN	O	B
,	NN	O	O
mild	NN	O	O
alopecia	NN	O	B
,	NN	O	O
phlebitis	NN	O	B
,	NN	O	O
and	NN	O	O
mucositis	NN	O	B
.	NN	O	O

Myelosuppression	NN	O	B
was	NN	O	O
more	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hepatic	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Pharmacokinetic	NN	O	O
analyses	NN	O	O
in	NN	O	O
21	NN	O	O
patients	NN	O	O
revealed	NN	O	O
Pirarubicin	NN	O	O
plasma	NN	O	O
T	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
alpha	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SE	NN	O	O
)	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
85	NN	O	O
minutes	NN	O	O
,	NN	O	O
T	NN	O	O
beta	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
of	NN	O	O
25	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
5	NN	O	O
minutes	NN	O	O
,	NN	O	O
and	NN	O	O
T	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
gamma	NN	O	O
of	NN	O	O
23	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
.	NN	O	O
6	NN	O	O
hours	NN	O	O
.	NN	O	O

The	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
curve	NN	O	O
was	NN	O	O
537	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
149	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
x	NN	O	O
hours	NN	O	O
,	NN	O	O
volume	NN	O	O
of	NN	O	O
distribution	NN	O	O
(	NN	O	O
Vd	NN	O	O
)	NN	O	O
3504	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
644	NN	O	O
l	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
and	NN	O	O
total	NN	O	O
clearance	NN	O	O
(	NN	O	O
ClT	NN	O	O
)	NN	O	O
was	NN	O	O
204	NN	O	O
+	NN	O	O
39	NN	O	O
.	NN	O	O
3	NN	O	O
l	NN	O	O
/	NN	O	O
hour	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

Adriamycinol	NN	O	O
,	NN	O	O
doxorubicin	NN	O	O
,	NN	O	O
adriamycinone	NN	O	O
,	NN	O	O
and	NN	O	O
tetrahydropyranyladriamycinol	NN	O	O
were	NN	O	O
the	NN	O	O
metabolites	NN	O	O
detected	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
doxorubicin	NN	O	O
was	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
10	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
total	NN	O	O
metabolites	NN	O	O
.	NN	O	O

Urinary	NN	O	O
excretion	NN	O	O
of	NN	O	O
Pirarubicin	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
24	NN	O	O
hours	NN	O	O
was	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
10	NN	O	O
%	NN	O	O
.	NN	O	O

Activity	NN	O	O
was	NN	O	O
noted	NN	O	O
in	NN	O	O
mesothelioma	NN	O	B
,	NN	O	O
leiomyosarcoma	NN	O	B
,	NN	O	O
and	NN	O	O
basal	NN	O	B
cell	NN	O	I
carcinoma	NN	O	I
.	NN	O	O

The	NN	O	O
recommended	NN	O	O
starting	NN	O	O
dose	NN	O	O
for	NN	O	O
Phase	NN	O	O
II	NN	O	O
trials	NN	O	O
is	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
IV	NN	O	O
bolus	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
.	NN	O	O

Ocular	NN	O	B
and	NN	O	I
auditory	NN	O	I
toxicity	NN	O	I
in	NN	O	O
hemodialyzed	NN	O	O
patients	NN	O	O
receiving	NN	O	O
desferrioxamine	NN	O	O
.	NN	O	O

During	NN	O	O
an	NN	O	O
18	NN	O	O
-	NN	O	O
month	NN	O	O
period	NN	O	O
of	NN	O	O
study	NN	O	O
41	NN	O	O
hemodialyzed	NN	O	O
patients	NN	O	O
receiving	NN	O	O
desferrioxamine	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BW	NN	O	O
/	NN	O	O
3	NN	O	O
times	NN	O	O
weekly	NN	O	O
)	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
were	NN	O	O
monitored	NN	O	O
for	NN	O	O
detection	NN	O	O
of	NN	O	O
audiovisual	NN	O	B
toxicity	NN	O	I
.	NN	O	O

6	NN	O	O
patients	NN	O	O
presented	NN	O	O
clinical	NN	O	O
symptoms	NN	O	O
of	NN	O	O
visual	NN	O	B
or	NN	O	I
auditory	NN	O	I
toxicity	NN	O	I
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
detailed	NN	O	O
ophthalmologic	NN	O	O
and	NN	O	O
audiologic	NN	O	O
studies	NN	O	O
disclosed	NN	O	O
abnormalities	NN	O	O
in	NN	O	O
7	NN	O	O
more	NN	O	O
asymptomatic	NN	O	O
patients	NN	O	O
.	NN	O	O

Visual	NN	O	B
toxicity	NN	O	I
was	NN	O	O
of	NN	O	O
retinal	NN	O	O
origin	NN	O	O
and	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
tritan	NN	O	O
-	NN	O	O
type	NN	O	O
dyschromatopsy	NN	O	B
,	NN	O	O
sometimes	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	B
loss	NN	O	I
of	NN	O	I
visual	NN	O	I
acuity	NN	O	I
and	NN	O	O
pigmentary	NN	O	B
retinal	NN	O	I
deposits	NN	O	I
.	NN	O	O

Auditory	NN	O	B
toxicity	NN	O	I
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
mid	NN	O	O
-	NN	O	O
to	NN	O	O
high	NN	O	O
-	NN	O	O
frequency	NN	O	O
neurosensorial	NN	O	B
hearing	NN	O	I
loss	NN	O	I
and	NN	O	O
the	NN	O	O
lesion	NN	O	O
was	NN	O	O
of	NN	O	O
the	NN	O	O
cochlear	NN	O	O
type	NN	O	O
.	NN	O	O

Desferrioxamine	NN	O	O
withdrawal	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
complete	NN	O	O
recovery	NN	O	O
of	NN	O	O
visual	NN	O	O
function	NN	O	O
in	NN	O	O
1	NN	O	O
patient	NN	O	O
and	NN	O	O
partial	NN	O	O
recovery	NN	O	O
in	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
complete	NN	O	O
reversal	NN	O	O
of	NN	O	O
hearing	NN	O	B
loss	NN	O	I
in	NN	O	O
3	NN	O	O
patients	NN	O	O
and	NN	O	O
partial	NN	O	O
recovery	NN	O	O
in	NN	O	O
3	NN	O	O
.	NN	O	O

This	NN	O	O
toxicity	NN	O	B
appeared	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
the	NN	O	O
higher	NN	O	O
doses	NN	O	O
of	NN	O	O
desferrioxamine	NN	O	O
or	NN	O	O
coincided	NN	O	O
with	NN	O	O
the	NN	O	O
normalization	NN	O	O
of	NN	O	O
ferritin	NN	O	O
or	NN	O	O
aluminium	NN	O	O
serum	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
audiovisual	NN	O	B
toxicity	NN	O	I
is	NN	O	O
not	NN	O	O
an	NN	O	O
infrequent	NN	O	O
complication	NN	O	O
in	NN	O	O
hemodialyzed	NN	O	O
patients	NN	O	O
receiving	NN	O	O
desferrioxamine	NN	O	O
.	NN	O	O

Periodical	NN	O	O
audiovisual	NN	O	O
monitoring	NN	O	O
should	NN	O	O
be	NN	O	O
performed	NN	O	O
on	NN	O	O
hemodialyzed	NN	O	O
patients	NN	O	O
receiving	NN	O	O
the	NN	O	O
drug	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
detect	NN	O	O
adverse	NN	O	O
effects	NN	O	O
as	NN	O	O
early	NN	O	O
as	NN	O	O
possible	NN	O	O
.	NN	O	O

Serial	NN	O	O
epilepsy	NN	O	B
caused	NN	O	O
by	NN	O	O
levodopa	NN	O	O
/	NN	O	O
carbidopa	NN	O	O
administration	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
on	NN	O	O
hemodialysis	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
with	NN	O	O
similar	NN	O	O
clinical	NN	O	O
features	NN	O	O
are	NN	O	O
presented	NN	O	O
:	NN	O	O
both	NN	O	O
patients	NN	O	O
had	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
,	NN	O	O
on	NN	O	O
hemodialysis	NN	O	O
for	NN	O	O
many	NN	O	O
years	NN	O	O
but	NN	O	O
recently	NN	O	O
begun	NN	O	O
on	NN	O	O
a	NN	O	O
high	NN	O	O
-	NN	O	O
flux	NN	O	O
dialyzer	NN	O	O
;	NN	O	O
both	NN	O	O
had	NN	O	O
been	NN	O	O
receiving	NN	O	O
a	NN	O	O
carbidopa	NN	O	O
/	NN	O	O
levodopa	NN	O	O
preparation	NN	O	O
;	NN	O	O
and	NN	O	O
both	NN	O	O
had	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
hallucinosis	NN	O	B
and	NN	O	O
recurrent	NN	O	O
seizures	NN	O	B
,	NN	O	O
which	NN	O	O
were	NN	O	O
refractory	NN	O	O
to	NN	O	O
anticonvulsants	NN	O	O
.	NN	O	O

The	NN	O	O
first	NN	O	O
patient	NN	O	O
died	NN	O	O
without	NN	O	O
a	NN	O	O
diagnosis	NN	O	O
;	NN	O	O
the	NN	O	O
second	NN	O	O
patient	NN	O	O
had	NN	O	O
a	NN	O	O
dramatic	NN	O	O
recovery	NN	O	O
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
vitamin	NN	O	O
B6	NN	O	O
.	NN	O	O

Neither	NN	O	O
patient	NN	O	O
was	NN	O	O
considered	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
renal	NN	O	O
state	NN	O	O
sufficiently	NN	O	O
severe	NN	O	O
enough	NN	O	O
to	NN	O	O
explain	NN	O	O
their	NN	O	O
presentation	NN	O	O
.	NN	O	O

Randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trial	NN	O	O
of	NN	O	O
mazindol	NN	O	O
in	NN	O	O
Duchenne	NN	O	B
dystrophy	NN	O	I
.	NN	O	O

There	NN	O	O
is	NN	O	O
evidence	NN	O	O
that	NN	O	O
growth	NN	O	O
hormone	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
weakness	NN	O	B
in	NN	O	O
Duchenne	NN	O	B
dystrophy	NN	O	I
.	NN	O	O

We	NN	O	O
conducted	NN	O	O
a	NN	O	O
12	NN	O	O
-	NN	O	O
month	NN	O	O
controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
mazindol	NN	O	O
,	NN	O	O
a	NN	O	O
putative	NN	O	O
growth	NN	O	O
hormone	NN	O	O
secretion	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
in	NN	O	O
83	NN	O	O
boys	NN	O	O
with	NN	O	O
Duchenne	NN	O	B
dystrophy	NN	O	I
.	NN	O	O

Muscle	NN	O	O
strength	NN	O	O
,	NN	O	O
contractures	NN	O	O
,	NN	O	O
functional	NN	O	O
ability	NN	O	O
and	NN	O	O
pulmonary	NN	O	O
function	NN	O	O
were	NN	O	O
tested	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
and	NN	O	O
6	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
mazindol	NN	O	O
(	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
power	NN	O	O
of	NN	O	O
greater	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
90	NN	O	O
to	NN	O	O
detect	NN	O	O
a	NN	O	O
slowing	NN	O	O
to	NN	O	O
25	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
expected	NN	O	O
rate	NN	O	O
of	NN	O	O
progression	NN	O	O
of	NN	O	O
weakness	NN	O	B
at	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
.	NN	O	O

Mazindol	NN	O	O
did	NN	O	O
not	NN	O	O
benefit	NN	O	O
strength	NN	O	O
at	NN	O	O
any	NN	O	O
point	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Side	NN	O	O
effects	NN	O	O
attributable	NN	O	O
to	NN	O	O
mazindol	NN	O	O
included	NN	O	O
decreased	NN	O	B
appetite	NN	O	I
(	NN	O	O
36	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
dry	NN	O	B
mouth	NN	O	I
(	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
behavioral	NN	O	O
change	NN	O	O
(	NN	O	O
22	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
gastrointestinal	NN	O	B
symptoms	NN	O	I
(	NN	O	O
18	NN	O	O
%	NN	O	O
)	NN	O	O
;	NN	O	O
mazindol	NN	O	O
dosage	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
43	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
mazindol	NN	O	O
on	NN	O	O
GH	NN	O	O
secretion	NN	O	O
was	NN	O	O
estimated	NN	O	O
indirectly	NN	O	O
by	NN	O	O
comparing	NN	O	O
the	NN	O	O
postabsorptive	NN	O	O
IGF	NN	O	O
-	NN	O	O
I	NN	O	O
levels	NN	O	O
obtained	NN	O	O
following	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
,	NN	O	O
9	NN	O	O
,	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
in	NN	O	O
the	NN	O	O
mazindol	NN	O	O
treated	NN	O	O
to	NN	O	O
those	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
groups	NN	O	O
.	NN	O	O

Although	NN	O	O
mazindol	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
gained	NN	O	O
less	NN	O	O
weight	NN	O	O
and	NN	O	O
height	NN	O	O
than	NN	O	O
placebo	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
,	NN	O	O
no	NN	O	O
significant	NN	O	O
effect	NN	O	O
on	NN	O	O
IGF	NN	O	O
-	NN	O	O
I	NN	O	O
levels	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Mazindol	NN	O	O
doses	NN	O	O
not	NN	O	O
slow	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
weakness	NN	O	B
in	NN	O	O
Duchenne	NN	O	B
dystrophy	NN	O	I
.	NN	O	O

Facilitation	NN	O	O
of	NN	O	O
memory	NN	O	O
retrieval	NN	O	O
by	NN	O	O
pre	NN	O	O
-	NN	O	O
test	NN	O	O
morphine	NN	O	O
and	NN	O	O
its	NN	O	O
state	NN	O	O
dependency	NN	O	O
in	NN	O	O
the	NN	O	O
step	NN	O	O
-	NN	O	O
through	NN	O	O
type	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
learning	NN	O	O
test	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Amnesia	NN	O	B
produced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
and	NN	O	O
cycloheximide	NN	O	O
were	NN	O	O
reversed	NN	O	O
by	NN	O	O
morphine	NN	O	O
given	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
the	NN	O	O
test	NN	O	O
trial	NN	O	O
(	NN	O	O
pre	NN	O	O
-	NN	O	O
test	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
pre	NN	O	O
-	NN	O	O
test	NN	O	O
morphine	NN	O	O
also	NN	O	O
facilitated	NN	O	O
the	NN	O	O
memory	NN	O	O
retrieval	NN	O	O
in	NN	O	O
the	NN	O	O
animals	NN	O	O
administered	NN	O	O
naloxone	NN	O	O
during	NN	O	O
the	NN	O	O
training	NN	O	O
trial	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
pre	NN	O	O
-	NN	O	O
test	NN	O	O
scopolamine	NN	O	O
partially	NN	O	O
reversed	NN	O	O
the	NN	O	O
scopolamine	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B
,	NN	O	O
but	NN	O	O
not	NN	O	O
significantly	NN	O	O
;	NN	O	O
and	NN	O	O
pre	NN	O	O
-	NN	O	O
test	NN	O	O
cycloheximide	NN	O	O
failed	NN	O	O
to	NN	O	O
reverse	NN	O	O
the	NN	O	O
cycloheximide	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
facilitation	NN	O	O
of	NN	O	O
memory	NN	O	O
retrieval	NN	O	O
by	NN	O	O
pre	NN	O	O
-	NN	O	O
test	NN	O	O
morphine	NN	O	O
might	NN	O	O
be	NN	O	O
the	NN	O	O
direct	NN	O	O
action	NN	O	O
of	NN	O	O
morphine	NN	O	O
rather	NN	O	O
than	NN	O	O
a	NN	O	O
state	NN	O	O
dependent	NN	O	O
effect	NN	O	O
.	NN	O	O

Naloxone	NN	O	O
reverses	NN	O	O
the	NN	O	O
antihypertensive	NN	O	O
effect	NN	O	O
of	NN	O	O
clonidine	NN	O	O
.	NN	O	O

In	NN	O	O
unanesthetized	NN	O	O
,	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
produced	NN	O	O
by	NN	O	O
intravenous	NN	O	O
clonidine	NN	O	O
,	NN	O	O
5	NN	O	O
to	NN	O	O
20	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
was	NN	O	O
inhibited	NN	O	O
or	NN	O	O
reversed	NN	O	O
by	NN	O	O
nalozone	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
to	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

The	NN	O	O
hypotensive	NN	O	B
effect	NN	O	O
of	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
was	NN	O	O
also	NN	O	O
partially	NN	O	O
reversed	NN	O	O
by	NN	O	O
naloxone	NN	O	O
.	NN	O	O

Naloxone	NN	O	O
alone	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
either	NN	O	O
blood	NN	O	O
pressure	NN	O	O
or	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

In	NN	O	O
brain	NN	O	O
membranes	NN	O	O
from	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
clonidine	NN	O	O
,	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
8	NN	O	O
)	NN	O	O
to	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
M	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
influence	NN	O	O
stereoselective	NN	O	O
binding	NN	O	O
of	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
-	NN	O	O
naloxone	NN	O	O
(	NN	O	O
8	NN	O	O
nM	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
naloxone	NN	O	O
,	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
8	NN	O	O
)	NN	O	O
to	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
4	NN	O	O
)	NN	O	O
M	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
influence	NN	O	O
clonidine	NN	O	O
-	NN	O	O
suppressible	NN	O	O
binding	NN	O	O
of	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
-	NN	O	O
dihydroergocryptine	NN	O	O
(	NN	O	O
1	NN	O	O
nM	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
in	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B
rats	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
central	NN	O	O
alpha	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
stimulation	NN	O	O
involve	NN	O	O
activation	NN	O	O
of	NN	O	O
opiate	NN	O	O
receptors	NN	O	O
.	NN	O	O

As	NN	O	O
naloxone	NN	O	O
and	NN	O	O
clonidine	NN	O	O
do	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
interact	NN	O	O
with	NN	O	O
the	NN	O	O
same	NN	O	O
receptor	NN	O	O
site	NN	O	O
,	NN	O	O
the	NN	O	O
observed	NN	O	O
functional	NN	O	O
antagonism	NN	O	O
suggests	NN	O	O
the	NN	O	O
release	NN	O	O
of	NN	O	O
an	NN	O	O
endogenous	NN	O	O
opiate	NN	O	O
by	NN	O	O
clonidine	NN	O	O
or	NN	O	O
alpha	NN	O	O
-	NN	O	O
methyldopa	NN	O	O
and	NN	O	O
the	NN	O	O
possible	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
opiate	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
control	NN	O	O
of	NN	O	O
sympathetic	NN	O	O
tone	NN	O	O
.	NN	O	O

Neurotoxicity	NN	O	B
of	NN	O	O
halogenated	NN	O	O
hydroxyquinolines	NN	O	O
:	NN	O	O
clinical	NN	O	O
analysis	NN	O	O
of	NN	O	O
cases	NN	O	O
reported	NN	O	O
outside	NN	O	O
Japan	NN	O	O
.	NN	O	O

An	NN	O	O
analysis	NN	O	O
is	NN	O	O
presented	NN	O	O
of	NN	O	O
220	NN	O	O
cases	NN	O	O
of	NN	O	O
possible	NN	O	O
neurotoxic	NN	O	B
reactions	NN	O	O
to	NN	O	O
halogenated	NN	O	O
hydroxyquinolines	NN	O	O
reported	NN	O	O
from	NN	O	O
outside	NN	O	O
Japan	NN	O	O
.	NN	O	O

In	NN	O	O
80	NN	O	O
cases	NN	O	O
insufficient	NN	O	O
information	NN	O	O
was	NN	O	O
available	NN	O	O
for	NN	O	O
adequate	NN	O	O
comment	NN	O	O
and	NN	O	O
in	NN	O	O
29	NN	O	O
a	NN	O	O
relationship	NN	O	O
to	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
clioquinol	NN	O	O
could	NN	O	O
be	NN	O	O
excluded	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
remainder	NN	O	O
,	NN	O	O
a	NN	O	O
relationship	NN	O	O
to	NN	O	O
clioquinol	NN	O	O
was	NN	O	O
considered	NN	O	O
probable	NN	O	O
in	NN	O	O
42	NN	O	O
and	NN	O	O
possible	NN	O	O
in	NN	O	O
69	NN	O	O
cases	NN	O	O
.	NN	O	O

In	NN	O	O
six	NN	O	O
of	NN	O	O
the	NN	O	O
probable	NN	O	O
cases	NN	O	O
the	NN	O	O
neurological	NN	O	B
disturbance	NN	O	I
consisted	NN	O	O
of	NN	O	O
an	NN	O	O
acute	NN	O	O
reversible	NN	O	O
encephalopathy	NN	O	B
usually	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
ingestion	NN	O	O
of	NN	O	O
a	NN	O	O
high	NN	O	O
dose	NN	O	O
of	NN	O	O
clioquinol	NN	O	O
over	NN	O	O
a	NN	O	O
short	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
manifestation	NN	O	O
,	NN	O	O
observed	NN	O	O
in	NN	O	O
15	NN	O	O
further	NN	O	O
cases	NN	O	O
,	NN	O	O
was	NN	O	O
isolated	NN	O	O
optic	NN	O	B
atrophy	NN	O	I
.	NN	O	O

This	NN	O	O
was	NN	O	O
most	NN	O	O
frequently	NN	O	O
found	NN	O	O
in	NN	O	O
children	NN	O	O
,	NN	O	O
many	NN	O	O
of	NN	O	O
whom	NN	O	O
had	NN	O	O
received	NN	O	O
clioquinol	NN	O	O
as	NN	O	O
treatment	NN	O	O
for	NN	O	O
acrodermatitis	NN	O	B
enteropathica	NN	O	I
.	NN	O	O

In	NN	O	O
the	NN	O	O
remaining	NN	O	O
cases	NN	O	O
,	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
myelopathy	NN	O	B
,	NN	O	O
visual	NN	O	B
disturbance	NN	O	I
,	NN	O	O
and	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
was	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
manifestation	NN	O	O
.	NN	O	O

Isolated	NN	O	O
myelopathy	NN	O	B
or	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
,	NN	O	O
or	NN	O	O
these	NN	O	O
manifestations	NN	O	O
occurring	NN	O	O
together	NN	O	O
,	NN	O	O
were	NN	O	O
infrequent	NN	O	O
.	NN	O	O

The	NN	O	O
onset	NN	O	O
of	NN	O	O
all	NN	O	O
manifestations	NN	O	O
(	NN	O	O
except	NN	O	O
toxic	NN	O	O
encephalopathy	NN	O	B
)	NN	O	O
was	NN	O	O
usually	NN	O	O
subacute	NN	O	O
,	NN	O	O
with	NN	O	O
subsequent	NN	O	O
partial	NN	O	O
recovery	NN	O	O
.	NN	O	O

Older	NN	O	O
subjects	NN	O	O
tended	NN	O	O
to	NN	O	O
display	NN	O	O
more	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
full	NN	O	O
syndrome	NN	O	O
of	NN	O	O
subacute	NN	O	O
myelo	NN	O	B
-	NN	O	I
optic	NN	O	I
neuropathy	NN	O	I
was	NN	O	O
more	NN	O	O
frequent	NN	O	O
in	NN	O	O
women	NN	O	O
,	NN	O	O
but	NN	O	O
they	NN	O	O
tended	NN	O	O
to	NN	O	O
have	NN	O	O
taken	NN	O	O
greater	NN	O	O
quantities	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Prazosin	NN	O	O
-	NN	O	O
induced	NN	O	O
stress	NN	O	B
incontinence	NN	O	I
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
genuine	NN	O	O
stress	NN	O	B
incontinence	NN	O	I
due	NN	O	O
to	NN	O	O
prazosin	NN	O	O
,	NN	O	O
a	NN	O	O
common	NN	O	O
antihypertensive	NN	O	O
drug	NN	O	O
,	NN	O	O
is	NN	O	O
presented	NN	O	O
.	NN	O	O

Prazosin	NN	O	O
exerts	NN	O	O
its	NN	O	O
antihypertensive	NN	O	O
effects	NN	O	O
through	NN	O	O
vasodilatation	NN	O	O
caused	NN	O	O
by	NN	O	O
selective	NN	O	O
blockade	NN	O	O
of	NN	O	O
postsynaptic	NN	O	O
alpha	NN	O	O
-	NN	O	O
1	NN	O	O
adrenergic	NN	O	O
receptors	NN	O	O
.	NN	O	O

As	NN	O	O
an	NN	O	O
alpha	NN	O	O
-	NN	O	O
blocker	NN	O	O
,	NN	O	O
it	NN	O	O
also	NN	O	O
exerts	NN	O	O
a	NN	O	O
significant	NN	O	O
relaxant	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
bladder	NN	O	O
neck	NN	O	O
and	NN	O	O
urethra	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
clinical	NN	O	O
course	NN	O	O
is	NN	O	O
described	NN	O	O
and	NN	O	O
correlated	NN	O	O
with	NN	O	O
initial	NN	O	O
urodynamic	NN	O	O
studies	NN	O	O
while	NN	O	O
on	NN	O	O
prazosin	NN	O	O
and	NN	O	O
subsequent	NN	O	O
studies	NN	O	O
while	NN	O	O
taking	NN	O	O
verapamil	NN	O	O
.	NN	O	O

Her	NN	O	O
incontinence	NN	O	B
resolved	NN	O	O
with	NN	O	O
the	NN	O	O
change	NN	O	O
of	NN	O	O
medication	NN	O	O
.	NN	O	O

The	NN	O	O
restoration	NN	O	O
of	NN	O	O
continence	NN	O	O
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
substantial	NN	O	O
rise	NN	O	O
in	NN	O	O
maximum	NN	O	O
urethral	NN	O	O
pressure	NN	O	O
,	NN	O	O
maximum	NN	O	O
urethral	NN	O	O
closure	NN	O	O
pressure	NN	O	O
,	NN	O	O
and	NN	O	O
functional	NN	O	O
urethral	NN	O	O
length	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
present	NN	O	O
with	NN	O	O
stress	NN	O	B
incontinence	NN	O	I
while	NN	O	O
taking	NN	O	O
prazosin	NN	O	O
should	NN	O	O
change	NN	O	O
their	NN	O	O
antihypertensive	NN	O	O
medication	NN	O	O
before	NN	O	O
considering	NN	O	O
surgery	NN	O	O
,	NN	O	O
because	NN	O	O
their	NN	O	O
incontinence	NN	O	B
may	NN	O	O
resolve	NN	O	O
spontaneously	NN	O	O
with	NN	O	O
a	NN	O	O
change	NN	O	O
in	NN	O	O
drug	NN	O	O
therapy	NN	O	O
.	NN	O	O

Myocardial	NN	O	B
infarction	NN	O	I
following	NN	O	O
sublingual	NN	O	O
administration	NN	O	O
of	NN	O	O
isosorbide	NN	O	O
dinitrate	NN	O	O
.	NN	O	O

A	NN	O	O
78	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
with	NN	O	O
healed	NN	O	O
septal	NN	O	O
necrosis	NN	O	B
suffered	NN	O	O
a	NN	O	O
recurrent	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
of	NN	O	O
the	NN	O	O
anterior	NN	O	O
wall	NN	O	O
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
isosorbide	NN	O	O
dinitrate	NN	O	O
5	NN	O	O
mg	NN	O	O
sublingually	NN	O	O
.	NN	O	O

After	NN	O	O
detailing	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
events	NN	O	O
,	NN	O	O
we	NN	O	O
discuss	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
paradoxical	NN	O	O
coronary	NN	O	O
spasm	NN	O	B
and	NN	O	O
hypotension	NN	O	B
-	NN	O	O
mediated	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
occurring	NN	O	O
downstream	NN	O	O
to	NN	O	O
significant	NN	O	O
coronary	NN	O	B
arterial	NN	O	I
stenosis	NN	O	I
in	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
acute	NN	O	B
coronary	NN	O	I
insufficiency	NN	O	I
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
the	NN	O	O
respiratory	NN	O	O
effects	NN	O	O
of	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
infusions	NN	O	O
of	NN	O	O
morphine	NN	O	O
and	NN	O	O
regional	NN	O	O
analgesia	NN	O	O
by	NN	O	O
extradural	NN	O	O
block	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
postoperative	NN	O	O
respiratory	NN	O	O
apnoea	NN	O	B
was	NN	O	O
compared	NN	O	O
between	NN	O	O
five	NN	O	O
patients	NN	O	O
receiving	NN	O	O
a	NN	O	O
continuous	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
infusion	NN	O	O
of	NN	O	O
morphine	NN	O	O
(	NN	O	O
mean	NN	O	O
73	NN	O	O
.	NN	O	O
6	NN	O	O
mg	NN	O	O
)	NN	O	O
and	NN	O	O
five	NN	O	O
patients	NN	O	O
receiving	NN	O	O
a	NN	O	O
continuous	NN	O	O
extradural	NN	O	O
infusion	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
%	NN	O	O
bupivacaine	NN	O	O
(	NN	O	O
mean	NN	O	O
192	NN	O	O
mg	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
24	NN	O	O
-	NN	O	O
h	NN	O	O
period	NN	O	O
following	NN	O	O
upper	NN	O	O
abdominal	NN	O	O
surgery	NN	O	O
.	NN	O	O

Monitoring	NN	O	O
consisted	NN	O	O
of	NN	O	O
airflow	NN	O	O
detection	NN	O	O
by	NN	O	O
a	NN	O	O
carbon	NN	O	O
dioxide	NN	O	O
analyser	NN	O	O
,	NN	O	O
chest	NN	O	O
wall	NN	O	O
movement	NN	O	O
detected	NN	O	O
by	NN	O	O
pneumatic	NN	O	O
capsules	NN	O	O
,	NN	O	O
and	NN	O	O
continuous	NN	O	O
electrocardiograph	NN	O	O
recorded	NN	O	O
with	NN	O	O
a	NN	O	O
Holter	NN	O	O
ambulatory	NN	O	O
monitor	NN	O	O
.	NN	O	O

Both	NN	O	O
obstructive	NN	O	B
(	NN	O	I
P	NN	O	I
less	NN	O	I
than	NN	O	I
0	NN	O	I
.	NN	O	I
05	NN	O	I
)	NN	O	I
and	NN	O	I
central	NN	O	I
apnoea	NN	O	I
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
occurred	NN	O	O
more	NN	O	O
frequently	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
morphine	NN	O	O
infusion	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
also	NN	O	O
a	NN	O	O
higher	NN	O	O
incidence	NN	O	O
of	NN	O	O
tachyarrhythmias	NN	O	B
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
and	NN	O	O
ventricular	NN	O	B
ectopic	NN	O	I
beats	NN	O	I
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
morphine	NN	O	O
infusion	NN	O	O
group	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
aminophylline	NN	O	O
on	NN	O	O
the	NN	O	O
threshold	NN	O	O
for	NN	O	O
initiating	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
during	NN	O	O
respiratory	NN	O	B
failure	NN	O	I
.	NN	O	O

Cardiac	NN	O	B
arrhythmias	NN	O	I
have	NN	O	O
frequently	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
respiratory	NN	O	B
failure	NN	O	I
.	NN	O	O

The	NN	O	O
possible	NN	O	O
additive	NN	O	O
role	NN	O	O
of	NN	O	O
pharmacologic	NN	O	O
agents	NN	O	O
in	NN	O	O
precipitating	NN	O	O
cardiac	NN	O	B
disturbances	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
respiratory	NN	O	B
failure	NN	O	I
has	NN	O	O
only	NN	O	O
recently	NN	O	O
been	NN	O	O
emphasized	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
aminophylline	NN	O	O
on	NN	O	O
the	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
threshold	NN	O	O
during	NN	O	O
normal	NN	O	O
acid	NN	O	O
-	NN	O	O
base	NN	O	O
conditions	NN	O	O
and	NN	O	O
during	NN	O	O
respiratory	NN	O	B
failure	NN	O	I
were	NN	O	O
studied	NN	O	O
in	NN	O	O
anesthetized	NN	O	O
open	NN	O	O
chest	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
threshold	NN	O	O
was	NN	O	O
measured	NN	O	O
by	NN	O	O
passing	NN	O	O
a	NN	O	O
gated	NN	O	O
train	NN	O	O
of	NN	O	O
12	NN	O	O
constant	NN	O	O
current	NN	O	O
pulses	NN	O	O
through	NN	O	O
the	NN	O	O
ventricular	NN	O	O
myocardium	NN	O	O
during	NN	O	O
the	NN	O	O
vulnerable	NN	O	O
period	NN	O	O
of	NN	O	O
the	NN	O	O
cardiac	NN	O	O
cycle	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
infusion	NN	O	O
of	NN	O	O
aminophylline	NN	O	O
,	NN	O	O
the	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
threshold	NN	O	O
was	NN	O	O
reduced	NN	O	O
by	NN	O	O
30	NN	O	O
to	NN	O	O
40	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
when	NN	O	O
pH	NN	O	O
and	NN	O	O
partial	NN	O	O
pressures	NN	O	O
of	NN	O	O
oxygen	NN	O	O
(	NN	O	O
PO2	NN	O	O
)	NN	O	O
and	NN	O	O
carbon	NN	O	O
dioxide	NN	O	O
(	NN	O	O
CO2	NN	O	O
)	NN	O	O
were	NN	O	O
kept	NN	O	O
within	NN	O	O
normal	NN	O	O
limits	NN	O	O
.	NN	O	O

When	NN	O	O
respiratory	NN	O	B
failure	NN	O	I
was	NN	O	O
produced	NN	O	O
by	NN	O	O
hypoventilation	NN	O	B
(	NN	O	O
pH	NN	O	O
7	NN	O	O
.	NN	O	O
05	NN	O	O
to	NN	O	O
7	NN	O	O
.	NN	O	O
25	NN	O	O
;	NN	O	O
PC02	NN	O	O
70	NN	O	O
to	NN	O	O
100	NN	O	O
mm	NN	O	O
Hg	NN	O	O
:	NN	O	O
P02	NN	O	O
20	NN	O	O
to	NN	O	O
40	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
,	NN	O	O
infusion	NN	O	O
of	NN	O	O
aminophylline	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
even	NN	O	O
greater	NN	O	O
decrease	NN	O	O
in	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
threshold	NN	O	O
to	NN	O	O
60	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
level	NN	O	O
.	NN	O	O

These	NN	O	O
experiments	NN	O	O
suggest	NN	O	O
that	NN	O	O
although	NN	O	O
many	NN	O	O
factors	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
ventricular	NN	O	B
arrhythmias	NN	O	I
in	NN	O	O
respiratory	NN	O	B
failure	NN	O	I
,	NN	O	O
pharmacologic	NN	O	O
agents	NN	O	O
,	NN	O	O
particularly	NN	O	O
aminophylline	NN	O	O
,	NN	O	O
may	NN	O	O
play	NN	O	O
a	NN	O	O
significant	NN	O	O
role	NN	O	O
.	NN	O	O

Pentoxifylline	NN	O	O
(	NN	O	O
Trental	NN	O	O
)	NN	O	O
does	NN	O	O
not	NN	O	O
inhibit	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
induced	NN	O	O
coronary	NN	O	O
hyperemia	NN	O	B
:	NN	O	O
implications	NN	O	O
for	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
thallium	NN	O	O
-	NN	O	O
201	NN	O	O
myocardial	NN	O	O
imaging	NN	O	O
.	NN	O	O

Dipyridamole	NN	O	O
-	NN	O	O
thallium	NN	O	O
-	NN	O	O
201	NN	O	O
imaging	NN	O	O
is	NN	O	O
often	NN	O	O
performed	NN	O	O
in	NN	O	O
patients	NN	O	O
unable	NN	O	O
to	NN	O	O
exercise	NN	O	O
because	NN	O	O
of	NN	O	O
peripheral	NN	O	B
vascular	NN	O	I
disease	NN	O	I
.	NN	O	O

Many	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
are	NN	O	O
taking	NN	O	O
pentoxifylline	NN	O	O
(	NN	O	O
Trental	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
methylxanthine	NN	O	O
derivative	NN	O	O
which	NN	O	O
may	NN	O	O
improve	NN	O	O
intermittent	NN	O	B
claudication	NN	O	I
.	NN	O	O

Whether	NN	O	O
pentoxifylline	NN	O	O
inhibits	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
induced	NN	O	O
coronary	NN	O	O
hyperemia	NN	O	B
like	NN	O	O
other	NN	O	O
methylxanthines	NN	O	O
such	NN	O	O
as	NN	O	O
theophylline	NN	O	O
and	NN	O	O
should	NN	O	O
be	NN	O	O
stopped	NN	O	O
prior	NN	O	O
to	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
thallium	NN	O	O
-	NN	O	O
201	NN	O	O
imaging	NN	O	O
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
we	NN	O	O
studied	NN	O	O
the	NN	O	O
hyperemic	NN	O	O
response	NN	O	O
to	NN	O	O
dipyridamole	NN	O	O
in	NN	O	O
seven	NN	O	O
open	NN	O	O
-	NN	O	O
chest	NN	O	O
anesthetized	NN	O	O
dogs	NN	O	O
after	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
either	NN	O	O
pentoxifylline	NN	O	O
(	NN	O	O
0	NN	O	O
,	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
or	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
or	NN	O	O
theophylline	NN	O	O
(	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

Baseline	NN	O	O
circumflex	NN	O	O
coronary	NN	O	O
blood	NN	O	O
flows	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
among	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O

Dipyridamole	NN	O	O
significantly	NN	O	O
increased	NN	O	O
coronary	NN	O	O
blood	NN	O	O
flow	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
or	NN	O	O
15	NN	O	O
mm	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
pentoxifylline	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
002	NN	O	O
)	NN	O	O
.	NN	O	O

Neither	NN	O	O
dose	NN	O	O
of	NN	O	O
pentoxifylline	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
the	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperemia	NN	O	B
,	NN	O	O
while	NN	O	O
peak	NN	O	O
coronary	NN	O	O
blood	NN	O	O
flow	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
after	NN	O	O
theophylline	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
pentoxyifylline	NN	O	O
does	NN	O	O
not	NN	O	O
inhibit	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
induced	NN	O	O
coronary	NN	O	O
hyperemia	NN	O	B
even	NN	O	O
at	NN	O	O
high	NN	O	O
doses	NN	O	O
.	NN	O	O

Cause	NN	O	O
of	NN	O	O
death	NN	O	B
among	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
:	NN	O	O
a	NN	O	O
rare	NN	O	O
mortality	NN	O	O
due	NN	O	O
to	NN	O	O
cerebral	NN	O	B
haemorrhage	NN	O	I
.	NN	O	O

Causes	NN	O	O
of	NN	O	O
death	NN	O	B
,	NN	O	O
with	NN	O	O
special	NN	O	O
reference	NN	O	O
to	NN	O	O
cerebral	NN	O	B
haemorrhage	NN	O	I
,	NN	O	O
among	NN	O	O
240	NN	O	O
patients	NN	O	O
with	NN	O	O
pathologically	NN	O	O
verified	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
were	NN	O	O
investigated	NN	O	O
using	NN	O	O
the	NN	O	O
Annuals	NN	O	O
of	NN	O	O
the	NN	O	O
Pathological	NN	O	O
Autopsy	NN	O	O
Cases	NN	O	O
in	NN	O	O
Japan	NN	O	O
from	NN	O	O
1981	NN	O	O
to	NN	O	O
1985	NN	O	O
.	NN	O	O

The	NN	O	O
leading	NN	O	O
causes	NN	O	O
of	NN	O	O
death	NN	O	B
were	NN	O	O
pneumonia	NN	O	B
and	NN	O	O
bronchitis	NN	O	B
(	NN	O	O
44	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
malignant	NN	O	O
neoplasms	NN	O	B
(	NN	O	O
11	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
heart	NN	O	B
diseases	NN	O	I
(	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
cerebral	NN	O	B
infarction	NN	O	I
(	NN	O	O
3	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
septicaemia	NN	O	B
(	NN	O	O
3	NN	O	O
.	NN	O	O
3	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Cerebral	NN	O	B
haemorrhage	NN	O	I
was	NN	O	O
the	NN	O	O
11th	NN	O	O
most	NN	O	O
frequent	NN	O	O
cause	NN	O	O
of	NN	O	O
death	NN	O	B
,	NN	O	O
accounting	NN	O	O
for	NN	O	O
only	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
of	NN	O	O
deaths	NN	O	B
among	NN	O	O
the	NN	O	O
patients	NN	O	O
,	NN	O	O
whereas	NN	O	O
it	NN	O	O
was	NN	O	O
the	NN	O	O
5th	NN	O	O
most	NN	O	O
common	NN	O	O
cause	NN	O	O
of	NN	O	O
death	NN	O	B
among	NN	O	O
the	NN	O	O
Japanese	NN	O	O
general	NN	O	O
population	NN	O	O
in	NN	O	O
1985	NN	O	O
.	NN	O	O

The	NN	O	O
low	NN	O	O
incidence	NN	O	O
of	NN	O	O
cerebral	NN	O	B
haemorrhage	NN	O	I
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
death	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
may	NN	O	O
reflect	NN	O	O
the	NN	O	O
hypotensive	NN	O	B
effect	NN	O	O
of	NN	O	O
levodopa	NN	O	O
and	NN	O	O
a	NN	O	O
hypotensive	NN	O	B
mechanism	NN	O	O
due	NN	O	O
to	NN	O	O
reduced	NN	O	O
noradrenaline	NN	O	O
levels	NN	O	O
in	NN	O	O
the	NN	O	O
parkinsonian	NN	O	B
brain	NN	O	O
.	NN	O	O

Possible	NN	O	O
intramuscular	NN	O	O
midazolam	NN	O	O
-	NN	O	O
associated	NN	O	O
cardiorespiratory	NN	O	B
arrest	NN	O	I
and	NN	O	O
death	NN	O	B
.	NN	O	O

Midazolam	NN	O	O
hydrochloride	NN	O	O
is	NN	O	O
commonly	NN	O	O
used	NN	O	O
for	NN	O	O
dental	NN	O	O
or	NN	O	O
endoscopic	NN	O	O
procedures	NN	O	O
.	NN	O	O

Although	NN	O	O
generally	NN	O	O
consisted	NN	O	O
safe	NN	O	O
when	NN	O	O
given	NN	O	O
intramuscularly	NN	O	O
,	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
cause	NN	O	O
respiratory	NN	O	B
and	NN	O	I
cardiovascular	NN	O	I
depression	NN	O	I
.	NN	O	O

This	NN	O	O
report	NN	O	O
describes	NN	O	O
the	NN	O	O
first	NN	O	O
published	NN	O	O
case	NN	O	O
of	NN	O	O
cardiorespiratory	NN	O	B
arrest	NN	O	I
and	NN	O	O
death	NN	O	B
associated	NN	O	O
with	NN	O	O
intramuscular	NN	O	O
administration	NN	O	O
of	NN	O	O
midazolam	NN	O	O
.	NN	O	O

Information	NN	O	O
regarding	NN	O	O
midazolam	NN	O	O
use	NN	O	O
is	NN	O	O
reviewed	NN	O	O
to	NN	O	O
provide	NN	O	O
recommendation	NN	O	O
for	NN	O	O
safe	NN	O	O
administration	NN	O	O
.	NN	O	O

Myasthenia	NN	O	B
gravis	NN	O	I
presenting	NN	O	O
as	NN	O	O
weakness	NN	O	O
after	NN	O	O
magnesium	NN	O	O
administration	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
no	NN	O	O
prior	NN	O	O
history	NN	O	O
of	NN	O	O
neuromuscular	NN	O	B
disease	NN	O	I
who	NN	O	O
became	NN	O	O
virtually	NN	O	O
quadriplegic	NN	O	B
after	NN	O	O
parenteral	NN	O	O
magnesium	NN	O	O
administration	NN	O	O
for	NN	O	O
preeclampsia	NN	O	B
.	NN	O	O

The	NN	O	O
serum	NN	O	O
magnesium	NN	O	O
concentration	NN	O	O
was	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
mEq	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
usually	NN	O	O
well	NN	O	O
tolerated	NN	O	O
.	NN	O	O

The	NN	O	O
magnesium	NN	O	O
was	NN	O	O
stopped	NN	O	O
and	NN	O	O
she	NN	O	O
recovered	NN	O	O
over	NN	O	O
a	NN	O	O
few	NN	O	O
days	NN	O	O
.	NN	O	O

While	NN	O	O
she	NN	O	O
was	NN	O	O
weak	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
Hz	NN	O	O
repetitive	NN	O	O
stimulation	NN	O	O
revealed	NN	O	O
a	NN	O	O
decrement	NN	O	O
without	NN	O	O
significant	NN	O	O
facilitation	NN	O	O
at	NN	O	O
rapid	NN	O	O
rates	NN	O	O
or	NN	O	O
after	NN	O	O
exercise	NN	O	O
,	NN	O	O
suggesting	NN	O	O
postsynaptic	NN	O	B
neuromuscular	NN	O	I
blockade	NN	O	I
.	NN	O	O

After	NN	O	O
her	NN	O	O
strength	NN	O	O
returned	NN	O	O
,	NN	O	O
repetitive	NN	O	O
stimulation	NN	O	O
was	NN	O	O
normal	NN	O	O
,	NN	O	O
but	NN	O	O
single	NN	O	O
fiber	NN	O	O
EMG	NN	O	O
revealed	NN	O	O
increased	NN	O	O
jitter	NN	O	O
and	NN	O	O
blocking	NN	O	O
.	NN	O	O

Her	NN	O	O
acetylcholine	NN	O	O
receptor	NN	O	O
antibody	NN	O	O
level	NN	O	O
was	NN	O	O
markedly	NN	O	O
elevated	NN	O	O
.	NN	O	O

Although	NN	O	O
paralysis	NN	O	B
after	NN	O	O
magnesium	NN	O	O
administration	NN	O	O
has	NN	O	O
been	NN	O	O
described	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
known	NN	O	O
myasthenia	NN	O	B
gravis	NN	O	I
,	NN	O	O
it	NN	O	O
has	NN	O	O
not	NN	O	O
previously	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
initial	NN	O	O
or	NN	O	O
only	NN	O	O
manifestation	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
.	NN	O	O

Patients	NN	O	O
who	NN	O	O
are	NN	O	O
unusually	NN	O	O
sensitive	NN	O	O
to	NN	O	O
the	NN	O	O
neuromuscular	NN	O	O
effects	NN	O	O
of	NN	O	O
magnesium	NN	O	O
should	NN	O	O
be	NN	O	O
suspected	NN	O	O
of	NN	O	O
having	NN	O	O
an	NN	O	O
underlying	NN	O	O
disorder	NN	O	B
of	NN	O	I
neuromuscular	NN	O	I
transmission	NN	O	I
.	NN	O	O

No	NN	O	O
enhancement	NN	O	O
by	NN	O	O
phenobarbital	NN	O	O
of	NN	O	O
the	NN	O	O
hepatocarcinogenicity	NN	O	O
of	NN	O	O
a	NN	O	O
choline	NN	O	O
-	NN	O	O
devoid	NN	O	O
diet	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

An	NN	O	O
experiment	NN	O	O
was	NN	O	O
performed	NN	O	O
to	NN	O	O
test	NN	O	O
whether	NN	O	O
inclusion	NN	O	O
of	NN	O	O
phenobarbital	NN	O	O
in	NN	O	O
a	NN	O	O
choline	NN	O	O
-	NN	O	O
devoid	NN	O	O
diet	NN	O	O
would	NN	O	O
increase	NN	O	O
the	NN	O	O
hepatocarcinogenicity	NN	O	O
of	NN	O	O
the	NN	O	O
diet	NN	O	O
.	NN	O	O

Groups	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
week	NN	O	O
old	NN	O	O
male	NN	O	O
Fischer	NN	O	O
-	NN	O	O
344	NN	O	O
rats	NN	O	O
were	NN	O	O
fed	NN	O	O
for	NN	O	O
7	NN	O	O
-	NN	O	O
25	NN	O	O
months	NN	O	O
semipurified	NN	O	O
choline	NN	O	O
-	NN	O	O
devoid	NN	O	O
or	NN	O	O
choline	NN	O	O
-	NN	O	O
supplemented	NN	O	O
diets	NN	O	O
,	NN	O	O
containing	NN	O	O
or	NN	O	O
not	NN	O	O
0	NN	O	O
.	NN	O	O
06	NN	O	O
%	NN	O	O
phenobarbital	NN	O	O
.	NN	O	O

No	NN	O	O
hepatic	NN	O	O
preneoplastic	NN	O	O
nodules	NN	O	O
or	NN	O	O
hepatocellular	NN	O	B
carcinomas	NN	O	I
developed	NN	O	O
in	NN	O	O
rats	NN	O	O
fed	NN	O	O
the	NN	O	O
plain	NN	O	O
choline	NN	O	O
-	NN	O	O
supplemented	NN	O	O
diet	NN	O	O
,	NN	O	O
while	NN	O	O
one	NN	O	O
preneoplastic	NN	O	O
nodule	NN	O	O
and	NN	O	O
one	NN	O	O
hepatocellular	NN	O	B
carcinoma	NN	O	I
developed	NN	O	O
in	NN	O	O
two	NN	O	O
rats	NN	O	O
fed	NN	O	O
the	NN	O	O
same	NN	O	O
diet	NN	O	O
containing	NN	O	O
phenobarbital	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
preneoplastic	NN	O	O
nodules	NN	O	O
and	NN	O	O
of	NN	O	O
hepatocellular	NN	O	B
carcinomas	NN	O	I
was	NN	O	O
10	NN	O	O
%	NN	O	O
and	NN	O	O
37	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
rats	NN	O	O
fed	NN	O	O
the	NN	O	O
plain	NN	O	O
choline	NN	O	O
-	NN	O	O
devoid	NN	O	O
diet	NN	O	O
,	NN	O	O
and	NN	O	O
17	NN	O	O
%	NN	O	O
and	NN	O	O
30	NN	O	O
%	NN	O	O
,	NN	O	O
in	NN	O	O
rats	NN	O	O
fed	NN	O	O
the	NN	O	O
phenobarbital	NN	O	O
-	NN	O	O
containing	NN	O	O
choline	NN	O	O
-	NN	O	O
devoid	NN	O	O
diet	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
evinced	NN	O	O
no	NN	O	O
enhancement	NN	O	O
of	NN	O	O
the	NN	O	O
hepatocarcinogenicity	NN	O	O
of	NN	O	O
the	NN	O	O
choline	NN	O	O
-	NN	O	O
devoid	NN	O	O
diet	NN	O	O
by	NN	O	O
phenobarbital	NN	O	O
.	NN	O	O

Sporadic	NN	O	O
neoplastic	NN	O	O
lesions	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
organs	NN	O	O
other	NN	O	O
than	NN	O	O
the	NN	O	O
liver	NN	O	O
of	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
,	NN	O	O
irrespective	NN	O	O
of	NN	O	O
the	NN	O	O
diet	NN	O	O
fed	NN	O	O
.	NN	O	O

On	NN	O	O
two	NN	O	O
paradoxical	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
of	NN	O	O
prednisolone	NN	O	O
in	NN	O	O
rats	NN	O	O
,	NN	O	O
ribosomal	NN	O	O
RNA	NN	O	O
biosyntheses	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
mechanism	NN	O	O
of	NN	O	O
action	NN	O	O
.	NN	O	O

Liver	NN	O	B
enlargement	NN	O	I
and	NN	O	O
muscle	NN	O	B
wastage	NN	O	I
occurred	NN	O	O
in	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
following	NN	O	O
the	NN	O	O
subcutaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
prednisolone	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
liver	NN	O	O
both	NN	O	O
the	NN	O	O
content	NN	O	O
of	NN	O	O
RNA	NN	O	O
and	NN	O	O
the	NN	O	O
biosynthesis	NN	O	O
of	NN	O	O
ribosomal	NN	O	O
RNA	NN	O	O
increased	NN	O	O
while	NN	O	O
both	NN	O	O
the	NN	O	O
RNA	NN	O	O
content	NN	O	O
and	NN	O	O
ribosomal	NN	O	O
RNA	NN	O	O
biosynthesis	NN	O	O
were	NN	O	O
reduced	NN	O	O
in	NN	O	O
the	NN	O	O
gastrocnemius	NN	O	O
muscle	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
drug	NN	O	O
acted	NN	O	O
in	NN	O	O
a	NN	O	O
selective	NN	O	O
and	NN	O	O
tissue	NN	O	O
-	NN	O	O
specific	NN	O	O
manner	NN	O	O
to	NN	O	O
enhance	NN	O	O
ribosomal	NN	O	O
RNA	NN	O	O
synthesis	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
depress	NN	O	O
such	NN	O	O
synthesis	NN	O	O
in	NN	O	O
the	NN	O	O
muscle	NN	O	O
.	NN	O	O

This	NN	O	O
view	NN	O	O
supports	NN	O	O
the	NN	O	O
contention	NN	O	O
that	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
muscle	NN	O	O
are	NN	O	O
independent	NN	O	O
sites	NN	O	O
of	NN	O	O
prednisolone	NN	O	O
action	NN	O	O
.	NN	O	O

Differential	NN	O	O
effects	NN	O	O
of	NN	O	O
gamma	NN	O	O
-	NN	O	O
hexachlorocyclohexane	NN	O	O
(	NN	O	O
lindane	NN	O	O
)	NN	O	O
on	NN	O	O
pharmacologically	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
.	NN	O	O

Gamma	NN	O	O
-	NN	O	O
hexachlorocyclohexane	NN	O	O
(	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
active	NN	O	O
ingredient	NN	O	O
of	NN	O	O
the	NN	O	O
insecticide	NN	O	O
lindane	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
decrease	NN	O	O
seizure	NN	O	B
threshold	NN	O	O
to	NN	O	O
pentylenetrazol	NN	O	O
(	NN	O	O
PTZ	NN	O	O
)	NN	O	O
3	NN	O	O
h	NN	O	O
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
and	NN	O	O
conversely	NN	O	O
increase	NN	O	O
threshold	NN	O	O
to	NN	O	O
PTZ	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
24	NN	O	O
h	NN	O	O
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
(	NN	O	O
Vohland	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O
1981	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
response	NN	O	O
to	NN	O	O
other	NN	O	O
seizure	NN	O	B
-	NN	O	O
inducing	NN	O	O
agents	NN	O	O
was	NN	O	O
tested	NN	O	O
in	NN	O	O
mice	NN	O	O
1	NN	O	O
and	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
intraperitoneal	NN	O	O
administration	NN	O	O
of	NN	O	O
80	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
.	NN	O	O

One	NN	O	O
hour	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
,	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
seizure	NN	O	B
-	NN	O	O
inducing	NN	O	O
agents	NN	O	O
was	NN	O	O
increased	NN	O	O
,	NN	O	O
regardless	NN	O	O
of	NN	O	O
their	NN	O	O
mechanism	NN	O	O
,	NN	O	O
while	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
a	NN	O	O
differential	NN	O	O
response	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Seizure	NN	O	B
activity	NN	O	O
due	NN	O	O
to	NN	O	O
PTZ	NN	O	O
and	NN	O	O
picrotoxin	NN	O	O
(	NN	O	O
PTX	NN	O	O
)	NN	O	O
was	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
seizure	NN	O	B
activity	NN	O	O
due	NN	O	O
to	NN	O	O
3	NN	O	O
-	NN	O	O
mercaptopropionic	NN	O	O
acid	NN	O	O
(	NN	O	O
MPA	NN	O	O
)	NN	O	O
,	NN	O	O
bicuculline	NN	O	O
(	NN	O	O
BCC	NN	O	O
)	NN	O	O
,	NN	O	O
methyl	NN	O	O
6	NN	O	O
,	NN	O	O
7	NN	O	O
-	NN	O	O
dimethoxy	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
ethyl	NN	O	O
-	NN	O	O
B	NN	O	O
-	NN	O	O
carboline	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
carboxylate	NN	O	O
(	NN	O	O
DMCM	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
strychnine	NN	O	O
(	NN	O	O
STR	NN	O	O
)	NN	O	O
was	NN	O	O
not	NN	O	O
different	NN	O	O
from	NN	O	O
control	NN	O	O
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
,	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
,	NN	O	O
pentylenetetrazol	NN	O	O
and	NN	O	O
picrotoxin	NN	O	O
were	NN	O	O
shown	NN	O	O
to	NN	O	O
inhibit	NN	O	O
3H	NN	O	O
-	NN	O	O
TBOB	NN	O	O
binding	NN	O	O
in	NN	O	O
mouse	NN	O	O
whole	NN	O	O
brain	NN	O	O
,	NN	O	O
with	NN	O	O
IC50	NN	O	O
values	NN	O	O
of	NN	O	O
4	NN	O	O
.	NN	O	O
6	NN	O	O
,	NN	O	O
404	NN	O	O
and	NN	O	O
9	NN	O	O
.	NN	O	O
4	NN	O	O
microM	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

MPA	NN	O	O
,	NN	O	O
BCC	NN	O	O
,	NN	O	O
DMCM	NN	O	O
,	NN	O	O
and	NN	O	O
STR	NN	O	O
showed	NN	O	O
no	NN	O	O
inhibition	NN	O	O
of	NN	O	O
3H	NN	O	O
-	NN	O	O
TBOB	NN	O	O
(	NN	O	O
t	NN	O	O
-	NN	O	O
butyl	NN	O	O
bicyclo	NN	O	O
-	NN	O	O
orthobenzoate	NN	O	O
)	NN	O	O
binding	NN	O	O
at	NN	O	O
concentrations	NN	O	O
of	NN	O	O
100	NN	O	O
micron	NN	O	O
.	NN	O	O

The	NN	O	O
pharmacological	NN	O	O
challenge	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
tolerance	NN	O	O
may	NN	O	O
occur	NN	O	O
to	NN	O	O
seizure	NN	O	B
activity	NN	O	O
induced	NN	O	O
by	NN	O	O
PTZ	NN	O	O
and	NN	O	O
PTX	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
,	NN	O	O
since	NN	O	O
the	NN	O	O
response	NN	O	O
to	NN	O	O
only	NN	O	O
these	NN	O	O
two	NN	O	O
seizure	NN	O	B
-	NN	O	O
inducing	NN	O	O
agents	NN	O	O
is	NN	O	O
decreased	NN	O	O
.	NN	O	O

The	NN	O	O
in	NN	O	O
vitro	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
site	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
seizure	NN	O	B
activity	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
gamma	NN	O	O
-	NN	O	O
HCH	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
GABA	NN	O	O
-	NN	O	O
A	NN	O	O
receptor	NN	O	O
-	NN	O	O
linked	NN	O	O
chloride	NN	O	O
channel	NN	O	O
.	NN	O	O

Tolerance	NN	O	O
and	NN	O	O
antiviral	NN	O	O
effect	NN	O	O
of	NN	O	O
ribavirin	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Argentine	NN	O	B
hemorrhagic	NN	O	I
fever	NN	O	I
.	NN	O	O

Tolerance	NN	O	O
and	NN	O	O
antiviral	NN	O	O
effect	NN	O	O
of	NN	O	O
ribavirin	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
6	NN	O	O
patients	NN	O	O
with	NN	O	O
Argentine	NN	O	B
hemorrhagic	NN	O	I
fever	NN	O	I
(	NN	O	O
AHF	NN	O	B
)	NN	O	O
of	NN	O	O
more	NN	O	O
than	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
evolution	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
ribavirin	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
neutralization	NN	O	O
of	NN	O	O
viremia	NN	O	B
and	NN	O	O
a	NN	O	O
drop	NN	O	O
of	NN	O	O
endogenous	NN	O	O
interferon	NN	O	O
titers	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
time	NN	O	O
of	NN	O	O
death	NN	O	B
was	NN	O	O
delayed	NN	O	O
.	NN	O	O

A	NN	O	O
reversible	NN	O	O
anemia	NN	O	B
was	NN	O	O
the	NN	O	O
only	NN	O	O
adverse	NN	O	O
effect	NN	O	O
observed	NN	O	O
.	NN	O	O

From	NN	O	O
these	NN	O	O
results	NN	O	O
,	NN	O	O
we	NN	O	O
conclude	NN	O	O
that	NN	O	O
ribavirin	NN	O	O
has	NN	O	O
an	NN	O	O
antiviral	NN	O	O
effect	NN	O	O
in	NN	O	O
advanced	NN	O	O
cases	NN	O	O
of	NN	O	O
AHF	NN	O	B
,	NN	O	O
and	NN	O	O
that	NN	O	O
anemia	NN	O	B
,	NN	O	O
the	NN	O	O
only	NN	O	O
secondary	NN	O	O
reaction	NN	O	O
observed	NN	O	O
,	NN	O	O
can	NN	O	O
be	NN	O	O
easily	NN	O	O
managed	NN	O	O
.	NN	O	O

The	NN	O	O
possible	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
ribavirin	NN	O	O
during	NN	O	O
the	NN	O	O
initial	NN	O	O
days	NN	O	O
of	NN	O	O
AHF	NN	O	B
is	NN	O	O
discussed	NN	O	O
.	NN	O	O

Is	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
scabies	NN	O	B
hazardous	NN	O	O
?	NN	O	O

Treatment	NN	O	O
for	NN	O	O
scabies	NN	O	B
is	NN	O	O
usually	NN	O	O
initiated	NN	O	O
by	NN	O	O
general	NN	O	O
practitioners	NN	O	O
;	NN	O	O
most	NN	O	O
consider	NN	O	O
lindane	NN	O	O
(	NN	O	O
gamma	NN	O	O
benzene	NN	O	O
hexachloride	NN	O	O
)	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
choice	NN	O	O
.	NN	O	O

Lindane	NN	O	O
is	NN	O	O
also	NN	O	O
widely	NN	O	O
used	NN	O	O
as	NN	O	O
an	NN	O	O
agricultural	NN	O	O
and	NN	O	O
industrial	NN	O	O
pesticide	NN	O	O
,	NN	O	O
and	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
the	NN	O	O
toxic	NN	O	O
profile	NN	O	O
of	NN	O	O
this	NN	O	O
insecticide	NN	O	O
is	NN	O	O
well	NN	O	O
understood	NN	O	O
.	NN	O	O

Evidence	NN	O	O
is	NN	O	O
accumulating	NN	O	O
that	NN	O	O
lindane	NN	O	O
can	NN	O	O
be	NN	O	O
toxic	NN	O	B
to	NN	O	I
the	NN	O	I
central	NN	O	I
nervous	NN	O	I
system	NN	O	I
and	NN	O	O
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
aplastic	NN	O	B
anaemia	NN	O	I
.	NN	O	O

Preparations	NN	O	O
containing	NN	O	O
lindane	NN	O	O
continue	NN	O	O
to	NN	O	O
be	NN	O	O
sold	NN	O	O
over	NN	O	O
the	NN	O	O
counter	NN	O	O
and	NN	O	O
may	NN	O	O
represent	NN	O	O
a	NN	O	O
hazard	NN	O	O
to	NN	O	O
poorly	NN	O	O
informed	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
literature	NN	O	O
review	NN	O	O
suggests	NN	O	O
that	NN	O	O
general	NN	O	O
practitioners	NN	O	O
should	NN	O	O
prescribe	NN	O	O
scabicides	NN	O	O
with	NN	O	O
increased	NN	O	O
caution	NN	O	O
for	NN	O	O
certain	NN	O	O
at	NN	O	O
-	NN	O	O
risk	NN	O	O
groups	NN	O	O
,	NN	O	O
and	NN	O	O
give	NN	O	O
adequate	NN	O	O
warnings	NN	O	O
regarding	NN	O	O
potential	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Mouse	NN	O	O
strain	NN	O	O
-	NN	O	O
dependent	NN	O	O
effect	NN	O	O
of	NN	O	O
amantadine	NN	O	O
on	NN	O	O
motility	NN	O	O
and	NN	O	O
brain	NN	O	O
biogenic	NN	O	O
amines	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
amantadine	NN	O	O
hydrochloride	NN	O	O
,	NN	O	O
injected	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
in	NN	O	O
6	NN	O	O
increments	NN	O	O
of	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
each	NN	O	O
over	NN	O	O
30	NN	O	O
hr	NN	O	O
,	NN	O	O
on	NN	O	O
mouse	NN	O	O
motility	NN	O	O
and	NN	O	O
whole	NN	O	O
brain	NN	O	O
content	NN	O	O
of	NN	O	O
selected	NN	O	O
biogenic	NN	O	O
amines	NN	O	O
and	NN	O	O
major	NN	O	O
metabolites	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
4	NN	O	O
strains	NN	O	O
of	NN	O	O
mice	NN	O	O
.	NN	O	O

These	NN	O	O
were	NN	O	O
the	NN	O	O
albino	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
ICR	NN	O	O
and	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
,	NN	O	O
the	NN	O	O
black	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
and	NN	O	O
the	NN	O	O
brown	NN	O	O
CDF	NN	O	O
-	NN	O	O
I	NN	O	O
mouse	NN	O	O
strains	NN	O	O
.	NN	O	O

Amantadine	NN	O	O
treatment	NN	O	O
produced	NN	O	O
a	NN	O	O
biphasic	NN	O	O
effect	NN	O	O
on	NN	O	O
mouse	NN	O	O
motility	NN	O	O
.	NN	O	O

The	NN	O	O
initial	NN	O	O
dose	NN	O	O
of	NN	O	O
amantadine	NN	O	O
depressed	NN	O	B
locomotor	NN	O	O
activity	NN	O	O
in	NN	O	O
all	NN	O	O
mouse	NN	O	O
strains	NN	O	O
studied	NN	O	O
with	NN	O	O
the	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
mice	NN	O	O
being	NN	O	O
the	NN	O	O
most	NN	O	O
sensitive	NN	O	O
.	NN	O	O

Subsequent	NN	O	O
amantadine	NN	O	O
treatments	NN	O	O
produced	NN	O	O
enhancement	NN	O	O
of	NN	O	O
motility	NN	O	O
from	NN	O	O
corresponding	NN	O	O
control	NN	O	O
in	NN	O	O
all	NN	O	O
mouse	NN	O	O
strains	NN	O	O
with	NN	O	O
the	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
mice	NN	O	O
being	NN	O	O
the	NN	O	O
least	NN	O	O
sensitive	NN	O	O
.	NN	O	O

The	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
was	NN	O	O
decreased	NN	O	O
from	NN	O	O
corresponding	NN	O	O
controls	NN	O	O
in	NN	O	O
all	NN	O	O
strains	NN	O	O
studied	NN	O	O
,	NN	O	O
except	NN	O	O
for	NN	O	O
the	NN	O	O
ICR	NN	O	O
mice	NN	O	O
,	NN	O	O
during	NN	O	O
an	NN	O	O
overnight	NN	O	O
drug	NN	O	O
-	NN	O	O
free	NN	O	O
period	NN	O	O
following	NN	O	O
the	NN	O	O
fourth	NN	O	O
amantadine	NN	O	O
treatment	NN	O	O
.	NN	O	O

Readministration	NN	O	O
of	NN	O	O
amantadine	NN	O	O
,	NN	O	O
after	NN	O	O
a	NN	O	O
drug	NN	O	O
-	NN	O	O
free	NN	O	O
overnight	NN	O	O
period	NN	O	O
,	NN	O	O
increased	NN	O	O
motility	NN	O	O
from	NN	O	O
respective	NN	O	O
saline	NN	O	O
control	NN	O	O
in	NN	O	O
all	NN	O	O
strains	NN	O	O
with	NN	O	O
exception	NN	O	O
of	NN	O	O
the	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
mice	NN	O	O
where	NN	O	O
suppression	NN	O	B
of	NN	O	I
motility	NN	O	I
occurred	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
amantadine	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
whole	NN	O	O
brain	NN	O	O
dopamine	NN	O	O
levels	NN	O	O
but	NN	O	O
decreased	NN	O	O
the	NN	O	O
amounts	NN	O	O
of	NN	O	O
3	NN	O	O
,	NN	O	O
4	NN	O	O
-	NN	O	O
dihydroxyphenylacetic	NN	O	O
acid	NN	O	O
in	NN	O	O
the	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
mice	NN	O	O
compared	NN	O	O
to	NN	O	O
saline	NN	O	O
control	NN	O	O
.	NN	O	O

Conversely	NN	O	O
,	NN	O	O
brain	NN	O	O
normetanephrine	NN	O	O
concentration	NN	O	O
was	NN	O	O
increased	NN	O	O
from	NN	O	O
saline	NN	O	O
control	NN	O	O
by	NN	O	O
amantadine	NN	O	O
in	NN	O	O
the	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
a	NN	O	O
strain	NN	O	O
-	NN	O	O
dependent	NN	O	O
effect	NN	O	O
of	NN	O	O
amantadine	NN	O	O
on	NN	O	O
motility	NN	O	O
and	NN	O	O
indicate	NN	O	O
a	NN	O	O
differential	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
acute	NN	O	O
and	NN	O	O
multiple	NN	O	O
dose	NN	O	O
regimens	NN	O	O
used	NN	O	O
.	NN	O	O

The	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
mouse	NN	O	O
was	NN	O	O
the	NN	O	O
most	NN	O	O
sensitive	NN	O	O
strain	NN	O	O
and	NN	O	O
could	NN	O	O
serve	NN	O	O
as	NN	O	O
the	NN	O	O
strain	NN	O	O
of	NN	O	O
choice	NN	O	O
for	NN	O	O
evaluating	NN	O	O
the	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
amantadine	NN	O	O
.	NN	O	O

The	NN	O	O
biochemical	NN	O	O
results	NN	O	O
of	NN	O	O
brain	NN	O	O
biogenic	NN	O	O
amines	NN	O	O
of	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
mouse	NN	O	O
strain	NN	O	O
suggest	NN	O	O
a	NN	O	O
probable	NN	O	O
decrease	NN	O	O
of	NN	O	O
catecholamine	NN	O	O
turnover	NN	O	O
rate	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
metabolism	NN	O	O
by	NN	O	O
monoamine	NN	O	O
oxidase	NN	O	O
and	NN	O	O
a	NN	O	O
resulting	NN	O	O
increase	NN	O	O
in	NN	O	O
O	NN	O	O
-	NN	O	O
methylation	NN	O	O
of	NN	O	O
norepinephrine	NN	O	O
which	NN	O	O
may	NN	O	O
account	NN	O	O
for	NN	O	O
a	NN	O	O
behavioral	NN	O	B
depression	NN	O	I
caused	NN	O	O
by	NN	O	O
amantadine	NN	O	O
in	NN	O	O
the	NN	O	O
BALB	NN	O	O
/	NN	O	O
C	NN	O	O
mice	NN	O	O
.	NN	O	O

Chloroacetaldehyde	NN	O	O
and	NN	O	O
its	NN	O	O
contribution	NN	O	O
to	NN	O	O
urotoxicity	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	O
or	NN	O	O
ifosfamide	NN	O	O
.	NN	O	O

An	NN	O	O
experimental	NN	O	O
study	NN	O	O
/	NN	O	O
short	NN	O	O
communication	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
clinical	NN	O	O
data	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
chloroacetaldehyde	NN	O	O
(	NN	O	O
CAA	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
metabolite	NN	O	O
of	NN	O	O
oxazaphosphorine	NN	O	O
cytostatics	NN	O	O
,	NN	O	O
an	NN	O	O
experimental	NN	O	O
study	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
elucidate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
CAA	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
.	NN	O	O

The	NN	O	O
data	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
CAA	NN	O	O
after	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
administration	NN	O	O
does	NN	O	O
not	NN	O	O
contribute	NN	O	O
to	NN	O	O
bladder	NN	O	B
damage	NN	O	I
.	NN	O	O

When	NN	O	O
instilled	NN	O	O
directly	NN	O	O
into	NN	O	O
the	NN	O	O
bladder	NN	O	O
,	NN	O	O
CAA	NN	O	O
exerts	NN	O	O
urotoxic	NN	O	O
effects	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
susceptible	NN	O	O
to	NN	O	O
detoxification	NN	O	O
with	NN	O	O
mesna	NN	O	O
.	NN	O	O

Source	NN	O	O
of	NN	O	O
pain	NN	O	B
and	NN	O	O
primitive	NN	O	O
dysfunction	NN	O	O
in	NN	O	O
migraine	NN	O	B
:	NN	O	O
an	NN	O	O
identical	NN	O	O
site	NN	O	O
?	NN	O	O

Twenty	NN	O	O
common	NN	O	O
migraine	NN	O	B
patients	NN	O	O
received	NN	O	O
a	NN	O	O
one	NN	O	O
sided	NN	O	O
frontotemporal	NN	O	O
application	NN	O	O
of	NN	O	O
nitroglycerin	NN	O	O
(	NN	O	O
10	NN	O	O
patients	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	O
ointment	NN	O	O
(	NN	O	O
10	NN	O	O
patients	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
blind	NN	O	O
study	NN	O	O
.	NN	O	O

Early	NN	O	O
onset	NN	O	O
migraine	NN	O	B
attacks	NN	O	O
were	NN	O	O
induced	NN	O	O
by	NN	O	O
nitroglycerin	NN	O	O
in	NN	O	O
seven	NN	O	O
out	NN	O	O
of	NN	O	O
10	NN	O	O
patients	NN	O	O
versus	NN	O	O
no	NN	O	O
patient	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

Subsequently	NN	O	O
20	NN	O	O
migraine	NN	O	B
patients	NN	O	O
,	NN	O	O
who	NN	O	O
developed	NN	O	O
an	NN	O	O
early	NN	O	O
onset	NN	O	O
attack	NN	O	O
with	NN	O	O
frontotemporal	NN	O	O
nitroglycerin	NN	O	O
,	NN	O	O
received	NN	O	O
the	NN	O	O
drug	NN	O	O
in	NN	O	O
a	NN	O	O
second	NN	O	O
induction	NN	O	O
test	NN	O	O
at	NN	O	O
other	NN	O	O
body	NN	O	O
areas	NN	O	O
.	NN	O	O

No	NN	O	O
early	NN	O	O
onset	NN	O	O
migraine	NN	O	B
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Thus	NN	O	O
the	NN	O	O
migraine	NN	O	B
-	NN	O	O
inducing	NN	O	O
effect	NN	O	O
of	NN	O	O
nitroglycerin	NN	O	O
seems	NN	O	O
to	NN	O	O
depend	NN	O	O
on	NN	O	O
direct	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
habitual	NN	O	O
site	NN	O	O
of	NN	O	O
pain	NN	O	B
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
the	NN	O	O
frontotemporal	NN	O	O
region	NN	O	O
is	NN	O	O
of	NN	O	O
crucial	NN	O	O
importance	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
a	NN	O	O
migraine	NN	O	B
crisis	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
not	NN	O	O
consistent	NN	O	O
with	NN	O	O
a	NN	O	O
CNS	NN	O	O
origin	NN	O	O
of	NN	O	O
migraine	NN	O	B
attack	NN	O	O
.	NN	O	O

Hypersensitivity	NN	O	B
to	NN	O	O
carbamazepine	NN	O	O
presenting	NN	O	O
with	NN	O	O
a	NN	O	O
leukemoid	NN	O	B
reaction	NN	O	I
,	NN	O	O
eosinophilia	NN	O	B
,	NN	O	O
erythroderma	NN	O	B
,	NN	O	O
and	NN	O	O
renal	NN	O	B
failure	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
patient	NN	O	O
in	NN	O	O
whom	NN	O	O
hypersensitivity	NN	O	B
to	NN	O	O
carbamazepine	NN	O	O
presented	NN	O	O
with	NN	O	O
generalized	NN	O	O
erythroderma	NN	O	B
,	NN	O	O
a	NN	O	O
severe	NN	O	O
leukemoid	NN	O	B
reaction	NN	O	I
,	NN	O	O
eosinophilia	NN	O	B
,	NN	O	O
hyponatremia	NN	O	B
,	NN	O	O
and	NN	O	O
renal	NN	O	B
failure	NN	O	I
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
report	NN	O	O
of	NN	O	O
such	NN	O	O
an	NN	O	O
unusual	NN	O	O
reaction	NN	O	O
to	NN	O	O
carbamazepine	NN	O	O
.	NN	O	O

Fluoxetine	NN	O	O
-	NN	O	O
induced	NN	O	O
akathisia	NN	O	B
:	NN	O	O
clinical	NN	O	O
and	NN	O	O
theoretical	NN	O	O
implications	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
receiving	NN	O	O
fluoxetine	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
obsessive	NN	O	B
compulsive	NN	O	I
disorder	NN	O	I
or	NN	O	O
major	NN	O	B
depression	NN	O	I
developed	NN	O	O
akathisia	NN	O	B
.	NN	O	O

The	NN	O	O
typical	NN	O	O
fluoxetine	NN	O	O
-	NN	O	O
induced	NN	O	O
symptoms	NN	O	O
of	NN	O	O
restlessness	NN	O	O
,	NN	O	O
constant	NN	O	O
pacing	NN	O	O
,	NN	O	O
purposeless	NN	O	O
movements	NN	O	O
of	NN	O	O
the	NN	O	O
feet	NN	O	O
and	NN	O	O
legs	NN	O	O
,	NN	O	O
and	NN	O	O
marked	NN	O	O
anxiety	NN	O	B
were	NN	O	O
indistinguishable	NN	O	O
from	NN	O	O
those	NN	O	O
of	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
akathisia	NN	O	B
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
experienced	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
akathisia	NN	O	B
in	NN	O	O
the	NN	O	O
past	NN	O	O
reported	NN	O	O
that	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
fluoxetine	NN	O	O
-	NN	O	O
induced	NN	O	O
akathisia	NN	O	B
were	NN	O	O
identical	NN	O	O
,	NN	O	O
although	NN	O	O
somewhat	NN	O	O
milder	NN	O	O
.	NN	O	O

Akathisia	NN	O	B
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
common	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
fluoxetine	NN	O	O
and	NN	O	O
generally	NN	O	O
responded	NN	O	O
well	NN	O	O
to	NN	O	O
treatment	NN	O	O
with	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
antagonist	NN	O	O
propranolol	NN	O	O
,	NN	O	O
dose	NN	O	O
reduction	NN	O	O
,	NN	O	O
or	NN	O	O
both	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
suggest	NN	O	O
that	NN	O	O
fluoxetine	NN	O	O
-	NN	O	O
induced	NN	O	O
akathisia	NN	O	B
may	NN	O	O
be	NN	O	O
caused	NN	O	O
by	NN	O	O
serotonergically	NN	O	O
mediated	NN	O	O
inhibition	NN	O	O
of	NN	O	O
dopaminergic	NN	O	O
neurotransmission	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
fluoxetine	NN	O	O
-	NN	O	O
induced	NN	O	O
akathisia	NN	O	B
and	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
-	NN	O	O
induced	NN	O	O
"	NN	O	O
jitteriness	NN	O	O
"	NN	O	O
may	NN	O	O
be	NN	O	O
identical	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibition	NN	O	O
on	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
(	NN	O	O
CEI	NN	O	O
)	NN	O	O
enalapril	NN	O	O
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
Munich	NN	O	O
-	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
with	NN	O	O
established	NN	O	O
adriamycin	NN	O	O
nephrosis	NN	O	B
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
given	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
adriamycin	NN	O	O
and	NN	O	O
one	NN	O	O
month	NN	O	O
later	NN	O	O
divided	NN	O	O
into	NN	O	O
four	NN	O	O
groups	NN	O	O
matched	NN	O	O
for	NN	O	O
albuminuria	NN	O	B
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
and	NN	O	O
plasma	NN	O	O
albumin	NN	O	O
concentration	NN	O	O
.	NN	O	O

Groups	NN	O	O
1	NN	O	O
and	NN	O	O
3	NN	O	O
remained	NN	O	O
untreated	NN	O	O
while	NN	O	O
groups	NN	O	O
2	NN	O	O
and	NN	O	O
4	NN	O	O
received	NN	O	O
enalapril	NN	O	O
.	NN	O	O

Groups	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
underwent	NN	O	O
micropuncture	NN	O	O
studies	NN	O	O
after	NN	O	O
10	NN	O	O
days	NN	O	O
.	NN	O	O

These	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
studies	NN	O	O
showed	NN	O	O
that	NN	O	O
enalapril	NN	O	O
reduced	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
101	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
vs	NN	O	O
.	NN	O	O
124	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
group	NN	O	O
2	NN	O	O
vs	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
and	NN	O	O
glomerular	NN	O	O
capillary	NN	O	O
pressure	NN	O	O
(	NN	O	O
54	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
vs	NN	O	O
.	NN	O	O
61	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
without	NN	O	O
reducing	NN	O	O
albuminuria	NN	O	B
(	NN	O	O
617	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
50	NN	O	O
vs	NN	O	O
.	NN	O	O
570	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
47	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
or	NN	O	O
GFR	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
03	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
04	NN	O	O
vs	NN	O	O
.	NN	O	O
1	NN	O	O
.	NN	O	O
04	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
11	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
.	NN	O	O

Groups	NN	O	O
3	NN	O	O
and	NN	O	O
4	NN	O	O
were	NN	O	O
studied	NN	O	O
at	NN	O	O
four	NN	O	O
and	NN	O	O
at	NN	O	O
six	NN	O	O
months	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
enalapril	NN	O	O
on	NN	O	O
progression	NN	O	O
of	NN	O	O
renal	NN	O	B
injury	NN	O	I
in	NN	O	O
adriamycin	NN	O	O
nephrosis	NN	O	B
.	NN	O	O

Chronic	NN	O	O
enalapril	NN	O	O
treatment	NN	O	O
reduced	NN	O	O
blood	NN	O	O
pressure	NN	O	O
without	NN	O	O
reducing	NN	O	O
albuminuria	NN	O	B
in	NN	O	O
group	NN	O	O
4	NN	O	O
.	NN	O	O

Untreated	NN	O	O
group	NN	O	O
3	NN	O	O
rats	NN	O	O
exhibited	NN	O	O
a	NN	O	O
progressive	NN	O	O
reduction	NN	O	O
in	NN	O	O
GFR	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
35	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
08	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
at	NN	O	O
4	NN	O	O
months	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
27	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
07	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
at	NN	O	O
6	NN	O	O
months	NN	O	O
)	NN	O	O
.	NN	O	O

Enalapril	NN	O	O
treatment	NN	O	O
blunted	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
reduction	NN	O	O
in	NN	O	O
GFR	NN	O	O
in	NN	O	O
group	NN	O	O
4	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
86	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
15	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
at	NN	O	O
4	NN	O	O
months	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
69	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
13	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
at	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
both	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
vs	NN	O	O
.	NN	O	O
group	NN	O	O
3	NN	O	O
)	NN	O	O
.	NN	O	O

Reduction	NN	O	O
in	NN	O	O
GFR	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
glomerular	NN	O	B
sclerosis	NN	O	I
in	NN	O	O
both	NN	O	O
treated	NN	O	O
and	NN	O	O
untreated	NN	O	O
rats	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Clotiazepam	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
with	NN	O	O
extensive	NN	O	B
hepatocellular	NN	O	I
necrosis	NN	O	I
,	NN	O	O
7	NN	O	O
months	NN	O	O
after	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
administration	NN	O	O
of	NN	O	O
clotiazepam	NN	O	O
,	NN	O	O
a	NN	O	O
thienodiazepine	NN	O	O
derivative	NN	O	O
.	NN	O	O

Clotiazepam	NN	O	O
withdrawal	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
prompt	NN	O	O
recovery	NN	O	O
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
several	NN	O	O
benzodiazepines	NN	O	O
,	NN	O	O
chemically	NN	O	O
related	NN	O	O
to	NN	O	O
clotiazepam	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
interfere	NN	O	O
with	NN	O	O
recovery	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
induce	NN	O	O
any	NN	O	O
relapse	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

This	NN	O	O
observation	NN	O	O
shows	NN	O	O
that	NN	O	O
clotiazepam	NN	O	O
can	NN	O	O
induce	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
and	NN	O	O
suggests	NN	O	O
that	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
cross	NN	O	O
hepatotoxicity	NN	O	B
between	NN	O	O
clotiazepam	NN	O	O
and	NN	O	O
several	NN	O	O
benzodiazepines	NN	O	O
.	NN	O	O

5	NN	O	O
-	NN	O	O
azacytidine	NN	O	O
potentiates	NN	O	O
initiation	NN	O	B
induced	NN	O	I
by	NN	O	I
carcinogens	NN	O	I
in	NN	O	O
rat	NN	O	O
liver	NN	O	O
.	NN	O	O

To	NN	O	O
test	NN	O	O
the	NN	O	O
validity	NN	O	O
of	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
hypomethylation	NN	O	O
of	NN	O	O
DNA	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
initiation	NN	O	B
of	NN	O	I
carcinogenic	NN	O	I
process	NN	O	I
,	NN	O	O
5	NN	O	O
-	NN	O	O
azacytidine	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
AzC	NN	O	O
)	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
DNA	NN	O	O
methylation	NN	O	O
,	NN	O	O
was	NN	O	O
given	NN	O	O
to	NN	O	O
rats	NN	O	O
during	NN	O	O
the	NN	O	O
phase	NN	O	O
of	NN	O	O
repair	NN	O	O
synthesis	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
three	NN	O	O
carcinogens	NN	O	O
,	NN	O	O
benzo	NN	O	O
[	NN	O	O
a	NN	O	O
]	NN	O	O
-	NN	O	O
pyrene	NN	O	O
(	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
N	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
N	NN	O	O
-	NN	O	O
nitrosourea	NN	O	O
(	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
dimethylhydrazine	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
DMH	NN	O	O
)	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
initiated	NN	O	O
hepatocytes	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
were	NN	O	O
assayed	NN	O	O
as	NN	O	O
the	NN	O	O
gamma	NN	O	O
-	NN	O	O
glutamyltransferase	NN	O	O
(	NN	O	O
gamma	NN	O	O
-	NN	O	O
GT	NN	O	O
)	NN	O	O
positive	NN	O	O
foci	NN	O	O
formed	NN	O	O
following	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
week	NN	O	O
selection	NN	O	O
regimen	NN	O	O
consisting	NN	O	O
of	NN	O	O
dietary	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
%	NN	O	O
2	NN	O	O
-	NN	O	O
acetylaminofluorene	NN	O	O
coupled	NN	O	O
with	NN	O	O
a	NN	O	O
necrogenic	NN	O	O
dose	NN	O	O
of	NN	O	O
CCl4	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
obtained	NN	O	O
indicate	NN	O	O
that	NN	O	O
with	NN	O	O
all	NN	O	O
three	NN	O	O
carcinogens	NN	O	O
,	NN	O	O
administration	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
AzC	NN	O	O
during	NN	O	O
repair	NN	O	O
synthesis	NN	O	O
increased	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
initiated	NN	O	O
hepatocytes	NN	O	O
,	NN	O	O
for	NN	O	O
example	NN	O	O
10	NN	O	O
-	NN	O	O
20	NN	O	O
foci	NN	O	O
/	NN	O	O
cm2	NN	O	O
in	NN	O	O
5	NN	O	O
-	NN	O	O
AzC	NN	O	O
and	NN	O	O
carcinogen	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
compared	NN	O	O
with	NN	O	O
3	NN	O	O
-	NN	O	O
5	NN	O	O
foci	NN	O	O
/	NN	O	O
cm2	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
carcinogen	NN	O	O
only	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
azadeoxycytidine	NN	O	O
during	NN	O	O
the	NN	O	O
repair	NN	O	O
synthesis	NN	O	O
induced	NN	O	O
by	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
DMH	NN	O	O
further	NN	O	O
showed	NN	O	O
that	NN	O	O
0	NN	O	O
.	NN	O	O
019	NN	O	O
mol	NN	O	O
%	NN	O	O
of	NN	O	O
cytosine	NN	O	O
residues	NN	O	O
in	NN	O	O
DNA	NN	O	O
were	NN	O	O
substituted	NN	O	O
by	NN	O	O
the	NN	O	O
analogue	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
incorporation	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
AzC	NN	O	O
occurs	NN	O	O
during	NN	O	O
repair	NN	O	O
synthesis	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
the	NN	O	O
carcinogen	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
AzC	NN	O	O
given	NN	O	O
after	NN	O	O
a	NN	O	O
two	NN	O	O
thirds	NN	O	O
partial	NN	O	O
hepatectomy	NN	O	O
,	NN	O	O
when	NN	O	O
its	NN	O	O
incorporation	NN	O	O
should	NN	O	O
be	NN	O	O
maximum	NN	O	O
,	NN	O	O
failed	NN	O	O
to	NN	O	O
induce	NN	O	O
any	NN	O	O
gamma	NN	O	O
-	NN	O	O
GT	NN	O	O
positive	NN	O	O
foci	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
hypomethylation	NN	O	O
of	NN	O	O
DNA	NN	O	O
per	NN	O	O
se	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
sufficient	NN	O	O
for	NN	O	O
initiation	NN	O	O
.	NN	O	O

Perhaps	NN	O	O
two	NN	O	O
events	NN	O	O
might	NN	O	O
be	NN	O	O
necessary	NN	O	O
for	NN	O	O
initiation	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
caused	NN	O	O
by	NN	O	O
the	NN	O	O
carcinogen	NN	O	O
and	NN	O	O
a	NN	O	O
second	NN	O	O
involving	NN	O	O
hypomethylation	NN	O	O
of	NN	O	O
DNA	NN	O	O
.	NN	O	O

Antihypertensive	NN	O	O
drugs	NN	O	O
and	NN	O	O
depression	NN	O	B
:	NN	O	O
a	NN	O	O
reappraisal	NN	O	O
.	NN	O	O

Eighty	NN	O	O
-	NN	O	O
nine	NN	O	O
new	NN	O	O
referral	NN	O	O
hypertensive	NN	O	B
out	NN	O	O
-	NN	O	O
patients	NN	O	O
and	NN	O	O
46	NN	O	O
new	NN	O	O
referral	NN	O	O
non	NN	O	O
-	NN	O	O
hypertensive	NN	O	B
chronically	NN	O	O
physically	NN	O	O
ill	NN	O	O
out	NN	O	O
-	NN	O	O
patients	NN	O	O
completed	NN	O	O
a	NN	O	O
mood	NN	O	O
rating	NN	O	O
scale	NN	O	O
at	NN	O	O
regular	NN	O	O
intervals	NN	O	O
for	NN	O	O
one	NN	O	O
year	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
a	NN	O	O
high	NN	O	O
prevalence	NN	O	O
of	NN	O	O
depression	NN	O	B
in	NN	O	O
both	NN	O	O
groups	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
preponderance	NN	O	O
in	NN	O	O
the	NN	O	O
hypertensive	NN	O	B
group	NN	O	O
.	NN	O	O

Hypertensive	NN	O	B
patients	NN	O	O
with	NN	O	O
psychiatric	NN	O	B
histories	NN	O	O
had	NN	O	O
a	NN	O	O
higher	NN	O	O
prevalence	NN	O	O
of	NN	O	O
depression	NN	O	B
than	NN	O	O
the	NN	O	O
comparison	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
accounted	NN	O	O
for	NN	O	O
by	NN	O	O
a	NN	O	O
significant	NN	O	O
number	NN	O	O
of	NN	O	O
depressions	NN	O	B
occurring	NN	O	O
in	NN	O	O
methyl	NN	O	O
dopa	NN	O	O
treated	NN	O	O
patients	NN	O	O
with	NN	O	O
psychiatric	NN	O	B
histories	NN	O	O
.	NN	O	O

Chronic	NN	O	B
active	NN	O	I
hepatitis	NN	O	I
associated	NN	O	O
with	NN	O	O
diclofenac	NN	O	O
sodium	NN	O	O
therapy	NN	O	O
.	NN	O	O

Diclofenac	NN	O	O
sodium	NN	O	O
(	NN	O	O
Voltarol	NN	O	O
,	NN	O	O
Geigy	NN	O	O
Pharmaceuticals	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
steroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
derivative	NN	O	O
of	NN	O	O
phenylacetic	NN	O	O
acid	NN	O	O
.	NN	O	O

Although	NN	O	O
generally	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
,	NN	O	O
asymptomatic	NN	O	O
abnormalities	NN	O	B
of	NN	O	I
liver	NN	O	I
function	NN	O	I
have	NN	O	O
been	NN	O	O
recorded	NN	O	O
and	NN	O	O
,	NN	O	O
less	NN	O	O
commonly	NN	O	O
,	NN	O	O
severe	NN	O	O
hepatitis	NN	O	B
induced	NN	O	O
by	NN	O	O
diclofenac	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
described	NN	O	O
developed	NN	O	O
chronic	NN	O	B
active	NN	O	I
hepatitis	NN	O	I
after	NN	O	O
six	NN	O	O
months	NN	O	O
therapy	NN	O	O
with	NN	O	O
diclofenac	NN	O	O
sodium	NN	O	O
which	NN	O	O
progressed	NN	O	O
despite	NN	O	O
the	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
,	NN	O	O
a	NN	O	O
finding	NN	O	O
not	NN	O	O
previously	NN	O	O
reported	NN	O	O
.	NN	O	O

Arterial	NN	O	O
hypertension	NN	O	B
as	NN	O	O
a	NN	O	O
complication	NN	O	O
of	NN	O	O
prolonged	NN	O	O
ketoconazole	NN	O	O
treatment	NN	O	O
.	NN	O	O

Two	NN	O	O
of	NN	O	O
14	NN	O	O
patients	NN	O	O
with	NN	O	O
Cushing	NN	O	B
'	NN	O	I
s	NN	O	I
syndrome	NN	O	I
treated	NN	O	O
on	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
basis	NN	O	O
with	NN	O	O
ketoconazole	NN	O	O
developed	NN	O	O
sustained	NN	O	O
hypertension	NN	O	B
.	NN	O	O

In	NN	O	O
both	NN	O	O
cases	NN	O	O
normal	NN	O	O
plasma	NN	O	O
and	NN	O	O
urinary	NN	O	O
free	NN	O	O
cortisol	NN	O	O
levels	NN	O	O
had	NN	O	O
been	NN	O	O
achieved	NN	O	O
following	NN	O	O
ketoconazole	NN	O	O
therapy	NN	O	O
,	NN	O	O
yet	NN	O	O
continuous	NN	O	O
blood	NN	O	O
pressure	NN	O	O
monitoring	NN	O	O
demonstrated	NN	O	O
hypertension	NN	O	B
31	NN	O	O
(	NN	O	O
patient	NN	O	O
1	NN	O	O
)	NN	O	O
and	NN	O	O
52	NN	O	O
weeks	NN	O	O
(	NN	O	O
patient	NN	O	O
2	NN	O	O
)	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
patient	NN	O	O
1	NN	O	O
,	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
deoxycorticosterone	NN	O	O
and	NN	O	O
11	NN	O	O
-	NN	O	O
deoxycortisol	NN	O	O
were	NN	O	O
elevated	NN	O	O
.	NN	O	O

In	NN	O	O
patient	NN	O	O
2	NN	O	O
,	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
both	NN	O	O
deoxycorticosterone	NN	O	O
and	NN	O	O
11	NN	O	O
-	NN	O	O
deoxycortisol	NN	O	O
levels	NN	O	O
,	NN	O	O
plasma	NN	O	O
aldosterone	NN	O	O
values	NN	O	O
were	NN	O	O
raised	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
concomitant	NN	O	O
suppression	NN	O	O
of	NN	O	O
renin	NN	O	O
levels	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
show	NN	O	O
that	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
ketoconazole	NN	O	O
may	NN	O	O
induce	NN	O	O
enzyme	NN	O	O
blockade	NN	O	O
leading	NN	O	O
to	NN	O	O
mineralocorticoid	NN	O	O
-	NN	O	O
related	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
Captopril	NN	O	O
)	NN	O	O
on	NN	O	O
pulmonary	NN	O	B
and	NN	O	I
renal	NN	O	I
insufficiency	NN	O	I
due	NN	O	O
to	NN	O	O
intravascular	NN	O	B
coagulation	NN	O	I
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
intravascular	NN	O	B
coagulation	NN	O	I
and	NN	O	O
inhibition	NN	O	O
of	NN	O	O
fibrinolysis	NN	O	O
by	NN	O	O
injection	NN	O	O
of	NN	O	O
thrombin	NN	O	O
and	NN	O	O
tranexamic	NN	O	O
acid	NN	O	O
(	NN	O	O
AMCA	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
gives	NN	O	O
rise	NN	O	O
to	NN	O	O
pulmonary	NN	O	B
and	NN	O	I
renal	NN	O	I
insufficiency	NN	O	I
resembling	NN	O	O
that	NN	O	O
occurring	NN	O	O
after	NN	O	O
trauma	NN	O	B
or	NN	O	O
sepsis	NN	O	B
in	NN	O	O
man	NN	O	O
.	NN	O	O

Injection	NN	O	O
of	NN	O	O
Captopril	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
,	NN	O	O
reduced	NN	O	O
both	NN	O	O
pulmonary	NN	O	B
and	NN	O	I
renal	NN	O	I
insufficiency	NN	O	I
in	NN	O	O
this	NN	O	O
rat	NN	O	O
model	NN	O	O
.	NN	O	O

The	NN	O	O
lung	NN	O	O
weights	NN	O	O
were	NN	O	O
lower	NN	O	O
and	NN	O	O
PaO2	NN	O	O
was	NN	O	O
improved	NN	O	O
in	NN	O	O
rats	NN	O	O
given	NN	O	O
this	NN	O	O
enzyme	NN	O	O
-	NN	O	O
blocking	NN	O	O
agent	NN	O	O
.	NN	O	O

The	NN	O	O
contents	NN	O	O
of	NN	O	O
albumin	NN	O	O
in	NN	O	O
the	NN	O	O
lungs	NN	O	O
were	NN	O	O
not	NN	O	O
changed	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
Captopril	NN	O	O
did	NN	O	O
not	NN	O	O
influence	NN	O	O
the	NN	O	O
extravasation	NN	O	O
of	NN	O	O
protein	NN	O	O
.	NN	O	O

Renal	NN	O	B
damage	NN	O	I
as	NN	O	O
reflected	NN	O	O
by	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
serum	NN	O	O
urea	NN	O	O
and	NN	O	O
in	NN	O	O
kidney	NN	O	O
weight	NN	O	O
was	NN	O	O
prevented	NN	O	O
by	NN	O	O
Captopril	NN	O	O
.	NN	O	O

The	NN	O	O
amount	NN	O	O
of	NN	O	O
fibrin	NN	O	O
in	NN	O	O
the	NN	O	O
kidneys	NN	O	O
was	NN	O	O
also	NN	O	O
considerably	NN	O	O
lower	NN	O	O
than	NN	O	O
in	NN	O	O
animals	NN	O	O
which	NN	O	O
received	NN	O	O
thrombin	NN	O	O
and	NN	O	O
AMCA	NN	O	O
alone	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
Captopril	NN	O	O
on	NN	O	O
the	NN	O	O
lungs	NN	O	O
may	NN	O	O
be	NN	O	O
attributable	NN	O	O
to	NN	O	O
a	NN	O	O
vasodilatory	NN	O	O
effect	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
circulating	NN	O	O
level	NN	O	O
of	NN	O	O
Angiotension	NN	O	O
II	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
prostacyclin	NN	O	O
(	NN	O	O
secondary	NN	O	O
to	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
bradykinin	NN	O	O
)	NN	O	O
.	NN	O	O

Captopril	NN	O	O
may	NN	O	O
,	NN	O	O
by	NN	O	O
the	NN	O	O
same	NN	O	O
mechanism	NN	O	O
,	NN	O	O
reduce	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
that	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
occur	NN	O	O
after	NN	O	O
an	NN	O	O
injection	NN	O	O
of	NN	O	O
thrombin	NN	O	O
,	NN	O	O
thereby	NN	O	O
diminishing	NN	O	O
the	NN	O	O
aggregation	NN	O	O
of	NN	O	O
fibrin	NN	O	O
monomers	NN	O	O
in	NN	O	O
the	NN	O	O
glomeruli	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
result	NN	O	O
that	NN	O	O
less	NN	O	O
fibrin	NN	O	O
will	NN	O	O
be	NN	O	O
deposited	NN	O	O
and	NN	O	O
thus	NN	O	O
less	NN	O	O
kidney	NN	O	B
damage	NN	O	I
will	NN	O	O
be	NN	O	O
produced	NN	O	O
.	NN	O	O

Stroke	NN	O	B
associated	NN	O	O
with	NN	O	O
cocaine	NN	O	O
use	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
eight	NN	O	O
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
cocaine	NN	O	O
use	NN	O	O
was	NN	O	O
related	NN	O	O
to	NN	O	O
stroke	NN	O	B
and	NN	O	O
review	NN	O	O
39	NN	O	O
cases	NN	O	O
from	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

Among	NN	O	O
these	NN	O	O
47	NN	O	O
patients	NN	O	O
the	NN	O	O
mean	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
age	NN	O	O
was	NN	O	O
32	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
.	NN	O	O
1	NN	O	O
years	NN	O	O
;	NN	O	O
76	NN	O	O
%	NN	O	O
(	NN	O	O
34	NN	O	O
/	NN	O	O
45	NN	O	O
)	NN	O	O
were	NN	O	O
men	NN	O	O
.	NN	O	O

Stroke	NN	O	B
followed	NN	O	O
cocaine	NN	O	O
use	NN	O	O
by	NN	O	O
inhalation	NN	O	O
,	NN	O	O
intranasal	NN	O	O
,	NN	O	O
intravenous	NN	O	O
,	NN	O	O
and	NN	O	O
intramuscular	NN	O	O
routes	NN	O	O
.	NN	O	O

Intracranial	NN	O	B
aneurysms	NN	O	I
or	NN	O	O
arteriovenous	NN	O	B
malformations	NN	O	I
were	NN	O	O
present	NN	O	O
in	NN	O	O
17	NN	O	O
of	NN	O	O
32	NN	O	O
patients	NN	O	O
studied	NN	O	O
angiographically	NN	O	O
or	NN	O	O
at	NN	O	O
autopsy	NN	O	O
;	NN	O	O
cerebral	NN	O	B
vasculitis	NN	O	I
was	NN	O	O
present	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
.	NN	O	O

Cerebral	NN	O	B
infarction	NN	O	I
occurred	NN	O	O
in	NN	O	O
10	NN	O	O
patients	NN	O	O
(	NN	O	O
22	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
in	NN	O	O
22	NN	O	O
(	NN	O	O
49	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
subarachnoid	NN	O	B
hemorrhage	NN	O	I
in	NN	O	O
13	NN	O	O
(	NN	O	O
29	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
the	NN	O	O
apparent	NN	O	O
incidence	NN	O	O
of	NN	O	O
stroke	NN	O	B
related	NN	O	O
to	NN	O	O
cocaine	NN	O	O
use	NN	O	O
is	NN	O	O
increasing	NN	O	O
;	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
stroke	NN	O	B
occurs	NN	O	O
primarily	NN	O	O
in	NN	O	O
young	NN	O	O
adults	NN	O	O
;	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
stroke	NN	O	B
may	NN	O	O
follow	NN	O	O
any	NN	O	O
route	NN	O	O
of	NN	O	O
cocaine	NN	O	O
administration	NN	O	O
;	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
stroke	NN	O	B
after	NN	O	O
cocaine	NN	O	O
use	NN	O	O
is	NN	O	O
frequently	NN	O	O
associated	NN	O	O
with	NN	O	O
intracranial	NN	O	B
aneurysms	NN	O	I
and	NN	O	O
arteriovenous	NN	O	B
malformations	NN	O	I
;	NN	O	O
and	NN	O	O
(	NN	O	O
5	NN	O	O
)	NN	O	O
in	NN	O	O
cocaine	NN	O	O
-	NN	O	O
associated	NN	O	O
stroke	NN	O	B
,	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
intracranial	NN	O	B
hemorrhage	NN	O	I
exceeds	NN	O	O
that	NN	O	O
of	NN	O	O
cerebral	NN	O	B
infarction	NN	O	I
.	NN	O	O

A	NN	O	O
randomized	NN	O	O
comparison	NN	O	O
of	NN	O	O
labetalol	NN	O	O
and	NN	O	O
nitroprusside	NN	O	O
for	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

In	NN	O	O
a	NN	O	O
randomized	NN	O	O
study	NN	O	O
,	NN	O	O
labetalol	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
and	NN	O	O
nitroprusside	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
were	NN	O	O
compared	NN	O	O
in	NN	O	O
20	NN	O	O
patients	NN	O	O
(	NN	O	O
10	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
)	NN	O	O
scheduled	NN	O	O
for	NN	O	O
major	NN	O	O
orthopedic	NN	O	O
procedures	NN	O	O
.	NN	O	O

Each	NN	O	O
patient	NN	O	O
was	NN	O	O
subjected	NN	O	O
to	NN	O	O
an	NN	O	O
identical	NN	O	O
anesthetic	NN	O	O
protocol	NN	O	O
and	NN	O	O
similar	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
reductions	NN	O	B
in	NN	O	I
mean	NN	O	I
arterial	NN	O	I
blood	NN	O	I
pressure	NN	O	I
(	NN	O	O
BP	NN	O	O
)	NN	O	O
(	NN	O	O
50	NN	O	O
to	NN	O	O
55	NN	O	O
mmHg	NN	O	O
)	NN	O	O
.	NN	O	O

Nitroprusside	NN	O	O
infusion	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
increase	NN	O	B
in	NN	O	I
heart	NN	O	I
rate	NN	O	I
and	NN	O	I
cardiac	NN	O	I
output	NN	O	I
;	NN	O	O
rebound	NN	O	O
hypertension	NN	O	B
was	NN	O	O
observed	NN	O	O
in	NN	O	O
three	NN	O	O
patients	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
nitroprusside	NN	O	O
.	NN	O	O

Labetalol	NN	O	O
administration	NN	O	O
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
any	NN	O	O
of	NN	O	O
these	NN	O	O
findings	NN	O	O
.	NN	O	O

Arterial	NN	O	O
PO2	NN	O	O
decreased	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
concluded	NN	O	O
that	NN	O	O
labetalol	NN	O	O
offers	NN	O	O
advantages	NN	O	O
over	NN	O	O
nitroprusside	NN	O	O
.	NN	O	O

Sodium	NN	O	O
status	NN	O	O
influences	NN	O	O
chronic	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
nephrotoxicity	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
nephrotoxic	NN	O	B
potential	NN	O	O
of	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
intraperitoneally	NN	O	O
for	NN	O	O
3	NN	O	O
weeks	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
investigated	NN	O	O
in	NN	O	O
salt	NN	O	O
-	NN	O	O
depleted	NN	O	O
,	NN	O	O
normal	NN	O	O
-	NN	O	O
salt	NN	O	O
,	NN	O	O
and	NN	O	O
salt	NN	O	O
-	NN	O	O
loaded	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
salt	NN	O	O
-	NN	O	O
depleted	NN	O	O
rats	NN	O	O
,	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
decreased	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
linearly	NN	O	O
with	NN	O	O
time	NN	O	O
,	NN	O	O
with	NN	O	O
an	NN	O	O
85	NN	O	O
%	NN	O	O
reduction	NN	O	O
by	NN	O	O
week	NN	O	O
3	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
in	NN	O	O
normal	NN	O	O
-	NN	O	O
salt	NN	O	O
rats	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
was	NN	O	O
decreased	NN	O	O
but	NN	O	O
to	NN	O	O
a	NN	O	O
lesser	NN	O	O
extent	NN	O	O
at	NN	O	O
week	NN	O	O
2	NN	O	O
and	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
salt	NN	O	O
-	NN	O	O
loaded	NN	O	O
rats	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
and	NN	O	O
was	NN	O	O
decreased	NN	O	O
by	NN	O	O
43	NN	O	O
%	NN	O	O
at	NN	O	O
week	NN	O	O
3	NN	O	O
.	NN	O	O

All	NN	O	O
rats	NN	O	O
in	NN	O	O
the	NN	O	O
sodium	NN	O	O
-	NN	O	O
depleted	NN	O	O
group	NN	O	O
had	NN	O	O
histopathological	NN	O	O
evidence	NN	O	O
of	NN	O	O
patchy	NN	O	O
tubular	NN	O	O
cytoplasmic	NN	O	O
degeneration	NN	O	O
in	NN	O	O
tubules	NN	O	O
that	NN	O	O
was	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
any	NN	O	O
normal	NN	O	O
-	NN	O	O
salt	NN	O	O
or	NN	O	O
salt	NN	O	O
-	NN	O	O
loaded	NN	O	O
rat	NN	O	O
.	NN	O	O

Concentrations	NN	O	O
of	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
in	NN	O	O
plasma	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
among	NN	O	O
the	NN	O	O
three	NN	O	O
groups	NN	O	O
at	NN	O	O
any	NN	O	O
time	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
3	NN	O	O
weeks	NN	O	O
,	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
levels	NN	O	O
in	NN	O	O
the	NN	O	O
kidneys	NN	O	O
and	NN	O	O
liver	NN	O	O
were	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
salt	NN	O	O
-	NN	O	O
depleted	NN	O	O
and	NN	O	O
normal	NN	O	O
-	NN	O	O
salt	NN	O	O
rats	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
salt	NN	O	O
-	NN	O	O
loaded	NN	O	O
rats	NN	O	O
,	NN	O	O
with	NN	O	O
plasma	NN	O	O
/	NN	O	O
kidney	NN	O	O
ratios	NN	O	O
of	NN	O	O
21	NN	O	O
,	NN	O	O
14	NN	O	O
,	NN	O	O
and	NN	O	O
8	NN	O	O
in	NN	O	O
salt	NN	O	O
-	NN	O	O
depleted	NN	O	O
,	NN	O	O
normal	NN	O	O
-	NN	O	O
salt	NN	O	O
,	NN	O	O
and	NN	O	O
salt	NN	O	O
-	NN	O	O
loaded	NN	O	O
rats	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
reductions	NN	O	O
in	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
and	NN	O	O
renal	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
accumulation	NN	O	O
after	NN	O	O
chronic	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
administration	NN	O	O
were	NN	O	O
enhanced	NN	O	O
by	NN	O	O
salt	NN	O	O
depletion	NN	O	O
and	NN	O	O
attenuated	NN	O	O
by	NN	O	O
sodium	NN	O	O
loading	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Flestolol	NN	O	O
:	NN	O	O
an	NN	O	O
ultra	NN	O	O
-	NN	O	O
short	NN	O	O
-	NN	O	O
acting	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
blocking	NN	O	O
agent	NN	O	O
.	NN	O	O

Flestolol	NN	O	O
(	NN	O	O
ACC	NN	O	O
-	NN	O	O
9089	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
nonselective	NN	O	O
,	NN	O	O
competitive	NN	O	O
,	NN	O	O
ultra	NN	O	O
-	NN	O	O
short	NN	O	O
-	NN	O	O
acting	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
blocking	NN	O	O
agent	NN	O	O
,	NN	O	O
without	NN	O	O
any	NN	O	O
intrinsic	NN	O	O
sympathomimetic	NN	O	O
activity	NN	O	O
.	NN	O	O

Flestolol	NN	O	O
is	NN	O	O
metabolized	NN	O	O
by	NN	O	O
plasma	NN	O	O
esterases	NN	O	O
and	NN	O	O
has	NN	O	O
an	NN	O	O
elimination	NN	O	O
half	NN	O	O
-	NN	O	O
life	NN	O	O
of	NN	O	O
approximately	NN	O	O
6	NN	O	O
.	NN	O	O
5	NN	O	O
minutes	NN	O	O
.	NN	O	O

This	NN	O	O
agent	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
in	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
at	NN	O	O
doses	NN	O	O
up	NN	O	O
to	NN	O	O
100	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
.	NN	O	O

In	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
infusion	NN	O	O
studies	NN	O	O
,	NN	O	O
flestolol	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
at	NN	O	O
the	NN	O	O
effective	NN	O	O
beta	NN	O	O
-	NN	O	O
blocking	NN	O	O
dose	NN	O	O
(	NN	O	O
5	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
seven	NN	O	O
days	NN	O	O
.	NN	O	O

Flestolol	NN	O	O
blood	NN	O	O
concentrations	NN	O	O
increased	NN	O	O
linearly	NN	O	O
with	NN	O	O
increasing	NN	O	O
dose	NN	O	O
and	NN	O	O
good	NN	O	O
correlation	NN	O	O
exists	NN	O	O
between	NN	O	O
blood	NN	O	O
concentrations	NN	O	O
of	NN	O	O
flestolol	NN	O	O
and	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
blockade	NN	O	O
.	NN	O	O

Flestolol	NN	O	O
produced	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
attenuation	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B
.	NN	O	O

Electrophysiologic	NN	O	O
and	NN	O	O
hemodynamic	NN	O	O
effects	NN	O	O
of	NN	O	O
flestolol	NN	O	O
are	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
other	NN	O	O
beta	NN	O	O
blockers	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
with	NN	O	O
other	NN	O	O
beta	NN	O	O
blockers	NN	O	O
,	NN	O	O
flestolol	NN	O	O
-	NN	O	O
induced	NN	O	O
effects	NN	O	O
reverse	NN	O	O
rapidly	NN	O	O
(	NN	O	O
within	NN	O	O
30	NN	O	O
minutes	NN	O	O
)	NN	O	O
following	NN	O	O
discontinuation	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
short	NN	O	O
half	NN	O	O
-	NN	O	O
life	NN	O	O
.	NN	O	O

Flestolol	NN	O	O
effectively	NN	O	O
reduced	NN	O	O
heart	NN	O	O
rate	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
supraventricular	NN	O	B
tachyarrhythmia	NN	O	I
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
unstable	NN	O	B
angina	NN	O	I
,	NN	O	O
flestolol	NN	O	O
infusion	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
safe	NN	O	O
and	NN	O	O
effective	NN	O	O
in	NN	O	O
controlling	NN	O	O
chest	NN	O	B
pain	NN	O	I
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
flestolol	NN	O	O
is	NN	O	O
a	NN	O	O
potent	NN	O	O
,	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
,	NN	O	O
ultra	NN	O	O
-	NN	O	O
short	NN	O	O
-	NN	O	O
acting	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
blocking	NN	O	O
agent	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
flestolol	NN	O	O
in	NN	O	O
the	NN	O	O
critical	NN	O	O
care	NN	O	O
setting	NN	O	O
is	NN	O	O
currently	NN	O	O
undergoing	NN	O	O
investigation	NN	O	O
.	NN	O	O

Immunohistochemical	NN	O	O
,	NN	O	O
electron	NN	O	O
microscopic	NN	O	O
and	NN	O	O
morphometric	NN	O	O
studies	NN	O	O
of	NN	O	O
estrogen	NN	O	O
-	NN	O	O
induced	NN	O	O
rat	NN	O	O
prolactinomas	NN	O	B
after	NN	O	O
bromocriptine	NN	O	O
treatment	NN	O	O
.	NN	O	O

To	NN	O	O
clarify	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
bromocriptine	NN	O	O
on	NN	O	O
prolactinoma	NN	O	B
cells	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
immunohistochemical	NN	O	O
,	NN	O	O
ultrastructural	NN	O	O
and	NN	O	O
morphometrical	NN	O	O
analyses	NN	O	O
were	NN	O	O
applied	NN	O	O
to	NN	O	O
estrogen	NN	O	O
-	NN	O	O
induced	NN	O	O
rat	NN	O	O
prolactinoma	NN	O	B
cells	NN	O	O
1	NN	O	O
h	NN	O	O
and	NN	O	O
6	NN	O	O
h	NN	O	O
after	NN	O	O
injection	NN	O	O
of	NN	O	O
bromocriptine	NN	O	O
(	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
of	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
h	NN	O	O
after	NN	O	O
treatment	NN	O	O
,	NN	O	O
serum	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
decreased	NN	O	O
markedly	NN	O	O
.	NN	O	O

Electron	NN	O	O
microscopy	NN	O	O
disclosed	NN	O	O
many	NN	O	O
secretory	NN	O	O
granules	NN	O	O
,	NN	O	O
slightly	NN	O	O
distorted	NN	O	O
rough	NN	O	O
endoplasmic	NN	O	O
reticulum	NN	O	O
,	NN	O	O
and	NN	O	O
partially	NN	O	O
dilated	NN	O	O
Golgi	NN	O	O
cisternae	NN	O	O
in	NN	O	O
the	NN	O	O
prolactinoma	NN	O	B
cells	NN	O	O
.	NN	O	O

Morphometric	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
volume	NN	O	O
density	NN	O	O
of	NN	O	O
secretory	NN	O	O
granules	NN	O	O
increased	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
volume	NN	O	O
density	NN	O	O
of	NN	O	O
cytoplasmic	NN	O	O
microtubules	NN	O	O
decreased	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
lowered	NN	O	O
serum	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
phase	NN	O	O
of	NN	O	O
bromocriptine	NN	O	O
treatment	NN	O	O
may	NN	O	O
result	NN	O	O
from	NN	O	O
an	NN	O	O
impaired	NN	O	O
secretion	NN	O	O
of	NN	O	O
prolactin	NN	O	O
due	NN	O	O
to	NN	O	O
decreasing	NN	O	O
numbers	NN	O	O
of	NN	O	O
cytoplasmic	NN	O	O
microtubules	NN	O	O
.	NN	O	O

At	NN	O	O
6	NN	O	O
h	NN	O	O
after	NN	O	O
injection	NN	O	O
,	NN	O	O
serum	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
were	NN	O	O
still	NN	O	O
considerably	NN	O	O
lower	NN	O	O
than	NN	O	O
in	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
prolactinoma	NN	O	B
cells	NN	O	O
at	NN	O	O
this	NN	O	O
time	NN	O	O
were	NN	O	O
well	NN	O	O
granulated	NN	O	O
,	NN	O	O
with	NN	O	O
vesiculated	NN	O	O
rough	NN	O	O
endoplasmic	NN	O	O
reticulum	NN	O	O
and	NN	O	O
markedly	NN	O	O
dilated	NN	O	O
Golgi	NN	O	O
cisternae	NN	O	O
.	NN	O	O

Electron	NN	O	O
microscopical	NN	O	O
immunohistochemistry	NN	O	O
revealed	NN	O	O
positive	NN	O	O
reaction	NN	O	O
products	NN	O	O
noted	NN	O	O
on	NN	O	O
the	NN	O	O
secretory	NN	O	O
granules	NN	O	O
,	NN	O	O
Golgi	NN	O	O
cisternae	NN	O	O
,	NN	O	O
and	NN	O	O
endoplasmic	NN	O	O
reticulum	NN	O	O
of	NN	O	O
the	NN	O	O
untreated	NN	O	O
rat	NN	O	O
prolactinoma	NN	O	B
cells	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
only	NN	O	O
secretory	NN	O	O
granules	NN	O	O
showed	NN	O	O
the	NN	O	O
positive	NN	O	O
reaction	NN	O	O
products	NN	O	O
for	NN	O	O
prolactin	NN	O	O
6	NN	O	O
h	NN	O	O
after	NN	O	O
bromocriptine	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
adenoma	NN	O	B
cells	NN	O	O
.	NN	O	O

An	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
volume	NN	O	O
density	NN	O	O
of	NN	O	O
secretory	NN	O	O
granules	NN	O	O
and	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
volume	NN	O	O
densities	NN	O	O
of	NN	O	O
rough	NN	O	O
endoplasmic	NN	O	O
reticulum	NN	O	O
and	NN	O	O
microtubules	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
morphometric	NN	O	O
analysis	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
bromocriptine	NN	O	O
inhibits	NN	O	O
protein	NN	O	O
synthesis	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
bringing	NN	O	O
about	NN	O	O
a	NN	O	O
disturbance	NN	O	O
of	NN	O	O
the	NN	O	O
prolactin	NN	O	O
secretion	NN	O	O
.	NN	O	O

Sulfasalazine	NN	O	O
-	NN	O	O
induced	NN	O	O
lupus	NN	O	B
erythematosus	NN	O	I
.	NN	O	O

Pneumonitis	NN	O	B
,	NN	O	O
bilateral	NN	O	O
pleural	NN	O	B
effusions	NN	O	I
,	NN	O	O
echocardiographic	NN	O	O
evidence	NN	O	O
of	NN	O	O
cardiac	NN	O	B
tamponade	NN	O	I
,	NN	O	O
and	NN	O	O
positive	NN	O	O
autoantibodies	NN	O	O
developed	NN	O	O
in	NN	O	O
a	NN	O	O
43	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
,	NN	O	O
who	NN	O	O
was	NN	O	O
receiving	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
sulfasalazine	NN	O	O
therapy	NN	O	O
for	NN	O	O
chronic	NN	O	O
ulcerative	NN	O	B
colitis	NN	O	I
.	NN	O	O

After	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
sulfasalazine	NN	O	O
and	NN	O	O
completion	NN	O	O
of	NN	O	O
a	NN	O	O
six	NN	O	O
-	NN	O	O
week	NN	O	O
course	NN	O	O
of	NN	O	O
corticosteroids	NN	O	O
,	NN	O	O
these	NN	O	O
problems	NN	O	O
resolved	NN	O	O
over	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
four	NN	O	O
to	NN	O	O
six	NN	O	O
months	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
sulfasalazine	NN	O	O
-	NN	O	O
induced	NN	O	O
lupus	NN	O	B
,	NN	O	O
which	NN	O	O
manifested	NN	O	O
with	NN	O	O
serositis	NN	O	B
and	NN	O	O
pulmonary	NN	O	O
parenchymal	NN	O	O
involvement	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
joint	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Physicians	NN	O	O
who	NN	O	O
use	NN	O	O
sulfasalazine	NN	O	O
to	NN	O	O
treat	NN	O	O
patients	NN	O	O
with	NN	O	O
inflammatory	NN	O	B
bowel	NN	O	I
disease	NN	O	I
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
signs	NN	O	O
of	NN	O	O
sulfasalazine	NN	O	O
-	NN	O	O
induced	NN	O	O
lupus	NN	O	B
syndrome	NN	O	I
.	NN	O	O

Chronic	NN	O	O
carbamazepine	NN	O	O
treatment	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
:	NN	O	O
efficacy	NN	O	O
,	NN	O	O
toxicity	NN	O	B
,	NN	O	O
and	NN	O	O
effect	NN	O	O
on	NN	O	O
plasma	NN	O	O
and	NN	O	O
tissue	NN	O	O
folate	NN	O	O
concentrations	NN	O	O
.	NN	O	O

Folate	NN	O	O
depletion	NN	O	O
has	NN	O	O
often	NN	O	O
been	NN	O	O
a	NN	O	O
problem	NN	O	O
in	NN	O	O
chronic	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
(	NN	O	O
AED	NN	O	O
)	NN	O	O
therapy	NN	O	O
.	NN	O	O

Carbamazepine	NN	O	O
(	NN	O	O
CBZ	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
commonly	NN	O	O
used	NN	O	O
AED	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
some	NN	O	O
clinical	NN	O	O
studies	NN	O	O
.	NN	O	O

A	NN	O	O
rat	NN	O	O
model	NN	O	O
was	NN	O	O
developed	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
chronic	NN	O	O
CBZ	NN	O	O
treatment	NN	O	O
on	NN	O	O
folate	NN	O	O
concentrations	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
developing	NN	O	O
this	NN	O	O
model	NN	O	O
,	NN	O	O
a	NN	O	O
common	NN	O	O
vehicle	NN	O	O
,	NN	O	O
propylene	NN	O	O
glycol	NN	O	O
,	NN	O	O
by	NN	O	O
itself	NN	O	O
in	NN	O	O
high	NN	O	O
doses	NN	O	O
,	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
exhibit	NN	O	O
protective	NN	O	O
properties	NN	O	O
against	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
inhibited	NN	O	O
weight	NN	O	B
gain	NN	O	I
.	NN	O	O

Seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
hexafluorodiethyl	NN	O	O
ether	NN	O	O
(	NN	O	O
HFDE	NN	O	O
)	NN	O	O
were	NN	O	O
also	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
more	NN	O	O
sensitive	NN	O	O
measure	NN	O	O
of	NN	O	O
protection	NN	O	O
by	NN	O	O
CBZ	NN	O	O
than	NN	O	O
seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
maximal	NN	O	O
electroshock	NN	O	O
(	NN	O	O
MES	NN	O	O
)	NN	O	O
.	NN	O	O

Oral	NN	O	O
administration	NN	O	O
of	NN	O	O
CBZ	NN	O	O
as	NN	O	O
an	NN	O	O
aqueous	NN	O	O
suspension	NN	O	O
every	NN	O	O
8	NN	O	O
h	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
was	NN	O	O
continuously	NN	O	O
protective	NN	O	O
against	NN	O	O
HFDE	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
and	NN	O	O
was	NN	O	O
minimally	NN	O	O
toxic	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
weight	NN	O	B
gain	NN	O	I
over	NN	O	O
8	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
CBZ	NN	O	O
levels	NN	O	O
measured	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
brain	NN	O	O
of	NN	O	O
these	NN	O	O
animals	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
were	NN	O	O
below	NN	O	O
those	NN	O	O
normally	NN	O	O
considered	NN	O	O
protective	NN	O	O
.	NN	O	O

This	NN	O	O
treatment	NN	O	O
with	NN	O	O
CBZ	NN	O	O
had	NN	O	O
no	NN	O	O
apparent	NN	O	O
adverse	NN	O	O
effect	NN	O	O
on	NN	O	O
folate	NN	O	O
concentrations	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
,	NN	O	O
and	NN	O	O
,	NN	O	O
indeed	NN	O	O
,	NN	O	O
the	NN	O	O
folate	NN	O	O
concentration	NN	O	O
increased	NN	O	O
in	NN	O	O
liver	NN	O	O
after	NN	O	O
6	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
and	NN	O	O
in	NN	O	O
plasma	NN	O	O
at	NN	O	O
8	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Dipyridamole	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
.	NN	O	O

Angina	NN	O	B
and	NN	O	O
ischemic	NN	O	O
electrocardiographic	NN	O	O
changes	NN	O	O
occurred	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
oral	NN	O	O
dipyridamole	NN	O	O
in	NN	O	O
four	NN	O	O
patients	NN	O	O
awaiting	NN	O	O
urgent	NN	O	O
myocardial	NN	O	O
revascularization	NN	O	O
procedures	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
has	NN	O	O
not	NN	O	O
previously	NN	O	O
been	NN	O	O
reported	NN	O	O
as	NN	O	O
a	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
preoperative	NN	O	O
dipyridamole	NN	O	O
therapy	NN	O	O
,	NN	O	O
although	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
ischemia	NN	O	I
has	NN	O	O
been	NN	O	O
demonstrated	NN	O	O
to	NN	O	O
occur	NN	O	O
in	NN	O	O
animals	NN	O	O
and	NN	O	O
humans	NN	O	O
with	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
.	NN	O	O

Epicardial	NN	O	O
coronary	NN	O	O
collateral	NN	O	O
vessels	NN	O	O
were	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
all	NN	O	O
four	NN	O	O
patients	NN	O	O
;	NN	O	O
a	NN	O	O
coronary	NN	O	O
"	NN	O	O
steal	NN	O	O
"	NN	O	O
phenomenon	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
the	NN	O	O
dipyridamole	NN	O	O
-	NN	O	O
induced	NN	O	O
ischemia	NN	O	B
observed	NN	O	O
.	NN	O	O

Inhibition	NN	O	O
of	NN	O	O
sympathoadrenal	NN	O	O
activity	NN	O	O
by	NN	O	O
atrial	NN	O	O
natriuretic	NN	O	O
factor	NN	O	O
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

In	NN	O	O
six	NN	O	O
conscious	NN	O	O
,	NN	O	O
trained	NN	O	O
dogs	NN	O	O
,	NN	O	O
maintained	NN	O	O
on	NN	O	O
a	NN	O	O
normal	NN	O	O
sodium	NN	O	O
intake	NN	O	O
of	NN	O	O
2	NN	O	O
to	NN	O	O
4	NN	O	O
mEq	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
sympathetic	NN	O	O
activity	NN	O	O
was	NN	O	O
assessed	NN	O	O
as	NN	O	O
the	NN	O	O
release	NN	O	O
rate	NN	O	O
of	NN	O	O
norepinephrine	NN	O	O
and	NN	O	O
epinephrine	NN	O	O
during	NN	O	O
15	NN	O	O
-	NN	O	O
minute	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
infusions	NN	O	O
of	NN	O	O
human	NN	O	O
alpha	NN	O	O
-	NN	O	O
atrial	NN	O	O
natriuretic	NN	O	O
factor	NN	O	O
.	NN	O	O

Mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
as	NN	O	O
a	NN	O	O
percentage	NN	O	O
of	NN	O	O
control	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SEM	NN	O	O
)	NN	O	O
during	NN	O	O
randomized	NN	O	O
infusions	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
or	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
microgram	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
was	NN	O	O
99	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
95	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
93	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
79	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
%	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
tachycardia	NN	O	B
and	NN	O	O
no	NN	O	O
augmentation	NN	O	O
of	NN	O	O
the	NN	O	O
norepinephrine	NN	O	O
release	NN	O	O
rate	NN	O	O
(	NN	O	O
up	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
microgram	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
were	NN	O	O
observed	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
comparable	NN	O	O
hypotension	NN	O	B
induced	NN	O	O
by	NN	O	O
hydralazine	NN	O	O
or	NN	O	O
nitroglycerin	NN	O	O
.	NN	O	O

The	NN	O	O
release	NN	O	O
rate	NN	O	O
of	NN	O	O
epinephrine	NN	O	O
(	NN	O	O
control	NN	O	O
,	NN	O	O
6	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
6	NN	O	O
ng	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
declined	NN	O	O
immediately	NN	O	O
during	NN	O	O
infusions	NN	O	O
of	NN	O	O
atrial	NN	O	O
natriuretic	NN	O	O
factor	NN	O	O
to	NN	O	O
a	NN	O	O
minimum	NN	O	O
of	NN	O	O
49	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
control	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
during	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
microgram	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
and	NN	O	O
to	NN	O	O
63	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
%	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
greater	NN	O	O
than	NN	O	O
p	NN	O	O
greater	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
or	NN	O	O
95	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
%	NN	O	O
(	NN	O	O
not	NN	O	O
significant	NN	O	O
)	NN	O	O
during	NN	O	O
0	NN	O	O
.	NN	O	O
3	NN	O	O
or	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
microgram	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
.	NN	O	O

Steady	NN	O	O
state	NN	O	O
arterial	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
atrial	NN	O	O
natriuretic	NN	O	O
factor	NN	O	O
were	NN	O	O
39	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
pg	NN	O	O
/	NN	O	O
ml	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
during	NN	O	O
infusions	NN	O	O
of	NN	O	O
saline	NN	O	O
and	NN	O	O
284	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
24	NN	O	O
pg	NN	O	O
/	NN	O	O
ml	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
and	NN	O	O
1520	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
300	NN	O	O
pg	NN	O	O
/	NN	O	O
ml	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
)	NN	O	O
during	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
microgram	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
infusions	NN	O	O
of	NN	O	O
the	NN	O	O
factor	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Inhibition	NN	O	O
of	NN	O	O
immunoreactive	NN	O	O
corticotropin	NN	O	O
-	NN	O	O
releasing	NN	O	O
factor	NN	O	O
secretion	NN	O	O
into	NN	O	O
the	NN	O	O
hypophysial	NN	O	O
-	NN	O	O
portal	NN	O	O
circulation	NN	O	O
by	NN	O	O
delayed	NN	O	O
glucocorticoid	NN	O	O
feedback	NN	O	O
.	NN	O	O

Nitroprusside	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
evokes	NN	O	O
ACTH	NN	O	O
secretion	NN	O	O
which	NN	O	O
is	NN	O	O
primarily	NN	O	O
mediated	NN	O	O
by	NN	O	O
enhanced	NN	O	O
secretion	NN	O	O
of	NN	O	O
immunoreactive	NN	O	O
corticotropin	NN	O	O
-	NN	O	O
releasing	NN	O	O
factor	NN	O	O
(	NN	O	O
irCRF	NN	O	O
)	NN	O	O
into	NN	O	O
the	NN	O	O
hypophysial	NN	O	O
-	NN	O	O
portal	NN	O	O
circulation	NN	O	O
.	NN	O	O

Portal	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
neither	NN	O	O
arginine	NN	O	O
vasopressin	NN	O	O
nor	NN	O	O
oxytocin	NN	O	O
are	NN	O	O
significantly	NN	O	O
altered	NN	O	O
in	NN	O	O
this	NN	O	O
paradigm	NN	O	O
.	NN	O	O

Application	NN	O	O
of	NN	O	O
a	NN	O	O
delayed	NN	O	O
feedback	NN	O	O
signal	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
h	NN	O	O
systemic	NN	O	O
corticosterone	NN	O	O
infusion	NN	O	O
in	NN	O	O
urethane	NN	O	O
-	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
with	NN	O	O
pharmacological	NN	O	O
blockade	NN	O	O
of	NN	O	O
glucocorticoid	NN	O	O
synthesis	NN	O	O
,	NN	O	O
is	NN	O	O
without	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
resting	NN	O	O
secretion	NN	O	O
of	NN	O	O
arginine	NN	O	O
vasopressin	NN	O	O
and	NN	O	O
oxytocin	NN	O	O
at	NN	O	O
any	NN	O	O
corticosterone	NN	O	O
feedback	NN	O	O
dose	NN	O	O
tested	NN	O	O
.	NN	O	O

Resting	NN	O	O
irCRF	NN	O	O
levels	NN	O	O
are	NN	O	O
suppressed	NN	O	O
only	NN	O	O
at	NN	O	O
the	NN	O	O
highest	NN	O	O
corticosterone	NN	O	O
infusion	NN	O	O
rate	NN	O	O
,	NN	O	O
which	NN	O	O
resulted	NN	O	O
in	NN	O	O
systemic	NN	O	O
corticosterone	NN	O	O
levels	NN	O	O
of	NN	O	O
40	NN	O	O
micrograms	NN	O	O
/	NN	O	O
dl	NN	O	O
.	NN	O	O

Suppression	NN	O	O
of	NN	O	O
irCRF	NN	O	O
secretion	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
nitroprusside	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
is	NN	O	O
observed	NN	O	O
and	NN	O	O
occurs	NN	O	O
at	NN	O	O
a	NN	O	O
plasma	NN	O	O
corticosterone	NN	O	O
level	NN	O	O
between	NN	O	O
8	NN	O	O
-	NN	O	O
12	NN	O	O
micrograms	NN	O	O
/	NN	O	O
dl	NN	O	O
.	NN	O	O

These	NN	O	O
studies	NN	O	O
provide	NN	O	O
further	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
strong	NN	O	O
central	NN	O	O
component	NN	O	O
of	NN	O	O
the	NN	O	O
delayed	NN	O	O
feedback	NN	O	O
process	NN	O	O
which	NN	O	O
is	NN	O	O
mediated	NN	O	O
by	NN	O	O
modulation	NN	O	O
of	NN	O	O
irCRF	NN	O	O
release	NN	O	O
.	NN	O	O

Noradrenergic	NN	O	O
involvement	NN	O	O
in	NN	O	O
catalepsy	NN	O	B
induced	NN	O	O
by	NN	O	O
delta	NN	O	O
9	NN	O	O
-	NN	O	O
tetrahydrocannabinol	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
elucidate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
catecholaminergic	NN	O	O
system	NN	O	O
in	NN	O	O
the	NN	O	O
cataleptogenic	NN	O	O
effect	NN	O	O
of	NN	O	O
delta	NN	O	O
9	NN	O	O
-	NN	O	O
tetrahydrocannabinol	NN	O	O
(	NN	O	O
THC	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
6	NN	O	O
-	NN	O	O
hydroxydopamine	NN	O	O
(	NN	O	O
6	NN	O	O
-	NN	O	O
OHDA	NN	O	O
)	NN	O	O
or	NN	O	O
with	NN	O	O
desipramine	NN	O	O
and	NN	O	O
6	NN	O	O
-	NN	O	O
OHDA	NN	O	O
and	NN	O	O
lesions	NN	O	O
of	NN	O	O
the	NN	O	O
locus	NN	O	O
coeruleus	NN	O	O
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
cataleptogenic	NN	O	O
effect	NN	O	O
of	NN	O	O
THC	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
6	NN	O	O
-	NN	O	O
OHDA	NN	O	O
and	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
lesions	NN	O	O
of	NN	O	O
the	NN	O	O
locus	NN	O	O
coeruleus	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
desipramine	NN	O	O
and	NN	O	O
6	NN	O	O
-	NN	O	O
OHDA	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
rats	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
contrary	NN	O	O
,	NN	O	O
the	NN	O	O
cataleptogenic	NN	O	O
effect	NN	O	O
of	NN	O	O
haloperidol	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
desipramine	NN	O	O
and	NN	O	O
6	NN	O	O
-	NN	O	O
OHDA	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
6	NN	O	O
-	NN	O	O
OHDA	NN	O	O
or	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
lesions	NN	O	O
of	NN	O	O
the	NN	O	O
locus	NN	O	O
coeruleus	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
noradrenergic	NN	O	O
neurons	NN	O	O
have	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
manifestation	NN	O	O
of	NN	O	O
catalepsy	NN	O	B
induced	NN	O	O
by	NN	O	O
THC	NN	O	O
,	NN	O	O
whereas	NN	O	O
dopaminergic	NN	O	O
neurons	NN	O	O
are	NN	O	O
important	NN	O	O
in	NN	O	O
catalepsy	NN	O	B
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	O
.	NN	O	O

Reversibility	NN	O	O
of	NN	O	O
captopril	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
after	NN	O	O
prolonged	NN	O	O
use	NN	O	O
in	NN	O	O
an	NN	O	O
unusual	NN	O	O
case	NN	O	O
of	NN	O	O
renovascular	NN	O	B
hypertension	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
severe	NN	O	O
hypertension	NN	O	B
with	NN	O	O
an	NN	O	O
occluded	NN	O	O
renal	NN	O	O
artery	NN	O	O
to	NN	O	O
a	NN	O	O
solitary	NN	O	O
kidney	NN	O	O
,	NN	O	O
who	NN	O	O
developed	NN	O	O
sudden	NN	O	B
deterioration	NN	O	I
of	NN	O	I
renal	NN	O	I
function	NN	O	I
following	NN	O	O
treatment	NN	O	O
with	NN	O	O
captopril	NN	O	O
.	NN	O	O

His	NN	O	O
renal	NN	O	O
function	NN	O	O
remained	NN	O	O
impaired	NN	O	O
but	NN	O	O
stable	NN	O	O
during	NN	O	O
2	NN	O	O
years	NN	O	O
'	NN	O	O
treatment	NN	O	O
with	NN	O	O
captopril	NN	O	O
but	NN	O	O
returned	NN	O	O
to	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
levels	NN	O	O
soon	NN	O	O
after	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

This	NN	O	O
indicates	NN	O	O
reversibility	NN	O	O
in	NN	O	O
captopril	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
failure	NN	O	I
even	NN	O	O
after	NN	O	O
its	NN	O	O
prolonged	NN	O	O
use	NN	O	O
and	NN	O	O
suggests	NN	O	O
that	NN	O	O
no	NN	O	O
organic	NN	O	O
damage	NN	O	O
occurs	NN	O	O
to	NN	O	O
glomerular	NN	O	O
arterioles	NN	O	O
following	NN	O	O
chronic	NN	O	O
ACE	NN	O	O
inhibition	NN	O	O
.	NN	O	O

HMG	NN	O	O
CoA	NN	O	O
reductase	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

Current	NN	O	O
clinical	NN	O	O
experience	NN	O	O
.	NN	O	O

Lovastatin	NN	O	O
and	NN	O	O
simvastatin	NN	O	O
are	NN	O	O
the	NN	O	O
2	NN	O	O
best	NN	O	O
-	NN	O	O
known	NN	O	O
members	NN	O	O
of	NN	O	O
the	NN	O	O
class	NN	O	O
of	NN	O	O
hypolipidaemic	NN	O	O
agents	NN	O	O
known	NN	O	O
as	NN	O	O
HMG	NN	O	O
CoA	NN	O	O
reductase	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

Clinical	NN	O	O
experience	NN	O	O
with	NN	O	O
lovastatin	NN	O	O
includes	NN	O	O
over	NN	O	O
5000	NN	O	O
patients	NN	O	O
,	NN	O	O
700	NN	O	O
of	NN	O	O
whom	NN	O	O
have	NN	O	O
been	NN	O	O
treated	NN	O	O
for	NN	O	O
2	NN	O	O
years	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
and	NN	O	O
experience	NN	O	O
with	NN	O	O
simvastatin	NN	O	O
includes	NN	O	O
over	NN	O	O
3500	NN	O	O
patients	NN	O	O
,	NN	O	O
of	NN	O	O
whom	NN	O	O
350	NN	O	O
have	NN	O	O
been	NN	O	O
treated	NN	O	O
for	NN	O	O
18	NN	O	O
months	NN	O	O
or	NN	O	O
more	NN	O	O
.	NN	O	O

Lovastatin	NN	O	O
has	NN	O	O
been	NN	O	O
marketed	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
for	NN	O	O
over	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

Both	NN	O	O
agents	NN	O	O
show	NN	O	O
substantial	NN	O	O
clinical	NN	O	O
efficacy	NN	O	O
,	NN	O	O
with	NN	O	O
reductions	NN	O	O
in	NN	O	O
total	NN	O	O
cholesterol	NN	O	O
of	NN	O	O
over	NN	O	O
30	NN	O	O
%	NN	O	O
and	NN	O	O
in	NN	O	O
LDL	NN	O	O
-	NN	O	O
cholesterol	NN	O	O
of	NN	O	O
40	NN	O	O
%	NN	O	O
in	NN	O	O
clinical	NN	O	O
studies	NN	O	O
.	NN	O	O

Modest	NN	O	O
increases	NN	O	O
in	NN	O	O
HDL	NN	O	O
-	NN	O	O
cholesterol	NN	O	O
levels	NN	O	O
of	NN	O	O
about	NN	O	O
10	NN	O	O
%	NN	O	O
are	NN	O	O
also	NN	O	O
reported	NN	O	O
.	NN	O	O

Clinical	NN	O	O
tolerability	NN	O	O
of	NN	O	O
both	NN	O	O
agents	NN	O	O
has	NN	O	O
been	NN	O	O
good	NN	O	O
,	NN	O	O
with	NN	O	O
fewer	NN	O	O
than	NN	O	O
3	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
withdrawn	NN	O	O
from	NN	O	O
treatment	NN	O	O
because	NN	O	O
of	NN	O	O
clinical	NN	O	O
adverse	NN	O	O
experiences	NN	O	O
.	NN	O	O

Ophthalmological	NN	O	O
examinations	NN	O	O
in	NN	O	O
over	NN	O	O
1100	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
one	NN	O	O
or	NN	O	O
the	NN	O	O
other	NN	O	O
agent	NN	O	O
have	NN	O	O
revealed	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
significant	NN	O	O
short	NN	O	O
term	NN	O	O
(	NN	O	O
up	NN	O	O
to	NN	O	O
2	NN	O	O
years	NN	O	O
)	NN	O	O
cataractogenic	NN	O	O
potential	NN	O	O
.	NN	O	O

One	NN	O	O
to	NN	O	O
2	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
have	NN	O	O
elevations	NN	O	O
of	NN	O	O
serum	NN	O	O
transaminases	NN	O	O
to	NN	O	O
greater	NN	O	O
than	NN	O	O
3	NN	O	O
times	NN	O	O
the	NN	O	O
upper	NN	O	O
limit	NN	O	O
of	NN	O	O
normal	NN	O	O
.	NN	O	O

These	NN	O	O
episodes	NN	O	O
are	NN	O	O
asymptomatic	NN	O	O
and	NN	O	O
reversible	NN	O	O
when	NN	O	O
therapy	NN	O	O
is	NN	O	O
discontinued	NN	O	O
.	NN	O	O

Minor	NN	O	O
elevations	NN	O	O
of	NN	O	O
creatine	NN	O	O
kinase	NN	O	O
levels	NN	O	O
are	NN	O	O
reported	NN	O	O
in	NN	O	O
about	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Myopathy	NN	O	B
,	NN	O	O
associated	NN	O	O
in	NN	O	O
some	NN	O	O
cases	NN	O	O
with	NN	O	O
myoglobinuria	NN	O	B
,	NN	O	O
and	NN	O	O
in	NN	O	O
2	NN	O	O
cases	NN	O	O
with	NN	O	O
transient	NN	O	O
renal	NN	O	B
failure	NN	O	I
,	NN	O	O
has	NN	O	O
been	NN	O	O
rarely	NN	O	O
reported	NN	O	O
with	NN	O	O
lovastatin	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
patients	NN	O	O
concomitantly	NN	O	O
treated	NN	O	O
with	NN	O	O
cyclosporin	NN	O	O
,	NN	O	O
gemfibrozil	NN	O	O
or	NN	O	O
niacin	NN	O	O
.	NN	O	O

Lovastatin	NN	O	O
and	NN	O	O
simvastatin	NN	O	O
are	NN	O	O
both	NN	O	O
effective	NN	O	O
and	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
agents	NN	O	O
for	NN	O	O
lowering	NN	O	O
elevated	NN	O	O
levels	NN	O	O
of	NN	O	O
serum	NN	O	O
cholesterol	NN	O	O
.	NN	O	O

As	NN	O	O
wider	NN	O	O
use	NN	O	O
confirms	NN	O	O
their	NN	O	O
safety	NN	O	O
profile	NN	O	O
,	NN	O	O
they	NN	O	O
will	NN	O	O
gain	NN	O	O
increasing	NN	O	O
importance	NN	O	O
in	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
approach	NN	O	O
to	NN	O	O
hypercholesterolaemia	NN	O	B
and	NN	O	O
its	NN	O	O
consequences	NN	O	O
.	NN	O	O

Hepatic	NN	O	O
reactions	NN	O	O
associated	NN	O	O
with	NN	O	O
ketoconazole	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
Kingdom	NN	O	O
.	NN	O	O

Ketoconazole	NN	O	O
was	NN	O	O
introduced	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
Kingdom	NN	O	O
in	NN	O	O
1981	NN	O	O
.	NN	O	O

By	NN	O	O
November	NN	O	O
1984	NN	O	O
the	NN	O	O
Committee	NN	O	O
on	NN	O	O
Safety	NN	O	O
of	NN	O	O
Medicines	NN	O	O
had	NN	O	O
received	NN	O	O
82	NN	O	O
reports	NN	O	O
of	NN	O	O
possible	NN	O	O
hepatotoxicity	NN	O	B
associated	NN	O	O
with	NN	O	O
the	NN	O	O
drug	NN	O	O
,	NN	O	O
including	NN	O	O
five	NN	O	O
deaths	NN	O	B
.	NN	O	O

An	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
75	NN	O	O
cases	NN	O	O
that	NN	O	O
had	NN	O	O
been	NN	O	O
adequately	NN	O	O
followed	NN	O	O
up	NN	O	O
suggested	NN	O	O
that	NN	O	O
16	NN	O	O
,	NN	O	O
including	NN	O	O
three	NN	O	O
deaths	NN	O	B
,	NN	O	O
were	NN	O	O
probably	NN	O	O
related	NN	O	O
to	NN	O	O
treatment	NN	O	O
with	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
remainder	NN	O	O
,	NN	O	O
48	NN	O	O
were	NN	O	O
possibly	NN	O	O
related	NN	O	O
to	NN	O	O
treatment	NN	O	O
,	NN	O	O
five	NN	O	O
were	NN	O	O
unlikely	NN	O	O
to	NN	O	O
be	NN	O	O
so	NN	O	O
,	NN	O	O
and	NN	O	O
six	NN	O	O
were	NN	O	O
unclassifiable	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
age	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
16	NN	O	O
probable	NN	O	O
cases	NN	O	O
was	NN	O	O
57	NN	O	O
.	NN	O	O
9	NN	O	O
,	NN	O	O
with	NN	O	O
hepatotoxicity	NN	O	B
being	NN	O	O
more	NN	O	O
common	NN	O	O
in	NN	O	O
women	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
duration	NN	O	O
of	NN	O	O
treatment	NN	O	O
before	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
jaundice	NN	O	B
was	NN	O	O
61	NN	O	O
days	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
these	NN	O	O
well	NN	O	O
validated	NN	O	O
cases	NN	O	O
occurred	NN	O	O
within	NN	O	O
the	NN	O	O
first	NN	O	O
10	NN	O	O
days	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
serum	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
suggested	NN	O	O
hepatocellular	NN	O	B
injury	NN	O	I
in	NN	O	O
10	NN	O	O
(	NN	O	O
63	NN	O	O
%	NN	O	O
)	NN	O	O
;	NN	O	O
the	NN	O	O
rest	NN	O	O
showed	NN	O	O
a	NN	O	O
mixed	NN	O	O
pattern	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
histological	NN	O	O
examination	NN	O	O
of	NN	O	O
the	NN	O	O
liver	NN	O	O
often	NN	O	O
showed	NN	O	O
evidence	NN	O	O
of	NN	O	O
cholestasis	NN	O	B
.	NN	O	O

The	NN	O	O
characteristics	NN	O	O
of	NN	O	O
the	NN	O	O
48	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
possible	NN	O	O
cases	NN	O	O
were	NN	O	O
similar	NN	O	O
.	NN	O	O

Allergic	NN	O	O
manifestations	NN	O	O
such	NN	O	O
as	NN	O	O
rash	NN	O	B
and	NN	O	O
eosinophilia	NN	O	B
were	NN	O	O
rare	NN	O	O
.	NN	O	O

Hepatitis	NN	O	B
was	NN	O	O
usually	NN	O	O
reversible	NN	O	O
when	NN	O	O
treatment	NN	O	O
was	NN	O	O
stopped	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
returning	NN	O	O
to	NN	O	O
normal	NN	O	O
after	NN	O	O
an	NN	O	O
average	NN	O	O
of	NN	O	O
3	NN	O	O
.	NN	O	O
1	NN	O	O
months	NN	O	O
.	NN	O	O

In	NN	O	O
two	NN	O	O
of	NN	O	O
the	NN	O	O
three	NN	O	O
deaths	NN	O	B
probably	NN	O	O
associated	NN	O	O
with	NN	O	O
ketoconazole	NN	O	O
treatment	NN	O	O
the	NN	O	O
drug	NN	O	O
had	NN	O	O
been	NN	O	O
continued	NN	O	O
after	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
jaundice	NN	O	B
and	NN	O	O
other	NN	O	O
symptoms	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

Clinical	NN	O	O
and	NN	O	O
biochemical	NN	O	O
monitoring	NN	O	O
at	NN	O	O
regular	NN	O	O
intervals	NN	O	O
for	NN	O	O
evidence	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
is	NN	O	O
advised	NN	O	O
during	NN	O	O
long	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
ketoconazole	NN	O	O
to	NN	O	O
prevent	NN	O	O
possible	NN	O	O
serious	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
.	NN	O	O

Glyburide	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatotoxicity	NN	O	B
,	NN	O	O
although	NN	O	O
common	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
only	NN	O	O
infrequently	NN	O	O
with	NN	O	O
sulfonylureas	NN	O	O
.	NN	O	O

For	NN	O	O
glyburide	NN	O	O
,	NN	O	O
a	NN	O	O
second	NN	O	O
-	NN	O	O
generation	NN	O	O
sulfonylurea	NN	O	O
,	NN	O	O
only	NN	O	O
two	NN	O	O
brief	NN	O	O
reports	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B
exist	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
with	NN	O	O
type	NN	O	B
II	NN	O	I
diabetes	NN	O	I
mellitus	NN	O	I
developed	NN	O	O
an	NN	O	O
acute	NN	O	B
hepatitis	NN	O	I
-	NN	O	I
like	NN	O	I
syndrome	NN	O	I
soon	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
glyburide	NN	O	O
therapy	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
serologic	NN	O	O
evidence	NN	O	O
of	NN	O	O
viral	NN	O	B
infection	NN	O	I
,	NN	O	O
and	NN	O	O
a	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
sample	NN	O	O
showed	NN	O	O
a	NN	O	O
histologic	NN	O	O
pattern	NN	O	O
consistent	NN	O	O
with	NN	O	O
drug	NN	O	B
-	NN	O	I
induced	NN	O	I
hepatitis	NN	O	I
.	NN	O	O

Both	NN	O	O
patients	NN	O	O
recovered	NN	O	O
quickly	NN	O	O
after	NN	O	O
stopping	NN	O	O
glyburide	NN	O	O
therapy	NN	O	O
and	NN	O	O
have	NN	O	O
remained	NN	O	O
well	NN	O	O
for	NN	O	O
a	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
of	NN	O	O
1	NN	O	O
year	NN	O	O
.	NN	O	O

Glyburide	NN	O	O
can	NN	O	O
produce	NN	O	O
an	NN	O	O
acute	NN	O	B
hepatitis	NN	O	I
-	NN	O	I
like	NN	O	I
illness	NN	O	I
in	NN	O	O
some	NN	O	O
persons	NN	O	O
.	NN	O	O

Intracranial	NN	O	O
pressure	NN	O	O
increases	NN	O	O
during	NN	O	O
alfentanil	NN	O	O
-	NN	O	O
induced	NN	O	O
rigidity	NN	O	B
.	NN	O	O

Intracranial	NN	O	O
pressure	NN	O	O
(	NN	O	O
ICP	NN	O	O
)	NN	O	O
was	NN	O	O
measured	NN	O	O
during	NN	O	O
alfentanil	NN	O	O
-	NN	O	O
induced	NN	O	O
rigidity	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Ten	NN	O	O
rats	NN	O	O
had	NN	O	O
arterial	NN	O	O
,	NN	O	O
central	NN	O	O
venous	NN	O	O
(	NN	O	O
CVP	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
subdural	NN	O	O
cannulae	NN	O	O
inserted	NN	O	O
under	NN	O	O
halothane	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

The	NN	O	O
animals	NN	O	O
were	NN	O	O
mechanically	NN	O	O
ventilated	NN	O	O
to	NN	O	O
achieve	NN	O	O
normocarbia	NN	O	O
(	NN	O	O
PCO2	NN	O	O
=	NN	O	O
42	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
mmHg	NN	O	O
,	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SE	NN	O	O
)	NN	O	O
.	NN	O	O

Following	NN	O	O
instrumentation	NN	O	O
,	NN	O	O
halothane	NN	O	O
was	NN	O	O
discontinued	NN	O	O
and	NN	O	O
alfentanil	NN	O	O
(	NN	O	O
125	NN	O	O
mu	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
administered	NN	O	O
iv	NN	O	O
during	NN	O	O
emergence	NN	O	O
from	NN	O	O
halothane	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
five	NN	O	O
rats	NN	O	O
that	NN	O	O
developed	NN	O	O
somatic	NN	O	B
rigidity	NN	O	I
,	NN	O	O
ICP	NN	O	O
and	NN	O	O
CVP	NN	O	O
increased	NN	O	O
significantly	NN	O	O
above	NN	O	O
baseline	NN	O	O
(	NN	O	O
delta	NN	O	O
ICP	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
mmHg	NN	O	O
,	NN	O	O
delta	NN	O	O
CVP	NN	O	O
5	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
mmHg	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
variables	NN	O	O
returned	NN	O	O
to	NN	O	O
baseline	NN	O	O
when	NN	O	O
rigidity	NN	O	B
was	NN	O	O
abolished	NN	O	O
with	NN	O	O
metocurine	NN	O	O
.	NN	O	O

In	NN	O	O
five	NN	O	O
rats	NN	O	O
that	NN	O	O
did	NN	O	O
not	NN	O	O
become	NN	O	O
rigid	NN	O	O
,	NN	O	O
ICP	NN	O	O
and	NN	O	O
CVP	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
following	NN	O	O
alfentanil	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
suggest	NN	O	O
that	NN	O	O
rigidity	NN	O	B
should	NN	O	O
be	NN	O	O
prevented	NN	O	O
when	NN	O	O
alfentanil	NN	O	O
,	NN	O	O
and	NN	O	O
,	NN	O	O
presumably	NN	O	O
,	NN	O	O
other	NN	O	O
opiates	NN	O	O
,	NN	O	O
are	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
anesthetic	NN	O	O
management	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
ICP	NN	O	O
problems	NN	O	O
.	NN	O	O

Verapamil	NN	O	O
withdrawal	NN	O	O
as	NN	O	O
a	NN	O	O
possible	NN	O	O
cause	NN	O	O
of	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
a	NN	O	O
hypertensive	NN	O	B
woman	NN	O	O
with	NN	O	O
a	NN	O	O
normal	NN	O	O
coronary	NN	O	O
angiogram	NN	O	O
.	NN	O	O

Verapamil	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
and	NN	O	O
relatively	NN	O	O
-	NN	O	O
safe	NN	O	O
antihypertensive	NN	O	O
drug	NN	O	O
.	NN	O	O

Serious	NN	O	O
adverse	NN	O	O
effects	NN	O	O
are	NN	O	O
uncommon	NN	O	O
and	NN	O	O
mainly	NN	O	O
have	NN	O	O
been	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
depression	NN	O	B
of	NN	O	O
cardiac	NN	O	O
contractility	NN	O	O
and	NN	O	O
conduction	NN	O	O
,	NN	O	O
especially	NN	O	O
when	NN	O	O
the	NN	O	O
drug	NN	O	O
is	NN	O	O
combined	NN	O	O
with	NN	O	O
beta	NN	O	O
-	NN	O	O
blocking	NN	O	O
agents	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
in	NN	O	O
which	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
coincided	NN	O	O
with	NN	O	O
the	NN	O	O
introduction	NN	O	O
of	NN	O	O
captopril	NN	O	O
and	NN	O	O
the	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
verapamil	NN	O	O
in	NN	O	O
a	NN	O	O
previously	NN	O	O
asymptomatic	NN	O	O
woman	NN	O	O
with	NN	O	O
severe	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Possible	NN	O	O
mechanisms	NN	O	O
that	NN	O	O
involve	NN	O	O
a	NN	O	O
verapamil	NN	O	O
-	NN	O	O
related	NN	O	O
increase	NN	O	O
in	NN	O	O
platelet	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
vascular	NN	O	O
alpha	NN	O	O
2	NN	O	O
-	NN	O	O
adrenoreceptor	NN	O	O
affinity	NN	O	O
for	NN	O	O
catecholamines	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Haemolytic	NN	O	B
-	NN	O	I
uraemic	NN	O	I
syndrome	NN	O	I
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
metronidazole	NN	O	O
.	NN	O	O

This	NN	O	O
paper	NN	O	O
describes	NN	O	O
the	NN	O	O
clinical	NN	O	O
features	NN	O	O
of	NN	O	O
six	NN	O	O
children	NN	O	O
who	NN	O	O
developed	NN	O	O
the	NN	O	O
haemolytic	NN	O	B
-	NN	O	I
uraemic	NN	O	I
syndrome	NN	O	I
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
metronidazole	NN	O	O
.	NN	O	O

These	NN	O	O
children	NN	O	O
were	NN	O	O
older	NN	O	O
and	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
undergone	NN	O	O
recent	NN	O	O
bowel	NN	O	O
surgery	NN	O	O
than	NN	O	O
are	NN	O	O
other	NN	O	O
children	NN	O	O
with	NN	O	O
this	NN	O	O
condition	NN	O	O
.	NN	O	O

While	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
metronidazole	NN	O	O
in	NN	O	O
the	NN	O	O
aetiology	NN	O	O
of	NN	O	O
the	NN	O	O
haemolytic	NN	O	B
-	NN	O	I
uraemic	NN	O	I
syndrome	NN	O	I
is	NN	O	O
not	NN	O	O
established	NN	O	O
firmly	NN	O	O
,	NN	O	O
the	NN	O	O
action	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
in	NN	O	O
sensitizing	NN	O	O
tissues	NN	O	O
to	NN	O	O
oxidation	NN	O	O
injury	NN	O	O
and	NN	O	O
the	NN	O	O
reported	NN	O	O
evidence	NN	O	O
of	NN	O	O
oxidation	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
haemolytic	NN	O	B
-	NN	O	I
uraemic	NN	O	I
syndrome	NN	O	I
suggest	NN	O	O
a	NN	O	O
possible	NN	O	O
link	NN	O	O
between	NN	O	O
metronidazole	NN	O	O
treatment	NN	O	O
and	NN	O	O
some	NN	O	O
cases	NN	O	O
of	NN	O	O
the	NN	O	O
haemolytic	NN	O	B
-	NN	O	I
uraemic	NN	O	I
syndrome	NN	O	I
.	NN	O	O

Adverse	NN	O	O
cardiac	NN	O	O
effects	NN	O	O
during	NN	O	O
induction	NN	O	O
chemotherapy	NN	O	O
treatment	NN	O	O
with	NN	O	O
cis	NN	O	O
-	NN	O	O
platin	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
.	NN	O	O

Survival	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
head	NN	O	B
and	NN	O	I
neck	NN	O	I
carcinoma	NN	O	I
and	NN	O	O
esophageal	NN	O	B
carcinoma	NN	O	I
is	NN	O	O
poor	NN	O	O
with	NN	O	O
radiotherapy	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
surgery	NN	O	O
.	NN	O	O

Obviously	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
need	NN	O	O
for	NN	O	O
effective	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
cis	NN	O	O
-	NN	O	O
platin	NN	O	O
(	NN	O	O
80	NN	O	O
-	NN	O	O
120	NN	O	O
mg	NN	O	O
/	NN	O	O
m2BSA	NN	O	O
)	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
(	NN	O	O
1000	NN	O	O
mg	NN	O	O
/	NN	O	O
m2BSA	NN	O	O
daily	NN	O	O
as	NN	O	O
a	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
during	NN	O	O
5	NN	O	O
days	NN	O	O
)	NN	O	O
were	NN	O	O
given	NN	O	O
to	NN	O	O
76	NN	O	O
patients	NN	O	O
before	NN	O	O
radiotherapy	NN	O	O
and	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
clarify	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
adverse	NN	O	O
cardiac	NN	O	O
effects	NN	O	O
to	NN	O	O
this	NN	O	O
treatment	NN	O	O
.	NN	O	O

Before	NN	O	O
treatment	NN	O	O
all	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
cardiac	NN	O	O
evaluation	NN	O	O
and	NN	O	O
during	NN	O	O
treatment	NN	O	O
serial	NN	O	O
ECG	NN	O	O
recordings	NN	O	O
were	NN	O	O
performed	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
evaluation	NN	O	O
,	NN	O	O
signs	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
were	NN	O	O
found	NN	O	O
in	NN	O	O
33	NN	O	O
patients	NN	O	O
(	NN	O	O
43	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
treatment	NN	O	O
,	NN	O	O
adverse	NN	O	O
cardiac	NN	O	O
effects	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
14	NN	O	O
patients	NN	O	O
(	NN	O	O
18	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
age	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
was	NN	O	O
the	NN	O	O
same	NN	O	O
as	NN	O	O
for	NN	O	O
the	NN	O	O
entire	NN	O	O
group	NN	O	O
,	NN	O	O
64	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B
was	NN	O	O
not	NN	O	O
higher	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
signs	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
than	NN	O	O
in	NN	O	O
those	NN	O	O
without	NN	O	O
in	NN	O	O
the	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
evaluation	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
signs	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B
were	NN	O	O
chest	NN	O	B
pain	NN	O	I
,	NN	O	O
ST	NN	O	O
-	NN	O	O
T	NN	O	O
wave	NN	O	O
changes	NN	O	O
and	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
.	NN	O	O

This	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
in	NN	O	O
one	NN	O	O
patient	NN	O	O
and	NN	O	O
sudden	NN	O	B
death	NN	O	I
in	NN	O	O
another	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
patients	NN	O	O
on	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
treatment	NN	O	O
should	NN	O	O
be	NN	O	O
under	NN	O	O
close	NN	O	O
supervision	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
treatment	NN	O	O
should	NN	O	O
be	NN	O	O
discontinued	NN	O	O
if	NN	O	O
chest	NN	O	B
pain	NN	O	I
or	NN	O	O
tachyarrhythmia	NN	O	B
is	NN	O	O
observed	NN	O	O
.	NN	O	O

Death	NN	O	B
from	NN	O	O
chemotherapy	NN	O	O
in	NN	O	O
gestational	NN	O	B
trophoblastic	NN	O	I
disease	NN	O	I
.	NN	O	O

Multiple	NN	O	O
cytotoxic	NN	O	O
drug	NN	O	O
administration	NN	O	O
is	NN	O	O
the	NN	O	O
generally	NN	O	O
accepted	NN	O	O
treatment	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
stage	NN	O	O
of	NN	O	O
choriocarcinoma	NN	O	B
.	NN	O	O

Based	NN	O	O
on	NN	O	O
this	NN	O	O
principle	NN	O	O
a	NN	O	O
27	NN	O	O
-	NN	O	O
year	NN	O	O
old	NN	O	O
woman	NN	O	O
,	NN	O	O
classified	NN	O	O
as	NN	O	O
being	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
group	NN	O	O
(	NN	O	O
Goldstein	NN	O	O
and	NN	O	O
Berkowitz	NN	O	O
score	NN	O	O
:	NN	O	O
11	NN	O	O
)	NN	O	O
,	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
multiple	NN	O	O
cytotoxic	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
multiple	NN	O	O
drug	NN	O	O
schema	NN	O	O
consisted	NN	O	O
of	NN	O	O
:	NN	O	O
Etoposide	NN	O	O
16	NN	O	O
.	NN	O	O
213	NN	O	O
,	NN	O	O
Methotrexate	NN	O	O
,	NN	O	O
Cyclophosphamide	NN	O	O
,	NN	O	O
Actomycin	NN	O	O
-	NN	O	O
D	NN	O	O
,	NN	O	O
and	NN	O	O
Cisplatin	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
first	NN	O	O
day	NN	O	O
of	NN	O	O
the	NN	O	O
schedule	NN	O	O
,	NN	O	O
moderate	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
Methotrexate	NN	O	O
,	NN	O	O
Etoposide	NN	O	O
and	NN	O	O
Cyclophosphamide	NN	O	O
were	NN	O	O
administered	NN	O	O
.	NN	O	O

Within	NN	O	O
8	NN	O	O
hours	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
therapy	NN	O	O
the	NN	O	O
patient	NN	O	O
died	NN	O	O
with	NN	O	O
a	NN	O	O
clinical	NN	O	O
picture	NN	O	O
resembling	NN	O	O
massive	NN	O	O
pulmonary	NN	O	B
obstruction	NN	O	I
due	NN	O	O
to	NN	O	O
choriocarcinomic	NN	O	O
tissue	NN	O	O
plugs	NN	O	O
,	NN	O	O
probably	NN	O	O
originating	NN	O	O
from	NN	O	O
the	NN	O	O
uterus	NN	O	O
.	NN	O	O

Formation	NN	O	O
of	NN	O	O
these	NN	O	O
plugs	NN	O	O
was	NN	O	O
probably	NN	O	O
due	NN	O	O
to	NN	O	O
extensive	NN	O	O
tumor	NN	O	B
necrosis	NN	O	B
at	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
the	NN	O	O
walls	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	O
uterine	NN	O	O
veins	NN	O	O
,	NN	O	O
which	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
open	NN	O	O
exchange	NN	O	O
of	NN	O	O
tumor	NN	O	B
plugs	NN	O	O
to	NN	O	O
the	NN	O	O
vascular	NN	O	O
spaces	NN	O	O
;	NN	O	O
decrease	NN	O	O
in	NN	O	O
tumor	NN	O	B
tissue	NN	O	O
coherence	NN	O	O
secondary	NN	O	O
to	NN	O	O
chemotherapy	NN	O	O
may	NN	O	O
have	NN	O	O
further	NN	O	O
contributed	NN	O	O
to	NN	O	O
the	NN	O	O
formation	NN	O	O
of	NN	O	O
tumor	NN	O	B
emboli	NN	O	O
.	NN	O	O

In	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
close	NN	O	O
time	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
the	NN	O	O
acute	NN	O	O
onset	NN	O	O
of	NN	O	O
massive	NN	O	O
embolism	NN	O	B
other	NN	O	O
explanations	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
spontaneous	NN	O	O
necrosis	NN	O	B
,	NN	O	O
must	NN	O	O
be	NN	O	O
considered	NN	O	O
less	NN	O	O
likely	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
large	NN	O	O
pelvic	NN	O	B
tumor	NN	O	I
loads	NN	O	O
are	NN	O	O
,	NN	O	O
according	NN	O	O
to	NN	O	O
existing	NN	O	O
classifications	NN	O	O
,	NN	O	O
at	NN	O	O
high	NN	O	O
risk	NN	O	O
to	NN	O	O
die	NN	O	O
and	NN	O	O
to	NN	O	O
develop	NN	O	O
drug	NN	O	O
resistance	NN	O	O
.	NN	O	O

Notwithstanding	NN	O	O
these	NN	O	O
facts	NN	O	O
our	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
these	NN	O	O
patients	NN	O	O
might	NN	O	O
benefit	NN	O	O
from	NN	O	O
relatively	NN	O	O
mild	NN	O	O
initial	NN	O	O
treatment	NN	O	O
,	NN	O	O
especially	NN	O	O
true	NN	O	O
for	NN	O	O
patients	NN	O	O
not	NN	O	O
previously	NN	O	O
exposed	NN	O	O
to	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O

Close	NN	O	O
observation	NN	O	O
of	NN	O	O
the	NN	O	O
response	NN	O	O
status	NN	O	O
both	NN	O	O
clinically	NN	O	O
and	NN	O	O
with	NN	O	O
beta	NN	O	O
-	NN	O	O
hCG	NN	O	O
values	NN	O	O
may	NN	O	O
indicate	NN	O	O
whether	NN	O	O
and	NN	O	O
when	NN	O	O
more	NN	O	O
agressive	NN	O	O
combination	NN	O	O
chemotherapy	NN	O	O
should	NN	O	O
be	NN	O	O
started	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Pulmonary	NN	O	O
shunt	NN	O	O
and	NN	O	O
cardiovascular	NN	O	O
responses	NN	O	O
to	NN	O	O
CPAP	NN	O	O
during	NN	O	O
nitroprusside	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
continuous	NN	O	O
positive	NN	O	O
airway	NN	O	O
pressure	NN	O	O
(	NN	O	O
CPAP	NN	O	O
)	NN	O	O
on	NN	O	O
cardiovascular	NN	O	O
dynamics	NN	O	O
and	NN	O	O
pulmonary	NN	O	O
shunt	NN	O	O
(	NN	O	O
QS	NN	O	O
/	NN	O	O
QT	NN	O	O
)	NN	O	O
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
12	NN	O	O
dogs	NN	O	O
before	NN	O	O
and	NN	O	O
during	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
infusion	NN	O	O
that	NN	O	O
decreased	NN	O	O
mean	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
40	NN	O	O
-	NN	O	O
50	NN	O	O
per	NN	O	O
cent	NN	O	O
.	NN	O	O

Before	NN	O	O
nitroprusside	NN	O	O
infusion	NN	O	O
,	NN	O	O
5	NN	O	O
cm	NN	O	O
H2O	NN	O	O
CPAP	NN	O	O
significantly	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.	NN	O	O
05	NN	O	O
,	NN	O	O
decreased	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
alter	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
cardiac	NN	O	O
output	NN	O	O
,	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
,	NN	O	O
or	NN	O	O
QS	NN	O	O
/	NN	O	O
QT	NN	O	O
.	NN	O	O

Ten	NN	O	O
cm	NN	O	O
H2O	NN	O	O
CPAP	NN	O	O
before	NN	O	O
nitroprusside	NN	O	O
infusion	NN	O	O
produced	NN	O	O
a	NN	O	O
further	NN	O	O
decrease	NN	O	B
in	NN	O	I
arterial	NN	O	I
blood	NN	O	I
pressure	NN	O	I
and	NN	O	O
significantly	NN	O	O
increased	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
decreased	NN	O	B
cardiac	NN	O	I
output	NN	O	I
and	NN	O	O
QS	NN	O	O
/	NN	O	O
QT	NN	O	O
.	NN	O	O

Nitroprusside	NN	O	O
caused	NN	O	O
significant	NN	O	O
decreases	NN	O	B
in	NN	O	I
arterial	NN	O	I
blood	NN	O	I
pressure	NN	O	I
and	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
and	NN	O	O
increases	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
cardiac	NN	O	O
output	NN	O	O
or	NN	O	O
QS	NN	O	O
/	NN	O	O
QT	NN	O	O
.	NN	O	O

Five	NN	O	O
cm	NN	O	O
H2O	NN	O	O
CPAP	NN	O	O
during	NN	O	O
nitroprusside	NN	O	O
did	NN	O	O
not	NN	O	O
further	NN	O	O
alter	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
above	NN	O	O
-	NN	O	O
mentioned	NN	O	O
variables	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
10	NN	O	O
cm	NN	O	O
H2O	NN	O	O
CPAP	NN	O	O
decreased	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
cardiac	NN	O	O
output	NN	O	O
,	NN	O	O
and	NN	O	O
QS	NN	O	O
/	NN	O	O
QT	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
nitroprusside	NN	O	O
infusion	NN	O	O
rates	NN	O	O
that	NN	O	O
decrease	NN	O	O
mean	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
by	NN	O	O
40	NN	O	O
-	NN	O	O
50	NN	O	O
per	NN	O	O
cent	NN	O	O
do	NN	O	O
not	NN	O	O
change	NN	O	O
cardiac	NN	O	O
output	NN	O	O
or	NN	O	O
QS	NN	O	O
/	NN	O	O
QT	NN	O	O
.	NN	O	O

During	NN	O	O
nitroprusside	NN	O	O
infusion	NN	O	O
low	NN	O	O
levels	NN	O	O
of	NN	O	O
CPAP	NN	O	O
do	NN	O	O
not	NN	O	O
markedly	NN	O	O
alter	NN	O	O
cardiovascular	NN	O	O
dynamics	NN	O	O
,	NN	O	O
but	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
CPAP	NN	O	O
(	NN	O	O
10	NN	O	O
cm	NN	O	O
H2O	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
decreasing	NN	O	O
QS	NN	O	O
/	NN	O	O
QT	NN	O	O
,	NN	O	O
produce	NN	O	O
marked	NN	O	O
decreases	NN	O	B
in	NN	O	I
arterial	NN	O	I
blood	NN	O	I
pressure	NN	O	I
and	NN	O	I
cardiac	NN	O	I
output	NN	O	I
.	NN	O	O

Systolic	NN	O	O
pressure	NN	O	O
variation	NN	O	O
is	NN	O	O
greater	NN	O	O
during	NN	O	O
hemorrhage	NN	O	B
than	NN	O	O
during	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
in	NN	O	O
ventilated	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
systolic	NN	O	O
pressure	NN	O	O
variation	NN	O	O
(	NN	O	O
SPV	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
the	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
maximal	NN	O	O
and	NN	O	O
minimal	NN	O	O
values	NN	O	O
of	NN	O	O
the	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
SBP	NN	O	O
)	NN	O	O
after	NN	O	O
one	NN	O	O
positive	NN	O	O
-	NN	O	O
pressure	NN	O	O
breath	NN	O	O
,	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
ventilated	NN	O	O
dogs	NN	O	O
subjected	NN	O	O
to	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
was	NN	O	O
decreased	NN	O	O
to	NN	O	O
50	NN	O	O
mm	NN	O	O
Hg	NN	O	O
for	NN	O	O
30	NN	O	O
minutes	NN	O	O
either	NN	O	O
by	NN	O	O
hemorrhage	NN	O	B
(	NN	O	O
HEM	NN	O	B
,	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
or	NN	O	O
by	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
(	NN	O	O
SNP	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
HEM	NN	O	B
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
the	NN	O	O
cardiac	NN	O	O
output	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
and	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
higher	NN	O	O
compared	NN	O	O
with	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
SNP	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
systemic	NN	O	O
,	NN	O	O
central	NN	O	O
venous	NN	O	O
,	NN	O	O
pulmonary	NN	O	O
capillary	NN	O	O
wedge	NN	O	O
pressures	NN	O	O
,	NN	O	O
and	NN	O	O
heart	NN	O	O
rates	NN	O	O
,	NN	O	O
were	NN	O	O
similar	NN	O	O
in	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
the	NN	O	O
respiratory	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
waveform	NN	O	O
enabled	NN	O	O
differentiation	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
SPV	NN	O	O
during	NN	O	O
hypotension	NN	O	B
was	NN	O	O
15	NN	O	O
.	NN	O	O
7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
.	NN	O	O
7	NN	O	O
mm	NN	O	O
Hg	NN	O	O
in	NN	O	O
the	NN	O	O
HEM	NN	O	B
group	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
9	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mm	NN	O	O
Hg	NN	O	O
in	NN	O	O
the	NN	O	O
SNP	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
delta	NN	O	O
down	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
the	NN	O	O
measure	NN	O	O
of	NN	O	O
decrease	NN	O	O
of	NN	O	O
SBP	NN	O	O
after	NN	O	O
a	NN	O	O
mechanical	NN	O	O
breath	NN	O	O
,	NN	O	O
was	NN	O	O
20	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
.	NN	O	O
4	NN	O	O
and	NN	O	O
10	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
.	NN	O	O
8	NN	O	O
mm	NN	O	O
Hg	NN	O	O
in	NN	O	O
the	NN	O	O
HEM	NN	O	B
and	NN	O	O
SNP	NN	O	O
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
during	NN	O	O
hypotension	NN	O	B
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
increases	NN	O	O
in	NN	O	O
the	NN	O	O
SPV	NN	O	O
and	NN	O	O
the	NN	O	O
delta	NN	O	O
down	NN	O	O
are	NN	O	O
characteristic	NN	O	O
of	NN	O	O
a	NN	O	O
hypotensive	NN	O	B
state	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
predominant	NN	O	O
decrease	NN	O	O
in	NN	O	O
preload	NN	O	O
.	NN	O	O

They	NN	O	O
are	NN	O	O
thus	NN	O	O
more	NN	O	O
important	NN	O	O
during	NN	O	O
absolute	NN	O	O
hypovolemia	NN	O	B
than	NN	O	O
during	NN	O	O
deliberate	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Ventricular	NN	O	B
tachyarrhythmias	NN	O	I
during	NN	O	O
cesarean	NN	O	O
section	NN	O	O
after	NN	O	O
ritodrine	NN	O	O
therapy	NN	O	O
:	NN	O	O
interaction	NN	O	O
with	NN	O	O
anesthetics	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
illustrates	NN	O	O
that	NN	O	O
patients	NN	O	O
receiving	NN	O	O
ritodrine	NN	O	O
for	NN	O	O
preterm	NN	O	B
labor	NN	O	I
may	NN	O	O
risk	NN	O	O
interactions	NN	O	O
between	NN	O	O
the	NN	O	O
residual	NN	O	O
betamimetic	NN	O	O
effects	NN	O	O
of	NN	O	O
ritodrine	NN	O	O
and	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
anesthetics	NN	O	O
during	NN	O	O
cesarean	NN	O	O
section	NN	O	O
.	NN	O	O

Such	NN	O	O
interactions	NN	O	O
may	NN	O	O
result	NN	O	O
in	NN	O	O
serious	NN	O	O
cardiovascular	NN	O	B
complications	NN	O	I
even	NN	O	O
after	NN	O	O
cessation	NN	O	O
of	NN	O	O
an	NN	O	O
infusion	NN	O	O
of	NN	O	O
ritodrine	NN	O	O
.	NN	O	O

Preoperative	NN	O	O
assessment	NN	O	O
should	NN	O	O
focus	NN	O	O
on	NN	O	O
cardiovascular	NN	O	O
status	NN	O	O
and	NN	O	O
serum	NN	O	O
potassium	NN	O	O
level	NN	O	O
.	NN	O	O

Delaying	NN	O	O
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
whenever	NN	O	O
possible	NN	O	O
.	NN	O	O

Careful	NN	O	O
fluid	NN	O	O
administration	NN	O	O
and	NN	O	O
cautious	NN	O	O
use	NN	O	O
of	NN	O	O
titrated	NN	O	O
doses	NN	O	O
of	NN	O	O
ephedrine	NN	O	O
are	NN	O	O
advised	NN	O	O
.	NN	O	O

After	NN	O	O
delivery	NN	O	O
of	NN	O	O
the	NN	O	O
infant	NN	O	O
,	NN	O	O
there	NN	O	O
should	NN	O	O
be	NN	O	O
no	NN	O	O
contraindication	NN	O	O
to	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
an	NN	O	O
alpha	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
vasopressor	NN	O	O
such	NN	O	O
as	NN	O	O
phenylephrine	NN	O	O
to	NN	O	O
treat	NN	O	O
hypotensive	NN	O	B
patients	NN	O	O
with	NN	O	O
tachycardia	NN	O	B
.	NN	O	O

Verapamil	NN	O	O
-	NN	O	O
induced	NN	O	O
carbamazepine	NN	O	O
neurotoxicity	NN	O	B
.	NN	O	O

A	NN	O	O
report	NN	O	O
of	NN	O	O
two	NN	O	O
cases	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
with	NN	O	O
signs	NN	O	O
of	NN	O	O
carbamazepine	NN	O	O
neurotoxicity	NN	O	B
after	NN	O	O
combined	NN	O	O
treatment	NN	O	O
with	NN	O	O
verapamil	NN	O	O
showed	NN	O	O
complete	NN	O	O
recovery	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
calcium	NN	O	O
entry	NN	O	O
blocker	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
verapamil	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
carbamazepine	NN	O	O
should	NN	O	O
either	NN	O	O
be	NN	O	O
avoided	NN	O	O
or	NN	O	O
prescribed	NN	O	O
only	NN	O	O
with	NN	O	O
appropriate	NN	O	O
adjustment	NN	O	O
of	NN	O	O
the	NN	O	O
carbamazepine	NN	O	O
dose	NN	O	O
(	NN	O	O
usually	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
carbamazepine	NN	O	O
dose	NN	O	O
by	NN	O	O
one	NN	O	O
half	NN	O	O
)	NN	O	O
.	NN	O	O

Paracetamol	NN	O	O
-	NN	O	O
associated	NN	O	O
coma	NN	O	B
,	NN	O	O
metabolic	NN	O	B
acidosis	NN	O	I
,	NN	O	O
renal	NN	O	B
and	NN	O	I
hepatic	NN	O	I
failure	NN	O	I
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
metabolic	NN	O	B
acidosis	NN	O	I
,	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
and	NN	O	I
hepatic	NN	O	I
failure	NN	O	I
following	NN	O	O
paracetamol	NN	O	O
ingestion	NN	O	O
is	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
diagnostic	NN	O	O
difficulty	NN	O	O
at	NN	O	O
presentation	NN	O	O
is	NN	O	O
highlighted	NN	O	O
.	NN	O	O

Continuous	NN	O	O
arteriovenous	NN	O	O
haemofiltration	NN	O	O
proved	NN	O	O
a	NN	O	O
valuable	NN	O	O
means	NN	O	O
of	NN	O	O
maintaining	NN	O	O
fluid	NN	O	O
and	NN	O	O
electrolyte	NN	O	O
balance	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
recovered	NN	O	O
.	NN	O	O

Sexual	NN	O	B
dysfunction	NN	O	I
among	NN	O	O
patients	NN	O	O
with	NN	O	O
arthritis	NN	O	B
.	NN	O	O

The	NN	O	O
relationship	NN	O	O
of	NN	O	O
arthritis	NN	O	B
and	NN	O	O
sexual	NN	O	B
dysfunction	NN	O	I
was	NN	O	O
investigated	NN	O	O
among	NN	O	O
169	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
,	NN	O	O
osteoarthritis	NN	O	B
and	NN	O	O
spondyloarthropathy	NN	O	B
,	NN	O	O
130	NN	O	O
of	NN	O	O
whom	NN	O	O
were	NN	O	O
pair	NN	O	O
-	NN	O	O
matched	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

Assessments	NN	O	O
of	NN	O	O
marital	NN	O	O
happiness	NN	O	O
and	NN	O	O
depressed	NN	O	B
mood	NN	O	I
were	NN	O	O
also	NN	O	O
made	NN	O	O
using	NN	O	O
the	NN	O	O
CES	NN	O	O
-	NN	O	O
D	NN	O	O
and	NN	O	O
the	NN	O	O
Azrin	NN	O	O
Marital	NN	O	O
Happiness	NN	O	O
Scale	NN	O	O
(	NN	O	O
AMHS	NN	O	O
)	NN	O	O
.	NN	O	O

Sexual	NN	O	B
dysfunctions	NN	O	I
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
common	NN	O	O
among	NN	O	O
patients	NN	O	O
and	NN	O	O
controls	NN	O	O
,	NN	O	O
the	NN	O	O
majority	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
reporting	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
dysfunctions	NN	O	O
.	NN	O	O

Impotence	NN	O	B
was	NN	O	O
more	NN	O	O
common	NN	O	O
among	NN	O	O
male	NN	O	O
patients	NN	O	O
than	NN	O	O
controls	NN	O	O
and	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
co	NN	O	O
-	NN	O	O
morbidity	NN	O	O
and	NN	O	O
the	NN	O	O
taking	NN	O	O
of	NN	O	O
methotrexate	NN	O	O
.	NN	O	O

Depressed	NN	O	B
mood	NN	O	I
was	NN	O	O
more	NN	O	O
common	NN	O	O
among	NN	O	O
patients	NN	O	O
and	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
certain	NN	O	O
sexual	NN	O	O
difficulties	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
with	NN	O	O
impotence	NN	O	B
.	NN	O	O

Marital	NN	O	O
unhappiness	NN	O	O
,	NN	O	O
as	NN	O	O
indicated	NN	O	O
by	NN	O	O
AMHS	NN	O	O
scores	NN	O	O
,	NN	O	O
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
arthritis	NN	O	B
but	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
sexual	NN	O	B
dysfunction	NN	O	I
,	NN	O	O
sexual	NN	O	O
dissatisfaction	NN	O	O
and	NN	O	O
being	NN	O	O
female	NN	O	O
.	NN	O	O

Does	NN	O	O
paracetamol	NN	O	O
cause	NN	O	O
urothelial	NN	O	B
cancer	NN	O	I
or	NN	O	O
renal	NN	O	B
papillary	NN	O	I
necrosis	NN	O	I
?	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
developing	NN	O	O
renal	NN	O	B
papillary	NN	O	I
necrosis	NN	O	I
or	NN	O	O
cancer	NN	O	B
of	NN	O	I
the	NN	O	I
renal	NN	O	I
pelvis	NN	O	I
,	NN	O	I
ureter	NN	O	I
or	NN	O	I
bladder	NN	O	I
associated	NN	O	O
with	NN	O	O
consumption	NN	O	O
of	NN	O	O
either	NN	O	O
phenacetin	NN	O	O
or	NN	O	O
paracetamol	NN	O	O
was	NN	O	O
calculated	NN	O	O
from	NN	O	O
data	NN	O	O
acquired	NN	O	O
by	NN	O	O
questionnaire	NN	O	O
from	NN	O	O
381	NN	O	O
cases	NN	O	O
and	NN	O	O
808	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
renal	NN	O	B
papillary	NN	O	I
necrosis	NN	O	I
was	NN	O	O
increased	NN	O	O
nearly	NN	O	O
20	NN	O	O
-	NN	O	O
fold	NN	O	O
by	NN	O	O
consumption	NN	O	O
of	NN	O	O
phenacetin	NN	O	O
,	NN	O	O
which	NN	O	O
also	NN	O	O
increased	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
cancer	NN	O	B
of	NN	O	I
the	NN	O	I
renal	NN	O	I
pelvis	NN	O	I
and	NN	O	I
bladder	NN	O	I
but	NN	O	O
not	NN	O	O
for	NN	O	O
ureteric	NN	O	B
cancer	NN	O	I
.	NN	O	O

By	NN	O	O
contrast	NN	O	O
,	NN	O	O
we	NN	O	O
were	NN	O	O
unable	NN	O	O
to	NN	O	O
substantiate	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
from	NN	O	O
paracetamol	NN	O	O
consumption	NN	O	O
for	NN	O	O
renal	NN	O	B
papillary	NN	O	I
necrosis	NN	O	I
or	NN	O	O
any	NN	O	O
of	NN	O	O
these	NN	O	O
cancers	NN	O	B
although	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
suggestion	NN	O	O
of	NN	O	O
an	NN	O	O
association	NN	O	O
with	NN	O	O
cancer	NN	O	B
of	NN	O	I
the	NN	O	I
ureter	NN	O	I
.	NN	O	O

Dapsone	NN	O	O
-	NN	O	O
associated	NN	O	O
Heinz	NN	O	O
body	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
in	NN	O	O
a	NN	O	O
Cambodian	NN	O	O
woman	NN	O	O
with	NN	O	O
hemoglobin	NN	O	O
E	NN	O	O
trait	NN	O	O
.	NN	O	O

A	NN	O	O
Cambodian	NN	O	O
woman	NN	O	O
with	NN	O	O
hemoglobin	NN	O	O
E	NN	O	O
trait	NN	O	O
(	NN	O	O
AE	NN	O	O
)	NN	O	O
and	NN	O	O
leprosy	NN	O	B
developed	NN	O	O
a	NN	O	O
Heinz	NN	O	O
body	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
while	NN	O	O
taking	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
dapsone	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
not	NN	O	O
usually	NN	O	O
associated	NN	O	O
with	NN	O	O
clinical	NN	O	O
hemolysis	NN	O	B
.	NN	O	O

Her	NN	O	O
red	NN	O	O
blood	NN	O	O
cells	NN	O	O
(	NN	O	O
RBCs	NN	O	O
)	NN	O	O
had	NN	O	O
increased	NN	O	O
incubated	NN	O	O
Heinz	NN	O	O
body	NN	O	O
formation	NN	O	O
,	NN	O	O
decreased	NN	O	O
reduced	NN	O	O
glutathione	NN	O	O
(	NN	O	O
GSH	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
decreased	NN	O	O
GSH	NN	O	O
stability	NN	O	O
.	NN	O	O

The	NN	O	O
pentose	NN	O	O
phosphate	NN	O	O
shunt	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
dapsone	NN	O	O
-	NN	O	O
exposed	NN	O	O
AE	NN	O	O
RBCs	NN	O	O
was	NN	O	O
increased	NN	O	O
compared	NN	O	O
to	NN	O	O
normal	NN	O	O
RBCs	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
AE	NN	O	O
RBCs	NN	O	O
from	NN	O	O
an	NN	O	O
individual	NN	O	O
not	NN	O	O
taking	NN	O	O
dapsone	NN	O	O
had	NN	O	O
increased	NN	O	O
incubated	NN	O	O
Heinz	NN	O	O
body	NN	O	O
formation	NN	O	O
,	NN	O	O
the	NN	O	O
GSH	NN	O	O
content	NN	O	O
and	NN	O	O
GSH	NN	O	O
stability	NN	O	O
were	NN	O	O
normal	NN	O	O
.	NN	O	O

The	NN	O	O
pentose	NN	O	O
phosphate	NN	O	O
shunt	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
dapsone	NN	O	O
-	NN	O	O
exposed	NN	O	O
AE	NN	O	O
RBCs	NN	O	O
was	NN	O	O
decreased	NN	O	O
compared	NN	O	O
to	NN	O	O
normal	NN	O	O
RBCs	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
AE	NN	O	O
RBCs	NN	O	O
appear	NN	O	O
to	NN	O	O
have	NN	O	O
an	NN	O	O
increased	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
oxidant	NN	O	O
stress	NN	O	O
both	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
since	NN	O	O
dapsone	NN	O	O
does	NN	O	O
not	NN	O	O
cause	NN	O	O
hemolytic	NN	O	B
anemia	NN	O	I
at	NN	O	O
this	NN	O	O
dose	NN	O	O
in	NN	O	O
hematologically	NN	O	O
normal	NN	O	O
individuals	NN	O	O
.	NN	O	O

Given	NN	O	O
the	NN	O	O
influx	NN	O	O
of	NN	O	O
Southeast	NN	O	O
Asians	NN	O	O
into	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
,	NN	O	O
oxidant	NN	O	O
medications	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
with	NN	O	O
caution	NN	O	O
,	NN	O	O
especially	NN	O	O
if	NN	O	O
an	NN	O	O
infection	NN	O	B
is	NN	O	O
present	NN	O	O
,	NN	O	O
in	NN	O	O
individuals	NN	O	O
of	NN	O	O
ethnic	NN	O	O
backgrounds	NN	O	O
that	NN	O	O
have	NN	O	O
an	NN	O	O
increased	NN	O	O
prevalence	NN	O	O
of	NN	O	O
hemoglobin	NN	O	O
E	NN	O	O
.	NN	O	O

Severe	NN	O	O
complications	NN	O	O
of	NN	O	O
antianginal	NN	O	O
drug	NN	O	O
therapy	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
identified	NN	O	O
as	NN	O	O
a	NN	O	O
poor	NN	O	O
metabolizer	NN	O	O
of	NN	O	O
metoprolol	NN	O	O
,	NN	O	O
propafenone	NN	O	O
,	NN	O	O
diltiazem	NN	O	O
,	NN	O	O
and	NN	O	O
sparteine	NN	O	O
.	NN	O	O

A	NN	O	O
47	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
suffering	NN	O	O
from	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
CCU	NN	O	O
in	NN	O	O
shock	NN	O	B
with	NN	O	O
III	NN	O	O
.	NN	O	O

AV	NN	O	B
block	NN	O	I
,	NN	O	O
severe	NN	O	O
hypotension	NN	O	B
,	NN	O	O
and	NN	O	O
impairment	NN	O	B
of	NN	O	I
ventricular	NN	O	I
function	NN	O	I
.	NN	O	O

One	NN	O	O
week	NN	O	O
prior	NN	O	O
to	NN	O	O
admission	NN	O	O
a	NN	O	O
therapy	NN	O	O
with	NN	O	O
standard	NN	O	O
doses	NN	O	O
of	NN	O	O
metoprolol	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
t	NN	O	O
.	NN	O	O
i	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
and	NN	O	O
then	NN	O	O
100	NN	O	O
mg	NN	O	O
b	NN	O	O
.	NN	O	O
i	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
)	NN	O	O
had	NN	O	O
been	NN	O	O
initiated	NN	O	O
.	NN	O	O

Two	NN	O	O
days	NN	O	O
before	NN	O	O
admission	NN	O	O
diltiazem	NN	O	O
(	NN	O	O
60	NN	O	O
mg	NN	O	O
b	NN	O	O
.	NN	O	O
i	NN	O	O
.	NN	O	O
d	NN	O	O
.	NN	O	O
)	NN	O	O
was	NN	O	O
prescribed	NN	O	O
in	NN	O	O
addition	NN	O	O
.	NN	O	O

Analyses	NN	O	O
of	NN	O	O
a	NN	O	O
blood	NN	O	O
sample	NN	O	O
revealed	NN	O	O
unusually	NN	O	O
high	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
metoprolol	NN	O	O
(	NN	O	O
greater	NN	O	O
than	NN	O	O
3000	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
and	NN	O	O
diltiazem	NN	O	O
(	NN	O	O
526	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
recovered	NN	O	O
within	NN	O	O
1	NN	O	O
week	NN	O	O
following	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
antianginal	NN	O	O
therapy	NN	O	O
.	NN	O	O

Three	NN	O	O
months	NN	O	O
later	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
exposed	NN	O	O
to	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
metoprolol	NN	O	O
,	NN	O	O
diltiazem	NN	O	O
,	NN	O	O
propafenone	NN	O	O
(	NN	O	O
since	NN	O	O
he	NN	O	O
had	NN	O	O
received	NN	O	O
this	NN	O	O
drug	NN	O	O
in	NN	O	O
the	NN	O	O
past	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
sparteine	NN	O	O
(	NN	O	O
as	NN	O	O
a	NN	O	O
probe	NN	O	O
for	NN	O	O
the	NN	O	O
debrisoquine	NN	O	O
/	NN	O	O
sparteine	NN	O	O
type	NN	O	O
polymorphism	NN	O	O
of	NN	O	O
oxidative	NN	O	O
drug	NN	O	O
metabolism	NN	O	O
)	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
found	NN	O	O
that	NN	O	O
he	NN	O	O
was	NN	O	O
a	NN	O	O
poor	NN	O	O
metabolizer	NN	O	O
of	NN	O	O
all	NN	O	O
four	NN	O	O
drugs	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
their	NN	O	O
metabolism	NN	O	O
is	NN	O	O
under	NN	O	O
the	NN	O	O
same	NN	O	O
genetic	NN	O	O
control	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
patients	NN	O	O
belonging	NN	O	O
to	NN	O	O
the	NN	O	O
poor	NN	O	O
-	NN	O	O
metabolizer	NN	O	O
phenotype	NN	O	O
of	NN	O	O
sparteine	NN	O	O
/	NN	O	O
debrisoquine	NN	O	O
polymorphism	NN	O	O
in	NN	O	O
drug	NN	O	O
metabolism	NN	O	O
,	NN	O	O
which	NN	O	O
constitutes	NN	O	O
6	NN	O	O
.	NN	O	O
4	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
German	NN	O	O
population	NN	O	O
,	NN	O	O
may	NN	O	O
experience	NN	O	O
adverse	NN	O	B
drug	NN	O	I
reactions	NN	O	I
when	NN	O	O
treated	NN	O	O
with	NN	O	O
standard	NN	O	O
doses	NN	O	O
of	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
alone	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
the	NN	O	O
coadministration	NN	O	O
of	NN	O	O
these	NN	O	O
frequently	NN	O	O
used	NN	O	O
drugs	NN	O	O
is	NN	O	O
expected	NN	O	O
to	NN	O	O
be	NN	O	O
especially	NN	O	O
harmful	NN	O	O
in	NN	O	O
this	NN	O	O
subgroup	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Clinical	NN	O	O
experiences	NN	O	O
in	NN	O	O
an	NN	O	O
open	NN	O	O
and	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trial	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
sixty	NN	O	O
patients	NN	O	O
were	NN	O	O
trated	NN	O	O
with	NN	O	O
bromperidol	NN	O	O
first	NN	O	O
in	NN	O	O
open	NN	O	O
conditions	NN	O	O
(	NN	O	O
20	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
then	NN	O	O
on	NN	O	O
a	NN	O	O
double	NN	O	O
blind	NN	O	O
basis	NN	O	O
(	NN	O	O
40	NN	O	O
patients	NN	O	O
)	NN	O	O
with	NN	O	O
haloperidol	NN	O	O
as	NN	O	O
the	NN	O	O
reference	NN	O	O
substance	NN	O	O
.	NN	O	O

The	NN	O	O
open	NN	O	O
study	NN	O	O
lasted	NN	O	O
for	NN	O	O
four	NN	O	O
weeks	NN	O	O
;	NN	O	O
the	NN	O	O
drug	NN	O	O
was	NN	O	O
administrated	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
1	NN	O	O
mg	NN	O	O
tablets	NN	O	O
.	NN	O	O

The	NN	O	O
daily	NN	O	O
dose	NN	O	O
(	NN	O	O
initial	NN	O	O
dose	NN	O	O
:	NN	O	O
1	NN	O	O
mg	NN	O	O
;	NN	O	O
mean	NN	O	O
dose	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
trial	NN	O	O
:	NN	O	O
4	NN	O	O
.	NN	O	O
47	NN	O	O
mg	NN	O	O
)	NN	O	O
was	NN	O	O
always	NN	O	O
administered	NN	O	O
in	NN	O	O
one	NN	O	O
single	NN	O	O
dose	NN	O	O
.	NN	O	O

Nineteen	NN	O	O
patients	NN	O	O
finished	NN	O	O
the	NN	O	O
trial	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
18	NN	O	O
cases	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
result	NN	O	O
was	NN	O	O
considered	NN	O	O
very	NN	O	O
good	NN	O	O
to	NN	O	O
good	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
were	NN	O	O
confirmed	NN	O	O
by	NN	O	O
statistical	NN	O	O
analysis	NN	O	O
.	NN	O	O

Nine	NN	O	O
patients	NN	O	O
exhibited	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
extrapyramidal	NN	O	B
concomitant	NN	O	I
symptoms	NN	O	I
;	NN	O	O
no	NN	O	O
other	NN	O	O
side	NN	O	O
effects	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
detailed	NN	O	O
laboratory	NN	O	O
tests	NN	O	O
and	NN	O	O
evaluations	NN	O	O
of	NN	O	O
various	NN	O	O
quantitative	NN	O	O
and	NN	O	O
qualitative	NN	O	O
tolerability	NN	O	O
parameters	NN	O	O
were	NN	O	O
not	NN	O	O
indicative	NN	O	O
of	NN	O	O
toxic	NN	O	O
effects	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
double	NN	O	O
blind	NN	O	O
study	NN	O	O
with	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
both	NN	O	O
substances	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
highly	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
psychotic	NN	O	B
syndromes	NN	O	I
belonging	NN	O	I
predominantly	NN	O	I
to	NN	O	I
the	NN	O	I
schizophrenia	NN	O	I
group	NN	O	I
.	NN	O	O

Certain	NN	O	O
clues	NN	O	O
,	NN	O	O
including	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
action	NN	O	O
,	NN	O	O
seem	NN	O	O
to	NN	O	O
be	NN	O	O
indicative	NN	O	O
of	NN	O	O
the	NN	O	O
superiority	NN	O	O
of	NN	O	O
bromperidol	NN	O	O
.	NN	O	O

No	NN	O	O
differences	NN	O	O
were	NN	O	O
observed	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
side	NN	O	O
effects	NN	O	O
and	NN	O	O
general	NN	O	O
tolerability	NN	O	O
.	NN	O	O

Prolonged	NN	O	O
cholestasis	NN	O	B
after	NN	O	O
troleandomycin	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
in	NN	O	O
whom	NN	O	O
troleandomycin	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatitis	NN	O	B
was	NN	O	O
followed	NN	O	O
by	NN	O	O
prolonged	NN	O	O
anicteric	NN	O	O
cholestasis	NN	O	B
.	NN	O	O

Jaundice	NN	O	B
occurred	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
troleandomycin	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
and	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
hypereosinophilia	NN	O	B
.	NN	O	O

Jaundice	NN	O	B
disappeared	NN	O	O
within	NN	O	O
3	NN	O	O
months	NN	O	O
but	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
prolonged	NN	O	O
anicteric	NN	O	O
cholestasis	NN	O	B
marked	NN	O	O
by	NN	O	O
pruritus	NN	O	B
and	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
alkaline	NN	O	O
phosphatase	NN	O	O
and	NN	O	O
gammaglutamyltransferase	NN	O	O
activities	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
pruritus	NN	O	B
disappeared	NN	O	O
within	NN	O	O
19	NN	O	O
months	NN	O	O
,	NN	O	O
and	NN	O	O
liver	NN	O	O
tests	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
27	NN	O	O
months	NN	O	O
after	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

This	NN	O	O
observation	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
prolonged	NN	O	O
cholestasis	NN	O	B
can	NN	O	O
follow	NN	O	O
troleandomycin	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

Serial	NN	O	O
studies	NN	O	O
of	NN	O	O
auditory	NN	O	B
neurotoxicity	NN	O	I
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
deferoxamine	NN	O	O
therapy	NN	O	O
.	NN	O	O

Visual	NN	O	B
and	NN	O	I
auditory	NN	O	I
neurotoxicity	NN	O	I
was	NN	O	O
previously	NN	O	O
documented	NN	O	O
in	NN	O	O
42	NN	O	O
of	NN	O	O
89	NN	O	O
patients	NN	O	O
with	NN	O	O
transfusion	NN	O	O
-	NN	O	O
dependent	NN	O	O
anemia	NN	O	B
who	NN	O	O
were	NN	O	O
receiving	NN	O	O
iron	NN	O	O
chelation	NN	O	O
therapy	NN	O	O
with	NN	O	O
daily	NN	O	O
subcutaneous	NN	O	O
deferoxamine	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
two	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
affected	NN	O	O
group	NN	O	O
had	NN	O	O
abnormal	NN	O	B
audiograms	NN	O	I
with	NN	O	I
deficits	NN	O	I
mostly	NN	O	I
in	NN	O	I
the	NN	O	I
high	NN	O	I
frequency	NN	O	I
range	NN	O	I
of	NN	O	I
4	NN	O	I
,	NN	O	I
000	NN	O	I
to	NN	O	I
8	NN	O	I
,	NN	O	I
000	NN	O	I
Hz	NN	O	I
and	NN	O	O
in	NN	O	O
the	NN	O	O
hearing	NN	O	O
threshold	NN	O	O
levels	NN	O	O
of	NN	O	O
30	NN	O	O
to	NN	O	O
100	NN	O	O
decibels	NN	O	O
.	NN	O	O

When	NN	O	O
deferoxamine	NN	O	O
therapy	NN	O	O
was	NN	O	O
discontinued	NN	O	O
and	NN	O	O
serial	NN	O	O
studies	NN	O	O
were	NN	O	O
performed	NN	O	O
,	NN	O	O
audiograms	NN	O	O
in	NN	O	O
seven	NN	O	O
cases	NN	O	O
reverted	NN	O	O
to	NN	O	O
normal	NN	O	O
or	NN	O	O
near	NN	O	O
normal	NN	O	O
within	NN	O	O
two	NN	O	O
to	NN	O	O
three	NN	O	O
weeks	NN	O	O
,	NN	O	O
and	NN	O	O
nine	NN	O	O
of	NN	O	O
13	NN	O	O
patients	NN	O	O
with	NN	O	O
symptoms	NN	O	O
became	NN	O	O
asymptomatic	NN	O	O
.	NN	O	O

Audiograms	NN	O	O
from	NN	O	O
15	NN	O	O
patients	NN	O	O
remained	NN	O	O
abnormal	NN	O	O
and	NN	O	O
four	NN	O	O
patients	NN	O	O
required	NN	O	O
hearing	NN	O	O
aids	NN	O	O
because	NN	O	O
of	NN	O	O
permanent	NN	O	B
disability	NN	O	I
.	NN	O	O

Since	NN	O	O
18	NN	O	O
of	NN	O	O
the	NN	O	O
22	NN	O	O
patients	NN	O	O
were	NN	O	O
initially	NN	O	O
receiving	NN	O	O
deferoxamine	NN	O	O
doses	NN	O	O
in	NN	O	O
excess	NN	O	O
of	NN	O	O
the	NN	O	O
commonly	NN	O	O
recommended	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
dose	NN	O	O
,	NN	O	O
therapy	NN	O	O
was	NN	O	O
restarted	NN	O	O
with	NN	O	O
lower	NN	O	O
doses	NN	O	O
,	NN	O	O
usually	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
dose	NN	O	O
or	NN	O	O
less	NN	O	O
depending	NN	O	O
on	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
auditory	NN	O	B
abnormality	NN	O	I
,	NN	O	O
and	NN	O	O
with	NN	O	O
the	NN	O	O
exception	NN	O	O
of	NN	O	O
two	NN	O	O
cases	NN	O	O
no	NN	O	O
further	NN	O	O
toxicity	NN	O	B
was	NN	O	O
demonstrated	NN	O	O
.	NN	O	O

Auditory	NN	O	O
deterioration	NN	O	O
and	NN	O	O
improvement	NN	O	O
,	NN	O	O
demonstrated	NN	O	O
serially	NN	O	O
in	NN	O	O
individual	NN	O	O
patients	NN	O	O
receiving	NN	O	O
and	NN	O	O
not	NN	O	O
receiving	NN	O	O
deferoxamine	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
provided	NN	O	O
convincing	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
cause	NN	O	O
-	NN	O	O
and	NN	O	O
-	NN	O	O
effect	NN	O	O
relation	NN	O	O
between	NN	O	O
deferoxamine	NN	O	O
administration	NN	O	O
and	NN	O	O
ototoxicity	NN	O	B
.	NN	O	O

Based	NN	O	O
on	NN	O	O
these	NN	O	O
data	NN	O	O
,	NN	O	O
a	NN	O	O
plan	NN	O	O
of	NN	O	O
management	NN	O	O
was	NN	O	O
developed	NN	O	O
that	NN	O	O
allows	NN	O	O
effective	NN	O	O
yet	NN	O	O
safe	NN	O	O
administration	NN	O	O
of	NN	O	O
deferoxamine	NN	O	O
.	NN	O	O

A	NN	O	O
dose	NN	O	O
of	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
is	NN	O	O
recommended	NN	O	O
in	NN	O	O
those	NN	O	O
without	NN	O	O
audiogram	NN	O	O
abnormalities	NN	O	O
.	NN	O	O

With	NN	O	O
mild	NN	O	O
toxicity	NN	O	B
,	NN	O	O
a	NN	O	O
reduction	NN	O	O
to	NN	O	O
30	NN	O	O
or	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
dose	NN	O	O
should	NN	O	O
result	NN	O	O
in	NN	O	O
a	NN	O	O
reversal	NN	O	O
of	NN	O	O
the	NN	O	O
abnormal	NN	O	O
results	NN	O	O
to	NN	O	O
normal	NN	O	O
within	NN	O	O
four	NN	O	O
weeks	NN	O	O
.	NN	O	O

Moderate	NN	O	O
abnormalities	NN	O	O
require	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
deferoxamine	NN	O	O
to	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
dose	NN	O	O
with	NN	O	O
careful	NN	O	O
monitoring	NN	O	O
.	NN	O	O

In	NN	O	O
those	NN	O	O
with	NN	O	O
symptoms	NN	O	O
of	NN	O	O
hearing	NN	O	B
loss	NN	O	I
,	NN	O	O
the	NN	O	O
drug	NN	O	O
should	NN	O	O
be	NN	O	O
stopped	NN	O	O
for	NN	O	O
four	NN	O	O
weeks	NN	O	O
,	NN	O	O
and	NN	O	O
when	NN	O	O
the	NN	O	O
audiogram	NN	O	O
is	NN	O	O
stable	NN	O	O
or	NN	O	O
improved	NN	O	O
,	NN	O	O
therapy	NN	O	O
should	NN	O	O
be	NN	O	O
restarted	NN	O	O
at	NN	O	O
10	NN	O	O
to	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
dose	NN	O	O
.	NN	O	O

Serial	NN	O	O
audiograms	NN	O	O
should	NN	O	O
be	NN	O	O
performed	NN	O	O
every	NN	O	O
six	NN	O	O
months	NN	O	O
in	NN	O	O
those	NN	O	O
without	NN	O	O
problems	NN	O	O
and	NN	O	O
more	NN	O	O
frequently	NN	O	O
in	NN	O	O
young	NN	O	O
patients	NN	O	O
with	NN	O	O
normal	NN	O	O
serum	NN	O	O
ferritin	NN	O	O
values	NN	O	O
and	NN	O	O
in	NN	O	O
those	NN	O	O
with	NN	O	O
auditory	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

Lidocaine	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
asystole	NN	O	I
.	NN	O	O

Intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
50	NN	O	O
-	NN	O	O
mg	NN	O	O
bolus	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
a	NN	O	O
67	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
resulted	NN	O	O
in	NN	O	O
profound	NN	O	O
depression	NN	O	B
of	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
sinoatrial	NN	O	O
and	NN	O	O
atrioventricular	NN	O	O
nodal	NN	O	O
pacemakers	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
no	NN	O	O
apparent	NN	O	O
associated	NN	O	O
conditions	NN	O	O
which	NN	O	O
might	NN	O	O
have	NN	O	O
predisposed	NN	O	O
him	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
bradyarrhythmias	NN	O	B
;	NN	O	O
and	NN	O	O
,	NN	O	O
thus	NN	O	O
,	NN	O	O
this	NN	O	O
probably	NN	O	O
represented	NN	O	O
a	NN	O	O
true	NN	O	O
idiosyncrasy	NN	O	O
to	NN	O	O
lidocaine	NN	O	O
.	NN	O	O

Flurbiprofen	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
juvenile	NN	O	B
rheumatoid	NN	O	I
arthritis	NN	O	I
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
four	NN	O	O
patients	NN	O	O
with	NN	O	O
juvenile	NN	O	B
rheumatoid	NN	O	I
arthritis	NN	O	I
,	NN	O	O
who	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
flurbiprofen	NN	O	O
at	NN	O	O
a	NN	O	O
maximum	NN	O	O
dose	NN	O	O
of	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
had	NN	O	O
statistically	NN	O	O
significant	NN	O	O
decreases	NN	O	O
from	NN	O	O
baseline	NN	O	O
in	NN	O	O
6	NN	O	O
arthritis	NN	O	B
indices	NN	O	O
after	NN	O	O
12	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Improvements	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
tender	NN	O	B
joints	NN	O	I
,	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
swelling	NN	O	B
and	NN	O	O
tenderness	NN	O	B
,	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
walk	NN	O	O
50	NN	O	O
feet	NN	O	O
,	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
morning	NN	O	B
stiffness	NN	O	I
and	NN	O	O
the	NN	O	O
circumference	NN	O	O
of	NN	O	O
the	NN	O	O
left	NN	O	O
knee	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
frequently	NN	O	O
observed	NN	O	O
side	NN	O	O
effect	NN	O	O
was	NN	O	O
fecal	NN	O	B
occult	NN	O	I
blood	NN	O	I
(	NN	O	O
25	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
)	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
other	NN	O	O
evidence	NN	O	O
of	NN	O	O
gastrointestinal	NN	O	B
(	NN	O	I
GI	NN	O	I
)	NN	O	I
bleeding	NN	O	I
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
was	NN	O	O
prematurely	NN	O	O
discontinued	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
for	NN	O	O
severe	NN	O	O
headache	NN	O	B
and	NN	O	O
abdominal	NN	O	B
pain	NN	O	I
.	NN	O	O

Most	NN	O	O
side	NN	O	O
effects	NN	O	O
were	NN	O	O
mild	NN	O	O
and	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
GI	NN	O	O
tract	NN	O	O
.	NN	O	O

Hyperkalemia	NN	O	B
associated	NN	O	O
with	NN	O	O
sulindac	NN	O	O
therapy	NN	O	O
.	NN	O	O

Hyperkalemia	NN	O	B
has	NN	O	O
recently	NN	O	O
been	NN	O	O
recognized	NN	O	O
as	NN	O	O
a	NN	O	O
complication	NN	O	O
of	NN	O	O
nonsteroidal	NN	O	O
antiinflammatory	NN	O	O
agents	NN	O	O
(	NN	O	O
NSAID	NN	O	O
)	NN	O	O
such	NN	O	O
as	NN	O	O
indomethacin	NN	O	O
.	NN	O	O

Several	NN	O	O
recent	NN	O	O
studies	NN	O	O
have	NN	O	O
stressed	NN	O	O
the	NN	O	O
renal	NN	O	O
sparing	NN	O	O
features	NN	O	O
of	NN	O	O
sulindac	NN	O	O
,	NN	O	O
owing	NN	O	O
to	NN	O	O
its	NN	O	O
lack	NN	O	O
of	NN	O	O
interference	NN	O	O
with	NN	O	O
renal	NN	O	O
prostacyclin	NN	O	O
synthesis	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
4	NN	O	O
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
hyperkalemia	NN	O	B
ranging	NN	O	O
from	NN	O	O
6	NN	O	O
.	NN	O	O
1	NN	O	O
to	NN	O	O
6	NN	O	O
.	NN	O	O
9	NN	O	O
mEq	NN	O	O
/	NN	O	O
l	NN	O	O
developed	NN	O	O
within	NN	O	O
3	NN	O	O
to	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
sulindac	NN	O	O
administration	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
of	NN	O	O
them	NN	O	O
normal	NN	O	O
serum	NN	O	O
potassium	NN	O	O
levels	NN	O	O
reached	NN	O	O
within	NN	O	O
2	NN	O	O
to	NN	O	O
4	NN	O	O
days	NN	O	O
of	NN	O	O
stopping	NN	O	O
sulindac	NN	O	O
.	NN	O	O

As	NN	O	O
no	NN	O	O
other	NN	O	O
medications	NN	O	O
known	NN	O	O
to	NN	O	O
effect	NN	O	O
serum	NN	O	O
potassium	NN	O	O
had	NN	O	O
been	NN	O	O
given	NN	O	O
concomitantly	NN	O	O
,	NN	O	O
this	NN	O	O
course	NN	O	O
of	NN	O	O
events	NN	O	O
is	NN	O	O
suggestive	NN	O	O
of	NN	O	O
a	NN	O	O
cause	NN	O	O
-	NN	O	O
and	NN	O	O
-	NN	O	O
effect	NN	O	O
relationship	NN	O	O
between	NN	O	O
sulindac	NN	O	O
and	NN	O	O
hyperkalemia	NN	O	B
.	NN	O	O

These	NN	O	O
observations	NN	O	O
indicate	NN	O	O
that	NN	O	O
initial	NN	O	O
hopes	NN	O	O
that	NN	O	O
sulindac	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
adverse	NN	O	O
renal	NN	O	O
effects	NN	O	O
of	NN	O	O
other	NN	O	O
NSAID	NN	O	O
are	NN	O	O
probably	NN	O	O
not	NN	O	O
justified	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
induced	NN	O	O
arterial	NN	O	O
spasm	NN	O	B
relieved	NN	O	O
by	NN	O	O
lidocaine	NN	O	O
.	NN	O	O

Case	NN	O	O
report	NN	O	O
.	NN	O	O

Following	NN	O	O
major	NN	O	O
intracranial	NN	O	O
surgery	NN	O	O
in	NN	O	O
a	NN	O	O
35	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
,	NN	O	O
sodium	NN	O	O
pentothal	NN	O	O
was	NN	O	O
intravenously	NN	O	O
infused	NN	O	O
to	NN	O	O
minimize	NN	O	O
cerebral	NN	O	B
ischaemia	NN	O	I
.	NN	O	O

Intense	NN	O	O
vasospasm	NN	O	B
with	NN	O	O
threatened	NN	O	O
gangrene	NN	O	B
arose	NN	O	O
in	NN	O	O
the	NN	O	O
arm	NN	O	O
used	NN	O	O
for	NN	O	O
the	NN	O	O
infusion	NN	O	O
.	NN	O	O

Since	NN	O	O
the	NN	O	O
cranial	NN	O	O
condition	NN	O	O
precluded	NN	O	O
use	NN	O	O
of	NN	O	O
more	NN	O	O
usual	NN	O	O
methods	NN	O	O
,	NN	O	O
lidocaine	NN	O	O
was	NN	O	O
given	NN	O	O
intra	NN	O	O
-	NN	O	O
arterially	NN	O	O
,	NN	O	O
with	NN	O	O
careful	NN	O	O
cardiovascular	NN	O	O
monitoring	NN	O	O
,	NN	O	O
to	NN	O	O
counteract	NN	O	O
the	NN	O	O
vasospasm	NN	O	B
.	NN	O	O

The	NN	O	O
treatment	NN	O	O
was	NN	O	O
rapidly	NN	O	O
successful	NN	O	O
.	NN	O	O

Regional	NN	O	O
localization	NN	O	O
of	NN	O	O
the	NN	O	O
antagonism	NN	O	O
of	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
by	NN	O	O
intracerebral	NN	O	O
calcitonin	NN	O	O
injections	NN	O	O
.	NN	O	O

Calcitonin	NN	O	O
receptors	NN	O	O
are	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
,	NN	O	O
and	NN	O	O
intracerebral	NN	O	O
infusions	NN	O	O
of	NN	O	O
calcitonin	NN	O	O
can	NN	O	O
produce	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
.	NN	O	O

Among	NN	O	O
these	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
are	NN	O	O
decreases	NN	O	O
in	NN	O	O
food	NN	O	O
intake	NN	O	O
and	NN	O	O
decreases	NN	O	O
in	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
.	NN	O	O

In	NN	O	O
previous	NN	O	O
experiments	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
decreases	NN	O	O
in	NN	O	O
food	NN	O	O
intake	NN	O	O
were	NN	O	O
induced	NN	O	O
by	NN	O	O
local	NN	O	O
administration	NN	O	O
of	NN	O	O
calcitonin	NN	O	O
into	NN	O	O
several	NN	O	O
hypothalamic	NN	O	O
sites	NN	O	O
and	NN	O	O
into	NN	O	O
the	NN	O	O
nucleus	NN	O	O
accumbens	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
experiment	NN	O	O
calcitonin	NN	O	O
decreased	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
when	NN	O	O
locally	NN	O	O
injected	NN	O	O
into	NN	O	O
the	NN	O	O
same	NN	O	O
sites	NN	O	O
where	NN	O	O
it	NN	O	O
decreases	NN	O	O
food	NN	O	O
intake	NN	O	O
.	NN	O	O

The	NN	O	O
areas	NN	O	O
where	NN	O	O
calcitonin	NN	O	O
is	NN	O	O
most	NN	O	O
effective	NN	O	O
in	NN	O	O
decreasing	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
are	NN	O	O
located	NN	O	O
in	NN	O	O
the	NN	O	O
hypothalamus	NN	O	O
and	NN	O	O
nucleus	NN	O	O
accumbens	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
these	NN	O	O
areas	NN	O	O
are	NN	O	O
the	NN	O	O
major	NN	O	O
sites	NN	O	O
of	NN	O	O
action	NN	O	O
of	NN	O	O
calcitonin	NN	O	O
in	NN	O	O
inhibiting	NN	O	O
amphetamine	NN	O	O
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
.	NN	O	O

The	NN	O	O
hematologic	NN	O	O
effects	NN	O	O
of	NN	O	O
cefonicid	NN	O	O
and	NN	O	O
cefazedone	NN	O	O
in	NN	O	O
the	NN	O	O
dog	NN	O	O
:	NN	O	O
a	NN	O	O
potential	NN	O	O
model	NN	O	O
of	NN	O	O
cephalosporin	NN	O	O
hematotoxicity	NN	O	B
in	NN	O	O
man	NN	O	O
.	NN	O	O

Cephalosporin	NN	O	O
antibiotics	NN	O	O
cause	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
hematologic	NN	O	B
disturbances	NN	O	I
in	NN	O	O
man	NN	O	O
,	NN	O	O
the	NN	O	O
pathogeneses	NN	O	O
and	NN	O	O
hematopathology	NN	O	O
of	NN	O	O
which	NN	O	O
remain	NN	O	O
poorly	NN	O	O
characterized	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
a	NN	O	O
need	NN	O	O
for	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
defined	NN	O	O
animal	NN	O	O
model	NN	O	O
in	NN	O	O
which	NN	O	O
these	NN	O	O
blood	NN	O	B
dyscrasias	NN	O	I
can	NN	O	O
be	NN	O	O
studied	NN	O	O
.	NN	O	O

In	NN	O	O
four	NN	O	O
subacute	NN	O	O
toxicity	NN	O	B
studies	NN	O	O
,	NN	O	O
the	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
cefonicid	NN	O	O
or	NN	O	O
cefazedone	NN	O	O
to	NN	O	O
beagle	NN	O	O
dogs	NN	O	O
caused	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
incidence	NN	O	O
of	NN	O	O
anemia	NN	O	B
,	NN	O	O
neutropenia	NN	O	B
,	NN	O	O
and	NN	O	O
thrombocytopenia	NN	O	B
after	NN	O	O
1	NN	O	O
-	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

A	NN	O	O
nonregenerative	NN	O	O
anemia	NN	O	B
was	NN	O	O
the	NN	O	O
most	NN	O	O
compromising	NN	O	O
of	NN	O	O
the	NN	O	O
cytopenias	NN	O	B
and	NN	O	O
occurred	NN	O	O
in	NN	O	O
approximately	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
dogs	NN	O	O
receiving	NN	O	O
400	NN	O	O
-	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
cefonicid	NN	O	O
or	NN	O	O
540	NN	O	O
-	NN	O	O
840	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
cefazedone	NN	O	O
.	NN	O	O

All	NN	O	O
three	NN	O	O
cytopenias	NN	O	B
were	NN	O	O
completely	NN	O	O
reversible	NN	O	O
following	NN	O	O
cessation	NN	O	O
of	NN	O	O
treatment	NN	O	O
;	NN	O	O
the	NN	O	O
time	NN	O	O
required	NN	O	O
for	NN	O	O
recovery	NN	O	O
of	NN	O	O
the	NN	O	O
erythron	NN	O	O
(	NN	O	O
approximately	NN	O	O
1	NN	O	O
month	NN	O	O
)	NN	O	O
was	NN	O	O
considerably	NN	O	O
longer	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
granulocytes	NN	O	O
and	NN	O	O
platelets	NN	O	O
(	NN	O	O
hours	NN	O	O
to	NN	O	O
a	NN	O	O
few	NN	O	O
days	NN	O	O
)	NN	O	O
.	NN	O	O

Upon	NN	O	O
rechallenge	NN	O	O
with	NN	O	O
either	NN	O	O
cephalosporin	NN	O	O
,	NN	O	O
the	NN	O	O
hematologic	NN	O	B
syndrome	NN	O	I
was	NN	O	O
reproduced	NN	O	O
in	NN	O	O
most	NN	O	O
dogs	NN	O	O
tested	NN	O	O
;	NN	O	O
cefonicid	NN	O	O
(	NN	O	O
but	NN	O	O
not	NN	O	O
cefazedone	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
dogs	NN	O	O
showed	NN	O	O
a	NN	O	O
substantially	NN	O	O
reduced	NN	O	O
induction	NN	O	O
period	NN	O	O
(	NN	O	O
15	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
days	NN	O	O
)	NN	O	O
compared	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
first	NN	O	O
exposure	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
(	NN	O	O
61	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
24	NN	O	O
days	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
observation	NN	O	O
,	NN	O	O
along	NN	O	O
with	NN	O	O
the	NN	O	O
rapid	NN	O	O
rate	NN	O	O
of	NN	O	O
decline	NN	O	O
in	NN	O	O
red	NN	O	O
cell	NN	O	O
mass	NN	O	O
parameters	NN	O	O
of	NN	O	O
affected	NN	O	O
dogs	NN	O	O
,	NN	O	O
suggests	NN	O	O
that	NN	O	O
a	NN	O	O
hemolytic	NN	O	B
component	NN	O	O
complicated	NN	O	O
the	NN	O	O
red	NN	O	O
cell	NN	O	O
production	NN	O	O
problem	NN	O	O
and	NN	O	O
that	NN	O	O
multiple	NN	O	O
toxicologic	NN	O	O
mechanisms	NN	O	O
contributed	NN	O	O
to	NN	O	O
the	NN	O	O
cytopenia	NN	O	B
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
cefonicid	NN	O	O
or	NN	O	O
cefazedone	NN	O	O
to	NN	O	O
dogs	NN	O	O
can	NN	O	O
induce	NN	O	O
hematotoxicity	NN	O	B
similar	NN	O	O
to	NN	O	O
the	NN	O	O
cephalosporin	NN	O	O
-	NN	O	O
induced	NN	O	O
blood	NN	O	B
dyscrasias	NN	O	I
described	NN	O	O
in	NN	O	O
man	NN	O	O
and	NN	O	O
thus	NN	O	O
provides	NN	O	O
a	NN	O	O
useful	NN	O	O
model	NN	O	O
for	NN	O	O
studying	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
these	NN	O	O
disorders	NN	O	O
.	NN	O	O

Cerebral	NN	O	O
blood	NN	O	O
flow	NN	O	O
and	NN	O	O
metabolism	NN	O	O
during	NN	O	O
isoflurane	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
in	NN	O	O
patients	NN	O	O
subjected	NN	O	O
to	NN	O	O
surgery	NN	O	O
for	NN	O	O
cerebral	NN	O	B
aneurysms	NN	O	I
.	NN	O	O

Cerebral	NN	O	O
blood	NN	O	O
flow	NN	O	O
and	NN	O	O
cerebral	NN	O	O
metabolic	NN	O	O
rate	NN	O	O
for	NN	O	O
oxygen	NN	O	O
were	NN	O	O
measured	NN	O	O
during	NN	O	O
isoflurane	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
in	NN	O	O
10	NN	O	O
patients	NN	O	O
subjected	NN	O	O
to	NN	O	O
craniotomy	NN	O	O
for	NN	O	O
clipping	NN	O	O
of	NN	O	O
a	NN	O	O
cerebral	NN	O	B
aneurysm	NN	O	I
.	NN	O	O

Flow	NN	O	O
and	NN	O	O
metabolism	NN	O	O
were	NN	O	O
measured	NN	O	O
5	NN	O	O
-	NN	O	O
13	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
subarachnoid	NN	O	B
haemorrhage	NN	O	I
by	NN	O	O
a	NN	O	O
modification	NN	O	O
of	NN	O	O
the	NN	O	O
classical	NN	O	O
Kety	NN	O	O
-	NN	O	O
Schmidt	NN	O	O
technique	NN	O	O
using	NN	O	O
xenon	NN	O	O
-	NN	O	O
133	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
Anaesthesia	NN	O	O
was	NN	O	O
maintained	NN	O	O
with	NN	O	O
an	NN	O	O
inspired	NN	O	O
isoflurane	NN	O	O
concentration	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
75	NN	O	O
%	NN	O	O
(	NN	O	O
plus	NN	O	O
67	NN	O	O
%	NN	O	O
nitrous	NN	O	O
oxide	NN	O	O
in	NN	O	O
oxygen	NN	O	O
)	NN	O	O
,	NN	O	O
during	NN	O	O
which	NN	O	O
CBF	NN	O	O
and	NN	O	O
CMRO2	NN	O	O
were	NN	O	O
34	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
1	NN	O	O
ml	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
.	NN	O	O
32	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
16	NN	O	O
ml	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
at	NN	O	O
PaCO2	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
kPa	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SEM	NN	O	O
)	NN	O	O
.	NN	O	O

Controlled	NN	O	O
hypotension	NN	O	B
to	NN	O	O
an	NN	O	O
average	NN	O	O
MAP	NN	O	O
of	NN	O	O
50	NN	O	O
-	NN	O	O
55	NN	O	O
mm	NN	O	O
Hg	NN	O	O
was	NN	O	O
induced	NN	O	O
by	NN	O	O
increasing	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
isoflurane	NN	O	O
,	NN	O	O
and	NN	O	O
maintained	NN	O	O
at	NN	O	O
an	NN	O	O
inspired	NN	O	O
concentration	NN	O	O
of	NN	O	O
2	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
.	NN	O	O

This	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
CMRO2	NN	O	O
(	NN	O	O
to	NN	O	O
1	NN	O	O
.	NN	O	O
73	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
16	NN	O	O
ml	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
CBF	NN	O	O
was	NN	O	O
unchanged	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
clipping	NN	O	O
of	NN	O	O
the	NN	O	O
aneurysm	NN	O	B
the	NN	O	O
isoflurane	NN	O	O
concentration	NN	O	O
was	NN	O	O
reduced	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
75	NN	O	O
%	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
CBF	NN	O	O
,	NN	O	O
although	NN	O	O
CMRO2	NN	O	O
was	NN	O	O
unchanged	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
pre	NN	O	O
-	NN	O	O
hypotensive	NN	O	B
values	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
might	NN	O	O
offer	NN	O	O
protection	NN	O	O
to	NN	O	O
brain	NN	O	O
tissue	NN	O	O
during	NN	O	O
periods	NN	O	O
of	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Triazolam	NN	O	O
-	NN	O	O
induced	NN	O	O
brief	NN	O	O
episodes	NN	O	O
of	NN	O	O
secondary	NN	O	O
mania	NN	O	B
in	NN	O	O
a	NN	O	O
depressed	NN	O	B
patient	NN	O	O
.	NN	O	O

Large	NN	O	O
doses	NN	O	O
of	NN	O	O
triazolam	NN	O	O
repeatedly	NN	O	O
induced	NN	O	O
brief	NN	O	O
episodes	NN	O	O
of	NN	O	O
mania	NN	O	B
in	NN	O	O
a	NN	O	O
depressed	NN	O	B
elderly	NN	O	O
woman	NN	O	O
.	NN	O	O

Features	NN	O	O
of	NN	O	O
organic	NN	O	B
mental	NN	O	I
disorder	NN	O	I
(	NN	O	O
delirium	NN	O	B
)	NN	O	O
were	NN	O	O
not	NN	O	O
present	NN	O	O
.	NN	O	O

Manic	NN	O	B
excitement	NN	O	O
was	NN	O	O
coincident	NN	O	O
with	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
of	NN	O	O
triazolam	NN	O	O
.	NN	O	O

The	NN	O	O
possible	NN	O	O
contribution	NN	O	O
of	NN	O	O
the	NN	O	O
triazolo	NN	O	O
group	NN	O	O
to	NN	O	O
changes	NN	O	O
in	NN	O	O
affective	NN	O	O
status	NN	O	O
is	NN	O	O
discussed	NN	O	O
.	NN	O	O

The	NN	O	O
correlation	NN	O	O
between	NN	O	O
neurotoxic	NN	O	B
esterase	NN	O	O
inhibition	NN	O	O
and	NN	O	O
mipafox	NN	O	O
-	NN	O	O
induced	NN	O	O
neuropathic	NN	O	B
damage	NN	O	I
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
correlation	NN	O	O
between	NN	O	O
neuropathic	NN	O	B
damage	NN	O	I
and	NN	O	O
inhibition	NN	O	O
of	NN	O	O
neurotoxic	NN	O	B
esterase	NN	O	O
or	NN	O	O
neuropathy	NN	O	B
target	NN	O	O
enzyme	NN	O	O
(	NN	O	O
NTE	NN	O	O
)	NN	O	O
was	NN	O	O
examined	NN	O	O
in	NN	O	O
rats	NN	O	O
acutely	NN	O	O
exposed	NN	O	O
to	NN	O	O
Mipafox	NN	O	O
(	NN	O	O
N	NN	O	O
,	NN	O	O
N	NN	O	O
'	NN	O	O
-	NN	O	O
diisopropylphosphorodiamidofluoridate	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
neurotoxic	NN	O	B
organophosphate	NN	O	O
.	NN	O	O

Brain	NN	O	O
and	NN	O	O
spinal	NN	O	O
cord	NN	O	O
NTE	NN	O	O
activities	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
Long	NN	O	O
-	NN	O	O
Evans	NN	O	O
male	NN	O	O
rats	NN	O	O
1	NN	O	O
hr	NN	O	O
post	NN	O	O
-	NN	O	O
exposure	NN	O	O
to	NN	O	O
various	NN	O	O
dosages	NN	O	O
of	NN	O	O
Mipafox	NN	O	O
(	NN	O	O
ip	NN	O	O
,	NN	O	O
1	NN	O	O
-	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
were	NN	O	O
correlated	NN	O	O
with	NN	O	O
histologically	NN	O	O
scored	NN	O	O
cervical	NN	O	O
cord	NN	O	B
damage	NN	O	I
in	NN	O	O
a	NN	O	O
separate	NN	O	O
group	NN	O	O
of	NN	O	O
similarly	NN	O	O
dosed	NN	O	O
rats	NN	O	O
sampled	NN	O	O
14	NN	O	O
-	NN	O	O
21	NN	O	O
days	NN	O	O
post	NN	O	O
-	NN	O	O
exposure	NN	O	O
.	NN	O	O

Those	NN	O	O
dosages	NN	O	O
(	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
that	NN	O	O
inhibited	NN	O	O
mean	NN	O	O
NTE	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
spinal	NN	O	O
cord	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
73	NN	O	O
%	NN	O	O
and	NN	O	O
brain	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
67	NN	O	O
%	NN	O	O
of	NN	O	O
control	NN	O	O
values	NN	O	O
produced	NN	O	O
severe	NN	O	O
(	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
3	NN	O	O
)	NN	O	O
cervical	NN	O	O
cord	NN	O	O
pathology	NN	O	O
in	NN	O	O
85	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
dosages	NN	O	O
of	NN	O	O
Mipafox	NN	O	O
(	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
which	NN	O	O
inhibited	NN	O	O
mean	NN	O	O
NTE	NN	O	O
activity	NN	O	O
in	NN	O	O
spinal	NN	O	O
cord	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
61	NN	O	O
%	NN	O	O
and	NN	O	O
brain	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
60	NN	O	O
%	NN	O	O
produced	NN	O	O
this	NN	O	O
degree	NN	O	O
of	NN	O	O
cord	NN	O	B
damage	NN	O	I
in	NN	O	O
only	NN	O	O
9	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
a	NN	O	O
critical	NN	O	O
percentage	NN	O	O
of	NN	O	O
NTE	NN	O	O
inhibition	NN	O	O
in	NN	O	O
brain	NN	O	O
and	NN	O	O
spinal	NN	O	O
cord	NN	O	O
sampled	NN	O	O
shortly	NN	O	O
after	NN	O	O
Mipafox	NN	O	O
exposure	NN	O	O
can	NN	O	O
predict	NN	O	O
neuropathic	NN	O	B
damage	NN	O	I
in	NN	O	O
rats	NN	O	O
several	NN	O	O
weeks	NN	O	O
later	NN	O	O
.	NN	O	O

Allergic	NN	O	B
reaction	NN	O	I
to	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
infusion	NN	O	O
.	NN	O	O

An	NN	O	O
allergic	NN	O	B
reaction	NN	O	I
consisting	NN	O	O
of	NN	O	O
angioneurotic	NN	O	B
edema	NN	O	I
secondary	NN	O	O
to	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
occurred	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
recurrent	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
oral	NN	O	I
cavity	NN	O	I
,	NN	O	O
cirrhosis	NN	O	B
,	NN	O	O
and	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
induced	NN	O	O
impaired	NN	O	B
renal	NN	O	I
function	NN	O	I
.	NN	O	O

This	NN	O	O
reaction	NN	O	O
occurred	NN	O	O
during	NN	O	O
the	NN	O	O
sixth	NN	O	O
and	NN	O	O
seventh	NN	O	O
courses	NN	O	O
of	NN	O	O
infusional	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Oral	NN	O	O
diphenhydramine	NN	O	O
and	NN	O	O
prednisone	NN	O	O
were	NN	O	O
ineffective	NN	O	O
in	NN	O	O
preventing	NN	O	O
the	NN	O	O
recurrence	NN	O	O
of	NN	O	O
the	NN	O	O
allergic	NN	O	B
reaction	NN	O	I
.	NN	O	O

Discontinuance	NN	O	O
of	NN	O	O
effective	NN	O	O
chemotherapy	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
during	NN	O	O
partial	NN	O	O
remission	NN	O	O
resulted	NN	O	O
in	NN	O	O
fatal	NN	O	O
disease	NN	O	O
progression	NN	O	O
.	NN	O	O

Myasthenia	NN	O	B
gravis	NN	O	I
caused	NN	O	O
by	NN	O	O
penicillamine	NN	O	O
and	NN	O	O
chloroquine	NN	O	O
therapy	NN	O	O
for	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
.	NN	O	O

We	NN	O	O
have	NN	O	O
described	NN	O	O
a	NN	O	O
unique	NN	O	O
patient	NN	O	O
who	NN	O	O
had	NN	O	O
reversible	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
related	NN	O	O
myasthenia	NN	O	B
gravis	NN	O	I
after	NN	O	O
penicillamine	NN	O	O
and	NN	O	O
chloroquine	NN	O	O
therapy	NN	O	O
for	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
.	NN	O	O

Although	NN	O	O
acetylcholine	NN	O	O
receptor	NN	O	O
antibodies	NN	O	O
were	NN	O	O
not	NN	O	O
detectable	NN	O	O
,	NN	O	O
the	NN	O	O
time	NN	O	O
course	NN	O	O
was	NN	O	O
consistent	NN	O	O
with	NN	O	O
an	NN	O	O
autoimmune	NN	O	O
process	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
tolerance	NN	O	O
to	NN	O	O
the	NN	O	O
muscular	NN	O	B
rigidity	NN	O	I
produced	NN	O	O
by	NN	O	O
morphine	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
tolerance	NN	O	O
to	NN	O	O
the	NN	O	O
muscular	NN	O	B
rigidity	NN	O	I
produced	NN	O	O
by	NN	O	O
morphine	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Saline	NN	O	O
-	NN	O	O
pretreated	NN	O	O
controls	NN	O	O
given	NN	O	O
a	NN	O	O
test	NN	O	O
dose	NN	O	O
of	NN	O	O
morphine	NN	O	O
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
showed	NN	O	O
a	NN	O	O
pronounced	NN	O	O
rigidity	NN	O	B
recorded	NN	O	O
as	NN	O	O
tonic	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
electromyogram	NN	O	O
.	NN	O	O

Rats	NN	O	O
treated	NN	O	O
for	NN	O	O
11	NN	O	O
days	NN	O	O
with	NN	O	O
morphine	NN	O	O
and	NN	O	O
withdrawn	NN	O	O
for	NN	O	O
36	NN	O	O
-	NN	O	O
40	NN	O	O
h	NN	O	O
showed	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
tolerance	NN	O	O
:	NN	O	O
about	NN	O	O
half	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
showed	NN	O	O
a	NN	O	O
rigidity	NN	O	B
after	NN	O	O
the	NN	O	O
test	NN	O	O
dose	NN	O	O
of	NN	O	O
morphine	NN	O	O
that	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
less	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
controls	NN	O	O
and	NN	O	O
were	NN	O	O
akinetic	NN	O	B
(	NN	O	O
A	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
other	NN	O	O
rats	NN	O	O
showed	NN	O	O
a	NN	O	O
strong	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
rigidity	NN	O	B
and	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
stereotyped	NN	O	O
(	NN	O	O
S	NN	O	O
)	NN	O	O
licking	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
gnawing	NN	O	O
in	NN	O	O
presence	NN	O	O
of	NN	O	O
akinetic	NN	O	B
or	NN	O	O
hyperkinetic	NN	O	B
(	NN	O	O
K	NN	O	O
)	NN	O	O
behaviour	NN	O	O
(	NN	O	O
AS	NN	O	O
/	NN	O	O
KS	NN	O	O
group	NN	O	O
)	NN	O	O
,	NN	O	O
suggesting	NN	O	O
signs	NN	O	O
of	NN	O	O
dopaminergic	NN	O	O
activation	NN	O	O
.	NN	O	O

The	NN	O	O
rigidity	NN	O	B
was	NN	O	O
considerably	NN	O	O
decreased	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
after	NN	O	O
20	NN	O	O
days	NN	O	O
'	NN	O	O
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
further	NN	O	O
series	NN	O	O
of	NN	O	O
experiments	NN	O	O
,	NN	O	O
haloperidol	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
was	NN	O	O
used	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
block	NN	O	O
the	NN	O	O
dopaminergic	NN	O	O
activation	NN	O	O
and	NN	O	O
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
real	NN	O	O
degree	NN	O	O
of	NN	O	O
the	NN	O	O
tolerance	NN	O	O
to	NN	O	O
the	NN	O	O
rigidity	NN	O	B
without	NN	O	O
any	NN	O	O
dopaminergic	NN	O	O
interference	NN	O	O
.	NN	O	O

Haloperidol	NN	O	O
enhanced	NN	O	O
the	NN	O	O
rigidity	NN	O	B
in	NN	O	O
the	NN	O	O
A	NN	O	O
group	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
level	NN	O	O
in	NN	O	O
the	NN	O	O
AS	NN	O	O
/	NN	O	O
KS	NN	O	O
group	NN	O	O
remained	NN	O	O
considerably	NN	O	O
lower	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
A	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
rigidity	NN	O	B
,	NN	O	O
which	NN	O	O
is	NN	O	O
assumed	NN	O	O
to	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
an	NN	O	O
action	NN	O	O
of	NN	O	O
morphine	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
,	NN	O	O
can	NN	O	O
be	NN	O	O
antagonized	NN	O	O
by	NN	O	O
another	NN	O	O
process	NN	O	O
leading	NN	O	O
to	NN	O	O
dopaminergic	NN	O	O
activation	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
.	NN	O	O

Nevertheless	NN	O	O
,	NN	O	O
there	NN	O	O
occurs	NN	O	O
some	NN	O	O
real	NN	O	O
tolerance	NN	O	O
to	NN	O	O
this	NN	O	O
effect	NN	O	O
.	NN	O	O

The	NN	O	O
rapid	NN	O	O
alternations	NN	O	O
of	NN	O	O
rigidity	NN	O	B
and	NN	O	O
the	NN	O	O
signs	NN	O	O
of	NN	O	O
dopaminergic	NN	O	O
activation	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
animals	NN	O	O
of	NN	O	O
the	NN	O	O
AS	NN	O	O
/	NN	O	O
KS	NN	O	O
group	NN	O	O
might	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
rapid	NN	O	O
shifts	NN	O	O
in	NN	O	O
the	NN	O	O
predominance	NN	O	O
of	NN	O	O
various	NN	O	O
DA	NN	O	O
-	NN	O	O
innervated	NN	O	O
structures	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
massive	NN	O	O
rhabdomyolysis	NN	O	B
following	NN	O	O
molindone	NN	O	O
administration	NN	O	O
.	NN	O	O

Rhabdomyolysis	NN	O	B
is	NN	O	O
a	NN	O	O
potentially	NN	O	O
lethal	NN	O	O
syndrome	NN	O	O
that	NN	O	O
psychiatric	NN	O	B
patients	NN	O	O
seem	NN	O	O
predisposed	NN	O	O
to	NN	O	O
develop	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
,	NN	O	O
typical	NN	O	O
laboratory	NN	O	O
features	NN	O	O
,	NN	O	O
and	NN	O	O
complications	NN	O	O
of	NN	O	O
rhabdomyolysis	NN	O	B
are	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
schizophrenic	NN	O	B
patient	NN	O	O
is	NN	O	O
reported	NN	O	O
to	NN	O	O
illustrate	NN	O	O
massive	NN	O	O
rhabdomyolysis	NN	O	B
and	NN	O	O
subsequent	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
following	NN	O	O
molindone	NN	O	O
administration	NN	O	O
.	NN	O	O

Physicians	NN	O	O
who	NN	O	O
prescribe	NN	O	O
molindone	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
reaction	NN	O	O
.	NN	O	O

Compression	NN	O	B
neuropathy	NN	O	I
of	NN	O	I
the	NN	O	I
radial	NN	O	I
nerve	NN	O	I
due	NN	O	O
to	NN	O	O
pentazocine	NN	O	O
-	NN	O	O
induced	NN	O	O
fibrous	NN	O	B
myopathy	NN	O	I
.	NN	O	O

Fibrous	NN	O	B
myopathy	NN	O	I
is	NN	O	O
a	NN	O	O
common	NN	O	O
,	NN	O	O
well	NN	O	O
-	NN	O	O
known	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
repeated	NN	O	O
pentazocine	NN	O	O
injection	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
compression	NN	O	B
neuropathy	NN	O	I
due	NN	O	O
to	NN	O	O
fibrotic	NN	O	O
muscle	NN	O	O
affected	NN	O	O
by	NN	O	O
pentazocine	NN	O	O
-	NN	O	O
induced	NN	O	O
myopathy	NN	O	B
has	NN	O	O
not	NN	O	O
previously	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
37	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
documented	NN	O	O
pentazocine	NN	O	O
-	NN	O	O
induced	NN	O	O
fibrous	NN	O	B
myopathy	NN	O	I
of	NN	O	O
triceps	NN	O	O
and	NN	O	O
deltoid	NN	O	O
muscles	NN	O	O
bilaterally	NN	O	O
and	NN	O	O
a	NN	O	O
three	NN	O	O
-	NN	O	O
week	NN	O	O
history	NN	O	O
of	NN	O	O
right	NN	O	O
wrist	NN	O	O
drop	NN	O	O
,	NN	O	O
electrodiagnostic	NN	O	O
examination	NN	O	O
showed	NN	O	O
a	NN	O	O
severe	NN	O	O
but	NN	O	O
partial	NN	O	O
lesion	NN	O	O
of	NN	O	O
the	NN	O	O
right	NN	O	O
radial	NN	O	O
nerve	NN	O	O
distal	NN	O	O
to	NN	O	O
the	NN	O	O
branches	NN	O	O
to	NN	O	O
the	NN	O	O
triceps	NN	O	O
,	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
the	NN	O	O
fibrous	NN	O	B
myopathy	NN	O	I
.	NN	O	O

Surgery	NN	O	O
revealed	NN	O	O
the	NN	O	O
right	NN	O	O
radial	NN	O	O
nerve	NN	O	O
to	NN	O	O
be	NN	O	O
severely	NN	O	O
compressed	NN	O	O
by	NN	O	O
the	NN	O	O
densely	NN	O	O
fibrotic	NN	O	O
lateral	NN	O	O
head	NN	O	O
of	NN	O	O
the	NN	O	O
triceps	NN	O	O
.	NN	O	O

Decompression	NN	O	O
and	NN	O	O
neurolysis	NN	O	O
were	NN	O	O
performed	NN	O	O
with	NN	O	O
good	NN	O	O
subsequent	NN	O	O
recovery	NN	O	O
of	NN	O	O
function	NN	O	O
.	NN	O	O

Recurrent	NN	O	O
reversible	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
from	NN	O	O
amphotericin	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
with	NN	O	O
cryptogenic	NN	O	O
cirrhosis	NN	O	B
and	NN	O	O
disseminated	NN	O	O
sporotrichosis	NN	O	B
developed	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
immediately	NN	O	O
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
amphotericin	NN	O	O
B	NN	O	O
on	NN	O	O
four	NN	O	O
separate	NN	O	O
occasions	NN	O	O
.	NN	O	O

The	NN	O	O
abruptness	NN	O	O
of	NN	O	O
the	NN	O	O
renal	NN	O	B
failure	NN	O	I
and	NN	O	O
its	NN	O	O
reversibility	NN	O	O
within	NN	O	O
days	NN	O	O
suggests	NN	O	O
that	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
functional	NN	O	O
component	NN	O	O
to	NN	O	O
the	NN	O	O
renal	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
amphotericin	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
reduced	NN	O	O
effective	NN	O	O
arterial	NN	O	O
volume	NN	O	O
,	NN	O	O
may	NN	O	O
activate	NN	O	O
tubuloglomerular	NN	O	O
feedback	NN	O	O
,	NN	O	O
thereby	NN	O	O
contributing	NN	O	O
to	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
.	NN	O	O

Cerebral	NN	O	B
infarction	NN	O	I
with	NN	O	O
a	NN	O	O
single	NN	O	O
oral	NN	O	O
dose	NN	O	O
of	NN	O	O
phenylpropanolamine	NN	O	O
.	NN	O	O

Phenylpropanolamine	NN	O	O
(	NN	O	O
PPA	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
synthetic	NN	O	O
sympathomimetic	NN	O	O
that	NN	O	O
is	NN	O	O
structurally	NN	O	O
similar	NN	O	O
to	NN	O	O
amphetamine	NN	O	O
,	NN	O	O
is	NN	O	O
available	NN	O	O
over	NN	O	O
the	NN	O	O
counter	NN	O	O
in	NN	O	O
anorectics	NN	O	O
,	NN	O	O
nasal	NN	O	O
congestants	NN	O	O
,	NN	O	O
and	NN	O	O
cold	NN	O	O
preparations	NN	O	O
.	NN	O	O

Its	NN	O	O
prolonged	NN	O	O
use	NN	O	O
or	NN	O	O
overuse	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
seizures	NN	O	B
,	NN	O	O
intracerebral	NN	O	B
hemorrhage	NN	O	I
,	NN	O	O
neuropsychiatric	NN	O	B
symptoms	NN	O	I
,	NN	O	O
and	NN	O	O
nonhemorrhagic	NN	O	O
cerebral	NN	O	B
infarction	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
young	NN	O	O
woman	NN	O	O
who	NN	O	O
suffered	NN	O	O
a	NN	O	O
cerebral	NN	O	B
infarction	NN	O	I
after	NN	O	O
taking	NN	O	O
a	NN	O	O
single	NN	O	O
oral	NN	O	O
dose	NN	O	O
of	NN	O	O
PPA	NN	O	O
.	NN	O	O

Remission	NN	O	O
induction	NN	O	O
of	NN	O	O
meningeal	NN	O	B
leukemia	NN	O	I
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
methotrexate	NN	O	O
.	NN	O	O

Twenty	NN	O	O
children	NN	O	O
with	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
who	NN	O	O
developed	NN	O	O
meningeal	NN	O	B
disease	NN	O	I
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
methotrexate	NN	O	O
regimen	NN	O	O
that	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
achieve	NN	O	O
and	NN	O	O
maintain	NN	O	O
CSF	NN	O	O
methotrexate	NN	O	O
concentrations	NN	O	O
of	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
mol	NN	O	O
/	NN	O	O
L	NN	O	O
without	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
concomitant	NN	O	O
intrathecal	NN	O	O
dosing	NN	O	O
.	NN	O	O

The	NN	O	O
methotrexate	NN	O	O
was	NN	O	O
administered	NN	O	O
as	NN	O	O
a	NN	O	O
loading	NN	O	O
dose	NN	O	O
of	NN	O	O
6	NN	O	O
,	NN	O	O
000	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
for	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
one	NN	O	O
hour	NN	O	O
followed	NN	O	O
by	NN	O	O
an	NN	O	O
infusion	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
h	NN	O	O
for	NN	O	O
23	NN	O	O
hours	NN	O	O
.	NN	O	O

Leucovorin	NN	O	O
rescue	NN	O	O
was	NN	O	O
initiated	NN	O	O
12	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
infusion	NN	O	O
with	NN	O	O
a	NN	O	O
loading	NN	O	O
dose	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
followed	NN	O	O
by	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
every	NN	O	O
three	NN	O	O
hours	NN	O	O
for	NN	O	O
six	NN	O	O
doses	NN	O	O
and	NN	O	O
then	NN	O	O
every	NN	O	O
six	NN	O	O
hours	NN	O	O
until	NN	O	O
the	NN	O	O
plasma	NN	O	O
methotrexate	NN	O	O
level	NN	O	O
decreased	NN	O	O
to	NN	O	O
less	NN	O	O
than	NN	O	O
1	NN	O	O
X	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
7	NN	O	O
)	NN	O	O
mol	NN	O	O
/	NN	O	O
L	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
steady	NN	O	O
-	NN	O	O
state	NN	O	O
plasma	NN	O	O
and	NN	O	O
CSF	NN	O	O
methotrexate	NN	O	O
concentrations	NN	O	O
achieved	NN	O	O
were	NN	O	O
1	NN	O	O
.	NN	O	O
1	NN	O	O
X	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
3	NN	O	O
)	NN	O	O
mol	NN	O	O
/	NN	O	O
L	NN	O	O
and	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
X	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
mol	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

All	NN	O	O
20	NN	O	O
patients	NN	O	O
responded	NN	O	O
to	NN	O	O
this	NN	O	O
regimen	NN	O	O
,	NN	O	O
16	NN	O	O
/	NN	O	O
20	NN	O	O
(	NN	O	O
80	NN	O	O
%	NN	O	O
)	NN	O	O
achieved	NN	O	O
a	NN	O	O
complete	NN	O	O
remission	NN	O	O
,	NN	O	O
and	NN	O	O
20	NN	O	O
%	NN	O	O
obtained	NN	O	O
a	NN	O	O
partial	NN	O	O
remission	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
toxicities	NN	O	B
encountered	NN	O	O
were	NN	O	O
transient	NN	O	O
serum	NN	O	O
transaminase	NN	O	O
and	NN	O	O
bilirubin	NN	O	O
elevations	NN	O	O
,	NN	O	O
neutropenia	NN	O	B
,	NN	O	O
and	NN	O	O
mucositis	NN	O	B
.	NN	O	O

One	NN	O	O
patient	NN	O	O
had	NN	O	O
focal	NN	O	O
seizures	NN	O	B
and	NN	O	O
transient	NN	O	B
hemiparesis	NN	O	I
but	NN	O	O
recovered	NN	O	O
completely	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
methotrexate	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
treatment	NN	O	O
for	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
remission	NN	O	O
after	NN	O	O
meningeal	NN	O	O
relapse	NN	O	O
in	NN	O	O
acute	NN	O	B
lymphoblastic	NN	O	I
leukemia	NN	O	I
.	NN	O	O

Interaction	NN	O	O
of	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
with	NN	O	O
antineoplastic	NN	O	O
agents	NN	O	O
.	NN	O	O

A	NN	O	O
synergistic	NN	O	O
effect	NN	O	O
of	NN	O	O
etoposide	NN	O	O
and	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
acute	NN	O	B
T	NN	O	I
-	NN	O	I
lymphocytic	NN	O	I
leukemia	NN	O	I
in	NN	O	O
relapse	NN	O	O
.	NN	O	O

The	NN	O	O
concomitant	NN	O	O
administration	NN	O	O
of	NN	O	O
etoposide	NN	O	O
and	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
resulted	NN	O	O
in	NN	O	O
eradication	NN	O	O
of	NN	O	O
hitherto	NN	O	O
refractory	NN	O	O
leukemic	NN	O	B
infiltration	NN	O	I
of	NN	O	O
bone	NN	O	O
marrow	NN	O	O
.	NN	O	O

Severe	NN	O	O
side	NN	O	O
effects	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
mental	NN	O	O
confusion	NN	O	B
and	NN	O	O
progressive	NN	O	O
hyperbilirubinemia	NN	O	B
,	NN	O	O
however	NN	O	O
,	NN	O	O
point	NN	O	O
to	NN	O	O
an	NN	O	O
enhancement	NN	O	O
not	NN	O	O
only	NN	O	O
of	NN	O	O
antineoplastic	NN	O	O
effects	NN	O	O
but	NN	O	O
also	NN	O	O
of	NN	O	O
toxicity	NN	O	B
in	NN	O	O
normal	NN	O	O
tissues	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
demonstrates	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
that	NN	O	O
the	NN	O	O
pharmacodynamic	NN	O	O
properties	NN	O	O
of	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
confined	NN	O	O
strictly	NN	O	O
to	NN	O	O
suppression	NN	O	O
of	NN	O	O
normal	NN	O	O
T	NN	O	O
-	NN	O	O
cell	NN	O	O
functions	NN	O	O
.	NN	O	O

Incidence	NN	O	O
of	NN	O	O
neoplasms	NN	O	B
in	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
exposed	NN	O	O
to	NN	O	O
different	NN	O	O
treatment	NN	O	O
regimens	NN	O	O
.	NN	O	O

Immunosuppressive	NN	O	O
drugs	NN	O	O
have	NN	O	O
been	NN	O	O
used	NN	O	O
during	NN	O	O
the	NN	O	O
last	NN	O	O
30	NN	O	O
years	NN	O	O
in	NN	O	O
treatment	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
.	NN	O	O

The	NN	O	O
drugs	NN	O	O
commonly	NN	O	O
used	NN	O	O
are	NN	O	O
cyclophosphamide	NN	O	O
and	NN	O	O
chlorambucil	NN	O	O
(	NN	O	O
alkylating	NN	O	O
agents	NN	O	O
)	NN	O	O
,	NN	O	O
azathioprine	NN	O	O
(	NN	O	O
purine	NN	O	O
analogue	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
methotrexate	NN	O	O
(	NN	O	O
folic	NN	O	O
acid	NN	O	O
analogue	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
evidence	NN	O	O
that	NN	O	O
all	NN	O	O
four	NN	O	O
immunosuppressive	NN	O	O
drugs	NN	O	O
can	NN	O	O
reduce	NN	O	O
synovitis	NN	O	B
,	NN	O	O
but	NN	O	O
disease	NN	O	O
activity	NN	O	O
almost	NN	O	O
always	NN	O	O
recurs	NN	O	O
after	NN	O	O
therapy	NN	O	O
is	NN	O	O
stopped	NN	O	O
.	NN	O	O

Since	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
are	NN	O	O
frequent	NN	O	O
,	NN	O	O
less	NN	O	O
than	NN	O	O
50	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
are	NN	O	O
able	NN	O	O
to	NN	O	O
continue	NN	O	O
a	NN	O	O
particular	NN	O	O
drug	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
year	NN	O	O
.	NN	O	O

Since	NN	O	O
it	NN	O	O
takes	NN	O	O
three	NN	O	O
to	NN	O	O
12	NN	O	O
months	NN	O	O
to	NN	O	O
achieve	NN	O	O
maximal	NN	O	O
effects	NN	O	O
,	NN	O	O
those	NN	O	O
patients	NN	O	O
who	NN	O	O
are	NN	O	O
unable	NN	O	O
to	NN	O	O
continue	NN	O	O
the	NN	O	O
drug	NN	O	O
receive	NN	O	O
little	NN	O	O
benefit	NN	O	O
from	NN	O	O
it	NN	O	O
.	NN	O	O

Patients	NN	O	O
treated	NN	O	O
with	NN	O	O
alkylating	NN	O	O
agents	NN	O	O
have	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
development	NN	O	O
of	NN	O	O
acute	NN	O	B
nonlymphocytic	NN	O	I
leukemia	NN	O	I
,	NN	O	O
and	NN	O	O
both	NN	O	O
alkylating	NN	O	O
agents	NN	O	O
and	NN	O	O
azathioprine	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
non	NN	O	B
-	NN	O	I
Hodgkin	NN	O	I
'	NN	O	I
s	NN	O	I
lymphoma	NN	O	I
.	NN	O	O

Cyclophosphamide	NN	O	O
therapy	NN	O	O
increases	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
bladder	NN	O	I
.	NN	O	O

There	NN	O	O
have	NN	O	O
been	NN	O	O
several	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
studies	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
treated	NN	O	O
with	NN	O	O
azathioprine	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
and	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
most	NN	O	O
of	NN	O	O
the	NN	O	O
common	NN	O	O
cancers	NN	O	B
is	NN	O	O
not	NN	O	O
increased	NN	O	O
.	NN	O	O

Data	NN	O	O
on	NN	O	O
the	NN	O	O
possible	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
malignancy	NN	O	B
in	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
are	NN	O	O
still	NN	O	O
being	NN	O	O
collected	NN	O	O
,	NN	O	O
and	NN	O	O
until	NN	O	O
further	NN	O	O
information	NN	O	O
is	NN	O	O
available	NN	O	O
,	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
immunosuppressive	NN	O	O
drugs	NN	O	O
,	NN	O	O
particularly	NN	O	O
alkylating	NN	O	O
agents	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
rheumatoid	NN	O	B
arthritis	NN	O	I
should	NN	O	O
be	NN	O	O
reserved	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
progressive	NN	O	O
disease	NN	O	O
or	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
complications	NN	O	O
.	NN	O	O

Warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
iliopsoas	NN	O	O
hemorrhage	NN	O	B
with	NN	O	O
subsequent	NN	O	O
femoral	NN	O	B
nerve	NN	O	I
palsy	NN	O	I
.	NN	O	O

We	NN	O	O
present	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
28	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
on	NN	O	O
chronic	NN	O	O
warfarin	NN	O	O
therapy	NN	O	O
who	NN	O	O
sustained	NN	O	O
a	NN	O	O
minor	NN	O	O
muscle	NN	O	B
tear	NN	O	I
and	NN	O	O
developed	NN	O	O
increasing	NN	O	O
pain	NN	O	B
and	NN	O	O
a	NN	O	O
flexure	NN	O	O
contracture	NN	O	B
of	NN	O	O
the	NN	O	O
right	NN	O	O
hip	NN	O	O
.	NN	O	O

Surgical	NN	O	O
exploration	NN	O	O
revealed	NN	O	O
an	NN	O	O
iliopsoas	NN	O	O
hematoma	NN	O	B
and	NN	O	O
femoral	NN	O	O
nerve	NN	O	B
entrapment	NN	O	I
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
femoral	NN	O	B
nerve	NN	O	I
palsy	NN	O	I
and	NN	O	O
partial	NN	O	B
loss	NN	O	I
of	NN	O	I
quadriceps	NN	O	I
functions	NN	O	I
.	NN	O	O

Anticoagulant	NN	O	O
-	NN	O	O
induced	NN	O	O
femoral	NN	O	B
nerve	NN	O	I
palsy	NN	O	I
represents	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
form	NN	O	O
of	NN	O	O
warfarin	NN	O	O
-	NN	O	O
induced	NN	O	O
peripheral	NN	O	B
neuropathy	NN	O	I
;	NN	O	O
it	NN	O	O
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
severe	NN	O	O
pain	NN	O	B
in	NN	O	O
the	NN	O	O
inguinal	NN	O	O
region	NN	O	O
,	NN	O	O
varying	NN	O	O
degrees	NN	O	O
of	NN	O	O
motor	NN	O	B
and	NN	O	I
sensory	NN	O	I
impairment	NN	O	I
,	NN	O	O
and	NN	O	O
flexure	NN	O	O
contracture	NN	O	B
of	NN	O	O
the	NN	O	O
involved	NN	O	O
extremity	NN	O	O
.	NN	O	O

Pneumonitis	NN	O	O
with	NN	O	O
pleural	NN	O	B
and	NN	O	I
pericardial	NN	O	I
effusion	NN	O	I
and	NN	O	O
neuropathy	NN	O	B
during	NN	O	O
amiodarone	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
with	NN	O	O
sinuatrial	NN	O	B
disease	NN	O	I
and	NN	O	O
implanted	NN	O	O
pacemaker	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
amiodarone	NN	O	O
(	NN	O	O
maximum	NN	O	O
dose	NN	O	O
1000	NN	O	O
mg	NN	O	O
,	NN	O	O
maintenance	NN	O	O
dose	NN	O	O
800	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
for	NN	O	O
10	NN	O	O
months	NN	O	O
,	NN	O	O
for	NN	O	O
control	NN	O	O
of	NN	O	O
supraventricular	NN	O	B
tachyarrhythmias	NN	O	I
.	NN	O	O

He	NN	O	O
developed	NN	O	O
pneumonitis	NN	O	B
,	NN	O	O
pleural	NN	O	B
and	NN	O	I
pericardial	NN	O	I
effusions	NN	O	I
,	NN	O	O
and	NN	O	O
a	NN	O	O
predominantly	NN	O	O
proximal	NN	O	B
motor	NN	O	I
neuropathy	NN	O	I
.	NN	O	O

Immediate	NN	O	O
but	NN	O	O
gradual	NN	O	O
improvement	NN	O	O
followed	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
and	NN	O	O
treatment	NN	O	O
with	NN	O	O
prednisolone	NN	O	O
.	NN	O	O

Review	NN	O	O
of	NN	O	O
this	NN	O	O
and	NN	O	O
previously	NN	O	O
reported	NN	O	O
cases	NN	O	O
indicates	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
early	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
pneumonitis	NN	O	B
,	NN	O	O
immediate	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
,	NN	O	O
and	NN	O	O
prompt	NN	O	O
but	NN	O	O
continued	NN	O	O
steroid	NN	O	O
therapy	NN	O	O
to	NN	O	O
ensure	NN	O	O
full	NN	O	O
recovery	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
-	NN	O	O
induced	NN	O	O
sinoatrial	NN	O	B
block	NN	O	I
.	NN	O	O

We	NN	O	O
observed	NN	O	O
sinoatrial	NN	O	B
block	NN	O	I
due	NN	O	O
to	NN	O	O
chronic	NN	O	O
amiodarone	NN	O	O
administration	NN	O	O
in	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
with	NN	O	O
primary	NN	O	B
cardiomyopathy	NN	O	I
,	NN	O	O
Wolff	NN	O	B
-	NN	O	I
Parkinson	NN	O	I
-	NN	O	I
White	NN	O	I
syndrome	NN	O	I
and	NN	O	O
supraventricular	NN	O	B
tachycardia	NN	O	I
.	NN	O	O

Reduction	NN	O	O
in	NN	O	O
the	NN	O	O
dosage	NN	O	O
of	NN	O	O
amiodarone	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
disappearance	NN	O	O
of	NN	O	O
the	NN	O	O
sinoatrial	NN	O	B
block	NN	O	I
and	NN	O	O
the	NN	O	O
persistence	NN	O	O
of	NN	O	O
asymptomatic	NN	O	O
sinus	NN	O	B
bradycardia	NN	O	I
.	NN	O	O

Desipramine	NN	O	O
-	NN	O	O
induced	NN	O	O
delirium	NN	O	B
at	NN	O	O
"	NN	O	O
subtherapeutic	NN	O	O
"	NN	O	O
concentrations	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

An	NN	O	O
elderly	NN	O	O
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
low	NN	O	O
dose	NN	O	O
Desipramine	NN	O	O
developed	NN	O	O
a	NN	O	O
delirium	NN	O	B
while	NN	O	O
her	NN	O	O
plasma	NN	O	O
level	NN	O	O
was	NN	O	O
in	NN	O	O
the	NN	O	O
"	NN	O	O
subtherapeutic	NN	O	O
"	NN	O	O
range	NN	O	O
.	NN	O	O

Delirium	NN	O	B
,	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
induced	NN	O	O
by	NN	O	O
tricyclic	NN	O	O
drug	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
elderly	NN	O	O
,	NN	O	O
can	NN	O	O
be	NN	O	O
caused	NN	O	O
by	NN	O	O
tricyclics	NN	O	O
with	NN	O	O
low	NN	O	O
anticholinergic	NN	O	O
potency	NN	O	O
.	NN	O	O

Therapeutic	NN	O	O
ranges	NN	O	O
for	NN	O	O
antidepressants	NN	O	O
that	NN	O	O
have	NN	O	O
been	NN	O	O
derived	NN	O	O
from	NN	O	O
general	NN	O	O
adult	NN	O	O
population	NN	O	O
studies	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
appropriate	NN	O	O
for	NN	O	O
the	NN	O	O
elderly	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
of	NN	O	O
specifically	NN	O	O
elderly	NN	O	O
patients	NN	O	O
are	NN	O	O
now	NN	O	O
required	NN	O	O
to	NN	O	O
establish	NN	O	O
safer	NN	O	O
and	NN	O	O
more	NN	O	O
appropriate	NN	O	O
guidelines	NN	O	O
for	NN	O	O
drug	NN	O	O
therapy	NN	O	O
.	NN	O	O

Indomethacin	NN	O	O
-	NN	O	O
induced	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
:	NN	O	O
recurrence	NN	O	O
on	NN	O	O
rechallenge	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
reported	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
oliguric	NN	O	O
renal	NN	O	B
failure	NN	O	I
with	NN	O	O
hyperkalemia	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
cirrhosis	NN	O	B
,	NN	O	O
ascites	NN	O	B
,	NN	O	O
and	NN	O	O
cor	NN	O	B
pulmonale	NN	O	I
after	NN	O	O
indomethacin	NN	O	O
therapy	NN	O	O
.	NN	O	O

Prompt	NN	O	O
restoration	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
followed	NN	O	O
drug	NN	O	O
withdrawal	NN	O	O
,	NN	O	O
while	NN	O	O
re	NN	O	O
-	NN	O	O
exposure	NN	O	O
to	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
indomethacin	NN	O	O
caused	NN	O	O
recurrence	NN	O	O
of	NN	O	O
acute	NN	O	O
reversible	NN	O	O
oliguria	NN	O	B
.	NN	O	O

Our	NN	O	O
case	NN	O	O
supports	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
endogenous	NN	O	O
renal	NN	O	O
prostaglandins	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
maintenance	NN	O	O
of	NN	O	O
renal	NN	O	O
blood	NN	O	O
flow	NN	O	O
when	NN	O	O
circulating	NN	O	O
plasma	NN	O	O
volume	NN	O	O
is	NN	O	O
diminished	NN	O	O
.	NN	O	O

Since	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
agents	NN	O	O
interfere	NN	O	O
with	NN	O	O
this	NN	O	O
compensatory	NN	O	O
mechanism	NN	O	O
and	NN	O	O
may	NN	O	O
cause	NN	O	O
acute	NN	O	B
renal	NN	O	I
failure	NN	O	I
,	NN	O	O
they	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
with	NN	O	O
caution	NN	O	O
in	NN	O	O
such	NN	O	O
patients	NN	O	O
.	NN	O	O

Patterns	NN	O	O
of	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
induced	NN	O	O
by	NN	O	O
methyldopa	NN	O	O
.	NN	O	O

Twelve	NN	O	O
patients	NN	O	O
with	NN	O	O
liver	NN	O	B
disease	NN	O	I
related	NN	O	O
to	NN	O	O
methyldopa	NN	O	O
were	NN	O	O
seen	NN	O	O
between	NN	O	O
1967	NN	O	O
and	NN	O	O
1977	NN	O	O
.	NN	O	O

Illness	NN	O	O
occurred	NN	O	O
within	NN	O	O
1	NN	O	O
-	NN	O	O
-	NN	O	O
9	NN	O	O
weeks	NN	O	O
of	NN	O	O
commencement	NN	O	O
of	NN	O	O
therapy	NN	O	O
in	NN	O	O
9	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
remaining	NN	O	O
3	NN	O	O
patients	NN	O	O
having	NN	O	O
received	NN	O	O
the	NN	O	O
drug	NN	O	O
for	NN	O	O
13	NN	O	O
months	NN	O	O
,	NN	O	O
15	NN	O	O
months	NN	O	O
and	NN	O	O
7	NN	O	O
years	NN	O	O
before	NN	O	O
experiencing	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Jaundice	NN	O	B
with	NN	O	O
tender	NN	O	O
hepatomegaly	NN	O	B
,	NN	O	O
usually	NN	O	O
preceded	NN	O	O
by	NN	O	O
symptoms	NN	O	O
of	NN	O	O
malaise	NN	O	O
,	NN	O	O
anorexia	NN	O	B
,	NN	O	O
nausea	NN	O	B
and	NN	O	O
vomiting	NN	O	B
,	NN	O	O
and	NN	O	O
associated	NN	O	O
with	NN	O	O
upper	NN	O	O
abdominal	NN	O	B
pain	NN	O	I
,	NN	O	O
was	NN	O	O
an	NN	O	O
invariable	NN	O	O
finding	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

Biochemical	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
indicated	NN	O	O
hepatocellular	NN	O	O
necrosis	NN	O	B
and	NN	O	O
correlated	NN	O	O
with	NN	O	O
histopathological	NN	O	O
evidence	NN	O	O
of	NN	O	O
hepatic	NN	O	B
injury	NN	O	I
,	NN	O	O
the	NN	O	O
spectrum	NN	O	O
of	NN	O	O
which	NN	O	O
ranged	NN	O	O
from	NN	O	O
fatty	NN	O	B
change	NN	O	I
and	NN	O	O
focal	NN	O	O
hepatocellular	NN	O	O
necrosis	NN	O	B
to	NN	O	O
massive	NN	O	B
hepatic	NN	O	I
necrosis	NN	O	I
.	NN	O	O

Most	NN	O	O
patients	NN	O	O
showed	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
acute	NN	O	B
hepatitis	NN	O	I
or	NN	O	O
chronic	NN	O	B
active	NN	O	I
hepatitis	NN	O	I
with	NN	O	O
associated	NN	O	O
cholestasis	NN	O	B
.	NN	O	O

The	NN	O	O
drug	NN	O	O
was	NN	O	O
withdrawn	NN	O	O
on	NN	O	O
presentation	NN	O	O
to	NN	O	O
hospital	NN	O	O
in	NN	O	O
11	NN	O	O
patients	NN	O	O
,	NN	O	O
with	NN	O	O
rapid	NN	O	O
clinical	NN	O	O
improvement	NN	O	O
in	NN	O	O
9	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
died	NN	O	O
,	NN	O	O
having	NN	O	O
presented	NN	O	O
in	NN	O	O
hepatic	NN	O	B
failure	NN	O	I
,	NN	O	O
and	NN	O	O
another	NN	O	O
,	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
taking	NN	O	O
methyldopa	NN	O	O
for	NN	O	O
7	NN	O	O
years	NN	O	O
,	NN	O	O
showed	NN	O	O
slower	NN	O	O
clinical	NN	O	O
and	NN	O	O
biochemical	NN	O	O
resolution	NN	O	O
over	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
several	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
remaining	NN	O	O
patient	NN	O	O
in	NN	O	O
the	NN	O	O
series	NN	O	O
developed	NN	O	O
fulminant	NN	O	B
hepatitis	NN	O	I
when	NN	O	O
the	NN	O	O
drug	NN	O	O
was	NN	O	O
accidentally	NN	O	O
recommenced	NN	O	O
1	NN	O	O
year	NN	O	O
after	NN	O	O
a	NN	O	O
prior	NN	O	O
episode	NN	O	O
of	NN	O	O
methyldopa	NN	O	O
-	NN	O	O
induced	NN	O	O
hepatitis	NN	O	B
.	NN	O	O

In	NN	O	O
this	NN	O	O
latter	NN	O	O
patient	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
2	NN	O	O
others	NN	O	O
,	NN	O	O
the	NN	O	O
causal	NN	O	O
relationship	NN	O	O
between	NN	O	O
methyldopa	NN	O	O
and	NN	O	O
hepatic	NN	O	B
dysfunction	NN	O	I
was	NN	O	O
proved	NN	O	O
with	NN	O	O
the	NN	O	O
recurrence	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
within	NN	O	O
2	NN	O	O
weeks	NN	O	O
of	NN	O	O
re	NN	O	O
-	NN	O	O
exposure	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Suxamethonium	NN	O	O
infusion	NN	O	O
rate	NN	O	O
and	NN	O	O
observed	NN	O	O
fasciculations	NN	O	B
.	NN	O	O

A	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
study	NN	O	O
.	NN	O	O

Suxamethonium	NN	O	O
chloride	NN	O	O
(	NN	O	O
Sch	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
to	NN	O	O
36	NN	O	O
adult	NN	O	O
males	NN	O	O
at	NN	O	O
six	NN	O	O
rates	NN	O	O
:	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
mg	NN	O	O
s	NN	O	O
-	NN	O	O
1	NN	O	O
to	NN	O	O
20	NN	O	O
mg	NN	O	O
s	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

The	NN	O	O
infusion	NN	O	O
was	NN	O	O
discontinued	NN	O	O
either	NN	O	O
when	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
muscular	NN	O	O
response	NN	O	O
to	NN	O	O
tetanic	NN	O	B
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
ulnar	NN	O	O
nerve	NN	O	O
or	NN	O	O
when	NN	O	O
Sch	NN	O	O
120	NN	O	O
mg	NN	O	O
was	NN	O	O
exceeded	NN	O	O
.	NN	O	O

Six	NN	O	O
additional	NN	O	O
patients	NN	O	O
received	NN	O	O
a	NN	O	O
30	NN	O	O
-	NN	O	O
mg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
bolus	NN	O	O
dose	NN	O	O
.	NN	O	O

Fasciculations	NN	O	B
in	NN	O	O
six	NN	O	O
areas	NN	O	O
of	NN	O	O
the	NN	O	O
body	NN	O	O
were	NN	O	O
scored	NN	O	O
from	NN	O	O
0	NN	O	O
to	NN	O	O
3	NN	O	O
and	NN	O	O
summated	NN	O	O
as	NN	O	O
a	NN	O	O
total	NN	O	O
fasciculation	NN	O	B
score	NN	O	O
.	NN	O	O

The	NN	O	O
times	NN	O	O
to	NN	O	O
first	NN	O	O
fasciculation	NN	O	B
,	NN	O	O
twitch	NN	O	B
suppression	NN	O	O
and	NN	O	O
tetanus	NN	O	B
suppression	NN	O	O
were	NN	O	O
inversely	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
infusion	NN	O	O
rates	NN	O	O
.	NN	O	O

Fasciculations	NN	O	B
in	NN	O	O
the	NN	O	O
six	NN	O	O
areas	NN	O	O
and	NN	O	O
the	NN	O	O
total	NN	O	O
fasciculation	NN	O	B
score	NN	O	O
were	NN	O	O
related	NN	O	O
directly	NN	O	O
to	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
infusion	NN	O	O
.	NN	O	O

Total	NN	O	O
fasciculation	NN	O	B
scores	NN	O	O
in	NN	O	O
the	NN	O	O
30	NN	O	O
-	NN	O	O
mg	NN	O	O
bolus	NN	O	O
group	NN	O	O
and	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
mg	NN	O	O
s	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
20	NN	O	O
-	NN	O	O
mg	NN	O	O
s	NN	O	O
-	NN	O	O
1	NN	O	O
infusion	NN	O	O
groups	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
psoriasis	NN	O	B
with	NN	O	O
azathioprine	NN	O	O
.	NN	O	O

Azathioprine	NN	O	O
treatment	NN	O	O
benefited	NN	O	O
19	NN	O	O
(	NN	O	O
66	NN	O	O
%	NN	O	O
)	NN	O	O
out	NN	O	O
of	NN	O	O
29	NN	O	O
patients	NN	O	O
suffering	NN	O	O
from	NN	O	O
severe	NN	O	O
psoriasis	NN	O	B
.	NN	O	O

Haematological	NN	O	O
complications	NN	O	O
were	NN	O	O
not	NN	O	O
troublesome	NN	O	O
and	NN	O	O
results	NN	O	O
of	NN	O	O
biochemical	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
remained	NN	O	O
normal	NN	O	O
.	NN	O	O

Minimal	NN	O	O
cholestasis	NN	O	B
was	NN	O	O
seen	NN	O	O
in	NN	O	O
two	NN	O	O
cases	NN	O	O
and	NN	O	O
portal	NN	O	O
fibrosis	NN	O	B
of	NN	O	O
a	NN	O	O
reversible	NN	O	O
degree	NN	O	O
in	NN	O	O
eight	NN	O	O
.	NN	O	O

Liver	NN	O	O
biopsies	NN	O	O
should	NN	O	O
be	NN	O	O
undertaken	NN	O	O
at	NN	O	O
regular	NN	O	O
intervals	NN	O	O
if	NN	O	O
azathioprine	NN	O	O
therapy	NN	O	O
is	NN	O	O
continued	NN	O	O
so	NN	O	O
that	NN	O	O
structural	NN	O	O
liver	NN	O	B
damage	NN	O	I
may	NN	O	O
be	NN	O	O
detected	NN	O	O
at	NN	O	O
an	NN	O	O
early	NN	O	O
and	NN	O	O
reversible	NN	O	O
stage	NN	O	O
.	NN	O	O

Angiosarcoma	NN	O	B
of	NN	O	I
the	NN	O	I
liver	NN	O	I
associated	NN	O	O
with	NN	O	O
diethylstilbestrol	NN	O	O
.	NN	O	O

Angiosarcoma	NN	O	B
of	NN	O	I
the	NN	O	I
liver	NN	O	I
occurred	NN	O	O
in	NN	O	O
a	NN	O	O
76	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
treated	NN	O	O
for	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
differentiated	NN	O	O
adenocarcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
liver	NN	O	I
with	NN	O	O
diethylstilbestrol	NN	O	O
for	NN	O	O
13	NN	O	O
years	NN	O	O
.	NN	O	O

Angiosarcoma	NN	O	B
was	NN	O	O
also	NN	O	O
present	NN	O	O
within	NN	O	O
pulmonary	NN	O	O
and	NN	O	O
renal	NN	O	O
arteries	NN	O	O
.	NN	O	O

The	NN	O	O
possibility	NN	O	O
that	NN	O	O
the	NN	O	O
intraarterial	NN	O	B
lesions	NN	O	I
might	NN	O	O
represent	NN	O	O
independent	NN	O	O
primary	NN	O	O
tumors	NN	O	B
is	NN	O	O
considered	NN	O	O
.	NN	O	O

Galanthamine	NN	O	O
hydrobromide	NN	O	O
,	NN	O	O
a	NN	O	O
longer	NN	O	O
acting	NN	O	O
anticholinesterase	NN	O	O
drug	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
the	NN	O	O
central	NN	O	O
effects	NN	O	O
of	NN	O	O
scopolamine	NN	O	O
(	NN	O	O
Hyoscine	NN	O	O
)	NN	O	O
.	NN	O	O

Galanthamine	NN	O	O
hydrobromide	NN	O	O
,	NN	O	O
an	NN	O	O
anticholinesterase	NN	O	O
drug	NN	O	O
capable	NN	O	O
of	NN	O	O
penetrating	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
,	NN	O	O
was	NN	O	O
used	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
demonstrating	NN	O	O
central	NN	O	O
effects	NN	O	O
of	NN	O	O
scopolamine	NN	O	O
(	NN	O	O
hyoscine	NN	O	O
)	NN	O	O
overdosage	NN	O	B
.	NN	O	O

It	NN	O	O
is	NN	O	O
longer	NN	O	O
acting	NN	O	O
than	NN	O	O
physostigmine	NN	O	O
and	NN	O	O
is	NN	O	O
used	NN	O	O
in	NN	O	O
anaesthesia	NN	O	O
to	NN	O	O
reverse	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
depolarizing	NN	O	O
neuromuscular	NN	O	O
block	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
studies	NN	O	O
into	NN	O	O
the	NN	O	O
dose	NN	O	O
necessary	NN	O	O
to	NN	O	O
combating	NN	O	O
scopolamine	NN	O	O
intoxication	NN	O	O
are	NN	O	O
indicated	NN	O	O
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
the	NN	O	O
subjective	NN	O	O
effects	NN	O	O
and	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
following	NN	O	O
oral	NN	O	O
and	NN	O	O
i	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
administration	NN	O	O
of	NN	O	O
flunitrazepam	NN	O	O
in	NN	O	O
volunteers	NN	O	O
.	NN	O	O

Flunitrazepam	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
0	NN	O	O
or	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
was	NN	O	O
given	NN	O	O
by	NN	O	O
the	NN	O	O
oral	NN	O	O
or	NN	O	O
i	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
routes	NN	O	O
to	NN	O	O
groups	NN	O	O
of	NN	O	O
volunteers	NN	O	O
and	NN	O	O
its	NN	O	O
effects	NN	O	O
compared	NN	O	O
.	NN	O	O

Plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
were	NN	O	O
estimated	NN	O	O
by	NN	O	O
gas	NN	O	O
-	NN	O	O
liquid	NN	O	O
chromatography	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
smaller	NN	O	O
number	NN	O	O
of	NN	O	O
the	NN	O	O
subjects	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
striking	NN	O	O
effect	NN	O	O
was	NN	O	O
sedation	NN	O	O
which	NN	O	O
increased	NN	O	O
with	NN	O	O
the	NN	O	O
dose	NN	O	O
,	NN	O	O
2	NN	O	O
mg	NN	O	O
producing	NN	O	O
deep	NN	O	O
sleep	NN	O	O
although	NN	O	O
the	NN	O	O
subjects	NN	O	O
could	NN	O	O
still	NN	O	O
be	NN	O	O
aroused	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
i	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
administration	NN	O	O
were	NN	O	O
apparent	NN	O	O
earlier	NN	O	O
and	NN	O	O
sometimes	NN	O	O
lasted	NN	O	O
longer	NN	O	O
than	NN	O	O
those	NN	O	O
following	NN	O	O
oral	NN	O	O
administration	NN	O	O
.	NN	O	O

Dizziness	NN	O	B
was	NN	O	O
less	NN	O	O
marked	NN	O	O
than	NN	O	O
sedation	NN	O	O
,	NN	O	O
but	NN	O	O
increased	NN	O	O
with	NN	O	O
the	NN	O	O
dose	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
pain	NN	O	B
on	NN	O	O
i	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
injection	NN	O	O
of	NN	O	O
flunitrazepam	NN	O	O
significantly	NN	O	O
more	NN	O	O
often	NN	O	O
than	NN	O	O
with	NN	O	O
isotonic	NN	O	O
saline	NN	O	O
.	NN	O	O

Plasma	NN	O	O
concentrations	NN	O	O
varied	NN	O	O
with	NN	O	O
dose	NN	O	O
and	NN	O	O
route	NN	O	O
and	NN	O	O
corresponded	NN	O	O
qualitatively	NN	O	O
with	NN	O	O
the	NN	O	O
subjective	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
drug	NN	O	O
was	NN	O	O
still	NN	O	O
present	NN	O	O
in	NN	O	O
measurable	NN	O	O
quantities	NN	O	O
after	NN	O	O
24	NN	O	O
h	NN	O	O
even	NN	O	O
with	NN	O	O
the	NN	O	O
smallest	NN	O	O
dose	NN	O	O
.	NN	O	O

Possible	NN	O	O
teratogenicity	NN	O	O
of	NN	O	O
sulphasalazine	NN	O	O
.	NN	O	O

Three	NN	O	O
infants	NN	O	O
,	NN	O	O
born	NN	O	O
of	NN	O	O
two	NN	O	O
mothers	NN	O	O
with	NN	O	O
inflammatory	NN	O	B
bowel	NN	O	I
disease	NN	O	I
who	NN	O	O
received	NN	O	O
treatment	NN	O	O
with	NN	O	O
sulphasalazine	NN	O	O
throughout	NN	O	O
pregnancy	NN	O	O
,	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
major	NN	O	O
congenital	NN	O	B
anomalies	NN	O	I
.	NN	O	O

In	NN	O	O
the	NN	O	O
singleton	NN	O	O
pregnancy	NN	O	O
,	NN	O	O
the	NN	O	O
mother	NN	O	O
had	NN	O	O
ulcerative	NN	O	B
colitis	NN	O	I
,	NN	O	O
and	NN	O	O
the	NN	O	O
infant	NN	O	O
,	NN	O	O
a	NN	O	O
male	NN	O	O
,	NN	O	O
had	NN	O	O
coarctation	NN	O	B
of	NN	O	I
the	NN	O	I
aorta	NN	O	I
and	NN	O	O
a	NN	O	O
ventricular	NN	O	B
septal	NN	O	I
defect	NN	O	I
.	NN	O	O

In	NN	O	O
the	NN	O	O
twin	NN	O	O
pregnancy	NN	O	O
,	NN	O	O
the	NN	O	O
mother	NN	O	O
had	NN	O	O
Crohn	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

The	NN	O	O
first	NN	O	O
twin	NN	O	O
,	NN	O	O
a	NN	O	O
female	NN	O	O
,	NN	O	O
had	NN	O	O
a	NN	O	O
left	NN	O	O
Potter	NN	O	B
-	NN	O	I
type	NN	O	I
IIa	NN	O	I
polycystic	NN	O	I
kidney	NN	O	I
and	NN	O	O
a	NN	O	O
rudimentary	NN	O	B
left	NN	O	I
uterine	NN	O	I
cornu	NN	O	I
.	NN	O	O

The	NN	O	O
second	NN	O	O
twin	NN	O	O
,	NN	O	O
a	NN	O	O
male	NN	O	O
,	NN	O	O
had	NN	O	O
some	NN	O	O
features	NN	O	O
of	NN	O	O
Potter	NN	O	B
'	NN	O	I
s	NN	O	I
facies	NN	O	I
,	NN	O	O
hypoplastic	NN	O	B
lungs	NN	O	I
,	NN	O	O
absent	NN	O	B
kidneys	NN	O	I
and	NN	O	I
ureters	NN	O	I
,	NN	O	O
and	NN	O	O
talipes	NN	O	B
equinovarus	NN	O	I
.	NN	O	O

Despite	NN	O	O
reports	NN	O	O
to	NN	O	O
the	NN	O	O
contrary	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
sulphasalazine	NN	O	O
may	NN	O	O
be	NN	O	O
teratogenic	NN	O	O
.	NN	O	O

Thrombotic	NN	O	B
microangiopathy	NN	O	I
and	NN	O	O
renal	NN	O	B
failure	NN	O	I
associated	NN	O	O
with	NN	O	O
antineoplastic	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
with	NN	O	O
carcinoma	NN	O	B
developed	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
(	NN	O	O
characterized	NN	O	O
by	NN	O	O
renal	NN	O	B
insufficiency	NN	O	I
,	NN	O	O
microangiopathic	NN	O	B
hemolytic	NN	O	I
anemia	NN	O	I
,	NN	O	O
and	NN	O	O
usually	NN	O	O
thrombocytopenia	NN	O	B
)	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
cisplatin	NN	O	O
,	NN	O	O
bleomycin	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
vinca	NN	O	O
alkaloid	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
had	NN	O	O
thrombotic	NN	O	B
thrombocytopenic	NN	O	I
purpura	NN	O	I
,	NN	O	O
three	NN	O	O
the	NN	O	O
hemolytic	NN	O	B
-	NN	O	I
uremic	NN	O	I
syndrome	NN	O	I
,	NN	O	O
and	NN	O	O
one	NN	O	O
an	NN	O	O
apparent	NN	O	O
forme	NN	O	O
fruste	NN	O	O
of	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
disorders	NN	O	O
.	NN	O	O

Histologic	NN	O	O
examination	NN	O	O
of	NN	O	O
the	NN	O	O
renal	NN	O	O
tissue	NN	O	O
showed	NN	O	O
evidence	NN	O	O
of	NN	O	O
intravascular	NN	O	B
coagulation	NN	O	I
,	NN	O	O
primarily	NN	O	O
affecting	NN	O	O
the	NN	O	O
small	NN	O	O
arteries	NN	O	O
,	NN	O	O
arterioles	NN	O	O
,	NN	O	O
and	NN	O	O
glomeruli	NN	O	O
.	NN	O	O

Because	NN	O	O
each	NN	O	O
patient	NN	O	O
was	NN	O	O
tumor	NN	O	B
-	NN	O	O
free	NN	O	O
or	NN	O	O
had	NN	O	O
only	NN	O	O
a	NN	O	O
small	NN	O	O
tumor	NN	O	B
at	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
,	NN	O	O
the	NN	O	O
thrombotic	NN	O	B
microangiopathy	NN	O	I
may	NN	O	O
have	NN	O	O
been	NN	O	O
induced	NN	O	O
by	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Diagnosis	NN	O	O
of	NN	O	O
this	NN	O	O
potentially	NN	O	O
fatal	NN	O	O
complication	NN	O	O
may	NN	O	O
be	NN	O	O
delayed	NN	O	O
or	NN	O	O
missed	NN	O	O
if	NN	O	O
renal	NN	O	O
tissue	NN	O	O
or	NN	O	O
the	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
smear	NN	O	O
is	NN	O	O
not	NN	O	O
examined	NN	O	O
,	NN	O	O
because	NN	O	O
renal	NN	O	B
failure	NN	O	I
may	NN	O	O
be	NN	O	O
ascribed	NN	O	O
to	NN	O	O
cisplatin	NN	O	O
nephrotoxicity	NN	O	B
and	NN	O	O
the	NN	O	O
anemia	NN	O	B
and	NN	O	O
thrombocytopenia	NN	O	B
to	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
bone	NN	O	B
marrow	NN	O	I
suppression	NN	O	I
.	NN	O	O

International	NN	O	O
mexiletine	NN	O	O
and	NN	O	O
placebo	NN	O	O
antiarrhythmic	NN	O	O
coronary	NN	O	O
trial	NN	O	O
:	NN	O	O
I	NN	O	O
.	NN	O	O

Report	NN	O	O
on	NN	O	O
arrhythmia	NN	O	B
and	NN	O	O
other	NN	O	O
findings	NN	O	O
.	NN	O	O

Impact	NN	O	O
Research	NN	O	O
Group	NN	O	O
.	NN	O	O

The	NN	O	O
antiarrhythmic	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
sustained	NN	O	O
release	NN	O	O
form	NN	O	O
of	NN	O	O
mexiletine	NN	O	O
(	NN	O	O
Mexitil	NN	O	O
-	NN	O	O
Perlongets	NN	O	O
)	NN	O	O
were	NN	O	O
evaluated	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
placebo	NN	O	O
trial	NN	O	O
in	NN	O	O
630	NN	O	O
patients	NN	O	O
with	NN	O	O
recent	NN	O	O
documented	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

The	NN	O	O
primary	NN	O	O
response	NN	O	O
variable	NN	O	O
was	NN	O	O
based	NN	O	O
on	NN	O	O
central	NN	O	O
reading	NN	O	O
of	NN	O	O
24	NN	O	O
hour	NN	O	O
ambulatory	NN	O	O
electrocardiographic	NN	O	O
recordings	NN	O	O
and	NN	O	O
was	NN	O	O
defined	NN	O	O
as	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
30	NN	O	O
or	NN	O	O
more	NN	O	O
single	NN	O	O
premature	NN	O	O
ventricular	NN	O	O
complexes	NN	O	O
in	NN	O	O
any	NN	O	O
two	NN	O	O
consecutive	NN	O	O
30	NN	O	O
minute	NN	O	O
blocks	NN	O	O
or	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
runs	NN	O	O
of	NN	O	O
two	NN	O	O
or	NN	O	O
more	NN	O	O
premature	NN	O	O
ventricular	NN	O	O
complexes	NN	O	O
in	NN	O	O
the	NN	O	O
entire	NN	O	O
24	NN	O	O
hour	NN	O	O
electrocardiographic	NN	O	O
recording	NN	O	O
.	NN	O	O

Large	NN	O	O
differences	NN	O	O
,	NN	O	O
regarded	NN	O	O
as	NN	O	O
statistically	NN	O	O
significant	NN	O	O
,	NN	O	O
between	NN	O	O
the	NN	O	O
mexiletine	NN	O	O
and	NN	O	O
placebo	NN	O	O
groups	NN	O	O
were	NN	O	O
noted	NN	O	O
in	NN	O	O
that	NN	O	O
end	NN	O	O
point	NN	O	O
at	NN	O	O
months	NN	O	O
1	NN	O	O
and	NN	O	O
4	NN	O	O
,	NN	O	O
but	NN	O	O
only	NN	O	O
trends	NN	O	O
were	NN	O	O
observed	NN	O	O
at	NN	O	O
month	NN	O	O
12	NN	O	O
.	NN	O	O

These	NN	O	O
differences	NN	O	O
were	NN	O	O
observed	NN	O	O
even	NN	O	O
though	NN	O	O
the	NN	O	O
serum	NN	O	O
mexiletine	NN	O	O
levels	NN	O	O
obtained	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
were	NN	O	O
generally	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
studies	NN	O	O
that	NN	O	O
have	NN	O	O
used	NN	O	O
the	NN	O	O
regular	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
more	NN	O	O
deaths	NN	O	B
in	NN	O	O
the	NN	O	O
mexiletine	NN	O	O
group	NN	O	O
(	NN	O	O
7	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
(	NN	O	O
4	NN	O	O
.	NN	O	O
8	NN	O	O
%	NN	O	O
)	NN	O	O
;	NN	O	O
the	NN	O	O
difference	NN	O	O
was	NN	O	O
not	NN	O	O
statistically	NN	O	O
significant	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
coronary	NN	O	O
events	NN	O	O
was	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Previously	NN	O	O
recognized	NN	O	O
side	NN	O	O
effects	NN	O	O
,	NN	O	O
particularly	NN	O	O
tremor	NN	O	B
and	NN	O	O
gastrointestinal	NN	O	B
problems	NN	O	I
,	NN	O	O
were	NN	O	O
more	NN	O	O
frequent	NN	O	O
in	NN	O	O
the	NN	O	O
mexiletine	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
heart	NN	O	O
size	NN	O	O
during	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
timolol	NN	O	O
treatment	NN	O	O
after	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
timolol	NN	O	O
treatment	NN	O	O
on	NN	O	O
heart	NN	O	O
size	NN	O	O
after	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
was	NN	O	O
evaluated	NN	O	O
by	NN	O	O
X	NN	O	O
-	NN	O	O
ray	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
including	NN	O	O
241	NN	O	O
patients	NN	O	O
(	NN	O	O
placebo	NN	O	O
126	NN	O	O
,	NN	O	O
timolol	NN	O	O
115	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
was	NN	O	O
12	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
timolol	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
showed	NN	O	O
a	NN	O	O
small	NN	O	O
but	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
size	NN	O	O
from	NN	O	O
baseline	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

These	NN	O	O
differences	NN	O	O
may	NN	O	O
be	NN	O	O
caused	NN	O	O
by	NN	O	O
timolol	NN	O	O
-	NN	O	O
induced	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
a	NN	O	O
compensatory	NN	O	O
increase	NN	O	O
in	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
volume	NN	O	O
.	NN	O	O

The	NN	O	O
timolol	NN	O	O
-	NN	O	O
related	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
size	NN	O	O
was	NN	O	O
observed	NN	O	O
only	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
normal	NN	O	O
and	NN	O	O
borderline	NN	O	O
heart	NN	O	O
size	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
cardiomegaly	NN	O	B
,	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
size	NN	O	O
was	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

After	NN	O	O
re	NN	O	O
-	NN	O	O
infarction	NN	O	B
,	NN	O	O
heart	NN	O	O
size	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
and	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
in	NN	O	O
the	NN	O	O
timolol	NN	O	O
group	NN	O	O
.	NN	O	O

Vitamin	NN	O	O
D3	NN	O	O
toxicity	NN	O	B
in	NN	O	O
dairy	NN	O	O
cows	NN	O	O
.	NN	O	O

Large	NN	O	O
parenteral	NN	O	O
doses	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
(	NN	O	O
15	NN	O	O
to	NN	O	O
17	NN	O	O
.	NN	O	O
5	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
IU	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
)	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
prolonged	NN	O	O
hypercalcemia	NN	O	B
,	NN	O	O
hyperphosphatemia	NN	O	B
,	NN	O	O
and	NN	O	O
large	NN	O	O
increases	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
and	NN	O	O
its	NN	O	O
metabolites	NN	O	O
in	NN	O	O
the	NN	O	O
blood	NN	O	O
plasma	NN	O	O
of	NN	O	O
nonlactating	NN	O	O
nonpregnant	NN	O	O
and	NN	O	O
pregnant	NN	O	O
Jersey	NN	O	O
cows	NN	O	O
.	NN	O	O

Calcium	NN	O	O
concentrations	NN	O	O
1	NN	O	O
day	NN	O	O
postpartum	NN	O	O
were	NN	O	O
higher	NN	O	O
in	NN	O	O
cows	NN	O	O
treated	NN	O	O
with	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
about	NN	O	O
32	NN	O	O
days	NN	O	O
prepartum	NN	O	O
(	NN	O	O
8	NN	O	O
.	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
100	NN	O	O
ml	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
control	NN	O	O
cows	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
100	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
cows	NN	O	O
treated	NN	O	O
with	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
showed	NN	O	O
signs	NN	O	O
of	NN	O	O
milk	NN	O	B
fever	NN	O	I
during	NN	O	O
the	NN	O	O
peripartal	NN	O	O
period	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
22	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
cows	NN	O	O
developed	NN	O	O
clinical	NN	O	O
signs	NN	O	O
of	NN	O	O
milk	NN	O	B
fever	NN	O	I
during	NN	O	O
this	NN	O	O
period	NN	O	O
.	NN	O	O

Signs	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
toxicity	NN	O	B
were	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
nonlactating	NN	O	O
nonpregnant	NN	O	O
cows	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
pregnant	NN	O	O
cows	NN	O	O
commonly	NN	O	O
developed	NN	O	O
severe	NN	O	O
signs	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
toxicity	NN	O	B
and	NN	O	O
10	NN	O	O
of	NN	O	O
17	NN	O	O
cows	NN	O	O
died	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
widespread	NN	O	O
metastatic	NN	O	O
calcification	NN	O	O
in	NN	O	O
the	NN	O	O
cows	NN	O	O
that	NN	O	O
died	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
extreme	NN	O	O
toxicity	NN	O	B
of	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
in	NN	O	O
pregnant	NN	O	O
Jersey	NN	O	O
cows	NN	O	O
and	NN	O	O
the	NN	O	O
low	NN	O	O
margin	NN	O	O
of	NN	O	O
safety	NN	O	O
between	NN	O	O
doses	NN	O	O
of	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
that	NN	O	O
prevent	NN	O	O
milk	NN	O	B
fever	NN	O	I
and	NN	O	O
doses	NN	O	O
that	NN	O	O
induce	NN	O	O
milk	NN	O	B
fever	NN	O	I
,	NN	O	O
we	NN	O	O
concluded	NN	O	O
that	NN	O	O
vitamin	NN	O	O
D3	NN	O	O
cannot	NN	O	O
be	NN	O	O
used	NN	O	O
practically	NN	O	O
to	NN	O	O
prevent	NN	O	O
milk	NN	O	B
fever	NN	O	I
when	NN	O	O
injected	NN	O	O
several	NN	O	O
weeks	NN	O	O
prepartum	NN	O	O
.	NN	O	O

Diseases	NN	O	B
of	NN	O	I
peripheral	NN	O	I
nerves	NN	O	I
as	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
Nigerian	NN	O	O
African	NN	O	O
.	NN	O	O

The	NN	O	O
anatomical	NN	O	O
and	NN	O	O
aetiological	NN	O	O
diagnoses	NN	O	O
of	NN	O	O
peripheral	NN	O	B
nerve	NN	O	I
disease	NN	O	I
excluding	NN	O	O
its	NN	O	O
primary	NN	O	O
benign	NN	O	O
and	NN	O	O
malignant	NN	O	O
disorders	NN	O	O
,	NN	O	O
as	NN	O	O
seen	NN	O	O
in	NN	O	O
358	NN	O	O
Nigerians	NN	O	O
are	NN	O	O
presented	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
a	NN	O	O
male	NN	O	O
preponderance	NN	O	O
and	NN	O	O
the	NN	O	O
peak	NN	O	O
incidence	NN	O	O
is	NN	O	O
in	NN	O	O
the	NN	O	O
fourth	NN	O	O
decade	NN	O	O
.	NN	O	O

Sensori	NN	O	B
-	NN	O	I
motor	NN	O	I
neuropathy	NN	O	I
was	NN	O	O
the	NN	O	O
commonest	NN	O	O
presentation	NN	O	O
(	NN	O	O
50	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Guillain	NN	O	B
-	NN	O	I
Barr	NN	O	I
syndrome	NN	O	I
was	NN	O	O
the	NN	O	O
commonest	NN	O	O
identifiable	NN	O	O
cause	NN	O	O
(	NN	O	O
15	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
accounting	NN	O	O
for	NN	O	O
half	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
with	NN	O	O
motor	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

Peripheral	NN	O	B
neuropathy	NN	O	I
due	NN	O	O
to	NN	O	O
nutritional	NN	O	B
deficiency	NN	O	I
of	NN	O	O
thiamine	NN	O	O
and	NN	O	O
riboflavin	NN	O	O
was	NN	O	O
common	NN	O	O
(	NN	O	O
10	NN	O	O
.	NN	O	O
1	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
presented	NN	O	O
mainly	NN	O	O
as	NN	O	O
sensory	NN	O	O
and	NN	O	O
sensori	NN	O	B
-	NN	O	I
motor	NN	O	I
neuropathy	NN	O	I
.	NN	O	O

Diabetes	NN	O	B
mellitus	NN	O	I
was	NN	O	O
the	NN	O	O
major	NN	O	O
cause	NN	O	O
of	NN	O	O
autonomic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

Isoniazid	NN	O	O
was	NN	O	O
the	NN	O	O
most	NN	O	O
frequent	NN	O	O
agent	NN	O	O
in	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
neuropathy	NN	O	B
.	NN	O	O

Migraine	NN	O	B
(	NN	O	O
20	NN	O	O
%	NN	O	O
)	NN	O	O
was	NN	O	O
not	NN	O	O
an	NN	O	O
uncommon	NN	O	O
cause	NN	O	O
of	NN	O	O
cranial	NN	O	B
neuropathy	NN	O	I
although	NN	O	O
malignancies	NN	O	B
arising	NN	O	O
from	NN	O	O
the	NN	O	O
reticuloendothelial	NN	O	O
system	NN	O	O
or	NN	O	O
related	NN	O	O
structures	NN	O	O
of	NN	O	O
the	NN	O	O
head	NN	O	O
and	NN	O	O
neck	NN	O	O
were	NN	O	O
more	NN	O	O
frequent	NN	O	O
(	NN	O	O
26	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
26	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
of	NN	O	O
all	NN	O	O
the	NN	O	O
cases	NN	O	O
,	NN	O	O
the	NN	O	O
aetiology	NN	O	O
of	NN	O	O
the	NN	O	O
neuropathy	NN	O	B
was	NN	O	O
undetermined	NN	O	O
.	NN	O	O

Heredofamilial	NN	O	O
and	NN	O	O
connective	NN	O	B
tissue	NN	O	I
disorders	NN	O	I
were	NN	O	O
rare	NN	O	O
.	NN	O	O

Some	NN	O	O
of	NN	O	O
the	NN	O	O
factors	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
clinical	NN	O	O
presentation	NN	O	O
and	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
the	NN	O	O
neuropathies	NN	O	B
are	NN	O	O
briefly	NN	O	O
discussed	NN	O	O
.	NN	O	O

Reduction	NN	O	O
in	NN	O	O
caffeine	NN	O	O
toxicity	NN	O	B
by	NN	O	O
acetaminophen	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
who	NN	O	O
allegedly	NN	O	O
consumed	NN	O	O
100	NN	O	O
tablets	NN	O	O
of	NN	O	O
an	NN	O	O
over	NN	O	O
-	NN	O	O
the	NN	O	O
-	NN	O	O
counter	NN	O	O
analgesic	NN	O	O
containing	NN	O	O
sodium	NN	O	O
acetylsalicylate	NN	O	O
,	NN	O	O
caffeine	NN	O	O
,	NN	O	O
and	NN	O	O
acetaminophen	NN	O	O
displayed	NN	O	O
no	NN	O	O
significant	NN	O	O
CNS	NN	O	O
stimulation	NN	O	O
despite	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
175	NN	O	O
micrograms	NN	O	O
of	NN	O	O
caffeine	NN	O	O
per	NN	O	O
mL	NN	O	O
of	NN	O	O
serum	NN	O	O
.	NN	O	O

Because	NN	O	O
salicylates	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
augment	NN	O	O
the	NN	O	O
stimulatory	NN	O	O
effects	NN	O	O
of	NN	O	O
caffeine	NN	O	O
on	NN	O	O
the	NN	O	O
CNS	NN	O	O
,	NN	O	O
attention	NN	O	O
was	NN	O	O
focused	NN	O	O
on	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
acetaminophen	NN	O	O
(	NN	O	O
52	NN	O	O
micrograms	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
reduced	NN	O	O
the	NN	O	O
CNS	NN	O	O
toxicity	NN	O	B
of	NN	O	O
caffeine	NN	O	O
.	NN	O	O

Studies	NN	O	O
in	NN	O	O
DBA	NN	O	O
/	NN	O	O
2J	NN	O	O
mice	NN	O	O
showed	NN	O	O
that	NN	O	O
:	NN	O	O
1	NN	O	O
)	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
acetaminophen	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
increased	NN	O	O
the	NN	O	O
interval	NN	O	O
between	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
caffeine	NN	O	O
(	NN	O	O
300	NN	O	O
to	NN	O	O
450	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
IP	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
fatal	NN	O	O
convulsions	NN	O	B
by	NN	O	O
a	NN	O	O
factor	NN	O	O
of	NN	O	O
about	NN	O	O
two	NN	O	O
;	NN	O	O
and	NN	O	O
2	NN	O	O
)	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
acetaminophen	NN	O	O
(	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
reduced	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
audiogenic	NN	O	O
seizures	NN	O	B
produced	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
caffeine	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
to	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
IP	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
frequency	NN	O	O
of	NN	O	O
sound	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B
after	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
or	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
caffeine	NN	O	O
was	NN	O	O
reduced	NN	O	O
from	NN	O	O
50	NN	O	O
to	NN	O	O
5	NN	O	O
%	NN	O	O
by	NN	O	O
acetaminophen	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
caffeine	NN	O	O
,	NN	O	O
acetaminophen	NN	O	O
(	NN	O	O
up	NN	O	O
to	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
modify	NN	O	O
the	NN	O	O
seizures	NN	O	B
induced	NN	O	O
by	NN	O	O
maximal	NN	O	O
electroshock	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
the	NN	O	O
convulsant	NN	O	O
dose	NN	O	O
of	NN	O	O
pentylenetetrezol	NN	O	O
in	NN	O	O
mice	NN	O	O
(	NN	O	O
tests	NN	O	O
performed	NN	O	O
by	NN	O	O
the	NN	O	O
Anticonvulsant	NN	O	O
Screening	NN	O	O
Project	NN	O	O
of	NN	O	O
NINCDS	NN	O	O
)	NN	O	O
.	NN	O	O

Acetaminophen	NN	O	O
(	NN	O	O
up	NN	O	O
to	NN	O	O
150	NN	O	O
micrograms	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
retard	NN	O	O
the	NN	O	O
incorporation	NN	O	O
of	NN	O	O
radioactive	NN	O	O
adenosine	NN	O	O
into	NN	O	O
ATP	NN	O	O
in	NN	O	O
slices	NN	O	O
of	NN	O	O
rat	NN	O	O
cerebral	NN	O	O
cortex	NN	O	O
.	NN	O	O

Thus	NN	O	O
the	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
acetaminophen	NN	O	O
antagonizes	NN	O	O
the	NN	O	O
actions	NN	O	O
of	NN	O	O
caffeine	NN	O	O
in	NN	O	O
the	NN	O	O
CNS	NN	O	O
remains	NN	O	O
unknown	NN	O	O
.	NN	O	O

A	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
dothiepin	NN	O	O
hydrochloride	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
major	NN	O	O
depressive	NN	O	B
disorder	NN	O	I
.	NN	O	O

In	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
week	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
parallel	NN	O	O
treatment	NN	O	O
study	NN	O	O
,	NN	O	O
dothiepin	NN	O	O
and	NN	O	O
amitriptyline	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
placebo	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
33	NN	O	O
depressed	NN	O	B
outpatients	NN	O	O
.	NN	O	O

Dothiepin	NN	O	O
and	NN	O	O
amitriptyline	NN	O	O
were	NN	O	O
equally	NN	O	O
effective	NN	O	O
in	NN	O	O
alleviating	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
depressive	NN	O	B
illness	NN	O	I
,	NN	O	O
and	NN	O	O
both	NN	O	O
were	NN	O	O
significantly	NN	O	O
superior	NN	O	O
to	NN	O	O
placebo	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
incidence	NN	O	O
of	NN	O	O
side	NN	O	O
effects	NN	O	O
and	NN	O	O
the	NN	O	O
frequency	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
blurred	NN	O	B
vision	NN	O	I
,	NN	O	O
dry	NN	O	B
mouth	NN	O	I
,	NN	O	O
and	NN	O	O
drowsiness	NN	O	O
were	NN	O	O
significantly	NN	O	O
less	NN	O	O
with	NN	O	O
dothiepin	NN	O	O
than	NN	O	O
with	NN	O	O
amitriptyline	NN	O	O
.	NN	O	O

Dothiepin	NN	O	O
also	NN	O	O
produced	NN	O	O
fewer	NN	O	O
CNS	NN	O	O
and	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
clinically	NN	O	O
important	NN	O	O
changes	NN	O	O
in	NN	O	O
laboratory	NN	O	O
parameters	NN	O	O
.	NN	O	O

Dothiepin	NN	O	O
thus	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
effective	NN	O	O
antidepressant	NN	O	O
drug	NN	O	O
associated	NN	O	O
with	NN	O	O
fewer	NN	O	O
side	NN	O	O
effects	NN	O	O
than	NN	O	O
amitriptyline	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
depressed	NN	O	B
outpatients	NN	O	O
.	NN	O	O

Behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
diazepam	NN	O	O
and	NN	O	O
propranolol	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
panic	NN	O	B
disorder	NN	O	I
and	NN	O	O
agoraphobia	NN	O	B
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
oral	NN	O	O
doses	NN	O	O
of	NN	O	O
diazepam	NN	O	O
(	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
10	NN	O	O
mg	NN	O	O
and	NN	O	O
a	NN	O	O
median	NN	O	O
dose	NN	O	O
of	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
)	NN	O	O
and	NN	O	O
propranolol	NN	O	O
(	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
80	NN	O	O
mg	NN	O	O
and	NN	O	O
a	NN	O	O
median	NN	O	O
dose	NN	O	O
of	NN	O	O
240	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
)	NN	O	O
on	NN	O	O
psychological	NN	O	O
performance	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
panic	NN	O	B
disorders	NN	O	I
and	NN	O	O
agoraphobia	NN	O	B
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
and	NN	O	O
crossover	NN	O	O
design	NN	O	O
.	NN	O	O

Both	NN	O	O
drugs	NN	O	O
impaired	NN	O	B
immediate	NN	O	I
free	NN	O	I
recall	NN	O	I
but	NN	O	O
the	NN	O	O
decrease	NN	O	O
was	NN	O	O
greater	NN	O	O
for	NN	O	O
diazepam	NN	O	O
than	NN	O	O
propranolol	NN	O	O
.	NN	O	O

Delayed	NN	O	B
free	NN	O	I
recall	NN	O	I
was	NN	O	I
also	NN	O	I
impaired	NN	O	I
but	NN	O	O
the	NN	O	O
two	NN	O	O
drugs	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
.	NN	O	O

Patients	NN	O	O
tapped	NN	O	O
faster	NN	O	O
after	NN	O	O
propranolol	NN	O	O
than	NN	O	O
diazepam	NN	O	O
and	NN	O	O
they	NN	O	O
were	NN	O	O
more	NN	O	O
sedated	NN	O	O
after	NN	O	O
diazepam	NN	O	O
than	NN	O	O
propranolol	NN	O	O
.	NN	O	O

After	NN	O	O
2	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
patients	NN	O	O
tested	NN	O	O
5	NN	O	O
-	NN	O	O
8	NN	O	O
h	NN	O	O
after	NN	O	O
the	NN	O	O
last	NN	O	O
dose	NN	O	O
of	NN	O	O
medication	NN	O	O
did	NN	O	O
not	NN	O	O
show	NN	O	O
any	NN	O	O
decrement	NN	O	O
of	NN	O	O
performance	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
are	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
previously	NN	O	O
found	NN	O	O
in	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
.	NN	O	O

Accumulation	NN	O	O
of	NN	O	O
drugs	NN	O	O
was	NN	O	O
not	NN	O	O
reflected	NN	O	O
in	NN	O	O
prolonged	NN	O	O
behavioral	NN	O	B
impairment	NN	O	I
.	NN	O	O

Comparison	NN	O	O
of	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
glycopyrrolate	NN	O	O
and	NN	O	O
atropine	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
arrhythmias	NN	O	B
following	NN	O	O
repeated	NN	O	O
doses	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

The	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
administration	NN	O	O
of	NN	O	O
glycopyrrolate	NN	O	O
5	NN	O	O
and	NN	O	O
10	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
atropine	NN	O	O
10	NN	O	O
and	NN	O	O
20	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
immediately	NN	O	O
before	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
,	NN	O	O
to	NN	O	O
prevent	NN	O	O
arrhythmia	NN	O	B
and	NN	O	O
bradycardia	NN	O	B
following	NN	O	O
repeated	NN	O	O
doses	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
in	NN	O	O
children	NN	O	O
,	NN	O	O
was	NN	O	O
studied	NN	O	O
.	NN	O	O

A	NN	O	O
control	NN	O	O
group	NN	O	O
was	NN	O	O
included	NN	O	O
for	NN	O	O
comparison	NN	O	O
with	NN	O	O
the	NN	O	O
lower	NN	O	O
dose	NN	O	O
range	NN	O	O
of	NN	O	O
glycopyrrolate	NN	O	O
and	NN	O	O
atropine	NN	O	O
.	NN	O	O

A	NN	O	O
frequency	NN	O	O
of	NN	O	O
bradycardia	NN	O	B
of	NN	O	O
50	NN	O	O
%	NN	O	O
was	NN	O	O
noted	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
but	NN	O	O
this	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
from	NN	O	O
the	NN	O	O
frequency	NN	O	O
with	NN	O	O
the	NN	O	O
active	NN	O	O
drugs	NN	O	O
.	NN	O	O

Bradycardia	NN	O	B
(	NN	O	O
defined	NN	O	O
as	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
to	NN	O	O
less	NN	O	O
than	NN	O	O
50	NN	O	O
beat	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
was	NN	O	O
prevented	NN	O	O
when	NN	O	O
the	NN	O	O
larger	NN	O	O
dose	NN	O	O
of	NN	O	O
either	NN	O	O
active	NN	O	O
drug	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
recommended	NN	O	O
that	NN	O	O
either	NN	O	O
glycopyrrolate	NN	O	O
10	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
or	NN	O	O
atropine	NN	O	O
20	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
should	NN	O	O
immediately	NN	O	O
precede	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
,	NN	O	O
in	NN	O	O
children	NN	O	O
,	NN	O	O
if	NN	O	O
the	NN	O	O
repeated	NN	O	O
administration	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
is	NN	O	O
anticipated	NN	O	O
.	NN	O	O

Veno	NN	O	B
-	NN	O	I
occlusive	NN	O	I
liver	NN	O	I
disease	NN	O	I
after	NN	O	O
dacarbazine	NN	O	O
therapy	NN	O	O
(	NN	O	O
DTIC	NN	O	O
)	NN	O	O
for	NN	O	O
melanoma	NN	O	B
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
veno	NN	O	B
-	NN	O	I
occlusive	NN	O	I
disease	NN	O	I
of	NN	O	I
the	NN	O	I
liver	NN	O	I
with	NN	O	O
fatal	NN	O	O
outcome	NN	O	O
after	NN	O	O
dacarbazine	NN	O	O
(	NN	O	O
DTIC	NN	O	O
)	NN	O	O
therapy	NN	O	O
for	NN	O	O
melanoma	NN	O	B
is	NN	O	O
reported	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
fulminant	NN	O	O
clinical	NN	O	O
course	NN	O	O
from	NN	O	O
start	NN	O	O
of	NN	O	O
symptoms	NN	O	O
until	NN	O	O
death	NN	O	B
.	NN	O	O

At	NN	O	O
autopsy	NN	O	O
the	NN	O	O
liver	NN	O	O
was	NN	O	O
enlarged	NN	O	O
and	NN	O	O
firm	NN	O	O
with	NN	O	O
signs	NN	O	O
of	NN	O	O
venous	NN	O	B
congestion	NN	O	I
.	NN	O	O

Small	NN	O	O
-	NN	O	O
and	NN	O	O
medium	NN	O	O
-	NN	O	O
sized	NN	O	O
hepatic	NN	O	O
veins	NN	O	O
were	NN	O	O
blocked	NN	O	O
by	NN	O	O
thrombosis	NN	O	B
.	NN	O	O

Eosinophilic	NN	O	O
infiltrations	NN	O	O
were	NN	O	O
found	NN	O	O
around	NN	O	O
the	NN	O	O
vessels	NN	O	O
.	NN	O	O

Published	NN	O	O
cases	NN	O	O
from	NN	O	O
the	NN	O	O
literature	NN	O	O
are	NN	O	O
reviewed	NN	O	O
and	NN	O	O
pertinent	NN	O	O
features	NN	O	O
discussed	NN	O	O
.	NN	O	O

Maternal	NN	O	O
lithium	NN	O	O
and	NN	O	O
neonatal	NN	O	O
Ebstein	NN	O	B
'	NN	O	I
s	NN	O	I
anomaly	NN	O	I
:	NN	O	O
evaluation	NN	O	O
with	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
echocardiography	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
two	NN	O	O
neonates	NN	O	O
whose	NN	O	O
mothers	NN	O	O
ingested	NN	O	O
lithium	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

In	NN	O	O
one	NN	O	O
infant	NN	O	O
,	NN	O	O
Ebstein	NN	O	B
'	NN	O	I
s	NN	O	I
anomaly	NN	O	I
of	NN	O	O
the	NN	O	O
tricuspid	NN	O	O
valve	NN	O	O
was	NN	O	O
identified	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
other	NN	O	O
infant	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
echocardiography	NN	O	O
provided	NN	O	O
reassurance	NN	O	O
that	NN	O	O
the	NN	O	O
infant	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
Ebstein	NN	O	B
'	NN	O	I
s	NN	O	I
anomaly	NN	O	I
.	NN	O	O

Cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
echocardiographic	NN	O	O
screening	NN	O	O
of	NN	O	O
newborns	NN	O	O
exposed	NN	O	O
to	NN	O	O
lithium	NN	O	O
during	NN	O	O
gestation	NN	O	O
can	NN	O	O
provide	NN	O	O
highly	NN	O	O
accurate	NN	O	O
,	NN	O	O
noninvasive	NN	O	O
assessment	NN	O	O
of	NN	O	O
the	NN	O	O
presence	NN	O	O
or	NN	O	O
absence	NN	O	O
of	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
malformations	NN	O	I
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
training	NN	O	O
on	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
experimental	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
in	NN	O	O
aging	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
exercise	NN	O	O
on	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
isoproterenol	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
were	NN	O	O
studied	NN	O	O
in	NN	O	O
female	NN	O	O
albino	NN	O	O
rats	NN	O	O
of	NN	O	O
20	NN	O	O
,	NN	O	O
40	NN	O	O
,	NN	O	O
60	NN	O	O
and	NN	O	O
80	NN	O	O
weeks	NN	O	O
of	NN	O	O
age	NN	O	O
.	NN	O	O

The	NN	O	O
rats	NN	O	O
were	NN	O	O
trained	NN	O	O
to	NN	O	O
swim	NN	O	O
for	NN	O	O
a	NN	O	O
specific	NN	O	O
duration	NN	O	O
and	NN	O	O
for	NN	O	O
a	NN	O	O
particular	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
occurrence	NN	O	O
of	NN	O	O
infarcts	NN	O	B
were	NN	O	O
confirmed	NN	O	O
by	NN	O	O
histological	NN	O	O
methods	NN	O	O
.	NN	O	O

Elevations	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
GOT	NN	O	O
and	NN	O	O
GPT	NN	O	O
were	NN	O	O
maximum	NN	O	O
in	NN	O	O
the	NN	O	O
sedentary	NN	O	O
-	NN	O	O
isoproterenols	NN	O	O
and	NN	O	O
minimum	NN	O	O
in	NN	O	O
the	NN	O	O
exercise	NN	O	O
-	NN	O	O
controls	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
transaminases	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
corresponding	NN	O	O
depletions	NN	O	O
in	NN	O	O
the	NN	O	O
cardiac	NN	O	O
GOT	NN	O	O
and	NN	O	O
GPT	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
age	NN	O	O
was	NN	O	O
seen	NN	O	O
to	NN	O	O
interfere	NN	O	O
with	NN	O	O
the	NN	O	O
responses	NN	O	O
exhibited	NN	O	O
by	NN	O	O
the	NN	O	O
young	NN	O	O
and	NN	O	O
old	NN	O	O
rats	NN	O	O
.	NN	O	O

Studies	NN	O	O
dealing	NN	O	O
with	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
are	NN	O	O
more	NN	O	O
informative	NN	O	O
when	NN	O	O
dealt	NN	O	O
with	NN	O	O
age	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
polyethylene	NN	O	O
glycol	NN	O	O
400	NN	O	O
on	NN	O	O
adriamycin	NN	O	O
toxicity	NN	O	B
in	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
widely	NN	O	O
used	NN	O	O
organic	NN	O	O
solvent	NN	O	O
,	NN	O	O
polyethylene	NN	O	O
glycol	NN	O	O
400	NN	O	O
(	NN	O	O
PEG	NN	O	O
400	NN	O	O
)	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
toxic	NN	O	O
action	NN	O	O
of	NN	O	O
an	NN	O	O
acute	NN	O	O
or	NN	O	O
chronic	NN	O	O
treatment	NN	O	O
with	NN	O	O
adriamycin	NN	O	O
(	NN	O	O
ADR	NN	O	O
)	NN	O	O
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

PEG	NN	O	O
400	NN	O	O
impressively	NN	O	O
decreased	NN	O	O
both	NN	O	O
acute	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
and	NN	O	O
chronic	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
-	NN	O	O
ADR	NN	O	O
-	NN	O	O
associated	NN	O	O
lethality	NN	O	O
.	NN	O	O

Light	NN	O	O
microscopic	NN	O	O
analysis	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
protection	NN	O	O
against	NN	O	O
ADR	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
morphological	NN	O	I
alterations	NN	O	I
.	NN	O	O

Such	NN	O	O
treatment	NN	O	O
did	NN	O	O
not	NN	O	O
diminish	NN	O	O
the	NN	O	O
ADR	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
in	NN	O	O
L1210	NN	O	B
leukemia	NN	O	I
and	NN	O	O
in	NN	O	O
Ehrlich	NN	O	B
ascites	NN	O	I
tumor	NN	O	I
.	NN	O	O

Sublingual	NN	O	O
absorption	NN	O	O
of	NN	O	O
the	NN	O	O
quaternary	NN	O	O
ammonium	NN	O	O
antiarrhythmic	NN	O	O
agent	NN	O	O
,	NN	O	O
UM	NN	O	O
-	NN	O	O
272	NN	O	O
.	NN	O	O

UM	NN	O	O
-	NN	O	O
272	NN	O	O
(	NN	O	O
N	NN	O	O
,	NN	O	O
N	NN	O	O
-	NN	O	O
dimethylpropranolol	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
quaternary	NN	O	O
antiarrhythmic	NN	O	O
agent	NN	O	O
,	NN	O	O
was	NN	O	O
administered	NN	O	O
sublingually	NN	O	O
to	NN	O	O
dogs	NN	O	O
with	NN	O	O
ouabain	NN	O	O
-	NN	O	O
induced	NN	O	O
ventricular	NN	O	B
tachycardias	NN	O	I
.	NN	O	O

Both	NN	O	O
anti	NN	O	O
-	NN	O	O
arrhythmic	NN	O	O
efficacy	NN	O	O
and	NN	O	O
bioavailability	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
oral	NN	O	O
drug	NN	O	O
.	NN	O	O

Sublingual	NN	O	O
UM	NN	O	O
-	NN	O	O
272	NN	O	O
converted	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
to	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
in	NN	O	O
all	NN	O	O
5	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
time	NN	O	O
curve	NN	O	O
at	NN	O	O
90	NN	O	O
min	NN	O	O
was	NN	O	O
4	NN	O	O
-	NN	O	O
12	NN	O	O
times	NN	O	O
greater	NN	O	O
than	NN	O	O
for	NN	O	O
oral	NN	O	O
drug	NN	O	O
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
existence	NN	O	O
of	NN	O	O
an	NN	O	O
absorption	NN	O	O
-	NN	O	O
limiting	NN	O	O
process	NN	O	O
in	NN	O	O
the	NN	O	O
intestine	NN	O	O
,	NN	O	O
and	NN	O	O
providing	NN	O	O
an	NN	O	O
alternate	NN	O	O
form	NN	O	O
of	NN	O	O
administration	NN	O	O
for	NN	O	O
quaternary	NN	O	O
drugs	NN	O	O
.	NN	O	O

Early	NN	O	O
adjuvant	NN	O	O
adriamycin	NN	O	O
in	NN	O	O
superficial	NN	O	O
bladder	NN	O	B
carcinoma	NN	O	I
.	NN	O	O

A	NN	O	O
multicenter	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
in	NN	O	O
110	NN	O	O
patients	NN	O	O
with	NN	O	O
superficial	NN	O	O
transitional	NN	O	O
cell	NN	O	O
carcinoma	NN	O	B
of	NN	O	I
the	NN	O	I
bladder	NN	O	I
.	NN	O	O

Adriamycin	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
50	NN	O	O
ml	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
intravesically	NN	O	O
within	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
transurethral	NN	O	O
resection	NN	O	O
of	NN	O	O
TA	NN	O	O
-	NN	O	O
T1	NN	O	O
(	NN	O	O
O	NN	O	O
-	NN	O	O
A	NN	O	O
)	NN	O	O
bladder	NN	O	B
tumors	NN	O	I
.	NN	O	O

Instillation	NN	O	O
was	NN	O	O
repeated	NN	O	O
twice	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
week	NN	O	O
,	NN	O	O
then	NN	O	O
weekly	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
month	NN	O	O
and	NN	O	O
afterwards	NN	O	O
monthly	NN	O	O
for	NN	O	O
1	NN	O	O
year	NN	O	O
.	NN	O	O

The	NN	O	O
tolerance	NN	O	O
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
these	NN	O	O
110	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
29	NN	O	O
patients	NN	O	O
presented	NN	O	O
with	NN	O	O
local	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
.	NN	O	O

In	NN	O	O
24	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
chemical	NN	O	O
cystitis	NN	O	B
was	NN	O	O
severe	NN	O	O
enough	NN	O	O
for	NN	O	O
them	NN	O	O
to	NN	O	O
drop	NN	O	O
out	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

No	NN	O	O
systemic	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

Recurrence	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
82	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
after	NN	O	O
1	NN	O	O
year	NN	O	O
of	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
and	NN	O	O
in	NN	O	O
72	NN	O	O
patients	NN	O	O
followed	NN	O	O
for	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
years	NN	O	O
(	NN	O	O
mean	NN	O	O
32	NN	O	O
months	NN	O	O
)	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
82	NN	O	O
patients	NN	O	O
studied	NN	O	O
after	NN	O	O
1	NN	O	O
year	NN	O	O
,	NN	O	O
23	NN	O	O
had	NN	O	O
primary	NN	O	O
and	NN	O	O
59	NN	O	O
recurrent	NN	O	O
disease	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
82	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
,	NN	O	O
50	NN	O	O
did	NN	O	O
not	NN	O	O
show	NN	O	O
any	NN	O	O
recurrence	NN	O	O
after	NN	O	O
1	NN	O	O
year	NN	O	O
(	NN	O	O
61	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
while	NN	O	O
32	NN	O	O
presented	NN	O	O
with	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
recurrences	NN	O	O
(	NN	O	O
39	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Of	NN	O	O
these	NN	O	O
recurrences	NN	O	O
,	NN	O	O
27	NN	O	O
were	NN	O	O
T1	NN	O	O
tumors	NN	O	B
while	NN	O	O
five	NN	O	O
progressed	NN	O	O
to	NN	O	O
more	NN	O	O
highly	NN	O	O
invasive	NN	O	O
lesions	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
that	NN	O	O
were	NN	O	O
free	NN	O	O
of	NN	O	O
recurrence	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
year	NN	O	O
,	NN	O	O
80	NN	O	O
%	NN	O	O
remained	NN	O	O
tumor	NN	O	B
-	NN	O	O
free	NN	O	O
during	NN	O	O
the	NN	O	O
2	NN	O	O
-	NN	O	O
to	NN	O	O
3	NN	O	O
-	NN	O	O
year	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
patients	NN	O	O
developing	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
recurrences	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
year	NN	O	O
,	NN	O	O
only	NN	O	O
50	NN	O	O
%	NN	O	O
presented	NN	O	O
with	NN	O	O
further	NN	O	O
recurrence	NN	O	O
once	NN	O	O
the	NN	O	O
instillations	NN	O	O
were	NN	O	O
stopped	NN	O	O
.	NN	O	O

The	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
Adriamycin	NN	O	O
appears	NN	O	O
obvious	NN	O	O
and	NN	O	O
might	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
itself	NN	O	O
,	NN	O	O
the	NN	O	O
early	NN	O	O
and	NN	O	O
repeated	NN	O	O
instillations	NN	O	O
after	NN	O	O
TUR	NN	O	O
,	NN	O	O
or	NN	O	O
both	NN	O	O
.	NN	O	O

D	NN	O	O
-	NN	O	O
penicillamine	NN	O	O
-	NN	O	O
induced	NN	O	O
angiopathy	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
high	NN	O	O
dose	NN	O	O
D	NN	O	O
-	NN	O	O
penicillamine	NN	O	O
treatment	NN	O	O
on	NN	O	O
aortic	NN	O	O
permeability	NN	O	O
to	NN	O	O
albumin	NN	O	O
and	NN	O	O
on	NN	O	O
the	NN	O	O
ultrastructure	NN	O	O
of	NN	O	O
the	NN	O	O
vessel	NN	O	O
.	NN	O	O

Male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
D	NN	O	O
-	NN	O	O
penicillamine	NN	O	O
(	NN	O	O
D	NN	O	O
-	NN	O	O
pen	NN	O	O
)	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
10	NN	O	O
or	NN	O	O
42	NN	O	O
days	NN	O	O
.	NN	O	O

Pair	NN	O	O
fed	NN	O	O
rats	NN	O	O
served	NN	O	O
as	NN	O	O
controls	NN	O	O
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
aortic	NN	O	O
morphology	NN	O	O
were	NN	O	O
examined	NN	O	O
by	NN	O	O
light	NN	O	O
-	NN	O	O
and	NN	O	O
transmission	NN	O	O
-	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
(	NN	O	O
TEM	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
endothelial	NN	O	O
permeability	NN	O	O
and	NN	O	O
the	NN	O	O
penetration	NN	O	O
through	NN	O	O
the	NN	O	O
aortic	NN	O	O
wall	NN	O	O
of	NN	O	O
albumin	NN	O	O
were	NN	O	O
studied	NN	O	O
10	NN	O	O
minutes	NN	O	O
,	NN	O	O
24	NN	O	O
and	NN	O	O
48	NN	O	O
hours	NN	O	O
after	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
injection	NN	O	O
of	NN	O	O
human	NN	O	O
serum	NN	O	O
131I	NN	O	O
-	NN	O	O
albumin	NN	O	O
(	NN	O	O
131I	NN	O	O
-	NN	O	O
HSA	NN	O	O
)	NN	O	O
.	NN	O	O

TEM	NN	O	O
revealed	NN	O	O
extensive	NN	O	O
elastolysis	NN	O	O
in	NN	O	O
the	NN	O	O
arterial	NN	O	O
wall	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
pen	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
consistent	NN	O	O
with	NN	O	O
an	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
on	NN	O	O
crosslink	NN	O	O
formation	NN	O	O
.	NN	O	O

In	NN	O	O
experimental	NN	O	O
animals	NN	O	O
excess	NN	O	O
deposition	NN	O	O
of	NN	O	O
collagen	NN	O	O
and	NN	O	O
glycoaminoglycans	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
subendothelial	NN	O	O
and	NN	O	O
medial	NN	O	O
layer	NN	O	O
of	NN	O	O
the	NN	O	O
aortic	NN	O	O
wall	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
prominent	NN	O	O
basal	NN	O	O
membrane	NN	O	O
substance	NN	O	O
around	NN	O	O
aortic	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
aorta	NN	O	O
/	NN	O	O
serum	NN	O	O
-	NN	O	O
ratio	NN	O	O
and	NN	O	O
the	NN	O	O
radioactive	NN	O	O
build	NN	O	O
-	NN	O	O
up	NN	O	O
24	NN	O	O
and	NN	O	O
48	NN	O	O
hours	NN	O	O
after	NN	O	O
injection	NN	O	O
of	NN	O	O
131I	NN	O	O
-	NN	O	O
HSA	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
D	NN	O	O
-	NN	O	O
pen	NN	O	O
for	NN	O	O
42	NN	O	O
days	NN	O	O
,	NN	O	O
indicating	NN	O	O
an	NN	O	O
impeded	NN	O	O
transmural	NN	O	O
transport	NN	O	O
of	NN	O	O
tracer	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
caused	NN	O	O
by	NN	O	O
a	NN	O	O
steric	NN	O	O
exclusion	NN	O	O
effect	NN	O	O
of	NN	O	O
abundant	NN	O	O
hyaluronate	NN	O	O
.	NN	O	O

The	NN	O	O
endothelial	NN	O	O
ultrastructure	NN	O	O
was	NN	O	O
unaffected	NN	O	O
by	NN	O	O
D	NN	O	O
-	NN	O	O
pen	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
aortic	NN	O	O
131I	NN	O	O
-	NN	O	O
HSA	NN	O	O
radioactivity	NN	O	O
or	NN	O	O
aorta	NN	O	O
/	NN	O	O
serum	NN	O	O
-	NN	O	O
ratio	NN	O	O
were	NN	O	O
recorded	NN	O	O
between	NN	O	O
experimental	NN	O	O
and	NN	O	O
control	NN	O	O
groups	NN	O	O
10	NN	O	O
minutes	NN	O	O
after	NN	O	O
tracer	NN	O	O
injection	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
permeability	NN	O	O
of	NN	O	O
the	NN	O	O
endothelial	NN	O	O
barrier	NN	O	O
to	NN	O	O
albumin	NN	O	O
remained	NN	O	O
unaffected	NN	O	O
by	NN	O	O
D	NN	O	O
-	NN	O	O
pen	NN	O	O
treatment	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
support	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
treatment	NN	O	O
with	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
D	NN	O	O
-	NN	O	O
pen	NN	O	O
may	NN	O	O
induce	NN	O	O
a	NN	O	O
fibroproliferative	NN	O	O
response	NN	O	O
in	NN	O	O
rat	NN	O	O
aorta	NN	O	O
,	NN	O	O
possibly	NN	O	O
by	NN	O	O
an	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
cross	NN	O	O
-	NN	O	O
linking	NN	O	O
of	NN	O	O
collagen	NN	O	O
and	NN	O	O
elastin	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
aspirin	NN	O	O
on	NN	O	O
N	NN	O	O
-	NN	O	O
[	NN	O	O
4	NN	O	O
-	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
nitro	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
furyl	NN	O	O
)	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
thiazolyl	NN	O	O
]	NN	O	O
-	NN	O	O
formamide	NN	O	O
-	NN	O	O
induced	NN	O	O
epithelial	NN	O	O
proliferation	NN	O	O
in	NN	O	O
the	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
and	NN	O	O
forestomach	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

The	NN	O	O
co	NN	O	O
-	NN	O	O
administration	NN	O	O
of	NN	O	O
aspirin	NN	O	O
with	NN	O	O
N	NN	O	O
-	NN	O	O
[	NN	O	O
4	NN	O	O
-	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
nitro	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
furyl	NN	O	O
)	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
thiazolyl	NN	O	O
]	NN	O	O
-	NN	O	O
formamide	NN	O	O
(	NN	O	O
FANFT	NN	O	O
)	NN	O	O
to	NN	O	O
rats	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
reduced	NN	O	O
incidence	NN	O	O
of	NN	O	O
FANFT	NN	O	O
-	NN	O	O
induced	NN	O	O
bladder	NN	O	B
carcinomas	NN	O	I
but	NN	O	O
a	NN	O	O
concomitant	NN	O	O
induction	NN	O	O
of	NN	O	O
forestomach	NN	O	B
tumors	NN	O	I
.	NN	O	O

An	NN	O	O
autoradiographic	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
on	NN	O	O
male	NN	O	O
F	NN	O	O
-	NN	O	O
344	NN	O	O
rats	NN	O	O
fed	NN	O	O
diet	NN	O	O
containing	NN	O	O
FANFT	NN	O	O
at	NN	O	O
a	NN	O	O
level	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
aspirin	NN	O	O
at	NN	O	O
a	NN	O	O
level	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
aspirin	NN	O	O
on	NN	O	O
the	NN	O	O
increased	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
induced	NN	O	O
by	NN	O	O
FANFT	NN	O	O
in	NN	O	O
the	NN	O	O
forestomach	NN	O	O
and	NN	O	O
bladder	NN	O	O
.	NN	O	O

FANFT	NN	O	O
-	NN	O	O
induced	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
in	NN	O	O
the	NN	O	O
bladder	NN	O	O
was	NN	O	O
significantly	NN	O	O
suppressed	NN	O	O
by	NN	O	O
aspirin	NN	O	O
co	NN	O	O
-	NN	O	O
administration	NN	O	O
after	NN	O	O
4	NN	O	O
weeks	NN	O	O
but	NN	O	O
not	NN	O	O
after	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
forestomach	NN	O	O
,	NN	O	O
and	NN	O	O
also	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
,	NN	O	O
aspirin	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
FANFT	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
labeling	NN	O	O
index	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
results	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
carcinogenicity	NN	O	O
experiment	NN	O	O
suggesting	NN	O	O
that	NN	O	O
different	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
FANFT	NN	O	O
carcinogenesis	NN	O	B
in	NN	O	O
the	NN	O	O
bladder	NN	O	O
and	NN	O	O
forestomach	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
aspirin	NN	O	O
'	NN	O	O
s	NN	O	O
effect	NN	O	O
on	NN	O	O
FANFT	NN	O	O
in	NN	O	O
the	NN	O	O
forestomach	NN	O	O
is	NN	O	O
not	NN	O	O
due	NN	O	O
to	NN	O	O
an	NN	O	O
irritant	NN	O	O
effect	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
there	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
adaptation	NN	O	O
by	NN	O	O
the	NN	O	O
rats	NN	O	O
to	NN	O	O
the	NN	O	O
chronic	NN	O	O
ingestion	NN	O	O
of	NN	O	O
aspirin	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
tardive	NN	O	B
dyskinesia	NN	O	I
caused	NN	O	O
by	NN	O	O
metoclopramide	NN	O	O
.	NN	O	O

Abnormal	NN	O	B
involuntary	NN	O	I
movements	NN	O	I
appeared	NN	O	O
in	NN	O	O
the	NN	O	O
mouth	NN	O	O
,	NN	O	O
tongue	NN	O	O
,	NN	O	O
neck	NN	O	O
and	NN	O	O
abdomen	NN	O	O
of	NN	O	O
a	NN	O	O
64	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
patient	NN	O	O
after	NN	O	O
he	NN	O	O
took	NN	O	O
metoclopramide	NN	O	O
for	NN	O	O
gastrointestinal	NN	O	B
disorder	NN	O	I
in	NN	O	O
a	NN	O	O
regimen	NN	O	O
of	NN	O	O
30	NN	O	O
mg	NN	O	O
per	NN	O	O
day	NN	O	O
for	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
about	NN	O	O
260	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
symptoms	NN	O	O
exacerbated	NN	O	O
to	NN	O	O
a	NN	O	O
maximum	NN	O	O
in	NN	O	O
a	NN	O	O
month	NN	O	O
.	NN	O	O

When	NN	O	O
the	NN	O	O
metoclopramide	NN	O	O
administration	NN	O	O
was	NN	O	O
discontinued	NN	O	O
,	NN	O	O
the	NN	O	O
abnormal	NN	O	B
movements	NN	O	I
gradually	NN	O	O
improved	NN	O	O
to	NN	O	O
a	NN	O	O
considerable	NN	O	O
extent	NN	O	O
.	NN	O	O

Attention	NN	O	O
to	NN	O	O
the	NN	O	O
possible	NN	O	O
induction	NN	O	O
of	NN	O	O
specific	NN	O	O
tardive	NN	O	B
dyskinesia	NN	O	I
is	NN	O	O
called	NN	O	O
for	NN	O	O
in	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O

Intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
BCNU	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
malignant	NN	O	B
gliomas	NN	O	I
of	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
rapid	NN	O	O
systemic	NN	O	O
clearance	NN	O	O
of	NN	O	O
BCNU	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
bis	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
chloroethyl	NN	O	O
)	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
nitrosourea	NN	O	O
)	NN	O	O
,	NN	O	O
intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
administration	NN	O	O
should	NN	O	O
provide	NN	O	O
a	NN	O	O
substantial	NN	O	O
advantage	NN	O	O
over	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
malignant	NN	O	B
gliomas	NN	O	I
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
six	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
BCNU	NN	O	O
every	NN	O	O
6	NN	O	O
to	NN	O	O
8	NN	O	O
weeks	NN	O	O
,	NN	O	O
either	NN	O	O
by	NN	O	O
transfemoral	NN	O	O
catheterization	NN	O	O
of	NN	O	O
the	NN	O	O
internal	NN	O	O
carotid	NN	O	O
or	NN	O	O
vertebral	NN	O	O
artery	NN	O	O
or	NN	O	O
through	NN	O	O
a	NN	O	O
fully	NN	O	O
implantable	NN	O	O
intracarotid	NN	O	O
drug	NN	O	O
delivery	NN	O	O
system	NN	O	O
,	NN	O	O
beginning	NN	O	O
with	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
sq	NN	O	O
m	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
.	NN	O	O

Twelve	NN	O	O
patients	NN	O	O
with	NN	O	O
Grade	NN	O	O
III	NN	O	O
or	NN	O	O
IV	NN	O	O
astrocytomas	NN	O	B
were	NN	O	O
treated	NN	O	O
after	NN	O	O
partial	NN	O	O
resection	NN	O	O
of	NN	O	O
the	NN	O	O
tumor	NN	O	B
without	NN	O	O
prior	NN	O	O
radiation	NN	O	O
therapy	NN	O	O
.	NN	O	O

After	NN	O	O
two	NN	O	O
to	NN	O	O
seven	NN	O	O
cycles	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
,	NN	O	O
nine	NN	O	O
patients	NN	O	O
showed	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
tumor	NN	O	B
size	NN	O	O
and	NN	O	O
surrounding	NN	O	O
edema	NN	O	B
on	NN	O	O
contrast	NN	O	O
-	NN	O	O
enhanced	NN	O	O
computerized	NN	O	O
tomography	NN	O	O
scans	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
nine	NN	O	O
responders	NN	O	O
,	NN	O	O
median	NN	O	O
duration	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
response	NN	O	O
from	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
operation	NN	O	O
was	NN	O	O
25	NN	O	O
weeks	NN	O	O
(	NN	O	O
range	NN	O	O
12	NN	O	O
to	NN	O	O
more	NN	O	O
than	NN	O	O
91	NN	O	O
weeks	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
duration	NN	O	O
of	NN	O	O
survival	NN	O	O
in	NN	O	O
the	NN	O	O
12	NN	O	O
patients	NN	O	O
was	NN	O	O
54	NN	O	O
weeks	NN	O	O
(	NN	O	O
range	NN	O	O
21	NN	O	O
to	NN	O	O
more	NN	O	O
than	NN	O	O
156	NN	O	O
weeks	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
an	NN	O	O
18	NN	O	O
-	NN	O	O
month	NN	O	O
survival	NN	O	O
rate	NN	O	O
of	NN	O	O
42	NN	O	O
%	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
four	NN	O	O
patients	NN	O	O
with	NN	O	O
recurrent	NN	O	O
Grade	NN	O	O
I	NN	O	O
to	NN	O	O
IV	NN	O	O
astrocytomas	NN	O	B
,	NN	O	O
whose	NN	O	O
resection	NN	O	O
and	NN	O	O
irradiation	NN	O	O
therapy	NN	O	O
had	NN	O	O
failed	NN	O	O
,	NN	O	O
received	NN	O	O
two	NN	O	O
to	NN	O	O
eight	NN	O	O
courses	NN	O	O
of	NN	O	O
intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
BCNU	NN	O	O
therapy	NN	O	O
.	NN	O	O

Seventeen	NN	O	O
of	NN	O	O
these	NN	O	O
had	NN	O	O
a	NN	O	O
response	NN	O	O
or	NN	O	O
were	NN	O	O
stable	NN	O	O
for	NN	O	O
a	NN	O	O
median	NN	O	O
of	NN	O	O
20	NN	O	O
weeks	NN	O	O
(	NN	O	O
range	NN	O	O
6	NN	O	O
to	NN	O	O
more	NN	O	O
than	NN	O	O
66	NN	O	O
weeks	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
catheterization	NN	O	O
procedure	NN	O	O
is	NN	O	O
safe	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
immediate	NN	O	O
complication	NN	O	O
in	NN	O	O
111	NN	O	O
infusions	NN	O	O
of	NN	O	O
BCNU	NN	O	O
.	NN	O	O

A	NN	O	O
delayed	NN	O	O
complication	NN	O	O
in	NN	O	O
nine	NN	O	O
patients	NN	O	O
has	NN	O	O
been	NN	O	O
unilateral	NN	O	O
loss	NN	O	B
of	NN	O	I
vision	NN	O	I
secondary	NN	O	O
to	NN	O	O
a	NN	O	O
retinal	NN	O	B
vasculitis	NN	O	I
.	NN	O	O

The	NN	O	O
frequency	NN	O	O
of	NN	O	O
visual	NN	O	B
loss	NN	O	I
decreased	NN	O	O
after	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
the	NN	O	O
ethanol	NN	O	O
diluent	NN	O	O
was	NN	O	O
lowered	NN	O	O
.	NN	O	O

Provocation	NN	O	O
of	NN	O	O
postural	NN	O	O
hypotension	NN	O	B
by	NN	O	O
nitroglycerin	NN	O	O
in	NN	O	O
diabetic	NN	O	B
autonomic	NN	O	I
neuropathy	NN	O	I
?	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
nitroglycerin	NN	O	O
on	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
was	NN	O	O
compared	NN	O	O
in	NN	O	O
5	NN	O	O
normal	NN	O	O
subjects	NN	O	O
,	NN	O	O
12	NN	O	O
diabetic	NN	O	B
subjects	NN	O	O
without	NN	O	O
autonomic	NN	O	B
neuropathy	NN	O	I
,	NN	O	O
and	NN	O	O
5	NN	O	O
diabetic	NN	O	B
subjects	NN	O	O
with	NN	O	O
autonomic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

The	NN	O	O
magnitude	NN	O	O
and	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
after	NN	O	O
nitroglycerin	NN	O	O
were	NN	O	O
similar	NN	O	O
in	NN	O	O
the	NN	O	O
normal	NN	O	O
and	NN	O	O
diabetic	NN	O	B
subjects	NN	O	O
without	NN	O	O
autonomic	NN	O	B
neuropathy	NN	O	I
,	NN	O	O
whereas	NN	O	O
a	NN	O	O
lesser	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
a	NN	O	O
greater	NN	O	O
decrease	NN	O	O
in	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
diabetic	NN	O	B
subjects	NN	O	O
with	NN	O	O
autonomic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

It	NN	O	O
is	NN	O	O
therefore	NN	O	O
suggested	NN	O	O
that	NN	O	O
caution	NN	O	O
should	NN	O	O
be	NN	O	O
exercised	NN	O	O
when	NN	O	O
prescribing	NN	O	O
vasodilator	NN	O	O
drugs	NN	O	O
in	NN	O	O
diabetic	NN	O	B
patients	NN	O	O
,	NN	O	O
particularly	NN	O	O
those	NN	O	O
with	NN	O	O
autonomic	NN	O	B
neuropathy	NN	O	I
.	NN	O	O

Blood	NN	O	O
pressure	NN	O	O
response	NN	O	O
to	NN	O	O
chronic	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
intrarenal	NN	O	O
noradrenaline	NN	O	O
infusion	NN	O	O
in	NN	O	O
conscious	NN	O	O
rats	NN	O	O
.	NN	O	O

Sodium	NN	O	O
chloride	NN	O	O
solution	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
or	NN	O	O
noradrenaline	NN	O	O
in	NN	O	O
doses	NN	O	O
of	NN	O	O
4	NN	O	O
,	NN	O	O
12	NN	O	O
and	NN	O	O
36	NN	O	O
micrograms	NN	O	O
h	NN	O	O
-	NN	O	O
1	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
was	NN	O	O
infused	NN	O	O
for	NN	O	O
five	NN	O	O
consecutive	NN	O	O
days	NN	O	O
,	NN	O	O
either	NN	O	O
intrarenally	NN	O	O
(	NN	O	O
by	NN	O	O
a	NN	O	O
new	NN	O	O
technique	NN	O	O
)	NN	O	O
or	NN	O	O
intravenously	NN	O	O
into	NN	O	O
rats	NN	O	O
with	NN	O	O
one	NN	O	O
kidney	NN	O	O
removed	NN	O	O
.	NN	O	O

Intrarenal	NN	O	O
infusion	NN	O	O
of	NN	O	O
noradrenaline	NN	O	O
caused	NN	O	O
hypertension	NN	O	B
at	NN	O	O
doses	NN	O	O
which	NN	O	O
did	NN	O	O
not	NN	O	O
do	NN	O	O
so	NN	O	O
when	NN	O	O
infused	NN	O	O
intravenously	NN	O	O
.	NN	O	O

Intrarenal	NN	O	O
compared	NN	O	O
with	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
noradrenaline	NN	O	O
caused	NN	O	O
higher	NN	O	O
plasma	NN	O	O
noradrenaline	NN	O	O
concentrations	NN	O	O
and	NN	O	O
a	NN	O	O
shift	NN	O	O
of	NN	O	O
the	NN	O	O
plasma	NN	O	O
noradrenaline	NN	O	O
concentration	NN	O	O
-	NN	O	O
blood	NN	O	O
pressure	NN	O	O
effect	NN	O	O
curve	NN	O	O
towards	NN	O	O
lower	NN	O	O
plasma	NN	O	O
noradrenaline	NN	O	O
levels	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
hypertension	NN	O	B
after	NN	O	O
chronic	NN	O	O
intrarenal	NN	O	O
noradrenaline	NN	O	O
infusion	NN	O	O
is	NN	O	O
produced	NN	O	O
by	NN	O	O
relatively	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
circulating	NN	O	O
noradrenaline	NN	O	O
and	NN	O	O
by	NN	O	O
triggering	NN	O	O
of	NN	O	O
an	NN	O	O
additional	NN	O	O
intrarenal	NN	O	O
pressor	NN	O	O
mechanism	NN	O	O
.	NN	O	O

Characterization	NN	O	O
of	NN	O	O
estrogen	NN	O	O
-	NN	O	O
induced	NN	O	O
adenohypophyseal	NN	O	B
tumors	NN	O	I
in	NN	O	O
the	NN	O	O
Fischer	NN	O	O
344	NN	O	O
rat	NN	O	O
.	NN	O	O

Pituitary	NN	O	B
tumors	NN	O	I
were	NN	O	O
induced	NN	O	O
in	NN	O	O
F344	NN	O	O
female	NN	O	O
rats	NN	O	O
by	NN	O	O
chronic	NN	O	O
treatment	NN	O	O
with	NN	O	O
diethylstilbestrol	NN	O	O
(	NN	O	O
DES	NN	O	O
,	NN	O	O
8	NN	O	O
-	NN	O	O
10	NN	O	O
mg	NN	O	O
)	NN	O	O
implanted	NN	O	O
subcutaneously	NN	O	O
in	NN	O	O
silastic	NN	O	O
capsules	NN	O	O
.	NN	O	O

Over	NN	O	O
a	NN	O	O
range	NN	O	O
of	NN	O	O
1	NN	O	O
-	NN	O	O
150	NN	O	O
days	NN	O	O
of	NN	O	O
DES	NN	O	O
treatment	NN	O	O
,	NN	O	O
pairs	NN	O	O
of	NN	O	O
control	NN	O	O
and	NN	O	O
DES	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
were	NN	O	O
sacrificed	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
pituitaries	NN	O	O
dissociated	NN	O	O
enzymatically	NN	O	O
into	NN	O	O
single	NN	O	O
-	NN	O	O
cell	NN	O	O
preparations	NN	O	O
.	NN	O	O

The	NN	O	O
cell	NN	O	O
populations	NN	O	O
were	NN	O	O
examined	NN	O	O
regarding	NN	O	O
total	NN	O	O
cell	NN	O	O
recovery	NN	O	O
correlated	NN	O	O
with	NN	O	O
gland	NN	O	O
weight	NN	O	O
,	NN	O	O
intracellular	NN	O	O
prolactin	NN	O	O
(	NN	O	O
PRL	NN	O	O
)	NN	O	O
content	NN	O	O
and	NN	O	O
subsequent	NN	O	O
release	NN	O	O
in	NN	O	O
primary	NN	O	O
culture	NN	O	O
,	NN	O	O
immunocytochemical	NN	O	O
PRL	NN	O	O
staining	NN	O	O
,	NN	O	O
density	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
size	NN	O	O
alterations	NN	O	O
via	NN	O	O
separation	NN	O	O
on	NN	O	O
Ficoll	NN	O	O
-	NN	O	O
Hypaque	NN	O	O
and	NN	O	O
by	NN	O	O
unit	NN	O	O
gravity	NN	O	O
sedimentation	NN	O	O
,	NN	O	O
and	NN	O	O
cell	NN	O	O
cycle	NN	O	O
analysis	NN	O	O
,	NN	O	O
after	NN	O	O
acriflavine	NN	O	O
DNA	NN	O	O
staining	NN	O	O
,	NN	O	O
by	NN	O	O
laser	NN	O	O
flow	NN	O	O
cytometry	NN	O	O
.	NN	O	O

Total	NN	O	O
cell	NN	O	O
yields	NN	O	O
from	NN	O	O
DES	NN	O	O
-	NN	O	O
treated	NN	O	O
pituitaries	NN	O	O
increased	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
3	NN	O	O
times	NN	O	O
control	NN	O	O
yields	NN	O	O
at	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
to	NN	O	O
58	NN	O	O
.	NN	O	O
9	NN	O	O
times	NN	O	O
control	NN	O	O
values	NN	O	O
by	NN	O	O
day	NN	O	O
150	NN	O	O
.	NN	O	O

Intracellular	NN	O	O
PRL	NN	O	O
content	NN	O	O
ranged	NN	O	O
from	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
to	NN	O	O
9	NN	O	O
.	NN	O	O
4	NN	O	O
times	NN	O	O
control	NN	O	O
levels	NN	O	O
,	NN	O	O
and	NN	O	O
PRL	NN	O	O
release	NN	O	O
in	NN	O	O
vitro	NN	O	O
was	NN	O	O
significantly	NN	O	O
and	NN	O	O
consistently	NN	O	O
higher	NN	O	O
than	NN	O	O
controls	NN	O	O
,	NN	O	O
after	NN	O	O
at	NN	O	O
least	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
DES	NN	O	O
exposure	NN	O	O
.	NN	O	O

Beyond	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
DES	NN	O	O
exposure	NN	O	O
,	NN	O	O
the	NN	O	O
immunochemically	NN	O	O
PRL	NN	O	O
-	NN	O	O
positive	NN	O	O
proportion	NN	O	O
of	NN	O	O
cells	NN	O	O
increased	NN	O	O
to	NN	O	O
over	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
total	NN	O	O
population	NN	O	O
.	NN	O	O

Increased	NN	O	O
density	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
size	NN	O	O
and	NN	O	O
PRL	NN	O	O
content	NN	O	O
were	NN	O	O
indicated	NN	O	O
for	NN	O	O
the	NN	O	O
majority	NN	O	O
of	NN	O	O
the	NN	O	O
PRL	NN	O	O
cell	NN	O	O
population	NN	O	O
in	NN	O	O
both	NN	O	O
types	NN	O	O
of	NN	O	O
separation	NN	O	O
protocols	NN	O	O
.	NN	O	O

All	NN	O	O
these	NN	O	O
effects	NN	O	O
of	NN	O	O
DES	NN	O	O
were	NN	O	O
more	NN	O	O
pronounced	NN	O	O
among	NN	O	O
previously	NN	O	O
ovariectomized	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
extend	NN	O	O
the	NN	O	O
findings	NN	O	O
of	NN	O	O
other	NN	O	O
investigators	NN	O	O
,	NN	O	O
further	NN	O	O
establishing	NN	O	O
the	NN	O	O
DES	NN	O	O
-	NN	O	O
induced	NN	O	O
tumor	NN	O	B
as	NN	O	O
a	NN	O	O
model	NN	O	O
for	NN	O	O
study	NN	O	O
of	NN	O	O
PRL	NN	O	O
cellular	NN	O	O
control	NN	O	O
mechanisms	NN	O	O
.	NN	O	O

Age	NN	O	O
and	NN	O	O
renal	NN	O	O
clearance	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
.	NN	O	O

In	NN	O	O
35	NN	O	O
patients	NN	O	O
(	NN	O	O
ages	NN	O	O
20	NN	O	O
to	NN	O	O
86	NN	O	O
yr	NN	O	O
)	NN	O	O
receiving	NN	O	O
cimetidine	NN	O	O
therapeutically	NN	O	O
two	NN	O	O
serum	NN	O	O
samples	NN	O	O
and	NN	O	O
all	NN	O	O
urine	NN	O	O
formed	NN	O	O
in	NN	O	O
the	NN	O	O
interim	NN	O	O
were	NN	O	O
collected	NN	O	O
for	NN	O	O
analysis	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
by	NN	O	O
high	NN	O	O
-	NN	O	O
pressure	NN	O	O
liquid	NN	O	O
chromatography	NN	O	O
and	NN	O	O
for	NN	O	O
creatinine	NN	O	O
.	NN	O	O

Cimetidine	NN	O	O
clearance	NN	O	O
decreased	NN	O	O
with	NN	O	O
age	NN	O	O
.	NN	O	O

The	NN	O	O
extrapolated	NN	O	O
6	NN	O	O
-	NN	O	O
hr	NN	O	O
serum	NN	O	O
concentration	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
per	NN	O	O
unit	NN	O	O
dose	NN	O	O
,	NN	O	O
after	NN	O	O
intravenous	NN	O	O
cimetidine	NN	O	O
,	NN	O	O
increased	NN	O	O
with	NN	O	O
age	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
ratio	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
clearance	NN	O	O
to	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
(	NN	O	O
Rc	NN	O	O
)	NN	O	O
averaged	NN	O	O
4	NN	O	O
.	NN	O	O
8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
0	NN	O	O
,	NN	O	O
indicating	NN	O	O
net	NN	O	O
tubular	NN	O	O
secretion	NN	O	O
for	NN	O	O
cimetidine	NN	O	O
.	NN	O	O

Rc	NN	O	O
seemed	NN	O	O
to	NN	O	O
be	NN	O	O
independent	NN	O	O
of	NN	O	O
age	NN	O	O
and	NN	O	O
decreased	NN	O	O
with	NN	O	O
increasing	NN	O	O
serum	NN	O	O
concentration	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
secretion	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
is	NN	O	O
a	NN	O	O
saturable	NN	O	O
process	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
only	NN	O	O
one	NN	O	O
case	NN	O	O
of	NN	O	O
dementia	NN	O	B
possibly	NN	O	O
due	NN	O	O
to	NN	O	O
cimetidine	NN	O	O
(	NN	O	O
with	NN	O	O
a	NN	O	O
drug	NN	O	O
level	NN	O	O
of	NN	O	O
1	NN	O	O
.	NN	O	O
9	NN	O	O
microgram	NN	O	O
/	NN	O	O
ml	NN	O	O
6	NN	O	O
hr	NN	O	O
after	NN	O	O
a	NN	O	O
dose	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
13	NN	O	O
patients	NN	O	O
without	NN	O	O
liver	NN	O	B
or	NN	O	I
kidney	NN	O	I
disease	NN	O	I
who	NN	O	O
had	NN	O	O
cimetidine	NN	O	O
levels	NN	O	O
above	NN	O	O
1	NN	O	O
.	NN	O	O
25	NN	O	O
microgram	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
high	NN	O	O
cimetidine	NN	O	O
levels	NN	O	O
alone	NN	O	O
do	NN	O	O
not	NN	O	O
always	NN	O	O
induce	NN	O	O
dementia	NN	O	B
.	NN	O	O

Further	NN	O	O
observations	NN	O	O
on	NN	O	O
the	NN	O	O
electrophysiologic	NN	O	O
effects	NN	O	O
of	NN	O	O
oral	NN	O	O
amiodarone	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
is	NN	O	O
presented	NN	O	O
of	NN	O	O
a	NN	O	O
reversible	NN	O	O
intra	NN	O	B
-	NN	O	I
Hisian	NN	O	I
block	NN	O	I
occurring	NN	O	O
under	NN	O	O
amiodarone	NN	O	O
treatment	NN	O	O
for	NN	O	O
atrial	NN	O	B
tachycardia	NN	O	I
in	NN	O	O
a	NN	O	O
patient	NN	O	O
without	NN	O	O
clear	NN	O	O
intraventricular	NN	O	B
conduction	NN	O	I
abnormalities	NN	O	I
.	NN	O	O

His	NN	O	O
bundle	NN	O	O
recordings	NN	O	O
showed	NN	O	O
an	NN	O	O
atrial	NN	O	B
tachycardia	NN	O	I
with	NN	O	O
intermittent	NN	O	O
exit	NN	O	O
block	NN	O	O
and	NN	O	O
greatly	NN	O	O
prolonged	NN	O	O
BH	NN	O	O
and	NN	O	O
HV	NN	O	O
intervals	NN	O	O
(	NN	O	O
40	NN	O	O
and	NN	O	O
100	NN	O	O
msec	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Thirty	NN	O	O
days	NN	O	O
after	NN	O	O
amiodarone	NN	O	O
discontinuation	NN	O	O
,	NN	O	O
His	NN	O	O
bundle	NN	O	O
electrograms	NN	O	O
showed	NN	O	O
atrial	NN	O	B
flutter	NN	O	I
without	NN	O	O
intra	NN	O	O
-	NN	O	O
Hisian	NN	O	O
or	NN	O	O
infra	NN	O	O
-	NN	O	O
Hisian	NN	O	O
delay	NN	O	O
.	NN	O	O

Amiodarone	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
with	NN	O	O
caution	NN	O	O
during	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
oral	NN	O	O
therapy	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
clear	NN	O	O
intraventricular	NN	O	O
conduction	NN	O	O
defects	NN	O	O
.	NN	O	O

Development	NN	O	O
of	NN	O	O
clear	NN	O	B
cell	NN	O	I
adenocarcinoma	NN	O	I
in	NN	O	O
DES	NN	O	O
-	NN	O	O
exposed	NN	O	O
offspring	NN	O	O
under	NN	O	O
observation	NN	O	O
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
clear	NN	O	B
cell	NN	O	I
adenocarcinoma	NN	O	I
of	NN	O	I
the	NN	O	I
vagina	NN	O	I
detected	NN	O	O
at	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
in	NN	O	O
young	NN	O	O
women	NN	O	O
exposed	NN	O	O
in	NN	O	O
utero	NN	O	O
to	NN	O	O
diethylstilbestrol	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
,	NN	O	O
aged	NN	O	O
23	NN	O	O
,	NN	O	O
had	NN	O	O
been	NN	O	O
followed	NN	O	O
for	NN	O	O
2	NN	O	O
years	NN	O	O
before	NN	O	O
carcinoma	NN	O	B
was	NN	O	O
diagnosed	NN	O	O
;	NN	O	O
the	NN	O	O
second	NN	O	O
patient	NN	O	O
,	NN	O	O
aged	NN	O	O
22	NN	O	O
,	NN	O	O
had	NN	O	O
been	NN	O	O
seen	NN	O	O
on	NN	O	O
a	NN	O	O
regular	NN	O	O
basis	NN	O	O
for	NN	O	O
5	NN	O	O
years	NN	O	O
,	NN	O	O
8	NN	O	O
months	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
instances	NN	O	O
,	NN	O	O
suspicion	NN	O	O
of	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
carcinoma	NN	O	B
was	NN	O	O
aroused	NN	O	O
by	NN	O	O
the	NN	O	O
palpation	NN	O	O
of	NN	O	O
a	NN	O	O
small	NN	O	O
nodule	NN	O	O
in	NN	O	O
the	NN	O	O
vaginal	NN	O	O
fornix	NN	O	O
.	NN	O	O

Hysterosalpingography	NN	O	O
was	NN	O	O
performed	NN	O	O
on	NN	O	O
both	NN	O	O
patients	NN	O	O
and	NN	O	O
,	NN	O	O
in	NN	O	O
1	NN	O	O
instance	NN	O	O
,	NN	O	O
an	NN	O	O
abnormal	NN	O	O
x	NN	O	O
-	NN	O	O
ray	NN	O	O
film	NN	O	O
was	NN	O	O
reflected	NN	O	O
by	NN	O	O
the	NN	O	O
gross	NN	O	O
appearance	NN	O	O
of	NN	O	O
the	NN	O	O
uterine	NN	O	O
cavity	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
surgical	NN	O	O
specimen	NN	O	O
.	NN	O	O

Neurologic	NN	O	O
effects	NN	O	O
of	NN	O	O
subarachnoid	NN	O	O
administration	NN	O	O
of	NN	O	O
2	NN	O	O
-	NN	O	O
chloroprocaine	NN	O	O
-	NN	O	O
CE	NN	O	O
,	NN	O	O
bupivacaine	NN	O	O
,	NN	O	O
and	NN	O	O
low	NN	O	O
pH	NN	O	O
normal	NN	O	O
saline	NN	O	O
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
neurologic	NN	O	O
consequences	NN	O	O
of	NN	O	O
deliberate	NN	O	O
subarachnoid	NN	O	O
injection	NN	O	O
of	NN	O	O
large	NN	O	O
volumes	NN	O	O
of	NN	O	O
2	NN	O	O
-	NN	O	O
chloroprocaine	NN	O	O
-	NN	O	O
CE	NN	O	O
in	NN	O	O
experimental	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
possible	NN	O	O
role	NN	O	O
of	NN	O	O
low	NN	O	O
pH	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
total	NN	O	O
volume	NN	O	O
as	NN	O	O
potential	NN	O	O
factors	NN	O	O
in	NN	O	O
causing	NN	O	O
neurotoxicity	NN	O	B
was	NN	O	O
evaluated	NN	O	O
.	NN	O	O

The	NN	O	O
65	NN	O	O
dogs	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
received	NN	O	O
injections	NN	O	O
in	NN	O	O
the	NN	O	O
subarachnoid	NN	O	O
space	NN	O	O
as	NN	O	O
follows	NN	O	O
:	NN	O	O
6	NN	O	O
to	NN	O	O
8	NN	O	O
ml	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
15	NN	O	O
)	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
chloroprocaine	NN	O	O
-	NN	O	O
CE	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
,	NN	O	O
low	NN	O	O
pH	NN	O	O
normal	NN	O	O
saline	NN	O	O
(	NN	O	O
pH	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
normal	NN	O	O
saline	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
20	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
subarachnoid	NN	O	O
injection	NN	O	O
of	NN	O	O
2	NN	O	O
-	NN	O	O
chloroprocaine	NN	O	O
-	NN	O	O
CE	NN	O	O
seven	NN	O	O
(	NN	O	O
35	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
hind	NN	O	O
-	NN	O	O
limb	NN	O	O
paralysis	NN	O	B
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
bupivacaine	NN	O	O
,	NN	O	O
normal	NN	O	O
saline	NN	O	O
,	NN	O	O
or	NN	O	O
normal	NN	O	O
saline	NN	O	O
titrated	NN	O	O
to	NN	O	O
a	NN	O	O
pH	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
developed	NN	O	O
hind	NN	O	O
-	NN	O	O
limb	NN	O	O
paralysis	NN	O	B
.	NN	O	O

Of	NN	O	O
the	NN	O	O
15	NN	O	O
spinal	NN	O	O
cords	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
2	NN	O	O
-	NN	O	O
chloroprocaine	NN	O	O
-	NN	O	O
CE	NN	O	O
,	NN	O	O
13	NN	O	O
showed	NN	O	O
subpial	NN	O	B
necrosis	NN	O	I
;	NN	O	O
the	NN	O	O
nerve	NN	O	O
roots	NN	O	O
and	NN	O	O
subarachnoid	NN	O	O
vessels	NN	O	O
were	NN	O	O
normal	NN	O	O
.	NN	O	O

The	NN	O	O
spinal	NN	O	O
cords	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
bupivacaine	NN	O	O
,	NN	O	O
low	NN	O	O
pH	NN	O	O
normal	NN	O	O
saline	NN	O	O
(	NN	O	O
pH	NN	O	O
3	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
normal	NN	O	O
saline	NN	O	O
did	NN	O	O
not	NN	O	O
show	NN	O	O
abnormal	NN	O	O
findings	NN	O	O
.	NN	O	O

Procainamide	NN	O	O
-	NN	O	O
induced	NN	O	O
polymorphous	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
.	NN	O	O

Seven	NN	O	O
cases	NN	O	O
of	NN	O	O
procainamide	NN	O	O
-	NN	O	O
induced	NN	O	O
polymorphous	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
are	NN	O	O
presented	NN	O	O
.	NN	O	O

In	NN	O	O
four	NN	O	O
patients	NN	O	O
,	NN	O	O
polymorphous	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
appeared	NN	O	O
after	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
200	NN	O	O
to	NN	O	O
400	NN	O	O
mg	NN	O	O
of	NN	O	O
procainamide	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
sustained	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
.	NN	O	O

In	NN	O	O
the	NN	O	O
remaining	NN	O	O
three	NN	O	O
patients	NN	O	O
,	NN	O	O
procainamide	NN	O	O
was	NN	O	O
administered	NN	O	O
orally	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
chronic	NN	O	O
premature	NN	O	B
ventricular	NN	O	I
contractions	NN	O	I
or	NN	O	O
atrial	NN	O	B
flutter	NN	O	I
.	NN	O	O

These	NN	O	O
patients	NN	O	O
had	NN	O	O
Q	NN	O	B
-	NN	O	I
T	NN	O	I
prolongation	NN	O	I
and	NN	O	O
recurrent	NN	O	O
syncope	NN	O	B
due	NN	O	O
to	NN	O	O
polymorphous	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
.	NN	O	O

In	NN	O	O
four	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B
was	NN	O	O
rapidly	NN	O	O
diagnosed	NN	O	O
and	NN	O	O
treated	NN	O	O
with	NN	O	O
disappearance	NN	O	O
of	NN	O	O
further	NN	O	O
episodes	NN	O	O
of	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B
.	NN	O	O

In	NN	O	O
two	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B
degenerated	NN	O	O
into	NN	O	O
irreversible	NN	O	O
ventricular	NN	O	B
fibrillation	NN	O	I
and	NN	O	O
both	NN	O	O
patients	NN	O	O
died	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
seventh	NN	O	O
patient	NN	O	O
,	NN	O	O
a	NN	O	O
permanent	NN	O	O
ventricular	NN	O	O
pacemaker	NN	O	O
was	NN	O	O
inserted	NN	O	O
and	NN	O	O
,	NN	O	O
despite	NN	O	O
continuation	NN	O	O
of	NN	O	O
procainamide	NN	O	O
therapy	NN	O	O
,	NN	O	O
polymorphous	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
did	NN	O	O
not	NN	O	O
reoccur	NN	O	O
.	NN	O	O

These	NN	O	O
seven	NN	O	O
cases	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
procainamide	NN	O	O
can	NN	O	O
produce	NN	O	O
an	NN	O	O
acquired	NN	O	O
prolonged	NN	O	B
Q	NN	O	I
-	NN	O	I
T	NN	O	I
syndrome	NN	O	I
with	NN	O	O
polymorphous	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
.	NN	O	O

Phenobarbitone	NN	O	O
-	NN	O	O
induced	NN	O	O
enlargement	NN	O	B
of	NN	O	I
the	NN	O	I
liver	NN	O	I
in	NN	O	O
the	NN	O	O
rat	NN	O	O
:	NN	O	O
its	NN	O	O
relationship	NN	O	O
to	NN	O	O
carbon	NN	O	O
tetrachloride	NN	O	O
-	NN	O	O
induced	NN	O	O
cirrhosis	NN	O	B
.	NN	O	O

The	NN	O	O
yield	NN	O	O
of	NN	O	O
severe	NN	O	O
cirrhosis	NN	O	B
of	NN	O	I
the	NN	O	I
liver	NN	O	I
(	NN	O	O
defined	NN	O	O
as	NN	O	O
a	NN	O	O
shrunken	NN	O	O
finely	NN	O	O
nodular	NN	O	O
liver	NN	O	O
with	NN	O	O
micronodular	NN	O	O
histology	NN	O	O
,	NN	O	O
ascites	NN	O	B
greater	NN	O	O
than	NN	O	O
30	NN	O	O
ml	NN	O	O
,	NN	O	O
plasma	NN	O	O
albumin	NN	O	O
less	NN	O	O
than	NN	O	O
2	NN	O	O
.	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
,	NN	O	O
splenomegaly	NN	O	B
2	NN	O	O
-	NN	O	O
3	NN	O	O
times	NN	O	O
normal	NN	O	O
,	NN	O	O
and	NN	O	O
testicular	NN	O	O
atrophy	NN	O	B
approximately	NN	O	O
half	NN	O	O
normal	NN	O	O
weight	NN	O	O
)	NN	O	O
after	NN	O	O
12	NN	O	O
doses	NN	O	O
of	NN	O	O
carbon	NN	O	O
tetrachloride	NN	O	O
given	NN	O	O
intragastrically	NN	O	O
in	NN	O	O
the	NN	O	O
phenobarbitone	NN	O	O
-	NN	O	O
primed	NN	O	O
rat	NN	O	O
was	NN	O	O
increased	NN	O	O
from	NN	O	O
25	NN	O	O
%	NN	O	O
to	NN	O	O
56	NN	O	O
%	NN	O	O
by	NN	O	O
giving	NN	O	O
the	NN	O	O
initial	NN	O	O
"	NN	O	O
calibrating	NN	O	O
"	NN	O	O
dose	NN	O	O
of	NN	O	O
carbon	NN	O	O
tetrachloride	NN	O	O
at	NN	O	O
the	NN	O	O
peak	NN	O	O
of	NN	O	O
the	NN	O	O
phenobarbitone	NN	O	O
-	NN	O	O
induced	NN	O	O
enlargement	NN	O	B
of	NN	O	I
the	NN	O	I
liver	NN	O	I
.	NN	O	O

At	NN	O	O
this	NN	O	O
point	NN	O	O
it	NN	O	O
was	NN	O	O
assumed	NN	O	O
that	NN	O	O
the	NN	O	O
cytochrome	NN	O	O
P450	NN	O	O
/	NN	O	O
CCl4	NN	O	O
toxic	NN	O	O
state	NN	O	O
was	NN	O	O
both	NN	O	O
maximal	NN	O	O
and	NN	O	O
stable	NN	O	O
.	NN	O	O

The	NN	O	O
optimal	NN	O	O
rat	NN	O	O
size	NN	O	O
to	NN	O	O
begin	NN	O	O
phenobarbitone	NN	O	O
was	NN	O	O
determined	NN	O	O
as	NN	O	O
100	NN	O	O
g	NN	O	O
,	NN	O	O
and	NN	O	O
this	NN	O	O
size	NN	O	O
as	NN	O	O
a	NN	O	O
group	NN	O	O
had	NN	O	O
a	NN	O	O
mean	NN	O	O
maximum	NN	O	O
relative	NN	O	O
liver	NN	O	O
weight	NN	O	O
increase	NN	O	O
47	NN	O	O
%	NN	O	O
greater	NN	O	O
than	NN	O	O
normal	NN	O	O
rats	NN	O	O
of	NN	O	O
the	NN	O	O
same	NN	O	O
body	NN	O	O
weight	NN	O	O
.	NN	O	O

The	NN	O	O
optimal	NN	O	O
time	NN	O	O
for	NN	O	O
the	NN	O	O
initial	NN	O	O
dose	NN	O	O
of	NN	O	O
carbon	NN	O	O
tetrachloride	NN	O	O
was	NN	O	O
after	NN	O	O
14	NN	O	O
days	NN	O	O
on	NN	O	O
phenobarbitone	NN	O	O
.	NN	O	O

Triamterene	NN	O	O
nephrolithiasis	NN	O	B
complicating	NN	O	O
dyazide	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
triamterene	NN	O	O
nephrolithiasis	NN	O	B
is	NN	O	O
reported	NN	O	O
in	NN	O	O
a	NN	O	O
man	NN	O	O
after	NN	O	O
4	NN	O	O
years	NN	O	O
of	NN	O	O
hydrochlorothiazide	NN	O	O
-	NN	O	O
triamterene	NN	O	O
therapy	NN	O	O
for	NN	O	O
hypertension	NN	O	B
.	NN	O	O

The	NN	O	O
stone	NN	O	O
passed	NN	O	O
spontaneously	NN	O	O
and	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
contain	NN	O	O
a	NN	O	O
triamterene	NN	O	O
metabolite	NN	O	O
admixed	NN	O	O
with	NN	O	O
uric	NN	O	O
acid	NN	O	O
salts	NN	O	O
.	NN	O	O

Factors	NN	O	O
affecting	NN	O	O
triamterene	NN	O	O
nephrolithiasis	NN	O	B
are	NN	O	O
discussed	NN	O	O
and	NN	O	O
2	NN	O	O
previously	NN	O	O
reported	NN	O	O
cases	NN	O	O
are	NN	O	O
reviewed	NN	O	O
.	NN	O	O

Busulfan	NN	O	O
-	NN	O	O
induced	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
busulfan	NN	O	O
-	NN	O	O
induced	NN	O	O
hemorrhage	NN	O	B
cystitis	NN	O	I
is	NN	O	O
reported	NN	O	O
.	NN	O	O

Spontaneous	NN	O	O
resolution	NN	O	O
occurred	NN	O	O
following	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

The	NN	O	O
similarity	NN	O	O
between	NN	O	O
the	NN	O	O
histologic	NN	O	O
appearances	NN	O	O
of	NN	O	O
busulfan	NN	O	O
cystitis	NN	O	B
and	NN	O	O
both	NN	O	O
radiation	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B
is	NN	O	O
discussed	NN	O	O
and	NN	O	O
the	NN	O	O
world	NN	O	O
literature	NN	O	O
reviewed	NN	O	O
.	NN	O	O

In	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
known	NN	O	O
tendency	NN	O	O
of	NN	O	O
busulfan	NN	O	O
to	NN	O	O
induce	NN	O	O
cellular	NN	O	O
atypia	NN	O	O
and	NN	O	O
carcinoma	NN	O	B
in	NN	O	O
other	NN	O	O
sites	NN	O	O
,	NN	O	O
periodic	NN	O	O
urinary	NN	O	O
cytology	NN	O	O
is	NN	O	O
suggested	NN	O	O
in	NN	O	O
patients	NN	O	O
on	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
therapy	NN	O	O
.	NN	O	O

Variant	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
in	NN	O	O
desipramine	NN	O	O
toxicity	NN	O	B
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
variant	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
induced	NN	O	O
by	NN	O	O
desipramine	NN	O	O
toxicity	NN	O	B
.	NN	O	O

Unusual	NN	O	O
features	NN	O	O
of	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B
are	NN	O	O
repetitive	NN	O	O
group	NN	O	O
beating	NN	O	O
,	NN	O	O
progressive	NN	O	O
shortening	NN	O	O
of	NN	O	O
the	NN	O	O
R	NN	O	O
-	NN	O	O
R	NN	O	O
interval	NN	O	O
,	NN	O	O
progressive	NN	O	O
widening	NN	O	O
of	NN	O	O
the	NN	O	O
QRS	NN	O	O
complex	NN	O	O
with	NN	O	O
eventual	NN	O	O
failure	NN	O	O
of	NN	O	O
intraventricular	NN	O	O
conduction	NN	O	O
,	NN	O	O
and	NN	O	O
changes	NN	O	O
in	NN	O	O
direction	NN	O	O
of	NN	O	O
the	NN	O	O
QRS	NN	O	O
axis	NN	O	O
.	NN	O	O

Recognition	NN	O	O
of	NN	O	O
variant	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
is	NN	O	O
important	NN	O	O
because	NN	O	O
therapy	NN	O	O
differs	NN	O	O
from	NN	O	O
that	NN	O	O
of	NN	O	O
classic	NN	O	O
ventricular	NN	O	B
tachycardia	NN	O	I
.	NN	O	O

Rebound	NN	O	O
hypertensive	NN	O	B
after	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
prevented	NN	O	O
by	NN	O	O
saralasin	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
renin	NN	O	O
-	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
in	NN	O	O
the	NN	O	O
maintenance	NN	O	O
of	NN	O	O
blood	NN	O	O
pressure	NN	O	O
during	NN	O	O
halothane	NN	O	O
anesthesia	NN	O	O
and	NN	O	O
sodium	NN	O	O
nitroprusside	NN	O	O
(	NN	O	O
SNP	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
was	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Control	NN	O	O
rats	NN	O	O
received	NN	O	O
halothane	NN	O	O
anesthesia	NN	O	O
(	NN	O	O
1	NN	O	O
MAC	NN	O	O
)	NN	O	O
for	NN	O	O
one	NN	O	O
hour	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
SNP	NN	O	O
infusion	NN	O	O
,	NN	O	O
40	NN	O	O
microgram	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
for	NN	O	O
30	NN	O	O
min	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
30	NN	O	O
-	NN	O	O
min	NN	O	O
recovery	NN	O	O
period	NN	O	O
.	NN	O	O

A	NN	O	O
second	NN	O	O
group	NN	O	O
of	NN	O	O
rats	NN	O	O
was	NN	O	O
treated	NN	O	O
identically	NN	O	O
and	NN	O	O
,	NN	O	O
in	NN	O	O
addition	NN	O	O
,	NN	O	O
received	NN	O	O
an	NN	O	O
infusion	NN	O	O
of	NN	O	O
saralasin	NN	O	O
(	NN	O	O
a	NN	O	O
competitive	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
)	NN	O	O
throughout	NN	O	O
the	NN	O	O
experimental	NN	O	O
period	NN	O	O
.	NN	O	O

In	NN	O	O
each	NN	O	O
group	NN	O	O
,	NN	O	O
SNP	NN	O	O
infusion	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
initial	NN	O	O
decrease	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
from	NN	O	O
86	NN	O	O
torr	NN	O	O
and	NN	O	O
83	NN	O	O
torr	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
to	NN	O	O
48	NN	O	O
torr	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
SNP	NN	O	O
infusion	NN	O	O
the	NN	O	O
control	NN	O	O
animals	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
progressive	NN	O	O
increase	NN	O	B
in	NN	O	I
blood	NN	O	I
pressure	NN	O	I
to	NN	O	O
61	NN	O	O
torr	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
saralasin	NN	O	O
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
showed	NN	O	O
no	NN	O	O
change	NN	O	O
.	NN	O	O

Following	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
SNP	NN	O	O
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
animals	NN	O	O
rebounded	NN	O	O
to	NN	O	O
94	NN	O	O
torr	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
78	NN	O	O
torr	NN	O	O
in	NN	O	O
the	NN	O	O
saralasin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
indicates	NN	O	O
that	NN	O	O
with	NN	O	O
stable	NN	O	O
halothane	NN	O	O
anesthesia	NN	O	O
,	NN	O	O
the	NN	O	O
partial	NN	O	O
recovery	NN	O	O
of	NN	O	O
blood	NN	O	O
pressure	NN	O	O
during	NN	O	O
SNP	NN	O	O
infusion	NN	O	O
and	NN	O	O
the	NN	O	O
post	NN	O	O
-	NN	O	O
SNP	NN	O	O
rebound	NN	O	O
of	NN	O	O
blood	NN	O	O
pressure	NN	O	O
can	NN	O	O
be	NN	O	O
completely	NN	O	O
blocked	NN	O	O
by	NN	O	O
saralasin	NN	O	O
.	NN	O	O

This	NN	O	O
demonstrates	NN	O	O
the	NN	O	O
participation	NN	O	O
of	NN	O	O
the	NN	O	O
renin	NN	O	O
-	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
in	NN	O	O
antagonizing	NN	O	O
the	NN	O	O
combined	NN	O	O
hypotensive	NN	O	B
effects	NN	O	O
of	NN	O	O
halothane	NN	O	O
and	NN	O	O
SNP	NN	O	O
.	NN	O	O

Clinical	NN	O	O
nephrotoxicity	NN	O	B
of	NN	O	O
tobramycin	NN	O	O
and	NN	O	O
gentamicin	NN	O	O
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
study	NN	O	O
.	NN	O	O

Nearly	NN	O	O
3	NN	O	O
.	NN	O	O
2	NN	O	O
million	NN	O	O
people	NN	O	O
in	NN	O	O
this	NN	O	O
country	NN	O	O
receive	NN	O	O
aminoglycoside	NN	O	O
antibiotics	NN	O	O
annually	NN	O	O
.	NN	O	O

Gentamicin	NN	O	O
sulfate	NN	O	O
and	NN	O	O
tobramycin	NN	O	O
sulfate	NN	O	O
continue	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
ototoxicity	NN	O	B
and	NN	O	O
nephrotoxicity	NN	O	B
in	NN	O	O
both	NN	O	O
animal	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
62	NN	O	O
patients	NN	O	O
with	NN	O	O
confirmed	NN	O	O
initial	NN	O	O
normal	NN	O	O
renal	NN	O	O
function	NN	O	O
and	NN	O	O
treated	NN	O	O
with	NN	O	O
2	NN	O	O
to	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
of	NN	O	O
gentamicin	NN	O	O
sulfate	NN	O	O
or	NN	O	O
tobramycin	NN	O	O
sulfate	NN	O	O
for	NN	O	O
a	NN	O	O
minimum	NN	O	O
of	NN	O	O
seven	NN	O	O
days	NN	O	O
were	NN	O	O
followed	NN	O	O
up	NN	O	O
prospectively	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
aminoglycoside	NN	O	O
-	NN	O	O
related	NN	O	O
renal	NN	O	B
failure	NN	O	I
,	NN	O	O
defined	NN	O	O
as	NN	O	O
at	NN	O	O
least	NN	O	O
a	NN	O	O
one	NN	O	O
-	NN	O	O
third	NN	O	O
reduction	NN	O	O
in	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

In	NN	O	O
these	NN	O	O
62	NN	O	O
patients	NN	O	O
,	NN	O	O
no	NN	O	O
other	NN	O	O
causes	NN	O	O
for	NN	O	O
renal	NN	O	B
failure	NN	O	I
could	NN	O	O
be	NN	O	O
identified	NN	O	O
.	NN	O	O

Five	NN	O	O
of	NN	O	O
33	NN	O	O
(	NN	O	O
15	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
tobramycin	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
and	NN	O	O
16	NN	O	O
of	NN	O	O
29	NN	O	O
(	NN	O	O
55	NN	O	O
.	NN	O	O
2	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
gentamicin	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
had	NN	O	O
renal	NN	O	B
failure	NN	O	I
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
gentamicin	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
renal	NN	O	B
failure	NN	O	I
more	NN	O	O
than	NN	O	O
three	NN	O	O
times	NN	O	O
as	NN	O	O
often	NN	O	O
as	NN	O	O
was	NN	O	O
tobramycin	NN	O	O
.	NN	O	O

Metabolic	NN	O	O
involvement	NN	O	O
in	NN	O	O
adriamycin	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

The	NN	O	O
cardiotoxic	NN	O	B
effects	NN	O	O
of	NN	O	O
adriamycin	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
mammalian	NN	O	O
myocardial	NN	O	O
cells	NN	O	O
in	NN	O	O
culture	NN	O	O
as	NN	O	O
a	NN	O	O
model	NN	O	O
system	NN	O	O
.	NN	O	O

Adriamycin	NN	O	O
inhibited	NN	O	O
cell	NN	O	O
growth	NN	O	O
and	NN	O	O
the	NN	O	O
rhythmic	NN	O	O
contractions	NN	O	O
characteristic	NN	O	O
of	NN	O	O
myocardial	NN	O	O
cells	NN	O	O
in	NN	O	O
culture	NN	O	O
.	NN	O	O

A	NN	O	O
possible	NN	O	O
involvement	NN	O	O
of	NN	O	O
energy	NN	O	O
metabolism	NN	O	O
was	NN	O	O
suggested	NN	O	O
previously	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
the	NN	O	O
adenylate	NN	O	O
energy	NN	O	O
charge	NN	O	O
and	NN	O	O
phosphorylcreatine	NN	O	O
mole	NN	O	O
fraction	NN	O	O
were	NN	O	O
determined	NN	O	O
in	NN	O	O
the	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
treated	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
adenylate	NN	O	O
energy	NN	O	O
charge	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
phophorylcreatine	NN	O	O
mole	NN	O	O
fraction	NN	O	O
was	NN	O	O
unchanged	NN	O	O
.	NN	O	O

Such	NN	O	O
disparity	NN	O	O
suggests	NN	O	O
an	NN	O	O
inhibition	NN	O	O
of	NN	O	O
creatine	NN	O	O
phosphokinase	NN	O	O
.	NN	O	O

The	NN	O	O
addition	NN	O	O
of	NN	O	O
1	NN	O	O
mM	NN	O	O
adenosine	NN	O	O
to	NN	O	O
the	NN	O	O
myocardial	NN	O	O
cell	NN	O	O
cultures	NN	O	O
markedly	NN	O	O
increases	NN	O	O
the	NN	O	O
ATP	NN	O	O
concentration	NN	O	O
through	NN	O	O
a	NN	O	O
pathway	NN	O	O
reportedly	NN	O	O
leading	NN	O	O
to	NN	O	O
a	NN	O	O
compartmentalized	NN	O	O
ATP	NN	O	O
pool	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
adriamycin	NN	O	O
-	NN	O	O
treated	NN	O	O
cells	NN	O	O
,	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
adenosine	NN	O	O
increased	NN	O	O
the	NN	O	O
adenylate	NN	O	O
charge	NN	O	O
and	NN	O	O
,	NN	O	O
concomitant	NN	O	O
with	NN	O	O
this	NN	O	O
inrcease	NN	O	O
,	NN	O	O
the	NN	O	O
cells	NN	O	O
'	NN	O	O
functional	NN	O	O
integrity	NN	O	O
,	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
percentage	NN	O	O
of	NN	O	O
beating	NN	O	O
cells	NN	O	O
and	NN	O	O
rate	NN	O	O
of	NN	O	O
contractions	NN	O	O
,	NN	O	O
was	NN	O	O
maintained	NN	O	O
.	NN	O	O

Age	NN	O	O
-	NN	O	O
dependent	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
to	NN	O	O
neurotoxic	NN	O	B
effects	NN	O	O
of	NN	O	O
streptomycin	NN	O	O
.	NN	O	O

Streptomycin	NN	O	O
sulfate	NN	O	O
(	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
)	NN	O	O
was	NN	O	O
injected	NN	O	O
for	NN	O	O
various	NN	O	O
periods	NN	O	O
into	NN	O	O
preweanling	NN	O	O
rats	NN	O	O
and	NN	O	O
for	NN	O	O
3	NN	O	O
weeks	NN	O	O
into	NN	O	O
weanling	NN	O	O
rats	NN	O	O
.	NN	O	O

Beginning	NN	O	O
at	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
body	NN	O	O
movement	NN	O	O
and	NN	O	O
hearing	NN	O	O
were	NN	O	O
examined	NN	O	O
for	NN	O	O
6	NN	O	O
and	NN	O	O
up	NN	O	O
to	NN	O	O
17	NN	O	O
weeks	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Abnormal	NN	O	B
movements	NN	O	I
and	NN	O	O
deafness	NN	O	B
occurred	NN	O	O
only	NN	O	O
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
during	NN	O	O
the	NN	O	O
preweaning	NN	O	O
period	NN	O	O
;	NN	O	O
within	NN	O	O
this	NN	O	O
period	NN	O	O
the	NN	O	O
greatest	NN	O	O
sensitivities	NN	O	O
for	NN	O	O
these	NN	O	O
abnormalities	NN	O	O
occurred	NN	O	O
from	NN	O	O
2	NN	O	O
to	NN	O	O
11	NN	O	O
-	NN	O	O
17	NN	O	O
and	NN	O	O
5	NN	O	O
to	NN	O	O
11	NN	O	O
days	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
cochlea	NN	O	O
is	NN	O	O
more	NN	O	O
sensitive	NN	O	O
to	NN	O	O
streptomycin	NN	O	O
than	NN	O	O
the	NN	O	O
site	NN	O	O
(	NN	O	O
vestibular	NN	O	O
or	NN	O	O
central	NN	O	O
)	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
dyskinesias	NN	O	B
.	NN	O	O

Late	NN	O	O
,	NN	O	O
late	NN	O	O
doxorubicin	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Cardiac	NN	O	B
toxicity	NN	O	I
is	NN	O	O
a	NN	O	O
major	NN	O	O
complication	NN	O	O
which	NN	O	O
limits	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
adriamycin	NN	O	O
as	NN	O	O
a	NN	O	O
chemotherapeutic	NN	O	O
agent	NN	O	O
.	NN	O	O

Cardiomyopathy	NN	O	B
is	NN	O	O
frequent	NN	O	O
when	NN	O	O
the	NN	O	O
total	NN	O	O
dose	NN	O	O
exceeds	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
and	NN	O	O
occurs	NN	O	O
within	NN	O	O
one	NN	O	O
to	NN	O	O
six	NN	O	O
months	NN	O	O
after	NN	O	O
cessation	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
is	NN	O	O
reported	NN	O	O
who	NN	O	O
developed	NN	O	O
progressive	NN	O	O
cardiomyopathy	NN	O	B
two	NN	O	O
and	NN	O	O
one	NN	O	O
-	NN	O	O
half	NN	O	O
years	NN	O	O
after	NN	O	O
receiving	NN	O	O
580	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
which	NN	O	O
apparently	NN	O	O
represents	NN	O	O
late	NN	O	O
,	NN	O	O
late	NN	O	O
cardiotoxicity	NN	O	B
.	NN	O	O

Attenuation	NN	O	O
of	NN	O	O
the	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B
-	NN	O	I
insipidus	NN	O	I
-	NN	O	I
like	NN	O	I
syndrome	NN	O	I
by	NN	O	O
amiloride	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
amiloride	NN	O	O
on	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
polydipsia	NN	O	B
and	NN	O	O
polyuria	NN	O	B
and	NN	O	O
on	NN	O	O
the	NN	O	O
lithium	NN	O	O
concentration	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
,	NN	O	O
brain	NN	O	O
,	NN	O	O
kidney	NN	O	O
,	NN	O	O
thyroid	NN	O	O
and	NN	O	O
red	NN	O	O
blood	NN	O	O
cells	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
rats	NN	O	O
,	NN	O	O
chronically	NN	O	O
treated	NN	O	O
with	NN	O	O
LiCl	NN	O	O
.	NN	O	O

Amiloride	NN	O	O
reduced	NN	O	O
the	NN	O	O
drinking	NN	O	O
and	NN	O	O
urine	NN	O	O
volume	NN	O	O
of	NN	O	O
rats	NN	O	O
in	NN	O	O
an	NN	O	O
acute	NN	O	O
(	NN	O	O
6	NN	O	O
or	NN	O	O
12	NN	O	O
h	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
subacute	NN	O	O
(	NN	O	O
3	NN	O	O
days	NN	O	O
)	NN	O	O
experiment	NN	O	O
.	NN	O	O

6	NN	O	O
h	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
amiloride	NN	O	O
,	NN	O	O
a	NN	O	O
reduction	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
lithium	NN	O	O
content	NN	O	O
of	NN	O	O
the	NN	O	O
renal	NN	O	O
medulla	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
organs	NN	O	O
studied	NN	O	O
.	NN	O	O

At	NN	O	O
12	NN	O	O
h	NN	O	O
,	NN	O	O
all	NN	O	O
the	NN	O	O
tissues	NN	O	O
showed	NN	O	O
a	NN	O	O
slight	NN	O	O
increase	NN	O	O
in	NN	O	O
lithium	NN	O	O
levels	NN	O	O
.	NN	O	O

After	NN	O	O
3	NN	O	O
days	NN	O	O
of	NN	O	O
combined	NN	O	O
treatment	NN	O	O
,	NN	O	O
a	NN	O	O
marked	NN	O	O
elevation	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
tissue	NN	O	O
lithium	NN	O	O
levels	NN	O	O
accompanied	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
water	NN	O	O
intake	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
the	NN	O	O
experiments	NN	O	O
,	NN	O	O
the	NN	O	O
attenuation	NN	O	O
of	NN	O	O
the	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B
-	NN	O	I
insipidus	NN	O	I
-	NN	O	I
like	NN	O	I
syndrome	NN	O	I
by	NN	O	O
amiloride	NN	O	O
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
ratio	NN	O	O
between	NN	O	O
the	NN	O	O
lithium	NN	O	O
concentration	NN	O	O
in	NN	O	O
the	NN	O	O
renal	NN	O	O
medulla	NN	O	O
and	NN	O	O
its	NN	O	O
levels	NN	O	O
in	NN	O	O
the	NN	O	O
blood	NN	O	O
and	NN	O	O
an	NN	O	O
elevation	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
potassium	NN	O	O
level	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
acute	NN	O	O
amiloride	NN	O	O
administration	NN	O	O
to	NN	O	O
lithium	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
suffering	NN	O	O
from	NN	O	O
polydipsia	NN	O	B
and	NN	O	O
polyuria	NN	O	B
might	NN	O	O
relieve	NN	O	O
these	NN	O	O
patients	NN	O	O
but	NN	O	O
prolonged	NN	O	O
amiloride	NN	O	O
supplementation	NN	O	O
would	NN	O	O
result	NN	O	O
in	NN	O	O
elevated	NN	O	O
lithium	NN	O	O
levels	NN	O	O
and	NN	O	O
might	NN	O	O
be	NN	O	O
hazardous	NN	O	O
.	NN	O	O

Cardiovascular	NN	O	B
complications	NN	O	I
associated	NN	O	O
with	NN	O	O
terbutaline	NN	O	O
treatment	NN	O	O
for	NN	O	O
preterm	NN	O	B
labor	NN	O	I
.	NN	O	O

Severe	NN	O	O
cardiovascular	NN	O	B
complications	NN	O	I
occurred	NN	O	O
in	NN	O	O
eight	NN	O	O
of	NN	O	O
160	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
terbutaline	NN	O	O
for	NN	O	O
preterm	NN	O	B
labor	NN	O	I
.	NN	O	O

Associated	NN	O	O
corticosteroid	NN	O	O
therapy	NN	O	O
and	NN	O	O
twin	NN	O	O
gestations	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
predisposing	NN	O	O
factors	NN	O	O
.	NN	O	O

Potential	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
are	NN	O	O
briefly	NN	O	O
discussed	NN	O	O
.	NN	O	O

Toxic	NN	O	B
hepatitis	NN	O	I
induced	NN	O	O
by	NN	O	O
antithyroid	NN	O	O
drugs	NN	O	O
:	NN	O	O
four	NN	O	O
cases	NN	O	O
including	NN	O	O
one	NN	O	O
with	NN	O	O
cross	NN	O	O
-	NN	O	O
reactivity	NN	O	O
between	NN	O	O
carbimazole	NN	O	O
and	NN	O	O
benzylthiouracil	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
hepatic	NN	O	B
adverse	NN	O	I
effects	NN	O	I
encountered	NN	O	O
with	NN	O	O
antithyroid	NN	O	O
drugs	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Retrospective	NN	O	O
review	NN	O	O
of	NN	O	O
medical	NN	O	O
records	NN	O	O
of	NN	O	O
236	NN	O	O
patients	NN	O	O
with	NN	O	O
hyperthyroidism	NN	O	B
admitted	NN	O	O
in	NN	O	O
our	NN	O	O
department	NN	O	O
(	NN	O	O
in	NN	O	O
-	NN	O	O
or	NN	O	O
out	NN	O	O
-	NN	O	O
patients	NN	O	O
)	NN	O	O
from	NN	O	O
1986	NN	O	O
to	NN	O	O
1992	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Four	NN	O	O
patients	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
identified	NN	O	O
with	NN	O	O
toxic	NN	O	B
hepatitis	NN	O	I
which	NN	O	O
could	NN	O	O
reasonably	NN	O	O
be	NN	O	O
attributed	NN	O	O
to	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
antithyroid	NN	O	O
agent	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
cholestatic	NN	O	B
hepatitis	NN	O	I
induced	NN	O	O
by	NN	O	O
carbimazole	NN	O	O
(	NN	O	O
N	NN	O	O
omercazole	NN	O	O
)	NN	O	O
.	NN	O	O

Two	NN	O	O
others	NN	O	O
had	NN	O	O
a	NN	O	O
mixed	NN	O	O
(	NN	O	O
cholestatic	NN	O	B
and	NN	O	O
cytolytic	NN	O	O
)	NN	O	O
hepatitis	NN	O	B
following	NN	O	O
carbimazole	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
latter	NN	O	O
two	NN	O	O
patients	NN	O	O
further	NN	O	O
experienced	NN	O	O
a	NN	O	O
cytolytic	NN	O	O
hepatitis	NN	O	B
which	NN	O	O
appeared	NN	O	O
after	NN	O	O
Benzylthiouracil	NN	O	O
(	NN	O	O
Basd	NN	O	O
ne	NN	O	O
)	NN	O	O
had	NN	O	O
replaced	NN	O	O
carbimazole	NN	O	O
.	NN	O	O

Biological	NN	O	O
features	NN	O	O
of	NN	O	O
hepatitis	NN	O	B
disappeared	NN	O	O
in	NN	O	O
all	NN	O	O
cases	NN	O	O
after	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
incriminated	NN	O	O
drug	NN	O	O
,	NN	O	O
while	NN	O	O
biliary	NN	O	O
,	NN	O	O
viral	NN	O	O
and	NN	O	O
immunological	NN	O	O
searches	NN	O	O
were	NN	O	O
negative	NN	O	O
.	NN	O	O

Only	NN	O	O
2	NN	O	O
patients	NN	O	O
of	NN	O	O
our	NN	O	O
retrospective	NN	O	O
study	NN	O	O
experienced	NN	O	O
a	NN	O	O
mild	NN	O	O
or	NN	O	O
severe	NN	O	O
neutropenia	NN	O	B
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Toxic	NN	O	B
hepatitis	NN	O	I
is	NN	O	O
a	NN	O	O
potential	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
antithyroid	NN	O	O
drugs	NN	O	O
which	NN	O	O
warrants	NN	O	O
,	NN	O	O
as	NN	O	O
for	NN	O	O
haematological	NN	O	O
disturbances	NN	O	O
,	NN	O	O
a	NN	O	O
pre	NN	O	O
-	NN	O	O
therapeutic	NN	O	O
determination	NN	O	O
and	NN	O	O
a	NN	O	O
careful	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
relevant	NN	O	O
biological	NN	O	O
markers	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
hepatotoxicity	NN	O	B
may	NN	O	O
not	NN	O	O
be	NN	O	O
restricted	NN	O	O
to	NN	O	O
one	NN	O	O
class	NN	O	O
of	NN	O	O
antithyroid	NN	O	O
agents	NN	O	O
.	NN	O	O

Interactive	NN	O	O
effects	NN	O	O
of	NN	O	O
variations	NN	O	O
in	NN	O	O
[	NN	O	O
Na	NN	O	O
]	NN	O	O
o	NN	O	O
and	NN	O	O
[	NN	O	O
Ca	NN	O	O
]	NN	O	O
o	NN	O	O
on	NN	O	O
rat	NN	O	O
atrial	NN	O	O
spontaneous	NN	O	O
frequency	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
varying	NN	O	O
the	NN	O	O
extracellular	NN	O	O
concentrations	NN	O	O
of	NN	O	O
Na	NN	O	O
and	NN	O	O
Ca	NN	O	O
(	NN	O	O
[	NN	O	O
Na	NN	O	O
]	NN	O	O
o	NN	O	O
and	NN	O	O
[	NN	O	O
Ca	NN	O	O
]	NN	O	O
o	NN	O	O
)	NN	O	O
on	NN	O	O
both	NN	O	O
,	NN	O	O
the	NN	O	O
spontaneous	NN	O	O
beating	NN	O	O
and	NN	O	O
the	NN	O	O
negative	NN	O	O
chronotropic	NN	O	O
action	NN	O	O
of	NN	O	O
verapamil	NN	O	O
,	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
the	NN	O	O
isolated	NN	O	O
rat	NN	O	O
atria	NN	O	O
.	NN	O	O

Basal	NN	O	O
frequency	NN	O	O
(	NN	O	O
BF	NN	O	O
)	NN	O	O
evaluated	NN	O	O
by	NN	O	O
surface	NN	O	O
electrogram	NN	O	O
was	NN	O	O
223	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
beats	NN	O	O
/	NN	O	O
min	NN	O	O
.	NN	O	O
in	NN	O	O
control	NN	O	O
Krebs	NN	O	O
-	NN	O	O
Ringer	NN	O	O
containing	NN	O	O
137	NN	O	O
mM	NN	O	O
Na	NN	O	O
and	NN	O	O
1	NN	O	O
.	NN	O	O
35	NN	O	O
mM	NN	O	O
Ca	NN	O	O
(	NN	O	O
N	NN	O	O
)	NN	O	O
.	NN	O	O

It	NN	O	O
decreased	NN	O	O
by	NN	O	O
16	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
%	NN	O	O
by	NN	O	O
lowering	NN	O	O
[	NN	O	O
Na	NN	O	O
]	NN	O	O
o	NN	O	O
to	NN	O	O
78	NN	O	O
mM	NN	O	O
(	NN	O	O
LNa	NN	O	O
)	NN	O	O
,	NN	O	O
23	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
%	NN	O	O
by	NN	O	O
lowering	NN	O	O
simultaneously	NN	O	O
[	NN	O	O
Na	NN	O	O
]	NN	O	O
o	NN	O	O
to	NN	O	O
78	NN	O	O
mM	NN	O	O
and	NN	O	O
[	NN	O	O
Ca	NN	O	O
]	NN	O	O
o	NN	O	O
to	NN	O	O
0	NN	O	O
.	NN	O	O
675	NN	O	O
mM	NN	O	O
(	NN	O	O
LNa	NN	O	O
+	NN	O	O
LCa	NN	O	O
)	NN	O	O
and	NN	O	O
31	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
%	NN	O	O
by	NN	O	O
lowering	NN	O	O
[	NN	O	O
Na	NN	O	O
]	NN	O	O
o	NN	O	O
to	NN	O	O
78	NN	O	O
mM	NN	O	O
plus	NN	O	O
increasing	NN	O	O
[	NN	O	O
Ca	NN	O	O
]	NN	O	O
o	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
mM	NN	O	O
(	NN	O	O
LNa	NN	O	O
+	NN	O	O
HCa	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
normal	NN	O	O
[	NN	O	O
Na	NN	O	O
]	NN	O	O
o	NN	O	O
,	NN	O	O
decrease	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
675	NN	O	O
mM	NN	O	O
)	NN	O	O
or	NN	O	O
increase	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
6	NN	O	O
mM	NN	O	O
)	NN	O	O
of	NN	O	O
[	NN	O	O
Ca	NN	O	O
]	NN	O	O
o	NN	O	O
did	NN	O	O
not	NN	O	O
modify	NN	O	O
BF	NN	O	O
;	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
ten	NN	O	O
times	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
135	NN	O	O
mM	NN	O	O
of	NN	O	O
normal	NN	O	O
[	NN	O	O
Ca	NN	O	O
]	NN	O	O
o	NN	O	O
was	NN	O	O
effective	NN	O	O
to	NN	O	O
reduce	NN	O	O
BF	NN	O	O
by	NN	O	O
40	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
%	NN	O	O
.	NN	O	O

All	NN	O	O
negative	NN	O	O
chronotropic	NN	O	O
effects	NN	O	O
were	NN	O	O
BF	NN	O	O
-	NN	O	O
dependent	NN	O	O
.	NN	O	O

Dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
bradycardia	NN	O	B
induced	NN	O	O
by	NN	O	O
verapamil	NN	O	O
was	NN	O	O
potentiated	NN	O	O
by	NN	O	O
LNa	NN	O	O
,	NN	O	O
LCa	NN	O	O
,	NN	O	O
and	NN	O	O
HCa	NN	O	O
.	NN	O	O

Independent	NN	O	O
but	NN	O	O
not	NN	O	O
additive	NN	O	O
effects	NN	O	O
of	NN	O	O
Na	NN	O	O
and	NN	O	O
Ca	NN	O	O
are	NN	O	O
shown	NN	O	O
by	NN	O	O
decreases	NN	O	O
in	NN	O	O
the	NN	O	O
values	NN	O	O
of	NN	O	O
[	NN	O	O
verapamil	NN	O	O
]	NN	O	O
o	NN	O	O
needed	NN	O	O
to	NN	O	O
reduce	NN	O	O
BF	NN	O	O
by	NN	O	O
30	NN	O	O
%	NN	O	O
(	NN	O	O
IC30	NN	O	O
)	NN	O	O
with	NN	O	O
the	NN	O	O
following	NN	O	O
order	NN	O	O
of	NN	O	O
inhibitory	NN	O	O
potency	NN	O	O
:	NN	O	O
LNa	NN	O	O
>	NN	O	O
LCa	NN	O	O
>	NN	O	O
HCa	NN	O	O
>	NN	O	O
N	NN	O	O
,	NN	O	O
resulting	NN	O	O
LNa	NN	O	O
+	NN	O	O
HCa	NN	O	O
similar	NN	O	O
to	NN	O	O
LNa	NN	O	O
.	NN	O	O

The	NN	O	O
[	NN	O	O
verapamil	NN	O	O
]	NN	O	O
o	NN	O	O
that	NN	O	O
arrested	NN	O	O
atrial	NN	O	O
beating	NN	O	O
(	NN	O	O
AC	NN	O	O
)	NN	O	O
was	NN	O	O
also	NN	O	O
potentiated	NN	O	O
with	NN	O	O
the	NN	O	O
order	NN	O	O
LNa	NN	O	O
=	NN	O	O
LNa	NN	O	O
+	NN	O	O
LCa	NN	O	O
=	NN	O	O
LNa	NN	O	O
+	NN	O	O
HCa	NN	O	O
=	NN	O	O
LCa	NN	O	O
>	NN	O	O
HCa	NN	O	O
=	NN	O	O
N	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
rat	NN	O	O
atrial	NN	O	O
spontaneous	NN	O	O
beating	NN	O	O
is	NN	O	O
more	NN	O	O
dependent	NN	O	O
on	NN	O	O
[	NN	O	O
Na	NN	O	O
]	NN	O	O
o	NN	O	O
than	NN	O	O
on	NN	O	O
[	NN	O	O
Ca	NN	O	O
]	NN	O	O
o	NN	O	O
in	NN	O	O
a	NN	O	O
range	NN	O	O
of	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
their	NN	O	O
normal	NN	O	O
concentration	NN	O	O
.	NN	O	O

Also	NN	O	O
the	NN	O	O
enhancement	NN	O	O
of	NN	O	O
verapamil	NN	O	O
effects	NN	O	O
on	NN	O	O
atrial	NN	O	O
beating	NN	O	O
was	NN	O	O
more	NN	O	O
pronounced	NN	O	O
at	NN	O	O
LNa	NN	O	O
than	NN	O	O
at	NN	O	O
LCa	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

Pseudo	NN	O	O
-	NN	O	O
allergic	NN	O	B
reactions	NN	O	I
to	NN	O	O
corticosteroids	NN	O	O
:	NN	O	O
diagnosis	NN	O	O
and	NN	O	O
alternatives	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
parenteral	NN	O	O
paramethasone	NN	O	O
(	NN	O	O
Triniol	NN	O	O
)	NN	O	O
and	NN	O	O
dexamethasone	NN	O	O
(	NN	O	O
Sedionbel	NN	O	O
)	NN	O	O
are	NN	O	O
described	NN	O	O
.	NN	O	O

A	NN	O	O
few	NN	O	O
minutes	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
drugs	NN	O	O
,	NN	O	O
they	NN	O	O
presented	NN	O	O
urticaria	NN	O	B
(	NN	O	O
patients	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
conjunctivitis	NN	O	B
(	NN	O	O
patient	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
our	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
'	NN	O	O
reactions	NN	O	O
,	NN	O	O
the	NN	O	O
immunological	NN	O	O
mechanisms	NN	O	O
involved	NN	O	O
and	NN	O	O
whether	NN	O	O
these	NN	O	O
patients	NN	O	O
would	NN	O	O
be	NN	O	O
able	NN	O	O
to	NN	O	O
tolerate	NN	O	O
any	NN	O	O
kind	NN	O	O
of	NN	O	O
corticoid	NN	O	O
.	NN	O	O

Clinical	NN	O	O
examinations	NN	O	O
and	NN	O	O
skin	NN	O	O
,	NN	O	O
oral	NN	O	O
and	NN	O	O
parenteral	NN	O	O
challenges	NN	O	O
with	NN	O	O
different	NN	O	O
corticosteroids	NN	O	O
and	NN	O	O
ELISA	NN	O	O
tests	NN	O	O
were	NN	O	O
performed	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
two	NN	O	O
patients	NN	O	O
,	NN	O	O
skin	NN	O	O
and	NN	O	O
ELISA	NN	O	O
tests	NN	O	O
with	NN	O	O
paramethasone	NN	O	O
were	NN	O	O
negative	NN	O	O
,	NN	O	O
as	NN	O	O
was	NN	O	O
the	NN	O	O
prick	NN	O	O
test	NN	O	O
with	NN	O	O
each	NN	O	O
of	NN	O	O
its	NN	O	O
excipients	NN	O	O
.	NN	O	O

A	NN	O	O
single	NN	O	O
-	NN	O	O
blind	NN	O	O
parenteral	NN	O	O
challenge	NN	O	O
with	NN	O	O
Triniol	NN	O	O
was	NN	O	O
positive	NN	O	O
in	NN	O	O
both	NN	O	O
patients	NN	O	O
after	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
1	NN	O	O
ml	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
,	NN	O	O
and	NN	O	O
negative	NN	O	O
with	NN	O	O
its	NN	O	O
excipients	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
carried	NN	O	O
out	NN	O	O
oral	NN	O	O
and	NN	O	O
parenteral	NN	O	O
challenges	NN	O	O
with	NN	O	O
other	NN	O	O
corticosteroids	NN	O	O
and	NN	O	O
found	NN	O	O
intolerance	NN	O	O
to	NN	O	O
some	NN	O	O
of	NN	O	O
them	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
paramethasone	NN	O	O
caused	NN	O	O
pseudoallergic	NN	O	O
reactions	NN	O	O
in	NN	O	O
our	NN	O	O
patients	NN	O	O
.	NN	O	O

Corticosteroids	NN	O	O
different	NN	O	O
from	NN	O	O
paramethasone	NN	O	O
also	NN	O	O
produced	NN	O	O
hypersensitivity	NN	O	B
reactions	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
a	NN	O	O
few	NN	O	O
of	NN	O	O
them	NN	O	O
were	NN	O	O
tolerated	NN	O	O
.	NN	O	O

The	NN	O	O
basic	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
those	NN	O	O
reactions	NN	O	O
are	NN	O	O
not	NN	O	O
yet	NN	O	O
fully	NN	O	O
understood	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
report	NN	O	O
of	NN	O	O
a	NN	O	O
pseudo	NN	O	O
-	NN	O	O
allergy	NN	O	B
caused	NN	O	O
by	NN	O	O
paramethasone	NN	O	O
.	NN	O	O

Study	NN	O	O
of	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
vitamin	NN	O	O
B12	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
supplementation	NN	O	O
in	NN	O	O
preventing	NN	O	O
hematologic	NN	O	O
toxicity	NN	O	B
of	NN	O	O
zidovudine	NN	O	O
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
vitamin	NN	O	O
B12	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
supplementation	NN	O	O
in	NN	O	O
preventing	NN	O	O
zidovudine	NN	O	O
(	NN	O	O
ZDV	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
bone	NN	O	B
marrow	NN	O	I
suppression	NN	O	I
.	NN	O	O

Seventy	NN	O	O
-	NN	O	O
five	NN	O	O
human	NN	O	B
immunodeficiency	NN	O	I
virus	NN	O	I
(	NN	O	I
HIV	NN	O	I
)	NN	O	I
-	NN	O	I
infected	NN	O	I
patients	NN	O	O
with	NN	O	O
CD4	NN	O	O
+	NN	O	O
cell	NN	O	O
counts	NN	O	O
<	NN	O	O
500	NN	O	O
/	NN	O	O
mm3	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
ZDV	NN	O	O
(	NN	O	O
500	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
alone	NN	O	O
(	NN	O	O
group	NN	O	O
I	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
38	NN	O	O
)	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
folinic	NN	O	O
acid	NN	O	O
(	NN	O	O
15	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
and	NN	O	O
intramascular	NN	O	O
vitamin	NN	O	O
B12	NN	O	O
(	NN	O	O
1000	NN	O	O
micrograms	NN	O	O
monthly	NN	O	O
)	NN	O	O
(	NN	O	O
group	NN	O	O
II	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
37	NN	O	O
)	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
15	NN	O	O
patients	NN	O	O
were	NN	O	O
excluded	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
(	NN	O	O
noncompliance	NN	O	O
14	NN	O	O
,	NN	O	O
death	NN	O	B
1	NN	O	O
)	NN	O	O
;	NN	O	O
thus	NN	O	O
,	NN	O	O
60	NN	O	O
patients	NN	O	O
(	NN	O	O
31	NN	O	O
in	NN	O	O
group	NN	O	O
I	NN	O	O
and	NN	O	O
29	NN	O	O
in	NN	O	O
group	NN	O	O
II	NN	O	O
)	NN	O	O
were	NN	O	O
eligible	NN	O	O
for	NN	O	O
analysis	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
groups	NN	O	O
were	NN	O	O
found	NN	O	O
at	NN	O	O
enrollment	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
vitamin	NN	O	O
B12	NN	O	O
and	NN	O	O
folate	NN	O	O
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
higher	NN	O	O
in	NN	O	O
group	NN	O	O
II	NN	O	O
patients	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
hemoglobin	NN	O	O
,	NN	O	O
hematocrit	NN	O	O
,	NN	O	O
mean	NN	O	O
corpuscular	NN	O	O
volume	NN	O	O
,	NN	O	O
and	NN	O	O
white	NN	O	O
-	NN	O	O
cell	NN	O	O
,	NN	O	O
neutrophil	NN	O	O
and	NN	O	O
platelet	NN	O	O
counts	NN	O	O
were	NN	O	O
observed	NN	O	O
between	NN	O	O
groups	NN	O	O
at	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
,	NN	O	O
9	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
.	NN	O	O

Severe	NN	O	O
hematologic	NN	O	O
toxicity	NN	O	B
(	NN	O	O
neutrophil	NN	O	O
count	NN	O	O
<	NN	O	O
1000	NN	O	O
/	NN	O	O
mm3	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
hemoglobin	NN	O	O
<	NN	O	O
8	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
)	NN	O	O
occurred	NN	O	O
in	NN	O	O
4	NN	O	O
patients	NN	O	O
assigned	NN	O	O
to	NN	O	O
group	NN	O	O
I	NN	O	O
and	NN	O	O
7	NN	O	O
assigned	NN	O	O
to	NN	O	O
group	NN	O	O
II	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
correlation	NN	O	O
between	NN	O	O
vitamin	NN	O	O
B12	NN	O	O
or	NN	O	O
folate	NN	O	O
levels	NN	O	O
and	NN	O	O
development	NN	O	O
of	NN	O	O
myelosuppression	NN	O	B
.	NN	O	O

Vitamin	NN	O	O
B12	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
supplementation	NN	O	O
of	NN	O	O
ZDV	NN	O	O
therapy	NN	O	O
does	NN	O	O
not	NN	O	O
seem	NN	O	O
useful	NN	O	O
in	NN	O	O
preventing	NN	O	O
or	NN	O	O
reducing	NN	O	O
ZDV	NN	O	O
-	NN	O	O
induced	NN	O	O
myelotoxicity	NN	O	B
in	NN	O	O
the	NN	O	O
overall	NN	O	O
treated	NN	O	O
population	NN	O	O
,	NN	O	O
although	NN	O	O
a	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
in	NN	O	O
certain	NN	O	O
subgroups	NN	O	O
of	NN	O	O
patients	NN	O	O
cannot	NN	O	O
be	NN	O	O
excluded	NN	O	O
.	NN	O	O

Safety	NN	O	O
and	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
of	NN	O	O
alprazolam	NN	O	O
.	NN	O	O

Controlled	NN	O	O
study	NN	O	O
in	NN	O	O
agoraphobia	NN	O	B
with	NN	O	O
panic	NN	O	B
disorder	NN	O	I
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
widespread	NN	O	O
use	NN	O	O
of	NN	O	O
benzodiazepines	NN	O	O
has	NN	O	O
led	NN	O	O
to	NN	O	O
increasing	NN	O	O
recognition	NN	O	O
of	NN	O	O
their	NN	O	O
unwanted	NN	O	O
effects	NN	O	O
.	NN	O	O

The	NN	O	O
efficacy	NN	O	O
of	NN	O	O
alprazolam	NN	O	O
and	NN	O	O
placebo	NN	O	O
in	NN	O	O
panic	NN	O	B
disorder	NN	O	I
with	NN	O	O
agoraphobia	NN	O	B
,	NN	O	O
and	NN	O	O
the	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
and	NN	O	O
adverse	NN	O	O
effect	NN	O	O
profiles	NN	O	O
of	NN	O	O
both	NN	O	O
drug	NN	O	O
groups	NN	O	O
were	NN	O	O
measured	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
In	NN	O	O
London	NN	O	O
and	NN	O	O
Toronto	NN	O	O
154	NN	O	O
patients	NN	O	O
who	NN	O	O
met	NN	O	O
DSM	NN	O	O
-	NN	O	O
III	NN	O	O
criteria	NN	O	O
for	NN	O	O
panic	NN	O	B
disorder	NN	O	I
with	NN	O	O
agoraphobia	NN	O	B
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
alprazolam	NN	O	O
or	NN	O	O
placebo	NN	O	O
.	NN	O	O

Subjects	NN	O	O
in	NN	O	O
each	NN	O	O
drug	NN	O	O
group	NN	O	O
also	NN	O	O
received	NN	O	O
either	NN	O	O
exposure	NN	O	O
or	NN	O	O
relaxation	NN	O	O
.	NN	O	O

Treatment	NN	O	O
was	NN	O	O
from	NN	O	O
weeks	NN	O	O
0	NN	O	O
to	NN	O	O
8	NN	O	O
and	NN	O	O
was	NN	O	O
then	NN	O	O
tapered	NN	O	O
from	NN	O	O
weeks	NN	O	O
8	NN	O	O
to	NN	O	O
16	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Mean	NN	O	O
alprazolam	NN	O	O
dose	NN	O	O
was	NN	O	O
5	NN	O	O
mg	NN	O	O
daily	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
placebo	NN	O	O
subjects	NN	O	O
,	NN	O	O
alprazolam	NN	O	O
patients	NN	O	O
developed	NN	O	O
more	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
(	NN	O	O
21	NN	O	O
%	NN	O	O
v	NN	O	O
.	NN	O	O
0	NN	O	O
%	NN	O	O
)	NN	O	O
of	NN	O	O
depression	NN	O	B
,	NN	O	O
enuresis	NN	O	B
,	NN	O	O
disinhibition	NN	O	O
and	NN	O	O
aggression	NN	O	B
;	NN	O	O
and	NN	O	O
more	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
,	NN	O	O
particularly	NN	O	O
sedation	NN	O	O
,	NN	O	O
irritability	NN	O	B
,	NN	O	O
impaired	NN	O	B
memory	NN	O	I
,	NN	O	O
weight	NN	O	B
loss	NN	O	I
and	NN	O	O
ataxia	NN	O	B
.	NN	O	O

Side	NN	O	O
-	NN	O	O
effects	NN	O	O
tended	NN	O	O
to	NN	O	O
diminish	NN	O	O
during	NN	O	O
treatment	NN	O	O
but	NN	O	O
remained	NN	O	O
significant	NN	O	O
at	NN	O	O
week	NN	O	O
8	NN	O	O
.	NN	O	O

Despite	NN	O	O
this	NN	O	O
,	NN	O	O
the	NN	O	O
drop	NN	O	O
-	NN	O	O
out	NN	O	O
rate	NN	O	O
was	NN	O	O
low	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Alprazolam	NN	O	O
caused	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
and	NN	O	O
adverse	NN	O	O
effects	NN	O	O
during	NN	O	O
treatment	NN	O	O
but	NN	O	O
many	NN	O	O
patients	NN	O	O
were	NN	O	O
willing	NN	O	O
to	NN	O	O
accept	NN	O	O
these	NN	O	O
.	NN	O	O

Crescentic	NN	O	O
fibrillary	NN	O	O
glomerulonephritis	NN	O	B
associated	NN	O	O
with	NN	O	O
intermittent	NN	O	O
rifampin	NN	O	O
therapy	NN	O	O
for	NN	O	O
pulmonary	NN	O	B
tuberculosis	NN	O	I
.	NN	O	O

This	NN	O	O
case	NN	O	O
study	NN	O	O
reveals	NN	O	O
an	NN	O	O
unusual	NN	O	O
finding	NN	O	O
of	NN	O	O
rapidly	NN	O	O
proliferative	NN	O	O
crescentic	NN	O	O
glomerulonephritis	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
rifampin	NN	O	O
who	NN	O	O
had	NN	O	O
no	NN	O	O
other	NN	O	O
identifiable	NN	O	O
causes	NN	O	O
for	NN	O	O
developing	NN	O	O
this	NN	O	O
disease	NN	O	O
.	NN	O	O

This	NN	O	O
patient	NN	O	O
underwent	NN	O	O
a	NN	O	O
10	NN	O	O
-	NN	O	O
month	NN	O	O
regimen	NN	O	O
of	NN	O	O
rifampin	NN	O	O
and	NN	O	O
isoniazid	NN	O	O
for	NN	O	O
pulmonary	NN	O	B
tuberculosis	NN	O	I
and	NN	O	O
was	NN	O	O
discovered	NN	O	O
to	NN	O	O
have	NN	O	O
developed	NN	O	O
signs	NN	O	O
of	NN	O	O
severe	NN	O	O
renal	NN	O	B
failure	NN	O	I
five	NN	O	O
weeks	NN	O	O
after	NN	O	O
completion	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

Renal	NN	O	O
biopsy	NN	O	O
revealed	NN	O	O
severe	NN	O	O
glomerulonephritis	NN	O	B
with	NN	O	O
crescents	NN	O	O
,	NN	O	O
electron	NN	O	O
dense	NN	O	O
fibrillar	NN	O	O
deposits	NN	O	O
and	NN	O	O
moderate	NN	O	O
lymphocytic	NN	O	O
interstitial	NN	O	O
infiltrate	NN	O	O
.	NN	O	O

Other	NN	O	O
possible	NN	O	O
causes	NN	O	O
of	NN	O	O
rapidly	NN	O	O
progressive	NN	O	O
glomerulonephritis	NN	O	B
were	NN	O	O
investigated	NN	O	O
and	NN	O	O
ruled	NN	O	O
out	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
documents	NN	O	O
the	NN	O	O
unusual	NN	O	O
occurrence	NN	O	O
of	NN	O	O
rapidly	NN	O	O
progressive	NN	O	O
glomerulonephritis	NN	O	B
with	NN	O	O
crescents	NN	O	O
and	NN	O	O
fibrillar	NN	O	O
glomerulonephritis	NN	O	B
in	NN	O	O
a	NN	O	O
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
rifampin	NN	O	O
.	NN	O	O

Acute	NN	O	O
confusion	NN	O	B
induced	NN	O	O
by	NN	O	O
a	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
infusion	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
.	NN	O	O

A	NN	O	O
61	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
combination	NN	O	O
chemotherapy	NN	O	O
incorporating	NN	O	O
cisplatinum	NN	O	O
,	NN	O	O
etoposide	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
2	NN	O	O
,	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
24	NN	O	O
hours	NN	O	O
)	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
for	NN	O	O
an	NN	O	O
inoperable	NN	O	O
gastric	NN	O	B
adenocarcinoma	NN	O	I
.	NN	O	O

He	NN	O	O
developed	NN	O	O
acute	NN	O	O
neurologic	NN	O	O
symptoms	NN	O	O
of	NN	O	O
mental	NN	O	O
confusion	NN	O	B
,	NN	O	O
disorientation	NN	O	B
and	NN	O	O
irritability	NN	O	B
,	NN	O	O
and	NN	O	O
then	NN	O	O
lapsed	NN	O	O
into	NN	O	O
a	NN	O	O
deep	NN	O	O
coma	NN	O	B
,	NN	O	O
lasting	NN	O	O
for	NN	O	O
approximately	NN	O	O
40	NN	O	O
hours	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
dose	NN	O	O
(	NN	O	O
day	NN	O	O
2	NN	O	O
)	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
infusion	NN	O	O
.	NN	O	O

This	NN	O	O
complication	NN	O	O
reappeared	NN	O	O
on	NN	O	O
day	NN	O	O
25	NN	O	O
during	NN	O	O
the	NN	O	O
second	NN	O	O
dose	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
and	NN	O	O
folinic	NN	O	O
acid	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
then	NN	O	O
the	NN	O	O
only	NN	O	O
drugs	NN	O	O
given	NN	O	O
.	NN	O	O

Because	NN	O	O
folinic	NN	O	O
acid	NN	O	O
was	NN	O	O
unlikely	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
this	NN	O	O
condition	NN	O	O
,	NN	O	O
neurotoxicity	NN	O	B
due	NN	O	O
to	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
was	NN	O	O
highly	NN	O	O
suspected	NN	O	O
.	NN	O	O

The	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
neurotoxicity	NN	O	B
may	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
Krebs	NN	O	O
cycle	NN	O	O
blockade	NN	O	O
by	NN	O	O
fluoroacetate	NN	O	O
and	NN	O	O
fluorocitrate	NN	O	O
,	NN	O	O
thiamine	NN	O	O
deficiency	NN	O	O
,	NN	O	O
or	NN	O	O
dihydrouracil	NN	O	O
dehydrogenase	NN	O	O
deficiency	NN	O	O
.	NN	O	O

High	NN	O	O
-	NN	O	O
dose	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
/	NN	O	O
folinic	NN	O	O
acid	NN	O	O
infusion	NN	O	O
therapy	NN	O	O
has	NN	O	O
recently	NN	O	O
become	NN	O	O
a	NN	O	O
popular	NN	O	O
regimen	NN	O	O
for	NN	O	O
various	NN	O	O
cancers	NN	O	B
.	NN	O	O

It	NN	O	O
is	NN	O	O
necessary	NN	O	O
that	NN	O	O
both	NN	O	O
oncologists	NN	O	O
and	NN	O	O
neurologists	NN	O	O
be	NN	O	O
fully	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
unusual	NN	O	O
complication	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
switching	NN	O	O
carbamazepine	NN	O	O
to	NN	O	O
oxcarbazepine	NN	O	O
on	NN	O	O
the	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
neuroleptics	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

Carbamazepine	NN	O	O
was	NN	O	O
switched	NN	O	O
to	NN	O	O
its	NN	O	O
10	NN	O	O
-	NN	O	O
keto	NN	O	O
analogue	NN	O	O
oxcarbazepine	NN	O	O
among	NN	O	O
six	NN	O	O
difficult	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
treat	NN	O	O
schizophrenic	NN	O	B
or	NN	O	O
organic	NN	O	B
psychotic	NN	O	I
patients	NN	O	O
using	NN	O	O
concomitantly	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
chlorpromazine	NN	O	O
or	NN	O	O
clozapine	NN	O	O
.	NN	O	O

This	NN	O	O
change	NN	O	O
resulted	NN	O	O
within	NN	O	O
2	NN	O	O
-	NN	O	O
4	NN	O	O
weeks	NN	O	O
in	NN	O	O
the	NN	O	O
50	NN	O	O
-	NN	O	O
200	NN	O	O
%	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
these	NN	O	O
neuroleptics	NN	O	O
and	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
extrapyramidal	NN	O	B
symptoms	NN	O	I
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
showed	NN	O	O
any	NN	O	O
clinical	NN	O	O
deteriotation	NN	O	O
during	NN	O	O
the	NN	O	O
following	NN	O	O
3	NN	O	O
-	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
case	NN	O	O
report	NN	O	O
support	NN	O	O
the	NN	O	O
idea	NN	O	O
that	NN	O	O
in	NN	O	O
contrast	NN	O	O
with	NN	O	O
carbamazepine	NN	O	O
oxcarbazepine	NN	O	O
does	NN	O	O
not	NN	O	O
induce	NN	O	O
the	NN	O	O
hepatic	NN	O	O
microsomal	NN	O	O
enzyme	NN	O	O
systems	NN	O	O
regulating	NN	O	O
the	NN	O	O
inactivation	NN	O	O
of	NN	O	O
antipsychotic	NN	O	O
drugs	NN	O	O
.	NN	O	O

Time	NN	O	O
course	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
in	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

Reactive	NN	O	O
oxygen	NN	O	O
species	NN	O	O
have	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
acute	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
(	NN	O	O
PAN	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
with	NN	O	O
antioxidants	NN	O	O
significantly	NN	O	O
reducing	NN	O	O
the	NN	O	O
proteinuria	NN	O	B
.	NN	O	O

The	NN	O	O
temporal	NN	O	O
relationship	NN	O	O
between	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
in	NN	O	O
the	NN	O	O
kidney	NN	O	O
and	NN	O	O
proteinuria	NN	O	B
was	NN	O	O
examined	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
single	NN	O	O
IV	NN	O	O
injection	NN	O	O
of	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
,	NN	O	O
(	NN	O	O
PAN	NN	O	O
,	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
24	NN	O	O
hour	NN	O	O
urine	NN	O	O
samples	NN	O	O
were	NN	O	O
obtained	NN	O	O
prior	NN	O	O
to	NN	O	O
sacrifice	NN	O	O
on	NN	O	O
days	NN	O	O
3	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
7	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
17	NN	O	O
,	NN	O	O
27	NN	O	O
,	NN	O	O
41	NN	O	O
(	NN	O	O
N	NN	O	O
=	NN	O	O
5	NN	O	O
-	NN	O	O
10	NN	O	O
per	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
kidneys	NN	O	O
were	NN	O	O
removed	NN	O	O
,	NN	O	O
flushed	NN	O	O
with	NN	O	O
ice	NN	O	O
cold	NN	O	O
TRIS	NN	O	O
buffer	NN	O	O
.	NN	O	O

Kidney	NN	O	O
cortices	NN	O	O
from	NN	O	O
each	NN	O	O
animal	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
prepare	NN	O	O
homogenates	NN	O	O
.	NN	O	O

Tissue	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
was	NN	O	O
measured	NN	O	O
in	NN	O	O
whole	NN	O	O
homogenates	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
lipid	NN	O	O
extracts	NN	O	O
from	NN	O	O
homogenates	NN	O	O
as	NN	O	O
thiobarbituric	NN	O	O
acid	NN	O	O
reactive	NN	O	O
substances	NN	O	O
.	NN	O	O

Proteinuria	NN	O	B
was	NN	O	O
evident	NN	O	O
at	NN	O	O
day	NN	O	O
5	NN	O	O
,	NN	O	O
peaked	NN	O	O
at	NN	O	O
day	NN	O	O
7	NN	O	O
and	NN	O	O
persisted	NN	O	O
to	NN	O	O
day	NN	O	O
27	NN	O	O
.	NN	O	O

Lipid	NN	O	O
peroxidation	NN	O	O
in	NN	O	O
homogenates	NN	O	O
was	NN	O	O
maximal	NN	O	O
at	NN	O	O
day	NN	O	O
3	NN	O	O
and	NN	O	O
declined	NN	O	O
rapidly	NN	O	O
to	NN	O	O
control	NN	O	O
levels	NN	O	O
by	NN	O	O
day	NN	O	O
17	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
supports	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
in	NN	O	O
mediating	NN	O	O
the	NN	O	O
proteinuric	NN	O	B
injury	NN	O	I
in	NN	O	O
PAN	NN	O	O
nephropathy	NN	O	B
.	NN	O	O

Composition	NN	O	O
of	NN	O	O
gall	NN	O	B
bladder	NN	O	I
stones	NN	O	I
associated	NN	O	O
with	NN	O	O
octreotide	NN	O	O
:	NN	O	O
response	NN	O	O
to	NN	O	O
oral	NN	O	O
ursodeoxycholic	NN	O	O
acid	NN	O	O
.	NN	O	O

Octreotide	NN	O	O
,	NN	O	O
an	NN	O	O
effective	NN	O	O
treatment	NN	O	O
for	NN	O	O
acromegaly	NN	O	B
,	NN	O	O
induces	NN	O	O
gall	NN	O	B
bladder	NN	O	I
stones	NN	O	I
in	NN	O	O
13	NN	O	O
-	NN	O	O
60	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Because	NN	O	O
knowledge	NN	O	O
of	NN	O	O
stone	NN	O	O
composition	NN	O	O
is	NN	O	O
essential	NN	O	O
for	NN	O	O
studies	NN	O	O
of	NN	O	O
their	NN	O	O
pathogenesis	NN	O	O
,	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
prevention	NN	O	O
,	NN	O	O
this	NN	O	O
was	NN	O	O
investigated	NN	O	O
by	NN	O	O
direct	NN	O	O
and	NN	O	O
indirect	NN	O	O
methods	NN	O	O
in	NN	O	O
14	NN	O	O
octreotide	NN	O	O
treated	NN	O	O
acromegalic	NN	O	B
patients	NN	O	O
with	NN	O	O
gall	NN	O	B
stones	NN	O	I
.	NN	O	O

Chemical	NN	O	O
analysis	NN	O	O
of	NN	O	O
gall	NN	O	B
stones	NN	O	I
retrieved	NN	O	O
at	NN	O	O
cholecystectomy	NN	O	O
from	NN	O	O
two	NN	O	O
patients	NN	O	O
,	NN	O	O
showed	NN	O	O
that	NN	O	O
they	NN	O	O
contained	NN	O	O
71	NN	O	O
%	NN	O	O
and	NN	O	O
87	NN	O	O
%	NN	O	O
cholesterol	NN	O	O
by	NN	O	O
weight	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
remaining	NN	O	O
12	NN	O	O
patients	NN	O	O
,	NN	O	O
localised	NN	O	O
computed	NN	O	O
tomography	NN	O	O
of	NN	O	O
the	NN	O	O
gall	NN	O	O
bladder	NN	O	O
showed	NN	O	O
that	NN	O	O
eight	NN	O	O
had	NN	O	O
stones	NN	O	O
with	NN	O	O
maximum	NN	O	O
attenuation	NN	O	O
scores	NN	O	O
of	NN	O	O
<	NN	O	O
100	NN	O	O
Hounsfield	NN	O	O
units	NN	O	O
(	NN	O	O
values	NN	O	O
of	NN	O	O
<	NN	O	O
100	NN	O	O
HU	NN	O	O
predict	NN	O	O
cholesterol	NN	O	O
rich	NN	O	O
,	NN	O	O
dissolvable	NN	O	O
stones	NN	O	O
)	NN	O	O
.	NN	O	O

Gall	NN	O	O
bladder	NN	O	O
bile	NN	O	O
was	NN	O	O
obtained	NN	O	O
by	NN	O	O
ultrasound	NN	O	O
guided	NN	O	O
,	NN	O	O
fine	NN	O	O
needle	NN	O	O
puncture	NN	O	O
from	NN	O	O
six	NN	O	O
patients	NN	O	O
.	NN	O	O

All	NN	O	O
six	NN	O	O
patients	NN	O	O
had	NN	O	O
supersaturated	NN	O	O
bile	NN	O	O
(	NN	O	O
mean	NN	O	O
(	NN	O	O
SEM	NN	O	O
)	NN	O	O
cholesterol	NN	O	O
saturation	NN	O	O
index	NN	O	O
of	NN	O	O
1	NN	O	O
.	NN	O	O
19	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
08	NN	O	O
)	NN	O	O
(	NN	O	O
range	NN	O	O
1	NN	O	O
.	NN	O	O
01	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
53	NN	O	O
)	NN	O	O
)	NN	O	O
and	NN	O	O
all	NN	O	O
had	NN	O	O
abnormally	NN	O	O
rapid	NN	O	O
cholesterol	NN	O	O
microcrystal	NN	O	O
nucleation	NN	O	O
times	NN	O	O
(	NN	O	O
<	NN	O	O
4	NN	O	O
days	NN	O	O
(	NN	O	O
range	NN	O	O
1	NN	O	O
-	NN	O	O
4	NN	O	O
)	NN	O	O
)	NN	O	O
,	NN	O	O
whilst	NN	O	O
in	NN	O	O
four	NN	O	O
,	NN	O	O
the	NN	O	O
bile	NN	O	O
contained	NN	O	O
cholesterol	NN	O	O
microcrystals	NN	O	O
immediately	NN	O	O
after	NN	O	O
sampling	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
12	NN	O	O
patients	NN	O	O
considered	NN	O	O
for	NN	O	O
oral	NN	O	O
ursodeoxycholic	NN	O	O
acid	NN	O	O
(	NN	O	O
UDCA	NN	O	O
)	NN	O	O
treatment	NN	O	O
,	NN	O	O
two	NN	O	O
had	NN	O	O
a	NN	O	O
blocked	NN	O	O
cystic	NN	O	O
duct	NN	O	O
and	NN	O	O
were	NN	O	O
not	NN	O	O
started	NN	O	O
on	NN	O	O
UDCA	NN	O	O
while	NN	O	O
one	NN	O	O
was	NN	O	O
lost	NN	O	O
to	NN	O	O
follow	NN	O	O
up	NN	O	O
.	NN	O	O

After	NN	O	O
one	NN	O	O
year	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
five	NN	O	O
of	NN	O	O
the	NN	O	O
remaining	NN	O	O
nine	NN	O	O
patients	NN	O	O
showed	NN	O	O
either	NN	O	O
partial	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
3	NN	O	O
)	NN	O	O
or	NN	O	O
complete	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
)	NN	O	O
gall	NN	O	B
stone	NN	O	I
dissolution	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
their	NN	O	O
stones	NN	O	O
were	NN	O	O
cholesterol	NN	O	O
rich	NN	O	O
.	NN	O	O

This	NN	O	O
corresponds	NN	O	O
,	NN	O	O
by	NN	O	O
actuarial	NN	O	O
(	NN	O	O
life	NN	O	O
table	NN	O	O
)	NN	O	O
analysis	NN	O	O
,	NN	O	O
to	NN	O	O
a	NN	O	O
combined	NN	O	O
gall	NN	O	B
stone	NN	O	I
dissolution	NN	O	O
rate	NN	O	O
of	NN	O	O
58	NN	O	O
.	NN	O	O
3	NN	O	O
(	NN	O	O
15	NN	O	O
.	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
octreotide	NN	O	O
induced	NN	O	O
gall	NN	O	B
stones	NN	O	I
are	NN	O	O
generally	NN	O	O
small	NN	O	O
,	NN	O	O
multiple	NN	O	O
,	NN	O	O
and	NN	O	O
cholesterol	NN	O	O
rich	NN	O	O
although	NN	O	O
,	NN	O	O
in	NN	O	O
common	NN	O	O
with	NN	O	O
spontaneous	NN	O	O
gall	NN	O	B
stone	NN	O	I
disease	NN	O	I
,	NN	O	O
at	NN	O	O
presentation	NN	O	O
some	NN	O	O
patients	NN	O	O
will	NN	O	O
have	NN	O	O
a	NN	O	O
blocked	NN	O	O
cystic	NN	O	O
duct	NN	O	O
and	NN	O	O
some	NN	O	O
gall	NN	O	B
stones	NN	O	I
containing	NN	O	O
calcium	NN	O	O
.	NN	O	O

Erythema	NN	O	B
multiforme	NN	O	I
and	NN	O	O
hypersensitivity	NN	O	B
myocarditis	NN	O	I
caused	NN	O	O
by	NN	O	O
ampicillin	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
erythema	NN	O	B
multiforme	NN	O	I
and	NN	O	O
hypersensitivity	NN	O	B
myocarditis	NN	O	I
caused	NN	O	O
by	NN	O	O
ampicillin	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
13	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
boy	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
ampicillin	NN	O	O
and	NN	O	O
gentamicin	NN	O	O
because	NN	O	O
of	NN	O	O
suspected	NN	O	O
septicemia	NN	O	B
.	NN	O	O

Medications	NN	O	O
were	NN	O	O
discontinued	NN	O	O
when	NN	O	O
erythema	NN	O	B
multiforme	NN	O	I
and	NN	O	O
congestive	NN	O	B
heart	NN	O	I
failure	NN	O	I
caused	NN	O	O
by	NN	O	O
myocarditis	NN	O	B
occurred	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
methylprednisolone	NN	O	O
and	NN	O	O
gradually	NN	O	O
improved	NN	O	O
.	NN	O	O

Macrophage	NN	O	O
-	NN	O	O
migration	NN	O	O
inhibition	NN	O	O
(	NN	O	O
MIF	NN	O	O
)	NN	O	O
test	NN	O	O
with	NN	O	O
ampicillin	NN	O	O
was	NN	O	O
positive	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
After	NN	O	O
most	NN	O	O
infections	NN	O	B
causing	NN	O	O
erythema	NN	O	B
multiforme	NN	O	I
and	NN	O	O
myocarditis	NN	O	B
were	NN	O	O
ruled	NN	O	O
out	NN	O	O
,	NN	O	O
a	NN	O	O
drug	NN	O	B
-	NN	O	I
induced	NN	O	I
allergic	NN	O	I
reaction	NN	O	I
was	NN	O	O
suspected	NN	O	O
.	NN	O	O

Positive	NN	O	O
MIF	NN	O	O
test	NN	O	O
for	NN	O	O
ampicillin	NN	O	O
showed	NN	O	O
sensitization	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
lymphocytes	NN	O	O
to	NN	O	O
ampicillin	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Hypersensitivity	NN	O	B
myocarditis	NN	O	I
is	NN	O	O
a	NN	O	O
rare	NN	O	O
and	NN	O	O
dangerous	NN	O	O
manifestation	NN	O	O
of	NN	O	O
allergy	NN	O	B
to	NN	O	O
penicillins	NN	O	O
.	NN	O	O

Clomipramine	NN	O	O
-	NN	O	O
induced	NN	O	O
sleep	NN	O	B
disturbance	NN	O	I
does	NN	O	O
not	NN	O	O
impair	NN	O	O
its	NN	O	O
prolactin	NN	O	O
-	NN	O	O
releasing	NN	O	O
action	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
sleep	NN	O	B
disturbance	NN	O	I
,	NN	O	O
induced	NN	O	O
by	NN	O	O
clomipramine	NN	O	O
administration	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
secretory	NN	O	O
rate	NN	O	O
of	NN	O	O
prolactin	NN	O	O
(	NN	O	O
PRL	NN	O	O
)	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
the	NN	O	O
direct	NN	O	O
drug	NN	O	O
effect	NN	O	O
.	NN	O	O

Two	NN	O	O
groups	NN	O	O
of	NN	O	O
supine	NN	O	O
subjects	NN	O	O
were	NN	O	O
studied	NN	O	O
under	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
conditions	NN	O	O
,	NN	O	O
one	NN	O	O
during	NN	O	O
the	NN	O	O
night	NN	O	O
,	NN	O	O
when	NN	O	O
sleeping	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
other	NN	O	O
at	NN	O	O
daytime	NN	O	O
,	NN	O	O
when	NN	O	O
awake	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

Each	NN	O	O
subject	NN	O	O
received	NN	O	O
a	NN	O	O
single	NN	O	O
50	NN	O	O
mg	NN	O	O
dose	NN	O	O
of	NN	O	O
clomipramine	NN	O	O
given	NN	O	O
orally	NN	O	O
2	NN	O	O
hours	NN	O	O
before	NN	O	O
blood	NN	O	O
collection	NN	O	O
.	NN	O	O

Plasma	NN	O	O
PRL	NN	O	O
concentrations	NN	O	O
were	NN	O	O
analysed	NN	O	O
at	NN	O	O
10	NN	O	O
min	NN	O	O
intervals	NN	O	O
and	NN	O	O
underlying	NN	O	O
secretory	NN	O	O
rates	NN	O	O
calculated	NN	O	O
by	NN	O	O
a	NN	O	O
deconvolution	NN	O	O
procedure	NN	O	O
.	NN	O	O

For	NN	O	O
both	NN	O	O
experiments	NN	O	O
the	NN	O	O
drug	NN	O	O
intake	NN	O	O
led	NN	O	O
to	NN	O	O
significant	NN	O	O
increases	NN	O	O
in	NN	O	O
PRL	NN	O	O
secretion	NN	O	O
,	NN	O	O
acting	NN	O	O
preferentially	NN	O	O
on	NN	O	O
tonic	NN	O	O
secretion	NN	O	O
as	NN	O	O
pulse	NN	O	O
amplitude	NN	O	O
and	NN	O	O
frequency	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
from	NN	O	O
corresponding	NN	O	O
control	NN	O	O
values	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
night	NN	O	O
clomipramine	NN	O	O
ingestion	NN	O	O
altered	NN	O	O
the	NN	O	O
complete	NN	O	O
sleep	NN	O	O
architecture	NN	O	O
in	NN	O	O
that	NN	O	O
it	NN	O	O
suppressed	NN	O	O
REM	NN	O	O
sleep	NN	O	O
and	NN	O	O
the	NN	O	O
sleep	NN	O	O
cycles	NN	O	O
and	NN	O	O
induced	NN	O	O
increased	NN	O	O
wakefulness	NN	O	O
.	NN	O	O

As	NN	O	O
the	NN	O	O
relative	NN	O	O
increase	NN	O	O
in	NN	O	O
PRL	NN	O	O
secretion	NN	O	O
expressed	NN	O	O
as	NN	O	O
a	NN	O	O
percentage	NN	O	O
of	NN	O	O
the	NN	O	O
mean	NN	O	O
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
differ	NN	O	O
between	NN	O	O
the	NN	O	O
night	NN	O	O
and	NN	O	O
day	NN	O	O
time	NN	O	O
studies	NN	O	O
(	NN	O	O
46	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
19	NN	O	O
%	NN	O	O
vs	NN	O	O
34	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
concluded	NN	O	O
that	NN	O	O
the	NN	O	O
observed	NN	O	O
sleep	NN	O	B
disturbance	NN	O	I
did	NN	O	O
not	NN	O	O
interfere	NN	O	O
with	NN	O	O
the	NN	O	O
drug	NN	O	O
action	NN	O	O
per	NN	O	O
se	NN	O	O
.	NN	O	O

The	NN	O	O
presence	NN	O	O
of	NN	O	O
REM	NN	O	O
sleep	NN	O	O
was	NN	O	O
shown	NN	O	O
not	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
determining	NN	O	O
factor	NN	O	O
either	NN	O	O
for	NN	O	O
secretory	NN	O	O
pulse	NN	O	O
amplitude	NN	O	O
and	NN	O	O
frequency	NN	O	O
,	NN	O	O
as	NN	O	O
,	NN	O	O
for	NN	O	O
both	NN	O	O
,	NN	O	O
mean	NN	O	O
nocturnal	NN	O	O
values	NN	O	O
were	NN	O	O
similar	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
prior	NN	O	O
clomipramine	NN	O	O
ingestion	NN	O	O
.	NN	O	O

Survey	NN	O	O
of	NN	O	O
complications	NN	O	O
of	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
angiography	NN	O	O
in	NN	O	O
Japan	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
We	NN	O	O
evaluated	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
for	NN	O	O
use	NN	O	O
in	NN	O	O
fundus	NN	O	O
angiography	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
sent	NN	O	O
a	NN	O	O
questionnaire	NN	O	O
concerning	NN	O	O
complications	NN	O	O
of	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
to	NN	O	O
32	NN	O	O
institutions	NN	O	O
in	NN	O	O
Japan	NN	O	O
,	NN	O	O
which	NN	O	O
were	NN	O	O
selected	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
the	NN	O	O
client	NN	O	O
list	NN	O	O
from	NN	O	O
the	NN	O	O
Topcon	NN	O	O
Company	NN	O	O
,	NN	O	O
which	NN	O	O
manufactures	NN	O	O
the	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
fundus	NN	O	O
camera	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Ophthalmologists	NN	O	O
at	NN	O	O
15	NN	O	O
institutions	NN	O	O
responded	NN	O	O
,	NN	O	O
reporting	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
3	NN	O	O
,	NN	O	O
774	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
angiograms	NN	O	O
performed	NN	O	O
on	NN	O	O
2	NN	O	O
,	NN	O	O
820	NN	O	O
patients	NN	O	O
between	NN	O	O
June	NN	O	O
1984	NN	O	O
and	NN	O	O
September	NN	O	O
1992	NN	O	O
.	NN	O	O

Before	NN	O	O
angiography	NN	O	O
,	NN	O	O
intradermal	NN	O	O
or	NN	O	O
intravenous	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
testing	NN	O	O
,	NN	O	O
or	NN	O	O
both	NN	O	O
was	NN	O	O
performed	NN	O	O
at	NN	O	O
13	NN	O	O
of	NN	O	O
15	NN	O	O
institutions	NN	O	O
.	NN	O	O

For	NN	O	O
three	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
decision	NN	O	O
was	NN	O	O
made	NN	O	O
not	NN	O	O
to	NN	O	O
proceed	NN	O	O
with	NN	O	O
angiography	NN	O	O
after	NN	O	O
positive	NN	O	O
preangiographic	NN	O	O
testing	NN	O	O
.	NN	O	O

The	NN	O	O
dosage	NN	O	O
of	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
used	NN	O	O
for	NN	O	O
angiography	NN	O	O
varied	NN	O	O
from	NN	O	O
25	NN	O	O
to	NN	O	O
75	NN	O	O
mg	NN	O	O
,	NN	O	O
depending	NN	O	O
upon	NN	O	O
the	NN	O	O
institution	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
13	NN	O	O
cases	NN	O	O
of	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
34	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
ten	NN	O	O
of	NN	O	O
which	NN	O	O
were	NN	O	O
mild	NN	O	O
reactions	NN	O	O
such	NN	O	O
as	NN	O	O
nausea	NN	O	B
,	NN	O	O
exanthema	NN	O	B
,	NN	O	O
urtication	NN	O	B
,	NN	O	O
itchiness	NN	O	B
,	NN	O	O
and	NN	O	O
urgency	NN	O	O
to	NN	O	O
defecate	NN	O	O
,	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
require	NN	O	O
treatment	NN	O	O
.	NN	O	O

Also	NN	O	O
recorded	NN	O	O
were	NN	O	O
one	NN	O	O
case	NN	O	O
of	NN	O	O
pain	NN	O	B
of	NN	O	O
the	NN	O	O
vein	NN	O	O
,	NN	O	O
which	NN	O	O
required	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
hypotension	NN	O	B
.	NN	O	O

The	NN	O	O
two	NN	O	O
hypotensive	NN	O	B
patients	NN	O	O
required	NN	O	O
treatment	NN	O	O
for	NN	O	O
shock	NN	O	B
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
A	NN	O	O
comparison	NN	O	O
of	NN	O	O
frequency	NN	O	O
of	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
to	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
with	NN	O	O
the	NN	O	O
previously	NN	O	O
reported	NN	O	O
frequency	NN	O	O
of	NN	O	O
such	NN	O	O
reactions	NN	O	O
to	NN	O	O
fluorescein	NN	O	O
sodium	NN	O	O
indicated	NN	O	O
that	NN	O	O
indocyanine	NN	O	O
green	NN	O	O
is	NN	O	O
a	NN	O	O
safe	NN	O	O
as	NN	O	O
fluorescein	NN	O	O
for	NN	O	O
use	NN	O	O
in	NN	O	O
angiography	NN	O	O
.	NN	O	O

Angioedema	NN	O	B
following	NN	O	O
the	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
metoprolol	NN	O	O
.	NN	O	O

A	NN	O	O
72	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
with	NN	O	O
"	NN	O	O
flash	NN	O	O
"	NN	O	O
pulmonary	NN	O	B
edema	NN	O	I
,	NN	O	O
preceded	NN	O	O
by	NN	O	O
chest	NN	O	B
pain	NN	O	I
,	NN	O	O
requiring	NN	O	O
intubation	NN	O	O
.	NN	O	O

Her	NN	O	O
medical	NN	O	O
history	NN	O	O
included	NN	O	O
coronary	NN	O	B
artery	NN	O	I
disease	NN	O	I
with	NN	O	O
previous	NN	O	O
myocardial	NN	O	B
infarctions	NN	O	I
,	NN	O	O
hypertension	NN	O	B
,	NN	O	O
and	NN	O	O
diabetes	NN	O	B
mellitus	NN	O	I
.	NN	O	O

A	NN	O	O
history	NN	O	O
of	NN	O	O
angioedema	NN	O	B
secondary	NN	O	O
to	NN	O	O
lisinopril	NN	O	O
therapy	NN	O	O
was	NN	O	O
elicited	NN	O	O
.	NN	O	O

Current	NN	O	O
medications	NN	O	O
did	NN	O	O
not	NN	O	O
include	NN	O	O
angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitors	NN	O	O
or	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
.	NN	O	O

She	NN	O	O
had	NN	O	O
no	NN	O	O
previous	NN	O	O
beta	NN	O	O
-	NN	O	O
blocking	NN	O	O
drug	NN	O	O
exposure	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
first	NN	O	O
day	NN	O	O
of	NN	O	O
hospitalization	NN	O	O
(	NN	O	O
while	NN	O	O
intubated	NN	O	O
)	NN	O	O
,	NN	O	O
intravenous	NN	O	O
metoprolol	NN	O	O
was	NN	O	O
given	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
severe	NN	O	O
angioedema	NN	O	B
.	NN	O	O

The	NN	O	O
angioedema	NN	O	B
resolved	NN	O	O
after	NN	O	O
therapy	NN	O	O
with	NN	O	O
intravenous	NN	O	O
steroids	NN	O	O
and	NN	O	O
diphenhydramine	NN	O	O
hydrochloride	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
coniine	NN	O	O
on	NN	O	O
the	NN	O	O
developing	NN	O	O
chick	NN	O	O
embryo	NN	O	O
.	NN	O	O

Coniine	NN	O	O
,	NN	O	O
an	NN	O	O
alkaloid	NN	O	O
from	NN	O	O
Conium	NN	O	O
maculatum	NN	O	O
(	NN	O	O
poison	NN	O	O
hemlock	NN	O	O
)	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
teratogenic	NN	O	O
in	NN	O	O
livestock	NN	O	O
.	NN	O	O

The	NN	O	O
major	NN	O	O
teratogenic	NN	O	O
outcome	NN	O	O
is	NN	O	O
arthrogryposis	NN	O	B
,	NN	O	O
presumably	NN	O	O
due	NN	O	O
to	NN	O	O
nicotinic	NN	O	O
receptor	NN	O	O
blockade	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
coniine	NN	O	O
has	NN	O	O
failed	NN	O	O
to	NN	O	O
produce	NN	O	O
arthrogryposis	NN	O	B
in	NN	O	O
rats	NN	O	O
or	NN	O	O
mice	NN	O	O
and	NN	O	O
is	NN	O	O
only	NN	O	O
weakly	NN	O	O
teratogenic	NN	O	O
in	NN	O	O
rabbits	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
and	NN	O	O
compare	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
coniine	NN	O	O
and	NN	O	O
nicotine	NN	O	O
in	NN	O	O
the	NN	O	O
developing	NN	O	O
chick	NN	O	O
.	NN	O	O

Concentrations	NN	O	O
of	NN	O	O
coniine	NN	O	O
and	NN	O	O
nicotine	NN	O	O
sulfate	NN	O	O
were	NN	O	O
0	NN	O	O
.	NN	O	O
015	NN	O	O
%	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
%	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
075	NN	O	O
%	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
15	NN	O	O
%	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
75	NN	O	O
%	NN	O	O
,	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
,	NN	O	O
3	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
6	NN	O	O
%	NN	O	O
and	NN	O	O
1	NN	O	O
%	NN	O	O
,	NN	O	O
5	NN	O	O
%	NN	O	O
,	NN	O	O
and	NN	O	O
10	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Both	NN	O	O
compounds	NN	O	O
caused	NN	O	O
deformations	NN	O	B
and	NN	O	O
lethality	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

All	NN	O	O
concentrations	NN	O	O
of	NN	O	O
nicotine	NN	O	O
sulfate	NN	O	O
caused	NN	O	O
some	NN	O	O
lethality	NN	O	O
but	NN	O	O
a	NN	O	O
no	NN	O	O
effect	NN	O	O
level	NN	O	O
for	NN	O	O
coniine	NN	O	O
lethality	NN	O	O
was	NN	O	O
0	NN	O	O
.	NN	O	O
75	NN	O	O
%	NN	O	O
.	NN	O	O

The	NN	O	O
deformations	NN	O	B
caused	NN	O	O
by	NN	O	O
both	NN	O	O
coniine	NN	O	O
and	NN	O	O
nicotine	NN	O	O
sulfate	NN	O	O
were	NN	O	O
excessive	NN	O	B
flexion	NN	O	I
or	NN	O	I
extension	NN	O	I
of	NN	O	I
one	NN	O	I
or	NN	O	I
more	NN	O	I
toes	NN	O	I
.	NN	O	O

No	NN	O	O
histopathological	NN	O	O
alterations	NN	O	O
or	NN	O	O
differences	NN	O	O
in	NN	O	O
bone	NN	O	O
formation	NN	O	O
were	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
limbs	NN	O	O
or	NN	O	O
toes	NN	O	O
of	NN	O	O
any	NN	O	O
chicks	NN	O	O
from	NN	O	O
any	NN	O	O
group	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
extensive	NN	O	O
cranial	NN	O	B
hemorrhage	NN	O	I
occurred	NN	O	O
in	NN	O	O
all	NN	O	O
nicotine	NN	O	O
sulfate	NN	O	O
-	NN	O	O
treated	NN	O	O
chicks	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
decrease	NN	O	O
in	NN	O	O
movement	NN	O	O
in	NN	O	O
coniine	NN	O	O
and	NN	O	O
nicotine	NN	O	O
sulfate	NN	O	O
treated	NN	O	O
chicks	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
ultrasound	NN	O	O
.	NN	O	O

Control	NN	O	O
chicks	NN	O	O
were	NN	O	O
in	NN	O	O
motion	NN	O	O
an	NN	O	O
average	NN	O	O
of	NN	O	O
33	NN	O	O
.	NN	O	O
67	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
time	NN	O	O
,	NN	O	O
while	NN	O	O
coniine	NN	O	O
-	NN	O	O
treated	NN	O	O
chicks	NN	O	O
were	NN	O	O
only	NN	O	O
moving	NN	O	O
8	NN	O	O
.	NN	O	O
95	NN	O	O
%	NN	O	O
of	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
min	NN	O	O
interval	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
movement	NN	O	O
was	NN	O	O
observed	NN	O	O
for	NN	O	O
nicotine	NN	O	O
sulfate	NN	O	O
treated	NN	O	O
chicks	NN	O	O
.	NN	O	O

In	NN	O	O
summary	NN	O	O
,	NN	O	O
the	NN	O	O
chick	NN	O	O
embryo	NN	O	O
provides	NN	O	O
a	NN	O	O
reliable	NN	O	O
and	NN	O	O
simple	NN	O	O
experimental	NN	O	O
animal	NN	O	O
model	NN	O	O
of	NN	O	O
coniine	NN	O	O
-	NN	O	O
induced	NN	O	O
arthrogryposis	NN	O	B
.	NN	O	O

Data	NN	O	O
from	NN	O	O
this	NN	O	O
model	NN	O	O
support	NN	O	O
a	NN	O	O
mechanism	NN	O	O
involving	NN	O	O
nicotinic	NN	O	O
receptor	NN	O	O
blockade	NN	O	O
with	NN	O	O
subsequent	NN	O	O
decreased	NN	O	O
fetal	NN	O	O
movement	NN	O	O
.	NN	O	O

Immediate	NN	O	O
allergic	NN	O	B
reactions	NN	O	I
to	NN	O	O
amoxicillin	NN	O	O
.	NN	O	O

A	NN	O	O
large	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
suspected	NN	O	O
allergic	NN	O	B
reactions	NN	O	I
to	NN	O	O
beta	NN	O	O
-	NN	O	O
lactam	NN	O	O
antibiotics	NN	O	O
was	NN	O	O
evaluated	NN	O	O
.	NN	O	O

A	NN	O	O
detailed	NN	O	O
clinical	NN	O	O
history	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
skin	NN	O	O
tests	NN	O	O
,	NN	O	O
RAST	NN	O	O
(	NN	O	O
radioallergosorbent	NN	O	O
test	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
controlled	NN	O	O
challenge	NN	O	O
tests	NN	O	O
,	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
establish	NN	O	O
whether	NN	O	O
patients	NN	O	O
allergic	NN	O	B
to	NN	O	O
beta	NN	O	O
-	NN	O	O
lactam	NN	O	O
antibiotics	NN	O	O
had	NN	O	O
selective	NN	O	O
immediate	NN	O	O
allergic	NN	O	B
responses	NN	O	O
to	NN	O	O
amoxicillin	NN	O	O
(	NN	O	O
AX	NN	O	O
)	NN	O	O
or	NN	O	O
were	NN	O	O
cross	NN	O	O
-	NN	O	O
reacting	NN	O	O
with	NN	O	O
other	NN	O	O
penicillin	NN	O	O
derivatives	NN	O	O
.	NN	O	O

Skin	NN	O	O
tests	NN	O	O
were	NN	O	O
performed	NN	O	O
with	NN	O	O
benzylpenicilloyl	NN	O	O
-	NN	O	O
poly	NN	O	O
-	NN	O	O
L	NN	O	O
-	NN	O	O
lysine	NN	O	O
(	NN	O	O
BPO	NN	O	O
-	NN	O	O
PLL	NN	O	O
)	NN	O	O
,	NN	O	O
benzylpenicilloate	NN	O	O
,	NN	O	O
benzylpenicillin	NN	O	O
(	NN	O	O
PG	NN	O	O
)	NN	O	O
,	NN	O	O
ampicillin	NN	O	O
(	NN	O	O
AMP	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
AX	NN	O	O
.	NN	O	O

RAST	NN	O	O
for	NN	O	O
BPO	NN	O	O
-	NN	O	O
PLL	NN	O	O
and	NN	O	O
AX	NN	O	O
-	NN	O	O
PLL	NN	O	O
was	NN	O	O
done	NN	O	O
.	NN	O	O

When	NN	O	O
both	NN	O	O
skin	NN	O	O
test	NN	O	O
and	NN	O	O
RAST	NN	O	O
for	NN	O	O
BPO	NN	O	O
were	NN	O	O
negative	NN	O	O
,	NN	O	O
single	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
challenge	NN	O	O
tests	NN	O	O
were	NN	O	O
done	NN	O	O
to	NN	O	O
ensure	NN	O	O
tolerance	NN	O	O
of	NN	O	O
PG	NN	O	O
or	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
AX	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
177	NN	O	O
patients	NN	O	O
were	NN	O	O
diagnosed	NN	O	O
as	NN	O	O
allergic	NN	O	B
to	NN	O	O
beta	NN	O	O
-	NN	O	O
lactam	NN	O	O
antibiotics	NN	O	O
.	NN	O	O

We	NN	O	O
selected	NN	O	O
the	NN	O	O
54	NN	O	O
(	NN	O	O
30	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
cases	NN	O	O
of	NN	O	O
immediate	NN	O	O
AX	NN	O	O
allergy	NN	O	B
with	NN	O	O
good	NN	O	O
tolerance	NN	O	O
of	NN	O	O
PG	NN	O	O
.	NN	O	O

Anaphylaxis	NN	O	B
was	NN	O	O
seen	NN	O	O
in	NN	O	O
37	NN	O	O
patients	NN	O	O
(	NN	O	O
69	NN	O	O
%	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
other	NN	O	O
17	NN	O	O
(	NN	O	O
31	NN	O	O
%	NN	O	O
)	NN	O	O
having	NN	O	O
urticaria	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
angioedema	NN	O	B
.	NN	O	O

All	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
skin	NN	O	O
test	NN	O	O
negative	NN	O	O
to	NN	O	O
BPO	NN	O	O
;	NN	O	O
49	NN	O	O
of	NN	O	O
51	NN	O	O
(	NN	O	O
96	NN	O	O
%	NN	O	O
)	NN	O	O
were	NN	O	O
also	NN	O	O
negative	NN	O	O
to	NN	O	O
MDM	NN	O	B
,	NN	O	O
and	NN	O	O
44	NN	O	O
of	NN	O	O
46	NN	O	O
(	NN	O	O
96	NN	O	O
%	NN	O	O
)	NN	O	O
to	NN	O	O
PG	NN	O	O
.	NN	O	O

Skin	NN	O	O
tests	NN	O	O
with	NN	O	O
AX	NN	O	O
were	NN	O	O
positive	NN	O	O
in	NN	O	O
34	NN	O	O
(	NN	O	O
63	NN	O	O
%	NN	O	O
)	NN	O	O
patients	NN	O	O
.	NN	O	O

RAST	NN	O	O
was	NN	O	O
positive	NN	O	O
for	NN	O	O
AX	NN	O	O
in	NN	O	O
22	NN	O	O
patients	NN	O	O
(	NN	O	O
41	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
to	NN	O	O
BPO	NN	O	O
in	NN	O	O
just	NN	O	O
5	NN	O	O
(	NN	O	O
9	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
sera	NN	O	O
with	NN	O	O
negative	NN	O	O
RAST	NN	O	O
for	NN	O	O
AX	NN	O	O
were	NN	O	O
positive	NN	O	O
to	NN	O	O
BPO	NN	O	O
.	NN	O	O

Challenge	NN	O	O
tests	NN	O	O
with	NN	O	O
AX	NN	O	O
were	NN	O	O
performed	NN	O	O
in	NN	O	O
23	NN	O	O
subjects	NN	O	O
(	NN	O	O
43	NN	O	O
%	NN	O	O
)	NN	O	O
to	NN	O	O
establish	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
immediate	NN	O	O
allergic	NN	O	B
reaction	NN	O	I
to	NN	O	O
AX	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
15	NN	O	O
cases	NN	O	O
(	NN	O	O
28	NN	O	O
%	NN	O	O
)	NN	O	O
both	NN	O	O
skin	NN	O	O
test	NN	O	O
and	NN	O	O
RAST	NN	O	O
for	NN	O	O
AX	NN	O	O
were	NN	O	O
negative	NN	O	O
.	NN	O	O

PG	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
by	NN	O	O
all	NN	O	O
54	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
the	NN	O	O
largest	NN	O	O
group	NN	O	O
of	NN	O	O
AX	NN	O	O
-	NN	O	O
allergic	NN	O	B
patients	NN	O	O
who	NN	O	O
have	NN	O	O
tolerated	NN	O	O
PG	NN	O	O
reported	NN	O	O
so	NN	O	O
far	NN	O	O
.	NN	O	O

Diagnosis	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
can	NN	O	O
be	NN	O	O
achieved	NN	O	O
only	NN	O	O
if	NN	O	O
specific	NN	O	O
AX	NN	O	O
-	NN	O	O
related	NN	O	O
reagents	NN	O	O
are	NN	O	O
employed	NN	O	O
.	NN	O	O

Further	NN	O	O
studies	NN	O	O
are	NN	O	O
necessary	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
exact	NN	O	O
extent	NN	O	O
of	NN	O	O
this	NN	O	O
problem	NN	O	O
and	NN	O	O
to	NN	O	O
improve	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
diagnostic	NN	O	O
methods	NN	O	O
.	NN	O	O

Reversal	NN	O	O
by	NN	O	O
phenylephrine	NN	O	O
of	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
intravenous	NN	O	O
nitroglycerin	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
myocardial	NN	O	I
infarction	NN	O	I
.	NN	O	O

Nitroglycerin	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
reduce	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
elevation	NN	O	O
during	NN	O	O
acute	NN	O	B
myocardial	NN	O	I
infarction	NN	O	I
,	NN	O	O
an	NN	O	O
effect	NN	O	O
potentiated	NN	O	O
in	NN	O	O
the	NN	O	O
dog	NN	O	O
by	NN	O	O
agents	NN	O	O
that	NN	O	O
reverse	NN	O	O
nitroglycerin	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Our	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
combined	NN	O	O
nitroglycerin	NN	O	O
and	NN	O	O
phenylephrine	NN	O	O
therapy	NN	O	O
.	NN	O	O

Ten	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	O
transmural	NN	O	O
myocardial	NN	O	B
infarctions	NN	O	I
received	NN	O	O
intravenous	NN	O	O
nitroglycerin	NN	O	O
,	NN	O	O
sufficient	NN	O	O
to	NN	O	O
reduce	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
from	NN	O	O
107	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
to	NN	O	O
85	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
mm	NN	O	O
Hg	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
,	NN	O	O
for	NN	O	O
60	NN	O	O
minutes	NN	O	O
.	NN	O	O

Left	NN	O	O
ventricular	NN	O	O
filling	NN	O	O
pressure	NN	O	O
decreased	NN	O	O
from	NN	O	O
19	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
to	NN	O	O
11	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
mm	NN	O	O
Hg	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

SigmaST	NN	O	O
,	NN	O	O
the	NN	O	O
sum	NN	O	O
of	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
elevations	NN	O	O
in	NN	O	O
16	NN	O	O
precordial	NN	O	O
leads	NN	O	O
,	NN	O	O
decreased	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
with	NN	O	O
intravenous	NN	O	O
nitroglycerin	NN	O	O
.	NN	O	O

Subsequent	NN	O	O
addition	NN	O	O
of	NN	O	O
phenylephrine	NN	O	O
infusion	NN	O	O
,	NN	O	O
sufficient	NN	O	O
to	NN	O	O
re	NN	O	O
-	NN	O	O
elevate	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
to	NN	O	O
106	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
mm	NN	O	O
Hg	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
for	NN	O	O
30	NN	O	O
minutes	NN	O	O
,	NN	O	O
increased	NN	O	O
left	NN	O	O
ventricular	NN	O	O
filling	NN	O	O
pressure	NN	O	O
to	NN	O	O
17	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
mm	NN	O	O
Hg	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
and	NN	O	O
also	NN	O	O
significantly	NN	O	O
increased	NN	O	O
sigmaST	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
addition	NN	O	O
of	NN	O	O
phenylephrine	NN	O	O
to	NN	O	O
nitroglycerin	NN	O	O
is	NN	O	O
not	NN	O	O
beneficial	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B
myocardial	NN	O	I
infarction	NN	O	I
.	NN	O	O

Acetazolamide	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrolithiasis	NN	O	B
:	NN	O	O
implications	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
neuromuscular	NN	O	B
disorders	NN	O	I
.	NN	O	O

Carbonic	NN	O	O
anhydrase	NN	O	O
inhibitors	NN	O	O
can	NN	O	O
cause	NN	O	O
nephrolithiasis	NN	O	B
.	NN	O	O

We	NN	O	O
studied	NN	O	O
20	NN	O	O
patients	NN	O	O
receiving	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
carbonic	NN	O	O
anhydrase	NN	O	O
inhibitor	NN	O	O
treatment	NN	O	O
for	NN	O	O
periodic	NN	O	O
paralysis	NN	O	B
and	NN	O	O
myotonia	NN	O	B
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
on	NN	O	O
acetazolamide	NN	O	O
(	NN	O	O
15	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
renal	NN	O	B
calculi	NN	O	I
.	NN	O	O

Extracorporeal	NN	O	O
lithotripsy	NN	O	O
successfully	NN	O	O
removed	NN	O	O
a	NN	O	O
renal	NN	O	B
calculus	NN	O	I
in	NN	O	O
one	NN	O	O
patient	NN	O	O
and	NN	O	O
surgery	NN	O	O
removed	NN	O	O
a	NN	O	O
staghorn	NN	O	O
calculus	NN	O	B
in	NN	O	O
another	NN	O	O
,	NN	O	O
permitting	NN	O	O
continued	NN	O	O
treatment	NN	O	O
.	NN	O	O

Renal	NN	O	O
function	NN	O	O
remained	NN	O	O
normal	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

Nephrolithiasis	NN	O	B
is	NN	O	O
a	NN	O	O
complication	NN	O	O
of	NN	O	O
acetazolamide	NN	O	O
but	NN	O	O
does	NN	O	O
not	NN	O	O
preclude	NN	O	O
its	NN	O	O
use	NN	O	O
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
on	NN	O	O
bupivacaine	NN	O	O
-	NN	O	O
induced	NN	O	O
toxicity	NN	O	B
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
on	NN	O	O
bupivacaine	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
toxicity	NN	O	B
.	NN	O	O

For	NN	O	O
each	NN	O	O
of	NN	O	O
the	NN	O	O
three	NN	O	O
tested	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
(	NN	O	O
diltiazem	NN	O	O
,	NN	O	O
verapamil	NN	O	O
and	NN	O	O
bepridil	NN	O	O
)	NN	O	O
6	NN	O	O
groups	NN	O	O
of	NN	O	O
mice	NN	O	O
were	NN	O	O
treated	NN	O	O
by	NN	O	O
two	NN	O	O
different	NN	O	O
doses	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
e	NN	O	O
.	NN	O	O
2	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
,	NN	O	O
or	NN	O	O
an	NN	O	O
equal	NN	O	O
volume	NN	O	O
of	NN	O	O
saline	NN	O	O
for	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
;	NN	O	O
15	NN	O	O
minutes	NN	O	O
later	NN	O	O
,	NN	O	O
all	NN	O	O
the	NN	O	O
animals	NN	O	O
were	NN	O	O
injected	NN	O	O
with	NN	O	O
a	NN	O	O
single	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
dose	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
.	NN	O	O

The	NN	O	O
convulsant	NN	O	O
activity	NN	O	O
,	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
latency	NN	O	O
to	NN	O	O
convulse	NN	O	O
and	NN	O	O
the	NN	O	O
mortality	NN	O	O
rate	NN	O	O
were	NN	O	O
assessed	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
-	NN	O	O
induced	NN	O	O
mortality	NN	O	O
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
by	NN	O	O
the	NN	O	O
three	NN	O	O
different	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
.	NN	O	O

The	NN	O	O
convulsant	NN	O	O
activity	NN	O	O
of	NN	O	O
bupivacaine	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
modified	NN	O	O
but	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
decreased	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
latency	NN	O	O
to	NN	O	O
obtain	NN	O	O
bupivacaine	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B
;	NN	O	O
this	NN	O	O
effect	NN	O	O
was	NN	O	O
less	NN	O	O
pronounced	NN	O	O
with	NN	O	O
bepridil	NN	O	O
.	NN	O	O

Epidural	NN	O	O
blood	NN	O	O
flow	NN	O	O
during	NN	O	O
prostaglandin	NN	O	O
E1	NN	O	O
or	NN	O	O
trimethaphan	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
prostaglandin	NN	O	O
E1	NN	O	O
(	NN	O	O
PGE1	NN	O	O
)	NN	O	O
or	NN	O	O
trimethaphan	NN	O	O
(	NN	O	O
TMP	NN	O	O
)	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
on	NN	O	O
epidural	NN	O	O
blood	NN	O	O
flow	NN	O	O
(	NN	O	O
EBF	NN	O	O
)	NN	O	O
during	NN	O	O
spinal	NN	O	O
surgery	NN	O	O
,	NN	O	O
EBF	NN	O	O
was	NN	O	O
measured	NN	O	O
using	NN	O	O
the	NN	O	O
heat	NN	O	O
clearance	NN	O	O
method	NN	O	O
in	NN	O	O
30	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
postero	NN	O	O
-	NN	O	O
lateral	NN	O	O
interbody	NN	O	O
fusion	NN	O	O
under	NN	O	O
isoflurane	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

An	NN	O	O
initial	NN	O	O
dose	NN	O	O
of	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
microgram	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
of	NN	O	O
PGE1	NN	O	O
(	NN	O	O
15	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
10	NN	O	O
micrograms	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
of	NN	O	O
TMP	NN	O	O
(	NN	O	O
15	NN	O	O
patients	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
intravenously	NN	O	O
after	NN	O	O
the	NN	O	O
dural	NN	O	O
opening	NN	O	O
and	NN	O	O
the	NN	O	O
dose	NN	O	O
was	NN	O	O
adjusted	NN	O	O
to	NN	O	O
maintain	NN	O	O
the	NN	O	O
mean	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
at	NN	O	O
about	NN	O	O
60	NN	O	O
mmHg	NN	O	O
.	NN	O	O

The	NN	O	O
hypotensive	NN	O	B
drug	NN	O	O
was	NN	O	O
discontinued	NN	O	O
at	NN	O	O
the	NN	O	O
completion	NN	O	O
of	NN	O	O
the	NN	O	O
operative	NN	O	O
procedure	NN	O	O
.	NN	O	O

After	NN	O	O
starting	NN	O	O
PGE1	NN	O	O
or	NN	O	O
TMP	NN	O	O
,	NN	O	O
MAP	NN	O	O
and	NN	O	O
rate	NN	O	O
pressure	NN	O	O
product	NN	O	O
(	NN	O	O
RPP	NN	O	O
)	NN	O	O
decreased	NN	O	O
significantly	NN	O	O
compared	NN	O	O
with	NN	O	O
preinfusion	NN	O	O
values	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
hypotension	NN	O	B
due	NN	O	O
to	NN	O	O
PGE1	NN	O	O
remained	NN	O	O
constant	NN	O	O
until	NN	O	O
60	NN	O	O
min	NN	O	O
after	NN	O	O
its	NN	O	O
discontinuation	NN	O	O
.	NN	O	O

Heart	NN	O	O
rate	NN	O	O
(	NN	O	O
HR	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
.	NN	O	O

EBFF	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
during	NN	O	O
PGE1	NN	O	O
infusion	NN	O	O
whereas	NN	O	O
in	NN	O	O
the	NN	O	O
TMP	NN	O	O
group	NN	O	O
,	NN	O	O
EBF	NN	O	O
decreased	NN	O	O
significantly	NN	O	O
at	NN	O	O
30	NN	O	O
and	NN	O	O
60	NN	O	O
min	NN	O	O
after	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
TMP	NN	O	O
(	NN	O	O
preinfusion	NN	O	O
:	NN	O	O
45	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
.	NN	O	O
9	NN	O	O
ml	NN	O	O
/	NN	O	O
100g	NN	O	O
/	NN	O	O
min	NN	O	O
.	NN	O	O
30	NN	O	O
min	NN	O	O
:	NN	O	O
32	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O
9	NN	O	O
ml	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
/	NN	O	O
min	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O
60	NN	O	O
min	NN	O	O
:	NN	O	O
30	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
ml	NN	O	O
/	NN	O	O
100	NN	O	O
g	NN	O	O
/	NN	O	O
min	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
PGE1	NN	O	O
may	NN	O	O
be	NN	O	O
preferable	NN	O	O
to	NN	O	O
TMP	NN	O	O
for	NN	O	O
hypotensive	NN	O	B
anaesthesia	NN	O	O
in	NN	O	O
spinal	NN	O	O
surgery	NN	O	O
because	NN	O	O
TMP	NN	O	O
decreased	NN	O	O
EBF	NN	O	O
.	NN	O	O

Dup	NN	O	O
753	NN	O	O
prevents	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrosis	NN	O	B
.	NN	O	O

The	NN	O	O
appearance	NN	O	O
of	NN	O	O
nephrotic	NN	O	B
syndromes	NN	O	I
such	NN	O	O
as	NN	O	O
proteinuria	NN	O	B
,	NN	O	O
hypoalbuminemia	NN	O	B
,	NN	O	O
hypercholesterolemia	NN	O	B
and	NN	O	O
increase	NN	O	O
in	NN	O	O
blood	NN	O	O
nitrogen	NN	O	O
urea	NN	O	O
,	NN	O	O
induced	NN	O	O
in	NN	O	O
rats	NN	O	O
by	NN	O	O
injection	NN	O	O
of	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
was	NN	O	O
markedly	NN	O	O
inhibited	NN	O	O
by	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
Dup	NN	O	O
753	NN	O	O
(	NN	O	O
losartan	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
novel	NN	O	O
angiotensin	NN	O	O
II	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
1	NN	O	O
or	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
a	NN	O	O
possible	NN	O	O
involvement	NN	O	O
of	NN	O	O
the	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	O
system	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
puromycin	NN	O	O
aminonucleoside	NN	O	O
-	NN	O	O
induced	NN	O	O
nephrosis	NN	O	B
.	NN	O	O

Neuroplasticity	NN	O	O
of	NN	O	O
the	NN	O	O
adult	NN	O	O
primate	NN	O	O
auditory	NN	O	O
cortex	NN	O	O
following	NN	O	O
cochlear	NN	O	O
hearing	NN	O	B
loss	NN	O	I
.	NN	O	O

Tonotopic	NN	O	O
organization	NN	O	O
is	NN	O	O
an	NN	O	O
essential	NN	O	O
feature	NN	O	O
of	NN	O	O
the	NN	O	O
primary	NN	O	O
auditory	NN	O	O
area	NN	O	O
(	NN	O	O
A1	NN	O	O
)	NN	O	O
of	NN	O	O
primate	NN	O	O
cortex	NN	O	O
.	NN	O	O

In	NN	O	O
A1	NN	O	O
of	NN	O	O
macaque	NN	O	O
monkeys	NN	O	O
,	NN	O	O
low	NN	O	O
frequencies	NN	O	O
are	NN	O	O
represented	NN	O	O
rostrolaterally	NN	O	O
and	NN	O	O
high	NN	O	O
frequencies	NN	O	O
are	NN	O	O
represented	NN	O	O
caudomedially	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
changes	NN	O	O
occur	NN	O	O
in	NN	O	O
this	NN	O	O
tonotopic	NN	O	O
organization	NN	O	O
following	NN	O	O
cochlear	NN	O	O
hearing	NN	O	B
loss	NN	O	I
.	NN	O	O

Under	NN	O	O
anesthesia	NN	O	O
,	NN	O	O
the	NN	O	O
superior	NN	O	O
temporal	NN	O	O
gyrus	NN	O	O
of	NN	O	O
adult	NN	O	O
macaque	NN	O	O
monkeys	NN	O	O
was	NN	O	O
exposed	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
tonotopic	NN	O	O
organization	NN	O	O
of	NN	O	O
A1	NN	O	O
was	NN	O	O
mapped	NN	O	O
using	NN	O	O
conventional	NN	O	O
microelectrode	NN	O	O
recording	NN	O	O
techniques	NN	O	O
.	NN	O	O

Following	NN	O	O
recovery	NN	O	O
,	NN	O	O
the	NN	O	O
monkeys	NN	O	O
were	NN	O	O
selectively	NN	O	O
deafened	NN	O	O
for	NN	O	O
high	NN	O	O
frequencies	NN	O	O
using	NN	O	O
kanamycin	NN	O	O
and	NN	O	O
furosemide	NN	O	O
.	NN	O	O

The	NN	O	O
actual	NN	O	O
frequencies	NN	O	O
deafened	NN	O	O
were	NN	O	O
determined	NN	O	O
by	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
tone	NN	O	O
-	NN	O	O
burst	NN	O	O
elicited	NN	O	O
auditory	NN	O	O
brainstem	NN	O	O
responses	NN	O	O
.	NN	O	O

Three	NN	O	O
months	NN	O	O
after	NN	O	O
deafening	NN	O	O
,	NN	O	O
A1	NN	O	O
was	NN	O	O
remapped	NN	O	O
.	NN	O	O

Postmortem	NN	O	O
cytoarchitectural	NN	O	O
features	NN	O	O
identifying	NN	O	O
A1	NN	O	O
were	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
electrophysiologic	NN	O	O
data	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
deprived	NN	O	O
area	NN	O	O
of	NN	O	O
A1	NN	O	O
undergoes	NN	O	O
extensive	NN	O	O
reorganization	NN	O	O
and	NN	O	O
becomes	NN	O	O
responsive	NN	O	O
to	NN	O	O
intact	NN	O	O
cochlear	NN	O	O
frequencies	NN	O	O
.	NN	O	O

The	NN	O	O
region	NN	O	O
of	NN	O	O
cortex	NN	O	O
that	NN	O	O
represents	NN	O	O
the	NN	O	O
low	NN	O	O
frequencies	NN	O	O
was	NN	O	O
not	NN	O	O
obviously	NN	O	O
affected	NN	O	O
by	NN	O	O
the	NN	O	O
cochlear	NN	O	O
hearing	NN	O	B
loss	NN	O	I
.	NN	O	O

Sodium	NN	O	O
bicarbonate	NN	O	O
alleviates	NN	O	O
penile	NN	O	B
pain	NN	O	I
induced	NN	O	O
by	NN	O	O
intracavernous	NN	O	O
injections	NN	O	O
for	NN	O	O
erectile	NN	O	B
dysfunction	NN	O	I
.	NN	O	O

In	NN	O	O
an	NN	O	O
attempt	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
penile	NN	O	B
pain	NN	O	I
associated	NN	O	O
with	NN	O	O
intracorporeal	NN	O	O
injections	NN	O	O
could	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
acidity	NN	O	O
of	NN	O	O
the	NN	O	O
medication	NN	O	O
,	NN	O	O
we	NN	O	O
performed	NN	O	O
a	NN	O	O
randomized	NN	O	O
study	NN	O	O
comparing	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
penile	NN	O	B
pain	NN	O	I
following	NN	O	O
intracorporeal	NN	O	O
injections	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
sodium	NN	O	O
bicarbonate	NN	O	O
to	NN	O	O
the	NN	O	O
intracorporeal	NN	O	O
medications	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
38	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
who	NN	O	O
presented	NN	O	O
to	NN	O	O
our	NN	O	O
clinic	NN	O	O
with	NN	O	O
impotence	NN	O	B
received	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
ml	NN	O	O
.	NN	O	O
of	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
3	NN	O	O
drugs	NN	O	O
:	NN	O	O
6	NN	O	O
mg	NN	O	O
.	NN	O	O
papaverine	NN	O	O
,	NN	O	O
100	NN	O	O
micrograms	NN	O	O
.	NN	O	O
phentolamine	NN	O	O
and	NN	O	O
10	NN	O	O
micrograms	NN	O	O
.	NN	O	O
prostaglandin	NN	O	O
E1	NN	O	O
with	NN	O	O
(	NN	O	O
pH	NN	O	O
7	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
or	NN	O	O
without	NN	O	O
(	NN	O	O
pH	NN	O	O
4	NN	O	O
.	NN	O	O
17	NN	O	O
)	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
sodium	NN	O	O
bicarbonate	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
mEq	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
19	NN	O	O
patients	NN	O	O
without	NN	O	O
sodium	NN	O	O
bicarbonate	NN	O	O
added	NN	O	O
to	NN	O	O
the	NN	O	O
medication	NN	O	O
11	NN	O	O
(	NN	O	O
58	NN	O	O
%	NN	O	O
)	NN	O	O
complained	NN	O	O
of	NN	O	O
penile	NN	O	B
pain	NN	O	I
due	NN	O	O
to	NN	O	O
the	NN	O	O
medication	NN	O	O
,	NN	O	O
while	NN	O	O
only	NN	O	O
1	NN	O	O
of	NN	O	O
the	NN	O	O
19	NN	O	O
men	NN	O	O
(	NN	O	O
5	NN	O	O
%	NN	O	O
)	NN	O	O
who	NN	O	O
received	NN	O	O
sodium	NN	O	O
bicarbonate	NN	O	O
complained	NN	O	O
of	NN	O	O
penile	NN	O	B
pain	NN	O	I
.	NN	O	O

From	NN	O	O
these	NN	O	O
data	NN	O	O
we	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
penile	NN	O	B
pain	NN	O	I
following	NN	O	O
intracorporeal	NN	O	O
injections	NN	O	O
is	NN	O	O
most	NN	O	O
likely	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
acidity	NN	O	O
of	NN	O	O
the	NN	O	O
medication	NN	O	O
,	NN	O	O
which	NN	O	O
can	NN	O	O
be	NN	O	O
overcome	NN	O	O
by	NN	O	O
elevating	NN	O	O
the	NN	O	O
pH	NN	O	O
to	NN	O	O
a	NN	O	O
neutral	NN	O	O
level	NN	O	O
.	NN	O	O

The	NN	O	O
use	NN	O	O
and	NN	O	O
toxicity	NN	O	B
of	NN	O	O
didanosine	NN	O	O
(	NN	O	O
ddI	NN	O	O
)	NN	O	O
in	NN	O	O
HIV	NN	O	B
antibody	NN	O	I
-	NN	O	I
positive	NN	O	I
individuals	NN	O	O
intolerant	NN	O	O
to	NN	O	O
zidovudine	NN	O	O
(	NN	O	O
AZT	NN	O	O
)	NN	O	O

One	NN	O	O
hundred	NN	O	O
and	NN	O	O
fifty	NN	O	O
-	NN	O	O
one	NN	O	O
patients	NN	O	O
intolerant	NN	O	O
to	NN	O	O
zidovudine	NN	O	O
(	NN	O	O
AZT	NN	O	O
)	NN	O	O
received	NN	O	O
didanosine	NN	O	O
(	NN	O	O
ddI	NN	O	O
)	NN	O	O
to	NN	O	O
a	NN	O	O
maximum	NN	O	O
dose	NN	O	O
of	NN	O	O
12	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

Patient	NN	O	O
response	NN	O	O
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
changes	NN	O	O
in	NN	O	O
CD4	NN	O	O
+	NN	O	O
lymphocyte	NN	O	O
subset	NN	O	O
count	NN	O	O
,	NN	O	O
HIV	NN	O	O
p24	NN	O	O
antigen	NN	O	O
,	NN	O	O
weight	NN	O	O
,	NN	O	O
and	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
.	NN	O	O

Seventy	NN	O	O
patients	NN	O	O
developed	NN	O	O
major	NN	O	O
opportunistic	NN	O	B
infections	NN	O	I
whilst	NN	O	O
on	NN	O	O
therapy	NN	O	O
;	NN	O	O
this	NN	O	O
was	NN	O	O
the	NN	O	O
first	NN	O	O
AIDS	NN	O	B
diagnosis	NN	O	O
in	NN	O	O
17	NN	O	O
.	NN	O	O

Only	NN	O	O
minor	NN	O	O
changes	NN	O	O
in	NN	O	O
CD4	NN	O	O
+	NN	O	O
lymphocyte	NN	O	O
subset	NN	O	O
count	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
AIDS	NN	O	B
patients	NN	O	O
,	NN	O	O
although	NN	O	O
a	NN	O	O
more	NN	O	O
significant	NN	O	O
rise	NN	O	O
occurred	NN	O	O
in	NN	O	O
those	NN	O	O
with	NN	O	O
earlier	NN	O	O
stages	NN	O	O
of	NN	O	O
disease	NN	O	O
.	NN	O	O

Of	NN	O	O
those	NN	O	O
positive	NN	O	O
for	NN	O	O
p24	NN	O	O
antigen	NN	O	O
at	NN	O	O
the	NN	O	O
commencement	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
67	NN	O	O
%	NN	O	O
showed	NN	O	O
a	NN	O	O
positive	NN	O	O
response	NN	O	O
,	NN	O	O
and	NN	O	O
this	NN	O	O
was	NN	O	O
most	NN	O	O
likely	NN	O	O
in	NN	O	O
those	NN	O	O
with	NN	O	O
CD4	NN	O	O
+	NN	O	O
lymphocyte	NN	O	O
subset	NN	O	O
counts	NN	O	O
above	NN	O	O
100	NN	O	O
mm3	NN	O	O
.	NN	O	O

A	NN	O	O
positive	NN	O	O
weight	NN	O	O
response	NN	O	O
was	NN	O	O
seen	NN	O	O
in	NN	O	O
16	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Most	NN	O	O
patients	NN	O	O
showed	NN	O	O
improvement	NN	O	O
in	NN	O	O
individual	NN	O	O
parameters	NN	O	O
and	NN	O	O
global	NN	O	O
score	NN	O	O
of	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
.	NN	O	O

Adverse	NN	O	O
reactions	NN	O	O
possibly	NN	O	O
attributable	NN	O	O
to	NN	O	O
didanosine	NN	O	O
were	NN	O	O
common	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
was	NN	O	O
diarrhoea	NN	O	B
,	NN	O	O
which	NN	O	O
resulted	NN	O	O
in	NN	O	O
cessation	NN	O	O
of	NN	O	O
therapy	NN	O	O
in	NN	O	O
19	NN	O	O
individuals	NN	O	O
.	NN	O	O

Peripheral	NN	O	B
neuropathy	NN	O	I
occurred	NN	O	O
in	NN	O	O
12	NN	O	O
patients	NN	O	O
and	NN	O	O
pancreatitis	NN	O	B
in	NN	O	O
six	NN	O	O
.	NN	O	O

Thirteen	NN	O	O
patients	NN	O	O
developed	NN	O	O
a	NN	O	O
raised	NN	O	O
serum	NN	O	O
amylase	NN	O	O
without	NN	O	O
abdominal	NN	O	B
pain	NN	O	I
.	NN	O	O

Seven	NN	O	O
patients	NN	O	O
developed	NN	O	O
glucose	NN	O	B
tolerance	NN	O	I
curves	NN	O	I
characteristic	NN	O	O
of	NN	O	O
diabetes	NN	O	B
but	NN	O	O
these	NN	O	O
were	NN	O	O
mild	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
require	NN	O	O
treatment	NN	O	O
and	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
on	NN	O	O
ceasing	NN	O	O
didanosine	NN	O	O
.	NN	O	O

Immunohistochemical	NN	O	O
studies	NN	O	O
with	NN	O	O
antibodies	NN	O	O
to	NN	O	O
neurofilament	NN	O	O
proteins	NN	O	O
on	NN	O	O
axonal	NN	O	B
damage	NN	O	I
in	NN	O	O
experimental	NN	O	O
focal	NN	O	O
lesions	NN	O	O
in	NN	O	O
rat	NN	O	O
.	NN	O	O

Immunohistochemistry	NN	O	O
with	NN	O	O
monoclonal	NN	O	O
antibodies	NN	O	O
against	NN	O	O
neurofilament	NN	O	O
(	NN	O	O
NF	NN	O	O
)	NN	O	O
proteins	NN	O	O
of	NN	O	O
middle	NN	O	O
and	NN	O	O
high	NN	O	O
molecular	NN	O	O
weight	NN	O	O
class	NN	O	O
,	NN	O	O
NF	NN	O	O
-	NN	O	O
M	NN	O	O
and	NN	O	O
NF	NN	O	O
-	NN	O	O
H	NN	O	O
,	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
study	NN	O	O
axonal	NN	O	B
injury	NN	O	I
in	NN	O	O
the	NN	O	O
borderzone	NN	O	O
of	NN	O	O
focal	NN	O	O
lesions	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Focal	NN	O	O
injury	NN	O	B
in	NN	O	I
the	NN	O	I
cortex	NN	O	I
was	NN	O	O
produced	NN	O	O
by	NN	O	O
infusion	NN	O	O
of	NN	O	O
lactate	NN	O	O
at	NN	O	O
acid	NN	O	O
pH	NN	O	O
or	NN	O	O
by	NN	O	O
stab	NN	O	O
caused	NN	O	O
by	NN	O	O
needle	NN	O	O
insertion	NN	O	O
.	NN	O	O

Infarcts	NN	O	B
in	NN	O	I
substantia	NN	O	I
nigra	NN	O	I
pars	NN	O	I
reticulata	NN	O	I
were	NN	O	O
evoked	NN	O	O
by	NN	O	O
prolonged	NN	O	O
pilocarpine	NN	O	O
-	NN	O	O
induced	NN	O	O
status	NN	O	B
epilepticus	NN	O	I
.	NN	O	O

Immunohistochemical	NN	O	O
staining	NN	O	O
for	NN	O	O
NFs	NN	O	O
showed	NN	O	O
characteristic	NN	O	O
terminal	NN	O	O
clubs	NN	O	O
of	NN	O	O
axons	NN	O	O
in	NN	O	O
the	NN	O	O
borderzone	NN	O	O
of	NN	O	O
lesions	NN	O	O
.	NN	O	O

Differences	NN	O	O
in	NN	O	O
the	NN	O	O
labelling	NN	O	O
pattern	NN	O	O
occurred	NN	O	O
with	NN	O	O
different	NN	O	O
antibodies	NN	O	O
which	NN	O	O
apparently	NN	O	O
depended	NN	O	O
on	NN	O	O
molecular	NN	O	O
weight	NN	O	O
class	NN	O	O
of	NN	O	O
NFs	NN	O	O
and	NN	O	O
phosphorylation	NN	O	O
state	NN	O	O
.	NN	O	O

These	NN	O	O
immunohistochemical	NN	O	O
changes	NN	O	O
of	NN	O	O
NFs	NN	O	O
can	NN	O	O
serve	NN	O	O
as	NN	O	O
a	NN	O	O
marker	NN	O	O
for	NN	O	O
axonal	NN	O	B
damage	NN	O	I
in	NN	O	O
various	NN	O	O
experimental	NN	O	O
traumatic	NN	O	B
or	NN	O	O
ischemic	NN	O	O
lesions	NN	O	O
.	NN	O	O

Pharmacokinetic	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cimetidine	NN	O	O
-	NN	O	O
associated	NN	O	O
mental	NN	O	O
confusion	NN	O	B
.	NN	O	O

15	NN	O	O
cases	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
-	NN	O	O
associated	NN	O	O
mental	NN	O	O
confusion	NN	O	B
have	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
that	NN	O	O
this	NN	O	O
syndrome	NN	O	O
might	NN	O	O
be	NN	O	O
investigated	NN	O	O
changes	NN	O	O
in	NN	O	O
mental	NN	O	O
status	NN	O	O
(	NN	O	O
M	NN	O	O
.	NN	O	O
S	NN	O	O
.	NN	O	O
)	NN	O	O
were	NN	O	O
correlated	NN	O	O
with	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
and	NN	O	O
renal	NN	O	O
and	NN	O	O
hepatic	NN	O	O
function	NN	O	O
in	NN	O	O
36	NN	O	O
patients	NN	O	O
,	NN	O	O
30	NN	O	O
patients	NN	O	O
had	NN	O	O
no	NN	O	O
M	NN	O	O
.	NN	O	O
S	NN	O	O
.	NN	O	O
change	NN	O	O
on	NN	O	O
cimetidine	NN	O	O
and	NN	O	O
6	NN	O	O
had	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
changes	NN	O	O
.	NN	O	O

These	NN	O	O
6	NN	O	O
patients	NN	O	O
had	NN	O	O
both	NN	O	O
renal	NN	O	B
and	NN	O	I
liver	NN	O	I
dysfunction	NN	O	I
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
cimetidine	NN	O	O
trough	NN	O	O
-	NN	O	O
concentrations	NN	O	O
of	NN	O	O
more	NN	O	O
than	NN	O	O
1	NN	O	O
.	NN	O	O
25	NN	O	O
microgram	NN	O	O
/	NN	O	O
ml	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
severity	NN	O	O
of	NN	O	O
M	NN	O	O
.	NN	O	O
S	NN	O	O
.	NN	O	O
changes	NN	O	O
increased	NN	O	O
as	NN	O	O
trough	NN	O	O
-	NN	O	O
concentrations	NN	O	O
rose	NN	O	O
,	NN	O	O
5	NN	O	O
patients	NN	O	O
had	NN	O	O
lumbar	NN	O	O
puncture	NN	O	O
.	NN	O	O

The	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
:	NN	O	O
serum	NN	O	O
ratio	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
concentrations	NN	O	O
was	NN	O	O
0	NN	O	O
.	NN	O	O
24	NN	O	O
:	NN	O	O
1	NN	O	O
and	NN	O	O
indicates	NN	O	O
that	NN	O	O
cimetidine	NN	O	O
passes	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
;	NN	O	O
it	NN	O	O
also	NN	O	O
raises	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
M	NN	O	O
.	NN	O	O
S	NN	O	O
.	NN	O	O
changes	NN	O	O
are	NN	O	O
due	NN	O	O
to	NN	O	O
blockade	NN	O	O
of	NN	O	O
histamine	NN	O	O
H2	NN	O	O
-	NN	O	O
receptors	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O

Patients	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
both	NN	O	O
raised	NN	O	O
trough	NN	O	O
-	NN	O	O
concentrations	NN	O	O
and	NN	O	O
mental	NN	O	O
confusion	NN	O	B
are	NN	O	O
those	NN	O	O
with	NN	O	O
both	NN	O	O
severe	NN	O	O
renal	NN	O	B
and	NN	O	I
hepatic	NN	O	I
dysfunction	NN	O	I
.	NN	O	O

They	NN	O	O
should	NN	O	O
be	NN	O	O
closely	NN	O	O
observed	NN	O	O
and	NN	O	O
should	NN	O	O
be	NN	O	O
given	NN	O	O
reduced	NN	O	O
doses	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
.	NN	O	O

Prospective	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
effects	NN	O	O
of	NN	O	O
somatostatin	NN	O	O
analog	NN	O	O
(	NN	O	O
octreotide	NN	O	O
)	NN	O	O
on	NN	O	O
gallbladder	NN	O	O
function	NN	O	O
and	NN	O	O
gallstone	NN	O	B
formation	NN	O	O
in	NN	O	O
Chinese	NN	O	O
acromegalic	NN	O	B
patients	NN	O	O
.	NN	O	O

This	NN	O	O
article	NN	O	O
reports	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
gallbladder	NN	O	O
function	NN	O	O
examined	NN	O	O
by	NN	O	O
ultrasonography	NN	O	O
in	NN	O	O
20	NN	O	O
Chinese	NN	O	O
patients	NN	O	O
with	NN	O	O
active	NN	O	O
acromegaly	NN	O	B
treated	NN	O	O
with	NN	O	O
sc	NN	O	O
injection	NN	O	O
of	NN	O	O
the	NN	O	O
somatostatin	NN	O	O
analog	NN	O	O
octreotide	NN	O	O
in	NN	O	O
dosages	NN	O	O
of	NN	O	O
300	NN	O	O
-	NN	O	O
1500	NN	O	O
micrograms	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
a	NN	O	O
mean	NN	O	O
of	NN	O	O
24	NN	O	O
.	NN	O	O
2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
.	NN	O	O
9	NN	O	O
months	NN	O	O
.	NN	O	O

During	NN	O	O
treatment	NN	O	O
with	NN	O	O
octreotide	NN	O	O
,	NN	O	O
17	NN	O	O
patients	NN	O	O
developed	NN	O	O
sludge	NN	O	O
,	NN	O	O
10	NN	O	O
had	NN	O	O
gallstones	NN	O	B
,	NN	O	O
and	NN	O	O
1	NN	O	O
developed	NN	O	O
acute	NN	O	B
cholecystitis	NN	O	I
requiring	NN	O	O
surgery	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
of	NN	O	O
7	NN	O	O
patients	NN	O	O
examined	NN	O	O
acutely	NN	O	O
,	NN	O	O
gallbladder	NN	O	O
contractility	NN	O	O
was	NN	O	O
inhibited	NN	O	O
after	NN	O	O
a	NN	O	O
single	NN	O	O
100	NN	O	O
-	NN	O	O
micrograms	NN	O	O
injection	NN	O	O
.	NN	O	O

In	NN	O	O
8	NN	O	O
patients	NN	O	O
followed	NN	O	O
for	NN	O	O
24	NN	O	O
weeks	NN	O	O
,	NN	O	O
gallbladder	NN	O	O
contractility	NN	O	O
remained	NN	O	O
depressed	NN	O	B
throughout	NN	O	O
therapy	NN	O	O
.	NN	O	O

After	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
octreotide	NN	O	O
in	NN	O	O
10	NN	O	O
patients	NN	O	O
without	NN	O	O
gallstones	NN	O	B
,	NN	O	O
8	NN	O	O
patients	NN	O	O
assessed	NN	O	O
had	NN	O	O
return	NN	O	O
of	NN	O	O
normal	NN	O	O
gallbladder	NN	O	O
contractility	NN	O	O
within	NN	O	O
1	NN	O	O
month	NN	O	O
.	NN	O	O

In	NN	O	O
8	NN	O	O
of	NN	O	O
the	NN	O	O
remaining	NN	O	O
10	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
gallstones	NN	O	B
during	NN	O	O
treatment	NN	O	O
,	NN	O	O
gallbladder	NN	O	O
contractility	NN	O	O
normalized	NN	O	O
in	NN	O	O
5	NN	O	O
patients	NN	O	O
(	NN	O	O
3	NN	O	O
of	NN	O	O
whom	NN	O	O
has	NN	O	O
disappearance	NN	O	O
of	NN	O	O
their	NN	O	O
stones	NN	O	O
within	NN	O	O
3	NN	O	O
weeks	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
remained	NN	O	O
depressed	NN	O	B
in	NN	O	O
3	NN	O	O
(	NN	O	O
2	NN	O	O
of	NN	O	O
whom	NN	O	O
had	NN	O	O
stones	NN	O	O
present	NN	O	O
at	NN	O	O
6	NN	O	O
months	NN	O	O
)	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
suppression	NN	O	O
of	NN	O	O
gallbladder	NN	O	O
contractility	NN	O	O
is	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
successive	NN	O	O
formation	NN	O	O
of	NN	O	O
bile	NN	O	O
sludge	NN	O	O
,	NN	O	O
gallstones	NN	O	B
,	NN	O	O
and	NN	O	O
cholecystitis	NN	O	B
during	NN	O	O
octreotide	NN	O	O
therapy	NN	O	O
in	NN	O	O
Chinese	NN	O	O
acromegalic	NN	O	B
patients	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
therefore	NN	O	O
very	NN	O	O
important	NN	O	O
to	NN	O	O
follow	NN	O	O
the	NN	O	O
changes	NN	O	O
of	NN	O	O
gallbladder	NN	O	O
function	NN	O	O
during	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
octreotide	NN	O	O
therapy	NN	O	O
of	NN	O	O
acromegalic	NN	O	B
patients	NN	O	O
.	NN	O	O

Increase	NN	O	O
of	NN	O	O
Parkinson	NN	O	B
disability	NN	O	I
after	NN	O	O
fluoxetine	NN	O	O
medication	NN	O	O
.	NN	O	O

Depression	NN	O	B
is	NN	O	O
a	NN	O	O
major	NN	O	O
clinical	NN	O	O
feature	NN	O	O
of	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
increased	NN	O	O
amount	NN	O	O
of	NN	O	O
motor	NN	O	B
disability	NN	O	I
in	NN	O	O
four	NN	O	O
patients	NN	O	O
with	NN	O	O
idiopathic	NN	O	B
Parkinson	NN	O	I
'	NN	O	I
s	NN	O	I
disease	NN	O	I
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
the	NN	O	O
antidepressant	NN	O	O
fluoxetine	NN	O	O
.	NN	O	O

The	NN	O	O
possibility	NN	O	O
of	NN	O	O
a	NN	O	O
clinically	NN	O	O
relevant	NN	O	O
dopamine	NN	O	O
-	NN	O	O
antagonistic	NN	O	O
capacity	NN	O	O
of	NN	O	O
fluoxetine	NN	O	O
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
patients	NN	O	O
must	NN	O	O
be	NN	O	O
considered	NN	O	O
.	NN	O	O

Sinus	NN	O	B
arrest	NN	O	I
associated	NN	O	O
with	NN	O	O
continuous	NN	O	O
-	NN	O	O
infusion	NN	O	O
cimetidine	NN	O	O
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
intermittent	NN	O	O
intravenous	NN	O	O
infusions	NN	O	O
of	NN	O	O
cimetidine	NN	O	O
is	NN	O	O
infrequently	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
bradyarrhythmias	NN	O	B
.	NN	O	O

A	NN	O	O
40	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
leukemia	NN	O	B
and	NN	O	O
no	NN	O	O
history	NN	O	O
of	NN	O	O
cardiac	NN	O	B
disease	NN	O	I
developed	NN	O	O
recurrent	NN	O	O
,	NN	O	O
brief	NN	O	O
episodes	NN	O	O
of	NN	O	O
apparent	NN	O	O
sinus	NN	O	B
arrest	NN	O	I
while	NN	O	O
receiving	NN	O	O
continuous	NN	O	O
-	NN	O	O
infusion	NN	O	O
cimetidine	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
hour	NN	O	O
.	NN	O	O

The	NN	O	O
arrhythmias	NN	O	B
were	NN	O	O
temporally	NN	O	O
related	NN	O	O
to	NN	O	O
cimetidine	NN	O	O
administration	NN	O	O
,	NN	O	O
disappeared	NN	O	O
after	NN	O	O
dechallenge	NN	O	O
,	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
recur	NN	O	O
during	NN	O	O
ranitidine	NN	O	O
treatment	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
of	NN	O	O
sinus	NN	O	B
arrest	NN	O	I
associated	NN	O	O
with	NN	O	O
continuous	NN	O	O
-	NN	O	O
infusion	NN	O	O
cimetidine	NN	O	O
.	NN	O	O

Phase	NN	O	O
II	NN	O	O
trial	NN	O	O
of	NN	O	O
vinorelbine	NN	O	O
in	NN	O	O
metastatic	NN	O	O
squamous	NN	O	B
cell	NN	O	I
esophageal	NN	O	I
carcinoma	NN	O	I
.	NN	O	O

European	NN	O	O
Organization	NN	O	O
for	NN	O	O
Research	NN	O	O
and	NN	O	O
Treatment	NN	O	O
of	NN	O	O
Cancer	NN	O	B
Gastrointestinal	NN	O	O
Treat	NN	O	O
Cancer	NN	O	B
Cooperative	NN	O	O
Group	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
response	NN	O	O
rate	NN	O	O
and	NN	O	O
toxic	NN	O	O
effects	NN	O	O
of	NN	O	O
vinorelbine	NN	O	O
(	NN	O	O
VNB	NN	O	O
)	NN	O	O
administered	NN	O	O
as	NN	O	O
a	NN	O	O
single	NN	O	O
agent	NN	O	O
in	NN	O	O
metastatic	NN	O	O
squamous	NN	O	B
cell	NN	O	I
esophageal	NN	O	I
carcinoma	NN	O	I
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Forty	NN	O	O
-	NN	O	O
six	NN	O	O
eligible	NN	O	O
patients	NN	O	O
with	NN	O	O
measurable	NN	O	O
lesions	NN	O	O
were	NN	O	O
included	NN	O	O
and	NN	O	O
were	NN	O	O
stratified	NN	O	O
according	NN	O	O
to	NN	O	O
previous	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

Thirty	NN	O	O
patients	NN	O	O
without	NN	O	O
prior	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
16	NN	O	O
pretreated	NN	O	O
with	NN	O	O
cisplatin	NN	O	O
-	NN	O	O
based	NN	O	O
chemotherapy	NN	O	O
were	NN	O	O
assessable	NN	O	O
for	NN	O	O
toxicity	NN	O	B
and	NN	O	O
response	NN	O	O
.	NN	O	O

VNB	NN	O	O
was	NN	O	O
administered	NN	O	O
weekly	NN	O	O
as	NN	O	O
a	NN	O	O
25	NN	O	O
-	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
short	NN	O	O
intravenous	NN	O	O
(	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
infusion	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Six	NN	O	O
of	NN	O	O
30	NN	O	O
patients	NN	O	O
(	NN	O	O
20	NN	O	O
%	NN	O	O
)	NN	O	O
without	NN	O	O
prior	NN	O	O
chemotherapy	NN	O	O
achieved	NN	O	O
a	NN	O	O
partial	NN	O	O
response	NN	O	O
(	NN	O	O
PR	NN	O	O
)	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
,	NN	O	O
8	NN	O	O
%	NN	O	O
to	NN	O	O
39	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
duration	NN	O	O
of	NN	O	O
response	NN	O	O
was	NN	O	O
21	NN	O	O
weeks	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
17	NN	O	O
to	NN	O	O
28	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
16	NN	O	O
patients	NN	O	O
(	NN	O	O
6	NN	O	O
%	NN	O	O
)	NN	O	O
with	NN	O	O
prior	NN	O	O
chemotherapy	NN	O	O
had	NN	O	O
a	NN	O	O
complete	NN	O	O
response	NN	O	O
(	NN	O	O
CR	NN	O	O
)	NN	O	O
of	NN	O	O
31	NN	O	O
weeks	NN	O	O
'	NN	O	O
duration	NN	O	O
(	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
0	NN	O	O
%	NN	O	O
to	NN	O	O
30	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
(	NN	O	O
World	NN	O	O
Health	NN	O	O
Organization	NN	O	O
[	NN	O	O
WHO	NN	O	O
]	NN	O	O
criteria	NN	O	O
)	NN	O	O
was	NN	O	O
15	NN	O	O
%	NN	O	O
(	NN	O	O
CR	NN	O	O
,	NN	O	O
2	NN	O	O
%	NN	O	O
;	NN	O	O
PR	NN	O	O
13	NN	O	O
%	NN	O	O
;	NN	O	O
95	NN	O	O
%	NN	O	O
CI	NN	O	O
,	NN	O	O
6	NN	O	O
%	NN	O	O
to	NN	O	O
29	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
dose	NN	O	O
-	NN	O	O
intensity	NN	O	O
(	NN	O	O
DI	NN	O	O
)	NN	O	O
was	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
wk	NN	O	O
.	NN	O	O

VNB	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
and	NN	O	O
zero	NN	O	O
instances	NN	O	O
of	NN	O	O
WHO	NN	O	O
grade	NN	O	O
4	NN	O	O
nonhematologic	NN	O	O
toxicity	NN	O	B
occurred	NN	O	O
.	NN	O	O

At	NN	O	O
least	NN	O	O
one	NN	O	O
episode	NN	O	O
of	NN	O	O
grade	NN	O	O
3	NN	O	O
or	NN	O	O
4	NN	O	O
granulocytopenia	NN	O	B
was	NN	O	O
seen	NN	O	O
in	NN	O	O
59	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

A	NN	O	O
grade	NN	O	O
2	NN	O	O
or	NN	O	O
3	NN	O	O
infection	NN	O	B
occurred	NN	O	O
in	NN	O	O
16	NN	O	O
%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
no	NN	O	O
toxic	NN	O	O
deaths	NN	O	B
occurred	NN	O	O
.	NN	O	O

Other	NN	O	O
side	NN	O	O
effects	NN	O	O
were	NN	O	O
rare	NN	O	O
,	NN	O	O
and	NN	O	O
peripheral	NN	O	B
neurotoxicity	NN	O	I
has	NN	O	O
been	NN	O	O
minor	NN	O	O
(	NN	O	O
26	NN	O	O
%	NN	O	O
grade	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
VNB	NN	O	O
is	NN	O	O
an	NN	O	O
active	NN	O	O
agent	NN	O	O
in	NN	O	O
metastatic	NN	O	O
esophageal	NN	O	B
squamous	NN	O	I
cell	NN	O	I
carcinoma	NN	O	I
.	NN	O	O

Given	NN	O	O
its	NN	O	O
excellent	NN	O	O
tolerance	NN	O	O
profile	NN	O	O
and	NN	O	O
low	NN	O	O
toxicity	NN	O	B
,	NN	O	O
further	NN	O	O
evaluation	NN	O	O
of	NN	O	O
VNB	NN	O	O
in	NN	O	O
combination	NN	O	O
therapy	NN	O	O
is	NN	O	O
warranted	NN	O	O
.	NN	O	O

Evaluation	NN	O	O
of	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
of	NN	O	O
aponidine	NN	O	O
hydrochloride	NN	O	O
ophthalmic	NN	O	O
solution	NN	O	O
.	NN	O	O

We	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
the	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
of	NN	O	O
apraclonidine	NN	O	O
in	NN	O	O
20	NN	O	O
normal	NN	O	O
volunteers	NN	O	O
by	NN	O	O
instilling	NN	O	O
a	NN	O	O
single	NN	O	O
drop	NN	O	O
of	NN	O	O
1	NN	O	O
%	NN	O	O
apraclonidine	NN	O	O
in	NN	O	O
their	NN	O	O
right	NN	O	O
eyes	NN	O	O
.	NN	O	O

Examinations	NN	O	O
,	NN	O	O
including	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
pulse	NN	O	O
rate	NN	O	O
,	NN	O	O
conjunctiva	NN	O	O
and	NN	O	O
cornea	NN	O	O
,	NN	O	O
intraocular	NN	O	O
pressure	NN	O	O
(	NN	O	O
IOP	NN	O	O
)	NN	O	O
,	NN	O	O
pupil	NN	O	O
diameter	NN	O	O
,	NN	O	O
basal	NN	O	O
tear	NN	O	O
secretion	NN	O	O
and	NN	O	O
margin	NN	O	O
reflex	NN	O	O
distance	NN	O	O
of	NN	O	O
both	NN	O	O
upper	NN	O	O
and	NN	O	O
lower	NN	O	O
eyelids	NN	O	O
,	NN	O	O
were	NN	O	O
performed	NN	O	O
prior	NN	O	O
to	NN	O	O
entry	NN	O	O
and	NN	O	O
at	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
5	NN	O	O
and	NN	O	O
7	NN	O	O
hours	NN	O	O
after	NN	O	O
instillation	NN	O	O
.	NN	O	O

The	NN	O	O
ocular	NN	O	B
hypotensive	NN	O	I
effects	NN	O	O
were	NN	O	O
statistically	NN	O	O
significant	NN	O	O
for	NN	O	O
apraclonidine	NN	O	O
-	NN	O	O
treated	NN	O	O
eyes	NN	O	O
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
and	NN	O	O
also	NN	O	O
statistically	NN	O	O
significant	NN	O	O
for	NN	O	O
contralateral	NN	O	O
eyes	NN	O	O
from	NN	O	O
three	NN	O	O
hours	NN	O	O
after	NN	O	O
topical	NN	O	O
administration	NN	O	O
of	NN	O	O
1	NN	O	O
%	NN	O	O
apraclonidine	NN	O	O
.	NN	O	O

Decreases	NN	O	B
in	NN	O	I
systolic	NN	O	I
blood	NN	O	I
pressure	NN	O	I
were	NN	O	O
statistically	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
clinically	NN	O	O
,	NN	O	O
significant	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
changes	NN	O	O
in	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
pulse	NN	O	O
rate	NN	O	O
and	NN	O	O
basal	NN	O	O
tear	NN	O	O
secretion	NN	O	O
were	NN	O	O
noted	NN	O	O
.	NN	O	O

Conjunctival	NN	O	B
blanching	NN	O	I
and	NN	O	O
mydriasis	NN	O	B
were	NN	O	O
commonly	NN	O	O
found	NN	O	O
.	NN	O	O

Upper	NN	O	O
lid	NN	O	O
retraction	NN	O	O
was	NN	O	O
frequently	NN	O	O
noted	NN	O	O
.	NN	O	O

While	NN	O	O
the	NN	O	O
elevations	NN	O	O
of	NN	O	O
the	NN	O	O
upper	NN	O	O
lid	NN	O	O
margin	NN	O	O
in	NN	O	O
most	NN	O	O
subjects	NN	O	O
were	NN	O	O
not	NN	O	O
more	NN	O	O
than	NN	O	O
2	NN	O	O
mm	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
cause	NN	O	O
noticeable	NN	O	O
change	NN	O	O
in	NN	O	O
appearance	NN	O	O
,	NN	O	O
one	NN	O	O
subject	NN	O	O
suffered	NN	O	O
from	NN	O	O
mechanical	NN	O	O
entropion	NN	O	B
and	NN	O	O
marked	NN	O	O
corneal	NN	O	B
abrasion	NN	O	I
3	NN	O	O
hours	NN	O	O
after	NN	O	O
instillation	NN	O	O
of	NN	O	O
the	NN	O	O
medication	NN	O	O
.	NN	O	O

This	NN	O	O
may	NN	O	O
well	NN	O	O
be	NN	O	O
a	NN	O	O
particularly	NN	O	O
notable	NN	O	O
finding	NN	O	O
in	NN	O	O
Asian	NN	O	O
people	NN	O	O
.	NN	O	O

Thiopentone	NN	O	O
pretreatment	NN	O	O
for	NN	O	O
propofol	NN	O	O
injection	NN	O	O
pain	NN	O	B
in	NN	O	O
ambulatory	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
investigated	NN	O	O
propofol	NN	O	O
injection	NN	O	O
pain	NN	O	B
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
ambulatory	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trial	NN	O	O
,	NN	O	O
90	NN	O	O
women	NN	O	O
were	NN	O	O
allocated	NN	O	O
to	NN	O	O
receive	NN	O	O
one	NN	O	O
of	NN	O	O
three	NN	O	O
treatments	NN	O	O
prior	NN	O	O
to	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
propofol	NN	O	O
.	NN	O	O

Patients	NN	O	O
in	NN	O	O
Group	NN	O	O
C	NN	O	O
received	NN	O	O
2	NN	O	O
ml	NN	O	O
normal	NN	O	O
saline	NN	O	O
,	NN	O	O
Group	NN	O	O
L	NN	O	O
,	NN	O	O
2	NN	O	O
ml	NN	O	O
,	NN	O	O
lidocaine	NN	O	O
2	NN	O	O
%	NN	O	O
(	NN	O	O
40	NN	O	O
mg	NN	O	O
)	NN	O	O
and	NN	O	O
Group	NN	O	O
T	NN	O	O
,	NN	O	O
2	NN	O	O
ml	NN	O	O
thiopentone	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
(	NN	O	O
50	NN	O	O
mg	NN	O	O
)	NN	O	O
.	NN	O	O

Venous	NN	O	O
discomfort	NN	O	O
was	NN	O	O
assessed	NN	O	O
with	NN	O	O
a	NN	O	O
visual	NN	O	O
analogue	NN	O	O
scale	NN	O	O
(	NN	O	O
VAS	NN	O	O
)	NN	O	O
5	NN	O	O
-	NN	O	O
15	NN	O	O
sec	NN	O	O
after	NN	O	O
commencing	NN	O	O
propofol	NN	O	O
administration	NN	O	O
using	NN	O	O
an	NN	O	O
infusion	NN	O	O
pump	NN	O	O
(	NN	O	O
rate	NN	O	O
1000	NN	O	O
micrograms	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

Loss	NN	O	B
of	NN	O	I
consciousness	NN	O	I
occurred	NN	O	O
in	NN	O	O
60	NN	O	O
-	NN	O	O
90	NN	O	O
sec	NN	O	O
.	NN	O	O

Visual	NN	O	O
analogue	NN	O	O
scores	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
during	NN	O	O
induction	NN	O	O
were	NN	O	O
lower	NN	O	O
in	NN	O	O
Groups	NN	O	O
L	NN	O	O
(	NN	O	O
3	NN	O	O
.	NN	O	O
3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
)	NN	O	O
and	NN	O	O
T	NN	O	O
(	NN	O	O
4	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
7	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
Group	NN	O	O
C	NN	O	O
(	NN	O	O
5	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
.	NN	O	O
3	NN	O	O
)	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0031	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
venous	NN	O	O
discomfort	NN	O	O
was	NN	O	O
lower	NN	O	O
in	NN	O	O
Group	NN	O	O
L	NN	O	O
(	NN	O	O
76	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
Group	NN	O	O
C	NN	O	O
(	NN	O	O
100	NN	O	O
%	NN	O	O
)	NN	O	O
but	NN	O	O
not	NN	O	O
different	NN	O	O
from	NN	O	O
Group	NN	O	O
T	NN	O	O
(	NN	O	O
90	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
VAS	NN	O	O
scores	NN	O	O
for	NN	O	O
recall	NN	O	O
of	NN	O	O
pain	NN	O	B
in	NN	O	O
the	NN	O	O
recovery	NN	O	O
room	NN	O	O
were	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
VAS	NN	O	O
scores	NN	O	O
during	NN	O	O
induction	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
7045	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

Recovery	NN	O	O
room	NN	O	O
discharge	NN	O	O
times	NN	O	O
were	NN	O	O
similar	NN	O	O
:	NN	O	O
C	NN	O	O
(	NN	O	O
75	NN	O	O
.	NN	O	O
9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
19	NN	O	O
.	NN	O	O
4	NN	O	O
min	NN	O	O
)	NN	O	O
;	NN	O	O
L	NN	O	O
73	NN	O	O
.	NN	O	O
6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
21	NN	O	O
.	NN	O	O
6	NN	O	O
min	NN	O	O
)	NN	O	O
;	NN	O	O
T	NN	O	O
(	NN	O	O
77	NN	O	O
.	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
18	NN	O	O
.	NN	O	O
9	NN	O	O
min	NN	O	O
)	NN	O	O
.	NN	O	O

Assessing	NN	O	O
their	NN	O	O
overall	NN	O	O
satisfaction	NN	O	O
,	NN	O	O
89	NN	O	O
.	NN	O	O
7	NN	O	O
%	NN	O	O
would	NN	O	O
choose	NN	O	O
propofol	NN	O	O
anaesthesia	NN	O	O
again	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
lidocaine	NN	O	O
reduces	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
propofol	NN	O	O
injection	NN	O	O
pain	NN	O	B
in	NN	O	O
ambulatory	NN	O	O
patients	NN	O	O
whereas	NN	O	O
thiopentone	NN	O	O
only	NN	O	O
reduces	NN	O	O
its	NN	O	O
severity	NN	O	O
.	NN	O	O

Persistent	NN	O	O
paralysis	NN	O	B
after	NN	O	O
prolonged	NN	O	O
use	NN	O	O
of	NN	O	O
atracurium	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
corticosteroids	NN	O	O
.	NN	O	O

Neuromuscular	NN	O	O
blocking	NN	O	O
agents	NN	O	O
(	NN	O	O
NMBAs	NN	O	O
)	NN	O	O
are	NN	O	O
often	NN	O	O
used	NN	O	O
for	NN	O	O
patients	NN	O	O
requiring	NN	O	O
prolonged	NN	O	O
mechanical	NN	O	O
ventilation	NN	O	O
.	NN	O	O

Reports	NN	O	O
of	NN	O	O
persistent	NN	O	O
paralysis	NN	O	B
after	NN	O	O
the	NN	O	O
discontinuance	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
have	NN	O	O
most	NN	O	O
often	NN	O	O
involved	NN	O	O
aminosteroid	NN	O	O
-	NN	O	O
based	NN	O	O
NMBAs	NN	O	O
such	NN	O	O
as	NN	O	O
vecuronium	NN	O	O
bromide	NN	O	O
,	NN	O	O
especially	NN	O	O
when	NN	O	O
used	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
corticosteroids	NN	O	O
.	NN	O	O

Atracurium	NN	O	O
besylate	NN	O	O
,	NN	O	O
a	NN	O	O
short	NN	O	O
-	NN	O	O
acting	NN	O	O
benzylisoquinolinium	NN	O	O
NMBA	NN	O	O
that	NN	O	O
is	NN	O	O
eliminated	NN	O	O
independently	NN	O	O
of	NN	O	O
renal	NN	O	O
or	NN	O	O
hepatic	NN	O	O
function	NN	O	O
,	NN	O	O
has	NN	O	O
also	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
persistent	NN	O	O
paralysis	NN	O	B
,	NN	O	O
but	NN	O	O
only	NN	O	O
when	NN	O	O
used	NN	O	O
with	NN	O	O
corticosteroids	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
atracurium	NN	O	O
-	NN	O	O
related	NN	O	O
paralysis	NN	O	B
persisting	NN	O	O
for	NN	O	O
approximately	NN	O	O
50	NN	O	O
hours	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
was	NN	O	O
not	NN	O	O
treated	NN	O	O
with	NN	O	O
corticosteroids	NN	O	O
.	NN	O	O

A	NN	O	O
phase	NN	O	O
I	NN	O	O
/	NN	O	O
II	NN	O	O
study	NN	O	O
of	NN	O	O
paclitaxel	NN	O	O
plus	NN	O	O
cisplatin	NN	O	O
as	NN	O	O
first	NN	O	O
-	NN	O	O
line	NN	O	O
therapy	NN	O	O
for	NN	O	O
head	NN	O	B
and	NN	O	I
neck	NN	O	I
cancers	NN	O	I
:	NN	O	O
preliminary	NN	O	O
results	NN	O	O
.	NN	O	O

Improved	NN	O	O
outcomes	NN	O	O
among	NN	O	O
patients	NN	O	O
with	NN	O	O
head	NN	O	B
and	NN	O	I
neck	NN	O	I
carcinomas	NN	O	I
require	NN	O	O
investigations	NN	O	O
of	NN	O	O
new	NN	O	O
drugs	NN	O	O
for	NN	O	O
induction	NN	O	O
therapy	NN	O	O
.	NN	O	O

Preliminary	NN	O	O
results	NN	O	O
of	NN	O	O
an	NN	O	O
Eastern	NN	O	O
Cooperative	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
study	NN	O	O
of	NN	O	O
single	NN	O	O
-	NN	O	O
agent	NN	O	O
paclitaxel	NN	O	O
(	NN	O	O
Taxol	NN	O	O
;	NN	O	O
Bristol	NN	O	O
-	NN	O	O
Myers	NN	O	O
Squibb	NN	O	O
Company	NN	O	O
,	NN	O	O
Princeton	NN	O	O
,	NN	O	O
NJ	NN	O	O
)	NN	O	O
reported	NN	O	O
a	NN	O	O
37	NN	O	O
%	NN	O	O
response	NN	O	O
rate	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
head	NN	O	B
and	NN	O	I
neck	NN	O	I
cancer	NN	O	I
,	NN	O	O
and	NN	O	O
the	NN	O	O
paclitaxel	NN	O	O
/	NN	O	O
cisplatin	NN	O	O
combination	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
successfully	NN	O	O
and	NN	O	O
has	NN	O	O
significantly	NN	O	O
improved	NN	O	O
median	NN	O	O
response	NN	O	O
duration	NN	O	O
in	NN	O	O
ovarian	NN	O	B
cancer	NN	O	I
patients	NN	O	O
.	NN	O	O

We	NN	O	O
initiated	NN	O	O
a	NN	O	O
phase	NN	O	O
I	NN	O	O
/	NN	O	O
II	NN	O	O
trial	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
response	NN	O	O
and	NN	O	O
toxicity	NN	O	B
of	NN	O	O
escalating	NN	O	O
paclitaxel	NN	O	O
doses	NN	O	O
combined	NN	O	O
with	NN	O	O
fixed	NN	O	O
-	NN	O	O
dose	NN	O	O
cisplatin	NN	O	O
with	NN	O	O
granulocyte	NN	O	O
colony	NN	O	O
-	NN	O	O
stimulating	NN	O	O
factor	NN	O	O
support	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
untreated	NN	O	O
locally	NN	O	O
advanced	NN	O	O
inoperable	NN	O	O
head	NN	O	B
and	NN	O	I
neck	NN	O	I
carcinoma	NN	O	I
.	NN	O	O

To	NN	O	O
date	NN	O	O
,	NN	O	O
23	NN	O	O
men	NN	O	O
with	NN	O	O
a	NN	O	O
median	NN	O	O
age	NN	O	O
of	NN	O	O
50	NN	O	O
years	NN	O	O
and	NN	O	O
good	NN	O	O
performance	NN	O	O
status	NN	O	O
have	NN	O	O
entered	NN	O	O
the	NN	O	O
trial	NN	O	O
.	NN	O	O

Primary	NN	O	O
tumor	NN	O	B
sites	NN	O	O
were	NN	O	O
oropharynx	NN	O	O
,	NN	O	O
10	NN	O	O
patients	NN	O	O
;	NN	O	O
hypopharynx	NN	O	O
,	NN	O	O
four	NN	O	O
;	NN	O	O
larynx	NN	O	O
,	NN	O	O
two	NN	O	O
;	NN	O	O
oral	NN	O	O
cavity	NN	O	O
,	NN	O	O
three	NN	O	O
;	NN	O	O
unknown	NN	O	O
primary	NN	O	O
,	NN	O	O
two	NN	O	O
;	NN	O	O
and	NN	O	O
nasal	NN	O	O
cavity	NN	O	O
and	NN	O	O
parotid	NN	O	O
gland	NN	O	O
,	NN	O	O
one	NN	O	O
each	NN	O	O
.	NN	O	O

Of	NN	O	O
20	NN	O	O
patients	NN	O	O
evaluable	NN	O	O
for	NN	O	O
toxicity	NN	O	B
,	NN	O	O
four	NN	O	O
had	NN	O	O
stage	NN	O	O
III	NN	O	O
and	NN	O	O
16	NN	O	O
had	NN	O	O
stage	NN	O	O
IV	NN	O	O
disease	NN	O	O
.	NN	O	O

Treatment	NN	O	O
,	NN	O	O
given	NN	O	O
every	NN	O	O
21	NN	O	O
days	NN	O	O
for	NN	O	O
a	NN	O	O
maximum	NN	O	O
of	NN	O	O
three	NN	O	O
cycles	NN	O	O
,	NN	O	O
consisted	NN	O	O
of	NN	O	O
paclitaxel	NN	O	O
by	NN	O	O
3	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
followed	NN	O	O
the	NN	O	O
next	NN	O	O
day	NN	O	O
by	NN	O	O
a	NN	O	O
fixed	NN	O	O
dose	NN	O	O
of	NN	O	O
cisplatin	NN	O	O
(	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
levels	NN	O	O
incorporate	NN	O	O
escalating	NN	O	O
paclitaxel	NN	O	O
doses	NN	O	O
,	NN	O	O
and	NN	O	O
intrapatient	NN	O	O
escalations	NN	O	O
within	NN	O	O
a	NN	O	O
given	NN	O	O
dose	NN	O	O
level	NN	O	O
are	NN	O	O
permitted	NN	O	O
if	NN	O	O
toxicity	NN	O	B
permits	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
this	NN	O	O
writing	NN	O	O
,	NN	O	O
dose	NN	O	O
level	NN	O	O
4	NN	O	O
(	NN	O	O
260	NN	O	O
,	NN	O	O
270	NN	O	O
,	NN	O	O
and	NN	O	O
280	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
)	NN	O	O
is	NN	O	O
being	NN	O	O
evaluated	NN	O	O
;	NN	O	O
three	NN	O	O
patients	NN	O	O
from	NN	O	O
this	NN	O	O
level	NN	O	O
are	NN	O	O
evaluable	NN	O	O
.	NN	O	O

With	NN	O	O
paclitaxel	NN	O	O
doses	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
and	NN	O	O
higher	NN	O	O
,	NN	O	O
granulocyte	NN	O	O
colony	NN	O	O
-	NN	O	O
stimulating	NN	O	O
factor	NN	O	O
5	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
d	NN	O	O
is	NN	O	O
given	NN	O	O
(	NN	O	O
days	NN	O	O
4	NN	O	O
through	NN	O	O
12	NN	O	O
)	NN	O	O
.	NN	O	O

Of	NN	O	O
18	NN	O	O
patients	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
,	NN	O	O
seven	NN	O	O
(	NN	O	O
39	NN	O	O
%	NN	O	O
)	NN	O	O
achieved	NN	O	O
a	NN	O	O
complete	NN	O	O
response	NN	O	O
and	NN	O	O
six	NN	O	O
(	NN	O	O
33	NN	O	O
%	NN	O	O
)	NN	O	O
achieved	NN	O	O
a	NN	O	O
partial	NN	O	O
response	NN	O	O
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
had	NN	O	O
no	NN	O	O
change	NN	O	O
and	NN	O	O
disease	NN	O	O
progressed	NN	O	O
in	NN	O	O
two	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
is	NN	O	O
72	NN	O	O
%	NN	O	O
.	NN	O	O

Eleven	NN	O	O
responding	NN	O	O
patients	NN	O	O
had	NN	O	O
subsequent	NN	O	O
surgery	NN	O	O
/	NN	O	O
radiotherapy	NN	O	O
or	NN	O	O
radical	NN	O	O
radiotherapy	NN	O	O
.	NN	O	O

Two	NN	O	O
pathologic	NN	O	O
complete	NN	O	O
responses	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
achieved	NN	O	O
clinical	NN	O	O
complete	NN	O	O
responses	NN	O	O
.	NN	O	O

Alopecia	NN	O	B
,	NN	O	O
paresthesias	NN	O	B
,	NN	O	O
and	NN	O	O
arthralgias	NN	O	B
/	NN	O	O
myalgias	NN	O	B
have	NN	O	O
occurred	NN	O	O
frequently	NN	O	O
,	NN	O	O
but	NN	O	O
with	NN	O	O
one	NN	O	O
exception	NN	O	O
(	NN	O	O
a	NN	O	O
grade	NN	O	O
3	NN	O	O
myalgia	NN	O	B
)	NN	O	O
they	NN	O	O
have	NN	O	O
been	NN	O	O
grade	NN	O	O
1	NN	O	O
or	NN	O	O
2	NN	O	O
.	NN	O	O

No	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
hematologic	NN	O	O
toxicity	NN	O	B
has	NN	O	O
been	NN	O	O
seen	NN	O	O
.	NN	O	O

Paclitaxel	NN	O	O
/	NN	O	O
cisplatin	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
first	NN	O	O
-	NN	O	O
line	NN	O	O
regimen	NN	O	O
for	NN	O	O
locoregionally	NN	O	O
advanced	NN	O	O
head	NN	O	B
and	NN	O	I
neck	NN	O	I
cancer	NN	O	I
and	NN	O	O
continued	NN	O	O
study	NN	O	O
is	NN	O	O
warranted	NN	O	O
.	NN	O	O

Results	NN	O	O
thus	NN	O	O
far	NN	O	O
suggest	NN	O	O
no	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
effect	NN	O	O
for	NN	O	O
paclitaxel	NN	O	O
doses	NN	O	O
above	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

Improvement	NN	O	O
of	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B
by	NN	O	O
propranolol	NN	O	O
in	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

Seven	NN	O	O
patients	NN	O	O
suffering	NN	O	O
from	NN	O	O
Parkinson	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
(	NN	O	O
PD	NN	O	B
)	NN	O	O
with	NN	O	O
severely	NN	O	O
disabling	NN	O	O
dyskinesia	NN	O	B
received	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
propranolol	NN	O	O
as	NN	O	O
an	NN	O	O
adjunct	NN	O	O
to	NN	O	O
the	NN	O	O
currently	NN	O	O
used	NN	O	O
medical	NN	O	O
treatment	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
40	NN	O	O
%	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
dyskinesia	NN	O	B
score	NN	O	O
without	NN	O	O
increase	NN	O	O
of	NN	O	O
parkinsonian	NN	O	B
motor	NN	O	B
disability	NN	O	I
.	NN	O	O

Ballistic	NN	O	O
and	NN	O	O
choreic	NN	O	O
dyskinesia	NN	O	B
were	NN	O	O
markedly	NN	O	O
ameliorated	NN	O	O
,	NN	O	O
whereas	NN	O	O
dystonia	NN	O	B
was	NN	O	O
not	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
administration	NN	O	O
of	NN	O	O
low	NN	O	O
doses	NN	O	O
of	NN	O	O
beta	NN	O	O
-	NN	O	O
blockers	NN	O	O
may	NN	O	O
improve	NN	O	O
levodopa	NN	O	O
-	NN	O	O
induced	NN	O	O
ballistic	NN	O	O
and	NN	O	O
choreic	NN	O	O
dyskinesia	NN	O	B
in	NN	O	O
PD	NN	O	B
.	NN	O	O

Habitual	NN	O	O
use	NN	O	O
of	NN	O	O
acetaminophen	NN	O	O
as	NN	O	O
a	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
:	NN	O	O
a	NN	O	O
comparison	NN	O	O
with	NN	O	O
phenacetin	NN	O	O
.	NN	O	O

Six	NN	O	O
epidemiologic	NN	O	O
studies	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
and	NN	O	O
Europe	NN	O	O
indicate	NN	O	O
that	NN	O	O
habitual	NN	O	O
use	NN	O	O
of	NN	O	O
phenacetin	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
and	NN	O	O
end	NN	O	B
-	NN	O	I
stage	NN	O	I
renal	NN	O	I
disease	NN	O	I
(	NN	O	O
ESRD	NN	O	B
)	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
relative	NN	O	O
risk	NN	O	O
in	NN	O	O
the	NN	O	O
range	NN	O	O
of	NN	O	O
4	NN	O	O
to	NN	O	O
19	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
these	NN	O	O
and	NN	O	O
other	NN	O	O
studies	NN	O	O
,	NN	O	O
phenacetin	NN	O	O
has	NN	O	O
now	NN	O	O
been	NN	O	O
withdrawn	NN	O	O
from	NN	O	O
the	NN	O	O
market	NN	O	O
in	NN	O	O
most	NN	O	O
countries	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
three	NN	O	O
case	NN	O	O
control	NN	O	O
studies	NN	O	O
,	NN	O	O
one	NN	O	O
each	NN	O	O
in	NN	O	O
North	NN	O	O
Carolina	NN	O	O
,	NN	O	O
northern	NN	O	O
Maryland	NN	O	O
,	NN	O	O
and	NN	O	O
West	NN	O	O
Berlin	NN	O	O
,	NN	O	O
Germany	NN	O	O
,	NN	O	O
showed	NN	O	O
that	NN	O	O
habitual	NN	O	O
use	NN	O	O
of	NN	O	O
acetaminophen	NN	O	O
is	NN	O	O
also	NN	O	O
associated	NN	O	O
with	NN	O	O
chronic	NN	O	B
renal	NN	O	I
failure	NN	O	I
and	NN	O	O
ESRD	NN	O	B
,	NN	O	O
with	NN	O	O
a	NN	O	O
relative	NN	O	O
risk	NN	O	O
in	NN	O	O
the	NN	O	O
range	NN	O	O
of	NN	O	O
2	NN	O	O
to	NN	O	O
4	NN	O	O
.	NN	O	O

These	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
both	NN	O	O
phenacetin	NN	O	O
and	NN	O	O
acetaminophen	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
burden	NN	O	O
of	NN	O	O
ESRD	NN	O	B
,	NN	O	O
with	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
the	NN	O	O
latter	NN	O	O
being	NN	O	O
somewhat	NN	O	O
less	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
former	NN	O	O
.	NN	O	O

This	NN	O	O
apparent	NN	O	O
difference	NN	O	O
in	NN	O	O
risk	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
differences	NN	O	O
in	NN	O	O
nephrotoxic	NN	O	B
potential	NN	O	O
of	NN	O	O
the	NN	O	O
drugs	NN	O	O
themselves	NN	O	O
.	NN	O	O

A	NN	O	O
lower	NN	O	O
relative	NN	O	O
risk	NN	O	O
would	NN	O	O
be	NN	O	O
expected	NN	O	O
for	NN	O	O
acetaminophen	NN	O	O
if	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
both	NN	O	O
drugs	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
analgesics	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
either	NN	O	O
agent	NN	O	O
alone	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
acetaminophen	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
both	NN	O	O
as	NN	O	O
a	NN	O	O
single	NN	O	O
agent	NN	O	O
and	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
analgesics	NN	O	O
,	NN	O	O
whereas	NN	O	O
phenacetin	NN	O	O
was	NN	O	O
available	NN	O	O
only	NN	O	O
in	NN	O	O
combinations	NN	O	O
.	NN	O	O

The	NN	O	O
possibility	NN	O	O
that	NN	O	O
habitual	NN	O	O
use	NN	O	O
of	NN	O	O
acetaminophen	NN	O	O
alone	NN	O	O
increases	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
ESRD	NN	O	B
has	NN	O	O
not	NN	O	O
been	NN	O	O
clearly	NN	O	O
demonstrated	NN	O	O
,	NN	O	O
but	NN	O	O
cannot	NN	O	O
be	NN	O	O
dismissed	NN	O	O
.	NN	O	O

Acetaminophen	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
.	NN	O	O

Through	NN	O	O
30	NN	O	O
years	NN	O	O
of	NN	O	O
widespread	NN	O	O
use	NN	O	O
,	NN	O	O
acetaminophen	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
remarkably	NN	O	O
safe	NN	O	O
medication	NN	O	O
in	NN	O	O
therapeutic	NN	O	O
dosages	NN	O	O
.	NN	O	O

The	NN	O	O
potential	NN	O	O
for	NN	O	O
acetaminophen	NN	O	O
to	NN	O	O
produce	NN	O	O
cardiovascular	NN	O	B
toxicities	NN	O	I
is	NN	O	O
very	NN	O	O
low	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
acetaminophen	NN	O	O
has	NN	O	O
been	NN	O	O
demonstrated	NN	O	O
to	NN	O	O
produce	NN	O	O
symptoms	NN	O	O
of	NN	O	O
anaphylaxis	NN	O	B
,	NN	O	O
including	NN	O	O
hypotension	NN	O	B
,	NN	O	O
in	NN	O	O
sensitive	NN	O	O
individuals	NN	O	O
.	NN	O	O

This	NN	O	O
article	NN	O	O
describes	NN	O	O
two	NN	O	O
critically	NN	O	B
ill	NN	O	I
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
transient	NN	O	O
episodes	NN	O	O
of	NN	O	O
hypotension	NN	O	B
reproducibly	NN	O	O
developed	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
acetaminophen	NN	O	O
.	NN	O	O

Other	NN	O	O
symptoms	NN	O	O
of	NN	O	O
allergic	NN	O	B
reactions	NN	O	I
were	NN	O	O
not	NN	O	O
clinically	NN	O	O
detectable	NN	O	O
.	NN	O	O

The	NN	O	O
hypotensive	NN	O	B
episodes	NN	O	O
were	NN	O	O
severe	NN	O	O
enough	NN	O	O
to	NN	O	O
require	NN	O	O
vasopressor	NN	O	O
administration	NN	O	O
.	NN	O	O

The	NN	O	O
reports	NN	O	O
illustrate	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
clinicians	NN	O	O
to	NN	O	O
consider	NN	O	O
acetaminophen	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hypotension	NN	O	B
of	NN	O	O
unknown	NN	O	O
origin	NN	O	O
.	NN	O	O

Reduction	NN	O	O
of	NN	O	O
heparan	NN	O	O
sulphate	NN	O	O
-	NN	O	O
associated	NN	O	O
anionic	NN	O	O
sites	NN	O	O
in	NN	O	O
the	NN	O	O
glomerular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
of	NN	O	O
rats	NN	O	O
with	NN	O	O
streptozotocin	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetic	NN	O	B
nephropathy	NN	O	I
.	NN	O	O

Heparan	NN	O	O
sulphate	NN	O	O
-	NN	O	O
associated	NN	O	O
anionic	NN	O	O
sites	NN	O	O
in	NN	O	O
the	NN	O	O
glomerular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
rats	NN	O	O
8	NN	O	O
months	NN	O	O
after	NN	O	O
induction	NN	O	O
of	NN	O	O
diabetes	NN	O	B
by	NN	O	O
streptozotocin	NN	O	O
and	NN	O	O
in	NN	O	O
age	NN	O	O
-	NN	O	O
adn	NN	O	O
sex	NN	O	O
-	NN	O	O
matched	NN	O	O
control	NN	O	O
rats	NN	O	O
,	NN	O	O
employing	NN	O	O
the	NN	O	O
cationic	NN	O	O
dye	NN	O	O
cuprolinic	NN	O	O
blue	NN	O	O
.	NN	O	O

Morphometric	NN	O	O
analysis	NN	O	O
at	NN	O	O
the	NN	O	O
ultrastructural	NN	O	O
level	NN	O	O
was	NN	O	O
performed	NN	O	O
using	NN	O	O
a	NN	O	O
computerized	NN	O	O
image	NN	O	O
processor	NN	O	O
.	NN	O	O

The	NN	O	O
heparan	NN	O	O
sulphate	NN	O	O
specificity	NN	O	O
of	NN	O	O
the	NN	O	O
cuprolinic	NN	O	O
blue	NN	O	O
staining	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
glycosaminoglycan	NN	O	O
-	NN	O	O
degrading	NN	O	O
enzymes	NN	O	O
,	NN	O	O
showing	NN	O	O
that	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
the	NN	O	O
sections	NN	O	O
with	NN	O	O
heparitinase	NN	O	O
abolished	NN	O	O
all	NN	O	O
staining	NN	O	O
,	NN	O	O
whereas	NN	O	O
chondroitinase	NN	O	O
ABC	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

The	NN	O	O
majority	NN	O	O
of	NN	O	O
anionic	NN	O	O
sites	NN	O	O
(	NN	O	O
74	NN	O	O
%	NN	O	O
in	NN	O	O
diabetic	NN	O	B
and	NN	O	O
81	NN	O	O
%	NN	O	O
in	NN	O	O
control	NN	O	O
rats	NN	O	O
)	NN	O	O
were	NN	O	O
found	NN	O	O
within	NN	O	O
the	NN	O	O
lamina	NN	O	O
rara	NN	O	O
externa	NN	O	O
of	NN	O	O
the	NN	O	O
glomerular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
.	NN	O	O

A	NN	O	O
minority	NN	O	O
of	NN	O	O
anionic	NN	O	O
sites	NN	O	O
were	NN	O	O
scattered	NN	O	O
throughout	NN	O	O
the	NN	O	O
lamina	NN	O	O
densa	NN	O	O
and	NN	O	O
lamina	NN	O	O
rara	NN	O	O
interna	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
significantly	NN	O	O
smaller	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
the	NN	O	O
lamina	NN	O	O
rara	NN	O	O
externa	NN	O	O
of	NN	O	O
the	NN	O	O
glomerular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
and	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
01	NN	O	O
for	NN	O	O
diabetic	NN	O	B
and	NN	O	O
control	NN	O	O
rats	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Diabetic	NN	O	B
rats	NN	O	O
progressively	NN	O	O
developed	NN	O	O
albuminuria	NN	O	B
reaching	NN	O	O
40	NN	O	O
.	NN	O	O
3	NN	O	O
(	NN	O	O
32	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
62	NN	O	O
.	NN	O	O
0	NN	O	O
)	NN	O	O
mg	NN	O	O
/	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
8	NN	O	O
months	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
animals	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
8	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
2	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
9	NN	O	O
)	NN	O	O
mg	NN	O	O
/	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
002	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
,	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
heparan	NN	O	O
sulphate	NN	O	O
anionic	NN	O	O
sites	NN	O	O
and	NN	O	O
the	NN	O	O
total	NN	O	O
anionic	NN	O	O
site	NN	O	O
surface	NN	O	O
(	NN	O	O
number	NN	O	O
of	NN	O	O
anionic	NN	O	O
sites	NN	O	O
x	NN	O	O
mean	NN	O	O
anionic	NN	O	O
site	NN	O	O
surface	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
lamina	NN	O	O
rara	NN	O	O
externa	NN	O	O
of	NN	O	O
the	NN	O	O
glomerular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
was	NN	O	O
reduced	NN	O	O
by	NN	O	O
19	NN	O	O
%	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
021	NN	O	O
)	NN	O	O
and	NN	O	O
by	NN	O	O
26	NN	O	O
%	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
02	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Number	NN	O	O
and	NN	O	O
total	NN	O	O
anionic	NN	O	O
site	NN	O	O
surface	NN	O	O
in	NN	O	O
the	NN	O	O
remaining	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
glomerular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
(	NN	O	O
lamina	NN	O	O
densa	NN	O	O
and	NN	O	O
lamina	NN	O	O
rara	NN	O	O
interna	NN	O	O
)	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
changed	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
in	NN	O	O
streptozotocin	NN	O	O
-	NN	O	O
diabetic	NN	O	B
rats	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
urinary	NN	O	O
albumin	NN	O	O
excretion	NN	O	O
,	NN	O	O
a	NN	O	O
reduced	NN	O	O
heparan	NN	O	O
sulphate	NN	O	O
charge	NN	O	O
barrier	NN	O	O
/	NN	O	O
density	NN	O	O
is	NN	O	O
found	NN	O	O
at	NN	O	O
the	NN	O	O
lamina	NN	O	O
rara	NN	O	O
externa	NN	O	O
of	NN	O	O
the	NN	O	O
glomerular	NN	O	O
basement	NN	O	O
membrane	NN	O	O
.	NN	O	O

Mediation	NN	O	O
of	NN	O	O
enhanced	NN	O	O
reflex	NN	O	O
vagal	NN	O	O
bradycardia	NN	O	B
by	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
via	NN	O	O
central	NN	O	O
dopamine	NN	O	O
formation	NN	O	O
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

L	NN	O	O
-	NN	O	O
Dopa	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
decreased	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
after	NN	O	O
extracerebral	NN	O	O
decarboxylase	NN	O	O
inhibition	NN	O	O
with	NN	O	O
MK	NN	O	O
-	NN	O	O
486	NN	O	O
(	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
in	NN	O	O
anesthetize	NN	O	O
MAO	NN	O	O
-	NN	O	O
inhibited	NN	O	O
dogs	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
reflex	NN	O	O
bradycardia	NN	O	B
caused	NN	O	O
by	NN	O	O
injected	NN	O	O
norepinephrine	NN	O	O
was	NN	O	O
significantly	NN	O	O
enhanced	NN	O	O
by	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
,	NN	O	O
DL	NN	O	O
-	NN	O	O
Threo	NN	O	O
-	NN	O	O
dihydroxyphenylserine	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
or	NN	O	O
reflex	NN	O	O
responses	NN	O	O
to	NN	O	O
norepinephrine	NN	O	O
.	NN	O	O

FLA	NN	O	O
-	NN	O	O
63	NN	O	O
,	NN	O	O
a	NN	O	O
dopamine	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
oxidase	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
any	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
hypotension	NN	O	B
,	NN	O	O
bradycardia	NN	O	B
or	NN	O	O
reflex	NN	O	O
-	NN	O	O
enhancing	NN	O	O
effect	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
.	NN	O	O

Pimozide	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
actions	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
on	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
but	NN	O	O
completely	NN	O	O
blocked	NN	O	O
the	NN	O	O
enhancement	NN	O	O
of	NN	O	O
reflexes	NN	O	O
.	NN	O	O

Removal	NN	O	O
of	NN	O	O
the	NN	O	O
carotid	NN	O	O
sinuses	NN	O	O
caused	NN	O	O
an	NN	O	O
elevation	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
abolished	NN	O	O
the	NN	O	O
negative	NN	O	O
chronotropic	NN	O	O
effect	NN	O	O
of	NN	O	O
norepinephrine	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
restored	NN	O	O
the	NN	O	O
bradycardia	NN	O	B
caused	NN	O	O
by	NN	O	O
norepinephrine	NN	O	O
in	NN	O	O
addition	NN	O	O
to	NN	O	O
decreasing	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

5	NN	O	O
-	NN	O	O
HTP	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
decreased	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
decreased	NN	O	O
the	NN	O	O
reflex	NN	O	O
bradycardia	NN	O	B
to	NN	O	O
norepinephrine	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
L	NN	O	O
-	NN	O	O
dopa	NN	O	O
enhances	NN	O	O
reflex	NN	O	O
bradycardia	NN	O	B
through	NN	O	O
central	NN	O	O
alpha	NN	O	O
-	NN	O	O
receptor	NN	O	O
stimulation	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
are	NN	O	O
mediated	NN	O	O
through	NN	O	O
dopamine	NN	O	O
rather	NN	O	O
than	NN	O	O
norepinephrine	NN	O	O
and	NN	O	O
do	NN	O	O
not	NN	O	O
require	NN	O	O
the	NN	O	O
carotid	NN	O	O
sinus	NN	O	O
baroreceptors	NN	O	O
.	NN	O	O

Microangiopathic	NN	O	B
hemolytic	NN	O	I
anemia	NN	O	I
complicating	NN	O	O
FK506	NN	O	O
(	NN	O	O
tacrolimus	NN	O	O
)	NN	O	O
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
3	NN	O	O
episodes	NN	O	O
of	NN	O	O
microangiopathic	NN	O	B
hemolytic	NN	O	I
anemia	NN	O	I
(	NN	O	O
MAHA	NN	O	B
)	NN	O	O
in	NN	O	O
2	NN	O	O
solid	NN	O	O
organ	NN	O	O
recipients	NN	O	O
under	NN	O	O
FK506	NN	O	O
(	NN	O	O
tacrolimus	NN	O	O
)	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
cases	NN	O	O
,	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
FK506	NN	O	O
and	NN	O	O
treatment	NN	O	O
with	NN	O	O
plasma	NN	O	O
exchange	NN	O	O
,	NN	O	O
fresh	NN	O	O
frozen	NN	O	O
plasma	NN	O	O
replacement	NN	O	O
,	NN	O	O
corticosteroids	NN	O	O
,	NN	O	O
aspirin	NN	O	O
,	NN	O	O
and	NN	O	O
dipyridamole	NN	O	O
led	NN	O	O
to	NN	O	O
resolution	NN	O	O
of	NN	O	O
MAHA	NN	O	B
.	NN	O	O

In	NN	O	O
one	NN	O	O
patient	NN	O	O
,	NN	O	O
reintroduction	NN	O	O
of	NN	O	O
FK506	NN	O	O
led	NN	O	O
to	NN	O	O
rapid	NN	O	O
recurrence	NN	O	O
of	NN	O	O
MAHA	NN	O	B
.	NN	O	O

FK506	NN	O	O
-	NN	O	O
associated	NN	O	O
MAHA	NN	O	B
is	NN	O	O
probably	NN	O	O
rare	NN	O	O
but	NN	O	O
physicians	NN	O	O
must	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
severe	NN	O	O
complication	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
experience	NN	O	O
and	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
FK506	NN	O	O
does	NN	O	O
not	NN	O	O
seem	NN	O	O
to	NN	O	O
cross	NN	O	O
-	NN	O	O
react	NN	O	O
with	NN	O	O
cyclosporin	NN	O	O
A	NN	O	O
(	NN	O	O
CyA	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
immuno	NN	O	O
-	NN	O	O
suppressive	NN	O	O
drug	NN	O	O
already	NN	O	O
known	NN	O	O
to	NN	O	O
induce	NN	O	O
MAHA	NN	O	B
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
some	NN	O	O
anticancer	NN	O	O
drugs	NN	O	O
and	NN	O	O
combined	NN	O	O
chemotherapy	NN	O	O
on	NN	O	O
renal	NN	O	B
toxicity	NN	O	I
.	NN	O	O

The	NN	O	O
nephrotoxic	NN	O	B
action	NN	O	O
of	NN	O	O
anticancer	NN	O	O
drugs	NN	O	O
such	NN	O	O
as	NN	O	O
nitrogranulogen	NN	O	O
(	NN	O	O
NG	NN	O	O
)	NN	O	O
,	NN	O	O
methotrexate	NN	O	O
(	NN	O	O
MTX	NN	O	O
)	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
and	NN	O	O
cyclophosphamide	NN	O	O
(	NN	O	O
CY	NN	O	O
)	NN	O	O
administered	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
[	NN	O	O
MTX	NN	O	O
+	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
+	NN	O	O
CY	NN	O	O
(	NN	O	O
CMF	NN	O	O
)	NN	O	O
]	NN	O	O
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
experiments	NN	O	O
on	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

After	NN	O	O
drug	NN	O	O
administration	NN	O	O
,	NN	O	O
creatinine	NN	O	O
concentrations	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
urine	NN	O	O
of	NN	O	O
the	NN	O	O
rats	NN	O	O
were	NN	O	O
determined	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
.	NN	O	O

Histopathologic	NN	O	O
evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
kidneys	NN	O	O
was	NN	O	O
also	NN	O	O
performed	NN	O	O
.	NN	O	O

After	NN	O	O
MTX	NN	O	O
administration	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0228	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
plasma	NN	O	O
creatinine	NN	O	O
concentration	NN	O	O
and	NN	O	O
a	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
decrease	NN	O	O
in	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
was	NN	O	O
noted	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
NG	NN	O	O
,	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
and	NN	O	O
CY	NN	O	O
neither	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
creatinine	NN	O	O
concentration	NN	O	O
nor	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
was	NN	O	O
observed	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
group	NN	O	O
receiving	NN	O	O
no	NN	O	O
cytostatics	NN	O	O
.	NN	O	O

Following	NN	O	O
polytherapy	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
CMF	NN	O	O
regimen	NN	O	O
,	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
decrease	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
0343	NN	O	O
)	NN	O	O
in	NN	O	O
creatinine	NN	O	O
clearance	NN	O	O
was	NN	O	O
found	NN	O	O
,	NN	O	O
but	NN	O	O
creatinine	NN	O	O
concentration	NN	O	O
did	NN	O	O
not	NN	O	O
increase	NN	O	O
significantly	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

CY	NN	O	O
caused	NN	O	O
hemorrhagic	NN	O	B
cystitis	NN	O	I
in	NN	O	O
40	NN	O	O
%	NN	O	O
of	NN	O	O
rats	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
cause	NN	O	O
this	NN	O	O
complication	NN	O	O
when	NN	O	O
combined	NN	O	O
with	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
and	NN	O	O
MTX	NN	O	O
.	NN	O	O

Histologic	NN	O	O
changes	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
rat	NN	O	O
kidneys	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
MTX	NN	O	O
,	NN	O	O
CY	NN	O	O
and	NN	O	O
NG	NN	O	O
,	NN	O	O
while	NN	O	O
no	NN	O	O
such	NN	O	O
change	NN	O	O
was	NN	O	O
observed	NN	O	O
after	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
and	NN	O	O
joint	NN	O	O
administration	NN	O	O
of	NN	O	O
MTX	NN	O	O
+	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
+	NN	O	O
CY	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
.	NN	O	O

Our	NN	O	O
studies	NN	O	O
indicate	NN	O	O
that	NN	O	O
nephrotoxicity	NN	O	B
of	NN	O	O
MTX	NN	O	O
+	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
+	NN	O	O
CY	NN	O	O
administered	NN	O	O
jointly	NN	O	O
is	NN	O	O
lower	NN	O	O
than	NN	O	O
in	NN	O	O
monotherapy	NN	O	O
.	NN	O	O

The	NN	O	O
interpeduncular	NN	O	O
nucleus	NN	O	O
regulates	NN	O	O
nicotine	NN	O	O
'	NN	O	O
s	NN	O	O
effects	NN	O	O
on	NN	O	O
free	NN	O	O
-	NN	O	O
field	NN	O	O
activity	NN	O	O
.	NN	O	O

Partial	NN	O	O
lesions	NN	O	O
were	NN	O	O
made	NN	O	O
with	NN	O	O
kainic	NN	O	O
acid	NN	O	O
in	NN	O	O
the	NN	O	O
interpeduncular	NN	O	O
nucleus	NN	O	O
of	NN	O	O
the	NN	O	O
ventral	NN	O	O
midbrain	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
sham	NN	O	O
-	NN	O	O
operated	NN	O	O
controls	NN	O	O
,	NN	O	O
lesions	NN	O	O
significantly	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
25	NN	O	O
)	NN	O	O
blunted	NN	O	O
the	NN	O	O
early	NN	O	O
(	NN	O	O
<	NN	O	O
60	NN	O	O
min	NN	O	O
)	NN	O	O
free	NN	O	O
-	NN	O	O
field	NN	O	O
locomotor	NN	O	B
hypoactivity	NN	O	I
caused	NN	O	O
by	NN	O	O
nicotine	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
mg	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
m	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
enhanced	NN	O	O
the	NN	O	O
later	NN	O	O
(	NN	O	O
60	NN	O	O
-	NN	O	O
120	NN	O	O
min	NN	O	O
)	NN	O	O
nicotine	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B
,	NN	O	O
and	NN	O	O
raised	NN	O	O
spontaneous	NN	O	O
nocturnal	NN	O	O
activity	NN	O	O
.	NN	O	O

Lesions	NN	O	O
reduced	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
immunohistological	NN	O	O
staining	NN	O	O
for	NN	O	O
choline	NN	O	O
acetyltransferase	NN	O	O
in	NN	O	O
the	NN	O	O
interpeduncular	NN	O	O
nucleus	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
025	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
for	NN	O	O
tyrosine	NN	O	O
hydroxylase	NN	O	O
in	NN	O	O
the	NN	O	O
surrounding	NN	O	O
catecholaminergic	NN	O	O
A10	NN	O	O
region	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
interpeduncular	NN	O	O
nucleus	NN	O	O
mediates	NN	O	O
nicotinic	NN	O	O
depression	NN	O	B
of	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
and	NN	O	O
dampens	NN	O	O
nicotinic	NN	O	O
arousal	NN	O	O
mechanisms	NN	O	O
located	NN	O	O
elsewhere	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

Lithium	NN	O	O
-	NN	O	O
associated	NN	O	O
cognitive	NN	O	B
and	NN	O	I
functional	NN	O	I
deficits	NN	O	I
reduced	NN	O	O
by	NN	O	O
a	NN	O	O
switch	NN	O	O
to	NN	O	O
divalproex	NN	O	O
sodium	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
series	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Lithium	NN	O	O
remains	NN	O	O
a	NN	O	O
first	NN	O	O
-	NN	O	O
line	NN	O	O
treatment	NN	O	O
for	NN	O	O
the	NN	O	O
acute	NN	O	O
and	NN	O	O
maintenance	NN	O	O
treatment	NN	O	O
of	NN	O	O
bipolar	NN	O	B
disorder	NN	O	I
.	NN	O	O

Although	NN	O	O
much	NN	O	O
has	NN	O	O
been	NN	O	O
written	NN	O	O
about	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
the	NN	O	O
more	NN	O	O
common	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
lithium	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
polyuria	NN	O	B
and	NN	O	O
tremor	NN	O	B
,	NN	O	O
more	NN	O	O
subtle	NN	O	O
lithium	NN	O	O
side	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
,	NN	O	O
loss	NN	O	B
of	NN	O	I
creativity	NN	O	I
,	NN	O	O
and	NN	O	O
functional	NN	O	B
impairments	NN	O	I
remain	NN	O	O
understudied	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
summarizes	NN	O	O
our	NN	O	O
experience	NN	O	O
in	NN	O	O
switching	NN	O	O
bipolar	NN	O	B
patients	NN	O	O
from	NN	O	O
lithium	NN	O	O
to	NN	O	O
divalproex	NN	O	O
sodium	NN	O	O
to	NN	O	O
alleviate	NN	O	O
such	NN	O	O
cognitive	NN	O	B
and	NN	O	I
functional	NN	O	I
impairments	NN	O	I
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Open	NN	O	O
,	NN	O	O
case	NN	O	O
series	NN	O	O
design	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
report	NN	O	O
seven	NN	O	O
cases	NN	O	O
where	NN	O	O
substitution	NN	O	O
of	NN	O	O
lithium	NN	O	O
,	NN	O	O
either	NN	O	O
fully	NN	O	O
or	NN	O	O
partially	NN	O	O
,	NN	O	O
with	NN	O	O
divalproex	NN	O	O
sodium	NN	O	O
was	NN	O	O
extremely	NN	O	O
helpful	NN	O	O
in	NN	O	O
reducing	NN	O	O
the	NN	O	O
cognitive	NN	O	B
,	NN	O	I
motivational	NN	O	I
,	NN	O	I
or	NN	O	I
creative	NN	O	I
deficits	NN	O	I
attributed	NN	O	O
to	NN	O	O
lithium	NN	O	O
in	NN	O	O
our	NN	O	O
bipolar	NN	O	B
patients	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
preliminary	NN	O	O
report	NN	O	O
,	NN	O	O
divalproex	NN	O	O
sodium	NN	O	O
was	NN	O	O
a	NN	O	O
superior	NN	O	O
alternative	NN	O	O
to	NN	O	O
lithium	NN	O	O
in	NN	O	O
bipolar	NN	O	B
patients	NN	O	O
experiencing	NN	O	O
cognitive	NN	O	B
deficits	NN	O	I
,	NN	O	O
loss	NN	O	B
of	NN	O	I
creativity	NN	O	I
,	NN	O	O
and	NN	O	O
functional	NN	O	B
impairments	NN	O	I
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
nifedipine	NN	O	O
on	NN	O	O
renal	NN	O	O
function	NN	O	O
in	NN	O	O
liver	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
receiving	NN	O	O
tacrolimus	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
nifedipine	NN	O	O
on	NN	O	O
renal	NN	O	O
function	NN	O	O
in	NN	O	O
liver	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
who	NN	O	O
were	NN	O	O
receiving	NN	O	O
tacrolimus	NN	O	O
was	NN	O	O
evaluated	NN	O	O
between	NN	O	O
January	NN	O	O
1992	NN	O	O
and	NN	O	O
January	NN	O	O
1996	NN	O	O
.	NN	O	O

Two	NN	O	O
groups	NN	O	O
of	NN	O	O
patients	NN	O	O
receiving	NN	O	O
tacrolimus	NN	O	O
were	NN	O	O
compared	NN	O	O
over	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
1	NN	O	O
year	NN	O	O
,	NN	O	O
one	NN	O	O
group	NN	O	O
comprising	NN	O	O
hypertensive	NN	O	B
patients	NN	O	O
who	NN	O	O
were	NN	O	O
receiving	NN	O	O
nifedipine	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
other	NN	O	O
comprising	NN	O	O
nonhypertensive	NN	O	O
patients	NN	O	O
not	NN	O	O
receiving	NN	O	O
nifedipine	NN	O	O
.	NN	O	O

The	NN	O	O
time	NN	O	O
from	NN	O	O
transplant	NN	O	O
to	NN	O	O
baseline	NN	O	O
was	NN	O	O
similar	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

Nifedipine	NN	O	O
significantly	NN	O	O
improved	NN	O	O
kidney	NN	O	O
function	NN	O	O
as	NN	O	O
indicated	NN	O	O
by	NN	O	O
a	NN	O	O
significant	NN	O	O
lowering	NN	O	O
of	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
at	NN	O	O
6	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
observed	NN	O	O
positive	NN	O	O
impact	NN	O	O
of	NN	O	O
nifedipine	NN	O	O
on	NN	O	O
reducing	NN	O	O
the	NN	O	O
nephrotoxicity	NN	O	B
associated	NN	O	O
with	NN	O	O
tacrolimus	NN	O	O
in	NN	O	O
liver	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
should	NN	O	O
be	NN	O	O
an	NN	O	O
important	NN	O	O
factor	NN	O	O
in	NN	O	O
selecting	NN	O	O
an	NN	O	O
agent	NN	O	O
to	NN	O	O
treat	NN	O	O
hypertension	NN	O	B
in	NN	O	O
this	NN	O	O
population	NN	O	O
.	NN	O	O

Alpha	NN	O	O
and	NN	O	O
beta	NN	O	O
coma	NN	O	B
in	NN	O	O
drug	NN	O	O
intoxication	NN	O	O
uncomplicated	NN	O	O
by	NN	O	O
cerebral	NN	O	B
hypoxia	NN	O	I
.	NN	O	O

Four	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
rendered	NN	O	O
comatose	NN	O	B
or	NN	O	O
stuporous	NN	O	B
by	NN	O	O
drug	NN	O	O
intoxication	NN	O	O
,	NN	O	O
but	NN	O	O
who	NN	O	O
were	NN	O	O
not	NN	O	O
hypoxic	NN	O	O
,	NN	O	O
are	NN	O	O
described	NN	O	O
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
received	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
chlormethiazole	NN	O	O
for	NN	O	O
alcohol	NN	O	O
withdrawal	NN	O	B
symptoms	NN	O	I
,	NN	O	O
and	NN	O	O
one	NN	O	O
took	NN	O	O
a	NN	O	O
suicidal	NN	O	O
overdose	NN	O	B
of	NN	O	O
nitrazepam	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
with	NN	O	O
nitrazepam	NN	O	O
overdose	NN	O	B
and	NN	O	O
two	NN	O	O
of	NN	O	O
those	NN	O	O
with	NN	O	O
chlormethiazole	NN	O	O
intoxication	NN	O	O
conformed	NN	O	O
to	NN	O	O
the	NN	O	O
criteria	NN	O	O
of	NN	O	O
'	NN	O	O
alpha	NN	O	O
coma	NN	O	B
'	NN	O	O
,	NN	O	O
showing	NN	O	O
non	NN	O	O
-	NN	O	O
reactive	NN	O	O
generalized	NN	O	O
or	NN	O	O
frontally	NN	O	O
predominant	NN	O	O
alpha	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
EEG	NN	O	O
.	NN	O	O

The	NN	O	O
fourth	NN	O	O
patient	NN	O	O
who	NN	O	O
was	NN	O	O
unconscious	NN	O	O
after	NN	O	O
chlormethiazole	NN	O	O
administration	NN	O	O
exhibite	NN	O	O
generalized	NN	O	O
non	NN	O	O
-	NN	O	O
reactive	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
slow	NN	O	O
beta	NN	O	O
range	NN	O	O
.	NN	O	O

All	NN	O	O
four	NN	O	O
recovered	NN	O	O
completely	NN	O	O
without	NN	O	O
neurological	NN	O	B
sequelae	NN	O	I
following	NN	O	O
the	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
the	NN	O	O
offending	NN	O	O
agents	NN	O	O
.	NN	O	O

The	NN	O	O
similarities	NN	O	O
between	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
structural	NN	O	O
lesions	NN	O	O
and	NN	O	O
pharmacological	NN	O	O
depression	NN	O	B
of	NN	O	O
the	NN	O	O
brain	NN	O	O
stem	NN	O	O
reticular	NN	O	O
formation	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
in	NN	O	O
both	NN	O	O
situations	NN	O	O
disturbed	NN	O	O
reticulo	NN	O	O
-	NN	O	O
thalamic	NN	O	O
interactions	NN	O	O
are	NN	O	O
important	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
alpha	NN	O	O
coma	NN	O	B
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
when	NN	O	O
this	NN	O	O
electroencephalographic	NN	O	O
and	NN	O	O
behavioural	NN	O	O
picture	NN	O	O
is	NN	O	O
seen	NN	O	O
in	NN	O	O
drug	NN	O	O
intoxication	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
significant	NN	O	O
hypoxaemia	NN	O	B
,	NN	O	O
a	NN	O	O
favourable	NN	O	O
outcome	NN	O	O
may	NN	O	O
be	NN	O	O
anticipated	NN	O	O
.	NN	O	O

Magnetic	NN	O	O
resonance	NN	O	O
volumetry	NN	O	O
of	NN	O	O
the	NN	O	O
cerebellum	NN	O	O
in	NN	O	O
epileptic	NN	O	B
patients	NN	O	O
after	NN	O	O
phenytoin	NN	O	O
overdosages	NN	O	B
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
phenytoin	NN	O	O
medication	NN	O	O
and	NN	O	O
cerebellar	NN	O	B
atrophy	NN	O	I
in	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
experienced	NN	O	O
clinical	NN	O	O
intoxication	NN	O	O
.	NN	O	O

Five	NN	O	O
females	NN	O	O
and	NN	O	O
6	NN	O	O
males	NN	O	O
,	NN	O	O
21	NN	O	O
-	NN	O	O
59	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
were	NN	O	O
examined	NN	O	O
with	NN	O	O
a	NN	O	O
1	NN	O	O
.	NN	O	O
5	NN	O	O
-	NN	O	O
T	NN	O	O
whole	NN	O	O
-	NN	O	O
body	NN	O	O
system	NN	O	O
using	NN	O	O
a	NN	O	O
circular	NN	O	O
polarized	NN	O	O
head	NN	O	O
coil	NN	O	O
.	NN	O	O

Conventional	NN	O	O
spin	NN	O	O
echo	NN	O	O
images	NN	O	O
were	NN	O	O
acquired	NN	O	O
in	NN	O	O
the	NN	O	O
sagittal	NN	O	O
and	NN	O	O
transverse	NN	O	O
orientation	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
we	NN	O	O
performed	NN	O	O
a	NN	O	O
high	NN	O	O
-	NN	O	O
resolution	NN	O	O
3D	NN	O	O
gradient	NN	O	O
echo	NN	O	O
,	NN	O	O
T1	NN	O	O
-	NN	O	O
weighted	NN	O	O
sequences	NN	O	O
at	NN	O	O
a	NN	O	O
1	NN	O	O
-	NN	O	O
mm	NN	O	O
slice	NN	O	O
thickness	NN	O	O
.	NN	O	O

The	NN	O	O
images	NN	O	O
were	NN	O	O
subsequently	NN	O	O
processed	NN	O	O
to	NN	O	O
obtain	NN	O	O
volumetric	NN	O	O
data	NN	O	O
for	NN	O	O
the	NN	O	O
cerebellum	NN	O	O
.	NN	O	O

Cerebellar	NN	O	O
volume	NN	O	O
for	NN	O	O
the	NN	O	O
patient	NN	O	O
group	NN	O	O
ranged	NN	O	O
between	NN	O	O
67	NN	O	O
.	NN	O	O
66	NN	O	O
and	NN	O	O
131	NN	O	O
.	NN	O	O
08	NN	O	O
ml	NN	O	O
(	NN	O	O
mean	NN	O	O
108	NN	O	O
.	NN	O	O
9	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
3D	NN	O	O
gradient	NN	O	O
echo	NN	O	O
data	NN	O	O
sets	NN	O	O
from	NN	O	O
10	NN	O	O
healthy	NN	O	O
male	NN	O	O
and	NN	O	O
10	NN	O	O
healthy	NN	O	O
female	NN	O	O
age	NN	O	O
-	NN	O	O
matched	NN	O	O
volunteers	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
compare	NN	O	O
cerebellar	NN	O	O
volumes	NN	O	O
.	NN	O	O

Using	NN	O	O
linear	NN	O	O
regression	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
no	NN	O	O
correlation	NN	O	O
exists	NN	O	O
between	NN	O	O
seizure	NN	O	B
duration	NN	O	O
,	NN	O	O
elevation	NN	O	O
of	NN	O	O
phenytoin	NN	O	O
serum	NN	O	O
levels	NN	O	O
and	NN	O	O
cerebellar	NN	O	O
volume	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
multiple	NN	O	O
regression	NN	O	O
for	NN	O	O
the	NN	O	O
daily	NN	O	O
dosage	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
phenytoin	NN	O	O
treatment	NN	O	O
and	NN	O	O
cerebellar	NN	O	O
volume	NN	O	O
revealed	NN	O	O
a	NN	O	O
correlation	NN	O	O
of	NN	O	O
these	NN	O	O
parameters	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
phenytoin	NN	O	O
overdosage	NN	O	B
does	NN	O	O
not	NN	O	O
necessarily	NN	O	O
result	NN	O	O
in	NN	O	O
cerebellar	NN	O	B
atrophy	NN	O	I
and	NN	O	O
it	NN	O	O
is	NN	O	O
unlikely	NN	O	O
that	NN	O	O
phenytoin	NN	O	O
medication	NN	O	O
was	NN	O	O
the	NN	O	O
only	NN	O	O
cause	NN	O	O
of	NN	O	O
cerebellar	NN	O	B
atrophy	NN	O	I
in	NN	O	O
the	NN	O	O
remaining	NN	O	O
patients	NN	O	O
.	NN	O	O

Quantitative	NN	O	O
morphometric	NN	O	O
studies	NN	O	O
of	NN	O	O
the	NN	O	O
cerebellum	NN	O	O
provide	NN	O	O
valuable	NN	O	O
insights	NN	O	O
into	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
cerebellar	NN	O	B
disorders	NN	O	I
.	NN	O	O

Late	NN	O	O
recovery	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
in	NN	O	O
a	NN	O	O
woman	NN	O	O
with	NN	O	O
the	NN	O	O
hemolytic	NN	O	B
uremic	NN	O	I
syndrome	NN	O	I
.	NN	O	O

A	NN	O	O
case	NN	O	O
is	NN	O	O
reported	NN	O	O
of	NN	O	O
the	NN	O	O
hemolytic	NN	O	B
uremic	NN	O	I
syndrome	NN	O	I
(	NN	O	O
HUS	NN	O	B
)	NN	O	O
in	NN	O	O
a	NN	O	O
woman	NN	O	O
taking	NN	O	O
oral	NN	O	O
contraceptives	NN	O	O
.	NN	O	O

She	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
heparin	NN	O	O
,	NN	O	O
dipyridamole	NN	O	O
and	NN	O	O
hemodialysis	NN	O	O
;	NN	O	O
and	NN	O	O
after	NN	O	O
more	NN	O	O
than	NN	O	O
three	NN	O	O
months	NN	O	O
,	NN	O	O
her	NN	O	O
urinary	NN	O	O
output	NN	O	O
rose	NN	O	O
above	NN	O	O
500	NN	O	O
ml	NN	O	O
;	NN	O	O
and	NN	O	O
six	NN	O	O
months	NN	O	O
after	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
anuria	NN	O	B
,	NN	O	O
dialysis	NN	O	O
treatment	NN	O	O
was	NN	O	O
stopped	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
emphasizes	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
HUS	NN	O	B
in	NN	O	O
adults	NN	O	O
is	NN	O	O
not	NN	O	O
invariably	NN	O	O
irreversible	NN	O	O
and	NN	O	O
that	NN	O	O
,	NN	O	O
despite	NN	O	O
prolonged	NN	O	O
oliguria	NN	O	B
,	NN	O	O
recovery	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
can	NN	O	O
be	NN	O	O
obtained	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
in	NN	O	O
adult	NN	O	O
patients	NN	O	O
affected	NN	O	O
by	NN	O	O
HUS	NN	O	B
,	NN	O	O
dialysis	NN	O	O
should	NN	O	O
not	NN	O	O
be	NN	O	O
discontinued	NN	O	O
prematurely	NN	O	O
;	NN	O	O
moreover	NN	O	O
,	NN	O	O
bilateral	NN	O	O
nephrectomy	NN	O	O
,	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
severe	NN	O	O
hypertension	NN	O	B
and	NN	O	O
microangiopathic	NN	O	B
hemolytic	NN	O	I
anemia	NN	O	I
,	NN	O	O
should	NN	O	O
be	NN	O	O
performed	NN	O	O
with	NN	O	O
caution	NN	O	O
.	NN	O	O

Morphological	NN	O	O
features	NN	O	O
of	NN	O	O
encephalopathy	NN	O	B
after	NN	O	O
chronic	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
valproate	NN	O	O
to	NN	O	O
rats	NN	O	O
.	NN	O	O

A	NN	O	O
transmission	NN	O	O
electron	NN	O	O
microscopic	NN	O	O
study	NN	O	O
of	NN	O	O
capillaries	NN	O	O
in	NN	O	O
the	NN	O	O
cerebellar	NN	O	O
cortex	NN	O	O
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
intragastric	NN	O	O
application	NN	O	O
of	NN	O	O
the	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
sodium	NN	O	O
valproate	NN	O	O
(	NN	O	O
Vupral	NN	O	O
"	NN	O	O
Polfa	NN	O	O
"	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
effective	NN	O	O
dose	NN	O	O
of	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
b	NN	O	O
.	NN	O	O

w	NN	O	O
.	NN	O	O
once	NN	O	O
daily	NN	O	O
to	NN	O	O
rats	NN	O	O
for	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
,	NN	O	O
9	NN	O	O
and	NN	O	O
12	NN	O	O
months	NN	O	O
revealed	NN	O	O
neurological	NN	O	B
disorders	NN	O	I
indicating	NN	O	O
cerebellum	NN	O	B
damage	NN	O	I
(	NN	O	O
"	NN	O	O
valproate	NN	O	O
encephalopathy	NN	O	B
"	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
first	NN	O	O
ultrastructural	NN	O	O
changes	NN	O	O
in	NN	O	O
structural	NN	O	O
elements	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
-	NN	O	O
barrier	NN	O	O
(	NN	O	O
BBB	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
cerebellar	NN	O	O
cortex	NN	O	O
were	NN	O	O
detectable	NN	O	O
after	NN	O	O
3	NN	O	O
months	NN	O	O
of	NN	O	O
the	NN	O	O
experiment	NN	O	O
.	NN	O	O

They	NN	O	O
became	NN	O	O
more	NN	O	O
severe	NN	O	O
in	NN	O	O
the	NN	O	O
later	NN	O	O
months	NN	O	O
of	NN	O	O
the	NN	O	O
experiment	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
most	NN	O	O
severe	NN	O	O
after	NN	O	O
12	NN	O	O
months	NN	O	O
,	NN	O	O
located	NN	O	O
mainly	NN	O	O
in	NN	O	O
the	NN	O	O
molecular	NN	O	O
layer	NN	O	O
of	NN	O	O
the	NN	O	O
cerebellar	NN	O	O
cortex	NN	O	O
.	NN	O	O

Lesions	NN	O	O
of	NN	O	O
the	NN	O	O
capillary	NN	O	O
included	NN	O	O
necrosis	NN	O	B
of	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
.	NN	O	O

Organelles	NN	O	O
of	NN	O	O
these	NN	O	O
cells	NN	O	O
,	NN	O	O
in	NN	O	O
particular	NN	O	O
the	NN	O	O
mitochondria	NN	O	O
(	NN	O	O
increased	NN	O	O
number	NN	O	O
and	NN	O	O
size	NN	O	O
,	NN	O	O
distinct	NN	O	O
degeneration	NN	O	O
of	NN	O	O
their	NN	O	O
matrix	NN	O	O
and	NN	O	O
cristae	NN	O	O
)	NN	O	O
and	NN	O	O
Golgi	NN	O	O
apparatus	NN	O	O
were	NN	O	O
altered	NN	O	O
.	NN	O	O

Reduced	NN	O	O
size	NN	O	O
of	NN	O	O
capillary	NN	O	O
lumen	NN	O	O
and	NN	O	O
occlusion	NN	O	O
were	NN	O	O
caused	NN	O	O
by	NN	O	O
swollen	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
which	NN	O	O
had	NN	O	O
luminal	NN	O	O
protrusions	NN	O	O
and	NN	O	O
swollen	NN	O	O
microvilli	NN	O	O
.	NN	O	O

Pressure	NN	O	O
on	NN	O	O
the	NN	O	O
vessel	NN	O	O
wall	NN	O	O
was	NN	O	O
produced	NN	O	O
by	NN	O	O
enlarged	NN	O	O
perivascular	NN	O	O
astrocytic	NN	O	O
processes	NN	O	O
.	NN	O	O

Fragments	NN	O	O
of	NN	O	O
necrotic	NN	O	B
endothelial	NN	O	O
cells	NN	O	O
were	NN	O	O
in	NN	O	O
the	NN	O	O
vascular	NN	O	O
lumens	NN	O	O
and	NN	O	O
in	NN	O	O
these	NN	O	O
there	NN	O	O
was	NN	O	O
loosening	NN	O	O
and	NN	O	O
breaking	NN	O	O
of	NN	O	O
tight	NN	O	O
cellular	NN	O	O
junctions	NN	O	O
.	NN	O	O

Damage	NN	O	O
to	NN	O	O
the	NN	O	O
vascular	NN	O	O
basement	NN	O	O
lamina	NN	O	O
was	NN	O	O
also	NN	O	O
observed	NN	O	O
.	NN	O	O

Damage	NN	O	O
to	NN	O	O
the	NN	O	O
capillary	NN	O	O
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
marked	NN	O	O
damage	NN	O	O
to	NN	O	O
neuroglial	NN	O	O
cells	NN	O	O
,	NN	O	O
mainly	NN	O	O
to	NN	O	O
perivascular	NN	O	O
processes	NN	O	O
of	NN	O	O
astrocytes	NN	O	O
.	NN	O	O

The	NN	O	O
proliferation	NN	O	O
of	NN	O	O
astrocytes	NN	O	O
(	NN	O	O
Bergmann	NN	O	O
'	NN	O	O
s	NN	O	O
in	NN	O	O
particular	NN	O	O
)	NN	O	O
and	NN	O	O
occasionally	NN	O	O
of	NN	O	O
oligodendrocytes	NN	O	O
was	NN	O	O
found	NN	O	O
.	NN	O	O

Alterations	NN	O	O
in	NN	O	O
the	NN	O	O
structural	NN	O	O
elements	NN	O	O
of	NN	O	O
the	NN	O	O
BBB	NN	O	O
coexisted	NN	O	O
with	NN	O	O
marked	NN	O	O
lesions	NN	O	O
of	NN	O	O
neurons	NN	O	O
of	NN	O	O
the	NN	O	O
cerebellum	NN	O	O
(	NN	O	O
Purkinje	NN	O	O
cells	NN	O	O
are	NN	O	O
earliest	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
electron	NN	O	O
micrographs	NN	O	O
both	NN	O	O
luminal	NN	O	O
and	NN	O	O
antiluminal	NN	O	O
sides	NN	O	O
of	NN	O	O
the	NN	O	O
BBB	NN	O	O
of	NN	O	O
the	NN	O	O
cerebellar	NN	O	O
cortex	NN	O	O
had	NN	O	O
similar	NN	O	O
lesions	NN	O	O
.	NN	O	O

The	NN	O	O
possible	NN	O	O
influence	NN	O	O
of	NN	O	O
the	NN	O	O
hepatic	NN	O	B
damage	NN	O	I
,	NN	O	O
mainly	NN	O	O
hyperammonemia	NN	O	B
,	NN	O	O
upon	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
valproate	NN	O	O
encephalopathy	NN	O	B
is	NN	O	O
discussed	NN	O	O
.	NN	O	O

Fatal	NN	O	O
intracranial	NN	O	B
bleeding	NN	O	I
associated	NN	O	O
with	NN	O	O
prehospital	NN	O	O
use	NN	O	O
of	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
paramedic	NN	O	O
misjudgment	NN	O	O
in	NN	O	O
the	NN	O	O
execution	NN	O	O
of	NN	O	O
a	NN	O	O
protocol	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
allergic	NN	O	B
reaction	NN	O	I
in	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
pulmonary	NN	O	B
edema	NN	O	I
with	NN	O	O
wheezing	NN	O	B
.	NN	O	O

The	NN	O	O
sudden	NN	O	O
onset	NN	O	O
of	NN	O	O
respiratory	NN	O	B
distress	NN	O	I
,	NN	O	O
rash	NN	O	B
,	NN	O	O
and	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
medicine	NN	O	O
led	NN	O	O
the	NN	O	O
two	NN	O	O
paramedics	NN	O	O
on	NN	O	O
the	NN	O	O
scene	NN	O	O
to	NN	O	O
administer	NN	O	O
subcutaneous	NN	O	O
epinephrine	NN	O	O
.	NN	O	O

Subsequently	NN	O	O
,	NN	O	O
acute	NN	O	O
cardiac	NN	O	B
arrest	NN	O	I
and	NN	O	O
fatal	NN	O	O
subarachnoid	NN	O	B
hemorrhage	NN	O	I
occurred	NN	O	O
.	NN	O	O

Epinephrine	NN	O	O
has	NN	O	O
a	NN	O	O
proven	NN	O	O
role	NN	O	O
in	NN	O	O
cardiac	NN	O	B
arrest	NN	O	I
in	NN	O	O
prehospital	NN	O	O
care	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
use	NN	O	O
by	NN	O	O
paramedics	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
suspected	NN	O	O
allergic	NN	O	B
reaction	NN	O	I
and	NN	O	O
severe	NN	O	O
hypertension	NN	O	B
should	NN	O	O
be	NN	O	O
viewed	NN	O	O
with	NN	O	O
caution	NN	O	O
.	NN	O	O

Role	NN	O	O
of	NN	O	O
activation	NN	O	O
of	NN	O	O
bradykinin	NN	O	O
B2	NN	O	O
receptors	NN	O	O
in	NN	O	O
disruption	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
during	NN	O	O
acute	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Cellular	NN	O	O
mechanisms	NN	O	O
which	NN	O	O
account	NN	O	O
for	NN	O	O
disruption	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
during	NN	O	O
acute	NN	O	O
hypertension	NN	O	B
are	NN	O	O
not	NN	O	O
clear	NN	O	O
.	NN	O	O

The	NN	O	O
goal	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
synthesis	NN	O	O
/	NN	O	O
release	NN	O	O
of	NN	O	O
bradykinin	NN	O	O
to	NN	O	O
activate	NN	O	O
B2	NN	O	O
receptors	NN	O	O
in	NN	O	O
disruption	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
during	NN	O	O
acute	NN	O	O
hypertension	NN	O	B
.	NN	O	O

Permeability	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
was	NN	O	O
quantitated	NN	O	O
by	NN	O	O
clearance	NN	O	O
of	NN	O	O
fluorescent	NN	O	O
-	NN	O	O
labeled	NN	O	O
dextran	NN	O	O
before	NN	O	O
and	NN	O	O
during	NN	O	O
phenylephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
hypertension	NN	O	B
in	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
vehicle	NN	O	O
and	NN	O	O
Hoe	NN	O	O
-	NN	O	O
140	NN	O	O
(	NN	O	O
0	NN	O	O
.	NN	O	O
1	NN	O	O
microM	NN	O	O
)	NN	O	O
.	NN	O	O

Phenylephrine	NN	O	O
infusion	NN	O	O
increased	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
,	NN	O	O
arteriolar	NN	O	O
diameter	NN	O	O
and	NN	O	O
clearance	NN	O	O
of	NN	O	O
fluorescent	NN	O	O
dextran	NN	O	O
by	NN	O	O
a	NN	O	O
similar	NN	O	O
magnitude	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
disruption	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
during	NN	O	O
acute	NN	O	O
hypertension	NN	O	B
is	NN	O	O
not	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
synthesis	NN	O	O
/	NN	O	O
release	NN	O	O
of	NN	O	O
bradykinin	NN	O	O
to	NN	O	O
activate	NN	O	O
B2	NN	O	O
receptors	NN	O	O
.	NN	O	O

Risk	NN	O	O
factors	NN	O	O
of	NN	O	O
sensorineural	NN	O	B
hearing	NN	O	I
loss	NN	O	I
in	NN	O	O
preterm	NN	O	O
infants	NN	O	O
.	NN	O	O

Among	NN	O	O
547	NN	O	O
preterm	NN	O	O
infants	NN	O	O
of	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
34	NN	O	O
weeks	NN	O	O
gestation	NN	O	O
born	NN	O	O
between	NN	O	O
1987	NN	O	O
and	NN	O	O
1991	NN	O	O
,	NN	O	O
8	NN	O	O
children	NN	O	O
(	NN	O	O
1	NN	O	O
.	NN	O	O
46	NN	O	O
%	NN	O	O
)	NN	O	O
developed	NN	O	O
severe	NN	O	O
progressive	NN	O	O
and	NN	O	O
bilateral	NN	O	O
sensorineural	NN	O	B
hearing	NN	O	I
loss	NN	O	I
.	NN	O	O

Perinatal	NN	O	O
risk	NN	O	O
factors	NN	O	O
of	NN	O	O
infants	NN	O	O
with	NN	O	O
hearing	NN	O	B
loss	NN	O	I
were	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
two	NN	O	O
control	NN	O	O
groups	NN	O	O
matched	NN	O	O
for	NN	O	O
gestation	NN	O	O
and	NN	O	O
birth	NN	O	O
weight	NN	O	O
and	NN	O	O
for	NN	O	O
perinatal	NN	O	O
complications	NN	O	O
.	NN	O	O

Our	NN	O	O
observations	NN	O	O
demonstrated	NN	O	O
an	NN	O	O
association	NN	O	O
of	NN	O	O
hearing	NN	O	B
loss	NN	O	I
with	NN	O	O
a	NN	O	O
higher	NN	O	O
incidence	NN	O	O
of	NN	O	O
perinatal	NN	O	O
complications	NN	O	O
.	NN	O	O

Ototoxicity	NN	O	B
appeared	NN	O	O
closely	NN	O	O
related	NN	O	O
to	NN	O	O
a	NN	O	O
prolonged	NN	O	O
administration	NN	O	O
and	NN	O	O
higher	NN	O	O
total	NN	O	O
dose	NN	O	O
of	NN	O	O
ototoxic	NN	O	B
drugs	NN	O	O
,	NN	O	O
particularly	NN	O	O
aminoglycosides	NN	O	O
and	NN	O	O
furosemide	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
we	NN	O	O
strongly	NN	O	O
recommend	NN	O	O
to	NN	O	O
prospectively	NN	O	O
and	NN	O	O
regularly	NN	O	O
perform	NN	O	O
audiologic	NN	O	O
assessment	NN	O	O
in	NN	O	O
sick	NN	O	O
preterm	NN	O	O
children	NN	O	O
as	NN	O	O
hearing	NN	O	B
loss	NN	O	I
is	NN	O	O
of	NN	O	O
delayed	NN	O	O
onset	NN	O	O
and	NN	O	O
in	NN	O	O
most	NN	O	O
cases	NN	O	O
bilateral	NN	O	O
and	NN	O	O
severe	NN	O	O
.	NN	O	O

Seizure	NN	O	B
resulting	NN	O	O
from	NN	O	O
a	NN	O	O
venlafaxine	NN	O	O
overdose	NN	O	B
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
venlafaxine	NN	O	O
overdose	NN	O	B
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
40	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
major	NN	O	B
depression	NN	O	I
took	NN	O	O
an	NN	O	O
overdose	NN	O	B
of	NN	O	O
venlafaxine	NN	O	O
in	NN	O	O
an	NN	O	O
apparent	NN	O	O
suicide	NN	O	O
attempt	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
ingestion	NN	O	O
of	NN	O	O
26	NN	O	O
venlafaxine	NN	O	O
50	NN	O	O
-	NN	O	O
mg	NN	O	O
tablets	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
experienced	NN	O	O
a	NN	O	O
witnessed	NN	O	O
generalized	NN	O	O
seizure	NN	O	B
.	NN	O	O

She	NN	O	O
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
the	NN	O	O
medical	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
,	NN	O	O
venlafaxine	NN	O	O
was	NN	O	O
discontinued	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
further	NN	O	O
sequelae	NN	O	O
were	NN	O	O
seen	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
of	NN	O	O
venlafaxine	NN	O	O
overdose	NN	O	B
that	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
generalized	NN	O	O
seizure	NN	O	B
.	NN	O	O

Based	NN	O	O
on	NN	O	O
nonoverdose	NN	O	O
pharmacokinetics	NN	O	O
and	NN	O	O
pharmacodynamics	NN	O	O
of	NN	O	O
venlafaxine	NN	O	O
and	NN	O	O
the	NN	O	O
potential	NN	O	O
risks	NN	O	O
of	NN	O	O
available	NN	O	O
interventions	NN	O	O
,	NN	O	O
no	NN	O	O
emergent	NN	O	O
therapy	NN	O	O
was	NN	O	O
instituted	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
venlafaxine	NN	O	O
overdose	NN	O	B
in	NN	O	O
our	NN	O	O
patient	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
episode	NN	O	O
of	NN	O	O
generalized	NN	O	O
seizure	NN	O	B
but	NN	O	O
elicited	NN	O	O
no	NN	O	O
further	NN	O	O
sequelae	NN	O	O
.	NN	O	O

Combined	NN	O	O
effects	NN	O	O
of	NN	O	O
prolonged	NN	O	O
prostaglandin	NN	O	O
E1	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
and	NN	O	O
haemodilution	NN	O	B
on	NN	O	O
human	NN	O	O
hepatic	NN	O	O
function	NN	O	O
.	NN	O	O

Combined	NN	O	O
effects	NN	O	O
of	NN	O	O
prolonged	NN	O	O
prostaglandin	NN	O	O
E1	NN	O	O
(	NN	O	O
PGE1	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
and	NN	O	O
haemodilution	NN	O	B
on	NN	O	O
hepatic	NN	O	O
function	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
30	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
hip	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
one	NN	O	O
of	NN	O	O
three	NN	O	O
groups	NN	O	O
;	NN	O	O
those	NN	O	O
in	NN	O	O
group	NN	O	O
A	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
controlled	NN	O	O
hypotension	NN	O	B
alone	NN	O	O
,	NN	O	O
those	NN	O	O
in	NN	O	O
group	NN	O	O
B	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
to	NN	O	O
haemodilution	NN	O	B
alone	NN	O	O
and	NN	O	O
those	NN	O	O
in	NN	O	O
group	NN	O	O
C	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
to	NN	O	O
both	NN	O	O
controlled	NN	O	O
hypotension	NN	O	B
and	NN	O	O
haemodilution	NN	O	B
.	NN	O	O

Haemodilution	NN	O	B
in	NN	O	O
groups	NN	O	O
B	NN	O	O
and	NN	O	O
C	NN	O	O
was	NN	O	O
produced	NN	O	O
by	NN	O	O
withdrawing	NN	O	O
approximately	NN	O	O
1000	NN	O	O
mL	NN	O	O
of	NN	O	O
blood	NN	O	O
and	NN	O	O
replacing	NN	O	O
it	NN	O	O
with	NN	O	O
the	NN	O	O
same	NN	O	O
amount	NN	O	O
of	NN	O	O
dextran	NN	O	O
solution	NN	O	O
,	NN	O	O
and	NN	O	O
final	NN	O	O
haematocrit	NN	O	O
values	NN	O	O
were	NN	O	O
21	NN	O	O
or	NN	O	O
22	NN	O	O
%	NN	O	O
.	NN	O	O

Controlled	NN	O	O
hypotension	NN	O	B
in	NN	O	O
groups	NN	O	O
A	NN	O	O
and	NN	O	O
C	NN	O	O
was	NN	O	O
induced	NN	O	O
with	NN	O	O
PGE1	NN	O	O
to	NN	O	O
maintain	NN	O	O
mean	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
at	NN	O	O
55	NN	O	O
mmHg	NN	O	O
for	NN	O	O
180	NN	O	O
min	NN	O	O
.	NN	O	O

Measurements	NN	O	O
included	NN	O	O
arterial	NN	O	O
ketone	NN	O	O
body	NN	O	O
ratio	NN	O	O
(	NN	O	O
AKBR	NN	O	O
,	NN	O	O
aceto	NN	O	O
-	NN	O	O
acetate	NN	O	O
/	NN	O	O
3	NN	O	O
-	NN	O	O
hydroxybutyrate	NN	O	O
)	NN	O	O
and	NN	O	O
clinical	NN	O	O
hepatic	NN	O	O
function	NN	O	O
parameters	NN	O	O
.	NN	O	O

AKBR	NN	O	O
and	NN	O	O
biological	NN	O	O
hepatic	NN	O	O
function	NN	O	O
tests	NN	O	O
showed	NN	O	O
no	NN	O	O
change	NN	O	O
throughout	NN	O	O
the	NN	O	O
time	NN	O	O
course	NN	O	O
in	NN	O	O
groups	NN	O	O
A	NN	O	O
and	NN	O	O
B	NN	O	O
.	NN	O	O

In	NN	O	O
group	NN	O	O
C	NN	O	O
,	NN	O	O
AKBR	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
at	NN	O	O
120	NN	O	O
min	NN	O	O
(	NN	O	O
-	NN	O	O
40	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
at	NN	O	O
180	NN	O	O
min	NN	O	O
(	NN	O	O
-	NN	O	O
49	NN	O	O
%	NN	O	O
)	NN	O	O
after	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
hypotension	NN	O	B
and	NN	O	O
at	NN	O	O
60	NN	O	O
min	NN	O	O
(	NN	O	O
-	NN	O	O
32	NN	O	O
%	NN	O	O
)	NN	O	O
after	NN	O	O
recovery	NN	O	O
of	NN	O	O
normotension	NN	O	O
,	NN	O	O
and	NN	O	O
SGOT	NN	O	O
,	NN	O	O
SGPT	NN	O	O
,	NN	O	O
LDH	NN	O	O
and	NN	O	O
total	NN	O	O
bilirubin	NN	O	O
showed	NN	O	O
significant	NN	O	O
increases	NN	O	O
after	NN	O	O
operation	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
a	NN	O	O
prolonged	NN	O	O
combination	NN	O	O
of	NN	O	O
more	NN	O	O
than	NN	O	O
120	NN	O	O
min	NN	O	O
of	NN	O	O
PGE1	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B
and	NN	O	O
moderate	NN	O	O
haemodilution	NN	O	B
would	NN	O	O
cause	NN	O	O
impairment	NN	O	B
of	NN	O	I
hepatic	NN	O	I
function	NN	O	I
.	NN	O	O

Cardiovascular	NN	O	B
alterations	NN	O	I
in	NN	O	O
rat	NN	O	O
fetuses	NN	O	O
exposed	NN	O	O
to	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
.	NN	O	O

Preclinical	NN	O	O
toxicologic	NN	O	O
investigation	NN	O	O
suggested	NN	O	O
that	NN	O	O
a	NN	O	O
new	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blocker	NN	O	O
,	NN	O	O
Ro	NN	O	O
40	NN	O	O
-	NN	O	O
5967	NN	O	O
,	NN	O	O
induced	NN	O	O
cardiovascular	NN	O	B
alterations	NN	O	I
in	NN	O	O
rat	NN	O	O
fetuses	NN	O	O
exposed	NN	O	O
to	NN	O	O
this	NN	O	O
agent	NN	O	O
during	NN	O	O
organogenesis	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
in	NN	O	O
general	NN	O	O
induce	NN	O	O
cardiovascular	NN	O	B
malformations	NN	O	I
indicating	NN	O	O
a	NN	O	O
pharmacologic	NN	O	O
class	NN	O	O
effect	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
three	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
of	NN	O	O
different	NN	O	O
structure	NN	O	O
,	NN	O	O
nifedipine	NN	O	O
,	NN	O	O
diltiazem	NN	O	O
,	NN	O	O
and	NN	O	O
verapamil	NN	O	O
,	NN	O	O
along	NN	O	O
with	NN	O	O
the	NN	O	O
new	NN	O	O
agent	NN	O	O
.	NN	O	O

Pregnant	NN	O	O
rats	NN	O	O
were	NN	O	O
administered	NN	O	O
one	NN	O	O
of	NN	O	O
these	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
during	NN	O	O
the	NN	O	O
period	NN	O	O
of	NN	O	O
cardiac	NN	O	O
morphogenesis	NN	O	O
and	NN	O	O
the	NN	O	O
offspring	NN	O	O
examined	NN	O	O
on	NN	O	O
day	NN	O	O
20	NN	O	O
of	NN	O	O
gestation	NN	O	O
for	NN	O	O
cardiovascular	NN	O	B
malformations	NN	O	I
.	NN	O	O

A	NN	O	O
low	NN	O	O
incidence	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B
malformations	NN	O	I
was	NN	O	O
observed	NN	O	O
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
each	NN	O	O
of	NN	O	O
the	NN	O	O
four	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
,	NN	O	O
but	NN	O	O
this	NN	O	O
incidence	NN	O	O
was	NN	O	O
statistically	NN	O	O
significant	NN	O	O
only	NN	O	O
for	NN	O	O
verapamil	NN	O	O
and	NN	O	O
nifedipine	NN	O	O
.	NN	O	O

All	NN	O	O
four	NN	O	O
agents	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
aortic	NN	O	O
arch	NN	O	O
branching	NN	O	O
variants	NN	O	O
,	NN	O	O
although	NN	O	O
significantly	NN	O	O
increased	NN	O	O
only	NN	O	O
for	NN	O	O
Ro	NN	O	O
40	NN	O	O
-	NN	O	O
5967	NN	O	O
and	NN	O	O
verapamil	NN	O	O
.	NN	O	O

The	NN	O	O
site	NN	O	O
of	NN	O	O
common	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
sumatriptan	NN	O	O
.	NN	O	O

Atypical	NN	O	B
sensations	NN	O	I
following	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
subcutaneous	NN	O	O
sumatriptan	NN	O	O
are	NN	O	O
common	NN	O	O
,	NN	O	O
but	NN	O	O
of	NN	O	O
uncertain	NN	O	O
origin	NN	O	O
.	NN	O	O

They	NN	O	O
are	NN	O	O
almost	NN	O	O
always	NN	O	O
benign	NN	O	O
,	NN	O	O
but	NN	O	O
can	NN	O	O
be	NN	O	O
mistaken	NN	O	O
for	NN	O	O
a	NN	O	O
serious	NN	O	O
adverse	NN	O	O
event	NN	O	O
by	NN	O	O
the	NN	O	O
patient	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
are	NN	O	O
presented	NN	O	O
with	NN	O	O
tingling	NN	O	B
or	NN	O	I
burning	NN	O	I
sensations	NN	O	I
limited	NN	O	O
to	NN	O	O
areas	NN	O	O
of	NN	O	O
heat	NN	O	O
exposure	NN	O	O
or	NN	O	O
sunburn	NN	O	B
.	NN	O	O

In	NN	O	O
these	NN	O	O
individuals	NN	O	O
,	NN	O	O
side	NN	O	O
effects	NN	O	O
are	NN	O	O
most	NN	O	O
likely	NN	O	O
generated	NN	O	O
superficially	NN	O	O
in	NN	O	O
the	NN	O	O
skin	NN	O	O
.	NN	O	O

Macula	NN	O	O
toxicity	NN	O	B
after	NN	O	O
intravitreal	NN	O	O
amikacin	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Although	NN	O	O
intravitreal	NN	O	O
aminoglycosides	NN	O	O
have	NN	O	O
substantially	NN	O	O
improved	NN	O	O
visual	NN	O	O
prognosis	NN	O	O
in	NN	O	O
endophthalmitis	NN	O	B
,	NN	O	O
macular	NN	O	O
infarction	NN	O	B
may	NN	O	O
impair	NN	O	O
full	NN	O	O
visual	NN	O	O
recovery	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
presumed	NN	O	O
amikacin	NN	O	O
retinal	NN	O	B
toxicity	NN	O	I
following	NN	O	O
treatment	NN	O	O
with	NN	O	O
amikacin	NN	O	O
and	NN	O	O
vancomycin	NN	O	O
for	NN	O	O
alpha	NN	O	O
-	NN	O	O
haemolytic	NN	O	O
streptococcal	NN	O	B
endophthalmitis	NN	O	I
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Endophthalmitis	NN	O	B
resolved	NN	O	O
with	NN	O	O
improvement	NN	O	O
in	NN	O	O
visual	NN	O	O
acuity	NN	O	O
to	NN	O	O
6	NN	O	O
/	NN	O	O
24	NN	O	O
at	NN	O	O
three	NN	O	O
months	NN	O	O
.	NN	O	O

Fundus	NN	O	O
fluorescein	NN	O	O
angiography	NN	O	O
confirmed	NN	O	O
macular	NN	O	O
capillary	NN	O	O
closure	NN	O	O
and	NN	O	O
telangiectasis	NN	O	B
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Currently	NN	O	O
accepted	NN	O	O
intravitreal	NN	O	O
antibiotic	NN	O	O
regimens	NN	O	O
may	NN	O	O
cause	NN	O	O
retinal	NN	O	B
toxicity	NN	O	I
and	NN	O	O
macular	NN	O	O
ischaemia	NN	O	B
.	NN	O	O

Treatment	NN	O	O
strategies	NN	O	O
aimed	NN	O	O
at	NN	O	O
avoiding	NN	O	O
retinal	NN	O	B
toxicity	NN	O	I
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
nicotine	NN	O	O
in	NN	O	O
smoking	NN	O	O
-	NN	O	O
related	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
.	NN	O	O

Nicotine	NN	O	O
activates	NN	O	O
the	NN	O	O
sympathetic	NN	O	O
nervous	NN	O	O
system	NN	O	O
and	NN	O	O
in	NN	O	O
this	NN	O	O
way	NN	O	O
could	NN	O	O
contribute	NN	O	O
to	NN	O	O
cardiovascular	NN	O	B
disease	NN	O	I
.	NN	O	O

Animal	NN	O	O
studies	NN	O	O
and	NN	O	O
mechanistic	NN	O	O
studies	NN	O	O
indicate	NN	O	O
that	NN	O	O
nicotine	NN	O	O
could	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
accelerating	NN	O	O
atherosclerosis	NN	O	B
,	NN	O	O
but	NN	O	O
evidence	NN	O	O
among	NN	O	O
humans	NN	O	O
is	NN	O	O
too	NN	O	O
inadequate	NN	O	O
to	NN	O	O
be	NN	O	O
definitive	NN	O	O
about	NN	O	O
such	NN	O	O
an	NN	O	O
effect	NN	O	O
.	NN	O	O

Almost	NN	O	O
certainly	NN	O	O
,	NN	O	O
nicotine	NN	O	O
via	NN	O	O
its	NN	O	O
hemodynamic	NN	O	O
effects	NN	O	O
contributes	NN	O	O
to	NN	O	O
acute	NN	O	O
cardiovascular	NN	O	O
events	NN	O	O
,	NN	O	O
although	NN	O	O
current	NN	O	O
evidence	NN	O	O
suggests	NN	O	O
that	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
nicotine	NN	O	O
are	NN	O	O
much	NN	O	O
less	NN	O	O
important	NN	O	O
than	NN	O	O
are	NN	O	O
the	NN	O	O
prothrombotic	NN	O	O
effects	NN	O	O
of	NN	O	O
cigarette	NN	O	O
smoking	NN	O	O
or	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
carbon	NN	O	O
monoxide	NN	O	O
.	NN	O	O

Nicotine	NN	O	O
does	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
enhance	NN	O	O
thrombosis	NN	O	B
among	NN	O	O
humans	NN	O	O
.	NN	O	O

Clinical	NN	O	O
studies	NN	O	O
of	NN	O	O
pipe	NN	O	O
smokers	NN	O	O
and	NN	O	O
people	NN	O	O
using	NN	O	O
transdermal	NN	O	O
nicotine	NN	O	O
support	NN	O	O
the	NN	O	O
idea	NN	O	O
that	NN	O	O
toxins	NN	O	O
other	NN	O	O
than	NN	O	O
nicotine	NN	O	O
are	NN	O	O
the	NN	O	O
most	NN	O	O
important	NN	O	O
causes	NN	O	O
of	NN	O	O
acute	NN	O	O
cardiovascular	NN	O	O
events	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
the	NN	O	O
dose	NN	O	O
response	NN	O	O
for	NN	O	O
cardiovascular	NN	O	O
events	NN	O	O
of	NN	O	O
nicotine	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
flat	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
if	NN	O	O
nicotine	NN	O	O
is	NN	O	O
involved	NN	O	O
,	NN	O	O
adverse	NN	O	O
effects	NN	O	O
might	NN	O	O
be	NN	O	O
seen	NN	O	O
with	NN	O	O
relatively	NN	O	O
low	NN	O	O
-	NN	O	O
level	NN	O	O
cigarette	NN	O	O
exposures	NN	O	O
.	NN	O	O

Iatrogenically	NN	O	O
induced	NN	O	O
intractable	NN	O	O
atrioventricular	NN	O	B
reentrant	NN	O	I
tachycardia	NN	O	I
after	NN	O	O
verapamil	NN	O	O
and	NN	O	O
catheter	NN	O	O
ablation	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
Wolff	NN	O	B
-	NN	O	I
Parkinson	NN	O	I
-	NN	O	I
White	NN	O	I
syndrome	NN	O	I
and	NN	O	O
idiopathic	NN	O	B
dilated	NN	O	I
cardiomyopathy	NN	O	I
.	NN	O	O

In	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
WPW	NN	O	B
syndrome	NN	O	I
and	NN	O	O
idiopathic	NN	O	B
dilated	NN	O	I
cardiomyopathy	NN	O	I
,	NN	O	O
intractable	NN	O	O
atrioventricular	NN	O	B
reentrant	NN	O	I
tachycardia	NN	O	I
(	NN	O	O
AVRT	NN	O	B
)	NN	O	O
was	NN	O	O
iatrogenically	NN	O	O
induced	NN	O	O
.	NN	O	O

QRS	NN	O	O
without	NN	O	O
preexcitation	NN	O	O
,	NN	O	O
caused	NN	O	O
by	NN	O	O
junctional	NN	O	O
escape	NN	O	O
beats	NN	O	O
after	NN	O	O
verapamil	NN	O	O
or	NN	O	O
unidirectional	NN	O	O
antegrade	NN	O	O
block	NN	O	O
of	NN	O	O
accessory	NN	O	O
pathway	NN	O	O
after	NN	O	O
catheter	NN	O	O
ablation	NN	O	O
,	NN	O	O
established	NN	O	O
frequent	NN	O	O
AVRT	NN	O	B
attack	NN	O	O
.	NN	O	O

Epidemic	NN	O	O
of	NN	O	O
liver	NN	O	B
disease	NN	O	I
caused	NN	O	O
by	NN	O	O
hydrochlorofluorocarbons	NN	O	O
used	NN	O	O
as	NN	O	O
ozone	NN	O	O
-	NN	O	O
sparing	NN	O	O
substitutes	NN	O	O
of	NN	O	O
chlorofluorocarbons	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Hydrochlorofluorocarbons	NN	O	O
(	NN	O	O
HCFCs	NN	O	O
)	NN	O	O
are	NN	O	O
used	NN	O	O
increasingly	NN	O	O
in	NN	O	O
industry	NN	O	O
as	NN	O	O
substitutes	NN	O	O
for	NN	O	O
ozone	NN	O	O
-	NN	O	O
depleting	NN	O	O
chlorofluorocarbons	NN	O	O
(	NN	O	O
CFCs	NN	O	O
)	NN	O	O
.	NN	O	O

Limited	NN	O	O
studies	NN	O	O
in	NN	O	O
animals	NN	O	O
indicate	NN	O	O
potential	NN	O	O
hepatotoxicity	NN	O	B
of	NN	O	O
some	NN	O	O
of	NN	O	O
these	NN	O	O
compounds	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
an	NN	O	O
epidemic	NN	O	O
of	NN	O	O
liver	NN	O	B
disease	NN	O	I
in	NN	O	O
nine	NN	O	O
industrial	NN	O	O
workers	NN	O	O
who	NN	O	O
had	NN	O	O
had	NN	O	O
repeated	NN	O	O
accidental	NN	O	O
exposure	NN	O	O
to	NN	O	O
a	NN	O	O
mixture	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
1	NN	O	O
-	NN	O	O
dichloro	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
trifluoroethane	NN	O	O
(	NN	O	O
HCFC	NN	O	O
123	NN	O	O
)	NN	O	O
and	NN	O	O
1	NN	O	O
-	NN	O	O
chloro	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
tetrafluoroethane	NN	O	O
(	NN	O	O
HCFC	NN	O	O
124	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
nine	NN	O	O
exposed	NN	O	O
workers	NN	O	O
were	NN	O	O
affected	NN	O	O
to	NN	O	O
various	NN	O	O
degrees	NN	O	O
.	NN	O	O

Both	NN	O	O
compounds	NN	O	O
are	NN	O	O
metabolised	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
way	NN	O	O
as	NN	O	O
1	NN	O	O
-	NN	O	O
bromo	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
chloro	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
trifluoroethane	NN	O	O
(	NN	O	O
halothane	NN	O	O
)	NN	O	O
to	NN	O	O
form	NN	O	O
reactive	NN	O	O
trifluoroacetyl	NN	O	O
halide	NN	O	O
intermediates	NN	O	O
,	NN	O	O
which	NN	O	O
have	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
hepatotoxicity	NN	O	B
of	NN	O	O
halothane	NN	O	O
.	NN	O	O

We	NN	O	O
aimed	NN	O	O
to	NN	O	O
test	NN	O	O
whether	NN	O	O
HCFCs	NN	O	O
123	NN	O	O
and	NN	O	O
124	NN	O	O
can	NN	O	O
result	NN	O	O
in	NN	O	O
serious	NN	O	O
liver	NN	O	B
disease	NN	O	I
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
For	NN	O	O
one	NN	O	O
severely	NN	O	O
affected	NN	O	O
worker	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
and	NN	O	O
immunohistochemical	NN	O	O
stainings	NN	O	O
for	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
trifluoroacetyl	NN	O	O
protein	NN	O	O
adducts	NN	O	O
were	NN	O	O
done	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	O
of	NN	O	O
six	NN	O	O
affected	NN	O	O
workers	NN	O	O
and	NN	O	O
five	NN	O	O
controls	NN	O	O
was	NN	O	O
tested	NN	O	O
for	NN	O	O
autoantibodies	NN	O	O
that	NN	O	O
react	NN	O	O
with	NN	O	O
human	NN	O	O
liver	NN	O	O
cytochrome	NN	O	O
-	NN	O	O
P450	NN	O	O
2E1	NN	O	O
(	NN	O	O
P450	NN	O	O
2E1	NN	O	O
)	NN	O	O
and	NN	O	O
P58	NN	O	O
protein	NN	O	O
disulphide	NN	O	O
isomerase	NN	O	O
isoform	NN	O	O
(	NN	O	O
P58	NN	O	O
)	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
:	NN	O	O
The	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
sample	NN	O	O
showed	NN	O	O
hepatocellular	NN	O	O
necrosis	NN	O	B
which	NN	O	O
was	NN	O	O
prominent	NN	O	O
in	NN	O	O
perivenular	NN	O	O
zone	NN	O	O
three	NN	O	O
and	NN	O	O
extended	NN	O	O
focally	NN	O	O
from	NN	O	O
portal	NN	O	O
tracts	NN	O	O
to	NN	O	O
portal	NN	O	O
tracts	NN	O	O
and	NN	O	O
centrilobular	NN	O	O
areas	NN	O	O
(	NN	O	O
bridging	NN	O	O
necrosis	NN	O	B
)	NN	O	O
.	NN	O	O

Trifluoroacetyl	NN	O	O
-	NN	O	O
adducted	NN	O	O
proteins	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
surviving	NN	O	O
hepatocytes	NN	O	O
.	NN	O	O

Autoantibodies	NN	O	O
against	NN	O	O
P450	NN	O	O
2E1	NN	O	O
or	NN	O	O
P58	NN	O	O
,	NN	O	O
previously	NN	O	O
associated	NN	O	O
with	NN	O	O
halothane	NN	O	B
hepatitis	NN	O	I
,	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
of	NN	O	O
five	NN	O	O
affected	NN	O	O
workers	NN	O	O
.	NN	O	O

INTERPRETATION	NN	O	O
:	NN	O	O
Repeated	NN	O	O
exposure	NN	O	O
of	NN	O	O
human	NN	O	O
beings	NN	O	O
to	NN	O	O
HCFCs	NN	O	O
123	NN	O	O
and	NN	O	O
124	NN	O	O
can	NN	O	O
result	NN	O	O
in	NN	O	O
serious	NN	O	O
liver	NN	O	B
injury	NN	O	I
in	NN	O	O
a	NN	O	O
large	NN	O	O
proportion	NN	O	O
of	NN	O	O
the	NN	O	O
exposed	NN	O	O
population	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
exact	NN	O	O
mechanism	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B
of	NN	O	O
these	NN	O	O
agents	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
,	NN	O	O
the	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
trifluoroacetyl	NN	O	O
-	NN	O	O
altered	NN	O	O
liver	NN	O	O
proteins	NN	O	O
are	NN	O	O
involved	NN	O	O
.	NN	O	O

In	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
potentially	NN	O	O
widespread	NN	O	O
use	NN	O	O
of	NN	O	O
these	NN	O	O
compounds	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
an	NN	O	O
urgent	NN	O	O
need	NN	O	O
to	NN	O	O
develop	NN	O	O
safer	NN	O	O
alternatives	NN	O	O
.	NN	O	O

Bile	NN	O	B
duct	NN	O	I
hamartoma	NN	O	I
occurring	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
danazol	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
bile	NN	O	B
duct	NN	O	I
hamartoma	NN	O	I
which	NN	O	O
developed	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
on	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
danazol	NN	O	O
treatment	NN	O	O
.	NN	O	O

Such	NN	O	O
patients	NN	O	O
should	NN	O	O
be	NN	O	O
under	NN	O	O
close	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
preferably	NN	O	O
with	NN	O	O
periodic	NN	O	O
ultrasound	NN	O	O
examination	NN	O	O
of	NN	O	O
the	NN	O	O
liver	NN	O	O
.	NN	O	O

If	NN	O	O
the	NN	O	O
patient	NN	O	O
develops	NN	O	O
a	NN	O	O
liver	NN	O	B
mass	NN	O	I
,	NN	O	O
because	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
specific	NN	O	O
clinical	NN	O	O
features	NN	O	O
and	NN	O	O
imaging	NN	O	O
appearances	NN	O	O
,	NN	O	O
biopsy	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
only	NN	O	O
way	NN	O	O
to	NN	O	O
achieve	NN	O	O
a	NN	O	O
definitive	NN	O	O
diagnosis	NN	O	O
.	NN	O	O

Endocrine	NN	O	O
screening	NN	O	O
in	NN	O	O
1	NN	O	O
,	NN	O	O
022	NN	O	O
men	NN	O	O
with	NN	O	O
erectile	NN	O	B
dysfunction	NN	O	I
:	NN	O	O
clinical	NN	O	O
significance	NN	O	O
and	NN	O	O
cost	NN	O	O
-	NN	O	O
effective	NN	O	O
strategy	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
We	NN	O	O
reviewed	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
serum	NN	O	O
testosterone	NN	O	O
and	NN	O	O
prolactin	NN	O	O
determination	NN	O	O
in	NN	O	O
1	NN	O	O
,	NN	O	O
022	NN	O	O
patients	NN	O	O
referred	NN	O	O
because	NN	O	O
of	NN	O	O
erectile	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
compared	NN	O	O
the	NN	O	O
data	NN	O	O
with	NN	O	O
history	NN	O	O
,	NN	O	O
results	NN	O	O
of	NN	O	O
physical	NN	O	O
examination	NN	O	O
,	NN	O	O
other	NN	O	O
etiological	NN	O	O
investigations	NN	O	O
and	NN	O	O
effects	NN	O	O
of	NN	O	O
endocrine	NN	O	O
therapy	NN	O	O
to	NN	O	O
refine	NN	O	O
the	NN	O	O
rules	NN	O	O
of	NN	O	O
cost	NN	O	O
-	NN	O	O
effective	NN	O	O
endocrine	NN	O	O
screening	NN	O	O
and	NN	O	O
to	NN	O	O
pinpoint	NN	O	O
actual	NN	O	O
responsibility	NN	O	O
for	NN	O	O
hormonal	NN	O	O
abnormalities	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Testosterone	NN	O	O
and	NN	O	O
prolactin	NN	O	O
were	NN	O	O
determined	NN	O	O
by	NN	O	O
radioimmunoassay	NN	O	O
.	NN	O	O

Every	NN	O	O
patient	NN	O	O
was	NN	O	O
screened	NN	O	O
for	NN	O	O
testosterone	NN	O	O
and	NN	O	O
451	NN	O	O
were	NN	O	O
screened	NN	O	O
for	NN	O	O
prolactin	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
low	NN	O	B
sexual	NN	O	I
desire	NN	O	I
,	NN	O	O
gynecomastia	NN	O	B
or	NN	O	O
testosterone	NN	O	O
less	NN	O	O
than	NN	O	O
4	NN	O	O
ng	NN	O	O
.	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

Determination	NN	O	O
was	NN	O	O
repeated	NN	O	O
in	NN	O	O
case	NN	O	O
of	NN	O	O
abnormal	NN	O	O
first	NN	O	O
results	NN	O	O
.	NN	O	O

Prolactin	NN	O	O
results	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
a	NN	O	O
previous	NN	O	O
personal	NN	O	O
cohort	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
340	NN	O	O
patients	NN	O	O
with	NN	O	O
erectile	NN	O	B
dysfunction	NN	O	I
and	NN	O	O
systematic	NN	O	O
prolactin	NN	O	O
determination	NN	O	O
.	NN	O	O

Main	NN	O	O
clinical	NN	O	O
criteria	NN	O	O
tested	NN	O	O
regarding	NN	O	O
efficiency	NN	O	O
in	NN	O	O
hormone	NN	O	O
determination	NN	O	O
were	NN	O	O
low	NN	O	B
sexual	NN	O	I
desire	NN	O	I
,	NN	O	O
small	NN	O	O
testes	NN	O	O
and	NN	O	O
gynecomastia	NN	O	B
.	NN	O	O

Endocrine	NN	O	O
therapy	NN	O	O
consisted	NN	O	O
of	NN	O	O
testosterone	NN	O	O
heptylate	NN	O	O
or	NN	O	O
human	NN	O	O
chorionic	NN	O	O
gonadotropin	NN	O	O
for	NN	O	O
hypogonadism	NN	O	B
and	NN	O	O
bromocriptine	NN	O	O
for	NN	O	O
hyperprolactinemia	NN	O	B
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Testosterone	NN	O	O
was	NN	O	O
less	NN	O	O
than	NN	O	O
3	NN	O	O
ng	NN	O	O
.	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O
in	NN	O	O
107	NN	O	O
patients	NN	O	O
but	NN	O	O
normal	NN	O	O
in	NN	O	O
40	NN	O	O
%	NN	O	O
at	NN	O	O
repeat	NN	O	O
determination	NN	O	O
.	NN	O	O

The	NN	O	O
prevalence	NN	O	O
of	NN	O	O
repeatedly	NN	O	O
low	NN	O	O
testosterone	NN	O	O
increased	NN	O	O
with	NN	O	O
age	NN	O	O
(	NN	O	O
4	NN	O	O
%	NN	O	O
before	NN	O	O
age	NN	O	O
50	NN	O	O
years	NN	O	O
and	NN	O	O
9	NN	O	O
%	NN	O	O
50	NN	O	O
years	NN	O	O
or	NN	O	O
older	NN	O	O
)	NN	O	O
.	NN	O	O

Two	NN	O	O
pituitary	NN	O	B
tumors	NN	O	I
were	NN	O	O
discovered	NN	O	O
after	NN	O	O
testosterone	NN	O	O
determination	NN	O	O
.	NN	O	O

Most	NN	O	O
of	NN	O	O
the	NN	O	O
other	NN	O	O
low	NN	O	O
testosterone	NN	O	O
levels	NN	O	O
seemed	NN	O	O
to	NN	O	O
result	NN	O	O
from	NN	O	O
nonorganic	NN	O	O
hypothalamic	NN	O	B
dysfunction	NN	O	I
because	NN	O	O
of	NN	O	O
normal	NN	O	O
serum	NN	O	O
luteinizing	NN	O	O
hormone	NN	O	O
and	NN	O	O
prolactin	NN	O	O
and	NN	O	O
to	NN	O	O
have	NN	O	O
only	NN	O	O
a	NN	O	O
small	NN	O	O
role	NN	O	O
in	NN	O	O
erectile	NN	O	B
dysfunction	NN	O	I
(	NN	O	O
definite	NN	O	O
improvement	NN	O	O
in	NN	O	O
only	NN	O	O
16	NN	O	O
of	NN	O	O
44	NN	O	O
[	NN	O	O
36	NN	O	O
%	NN	O	O
]	NN	O	O
after	NN	O	O
androgen	NN	O	O
therapy	NN	O	O
,	NN	O	O
normal	NN	O	O
morning	NN	O	O
or	NN	O	O
nocturnal	NN	O	O
erections	NN	O	O
in	NN	O	O
30	NN	O	O
%	NN	O	O
and	NN	O	O
definite	NN	O	O
vasculogenic	NN	O	O
contributions	NN	O	O
in	NN	O	O
42	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Determining	NN	O	O
testosterone	NN	O	O
only	NN	O	O
in	NN	O	O
cases	NN	O	O
of	NN	O	O
low	NN	O	B
sexual	NN	O	I
desire	NN	O	I
or	NN	O	O
abnormal	NN	O	O
physical	NN	O	O
examination	NN	O	O
would	NN	O	O
have	NN	O	O
missed	NN	O	O
40	NN	O	O
%	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
with	NN	O	O
low	NN	O	O
testosterone	NN	O	O
,	NN	O	O
including	NN	O	O
37	NN	O	O
%	NN	O	O
of	NN	O	O
those	NN	O	O
subsequently	NN	O	O
improved	NN	O	O
by	NN	O	O
androgen	NN	O	O
therapy	NN	O	O
.	NN	O	O

Prolactin	NN	O	O
exceeded	NN	O	O
20	NN	O	O
ng	NN	O	O
.	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O
in	NN	O	O
5	NN	O	O
men	NN	O	O
and	NN	O	O
was	NN	O	O
normal	NN	O	O
in	NN	O	O
2	NN	O	O
at	NN	O	O
repeat	NN	O	O
determination	NN	O	O
.	NN	O	O

Only	NN	O	O
1	NN	O	O
prolactinoma	NN	O	B
was	NN	O	O
discovered	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
are	NN	O	O
lower	NN	O	O
than	NN	O	O
those	NN	O	O
we	NN	O	O
found	NN	O	O
during	NN	O	O
the	NN	O	O
last	NN	O	O
2	NN	O	O
decades	NN	O	O
(	NN	O	O
overall	NN	O	O
prolactin	NN	O	O
greater	NN	O	O
than	NN	O	O
20	NN	O	O
ng	NN	O	O
.	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O
in	NN	O	O
1	NN	O	O
.	NN	O	O
86	NN	O	O
%	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
821	NN	O	O
patients	NN	O	O
,	NN	O	O
prolactinomas	NN	O	B
in	NN	O	O
7	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
38	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

Bromocriptine	NN	O	O
was	NN	O	O
definitely	NN	O	O
effective	NN	O	O
in	NN	O	O
cases	NN	O	O
with	NN	O	O
prolactin	NN	O	O
greater	NN	O	O
than	NN	O	O
35	NN	O	O
ng	NN	O	O
.	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

(	NN	O	O
8	NN	O	O
of	NN	O	O
12	NN	O	O
compared	NN	O	O
to	NN	O	O
only	NN	O	O
9	NN	O	O
of	NN	O	O
22	NN	O	O
cases	NN	O	O
with	NN	O	O
prolactin	NN	O	O
between	NN	O	O
20	NN	O	O
and	NN	O	O
35	NN	O	O
ng	NN	O	O
.	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O
)	NN	O	O
.	NN	O	O

Testosterone	NN	O	O
was	NN	O	O
low	NN	O	O
in	NN	O	O
less	NN	O	O
than	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
cases	NN	O	O
with	NN	O	O
prolactin	NN	O	O
greater	NN	O	O
than	NN	O	O
35	NN	O	O
ng	NN	O	O
.	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Low	NN	O	O
prevalences	NN	O	O
and	NN	O	O
effects	NN	O	O
of	NN	O	O
low	NN	O	O
testosterone	NN	O	O
and	NN	O	O
high	NN	O	O
prolactin	NN	O	O
in	NN	O	O
erectile	NN	O	B
dysfunction	NN	O	I
cannot	NN	O	O
justify	NN	O	O
their	NN	O	O
routine	NN	O	O
determination	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
cost	NN	O	O
-	NN	O	O
effective	NN	O	O
screening	NN	O	O
strategies	NN	O	O
recommended	NN	O	O
so	NN	O	O
far	NN	O	O
missed	NN	O	O
40	NN	O	O
to	NN	O	O
50	NN	O	O
%	NN	O	O
of	NN	O	O
cases	NN	O	O
improved	NN	O	O
with	NN	O	O
endocrine	NN	O	O
therapy	NN	O	O
and	NN	O	O
the	NN	O	O
pituitary	NN	O	B
tumors	NN	O	I
.	NN	O	O

We	NN	O	O
now	NN	O	O
advocate	NN	O	O
that	NN	O	O
before	NN	O	O
age	NN	O	O
50	NN	O	O
years	NN	O	O
testosterone	NN	O	O
be	NN	O	O
determined	NN	O	O
only	NN	O	O
in	NN	O	O
cases	NN	O	O
of	NN	O	O
low	NN	O	B
sexual	NN	O	I
desire	NN	O	I
and	NN	O	O
abnormal	NN	O	O
physical	NN	O	O
examination	NN	O	O
but	NN	O	O
that	NN	O	O
it	NN	O	O
be	NN	O	O
measured	NN	O	O
in	NN	O	O
all	NN	O	O
men	NN	O	O
older	NN	O	O
than	NN	O	O
50	NN	O	O
years	NN	O	O
.	NN	O	O

Prolactin	NN	O	O
should	NN	O	O
be	NN	O	O
determined	NN	O	O
only	NN	O	O
in	NN	O	O
cases	NN	O	O
of	NN	O	O
low	NN	O	B
sexual	NN	O	I
desire	NN	O	I
,	NN	O	O
gynecomastia	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
testosterone	NN	O	O
less	NN	O	O
than	NN	O	O
4	NN	O	O
ng	NN	O	O
.	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

Extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
with	NN	O	O
risperidone	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
at	NN	O	O
comparable	NN	O	O
D2	NN	O	O
receptor	NN	O	O
occupancy	NN	O	O
levels	NN	O	O
.	NN	O	O

Risperidone	NN	O	O
is	NN	O	O
an	NN	O	O
antipsychotic	NN	O	O
drug	NN	O	O
with	NN	O	O
high	NN	O	O
affinity	NN	O	O
at	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
and	NN	O	O
serotonin	NN	O	O
5	NN	O	O
-	NN	O	O
HT2	NN	O	O
receptors	NN	O	O
.	NN	O	O

Previous	NN	O	O
clinical	NN	O	O
studies	NN	O	O
have	NN	O	O
proposed	NN	O	O
that	NN	O	O
risperidone	NN	O	O
'	NN	O	O
s	NN	O	O
pharmacologic	NN	O	O
profile	NN	O	O
may	NN	O	O
produce	NN	O	O
improved	NN	O	O
efficacy	NN	O	O
for	NN	O	O
negative	NN	O	O
psychotic	NN	O	B
symptoms	NN	O	I
and	NN	O	O
decreased	NN	O	O
propensity	NN	O	O
for	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
;	NN	O	O
features	NN	O	O
shared	NN	O	O
by	NN	O	O
so	NN	O	O
-	NN	O	O
called	NN	O	O
'	NN	O	O
atypical	NN	O	O
'	NN	O	O
neuroleptics	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
if	NN	O	O
routine	NN	O	O
risperidone	NN	O	O
treatment	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
unique	NN	O	O
degree	NN	O	O
of	NN	O	O
D2	NN	O	O
receptor	NN	O	O
occupancy	NN	O	O
and	NN	O	O
pattern	NN	O	O
of	NN	O	O
clinical	NN	O	O
effects	NN	O	O
,	NN	O	O
we	NN	O	O
used	NN	O	O
[	NN	O	O
123I	NN	O	O
]	NN	O	O
IBZM	NN	O	O
SPECT	NN	O	O
to	NN	O	O
determine	NN	O	O
D2	NN	O	O
occupancy	NN	O	O
in	NN	O	O
subjects	NN	O	O
treated	NN	O	O
with	NN	O	O
routine	NN	O	O
clinical	NN	O	O
doses	NN	O	O
of	NN	O	O
risperidone	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
12	NN	O	O
)	NN	O	O
or	NN	O	O
haloperidol	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
.	NN	O	O

Both	NN	O	O
risperidone	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
produced	NN	O	O
D2	NN	O	O
occupancy	NN	O	O
levels	NN	O	O
between	NN	O	O
approximately	NN	O	O
60	NN	O	O
and	NN	O	O
90	NN	O	O
%	NN	O	O
at	NN	O	O
standard	NN	O	O
clinical	NN	O	O
doses	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
occupancy	NN	O	O
levels	NN	O	O
obtained	NN	O	O
with	NN	O	O
haloperidol	NN	O	O
or	NN	O	O
risperidone	NN	O	O
.	NN	O	O

Drug	NN	O	B
-	NN	O	I
induced	NN	O	I
parkinsonism	NN	O	I
was	NN	O	O
observed	NN	O	O
in	NN	O	O
subjects	NN	O	O
treated	NN	O	O
with	NN	O	O
risperidone	NN	O	O
(	NN	O	O
42	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
(	NN	O	O
29	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
was	NN	O	O
observed	NN	O	O
at	NN	O	O
occupancy	NN	O	O
levels	NN	O	O
above	NN	O	O
60	NN	O	O
%	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
these	NN	O	O
observations	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
5	NN	O	O
-	NN	O	O
HT2	NN	O	O
blockade	NN	O	O
obtained	NN	O	O
with	NN	O	O
risperidone	NN	O	O
at	NN	O	O
D2	NN	O	O
occupancy	NN	O	O
rates	NN	O	O
of	NN	O	O
60	NN	O	O
%	NN	O	O
and	NN	O	O
above	NN	O	O
does	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
protect	NN	O	O
against	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Treatment	NN	O	O
of	NN	O	O
previously	NN	O	O
treated	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
by	NN	O	O
mitoxantrone	NN	O	O
and	NN	O	O
48	NN	O	O
-	NN	O	O
hour	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
and	NN	O	O
leucovorin	NN	O	O
(	NN	O	O
MFL	NN	O	O
)	NN	O	O
:	NN	O	O
low	NN	O	O
palliative	NN	O	O
benefit	NN	O	O
and	NN	O	O
high	NN	O	O
treatment	NN	O	O
-	NN	O	O
related	NN	O	O
toxicity	NN	O	B
.	NN	O	O

For	NN	O	O
previously	NN	O	O
treated	NN	O	O
advanced	NN	O	O
breast	NN	O	B
cancer	NN	O	I
,	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
standard	NN	O	O
second	NN	O	O
-	NN	O	O
line	NN	O	O
therapy	NN	O	O
.	NN	O	O

Combination	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
mitoxantrone	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
5	NN	O	O
-	NN	O	O
fluorouracil	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
)	NN	O	O
and	NN	O	O
leucovorin	NN	O	O
(	NN	O	O
MFL	NN	O	O
regimen	NN	O	O
)	NN	O	O
had	NN	O	O
been	NN	O	O
reported	NN	O	O
as	NN	O	O
an	NN	O	O
effective	NN	O	O
and	NN	O	O
well	NN	O	O
tolerated	NN	O	O
regimen	NN	O	O
.	NN	O	O

From	NN	O	O
October	NN	O	O
1993	NN	O	O
to	NN	O	O
November	NN	O	O
1995	NN	O	O
,	NN	O	O
we	NN	O	O
treated	NN	O	O
13	NN	O	O
patients	NN	O	O
with	NN	O	O
previously	NN	O	O
chemotherapy	NN	O	O
-	NN	O	O
treated	NN	O	O
metastatic	NN	O	O
breast	NN	O	B
cancer	NN	O	I
by	NN	O	O
mitoxantrone	NN	O	O
,	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
on	NN	O	O
day	NN	O	O
1	NN	O	O
and	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
FU	NN	O	O
,	NN	O	O
3000	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
leucovorin	NN	O	O
,	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
for	NN	O	O
48	NN	O	O
h	NN	O	O
from	NN	O	O
day	NN	O	O
1	NN	O	O
to	NN	O	O
2	NN	O	O
.	NN	O	O

Each	NN	O	O
course	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
was	NN	O	O
given	NN	O	O
every	NN	O	O
4	NN	O	O
weeks	NN	O	O
.	NN	O	O

Most	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
had	NN	O	O
more	NN	O	O
than	NN	O	O
two	NN	O	O
metastatic	NN	O	O
sites	NN	O	O
,	NN	O	O
with	NN	O	O
lung	NN	O	O
metastasis	NN	O	O
predominant	NN	O	O
.	NN	O	O

Seven	NN	O	O
patients	NN	O	O
had	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
anthracycline	NN	O	O
.	NN	O	O

Seven	NN	O	O
patients	NN	O	O
had	NN	O	O
previously	NN	O	O
received	NN	O	O
radiotherapy	NN	O	O
and	NN	O	O
seven	NN	O	O
had	NN	O	O
received	NN	O	O
hormone	NN	O	O
therapy	NN	O	O
.	NN	O	O

Median	NN	O	O
number	NN	O	O
of	NN	O	O
courses	NN	O	O
of	NN	O	O
MFL	NN	O	O
regimen	NN	O	O
given	NN	O	O
was	NN	O	O
six	NN	O	O
and	NN	O	O
the	NN	O	O
median	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
of	NN	O	O
mitoxantrone	NN	O	O
was	NN	O	O
68	NN	O	O
.	NN	O	O
35	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
had	NN	O	O
complete	NN	O	O
response	NN	O	O
,	NN	O	O
seven	NN	O	O
had	NN	O	O
stable	NN	O	O
disease	NN	O	O
,	NN	O	O
none	NN	O	O
had	NN	O	O
partial	NN	O	O
response	NN	O	O
and	NN	O	O
five	NN	O	O
had	NN	O	O
progressive	NN	O	O
disease	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
objective	NN	O	O
response	NN	O	O
rate	NN	O	O
was	NN	O	O
7	NN	O	O
.	NN	O	O
6	NN	O	O
%	NN	O	O
.	NN	O	O

The	NN	O	O
median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
was	NN	O	O
14	NN	O	O
months	NN	O	O
.	NN	O	O

Median	NN	O	O
survival	NN	O	O
was	NN	O	O
16	NN	O	O
months	NN	O	O
.	NN	O	O

Median	NN	O	O
progression	NN	O	O
-	NN	O	O
free	NN	O	O
survival	NN	O	O
was	NN	O	O
5	NN	O	O
months	NN	O	O
.	NN	O	O

A	NN	O	O
complete	NN	O	O
responder	NN	O	O
had	NN	O	O
relapse	NN	O	O
-	NN	O	O
free	NN	O	O
survival	NN	O	O
up	NN	O	O
to	NN	O	O
17	NN	O	O
months	NN	O	O
.	NN	O	O

Major	NN	O	O
toxicities	NN	O	B
were	NN	O	O
cardiotoxicity	NN	O	B
and	NN	O	O
leukopenia	NN	O	B
.	NN	O	O

Eight	NN	O	O
patients	NN	O	O
were	NN	O	O
dead	NN	O	O
in	NN	O	O
the	NN	O	O
last	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
;	NN	O	O
two	NN	O	O
of	NN	O	O
them	NN	O	O
died	NN	O	O
of	NN	O	O
treatment	NN	O	O
-	NN	O	O
related	NN	O	O
toxicity	NN	O	B
.	NN	O	O

The	NN	O	O
MFL	NN	O	O
regimen	NN	O	O
achieves	NN	O	O
little	NN	O	O
palliative	NN	O	O
benefit	NN	O	O
and	NN	O	O
induces	NN	O	O
severe	NN	O	O
toxicity	NN	O	B
at	NN	O	O
a	NN	O	O
fairly	NN	O	O
high	NN	O	O
rate	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
this	NN	O	O
regimen	NN	O	O
to	NN	O	O
breast	NN	O	B
cancer	NN	O	I
patients	NN	O	O
who	NN	O	O
have	NN	O	O
been	NN	O	O
treated	NN	O	O
by	NN	O	O
chemotherapy	NN	O	O
and	NN	O	O
those	NN	O	O
with	NN	O	O
impaired	NN	O	B
heart	NN	O	I
function	NN	O	I
requires	NN	O	O
careful	NN	O	O
attention	NN	O	O
.	NN	O	O

Ticlopidine	NN	O	O
-	NN	O	O
induced	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
:	NN	O	O
report	NN	O	O
of	NN	O	O
three	NN	O	O
Chinese	NN	O	O
patients	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
three	NN	O	O
Chinese	NN	O	O
patients	NN	O	O
with	NN	O	O
ticlopidine	NN	O	O
-	NN	O	O
induced	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
were	NN	O	O
reported	NN	O	O
and	NN	O	O
another	NN	O	O
13	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
English	NN	O	O
literature	NN	O	O
were	NN	O	O
reviewed	NN	O	O
.	NN	O	O

We	NN	O	O
attempted	NN	O	O
to	NN	O	O
find	NN	O	O
underlying	NN	O	O
similarities	NN	O	O
,	NN	O	O
evaluate	NN	O	O
the	NN	O	O
risk	NN	O	O
factors	NN	O	O
,	NN	O	O
and	NN	O	O
identify	NN	O	O
appropriate	NN	O	O
treatment	NN	O	O
for	NN	O	O
this	NN	O	O
complication	NN	O	O
.	NN	O	O

All	NN	O	O
but	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
over	NN	O	O
60	NN	O	O
years	NN	O	O
old	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
6	NN	O	O
who	NN	O	O
died	NN	O	O
were	NN	O	O
all	NN	O	O
older	NN	O	O
than	NN	O	O
65	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
old	NN	O	O
age	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
developing	NN	O	O
this	NN	O	O
complication	NN	O	O
.	NN	O	O

Agranulocytosis	NN	O	B
occurred	NN	O	O
3	NN	O	O
-	NN	O	O
20	NN	O	O
weeks	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
ticlopidine	NN	O	O
,	NN	O	O
so	NN	O	O
frequent	NN	O	O
examination	NN	O	O
of	NN	O	O
white	NN	O	O
cell	NN	O	O
count	NN	O	O
during	NN	O	O
treatment	NN	O	O
is	NN	O	O
recommended	NN	O	O
.	NN	O	O

There	NN	O	O
seemed	NN	O	O
to	NN	O	O
be	NN	O	O
no	NN	O	O
direct	NN	O	O
correlation	NN	O	O
between	NN	O	O
the	NN	O	O
dose	NN	O	O
or	NN	O	O
duration	NN	O	O
used	NN	O	O
and	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
bone	NN	O	B
marrow	NN	O	I
suppression	NN	O	I
.	NN	O	O

Treatment	NN	O	O
for	NN	O	O
ticlopidine	NN	O	O
-	NN	O	O
induced	NN	O	O
aplastic	NN	O	B
anemia	NN	O	I
with	NN	O	O
colony	NN	O	O
-	NN	O	O
stimulating	NN	O	O
factors	NN	O	O
seemed	NN	O	O
to	NN	O	O
have	NN	O	O
little	NN	O	O
effect	NN	O	O
.	NN	O	O

The	NN	O	O
fact	NN	O	O
that	NN	O	O
5	NN	O	O
of	NN	O	O
the	NN	O	O
6	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
concurrent	NN	O	O
calcium	NN	O	O
channel	NN	O	O
blockers	NN	O	O
died	NN	O	O
,	NN	O	O
should	NN	O	O
alert	NN	O	O
clinicians	NN	O	O
to	NN	O	O
be	NN	O	O
more	NN	O	O
cautious	NN	O	O
when	NN	O	O
using	NN	O	O
these	NN	O	O
two	NN	O	O
drugs	NN	O	O
simultaneously	NN	O	O
.	NN	O	O

Upregulation	NN	O	O
of	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
vasopressin	NN	O	O
gene	NN	O	O
in	NN	O	O
the	NN	O	O
paraventricular	NN	O	O
and	NN	O	O
supraoptic	NN	O	O
nuclei	NN	O	O
of	NN	O	O
the	NN	O	O
lithium	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B
insipidus	NN	O	I
rat	NN	O	O
.	NN	O	O

The	NN	O	O
expression	NN	O	O
of	NN	O	O
arginine	NN	O	O
vasopressin	NN	O	O
(	NN	O	O
AVP	NN	O	O
)	NN	O	O
gene	NN	O	O
in	NN	O	O
the	NN	O	O
paraventricular	NN	O	O
(	NN	O	O
PVN	NN	O	O
)	NN	O	O
and	NN	O	O
supraoptic	NN	O	O
nuclei	NN	O	O
(	NN	O	O
SON	NN	O	O
)	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
lithium	NN	O	O
(	NN	O	O
Li	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
polyuria	NN	O	B
,	NN	O	O
using	NN	O	O
in	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
histochemistry	NN	O	O
and	NN	O	O
radioimmunoassay	NN	O	O
.	NN	O	O

The	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
consuming	NN	O	O
a	NN	O	O
diet	NN	O	O
that	NN	O	O
contained	NN	O	O
LiCl	NN	O	O
(	NN	O	O
60	NN	O	O
mmol	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
for	NN	O	O
4	NN	O	O
weeks	NN	O	O
developed	NN	O	O
marked	NN	O	O
polyuria	NN	O	B
.	NN	O	O

The	NN	O	O
Li	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
produced	NN	O	O
a	NN	O	O
large	NN	O	O
volume	NN	O	O
of	NN	O	O
hypotonic	NN	O	O
urine	NN	O	O
with	NN	O	O
low	NN	O	O
ionic	NN	O	O
concentrations	NN	O	O
.	NN	O	O

Plasma	NN	O	O
sodium	NN	O	O
concentrations	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
slightly	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
Li	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
in	NN	O	O
controls	NN	O	O
.	NN	O	O

Plasma	NN	O	O
concentration	NN	O	O
of	NN	O	O
AVP	NN	O	O
and	NN	O	O
transcripts	NN	O	O
of	NN	O	O
AVP	NN	O	O
gene	NN	O	O
in	NN	O	O
the	NN	O	O
PVN	NN	O	O
and	NN	O	O
SON	NN	O	O
were	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
Li	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
dehydration	NN	O	B
and	NN	O	O
/	NN	O	O
or	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
visceral	NN	O	O
afferent	NN	O	O
inputs	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
elevation	NN	O	O
of	NN	O	O
plasma	NN	O	O
AVP	NN	O	O
and	NN	O	O
the	NN	O	O
upregulation	NN	O	O
of	NN	O	O
AVP	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
PVN	NN	O	O
and	NN	O	O
the	NN	O	O
SON	NN	O	O
of	NN	O	O
the	NN	O	O
Li	NN	O	O
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B
insipidus	NN	O	I
rat	NN	O	O
.	NN	O	O

Antinociceptive	NN	O	O
and	NN	O	O
antiamnesic	NN	O	O
properties	NN	O	O
of	NN	O	O
the	NN	O	O
presynaptic	NN	O	O
cholinergic	NN	O	O
amplifier	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O

The	NN	O	O
antinociceptive	NN	O	O
effect	NN	O	O
of	NN	O	O
3	NN	O	O
alpha	NN	O	O
-	NN	O	O
tropyl	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
p	NN	O	O
-	NN	O	O
bromophenyl	NN	O	O
)	NN	O	O
propionate	NN	O	O
[	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
]	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
40	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
s	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
;	NN	O	O
30	NN	O	O
-	NN	O	O
60	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
p	NN	O	O
.	NN	O	O
o	NN	O	O
.	NN	O	O
;	NN	O	O
10	NN	O	O
-	NN	O	O
30	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
;	NN	O	O
10	NN	O	O
-	NN	O	O
30	NN	O	O
micrograms	NN	O	O
/	NN	O	O
mouse	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
was	NN	O	O
examined	NN	O	O
in	NN	O	O
mice	NN	O	O
,	NN	O	O
rats	NN	O	O
and	NN	O	O
guinea	NN	O	O
pigs	NN	O	O
by	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
hot	NN	O	O
-	NN	O	O
plate	NN	O	O
,	NN	O	O
abdominal	NN	O	O
-	NN	O	O
constriction	NN	O	O
,	NN	O	O
tail	NN	O	O
-	NN	O	O
flick	NN	O	O
and	NN	O	O
paw	NN	O	O
-	NN	O	O
pressure	NN	O	O
tests	NN	O	O
.	NN	O	O

(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
antinociception	NN	O	O
peaked	NN	O	O
15	NN	O	O
min	NN	O	O
after	NN	O	O
injection	NN	O	O
and	NN	O	O
then	NN	O	O
slowly	NN	O	O
diminished	NN	O	O
.	NN	O	O

The	NN	O	O
antinociception	NN	O	O
produced	NN	O	O
by	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
was	NN	O	O
prevented	NN	O	O
by	NN	O	O
the	NN	O	O
unselective	NN	O	O
muscarinic	NN	O	O
antagonist	NN	O	O
atropine	NN	O	O
,	NN	O	O
the	NN	O	O
M1	NN	O	O
-	NN	O	O
selective	NN	O	O
antagonists	NN	O	O
pirenzepine	NN	O	O
and	NN	O	O
dicyclomine	NN	O	O
and	NN	O	O
the	NN	O	O
acetylcholine	NN	O	O
depletor	NN	O	O
hemicholinium	NN	O	O
-	NN	O	O
3	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
the	NN	O	O
opioid	NN	O	O
antagonist	NN	O	O
naloxone	NN	O	O
,	NN	O	O
the	NN	O	O
gamma	NN	O	O
-	NN	O	O
aminobutyric	NN	O	O
acidB	NN	O	O
antagonist	NN	O	O
3	NN	O	O
-	NN	O	O
aminopropyl	NN	O	O
-	NN	O	O
diethoxy	NN	O	O
-	NN	O	O
methyl	NN	O	O
-	NN	O	O
phosphinic	NN	O	O
acid	NN	O	O
,	NN	O	O
the	NN	O	O
H3	NN	O	O
agonist	NN	O	O
R	NN	O	O
-	NN	O	O
(	NN	O	O
alpha	NN	O	O
)	NN	O	O
-	NN	O	O
methylhistamine	NN	O	O
,	NN	O	O
the	NN	O	O
D2	NN	O	O
antagonist	NN	O	O
quinpirole	NN	O	O
,	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxytryptamine4	NN	O	O
antagonist	NN	O	O
2	NN	O	O
-	NN	O	O
methoxy	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
amino	NN	O	O
-	NN	O	O
5	NN	O	O
-	NN	O	O
chlorobenzoic	NN	O	O
acid	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
diethylamino	NN	O	O
)	NN	O	O
ethyl	NN	O	O
ester	NN	O	O
hydrochloride	NN	O	O
,	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxytryptamin1A	NN	O	O
antagonist	NN	O	O
1	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
methoxyphenyl	NN	O	O
)	NN	O	O
-	NN	O	O
4	NN	O	O
-	NN	O	O
[	NN	O	O
4	NN	O	O
-	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
phthalimido	NN	O	O
)	NN	O	O
butyl	NN	O	O
]	NN	O	O
piperazine	NN	O	O
hydrobromide	NN	O	O
and	NN	O	O
the	NN	O	O
polyamines	NN	O	O
depletor	NN	O	O
reserpine	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
these	NN	O	O
data	NN	O	O
,	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
postulated	NN	O	O
that	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
exerted	NN	O	O
an	NN	O	O
antinociceptive	NN	O	O
effect	NN	O	O
mediated	NN	O	O
by	NN	O	O
a	NN	O	O
central	NN	O	O
potentiation	NN	O	O
of	NN	O	O
cholinergic	NN	O	O
transmission	NN	O	O
.	NN	O	O

(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
40	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
was	NN	O	O
able	NN	O	O
to	NN	O	O
prevent	NN	O	O
amnesia	NN	O	B
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
and	NN	O	O
dicyclomine	NN	O	O
(	NN	O	O
2	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
mouse	NN	O	O
passive	NN	O	O
-	NN	O	O
avoidance	NN	O	O
test	NN	O	O
.	NN	O	O

Affinity	NN	O	O
profiles	NN	O	O
of	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
for	NN	O	O
muscarinic	NN	O	O
receptor	NN	O	O
subtypes	NN	O	O
,	NN	O	O
determined	NN	O	O
by	NN	O	O
functional	NN	O	O
studies	NN	O	O
(	NN	O	O
rabbit	NN	O	O
vas	NN	O	O
deferens	NN	O	O
for	NN	O	O
M1	NN	O	O
,	NN	O	O
guinea	NN	O	O
pig	NN	O	O
atrium	NN	O	O
for	NN	O	O
M2	NN	O	O
,	NN	O	O
guinea	NN	O	O
pig	NN	O	O
ileum	NN	O	O
for	NN	O	O
M3	NN	O	O
and	NN	O	O
immature	NN	O	O
guinea	NN	O	O
pig	NN	O	O
uterus	NN	O	O
for	NN	O	O
putative	NN	O	O
M4	NN	O	O
)	NN	O	O
,	NN	O	O
have	NN	O	O
shown	NN	O	O
an	NN	O	O
M4	NN	O	O
/	NN	O	O
M1	NN	O	O
selectivity	NN	O	O
ratio	NN	O	O
of	NN	O	O
10	NN	O	O
.	NN	O	O
2	NN	O	O
that	NN	O	O
might	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
antinociception	NN	O	O
and	NN	O	O
the	NN	O	O
anti	NN	O	O
-	NN	O	O
amnesic	NN	O	B
effect	NN	O	O
induced	NN	O	O
by	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
through	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
acetylcholine	NN	O	O
extracellular	NN	O	O
levels	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
antinociceptive	NN	O	O
and	NN	O	O
antiamnesic	NN	O	O
dose	NN	O	O
range	NN	O	O
,	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
did	NN	O	O
not	NN	O	O
impair	NN	O	O
mouse	NN	O	O
performance	NN	O	O
evaluated	NN	O	O
by	NN	O	O
the	NN	O	O
rota	NN	O	O
-	NN	O	O
rod	NN	O	O
test	NN	O	O
and	NN	O	O
Animex	NN	O	O
apparatus	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
different	NN	O	O
anaesthetic	NN	O	O
agents	NN	O	O
in	NN	O	O
hearing	NN	O	B
loss	NN	O	I
following	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

The	NN	O	O
cause	NN	O	O
of	NN	O	O
hearing	NN	O	B
loss	NN	O	I
after	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

Up	NN	O	O
until	NN	O	O
now	NN	O	O
,	NN	O	O
the	NN	O	O
only	NN	O	O
factor	NN	O	O
studied	NN	O	O
has	NN	O	O
been	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
diameter	NN	O	O
of	NN	O	O
the	NN	O	O
spinal	NN	O	O
needle	NN	O	O
on	NN	O	O
post	NN	O	O
-	NN	O	O
operative	NN	O	O
sensorineural	NN	O	B
hearing	NN	O	I
loss	NN	O	I
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
describe	NN	O	O
this	NN	O	O
hearing	NN	O	B
loss	NN	O	I
and	NN	O	O
to	NN	O	O
investigate	NN	O	O
other	NN	O	O
factors	NN	O	O
influencing	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
hearing	NN	O	B
loss	NN	O	I
.	NN	O	O

Two	NN	O	O
groups	NN	O	O
of	NN	O	O
22	NN	O	O
similar	NN	O	O
patients	NN	O	O
were	NN	O	O
studied	NN	O	O
:	NN	O	O
one	NN	O	O
group	NN	O	O
received	NN	O	O
6	NN	O	O
mL	NN	O	O
prilocaine	NN	O	O
2	NN	O	O
%	NN	O	O
;	NN	O	O
and	NN	O	O
the	NN	O	O
other	NN	O	O
received	NN	O	O
3	NN	O	O
mL	NN	O	O
bupivacaine	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
.	NN	O	O

Patients	NN	O	O
given	NN	O	O
prilocaine	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
develop	NN	O	O
hearing	NN	O	B
loss	NN	O	I
(	NN	O	O
10	NN	O	O
out	NN	O	O
of	NN	O	O
22	NN	O	O
)	NN	O	O
than	NN	O	O
those	NN	O	O
given	NN	O	O
bupivacaine	NN	O	O
(	NN	O	O
4	NN	O	O
out	NN	O	O
of	NN	O	O
22	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
average	NN	O	O
hearing	NN	O	B
loss	NN	O	I
for	NN	O	O
speech	NN	O	O
frequencies	NN	O	O
was	NN	O	O
about	NN	O	O
10	NN	O	O
dB	NN	O	O
after	NN	O	O
prilocaine	NN	O	O
and	NN	O	O
15	NN	O	O
dB	NN	O	O
after	NN	O	O
bupivacaine	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
complained	NN	O	O
of	NN	O	O
subjective	NN	O	O
hearing	NN	O	B
loss	NN	O	I
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
was	NN	O	O
not	NN	O	O
possible	NN	O	O
.	NN	O	O

A	NN	O	O
transient	NN	O	O
neurological	NN	O	B
deficit	NN	O	I
following	NN	O	O
intrathecal	NN	O	O
injection	NN	O	O
of	NN	O	O
1	NN	O	O
%	NN	O	O
hyperbaric	NN	O	O
bupivacaine	NN	O	O
for	NN	O	O
unilateral	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
transient	NN	O	O
neurological	NN	O	B
deficit	NN	O	I
that	NN	O	O
occurred	NN	O	O
after	NN	O	O
unilateral	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
8	NN	O	O
mg	NN	O	O
of	NN	O	O
1	NN	O	O
%	NN	O	O
hyperbaric	NN	O	O
bupivacaine	NN	O	O
slowly	NN	O	O
injected	NN	O	O
through	NN	O	O
a	NN	O	O
25	NN	O	O
-	NN	O	O
gauge	NN	O	O
pencil	NN	O	O
-	NN	O	O
point	NN	O	O
spinal	NN	O	O
needle	NN	O	O
.	NN	O	O

The	NN	O	O
surgery	NN	O	O
and	NN	O	O
anaesthesia	NN	O	O
were	NN	O	O
uneventful	NN	O	O
,	NN	O	O
but	NN	O	O
3	NN	O	O
days	NN	O	O
after	NN	O	O
surgery	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
reported	NN	O	O
an	NN	O	O
area	NN	O	O
of	NN	O	O
hypoaesthesia	NN	O	O
over	NN	O	O
L3	NN	O	O
-	NN	O	O
L4	NN	O	O
dermatomes	NN	O	O
of	NN	O	O
the	NN	O	O
leg	NN	O	O
which	NN	O	O
had	NN	O	O
been	NN	O	O
operated	NN	O	O
on	NN	O	O
(	NN	O	O
loss	NN	O	B
of	NN	O	I
pinprick	NN	O	I
sensation	NN	O	I
)	NN	O	O
without	NN	O	O
reduction	NN	O	O
in	NN	O	O
muscular	NN	O	O
strength	NN	O	O
.	NN	O	O

Sensation	NN	O	O
in	NN	O	O
this	NN	O	O
area	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
over	NN	O	O
the	NN	O	O
following	NN	O	O
2	NN	O	O
weeks	NN	O	O
.	NN	O	O

Prospective	NN	O	O
multicentre	NN	O	O
studies	NN	O	O
with	NN	O	O
a	NN	O	O
large	NN	O	O
population	NN	O	O
and	NN	O	O
a	NN	O	O
long	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
should	NN	O	O
be	NN	O	O
performed	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
this	NN	O	O
unusual	NN	O	O
side	NN	O	O
effect	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
we	NN	O	O
suggest	NN	O	O
that	NN	O	O
a	NN	O	O
low	NN	O	O
solution	NN	O	O
concentration	NN	O	O
should	NN	O	O
be	NN	O	O
preferred	NN	O	O
for	NN	O	O
unilateral	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
a	NN	O	O
hyperbaric	NN	O	O
anaesthetic	NN	O	O
solution	NN	O	O
(	NN	O	O
if	NN	O	O
pencil	NN	O	O
-	NN	O	O
point	NN	O	O
needle	NN	O	O
and	NN	O	O
slow	NN	O	O
injection	NN	O	O
rate	NN	O	O
are	NN	O	O
employed	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
minimize	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
a	NN	O	O
localized	NN	O	O
high	NN	O	O
peak	NN	O	O
anaesthetic	NN	O	O
concentration	NN	O	O
,	NN	O	O
which	NN	O	O
might	NN	O	O
lead	NN	O	O
to	NN	O	O
a	NN	O	O
transient	NN	O	O
neurological	NN	O	B
deficit	NN	O	I
.	NN	O	O

Transient	NN	O	B
neurologic	NN	O	I
symptoms	NN	O	I
after	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
:	NN	O	O
a	NN	O	O
lower	NN	O	O
incidence	NN	O	O
with	NN	O	O
prilocaine	NN	O	O
and	NN	O	O
bupivacaine	NN	O	O
than	NN	O	O
with	NN	O	O
lidocaine	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Recent	NN	O	O
evidence	NN	O	O
suggests	NN	O	O
that	NN	O	O
transient	NN	O	B
neurologic	NN	O	I
symptoms	NN	O	I
(	NN	O	O
TNSs	NN	O	B
)	NN	O	O
frequently	NN	O	O
follow	NN	O	O
lidocaine	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
but	NN	O	O
are	NN	O	O
infrequent	NN	O	O
with	NN	O	O
bupivacaine	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
identification	NN	O	O
of	NN	O	O
a	NN	O	O
short	NN	O	O
-	NN	O	O
acting	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
to	NN	O	O
substitute	NN	O	O
for	NN	O	O
lidocaine	NN	O	O
for	NN	O	O
brief	NN	O	O
surgical	NN	O	O
procedures	NN	O	O
remains	NN	O	O
an	NN	O	O
important	NN	O	O
goal	NN	O	O
.	NN	O	O

Prilocaine	NN	O	O
is	NN	O	O
an	NN	O	O
amide	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
with	NN	O	O
a	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
lidocaine	NN	O	O
.	NN	O	O

Accordingly	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
,	NN	O	O
prospective	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
compares	NN	O	O
prilocaine	NN	O	O
with	NN	O	O
lidocaine	NN	O	O
and	NN	O	O
bupivacaine	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
and	NN	O	O
relative	NN	O	O
risk	NN	O	O
of	NN	O	O
TNSs	NN	O	B
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Ninety	NN	O	O
patients	NN	O	O
classified	NN	O	O
as	NN	O	O
American	NN	O	O
Society	NN	O	O
of	NN	O	O
Anesthesiologists	NN	O	O
physical	NN	O	O
status	NN	O	O
I	NN	O	O
or	NN	O	O
II	NN	O	O
who	NN	O	O
were	NN	O	O
scheduled	NN	O	O
for	NN	O	O
short	NN	O	O
gynecologic	NN	O	O
procedures	NN	O	O
under	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
receive	NN	O	O
2	NN	O	O
.	NN	O	O
5	NN	O	O
ml	NN	O	O
2	NN	O	O
%	NN	O	O
lidocaine	NN	O	O
in	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
glucose	NN	O	O
,	NN	O	O
2	NN	O	O
%	NN	O	O
prilocaine	NN	O	O
in	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
glucose	NN	O	O
,	NN	O	O
or	NN	O	O
0	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
bupivacaine	NN	O	O
in	NN	O	O
7	NN	O	O
.	NN	O	O
5	NN	O	O
%	NN	O	O
glucose	NN	O	O
.	NN	O	O

All	NN	O	O
solutions	NN	O	O
were	NN	O	O
provided	NN	O	O
in	NN	O	O
blinded	NN	O	O
vials	NN	O	O
by	NN	O	O
the	NN	O	O
hospital	NN	O	O
pharmacy	NN	O	O
.	NN	O	O

Details	NN	O	O
of	NN	O	O
spinal	NN	O	O
puncture	NN	O	O
,	NN	O	O
extension	NN	O	O
and	NN	O	O
regression	NN	O	O
of	NN	O	O
spinal	NN	O	O
block	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
times	NN	O	O
to	NN	O	O
reach	NN	O	O
discharge	NN	O	O
criteria	NN	O	O
were	NN	O	O
noted	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
evening	NN	O	O
of	NN	O	O
postoperative	NN	O	O
day	NN	O	O
1	NN	O	O
,	NN	O	O
patients	NN	O	O
were	NN	O	O
evaluated	NN	O	O
for	NN	O	O
TNSs	NN	O	B
by	NN	O	O
a	NN	O	O
physician	NN	O	O
unaware	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
administered	NN	O	O
and	NN	O	O
the	NN	O	O
details	NN	O	O
of	NN	O	O
the	NN	O	O
anesthetic	NN	O	O
procedure	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Nine	NN	O	O
of	NN	O	O
30	NN	O	O
patients	NN	O	O
receiving	NN	O	O
lidocaine	NN	O	O
experienced	NN	O	O
TNSs	NN	O	B
,	NN	O	O
1	NN	O	O
of	NN	O	O
30	NN	O	O
patients	NN	O	O
receiving	NN	O	O
prilocaine	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0	NN	O	O
.	NN	O	O
03	NN	O	O
)	NN	O	O
had	NN	O	O
them	NN	O	O
,	NN	O	O
and	NN	O	O
none	NN	O	O
of	NN	O	O
30	NN	O	O
patients	NN	O	O
receiving	NN	O	O
bupivacaine	NN	O	O
had	NN	O	O
TNSs	NN	O	B
.	NN	O	O

Times	NN	O	O
to	NN	O	O
ambulate	NN	O	O
and	NN	O	O
to	NN	O	O
void	NN	O	O
were	NN	O	O
similar	NN	O	O
after	NN	O	O
lidocaine	NN	O	O
and	NN	O	O
prilocaine	NN	O	O
(	NN	O	O
150	NN	O	O
vs	NN	O	O
.	NN	O	O
165	NN	O	O
min	NN	O	O
and	NN	O	O
238	NN	O	O
vs	NN	O	O
.	NN	O	O
253	NN	O	O
min	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
but	NN	O	O
prolonged	NN	O	O
after	NN	O	O
bupivacaine	NN	O	O
(	NN	O	O
200	NN	O	O
and	NN	O	O
299	NN	O	O
min	NN	O	O
,	NN	O	O
respectively	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Prilocaine	NN	O	O
may	NN	O	O
be	NN	O	O
preferable	NN	O	O
to	NN	O	O
lidocaine	NN	O	O
for	NN	O	O
short	NN	O	O
surgical	NN	O	O
procedures	NN	O	O
because	NN	O	O
it	NN	O	O
has	NN	O	O
a	NN	O	O
similar	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
but	NN	O	O
a	NN	O	O
lower	NN	O	O
incidence	NN	O	O
of	NN	O	O
TNSs	NN	O	B
.	NN	O	O

Suxamethonium	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B
arrest	NN	O	I
and	NN	O	O
death	NN	O	B
following	NN	O	O
5	NN	O	O
days	NN	O	O
of	NN	O	O
immobilization	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
report	NN	O	O
describes	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
cardiac	NN	O	B
arrest	NN	O	I
and	NN	O	O
subsequent	NN	O	O
death	NN	O	B
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
hyperkalaemia	NN	O	B
following	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
in	NN	O	O
a	NN	O	O
23	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Malawian	NN	O	O
woman	NN	O	O
.	NN	O	O

Five	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
meningitis	NN	O	B
,	NN	O	O
the	NN	O	O
patient	NN	O	O
aspirated	NN	O	O
stomach	NN	O	O
contents	NN	O	O
and	NN	O	O
needed	NN	O	O
endotracheal	NN	O	O
intubation	NN	O	O
.	NN	O	O

Forty	NN	O	O
seconds	NN	O	O
after	NN	O	O
injection	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
,	NN	O	O
bradycardia	NN	O	B
and	NN	O	O
cardiac	NN	O	B
arrest	NN	O	I
occurred	NN	O	O
.	NN	O	O

Attempts	NN	O	O
to	NN	O	O
resuscitate	NN	O	O
the	NN	O	O
patient	NN	O	O
were	NN	O	O
not	NN	O	O
successful	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	O
level	NN	O	O
of	NN	O	O
potassium	NN	O	O
was	NN	O	O
observed	NN	O	O
to	NN	O	O
be	NN	O	O
8	NN	O	O
.	NN	O	O
4	NN	O	O
mequiv	NN	O	O
L	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

Apart	NN	O	O
from	NN	O	O
the	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
level	NN	O	O
of	NN	O	O
consciousness	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
signs	NN	O	O
of	NN	O	O
motor	NN	O	O
neurone	NN	O	O
damage	NN	O	O
or	NN	O	O
of	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
other	NN	O	O
known	NN	O	O
predisposing	NN	O	O
conditions	NN	O	O
for	NN	O	O
hyperkalaemia	NN	O	B
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
suxamethonium	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
postulated	NN	O	O
that	NN	O	O
her	NN	O	O
death	NN	O	B
was	NN	O	O
caused	NN	O	O
by	NN	O	O
hypersensitivity	NN	O	B
to	NN	O	O
suxamethonium	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
her	NN	O	O
5	NN	O	O
-	NN	O	O
day	NN	O	O
immobilization	NN	O	O
.	NN	O	O

Acute	NN	O	O
hepatitis	NN	O	B
,	NN	O	O
autoimmune	NN	O	B
hemolytic	NN	O	I
anemia	NN	O	I
,	NN	O	O
and	NN	O	O
erythroblastocytopenia	NN	O	B
induced	NN	O	O
by	NN	O	O
ceftriaxone	NN	O	O
.	NN	O	O

An	NN	O	O
80	NN	O	O
-	NN	O	O
yr	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
developed	NN	O	O
acute	NN	O	O
hepatitis	NN	O	B
shortly	NN	O	O
after	NN	O	O
ingesting	NN	O	O
oral	NN	O	O
ceftriaxone	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
transaminases	NN	O	O
gradually	NN	O	O
returned	NN	O	O
to	NN	O	O
baseline	NN	O	O
after	NN	O	O
withholding	NN	O	O
the	NN	O	O
beta	NN	O	O
lactam	NN	O	O
antibiotic	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
gradual	NN	O	O
increase	NN	O	O
in	NN	O	O
serum	NN	O	O
bilirubin	NN	O	O
and	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
hemoglobin	NN	O	O
concentration	NN	O	O
caused	NN	O	O
by	NN	O	O
an	NN	O	O
autoimmune	NN	O	B
hemolytic	NN	O	I
anemia	NN	O	I
and	NN	O	O
erythroblastocytopenia	NN	O	B
.	NN	O	O

These	NN	O	O
responded	NN	O	O
to	NN	O	O
systemic	NN	O	O
steroids	NN	O	O
and	NN	O	O
immunoglobulins	NN	O	O
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
widespread	NN	O	O
use	NN	O	O
of	NN	O	O
these	NN	O	O
agents	NN	O	O
this	NN	O	O
triad	NN	O	O
of	NN	O	O
side	NN	O	O
effects	NN	O	O
has	NN	O	O
not	NN	O	O
previously	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
connection	NN	O	O
with	NN	O	O
beta	NN	O	O
lactam	NN	O	O
antibiotics	NN	O	O
.	NN	O	O

Thyroxine	NN	O	O
abuse	NN	O	O
:	NN	O	O
an	NN	O	O
unusual	NN	O	O
case	NN	O	O
of	NN	O	O
thyrotoxicosis	NN	O	B
in	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

Eating	NN	O	B
disorders	NN	O	I
and	NN	O	O
the	NN	O	O
associated	NN	O	O
behavioural	NN	O	O
problems	NN	O	O
and	NN	O	O
drug	NN	O	B
abuse	NN	O	I
are	NN	O	O
uncommon	NN	O	O
in	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

When	NN	O	O
they	NN	O	O
do	NN	O	O
occur	NN	O	O
they	NN	O	O
are	NN	O	O
often	NN	O	O
unrecognized	NN	O	O
because	NN	O	O
of	NN	O	O
denial	NN	O	O
but	NN	O	O
when	NN	O	O
significant	NN	O	O
may	NN	O	O
pose	NN	O	O
a	NN	O	O
risk	NN	O	O
to	NN	O	O
both	NN	O	O
the	NN	O	O
mother	NN	O	O
and	NN	O	O
her	NN	O	O
fetus	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
illustrates	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
problems	NN	O	O
that	NN	O	O
may	NN	O	O
be	NN	O	O
encountered	NN	O	O
in	NN	O	O
women	NN	O	O
with	NN	O	O
eating	NN	O	B
disorders	NN	O	I
in	NN	O	O
pregnancy	NN	O	O
,	NN	O	O
including	NN	O	O
prolonged	NN	O	O
and	NN	O	O
recurrent	NN	O	O
metabolic	NN	O	O
disturbances	NN	O	O
and	NN	O	O
diuretic	NN	O	O
abuse	NN	O	O
.	NN	O	O

In	NN	O	O
particular	NN	O	O
it	NN	O	O
illustrates	NN	O	O
the	NN	O	O
derangements	NN	O	O
of	NN	O	O
thyroid	NN	O	O
function	NN	O	O
seen	NN	O	O
in	NN	O	O
pregnant	NN	O	O
women	NN	O	O
with	NN	O	O
eating	NN	O	B
disorders	NN	O	I
and	NN	O	O
reminds	NN	O	O
us	NN	O	O
that	NN	O	O
when	NN	O	O
a	NN	O	O
cause	NN	O	O
for	NN	O	O
thyrotoxicosis	NN	O	B
remains	NN	O	O
obscure	NN	O	O
,	NN	O	O
thyroxine	NN	O	O
abuse	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
and	NN	O	O
explored	NN	O	O
.	NN	O	O

Repeated	NN	O	O
trimipramine	NN	O	O
induces	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
/	NN	O	O
D3	NN	O	O
and	NN	O	O
alpha1	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
.	NN	O	O

Trimipramine	NN	O	O
(	NN	O	O
TRI	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
shows	NN	O	O
a	NN	O	O
clinical	NN	O	O
antidepressant	NN	O	O
activity	NN	O	O
,	NN	O	O
is	NN	O	O
chemically	NN	O	O
related	NN	O	O
to	NN	O	O
imipramine	NN	O	O
but	NN	O	O
does	NN	O	O
not	NN	O	O
inhibit	NN	O	O
the	NN	O	O
reuptake	NN	O	O
of	NN	O	O
noradrenaline	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxytryptamine	NN	O	O
,	NN	O	O
nor	NN	O	O
does	NN	O	O
it	NN	O	O
induce	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
down	NN	O	O
-	NN	O	O
regulation	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
its	NN	O	O
antidepressant	NN	O	O
activity	NN	O	O
is	NN	O	O
still	NN	O	O
unknown	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
find	NN	O	O
out	NN	O	O
whether	NN	O	O
TRI	NN	O	O
given	NN	O	O
repeatedly	NN	O	O
was	NN	O	O
able	NN	O	O
to	NN	O	O
induce	NN	O	O
adaptive	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
dopaminergic	NN	O	O
and	NN	O	O
alpha1	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
systems	NN	O	O
,	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
us	NN	O	O
previously	NN	O	O
for	NN	O	O
various	NN	O	O
antidepressants	NN	O	O
.	NN	O	O

TRI	NN	O	O
was	NN	O	O
given	NN	O	O
to	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
and	NN	O	O
male	NN	O	O
Albino	NN	O	O
Swiss	NN	O	O
mice	NN	O	O
perorally	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
acute	NN	O	O
experiment	NN	O	O
TRI	NN	O	O
(	NN	O	O
given	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
does	NN	O	O
not	NN	O	O
antagonize	NN	O	O
the	NN	O	O
reserpine	NN	O	O
hypothermia	NN	O	B
in	NN	O	O
mice	NN	O	O
and	NN	O	O
does	NN	O	O
not	NN	O	O
potentiate	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
hydroxytryptophan	NN	O	O
head	NN	O	O
twitches	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

TRI	NN	O	O
given	NN	O	O
repeatedly	NN	O	O
to	NN	O	O
rats	NN	O	O
increases	NN	O	O
the	NN	O	O
locomotor	NN	O	O
hyperactivity	NN	O	B
induced	NN	O	O
by	NN	O	O
d	NN	O	O
-	NN	O	O
amphetamine	NN	O	O
,	NN	O	O
quinpirole	NN	O	O
and	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
7	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
dipropyloaminotetralin	NN	O	O
(	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
and	NN	O	O
D3	NN	O	O
effects	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
stereotypies	NN	O	O
induced	NN	O	O
by	NN	O	O
d	NN	O	O
-	NN	O	O
amphetamine	NN	O	O
or	NN	O	O
apomorphine	NN	O	O
are	NN	O	O
not	NN	O	O
potentiated	NN	O	O
by	NN	O	O
TRI	NN	O	O
.	NN	O	O

It	NN	O	O
increases	NN	O	O
the	NN	O	O
behaviour	NN	O	O
stimulation	NN	O	O
evoked	NN	O	O
by	NN	O	O
phenylephrine	NN	O	O
(	NN	O	O
given	NN	O	O
intraventricularly	NN	O	O
)	NN	O	O
in	NN	O	O
rats	NN	O	O
,	NN	O	O
evaluated	NN	O	O
in	NN	O	O
the	NN	O	O
open	NN	O	O
field	NN	O	O
test	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
aggressiveness	NN	O	B
evoked	NN	O	O
by	NN	O	O
clonidine	NN	O	O
in	NN	O	O
mice	NN	O	O
,	NN	O	O
both	NN	O	O
these	NN	O	O
effects	NN	O	O
being	NN	O	O
mediated	NN	O	O
by	NN	O	O
an	NN	O	O
alpha1	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
receptor	NN	O	O
.	NN	O	O

It	NN	O	O
may	NN	O	O
be	NN	O	O
concluded	NN	O	O
that	NN	O	O
,	NN	O	O
like	NN	O	O
other	NN	O	O
tricyclic	NN	O	O
antidepressants	NN	O	O
studied	NN	O	O
previously	NN	O	O
,	NN	O	O
TRI	NN	O	O
given	NN	O	O
repeatedly	NN	O	O
increases	NN	O	O
the	NN	O	O
responsiveness	NN	O	O
of	NN	O	O
brain	NN	O	O
dopamine	NN	O	O
D2	NN	O	O
and	NN	O	O
D3	NN	O	O
(	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
but	NN	O	O
not	NN	O	O
stereotypy	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
alpha1	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
receptors	NN	O	O
to	NN	O	O
their	NN	O	O
agonists	NN	O	O
.	NN	O	O

A	NN	O	O
question	NN	O	O
arises	NN	O	O
whether	NN	O	O
the	NN	O	O
reuptake	NN	O	O
inhibition	NN	O	O
is	NN	O	O
of	NN	O	O
any	NN	O	O
importance	NN	O	O
to	NN	O	O
the	NN	O	O
adaptive	NN	O	O
changes	NN	O	O
induced	NN	O	O
by	NN	O	O
repeated	NN	O	O
antidepressants	NN	O	O
,	NN	O	O
suggested	NN	O	O
to	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
antidepressant	NN	O	O
activity	NN	O	O
.	NN	O	O

Pethidine	NN	O	O
-	NN	O	O
associated	NN	O	O
seizure	NN	O	B
in	NN	O	O
a	NN	O	O
healthy	NN	O	O
adolescent	NN	O	O
receiving	NN	O	O
pethidine	NN	O	O
for	NN	O	O
postoperative	NN	O	B
pain	NN	O	I
control	NN	O	O
.	NN	O	O

A	NN	O	O
healthy	NN	O	O
17	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
received	NN	O	O
standard	NN	O	O
intermittent	NN	O	O
doses	NN	O	O
of	NN	O	O
pethidine	NN	O	O
via	NN	O	O
a	NN	O	O
patient	NN	O	O
-	NN	O	O
controlled	NN	O	O
analgesia	NN	O	O
(	NN	O	O
PCA	NN	O	O
)	NN	O	O
pump	NN	O	O
for	NN	O	O
management	NN	O	O
of	NN	O	O
postoperative	NN	O	B
pain	NN	O	I
control	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
three	NN	O	O
h	NN	O	O
postoperatively	NN	O	O
he	NN	O	O
developed	NN	O	O
a	NN	O	O
brief	NN	O	O
self	NN	O	O
-	NN	O	O
limited	NN	O	O
seizure	NN	O	B
.	NN	O	O

Both	NN	O	O
plasma	NN	O	O
pethidine	NN	O	O
and	NN	O	O
norpethidine	NN	O	O
were	NN	O	O
elevated	NN	O	O
in	NN	O	O
the	NN	O	O
range	NN	O	O
associated	NN	O	O
with	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
of	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
excitation	NN	O	O
.	NN	O	O

No	NN	O	O
other	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
CNS	NN	O	O
toxicity	NN	O	B
were	NN	O	O
identified	NN	O	O
.	NN	O	O

This	NN	O	O
method	NN	O	O
allowed	NN	O	O
frequent	NN	O	O
self	NN	O	O
-	NN	O	O
dosing	NN	O	O
of	NN	O	O
pethidine	NN	O	O
at	NN	O	O
short	NN	O	O
time	NN	O	O
intervals	NN	O	O
and	NN	O	O
rapid	NN	O	O
accumulation	NN	O	O
of	NN	O	O
pethidine	NN	O	O
and	NN	O	O
norpethidine	NN	O	O
.	NN	O	O

The	NN	O	O
routine	NN	O	O
use	NN	O	O
of	NN	O	O
pethidine	NN	O	O
via	NN	O	O
PCA	NN	O	O
even	NN	O	O
for	NN	O	O
a	NN	O	O
brief	NN	O	O
postoperative	NN	O	O
analgesia	NN	O	O
should	NN	O	O
be	NN	O	O
reconsidered	NN	O	O
.	NN	O	O

An	NN	O	O
unusual	NN	O	O
toxic	NN	O	O
reaction	NN	O	O
to	NN	O	O
axillary	NN	O	O
block	NN	O	O
by	NN	O	O
mepivacaine	NN	O	O
with	NN	O	O
adrenaline	NN	O	O
.	NN	O	O

An	NN	O	O
increase	NN	O	B
in	NN	O	I
blood	NN	O	I
pressure	NN	O	I
,	NN	O	O
accompanied	NN	O	O
by	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
,	NN	O	O
agitation	NN	O	B
,	NN	O	O
incomprehensible	NN	O	B
shouts	NN	O	I
and	NN	O	O
loss	NN	O	B
of	NN	O	I
consciousness	NN	O	I
,	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
an	NN	O	O
elderly	NN	O	O
,	NN	O	O
ASA	NN	O	O
classification	NN	O	O
group	NN	O	O
II	NN	O	O
,	NN	O	O
cardiovascularly	NN	O	O
medicated	NN	O	O
male	NN	O	O
,	NN	O	O
12	NN	O	O
min	NN	O	O
after	NN	O	O
performance	NN	O	O
of	NN	O	O
axillary	NN	O	O
block	NN	O	O
with	NN	O	O
mepivacaine	NN	O	O
850	NN	O	O
mg	NN	O	O
containing	NN	O	O
adrenaline	NN	O	O
0	NN	O	O
.	NN	O	O
225	NN	O	O
mg	NN	O	O
,	NN	O	O
for	NN	O	O
correction	NN	O	O
of	NN	O	O
Dupuytren	NN	O	B
'	NN	O	I
s	NN	O	I
contracture	NN	O	I
.	NN	O	O

After	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
labetalol	NN	O	O
,	NN	O	O
metoprolol	NN	O	O
and	NN	O	O
midazolam	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
condition	NN	O	O
improved	NN	O	O
,	NN	O	O
and	NN	O	O
15	NN	O	O
min	NN	O	O
later	NN	O	O
he	NN	O	O
woke	NN	O	O
up	NN	O	O
.	NN	O	O

The	NN	O	O
block	NN	O	O
was	NN	O	O
successful	NN	O	O
and	NN	O	O
surgery	NN	O	O
was	NN	O	O
conducted	NN	O	O
as	NN	O	O
scheduled	NN	O	O
despite	NN	O	O
persisting	NN	O	O
atrial	NN	O	B
fibrillation	NN	O	I
.	NN	O	O

Postoperatively	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
refused	NN	O	O
DC	NN	O	O
cardioversion	NN	O	O
and	NN	O	O
was	NN	O	O
treated	NN	O	O
medically	NN	O	O
.	NN	O	O

Both	NN	O	O
the	NN	O	O
temporal	NN	O	O
relationship	NN	O	O
of	NN	O	O
events	NN	O	O
and	NN	O	O
the	NN	O	O
response	NN	O	O
to	NN	O	O
treatment	NN	O	O
suggest	NN	O	O
that	NN	O	O
a	NN	O	O
rapid	NN	O	O
systemic	NN	O	O
absorption	NN	O	O
of	NN	O	O
mepivacaine	NN	O	O
with	NN	O	O
adrenaline	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
interaction	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
with	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
cardiovascular	NN	O	O
medications	NN	O	O
were	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
perioperative	NN	O	O
complications	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
associated	NN	O	O
acute	NN	O	O
-	NN	O	O
onset	NN	O	O
vanishing	NN	O	B
bile	NN	O	I
duct	NN	O	I
and	NN	O	O
Stevens	NN	O	B
-	NN	O	I
Johnson	NN	O	I
syndromes	NN	O	I
in	NN	O	O
a	NN	O	O
child	NN	O	O
.	NN	O	O

Acute	NN	O	O
vanishing	NN	O	B
bile	NN	O	I
duct	NN	O	I
syndrome	NN	O	O
is	NN	O	O
a	NN	O	O
rare	NN	O	O
but	NN	O	O
established	NN	O	O
cause	NN	O	O
of	NN	O	O
progressive	NN	O	O
cholestasis	NN	O	B
in	NN	O	O
adults	NN	O	O
,	NN	O	O
is	NN	O	O
most	NN	O	O
often	NN	O	O
drug	NN	O	O
or	NN	O	O
toxin	NN	O	O
related	NN	O	O
,	NN	O	O
and	NN	O	O
is	NN	O	O
of	NN	O	O
unknown	NN	O	O
pathogenesis	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
reported	NN	O	O
previously	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

Stevens	NN	O	B
-	NN	O	I
Johnson	NN	O	I
syndrome	NN	O	I
is	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
recognized	NN	O	O
immune	NN	O	O
complex	NN	O	O
-	NN	O	O
mediated	NN	O	O
hypersensitivity	NN	O	B
reaction	NN	O	O
that	NN	O	O
affects	NN	O	O
all	NN	O	O
age	NN	O	O
groups	NN	O	O
,	NN	O	O
is	NN	O	O
drug	NN	O	O
or	NN	O	O
infection	NN	O	B
induced	NN	O	O
,	NN	O	O
and	NN	O	O
has	NN	O	O
classic	NN	O	O
systemic	NN	O	O
,	NN	O	O
mucosal	NN	O	O
,	NN	O	O
and	NN	O	O
dermatologic	NN	O	O
manifestations	NN	O	O
.	NN	O	O

A	NN	O	O
previously	NN	O	O
healthy	NN	O	O
child	NN	O	O
who	NN	O	O
developed	NN	O	O
acute	NN	O	O
,	NN	O	O
severe	NN	O	O
,	NN	O	O
rapidly	NN	O	O
progressive	NN	O	O
vanishing	NN	O	B
bile	NN	O	I
duct	NN	O	I
syndrome	NN	O	I
shortly	NN	O	O
after	NN	O	O
Stevens	NN	O	B
-	NN	O	I
Johnson	NN	O	I
syndrome	NN	O	I
is	NN	O	O
described	NN	O	O
;	NN	O	O
this	NN	O	O
was	NN	O	O
temporally	NN	O	O
associated	NN	O	O
with	NN	O	O
ibuprofen	NN	O	O
use	NN	O	O
.	NN	O	O

Despite	NN	O	O
therapy	NN	O	O
with	NN	O	O
ursodeoxycholic	NN	O	O
acid	NN	O	O
,	NN	O	O
prednisone	NN	O	O
,	NN	O	O
and	NN	O	O
then	NN	O	O
tacrolimus	NN	O	O
,	NN	O	O
her	NN	O	O
cholestatic	NN	O	B
disease	NN	O	I
was	NN	O	O
unrelenting	NN	O	O
,	NN	O	O
with	NN	O	O
cirrhosis	NN	O	B
shown	NN	O	O
by	NN	O	O
biopsy	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
presentation	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
documents	NN	O	O
acute	NN	O	O
drug	NN	O	O
-	NN	O	O
related	NN	O	O
vanishing	NN	O	B
bile	NN	O	I
duct	NN	O	I
syndrome	NN	O	I
in	NN	O	O
the	NN	O	O
pediatric	NN	O	O
age	NN	O	O
group	NN	O	O
and	NN	O	O
suggests	NN	O	O
shared	NN	O	O
immune	NN	O	O
mechanisms	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
both	NN	O	O
Stevens	NN	O	B
-	NN	O	I
Johnson	NN	O	I
syndrome	NN	O	I
and	NN	O	O
vanishing	NN	O	B
bile	NN	O	I
duct	NN	O	I
syndrome	NN	O	I
.	NN	O	O

High	NN	O	O
incidence	NN	O	O
of	NN	O	O
primary	NN	O	B
pulmonary	NN	O	I
hypertension	NN	O	I
associated	NN	O	O
with	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
in	NN	O	O
Belgium	NN	O	O
.	NN	O	O

Primary	NN	O	B
pulmonary	NN	O	I
hypertension	NN	O	I
is	NN	O	O
a	NN	O	O
rare	NN	O	O
,	NN	O	O
progressive	NN	O	O
and	NN	O	O
incurable	NN	O	O
disease	NN	O	O
,	NN	O	O
which	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
intake	NN	O	O
of	NN	O	O
appetite	NN	O	O
suppressant	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
importance	NN	O	O
of	NN	O	O
this	NN	O	O
association	NN	O	O
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
Belgium	NN	O	O
while	NN	O	O
this	NN	O	O
country	NN	O	O
still	NN	O	O
had	NN	O	O
no	NN	O	O
restriction	NN	O	O
on	NN	O	O
the	NN	O	O
prescription	NN	O	O
of	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
with	NN	O	O
primary	NN	O	B
pulmonary	NN	O	I
hypertension	NN	O	I
and	NN	O	O
85	NN	O	O
matched	NN	O	O
controls	NN	O	O
were	NN	O	O
recruited	NN	O	O
over	NN	O	O
32	NN	O	O
months	NN	O	O
(	NN	O	O
1992	NN	O	O
-	NN	O	O
1994	NN	O	O
)	NN	O	O
in	NN	O	O
Belgium	NN	O	O
.	NN	O	O

Exposure	NN	O	O
to	NN	O	O
appetite	NN	O	O
-	NN	O	O
suppressants	NN	O	O
was	NN	O	O
assessed	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
hospital	NN	O	O
records	NN	O	O
and	NN	O	O
standardized	NN	O	O
interview	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
three	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
had	NN	O	O
previously	NN	O	O
taken	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
,	NN	O	O
mainly	NN	O	O
fenfluramines	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
only	NN	O	O
5	NN	O	O
of	NN	O	O
the	NN	O	O
controls	NN	O	O
(	NN	O	O
66	NN	O	O
versus	NN	O	O
6	NN	O	O
%	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
0001	NN	O	O
)	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
died	NN	O	O
before	NN	O	O
the	NN	O	O
interview	NN	O	O
,	NN	O	O
all	NN	O	O
of	NN	O	O
them	NN	O	O
had	NN	O	O
taken	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
.	NN	O	O

In	NN	O	O
8	NN	O	O
patients	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
primary	NN	O	B
pulmonary	NN	O	I
hypertension	NN	O	I
was	NN	O	O
uncertain	NN	O	O
,	NN	O	O
5	NN	O	O
of	NN	O	O
them	NN	O	O
had	NN	O	O
taken	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
exposed	NN	O	O
to	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
tended	NN	O	O
to	NN	O	O
be	NN	O	O
on	NN	O	O
average	NN	O	O
more	NN	O	O
severely	NN	O	O
ill	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
shorter	NN	O	O
median	NN	O	O
delay	NN	O	O
between	NN	O	O
onset	NN	O	O
of	NN	O	O
symptoms	NN	O	O
and	NN	O	O
diagnosis	NN	O	O
.	NN	O	O

A	NN	O	O
policy	NN	O	O
of	NN	O	O
unrestricted	NN	O	O
prescription	NN	O	O
of	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
a	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
associated	NN	O	O
primary	NN	O	B
pulmonary	NN	O	I
hypertension	NN	O	I
.	NN	O	O

Intake	NN	O	O
of	NN	O	O
appetite	NN	O	O
suppressants	NN	O	O
may	NN	O	O
accelerate	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
.	NN	O	O

Inappropriate	NN	O	O
use	NN	O	O
of	NN	O	O
carbamazepine	NN	O	O
and	NN	O	O
vigabatrin	NN	O	O
in	NN	O	O
typical	NN	O	O
absence	NN	O	B
seizures	NN	O	I
.	NN	O	O

Carbamazepine	NN	O	O
and	NN	O	O
vigabatrin	NN	O	O
are	NN	O	O
contraindicated	NN	O	O
in	NN	O	O
typical	NN	O	O
absence	NN	O	B
seizures	NN	O	I
.	NN	O	O

Of	NN	O	O
18	NN	O	O
consecutive	NN	O	O
referrals	NN	O	O
of	NN	O	O
children	NN	O	O
with	NN	O	O
resistant	NN	O	O
typical	NN	O	O
absences	NN	O	O
only	NN	O	O
,	NN	O	O
eight	NN	O	O
were	NN	O	O
erroneously	NN	O	O
treated	NN	O	O
with	NN	O	O
carbamazepine	NN	O	O
either	NN	O	O
as	NN	O	O
monotherapy	NN	O	O
or	NN	O	O
as	NN	O	O
an	NN	O	O
add	NN	O	O
-	NN	O	O
on	NN	O	O
.	NN	O	O

Vigabatrin	NN	O	O
was	NN	O	O
also	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
two	NN	O	O
children	NN	O	O
.	NN	O	O

Frequency	NN	O	O
of	NN	O	O
absences	NN	O	O
increased	NN	O	O
in	NN	O	O
four	NN	O	O
children	NN	O	O
treated	NN	O	O
with	NN	O	O
carbamazepine	NN	O	O
and	NN	O	O
two	NN	O	O
of	NN	O	O
these	NN	O	O
developed	NN	O	O
myoclonic	NN	O	B
jerks	NN	O	I
,	NN	O	O
which	NN	O	O
resolved	NN	O	O
on	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
carbamazepine	NN	O	O
.	NN	O	O

Absences	NN	O	O
were	NN	O	O
aggravated	NN	O	O
in	NN	O	O
both	NN	O	O
cases	NN	O	O
where	NN	O	O
vigabatrin	NN	O	O
was	NN	O	O
added	NN	O	O
on	NN	O	O
to	NN	O	O
concurrent	NN	O	O
treatment	NN	O	O
.	NN	O	O

Optimal	NN	O	O
control	NN	O	O
of	NN	O	O
the	NN	O	O
absences	NN	O	O
was	NN	O	O
achieved	NN	O	O
with	NN	O	O
sodium	NN	O	O
valproate	NN	O	O
,	NN	O	O
lamotrigine	NN	O	O
,	NN	O	O
or	NN	O	O
ethosuximide	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
.	NN	O	O

Choreoathetoid	NN	O	B
movements	NN	O	I
associated	NN	O	O
with	NN	O	O
rapid	NN	O	O
adjustment	NN	O	O
to	NN	O	O
methadone	NN	O	O
.	NN	O	O

Choreatiform	NN	O	B
hyperkinesias	NN	O	I
are	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
occasional	NN	O	O
movement	NN	O	B
abnormalities	NN	O	I
during	NN	O	O
intoxications	NN	O	O
with	NN	O	O
cocaine	NN	O	O
but	NN	O	O
not	NN	O	O
opiates	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
of	NN	O	O
euphoria	NN	O	O
and	NN	O	O
choreoathetoid	NN	O	B
movements	NN	O	I
both	NN	O	O
transiently	NN	O	O
induced	NN	O	O
by	NN	O	O
rapid	NN	O	O
adjustment	NN	O	O
to	NN	O	O
the	NN	O	O
selective	NN	O	O
mu	NN	O	O
-	NN	O	O
opioid	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
methadone	NN	O	O
in	NN	O	O
an	NN	O	O
inpatient	NN	O	O
previously	NN	O	O
abusing	NN	O	O
heroine	NN	O	O
and	NN	O	O
cocaine	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
minor	NN	O	O
EEG	NN	O	O
abnormalities	NN	O	O
occurred	NN	O	O
.	NN	O	O

Possible	NN	O	O
underlying	NN	O	O
neurobiological	NN	O	O
phenomena	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O

Adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
the	NN	O	O
atypical	NN	O	O
antipsychotics	NN	O	O
.	NN	O	O

Collaborative	NN	O	O
Working	NN	O	O
Group	NN	O	O
on	NN	O	O
Clinical	NN	O	O
Trial	NN	O	O
Evaluations	NN	O	O
.	NN	O	O

Adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
antipsychotics	NN	O	O
often	NN	O	O
lead	NN	O	O
to	NN	O	O
noncompliance	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
clinicians	NN	O	O
should	NN	O	O
address	NN	O	O
patients	NN	O	O
'	NN	O	O
concerns	NN	O	O
about	NN	O	O
adverse	NN	O	O
effects	NN	O	O
and	NN	O	O
attempt	NN	O	O
to	NN	O	O
choose	NN	O	O
medications	NN	O	O
that	NN	O	O
will	NN	O	O
improve	NN	O	O
their	NN	O	O
patients	NN	O	O
'	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
overall	NN	O	O
health	NN	O	O
.	NN	O	O

The	NN	O	O
side	NN	O	O
effect	NN	O	O
profiles	NN	O	O
of	NN	O	O
the	NN	O	O
atypical	NN	O	O
antipsychotics	NN	O	O
are	NN	O	O
more	NN	O	O
advantageous	NN	O	O
than	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
conventional	NN	O	O
neuroleptics	NN	O	O
.	NN	O	O

Conventional	NN	O	O
agents	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
unwanted	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
effects	NN	O	O
,	NN	O	O
including	NN	O	O
extrapyramidal	NN	O	B
symptoms	NN	O	I
(	NN	O	O
EPS	NN	O	B
)	NN	O	O
,	NN	O	O
tardive	NN	O	B
dyskinesia	NN	O	I
,	NN	O	O
sedation	NN	O	O
,	NN	O	O
and	NN	O	O
possible	NN	O	O
impairment	NN	O	O
of	NN	O	O
some	NN	O	O
cognitive	NN	O	O
measures	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
cardiac	NN	O	O
effects	NN	O	O
,	NN	O	O
orthostatic	NN	O	B
hypotension	NN	O	I
,	NN	O	O
hepatic	NN	O	O
changes	NN	O	O
,	NN	O	O
anticholinergic	NN	O	O
side	NN	O	O
effects	NN	O	O
,	NN	O	O
sexual	NN	O	B
dysfunction	NN	O	I
,	NN	O	O
and	NN	O	O
weight	NN	O	B
gain	NN	O	I
.	NN	O	O

The	NN	O	O
newer	NN	O	O
atypical	NN	O	O
agents	NN	O	O
have	NN	O	O
a	NN	O	O
lower	NN	O	O
risk	NN	O	O
of	NN	O	O
EPS	NN	O	B
,	NN	O	O
but	NN	O	O
are	NN	O	O
associated	NN	O	O
in	NN	O	O
varying	NN	O	O
degrees	NN	O	O
with	NN	O	O
sedation	NN	O	O
,	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
,	NN	O	O
anticholinergic	NN	O	O
effects	NN	O	O
,	NN	O	O
weight	NN	O	B
gain	NN	O	I
,	NN	O	O
sexual	NN	O	B
dysfunction	NN	O	I
,	NN	O	O
hepatic	NN	O	O
effects	NN	O	O
,	NN	O	O
lowered	NN	O	O
seizure	NN	O	B
threshold	NN	O	O
(	NN	O	O
primarily	NN	O	O
clozapine	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
agranulocytosis	NN	O	B
(	NN	O	O
clozapine	NN	O	O
only	NN	O	O
)	NN	O	O
.	NN	O	O

Since	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
specific	NN	O	O
adverse	NN	O	O
effects	NN	O	O
differ	NN	O	O
among	NN	O	O
the	NN	O	O
various	NN	O	O
atypicals	NN	O	O
,	NN	O	O
the	NN	O	O
clinician	NN	O	O
should	NN	O	O
carefully	NN	O	O
consider	NN	O	O
which	NN	O	O
side	NN	O	O
effects	NN	O	O
are	NN	O	O
most	NN	O	O
likely	NN	O	O
to	NN	O	O
lead	NN	O	O
to	NN	O	O
the	NN	O	O
individual	NN	O	O
'	NN	O	O
s	NN	O	O
dissatisfaction	NN	O	O
and	NN	O	O
noncompliance	NN	O	O
before	NN	O	O
choosing	NN	O	O
an	NN	O	O
antipsychotic	NN	O	O
for	NN	O	O
a	NN	O	O
particular	NN	O	O
patient	NN	O	O
.	NN	O	O

A	NN	O	O
randomized	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
dose	NN	O	O
-	NN	O	O
comparison	NN	O	O
trial	NN	O	O
of	NN	O	O
haloperidol	NN	O	O
for	NN	O	O
psychosis	NN	O	B
and	NN	O	O
disruptive	NN	O	B
behaviors	NN	O	I
in	NN	O	O
Alzheimer	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
goal	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
two	NN	O	O
doses	NN	O	O
of	NN	O	O
haloperidol	NN	O	O
and	NN	O	O
placebo	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
psychosis	NN	O	B
and	NN	O	O
disruptive	NN	O	B
behaviors	NN	O	I
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Alzheimer	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
In	NN	O	O
a	NN	O	O
6	NN	O	O
-	NN	O	O
week	NN	O	O
random	NN	O	O
-	NN	O	O
assignment	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
(	NN	O	O
phase	NN	O	O
A	NN	O	O
)	NN	O	O
,	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
standard	NN	O	O
dose	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
haloperidol	NN	O	O
,	NN	O	O
0	NN	O	O
.	NN	O	O
50	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O
75	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
low	NN	O	O
dose	NN	O	O
)	NN	O	O
,	NN	O	O
were	NN	O	O
compared	NN	O	O
in	NN	O	O
71	NN	O	O
outpatients	NN	O	O
with	NN	O	O
Alzheimer	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
.	NN	O	O

For	NN	O	O
the	NN	O	O
subsequent	NN	O	O
6	NN	O	O
-	NN	O	O
week	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
crossover	NN	O	O
phase	NN	O	O
(	NN	O	O
phase	NN	O	O
B	NN	O	O
)	NN	O	O
,	NN	O	O
patients	NN	O	O
taking	NN	O	O
standard	NN	O	O
-	NN	O	O
or	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
haloperidol	NN	O	O
were	NN	O	O
switched	NN	O	O
to	NN	O	O
placebo	NN	O	O
,	NN	O	O
and	NN	O	O
patients	NN	O	O
taking	NN	O	O
placebo	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
standard	NN	O	O
-	NN	O	O
or	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
haloperidol	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
For	NN	O	O
the	NN	O	O
60	NN	O	O
patients	NN	O	O
who	NN	O	O
completed	NN	O	O
phase	NN	O	O
A	NN	O	O
,	NN	O	O
standard	NN	O	O
-	NN	O	O
dose	NN	O	O
haloperidol	NN	O	O
was	NN	O	O
efficacious	NN	O	O
and	NN	O	O
superior	NN	O	O
to	NN	O	O
both	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
haloperidol	NN	O	O
and	NN	O	O
placebo	NN	O	O
for	NN	O	O
scores	NN	O	O
on	NN	O	O
the	NN	O	O
Brief	NN	O	O
Psychiatric	NN	O	O
Rating	NN	O	O
Scale	NN	O	O
psychosis	NN	O	B
factor	NN	O	O
and	NN	O	O
on	NN	O	O
psychomotor	NN	O	B
agitation	NN	O	I
.	NN	O	O

Response	NN	O	O
rates	NN	O	O
according	NN	O	O
to	NN	O	O
three	NN	O	O
sets	NN	O	O
of	NN	O	O
criteria	NN	O	O
were	NN	O	O
greater	NN	O	O
with	NN	O	O
the	NN	O	O
standard	NN	O	O
dose	NN	O	O
(	NN	O	O
55	NN	O	O
%	NN	O	O
-	NN	O	O
60	NN	O	O
%	NN	O	O
)	NN	O	O
than	NN	O	O
the	NN	O	O
low	NN	O	O
dose	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
-	NN	O	O
35	NN	O	O
%	NN	O	O
)	NN	O	O
and	NN	O	O
placebo	NN	O	O
(	NN	O	O
25	NN	O	O
%	NN	O	O
-	NN	O	O
30	NN	O	O
%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
advantage	NN	O	O
of	NN	O	O
standard	NN	O	O
dose	NN	O	O
over	NN	O	O
low	NN	O	O
dose	NN	O	O
was	NN	O	O
replicated	NN	O	O
in	NN	O	O
phase	NN	O	O
B	NN	O	O
.	NN	O	O

In	NN	O	O
phase	NN	O	O
A	NN	O	O
,	NN	O	O
extrapyramidal	NN	O	B
signs	NN	O	I
tended	NN	O	O
to	NN	O	O
be	NN	O	O
greater	NN	O	O
with	NN	O	O
the	NN	O	O
standard	NN	O	O
dose	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
two	NN	O	O
conditions	NN	O	O
,	NN	O	O
primarily	NN	O	O
because	NN	O	O
of	NN	O	O
a	NN	O	O
subgroup	NN	O	O
(	NN	O	O
20	NN	O	O
%	NN	O	O
)	NN	O	O
who	NN	O	O
developed	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
signs	NN	O	O
.	NN	O	O

Low	NN	O	O
-	NN	O	O
dose	NN	O	O
haloperidol	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
from	NN	O	O
placebo	NN	O	O
on	NN	O	O
any	NN	O	O
measure	NN	O	O
of	NN	O	O
efficacy	NN	O	O
or	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
indicated	NN	O	O
a	NN	O	O
favorable	NN	O	O
therapeutic	NN	O	O
profile	NN	O	O
for	NN	O	O
haloperidol	NN	O	O
in	NN	O	O
doses	NN	O	O
of	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
although	NN	O	O
a	NN	O	O
subgroup	NN	O	O
developed	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
extrapyramidal	NN	O	B
signs	NN	O	I
.	NN	O	O

A	NN	O	O
starting	NN	O	O
dose	NN	O	O
of	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
with	NN	O	O
gradual	NN	O	O
,	NN	O	O
upward	NN	O	O
dose	NN	O	O
titration	NN	O	O
is	NN	O	O
recommended	NN	O	O
.	NN	O	O

The	NN	O	O
narrow	NN	O	O
therapeutic	NN	O	O
window	NN	O	O
observed	NN	O	O
with	NN	O	O
haloperidol	NN	O	O
may	NN	O	O
also	NN	O	O
apply	NN	O	O
to	NN	O	O
other	NN	O	O
neuroleptics	NN	O	O
used	NN	O	O
in	NN	O	O
Alzheimer	NN	O	B
'	NN	O	I
s	NN	O	I
disease	NN	O	I
patients	NN	O	O
with	NN	O	O
psychosis	NN	O	B
and	NN	O	O
disruptive	NN	O	B
behaviors	NN	O	I
.	NN	O	O

Effects	NN	O	O
of	NN	O	O
acetylsalicylic	NN	O	O
acid	NN	O	O
,	NN	O	O
dipyridamole	NN	O	O
,	NN	O	O
and	NN	O	O
hydrocortisone	NN	O	O
on	NN	O	O
epinephrine	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

A	NN	O	O
reproducible	NN	O	O
model	NN	O	O
for	NN	O	O
producing	NN	O	O
diffuse	NN	O	O
myocardial	NN	O	B
injury	NN	O	I
(	NN	O	O
epinephrine	NN	O	O
infusion	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
developed	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
cardioprotective	NN	O	O
effects	NN	O	O
of	NN	O	O
agents	NN	O	O
or	NN	O	O
maneuvers	NN	O	O
which	NN	O	O
might	NN	O	O
alter	NN	O	O
the	NN	O	O
evolution	NN	O	O
of	NN	O	O
acute	NN	O	O
myocardial	NN	O	B
infarction	NN	O	I
.	NN	O	O

Infusions	NN	O	O
of	NN	O	O
epinephrine	NN	O	O
(	NN	O	O
4	NN	O	O
mug	NN	O	O
per	NN	O	O
kilogram	NN	O	O
per	NN	O	O
minute	NN	O	O
for	NN	O	O
6	NN	O	O
hours	NN	O	O
)	NN	O	O
increased	NN	O	O
radiocalcium	NN	O	O
uptakes	NN	O	O
into	NN	O	O
intact	NN	O	O
myocardium	NN	O	O
and	NN	O	O
each	NN	O	O
of	NN	O	O
its	NN	O	O
subcellular	NN	O	O
components	NN	O	O
with	NN	O	O
the	NN	O	O
mitochondrial	NN	O	O
fraction	NN	O	O
showing	NN	O	O
the	NN	O	O
most	NN	O	O
consistent	NN	O	O
changes	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
saline	NN	O	O
-	NN	O	O
infused	NN	O	O
control	NN	O	O
animals	NN	O	O
(	NN	O	O
4	NN	O	O
,	NN	O	O
957	NN	O	O
vs	NN	O	O
.	NN	O	O
827	NN	O	O
counts	NN	O	O
per	NN	O	O
minute	NN	O	O
per	NN	O	O
gram	NN	O	O
of	NN	O	O
dried	NN	O	O
tissue	NN	O	O
or	NN	O	O
fraction	NN	O	O
)	NN	O	O
.	NN	O	O

Myocardial	NN	O	O
concentrations	NN	O	O
of	NN	O	O
calcium	NN	O	O
also	NN	O	O
increased	NN	O	O
significantly	NN	O	O
(	NN	O	O
12	NN	O	O
.	NN	O	O
0	NN	O	O
vs	NN	O	O
.	NN	O	O
5	NN	O	O
.	NN	O	O
0	NN	O	O
mg	NN	O	O
.	NN	O	O
per	NN	O	O
100	NN	O	O
Gm	NN	O	O
.	NN	O	O
of	NN	O	O
fat	NN	O	O
-	NN	O	O
free	NN	O	O
dry	NN	O	O
weight	NN	O	O
)	NN	O	O
.	NN	O	O

Infusions	NN	O	O
of	NN	O	O
calcium	NN	O	O
chloride	NN	O	O
sufficient	NN	O	O
to	NN	O	O
raise	NN	O	O
serum	NN	O	O
calcium	NN	O	O
concentrations	NN	O	O
2	NN	O	O
mEq	NN	O	O
.	NN	O	O
per	NN	O	O
liter	NN	O	O
failed	NN	O	O
to	NN	O	O
increase	NN	O	O
calcium	NN	O	O
influx	NN	O	O
into	NN	O	O
the	NN	O	O
myocardial	NN	O	O
cell	NN	O	O
.	NN	O	O

Mitochondrial	NN	O	O
radiocalcium	NN	O	O
uptakes	NN	O	O
were	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
in	NN	O	O
animals	NN	O	O
pretreated	NN	O	O
with	NN	O	O
acetylsalicylic	NN	O	O
acid	NN	O	O
or	NN	O	O
dipyridamole	NN	O	O
or	NN	O	O
when	NN	O	O
hydrocortisone	NN	O	O
was	NN	O	O
added	NN	O	O
to	NN	O	O
the	NN	O	O
epinephrine	NN	O	O
infusion	NN	O	O
(	NN	O	O
2	NN	O	O
,	NN	O	O
682	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
803	NN	O	O
,	NN	O	O
and	NN	O	O
3	NN	O	O
,	NN	O	O
424	NN	O	O
counts	NN	O	O
per	NN	O	O
minute	NN	O	O
per	NN	O	O
gram	NN	O	O
of	NN	O	O
dried	NN	O	O
fraction	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Myocardial	NN	O	O
calcium	NN	O	O
concentrations	NN	O	O
also	NN	O	O
were	NN	O	O
decreased	NN	O	O
(	NN	O	O
11	NN	O	O
.	NN	O	O
2	NN	O	O
,	NN	O	O
8	NN	O	O
.	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
8	NN	O	O
.	NN	O	O
9	NN	O	O
mg	NN	O	O
.	NN	O	O
per	NN	O	O
100	NN	O	O
Gm	NN	O	O
.	NN	O	O
of	NN	O	O
fat	NN	O	O
-	NN	O	O
free	NN	O	O
dry	NN	O	O
weight	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
three	NN	O	O
treatment	NN	O	O
groups	NN	O	O
,	NN	O	O
being	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
last	NN	O	O
two	NN	O	O
.	NN	O	O

Evidence	NN	O	O
of	NN	O	O
microscopic	NN	O	O
damage	NN	O	O
was	NN	O	O
graded	NN	O	O
as	NN	O	O
less	NN	O	O
severe	NN	O	O
in	NN	O	O
the	NN	O	O
three	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O

Acetylsalicylic	NN	O	O
acid	NN	O	O
,	NN	O	O
dipyridamole	NN	O	O
,	NN	O	O
and	NN	O	O
hydrocortisone	NN	O	O
all	NN	O	O
appear	NN	O	O
to	NN	O	O
have	NN	O	O
cardioprotective	NN	O	O
effects	NN	O	O
when	NN	O	O
tested	NN	O	O
in	NN	O	O
this	NN	O	O
model	NN	O	O
.	NN	O	O

Clinical	NN	O	O
and	NN	O	O
histopathologic	NN	O	O
examination	NN	O	O
of	NN	O	O
renal	NN	O	O
allografts	NN	O	O
treated	NN	O	O
with	NN	O	O
tacrolimus	NN	O	O
(	NN	O	O
FK506	NN	O	O
)	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
year	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
We	NN	O	O
clinically	NN	O	O
and	NN	O	O
pathologically	NN	O	O
analyzed	NN	O	O
renal	NN	O	O
allografts	NN	O	O
from	NN	O	O
1	NN	O	O
9	NN	O	O
renal	NN	O	O
transplant	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
tacrolimus	NN	O	O
(	NN	O	O
FK506	NN	O	O
)	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
1	NN	O	O
year	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
six	NN	O	O
renal	NN	O	O
allograft	NN	O	O
biopsy	NN	O	O
specimens	NN	O	O
from	NN	O	O
1	NN	O	O
9	NN	O	O
renal	NN	O	O
transplant	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
transplantations	NN	O	O
between	NN	O	O
1991	NN	O	O
and	NN	O	O
1993	NN	O	O
were	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Thirteen	NN	O	O
biopsies	NN	O	O
were	NN	O	O
performed	NN	O	O
from	NN	O	O
stable	NN	O	O
functioning	NN	O	O
renal	NN	O	O
allografts	NN	O	O
with	NN	O	O
informed	NN	O	O
consent	NN	O	O
(	NN	O	O
nonepisode	NN	O	O
biopsy	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
other	NN	O	O
13	NN	O	O
were	NN	O	O
from	NN	O	O
dysfunctional	NN	O	O
renal	NN	O	O
allografts	NN	O	O
with	NN	O	O
a	NN	O	O
clinical	NN	O	O
indication	NN	O	O
for	NN	O	O
biopsy	NN	O	O
(	NN	O	O
episode	NN	O	O
biopsy	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
main	NN	O	O
pathologic	NN	O	O
diagnoses	NN	O	O
(	NN	O	O
some	NN	O	O
overlap	NN	O	O
)	NN	O	O
were	NN	O	O
acute	NN	O	O
rejection	NN	O	O
(	NN	O	O
AR	NN	O	O
;	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
,	NN	O	O
chronic	NN	O	O
rejection	NN	O	O
(	NN	O	O
CR	NN	O	O
;	NN	O	O
n	NN	O	O
=	NN	O	O
5	NN	O	O
)	NN	O	O
,	NN	O	O
AR	NN	O	O
+	NN	O	O
CR	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
,	NN	O	O
recurrent	NN	O	O
IgA	NN	O	B
nephropathy	NN	O	I
(	NN	O	O
n	NN	O	O
=	NN	O	O
5	NN	O	O
)	NN	O	O
,	NN	O	O
normal	NN	O	O
findings	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
minimal	NN	O	O
-	NN	O	O
type	NN	O	O
chronic	NN	O	O
FK506	NN	O	O
nephropathy	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
mild	NN	O	O
-	NN	O	O
type	NN	O	O
FK506	NN	O	O
nephropathy	NN	O	B
(	NN	O	O
n	NN	O	O
=	NN	O	O
11	NN	O	O
)	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
nonepisode	NN	O	O
biopsies	NN	O	O
,	NN	O	O
7	NN	O	O
and	NN	O	O
4	NN	O	O
biopsies	NN	O	O
showed	NN	O	O
minimal	NN	O	O
-	NN	O	O
type	NN	O	O
and	NN	O	O
mild	NN	O	O
-	NN	O	O
type	NN	O	O
chronic	NN	O	O
FK506	NN	O	O
nephropathy	NN	O	B
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Chronic	NN	O	O
FK506	NN	O	O
nephropathy	NN	O	B
consisted	NN	O	O
of	NN	O	O
rough	NN	O	O
and	NN	O	O
foamy	NN	O	O
tubular	NN	O	O
vacuolization	NN	O	O
(	NN	O	O
5	NN	O	O
biopsies	NN	O	O
)	NN	O	O
,	NN	O	O
arteriolopathy	NN	O	O
(	NN	O	O
angiodegeneration	NN	O	O
of	NN	O	O
the	NN	O	O
arteriolar	NN	O	O
wall	NN	O	O
;	NN	O	O
20	NN	O	O
biopsies	NN	O	O
)	NN	O	O
,	NN	O	O
focal	NN	O	B
segmental	NN	O	I
glomerulosclerosis	NN	O	I
(	NN	O	O
4	NN	O	O
biopsies	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
striped	NN	O	O
form	NN	O	O
of	NN	O	O
interstitial	NN	O	B
fibrosis	NN	O	I
(	NN	O	O
11	NN	O	O
biopsies	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	O
creatinine	NN	O	O
levels	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
mild	NN	O	O
-	NN	O	O
type	NN	O	O
chronic	NN	O	O
FK506	NN	O	O
nephropathy	NN	O	B
group	NN	O	O
,	NN	O	O
which	NN	O	O
included	NN	O	O
7	NN	O	O
episode	NN	O	O
biopsies	NN	O	O
,	NN	O	O
were	NN	O	O
statistically	NN	O	O
higher	NN	O	O
than	NN	O	O
those	NN	O	O
in	NN	O	O
the	NN	O	O
minimum	NN	O	O
-	NN	O	O
type	NN	O	O
chronic	NN	O	O
FK506	NN	O	O
-	NN	O	O
nephropathy	NN	O	B
group	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0	NN	O	O
.	NN	O	O
001	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
chronic	NN	O	O
FK506	NN	O	O
nephropathy	NN	O	B
consists	NN	O	O
primarily	NN	O	O
of	NN	O	O
arteriolopathy	NN	O	O
manifesting	NN	O	O
as	NN	O	O
insudative	NN	O	O
hyalinosis	NN	O	O
of	NN	O	O
the	NN	O	O
arteriolar	NN	O	O
wall	NN	O	O
,	NN	O	O
and	NN	O	O
suggests	NN	O	O
that	NN	O	O
mild	NN	O	O
-	NN	O	O
type	NN	O	O
chronic	NN	O	O
FK506	NN	O	O
nephropathy	NN	O	B
is	NN	O	O
a	NN	O	O
condition	NN	O	O
which	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
deterioration	NN	O	O
of	NN	O	O
renal	NN	O	O
allograft	NN	O	O
function	NN	O	O
.	NN	O	O

Different	NN	O	O
lobular	NN	O	O
distributions	NN	O	O
of	NN	O	O
altered	NN	O	O
hepatocyte	NN	O	O
tight	NN	O	O
junctions	NN	O	O
in	NN	O	O
rat	NN	O	O
models	NN	O	O
of	NN	O	O
intrahepatic	NN	O	B
and	NN	O	I
extrahepatic	NN	O	I
cholestasis	NN	O	I
.	NN	O	O

Hepatocyte	NN	O	O
tight	NN	O	O
junctions	NN	O	O
(	NN	O	O
TJs	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
only	NN	O	O
intercellular	NN	O	O
barrier	NN	O	O
between	NN	O	O
the	NN	O	O
sinusoidal	NN	O	O
and	NN	O	O
the	NN	O	O
canalicular	NN	O	O
spaces	NN	O	O
,	NN	O	O
play	NN	O	O
a	NN	O	O
key	NN	O	O
role	NN	O	O
in	NN	O	O
bile	NN	O	O
formation	NN	O	O
.	NN	O	O

Although	NN	O	O
hepatocyte	NN	O	O
TJs	NN	O	O
are	NN	O	O
impaired	NN	O	O
in	NN	O	O
cholestasis	NN	O	B
,	NN	O	O
attempts	NN	O	O
to	NN	O	O
localize	NN	O	O
the	NN	O	O
precise	NN	O	O
site	NN	O	O
of	NN	O	O
hepatocyte	NN	O	O
TJ	NN	O	O
damage	NN	O	O
by	NN	O	O
freeze	NN	O	O
-	NN	O	O
fracture	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
have	NN	O	O
produced	NN	O	O
limited	NN	O	O
information	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
several	NN	O	O
TJ	NN	O	O
-	NN	O	O
associated	NN	O	O
proteins	NN	O	O
like	NN	O	O
ZO	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
7H6	NN	O	O
have	NN	O	O
been	NN	O	O
identified	NN	O	O
and	NN	O	O
characterized	NN	O	O
.	NN	O	O

Immunolocalization	NN	O	O
of	NN	O	O
7H6	NN	O	O
appears	NN	O	O
to	NN	O	O
closely	NN	O	O
correlate	NN	O	O
with	NN	O	O
paracellular	NN	O	O
permeability	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
rat	NN	O	O
models	NN	O	O
of	NN	O	O
intrahepatic	NN	O	B
cholestasis	NN	O	I
by	NN	O	O
ethinyl	NN	O	O
estradiol	NN	O	O
(	NN	O	O
EE	NN	O	O
)	NN	O	O
treatment	NN	O	O
and	NN	O	O
extrahepatic	NN	O	B
cholestasis	NN	O	I
by	NN	O	O
bile	NN	O	O
duct	NN	O	O
ligation	NN	O	O
(	NN	O	O
BDL	NN	O	O
)	NN	O	O
to	NN	O	O
precisely	NN	O	O
determine	NN	O	O
the	NN	O	O
site	NN	O	O
of	NN	O	O
TJ	NN	O	O
damage	NN	O	O
.	NN	O	O

Alterations	NN	O	O
in	NN	O	O
hepatocyte	NN	O	O
TJs	NN	O	O
were	NN	O	O
assessed	NN	O	O
by	NN	O	O
double	NN	O	O
-	NN	O	O
immunolabeling	NN	O	O
for	NN	O	O
7H6	NN	O	O
and	NN	O	O
ZO	NN	O	O
-	NN	O	O
1	NN	O	O
using	NN	O	O
a	NN	O	O
confocal	NN	O	O
laser	NN	O	O
scanning	NN	O	O
microscope	NN	O	O
.	NN	O	O

In	NN	O	O
control	NN	O	O
rats	NN	O	O
,	NN	O	O
immunostaining	NN	O	O
for	NN	O	O
7H6	NN	O	O
and	NN	O	O
ZO	NN	O	O
-	NN	O	O
1	NN	O	O
colocalized	NN	O	O
to	NN	O	O
outline	NN	O	O
bile	NN	O	O
canaliculi	NN	O	O
in	NN	O	O
a	NN	O	O
continuous	NN	O	O
fashion	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
7H6	NN	O	O
and	NN	O	O
ZO	NN	O	O
-	NN	O	O
1	NN	O	O
immunostaining	NN	O	O
was	NN	O	O
more	NN	O	O
discontinuous	NN	O	O
,	NN	O	O
outlining	NN	O	O
the	NN	O	O
bile	NN	O	O
canaliculi	NN	O	O
after	NN	O	O
BDL	NN	O	O
.	NN	O	O

Immunostaining	NN	O	O
for	NN	O	O
7H6	NN	O	O
,	NN	O	O
not	NN	O	O
ZO	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
decreased	NN	O	O
and	NN	O	O
predominantly	NN	O	O
appeared	NN	O	O
as	NN	O	O
discrete	NN	O	O
signals	NN	O	O
in	NN	O	O
the	NN	O	O
submembranous	NN	O	O
cytoplasm	NN	O	O
of	NN	O	O
periportal	NN	O	O
hepatocytes	NN	O	O
after	NN	O	O
BDL	NN	O	O
.	NN	O	O

After	NN	O	O
EE	NN	O	O
treatment	NN	O	O
,	NN	O	O
changes	NN	O	O
in	NN	O	O
immunostaining	NN	O	O
for	NN	O	O
7H6	NN	O	O
and	NN	O	O
ZO	NN	O	O
-	NN	O	O
1	NN	O	O
were	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
seen	NN	O	O
in	NN	O	O
periportal	NN	O	O
hepatocytes	NN	O	O
after	NN	O	O
BDL	NN	O	O
,	NN	O	O
but	NN	O	O
distributed	NN	O	O
more	NN	O	O
diffusely	NN	O	O
throughout	NN	O	O
the	NN	O	O
lobule	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
impairment	NN	O	O
of	NN	O	O
hepatocyte	NN	O	O
TJs	NN	O	O
occurs	NN	O	O
heterogenously	NN	O	O
in	NN	O	O
the	NN	O	O
liver	NN	O	O
lobule	NN	O	O
after	NN	O	O
BDL	NN	O	O
and	NN	O	O
suggests	NN	O	O
that	NN	O	O
BDL	NN	O	O
and	NN	O	O
EE	NN	O	O
treatments	NN	O	O
produce	NN	O	O
different	NN	O	O
lobular	NN	O	O
distributions	NN	O	O
of	NN	O	O
increased	NN	O	O
paracellular	NN	O	O
permeability	NN	O	O
.	NN	O	O

Memory	NN	O	O
facilitation	NN	O	O
and	NN	O	O
stimulation	NN	O	O
of	NN	O	O
endogenous	NN	O	O
nerve	NN	O	O
growth	NN	O	O
factor	NN	O	O
synthesis	NN	O	O
by	NN	O	O
the	NN	O	O
acetylcholine	NN	O	O
releaser	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
(	NN	O	O
3alpha	NN	O	O
-	NN	O	O
tropyl	NN	O	O
2	NN	O	O
-	NN	O	O
(	NN	O	O
p	NN	O	O
-	NN	O	O
bromophenyl	NN	O	O
)	NN	O	O
propionate	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
acetylcholine	NN	O	O
releaser	NN	O	O
,	NN	O	O
on	NN	O	O
memory	NN	O	O
processes	NN	O	O
and	NN	O	O
nerve	NN	O	O
growth	NN	O	O
factor	NN	O	O
(	NN	O	O
NGF	NN	O	O
)	NN	O	O
synthesis	NN	O	O
were	NN	O	O
evaluated	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
mouse	NN	O	O
passive	NN	O	O
-	NN	O	O
avoidance	NN	O	O
test	NN	O	O
,	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
p	NN	O	O
.	NN	O	O
)	NN	O	O
,	NN	O	O
administered	NN	O	O
20	NN	O	O
min	NN	O	O
before	NN	O	O
the	NN	O	O
training	NN	O	O
session	NN	O	O
,	NN	O	O
prevented	NN	O	O
amnesia	NN	O	B
induced	NN	O	O
by	NN	O	O
both	NN	O	O
the	NN	O	O
non	NN	O	O
selective	NN	O	O
antimuscarinic	NN	O	O
drug	NN	O	O
scopolamine	NN	O	O
and	NN	O	O
the	NN	O	O
M1	NN	O	O
-	NN	O	O
selective	NN	O	O
antagonist	NN	O	O
S	NN	O	O
-	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
ET	NN	O	O
-	NN	O	O
126	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
same	NN	O	O
experimental	NN	O	O
conditions	NN	O	O
,	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
20	NN	O	O
microg	NN	O	O
per	NN	O	O
mouse	NN	O	O
,	NN	O	O
i	NN	O	O
.	NN	O	O
c	NN	O	O
.	NN	O	O
v	NN	O	O
.	NN	O	O
)	NN	O	O
was	NN	O	O
also	NN	O	O
able	NN	O	O
to	NN	O	O
prevent	NN	O	O
antimuscarine	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B
,	NN	O	O
demonstrating	NN	O	O
a	NN	O	O
central	NN	O	O
localization	NN	O	O
of	NN	O	O
the	NN	O	O
activity	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
highest	NN	O	O
effective	NN	O	O
doses	NN	O	O
,	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
any	NN	O	O
collateral	NN	O	O
symptoms	NN	O	O
as	NN	O	O
revealed	NN	O	O
by	NN	O	O
the	NN	O	O
Irwin	NN	O	O
test	NN	O	O
,	NN	O	O
and	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
modify	NN	O	O
spontaneous	NN	O	O
motility	NN	O	O
and	NN	O	O
inspection	NN	O	O
activity	NN	O	O
,	NN	O	O
as	NN	O	O
revealed	NN	O	O
by	NN	O	O
the	NN	O	O
hole	NN	O	O
-	NN	O	O
board	NN	O	O
test	NN	O	O
.	NN	O	O

PG	NN	O	O
-	NN	O	O
9	NN	O	O
was	NN	O	O
also	NN	O	O
able	NN	O	O
to	NN	O	O
increase	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
NGF	NN	O	O
secreted	NN	O	O
in	NN	O	O
vitro	NN	O	O
by	NN	O	O
astrocytes	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

The	NN	O	O
maximal	NN	O	O
NGF	NN	O	O
contents	NN	O	O
obtained	NN	O	O
by	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
were	NN	O	O
17	NN	O	O
.	NN	O	O
6	NN	O	O
-	NN	O	O
fold	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
value	NN	O	O
.	NN	O	O

During	NN	O	O
culture	NN	O	O
,	NN	O	O
no	NN	O	O
morphological	NN	O	O
changes	NN	O	O
were	NN	O	O
found	NN	O	O
at	NN	O	O
effective	NN	O	O
concentrations	NN	O	O
of	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
.	NN	O	O

The	NN	O	O
current	NN	O	O
work	NN	O	O
indicates	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
to	NN	O	O
induce	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
on	NN	O	O
cognitive	NN	O	O
processes	NN	O	O
and	NN	O	O
stimulate	NN	O	O
activity	NN	O	O
of	NN	O	O
NGF	NN	O	O
synthesis	NN	O	O
in	NN	O	O
astroglial	NN	O	O
cells	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
PG	NN	O	O
-	NN	O	O
9	NN	O	O
could	NN	O	O
represent	NN	O	O
a	NN	O	O
potential	NN	O	O
useful	NN	O	O
drug	NN	O	O
able	NN	O	O
to	NN	O	O
improve	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
impaired	NN	O	O
cognitive	NN	O	O
processes	NN	O	O
.	NN	O	O

Mechanisms	NN	O	O
of	NN	O	O
FK	NN	O	O
506	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

-	NN	O	O
Tacrolimus	NN	O	O
(	NN	O	O
FK	NN	O	O
506	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
powerful	NN	O	O
,	NN	O	O
widely	NN	O	O
used	NN	O	O
immunosuppressant	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
utility	NN	O	O
of	NN	O	O
FK	NN	O	O
506	NN	O	O
is	NN	O	O
complicated	NN	O	O
by	NN	O	O
substantial	NN	O	O
hypertension	NN	O	B
and	NN	O	O
nephrotoxicity	NN	O	B
.	NN	O	O

To	NN	O	O
clarify	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
FK	NN	O	O
506	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
,	NN	O	O
we	NN	O	O
studied	NN	O	O
the	NN	O	O
chronic	NN	O	O
effects	NN	O	O
of	NN	O	O
FK	NN	O	O
506	NN	O	O
on	NN	O	O
the	NN	O	O
synthesis	NN	O	O
of	NN	O	O
endothelin	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
ET	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
mRNA	NN	O	O
of	NN	O	O
ET	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
endothelin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
ECE	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
endothelial	NN	O	O
nitric	NN	O	O
oxide	NN	O	O
synthase	NN	O	O
(	NN	O	O
eNOS	NN	O	O
)	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
mRNA	NN	O	O
of	NN	O	O
eNOS	NN	O	O
and	NN	O	O
C	NN	O	O
-	NN	O	O
type	NN	O	O
natriuretic	NN	O	O
peptide	NN	O	O
(	NN	O	O
CNP	NN	O	O
)	NN	O	O
in	NN	O	O
rat	NN	O	O
blood	NN	O	O
vessels	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
specific	NN	O	O
endothelin	NN	O	O
type	NN	O	O
A	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
FR	NN	O	O
139317	NN	O	O
on	NN	O	O
FK	NN	O	O
506	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
in	NN	O	O
rats	NN	O	O
was	NN	O	O
studied	NN	O	O
.	NN	O	O

FK	NN	O	O
506	NN	O	O
,	NN	O	O
5	NN	O	O
mg	NN	O	O
.	NN	O	O

kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

d	NN	O	O
-	NN	O	O
1	NN	O	O
given	NN	O	O
for	NN	O	O
4	NN	O	O
weeks	NN	O	O
,	NN	O	O
elevated	NN	O	O
blood	NN	O	O
pressure	NN	O	O
from	NN	O	O
102	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
to	NN	O	O
152	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
15	NN	O	O
mm	NN	O	O
Hg	NN	O	O
and	NN	O	O
increased	NN	O	O
the	NN	O	O
synthesis	NN	O	O
of	NN	O	O
ET	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
ET	NN	O	O
-	NN	O	O
1	NN	O	O
mRNA	NN	O	O
in	NN	O	O
the	NN	O	O
mesenteric	NN	O	O
artery	NN	O	O
(	NN	O	O
240	NN	O	O
%	NN	O	O
and	NN	O	O
230	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Little	NN	O	O
change	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
ECE	NN	O	O
-	NN	O	O
1	NN	O	O
mRNA	NN	O	O
and	NN	O	O
CNP	NN	O	O
mRNA	NN	O	O
.	NN	O	O

FK	NN	O	O
506	NN	O	O
decreased	NN	O	O
eNOS	NN	O	O
activity	NN	O	O
and	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
eNOS	NN	O	O
mRNA	NN	O	O
in	NN	O	O
the	NN	O	O
aorta	NN	O	O
(	NN	O	O
48	NN	O	O
%	NN	O	O
and	NN	O	O
55	NN	O	O
%	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
FR	NN	O	O
139317	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
.	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O
d	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
prevented	NN	O	O
FK	NN	O	O
506	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B
in	NN	O	O
rats	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
FK	NN	O	O
506	NN	O	O
may	NN	O	O
increase	NN	O	O
blood	NN	O	O
pressure	NN	O	O
not	NN	O	O
only	NN	O	O
by	NN	O	O
increasing	NN	O	O
ET	NN	O	O
-	NN	O	O
1	NN	O	O
production	NN	O	O
but	NN	O	O
also	NN	O	O
by	NN	O	O
decreasing	NN	O	O
NO	NN	O	O
synthesis	NN	O	O
in	NN	O	O
the	NN	O	O
vasculature	NN	O	O
.	NN	O	O

